PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Lichtenegger, HC; Schoberl, T; Bartl, MH; Waite, H; Stucky, GD				Lichtenegger, HC; Schoberl, T; Bartl, MH; Waite, H; Stucky, GD			High abrasion resistance with sparse mineralization: Copper biomineral in worm jaws	SCIENCE			English	Article							MECHANICAL-PROPERTIES; CRYSTALS; SUBUNITS; TISSUES; DENTIN; DAMAGE	Biominerals are widely exploited to harden or stiffen tissues in living organisms, with calcium-, silicon-, and iron-based minerals being most common. In notable contrast, the jaws of the marine bloodworm Glycera dibranchiata contain the copper-based biomineral atacamite [Cu-2(OH)(3)Cl]. Polycrystalline fibers are oriented with the outer contour of the jaw. Using nanoindentation, we show that the mineral has a structural role and enhances hardness and stiffness. Despite the low degree of mineralization, bloodworm jaws exhibit an extraordinary resistance to abrasion, significantly exceeding that of vertebrate dentin and approaching that of tooth enamel.	Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93106 USA; Austrian Acad Sci, Erich Schmid Inst Mat Sci, A-8700 Leoben, Austria; Univ Leoben, A-8700 Leoben, Austria; Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; Austrian Academy of Sciences; University of Leoben; University of California System; University of California Santa Barbara	Lichtenegger, HC (corresponding author), Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93106 USA.			Lichtenegger, Helga/0000-0002-6624-1419				Addadi L, 2001, NATURE, V411, P753, DOI 10.1038/35081227; Aizenberg J, 2001, NATURE, V412, P819, DOI 10.1038/35090573; Bandy MC, 1938, AM MINERAL, V23, P669; BAO G, 1991, ACTA METALL MATER, V39, P1871, DOI 10.1016/0956-7151(91)90156-U; Bhushan B., 1999, PRINCIPLES APPL TRIB; BRYAN GW, 1980, J MAR BIOL ASSOC UK, V60, P641, DOI 10.1017/S0025315400040339; BRYAN GW, 1979, J MAR BIOL ASSOC UK, V59, P969, DOI 10.1017/S0025315400036961; Cha JN, 1999, P NATL ACAD SCI USA, V96, P361, DOI 10.1073/pnas.96.2.361; CHISHOLM JE, 1987, MINERAL MAG, V51, P715, DOI 10.1180/minmag.1987.051.363.12; Currey JD, 1999, J EXP BIOL, V202, P3285; Curtain CC, 2001, J BIOL CHEM, V276, P20466, DOI 10.1074/jbc.M100175200; Fong H, 2000, MAT SCI ENG C-BIO S, V7, P119, DOI 10.1016/S0928-4931(99)00133-2; FRATZL P, 1994, J STAT PHYS, V77, P125, DOI 10.1007/BF02186835; GIBBS PE, 1980, J MAR BIOL ASSOC UK, V60, P205, DOI 10.1017/S0025315400024267; HANNINGTON MD, 1993, CAN MINERAL, V31, P945; Holm RH, 1996, CHEM REV, V96, P2239, DOI 10.1021/cr9500390; Jones R.M., 1999, MECH COMPOS MATER, V2nd, DOI DOI 10.1201/9781498711067; Kamat S, 2000, NATURE, V405, P1036, DOI 10.1038/35016535; KRAMER R, 1993, P NATL ACAD SCI USA, V90, P5394, DOI 10.1073/pnas.90.12.5394; Landis WJ, 1996, CONNECT TISSUE RES, V35, P1; LOWENSTAM HA, 1967, SCIENCE, V156, P1373, DOI 10.1126/science.156.3780.1373; Lowenstam HA, 1989, BIOMINERALIZATION; MANN S, 1993, NATURE, V365, P499, DOI 10.1038/365499a0; MICHEL C, 1973, Bulletin Biologique de la France et de la Belgique, V107, P301; OLIVER WC, 1992, J MATER RES, V7, P1564, DOI 10.1557/JMR.1992.1564; *PDF, 25269 PDF; Roberts W. L., 1990, ENCY MINERALS; Shiraishi N, 2002, FEBS LETT, V511, P118, DOI 10.1016/S0014-5793(01)03324-5; Suresh S, 1999, ACTA MATER, V47, P3915, DOI 10.1016/S1359-6454(99)00205-0; Suresh S, 2001, SCIENCE, V292, P2447, DOI 10.1126/science.1059716; Tesch W, 2001, CALCIFIED TISSUE INT, V69, P147, DOI 10.1007/s00223-001-2012-z; THIEFFRY M, 1982, J PHYSIOL-PARIS, V78, P343; Vaccaro E, 2001, BIOMACROMOLECULES, V2, P906, DOI 10.1021/bm0100514; Vincent J, 1990, STRUCTURAL BIOMATERI; Waters N E, 1980, Symp Soc Exp Biol, V34, P99; [No title captured]	36	175	180	6	80	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 11	2002	298	5592					389	392		10.1126/science.1075433	http://dx.doi.org/10.1126/science.1075433			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	602NB	12376695				2022-12-28	WOS:000178510400041
J	Ha, T; Rasnik, I; Cheng, W; Babcock, HP; Gauss, GH; Lohman, TM; Chu, S				Ha, T; Rasnik, I; Cheng, W; Babcock, HP; Gauss, GH; Lohman, TM; Chu, S			Initiation and re-initiation of DNA unwinding by the Escherichia coli Rep helicase	NATURE			English	Article							RESONANCE ENERGY-TRANSFER; SINGLE-MOLECULE; TRANSLOCATION; MECHANISM; HYDROLYSIS; MONOMER; PROTEIN	Helicases are motor proteins that couple conformational changes induced by ATP binding and hydrolysis with unwinding of duplex nucleic acid(1-3), and are involved in several human diseases. Some function as hexameric rings(4), but the functional form of non-hexameric helicases has been debated(5-10). Here we use a combination of a surface immobilization scheme and single-molecule fluorescence assays-which do not interfere with biological activity-to probe DNA unwinding by the Escherichia coli Rep helicase. Our studies indicate that a Rep monomer uses ATP hydrolysis to move toward the junction between single-stranded and double-stranded DNA but then displays conformational fluctuations that do not lead to DNA unwinding. DNA unwinding initiates only if a functional helicase is formed via additional protein binding. Partial dissociation of the functional complex during unwinding results in interruptions ('stalls') that lead either to duplex rewinding upon complete dissociation of the complex, or to re-initiation of unwinding upon re-formation of the functional helicase. These results suggest that the low unwinding processivity observed in vitro for Rep is due to the relative instability of the functional complex. We expect that these techniques will be useful for dynamic studies of other helicases and protein-DNA interactions.	Univ Illinois, Dept Phys, Urbana, IL 61801 USA; Washington Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63110 USA; Stanford Univ, Dept Phys, Stanford, CA 94305 USA	University of Illinois System; University of Illinois Urbana-Champaign; Washington University (WUSTL); Stanford University	Ha, T (corresponding author), Univ Illinois, Dept Phys, 1110 W Green St, Urbana, IL 61801 USA.	tjha@uiuc.edu	Ha, Taekjip/B-9506-2009	Ha, Taekjip/0000-0003-2195-6258; Babcock, Hazen/0000-0003-4835-3692	NIGMS NIH HHS [R01 GM045948, R01 GM065367] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065367, R01GM045948] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ail JA, 1999, J MOL BIOL, V293, P815, DOI 10.1006/jmbi.1999.3185; Bianco PR, 2001, NATURE, V409, P374, DOI 10.1038/35053131; BJORNSON KP, 1994, BIOCHEMISTRY-US, V33, P14306, DOI 10.1021/bi00251a044; CHAO KL, 1991, J MOL BIOL, V221, P1165, DOI 10.1016/0022-2836(91)80119-F; Cheng W, 2001, J MOL BIOL, V310, P327, DOI 10.1006/jmbi.2001.4758; Dillingham MS, 2000, BIOCHEMISTRY-US, V39, P205, DOI 10.1021/bi992105o; Dillingham MS, 2002, BIOCHEMISTRY-US, V41, P643, DOI 10.1021/bi011137k; Dohoney KM, 2001, NATURE, V409, P370, DOI 10.1038/35053124; Ha T, 1996, P NATL ACAD SCI USA, V93, P6264, DOI 10.1073/pnas.93.13.6264; Ha T, 2001, METHODS, V25, P78, DOI 10.1006/meth.2001.1217; Hall MC, 1999, MOL MICROBIOL, V34, P867, DOI 10.1046/j.1365-2958.1999.01659.x; Levin MK, 1999, J BIOL CHEM, V274, P31839, DOI 10.1074/jbc.274.45.31839; LOHMAN TM, 1989, J BIOL CHEM, V264, P10139; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Mechanic LE, 1999, J BIOL CHEM, V274, P12488, DOI 10.1074/jbc.274.18.12488; MOORE KJM, 1994, BIOCHEMISTRY-US, V33, P14550, DOI 10.1021/bi00252a023; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; Sofia SJ, 1998, MACROMOLECULES, V31, P5059, DOI 10.1021/ma971016l; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; von Hippel PH, 2001, CELL, V104, P177, DOI 10.1016/S0092-8674(01)00203-3; Weiss S, 2000, NAT STRUCT BIOL, V7, P724, DOI 10.1038/78941; Wong I, 1997, BIOCHEMISTRY-US, V36, P3115, DOI 10.1021/bi9621977; YARRANTON GT, 1979, P NATL ACAD SCI USA, V76, P1658, DOI 10.1073/pnas.76.4.1658; Zhuang XW, 2000, SCIENCE, V288, P2048, DOI 10.1126/science.288.5473.2048	24	376	387	0	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 10	2002	419	6907					638	641		10.1038/nature01083	http://dx.doi.org/10.1038/nature01083			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	602AT	12374984				2022-12-28	WOS:000178483100050
J	Ong, PY; Ohtake, T; Brandt, C; Strickland, I; Boguniewicz, M; Ganz, T; Gallo, RL; Leung, DYM				Ong, PY; Ohtake, T; Brandt, C; Strickland, I; Boguniewicz, M; Ganz, T; Gallo, RL; Leung, DYM			Endogenous antimicrobial peptides and skin infections in atopic dermatitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							STAPHYLOCOCCUS-AUREUS; DEFENSINS; KERATINOCYTES; EXPRESSION; PSORIASIS; BINDING	Background: The innate immune system of human skin contains antimicrobial peptides known as cathelicidins (LL-37) and (beta)-defensins. In normal skin these peptides are negligible, but they accumulate in skin affected by inflammatory diseases such as psoriasis. We compared the levels of expression of LL-37 and human (beta)-defensin 2 (HBD-2) in inflamed skin from patients with atopic dermatitis and from those with psoriasis. Methods: The expression of LL-37 and HBD-2 protein in skin-biopsy specimens from patients with psoriasis, patients with atopic dermatitis, and normal subjects was determined by immunohistochemical analysis. The amount of antimicrobial peptides in extracts of skin samples was also analyzed by immunodot blot analysis (for LL-37) and Western blot analysis (for HBD-2). Quantitative, real-time reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assays were used to confirm the relative expression of HBD-2 and LL-37 messenger RNA (mRNA) in the skin-biopsy specimens. These peptides were also tested for antimicrobial activity against Staphylococcus aureus with the use of a colony-forming assay. Results: Immunohistochemical analysis confirmed the presence of abundant LL-37 and HBD-2 in the superficial epidermis of all patients with psoriasis. In comparison, immunostaining for these peptides was significantly decreased in acute and chronic lesions from patients with atopic dermatitis (P=0.006 and P=0.03, respectively). These results were confirmed by immunodot blot and Western blot analyses. Real-time RT-PCR showed significantly lower expression of HBD-2 mRNA and LL-37 mRNA in atopic lesions than in psoriatic lesions (P=0.009 and P=0.02, respectively). The combination of LL-37 and HBD-2 showed synergistic antimicrobial activity by effectively killing S. aureus. Conclusions: A deficiency in the expression of antimicrobial peptides may account for the susceptibility of patients with atopic dermatitis to skin infection with S. aureus.	Natl Jewish Med & Res Ctr, Dept Pediat, Div Allergy & Immunol, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA; Univ Calif San Diego, Dept Med & Pediat, Div Dermatol, San Diego, CA USA; Vet Affairs San Diego Hlth Care Syst, San Diego, CA USA; Univ Calif Los Angeles, Sch Med, Div Pulm & Crit Care Med, Dept Med, Los Angeles, CA USA; Univ Calif Los Angeles, Sch Med, Div Pulm & Crit Care Med, Dept Pathol, Los Angeles, CA USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Leung, DYM (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Allergy & Immunol, Rm K926,1400 Jackson St, Denver, CO 80206 USA.		Ong, Peck Y/AAE-2944-2021; Ganz, Tomas/AAN-3308-2020; Gallo, Richard L/A-8931-2009; Ganz, Tomas/D-4567-2009	Ong, Peck Y/0000-0002-6664-463X; Gallo, Richard L/0000-0002-1401-7861; Ganz, Tomas/0000-0002-2830-5469	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000051] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037260, R01HL046809, R37HL037260, P01HL036577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007365, R21AI048176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041256] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00051] Funding Source: Medline; NHLBI NIH HHS [HL36577, HL37260, HL46809] Funding Source: Medline; NIAID NIH HHS [T32 AI 07365, AI48176] Funding Source: Medline; NIAMS NIH HHS [AR41256] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bunikowski R, 2000, J ALLERGY CLIN IMMUN, V105, P814, DOI 10.1067/mai.2000.105528; Cho SH, 2001, J ALLERGY CLIN IMMUN, V108, P269, DOI 10.1067/mai.2001.117455; Cho SH, 2001, J INVEST DERMATOL, V116, P658, DOI 10.1046/j.0022-202x.2001.01331.x; CHRISTOPHERS E, 1987, ARCH DERMATOL RES, V279, pS48, DOI 10.1007/BF00585919; CONOVER W. J, 1980, PRACTICAL NONPARAMET; Dorschner RA, 2001, J INVEST DERMATOL, V117, P91, DOI 10.1046/j.1523-1747.2001.01340.x; Frohm M, 1997, J BIOL CHEM, V272, P15258, DOI 10.1074/jbc.272.24.15258; Fulton C, 1997, LANCET, V350, P1750, DOI 10.1016/S0140-6736(05)63574-X; Gallo RL, 1998, J INVEST DERMATOL, V111, P739, DOI 10.1046/j.1523-1747.1998.00361.x; GALLO RL, 1994, P NATL ACAD SCI USA, V91, P11035, DOI 10.1073/pnas.91.23.11035; Giustizieri ML, 2001, J ALLERGY CLIN IMMUN, V107, P871, DOI 10.1067/mai.2001.114707; GRICE K, 1975, J INVEST DERMATOL, V64, P313, DOI 10.1111/1523-1747.ep12512258; Gropp R, 1999, HUM GENE THER, V10, P957, DOI 10.1089/10430349950018355; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; Jackson G, 1996, BRIT J CLIN PRACT, V50, P3; LEHRER RI, 1993, ANNU REV IMMUNOL, V11, P105, DOI 10.1146/annurev.iy.11.040193.000541; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; LEUNG DYM, 1998, FITZPATRICKS DERMATO, V1, P1464; LEYDEN JJ, 1977, BRIT J DERMATOL, V96, P179, DOI 10.1111/j.1365-2133.1977.tb12541.x; Liu AY, 2002, J INVEST DERMATOL, V118, P275, DOI 10.1046/j.0022-202x.2001.01651.x; Morishita Y, 1999, CLIN EXP ALLERGY, V29, P1110; NILSSON EJ, 1992, J AM ACAD DERMATOL, V27, P29, DOI 10.1016/0190-9622(92)70151-5; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; Panyutich A, 1997, INFECT IMMUN, V65, P978, DOI 10.1128/IAI.65.3.978-985.1997; Peschel A, 2001, J EXP MED, V193, P1067, DOI 10.1084/jem.193.9.1067; Remitz A, 2001, J ALLERGY CLIN IMMUN, V107, P196, DOI 10.1067/mai.2001.112131; Stolzenberg ED, 1997, P NATL ACAD SCI USA, V94, P8686, DOI 10.1073/pnas.94.16.8686	27	1403	1482	2	118	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 10	2002	347	15					1151	1160		10.1056/NEJMoa021481	http://dx.doi.org/10.1056/NEJMoa021481			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	601TW	12374875				2022-12-28	WOS:000178465100005
J	Debnath, J; Mills, KR; Collins, NL; Reginato, MJ; Muthuswamy, SK; Brugge, JS				Debnath, J; Mills, KR; Collins, NL; Reginato, MJ; Muthuswamy, SK; Brugge, JS			The role of apoptosis in creating and maintaining luminal space with normal and oncogene-expressing mammary acini	CELL			English	Article							PROGRAMMED CELL-DEATH; BREAST EPITHELIAL-CELLS; EXTRACELLULAR-MATRIX; TRANSGENIC MICE; SURVIVAL; DIFFERENTIATION; PROTEIN; CANCER; GROWTH; LINE	We have utilized in vitro three-dimensional epithelial cell cultures to analyze the role of apoptosis in the formation and maintenance of a hollow glandular architecture. Lumen formation is associated with the selective apoptosis of centrally located cells; this apoptosis follows apicobasal polarization and precedes proliferative suppression during acinar development. Notably, either inhibiting apoptosis (by exogenously expressing antiapoptotic Bcl family proteins) or enhancing proliferation (via Cyclin D1 or HPV E7 overexpression) does not result in luminal filling, suggesting glandular architecture is resistant to such isolated oncogenic insults. However, the lumen is filled when oncogenes that enhance proliferation are coexpressed with those that inhibit apoptosis, or when ErbB2, which induces both activities, is activated by homodimerization. Hence, apoptosis can counteract increased proliferation to maintain luminal space, suggesting that tumor cells must restrain apoptosis to populate the lumen.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Brugge, JS (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.		Reginato, Mauricio/I-6155-2013; Muthuswamy, Senthil K/AGY-2834-2022	Reginato, Mauricio/0000-0002-7541-4094; Muthuswamy, Senthil K/0000-0001-6564-9634; Debnath, Jayanta/0000-0002-8745-4069	NATIONAL CANCER INSTITUTE [P01CA080111, P50CA089393] Funding Source: NIH RePORTER; NCI NIH HHS [CA89393, CA80111] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Blatchford DR, 1999, J CELL PHYSIOL, V181, P304, DOI 10.1002/(SICI)1097-4652(199911)181:2<304::AID-JCP12>3.0.CO;2-5; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Boyer SN, 1996, CANCER RES, V56, P4620; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Bursch W, 2000, ANN NY ACAD SCI, V926, P1, DOI 10.1111/j.1749-6632.2000.tb05594.x; COUCOUVANIS E, 1995, CELL, V83, P279, DOI 10.1016/0092-8674(95)90169-8; Coucouvanis E, 1999, DEVELOPMENT, V126, P535; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Furth PA, 1999, ONCOGENE, V18, P6589, DOI 10.1038/sj.onc.1203073; GILLETT C, 1994, CANCER RES, V54, P1812; Gudjonsson T, 2002, J CELL SCI, V115, P39; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; Harris J, 1999, DIS BREAST; Hoffman MP, 1996, J CELL SCI, V109, P2013; Humphreys RC, 1996, DEVELOPMENT, V122, P4013; Korff T, 1998, J CELL BIOL, V143, P1341, DOI 10.1083/jcb.143.5.1341; LAMMIE GA, 1991, ONCOGENE, V6, P439; Lee CY, 2001, DEVELOPMENT, V128, P1443; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Moreno A, 2001, Breast J, V7, P245, DOI 10.1046/j.1524-4741.2001.98116.x; Muller H, 2000, BBA-REV CANCER, V1470, pM1, DOI 10.1016/S0304-419X(99)00030-X; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Murphy KL, 1999, ONCOGENE, V18, P6597, DOI 10.1038/sj.onc.1203099; Murray P, 2000, J CELL BIOL, V150, P1215, DOI 10.1083/jcb.150.5.1215; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; O'Brien LE, 2002, NAT REV MOL CELL BIO, V3, P531, DOI 10.1038/nrm859; Ojakian GK, 1997, J CELL SCI, V110, P2781; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; PETERSEN OW, 1992, P NATL ACAD SCI USA, V89, P9064, DOI 10.1073/pnas.89.19.9064; Plas DR, 2001, J BIOL CHEM, V276, P12041, DOI 10.1074/jbc.M010551200; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; SCHUURING E, 1992, ONCOGENE, V7, P355; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SOULE HD, 1990, CANCER RES, V50, P6075; Spancake KM, 1999, CANCER RES, V59, P6042; Sperandio S, 2000, P NATL ACAD SCI USA, V97, P14376, DOI 10.1073/pnas.97.26.14376; STREULI CH, 1990, J CELL BIOL, V110, P1405; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; Weaver VM, 2002, CANCER CELL, V2, P205, DOI 10.1016/S1535-6108(02)00125-3	49	606	618	0	20	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 4	2002	111	1					29	40		10.1016/S0092-8674(02)01001-2	http://dx.doi.org/10.1016/S0092-8674(02)01001-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	601RQ	12372298	Bronze			2022-12-28	WOS:000178461900006
J	Hill, CA; Fox, AN; Pitts, RJ; Kent, LB; Tan, PL; Chrystal, MA; Cravchik, A; Collins, FH; Robertson, HM; Zwiebel, LJ				Hill, CA; Fox, AN; Pitts, RJ; Kent, LB; Tan, PL; Chrystal, MA; Cravchik, A; Collins, FH; Robertson, HM; Zwiebel, LJ			G protein coupled receptors in Anopheles gambiae	SCIENCE			English	Article							CANDIDATE ODORANT RECEPTORS; DROSOPHILA-MELANOGASTER; TASTE RECEPTORS; EXPRESSION; FAMILY; SYSTEM	We used bioinformatic approaches to identify total of 276 G protein-coupled receptors (GPCRs) from the Anopheles gambiae genome. These include GPCRs that are likely to play roles in pathways affecting almost every aspect of the mosquito's life cycle. Seventy-nine candidate odorant receptors were characterized for tissue expression and, along with 76 putative gustatory receptors, for their molecular evolution relative to Drosophila melanogaster. Examples of lineage-specific gene expansions were observed as well as single instance of unusually high sequence conservation.	Vanderbilt Univ, Dept Biol Sci, Program Dev Biol, Nashville, TN 37235 USA; Vanderbilt Univ, Ctr Mol Neurosci, Nashville, TN 37235 USA; Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA; Univ Illinois, Dept Entomol, Urbana, IL 61801 USA; Celera Diagnost, Rockville, MD 20850 USA	Vanderbilt University; Vanderbilt University; University of Notre Dame; University of Illinois System; University of Illinois Urbana-Champaign	Zwiebel, LJ (corresponding author), Vanderbilt Univ, Dept Biol Sci, Program Dev Biol, 221 Kirkland Hall, Nashville, TN 37235 USA.			Fox, Nicole/0000-0001-5012-9177; Pitts, Jason/0000-0002-4863-9634; Zwiebel, Laurence/0000-0001-6686-7289	NIAID NIH HHS [U01AI50687, U01AI48846] Funding Source: Medline; NIDCD NIH HHS [R01 DC04692-01, F31 DC05265-01A1, R01 DC004692] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI048846, U01AI050687] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC004692, F31DC005265] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Briscoe AD, 2001, MOL BIOL EVOL, V18, P2270, DOI 10.1093/oxfordjournals.molbev.a003773; Brody T, 2000, J CELL BIOL, V150, pF83, DOI 10.1083/jcb.150.2.F83; Clyne PJ, 1999, NEURON, V22, P327, DOI 10.1016/S0896-6273(00)81093-4; Clyne PJ, 2000, SCIENCE, V287, P1830, DOI 10.1126/science.287.5459.1830; Dahanukar A, 2001, NAT NEUROSCI, V4, P1182, DOI 10.1038/nn765; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; Dunipace L, 2001, CURR BIOL, V11, P822, DOI 10.1016/S0960-9822(01)00258-5; Fox AN, 2002, CHEM SENSES, V27, P453, DOI 10.1093/chemse/27.5.453; Fox AN, 2001, P NATL ACAD SCI USA, V98, P14693, DOI 10.1073/pnas.261432998; Holt RA, 2002, SCIENCE, V298, P129, DOI 10.1126/science.1076181; Kim J, 2000, BIOINFORMATICS, V16, P767, DOI 10.1093/bioinformatics/16.9.767; Macdonald G., 1957, EPIDEMIOLOGY CONTROL; MOUTSAKI P, IN PRESS J EXP BIOL; Robertson HM, 2001, CHEM SENSES, V26, P151, DOI 10.1093/chemse/26.2.151; Scott K, 2001, CELL, V104, P661, DOI 10.1016/S0092-8674(01)00263-X; Stortkuhl KF, 2001, P NATL ACAD SCI USA, V98, P9381, DOI 10.1073/pnas.151105698; Takken W, 1999, ANNU REV ENTOMOL, V44, P131, DOI 10.1146/annurev.ento.44.1.131; Ueno K, 2001, CURR BIOL, V11, P1451, DOI 10.1016/S0960-9822(01)00450-X; Vosshall LB, 2000, CELL, V102, P147, DOI 10.1016/S0092-8674(00)00021-0; West AP, 2001, P NATL ACAD SCI USA, V98, P3744, DOI 10.1073/pnas.051625298; Wetzel CH, 2001, P NATL ACAD SCI USA, V98, P9377, DOI 10.1073/pnas.151103998	22	509	566	10	75	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 4	2002	298	5591					176	178		10.1126/science.1076196	http://dx.doi.org/10.1126/science.1076196			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	600BJ	12364795				2022-12-28	WOS:000178370500052
J	Berde, CB; Sethna, NF				Berde, CB; Sethna, NF			Drug therapy - Analgesics for the treatment of pain in children	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PATIENT-CONTROLLED ANALGESIA; TETRACAINE-ADRENALINE-COCAINE; TRANSMUCOSAL FENTANYL CITRATE; RANDOMIZED CONTROLLED TRIAL; DOUBLE-BLIND EVALUATION; PRETERM INFANTS; INTRAVENOUS MORPHINE; POSTOPERATIVE PAIN; NEWBORN-INFANTS; PEDIATRIC MIGRAINE		Childrens Hosp, Dept Anesthesia, Pain Treatment Serv, Boston, MA 02115 USA; Childrens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Anesthesia, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Berde, CB (corresponding author), Childrens Hosp, Dept Anesthesia, Pain Treatment Serv, 333 Longwood Ave,Rm 555, Boston, MA 02115 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD035737] Funding Source: NIH RePORTER; NICHD NIH HHS [1R01HD35737] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALS H, 1994, JAMA-J AM MED ASSOC, V272, P853, DOI 10.1001/jama.272.11.853; ANAND KJS, 1987, LANCET, V1, P62; ANAND R, 1987, LANCET, V2, P234; Anderson BJ, 1999, ANESTHESIOLOGY, V90, P411, DOI 10.1097/00000542-199902000-00014; BAER GA, 1992, ANAESTHESIA, V47, P1078, DOI 10.1111/j.1365-2044.1992.tb04210.x; BATTISTELLA PA, 1993, HEADACHE, V33, P36, DOI 10.1111/j.1526-4610.1993.hed3301036.x; Belay ED, 1999, NEW ENGL J MED, V340, P1377, DOI 10.1056/NEJM199905063401801; BENINI F, 1994, JAMA-J AM MED ASSOC, V271, P274; BERDE CB, 1991, J PEDIATR-US, V118, P460, DOI 10.1016/S0022-3476(05)82169-9; BERDE CB, 1991, J PEDIATR-US, V119, P136, DOI 10.1016/S0022-3476(05)81054-6; BERRY FA, 1987, ANESTHESIOLOGY, V67, P291; Beyer J E, 1990, J Pain Symptom Manage, V5, P350, DOI 10.1016/0885-3924(90)90029-J; Beyer J E, 1992, J Pediatr Nurs, V7, P335; BHAT R, 1990, J PEDIATR-US, V117, P477, DOI 10.1016/S0022-3476(05)81102-3; BIERI D, 1990, PAIN, V41, P139, DOI 10.1016/0304-3959(90)90018-9; BILLE B, 1962, ACTA PAED STOCK S136, V51, P1, DOI DOI 10.1111/J.1651-2227.1962.TB06591.X; Birmingham PK, 1997, ANESTHESIOLOGY, V87, P244, DOI 10.1097/00000542-199708000-00010; Blanco JG, 2000, DRUG METAB DISPOS, V28, P379; BONADIO, 1991, PEDIATRICS, V87, P185; BONADIO WA, 1990, PEDIATRICS, V86, P856; Bouwmeester NJ, 2001, BRIT J ANAESTH, V87, P390, DOI 10.1093/bja/87.3.390; Breau LM, 2002, ANESTHESIOLOGY, V96, P528, DOI 10.1097/00000542-200203000-00004; Caraco Y, 1997, J PHARMACOL EXP THER, V281, P330; Chambers CT, 1999, PAIN, V83, P25, DOI 10.1016/S0304-3959(99)00086-X; Cohen G, 1997, PEDIATR PULM, V24, P163; COHEN MM, 1990, ANESTH ANALG, V70, P160; Collins JJ, 1996, J PEDIATR-US, V129, P722, DOI 10.1016/S0022-3476(96)70156-7; Collins JJ, 1999, J PEDIATR-US, V134, P319, DOI 10.1016/S0022-3476(99)70457-9; Collins JJ, 1996, PAIN, V65, P63, DOI 10.1016/0304-3959(95)00193-X; COLLINS JJ, 1995, J PEDIATR-US, V126, P653, DOI 10.1016/S0022-3476(95)70370-5; Constant I, 1998, BRIT J ANAESTH, V80, P294, DOI 10.1093/bja/80.3.294; Cote CJ, 1996, PEDIATRICS, V98, P118; DALENS B, 1989, ANESTH ANALG, V69, P705; DALENS B, 1990, ANESTH ANALG, V70, P131; Esmail Z, 1999, PAEDIATR ANAESTH, V9, P321, DOI 10.1046/j.1460-9592.1999.00384.x; Fahnenstich H, 2000, CRIT CARE MED, V28, P836, DOI 10.1097/00003246-200003000-00037; Finley GA, 1996, PAIN, V64, P83, DOI 10.1016/0304-3959(95)00091-7; Fitzgerald M, 2001, NEUROSCIENTIST, V7, P246, DOI 10.1177/107385840100700309; FITZGERALD M, 1986, DEV BRAIN RES, V24, P261, DOI 10.1016/0165-3806(86)90194-X; GAUNTLETT IS, 1988, ANESTHESIOLOGY, V69, P683, DOI 10.1097/00000542-198811000-00008; GIANNINI EH, 1990, J PEDIATR-US, V117, P645, DOI 10.1016/S0022-3476(05)80708-5; Giaufre E, 1996, ANESTH ANALG, V83, P904, DOI 10.1097/00000539-199611000-00003; Gill AM, 1996, ANN PHARMACOTHER, V30, P125, DOI 10.1177/106002809603000202; Goldman A, 1996, J PALLIATIVE CARE, V12, P16, DOI 10.1177/082585979601200304; Gorman AL, 1997, NEUROSCI LETT, V223, P5; GREELEY WJ, 1987, ANESTH ANALG, V66, P1067; GRUNAU RVE, 1990, PAIN, V42, P295, DOI 10.1016/0304-3959(90)91142-6; GUNTER JB, 1995, ANESTH ANALG, V81, P1136, DOI 10.1097/00000539-199512000-00004; Gunter JB, 1999, ANESTH ANALG, V89, P647, DOI 10.1097/00000539-199909000-00020; Hamalainen ML, 1997, PEDIATR NEUROL, V16, P114, DOI 10.1016/S0887-8994(96)00289-5; Hamalainen ML, 1997, NEUROLOGY, V48, P103, DOI 10.1212/WNL.48.1.103; HAMUNEN K, 1993, ACTA ANAESTH SCAND, V37, P449, DOI 10.1111/j.1399-6576.1993.tb03744.x; HAMUNEN K, 1993, PHARMACOL TOXICOL, V73, P120, DOI 10.1111/j.1600-0773.1993.tb01547.x; HANSEN DD, 1986, ANESTH ANALG, V65, P127; HENDERSON K, 1993, J CLIN ANESTH, V5, P129, DOI 10.1016/0952-8180(93)90140-A; Henthorn TK, 1999, J PHARMACOL EXP THER, V289, P1084; HERMANN C, 1995, PAIN, V60, P239, DOI 10.1016/0304-3959(94)00210-6; Hershey AD, 2000, HEADACHE, V40, P539, DOI 10.1046/j.1526-4610.2000.00085.x; HERTZKA RE, 1989, ANESTHESIOLOGY, V70, P213, DOI 10.1097/00000542-198902000-00006; Hunt A, 1999, J PEDIATR-US, V135, P47, DOI 10.1016/S0022-3476(99)70326-4; Ivani G, 1998, PAEDIATR ANAESTH, V8, P127, DOI 10.1046/j.1460-9592.1998.00246.x; Jacobson SJ, 1997, LANCET, V350, P1358, DOI 10.1016/S0140-6736(97)08462-6; JAY S, 1995, PAIN, V62, P3, DOI 10.1016/0304-3959(94)00216-2; Kart T, 1997, PAEDIATR ANAESTH, V7, P5, DOI 10.1046/j.1460-9592.1997.d01-30.x; KatzSalamon M, 1996, ARCH DIS CHILD-FETAL, V75, pF4, DOI 10.1136/fn.75.1.F4; KLIMACH VJ, 1988, DEV MED CHILD NEUROL, V30, P208; Kohane DS, 1998, ANESTHESIOLOGY, V89, P1199, DOI 10.1097/00000542-199811000-00021; KOREN G, 1985, J PEDIATR-US, V107, P963, DOI 10.1016/S0022-3476(85)80205-5; Kozer E, 2002, NEW ENGL J MED, V346, P1175, DOI 10.1056/NEJM200204113461518; KRANE EJ, 1995, J PAIN SYMPTOM MANAG, V10, P21, DOI 10.1016/0885-3924(94)00062-P; KRANE EJ, 1987, ANESTH ANALG, V66, P647; Lander J, 1997, JAMA-J AM MED ASSOC, V278, P2157, DOI 10.1001/jama.278.24.2157; Larsson BA, 1997, ANESTH ANALG, V84, P501, DOI 10.1097/00000539-199703000-00006; LAWSON RA, 1995, BRIT J ANAESTH, V75, P282, DOI 10.1093/bja/75.3.282; Lee BH, 2002, J PEDIATR-US, V141, P135, DOI 10.1067/mpd.2002.124380; Lesko SM, 1999, PEDIATRICS, V104, part. no., DOI 10.1542/peds.104.4.e39; Lichtor JL, 1999, ANESTH ANALG, V89, P732, DOI 10.1097/00000539-199909000-00038; Lin YC, 1997, PAEDIATR ANAESTH, V7, P457, DOI 10.1046/j.1460-9592.1997.d01-126.x; LIPPMANN M, 1976, BRIT J ANAESTH, V48, P365, DOI 10.1093/bja/48.4.365; LUTSCHG J, 1990, SCHWEIZ MED WSCHR, V120, P1731; LYNN AM, 1993, ANESTH ANALG, V77, P695; Martin RJ, 1998, J PEDIATR-US, V132, P960, DOI 10.1016/S0022-3476(98)70391-9; MAUNUKSELA EL, 1986, BRIT J ANAESTH, V58, P1242, DOI 10.1093/bja/58.11.1242; MAZOIT JX, 1988, ANESTHESIOLOGY, V68, P387, DOI 10.1097/00000542-198803000-00011; McGrath P, 1996, PAIN, V64, P435, DOI 10.1016/0304-3959(95)00171-9; MCGRATH PJ, 1985, ADV PAIN RES THER, V9, P395; McNeely JK, 1997, J PAIN SYMPTOM MANAG, V13, P268, DOI 10.1016/S0885-3924(96)00324-7; McQuay H. J., 1998, EVIDENCE BASED RESOU, P94; MISER AW, 1983, AM J DIS CHILD, V137, P383, DOI 10.1001/archpedi.1983.02140300061017; Monitto CL, 2000, ANESTH ANALG, V91, P573, DOI 10.1213/00000539-200009000-00014; MURRELL D, 1993, J PEDIATR SURG, V28, P548, DOI 10.1016/0022-3468(93)90614-Q; Needleman P, 1997, J RHEUMATOL, V24, P6; OLKKOLA KT, 1988, CLIN PHARMACOL THER, V44, P128, DOI 10.1038/clpt.1988.127; OLKKOLA KT, 1991, BRIT J CLIN PHARMACO, V31, P182, DOI 10.1111/j.1365-2125.1991.tb05510.x; OLNESS K, 1987, PEDIATRICS, V79, P593; Pasquale G, 1993, Drugs, V46 Suppl 1, P234; Pickering AE, 2002, BRIT J ANAESTH, V88, P72, DOI 10.1093/bja/88.1.72; PURCELLJONES G, 1987, ANAESTHESIA, V42, P1316, DOI 10.1111/j.1365-2044.1987.tb05283.x; RACKOW H, 1961, PEDIATRICS, V28, P697; Ripamonti C, 1998, ANN ONCOL, V9, P79, DOI 10.1023/A:1008263910494; ROBINSON S, 1981, ANESTH ANALG, V60, P331; Rowbotham M, 1998, JAMA-J AM MED ASSOC, V280, P1837, DOI 10.1001/jama.280.21.1837; RUSY LM, 1995, ANESTH ANALG, V80, P226, DOI 10.1097/00000539-199502000-00004; Saarenmaa E, 1999, J PEDIATR-US, V134, P144, DOI 10.1016/S0022-3476(99)70407-5; Santeiro M L, 1997, J Perinatol, V17, P135; Sartory G, 1998, BEHAV RES THER, V36, P1155, DOI 10.1016/S0005-7967(98)00081-3; SCHACHTEL BP, 1993, CLIN PHARMACOL THER, V53, P593, DOI 10.1038/clpt.1993.75; SCHECHTER NL, 1986, PEDIATRICS, V77, P11; SCHECHTER NL, 1995, PEDIATRICS, V95, P335; Schechter NL, 1997, PEDIATRICS, V99, P890, DOI 10.1542/peds.99.6.890; SHAFER SL, 1991, ANESTHESIOLOGY, V74, P53, DOI 10.1097/00000542-199101000-00010; SHAPIRO BS, 1995, PAIN, V61, P139, DOI 10.1016/0304-3959(94)00164-A; SHOAF SE, 1987, DRUG METAB DISPOS, V15, P676; Sindrup SH, 1999, PAIN, V83, P389, DOI 10.1016/S0304-3959(99)00154-2; Smith GA, 1997, PEDIATRICS, V100, P825, DOI 10.1542/peds.100.5.825; Stevens B, 1996, CLIN J PAIN, V12, P13, DOI 10.1097/00002508-199603000-00004; Taddio A, 1997, LANCET, V349, P599, DOI 10.1016/S0140-6736(96)10316-0; TRUJILLO KA, 1991, SCIENCE, V251, P85, DOI 10.1126/science.1824728; TYLER DC, 1995, ANESTH ANALG, V80, P14, DOI 10.1097/00000539-199501000-00004; vandenAnker JN, 1996, ACTA PAEDIATR, V85, P1393, DOI 10.1111/j.1651-2227.1996.tb13942.x; Vaughn PR, 1996, J PEDIATR SURG, V31, P1616, DOI 10.1016/S0022-3468(96)90033-0; VETTER TR, 1994, J CLIN ANESTH, V6, P110, DOI 10.1016/0952-8180(94)90006-X; VETTER TR, 1992, J PAIN SYMPTOM MANAG, V7, P204, DOI 10.1016/0885-3924(92)90076-T; WALCO GA, 1994, NEW ENGL J MED, V331, P541, DOI 10.1056/NEJM199408253310812; Weisman SJ, 1998, ARCH PEDIAT ADOL MED, V152, P147; WHO, 1998, CANC PAIN REL PALL C; Winner P, 2000, PEDIATRICS, V106, P989, DOI 10.1542/peds.106.5.989; WOLF AR, 1993, BRIT J ANAESTH, V70, P10, DOI 10.1093/bja/70.1.10; WOLF AR, 1993, BRIT J ANAESTH, V70, P654, DOI 10.1093/bja/70.6.654; Wolfe J, 2000, NEW ENGL J MED, V342, P326, DOI 10.1056/NEJM200002033420506; Wong D L, 1988, Pediatr Nurs, V14, P9	132	217	226	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 3	2002	347	14					1094	1103		10.1056/NEJMra012626	http://dx.doi.org/10.1056/NEJMra012626			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	599KD	12362012				2022-12-28	WOS:000178332900009
J	Lasonder, E; Ishihama, Y; Andersen, JS; Vermunt, AMW; Pain, A; Sauerwein, RW; Eling, WMC; Hall, N; Waters, AP; Stunnenberg, HG; Mann, M				Lasonder, E; Ishihama, Y; Andersen, JS; Vermunt, AMW; Pain, A; Sauerwein, RW; Eling, WMC; Hall, N; Waters, AP; Stunnenberg, HG; Mann, M			Analysis of the Plasmodium falciparum proteome by high-accuracy mass spectrometry	NATURE			English	Article							PROTEINS; IDENTIFICATION; SEQUENCE; ANTIGEN; EXPRESSION; CLONING	The annotated genomes of organisms define a 'blueprint' of their possible gene products. Post-genome analyses attempt to confirm and modify the annotation and impose a sense of the spatial, temporal and developmental usage of genetic information by the organism. Here we describe a large-scale, high-accuracy (average deviation less than 0.02 Da at 1,000 Da) mass spectrometric proteome analysis(1-3) of selected stages of the human malaria parasite Plasmodium falciparum. The analysis revealed 1,289 proteins of which 714 proteins were identified in asexual blood stages, 931 in gametocytes and 645 in gametes. The last two groups provide insights into the biology of the sexual stages of the parasite, and include conserved, stage-specific, secreted and membrane-associated proteins. A subset of these proteins contain domains that indicate a role in cell-cell interactions, and therefore can be evaluated as potential components of a malaria vaccine formulation. We also report a set of peptides with significant matches in the parasite genome but not in the protein set predicted by computational methods.	Univ Nijmegen, Dept Mol Biol, NCMLS, NL-6525 GA Nijmegen, Netherlands; Univ So Denmark, Ctr Expt Bioinformat, Dept Biochem & Mol Biol, DK-5230 Odense M, Denmark; Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England; Univ Med Ctr, Dept Med Microbiol, NCMLS, NL-6500 HB Nijmegen, Netherlands; Leiden Univ, Leiden Malaria Res Grp, Med Ctr, Dept Parasitol, Ctr Infect Dis, NL-2333 ZA Leiden, Netherlands	Radboud University Nijmegen; University of Southern Denmark; Wellcome Trust Sanger Institute; Radboud University Nijmegen; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Stunnenberg, HG (corresponding author), Univ Nijmegen, Dept Mol Biol, NCMLS, Geert Grooteplein 26, NL-6525 GA Nijmegen, Netherlands.	h.stunnenberg@ncmls.kun.nl; mann@bmb.sdu.dk	Ishihama, Yasushi/B-3101-2016; Hall, Neil/A-8717-2013; Stunnenberg, Hendrik G./D-6875-2012; Waters, Andy P/C-9377-2009; Mann, Matthias/A-3454-2013; Sauerwein, Robert/C-8519-2013; Pain, Arnab/L-5766-2015; Andersen, Jens S/L-2100-2015	Ishihama, Yasushi/0000-0001-7714-203X; Hall, Neil/0000-0002-7995-3810; Stunnenberg, Hendrik G./0000-0002-0066-1576; Waters, Andy P/0000-0001-8900-2982; Mann, Matthias/0000-0003-1292-4799; Pain, Arnab/0000-0002-1755-2819; Andersen, Jens S/0000-0002-6091-140X; Lasonder, Edwin/0000-0003-2582-3444				Alano P, 1995, MOL BIOCHEM PARASIT, V74, P143, DOI 10.1016/0166-6851(95)02491-3; Brooks SR, 2000, MOL BIOCHEM PARASIT, V106, P77, DOI 10.1016/S0166-6851(99)00201-7; BRUCE MC, 1990, PARASITOLOGY, V100, P191, DOI 10.1017/S0031182000061199; Cowman AF, 2000, FEBS LETT, V476, P84, DOI 10.1016/S0014-5793(00)01703-8; Delrieu I, 2002, MOL BIOCHEM PARASIT, V121, P11, DOI 10.1016/S0166-6851(02)00016-6; Fowler RE, 2001, MOL BIOCHEM PARASIT, V117, P187, DOI 10.1016/S0166-6851(01)00351-6; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Griffin TJ, 2001, J BIOL CHEM, V276, P45497, DOI 10.1074/jbc.R100014200; KOCKEN CHM, 1993, MOL BIOCHEM PARASIT, V61, P59, DOI 10.1016/0166-6851(93)90158-T; Kuster B, 2001, PROTEOMICS, V1, P641; Link AJ, 1999, NAT BIOTECHNOL, V17, P676, DOI 10.1038/10890; Pandey A, 2000, NATURE, V405, P837, DOI 10.1038/35015709; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Rahlfs S, 2001, J BIOL CHEM, V276, P37133, DOI 10.1074/jbc.M105524200; Rappsilber J, 2002, GENOME RES, V12, P1231, DOI 10.1101/gr.473902; Richie TL, 2002, NATURE, V415, P694, DOI 10.1038/415694a; Rutherford K, 2000, BIOINFORMATICS, V16, P944, DOI 10.1093/bioinformatics/16.10.944; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Templeton TJ, 1998, J EXP MED, V187, P1599, DOI 10.1084/jem.187.10.1599; van Dijk MR, 2001, CELL, V104, P153, DOI 10.1016/S0092-8674(01)00199-4; Wickham ME, 2001, EMBO J, V20, P5636, DOI 10.1093/emboj/20.20.5636	22	517	544	4	39	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 3	2002	419	6906					537	542		10.1038/nature01111	http://dx.doi.org/10.1038/nature01111			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	599RF	12368870				2022-12-28	WOS:000178348400051
J	Piantadosi, CA				Piantadosi, CA			Perspective - Carbon monoxide poisoning	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Duke Univ, Med Ctr, Durham, NC 27710 USA	Duke University	Piantadosi, CA (corresponding author), Duke Univ, Med Ctr, Durham, NC 27710 USA.								0	75	79	0	4	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 3	2002	347	14					1054	1055		10.1056/NEJMp020104	http://dx.doi.org/10.1056/NEJMp020104			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	599KD	12362005				2022-12-28	WOS:000178332900001
J	Luo, RF				Luo, RF			Understanding the threat of HIV/AIDS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA	Johns Hopkins University	Luo, RF (corresponding author), Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA.							De Cock KM, 2002, JAMA-J AM MED ASSOC, V288, P236, DOI 10.1001/jama.288.2.236; HSU L, 2001, HIV SUBVERTS NATL SE; Piot P, 2001, NATURE, V410, P968, DOI 10.1038/35073639; PIOT P, 2001, COMMUNICATION   0902; PIOT P, 2002, 14 INT AIDS C JUL 7; *UN POP DIV JOINT, 1998, TECHN M NOV 10 NEW Y; *US GOV NAT INT CO, 2000, GLOB INF DIS THREAT; 2000, NATURE, V405, P9	8	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	2002	288	13					1649	1649		10.1001/jama.288.13.1649	http://dx.doi.org/10.1001/jama.288.13.1649			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	599BJ	12350199	hybrid			2022-12-28	WOS:000178314000028
J	Paice, E; Heard, S; Moss, F				Paice, E; Heard, S; Moss, F			How important are role models in making good doctors?	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CLINICAL TEACHERS; PERCEPTIONS; THEMSELVES; CLERKS	The use of teaching staff as role models for professional behaviour has long been an informal part of medical training. The authors consider whether role models can still be an effective means of imparting professional values, attitudes, and behaviours in a health service that is increasingly sensitive to society's expectations.	London Postgrad Med & Dent Educ, London WC1N 1DZ, England		Paice, E (corresponding author), London Postgrad Med & Dent Educ, London WC1N 1DZ, England.	epaice@londendeanery.ac.uk						ALLEN I, 1997, COMMITTED CRITICAL E; Ambrozy DM, 1997, ACAD MED, V72, P1119, DOI 10.1097/00001888-199712000-00028; Barondess JA, 1997, J ROY SOC MED, V90, P347, DOI 10.1177/014107689709000617; Beaudoin C, 1998, CAN MED ASSOC J, V159, P765; CHRISTAKIS NA, 1995, JAMA-J AM MED ASSOC, V274, P706, DOI 10.1001/jama.274.9.706; Cote L, 2000, ACAD MED, V75, P1117, DOI 10.1097/00001888-200011000-00020; FEUDTNER C, 1994, ACAD MED, V69, P670, DOI 10.1097/00001888-199408000-00017; HEARD SR, 2001, QUAL HLTH CARE S2, V10, pS70; Kushner T. K., 2001, WARD ETHICS DILEMMAS; LUBLIN JR, 1992, MED EDUC, V26, P116, DOI 10.1111/j.1365-2923.1992.tb00136.x; MCMURRAY JE, 1993, ANN INTERN MED, V119, P812, DOI 10.7326/0003-4819-119-8-199310150-00007; Paice E, 2002, MED EDUC, V36, P26, DOI 10.1046/j.1365-2923.2002.01100.x; Sachdeva A K, 1996, J Cancer Educ, V11, P131; SINCLAIR S., 1997, MAKING DOCTORS I APP; Swick HM, 1999, JAMA-J AM MED ASSOC, V282, P830, DOI 10.1001/jama.282.9.830; Wear D, 1998, ANN INTERN MED, V129, P734, DOI 10.7326/0003-4819-129-9-199811010-00010; Whitehouse Andrew, 2002, BMJ, V325, pS55, DOI 10.1136/bmj.325.7360.S55; Wright S, 1997, J GEN INTERN MED, V12, P53, DOI 10.1007/s11606-006-0007-1; Wright S, 1996, ACAD MED, V71, P290, DOI 10.1097/00001888-199603000-00024; Wright SM, 1998, NEW ENGL J MED, V339, P1986, DOI 10.1056/NEJM199812313392706	20	239	254	2	25	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 28	2002	325	7366					707	710		10.1136/bmj.325.7366.707	http://dx.doi.org/10.1136/bmj.325.7366.707			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	600JV	12351368	Green Published			2022-12-28	WOS:000178387600033
J	Regev, A; Shapiro, E				Regev, A; Shapiro, E			Cellular abstractions: Cells as computation	NATURE			English	Editorial Material									Weizmann Inst Sci, Dept Comp Sci & Appl Math, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Regev, A (corresponding author), Weizmann Inst Sci, Dept Comp Sci & Appl Math, IL-76100 Rehovot, Israel.				European Research Council [233047] Funding Source: Medline	European Research Council(European Research Council (ERC)European Commission)		Fontana W, 1996, BOUNDARIES BARRIERS, P55; Milner R., 2000, COMMUNICATING MOBILE	2	195	199	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 26	2002	419	6905					343	343		10.1038/419343a	http://dx.doi.org/10.1038/419343a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	596ZB	12353013	Green Accepted			2022-12-28	WOS:000178195400023
J	Dweik, RA				Dweik, RA			Pulmonary hypertension and the search for the selective pulmonary vasodilator	LANCET			English	Editorial Material							NITRIC-OXIDE; INHALED ILOPROST; ORAL SILDENAFIL; LUNG		Cleveland Clin Fdn, Dept Pulm & Crit Care Med, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Dweik, RA (corresponding author), Cleveland Clin Fdn, Dept Pulm & Crit Care Med, 9500 Euclid Ave, Cleveland, OH 44195 USA.	dweikr@ccf.org						Arroliga AC, 2000, CLEV CLIN J MED, V67, P175, DOI 10.3949/ccjm.67.3.175; Channick RN, 1996, CHEST, V109, P1545, DOI 10.1378/chest.109.6.1545; DALONZO GE, 1991, ANN INTERN MED, V115, P343, DOI 10.7326/0003-4819-115-5-343; Dweik RA, 1998, J CLIN INVEST, V101, P660, DOI 10.1172/JCI1378; Ghofrani HA, 2002, ANN INTERN MED, V136, P515, DOI 10.7326/0003-4819-136-7-200204020-00008; GUSTAFSSON LE, 1991, BIOCHEM BIOPH RES CO, V181, P852, DOI 10.1016/0006-291X(91)91268-H; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; Kaneko FT, 1998, AM J RESP CRIT CARE, V158, P917, DOI 10.1164/ajrccm.158.3.9802066; KOBZIK L, 1993, AM J RESP CELL MOL, V9, P371, DOI 10.1165/ajrcmb/9.4.371; LUNDBERG JON, 1995, NAT MED, V1, P370, DOI 10.1038/nm0495-370; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; Ozkan M, 2001, LUNG, V179, P233, DOI 10.1007/s004080000064; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Rubin LJ, 1997, NEW ENGL J MED, V336, P111, DOI 10.1056/NEJM199701093360207; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; Wilkens H, 2001, CIRCULATION, V104, P1218, DOI 10.1161/hc3601.096826; Zhao L, 2001, CIRCULATION, V104, P424, DOI 10.1161/hc2901.093117	18	18	20	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 21	2002	360	9337					886	887		10.1016/S0140-6736(02)11067-1	http://dx.doi.org/10.1016/S0140-6736(02)11067-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	596AU	12354465				2022-12-28	WOS:000178142200002
J	Teklehaimanot, A; Snow, RW				Teklehaimanot, A; Snow, RW			Will the Global Fund help roll back malaria in Africa?	LANCET			English	Editorial Material									Columbia Univ, Ctr Global Hlth & Econ Dev, New York, NY 10002 USA; KEMRI Wellcome Trust Collaborat Program, Nairobi, Kenya; Univ Oxford, Ctr Trop Med, Oxford OX1 2JD, England	Columbia University; University of Oxford	Teklehaimanot, A (corresponding author), Columbia Univ, Ctr Global Hlth & Econ Dev, New York, NY 10002 USA.		Snow, Robert William/AFR-1436-2022	Snow, Robert William/0000-0003-3725-6088				[Anonymous], 2000, GLOB PARTN ROLL BACK; *COMM MACR HLTH, 2002, IMPR HLTH OUTC POOR; Craig MH, 1999, PARASITOL TODAY, V15, P105, DOI 10.1016/S0169-4758(99)01396-4; Deichmann U, 1996, AFRICAN POPULATION D; *GLOB FUND FIGHT A, 2002, TUB MAL; Ramsay S, 2002, LANCET, V359, P1581, DOI 10.1016/S0140-6736(02)08531-8; *UN POP DIV, 2002, WORLD POP PROSP POP	7	19	19	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 21	2002	360	9337					888	889		10.1016/S0140-6736(02)11069-5	http://dx.doi.org/10.1016/S0140-6736(02)11069-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	596AU	12354467				2022-12-28	WOS:000178142200004
J	Nguyen, KB; Watford, WT; Salomon, R; Hofmann, SR; Pien, GC; Morinobu, A; Gadina, M; O'Shea, JJ; Biron, CA				Nguyen, KB; Watford, WT; Salomon, R; Hofmann, SR; Pien, GC; Morinobu, A; Gadina, M; O'Shea, JJ; Biron, CA			Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection	SCIENCE			English	Article							IFN-GAMMA; T-CELLS; NATURAL-KILLER; ANTIVIRAL DEFENSE; GENE-EXPRESSION; I IFNS; ALPHA/BETA; IL-12; INTERLEUKIN-12; REQUIREMENT	Interferons (IFNs) are essential for host defense. Although the antiviral effects of the type 1 IFNs IFN-alpha and IFN-beta (IFN-alpha/beta) have been established, their immunoregulatory functions, especially their ability to regulate IFN-gamma production, are poorly understood. Here we show that IFN-alpha/beta activate STAT4 directly (STAT, signal transducers and activators of transcription) and that this is required for IFN-gamma production during viral infections of mice, in concert with T cell receptor derived signals. In contrast, STAT1 appears to negatively regulate IFN-alpha/beta induction of IFN-gamma. Thus, type 1 IFNs, in addition to interleukin-12, provide pathways for innate regulation of adaptive immunity, and their immunoregulatory functions are controlled by modulating the activity of individual STATs.	Brown Univ, Dept Mol Microbiol & Immunol, Div Biol & Med, Providence, RI 02912 USA; NIAMSD, Mol Immunol & Inflammat Branch, NIH, Bethesda, MD 20892 USA	Brown University; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Biron, CA (corresponding author), Brown Univ, Dept Mol Microbiol & Immunol, Div Biol & Med, Providence, RI 02912 USA.		Gadina, Massimo/R-4195-2019		NATIONAL CANCER INSTITUTE [R01CA041268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041106, ZIAAR041106] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM020760] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA41268] Funding Source: Medline; NIGMS NIH HHS [F31-GM20760-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Avni O, 2002, NAT IMMUNOL, V3, P643, DOI 10.1038/ni808; BACON CM, 1995, J EXP MED, V181, P399, DOI 10.1084/jem.181.1.399; Biron CA, 1999, ANNU REV IMMUNOL, V17, P189, DOI 10.1146/annurev.immunol.17.1.189; Biron CA, 2001, IMMUNITY, V14, P661, DOI 10.1016/S1074-7613(01)00154-6; Butz EA, 1998, IMMUNITY, V8, P167, DOI 10.1016/S1074-7613(00)80469-0; Byrnes AA, 2001, EUR J IMMUNOL, V31, P2026, DOI 10.1002/1521-4141(200107)31:7<2026::AID-IMMU2026>3.3.CO;2-L; Cousens LP, 1999, J EXP MED, V189, P1315, DOI 10.1084/jem.189.8.1315; Cousens LP, 1997, P NATL ACAD SCI USA, V94, P634, DOI 10.1073/pnas.94.2.634; Farrar JD, 2000, NAT IMMUNOL, V1, P65, DOI 10.1038/76932; Farrar JD, 2000, J BIOL CHEM, V275, P2693, DOI 10.1074/jbc.275.4.2693; Gil MP, 2001, P NATL ACAD SCI USA, V98, P6680, DOI 10.1073/pnas.111163898; Kuroda E, 2002, J IMMUNOL, V168, P5477, DOI 10.4049/jimmunol.168.11.5477; Lighvani AA, 2001, P NATL ACAD SCI USA, V98, P15137, DOI 10.1073/pnas.261570598; McRae BL, 1998, J IMMUNOL, V160, P4298; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; Murphy KM, 2000, ANNU REV IMMUNOL, V18, P451, DOI 10.1146/annurev.immunol.18.1.451; Nguyen KB, 2000, NAT IMMUNOL, V1, P70, DOI 10.1038/76940; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Orange JS, 1996, J IMMUNOL, V156, P1138; PIEN GC, UNPUB; Ramana CV, 2000, EMBO J, V19, P263, DOI 10.1093/emboj/19.2.263; Ramana CV, 2001, P NATL ACAD SCI USA, V98, P6674, DOI 10.1073/pnas.111164198; Rogge L, 1998, J IMMUNOL, V161, P6567; Sareneva T, 1998, J IMMUNOL, V160, P6032; Su HC, 1998, J IMMUNOL, V160, P5007; Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0; Wang YJ, 2000, MOL CELL BIOL, V20, P4505, DOI 10.1128/MCB.20.13.4505-4512.2000; Wenner CA, 1996, J IMMUNOL, V156, P1442; Wu CB, 2001, NAT IMMUNOL, V2, P410, DOI 10.1038/87713; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794	30	395	406	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 20	2002	297	5589					2063	2066		10.1126/science.1074900	http://dx.doi.org/10.1126/science.1074900			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	594XV	12242445				2022-12-28	WOS:000178078500050
J	Kinsinger, LS; Harris, R				Kinsinger, LS; Harris, R			Chemoprevention of breast cancer: a promising idea with an uncertain future	LANCET			English	Editorial Material							TAMOXIFEN; MAMMOGRAPHY; PREVENTION; TRIAL		Univ N Carolina, Cecil G Sheps Ctr Hlth Serv Res, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Kinsinger, LS (corresponding author), Univ N Carolina, Cecil G Sheps Ctr Hlth Serv Res, Chapel Hill, NC 27599 USA.	lkins@med.unc.edu						Berg AO, 2002, ANN INTERN MED, V137, P344, DOI 10.7326/0003-4819-137-5_Part_1-200209030-00011; Cummings SR, 2002, JAMA-J AM MED ASSOC, V287, P216, DOI 10.1001/jama.287.2.216; CUMMINGS SR, 1999, JAMA-J AM MED ASSOC, V281, P189; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Goodman SN, 2002, ANN INTERN MED, V137, P363, DOI 10.7326/0003-4819-137-5_Part_1-200209030-00015; Kinsinger LS, 2002, ANN INTERN MED, V137, P59, DOI 10.7326/0003-4819-137-1-200207020-00017; Miller AB, 2002, ANN INTERN MED, V137, P305, DOI 10.7326/0003-4819-137-5_Part_1-200209030-00005; Olsen O, 2001, LANCET, V358, P1340, DOI 10.1016/S0140-6736(01)06449-2; Powles T, 1998, LANCET, V352, P98; Rockhill B, 2001, AM J PUBLIC HEALTH, V91, P365, DOI 10.2105/AJPH.91.3.365; Veronesi U, 1998, LANCET, V352, P93; Veronesi U, 2002, LANCET, V359, P1122, DOI 10.1016/S0140-6736(02)08159-X	12	1	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 14	2002	360	9336					813	814		10.1016/S0140-6736(02)11009-9	http://dx.doi.org/10.1016/S0140-6736(02)11009-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	594MC	12243912				2022-12-28	WOS:000178053500003
J	Packman, A; Onslow, M				Packman, A; Onslow, M			Searching for the cause of stuttering	LANCET			English	Editorial Material									Univ Sydney, Australian Stuttering Res Ctr, Lidcombe, NSW 1825, Australia	University of Sydney	Packman, A (corresponding author), Univ Sydney, Australian Stuttering Res Ctr, Lidcombe, NSW 1825, Australia.			Onslow, Mark/0000-0003-2629-2390; Packman, Ann/0000-0001-7378-326X				Bloodstein O., 1995, HDB STUTTERING; Bloodstein O., 1993, STUTTERING SEARCH CA; Foundas AL, 2001, NEUROLOGY, V57, P207, DOI 10.1212/WNL.57.2.207; Ingham RJ, 2001, J COMMUN DISORD, V34, P493, DOI 10.1016/S0021-9924(01)00061-2; Ingham RJ, 1996, J SPEECH HEAR RES, V39, P1208, DOI 10.1044/jshr.3906.1208; INGHAM RJ, IN PRESS EVIDENCE BA; Packman A, 1996, CLIN LINGUIST PHONET, V10, P235, DOI 10.3109/02699209608985174; Sommer M, 2002, LANCET, V360, P380, DOI 10.1016/S0140-6736(02)09610-1	8	17	17	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 31	2002	360	9334					655	656		10.1016/S0140-6736(02)09880-X	http://dx.doi.org/10.1016/S0140-6736(02)09880-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	590AM	12241868				2022-12-28	WOS:000177795100003
J	John, TJ; Abel, R				John, TJ; Abel, R			Sustainable development and health: an Indian perspective	LANCET			English	Editorial Material									Christian Med Coll & Hosp, Vellore 632004, Tamil Nadu, India	Christian Medical College & Hospital (CMCH) Vellore	John, TJ (corresponding author), Christian Med Coll & Hosp, Vellore 632004, Tamil Nadu, India.							CHENGAPPA R, 2002, INDIA TODAY, V27, P38; *INT I POP SCI, 2000, IND NAT FAM HLTH SUR, P178; *MIN INF BROAD, 2000, IND 1999 A REF MAN, P242; SOHONI NK, 1994, REACHING INDIAS POOR, P148; WALSH JA, 1979, NEW ENGL J MED, V301, P967, DOI 10.1056/NEJM197911013011804; Walsh Julia A., 1986, STRATEGIES PRIMARY H; WHO, 2002, MACR HLTH INV HLTH E; *WHO UN CHILDR FUN, 1978, PRIM HLTH CAR; 2002, HINDU           0615, P13; 2002, HINDU           0518, P6	10	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 24	2002	360	9333					638	639		10.1016/S0140-6736(02)09778-7	http://dx.doi.org/10.1016/S0140-6736(02)09778-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	586TD	12241951				2022-12-28	WOS:000177600400028
J	Mason, S; Tovey, P; Long, AF				Mason, S; Tovey, P; Long, AF			Evaluating complementary challenges of randomised medicine: methodological controlled trials	BRITISH MEDICAL JOURNAL			English	Article							ALTERNATIVE MEDICINE; THERAPY		Univ Leeds, No & Yorkshire Clin Trials & Res Unit, Acad Unit Epidemiol & Hlth Serv Res, Leeds LS2 9NG, W Yorkshire, England; Univ Leeds, Sch Healthcare Studies, Leeds LS2 9NG, W Yorkshire, England; Univ Salford, Hlth Care Practice Res & Dev Unit, Salford M5 4WT, Lancs, England	University of Leeds; University of Leeds; University of Salford	Mason, S (corresponding author), Univ Leeds, No & Yorkshire Clin Trials & Res Unit, Acad Unit Epidemiol & Hlth Serv Res, Leeds LS2 9NG, W Yorkshire, England.							Angell M, 1998, NEW ENGL J MED, V339, P839, DOI 10.1056/NEJM199809173391210; BORKOVEC TD, 1972, J BEHAV THER EXP PSY, V3, P257, DOI 10.1016/0005-7916(72)90045-6; BROWN C, 1998, OPTIMUM HEALING LIFE; Brown CK, 2000, J ALTERN COMPLEM MED, V6, P171, DOI 10.1089/acm.2000.6.171; Cornbleet MA, 2001, BRIT MED J, V322, P736, DOI 10.1136/bmj.322.7288.736; *HOUS LORDS SEL CO, 2000, COMPL ALT MED; Long AF, 2000, COMPLEMENT THER MED, V8, P26, DOI 10.1016/S0965-2299(00)90807-0; Long AF, 1999, J CONT HLTH, V8, P13; *MED RES COUNC, 2000, FRAM DEV EV RCTS COM; Morley S, 1999, PAIN, V80, P1, DOI 10.1016/S0304-3959(98)00255-3; Nahin RL, 2001, BRIT MED J, V322, P161, DOI 10.1136/bmj.322.7279.161; Rees L, 2001, BMJ-BRIT MED J, V322, P119, DOI 10.1136/bmj.322.7279.119; Stevinson C, 2001, DESKTOP GUIDE COMPLE; White A., 2001, DESKTOP GUIDE COMPLE; WRIGHT S, 2001, NURSES HDB COMPLEMEN	15	88	90	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 12	2002	325	7368					832	834		10.1136/bmj.325.7368.832	http://dx.doi.org/10.1136/bmj.325.7368.832			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604YM	12376448	Green Published, Green Accepted			2022-12-28	WOS:000178648700026
J	Zhang, J; Huang, WD; Chua, SS; Wei, P; Moore, DD				Zhang, J; Huang, WD; Chua, SS; Wei, P; Moore, DD			Modulation of acetaminophen-induced hepatotoxicity by the xenobiotic receptor CAR	SCIENCE			English	Article							NUCLEAR TRANSLOCATION; MEDIATED INCREASES; MOUSE-LIVER; CYP2B GENE; MICE; POTENTIATION; GLUTATHIONE; ACTIVATION; INDUCTION; TOXICITY	We have identified the xenobiotic receptor CAR (constitutive androstane receptor) as a key regulator of acetaminophen metabolism and hepatotoxicity. Known CAR activators as well as high doses of acetaminophen induced expression of three acetaminophen-metabolizing enzymes in wild-type but not in CAR null mice, and the CAR null mice were resistant to acetaminophen toxicity. Inhibition of CAR activity by administration of the inverse agonist ligand androstanol 1 hour after acetaminophen treatment blocked hepatotoxicity in wild type but not in CAR null mice. These results suggest an innovative therapeutic approach for treating the adverse effects of acetaminophen and potentially other hepatotoxic agents.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine	Moore, DD (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046546] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK46546] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARNAIZ SL, 1995, FREE RADICAL BIO MED, V19, P303, DOI 10.1016/0891-5849(95)00023-Q; BURK RF, 1990, RES COMMUN CHEM PATH, V69, P115; COLES B, 1988, ARCH BIOCHEM BIOPHYS, V264, P253, DOI 10.1016/0003-9861(88)90592-9; CORCORAN GB, 1985, J PHARMACOL EXP THER, V232, P864; Forman BM, 1998, NATURE, V395, P612, DOI 10.1038/26996; Gill RQ, 2001, J CLIN GASTROENTEROL, V33, P191, DOI 10.1097/00004836-200109000-00005; Henderson CJ, 2000, P NATL ACAD SCI USA, V97, P12741, DOI 10.1073/pnas.220176997; HINSON JA, 1990, LANCET, V335, P732, DOI 10.1016/0140-6736(90)90851-U; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; Kawamoto T, 1999, MOL CELL BIOL, V19, P6318; Kostrubsky VE, 1997, TOXICOL APPL PHARM, V143, P315, DOI 10.1006/taap.1996.8081; MINTON NA, 1988, HUM TOXICOL, V7, P33, DOI 10.1177/096032718800700106; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; PATTEN CJ, 1993, CHEM RES TOXICOL, V6, P511, DOI 10.1021/tx00034a019; PIROTTE JH, 1984, ANN INTERN MED, V101, P403, DOI 10.7326/0003-4819-101-3-403_1; PRESCOTT LF, 1983, DRUGS, V25, P290, DOI 10.2165/00003495-198325030-00002; PRESCOTT LF, 1983, ANNU REV PHARMACOL, V23, P87, DOI 10.1146/annurev.pa.23.040183.000511; RAUCY JL, 1989, ARCH BIOCHEM BIOPHYS, V271, P270, DOI 10.1016/0003-9861(89)90278-6; Rogers LK, 1997, CHEM RES TOXICOL, V10, P470, DOI 10.1021/tx960159i; Sinclair J, 1998, BIOCHEM PHARMACOL, V55, P1557; SNAWDER JE, 1994, BIOCHEM BIOPH RES CO, V203, P532, DOI 10.1006/bbrc.1994.2215; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; THUMMEL KE, 1993, BIOCHEM PHARMACOL, V45, P1563, DOI 10.1016/0006-2952(93)90295-8; Tzameli I, 2000, MOL CELL BIOL, V20, P2951, DOI 10.1128/MCB.20.9.2951-2958.2000; Wei P., 2002, Pharmacogenomics Journal, V2, P117, DOI 10.1038/sj.tpj.6500087; Wei P, 2000, NATURE, V407, P920, DOI 10.1038/35038112; WILSON JT, 1978, AM J DIS CHILD, V132, P466, DOI 10.1001/archpedi.1978.02120300026004; Xie W, 2000, NATURE, V406, P435, DOI 10.1038/35019116; Zelko I, 2001, MOL CELL BIOL, V21, P2838, DOI 10.1128/MCB.21.8.2838-2846.2001	29	253	266	2	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 11	2002	298	5592					422	424		10.1126/science.1073502	http://dx.doi.org/10.1126/science.1073502			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	602NB	12376703				2022-12-28	WOS:000178510400051
J	Small, KM; Wagoner, LE; Levin, AM; Kardia, SLR; Liggett, SB				Small, KM; Wagoner, LE; Levin, AM; Kardia, SLR; Liggett, SB			Synergistic polymorphisms of beta(1)- and alpha(2C)-adrenergic receptors and the risk of congestive heart failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUPPRESSING SYMPATHETIC ACTIVATION; HUMAN BETA(1)-ADRENERGIC RECEPTOR; ADRENERGIC-RECEPTORS; VENTRICULAR ARRHYTHMIAS; TRANSGENIC MICE; CLONIDINE; HYPERTROPHY; BLOCKERS	Background: Sustained cardiac adrenergic stimulation has been implicated in the development and progression of heart failure. Release of norepinephrine is controlled by negative feedback from presynaptic (alpha)(sub 2)-adrenergic receptors, and the targets of the released norepinephrine on myocytes are (beta)(sub 1)-adrenergic receptors. In transfected cells, a polymorphic (alpha)(sub 2C)-adrenergic receptor ((alpha)(sub 2C)Del322-325) has decreased function, and a variant of the (beta)(sub 1)-adrenergic receptor ((beta)(sub 1)Arg389) has increased function. We hypothesized that this combination of receptor variants, which results in increased synaptic norepinephrine release and enhanced receptor function at the myocyte, would predispose persons to heart failure. Methods: Genotyping at these loci was performed in 159 patients with heart failure and 189 controls. Logistic-regression methods were used to determine the potential effect of each genotype and the interaction between them on the risk of heart failure. Results: Among black subjects, the adjusted odds ratio for heart failure among persons who were homozygous for (alpha)(sub 2C)Del322-325 as compared with those with the other (alpha)(sub 2C)-adrenergic receptor genotypes was 5.65 (95 percent confidence interval, 2.67 to 11.95; P<0.001). There was no increase in risk with (beta)(sub 1)Arg389 alone. However, there was a marked increase in the risk of heart failure among persons who were homozygous for both variants (adjusted odds ratio, 10.11; 95 percent confidence interval, 2.11 to 48.53; P=0.004). The patients with heart failure did not differ from the controls in the frequencies of nine short tandem-repeat alleles. Among white subjects, there were too few who were homozygous for both polymorphisms to allow an adequate assessment of risk. Conclusions: The (alpha)(sub 2C)Del322-325 and (beta)(sub 1)Arg389 receptors act synergistically to increase the risk of heart failure in blacks. Genotyping at these two loci may be a useful approach for identification of persons at risk for heart failure or its progression, who may be candidates for early preventive measures.	Univ Cincinnati, Coll Med, Div Pulm Med, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Div Cardiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Med, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Mol Genet, Cincinnati, OH 45267 USA; Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University of Michigan System; University of Michigan	Liggett, SB (corresponding author), Univ Cincinnati, Coll Med, Div Pulm Med, 231 Albert Sabin Way,ML 0564, Cincinnati, OH 45267 USA.		liggett, stephen b/E-7453-2012	Liggett, Stephen B./0000-0002-0128-3669	NHGRI NIH HHS [HG-00040] Funding Source: Medline; NHLBI NIH HHS [HL-22619, HL-52318] Funding Source: Medline; NIEHS NIH HHS [ES-06096] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL052318, P01HL022619] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aggarwal A, 2001, J AM COLL CARDIOL, V37, P1246, DOI 10.1016/S0735-1097(01)01121-4; Bisognano JD, 2000, J MOL CELL CARDIOL, V32, P817, DOI 10.1006/jmcc.2000.1123; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; Bristow MR, 1998, LANCET, V352, P8; BRISTOW MR, 1989, MOL PHARMACOL, V35, P295; Bristow MR, 2000, J CARD FAIL, V6, P8; COHN JN, 1993, CIRCULATION, V87, P5; Engelhardt S, 1999, P NATL ACAD SCI USA, V96, P7059, DOI 10.1073/pnas.96.12.7059; Friddle CJ, 2000, P NATL ACAD SCI USA, V97, P6745, DOI 10.1073/pnas.100127897; GILES TD, 1981, CLIN PHARMACOL THER, V30, P724, DOI 10.1038/clpt.1981.229; Grassi G, 2001, HYPERTENSION, V38, P286, DOI 10.1161/01.HYP.38.2.286; Hein L, 1999, NATURE, V402, P181, DOI 10.1038/46040; HERMILLER JB, 1983, AM J CARDIOL, V51, P791, DOI 10.1016/S0002-9149(83)80135-0; HOSMER DW, 1989, APPL LOGISTIC REGRES; Liggett SB, 1999, AM J RESP CELL MOL, V21, P564, DOI 10.1165/ajrcmb.21.5.f175; Liggett SB, 2001, J CLIN INVEST, V107, P947, DOI 10.1172/JCI12774; LIGGETT SB, 1989, AM J PHYSIOL, V256, pE600, DOI 10.1152/ajpendo.1989.256.5.E600; MANOLIS AJ, 1995, HYPERTENSION, V26, P719, DOI 10.1161/01.HYP.26.5.719; Mason DA, 1999, J BIOL CHEM, V274, P12670, DOI 10.1074/jbc.274.18.12670; MINATOGUCHI S, 1995, AM HEART J, V130, P516, DOI 10.1016/0002-8703(95)90360-7; Moore MM, 1999, MUTAGENESIS, V14, P271, DOI 10.1093/mutage/14.3.271; Packer M, 1998, EUR HEART J, V19, pB40; PARKER JD, 1995, CIRCULATION, V92, P1793, DOI 10.1161/01.CIR.92.7.1793; Pritchard JK, 1999, AM J HUM GENET, V65, P220, DOI 10.1086/302449; Sacchetti L, 1999, CLIN CHEM, V45, P178; Small KM, 2000, J BIOL CHEM, V275, P23059, DOI 10.1074/jbc.M000796200; Small KM, 2002, METHOD ENZYMOL, V343, P459; van Campen LCMC, 1998, J CARDIOVASC PHARM, V32, pS31, DOI 10.1097/00005344-199806321-00006; Zhang YH, 1998, INT J CARDIOL, V65, P233, DOI 10.1016/S0167-5273(98)00127-2	29	403	422	0	8	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 10	2002	347	15					1135	1142		10.1056/NEJMoa020803	http://dx.doi.org/10.1056/NEJMoa020803			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	601TW	12374873	Bronze			2022-12-28	WOS:000178465100003
J	Hurley, SM; Dermota, TE; Hydutsky, DP; Castleman, AW				Hurley, SM; Dermota, TE; Hydutsky, DP; Castleman, AW			Dynamics of hydrogen bromide dissolution in the ground and excited states	SCIENCE			English	Article							ACID IONIZATION; WATER CLUSTER; HBR; SPECTROSCOPY; SURFACES; HALIDES; IONS; HCL	The dissolution of acids is one of the most fundamental solvation processes, and an important issue is the nature of the hydration complex resulting in ion pair formation. We used femtosecond pump-probe spectroscopy to show that five water molecules are necessary for complete dissolution of a hydrogen bromide molecule to form the contact ion pair H+.Br-(H2O)(n) in the electronic ground state. In smaller mixed clusters (n < 5), the ion pair formation can be photoinduced by electronic excitation.	Penn State Univ, Dept Chem, University Pk, PA 16802 USA; Penn State Univ, Dept Phys, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Castleman, AW (corresponding author), Penn State Univ, Dept Chem, University Pk, PA 16802 USA.							Al-Halabi A, 2002, J PHYS CHEM A, V106, P7639, DOI 10.1021/jp020384a; Ando K, 1997, J PHYS CHEM B, V101, P10464, DOI 10.1021/jp970173j; BREEN JJ, 1989, J CHEM PHYS, V90, P11, DOI 10.1063/1.456517; CHAPMAN DA, 1987, CHEM PHYS, V118, P333, DOI 10.1016/0301-0104(87)85068-1; Conley C, 1999, CHEM PHYS LETT, V301, P29, DOI 10.1016/S0009-2614(99)00018-4; Dedonder-Lardeux C, 2000, CHEM REV, V100, P4023, DOI 10.1021/cr990059s; Gertner BJ, 1999, ISR J CHEM, V39, P273; Gilligan JJ, 2001, J PHYS CHEM A, V105, P5601, DOI 10.1021/jp003480p; Hurley SM, 2000, J CHEM PHYS, V112, P4644, DOI 10.1063/1.481019; HURLEY SM, UNPUB; Kvaran A, 2000, J CHEM PHYS, V112, P10811, DOI 10.1063/1.481725; Kvaran A, 1998, J CHEM PHYS, V109, P5856, DOI 10.1063/1.477208; NEE JB, 1986, J CHEM PHYS, V85, P4919, DOI 10.1063/1.451728; Poth L, 1996, INT J MASS SPECTROM, V154, P35, DOI 10.1016/0168-1176(96)04371-6; Robertson SH, 1995, FARADAY DISCUSS, V100, P309, DOI 10.1039/fd9950000309; ROSE TS, 1989, J CHEM PHYS, V91, P7415, DOI 10.1063/1.457266; SCHMIDT MW, 1993, J COMPUT CHEM, V14, P1347, DOI 10.1002/jcc.540141112; Tachikawa M, 2002, MOL PHYS, V100, P881, DOI 10.1080/00268970110099602; Zhong Q, 1997, J PHYS CHEM B, V101, P4203, DOI 10.1021/jp963902o	19	99	99	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 4	2002	298	5591					202	204		10.1126/science.1075307	http://dx.doi.org/10.1126/science.1075307			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	600BJ	12364802				2022-12-28	WOS:000178370500059
J	Weinberger, M; Murray, MD; Marrero, DG; Brewer, N; Lykens, M; Harris, LE; Seshadri, R; Caffrey, H; Roesner, JF; Smith, F; Newell, AJ; Collins, JC; McDonald, CJ; Tierney, WM				Weinberger, M; Murray, MD; Marrero, DG; Brewer, N; Lykens, M; Harris, LE; Seshadri, R; Caffrey, H; Roesner, JF; Smith, F; Newell, AJ; Collins, JC; McDonald, CJ; Tierney, WM			Effectiveness of pharmacist care for patients with reactive airways disease - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PEAK EXPIRATORY FLOW; QUALITY-OF-LIFE; INNER-CITY PATIENTS; PHARMACEUTICAL CARE; IMPACT; MANAGEMENT; RISK; HOSPITALIZATION; EXACERBATIONS; INTERVENTIONS	Context It is not known whether patient outcomes are enhanced by effective pharmacist-patient interactions. Objective To assess the effectiveness of a pharmaceutical care program for patients with asthma or chronic obstructive pulmonary disease (COPD). Design, Setting, and Participants Randomized controlled trial conducted at 36 community drugstores in Indianapolis, Ind. We enrolled 1113 participants with active COPD or asthma from July 1998 to December 1999. Outcomes were assessed in 947 (85.1%) participants at 6 months and 898 (80.7%) at 12 months. Interventions The pharmaceutical care program (n=447) provided pharmacists with recent patient-specific clinical data (peak expiratory flow rates [PEFRs], emergency department [ED] visits, hospitalizations, and medication compliance), training, customized patient educational materials, and resources to facilitate program implementation. The PEFR monitoring control group (n=363) received a peak flow meter, instructions about its use, and monthly calls to elicit PEFRs. However, PEFR data were not provided to the pharmacist. Patients in the usual care group (n=303) received neither peak flow meters nor instructions in their use; during monthly telephone interviews, PEFR rates were not elicited. Pharmacists in both control groups had a training session but received no components of the pharmaceutical care intervention. Main Outcome Measures Peak expiratory flow rates, breathing-related ED or hospital visits, health-related quality of life (HRQOL), medication compliance, and patient satisfaction. Results At 12 months, patients receiving pharmaceutical care had significantly higher peak flow rates than the usual care group (P=.02) but not than PEFR monitoring controls (P=.28). There were no significant between-group differences in medication compliance or HRQOL. Asthma patients receiving pharmaceutical care had significantly more breathing-related ED or hospital visits than the usual care group (odds ratio, 2.16; 95% confidence interval, 1.76-2.63; P<.001). Patients receiving pharmaceutical care were more satisfied with their pharmacist than the usual care group (P=.03) and the PEFR monitoring group (P=.001) and were more satisfied with their health care than the usual care group at 6 months only (P=.01). Despite ample opportunities to implement the program, pharmacists accessed patient-specific data only about half of the time and documented actions about half of the time that records were accessed. Conclusions This pharmaceutical care program increased patients' PEFRs compared with usual care but provided little benefit compared with peak flow monitoring alone. Pharmaceutical care increased patient satisfaction but also increased the amount of breathing-related medical care sought.	Regenstrief Inst Hlth Care, Indianapolis, IN 46202 USA; Richard L Roudebush Vet Affairs Med Ctr, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med, Indianapolis, IN USA; Purdue Univ, Sch Pharm, W Lafayette, IN 47907 USA; CVS Pharm, Woonsocket, RI USA	Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center; Indiana University System; Indiana University-Purdue University Indianapolis; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Weinberger, M (corresponding author), Univ N Carolina, Dept Hlth Policy & Adm, 1105C McGavran Greenberg Hall,CB 7411, Chapel Hill, NC 27599 USA.	mweinber@email.unc.edu			AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS009083] Funding Source: NIH RePORTER; AHRQ HHS [5 R01 HS09083] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; BADGETT RG, 1994, CHEST, V106, P1427, DOI 10.1378/chest.106.5.1427; BANNER AS, 1976, JAMA-J AM MED ASSOC, V235, P1337, DOI 10.1001/jama.235.13.1337; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Berger B A, 1997, J Am Pharm Assoc (Wash), VNS37, P535; CARLSON DK, 2001, NURSES REMAIN TOP HO; Choo PW, 1999, MED CARE, V37, P846, DOI 10.1097/00005650-199909000-00002; COWEN DL, 1992, AM J HOSP PHARM, V49, P2715, DOI 10.1093/ajhp/49.11.2715; Cowie RL, 1997, CHEST, V112, P1534, DOI 10.1378/chest.112.6.1534; Donahue JG, 1997, JAMA-J AM MED ASSOC, V277, P887, DOI 10.1001/jama.277.11.887; Erickson S R, 1998, J Am Pharm Assoc (Wash), V38, P333; FERGUSON GT, 1993, NEW ENGL J MED, V328, P1017; GIBSON PG, 1995, ANN INTERN MED, V123, P488, DOI 10.7326/0003-4819-123-7-199510010-00002; Gourley D R, 1998, J Am Pharm Assoc (Wash), V38, P567; Gourley G A, 1998, J Am Pharm Assoc (Wash), V38, P586; GUYATT GH, 1987, THORAX, V42, P773, DOI 10.1136/thx.42.10.773; HATOUM HT, 1993, ANN PHARMACOTHER, V27, P1106, DOI 10.1177/106002809302700917; HEPLER CD, 1990, AM J HOSP PHARM, V47, P533, DOI 10.1093/ajhp/47.3.533; HETZEL MR, 1979, LANCET, V1, P597; HOLM S, 1979, SCAND J STAT, V6, P65; INUI TS, 1981, MED CARE, V19, P1061, DOI 10.1097/00005650-198110000-00008; JANSONBJERKLIE S, 1988, HEART LUNG, V17, P543; JUNIPER EF, 1992, THORAX, V47, P76, DOI 10.1136/thx.47.2.76; JUNIPER EF, 1993, AM REV RESPIR DIS, V147, P832, DOI 10.1164/ajrccm/147.4.832; Keely JL, 2002, ANN INTERN MED, V136, P79, DOI 10.7326/0003-4819-136-1-200201010-00014; Kennie NR, 1998, ANN PHARMACOTHER, V32, P17, DOI 10.1177/106002809803200101; LATNER AW, 2000, PHARM TIMES, V66, P16; LIPTON HL, 1994, GERONTOLOGIST, V34, P307, DOI 10.1093/geront/34.3.307; LIPTON HL, 1992, MED CARE, V30, P646, DOI 10.1097/00005650-199207000-00006; McDonald CJ, 1999, INT J MED INFORM, V54, P225, DOI 10.1016/S1386-5056(99)00009-X; MCDONOUGH RP, 1998, J AM PHARM ASSOC, V38, P87; MCFADDEN ER, 1992, NEW ENGL J MED, V327, P1928, DOI 10.1056/NEJM199212313272708; MITCHELL DM, 1986, THORAX, V41, P606, DOI 10.1136/thx.41.8.606; MORISKY DE, 1986, MED CARE, V24, P67, DOI 10.1097/00005650-198601000-00007; Murray MD, 1999, AM J HEALTH-SYST PH, V56, P225, DOI 10.1093/ajhp/56.3.225; Murray MD, 1997, J CLIN EPIDEMIOL, V50, P167, DOI 10.1016/S0895-4356(96)00333-2; NUNN AJ, 1989, BRIT MED J, V298, P1068, DOI 10.1136/bmj.298.6680.1068; Paggiaro PL, 1998, LANCET, V351, P773, DOI 10.1016/S0140-6736(97)03471-5; SACHS APE, 1995, THORAX, V50, P758, DOI 10.1136/thx.50.7.758; Singhal PK, 1999, ANN PHARMACOTHER, V33, P1336, DOI 10.1345/aph.18440; Solomon D K, 1998, J Am Pharm Assoc (Wash), V38, P574; STRAND LM, 1991, AM J HOSP PHARM, V48, P547, DOI 10.1093/ajhp/48.3.547; Stroupe KT, 1999, J ASTHMA, V36, P645, DOI 10.3109/02770909909055416; Suissa S, 2000, NEW ENGL J MED, V343, P332, DOI 10.1056/NEJM200008033430504; TETT SE, 1993, ANN PHARMACOTHER, V27, P80, DOI 10.1177/106002809302700118; Tierney W. M., 1999, JGIM, V14, P125; TROYANOV S, 1994, THORAX, V49, P775, DOI 10.1136/thx.49.8.775; Tsuyuki RT, 2002, ARCH INTERN MED, V162, P1149, DOI 10.1001/archinte.162.10.1149; Ware J E Jr, 1983, Eval Program Plann, V6, P247, DOI 10.1016/0149-7189(83)90005-8; WAREING PF, 1978, BOT MAG TOKYO SPECIA, V1, P3; WEINBERGER M, 1989, ARTHRITIS RHEUM, V32, P1577, DOI 10.1002/anr.1780321212; Weinberger M, 2002, HEALTH SERV RES, V37, P1067, DOI 10.1034/j.1600-0560.2002.66.x; Weinberger M, 2001, AM J HEALTH-SYST PH, V58, P791, DOI 10.1093/ajhp/58.9.791; Weiss K B, 1993, Pharmacoeconomics, V4, P14, DOI 10.2165/00019053-199304010-00004	54	141	146	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	2002	288	13					1594	1602		10.1001/jama.288.13.1594	http://dx.doi.org/10.1001/jama.288.13.1594			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	599BJ	12350190	Bronze			2022-12-28	WOS:000178314000020
J	Bidartondo, MI; Redecker, D; Hijri, I; Wiemken, A; Bruns, TD; Dominguez, L; Sersic, A; Leake, JR; Read, DJ				Bidartondo, MI; Redecker, D; Hijri, I; Wiemken, A; Bruns, TD; Dominguez, L; Sersic, A; Leake, JR; Read, DJ			Epiparasitic plants specialized on arbuscular mycorrhizal fungi	NATURE			English	Article							CARBON TRANSFER; SPECIFICITY; DIVERSITY; IDENTIFICATION; ASSOCIATIONS; VARIABILITY; MUTUALISM; PRIMERS; GLOMUS; ROOTS	Over 400 non-photosynthetic species from 10 families of vascular plants obtain their carbon from fungi and are thus defined as myco-heterotrophs(1). Many of these plants are epiparasitic on green plants from which they obtain carbon by 'cheating' shared mycorrhizal fungi(2-7). Epiparasitic plants examined to date depend on ectomycorrhizal fungi for carbon transfer and exhibit exceptional specificity for these fungi(3-7), but for most mycoheterotrophs neither the identity of the fungi nor the sources of their carbon are known. Because many myco-heterotrophs grow in forests dominated by plants associated with arbuscular mycorrhizal fungi (AMF; phylum Glomeromycota), we proposed that epiparasitism would occur also between plants linked by AMF. On a global scale AMF form the most widespread mycorrhizae, thus the ability of plants to cheat this symbiosis would be highly significant. We analysed mycorrhizae from three populations of Arachnitis uniflora (Corsiaceae, Monocotyledonae), five Voyria species and one Voyriella species (Gentianaceae, Dicotyledonae), and neighbouring green plants. Here we show that non-photosynthetic plants associate with AMF and can display the characteristic specificity of epiparasites. This suggests that AMF mediate significant inter-plant carbon transfer in nature.	Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA; Univ Basel, Inst Bot, CH-4056 Basel, Switzerland; Inst Multidisciplinario Biol Vegetal, RA-5000 Cordoba, Argentina; Univ Sheffield, Dept Anim & Plant Sci, Sheffield S10 2TN, S Yorkshire, England	University of California System; University of California Berkeley; University of Basel; University of Sheffield	Bidartondo, MI (corresponding author), Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA.		Bidartondo, Martin/AAC-9454-2021; Read, David/C-2454-2013	Leake, Jonathan/0000-0001-8364-7616				Bever JD, 1996, J ECOL, V84, P71, DOI 10.2307/2261701; Bidartondo MI, 2002, MOL ECOL, V11, P557, DOI 10.1046/j.0962-1083.2001.01443.x; Bidartondo MI, 2001, MOL ECOL, V10, P2285, DOI 10.1046/j.1365-294X.2001.01358.x; BJORKMAN E, 1960, PHYSIOL PLANTARUM, V13, P308, DOI 10.1111/j.1399-3054.1960.tb08034.x; Cullings KW, 1996, NATURE, V379, P63, DOI 10.1038/379063a0; Fitter AH, 1998, FUNCT ECOL, V12, P406, DOI 10.1046/j.1365-2435.1998.00206.x; GARDES M, 1993, MOL ECOL, V2, P113, DOI 10.1111/j.1365-294X.1993.tb00005.x; Helgason T, 1998, NATURE, V394, P431, DOI 10.1038/28764; Helgason T, 1999, MOL ECOL, V8, P659, DOI 10.1046/j.1365-294x.1999.00604.x; Imhof S, 1997, BOT ACTA, V110, P298, DOI 10.1111/j.1438-8677.1997.tb00643.x; JOHNSON NC, 1992, ECOLOGY, V73, P2034, DOI 10.2307/1941453; Johnson NC, 1997, NEW PHYTOL, V135, P575, DOI 10.1046/j.1469-8137.1997.00729.x; Lanfranco L, 1999, MOL ECOL, V8, P37, DOI 10.1046/j.1365-294X.1999.00535.x; LEAKE JR, 1994, NEW PHYTOL, V127, P171, DOI 10.1111/j.1469-8137.1994.tb04272.x; MCGONIGLE TP, 1990, MYCOL RES, V94, P120, DOI 10.1016/S0953-7562(09)81272-0; McKendrick SL, 2000, NEW PHYTOL, V145, P539, DOI 10.1046/j.1469-8137.2000.00592.x; Molina R., 1992, Mycorrhizal functioning: an integrative plant-fungal process., P357; Price P. W., 1980, EVOLUTIONARY BIOL PA; Redecker D, 2000, MYCORRHIZA, V10, P73, DOI 10.1007/s005720000061; Redecker D, 2000, MYCOLOGIA, V92, P282, DOI 10.2307/3761561; Robinson D, 1999, J EXP BOT, V50, P9, DOI 10.1093/jexbot/50.330.9; Schwarzott D, 2001, MOL PHYLOGENET EVOL, V21, P190, DOI 10.1006/mpev.2001.1007; Simard SW, 1997, NATURE, V388, P579, DOI 10.1038/41557; SMIT LS, 1996, GROW FACT CYTOK  A&B, V1, P43; Smith S., 1997, MYCORRHIZAL SYMBIOSI, V2nd Edn; SWOFFORD DL, 2002, PAUP ASTERISQUE PHYL; Taylor DL, 1997, P NATL ACAD SCI USA, V94, P4510, DOI 10.1073/pnas.94.9.4510; van der Heijden MGA, 1998, NATURE, V396, P69, DOI 10.1038/23932; White T.J., 1990, PCR PROTOCOLS GUIDE, P315; Yamato M, 2001, MYCORRHIZA, V11, P83, DOI 10.1007/s005720100099	30	187	212	4	114	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 26	2002	419	6905					389	392		10.1038/nature01054	http://dx.doi.org/10.1038/nature01054			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	596ZB	12353033	Green Accepted			2022-12-28	WOS:000178195400044
J	Marcus, AJ; Broekman, MJ; Pinsky, DJ				Marcus, AJ; Broekman, MJ; Pinsky, DJ			COX inhibitors and thromboregulation.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Vet Affairs New York Harbor Healthcare Syst, New York, NY 10010 USA; Cornell Univ, Weill Med Coll, New York, NY 10010 USA; Columbia Univ Coll Phys & Surg, New York, NY 10032 USA	Cornell University; Columbia University	Marcus, AJ (corresponding author), Vet Affairs New York Harbor Healthcare Syst, New York, NY 10010 USA.							Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; Cheng Y, 2002, SCIENCE, V296, P539, DOI 10.1126/science.1068711; COLLINS R, 1995, LANCET, V345, P669; Marcus AJ, 1997, J CLIN INVEST, V99, P1351, DOI 10.1172/JCI119294; Pinsky DJ, 2002, J CLIN INVEST, V109, P1031, DOI 10.1172/JCI200210649	5	48	52	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 26	2002	347	13					1025	1026		10.1056/NEJMcibr021805	http://dx.doi.org/10.1056/NEJMcibr021805			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	596RD	12324561				2022-12-28	WOS:000178178400011
J	Monnier, PP; Sierra, A; Macchi, P; Deitinghoff, L; Andersen, JS; Mann, M; Flad, M; Hornberger, MR; Stahl, B; Bonhoeffer, F; Mueller, BK				Monnier, PP; Sierra, A; Macchi, P; Deitinghoff, L; Andersen, JS; Mann, M; Flad, M; Hornberger, MR; Stahl, B; Bonhoeffer, F; Mueller, BK			RGM is a repulsive guidance molecule for retinal axons	NATURE			English	Article							CHICK VISUAL-SYSTEM; RECOGNITION; GRADIENTS; MEMBRANES; SEQUENCES; PROTEIN	Axons rely on guidance cues to reach remote targets during nervous system development(1). A well-studied model system for axon guidance is the retinotectal projection. The retina can be divided into halves; the nasal half, next to the nose, and the temporal half. A subset of retinal axons, those from the temporal half, is guided by repulsive cues expressed in a graded fashion in the optic tectum(2,3), part of the midbrain. Here we report the cloning and functional characterization of a membrane-associated glycoprotein, which we call RGM (repulsive guidance molecule). This molecule shares no sequence homology with known guidance cues, and its messenger RNA is distributed in a gradient with increasing concentration from the anterior to posterior pole of the embryonic tectum. Recombinant RGM at low nanomolar concentration induces collapse of temporal but not of nasal growth cones and guides temporal retinal axons in vitro, demonstrating its repulsive and axon-specific guiding activity.	Migragen AG, D-72076 Tubingen, Germany; Max Planck Inst Entwicklungsbiol, D-72076 Tubingen, Germany; Univ So Denmark, Dept Biochem & Mol Biol, DK-5230 Odense, Denmark; Develogen AG, D-37079 Gottingen, Germany	Max Planck Society; University of Southern Denmark	Mueller, BK (corresponding author), Migragen AG, Spemannstr 34, D-72076 Tubingen, Germany.		Sierra, Ana/U-5997-2019; Andersen, Jens S/L-2100-2015; Mann, Matthias/A-3454-2013	Andersen, Jens S/0000-0002-6091-140X; Mann, Matthias/0000-0003-1292-4799; monnier, philippe/0000-0002-6221-4130				BAIER H, 1992, SCIENCE, V255, P472, DOI 10.1126/science.1734526; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; COX EC, 1990, NEURON, V4, P31, DOI 10.1016/0896-6273(90)90441-H; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; RATHJEN FG, 1987, J CELL BIOL, V104, P343, DOI 10.1083/jcb.104.2.343; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; Sadler JE, 1998, ANNU REV BIOCHEM, V67, P395, DOI 10.1146/annurev.biochem.67.1.395; STAHL B, 1990, NEURON, V5, P735, DOI 10.1016/0896-6273(90)90227-7; WALTER J, 1987, DEVELOPMENT, V101, P685; WALTER J, 1990, J PHYSIOL-PARIS, V84, P104; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Yu TW, 2001, NAT NEUROSCI, V4, P1169, DOI 10.1038/nn748	14	243	263	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 26	2002	419	6905					392	395		10.1038/nature01041	http://dx.doi.org/10.1038/nature01041			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	596ZB	12353034				2022-12-28	WOS:000178195400045
J	Percec, V; Glodde, M; Bera, TK; Miura, Y; Shiyanovskaya, I; Singer, KD; Balagurusamy, VSK; Heiney, PA; Schnell, I; Rapp, A; Spiess, HW; Hudson, SD; Duan, H				Percec, V; Glodde, M; Bera, TK; Miura, Y; Shiyanovskaya, I; Singer, KD; Balagurusamy, VSK; Heiney, PA; Schnell, I; Rapp, A; Spiess, HW; Hudson, SD; Duan, H			Self-organization of supramolecular helical dendrimers into complex electronic materials	NATURE			English	Article							LIQUID-CRYSTALLINE; TRANSPORT-PROPERTIES; HOLE MOBILITY; CHARGE; POLYMERS	The discovery of electrically conducting organic crystals 1 and polymers(1-4) has widened the range of potential optoelectronic materials(5-9), provided these exhibit sufficiently high charge carrier mobilities(6-10) and are easy to make and process. Organic single crystals have high charge carrier mobilities but are usually impractical(11), whereas polymers have good processability but low mobilities(1,12). Liquid crystals exhibit mobilities approaching those of single crystals and are suitable for applications(13-18), but demanding fabrication and processing methods limit their use. Here we show that the self-assembly of fluorinated tapered dendrons can drive the formation of supramolecular liquid crystals with promising optoelectronic properties from a wide range of organic materials. We find that attaching conducting organic donor or acceptor groups to the apex of the dendrons leads to supramolecular nanometre-scale columns that contain in their cores pi-stacks of donors, acceptors or donor-acceptor complexes exhibiting high charge carrier mobilities. When we use functionalized dendrons and amorphous polymers carrying compatible side groups, these co-assemble so that the polymer is incorporated in the centre of the columns through donor-acceptor interactions and exhibits enhanced charge carrier mobilities. We anticipate that this simple and versatile strategy for producing conductive pi-stacks of aromatic groups, surrounded by helical dendrons, will lead to a new class of supramolecular materials suitable for electronic and optoelectronic applications.	Univ Penn, Dept Chem, Roy & Diana Vagelos Labs, Philadelphia, PA 19104 USA; Case Western Reserve Univ, Dept Phys, Cleveland, OH 44106 USA; Univ Penn, Dept Phys & Astron, Philadelphia, PA 19104 USA; Max Planck Inst Polymer Res, D-55021 Mainz, Germany; Natl Inst Stand & Technol, Gaithersburg, MD 20899 USA	University of Pennsylvania; Case Western Reserve University; University of Pennsylvania; Max Planck Society; National Institute of Standards & Technology (NIST) - USA	Percec, V (corresponding author), Univ Penn, Dept Chem, Roy & Diana Vagelos Labs, Philadelphia, PA 19104 USA.	percec@sas.upenn.edu	Hudson, Steven/AAB-2909-2019; Miura, Yoshiko/AAD-1166-2020; Singer, Kenneth D/G-6553-2011; Spiess, Hans Wolfgang/G-6777-2011; Hudson, Steven/W-3211-2019; Percec, Virgil/H-6316-2014	Hudson, Steven/0000-0002-3203-4833; Miura, Yoshiko/0000-0001-8590-6079; Spiess, Hans Wolfgang/0000-0002-4779-654X; Percec, Virgil/0000-0001-5926-0489; Singer, Kenneth/0000-0001-9320-0148; Balagurusamy, Venkat/0000-0002-1994-2634				ADAM D, 1994, NATURE, V371, P141, DOI 10.1038/371141a0; Brown J.M, 1999, COMPREHENSIVE ASYMME, V1, P121; EMERALD RL, 1974, J APPL PHYS, V45, P3943, DOI 10.1063/1.1663892; FONTES E, 1988, PHYS REV LETT, V61, P1202, DOI 10.1103/PhysRevLett.61.1202; Funahashi M, 1997, PHYS REV LETT, V78, P2184, DOI 10.1103/PhysRevLett.78.2184; GILL WD, 1972, J APPL PHYS, V43, P5033, DOI 10.1063/1.1661065; Heeger AJ, 2001, ANGEW CHEM INT EDIT, V40, P2591, DOI 10.1002/1521-3773(20010716)40:14<2591::AID-ANIE2591>3.0.CO;2-0; Heringdorf FJMZ, 2001, NATURE, V412, P517, DOI 10.1038/35087532; Hudson SD, 1997, SCIENCE, V278, P449, DOI 10.1126/science.278.5337.449; Katz HE, 2001, ACCOUNTS CHEM RES, V34, P359, DOI 10.1021/ar990114j; Katz HE, 2000, NATURE, V404, P478, DOI 10.1038/35006603; Kreouzis T, 2001, J CHEM PHYS, V114, P1797, DOI 10.1063/1.1334958; Kreouzis T, 2000, CHEM PHYS, V262, P489, DOI 10.1016/S0301-0104(00)00323-2; Lehn JM, 2002, P NATL ACAD SCI USA, V99, P4763, DOI 10.1073/pnas.072065599; MacDiarmid AG, 2001, ANGEW CHEM INT EDIT, V40, P2581, DOI 10.1002/1521-3773(20010716)40:14<2581::AID-ANIE2581>3.0.CO;2-2; Percec V, 1998, NATURE, V391, P161, DOI 10.1038/34384; Percec V, 1996, J AM CHEM SOC, V118, P9855, DOI 10.1021/ja9615738; Pope M., 1999, ELECT PROCESSES ORGA; Ratner M, 1999, NATURE, V397, P480, DOI 10.1038/17232; RODRIGUEZPARADA JM, 1986, MACROMOLECULES, V19, P55, DOI 10.1021/ma00155a011; Schmidt-Mende L, 2001, SCIENCE, V293, P1119, DOI 10.1126/science.293.5532.1119; Shirakawa H, 2001, ANGEW CHEM INT EDIT, V40, P2575, DOI 10.1002/1521-3773(20010716)40:14<2574::AID-ANIE2574>3.0.CO;2-N; Shiyanovskaya I, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.041715; Sirringhaus H, 1999, NATURE, V401, P685, DOI 10.1038/44359; Sirringhaus H, 1998, SCIENCE, V280, P1741, DOI 10.1126/science.280.5370.1741; Thurn-Albrecht T, 2000, SCIENCE, V290, P2126, DOI 10.1126/science.290.5499.2126; Tomalia DA, 2002, J POLYM SCI POL CHEM, V40, P2719, DOI 10.1002/pola.10301; TURNER SR, 1980, MACROMOLECULES, V13, P782, DOI 10.1021/ma60076a002; URYU T, 1987, MACROMOLECULES, V20, P712, DOI 10.1021/ma00170a002; van de Craats AM, 2001, ADV MATER, V13, P130; vandeCraats AM, 1997, SYNTHETIC MET, V86, P2125, DOI 10.1016/S0379-6779(97)81058-2; Wurthner F, 2001, ANGEW CHEM INT EDIT, V40, P1037	32	886	891	2	404	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 26	2002	419	6905					384	387		10.1038/nature01072	http://dx.doi.org/10.1038/nature01072			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	596ZB	12352988				2022-12-28	WOS:000178195400042
J	Wigley, FM				Wigley, FM			Raynaud's phenomenon.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONNECTIVE-TISSUE DISEASE; PHENOMENON SECONDARY; SYSTEMIC-SCLEROSIS; VASCULAR-RESPONSES; BLOCKING DRUGS; PROSTACYCLIN; SCLERODERMA; PREVALENCE; MULTICENTER; INFUSION		Johns Hopkins Univ, Sch Med, Div Rheumatol, Baltimore, MD 21205 USA	Johns Hopkins University	Wigley, FM (corresponding author), Johns Hopkins Univ, Sch Med, Div Rheumatol, 1830 E Monument St,Suite 7300, Baltimore, MD 21205 USA.	lmurray3@jhmi.edu						Allen EV, 1932, AM J MED SCI, V183, P187, DOI 10.1097/00000441-193202000-00004; BELCH JJF, 1983, LANCET, V1, P313; Brown KM, 2001, J BEHAV MED, V24, P137, DOI 10.1023/A:1010758530555; COFFMAN JD, 1985, CIRCULATION, V72, P466, DOI 10.1161/01.CIR.72.3.466; Coleiro B, 2001, RHEUMATOLOGY, V40, P1038, DOI 10.1093/rheumatology/40.9.1038; de Trafford J C, 1988, Eur J Vasc Surg, V2, P167; DOWD PM, 1982, BRIT J DERMATOL, V106, P81, DOI 10.1111/j.1365-2133.1982.tb00905.x; Dziadzio M, 1999, ARTHRITIS RHEUM-US, V42, P2646, DOI 10.1002/1529-0131(199912)42:12<2646::AID-ANR21>3.0.CO;2-T; FLATT AE, 1980, J HAND SURG-AM, V5, P550, DOI 10.1016/S0363-5023(80)80104-3; FRANSSEN C, 1992, J CLIN PHARMACOL, V32, P652, DOI 10.1002/j.1552-4604.1992.tb05777.x; Freedman RR, 1996, ARTHRITIS RHEUM, V39, P1189, DOI 10.1002/art.1780390717; GOODFIELD MJD, 1990, BRIT J RHEUMATOL, V29, P89; HARPER FE, 1982, AM J MED, V72, P883, DOI 10.1016/0002-9343(82)90846-4; Jennings JR, 1999, HEALTH PSYCHOL, V18, P421, DOI 10.1037/0278-6133.18.4.421; KALLENBERG CGM, 1990, RHEUM DIS CLIN N AM, V16, P11; KALLENBERG CGM, 1988, ANN RHEUM DIS, V47, P634, DOI 10.1136/ard.47.8.634; Khan F, 1997, ARTHRITIS RHEUM, V40, P352, DOI 10.1002/art.1780400220; Landry GJ, 1996, J VASC SURG, V23, P76, DOI 10.1016/S0741-5214(05)80037-0; LAU CS, 1993, CLIN EXP RHEUMATOL, V11, P35; LEROY EC, 1992, CLIN EXP RHEUMATOL, V10, P485; LUGGEN M, 1995, J RHEUMATOL, V22, P2226; Maricq HR, 1996, J RHEUMATOL, V23, P2068; MARICQ HR, 1988, J RHEUMATOL, V15, P454; Maricq HR, 1997, J RHEUMATOL, V24, P879; MARICQ HR, 1989, ARTHRITIS RHEUM-US, V32, P998, DOI 10.1002/anr.1780320809; MILLER D, 1981, NEW ENGL J MED, V304, P763, DOI 10.1056/NEJM198103263041306; MOHRLAND JS, 1985, ANN RHEUM DIS, V44, P754, DOI 10.1136/ard.44.11.754; OBRIEN BM, 1992, J HAND SURG-BRIT EUR, V17B, P447, DOI 10.1016/S0266-7681(05)80272-4; OKEEFFE ST, 1992, ANN INTERN MED, V116, P985, DOI 10.7326/0003-4819-116-12-985; Palesch YY, 1999, J CLIN EPIDEMIOL, V52, P321, DOI 10.1016/S0895-4356(99)00005-0; PARDY BJ, 1982, SURGERY, V92, P953; PLANCHON B, 1994, ANGIOLOGY, V45, P677, DOI 10.1177/000331979404500802; Pope J, 1998, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000953, DOI 10.1002/14651858.CD000953]; RADEMAKER M, 1989, BRIT MED J, V298, P561, DOI 10.1136/bmj.298.6673.561; SILMAN A, 1990, BMJ-BRIT MED J, V301, P590, DOI 10.1136/bmj.301.6752.590; Spencer-Green G, 1998, ARCH INTERN MED, V158, P595, DOI 10.1001/archinte.158.6.595; Thompson AE, 2001, ARTHRITIS RHEUM-US, V44, P1841, DOI 10.1002/1529-0131(200108)44:8<1841::AID-ART322>3.0.CO;2-8; Vayssairat M, 1996, J RHEUMATOL, V23, P1917; Watson HR, 1999, J RHEUMATOL, V26, P1734; Wigley FM, 1998, ARTHRITIS RHEUM-US, V41, P670, DOI 10.1002/1529-0131(199804)41:4<670::AID-ART14>3.0.CO;2-I; Wigley FM, 2000, ARCH INTERN MED, V160, P1101; WIGLEY FM, 1994, ANN INTERN MED, V120, P199, DOI 10.7326/0003-4819-120-3-199402010-00004; Wigley Fredrick M., 1993, Current Opinion in Rheumatology, V5, P773; WISE RA, 1994, J RHEUMATOL, V21, P80; WOLLERSHEIM H, 1989, EUR J CLIN INVEST, V19, P535, DOI 10.1111/j.1365-2362.1989.tb00271.x; ZUFFEREY P, 1992, CLIN RHEUMATOL, V11, P536, DOI 10.1007/BF02283115	46	267	279	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 26	2002	347	13					1001	1008		10.1056/NEJMcp013013	http://dx.doi.org/10.1056/NEJMcp013013			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	596RD	12324557				2022-12-28	WOS:000178178400007
J	McCormick, D; Himmelstein, DU; Woolhandler, S; Wolfe, SM; Bor, DH				McCormick, D; Himmelstein, DU; Woolhandler, S; Wolfe, SM; Bor, DH			Relationship between low quality-of-care scores and HMO's subsequent public disclosure of quality-of-care scores	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEW-YORK-STATE; MANAGED-CARE; HEALTH-CARE; PERFORMANCE REPORTS; CARDIAC-SURGERY; PLAN; INFORMATION; ACCOUNTABILITY; DIFFERENCE; EMPLOYERS	Context Public disclosure of quality data on health maintenance organizations (HMOs) might improve public accountability, inform consumer decision making, and promote quality improvement. But, because disclosure is voluntary, some HMOs could subvert these objectives by refusing to release unfavorable data. Objective To determine the association between HMO quality of care and withdrawal from public disclosure of quality-of-care data the subsequent year, Design and Setting Retrospective cohort study of administrative and quality-of-care data on HMOs from the National Committee for Quality Assurance (NCQA) annual Quality Compass databases for 1997,1998, and 1999, including Health Plan Employer Data and information Set (HEDIS) quality scores. Main Outcome Measure One-year rates of HMO withdrawal from public disclosure of HEDIS scores for plans in the highest and lowest tertiles of HEDIS scores, adjusted for method of data collection and plan model type. Results Of the 329 HMOs that publicly disclosed HEDIS scores in 1997, 161 plans (49%) withdrew from public disclosure in 1998. Of the 292 HMOs that disclosed their scores in 1998 (including 130 newly participating plans), 67 plans (23%) withdrew from public disclosure in 1999. Plans whose scores ranked in the lowest-quality tertile were much more likely than plans ranking in the highest-quality tertile to withdraw from public disclosure in 1998 (odds ratio [OR], 3.6; 95% confidence interval [CI], 2.1-7.0) and 1999 (OR, 5.7; 95% Cl, 2.7-17.7). Conclusion Compared with HMOs receiving higher quality-of-care scores, lower-scoring plans are more likely to stop disclosing their quality data. Voluntary reporting of quality data by HMOs is ineffective; selective nondisclosure undermines both informed consumer decision making and public accountability.	Cambridge Hosp, Dept Med, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Cambridge, MA 02138 USA; Publ Citizen Hlth Res Grp, Washington, DC USA	Harvard University; Cambridge Health Alliance; Cambridge Hospital; Harvard University	McCormick, D (corresponding author), Cambridge Hosp, Dept Med, 1493 Cambridge St, Cambridge, MA 02139 USA.		Young, Alexander/A-1523-2009	Young, Alexander/0000-0002-9367-9213				Bodenheimer T, 1999, NEW ENGL J MED, V341, P2029, DOI 10.1056/NEJM199912233412623; Bodenheimer T, 1999, NEW ENGL J MED, V340, P488, DOI 10.1056/NEJM199902113400621; *CAL OFF STAT HLTH, 1993, ANN REP CAL HOSP OUT; Chernew M, 1998, INQUIRY-J HEALTH CAR, V35, P9; Eddy DM, 1998, HEALTH AFFAIR, V17, P7, DOI 10.1377/hlthaff.17.4.7; EPSTEIN A, 1995, NEW ENGL J MED, V333, P57, DOI 10.1056/NEJM199507063330114; Epstein AM, 2000, JAMA-J AM MED ASSOC, V283, P1884, DOI 10.1001/jama.283.14.1884; FARLEY D, 1998, ASSESSING QUALITY MA; Gabel JR, 1997, HEALTH AFFAIR, V16, P103, DOI 10.1377/hlthaff.16.5.103; Gabel JR, 1998, EMPLOYERS CHOOSE HLT; HANNAN EL, 1994, JAMA-J AM MED ASSOC, V271, P761, DOI 10.1001/jama.271.10.761; Harris JR, 1998, AM J PREV MED, V14, P9; Hibbard JH, 1997, HEALTH AFFAIR, V16, P218, DOI 10.1377/hlthaff.16.3.218; Hibbard JH, 1997, HEALTH AFFAIR, V16, P172, DOI 10.1377/hlthaff.16.6.172; Hibbard JH, 1996, HEALTH CARE FINANC R, V18, P95; Leatherman S, 1999, INT J QUAL HEALTH C, V11, P93, DOI 10.1093/intqhc/11.2.93; Longo DR, 1997, JAMA-J AM MED ASSOC, V278, P1579, DOI 10.1001/jama.278.19.1579; Marshall MN, 2000, JAMA-J AM MED ASSOC, V283, P1866, DOI 10.1001/jama.283.14.1866; Miller TE, 1997, JAMA-J AM MED ASSOC, V278, P1102, DOI 10.1001/jama.278.13.1102; Mukamel DB, 1998, MED CARE, V36, P945, DOI 10.1097/00005650-199807000-00002; *NAT COMM QUAL ASS, 1997, NCQAS QUAL COMP DAT; *NAT COMM QUAL ASS, 1999, NCQAS QUAL COMP DAT; *NAT COMM QUAL ASS, 1998, NCQAS QUAL COMP DAT; Noble AA, 1999, J HEALTH POLIT POLIC, V24, P1275, DOI 10.1215/03616878-24-6-1275; *PRES ADV COMM CON, 1998, FIN REP; *PRINC SURV RES AS, 1996, AM HLTH CAR CONS ROL; Roper WL, 1998, HEALTH AFFAIR, V17, P152, DOI 10.1377/hlthaff.17.2.152; Rosenbaum S, 1998, AM J PREV MED, V14, P67, DOI 10.1016/S0749-3797(97)00046-9; SAS Institute, 2000, SAS SOFTW VERS 8 1; Schneider EC, 1998, JAMA-J AM MED ASSOC, V279, P1638, DOI 10.1001/jama.279.20.1638; Schneider EC, 1999, JAMA-J AM MED ASSOC, V282, P1184, DOI 10.1001/jama.282.12.1184; Sisk JE, 1998, MILBANK Q, V76, P687, DOI 10.1111/1468-0009.00110; Spoeri RK, 1997, ANN INTERN MED, V127, P726, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00058; Tumlinson A, 1997, HEALTH AFFAIR, V16, P229, DOI 10.1377/hlthaff.16.3.229; *US PHS, 1990, HLTH PEOPL 2000 NAT; YUSEF S, 1988, JAMA-J AM MED ASSOC, V260, P2088; YUSEF S, 1985, PROG CARDIOVASC DIS, V27, P335; 1999, INTERSTUDY COMPETITI; 2000, INTERSTUDY COMPETITI	39	64	64	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	2002	288	12					1484	1490		10.1001/jama.288.12.1484	http://dx.doi.org/10.1001/jama.288.12.1484			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	596AT	12243635	Bronze			2022-12-28	WOS:000178142000019
J	Hilton, DA; Ghani, AC; Conyers, L; Edwards, P; McCardle, L; Penney, M; Ritchie, D; Ironside, JW				Hilton, DA; Ghani, AC; Conyers, L; Edwards, P; McCardle, L; Penney, M; Ritchie, D; Ironside, JW			Accumulation of prion protein in tonsil and appendix: review of tissue samples	BRITISH MEDICAL JOURNAL			English	Article							CREUTZFELDT-JAKOB-DISEASE		Derriford Hosp, Dept Histopathol, Plymouth PL6 8DH, Devon, England; Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Infect Dis Epidemiol, London SW7 2AZ, England; Univ Edinburgh, Natl CJD Surveillance Unit, Edinburgh EH4 2XU, Midlothian, Scotland	Derriford Hospital; Imperial College London; University of Edinburgh	Hilton, DA (corresponding author), Derriford Hosp, Dept Histopathol, Plymouth PL6 8DH, Devon, England.		Ghani, Azra/B-8560-2009	Ghani, Azra/0000-0002-0007-4910; Ironside, James/0000-0001-5869-2108				Collinge J, 1999, LANCET, V354, P317, DOI 10.1016/S0140-6736(99)05128-4; Hill AF, 1999, LANCET, V353, P183, DOI 10.1016/S0140-6736(98)12075-5; Hilton DA, 1998, LANCET, V352, P703, DOI 10.1016/S0140-6736(98)24035-9; O'Rourke KI, 2000, J CLIN MICROBIOL, V38, P3254, DOI 10.1128/JCM.38.9.3254-3259.2000; Schreuder BEC, 1996, NATURE, V381, P563, DOI 10.1038/381563a0	5	109	115	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 21	2002	325	7365					633	634		10.1136/bmj.325.7365.633	http://dx.doi.org/10.1136/bmj.325.7365.633			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	597WM	12242174	Green Accepted, Green Published, Bronze, Green Submitted			2022-12-28	WOS:000178243800027
J	Gruber, SB; Ellis, NA; Rennert, G; Offit, K				Gruber, SB; Ellis, NA; Rennert, G; Offit, K			BLM heterozygosity and the risk of colorectal cancer	SCIENCE			English	Article							FREQUENCY; MUTATION; JEWS		Carmel Hosp, Clalit Hlth Serv Natl Canc Control Ctr, Haifa, Israel; Technion Israel Inst Technol, Fac Med, Haifa, Israel; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA; Mem Sloan Kettering Canc Ctr, Dept Med Pathol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Biostat, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Epidemiol, New York, NY 10021 USA; Univ Cincinnati, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; N Shore Long Island Jewish Res Inst, Manhasset, NY 11030 USA; Columbia Univ, Dept Med Informat, New York, NY 10032 USA; NCI, Bethesda, MD 20892 USA	Clalit Health Services; Carmel Medical Center; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University System of Ohio; University of Cincinnati; Northwell Health; Columbia University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Rennert, G (corresponding author), Carmel Hosp, Clalit Hlth Serv Natl Canc Control Ctr, Haifa, Israel.			Rennert, Gad/0000-0002-8512-068X; Kirchhoff, Tomas/0000-0002-9055-2364; Shia, Jinru/0000-0002-4351-2511	NATIONAL CANCER INSTITUTE [R01CA081488] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA81488] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Goss KH, 2002, SCIENCE, V297, P2051, DOI 10.1126/science.1074340; Laken SJ, 1997, NAT GENET, V17, P79, DOI 10.1038/ng0997-79; Li L, 1998, MOL GENET METAB, V64, P286, DOI 10.1006/mgme.1998.2733; Oddoux C, 1999, AM J HUM GENET, V64, P1241, DOI 10.1086/302312; Peleg L, 2002, ISRAEL MED ASSOC J, V4, P95; Shahrabani-Gargir L, 1998, GENET TEST, V2, P293, DOI 10.1089/gte.1998.2.293	7	146	150	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 20	2002	297	5589					2013	2013		10.1126/science.1074399	http://dx.doi.org/10.1126/science.1074399			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	594XV	12242432				2022-12-28	WOS:000178078500035
J	Faergemann, J				Faergemann, J			Medical history	LANCET			English	Article									Sahlgrens Univ Hosp, Dept Dermatol, S-41345 Gothenburg, Sweden	Sahlgrenska University Hospital	Faergemann, J (corresponding author), Sahlgrens Univ Hosp, Dept Dermatol, S-41345 Gothenburg, Sweden.								0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 31	2002	360	9334					689	689		10.1016/S0140-6736(02)09839-2	http://dx.doi.org/10.1016/S0140-6736(02)09839-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	590AM	12241876				2022-12-28	WOS:000177795100011
J	Huxley, R; Neil, A; Collins, R				Huxley, R; Neil, A; Collins, R			Unravelling the fetal origins hypothesis: is there really an inverse association between birthweight and subsequent blood pressure?	LANCET			English	Article							ISCHEMIC-HEART-DISEASE; PRENATAL EXPOSURE; EARLY NUTRITION; ADULT DISEASE; IN-UTERO; HYPERTENSION; MORTALITY; INFANTS; TWINS; SIZE	Background The association between birthweight and subsequent blood pressure levels has been considered to provide some of the strongest, and most consistent, support for the "fetal origins" hypothesis of adult disease. It had been estimated that a 1 kg higher birthweight is typically associated with a 2-4 mm Hg lower systolic blood pressure. Methods 55 studies that had reported regression coefficients of systolic blood pressure on birthweight (with 48 further studies that reported only the direction of this association), and seven such studies within twin pairs, were identified. Each study was weighted according to the inverse of the variance of the regression coefficient (ie, "statistical size"), and combined using a "fixed effects" approach. Findings Among the 55 studies that reported regression coefficients, there was a clear trend (p<0.0001) towards weaker associations in the larger studies: -1.9 mm Hg/kg in those with less than about 1000 participants; -1.5 mm Hg/kg with about 1000-3000 participants; and -0.6 mm Hg/kg with more than 3000 participants. By contrast with the inverse associations reported in 52 of these 55 studies, only 25 of the 48 studies that did not report regression coefficients found an inverse association (p<0.0001 for heterogeneity). Almost all of these regression coefficients had been adjusted for current weight (whereas few were adjusted for potential confounding factors), and removal of this adjustment in the larger studies reduced the estimated association to -0.4 mm Hg/kg. For studies within monozygotic twin pairs, the combined estimate was -0.6 mm Hg/kg with adjustment for current weight, and was also reduced without this adjustment. Interpretation Claims of a strong inverse association between birthweight and subsequent blood pressure may chiefly reflect the impact of random error, selective emphasis of particular results, and inappropriate adjustment for current weight and for confounding factors. These findings suggest that birthweight is of little relevance to blood pressure levels in later life.	Univ Oxford, Inst Hlth Sci, Div Publ Hlth & Primary Hlth Care, Oxford, England; Univ Oxford, Clin Trial Serv Unit, Oxford, England; Univ Oxford, Epidemiol Studies Unit, Oxford, England	University of Oxford; University of Oxford; University of Oxford	Huxley, R (corresponding author), Inst Int Hlth, 144 Burren St, Sydney, NSW 2042, Australia.	rhuxley@iih.usyd.edu.au	Huxley, Rachel R/J-4638-2013; Huxley, Rachel R/C-7032-2013	Huxley, Rachel R/0000-0002-2705-6616; Huxley, Rachel R/0000-0002-2705-6616				[Anonymous], 2001, LANCET, V357, P405; BARKER DJP, 1986, LANCET, V1, P1077; Campbell DM, 1996, BRIT J OBSTET GYNAEC, V103, P273, DOI 10.1111/j.1471-0528.1996.tb09718.x; CHRISTENSEN K, 1995, BRIT MED J, V310, P432, DOI 10.1136/bmj.310.6977.432; Christensen K, 2001, J EPIDEMIOL COMMUN H, V55, P583, DOI 10.1136/jech.55.8.583; Clarke R, 1999, AM J EPIDEMIOL, V150, P341; *COLL GRP HORM FAC, 2001, LANCET, V350, P1047; Curhan GC, 1996, CIRCULATION, V94, P1310, DOI 10.1161/01.CIR.94.6.1310; Dickersin K, 1997, AIDS EDUC PREV, V9, P15; EIFORD J, 1991, INT J EPIDEMIOL, V20, P833; GREENLAND S, 1980, AM J EPIDEMIOL, V112, P564, DOI 10.1093/oxfordjournals.aje.a113025; Huxley RR, 2000, J HYPERTENS, V18, P815, DOI 10.1097/00004872-200018070-00002; Joseph KS, 1996, EPIDEMIOL REV, V18, P158, DOI 10.1093/oxfordjournals.epirev.a017923; KRAMER MS, 1987, B WORLD HEALTH ORGAN, V65, P663; LANGLEY SC, 1994, CLIN SCI, V86, P217, DOI 10.1042/cs0860217; Law CM, 1996, J HYPERTENS, V14, P935; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; Leon DA, 1999, BMJ-BRIT MED J, V319, P1313, DOI 10.1136/bmj.319.7221.1313; LEON DA, IN PRESS FETALORIGIN; Lucas A, 1999, BRIT MED J, V319, P245, DOI 10.1136/bmj.319.7204.245; LUCAS A, 1994, BRIT MED J, V309, P304, DOI 10.1136/bmj.309.6950.304; Lumey LH, 2001, LANCET, V357, P472, DOI 10.1016/S0140-6736(00)04003-4; PANETH N, 1995, BRIT MED J, V310, P411, DOI 10.1136/bmj.310.6977.411; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; Pietilainen KH, 2001, AM J EPIDEMIOL, V154, P21, DOI 10.1093/aje/154.1.21; Robinson R, 2001, BRIT MED J, V322, P375, DOI 10.1136/bmj.322.7283.375; RODGERS A, 1995, THROMB HAEMOSTASIS, V73, P167; Roseboom TJ, 1999, J HYPERTENS, V17, P325, DOI 10.1097/00004872-199917030-00004; Said MH, 1998, REV EPIDEMIOL SANTE, V46, P351; SHADISH WR, 1984, HDB RES SYNTHESIS; Singhal A, 2001, LANCET, V357, P413, DOI 10.1016/S0140-6736(00)04004-6; Stanner SA, 1997, BMJ-BRIT MED J, V315, P1342, DOI 10.1136/bmj.315.7119.1342; VAGERO D, 1994, LANCET, V343, P260, DOI 10.1016/S0140-6736(94)91112-6; Walker BR, 1998, BRIT MED J, V316, P834, DOI 10.1136/bmj.316.7134.834; Wang XB, 2002, JAMA-J AM MED ASSOC, V287, P195, DOI 10.1001/jama.287.2.195	35	496	511	0	20	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 31	2002	360	9334					659	665		10.1016/S0140-6736(02)09834-3	http://dx.doi.org/10.1016/S0140-6736(02)09834-3			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	590AM	12241871				2022-12-28	WOS:000177795100006
J	Punt, CJA; Nagy, A; Douillard, JY; Figer, A; Skovsgaard, T; Monson, J; Barone, C; Fountzilas, G; Riess, H; Moylan, E; Jones, D; Dethling, J; Colman, J; Coward, L; MacGregor, S				Punt, CJA; Nagy, A; Douillard, JY; Figer, A; Skovsgaard, T; Monson, J; Barone, C; Fountzilas, G; Riess, H; Moylan, E; Jones, D; Dethling, J; Colman, J; Coward, L; MacGregor, S			Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study	LANCET			English	Article							SURFACE-ANTIGEN 17-1A; MONOCLONAL-ANTIBODIES; THERAPY; CARCINOMA; EXPRESSION; BREAST	Background Edrecolomab is a murine monoclonal antibody to the cell-surface glycoprotein 17-1A, which is expressed on epithelial tissues and on various carcinomas. Preliminary data suggested that it Might be of use in the adjuvant treatment of patients with resected stage III colon cancer. We did a randomised trial in 27 countries to determine the effect of adding edrecolomab to the combination of fluorouracil and folinic acid in these patients. Methods After surgery, 2761 patients were randomly assigned edrecolomab plus fluorouracil-folinic acid (combination therapy [n=912]); fluorouracil-folinic acid alone (chemotherapy [n=927]); or edrecolomab alone (edrecolomab monotherapy [n=922]). Patients were assessed for survival and disease recurrence after surgery. The primary endpoint tested the hypothesis that combination therapy improved overall survival relative to chemotherapy. The key secondary endpoint was to test whether edrecolomab monotherapy was non-inferior to chemotherapy in terms of disease-free survival. Analysis was by intention to treat. Findings Median follow-up time was 26 months (IQR 20-36). 3-year overall survival on combination therapy was no different from that on chemotherapy (74.7% vs 76.1%, hazard ratio 0.94 [95% Cl 0.76-1.15], p=0.53). Disease-free survival was significantly lower on edrecolomab monotherapy than on chemotherapy (53.0% vs 65.5%, 0.62 [0.53-0.73], p<0.0001). Hypersensitivity reactions occurred in 452 (25%) patients receiving edrecolomab, causing treatment discontinuation in 71 (4%). The addition of edrecolomab to chemotherapy did not increase neutropenia, diarrhoea, or mucositis. Interpretation The addition of edrecolomab to fluorouracil and folinic acid in the adjuvant treatment of resected stage III colon cancer does not improve overall or disease-free survival, and edrecolomab monotherapy is associated with significantly shorter overall and disease-free survival than fluorouracil and folinic acid and is therefore an inferior treatment option. Edrecolomab is well tolerated and its addition to fluorouracil and folinic acid does not increase the toxicity of chemotherapy.	Radboud Univ Nijmegen Med Ctr, Dept Med Oncol, NL-6500 HB Nijmegen, Netherlands; Csolnoky Hosp, Veszprem, Hungary; Ctr Rene Gauducheau, F-44035 Nantes, France; Ichilov Hosp, IL-64239 Tel Aviv, Israel; Herlev Hosp, DK-2730 Herlev, Denmark; Univ Hull, Kingston Upon Hull HU6 7RX, N Humberside, England; Univ Cattolica, Rome, Italy; Aristotle Univ Thessaloniki, Thessaloniki, Greece; Virchow Hosp, Berlin, Germany; Liverpool Hosp, Sydney, NSW, Australia	Radboud University Nijmegen; UNICANCER; Institut de Cancerologie de l'Ouest (ICO); Tel Aviv University; University of Copenhagen; Herlev & Gentofte Hospital; University of Hull; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Aristotle University of Thessaloniki; Liverpool Hospital	Punt, CJA (corresponding author), Radboud Univ Nijmegen Med Ctr, Dept Med Oncol, POB 9101, NL-6500 HB Nijmegen, Netherlands.	c.punt@onco.azn.nl	Fountzilas, George/ABF-2139-2020					Fagerberg J, 1996, CANCER IMMUNOL IMMUN, V42, P81; FAGERBERG J, 1995, CANCER RES, V55, P1824; GOODWIN RA, 1987, AM J CLIN PATHOL, V88, P462, DOI 10.1093/ajcp/88.4.462; GOTTLINGER HG, 1986, INT J CANCER, V38, P47; GREEN S, 1992, INVEST NEW DRUG, V10, P239, DOI 10.1007/BF00944177; Holz E, 1996, CLIN IMMUNOTHER, V5, P214, DOI 10.1007/BF03259084; LABIANCA R, 1995, LANCET, V345, P939; MACHIN D, 1987, COMPARISON 2 SURVIVA, P94; Mamounas E, 1999, J CLIN ONCOL, V17, P1349, DOI 10.1200/JCO.1999.17.5.1349; Martin IG, 1999, J CLIN PATHOL, V52, P701, DOI 10.1136/jcp.52.9.701; MELLSTEDT H, 1991, SEMIN ONCOL, V18, P462; MOERTEL CG, 1995, ANN INTERN MED, V122, P321, DOI 10.7326/0003-4819-122-5-199503010-00001; OConnell MJ, 1997, J CLIN ONCOL, V15, P246, DOI 10.1200/JCO.1997.15.1.246; Packeisen J, 1999, HYBRIDOMA, V18, P37, DOI 10.1089/hyb.1999.18.37; Parkin DM, 1999, INT J CANCER, V80, P827, DOI 10.1002/(SICI)1097-0215(19990315)80:6&lt;827::AID-IJC6&gt;3.0.CO;2-P; Passlick B, 2000, INT J CANCER, V87, P548, DOI 10.1002/1097-0215(20000815)87:4<548::AID-IJC14>3.0.CO;2-9; Pisani P, 1999, INT J CANCER, V83, P18, DOI 10.1002/(SICI)1097-0215(19990924)83:1&lt;18::AID-IJC5&gt;3.0.CO;2-M; Poczatek RB, 1999, J UROLOGY, V162, P1462, DOI 10.1016/S0022-5347(05)68341-3; RIETHMULLER G, 1994, LANCET, V343, P1177, DOI 10.1016/S0140-6736(94)92398-1; Riethmuller G, 1998, J CLIN ONCOL, V16, P1788, DOI 10.1200/JCO.1998.16.5.1788; VELDERS MP, 1995, CANCER RES, V55, P4398	21	171	190	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 31	2002	360	9334					671	677		10.1016/S0140-6736(02)09836-7	http://dx.doi.org/10.1016/S0140-6736(02)09836-7			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	590AM	12241873				2022-12-28	WOS:000177795100008
J	Talal, A				Talal, A			Opportunistic infections in HIV-infected individuals: hepatitis C virus	LANCET			English	Editorial Material							LIVER FIBROSIS PROGRESSION; INTERFERON-ALPHA; COINFECTION; RIBAVIRIN; RESPONSES; DISEASE		Cornell Univ, Ctr Study Hepatitis C, Weill Med Coll, New York, NY 10021 USA; Cornell Univ, Dept Med, Weill Med Coll, New York, NY 10021 USA	Cornell University; Cornell University	Talal, A (corresponding author), Cornell Univ, Ctr Study Hepatitis C, Weill Med Coll, New York, NY 10021 USA.	aht2002@med.cornell.edu						Benhamou Y, 1999, HEPATOLOGY, V30, P1054, DOI 10.1002/hep.510300409; CHUNG R, 2002, 9 C RETR OPP INF SEA; DIENSTAG JL, 2002, NIH CONS DEV C MAN H, P81; EYSTER ME, 1993, J ACQ IMMUN DEF SYND, V6, P602; FRIED M, 2001, GASTROENTEROLOG SA55, V120; Greub G, 2000, LANCET, V356, P1800, DOI 10.1016/S0140-6736(00)03232-3; Kaplan Jonathan E, 2002, MMWR Recomm Rep, V51, P1; Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5; PESCE A, 1993, LANCET, V341, P1597, DOI 10.1016/0140-6736(93)90736-Z; Puoti M, 2001, J INFECT DIS, V183, P134, DOI 10.1086/317644; Soriano V, 1996, CLIN INFECT DIS, V23, P585, DOI 10.1093/clinids/23.3.585; Soriano V, 2002, AIDS, V16, P813, DOI 10.1097/00002030-200204120-00001; Sulkowski MS, 2000, CLIN INFECT DIS, V30, pS77, DOI 10.1086/313842; Sulkowski MS, 2002, JAMA-J AM MED ASSOC, V288, P199, DOI 10.1001/jama.288.2.199; Tam RC, 1999, J HEPATOL, V30, P376, DOI 10.1016/S0168-8278(99)80093-2; TELFER P, 1994, BRIT J HAEMATOL, V87, P555, DOI 10.1111/j.1365-2141.1994.tb08312.x; Zhang ZX, 1997, J INFECT DIS, V175, P1294, DOI 10.1086/516459	17	9	9	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 24	2002	360	9333					584	586		10.1016/S0140-6736(02)09811-2	http://dx.doi.org/10.1016/S0140-6736(02)09811-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	586TD	12241926				2022-12-28	WOS:000177600400004
J	George, L; Mills, JL; Johansson, ALV; Nordmark, A; Olander, B; Granath, F; Cnattingius, S				George, L; Mills, JL; Johansson, ALV; Nordmark, A; Olander, B; Granath, F; Cnattingius, S			Plasma foliate levels and risk of spontaneous abortion	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEURAL-TUBE DEFECTS; EARLY-PREGNANCY LOSS; ACID SUPPLEMENTATION; BIRTH-DEFECTS; FOLATE LEVELS; MISCARRIAGE; PREVENTION; FORTIFICATION; HOMOCYSTEINE; TERATHANASIA	Context Both folate deficiency and folic acid supplements have been reported to increase the risk of spontaneous abortion. The results are inconclusive, however, and measurements of folate have not been available in all studies. Objective To study the association between plasma folate levels and the risk of spontaneous abortion. Design, Setting, and Population Population-based, matched, case-control study of case women with spontaneous abortion and control women from January 1996 through December 1998 in Uppsala County, Sweden. Plasma folate measurements were available for 468 cases and 921 controls at 6 to 12 gestational weeks. Main Outcome Measure Risk of spontaneous abortion vs maternal plasma folate level. Results Compared with women with plasma folate levels between 2.20 and 3.95 ng/mL (5.0 and 8.9 nmol/L), women with low (less than or equal to2.19 ng/mL [less than or equal to 4.9 nmol/L]) folate levels were at increased risk of spontaneous abortion (adjusted odds ratio [OR], 1.47; 95% confidence interval [CI], 1.01-2.14), whereas women with higher folate levels (3.96-6.16 ng/mL [9.0-13.9 nmol/L] and greater than or equal to6.17 ng/mL [greater than or equal to14.0 nmol/L]) showed no increased risk of spontaneous abortion (OR, 0.84; 95% Cl, 0.59-1.20; and OR, 0.74; 95% Cl, 0.47-1.16, respectively). Low folate levels were associated with a significantly increased risk when the fetal karyotype was abnormal (OR, 1.95; 95% Cl, 1.09-3.48) but not when the fetal karyotype was normal (OR, 1.11; 95% Cl, 0.55-2.24) or unknown (OR, 1.45; 95% Cl, 0.90-2.33). Conclusion Low plasma folate levels were associated with an increased risk of early spontaneous abortion.	Karolinska Inst, Huddinge Univ Hosp, Dept Med Epidemiol, Stockholm, Sweden; Karolinska Inst, Huddinge Univ Hosp, Dept Med Lab Sci & Technol, Stockholm, Sweden; NICHHD, Pediat Epidemiol Sect, Div Epidemiol Stat & Prevent Res, NIH, Bethesda, MD 20892 USA; Danderyd Hosp, Karolinska Lab, Dept Clin Chem, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Danderyds Hospital	Cnattingius, S (corresponding author), Karolinska Inst, Dept Med Epidemiol, POB 281, SE-17177 Stockholm, Sweden.			Johansson, Anna/0000-0002-1191-7231; Mills, James/0000-0003-4496-332X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD002502] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD002502] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAILEY LB, 1990, J NUTR, V120, P1508, DOI 10.1093/jn/120.suppl_11.1508; Burn J, 1997, LANCET, V350, P1322, DOI 10.1016/S0140-6736(05)62480-4; BYRNE J, 1986, AM J MED GENET, V25, P327, DOI 10.1002/ajmg.1320250219; CARMI R, 1994, AM J MED GENET, V51, P93, DOI 10.1002/ajmg.1320510203; Cnattingius S, 2000, NEW ENGL J MED, V343, P1839, DOI 10.1056/NEJM200012213432503; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; Czeizel AE, 2001, AM J MED GENET, V104, P179, DOI 10.1002/ajmg.10052; FEX G, 1997, LAURELLS KLIN KEMI P, P589; Food and Drug Administration, 1996, FED REGISTER, V61, P8781; FRIEDMAN S, 1977, PANMINERVA MED, V19, P271; Gindler J, 2001, LANCET, V358, P796, DOI 10.1016/S0140-6736(01)05969-4; Hall JG, 1997, LANCET, V350, P1322, DOI 10.1016/S0140-6736(97)26044-7; HALL JG, 1997, LANCET, V350, P1323; HIBBARD BM, 1975, S AFR MED J, V49, P1223; HIBBARD BM, 1964, J OBSTET GYN BR COMM, V71, P529; Honein MA, 2001, JAMA-J AM MED ASSOC, V285, P2981, DOI 10.1001/jama.285.23.2981; Hook EB, 1997, LANCET, V350, P513, DOI 10.1016/S0140-6736(97)01342-1; Hook EB, 2001, AM J MED GENET, V104, P181, DOI 10.1002/ajmg.1602; Hook EB, 2000, AM J MED GENET, V92, P301, DOI 10.1002/1096-8628(20000619)92:5<301::AID-AJMG1>3.0.CO;2-J; Jacques PF, 1999, NEW ENGL J MED, V340, P1449, DOI 10.1056/NEJM199905133401901; Locksmith GJ, 1998, OBSTET GYNECOL, V91, P1027, DOI 10.1016/S0029-7844(98)00060-X; NEIGER R, 1993, AM J PERINAT, V10, P460; Nelen WLDM, 1997, LANCET, V350, P861, DOI 10.1016/S0140-6736(97)24038-9; Nelen WLDM, 2000, OBSTET GYNECOL, V95, P519, DOI 10.1016/S0029-7844(99)00610-9; OLSSON P, 1991, ADV PHAR SC, P57; Peacock JL, 1998, INT J EPIDEMIOL, V27, P647, DOI 10.1093/ije/27.4.647; Ray JG, 1999, PLACENTA, V20, P519, DOI 10.1053/plac.1999.0417; *SAS INC, 1999, SAS SYST VERS 8 1; Schorah CJ, 1997, LANCET, V350, P1323, DOI 10.1016/S0140-6736(05)62481-6; SCOTT JM, 1995, FOLATE HLTH DIS, P329; STREIFF RR, 1967, NEW ENGL J MED, V276, P776, DOI 10.1056/NEJM196704062761403; Sutterlin M, 1997, HUM REPROD, V12, P2292, DOI 10.1093/humrep/12.10.2292; Wald N, 1997, LANCET, V350, P665, DOI 10.1016/S0140-6736(05)63358-2; WALD N, 1991, LANCET, V338, P131; Wald NJ, 2001, AM J MED GENET, V98, P204, DOI 10.1002/1096-8628(20010115)98:2<204::AID-AJMG1032>3.0.CO;2-D; WILCOX AJ, 1988, NEW ENGL J MED, V319, P189, DOI 10.1056/NEJM198807283190401; Windham GC, 2000, AM J MED GENET, V90, P261, DOI 10.1002/(SICI)1096-8628(20000131)90:3<261::AID-AJMG18>3.0.CO;2-L; WOUTERS MGAJ, 1993, FERTIL STERIL, V60, P820	38	145	155	0	15	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 16	2002	288	15					1867	1873		10.1001/jama.288.15.1867	http://dx.doi.org/10.1001/jama.288.15.1867			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604EU	12377085	Bronze			2022-12-28	WOS:000178604200025
J	Downer, MC				Downer, MC			A new low for nonlinear optics	SCIENCE			English	Editorial Material							LASER-PULSES; GENERATION		Univ Texas, Dept Phys, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Downer, MC (corresponding author), Univ Texas, Dept Phys, Austin, TX 78712 USA.							Agrawal G.P., 2019, NONLINEAR FIBER OPTI, V6th, DOI 10.1016/C2018-0-01168-8; Benabid F, 2002, SCIENCE, V298, P399, DOI 10.1126/science.1076408; BLOEMBERGEN N, 1967, AM J PHYS, V35, P989, DOI 10.1119/1.1973774; Cregan RF, 1999, SCIENCE, V285, P1537, DOI 10.1126/science.285.5433.1537; Dmitriev V.G., 1999, HDB NONLINEAR OPTICA; Dorchies F, 1999, PHYS REV LETT, V82, P4655, DOI 10.1103/PhysRevLett.82.4655; FEJER MM, 1992, IEEE J QUANTUM ELECT, V28, P2631, DOI 10.1109/3.161322; FRANKEN P, 1962, PHYS REV LETT, V7, P118; Korn G, 1998, PHYS REV LETT, V81, P1215, DOI 10.1103/PhysRevLett.81.1215; Nie SM, 1997, SCIENCE, V275, P1102, DOI 10.1126/science.275.5303.1102; OTTO A, 1984, LIGHT SCATTERING SOL, V4, P289; OWYOUNG A, 1979, LASER SPECTROSCOPY, V4, P175; Perlin VE, 2002, J LIGHTWAVE TECHNOL, V20, P409, DOI 10.1109/50.988989; Raman C.V., 1928, INDIAN J PHYS, V2, P399; Rundquist A, 1998, SCIENCE, V280, P1412, DOI 10.1126/science.280.5368.1412; Shvets G, 1999, PHYS REV E, V60, P2218, DOI 10.1103/PhysRevE.60.2218; Sokolov AV, 1999, OPT LETT, V24, P557, DOI 10.1364/OL.24.000557; WOOD WM, 1991, PHYS REV LETT, V67, P3523, DOI 10.1103/PhysRevLett.67.3523	18	6	6	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 11	2002	298	5592					373	375		10.1126/science.1078098	http://dx.doi.org/10.1126/science.1078098			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	602NB	12376691				2022-12-28	WOS:000178510400035
J	Varambally, S; Dhanasekaran, SM; Zhou, M; Barrette, TR; Kumar-Sinha, C; Sanda, MG; Ghosh, D; Pienta, KJ; Sewalt, RGAB; Otte, AP; Rubin, MA; Chinnaiyan, AM				Varambally, S; Dhanasekaran, SM; Zhou, M; Barrette, TR; Kumar-Sinha, C; Sanda, MG; Ghosh, D; Pienta, KJ; Sewalt, RGAB; Otte, AP; Rubin, MA; Chinnaiyan, AM			The polycomb group protein EZH2 is involved in progression of prostate cancer	NATURE			English	Article							GROUP GENE; C-MYC; BMI-1; EED; PROLIFERATION; APOPTOSIS; DOMAIN; CELLS	Prostate cancer is a leading cause of cancer-related death in males and is second only to lung cancer. Although effective surgical and radiation treatments exist for clinically localized prostate cancer, metastatic prostate cancer remains essentially incurable. Here we show, through gene expression profiling(1), that the polycomb group protein enhancer of zeste homolog 2 (EZH2)(2,3) is overexpressed in hormone-refractory, metastatic prostate cancer. Small interfering RNA (siRNA) duplexes(4) targeted against EZH2 reduce the amounts of EZH2 protein present in prostate cells and also inhibit cell proliferation in vitro. Ectopic expression of EZH2 in prostate cells induces transcriptional repression of a specific cohort of genes. Gene silencing mediated by EZH2 requires the SET domain and is attenuated by inhibiting histone deacetylase activity. Amounts of both EZH2 messenger RNA and EZH2 protein are increased in metastatic prostate cancer; in addition, clinically localized prostate cancers that express higher concentrations of EZH2 show a poorer prognosis. Thus, dysregulated expression of EZH2 may be involved in the progression of prostate cancer, as well as being a marker that distinguishes indolent prostate cancer from those at risk of lethal progression.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Urol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Biostat, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Univ Amsterdam, Biocentrum Amsterdam, Swammerdam Inst Life Sci, NL-1018 TV Amsterdam, Netherlands	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Amsterdam	Chinnaiyan, AM (corresponding author), Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA.	arul@umich.edu	Sanda, Martin G/B-2023-2015; Sanda, Martin G/A-6202-2013; Pienta, Kenneth/E-7679-2015	Varambally, Sooryanarayana/0000-0002-2277-1127; Dhanasekaran, saravana mohan/0000-0002-0489-2224; Pienta, Kenneth/0000-0002-4138-2186; Rubin, Mark/0000-0002-8321-9950; Ghosh, Debashis/0000-0001-6618-1316; Kumar, Chandan/0000-0002-8696-3400				Bello D, 1997, CARCINOGENESIS, V18, P1215, DOI 10.1093/carcin/18.6.1215; Bova GS, 2001, HUM PATHOL, V32, P417, DOI 10.1053/hupa.2001.23517; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Francis NJ, 2001, NAT REV MOL CELL BIO, V2, P409, DOI 10.1038/35073039; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 1999, SEMIN CELL DEV BIOL, V10, P227, DOI 10.1006/scdb.1999.0304; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Jenuwein T, 1998, CELL MOL LIFE SCI, V54, P80, DOI 10.1007/s000180050127; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kumar-Sinha C, 2002, J BIOL CHEM, V277, P575, DOI 10.1074/jbc.M107795200; Laible G, 1997, EMBO J, V16, P3219, DOI 10.1093/emboj/16.11.3219; LaJeunesse D, 1996, DEVELOPMENT, V122, P2189; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Mahmoudi T, 2001, ONCOGENE, V20, P3055, DOI 10.1038/sj.onc.1204330; Manley S, 2001, AM J PATHOL, V159, P837, DOI 10.1016/S0002-9440(10)61759-2; Perrone EE, 2000, JNCI-J NATL CANCER I, V92, P937, DOI 10.1093/jnci/92.11.937; Raaphorst FM, 2000, AM J PATHOL, V157, P709, DOI 10.1016/S0002-9440(10)64583-X; Rubin MA, 2000, CLIN CANCER RES, V6, P1038; Satijn DPE, 1999, BBA-GENE STRUCT EXPR, V1447, P1, DOI 10.1016/S0167-4781(99)00130-X; Sewalt RGAB, 1998, MOL CELL BIOL, V18, P3586, DOI 10.1128/MCB.18.6.3586; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; van Lohuizen M, 1998, MOL CELL BIOL, V18, P3572, DOI 10.1128/MCB.18.6.3572; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; Webber MM, 1997, CARCINOGENESIS, V18, P1225, DOI 10.1093/carcin/18.6.1225	28	2006	2167	4	175	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 10	2002	419	6907					624	629		10.1038/nature01075	http://dx.doi.org/10.1038/nature01075			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	602AT	12374981	Green Published			2022-12-28	WOS:000178483100047
J	Amoretti, M; Amsler, C; Bonomi, G; Bouchta, A; Bowe, P; Carraro, C; Cesar, CL; Charlton, M; Collier, MJT; Doser, M; Filippini, V; Fine, KS; Fontana, A; Fujiwara, MC; Funakoshi, R; Genova, P; Hangst, JS; Hayano, RS; Holzscheiter, MH; Jorgensen, LV; Lagomarsino, V; Landua, R; Lindelof, D; Rizzini, EL; Macri, M; Madsen, N; Manuzio, G; Marchesotti, M; Montagna, P; Pruys, H; Regenfus, C; Riedler, P; Rochet, J; Rotondi, A; Rouleau, G; Testera, G; Variola, A; Watson, TL; van der Werf, DP				Amoretti, M; Amsler, C; Bonomi, G; Bouchta, A; Bowe, P; Carraro, C; Cesar, CL; Charlton, M; Collier, MJT; Doser, M; Filippini, V; Fine, KS; Fontana, A; Fujiwara, MC; Funakoshi, R; Genova, P; Hangst, JS; Hayano, RS; Holzscheiter, MH; Jorgensen, LV; Lagomarsino, V; Landua, R; Lindelof, D; Rizzini, EL; Macri, M; Madsen, N; Manuzio, G; Marchesotti, M; Montagna, P; Pruys, H; Regenfus, C; Riedler, P; Rochet, J; Rotondi, A; Rouleau, G; Testera, G; Variola, A; Watson, TL; van der Werf, DP			Production and detection of cold antihydrogen atoms	NATURE			English	Article								A theoretical underpinning of the standard model of fundamental particles and interactions is CPT invariance, which requires that the laws of physics be invariant under the combined discrete operations of charge conjugation, parity and time reversal. Antimatter, the existence of which was predicted by Dirac, can be used to test the CPT theorem-experimental investigations involving comparisons of particles with antiparticles are numerous(1). Cold atoms and anti-atoms, such as hydrogen and antihydrogen, could form the basis of a new precise test, as CPT invariance implies that they must have the same spectrum. Observations of antihydrogen in small quantities and at high energies have been reported at the European Organization for Nuclear Research (CERN)(2) and at Fermilab(3), but these experiments were not suited to precision comparison measurements. Here we demonstrate the production of antihydrogen atoms at very low energy by mixing trapped antiprotons and positrons in a cryogenic environment. The neutral anti-atoms have been detected directly when they escape the trap and annihilate, producing a characteristic signature in an imaging particle detector.	Univ Aarhus, Dept Phys & Astron, DK-8000 Aarhus C, Denmark; Univ Genoa, Ist Nazl Fis Nucl, Sez Genova, I-16146 Genoa, Italy; Univ Genoa, Dipartimento Fis, I-16146 Genoa, Italy; Univ Zurich, Inst Phys, CH-8057 Zurich, Switzerland; CERN, Div EP, CH-1211 Geneva 23, Switzerland; Univ Brescia, Dipartimento Chim & Fis Ingn & Mat, I-25123 Brescia, Italy; Univ Fed Rio de Janeiro, Inst Fis, BR-21945970 Rio De Janeiro, Brazil; Ctr Fed Educ Tecnol Ceara, BR-60040531 Fortaleza, Ceara, Brazil; Univ Wales Swansea, Dept Phys, Swansea SA2 8PP, W Glam, Wales; Univ Pavia, Ist Nazl Fis Nucl, Sez Pavia, I-27100 Pavia, Italy; Univ Pavia, Dipartimento Fis Nucl & Teor, I-27100 Pavia, Italy; Univ Tokyo, Dept Phys, Tokyo 1130033, Japan	Aarhus University; Istituto Nazionale di Fisica Nucleare (INFN); University of Genoa; University of Genoa; University of Zurich; European Organization for Nuclear Research (CERN); University of Brescia; Universidade Federal do Rio de Janeiro; Swansea University; Istituto Nazionale di Fisica Nucleare (INFN); University of Pavia; University of Pavia; University of Tokyo	Hangst, JS (corresponding author), Univ Aarhus, Dept Phys & Astron, DK-8000 Aarhus C, Denmark.	jeffrey.hangst@cern.ch	Fontana, Andrea/I-4375-2012; Madsen, Niels/I-2314-2019; Funakoshi, Ryo/AAA-3907-2020; Bonomi, Germano/G-4236-2010; Cesar, Claudio/AAH-4612-2021; Hayano, Ryugo/F-7889-2012; Testera, Gemma/AAG-2260-2020; Variola, Alessandro/F-6549-2018; Madsen, Niels/G-3548-2013; Jørgensen, Lars V/B-8991-2012; Lu, YuCheng/L-2929-2015	Fontana, Andrea/0000-0003-4718-5711; Madsen, Niels/0000-0002-7372-0784; Bonomi, Germano/0000-0003-1618-9648; Hayano, Ryugo/0000-0002-1214-7806; Variola, Alessandro/0000-0002-2812-6276; Madsen, Niels/0000-0002-7372-0784; van der Werf, Dirk/0000-0001-5436-5214; Rotondi, Alberto/0000-0003-1921-6808				Amsler C, 2002, NUCL INSTRUM METH A, V480, P494, DOI 10.1016/S0168-9002(01)01239-6; Baur G, 1996, PHYS LETT B, V368, P251, DOI 10.1016/0370-2693(96)00005-6; BENDISCIOLI G, 1994, RIV NUOVO CIMENTO, V17, P1, DOI 10.1007/BF02724447; Blanford G, 1998, PHYS REV LETT, V80, P3037, DOI 10.1103/PhysRevLett.80.3037; CALLIGARICH E, 1992, NUCL INSTRUM METH A, V311, P151, DOI 10.1016/0168-9002(92)90860-7; Charlton M., 2001, POSITRON PHYS, VII; DEHMELT H, 1990, REV MOD PHYS, V62, P525, DOI 10.1103/RevModPhys.62.525; FUJIWARA MC, IN PRESS HYPERFINE I; GABRIELSE G, 1988, PHYS LETT A, V129, P38, DOI 10.1016/0375-9601(88)90470-7; Gabrielse G, 2001, PHYS LETT B, V507, P1, DOI 10.1016/S0370-2693(01)00450-6; Hagiwara K, 2002, PHYS REV D, V66, DOI 10.1103/PhysRevD.66.010001; Hellemans A, 2000, NATURE, V406, P556, DOI 10.1038/35020740; Jorgensen LV, 2002, AIP CONF PROC, V606, P35, DOI 10.1063/1.1454265; Niering M, 2000, PHYS REV LETT, V84, P5496, DOI 10.1103/PhysRevLett.84.5496; REGENFUS CA, IN PRESS NUCL INST A; Surko CM, 1999, AIP CONF PROC, V498, P3, DOI 10.1063/1.1302095; Testera G, 2001, NUCL INSTRUM METH A, V461, P253, DOI 10.1016/S0168-9002(00)01219-5; TINKLE MD, 1994, PHYS REV LETT, V72, P352, DOI 10.1103/PhysRevLett.72.352	18	691	698	5	88	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 3	2002	419	6906					456	459		10.1038/nature01096	http://dx.doi.org/10.1038/nature01096			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	599RF	12368849	Green Submitted			2022-12-28	WOS:000178348400030
J	Zhu, SH; Anderson, CM; Tedeschi, GJ; Rosbrook, B; Johnson, CE; Byrd, M; Gutierrez-Terrell, E				Zhu, SH; Anderson, CM; Tedeschi, GJ; Rosbrook, B; Johnson, CE; Byrd, M; Gutierrez-Terrell, E			Evidence of real-world effectiveness of a telephone quitline for smokers	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SMOKING-CESSATION; INTERVENTIONS; SERVICES; OUTCOMES	Background: Telephone services that offer smoking-cessation counseling (quitlines) have proliferated in recent years, encouraged by positive results of clinical trials. The question remains, however, whether those results can be translated into real-world effectiveness. Methods: We embedded a randomized, controlled trial into the ongoing service of the California Smokers' Helpline. Callers were randomly assigned to a treatment group (1973 callers) or a control group (1309 callers). All participants received self-help materials. Those in the treatment group were assigned to receive up to seven counseling sessions; those in the control group could also receive counseling if they called back for it after randomization. Results: Counseling was provided to 72.1 percent of those in the treatment group and 31.6 percent of those in the control group (mean, 3.0 sessions). The rates of abstinence for 1, 3, 6, and 12 months, according to an intention-to-treat analysis, were 23.7 percent, 17.9 percent, 12.8 percent, and 9.1 percent, respectively, for those in the treatment group and 16.5 percent, 12.1 percent, 8.6 percent, and 6.9 percent, respectively, for those in the control group (P<0.001). Analyses factoring out both the subgroup of control subjects who received counseling and the corresponding treatment subgroup indicate that counseling approximately doubled abstinence rates: rates of abstinence for 1, 3, 6, and 12 months were 20.7 percent, 15.9 percent, 11.7 percent, and 7.5 percent, respectively, in the remaining subjects in the treatment group and 9.6 percent, 6.7 percent, 5.2 percent, and 4.1 percent, respectively, in the remaining subjects in the control group (P<0.001). Therefore, the absolute difference in the rate of abstinence for 12 months between the remaining subjects in the treatment and control groups was 3.4 percent. The 12-month abstinence rates for those who made at least one attempt to quit were 23.3 percent in the treatment group and 18.4 percent in the control group (P<0.001). Conclusions: A telephone counseling protocol for smoking cessation, previously proven efficacious, was effective when translated to a real-world setting. Its success supports Public Health Service guidelines calling for greater availability of quitlines.	Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Zhu, SH (corresponding author), Univ Calif San Diego, Dept Family & Prevent Med, 9500 Gilman Dr,Mail Code 0905, La Jolla, CA 92093 USA.		Zhu, Shu-Hong/AAF-5164-2019					Coffield AB, 2001, AM J PREV MED, V21, P1, DOI 10.1016/S0749-3797(01)00308-7; FIORE MC, 2000, TREATING TOBACCO USE; Hopkins DP, 2001, AM J PREV MED, V20, P16, DOI 10.1016/S0749-3797(00)00297-X; HORWITZ RI, 1993, ARCH INTERN MED, V153, P1863, DOI 10.1001/archinte.153.16.1863; HUGHES JR, IN PRESS NICOTINE TO; Kalbfleisch D., 1980, STAT ANAL FAILURE TI; Lichtenstein E, 1996, HEALTH EDUC RES, V11, P243, DOI 10.1093/her/11.2.243; McAfee T, 1998, AM J PREV MED, V14, P46, DOI 10.1016/S0749-3797(97)00051-2; McDermott MM, 1997, ARCH INTERN MED, V157, P1921, DOI 10.1001/archinte.157.17.1921; Miller W, 2002, MOTIVATIONAL INTERVI, V2nd; Peterson AL, 1998, BEHAV THER, V29, P3, DOI 10.1016/S0005-7894(98)80015-4; SRNT Subcommittee on Biochemical Verification, 2002, Nicotine Tob Res, V4, P149, DOI 10.1080/14622200210123581; STEAD LF, 2002, COCHRANE LIB, V1; Stevens VJ, 2000, MED CARE, V38, P451, DOI 10.1097/00005650-200005000-00002; VELICER WF, 1992, PSYCHOL BULL, V111, P23, DOI 10.1037/0033-2909.111.1.23; Wakefield M, 2000, TOB CONTROL, V9, P117, DOI 10.1136/tc.9.2.117; ZELEN M, 1979, NEW ENGL J MED, V300, P1242, DOI 10.1056/NEJM197905313002203; Zhu SH, 1996, J COUNS DEV, V75, P93, DOI 10.1002/j.1556-6676.1996.tb02319.x; Zhu SH, 1996, J CONSULT CLIN PSYCH, V64, P202, DOI 10.1037/0022-006X.64.1.202; Zhu SH, 1999, EVALUATION REV, V23, P363, DOI 10.1177/0193841X9902300401; ZHU SH, 2000, TOB CONTROL S2, V9	21	356	358	0	25	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 3	2002	347	14					1087	1093		10.1056/NEJMsa020660	http://dx.doi.org/10.1056/NEJMsa020660			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	599KD	12362011	Green Published			2022-12-28	WOS:000178332900008
J	Rothman, DJ				Rothman, DJ			Ethical and social consequences of selling a kidney	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ORGANS; TRANSPLANTATION; INCENTIVES		Columbia Univ Coll Phys & Surg, Ctr Study Soc & Med, New York, NY 10032 USA	Columbia University	Rothman, DJ (corresponding author), Columbia Univ Coll Phys & Surg, Ctr Study Soc & Med, 630 W 168th St, New York, NY 10032 USA.	djr5@columbia.edu						Adams AF, 1999, CONTEMP ECON POLICY, V17, P147; [Anonymous], 1999, DEV FREEDOM; Cohen L, 1999, DAEDALUS, V128, P135; COHEN LR, 1989, GEORGE WASH LAW REV, V58, P1; Delmonico FL, 2002, NEW ENGL J MED, V346, P2002, DOI 10.1056/NEJMsb013216; Friedlaender MM, 2002, LANCET, V359, P971, DOI 10.1016/S0140-6736(02)08030-3; Frishberg Y, 1998, J AM SOC NEPHROL, V9, P1100; Goyal M, 2002, JAMA-J AM MED ASSOC, V288, P1589, DOI 10.1001/jama.288.13.1589; Harris CE, 2001, ISSUES LAW MED, V16, P213; KASERMAN DL, 2002, US ORGAN PROCUREMENT, P51; Radcliffe-Richards J, 1998, LANCET, V351, P1950, DOI 10.1016/S0140-6736(97)08211-1; Rothman DJ, 1998, NEW YORK REV BOOKS, V45, P14; Rothman DJ, 1997, TRANSPL P, V29, P2739, DOI 10.1016/S0041-1345(97)00577-0; *WORLD MED ASS, 2002, STAT HUM ORG TISS DO	14	26	26	1	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	2002	288	13					1640	1641		10.1001/jama.288.13.1640	http://dx.doi.org/10.1001/jama.288.13.1640			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	599BJ	12350195				2022-12-28	WOS:000178314000025
J	Jenuwein, H				Jenuwein, H			Molecular biology - An RNA-guided pathway for the epigenome	SCIENCE			English	Editorial Material							SATELLITE DNA; METHYLATION; NOISE; GENES		Vienna Bioctr, Res Inst Mol Pathol, A-1030 Vienna, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Jenuwein, H (corresponding author), Vienna Bioctr, Res Inst Mol Pathol, Dr Bohrgasse 7, A-1030 Vienna, Austria.							AKTHAWR A, 2000, NATURE, V407, P405; ALLSHIRE R, COMMUNICATION; Birchler JA, 2000, CURR OPIN GENET DEV, V10, P211, DOI 10.1016/S0959-437X(00)00065-4; BIRD AP, 1995, TRENDS GENET, V11, P94, DOI 10.1016/S0168-9525(00)89009-5; Chalker DL, 2001, GENE DEV, V15, P1287, DOI 10.1101/gad.884601; Csink AK, 1998, TRENDS GENET, V14, P200, DOI 10.1016/S0168-9525(98)01444-9; Dudley NR, 2002, P NATL ACAD SCI USA, V99, P4191, DOI 10.1073/pnas.062605199; Hall IM, 2002, SCIENCE, V297, P2232, DOI 10.1126/science.1076466; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; Hutvagner G, 2002, CURR OPIN GENET DEV, V12, P225, DOI 10.1016/S0959-437X(02)00290-3; Jackson JP, 2002, NATURE, V416, P556, DOI 10.1038/nature731; Karpen GH, 1997, TRENDS GENET, V13, P489, DOI 10.1016/S0168-9525(97)01298-5; Kelley RL, 2000, CELL, V103, P9, DOI 10.1016/S0092-8674(00)00099-4; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Maison C, 2002, NAT GENET, V30, P329, DOI 10.1038/ng843; Mak W, 2002, CURR BIOL, V12, P1016, DOI 10.1016/S0960-9822(02)00892-8; Matzke M, 2001, SCIENCE, V293, P1080, DOI 10.1126/science.1063051; MCCLINTOCK B, 1951, COLD SPRING HARB SYM, V16, P13, DOI 10.1101/SQB.1951.016.01.004; Mette MF, 2000, EMBO J, V19, P5194, DOI 10.1093/emboj/19.19.5194; MOCHIZUKI K, 2002, CELL            0814; Muller H.J, 1932, P 6 INT C GEN, V1, P213; PARDUE ML, 1970, SCIENCE, V168, P1356, DOI 10.1126/science.168.3937.1356; PARTRIDGE JF, IN PRESS CURR BIOL; Reinhart BJ, 2002, SCIENCE, V297, P1831, DOI 10.1126/science.1077183; RUDERT F, 1995, MAMM GENOME, V6, P76, DOI 10.1007/BF00303248; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; TAVERNA SD, 2002, CELL            0906; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; Vaistij FE, 2002, PLANT CELL, V14, P857, DOI 10.1105/tpc.010480; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973	30	56	166	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 27	2002	297	5590					2215	+		10.1126/science.1077903	http://dx.doi.org/10.1126/science.1077903			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	597LA	12351775				2022-12-28	WOS:000178222000031
J	Khan, SUM; Al-Shahry, M; Ingler, WB				Khan, SUM; Al-Shahry, M; Ingler, WB			Efficient photochemical water splitting by a chemically modified n-TiO2 2	SCIENCE			English	Article							TITANIUM; PHOTOCATALYSIS; HYDROGEN	Although n-type titanium dioxide (TiO2) is a promising substrate for photogeneration of hydrogen from water, most attempts at doping this material so that it absorbs light in the visible region of the solar spectrum have met with limited success. We synthesized a chemically modified n-type TiO2 by controlled combustion of Ti metal in a natural gas flame. This material, in which carbon substitutes for some of the lattice oxygen atoms, absorbs light at wavelengths below 535 nanometers and has a lower band-gap energy than rutile (2.32 versus 3.00 electron volts). At an applied potential of 0.3 volt, chemically modified n-type TiO2 performs water splitting with a total conversion efficiency of 11% and a maximum photoconversion efficiency of 8.35% when illuminated at 40 milliwatts per square centimeter. The latter value compares favorably with a maximum photoconversion efficiency of 1% for n-type TiO2 biased at 0.6 volt.	Duquesne Univ, Dept Chem & Biochem, Pittsburgh, PA 15282 USA	Duquesne University	Khan, SUM (corresponding author), Duquesne Univ, Dept Chem & Biochem, Pittsburgh, PA 15282 USA.	khan@duq.edu						Akikusa J, 2002, INT J HYDROGEN ENERG, V27, P863, DOI 10.1016/S0360-3199(01)00191-4; AKIKUSA J, 1997, THESIS DUQUESNE U; ANPO M, 1997, CATAL SURV JPN, V1, P169, DOI [DOI 10.1023/A:1019024913274, DOI 10.1023/A:1019024913274)]; Asahi R, 2001, SCIENCE, V293, P269, DOI 10.1126/science.1061051; BIRD RE, 1983, SOL ENERGY, V30, P563, DOI 10.1016/0038-092X(83)90068-3; Bolton JR, 1996, SOL ENERGY, V57, P37, DOI 10.1016/0038-092X(96)00032-1; BRECKENRIDGE RG, 1953, PHYS REV, V91, P793, DOI 10.1103/PhysRev.91.793; CHOI WY, 1994, J PHYS CHEM-US, V98, P13669, DOI 10.1021/j100102a038; CRONEMEYER DC, 1959, PHYS REV, V113, P1222, DOI 10.1103/PhysRev.113.1222; FUJISHIMA A, 1972, NATURE, V238, P37, DOI 10.1038/238037a0; GHOSH AK, 1977, J ELECTROCHEM SOC, V124, P1516, DOI 10.1149/1.2133104; HOFFMANN MR, 1995, CHEM REV, V95, P69, DOI 10.1021/cr00033a004; Khan SUM, 1999, J PHYS CHEM B, V103, P7184, DOI 10.1021/jp990066k; Khan SUM, 1998, J ELECTROCHEM SOC, V145, P89, DOI 10.1149/1.1838217; Khaselev O, 1998, SCIENCE, V280, P425, DOI 10.1126/science.280.5362.425; Licht S, 2000, J PHYS CHEM B, V104, P8920, DOI 10.1021/jp002083b; O'regan B., 1991, NATURE, V353, P737, DOI [DOI 10.1038/53737A0, 10.1038/353737a0, DOI 10.1038/353737A0]; Ollis D.F., 1993, PHOTOCATALYTIC PURIF; Rothenberger G, 1999, SOL ENERG MAT SOL C, V58, P321, DOI 10.1016/S0927-0248(99)00015-X; Sauve G, 2000, J PHYS CHEM B, V104, P3488, DOI 10.1021/jp994033g; Wouters Y, 1997, SOLID STATE IONICS, V104, P89, DOI 10.1016/S0167-2738(97)00400-1	21	3880	4046	44	2796	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 27	2002	297	5590					2243	2245		10.1126/science.1075035	http://dx.doi.org/10.1126/science.1075035			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	597LA	12351783				2022-12-28	WOS:000178222000041
J	Manns, BJ; Lee, H; Doig, CJ; Johnson, D; Donaldson, C				Manns, BJ; Lee, H; Doig, CJ; Johnson, D; Donaldson, C			An economic evaluation of activated protein C treatment for severe sepsis.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							QUALITY-OF-LIFE; INTENSIVE-CARE; SEPTIC SHOCK; COSTS; HEALTH; UNCERTAINTY; SURVIVORS	Background: Recombinant human activated protein C was shown in the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study to reduce mortality among patients with severe sepsis. A post hoc reanalysis by the Food and Drug Administration (FDA) of data from this study suggested that the reduction in mortality was restricted to patients with Acute Physiology and Chronic Health Evaluation (APACHE II) scores of 25 or more. Methods: We estimated the cost effectiveness of activated protein C as compared with conventional care for patients with severe sepsis. We performed an economic analysis involving all patients, as well as analyses of subgroups defined according to age and severity of illness. The probabilities of transition between clinical states and the estimates of resource use were derived from a population-based cohort of patients with severe sepsis. We used data on the effectiveness of activated protein C from the PROWESS study and analyses by the FDA. Results: The cost per life-year gained by treating all patients with activated protein C was $27,936. It was more cost effective to treat patients with an APACHE II score of 25 or more ($24,484 per life-year gained) than those with a lower APACHE II score ($35,632 per life-year gained). The cost effectiveness of treating patients with an APACHE II score of 24 or less increased to $575,054 per life-year gained when the FDA's estimates of effectiveness were considered. For patients with an APACHE II score of 25 or more, the cost per life-year gained increased with age ($16,309 for patients less than 40 years of age; $28,100 for those 80 years of age or older). Conclusions: Activated protein C is relatively cost effective when targeted to patients with severe sepsis, greater severity of illness (an APACHE II score of 25 or more), and a reasonable life expectancy if they survive the episode of sepsis. Further research is needed to determine the cost effectiveness of activated protein C for patients with sepsis and less severe illness.	Inst Hlth Econ, Edmonton, AB, Canada; Univ Calgary, Dept Med, Calgary, AB, Canada; Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada; Univ Calgary, Dept Econ, Calgary, AB T2N 1N4, Canada; Alberta Ctr Hlth Serv Utilizat Res, Edmonton, AB, Canada; Univ Alberta, Div Crit Care Med, Edmonton, AB, Canada	University of Calgary; University of Calgary; University of Calgary; University of Alberta	Manns, BJ (corresponding author), Foothills Med Ctr, 1403 29th St NW, Calgary, AB T2N 2T9, Canada.	manns@calgaryhealthregion.ca	Doig, Christopher/AAC-7949-2020; Manns, Braden J/I-8942-2012	Doig, Christopher/0000-0002-8576-9139; Donaldson, Cam/0000-0003-4670-5340				*AC RESP DISTR SYN, 2000, NEW ENGL J MED, V342, P1301, DOI DOI 10.1056/NEJM200005043421801; Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; Angus DC, 2001, AM J RESP CRIT CARE, V163, P1389, DOI 10.1164/ajrccm.163.6.2005123; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; Briggs A, 1998, HEALTH ECON, V7, P723, DOI 10.1002/(SICI)1099-1050(199812)7:8<723::AID-HEC392>3.3.CO;2-F; BRIGGS A, 1994, HEALTH ECON, V3, P95, DOI 10.1002/hec.4730030206; BRUNBUISSON C, 1995, JAMA-J AM MED ASSOC, V274, P968, DOI 10.1001/jama.274.12.968; *CAN I HLTH INF, 1999, GUID MAN INF SYST CA; CRITCHFIELD GC, 1986, MED DECIS MAKING, V6, P85, DOI 10.1177/0272989X8600600205; Davidson TA, 1999, JAMA-J AM MED ASSOC, V281, P354, DOI 10.1001/jama.281.4.354; Drummond MF, 1996, BRIT MED J, V313, P275, DOI 10.1136/bmj.313.7052.275; Edbrooke DL, 1997, INTENS CARE MED, V23, P645, DOI 10.1007/s001340050388; Edbrooke DL, 1999, CRIT CARE MED, V27, P1760, DOI 10.1097/00003246-199909000-00010; *FDA, XIGR DROTR ALF ACT P; Gold MR, 1996, COST EFFECTIVENESS H; Heyland DK, 2000, CRIT CARE MED, V28, P3599, DOI 10.1097/00003246-200011000-00006; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KONOPAD E, 1995, CRIT CARE MED, V23, P1653, DOI 10.1097/00003246-199510000-00008; Liljas B, 1998, PHARMACOECONOMICS, V13, P1, DOI 10.2165/00019053-199813010-00001; MCKILLOP I, 1995, RES PROJECT EXAMINE; MCKILLOP I, 2001, FINANC MANAGE, P83; Montuclard L, 2000, CRIT CARE MED, V28, P3389, DOI 10.1097/00003246-200010000-00002; MUNN J, 1995, ANAESTHESIA, V50, P1017, DOI 10.1111/j.1365-2044.1995.tb05942.x; OBrien B, 1996, MED CARE, V34, pDS99; PITTET D, 1995, INTENS CARE MED, V21, P302, DOI 10.1007/BF01705408; Quan HD, 2002, MED CARE, V40, P675, DOI 10.1097/00005650-200208000-00007; Quartin AA, 1997, JAMA-J AM MED ASSOC, V277, P1058, DOI 10.1001/jama.277.13.1058; *STAT CAN, 1992, 62553 STAT CAN; *STAT CAN, 1998, 13F0016XPB STAT CAN; The World Bank, 2001, WORLD DEV IND 2000; 1997, GUIDELINES EC EVALUA; [No title captured]	32	166	169	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 26	2002	347	13					993	1000		10.1056/NEJMsa020969	http://dx.doi.org/10.1056/NEJMsa020969			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	596RD	12324556				2022-12-28	WOS:000178178400006
J	Spurdle, AB; Hopper, JL; Chen, XQ; McCredie, MRE; Giles, GG; Newman, B; Chenevix-Trench, G				Spurdle, AB; Hopper, JL; Chen, XQ; McCredie, MRE; Giles, GG; Newman, B; Chenevix-Trench, G			Prohibitin 3 ' untranslated region polymorphism and breast cancer risk in Australian women	LANCET			English	Article							3'-UNTRANSLATED REGION	A C to T transition within the 3' untranslated region of the prohibitin gene alters mRNA function, and an association between the T allele and an increased risk of breast cancer has been reported in North American women, specifically in those aged under 50 years with a first-degree family history of breast cancer. We did a population-based case-control study to assess whether this association existed in Australian women. We did not note such an association in our sample of 1446 patients and 786 controls (odds ratio 0.96, 95% Cl 0.80-1.16; p=0.7), or in subgroups defined by age or family history, or both. Hence, our results do not lend support to the hypothesis that this polymorphism contributes to risk of breast cancer.	Queensland Inst Med Res, Joint Expt Oncol Programme, Canc & Cell Biol Div, Brisbane, Qld 4006, Australia; Univ Queensland, Brisbane, Qld, Australia; Univ Melbourne, Ctr Genet Epidemiol, Carlton, Vic 3053, Australia; New S Wales Canc Council, Kings Cross, NSW, Australia; Univ Otago, Dept Prevent & Social Med, Dunedin, New Zealand; Anticanc Council Victoria, Canc Epidemiol Ctr, Carlton, Vic, Australia; Queensland Univ Technol, Sch Publ Hlth, Brisbane, Qld, Australia	QIMR Berghofer Medical Research Institute; University of Queensland; University of Melbourne; Cancer Council New South Wales; University of Otago; Queensland University of Technology (QUT); University of Queensland	Spurdle, AB (corresponding author), PO Royal Brisbane Hosp, Queensland Inst Med Res, Canc & Cell Biol Div, Melbourne, Vic 4029, Australia.		Chenevix-Trench, Georgia/AAV-2014-2020; Spurdle, Amanda B/A-4978-2011	Chenevix-Trench, Georgia/0000-0002-1878-2587; Spurdle, Amanda B/0000-0003-1337-7897; Giles, Graham/0000-0003-4946-9099				Hopper J L, 1999, J Natl Cancer Inst Monogr, P95; Jupe ER, 2001, LANCET, V357, P1588, DOI 10.1016/S0140-6736(00)04747-4; Jupe ER, 1996, CELL GROWTH DIFFER, V7, P871; Spurdle AB, 2000, J NATL CANCER I, V92, P1674, DOI 10.1093/jnci/92.20.1674; Wang S, 1999, ONCOGENE, V18, P3501, DOI 10.1038/sj.onc.1202684	5	23	29	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 21	2002	360	9337					925	926		10.1016/S0140-6736(02)11043-9	http://dx.doi.org/10.1016/S0140-6736(02)11043-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	596AU	12354477				2022-12-28	WOS:000178142200014
J	Kang, DE; Soriano, S; Xia, XF; Eberhart, CG; De Strooper, B; Zheng, H; Koo, EH				Kang, DE; Soriano, S; Xia, XF; Eberhart, CG; De Strooper, B; Zheng, H; Koo, EH			Presenilin couples the paired phosphorylation of beta-catenin independent of axin: Implications for beta-catenin activation in tumorigenesis	CELL			English	Article							GLYCOGEN-SYNTHASE KINASE-3; FAMILIAL ALZHEIMERS-DISEASE; CENTRAL-NERVOUS-SYSTEM; SUBCELLULAR-DISTRIBUTION; NEGATIVE REGULATOR; MISSENSE MUTATIONS; SIGNALING PATHWAY; GENE-EXPRESSION; CELL-ADHESION; PROTEIN	The Alzheimer's disease-linked gene presenilin 1 (PS1) is required for intramembrane proteolysis of APP and Notch. In addition, recent observations strongly implicate PS1 as a negative regulator of the Wnt/beta-catenin signaling pathway, although the mechanism underlying this activity is unknown. Here, we show that presenilin functions as a scaffold that rapidly couples beta-catenin phosphorylation through two sequential kinase activities independent of the Wnt-regulated Axin/ CK1alpha complex. Thus, presenilin deficiency results in increased beta-catenin stability in vitro and in vivo by disconnecting the stepwise phosphorylation of beta-catenin, both in the presence and absence of Wnt stimulation. These findings highlight an aspect of beta-catenin regulation outside of the canonical Writ-regulated pathway and a function of presenilin separate from intramembrane proteolysis.	Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; Baylor Coll Med, Huffington Ctr Aging, Dept Mol & Human Genet, Houston, TX 77030 USA; Johns Hopkins Univ Hosp, Dept Pathol, Baltimore, MD 21287 USA; Flanders Interuniv, Inst Biotechnol, Dept Human Genet, B-3000 Louvain, Belgium; Katholieke Univ Leuven, B-3000 Louvain, Belgium	University of California System; University of California San Diego; Baylor College of Medicine; Johns Hopkins University; Johns Hopkins Medicine; KU Leuven	Koo, EH (corresponding author), Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA.		soriano, salvador/AAB-5595-2022; de+Strooper, Bart/Z-1638-2019; Kang, David E./E-5234-2012; De Strooper, Bart/F-6507-2012	De Strooper, Bart/0000-0001-5455-5819; Kang, David E./0000-0002-7132-821X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040039, P01NS028121] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000216] Funding Source: NIH RePORTER; NIA NIH HHS [5T32 AG00216-10] Funding Source: Medline; NINDS NIH HHS [NS40039, NS28121] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302; Barth AIM, 1997, J CELL BIOL, V136, P693, DOI 10.1083/jcb.136.3.693; Ben-Ze'ev A, 2000, EXP CELL RES, V261, P75, DOI 10.1006/excr.2000.5045; BIERER LM, 1990, LANCET, V335, P163, DOI 10.1016/0140-6736(90)90031-Y; Cox RT, 2000, GENETICS, V155, P1725; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; De Strooper B, 2001, NAT CELL BIOL, V3, pE221, DOI 10.1038/ncb1001-e221; De Strooper B, 2001, J CELL BIOL, V152, pF17, DOI 10.1083/jcb.152.4.F17; DICKINSON ME, 1994, DEVELOPMENT, V120, P1453; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Eberhart CG, 2000, J NEUROPATH EXP NEUR, V59, P333, DOI 10.1093/jnen/59.4.333; FIOL CJ, 1990, J BIOL CHEM, V265, P6061; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; Fujiwara H, 2002, NAT CELL BIOL, V4, P160, DOI 10.1038/ncb748; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; ISHIGURO K, 1992, J BIOL CHEM, V267, P10897; Jicha GA, 1999, J NEUROSCI, V19, P7486, DOI 10.1523/JNEUROSCI.19-17-07486.1999; Kang DE, 1999, J NEUROSCI, V19, P4229; Killick R, 2001, J BIOL CHEM, V276, P48554, DOI 10.1074/jbc.M108332200; Kopan R, 2000, GENE DEV, V14, P2799, DOI 10.1101/gad.836900; Kosik KS, 1999, NAT MED, V5, P149, DOI 10.1038/5510; Lardelli M, 1996, MECH DEVELOP, V59, P177, DOI 10.1016/0925-4773(96)00589-8; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Megason SG, 2002, DEVELOPMENT, V129, P2087; Neo SY, 2000, BIOCHEM BIOPH RES CO, V272, P144, DOI 10.1006/bbrc.2000.2751; Noll E, 2000, DEV BIOL, V227, P450, DOI 10.1006/dbio.2000.9925; Pai LM, 1997, DEVELOPMENT, V124, P2255; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Polakis P, 2000, GENE DEV, V14, P1837; Price MA, 2002, CELL, V108, P823, DOI 10.1016/S0092-8674(02)00664-5; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Seeger M, 1997, P NATL ACAD SCI USA, V94, P5090, DOI 10.1073/pnas.94.10.5090; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Shibamoto S, 1998, GENES CELLS, V3, P659; SONANO S, 2001, J CELL BIOL, V152, P785; Walter J, 1998, BIOCHEMISTRY-US, V37, P5961, DOI 10.1021/bi971763a; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Xia XF, 2001, P NATL ACAD SCI USA, V98, P10863, DOI 10.1073/pnas.191284198; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhang JM, 1998, J BIOL CHEM, V273, P12436, DOI 10.1074/jbc.273.20.12436	50	208	216	0	12	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 20	2002	110	6					751	762		10.1016/S0092-8674(02)00970-4	http://dx.doi.org/10.1016/S0092-8674(02)00970-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	596TV	12297048	Bronze			2022-12-28	WOS:000178182800010
J	Ashraf, H				Ashraf, H			Europe's response to bioterrorism starts slowly but gathers pace	LANCET			English	Article																		2001, EURO SURVEILL, V6, P159	1	4	4	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 7	2002	360	9335					733	734		10.1016/S0140-6736(02)09943-9	http://dx.doi.org/10.1016/S0140-6736(02)09943-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	592HX	12296303				2022-12-28	WOS:000177933000005
J	Gollogly, L				Gollogly, L			The dilemmas of aid: Cambodia 1992-2002	LANCET			English	Article								Cambodia is a small, poor, and sparsely-populated country between Vietnam and Thailand, which is making a slow recovery from a long history of conflict. 80% of its 11.4 million people live by subsistence farming; rice is their main crop. Infant mortality is 89.4/1000, and 12% of children die before the age of 5 years. Life expectancy is around 50 years, and about 45 000 Khmers (Cambodians) are missing at least one limb from a 30 year deposit of landmines and dumping unexploded ordinance. Despite a decade of concerted effort by the international community to improve Cambodia's prospects, disease and poverty still define life for most of the population. In April, 2002, 1 visited Cambodia for the fourth time in 10 years, to see how medical aid projects were faring in particular, and to assess whether the past decade of international aid and intervention has improved the provision of health care for Khmers.	Lancet, London NW1 7BY, England		Gollogly, L (corresponding author), Lancet, 32 Jamestown Rd, London NW1 7BY, England.							BIDDULPH R, 2000, LANDLESSNESS DEV RES; CHANDLER DP, 1983, HIST CAMBODIA, P162; *COMM RES STUD COU, 2001, REP COUNT SUBST DRUG; EASTERLY W, 2001, ELUSIVE QUEST GROWTH, P118; Feenstra P., 2001, CONTRACTING SIMILAR; *HLTH NET INT, 2000, ANN REP; *MED SANS FRONT, 2000, ACT REP 1999 2000, P80; *MIN HLTH KINGD CA, 2000, NAT HLTH STAT; ROSE G, 2002, PRIVATE PRACTITIONER; Shawcross William, 1994, CAMBODIAS NEW DEAL; *SIH HOSP CTR HOPE, 2001, ANN REP PROGR UPD 20; *US DEP STAT, 2000, 1999 COUNTR REP HUM; *US DEP STAT, 1996, BACKGR NOT; Wilkinson D, 2001, IMPACT USER FEES ACC; 2000, ASIA TIMES ONLI 0926	15	12	12	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 7	2002	360	9335					793	798		10.1016/S0140-6736(02)09904-X	http://dx.doi.org/10.1016/S0140-6736(02)09904-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	592HX	12241843				2022-12-28	WOS:000177933000026
J	Verheugt, FWA				Verheugt, FWA			Who is to blame?	LANCET			English	Article									Univ Med Ctr St Radboud, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	Verheugt, FWA (corresponding author), Univ Med Ctr St Radboud, NL-6500 HB Nijmegen, Netherlands.		Verheugt, F.W.A./H-8105-2014						0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 7	2002	360	9335					789	789		10.1016/S0140-6736(02)09902-6	http://dx.doi.org/10.1016/S0140-6736(02)09902-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	592HX	12241841				2022-12-28	WOS:000177933000024
J	Watts, J				Watts, J			Balancing the "axis of evil" in northeast Asia	LANCET			English	Article																			0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 7	2002	360	9335					735	735		10.1016/S0140-6736(02)09940-3	http://dx.doi.org/10.1016/S0140-6736(02)09940-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	592HX	12296305				2022-12-28	WOS:000177933000007
J	Shaw, T; Elliott, P; McKenna, WJ				Shaw, T; Elliott, P; McKenna, WJ			Dilated cardiomyopathy: a genetically heterogeneous disease	LANCET			English	Editorial Material							MICE; HEART; GENE		St George Hosp, Sch Med, Dept Cardiol Sci, London SW17 0RE, England	St Georges University London	Shaw, T (corresponding author), St George Hosp, Sch Med, Dept Cardiol Sci, London SW17 0RE, England.		McKenna, William J/C-3243-2008; Elliott, Perry/AAR-3430-2020	McKenna, William J/0000-0001-7994-2460; Elliott, Perry/0000-0003-3383-3984				Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; Crone SA, 2002, NAT MED, V8, P459, DOI 10.1038/nm0502-459; Emanueli C, 1999, CIRCULATION, V100, P2359, DOI 10.1161/01.CIR.100.23.2359; Fatkin D, 1999, NEW ENGL J MED, V341, P1715, DOI 10.1056/NEJM199912023412302; Fentzke RC, 1998, J CLIN INVEST, V101, P2415, DOI 10.1172/JCI2950; Grunig E, 1998, J AM COLL CARDIOL, V31, P186, DOI 10.1016/S0735-1097(97)00434-8; Kiriazis H, 2000, ANNU REV PHYSIOL, V62, P321, DOI 10.1146/annurev.physiol.62.1.321; MUNTONI F, 1993, NEW ENGL J MED, V329, P921, DOI 10.1056/NEJM199309233291304; Nebigil CG, 2001, CIRCULATION, V103, P2973, DOI 10.1161/01.CIR.103.24.2973; Olson TM, 2002, CIRCULATION, V105, P431, DOI 10.1161/hc0402.102930; Ross J, 2002, CIRC J, V66, P219, DOI 10.1253/circj.66.219; Subbarayan V, 2000, J CLIN INVEST, V105, P387, DOI 10.1172/JCI8150; Towbin JA, 2002, NATURE, V415, P227, DOI 10.1038/415227a; TOWBIN JA, 1993, CIRCULATION, V87, P1854, DOI 10.1161/01.CIR.87.6.1854; TOWBIN JA, 2000, MOL CLIN GENETICS CA, P195	15	34	36	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 31	2002	360	9334					654	655		10.1016/S0140-6736(02)09879-3	http://dx.doi.org/10.1016/S0140-6736(02)09879-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	590AM	12241867				2022-12-28	WOS:000177795100002
J	Young, RK				Young, RK			What will I do without you?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 16	2002	288	15					1823	1824		10.1001/jama.288.15.1823	http://dx.doi.org/10.1001/jama.288.15.1823			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604EU	12377066				2022-12-28	WOS:000178604200001
J	Santori, C; Fattal, D; Vuckovic, J; Solomon, GS; Yamamoto, Y				Santori, C; Fattal, D; Vuckovic, J; Solomon, GS; Yamamoto, Y			Indistinguishable photons from a single-photon device	NATURE			English	Article							QUANTUM-DOT; TURNSTILE DEVICE; ROOM-TEMPERATURE; MICROCAVITIES; INTERFERENCE; EMISSION; MOLECULE; TIME	Single-photon sources have recently been demonstrated using a variety of devices, including molecules(1-3), mesoscopic quantum wells(4), colour centres(5), trapped ions(6) and semiconductor quantum dots(7-11). Compared with a Poisson-distributed source of the same intensity, these sources rarely emit two or more photons in the same pulse. Numerous applications for single-photon sources have been proposed in the field of quantum information, but most-including linear-optical quantum computation(12)-also require consecutive photons to have identical wave packets. For a source based on a single quantum emitter, the emitter must therefore be excited in a rapid or deterministic way, and interact little with its surrounding environment. Here we test the indistinguishability of photons emitted by a semiconductor quantum dot in a microcavity through a Hong-Ou-Mandel-type two-photon interference experiment(13,14). We find that consecutive photons are largely indistinguishable, with a mean wave-packet overlap as large as 0.81, making this source useful in a variety of experiments in quantum optics and quantum information.	Stanford Univ, Edward L Ginzton Lab, JST, ICORP,Quantum Entanglement Project, Stanford, CA 94305 USA; Stanford Univ, Solid State Photon Lab, Stanford, CA 94305 USA; NTT Corp, Basic Res Labs, Kanagawa 2430198, Japan	Stanford University; Stanford University; Nippon Telegraph & Telephone Corporation	Santori, C (corresponding author), Stanford Univ, Edward L Ginzton Lab, JST, ICORP,Quantum Entanglement Project, Stanford, CA 94305 USA.	chars@stanford.edu	Vuckovic, Jelena/A-7335-2019; Santori, Charles/A-7314-2009; Yamamoto, Yoshihisa/A-2811-2012; Fattal, David A/A-8920-2013	Vuckovic, Jelena/0000-0002-4603-9686; Yamamoto, Yoshihisa/0000-0002-4150-6804; Fattal, David A/0000-0003-1902-6115				Bayer M, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.041308; Bennett CH., 1984, P IEEE INT C COMP SY, P175; Beveratos A, 2002, EUR PHYS J D, V18, P191, DOI 10.1140/epjd/e20020023; Borri P, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.157401; Bouwmeester D, 2000, PHYSICS OF QUANTUM INFORMATION, P49; Brunel C, 1999, PHYS REV LETT, V83, P2722, DOI 10.1103/PhysRevLett.83.2722; De Martini F, 1996, PHYS REV LETT, V76, P900, DOI 10.1103/PhysRevLett.76.900; Fan XD, 1998, SOLID STATE COMMUN, V108, P857, DOI 10.1016/S0038-1098(98)00461-X; FEARN H, 1989, J OPT SOC AM B, V6, P917, DOI 10.1364/JOSAB.6.000917; Gammon D, 1996, SCIENCE, V273, P87, DOI 10.1126/science.273.5271.87; Gerard JM, 1999, J LIGHTWAVE TECHNOL, V17, P2089, DOI 10.1109/50.802999; HONG CK, 1987, PHYS REV LETT, V59, P2044, DOI 10.1103/PhysRevLett.59.2044; Kim J, 1999, NATURE, V397, P500, DOI 10.1038/17295; Knill E, 2001, NATURE, V409, P46, DOI 10.1038/35051009; Kuhn A, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.067901; Kulakovskii VD, 1999, PHYS REV LETT, V82, P1780, DOI 10.1103/PhysRevLett.82.1780; Lounis B, 2000, NATURE, V407, P491, DOI 10.1038/35035032; Michler P, 2000, SCIENCE, V290, P2282, DOI 10.1126/science.290.5500.2282; Moreau E, 2001, APPL PHYS LETT, V79, P2865, DOI 10.1063/1.1415346; Santori C, 2001, PHYS REV LETT, V86, P1502, DOI 10.1103/PhysRevLett.86.1502; SHIH YH, 1988, PHYS REV LETT, V61, P2921, DOI 10.1103/PhysRevLett.61.2921; Solomon GS, 2001, PHYS REV LETT, V86, P3903, DOI 10.1103/PhysRevLett.86.3903; Yuan ZL, 2002, SCIENCE, V295, P102, DOI 10.1126/science.1066790; Zwiller V, 2001, APPL PHYS LETT, V78, P2476, DOI 10.1063/1.1366367	25	1224	1237	7	335	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 10	2002	419	6907					594	597		10.1038/nature01086	http://dx.doi.org/10.1038/nature01086			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	602AT	12374958				2022-12-28	WOS:000178483100038
J	Macfarlane, C; Connor, E				Macfarlane, C; Connor, E			Development of BNF for handheld devices is taking time	BRITISH MEDICAL JOURNAL			English	Letter									British Natl Formulary, London SE1 7JN, England; Pharmaceut Press, London SE1 7JN, England		Macfarlane, C (corresponding author), British Natl Formulary, London SE1 7JN, England.								0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 5	2002	325	7367					777	777		10.1136/bmj.325.7367.777	http://dx.doi.org/10.1136/bmj.325.7367.777			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	603AU	12364316	Green Published			2022-12-28	WOS:000178537300034
J	Volkman, SK; Hartl, DL; Wirth, DF; Nielsen, KM; Choi, M; Batalov, S; Zhou, YY; Plouffe, D; Le Roch, KG; Abagyan, R; Winzeler, EA				Volkman, SK; Hartl, DL; Wirth, DF; Nielsen, KM; Choi, M; Batalov, S; Zhou, YY; Plouffe, D; Le Roch, KG; Abagyan, R; Winzeler, EA			Excess Polymorphisms in genes for membrane proteins in Plasmodium falciparum	SCIENCE			English	Article							RECOMBINATION; SEQUENCE; ARRAYS; SIZE	The detection of single-nucleotide polymorphisms in pathogenic microorganisms has normally been carried out by trial and error. Here we show that DNA hybridization with high-density oligonucleotide arrays provides rapid and convenient detection of single-nucleotide polymorphisms in Plasmodium falciparum, despite its exceptionally high adenine-thymine (AT) content (82%). A disproportionate number of polymorphisms are found in genes encoding proteins associated with the cell membrane. These genes are targets for only 22% of the oligonucleotide probes but account for 69% of the polymorphisms. Genetic variation is also enriched in subtelomeric regions, which account for 22% of the chromosome but 76% of the polymorphisms.	Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA; Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA; Univ Tromso, Dept Pharm, N-9037 Tromso, Norway	Novartis; Scripps Research Institute; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; UiT The Arctic University of Tromso	Winzeler, EA (corresponding author), Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA.		Winzeler, Elizabeth/AAP-6752-2020; Nielsen, Kaare Magne/G-8107-2018	Winzeler, Elizabeth/0000-0002-4049-2113; Nielsen, Kaare Magne/0000-0002-7217-2114; Batalov, Sergey/0000-0002-0925-0554	NIGMS NIH HHS [GM61351] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061351] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; Clark AG, 2002, NATURE, V418, P283, DOI 10.1038/418283a; CORCORAN LM, 1988, CELL, V53, P807, DOI 10.1016/0092-8674(88)90097-9; Freitas-Junior LH, 2000, NATURE, V407, P1018, DOI 10.1038/35039531; Gardner MJ, 1998, SCIENCE, V282, P1126, DOI 10.1126/science.282.5391.1126; Hughes AL, 2001, P ROY SOC B-BIOL SCI, V268, P1855, DOI 10.1098/rspb.2001.1759; Mu JB, 2002, NATURE, V418, P323, DOI 10.1038/nature00836; PEASE AC, 1994, P NATL ACAD SCI USA, V91, P5022, DOI 10.1073/pnas.91.11.5022; Taylor HM, 2000, MOL BIOCHEM PARASIT, V110, P391, DOI 10.1016/S0166-6851(00)00286-3; Volkman SK, 2001, SCIENCE, V293, P482, DOI 10.1126/science.1059878; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901	11	76	79	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 4	2002	298	5591					216	218		10.1126/science.1075642	http://dx.doi.org/10.1126/science.1075642			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	600BJ	12364807				2022-12-28	WOS:000178370500064
J	Abbott, A				Abbott, A			Rising star crashes back to Earth	NATURE			English	News Item																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 3	2002	419	6906					420	421		10.1038/419420a	http://dx.doi.org/10.1038/419420a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	599RF	12368820	Bronze			2022-12-28	WOS:000178348400005
J	Hyman, RW; Fung, E; Conway, A; Kurdi, O; Mao, J; Miranda, M; Nakao, B; Rowley, D; Tamaki, T; Wang, F; Davis, RW				Hyman, RW; Fung, E; Conway, A; Kurdi, O; Mao, J; Miranda, M; Nakao, B; Rowley, D; Tamaki, T; Wang, F; Davis, RW			Sequence of Plasmodium falciparum chromosome 12	NATURE			English	Article							PROTEINS; SITES; TOOL	The human malaria parasite Plasmodium falciparum is responsible for the death of more than a million people every year(1). To stimulate basic research on the disease, and to promote the development of effective drugs and vaccines against the parasite, the complete genome of P. falciparum clone 3D7 has been sequenced, using a chromosome-by-chromosome shotgun strategy(2-4). Here we report the nucleotide sequence of the third largest of the parasite's 14 chromosomes, chromosome 12, which comprises about 10% of the 23-megabase genome. As the most (A + T)-rich (80.6%) genome sequenced to date, the P. falciparum genome presented severe problems during the assembly of primary sequence reads. We discuss the methodology that yielded a finished and fully contiguous sequence for chromosome 12. The biological implications of the sequence data are more thoroughly discussed in an accompanying Article (ref. 3).	Stanford Univ, Genome Technol Ctr, Palo Alto, CA 94304 USA; Stanford Univ, Dept Biochem, Coll Med, Stanford, CA 94305 USA; Stanford Univ, Dept Genet, Coll Med, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University	Hyman, RW (corresponding author), Stanford Univ, Genome Technol Ctr, 855 Calif Ave, Palo Alto, CA 94304 USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Apweiler R, 2001, NUCLEIC ACIDS RES, V29, P37, DOI 10.1093/nar/29.1.37; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Bowman S, 1999, NATURE, V400, P532, DOI 10.1038/22964; Breman JG, 2001, AM J TROP MED HYG, V64, P1; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Florens L, 2002, NATURE, V419, P520, DOI 10.1038/nature01107; Gardner MJ, 1998, SCIENCE, V282, P1126, DOI 10.1126/science.282.5391.1126; Gardner MJ, 2002, NATURE, V419, P531, DOI 10.1038/nature01094; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; Hall N, 2002, NATURE, V419, P527, DOI 10.1038/nature01095; Jing JP, 1999, GENOME RES, V9, P175; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Lasonder E, 2002, NATURE, V419, P537, DOI 10.1038/nature01111; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Oefner PJ, 1996, NUCLEIC ACIDS RES, V24, P3879, DOI 10.1093/nar/24.20.3879; Rubio JP, 1996, EMBO J, V15, P4069, DOI 10.1002/j.1460-2075.1996.tb00780.x; Su XZ, 1999, SCIENCE, V286, P1351, DOI 10.1126/science.286.5443.1351; Su XZ, 1999, EXP PARASITOL, V91, P367, DOI 10.1006/expr.1998.4390	24	50	52	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 3	2002	419	6906					534	537		10.1038/nature01102	http://dx.doi.org/10.1038/nature01102			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	599RF	12368869				2022-12-28	WOS:000178348400050
J	O'Sullivan, BP; Jaramillo, D; Colvin, RB; Anselmo, MA; Niles, JL; Erickson, LA; Whelan, JP				O'Sullivan, BP; Jaramillo, D; Colvin, RB; Anselmo, MA; Niles, JL; Erickson, LA; Whelan, JP			An eight-year-old girl with fever, hemoptysis, and pulmonary consolidations. Antimyeloperoxidase ANCA associated vasculitis (microscopic polyangiitis), with pulmonary hemorrhage.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							DIFFUSE ALVEOLAR HEMORRHAGE; WEGENER GRANULOMATOSIS; CLINICAL PRESENTATION; GLOMERULONEPHRITIS; CYCLOPHOSPHAMIDE; CHILDHOOD; CHILDREN; DISEASE		UMass Mem Hlth Care, Cyst Fibrosis Ctr, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Worcester, MA USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	O'Sullivan, BP (corresponding author), UMass Mem Hlth Care, Cyst Fibrosis Ctr, Worcester, MA 01655 USA.							Ball JA, 1998, CLIN CHEST MED, V19, P777, DOI 10.1016/S0272-5231(05)70116-7; Cordier JF, 1996, SARCOIDOSIS VASC DIF, V13, P235; DEVITA VT, 2001, CANC PRINCIPLES PRAC, V2, P2929; Falk RJ, 1997, J AM SOC NEPHROL, V8, P314; Falk RJ, 2000, SEMIN NEPHROL, V20, P233; FANBURG BL, 1993, NEW ENGL J MED, V329, P2019; GAUDIN PB, 1995, AM J CLIN PATHOL, V104, P7, DOI 10.1093/ajcp/104.1.7; Guillevin L, 1999, ARTHRITIS RHEUM-US, V42, P421, DOI 10.1002/1529-0131(199904)42:3<421::AID-ANR5>3.0.CO;2-6; Hattori M, 2001, J AM SOC NEPHROL, V12, P1493, DOI 10.1681/ASN.V1271493; HOFFMAN GS, 1992, ANN INTERN MED, V116, P488, DOI 10.7326/0003-4819-116-6-488; Jennette JC, 1997, NEW ENGL J MED, V337, P1512, DOI 10.1056/NEJM199711203372106; JENNETTE JC, 1994, ARTHRITIS RHEUM-US, V37, P187, DOI 10.1002/art.1780370206; JONES EM, 1991, PEDIATR CLIN N AM, V38, P1019; KELLY PT, 1994, MEDICINE, V73, P171, DOI 10.1097/00005792-199407000-00001; Langford CA, 1999, ARTHRITIS RHEUM, V42, P2666, DOI 10.1002/1529-0131(199912)42:12<2666::AID-ANR24>3.0.CO;2-E; Langford CA, 2001, AM J MED SCI, V321, P76, DOI 10.1097/00000441-200101000-00011; Lauque D, 2000, MEDICINE, V79, P222, DOI 10.1097/00005792-200007000-00003; LEAVITT RY, 1990, ARTHRITIS RHEUM, V33, P1101, DOI 10.1002/art.1780330807; MILLER RW, 1986, J PEDIATR-US, V108, P576, DOI 10.1016/S0022-3476(86)80839-3; MILLS JA, 1994, NEW ENGL J MED, V330, P1871, DOI 10.1056/NEJM199406303302608; Niles JL, 1996, ARCH INTERN MED, V156, P440, DOI 10.1001/archinte.156.4.440; QUIGLEY C, 1989, NEW ENGL J MED, V321, P143, DOI 10.1056/NEJM198907203210303; Rasmussen N, 2001, CURR OPIN RHEUMATOL, V13, P3, DOI 10.1097/00002281-200101000-00002; ROTTEM M, 1993, J PEDIATR-US, V122, P26, DOI 10.1016/S0022-3476(05)83482-1; Salama AD, 2001, LANCET, V358, P917, DOI 10.1016/S0140-6736(01)06077-9; Savage COS, 2000, BRIT MED J, V320, P1325, DOI 10.1136/bmj.320.7245.1325; Specks U, 2001, CURR OPIN RHEUMATOL, V13, P12, DOI 10.1097/00002281-200101000-00003; Stone JH, 2001, CURR OPIN RHEUMATOL, V13, P23, DOI 10.1097/00002281-200101000-00005; von Vigier RO, 2000, PEDIATR PULM, V29, P382, DOI 10.1002/(SICI)1099-0496(200005)29:5<382::AID-PPUL7>3.0.CO;2-D; WATSON AR, 1986, FERTIL STERIL, V46, P331; Zamora MR, 1997, MEDICINE, V76, P192, DOI 10.1097/00005792-199705000-00005; Zeitouni NC, 2000, BRIT J DERMATOL, V142, P343, DOI 10.1046/j.1365-2133.2000.03306.x; 1993, N ENGL J MED, V328, P1138	33	3	3	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 26	2002	347	13					1009	1017		10.1056/NEJMcpc020022	http://dx.doi.org/10.1056/NEJMcpc020022			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	596RD	12324558				2022-12-28	WOS:000178178400008
J	Akinyinka, OO				Akinyinka, OO			Infrared ear thermometry versus rectal thermometry in children	LANCET			English	Editorial Material							TYMPANIC MEMBRANE TEMPERATURES; PULMONARY-ARTERY; AXILLARY		Univ Coll Hosp, Dept Paediat, Coll Med, Ibadan, Nigeria	University of Ibadan; University College Hospital, Ibadan	Akinyinka, OO (corresponding author), Univ Coll Hosp, Dept Paediat, Coll Med, Ibadan, Nigeria.			Akinyinka, Olusegun/0000-0001-6752-8502				Akinyinka OO, 2001, ANN TROP PAEDIATR, V21, P169, DOI 10.1080/02724930120058269; Barber N, 1989, Pediatr Nurs, V15, P477; BRENNAN DF, 1995, ANN EMERG MED, V25, P21, DOI 10.1016/S0196-0644(95)70350-0; BROGAN P, 1993, LANCET, V342, P1364, DOI 10.1016/0140-6736(93)92275-X; FREED GL, 1992, PEDIATRICS, V89, P384; MILEWSKI A, 1991, CLIN PEDIATR, V30, P13, DOI 10.1177/0009922891030004S05; MUMA BK, 1991, ANN EMERG MED, V20, P41, DOI 10.1016/S0196-0644(05)81116-3; PETERSENSMITH A, 1994, J PEDIATR-US, V125, P83, DOI 10.1016/S0022-3476(94)70129-6; RHOADS FA, 1990, CLIN PEDIATR, V29, P112, DOI 10.1177/000992289002900209; Robinson JL, 1998, J PEDIATR-US, V133, P553, DOI 10.1016/S0022-3476(98)70067-8; Silverman BG, 1998, PUBLIC HEALTH REP, V113, P268; STEWART JV, 1992, ANN EMERG MED, V21, P158, DOI 10.1016/S0196-0644(05)80151-9; YETMAN RJ, 1993, J PEDIATR-US, V122, P769, DOI 10.1016/S0022-3476(06)80024-7	13	3	5	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 24	2002	360	9333					584	584		10.1016/S0140-6736(02)09810-0	http://dx.doi.org/10.1016/S0140-6736(02)09810-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	586TD	12241925				2022-12-28	WOS:000177600400003
J	Petersen, LR; Roehrig, JT; Hughes, JM				Petersen, LR; Roehrig, JT; Hughes, JM			Outlook: West Nile virus encephalitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Ctr Dis Control & Prevent, Ft Collins, CO 80522 USA; Ctr Dis Control & Prevent, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Petersen, LR (corresponding author), Ctr Dis Control & Prevent, Ft Collins, CO 80522 USA.			Roehrig, John/0000-0001-7581-0479					0	90	98	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 17	2002	347	16					1225	1226		10.1056/NEJMo020128	http://dx.doi.org/10.1056/NEJMo020128			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604CP	12270973				2022-12-28	WOS:000178598300002
J	Joyce, GF; Escarce, JJ; Solomon, MD; Goldman, DP				Joyce, GF; Escarce, JJ; Solomon, MD; Goldman, DP			Employer drug benefit plans and spending on prescription drugs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH MAINTENANCE ORGANIZATION; COST-CONTAINMENT; MEDICAID; PAYMENT; FORMULARY; MEMBERS; IMPACT	Context With drug spending rising rapidly for working-aged adults, many employers and health insurance providers have changed benefits packages to encourage use of fewer or less expensive drugs. It is unknown how these initiatives affect drug costs. Objective To examine how innovations in benefits packages, such as those that include multitier formularies and mandatory generic substitution, affect total cost to insurance providers for generic and brand drugs and out-of-pocket payments to beneficiaries. Design and Participants Retrospective study from 1997 to 1999 linking claims data of 420786 primary beneficiaries aged 18 through 64 years who worked at large firms (n = 25) with health insurance benefits that included outpatient drugs. Main Outcome Measures Overall drug costs; generic, single-source brand, and multisource brand costs; and drug expenditures by health insurance providers and out-of-pocket costs for beneficiaries. Results For a 1-tier plan with a $5 co-payment for all drugs,,the average annual spending was $725 per member. Doubling co-payments to $10 for all drugs reduced the annual average drug cost from $725 to $563 per member (22.3%, P<.001). Doubling co-payments in a 2-tier plan from $5 for generics and $10 for brand drugs to $10 for generics and $20 for brand drugs reduced costs from $678 to $455 (32.9%, P<.001). Adding an additional co-payment of $30 for nonpreferred brand drugs to a 2-tier plan ($10 generics; $20 brand) lowered overall drug spending by 4% (P<.001). Requiring mandatory generic substitution in a 2-tier plan reduced drug spending by 8% (P<.001). Doubling co-payments in a 2-tier plan increased the fraction beneficiaries' paid out-of-pocket from 17.6% to 25.6%. Conclusions Adding an additional level of co-payment, increasing existing co-, payments or coinsurance rates, and requiring mandatory generic substitution all reduced plan payments and overall drug spending among working-age enrollees with employer-provided drug coverage. The reduction in drug spending largely benefited health insurance plans because the percentage of drug expenses beneficiaries paid out-of-pocket rose significantly.	RAND Hlth, Santa Monica, CA 90407 USA	RAND Corporation	Joyce, GF (corresponding author), RAND Hlth, 1700 Main St, Santa Monica, CA 90407 USA.		Goldman, Dana P/E-7667-2013	Goldman, Dana P/0000-0001-8498-6396				Berndt ER, 2001, HEALTH AFFAIR, V20, P100, DOI 10.1377/hlthaff.20.2.100; BYMARK L, 2002, PRESCRIPTION DRUG US; *CA HEALTHC FDN FO, 2002, PRESCR DRUG COV FORM; Duan N., 1983, J BUS STAT, V1, P115, DOI DOI 10.2307/1391852; Dubois RW, 2000, HEALTH AFFAIR, V19, P231, DOI 10.1377/hlthaff.19.2.231; Ernst ME, 2000, ARCH FAM MED, V9, P1002, DOI 10.1001/archfami.9.10.1002; Goldman DP, 1998, J AM STAT ASSOC, V93, P54, DOI 10.2307/2669602; HARRIS BL, 1990, MED CARE, V28, P907, DOI 10.1097/00005650-199010000-00005; HILLMAN AL, 1999, HLTH AFF MILLWOOD, V18, P188; Horn SD, 1998, AM J MANAG CARE, V4, P1105; Johnson RE, 1997, HEALTH SERV RES, V32, P103; Johnson RE, 1997, MED CARE, V35, P1119, DOI 10.1097/00005650-199711000-00004; LEIBOWITZ A, 1985, SOC SCI MED, V21, P1063, DOI 10.1016/0277-9536(85)90161-3; Levit K, 2000, HEALTH AFFAIR, V19, P124, DOI 10.1377/hlthaff.19.1.124; Manning WG, 2001, J HEALTH ECON, V20, P461, DOI 10.1016/S0167-6296(01)00086-8; Motheral B, 2001, MED CARE, V39, P1293, DOI 10.1097/00005650-200112000-00005; Motheral BR, 1999, INQUIRY-J HEALTH CAR, V36, P481; Mullahy J, 1998, J HEALTH ECON, V17, P247, DOI 10.1016/S0167-6296(98)00030-7; *NIH CAR MAN FDN, 2001, PRESCR DRUG EXP 2000; PENNA P, 2000, J MANAGE CARE PHARM, V6, P351; REEDER CE, 1985, INQUIRY-J HEALTH CAR, V22, P396; REISSMAN D, 2001, DRUG BENEFIT TRENDS, V13, P24; Schneeweiss S, 2002, NEW ENGL J MED, V346, P822, DOI 10.1056/NEJMsa003087; SMITH DG, 1993, INQUIRY-J HEALTH CAR, V30, P189; SOUMERAI SB, 1991, NEW ENGL J MED, V325, P1072, DOI 10.1056/NEJM199110103251505; SOUMERAI SB, 1994, NEW ENGL J MED, V331, P650, DOI 10.1056/NEJM199409083311006; SOUMERAI SB, 1987, NEW ENGL J MED, V317, P550, DOI 10.1056/NEJM198708273170906; Stuart B, 1999, HEALTH AFFAIR, V18, P201, DOI 10.1377/hlthaff.18.2.201; Tamblyn R, 2001, JAMA-J AM MED ASSOC, V285, P421, DOI 10.1001/jama.285.4.421; Walser BL, 1996, HEALTH AFFAIR, V15, P95, DOI 10.1377/hlthaff.15.3.95	30	183	184	1	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	2002	288	14					1733	1739		10.1001/jama.288.14.1733	http://dx.doi.org/10.1001/jama.288.14.1733			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	602BJ	12365957	Bronze			2022-12-28	WOS:000178484700026
J	Serwold, T; Gonzalez, F; Kim, J; Jacob, R; Shastri, N				Serwold, T; Gonzalez, F; Kim, J; Jacob, R; Shastri, N			ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum	NATURE			English	Article							CELLS; AMINOPEPTIDASE; PROTEASOME; GENERATION; RESPONSES; CLEAVAGE; COMPLEX; MOTIFS; MICE; ER	The ability of killer T cells carrying the CD8 antigen to detect tumours or intracellular pathogens requires an extensive display of antigenic peptides by major histocompatibility complex (MHC) class I molecules on the surface of potential target cells(1). These peptides are derived from almost all intracellular proteins and reveal the presence of foreign pathogens and mutations. How cells produce thousands of distinct peptides cleaved to the precise lengths required for binding different MHC class I molecules remains unknown(2,3). The peptides are cleaved from endogenously synthesized proteins by the proteasome in the cytoplasm(4,5) and then trimmed by an unknown aminopeptidase in the endoplasmic reticulum (ER)(6-8). Here we identify ERAAP, the aminopeptidase associated with antigen processing in the ER. ERAAP has a broad substrate specificity, and its expression is strongly upregulated by interferon-gamma. Reducing the expression of ERAAP through RNA interference prevents the trimming of peptides for MHC class I molecules in the ER and greatly reduces the expression of MHC class I molecules on the cell surface. Thus, ERAAP is the missing link between the products of cytosolic processing and the final peptides presented by MHC class I molecules on the cell surface.	Univ Calif Berkeley, Dept Mol & Cell Biol, Div Immunol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Shastri, N (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Div Immunol, Berkeley, CA 94720 USA.			Jacob, Richard/0000-0003-0910-5282				ANDERSON K, 1991, J EXP MED, V174, P489, DOI 10.1084/jem.174.2.489; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Brouwenstijn N, 2001, IMMUNITY, V15, P95, DOI 10.1016/S1074-7613(01)00174-1; Cascio P, 2001, EMBO J, V20, P2357, DOI 10.1093/emboj/20.10.2357; Clauser KR, 1999, ANAL CHEM, V71, P2871, DOI 10.1021/ac9810516; Egen JG, 2002, IMMUNITY, V16, P23, DOI 10.1016/S1074-7613(01)00259-X; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FEHLING HJ, 1994, SCIENCE, V265, P1234, DOI 10.1126/science.8066463; Fruci D, 2001, IMMUNITY, V15, P467, DOI 10.1016/S1074-7613(01)00203-5; Hattori A, 1999, J BIOCHEM-TOKYO, V125, P931, DOI 10.1093/oxfordjournals.jbchem.a022371; HELEN I, 2001, PROTEOMICS, V2, P36; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; Kloetzel PM, 2001, NAT REV MOL CELL BIO, V2, P179, DOI 10.1038/35056572; Medzihradszky KF, 2000, ANAL CHEM, V72, P552, DOI 10.1021/ac990809y; Miyashita H, 2002, BLOOD, V99, P3241, DOI 10.1182/blood.V99.9.3241; Paz P, 1999, IMMUNITY, V11, P241, DOI 10.1016/S1074-7613(00)80099-0; Preckel T, 1999, SCIENCE, V286, P2162, DOI 10.1126/science.286.5447.2162; Rawlings ND, 2002, NUCLEIC ACIDS RES, V30, P343, DOI 10.1093/nar/30.1.343; Rock KL, 1999, ANNU REV IMMUNOL, V17, P739, DOI 10.1146/annurev.immunol.17.1.739; Schomburg L, 2000, EUR J BIOCHEM, V267, P3198, DOI 10.1046/j.1432-1327.2000.01348.x; Serwold T, 2001, NAT IMMUNOL, V2, P644, DOI 10.1038/89800; SHASTRI N, 1993, J IMMUNOL, V150, P2724; Toes REM, 2001, J EXP MED, V194, P1, DOI 10.1084/jem.194.1.1	26	466	472	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 3	2002	419	6906					480	483		10.1038/nature01074	http://dx.doi.org/10.1038/nature01074			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	599RF	12368856				2022-12-28	WOS:000178348400037
J	Zignego, AL; Ferri, C; Giannelli, F; Giannini, C; Caini, P; Monti, M; Marrocchi, ME; Di Pietro, E; La Villa, G; Laffi, G; Gentilini, P				Zignego, AL; Ferri, C; Giannelli, F; Giannini, C; Caini, P; Monti, M; Marrocchi, ME; Di Pietro, E; La Villa, G; Laffi, G; Gentilini, P			Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas	ANNALS OF INTERNAL MEDICINE			English	Article							NON-HODGKINS-LYMPHOMA; IMMUNOGLOBULIN GENE REARRANGEMENT; POLYMERASE-CHAIN-REACTION; GRADE MALIGNANT-LYMPHOMA; FOLLICULAR LYMPHOMA; CHROMOSOMAL TRANSLOCATION; T(14-18) TRANSLOCATION; HELICOBACTER-PYLORI; INFECTION; BLOOD	Background: Hepatitis C virus (HCV) infection is strictly associated with mixed cryoglobulinemia, a benign B-cell lymphoproliferative disorder that may evolve to lymphoma. An increased prevalence of bcl-2 rearrangement (the t(14;18) translocation) has been shown in patients infected with HCV. Objective: To evaluate the prevalence of bcl-2 rearrangement in patients with HCV-related mixed cryoglobulinemia and patients with chronic hepatitis but no cryoglobulinemia. Design: Prospective study. Setting: Two university hospitals. Patients: 37 consecutively recruited patients with HCV-related mixed cryoglobulinemia and 101 patients with chronic HCV infection but without mixed cryoglobulinemia. Measurements: Clinical and serologic characteristics; liver biopsy; bcl-2 rearrangement, Bcl-2 expression, and the ratio of Bcl-2 to Bax in total peripheral blood mononuclear cells and cell subgroups; and sequence analysis of the junction of bcl-2 and IgH joining segments in positive samples. Results: Rearrangement of bcl-2 was observed in 28 of 37 (75.7%) patients with mixed cryoglobulinemia (65% of those with type III disease and 85% of those with type 11 disease, including 3 of 4 patients with lymphoma) and in 38 of 101 (37.6%) patients with chronic HCV infection but not mixed cryoglobulinemia (P < 0.001). Overexpression of Bcl-2 protein and a high ratio of Bcl-2 to Bax were observed in samples from patients with bcl-2 rearrangement. In 2 patients followed over time, peripheral blood cells bearing the t(14;18) translocation disappeared after antiviral therapy. Conclusions: Rearrangement of bcl-2 was found with increased frequency in patients with chronic HCV infection and mixed cryoglobulinemia. The frequency was greatest in patients with type 11 mixed cryoglobulinemia. The high ratio of Bcl-2 to Bax in patients with bcl-2 rearrangement and disappearance of the rearrangement with antiviral therapy suggest that the translocation is associated with the antiapoptotic function of Bcl-2 and that HCV infection is linked to inhibition of B-cell apoptosis.	Univ Florence, Sch Med, Dept Internal Med, I-50134 Florence, Italy; Univ Pisa, Sch Med, I-56100 Pisa, Italy	University of Florence; University of Pisa	Zignego, AL (corresponding author), Univ Florence, Sch Med, Dept Internal Med, Viale Morgagni,85, I-50134 Florence, Italy.	a.zignego@dmi.unifi.it	Zignego, Anna Linda/AAL-8205-2021	Laffi, Giacomo/0000-0001-6916-1134				ABEL G, 1993, ARTHRITIS RHEUM, V36, P1341, DOI 10.1002/art.1780361003; Aiello A, 1999, BLOOD, V94, P2247, DOI 10.1182/blood.V94.7.2247.419k12_2247_2251; Andreone P, 1998, ANN INTERN MED, V129, P294, DOI 10.7326/0003-4819-129-4-199808150-00005; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BROUET JC, 1974, AM J MED, V57, P775, DOI 10.1016/0002-9343(74)90852-3; Carlson SJ, 1996, JAMA-J AM MED ASSOC, V275, P937; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; Cory S, 1999, CANCER RES, V59, p1685S; Dolken G, 1996, J CLIN ONCOL, V14, P1333; Ferri C, 2000, INFEC DIS S, P349; FRANZIN F, 1995, BRIT J HAEMATOL, V90, P548, DOI 10.1111/j.1365-2141.1995.tb05582.x; Fuscoe JC, 1996, CARCINOGENESIS, V17, P1013, DOI 10.1093/carcin/17.5.1013; Giannini C, 1999, J LAB CLIN MED, V134, P68, DOI 10.1016/S0022-2143(99)90055-0; GOREVIC PD, 1991, SEMIN HEMATOL, V28, P79; HARRIS NL, 1994, BLOOD, V84, P1361; Ivanovski M, 1998, BLOOD, V91, P2433, DOI 10.1182/blood.V91.7.2433.2433_2433_2442; JENNETTE JC, 1994, ARTHRITIS RHEUM-US, V37, P187, DOI 10.1002/art.1780370206; Johnson PWM, 1999, ANN ONCOL, V10, P1349, DOI 10.1023/A:1008385924543; Kitay-Cohen Y, 2000, BLOOD, V96, P2910; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; KORSMEYER SJ, 1992, BLOOD, V80, P879; Lauer GM, 2001, NEW ENGL J MED, V345, P41, DOI 10.1056/NEJM200107053450107; LIMPENS J, 1995, BLOOD, V85, P2528, DOI 10.1182/blood.V85.9.2528.bloodjournal8592528; LIMPENS J, 1991, ONCOGENE, V6, P2271; LIU YF, 1994, P NATL ACAD SCI USA, V91, P8910, DOI 10.1073/pnas.91.19.8910; Lopez-Guillermo A, 1999, BLOOD, V93, P3081, DOI 10.1182/blood.V93.9.3081; Magalini AR, 1998, J PATHOL, V185, P86; Mazzaro C, 1996, CANCER, V77, P2604, DOI 10.1002/(SICI)1097-0142(19960615)77:12<2604::AID-CNCR26>3.0.CO;2-V; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MEIJERINK JPP, 1995, BRIT J HAEMATOL, V91, P630, DOI 10.1111/j.1365-2141.1995.tb05359.x; Monteverde A, 1997, SPRINGER SEMIN IMMUN, V19, P99, DOI 10.1007/BF00945028; MONTEVERDE A, 1988, ACTA HAEMATOL-BASEL, V79, P20, DOI 10.1159/000205684; Monteverde A, 1995, CLIN EXP RHEUMATOL, V13, pS141; MONTI G, 1995, QJM-MON J ASSOC PHYS, V88, P115; MUSSET L, 1992, CLIN CHEM, V38, P798; NGAN BY, 1989, BLOOD, V73, P1759; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; Otter I, 1998, J BIOL CHEM, V273, P6110, DOI 10.1074/jbc.273.11.6110; Poetsch M, 1996, J CLIN ONCOL, V14, P963, DOI 10.1200/JCO.1996.14.3.963; Rasul I, 1999, HEPATOLOGY, V29, P543, DOI 10.1002/hep.510290224; RIVAS C, 1992, LEUKEMIA LYMPHOMA, V8, P87, DOI 10.3109/10428199209049822; ROBLEDO M, 1991, Sangre (Saragossa), V36, P295; Silvestri F, 1998, ANN ONCOL, V9, P499, DOI 10.1023/A:1008265804550; STOLTE M, 1992, LANCET, V339, P745, DOI 10.1016/0140-6736(92)90645-J; TISSOT JD, 1994, J IMMUNOL METHODS, V173, P63, DOI 10.1016/0022-1759(94)90284-4; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; WINFIELD JB, 1983, HUM PATHOL, V14, P350, DOI 10.1016/S0046-8177(83)80121-X; Zignego AL, 1999, J HEPATOL, V31, P369, DOI 10.1016/S0168-8278(99)80239-6; Zignego AL, 1996, ANN INTERN MED, V124, P31, DOI 10.7326/0003-4819-124-1_Part_1-199601010-00006; ZIGNEGO AL, 1992, J HEPATOL, V15, P382, DOI 10.1016/0168-8278(92)90073-X; Zignego AL, 1997, CLIN EXP RHEUMATOL, V15, P711; Zignego AL, 2000, HEPATOLOGY, V31, P474, DOI 10.1002/hep.510310230; Zuckerman E, 2001, BLOOD, V97, P1555, DOI 10.1182/blood.V97.6.1555; Zuckerman E, 2001, BRIT J HAEMATOL, V112, P364, DOI 10.1046/j.1365-2141.2001.02573.x	55	152	163	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	2002	137	7					571	580		10.7326/0003-4819-137-7-200210010-00008	http://dx.doi.org/10.7326/0003-4819-137-7-200210010-00008			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	599VD	12353944				2022-12-28	WOS:000178355100003
J	Harman, TC; Taylor, PJ; Walsh, MP; LaForge, BE				Harman, TC; Taylor, PJ; Walsh, MP; LaForge, BE			Quantum dot superlattice thermoelectric materials and devices	SCIENCE			English	Article							THERMAL-CONDUCTIVITY	PbSeTe-based quantum dot superlattice structures grown by molecular beam epitaxy have been investigated for applications in thermoelectrics. We demonstrate improved cooling values relative to the conventional bulk (Bi,Sb)(2)(Se,Te)(3) thermoelectric materials using a n-type film in a one-leg thermoelectric device test setup, which cooled the cold junction 43.7 K below the room temperature hot junction temperature of 299.7 K. The typical device consists of a substrate-free, bulk-like ( typically 0.1 millimeter in thickness, 10 millimeters in width, and 5 millimeters in length) slab of nanostructured PbSeTe/PbTe as the n-type leg and a metal wire as the p-type leg.	MIT, Lincoln Lab, Lexington, MA 02420 USA	Lincoln Laboratory; Massachusetts Institute of Technology (MIT)	Harman, TC (corresponding author), MIT, Lincoln Lab, 244 Wood St, Lexington, MA 02420 USA.							DRESSELHAUS MS, 2001, RECENT TRENDS THERMO, V71, pCH1; Harman T. C., 1999, Eighteenth International Conference on Thermoelectrics. Proceedings, ICT'99 (Cat. No.99TH8407), P280, DOI 10.1109/ICT.1999.843386; HARMAN TC, 1958, J APPL PHYS, V29, P1373, DOI 10.1063/1.1723445; Harman TC, 2000, J ELECTRON MATER, V29, pL1, DOI 10.1007/s11664-000-0117-1; HARMAN TC, 1959, J APPL PHYS, V30, P1351, DOI 10.1063/1.1735334; HARMAN TC, 1967, THERMOELECTRIC THERM, P291; Liu WL, 2001, J NANOSCI NANOTECHNO, V1, P39, DOI 10.1166/jnn.2001.013; Nolas G.S., 2001, SPRINGER SERIES MATE, V45; ROWE RM, 1995, CRC HDB THERMOELECTR; TAYLOR PJ, 1993, THESIS U VIRGINIA; Venkatasubramanian R, 2001, NATURE, V413, P597, DOI 10.1038/35098012; YIM WM, 1972, SOLID STATE ELECTRON, V15, P1121, DOI 10.1016/0038-1101(72)90172-4	12	2138	2230	33	1089	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 27	2002	297	5590					2229	2232		10.1126/science.1072886	http://dx.doi.org/10.1126/science.1072886			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	597LA	12351781				2022-12-28	WOS:000178222000037
J	Warren, HS; Suffredini, AF; Eichacker, PQ; Munford, RS				Warren, HS; Suffredini, AF; Eichacker, PQ; Munford, RS			Risks and benefits of activated protein C treatment for severe sepsis.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							APACHE-II; VARIABILITY		Massachusetts Gen Hosp, Boston, MA 02114 USA; NIH, Bethesda, MD 20892 USA; Univ Texas, SW Med Ctr, Dallas, TX 75390 USA	Harvard University; Massachusetts General Hospital; National Institutes of Health (NIH) - USA; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Warren, HS (corresponding author), Massachusetts Gen Hosp, Boston, MA 02114 USA.				NIAID NIH HHS [AI18188] Funding Source: Medline; NIGMS NIH HHS [R01-GM59694-02] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI018188, R56AI018188, R01AI018188] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059694] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		*ANT ADV COMM, 2002, FDA BRIEF DOC DROTR; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; *FDA DOCK MAN BRAN, 2001, CDER 2001 M DOC ROCK; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Natanson C, 1998, CRIT CARE MED, V26, P1927, DOI 10.1097/00003246-199812000-00001; Polderman KH, 2001, INTENS CARE MED, V27, P1550, DOI 10.1007/s001340101033; Polderman KH, 2001, INTENS CARE MED, V27, P1365, DOI 10.1007/s001340101012; TAYLOR FB, 1987, J CLIN INVEST, V79, P918, DOI 10.1172/JCI112902; Warren BL, 2001, JAMA-J AM MED ASSOC, V286, P1869, DOI 10.1001/jama.286.15.1869; Warren BL, 2002, JAMA-J AM MED ASSOC, V287, P192; YAN SCB, 1990, BIO-TECHNOL, V8, P655, DOI 10.1038/nbt0790-655; Zeni F, 1997, CRIT CARE MED, V25, P1095, DOI 10.1097/00003246-199707000-00001; 2002, CBER BIOL LICENSE AP; 2001, CHIRON ANNOUNCES RES	14	179	186	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 26	2002	347	13					1027	1030		10.1056/NEJMsb020574	http://dx.doi.org/10.1056/NEJMsb020574			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	596RD	12324562				2022-12-28	WOS:000178178400012
J	Kjeldsen, SE; Dahlof, B; Devereux, RB; Julius, S; Aurup, P; Edelman, J; Beevers, G; de Faire, U; Fyhrquist, F; Ibsen, H; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, S; Wedel, H				Kjeldsen, SE; Dahlof, B; Devereux, RB; Julius, S; Aurup, P; Edelman, J; Beevers, G; de Faire, U; Fyhrquist, F; Ibsen, H; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, S; Wedel, H		LIFE Study Grp	Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy - A Losartan Intervention For Endpoint Reduction (LIFE) substudy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BLOOD-PRESSURE; ELECTROCARDIOGRAPHIC IDENTIFICATION; MYOCARDIAL-INFARCTION; RANDOMIZED TRIAL; ACTIVE TREATMENT; ANGIOTENSIN-II; RISK; EFFICACY; PLACEBO; EVENTS	Context Drug intervention in placebo-controlled trials has been beneficial in isolated systolic hypertension. Objective To test the hypothesis that losartan improves outcome better than atenolol in patients with isolated systolic hypertension and electrocardiographically documented left ventricular hypertrophy (ECG-LVH). Design Double-blind, randomized, parallel-group study conducted in 1995-2001. Setting and Participants A total of 1326 men and women aged 55 through 80 years (mean, 70 years) with systolic blood pressure of 160 to 200 mm Hg and diastolic blood pressure of less than 90 mm Hg (mean, 174/83 mm Hg) and ECG-LVH, recruited from 945 outpatient settings in the Nordic countries, the United Kingdom, and the United States. Interventions Patients were randomly assigned to receive once-daily losartan (n =660) or atenolol (n=666) with hydrochlorothiazide as the second agent in both arms, for a mean of 4.7 years. Main Outcome Measure Composite end point of cardiovascular death, stroke, or myocardial infarction. Results Blood pressure was reduced by 28/9 and 28/9 mm Hg in the losartan and atenolol arms. The main outcome was reduced by 25% with losartan compared with atenolol, 25.1 vs 35.4 events per 1000 patient-years (relative risk [RR], 0.75; 95% confidence interval [CI], 0.56-1.01; P=.06, adjusted for risk and degree of ECG-LVH; unadjusted RR, 0.71; 95% Cl, 0.53-0.95; P=.02). Patients receiving losartan had reductions in the following without a difference in the incidence of myocardial infarction: cardiovascular mortality (8.7 vs 16.9 events per 1000 patient-years; RR, 0.54; 95% Cl, 0.34-0.87; P=.01), nonfatal and fatal stroke (10.6 vs 18.9 events per 1000 patient-years; RR, 0.60; 95% Cl, 0.38-0.92; P=.02), new-onset diabetes (12.6 vs 20.1 events per 1000 patient-years; RR, 0.62; 95% Cl, 0.40-0.97; P,=.04), and total mortality (21.2 vs 30.2 events per 1000 patient-years; RR, 0.72; 95% Cl, 0.53-1.00; P=.046). Losartan decreased ECG-LVH,more than atenolol (P<.001) and was better tolerated. Conclusion These data suggest that losartan is superior to atenolol for treatment of patients with isolated systolic hypertension and ECG-LVH.	Univ Michigan, Dept Internal Med, Div Hypertens, Ann Arbor, MI 48109 USA; Ullevaal Univ Hosp, Dept Cardiol, Oslo, Norway; Sahlgrens Univ Hosp, Dept Med, Gothenburg, Sweden; Cornell Med Ctr, Div Cardiol, New York, NY USA; Merck & Co Inc, Whitehouse Stn, NJ USA; City Hosp, Birmingham, W Midlands, England; Karolinska Univ Hosp, Dept Med, Div Cardiovasc Med, Stockholm, Sweden; Univ Helsinki, Cent Hosp, Dept Med, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, Div Cardiol, FIN-00014 Helsinki, Finland; Glostrup Univ Hosp, Dept Internal Med, Glostrup, Denmark; Merck Res Labs Scandinavia, Stockholm, Sweden; Viborg Hosp, Dept Internal Med, Viborg, Denmark; Umea Univ, S-90187 Umea, Sweden; Haukeland Hosp, Div Cardiol, N-5021 Bergen, Norway; Univ Alabama Birmingham, Div Cardiovasc Dis, Birmingham, AL 35294 USA; Nord Sch Publ Hlth, Gothenburg, Sweden	University of Michigan System; University of Michigan; University of Oslo; Sahlgrenska University Hospital; Cornell University; Merck & Company; University of Birmingham; Karolinska Institutet; Karolinska University Hospital; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; University of Copenhagen; Merck & Company; Aarhus University; Umea University; University of Bergen; Haukeland University Hospital; University of Alabama System; University of Alabama Birmingham	Kjeldsen, SE (corresponding author), Ulleval Hosp, Dept Cardiol, Kirkeveien 166, N-0407 Oslo, Norway.							ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1986, Lancet, V2, P57; Brunner HR, 2001, AM J CARDIOL, V87, p3C; CASALE PN, 1987, CIRCULATION, V75, P565, DOI 10.1161/01.CIR.75.3.565; Dahlof B, 1997, AM J HYPERTENS, V10, P705; Dahlof B, 2002, LANCET, V359, P995, DOI 10.1016/S0140-6736(02)08089-3; Dahlof B, 1998, HYPERTENSION, V32, P989, DOI 10.1161/01.HYP.32.6.989; DAHLOF B, 1995, AM J HYPERTENS, V8, P578, DOI 10.1016/0895-7061(95)00081-Y; DAHLOF B, 1992, AM J HYPERTENS, V5, P95, DOI 10.1093/ajh/5.2.95; Devereux RB, 1996, J HYPERTENS, V14, pS95, DOI 10.1097/00004872-199609002-00018; HOSMER DW, 1989, APPL LOGISTIC REGRES; ISLES CG, 1986, J HYPERTENS, V4, P141, DOI 10.1097/00004872-198604000-00003; KANNEL WB, 1981, JAMA-J AM MED ASSOC, V245, P1225, DOI 10.1001/jama.245.12.1225; KANNEL WB, 1971, AM J CARDIOL, V27, P335, DOI 10.1016/0002-9149(71)90428-0; KJEKSHUS JK, 1986, AM J CARDIOL, V57, pF43, DOI 10.1016/0002-9149(86)90888-X; Kjeldsen SE, 2001, BLOOD PRESSURE, V10, P190, DOI 10.1080/08037050152669684; Kjeldsen SE, 2000, AM J HYPERTENS, V13, P899, DOI 10.1016/S0895-7061(00)00280-6; LEVY D, 1994, CIRCULATION, V90, P1786, DOI 10.1161/01.CIR.90.4.1786; LINDHOLM L, 1984, ACTA MED SCAND, V216, P251; Lindholm LH, 2002, LANCET, V359, P1004, DOI 10.1016/S0140-6736(02)08090-X; Liu LS, 1998, J HYPERTENS, V16, P1823, DOI 10.1097/00004872-199816120-00016; Messerli FH, 1998, JAMA-J AM MED ASSOC, V279, P1903, DOI 10.1001/jama.279.23.1903; MUIESAN ML, 1995, J HYPERTENS, V13, P1091, DOI 10.1097/00004872-199510000-00003; Neal B, 2000, LANCET, V356, P1955; NORMAN JE, 1995, J AM COLL CARDIOL, V26, P1022, DOI 10.1016/0735-1097(95)00269-5; OKIN PM, 1995, J AM COLL CARDIOL, V25, P417, DOI 10.1016/0735-1097(94)00371-V; Okin PM, 1996, J AM COLL CARDIOL, V27, P124, DOI 10.1016/0735-1097(95)00421-1; PEDERSEN TR, 1981, NEW ENGL J MED, V304, P801; Rubin DB, 1997, ANN INTERN MED, V127, P757, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00064; SAMUELSSON O, 1987, JAMA-J AM MED ASSOC, V258, P1768; Schiffrin EL, 2000, CIRCULATION, V101, P1653; SCHILLACI G, 1994, AM J CARDIOL, V74, P714, DOI 10.1016/0002-9149(94)90316-6; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; Timmermans PBMWM, 1999, HYPERTENS RES-CLIN E, V22, P147, DOI 10.1291/hypres.22.147; Verdecchia P, 2001, CIRCULATION, V104, P2039, DOI 10.1161/hc4201.097944; *WHO STUD GROUP, 1985, TECHN REP SER WHO ST, V727	37	306	323	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	2002	288	12					1491	1498		10.1001/jama.288.12.1491	http://dx.doi.org/10.1001/jama.288.12.1491			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	596AT	12243636	Bronze			2022-12-28	WOS:000178142000020
J	Seidel, HM				Seidel, HM			A man of his words	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	2002	288	12					1445	1446		10.1001/jama.288.12.1445	http://dx.doi.org/10.1001/jama.288.12.1445			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	596AT	12243623				2022-12-28	WOS:000178142000001
J	Green, R; Lorsch, JR				Green, R; Lorsch, JR			The path to perdition is paved with protons	CELL			English	Review							PEPTIDYL TRANSFERASE CENTER; TRANSITION; MECHANISM; RIBOZYME		Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, Baltimore, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University	Green, R (corresponding author), Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Biol & Genet, 725 N Wolfe St, Baltimore, MD 21205 USA.			Lorsch, Jon/0000-0002-4521-4999				Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Berg J M, 2001, Science, V291, P203; Bayfield MA, 2001, P NATL ACAD SCI USA, V98, P10096, DOI 10.1073/pnas.171319598; Cai ZP, 1996, BIOCHEMISTRY-US, V35, P6026, DOI 10.1021/bi952985g; FAHNESTOCK S, 1970, BIOCHEMISTRY-US, V9, P2477, DOI 10.1021/bi00814a013; Green R, 1997, ANNU REV BIOCHEM, V66, P679, DOI 10.1146/annurev.biochem.66.1.679; Jencks W. P., 1969, CATALYSIS CHEM ENZYM; Katunin VI, 2002, MOL CELL, V10, P339, DOI 10.1016/S1097-2765(02)00566-X; KNOWLES JR, 1976, CRC CR REV BIOCH MOL, V4, P165, DOI 10.3109/10409237609105457; MADEN BEH, 1968, EUR J BIOCHEM, V6, P309, DOI 10.1111/j.1432-1033.1968.tb00450.x; Muth GW, 2000, SCIENCE, V289, P947, DOI 10.1126/science.289.5481.947; Nakano S, 2000, SCIENCE, V287, P1493, DOI 10.1126/science.287.5457.1493; Parnell KM, 2002, P NATL ACAD SCI USA, V99, P11658, DOI 10.1073/pnas.182210099; SATTERTH.AC, 1974, J AM CHEM SOC, V96, P7018, DOI 10.1021/ja00829a034; Schmeing TM, 2002, NAT STRUCT BIOL, V9, P225, DOI 10.1038/nsb758; SCHMIDT DE, 1971, BIOCHEMISTRY-US, V10, P1249; WELCH M, 1995, BIOCHEMISTRY-US, V34, P385, DOI 10.1021/bi00002a001	18	24	24	0	1	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 20	2002	110	6					665	668		10.1016/S0092-8674(02)00965-0	http://dx.doi.org/10.1016/S0092-8674(02)00965-0			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	596TV	12297040	Bronze			2022-12-28	WOS:000178182800002
J	Ronkainen, J; Nuutinen, M; Koskimies, O				Ronkainen, J; Nuutinen, M; Koskimies, O			The adult kidney 24 years after childhood Henoch-Schonlein purpura: a retrospective cohort study	LANCET			English	Article							LONG-TERM PROGNOSIS; NEPHRITIS; CHILDREN; HYPERTENSION; MANAGEMENT; POPULATION	Background Henoch-Schonlein purpura arising in childhood could cause renal impairment or even an end-stage renal disease later in life. We aimed to assess long-term outcome of childhood Henoch-Schonlein purpura after 24 years. Methods We studied a cohort of 26 boys and 26 girls who were treated for Henoch-Schonlein purpura at Helsinki University Hospital during 1964-83. Mean follow-up was 24.1 years (SD 6.0; 16.4-36.5). All participants were asked about their state of health in a questionnaire, and 47 (90%) were examined by a doctor. Patients' medical history data were obtained from health-care centres and regional hospitals. Findings Seven (35%) of 20 adults who had severe Henoch-Schonlein purpura and glomerulonephritis at onset had renal impairment as adults, compared with two (7%) of 27 with mild or no renal symptoms at onset (relative risk 4.7, 95% Cl 1.3-18.7). Relative risk for a poor outcome was 5.0 in women (1.1-32.5) and 2.0 in men (0.2-17.5). All patients with no renal symptoms at onset had a good outcome after 24 years of follow-up. Severity of first kidney biopsy finding did not correlate with risk of a poor outcome. 16 (70%) of 23 pregnancies had been complicated by hypertension, proteinuria, or both. Five (56%) of the nine women with complicated pregnancies had a poor renal outcome. Interpretation Long-term follow-up of all patients who had Henoch-Schonlein purpura with severe renal symptoms at onset is needed during adulthood. All women who had even mild renal symptoms at onset of Henoch-Schonlein purpura should be carefully observed during and after pregnancy.	Oulu Univ Hosp, Dept Paediat & Adolescence, FIN-90029 Oulu, Finland; Univ Helsinki, Hosp Children & Adolescents, Helsinki, Finland	University of Oulu; University of Helsinki	Nuutinen, M (corresponding author), Oulu Univ Hosp, Dept Paediat & Adolescence, POB 23, FIN-90029 Oulu, Finland.							Balmelli C, 1996, SCHWEIZ MED WSCHR, V126, P293; Calvino MC, 2001, MEDICINE, V80, P279, DOI 10.1097/00005792-200109000-00001; Coppo R, 1997, NEPHROL DIAL TRANSPL, V12, P2277, DOI 10.1093/ndt/12.11.2277; COUNAHAN R, 1977, BRIT MED J, V2, P11, DOI 10.1136/bmj.2.6078.11; GOLDSTEIN AR, 1992, LANCET, V339, P280, DOI 10.1016/0140-6736(92)91341-5; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; Kaku Y, 1998, KIDNEY INT, V53, P1755, DOI 10.1046/j.1523-1755.1998.00915.x; KOSKIMIES O, 1981, ARCH DIS CHILD, V56, P482, DOI 10.1136/adc.56.6.482; Magee LA, 1999, BMJ-BRIT MED J, V318, P1332, DOI 10.1136/bmj.318.7194.1332; Niaudet P, 1993, Adv Nephrol Necker Hosp, V22, P121; Ramsay LE, 1999, BMJ-BRIT MED J, V319, P630, DOI 10.1136/bmj.319.7210.630; Ros HS, 1998, AM J EPIDEMIOL, V147, P1062; Scharer K, 1999, PEDIATR NEPHROL, V13, P816, DOI 10.1007/s004670050707; STEWART M, 1988, EUR J PEDIATR, V147, P113, DOI 10.1007/BF00442205; Szer Ilona S., 1994, Current Opinion in Rheumatology, V6, P25, DOI 10.1097/00002281-199401000-00005; Tizard EJ, 1999, ARCH DIS CHILD, V80, P380, DOI 10.1136/adc.80.4.380; WHITE RHR, 1994, NEPHRON, V68, P1, DOI 10.1159/000188216	17	175	192	0	9	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 31	2002	360	9334					666	670		10.1016/S0140-6736(02)09835-5	http://dx.doi.org/10.1016/S0140-6736(02)09835-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	590AM	12241872				2022-12-28	WOS:000177795100007
J	Phillips, D				Phillips, D			George Porter (1920-2002) - Obituary	NATURE			English	Biographical-Item									Univ London Imperial Coll Sci Technol & Med, Dept Phys Chem, London SW7 2AZ, England	Imperial College London	Phillips, D (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Phys Chem, Exhibit Rd, London SW7 2AZ, England.								0	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 10	2002	419	6907					578	578		10.1038/419578a	http://dx.doi.org/10.1038/419578a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	602AT	12374966	Bronze			2022-12-28	WOS:000178483100030
J	Bowler, PJ				Bowler, PJ			Climb Chimborazo and see the world	SCIENCE			English	Editorial Material									Queens Univ Belfast, Sch Anthropol Studies, Hist Sci Program, Belfast BT7 1NN, Antrim, North Ireland	Queens University Belfast	Bowler, PJ (corresponding author), Queens Univ Belfast, Sch Anthropol Studies, Hist Sci Program, Belfast BT7 1NN, Antrim, North Ireland.							Bowen Margarita, 1981, EMPIRICISM GEOGRAPHI; Bowler P. J., 1993, EARTH ENCOMPASSED HI; CANNON SF, 1978, SCI CULTURE EARLY VI; Dettelbach Michael, 1996, VISIONS EMPIRE VOYAG, P258; Godlewska Anne Marie Claire, 1999, GEOGRAPHY ENLIGHTENM, P236; Livingstone D., 1992, GEOGRAPHICAL TRADITI; NICOLSON M, 1987, HIST SCI, V25, P167, DOI 10.1177/007327538702500203; Nicolson M., 1990, ROMANTICISM SCI, P169; RUpKE Nicolas, 1999, GEOGRAPHY ENLIGHTENM, P319; VOMHUMBOLDT A, 1997, COSMOS, V1	10	2	3	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 4	2002	298	5591					63	64		10.1126/science.1071988	http://dx.doi.org/10.1126/science.1071988			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	600BJ	12364767				2022-12-28	WOS:000178370500024
J	Hemingway, J; Field, L; Vontas, J				Hemingway, J; Field, L; Vontas, J			An overview of insecticide resistance	SCIENCE			English	Editorial Material							ANOPHELES-GAMBIAE; MALARIA VECTOR; EXPRESSION; GENES; DDT		Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England; Rothamsted, Harpenden AL5 2JQ, Herts, England; Inst Mol Biol & Biotechnol, Crete, NE USA	Liverpool School of Tropical Medicine; University of Liverpool; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research	Hemingway, J (corresponding author), Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England.		Vontas, John/X-5112-2018	Vontas, John/0000-0002-8704-2574; Hemingway, Janet/0000-0002-3200-7173				Blackman RL, 1999, HEREDITY, V82, P180, DOI 10.1038/sj.hdy.6884580; Chandre F, 1999, B WORLD HEALTH ORGAN, V77, P230; Curtis CF, 1998, PHILOS T ROY SOC B, V353, P1769, DOI 10.1098/rstb.1998.0329; Dimopoulos G, 2002, P NATL ACAD SCI USA, V99, P8814, DOI 10.1073/pnas.092274999; Field LM, 2000, BIOCHEM J, V349, P863, DOI 10.1042/bj3490863; Grauso M, 1998, FEBS LETT, V424, P279, DOI 10.1016/S0014-5793(98)00191-4; Huang Y, 2000, NEUROSCI LETT, V284, P116, DOI 10.1016/S0304-3940(00)00969-1; McCarroll L, 2000, NATURE, V407, P961, DOI 10.1038/35039671; Paton MG, 2000, BIOCHEM J, V346, P17, DOI 10.1042/0264-6021:3460017; Ranson H, 2000, INSECT MOL BIOL, V9, P499, DOI 10.1046/j.1365-2583.2000.00214.x; Ranson H, 2000, INSECT MOL BIOL, V9, P491, DOI 10.1046/j.1365-2583.2000.00209.x; Ranson H, 2002, SCIENCE, V298, P179, DOI 10.1126/science.1076781; Ranson H, 2002, INSECT MOL BIOL, V11, P409, DOI 10.1046/j.1365-2583.2002.00350.x	13	239	266	1	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 4	2002	298	5591					96	97		10.1126/science.1078052	http://dx.doi.org/10.1126/science.1078052			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	600BJ	12364782				2022-12-28	WOS:000178370500039
J	Conway, H; Catania, G; Raymond, CF; Gades, AM; Scambos, TA; Engelhardt, H				Conway, H; Catania, G; Raymond, CF; Gades, AM; Scambos, TA; Engelhardt, H			Switch of flow direction in an Antarctic ice stream	NATURE			English	Article							WEST ANTARCTICA; SHEET; STAGNATION; CREVASSES; RETREAT; FUTURE; MARGIN; RADAR; MODEL	Fast-flowing ice streams transport ice from the interior of West Antarctica to the ocean, and fluctuations in their activity control the mass balance of the ice sheet. The mass balance of the Ross Sea sector of the West Antarctic ice sheet is now positive-that is, it is growing-mainly because one of the ice streams (ice stream C) slowed down about 150 years ago(1). Here we present evidence from both surface measurements and remote sensing that demonstrates the highly dynamic nature of the Ross drainage system. We show that the flow in an area that once discharged into ice stream C has changed direction, now draining into the Whillans ice stream (formerly ice stream B). This switch in flow direction is a result of continuing thinning of the Whillans ice stream and recent thickening of ice stream C. Further abrupt reorganization of the activity and configuration of the ice streams over short timescales is to be expected in the future as the surface topography of the ice sheet responds to the combined effects of internal dynamics and long-term climate change. We suggest that caution is needed when using observations of short-term mass changes to draw conclusions about the large-scale mass balance of the ice sheet.	Univ Washington, Seattle, WA 98195 USA; Univ Colorado, Natl Snow & Ice Data Ctr, Boulder, CO 80309 USA; CALTECH, Pasadena, CA USA	University of Washington; University of Washington Seattle; University of Colorado System; University of Colorado Boulder; California Institute of Technology	Conway, H (corresponding author), Univ Washington, Seattle, WA 98195 USA.		Scambos, Ted A/B-1856-2009; Catania, Ginny/B-9787-2008	Catania, Ginny/0000-0002-7561-5902				Anandakrishnan S, 1997, GEOPHYS RES LETT, V24, P265, DOI 10.1029/96GL04016; [Anonymous], [No title captured], DOI DOI 10.1017/S0260305500006236; Bentley CE, 1997, SCIENCE, V276, P663; Bindschadler R, 1998, SCIENCE, V282, P428, DOI 10.1126/science.282.5388.428; Bindschadler R, 1998, SCIENCE, V279, P689, DOI 10.1126/science.279.5351.689; Catania G, 2001, GEOLOGY, V29, P259, DOI 10.1130/0091-7613(2001)029<0259:BUG>2.0.CO;2; Clarke TS, 2000, J GEOPHYS RES-SOL EA, V105, P13409, DOI 10.1029/2000JB900037; Conway H, 1999, SCIENCE, V286, P280, DOI 10.1126/science.286.5438.280; Denton GH, 2002, QUATERNARY SCI REV, V21, P193, DOI 10.1016/S0277-3791(01)00090-7; Fahnestock MA, 2000, J GLACIOL, V46, P652, DOI 10.3189/172756500781832693; Jacobel RW, 2000, J GLACIOL, V46, P102, DOI 10.3189/172756500781833485; JEZEK KC, 1999, ANN GLACIOL, V27, P33; Joughin I, 2002, SCIENCE, V295, P476, DOI 10.1126/science.1066875; Kamb B., 2001, ANTARCT RES SER, V77, DOI DOI 10.1029/AR077P0157; MURRAY AB, 1994, NATURE, V371, P54, DOI 10.1038/371054a0; Nereson NA, 2001, J GLACIOL, V47, P303, DOI 10.3189/172756501781832197; Oppenheimer M, 1998, NATURE, V393, P325, DOI 10.1038/30661; Patterson W.S.B, 1994, PHYS GLACIERS, Vthird, P496; Price SF, 2001, J GLACIOL, V47, P283, DOI 10.3189/172756501781832232; Raymond CF, 2000, J GLACIOL, V46, P665, DOI 10.3189/172756500781832701; RETZLAFF R, 1993, J GLACIOL, V39, P553, DOI 10.3189/S0022143000016440; Rose K. E., 1979, J GLACIOL, V24, P63; Scambos TA, 1998, J GLACIOL, V44, P97, DOI 10.3189/S0022143000002392; SHABTAIE S, 1988, ANN GLACIOL, V11, P165; Shipp S, 1999, GEOL SOC AM BULL, V111, P1486, DOI 10.1130/0016-7606(1999)111<1486:LPHROT>2.3.CO;2; Tulaczyk S, 2000, J GEOPHYS RES-SOL EA, V105, P483, DOI 10.1029/1999JB900328; VAUGHAN DG, 1993, J GLACIOL, V39, P255, DOI 10.3189/S0022143000015926; WEERTMAN J, 1972, REV GEOPHYS SPACE GE, V10, P287, DOI 10.1029/RG010i001p00287; Whillans I.M., 2001, ANTARCT RES SER, V77, P257, DOI DOI 10.1029/AR077P0257	29	112	113	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 3	2002	419	6906					465	467		10.1038/nature01081	http://dx.doi.org/10.1038/nature01081			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	599RF	12368852				2022-12-28	WOS:000178348400033
J	Pollock, K; Grime, J				Pollock, K; Grime, J			Patients' perceptions of entitlement to time in general practice consultations for depression: qualitative study	BRITISH MEDICAL JOURNAL			English	Article							EMOTIONAL-PROBLEMS; LENGTH; CARE; PRACTITIONERS; MANAGEMENT; SIZE	Objective: To investigate patients' perceptions of entitlement to time in general practice consultations for depression. Design: Qualitative study based on interviews with patients with mild to moderate depression. Setting: Eight general practices in the West Midlands and the regional membership of the Depression Alliance. Participants: 32 general practice patients and 30 respondents from the Depression Alliance. Results: An intense sense of time pressure and a self imposed rationing of time in consultations were key concerns among the interviewees. Anxiety about time affected patients' freedom to talk about their problems. Patients took upon themselves part of the. responsibility for managing time in the consultation to relieve the burden they perceived their doctors to be working under. Respondents' accounts often showed a mismatch between their own sense of time. entitlement and the doctors' capacity to respond flexibly and constructively in offering extended consultation time when this was necessary. Patients valued time to talk and would often have liked more, but they did not necessarily associate length of consultation with quality. The impression doctors gave in handling time in consultations sent strong messages about legitimising the patients' illness and their decision to consult. Conclusions: Patients' self imposed restraint in Liking up doctors' time has important consequences for the recognition and treatment of depression. Doctors need to have a greater awareness of patients' anxieties about time and should move to allay such anxieties by pre-emptive reassurance and reinforcing patients' sense of entitlement to time. Far from acting as "consumers" patients voluntarily assume responsibility for conserving scarce resources in a health service that they regard as a collective rather than a personal resource.	Univ Keele, Dept Med Management, Keele ST5 5BG, Staffs, England	Keele University	Pollock, K (corresponding author), Univ Keele, Dept Med Management, Keele ST5 5BG, Staffs, England.		Pollock, Kristian/B-9734-2008; Grime, Janet C/M-1122-2018	Pollock, Kristian/0000-0002-6836-8595; 				AIREY C, 1999, GEN PRACTICE 1998, P87; Campbell JL, 2001, BRIT J GEN PRACT, V51, P644; Cape J, 1999, BRIT J GEN PRACT, V49, P875; Cape J, 2000, BRIT J GEN PRACT, V50, P396; Carr-Hill R, 1998, J Health Serv Res Policy, V3, P207; Clark NM, 2000, BMJ-BRIT MED J, V320, P572, DOI 10.1136/bmj.320.7234.572; Cornford CS, 1998, BRIT J GEN PRACT, V48, P1751; Cromarty I, 1996, BRIT J GEN PRACT, V46, P525; Dugdale DC, 1999, J GEN INTERN MED, V14, pS34, DOI 10.1046/j.1525-1497.1999.00263.x; Freeman GK, 2002, BRIT MED J, V324, P880, DOI 10.1136/bmj.324.7342.880; Howie JGR, 1999, BMJ-BRIT MED J, V319, P738, DOI 10.1136/bmj.319.7212.738; Kadam UT, 2001, BRIT J GEN PRACT, V51, P375; KNIGHT R, 1987, J ROY COLL GEN PRACT, V37, P19; Martin CM, 1999, MED J AUSTRALIA, V171, P77, DOI 10.5694/j.1326-5377.1999.tb123525.x; Mechanic D, 2001, BRIT MED J, V323, P266, DOI 10.1136/bmj.323.7307.266; MEREDITH P, 1993, SOC SCI MED, V37, P591, DOI 10.1016/0277-9536(93)90098-O; POLLOCK K, 2001, UNDERSTANDING DEPRES; Royal Pharmaceutical Society of Great Britain, 1997, COMPL CONC ACH SHAR; Saltman DC, 1999, MED J AUSTRALIA, V171, P76, DOI 10.5694/j.1326-5377.1999.tb123524.x; Stirling AM, 2001, BRIT J GEN PRACT, V51, P456; Tomlin Z, 1999, BMJ-BRIT MED J, V318, P1532, DOI 10.1136/bmj.318.7197.1532; Wiggers JH, 1997, SOC SCI MED, V44, P925, DOI 10.1016/S0277-9536(96)00175-X; WILSON A, 1991, BRIT J GEN PRACT, V41, P119	23	66	68	1	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 28	2002	325	7366					687	+		10.1136/bmj.325.7366.687	http://dx.doi.org/10.1136/bmj.325.7366.687			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	600JV	12351362	Bronze, Green Published			2022-12-28	WOS:000178387600024
J	Santos-Rosa, H; Schneider, R; Bannister, AJ; Sherriff, J; Bernstein, BE; Emre, NCT; Schreiber, SL; Mellor, J; Kouzarides, T				Santos-Rosa, H; Schneider, R; Bannister, AJ; Sherriff, J; Bernstein, BE; Emre, NCT; Schreiber, SL; Mellor, J; Kouzarides, T			Active genes are tri-methylated at K4 of histone H3	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; LYSINE 9; SET1; EXPRESSION; CHROMATIN; INCLUDES; HOMOLOG; COMPLEX	Lysine methylation of histones in vivo occurs in three states: mono-, di- and tri-methyl(1). Histone H3 has been found to be dimethylated at lysine 4 (K4) in active euchromatic regions but not in silent heterochromatic sites(2). Here we show that the Saccharomyces cerevisiae Set1 protein can catalyse di- and tri- methylation of K4 and stimulate the activity of many genes. Using antibodies that discriminate between the di- and tri- methylated state of K4 we show that di- methylation occurs at both inactive and active euchromatic genes, whereas tri- methylation is present exclusively at active genes. It is therefore the presence of a trimethylated K4 that defines an active state of gene expression. These findings establish the concept of methyl status as a determinant for gene activity and thus extend considerably the complexity of histone modifications.	Wellcome Trust Canc Res UK Inst, Cambridge CG2 1QR, England; Dept Pathol, Cambridge CG2 1QR, England; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England; Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Wilstar Inst, Philadelphia, PA 19104 USA	University of Oxford; Harvard University	Kouzarides, T (corresponding author), Wellcome Trust Canc Res UK Inst, Tennis Court Rd, Cambridge CG2 1QR, England.	tk106@mole.bio.cam.ac.uk	Emre, Tolga/A-1787-2016	Emre, Tolga/0000-0001-8021-5228; Bannister, Andrew/0000-0002-6312-4436; Kouzarides, Tony/0000-0002-8918-4162				Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499; Briggs SD, 2001, GENE DEV, V15, P3286, DOI 10.1101/gad.940201; Bryk M, 2002, CURR BIOL, V12, P165, DOI 10.1016/S0960-9822(01)00652-2; Carroll AS, 2001, P NATL ACAD SCI USA, V98, P12578, DOI 10.1073/pnas.211195798; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Kent NA, 2001, GENE DEV, V15, P619, DOI 10.1101/gad.190301; Krogan NJ, 2002, J BIOL CHEM, V277, P10753, DOI 10.1074/jbc.C200023200; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; Miller T, 2001, P NATL ACAD SCI USA, V98, P12902, DOI 10.1073/pnas.231473398; Nislow C, 1997, MOL BIOL CELL, V8, P2421, DOI 10.1091/mbc.8.12.2421; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Roguev A, 2001, EMBO J, V20, P7137, DOI 10.1093/emboj/20.24.7137; Siniossoglou S, 1996, CELL, V84, P265, DOI 10.1016/S0092-8674(00)80981-2; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strahl BD, 1999, P NATL ACAD SCI USA, V96, P14967, DOI 10.1073/pnas.96.26.14967	20	1532	1586	4	101	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 26	2002	419	6905					407	411		10.1038/nature01080	http://dx.doi.org/10.1038/nature01080			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	596ZB	12353038				2022-12-28	WOS:000178195400049
J	Lyketsos, CG; Lopez, O; Jones, B; Fitzpatrick, AL; Breitner, J; DeKosky, S				Lyketsos, CG; Lopez, O; Jones, B; Fitzpatrick, AL; Breitner, J; DeKosky, S			Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment - Results from the Cardiovascular Health Study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PLACEBO-CONTROLLED TRIAL; ALZHEIMERS-DISEASE; DOUBLE-BLIND; PSYCHIATRIC PHENOMENA; BEHAVIORAL DISTURBANCES; DEPRESSED-PATIENTS; AGGRESSION; DISORDERS; PSYCHOSIS; CARE	Context Mild cognitive impairment (MCI) may be a precursor to dementia, at least in some cases. Dementia and MCI are associated with neuropsychiatric symptoms in clinical samples. Only 2 population-based studies exist of the prevalence of these symptoms in dementia, and none exist for MCI. Objective To estimate the prevalence of neuropsychiatric symptoms in dementia and MCI in a population-based study. Design Cross-sectional study derived from the Cardiovascular Health Study, a longitudinal cohort study. Setting and Participants A total of 3608 participants were cognitively evaluated using data collected longitudinally over 10 years and additional data collected in 19992000 in 4 US counties. Dementia and MCI were classified using clinical criteria and adjudicated by committee review by expert neurologists and psychiatrists. A total of 824 individuals completed the Neuropsychiatric Inventory (NPI); 362 were classified as having dementia, 320 as having MCI; and 142 did not meet criteria for MCI or dementia. Main Outcome Measure Prevalence of neuropsychiatric symptoms, based on ratings on the NPI in the previous month and from the onset of cognitive symptoms. Results Of the 682 individuals with dementia or MCI, 43% of MCI participants (n = 138) exhibited neuropsychiatric symptoms in the previous month (29% rated as clinically significant) with depression (20%), apathy (15%), and irritability (15%) being most common. Among the dementia participants, 75% (n=270) had exhibited a neuropsychiatric symptom in the past month (62% were clinically significant); 55% (n=199) reported 2 or more and 44% (n=159) 3 or more disturbances in the past month. In participants with dementia, the most frequent disturbances were apathy (36%), depression (32%), and agitation/aggression (30%). Eighty percent of dementia participants (n=233) and 50% of MCI participants (n=139) exhibited at least 1 NPI symptom from the onset of cognitive symptoms. There were no differences in prevalence of neuropsychiatric symptoms between participants with Alzheimer-type dementia and those with other dementias, with the exception of aberrant motor behavior, which was more frequent in Alzheimer-type dementia (5.4% vs 1 %; P=.02). Conclusions Neuropsychiatric symptoms occur in the majority of persons with dementia over the course of the disease. These are the first population-based estimates for neuropsychiatric symptoms in MCI, indicating a high prevalence associated with this condition as well. These symptoms have serious adverse consequences and should be inquired about and treated as necessary. Study of neuropsychiatric symptoms in the context of dementia may improve our understanding of brain-behavior relationships.	Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA; Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Psychiat, Winston Salem, NC USA; Univ Washington, Sch Med, Dept Epidemiol, Seattle, WA USA; Dept Vet Affairs Puget Sound Hlth Care Syst, Ctr Geriatr Res Educ & Clin, Seattle, WA USA; Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA	Johns Hopkins University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Wake Forest University; Wake Forest Baptist Medical Center; University of Washington; University of Washington Seattle; Geriatric Research Education & Clinical Center; University of Washington; University of Washington Seattle	Lyketsos, CG (corresponding author), Johns Hopkins Univ Hosp, Osler 320,600 N Wolfe St, Baltimore, MD 21287 USA.			DeKosky, Steven/0000-0003-3743-2758	NHLBI NIH HHS [N01-HC-15103, N01-HC-85079, N01-HC-35129, N01-HC-85086] Funding Source: Medline; NIA NIH HHS [5 R01 AG15928-02, R01-AG11380] Funding Source: Medline; NIMH NIH HHS [R01-MH56511] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC085079, N01HC085086, N01HC035129, N01HC015103] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH056511] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015928, R01AG011380] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Brookmeyer R, 1998, AM J PUBLIC HEALTH, V88, P1337, DOI 10.2105/AJPH.88.9.1337; BRYANT J, 2001, HEALTH TECHNOL ASSES, V5, P1; BURNS A, 1990, BRIT J PSYCHIAT, V157, P81, DOI 10.1192/bjp.157.1.81; BURNS A, 1990, BRIT J PSYCHIAT, V157, P72, DOI 10.1192/bjp.157.1.72; BURNS A, 1990, BRIT J PSYCHIAT, V157, P86, DOI 10.1192/bjp.157.1.86; BURNS A, 1990, BRIT J PSYCHIAT, V157, P76, DOI 10.1192/bjp.157.1.76; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; De Deyn PP, 1999, NEUROLOGY, V53, P946, DOI 10.1212/WNL.53.5.946; Devanand DP, 1998, AM J PSYCHIAT, V155, P1512, DOI 10.1176/ajp.155.11.1512; Finkel S I, 1996, Int Psychogeriatr, V8 Suppl 3, P497; FORSTL H, 1992, PSYCHOL MED, V22, P877, DOI 10.1017/S0033291700038459; Fried Linda P., 1991, Annals of Epidemiology, V1, P263; Gonzalez-Salvador MT, 1999, INT J GERIATR PSYCH, V14, P701, DOI 10.1002/(SICI)1099-1166(199909)14:9<701::AID-GPS5>3.0.CO;2-#; Gonzalez-Salvador T, 2000, INT J GERIATR PSYCH, V15, P181, DOI 10.1002/(SICI)1099-1166(200002)15:2<181::AID-GPS96>3.0.CO;2-I; Grutzendler J, 2001, DRUGS, V61, P41, DOI 10.2165/00003495-200161010-00005; Ives Diane G., 1995, Annals of Epidemiology, V5, P278, DOI 10.1016/1047-2797(94)00093-9; Jeste DV, 2000, AM J GERIAT PSYCHIAT, V8, P29, DOI 10.1097/00019442-200002000-00004; JORM AF, 1988, BRIT J PSYCHIAT, V152, P209, DOI 10.1192/bjp.152.2.209; Katz IR, 1999, J CLIN PSYCHIAT, V60, P107, DOI 10.4088/JCP.v60n0207; KAWAS C, 1994, ARCH NEUROL-CHICAGO, V51, P901, DOI 10.1001/archneur.1994.00540210073015; Klein DA, 1999, INT J GERIATR PSYCH, V14, P272, DOI 10.1002/(SICI)1099-1166(199904)14:4<272::AID-GPS896>3.0.CO;2-P; LOPEZ OL, IN PRESS NEUROEPIDEM; LOPEZ OL, IN PRESS NEUROLOGY; Lopez Oscar L, 2010, Neuroepidemiology, V34, P63, DOI 10.1159/000264678; Lyketsos CG, 2000, AM J PSYCHIAT, V157, P708, DOI 10.1176/appi.ajp.157.5.708; Lyketsos CG, 1997, J NEUROPSYCH CLIN N, V9, P556; LYKETSOS CG, 1995, J NEUROPSYCH CLIN N, V7, P350; Lyketsos CG, 2001, INT J GERIATR PSYCH, V16, P1037, DOI 10.1002/gps.440; Lyketsos CG, 2000, AM J PSYCHIAT, V157, P1686, DOI 10.1176/appi.ajp.157.10.1686; LYKETSOS CG, 2000, BEHAV MEASURES COGNI, P393; LYKETSOS CG, 1999, REICHELS CARE ELDERL, P214; MANOLIO TA, 1994, STROKE, V25, P318, DOI 10.1161/01.STR.25.2.318; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Morris JC, 2001, ARCH NEUROL-CHICAGO, V58, P397, DOI 10.1001/archneur.58.3.397; NYTH AL, 1992, ACTA PSYCHIAT SCAND, V86, P138, DOI 10.1111/j.1600-0447.1992.tb03242.x; Olin JT, 2002, AM J GERIAT PSYCHIAT, V10, P125; Petersen RC, 2001, NEUROLOGY, V56, P1133, DOI 10.1212/WNL.56.9.1133; Petracca G, 1996, J NEUROPSYCH CLIN N, V8, P270; Porsteinsson AP, 2001, AM J GERIAT PSYCHIAT, V9, P58, DOI 10.1176/appi.ajgp.9.1.58; PROCTER AW, 1992, NEUROCHEM RES, V17, P917, DOI 10.1007/BF00993268; Rabins P, 1997, AM J PSYCHIAT, V154, P1; RABINS PV, 1999, PRACTICAL DEMENTIA C; Roth M., 1996, British Journal of Psychiatry, V168, P149, DOI 10.1192/bjp.168.2.149; Schneider LS, 2001, AM J GERIAT PSYCHIAT, V9, P346, DOI 10.1176/appi.ajgp.9.4.346; Shankle WR, 1995, ALZ DIS ASSOC DIS, V9, P233, DOI 10.1097/00002093-199509040-00010; STARKSTEIN SE, 1994, NEUROLOGY, V44, P2055, DOI 10.1212/WNL.44.11.2055; STEELE C, 1990, AM J PSYCHIAT, V147, P1049; Stern Y, 1997, JAMA-J AM MED ASSOC, V277, P806, DOI 10.1001/jama.277.10.806; Street JS, 2000, ARCH GEN PSYCHIAT, V57, P968, DOI 10.1001/archpsyc.57.10.968; Sweet RA, 1998, ARCH NEUROL-CHICAGO, V55, P1335, DOI 10.1001/archneur.55.10.1335; Tariot PN, 1998, AM J PSYCHIAT, V155, P54, DOI 10.1176/ajp.155.1.54; Tariot PN, 2000, NEUROLOGY, V54, P2269, DOI 10.1212/WNL.54.12.2269; Tell G S, 1993, Ann Epidemiol, V3, P358, DOI 10.1016/1047-2797(93)90062-9; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; TERI L, 1997, J GERONTOL B-PSYCHOL, V52, P159, DOI DOI 10.1093/GER0NB/52B.4.P159; Valcour VG, 2000, ARCH INTERN MED, V160, P2964, DOI 10.1001/archinte.160.19.2964; Victoroff J, 1996, ARCH NEUROL-CHICAGO, V53, P428, DOI 10.1001/archneur.1996.00550050058024; Wechsler D., 2008, WECHSLER ADULT INTEL, P257; ZUBENKO GS, 1990, ARCH NEUROL-CHICAGO, V47, P209, DOI 10.1001/archneur.1990.00530020117023; ZWEIG RM, 1988, ANN NEUROL, V24, P233, DOI 10.1002/ana.410240210	61	1338	1391	3	79	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	2002	288	12					1475	1483		10.1001/jama.288.12.1475	http://dx.doi.org/10.1001/jama.288.12.1475			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	596AT	12243634	Bronze			2022-12-28	WOS:000178142000018
J	Deddish, PA; Erdos, EG				Deddish, PA; Erdos, EG			Effect of angiotensin-converting-enzyme inhibitors	LANCET			English	Letter							BRADYKININ; RECEPTOR		Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Erdos, EG (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, 835 S Wolcott Ave, Chicago, IL 60612 USA.							Boix F, 2002, LANCET, V359, P1157, DOI 10.1016/S0140-6736(02)08142-4; Deddish PA, 2002, HYPERTENSION, V39, P619, DOI 10.1161/hy0202.103298; Marcic B, 2000, J BIOL CHEM, V275, P16110, DOI 10.1074/jbc.M909490199; Marcic B, 1999, HYPERTENSION, V33, P835, DOI 10.1161/01.HYP.33.3.835; Minshall RD, 1997, CIRC RES, V81, P848	5	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 21	2002	360	9337					947	947		10.1016/S0140-6736(02)11047-6	http://dx.doi.org/10.1016/S0140-6736(02)11047-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	596AU	12354491				2022-12-28	WOS:000178142200028
J	Hazir, T; Latif, E; Qazi, SA; Rafi, M; Latif, E; Ansari, S; Farouki, S; Murtaza, A; Munir, S; Maqbool, S; Randhawa, S; Iqbal, I; Riaz, S; Kundi, Z; Aslam, S; Asghar, R; Hazir, T; Latif, E; Ansari, S; Farouki, S; Bin Nisar, Y; Munir, S; Iqbal, I; Asghar, R; Aslam, S; Qazi, SA; Bari, A				Hazir, T; Latif, E; Qazi, SA; Rafi, M; Latif, E; Ansari, S; Farouki, S; Murtaza, A; Munir, S; Maqbool, S; Randhawa, S; Iqbal, I; Riaz, S; Kundi, Z; Aslam, S; Asghar, R; Hazir, T; Latif, E; Ansari, S; Farouki, S; Bin Nisar, Y; Munir, S; Iqbal, I; Asghar, R; Aslam, S; Qazi, SA; Bari, A		MASCOT Pneumonia Study Grp	Clinical efficacy of 3 days versus 5 days of oral amoxicillin for treatment of childhood pneumonia: a multicentre double-blind trial	LANCET			English	Article							RESPIRATORY-TRACT INFECTIONS; PENICILLIN-RESISTANT PNEUMOCOCCI; ANTIMICROBIAL RESISTANCE; 5-DAY COURSE; CHILDREN; AZITHROMYCIN; MANAGEMENT; COTRIMOXAZOLE; EPIDEMIOLOGY; 3-DAY	Background For most infections, especially acute respiratory infections (ARIs), the recommended duration of therapy is not based on strong scientific or clinical criteria. Shorter courses of antibiotics for non-severe pneumonia would result in lower costs, enhance patient compliance, and might help to contain antimicrobial resistance. We aimed to compare the clinical efficacy of 3-day and 5-day courses of amoxicillin in children with non-severe pneumonia. Methods We recruited 2000 children, aged 2-59 months, with non-severe pneumonia (WHO criteria) diagnosed in the outpatient departments of seven hospitals. Patients were randomly assigned to 3 days or 5 days of treatment with oral amoxicillin. The primary outcome was treatment failure. Analyses were by intention to treat. Findings We allocated 1000 children to 3 days of treatment and 1000 to 5 days. Treatment failed in 209 (21%) patients in the 3-day group, and in 202 (20%) in the 5-day group (difference 0.7%; 95% Cl -1.8 to 3.2). In 12 (1%) children in the 3-day group and in 13 (1%) in the 5-day group the disease relapsed (difference 0.1%; -0.6 to 0.8). Treatment was more likely to fail in children who did not adhere to treatment (p<0.0001), in those younger than 12 months (p<0.0001), in those whose illness lasted for 3 days or longer (p=0.004), in those whose respiratory rate was more than 10 breaths/min above the age-specific cut-off (p=0.004), and in those with vomiting (p=0.009). Non-adherence was also associated with failure of treatment in the 5-day group (p<0.0001). Interpretation Treatment with oral amoxicillin for 3-days was equally as effective as treatment for 5 days in children with non-severe pneumonia. The most important risk factor for treatment failure was non-compliance, which was also associated with longer duration of therapy.	WHO, Dept Child & Adolescent Hlth & Dev, CH-1211 Geneva 27, Switzerland; Dist Headquarters Quarters Hosp, Gilgit, Pakistan; Childrens Hosp, Islamabad, Pakistan; Fed Govt Serv Hosp, Islamabad, Pakistan; Childrens Hosp, Lahore, Pakistan; Sheikh Zayed Hosp, Lahore, Pakistan; Nishtar Hosp, Multan, Pakistan; Rawalpindi Gen Hosp, Rawalpindi, Pakistan	University of Geneva; World Health Organization; Rawalpindi Medical College	Qazi, SA (corresponding author), WHO, Dept Child & Adolescent Hlth & Dev, 20 Ave Appia, CH-1211 Geneva 27, Switzerland.	qazis@who.ch						Adam D, 2000, J INT MED RES, V28, p13A; Alvarez-Elcoro S, 1999, MAYO CLIN PROC, V74, P613, DOI 10.4065/74.6.613; Arason VA, 1996, BMJ-BRIT MED J, V313, P387; Baquero F, 1996, CURR OPIN INFECT DIS, V9, P372, DOI 10.1097/00001432-199612000-00003; BENNETT JB, 1988, J ANTIMICROB CHEMOTH, V21, P225, DOI 10.1093/jac/21.2.225; BETTENAY FAL, 1988, PEDIATR RADIOL, V18, P453, DOI 10.1007/BF00974077; Butler JC, 1996, J INFECT DIS, V174, P986, DOI 10.1093/infdis/174.5.986; COURTOY I, 1989, CLIN PEDIATR, V28, P261, DOI 10.1177/000992288902800604; de Francisco A, 1998, ANN TROP PAEDIATR, V18, P17, DOI 10.1080/02724936.1998.11747920; Ficnar B, 1997, J CHEMOTHERAPY, V9, P38, DOI 10.1179/joc.1997.9.1.38; FORGIE IM, 1991, PEDIATR INFECT DIS J, V10, P33, DOI 10.1097/00006454-199101000-00008; FRIEDMAN LM, 1996, FUNDAMENTALS CLIN TR; Garenne Michel, 1992, World Health Statistics Quarterly, V45, P180; GHAFOOR A, 1990, REV INFECT DIS, V12, pS907; Guay DRP, 2000, CLIN THER, V22, P673, DOI 10.1016/S0149-2918(00)90003-1; Hoepelman IM, 1998, INT J ANTIMICROB AG, V9, P141, DOI 10.1016/S0924-8579(97)00043-5; HOEPELMAN IM, 1995, INT J ANTIMICROB AG, V5, P145, DOI 10.1016/0924-8579(95)00009-W; Hoppe JE, 1996, PHARMACOECONOMICS, V10, P552, DOI 10.2165/00019053-199610060-00004; Kristinsson KG, 1997, MICROB DRUG RESIST, V3, P117, DOI 10.1089/mdr.1997.3.117; Kristinsson KG, 1995, MICROB DRUG RESIST, V1, P121, DOI 10.1089/mdr.1995.1.121; Lambert HP, 1999, LANCET, V354, P943, DOI 10.1016/S0140-6736(99)01139-3; Langtry HD, 1998, DRUGS, V56, P273, DOI 10.2165/00003495-199856020-00014; MERTENS JCC, 1992, ANTIMICROB AGENTS CH, V36, P1456, DOI 10.1128/AAC.36.7.1456; NOWAK R, 1994, SCIENCE, V264, P364, DOI 10.1126/science.8153619; Pichichero ME, 2000, J INT MED RES, V28, p25A; RASMUSSEN Z, 1997, GLOB C LUNG HLTH WOR; SAZAWAL S, 1992, LANCET, V340, P528, DOI 10.1016/0140-6736(92)91720-S; Schrag SJ, 2000, CLIN MICROBIOL REV, V13, P588, DOI 10.1128/CMR.13.4.588-601.2000; SCLAR DA, 1994, INFECT AGENT DIS, V3, P266; Straus WL, 1998, LANCET, V352, P270, DOI 10.1016/S0140-6736(97)10294-X; TUPASI TE, 1990, REV INFECT DIS, V12, pS929; *WHO, 1991, WHOARI912; WHO, 1990, AC RESP INF CHILDR C; *WHO, 1999, WORKSH DEV TOOLS PRO; WHO, 2001, WHOCDSCSRDRS20012; World Health Organization, 2000, WHOFCHCAH0012	36	123	125	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 14	2002	360	9336					835	841						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	594MC	12243918				2022-12-28	WOS:000178053500009
J	Laxminarayana, D; Khan, IU; Kammer, GM				Laxminarayana, D; Khan, IU; Kammer, GM			Transcript mutations of the a regulatory subunit of protein kinase A and up-regulation of the RNA-editing gene transcript in lupus T lymphocytes	LANCET			English	Article							RI-ALPHA; ADENOSINE DEAMINASES; SIGNAL-TRANSDUCTION; MESSENGER-RNA; ACT; SELECTION	Background Systemic lupus erythematosus (SLE) is an autoimmune disorder characterised by diverse dysfunctions of immune effector cells, including proliferation and cytotoxicity. In T cells from patients with SLE, activity of type 1 protein kinase A isozymes is greatly reduced because of decreased expression of the alpha and beta regulatory subunits (RIalpha and RIP). We aimed to identify a molecular mechanism or mechanisms for this isozyme deficiency by assessing occurrence of mutations in transcripts of the RIalpha Subunit in patients with SLE. Methods We cloned and sequenced cIDNA of RIalpha and corresponding genomic DNA of the coding region to detect sequence changes from eight patients with SLE and six healthy controls. Because transcript editing is regulated by adenosine deaminases that act on RNA (ADAR), we quantified expression of ADAR1 transcripts in SLE and control T cells by competitive PCR. Findings Sequence analyses of cDNA showed heterogeneous transcript mutations, including deletions, transitions, and transversions. We identified 1.22X10(-3)/bp transcript mutations in SLE T cells-a frequency 7.5 times higher than that in control T cells. By contrast, we identified no genomic mutations. Two hotspots were identified in the RIalpha subunit transcripts from SLE T cells, one located adjacent to a pseudosubstrate site of the RIalpha subunit and the other a component of the cAMP binding A domain. ADAR1 mRNA content was 3.5 times higher in SLE cells than in control T cells (p=0.001). Interpretation An RNA-editing enzyme could be converting adenosine to inosine within double-stranded regions of RNA, resulting in transcript mutations. This process could be one mechanism resulting in mutations in the RIalpha subunit of type 1 protein kinase A.	Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Sect Rheumatol & Clin Immunol, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Microbiol & Immunol, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	Laxminarayana, D (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Sect Rheumatol & Clin Immunol, Med Ctr Blvd, Winston Salem, NC 27157 USA.	diaxmina@wfubmc.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR007122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046526] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR046385, R01AR039501] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR07122] Funding Source: Medline; NIAID NIH HHS [R01-AI46526] Funding Source: Medline; NIAMS NIH HHS [R01-AR39501, R03-AR46385] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bass BL, 2002, ANNU REV BIOCHEM, V71, P817, DOI 10.1146/annurev.biochem.71.110601.135501; BOMBARDIER C, 1992, ARTHRITIS RHEUM, V35, P630, DOI 10.1002/art.1780350606; Davidson NO, 2002, J CLIN INVEST, V109, P291, DOI 10.1172/JCI14979; GMELIGMEYLING F, 1992, J EXP MED, V175, P297, DOI 10.1084/jem.175.1.297; HASLER P, 1990, P NATL ACAD SCI USA, V87, P1978, DOI 10.1073/pnas.87.5.1978; HOOKS JJ, 1979, NEW ENGL J MED, V301, P5, DOI 10.1056/NEJM197907053010102; Jacob AM, 2001, AUTOIMMUNITY, V33, P61, DOI 10.3109/08916930108994110; Kammer Gary M, 2002, Curr Dir Autoimmun, V5, P131; Kammer GM, 1999, ARTHRITIS RHEUM, V42, P1458, DOI 10.1002/1529-0131(199907)42:7<1458::AID-ANR20>3.0.CO;2-P; Kammer GM, 1996, J IMMUNOL, V157, P2690; Kammer GM, 2002, ARTHRITIS RHEUM-US, V46, P1139, DOI 10.1002/art.10192; KAMMER GM, 1994, J CLIN INVEST, V94, P422, DOI 10.1172/JCI117340; KHAN IU, 1999, LUPUS MOL CELLULAR P, P257; Laxminarayana D, 1999, J IMMUNOL, V162, P5639; Laxminarayana D, 2000, INT IMMUNOL, V12, P1521, DOI 10.1093/intimm/12.11.1521; Lee JS, 2000, J IMMUNOL, V165, P6322, DOI 10.4049/jimmunol.165.11.6322; Maas S, 2000, BIOESSAYS, V22, P790, DOI 10.1002/1521-1878(200009)22:9<790::AID-BIES4>3.0.CO;2-0; MANDLER R, 1982, P NATL ACAD SCI-BIOL, V79, P7542, DOI 10.1073/pnas.79.23.7542; Mishra N, 2000, J IMMUNOL, V165, P2830, DOI 10.4049/jimmunol.165.5.2830; Morse DP, 2002, P NATL ACAD SCI USA, V99, P7906, DOI 10.1073/pnas.112704299; Nambiar MP, 2001, J AUTOIMMUN, V16, P133, DOI 10.1006/jaut.2000.0475; Ronnblom L, 2001, TRENDS IMMUNOL, V22, P427, DOI 10.1016/S1471-4906(01)01955-X; Rueter SM, 1999, NATURE, V399, P75, DOI 10.1038/19992; Sale JE, 2001, NATURE, V412, P921, DOI 10.1038/35091100; SOLBERG R, 1993, GENOMICS, V15, P591, DOI 10.1006/geno.1993.1112; Solberg R, 1997, ENDOCRINOLOGY, V138, P169, DOI 10.1210/en.138.1.169; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; van Leeuwen FW, 1998, SCIENCE, V279, P242, DOI 10.1126/science.279.5348.242; van Leeuwen FW, 1998, TRENDS NEUROSCI, V21, P331, DOI 10.1016/S0166-2236(98)01280-6; Yoshikawa K, 2002, SCIENCE, V296, P2033, DOI 10.1126/science.1071556	30	35	35	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 14	2002	360	9336					842	849		10.1016/S0140-6736(02)09966-X	http://dx.doi.org/10.1016/S0140-6736(02)09966-X			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	594MC	12243919				2022-12-28	WOS:000178053500010
J	Ikeda, M; Matsunaga, T; Irabu, N; Yoshida, S				Ikeda, M; Matsunaga, T; Irabu, N; Yoshida, S			Using vital signs to diagnose impaired consciousness: cross sectional observational study	BRITISH MEDICAL JOURNAL			English	Article							LIKELIHOOD RATIOS; CURVES; COMA	Objectives To determine whether any vital signs can be used to quickly identify brain lesions in patients with impaired consciousness. Design Cross sectional observational study. Setting Emergency department of m urban hospital, Japan. Participants 529 consecutive patients (mean age 65 years) presenting with impaired consciousness (score < 15 on the Glasgow coma scale) during 2000. Main outcome measures The receiver operating characteristic curve was used to quantify the relation between the vital signs on arrival and the final diagnosis of a brain lesion. Stratum specific likelihood ratios were calculated to define strata with optimal discriminating power. Results 312 (59%) had a brain lesion which accounted for the impaired consciousness. The area under the receiver operating curve for systolic blood pressure was 0.90 (SE 0.01), indicating significantly higher accuracy (P < 0.01) in the identification of a brain lesion than using diastolic pressure 0.82 (0.02) or pulse rate 0.63 (0.03). Likelihood ratios for systolic blood pressure lower than 90 mm Hg were less than 0.04, and those for systolic pressure higher than 170 mm Hg were greater than 6.09. Conclusions Systolic blood pressure is useful for diagnosing brain lesions in patients with impaired consciousness.	Natl Saigata Hosp, Dept Clin Res, Ohgata, Niigata 9493193, Japan; Asahi Gen Hosp, Dept Neurol, Chiba, Japan; Asahi Gen Hosp, Dept Emergency Med, Chiba, Japan; Asahi Gen Hosp, Dept Med, Chiba, Japan		Ikeda, M (corresponding author), Natl Saigata Hosp, Dept Clin Res, Ohgata, Niigata 9493193, Japan.							BATES D, 1977, ANN NEUROL, V2, P211, DOI 10.1002/ana.410020306; Furukawa TA, 2001, PSYCHOL MED, V31, P519, DOI 10.1017/S0033291701003713; Graham ID, 1998, ACAD EMERG MED, V5, P134, DOI 10.1111/j.1553-2712.1998.tb02598.x; Guyton AC, 1996, TXB MED PHYSL, P209; HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708; LEVY LL, 1976, STROKE, V7, P147, DOI 10.1161/01.STR.7.2.147; LEVY LL, 1977, STROKE, V8, P189, DOI 10.1161/01.STR.8.2.189; MILLS ML, 1986, ANN EMERG MED, V15, P1167, DOI 10.1016/S0196-0644(86)80859-9; PEIRCE JC, 1993, MED DECIS MAKING, V13, P141, DOI 10.1177/0272989X9301300208; Plum F, 1980, DIAGNOSIS STUPOR COM, Vthird; SWETS JA, 1988, SCIENCE, V240, P1285, DOI 10.1126/science.3287615; TEASDALE G, 1974, LANCET, V2, P81; VICTOR M, 2001, ADAMS VICTORS PRINCI, P366; WALLACE JD, 1981, JAMA-J AM MED ASSOC, V246, P2177, DOI 10.1001/jama.246.19.2177; Yamashiro Seiji, 1994, Fukuoka Acta Medica, V85, P353	15	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 12	2002	325	7368					800	U5		10.1136/bmj.325.7368.800	http://dx.doi.org/10.1136/bmj.325.7368.800			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604YM	12376438	Bronze, Green Published			2022-12-28	WOS:000178648700015
J	Connor, CE				Connor, CE			Reconstructing a 3D world	SCIENCE			English	Editorial Material							HUMAN VISUAL-CORTEX; NEURONS; MOTION; DEPTH; SELECTIVITY; ORIENTATION; SURFACE; AREAS; STRIATE; REGIONS		Johns Hopkins Univ, Dept Neurosci, Baltimore, MD 21218 USA; Johns Hopkins Univ, Zanvyl Krieger Mind Brain Inst, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University	Connor, CE (corresponding author), Johns Hopkins Univ, Dept Neurosci, Baltimore, MD 21218 USA.							BARLOW HB, 1967, J PHYSIOL-LONDON, V193, P327, DOI 10.1113/jphysiol.1967.sp008360; Bradley DC, 1998, NATURE, V392, P714, DOI 10.1038/33688; DeYoe EA, 1996, P NATL ACAD SCI USA, V93, P2382, DOI 10.1073/pnas.93.6.2382; Hinkle DA, 2002, NAT NEUROSCI, V5, P665, DOI 10.1038/nn875; HUBEL DH, 1970, NATURE, V225, P41, DOI 10.1038/225041a0; Janssen P, 2000, SCIENCE, V288, P2054, DOI 10.1126/science.288.5473.2054; Janssen P, 1999, P NATL ACAD SCI USA, V96, P8217, DOI 10.1073/pnas.96.14.8217; NGUYENKIM JD, 2001, SOC NEUR ABSTR, V27; ORBAN GA, 1995, P NATL ACAD SCI USA, V92, P993, DOI 10.1073/pnas.92.4.993; Orban GA, 1999, NEURON, V24, P929, DOI 10.1016/S0896-6273(00)81040-5; POGGIO GF, 1977, J NEUROPHYSIOL, V40, P1392, DOI 10.1152/jn.1977.40.6.1392; Sereno ME, 2002, NEURON, V33, P635, DOI 10.1016/S0896-6273(02)00598-6; SERENO MI, 1995, SCIENCE, V268, P889, DOI 10.1126/science.7754376; Shikata E, 1996, NEUROREPORT, V7, P2389, DOI 10.1097/00001756-199610020-00022; Sunaert S, 1999, EXP BRAIN RES, V127, P355, DOI 10.1007/s002210050804; Tootell RBH, 2001, CEREB CORTEX, V11, P298, DOI 10.1093/cercor/11.4.298; Tsutsui KI, 2002, SCIENCE, V298, P409, DOI 10.1126/science.1074128; Tsutsui KI, 2001, J NEUROPHYSIOL, V86, P2856, DOI 10.1152/jn.2001.86.6.2856; Vanduffel W, 2002, SCIENCE, V298, P413, DOI 10.1126/science.1073574; VanOostende S, 1997, CEREB CORTEX, V7, P690, DOI 10.1093/cercor/7.7.690; WALLACH H, 1953, J EXP PSYCHOL, V45, P205, DOI 10.1037/h0056880; Xiao DK, 1997, EUR J NEUROSCI, V9, P956, DOI 10.1111/j.1460-9568.1997.tb01446.x	22	2	2	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 11	2002	298	5592					376	377		10.1126/science.1078095	http://dx.doi.org/10.1126/science.1078095			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	602NB	12376693				2022-12-28	WOS:000178510400037
J	Ahmed, S; Saleem, M; Modell, B; Petrou, M				Ahmed, S; Saleem, M; Modell, B; Petrou, M			Screening extended families for genetic hemoglobin disorders in Pakistan	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PRENATAL-DIAGNOSIS; BETA-THALASSEMIA; CONSANGUINITY; EXPERIENCE	Background: We have investigated a strategy for identifying and counseling carriers of recessively inherited disorders in developing countries where consanguineous marriage is common. In such communities, gene variants are trapped within extended families, so that an affected child is a marker of a group at high genetic risk. Methods: Fifteen large Pakistani families, 10 with a history of a hemoglobin disorder and 5 without any such history (controls), were screened for (beta)-thalassemia and abnormal hemoglobins. All carriers and married couples consisting of two carriers received counseling, and eight families have been followed for two years. Results: In the control families, no carrier was found among 397 members tested. In the 10 families with an index case, 183 of 591 persons tested (31 percent) were carriers; carriers had a 25 percent risk of being in a marriage at risk for producing an affected child, and 17 of 214 married couples (8 percent) consisted of two carriers. No couple at risk was identified among 350 randomly selected pregnant women and their partners. All carriers reported that they have used the information provided in the testing and counseling process: carriers married to carriers with two or more healthy children have avoided further pregnancy, and most such couples with one or no healthy children have used prenatal diagnosis. Seven of eight new marriages and engagements are known not to be at risk. Conclusions: Testing of extended families is a feasible way of deploying DNA-based genetic screening in communities in which consanguineous marriage is common.	UCL Royal Free & Univ Coll Med Sch, Dept Obstet & Gynaecol, Perinatal Ctr, London WC1E 6HX, England; Armed Forces Inst Pathol, Rawalpindi, Pakistan	University of London; University College London; UCL Medical School	Petrou, M (corresponding author), UCL Royal Free & Univ Coll Med Sch, Dept Obstet & Gynaecol, Perinatal Ctr, 86-96 Chenies Mews, London WC1E 6HX, England.	m.petrou@ucl.ac.uk						Ahmed S, 1996, BRIT J HAEMATOL, V94, P476; Ahmed S, 2000, PRENATAL DIAG, V20, P378; Alwan A, 1997, EMRO TECHNICAL PUBLI; ANGASTINIOTIS M, 1986, World Health Forum, V7, P291; Bain BJ, 1998, BRIT J HAEMATOL, V101, P783, DOI 10.1046/j.1365-2141.1998.00809.x; BITTLES AH, 1994, POPUL DEV REV, V20, P561, DOI 10.2307/2137601; BURNEY MI, 1994, HLTH MED PROFILE MUS; Cao A, 1996, CIBA F SYMP, V197, P137; *GOV PAK MIN HLTH, 1997, ANN REP HLTH SERV PA; Harper P., 1993, PRACTICAL GENETIC CO; *HLTH ED AUTH, 1998, SICKL CELL THAL ACH; KHATTAK M F, 1992, JPMA (Journal of the Pakistan Medical Association), V42, P32; Loukopoulos D, 1996, SEMIN HEMATOL, V33, P76; Modell B., 1984, CLIN APPROACH THALAS; MOUZOURAS M, 1980, LANCET, V2, P574; Petrou M, 1995, PRENATAL DIAG, V15, P1275, DOI 10.1002/pd.1970151308; Petrou M, 2000, PRENATAL DIAG, V20, P469, DOI 10.1002/1097-0223(200006)20:6<469::AID-PD857>3.0.CO;2-V; Rajab A, 1999, Community Genet, V2, P23, DOI 10.1159/000016179; SHARMA NP, 1976, INDIAN J MED RES, V64, P883; Stamatoyannoulos G., 1974, BIRTH DEFECTS, P268; STEINBERG MH, 1991, BLOOD, V78, P2165; Stoltenberg C, 1997, AM J EPIDEMIOL, V145, P439; *WHO, 2000, WHO M CAIR EG 6 8 DE	23	120	126	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 10	2002	347	15					1162	1168		10.1056/NEJMsa013234	http://dx.doi.org/10.1056/NEJMsa013234			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	601TW	12374877	Green Published			2022-12-28	WOS:000178465100007
J	Brumfiel, G				Brumfiel, G			China ponders joining fusion project	NATURE			English	News Item																		2002, NATURE, V417, P676	1	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 10	2002	419	6907					545	545		10.1038/419545b	http://dx.doi.org/10.1038/419545b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	602AT	12374935	Bronze			2022-12-28	WOS:000178483100003
J	Cyranoski, D				Cyranoski, D			Winning universities set out to fulfil Japan's plans for excellence	NATURE			English	News Item																			0	0	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 10	2002	419	6907					547	547		10.1038/419547b	http://dx.doi.org/10.1038/419547b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	602AT	12374940	Bronze			2022-12-28	WOS:000178483100007
J	Hurlen, M; Abdelnoor, M; Smith, P; Erikssen, J; Arnesen, H				Hurlen, M; Abdelnoor, M; Smith, P; Erikssen, J; Arnesen, H			Warfarin, aspirin, or both after myocardial infarction.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TERM ANTICOAGULANT TREATMENT; DOUBLE-BLIND TRIAL; ACETYLSALICYLIC-ACID; MORTALITY; REINFARCTION; PREVENTION; THROMBOSIS; THERAPY	Background: The role of antithrombotic therapy in secondary prevention after myocardial infarction is well established. Although the available literature suggests that warfarin is superior to aspirin, aspirin is currently the more widely used drug. We studied the efficacy and safety of warfarin, aspirin, or both after myocardial infarction. Methods: In a randomized, multicenter trial in 3630 patients, 1216 received warfarin (in a dose intended to achieve an international normalized ratio [INR] of 2.8 to 4.2), 1206 received aspirin (160 mg daily), and 1208 received aspirin (75 mg daily) combined with warfarin (in a dose intended to achieve an INR of 2.0 to 2.5). The mean duration of observation was four years. Results: The primary outcome, a composite of death, nonfatal reinfarction, or thromboembolic cerebral stroke, occurred in 241 of 1206 patients receiving aspirin (20.0 percent), 203 of 1216 receiving warfarin (16.7 percent; rate ratio as compared with aspirin, 0.81; 95 percent confidence interval, 0.69 to 0.95; P=0.03), and 181 of 1208 receiving warfarin and aspirin (15.0 percent; rate ratio as compared with aspirin, 0.71; 95 percent confidence interval, 0.60 to 0.83; P=0.001). The difference between the two groups receiving warfarin was not statistically significant. Episodes of major, nonfatal bleeding were observed in 0.62 percent of patients per treatment-year in both groups receiving warfarin and in 0.17 percent of patients receiving aspirin (P<0.001). Conclusions: Warfarin, in combination with aspirin or given alone, was superior to aspirin alone in reducing the incidence of composite events after an acute myocardial infarction but was associated with a higher risk of bleeding.	Ullevaal Univ Hosp, Dept Cardiol, N-0407 Oslo, Norway; Ullevaal Univ Hosp, Res Forum, N-0407 Oslo, Norway; Baerum Hosp, Baerum, Norway; Akershus Univ Hosp, Akershus, Norway	University of Oslo; University of Oslo; University of Oslo	Hurlen, M (corresponding author), Ullevaal Univ Hosp, Dept Med, N-0407 Oslo, Norway.		abdelnoor, michael/K-4248-2019					Anand SS, 1999, JAMA-J AM MED ASSOC, V282, P2058, DOI 10.1001/jama.282.21.2058; ANAND SS, 2000, JAMA-J AM MED ASSOC, V284, P45; [Anonymous], 1979, Circulation, V59, P607; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1994, Lancet, V343, P499; Antithrombotic Trialists' Collaboration, 2002, BMJ-BRIT MED J, V324, P141, DOI DOI 10.1136/BMJ.324.7330.141; ASINGER RW, 1981, NEW ENGL J MED, V305, P297, DOI 10.1056/NEJM198108063050601; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Blackshear JL, 1996, LANCET, V348, P633; BOISSEL JP, 1982, NEW ENGL J MED, V307, P701; BREDDIN K, 1980, HAEMOSTASIS, V9, P325; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; DAVIES MJ, 1976, BRIT HEART J, V38, P659; DEWOOD MA, 1980, NEW ENGL J MED, V303, P897, DOI 10.1056/NEJM198010163031601; DRAPKIN A, 1972, J AMER MED ASSOC, V222, P541, DOI 10.1001/jama.222.5.541; ELWOOD PC, 1979, LANCET, V2, P1313; Fiore LD, 2002, CIRCULATION, V105, P557, DOI 10.1161/hc0502.103329; Fuster V, 1997, LANCET, V350, P389; HORIE T, 1978, BRIT HEART J, V40, P153; HURLEN M, 1994, J INTERN MED, V236, P299, DOI 10.1111/j.1365-2796.1994.tb00800.x; Julian DG, 1996, BMJ-BRIT MED J, V313, P1429, DOI 10.1136/bmj.313.7070.1429; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR; KLIMT CR, 1986, J AM COLL CARDIOL, V7, P251, DOI 10.1016/S0735-1097(86)80489-2; Lee E, 1980, STAT METHODS SURVIVA; LOELIGER EA, 1967, ACTA MED SCAND, V182, P549; Meade TW, 1998, LANCET, V351, P233; MEUWISSE.OJ, 1969, ACTA MED SCAND, V186, P361; PEDERSEN TR, 1981, NEW ENGL J MED, V304, P801; RIDOLFI RL, 1977, AM HEART J, V93, P468, DOI 10.1016/S0002-8703(77)80410-9; ROOS J, 1980, LANCET, V2, P989; SCHWARTZ D, 1982, CLIN TRIALS; SELF SG, 1988, BIOMETRICS, V44, P79, DOI 10.2307/2531897; SELF SG, 1992, BIOMETRICS, V48, P31, DOI 10.2307/2532736; SMITH P, 1990, NEW ENGL J MED, V323, P147, DOI 10.1056/NEJM199007193230302; SORENSEN OH, 1969, ACTA MED SCAND, V185, P65; WASSERMAN AJ, 1966, AM HEART J, V71, P43, DOI 10.1016/0002-8703(66)90655-7; WICHMANN BA, 1982, APPLIED STATISTICS, V31, P188	37	624	657	0	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 26	2002	347	13					969	974		10.1056/NEJMoa020496	http://dx.doi.org/10.1056/NEJMoa020496			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	596RD	12324552				2022-12-28	WOS:000178178400002
J	Irigoien, X; Harris, RP; Verheye, HM; Joly, P; Runge, J; Starr, M; Pond, D; Campbell, R; Shreeve, R; Ward, P; Smith, AN; Dam, HG; Peterson, W; Tirelli, V; Koski, M; Smith, T; Harbour, D; Davidson, R				Irigoien, X; Harris, RP; Verheye, HM; Joly, P; Runge, J; Starr, M; Pond, D; Campbell, R; Shreeve, R; Ward, P; Smith, AN; Dam, HG; Peterson, W; Tirelli, V; Koski, M; Smith, T; Harbour, D; Davidson, R			Copepod hatching success in marine ecosystems with high diatom concentrations	NATURE			English	Article							CALANUS-HELGOLANDICUS; ORGANIC-CARBON; EGG-PRODUCTION; PHYTOPLANKTON; FISHERIES	Diatoms dominate spring bloom phytoplankton assemblages in temperate waters and coastal upwelling regions of the global ocean. Copepods usually dominate the zooplankton in these regions and are the prey of many larval fish species. Recent laboratory studies suggest that diatoms may have a deleterious effect on the success of copepod egg hatching(1-4). These findings challenge the classical view of marine food-web energy flow from diatoms to fish by means of copepods(5-7). Egg mortality is an important factor in copepod population dynamics(8), thus, if diatoms have a deleterious in situ effect, paradoxically, high diatom abundance could limit secondary production. Therefore, the current understanding of energy transfer from primary production to fisheries in some of the most productive and economically important marine ecosystems(9) may be seriously flawed(1,10). Here we present in situ estimates of copepod egg hatching success from twelve globally distributed areas, where diatoms dominate the phytoplankton assemblage. We did not observe a negative relationship between copepod egg hatching success and either diatom biomass or dominance in the microplankton in any of these regions. The classical model for diatom-dominated system remains valid.	AZTI, Pasaia 20110, Spain; Plymouth Marine Lab, Plymouth PL1 3DH, Devon, England; Marine & Coastal Management, ZA-8012 Cape Town, Cape Town, South Africa; Inst Maurice Lamontagne, Mont Joli, PQ G5H 3Z4, Canada; British Antarctic Survey, Cambridge CB3 0ET, England; Univ Victoria, Sch Earth & Ocean Sci, Victoria, BC V8W 3P6, Canada; Univ Connecticut, Dept Marine Sci, Groton, CT 06340 USA; Natl Marine Fisheries Serv, Newport, OR 97365 USA; Univ Trieste, Dept Biol, Trieste, Italy; LBM, Trieste, Italy; Netherlands Inst Sea Res, NL-1790 AB Den Burg, Netherlands; Southampton Oceanog Ctr, Southampton SO14 3ZH, Hants, England	AZTI; Plymouth Marine Laboratory; University of Cape Town; Fisheries & Oceans Canada; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); NERC British Antarctic Survey; University of Victoria; University of Connecticut; National Aeronautics & Space Administration (NASA); National Oceanic Atmospheric Admin (NOAA) - USA; University of Trieste; Utrecht University; Royal Netherlands Institute for Sea Research (NIOZ); NERC National Oceanography Centre; University of Southampton	Irigoien, X (corresponding author), AZTI, Herrera Kaia Portualdea S-G, Pasaia 20110, Spain.	xirigoien@pas.azti.es	Dam, Hans G/A-9723-2015; Irigoien, Xabier/B-8171-2009; Tirelli, Valentina/GPG-4131-2022	Dam, Hans G/0000-0001-6121-5038; Irigoien, Xabier/0000-0002-5411-6741; Tirelli, Valentina/0000-0002-5152-2891; Koski, Marja/0000-0002-1860-9768				Ban SH, 1997, MAR ECOL PROG SER, V157, P287, DOI 10.3354/meps157287; CUSHING DH, 1989, J PLANKTON RES, V11, P1, DOI 10.1093/plankt/11.1.1; HOLLIGAN PM, 1977, J MAR BIOL ASSOC UK, V57, P1075, DOI 10.1017/S002531540002614X; Ianora A, 1999, MAR ECOL PROG SER, V177, P305; Ianora A, 1996, MAR BIOL, V125, P279, DOI 10.1007/BF00346308; Irigoien X, 2000, LIMNOL OCEANOGR, V45, P44, DOI 10.4319/lo.2000.45.1.0044; Irigoien X, 2000, LIMNOL OCEANOGR, V45, P1433, DOI 10.4319/lo.2000.45.6.1433; Jonasdottir SH, 1998, MAR ECOL PROG SER, V172, P305, DOI 10.3354/meps172305; LEGENDRE L, 1990, J PLANKTON RES, V12, P681, DOI 10.1093/plankt/12.4.681; LESSARD EJ, 1986, J PLANKTON RES, V8, P1209, DOI 10.1093/plankt/8.6.1209; Miralto A, 1999, NATURE, V402, P173, DOI 10.1038/46023; OHMAN MD, 1994, LIMNOL OCEANOGR, V39, P21, DOI 10.4319/lo.1994.39.1.0021; Ohman MD, 2001, NATURE, V412, P638, DOI 10.1038/35088068; Paffenhofer GA, 2002, MAR ECOL PROG SER, V227, P305, DOI 10.3354/meps227305; PAULY D, 1995, NATURE, V374, P255, DOI 10.1038/374255a0; Peterson WT, 2001, HYDROBIOLOGIA, V453, P91, DOI 10.1023/A:1013111832700; Pohnert G, 2000, ANGEW CHEM INT EDIT, V39, P4352, DOI 10.1002/1521-3773(20001201)39:23<4352::AID-ANIE4352>3.0.CO;2-U; POULET SA, 1994, MAR ECOL PROG SER, V111, P79, DOI 10.3354/meps111079; Runge J.A., 2000, P401, DOI 10.1016/B978-012327645-2/50010-4; RUNGE JA, 1988, HYDROBIOLOGIA, V167, P61, DOI 10.1007/BF00026294; STRATHMANN RR, 1967, LIMNOL OCEANOGR, V12, P411, DOI 10.4319/lo.1967.12.3.0411; Uye S, 1996, MAR ECOL PROG SER, V133, P89, DOI 10.3354/meps133089	22	181	211	1	67	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 26	2002	419	6905					387	389		10.1038/nature01055	http://dx.doi.org/10.1038/nature01055			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	596ZB	12353032				2022-12-28	WOS:000178195400043
J	Horwitz, SM; Kelleher, K; Boyce, T; Jensen, P; Murphy, M; Perrin, E; Stein, REK; Weitzman, M				Horwitz, SM; Kelleher, K; Boyce, T; Jensen, P; Murphy, M; Perrin, E; Stein, REK; Weitzman, M			Barriers to health care research for children and youth with psychosocial problems	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Annual Meeting of the Pediatric-Academic-Societies	APR 29-MAY 13, 2001	BALTIMORE, MARYLAND	Pediatr Acad Soci			PEDIATRIC PRIMARY CARE; IDENTIFICATION; PREVALENCE; DISORDERS	Context The 1999 surgeon general's report on mental health concluded that insufficient attention to mental health disorders is being paid in children's primary medical care services. This lack of attention has occurred despite considerable attention to this issue in the planning documents of many federal agencies. Objective To assess the extent to which federal agencies' portfolios of funded research grants were consistent with the directives for primary care-based mental health services for children and adolescents featured in their planning documents. Data Source A cross-sectional review of the 66749 abstracts listed in the April 2001 Computer Retrieval of information on Scientific Projects (CRISP) database of currently funded research grants supported by the US Department of Health and Human Services. Abstracts were rated by whether they targeted primary care, examined behavioral or emotional issues, and examined or modified a facet of primary care. Data Synthesis Of the 45022 research abstracts in the CRISP database, 2720 (6%) contained the words children, adolescents, or youth. Sixty-three abstracts contained work on children, adolescents, or youth in primary care (0.14% of the portfolio). Of these 63 abstracts, only 21 (0.05% of the portfolio) addressed behavioral or emotional issues. Of the 21 projects, only 11 examined aspects of the primary care process. When the distribution of child and adult studies on the treatment of depression within primary care settings was examined, it was found that adults received 15 times the research attention compared with children. Conclusion Even though the importance of primary care as a system for identifying and treating behavioral and emotional problems in children has been recognized for more than 20 years, little attention is being paid to this topic in the research portfolios of the National Institutes of Health and other federal agencies that support research.	Yale Univ, Sch Med, Ctr Child Study, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA; Ohio State Univ, Childrens Res Inst, Columbus, OH 43210 USA; Univ Calif Berkeley, Sch Publ Hlth, Inst Human Dev, Berkeley, CA 94720 USA; Columbia Univ, Ctr Advancement Childrens Mental Hlth, New York, NY USA; Massachusetts Gen Hosp, Child Psychiat Serv, Boston, MA 02114 USA; Tufts Univ, New England Med Ctr, Dept Pediat, Boston, MA 02111 USA; Childrens Hosp Montefiore, Albert Einstein Coll Med, Bronx, NY USA; Amer Acad Pediat Ctr Child Hlth Res, Rochester, NY USA; Univ Rochester, Sch Med & Dent, Strong Childrens Res Ctr, Rochester, NY USA	Yale University; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; University of California System; University of California Berkeley; Columbia University; Harvard University; Massachusetts General Hospital; Tufts Medical Center; Tufts University; Yeshiva University; Albert Einstein College of Medicine; Childrens Hospital at Montefiore; University of Rochester	Horwitz, SM (corresponding author), Yale Univ, Sch Med, Ctr Child Study, Dept Epidemiol & Publ Hlth, 60 Coll St,Box 208034, New Haven, CT 06520 USA.			Jensen, Peter/0000-0003-2387-0650; Horwitz, Sarah/0000-0002-5262-1170				COSTELLO EJ, 1988, ARCH GEN PSYCHIAT, V45, P1107; Haggerty RJ, 1975, CHILD HLTH COMMUNITY; HORWITZ SM, 1992, PEDIATRICS, V89, P480; *I MED, 1994, REP CARD NAT PLAN RE; *I MED, 1989, RES CHILDR AD MENT B; Kelleher KJ, 2000, PEDIATRICS, V105, P1313, DOI 10.1542/peds.105.6.1313; KELLEHER KJ, 1989, AM J DIS CHILD, V143, P855, DOI 10.1001/archpedi.1989.02150190105033; LAVIGNE JV, 1993, PEDIATRICS, V91, P649; *NAT ADV MENT HLTH, 1998, BRIDG SCI SERV REP N; *NAT I MENT HLTH, 1998, NAT PLAN RES CHILD A; *NIH, GRANTS FUND OPP; Office of the Surgeon General, 2019, SURG GEN ADV MAR US; REGIER DA, 1982, ARCH GEN PSYCHIAT, V39, P219; REGIER DA, 1978, ARCH GEN PSYCHIAT, V35, P685; WELLS K, 1996, CARING DEPRESSION	15	33	33	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	2002	288	12					1508	1512		10.1001/jama.288.12.1508	http://dx.doi.org/10.1001/jama.288.12.1508			5	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	596AT	12243638				2022-12-28	WOS:000178142000022
J	Over, H; Seitsonen, AP				Over, H; Seitsonen, AP			Oxidation of metal surfaces	SCIENCE			English	Editorial Material							OXYGEN		Univ Giessen, Inst Phys Chem, D-35392 Giessen, Germany; Univ Zurich, Inst Phys Chem, CH-8057 Zurich, Switzerland	Justus Liebig University Giessen; University of Zurich	Over, H (corresponding author), Univ Giessen, Inst Phys Chem, Heinrich Buff Ring 58, D-35392 Giessen, Germany.		Seitsonen, Ari P/B-1552-2009	Seitsonen, Ari P/0000-0003-4331-0650				Bottcher A, 1999, PHYS REV B, V60, P14396, DOI 10.1103/PhysRevB.60.14396; Carlisle CI, 2000, SURF SCI, V470, P15, DOI 10.1016/S0039-6028(00)00831-1; Duke C. B., 2001, SURF SCI, V500; Kim YD, 2001, TOP CATAL, V14, P95; LIU W, 1995, SURF SCI, V339, P151, DOI 10.1016/0039-6028(95)00611-7; Lundgren E, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.246103; Over H, 2002, SURF SCI, V515, P143, DOI 10.1016/S0039-6028(02)01853-8; Thurmer K, 2002, SCIENCE, V297, P2033, DOI 10.1126/science.297.5589.2033; Todorova M, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.096103; Trost J, 1998, J CHEM PHYS, V108, P1740, DOI 10.1063/1.475546; WILHELMI G, 1991, STRUCTURE SURFACES, V3, P448	11	149	149	1	95	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 20	2002	297	5589					2003	+		10.1126/science.1077063	http://dx.doi.org/10.1126/science.1077063			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	594XV	12242427				2022-12-28	WOS:000178078500030
J	Smith, IE				Smith, IE			New drugs for breast cancer	LANCET			English	Review							FIRST-LINE THERAPY; PHASE-III; POSTMENOPAUSAL WOMEN; TAMOXIFEN; LETROZOLE; SUPERIOR; EFFICACY; CHEMOTHERAPY; CAPECITABINE; TRASTUZUMAB		Royal Marsden Hosp, Breast Unit, London SW3 6JJ, England	Royal Marsden NHS Foundation Trust	Smith, IE (corresponding author), Royal Marsden Hosp, Breast Unit, London SW3 6JJ, England.	ian.smith@rmh.nthames.nhs.uk						Baum M, 2002, LANCET, V359, P2131; Biganzoli L, 2002, J CLIN ONCOL, V20, P3114, DOI 10.1200/JCO.2002.11.005; Blum JL, 1999, J CLIN ONCOL, V17, P485, DOI 10.1200/JCO.1999.17.2.485; Bonneterre J, 2000, J CLIN ONCOL, V18, P3748, DOI 10.1200/JCO.2000.18.22.3748; Burstein HJ, 2001, J CLIN ONCOL, V19, P2722, DOI 10.1200/JCO.2001.19.10.2722; Chan S, 1999, J CLIN ONCOL, V17, P2341, DOI 10.1200/JCO.1999.17.8.2341; Coleman RE, 2001, SEMIN ONCOL, V28, P35, DOI 10.1053/sonc.2001.25427; Diel IJ, 1998, NEW ENGL J MED, V339, P357, DOI 10.1056/NEJM199808063390601; Eiermann W, 2001, ANN ONCOL, V12, P1527, DOI 10.1023/A:1013128213451; Ellis MJ, 2001, J CLIN ONCOL, V19, P3808, DOI 10.1200/JCO.2001.19.18.3808; Goldhirsch A, 2001, J CLIN ONCOL, V19, P3817, DOI 10.1200/JCO.2001.19.18.3817; Hamilton A, 1999, ANN ONCOL, V10, P377, DOI 10.1023/A:1008368300827; HENDERSON IC, 1998, P AN M AM SOC CLIN, V17, P101; HOWELL A, 1995, LANCET, V345, P29, DOI 10.1016/S0140-6736(95)91156-1; Klijn JGM, 2001, J CLIN ONCOL, V19, P343, DOI 10.1200/JCO.2001.19.2.343; Klijn JGM, 2000, JNCI-J NATL CANCER I, V92, P903, DOI 10.1093/jnci/92.11.903; Mouridsen H, 2001, J CLIN ONCOL, V19, P2596, DOI 10.1200/JCO.2001.19.10.2596; Nabholtz JM, 2000, J CLIN ONCOL, V18, P3758, DOI 10.1200/JCO.2000.18.22.3758; NABHOLTZ JM, 2002, P ASCO, V21, P141; O'Shaughnessy J, 2002, J CLIN ONCOL, V20, P2812, DOI 10.1200/JCO.2002.09.002; Powles T, 2002, J CLIN ONCOL, V20, P3219, DOI 10.1200/JCO.2002.11.080; Saarto T, 2001, J CLIN ONCOL, V19, P10, DOI 10.1200/JCO.2001.19.1.10; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719	24	23	26	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 7	2002	360	9335					790	792		10.1016/S0140-6736(02)09903-8	http://dx.doi.org/10.1016/S0140-6736(02)09903-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	592HX	12241842				2022-12-28	WOS:000177933000025
J	Ohkouchi, N; Eglinton, TI; Keigwin, LD; Hayes, JM				Ohkouchi, N; Eglinton, TI; Keigwin, LD; Hayes, JM			Spatial and temporal offsets between proxy records in a sediment drift	SCIENCE			English	Article							SEA-SURFACE TEMPERATURE; PALEOCEANOGRAPHIC CONDITIONS; OCEAN; DEGLACIATION; CIRCULATION; STRATIGRAPHY; VARIABILITY; ISOTOPE; CLIMATE; SAMPLES	Chronologies for Late Quaternary marine sediment records are usually based on radiocarbon ages of planktonic foraminifera. Signals carried by other sedimentary components measured in parallel can provide complementary paleoclimate information. A key premise is that microfossils and other indicators within a given sediment horizon are of equal age. We show here that haptophyte-derived alkenones isolated from Bermuda Rise drift sediments are up to 7000 years older than coexisting planktonic foraminifera. This temporal offset, which is apparently due to lateral transport of alkenones on fine-grained particles from the Nova Scotian margin, markedly influences molecular estimates of sea surface temperatures. More broadly, the observation raises questions about both the temporal and the geographic delity of paleoenvironmental records encoded by readily transported components of sediments.	Woods Hole Oceanog Inst, Dept Marine Chem & Geochem, Woods Hole, MA 02543 USA; Woods Hole Oceanog Inst, Dept Geol & Geophys, Woods Hole, MA 02543 USA	Woods Hole Oceanographic Institution; Woods Hole Oceanographic Institution	Eglinton, TI (corresponding author), Woods Hole Oceanog Inst, Dept Marine Chem & Geochem, Woods Hole, MA 02543 USA.		Ohkouchi, Naohiko/B-2071-2008	Eglinton, Timothy/0000-0001-5060-2155				Adkins JF, 1997, NATURE, V390, P154, DOI 10.1038/36540; ADKINS JF, 1995, EOS, V76, P282; Balsam WL, 1987, PALEOCEANOGRAPHY, V2, P531, DOI 10.1029/PA002i005p00531; Bard E, 2001, PALEOCEANOGRAPHY, V16, P235, DOI 10.1029/2000PA000537; Benthien A, 2000, DEEP-SEA RES PT I, V47, P2369, DOI 10.1016/S0967-0637(00)00030-3; Bradley R. S., 1995, CLIMATE AD 1500; BRASSELL SC, 1986, NATURE, V320, P129, DOI 10.1038/320129a0; Conte MH, 2001, GEOCHIM COSMOCHIM AC, V65, P4275, DOI 10.1016/S0016-7037(01)00718-9; Druffel ERM, 1997, SCIENCE, V275, P1454, DOI 10.1126/science.275.5305.1454; DUPLESSY JC, 1986, NATURE, V320, P350, DOI 10.1038/320350a0; FOKPUN L, 1983, J FORAMIN RES, V13, P60, DOI 10.2113/gsjfr.13.1.60; GARDNER WD, 1981, SCIENCE, V213, P329, DOI 10.1126/science.213.4505.329; Henderson GM, 2000, NATURE, V404, P61, DOI 10.1038/35003541; Ikehara M, 1997, GEOPHYS RES LETT, V24, P679, DOI 10.1029/97GL00429; KEIGWIN LD, 1994, J GEOPHYS RES-OCEANS, V99, P12397, DOI 10.1029/94JC00525; Keigwin LD, 1999, SCIENCE, V286, P520, DOI 10.1126/science.286.5439.520; Keigwin LD, 1996, SCIENCE, V274, P1504, DOI 10.1126/science.274.5292.1504; KEIGWIN LD, 1989, DEEP-SEA RES, V36, P845, DOI 10.1016/0198-0149(89)90032-0; KEIGWIN LD, 1984, QUATERNARY RES, V22, P383, DOI 10.1016/0033-5894(84)90031-0; KEIL RG, 1994, GEOCHIM COSMOCHIM AC, V58, P879, DOI 10.1016/0016-7037(94)90512-6; LAINE EP, 1981, MAR GEOL, V39, P277, DOI 10.1016/0025-3227(81)90076-1; MCCAVE IN, 1995, PHILOS T R SOC B, V348, P229, DOI 10.1098/rstb.1995.0065; MOLLENHAUER G, UNPUB; Mook WG, 1999, RADIOCARBON, V41, P227, DOI 10.1017/S0033822200057106; OBRIEN SR, 1995, SCIENCE, V270, P1962, DOI 10.1126/science.270.5244.1962; *OC CLIM LAB, 1999, WORLD OC ATL 1998; OHKOUCHI N, UNPUB; Pearson A, 1998, RADIOCARBON, V40, P61, DOI 10.1017/S0033822200017902; Piper DJW, 1985, SUBMARINE FANS RELAT, P137; PRAHL FG, 1988, GEOCHIM COSMOCHIM AC, V52, P2303, DOI 10.1016/0016-7037(88)90132-9; ROSTEK F, 1993, NATURE, V364, P319, DOI 10.1038/364319a0; Sachs JP, 1999, SCIENCE, V286, P756, DOI 10.1126/science.286.5440.756; SCHMITZ WJ, 1993, REV GEOPHYS, V31, P29, DOI 10.1029/92RG02583; Stuiver M, 1998, RADIOCARBON, V40, P1127, DOI 10.1017/S0033822200019172; SUMAN DO, 1989, DEEP-SEA RES, V36, P869, DOI 10.1016/0198-0149(89)90033-2; Von Reden KF, 1998, RADIOCARBON, V40, P247, DOI 10.1017/S0033822200018117; WEAVER PPE, 1992, MAR GEOL, V109, P1, DOI 10.1016/0025-3227(92)90218-7; Weaver PPE, 1999, PALEOCEANOGRAPHY, V14, P336, DOI 10.1029/1999PA900009	38	206	212	3	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 8	2002	298	5596					1224	1227		10.1126/science.1075287	http://dx.doi.org/10.1126/science.1075287			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	612MQ	12376593				2022-12-28	WOS:000179080400047
J	Nelson, MR; Reid, CM; Krum, H; Muir, T; Ryan, P; McNeil, JJ				Nelson, MR; Reid, CM; Krum, H; Muir, T; Ryan, P; McNeil, JJ			Predictors of normotension on withdrawal of antihypertensive drugs in elderly patients: prospective study in second Australian national blood pressure study cohort	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HYPERTENSION; THERAPY; TRIAL	Objectives To identify simple long term predictors of maintenance of normotension after withdrawal of antihypertensive drugs in elderly patients in general practice. Design Prospective cohort study. Setting 169 general practices in Victoria, Australia. Participants 503 patients aged 65-84 with treated hypertension who were withdrawn from all antihypertensive drugs and remained drug free and normotensive for an initial two week period; all were followed for a further 12 months. Main outcome measures Relative likelihood of maintaining normotension 12 months after drug withdrawal; relative likelihood of early return to hypertension after drug withdrawal. Results The likelihood of remaining normotensive at 12 months was greater among younger patients (65-74 years), patients with lower "on-treatment" systolic blood pressure, patients on single agent treatment, and patients with a greater waist:hip ratio. The likelihood of return to hypertension was greatest for patients with higher "on-treatment" systolic blood pressure. Conclusions Age, blood pressure control, and the number of antihypertensive drugs are important factors in the clinical decision to withdraw drug treatment. Because of consistent rates of return to antihypertensive treatment, all patients from whom such treatment is withdrawn should be monitored indefinitely to detect a recurrence of hypertension.	Monash Univ, Alfred Hosp, Dept Epidemiol & Prevent Med, Prahran, Vic 3181, Australia; Alfred Hosp, Baker Heart Res Inst, Cardiovasc Dis Prevent Unit, Melbourne, Vic, Australia; Univ Adelaide, Fac Hlth Sci, Dept Publ Hlth, Adelaide, SA 5005, Australia	Florey Institute of Neuroscience & Mental Health; Monash University; Baker Heart and Diabetes Institute; Florey Institute of Neuroscience & Mental Health; University of Adelaide	Nelson, MR (corresponding author), Monash Univ, Alfred Hosp, Dept Epidemiol & Prevent Med, Prahran, Vic 3181, Australia.	niark.nelson@med.monash.edu.au	Reid, Christopher M/AAP-8135-2021; McNeil, John/L-6440-2019	McNeil, John/0000-0002-1049-5129; Reid, Christopher/0000-0001-9173-3944				ALDERMAN MH, 1986, ARCH INTERN MED, V146, P1309, DOI 10.1001/archinte.146.7.1309; [Anonymous], 1975, CIRCULATION, V51, P1107; BLAUFOX MD, 1984, J HYPERTENS       S3, V2, P179; FOTHERBY MD, 1992, BMJ-BRIT MED J, V305, P750, DOI 10.1136/bmj.305.6856.750; GREENBERG G, 1986, BRIT MED J, V293, P988; HOWES L, 1988, CURR THERAPEUTIC NOV, P15; Jennings G L, 1995, Blood Press Suppl, V2, P99; LEE J, 1994, INT J EPIDEMIOL, V23, P201, DOI 10.1093/ije/23.1.201; LIN DY, 1989, J AM STAT ASSOC, V84, P1074, DOI 10.2307/2290085; MITCHELL A, 1989, J GEN INTERN MED, V4, P221, DOI 10.1007/BF02599527; Myers MG, 1996, AM J HYPERTENS, V9, P419, DOI 10.1016/0895-7061(96)00030-1; Nelson M, 2001, AM J HYPERTENS, V14, P98, DOI 10.1016/S0895-7061(00)01246-2; STAMLER R, 1984, J HYPERTENSION S3, V2, P167; TAKATA Y, 1992, AM HEART J, V124, P1574, DOI 10.1016/0002-8703(92)90075-7; Whelton PK, 1998, JAMA-J AM MED ASSOC, V279, P839, DOI 10.1001/jama.279.11.839; Wing LMH, 1997, CLIN EXP HYPERTENS, V19, P779, DOI 10.3109/10641969709083186; Yusuf S, 2000, NEW ENGL J MED, V342, P145	17	29	29	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 12	2002	325	7368					815	817		10.1136/bmj.325.7368.815	http://dx.doi.org/10.1136/bmj.325.7368.815			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604YM	12376444	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000178648700021
J	Benabid, F; Knight, JC; Antonopoulos, G; Russell, PSJ				Benabid, F; Knight, JC; Antonopoulos, G; Russell, PSJ			Stimulated Raman scattering in hydrogen-filled hollow-core photonic crystal fiber	SCIENCE			English	Article							SUBFEMTOSECOND PULSE GENERATION; MOLECULAR MODULATION; GUIDANCE; LASER	We report on stimulated Raman scattering in an approximately 1-meter-long hollow-core photonic crystal fiber filled with hydrogen gas under pressure. Light was guided and confined in the 15-micrometer-diameter hollow core by two-dimensional photonic bandgap. Using pulsed laser source (pulse duration, 6 nanoseconds; wavelength, 532 nanometers), the threshold for Stokes (longer wavelength) generation was observed at pulse energies as low as 800 +/- nanojoules, followed by coherent anti-Stokes (shorter wavelength) generation threshold at 3.4 +/- 0.7 microjoules. The pump-to-Stokes conversion efficiency was 30 +/- 3% at pulse energy of only 4.5 microjoules. These energies are almost two orders of magnitude lower than any other reported energy, moving gas-based nonlinear optics to previously inaccessible parameter regimes of high intensity and long interaction length.	Univ Bath, Dept Phys, Optoelect Grp, Bath BA2 7AY, Avon, England	University of Bath	Benabid, F (corresponding author), Univ Bath, Dept Phys, Optoelect Grp, Claverton Down, Bath BA2 7AY, Avon, England.		Antonopoulos, Grigorios/O-4092-2014; Knight, Jonathan C/D-3879-2011; Antonopoulos, Grigoris/M-3956-2019; Antonopoulos, Grigoris/G-6469-2019; Russell, Philip St.J./G-5132-2012	Knight, Jonathan C/0000-0002-0802-8804; Antonopoulos, Grigoris/0000-0002-7577-3134; Antonopoulos, Grigoris/0000-0002-7577-3134; Russell, Philip St.J./0000-0002-8972-2477				BIRKS TA, 1995, ELECTRON LETT, V31, P1941, DOI 10.1049/el:19951306; Cregan RF, 1999, SCIENCE, V285, P1537, DOI 10.1126/science.285.5433.1537; Harris SE, 1997, PHYS REV A, V55, pR4019, DOI 10.1103/PhysRevA.55.R4019; Harris SE, 1998, PHYS REV LETT, V81, P2894, DOI 10.1103/PhysRevLett.81.2894; HELLWARTH RW, 1978, J OPT SOC AM, V68, P1050, DOI 10.1364/JOSA.68.001050; Knight JC, 1996, OPT LETT, V21, P1547, DOI 10.1364/OL.21.001547; Meng LS, 2000, OPT LETT, V25, P472, DOI 10.1364/OL.25.000472; RABINOWITZ P, 1976, APPL OPTICS, V15, P2005, DOI 10.1364/AO.15.002005; Renn MJ, 1998, J VAC SCI TECHNOL B, V16, P3859, DOI 10.1116/1.590424; Rundquist A, 1998, SCIENCE, V280, P1412, DOI 10.1126/science.280.5368.1412; Shen Y. R., 1984, PRINCIPLES NONLINEAR; Sokolov AV, 1999, OPT LETT, V24, P557, DOI 10.1364/OL.24.000557; SUZUKI K, 2002, C LAS EL PAC RIM CHI; Tempea G, 1998, OPT LETT, V23, P762, DOI 10.1364/OL.23.000762; WEST JA, 2001, P 27 EUR C OPT COMM, V1, P582; WEST JA, 2000, P 26 EUR C OPT COMM, V4, P41	16	802	845	14	302	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 11	2002	298	5592					399	402		10.1126/science.1076408	http://dx.doi.org/10.1126/science.1076408			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	602NB	12376698				2022-12-28	WOS:000178510400044
J	Kulynych, J; Korn, D				Kulynych, J; Korn, D			Perspective - The new federal medical-privacy rule	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Ropes & Gray, Washington, DC 20005 USA; Assoc Amer Med Coll, Washington, DC 20037 USA	Association of American Medical Colleges	Kulynych, J (corresponding author), Ropes & Gray, Washington, DC 20005 USA.							2002, FED REGISTER, V67, P53182	1	21	21	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 10	2002	347	15					1133	1134		10.1056/NEJMp020113	http://dx.doi.org/10.1056/NEJMp020113			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	601TW	12374872				2022-12-28	WOS:000178465100002
J	Smetacek, V				Smetacek, V			Microbial food webs: The ocean's veil	NATURE			English	Editorial Material									Alfred Wegener Inst Polar & Marine Res, D-27570 Bremerhaven, Germany	Helmholtz Association; Alfred Wegener Institute, Helmholtz Centre for Polar & Marine Research	Smetacek, V (corresponding author), Alfred Wegener Inst Polar & Marine Res, Handelshafen 12, D-27570 Bremerhaven, Germany.							ENCHEL T, 2002, SCIENCE, V296, P1068; Finlay BJ, 2002, SCIENCE, V296, P1061, DOI 10.1126/science.1070710; MATZ C, 2002, MECH GAZING RESISTAN; OOPLEY J, 2002, NATURE, V415, P572; PURCELL EM, 1977, AM J PHYS, V45, P3, DOI 10.1119/1.10903	5	21	23	5	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 10	2002	419	6907					565	565		10.1038/419565a	http://dx.doi.org/10.1038/419565a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	602AT	12374956	Bronze			2022-12-28	WOS:000178483100020
J	Lu-Yao, G; Albertsen, PC; Stanford, JL; Stukel, TA; Walker-Corkery, ES; Barry, MJ				Lu-Yao, G; Albertsen, PC; Stanford, JL; Stukel, TA; Walker-Corkery, ES; Barry, MJ			Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INTERPRETING TRENDS; SURVEILLANCE SERIES; DEATH CERTIFICATES; RECENT DECLINES; REGRESSION	Objective To determine whether the more intensive screening and treatment for prostate cancer in the Seattle-Puget Sound area in 1987-90 led to lower mortality from prostate cancer than in Connecticut. Design Natural experiment comparing two fixed cohorts from 1987 to 1997. Setting Seattle-Puget Sound and Connecticut surveillance, epidemiology, and end results areas. Participants Population based cohorts of male Medicare beneficiaries aged 65-79 drawn from the Seattle (n=94 900) and Connecticut (n=1 20 62 1) areas. Main outcome measures Rates of screening for prostate cancer, treatment with radical prostatectomy and external beam radiotherapy, and prostate cancer specific mortality. Results The prostate specific antigen testing rate in Seattle was 5.39 (95% confidence interval 4.76 to 6.11) times that of Connecticut, and the prostate biopsy rate was 2.20 (1.81 to 2.68) times that of Connecticut during 1987-90. The 10 year cumulative incidences of radical prostatectomy and external beam radiotherapy tip to 1996 were 2.7% and 3.9% for Seattle cohort members compared with 0.5% and 3.1% for Connecticut cohort members. The adjusted rate ratio of prostate cancer mortality up to 1997 was 1.03 (0.95 to 1.11) in Seattle compared with Connecticut. Conclusion More intensive screening for prostate cancer and treatment with radical prostatectomy and external beam radiotherapy among Medicare beneficiaries in the Seattle area than in the Connecticut area was not associated with lower prostate cancer specific mortality over 11 years of follow up.	Harvard Univ, Sch Med, Boston, MA 02215 USA; HealthStat, Princeton, NJ 08543 USA; Univ Connecticut, Ctr Hlth, Dept Surg, Div Urol, Farmington, CT 06030 USA; Fred Hutchinson Canc Res Ctr, Program Epidemiol, Div Publ Hlth Sci, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Program Prostate Canc Res, Seattle, WA 98109 USA; Dartmouth Coll, Sch Med, Ctr Evaluat Clin Sci, Hanover, NH 03755 USA; Massachusetts Gen Hosp, Med Practices Evaluat Ctr, Boston, MA 02114 USA	Harvard University; Harvard Medical School; University of Connecticut; Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; Dartmouth College; Harvard University; Massachusetts General Hospital	Barry, MJ (corresponding author), Harvard Univ, Sch Med, Boston, MA 02215 USA.	mbarry@partners.org		Lu-Yao, Grace/0000-0002-6017-9175; Stukel, Therese/0000-0002-2951-1360	AHRQ HHS [R01 HS008397, R01 HS010278] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS010278, R01HS008397] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Albertsen PC, 2000, J UROLOGY, V163, P519, DOI 10.1016/S0022-5347(05)67915-3; Bartsch G, 2001, UROLOGY, V58, P417, DOI 10.1016/S0090-4295(01)01264-X; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; COX DR, 1972, J R STAT SOC B, V34, P187; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; Etzioni R, 1999, J NATL CANCER I, V91, P1033, DOI 10.1093/jnci/91.12.1033; Feuer EJ, 1999, JNCI-J NATL CANCER I, V91, P1025, DOI 10.1093/jnci/91.12.1025; Hankey BF, 1999, JNCI-J NATL CANCER I, V91, P1017, DOI 10.1093/jnci/91.12.1017; LUYAO GL, 1993, JAMA-J AM MED ASSOC, V269, P2633, DOI 10.1001/jama.269.20.2633; McCullagh P., 1989, GEN LINEAR MODELS, V2nd; Penson DF, 2001, J NATL CANCER I, V93, P1822, DOI 10.1093/jnci/93.23.1822; PERCY C, 1981, AM J PUBLIC HEALTH, V71, P242, DOI 10.2105/AJPH.71.3.242; POTOSKY AL, 1995, JAMA-J AM MED ASSOC, V273, P548, DOI 10.1001/jama.273.7.548; Ries L, 2000, SEER CANC STAT REV 1; Tarone RE, 2000, EPIDEMIOLOGY, V11, P167, DOI 10.1097/00001648-200003000-00014	15	148	153	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 5	2002	325	7367					740	743		10.1136/bmj.325.7367.740	http://dx.doi.org/10.1136/bmj.325.7367.740			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	603AU	12364300	Bronze, Green Published			2022-12-28	WOS:000178537300014
J	Prieto, MA; Brunetti, G; Mack, KH				Prieto, MA; Brunetti, G; Mack, KH			Particle accelerators in the hot spots of radio galaxy 3C 445, imaged with the VLT	SCIENCE			English	Article							SYNCHROTRON SPECTRA; OPTICAL-EMISSION; DYNAMICS; PLASMA; LOBES; JETS	Hot spots (HSs) are regions of enhanced radio emission produced by supersonic jets at the tip of the radio lobes of powerful radio sources. Obtained with the Very Large Telescope (VLT), images of the HSs in the radio galaxy 3C 445 show bright knots embedded in diffuse optical emission distributed along the post-shock region created by the impact of the jet into the intergalactic medium. The observations reported here confirm that relativistic electrons are accelerated by Fermi-I acceleration processes in HSs. Furthermore, both the diffuse emission tracing the rims of the front shock and the multiple knots demonstrate the presence of additional continuous re-acceleration processes of electrons (Fermi-II).	European So Observ, D-85748 Garching, Germany; CNR, Ist Radioastron, I-40129 Bologna, Italy; Netherlands Fdn Res Astron, ASTRON, NL-7990 AA Dwingeloo, Netherlands; Univ Bonn, Radioastron Inst, D-53121 Bonn, Germany	European Southern Observatory; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale Astrofisica (INAF); University of Bonn	Prieto, MA (corresponding author), European So Observ, Karl Schwarzschild Str 2, D-85748 Garching, Germany.	aprieto@eso.org	Prieto, M. Almudena/ABF-7926-2020	Prieto, M. Almudena/0000-0002-3585-2639; Brunetti, Gianfranco/0000-0003-4195-8613				Aloy MA, 2000, ASTROPHYS J, V528, pL85, DOI 10.1086/312436; Brunetti G, 2002, ASTRON ASTROPHYS, V381, P795, DOI 10.1051/0004-6361:20011462; Brunetti G, 2001, ASTROPHYS J, V561, pL157, DOI 10.1086/324764; CRANE P, 1983, ASTROPHYS J, V265, P681, DOI 10.1086/160713; Gitti M, 2002, ASTRON ASTROPHYS, V386, P456, DOI 10.1051/0004-6361:20020284; Gopal-Krishna, 2001, ASTRON ASTROPHYS, V377, P827, DOI 10.1051/0004-6361:20011149; Jester S, 2001, ASTRON ASTROPHYS, V373, P447, DOI 10.1051/0004-6361:20010593; KEEL WC, 1988, ASTROPHYS J, V329, P532, DOI 10.1086/166400; KUNDT W, 1980, NATURE, V288, P149, DOI 10.1038/288149a0; LACOMBE C, 1977, ASTRON ASTROPHYS, V54, P1; Leahy JP, 1997, MON NOT R ASTRON SOC, V291, P20, DOI 10.1093/mnras/291.1.20; Marti JM, 1997, ASTROPHYS J, V479, P151, DOI 10.1086/303842; Massaglia S, 1996, ASTRON ASTROPHYS, V307, P997; Meisenheimer K, 1997, ASTRON ASTROPHYS, V325, P57; MEISENHEIMER K, 1989, ASTRON ASTROPHYS, V219, P63; NORMAN ML, 1982, ASTRON ASTROPHYS, V113, P285; Pacholczyk A. G., 1970, RADIO ASTROPHYSICS; Prieto MA, 1997, MON NOT R ASTRON SOC, V284, P627, DOI 10.1093/mnras/284.3.627; SASLAW WC, 1978, ASTROPHYS J, V222, P435, DOI 10.1086/156157; SIMKIN SM, 1978, ASTROPHYS J, V222, pL55, DOI 10.1086/182691; SMITH MD, 1985, MON NOT R ASTRON SOC, V214, P67, DOI 10.1093/mnras/214.2.67; THOMSON RC, 1995, ASTROPHYS J, V446, pL93, DOI 10.1086/187938	22	30	30	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 4	2002	298	5591					193	195		10.1126/science.1075990	http://dx.doi.org/10.1126/science.1075990			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	600BJ	12364799	Green Submitted			2022-12-28	WOS:000178370500056
J	Yeates, TO				Yeates, TO			Structures of SET domain proteins: Protein lysine methyltransferases make their mark	CELL			English	Review							CHROMATIN	Proteins bearing the widely distributed SET domain have been shown to methylate lysine residues in histones and other proteins. In this issue, three-dimensional structures are reported for three very different SET domain-containing proteins. The structures reveal novel folds for several new domains, including SET, and provide early insights into mechanisms of catalysis and molecular recognition in this family of enzymes.	Univ Calif Los Angeles, DOE Ctr genom & Proteom, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	United States Department of Energy (DOE); University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Yeates, TO (corresponding author), Univ Calif Los Angeles, Inst Mol Biol, 611 Charles Young Dr E,Box 951570, Los Angeles, CA 90095 USA.			Yeates, Todd/0000-0001-5709-9839				Cheng XD, 2001, NUCLEIC ACIDS RES, V29, P3784, DOI 10.1093/nar/29.18.3784; Djordjevic S, 1997, STRUCTURE, V5, P545, DOI 10.1016/S0969-2126(97)00210-4; Griffith SC, 2001, J MOL BIOL, V313, P1103, DOI 10.1006/jmbi.2001.5095; Jacobs SA, 2002, SCIENCE, V295, P2080, DOI 10.1126/science.1069473; Jenuwein T, 1998, CELL MOL LIFE SCI, V54, P80, DOI 10.1007/s000180050127; KLEIN RR, 1995, PLANT MOL BIOL, V27, P249, DOI 10.1007/BF00020181; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Liu Y, 2002, PROTEIN SCI, V11, P1285, DOI 10.1110/ps.0201402; Nielsen PR, 2002, NATURE, V416, P103, DOI 10.1038/nature722; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Roguev A, 2001, EMBO J, V20, P7137, DOI 10.1093/emboj/20.24.7137; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Trievel RC, 2002, CELL, V111, P91, DOI 10.1016/S0092-8674(02)01000-0; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; Wang HB, 2001, MOL CELL, V8, P1207, DOI 10.1016/S1097-2765(01)00405-1; Wilson JR, 2002, CELL, V111, P105, DOI 10.1016/S0092-8674(02)00964-9; Zhang X, 2002, CELL, V111, P117, DOI 10.1016/S0092-8674(02)00999-6	21	52	58	2	7	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 4	2002	111	1					5	7		10.1016/S0092-8674(02)01010-3	http://dx.doi.org/10.1016/S0092-8674(02)01010-3			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	601RQ	12372294	Bronze			2022-12-28	WOS:000178461900002
J	Bluto, MJ; Norman, DA				Bluto, MJ; Norman, DA			Acute episode of Raynaud's disease.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Barton Mem Hosp, S Lake Tahoe, CA 96150 USA		Bluto, MJ (corresponding author), Barton Mem Hosp, S Lake Tahoe, CA 96150 USA.								0	1	1	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 26	2002	347	13					992	992		10.1056/NEJMicm010934	http://dx.doi.org/10.1056/NEJMicm010934			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	596RD	12324555				2022-12-28	WOS:000178178400005
J	Hoffman, KL; McNaughton, BL				Hoffman, KL; McNaughton, BL			Coordinated reactivation of distributed memory traces in primate neocortex	SCIENCE			English	Article							PREFRONTAL CORTEX; SLEEP; HIPPOCAMPUS; REPLAY; EXPERIENCE; ACTIVATION	Conversion of new memories into a lasting form may involve the gradual refinement and linking together of neural representations stored widely throughout neocortex. This consolidation process may require coordinated reactivation of distributed components of memory traces while the cortex is "offline", i.e., not engaged in processing external stimuli. Simultaneous neural ensemble recordings from four sites in the macaque neocortex revealed such coordinated reactivation. In motor, somatosensory, and parietal cortex (but not prefrontal cortex), the behaviorally induced correlation structure and temporal patterning of neural ensembles within and between regions were preserved, confirming a major tenet of the trace-reactivation theory of memory consolidation.	Univ Arizona, Div Neural Syst Memory & Aging, Tucson, AZ 85724 USA	University of Arizona	McNaughton, BL (corresponding author), Univ Arizona, Div Neural Syst Memory & Aging, Tucson, AZ 85724 USA.		Hoffman, Kari L/I-3062-2012	Hoffman, Kari L/0000-0003-0560-8157	NIMH NIH HHS [MH01565] Funding Source: Medline	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BUZSAKI G, 1989, NEUROSCIENCE, V31, P551, DOI 10.1016/0306-4522(89)90423-5; Dave AS, 2000, SCIENCE, V290, P812, DOI 10.1126/science.290.5492.812; Kudrimoti HS, 1999, J NEUROSCI, V19, P4090; Lepage M, 2000, P NATL ACAD SCI USA, V97, P506, DOI 10.1073/pnas.97.1.506; Louie K, 2001, NEURON, V29, P145, DOI 10.1016/S0896-6273(01)00186-6; MacLeod AK, 1998, NEUROIMAGE, V7, P41, DOI 10.1006/nimg.1997.0308; Maquet P, 2000, NAT NEUROSCI, V3, P831, DOI 10.1038/77744; MARR D, 1971, PHILOS T ROY SOC B, V262, P23, DOI 10.1098/rstb.1971.0078; MCCLELLAND JL, 1995, PSYCHOL REV, V102, P419, DOI 10.1037/0033-295X.102.3.419; Nadasdy Z, 1999, J NEUROSCI, V19, P9497; Squire L. R., 1984, MEMORY CONSOLIDATION, P185; TREVES A, 1994, HIPPOCAMPUS, V4, P374, DOI 10.1002/hipo.450040319; WILSON MA, 1994, SCIENCE, V265, P676, DOI 10.1126/science.8036517	14	297	303	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 20	2002	297	5589					2070	2073		10.1126/science.1073538	http://dx.doi.org/10.1126/science.1073538			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	594XV	12242447				2022-12-28	WOS:000178078500052
J	Chiam, P; Poulose, V; Hui, KP; Narendran, K				Chiam, P; Poulose, V; Hui, KP; Narendran, K			Wheezing	LANCET			English	Editorial Material									Changhi Gen Hosp, Dept Med, Singapore 529889, Singapore	Changi General Hospital	Poulose, V (corresponding author), Changhi Gen Hosp, Dept Med, Singapore 529889, Singapore.	vijopoulose@pol.net		Chiam, Paul/0000-0002-1901-757X				FLINK G, 2001, CHEST, V119, P1647; HSU JT, 1979, CHEST, V76, P325, DOI 10.1378/chest.76.3.325; Liu SF, 2000, CLIN IMAG, V24, P159, DOI 10.1016/S0899-7071(00)00193-5	3	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 14	2002	360	9336					850	850		10.1016/S0140-6736(02)09967-1	http://dx.doi.org/10.1016/S0140-6736(02)09967-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	594MC	12243920				2022-12-28	WOS:000178053500011
J	Eppel, S				Eppel, S			Reburial ceremonies for health and healing after state terror in Zimbabwe	LANCET			English	Editorial Material									Amani Trust, Bulawayo, Zimbabwe		Eppel, S (corresponding author), Amani Trust, 10 Derby Rd,Hillside, Bulawayo, Zimbabwe.							Bagilishya DUogratias., 2000, TRANSCULT PSYCHIATRY, V37, P337; Bloom S., 1997, POSTTRAUMATIC GROWTH, P173; Catholic Commission for Justice Peace in Zimbabwe & Legal Resources Foundation (Zimbabwe), 1997, BREAK SIL BUILD TRUE; MOLLICA RF, 1992, TORTURE ITS CONSEQUE, P253; Summerfield D, 2000, BRIT MED J, V321, P232, DOI 10.1136/bmj.321.7255.232	5	13	13	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 14	2002	360	9336					869	870		10.1016/S0140-6736(02)09960-9	http://dx.doi.org/10.1016/S0140-6736(02)09960-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	594MC	12243935				2022-12-28	WOS:000178053500025
J	Eyber, C; Ager, A				Eyber, C; Ager, A			Conselho: psychological healing in displaced communities in Angola	LANCET			English	Editorial Material									Queen Margaret Univ Coll, Ctr Int Hlth Studies, Edinburgh EH12 8TS, Midlothian, Scotland	Queen Margaret University	Eyber, C (corresponding author), Queen Margaret Univ Coll, Ctr Int Hlth Studies, Edinburgh EH12 8TS, Midlothian, Scotland.			Ager, Alastair/0000-0002-9474-3563					0	17	17	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 14	2002	360	9336					871	871		10.1016/S0140-6736(02)09961-0	http://dx.doi.org/10.1016/S0140-6736(02)09961-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	594MC	12243936				2022-12-28	WOS:000178053500026
J	Heron, SE; Crossland, KM; Andermann, E; Phillips, HA; Hall, AJ; Bleasel, A; Shevell, M; Mercho, S; Seni, MH; Guiot, MC; Mulley, JC; Berkovic, SF; Scheffer, IE				Heron, SE; Crossland, KM; Andermann, E; Phillips, HA; Hall, AJ; Bleasel, A; Shevell, M; Mercho, S; Seni, MH; Guiot, MC; Mulley, JC; Berkovic, SF; Scheffer, IE			Sodium-channel defects in benign familial neonatal-infantile seizures	LANCET			English	Article								Ion-channel gene defects are associated with a range of paroxysmal disorders, including several monogenic epilepsy syndromes. Two autosomal dominant disorders present in the first year of life: benign familial neonatal seizures, which is associated with potassium-channel gene defects; and benign familial infantile seizures, for which no genes have been identified. Here, we describe a clinically intermediate variant, benign familial neonatal-infantile seizures, with mutations in the sodium-channel subunit gene SCN2A. This clinico-molecular correlation defines a new benign familial epilepsy syndrome beginning in early infancy, an age at which seizure disorders frequently have a sombre prognosis.	Womens & Childrens Hosp, Dept Lab Genet, Adelaide, SA, Australia; Univ Melbourne, Dept Med Neurol, Heidelberg, Vic, Australia; AUstin & Repatriat Med Ctr, Heidelberg, Vic, Australia; Westmead Hosp, Royal Alexandra Hosp Children, Dept Neurol, Westmead, NSW 2145, Australia; McGill Univ, Dept Neurol, Montreal, PQ H3A 2T5, Canada; McGill Univ, Dept Neurosurg, Montreal, PQ H3A 2T5, Canada; McGill Univ, Dept Paediat, Montreal, PQ H3A 2T5, Canada; Montreal Neurol Hosp & Inst, Neurogenet Unit, Montreal, PQ H3A 2B4, Canada	Womens & Childrens Hospital Australia; University of Melbourne; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Sydney; McGill University; McGill University; McGill University; McGill University	Heron, SE (corresponding author), Bion Res Facil, 31 Dalgleish St, Thebarton 5031, Australia.		Heron, Sarah/F-4222-2013; jiang, yu/HGU-0029-2022; Scheffer, Ingrid E/G-1668-2013; Bleasel, Andrew/W-6205-2019	Heron, Sarah/0000-0001-8759-6748; Scheffer, Ingrid E/0000-0002-2311-2174; Bleasel, Andrew/0000-0002-1843-3619; Berkovic, Samuel/0000-0003-4580-841X					0	260	279	0	16	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 14	2002	360	9336					851	852		10.1016/S0140-6736(02)09968-3	http://dx.doi.org/10.1016/S0140-6736(02)09968-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	594MC	12243921				2022-12-28	WOS:000178053500012
J	Aronow, WS				Aronow, WS			Clinical judgment	LANCET			English	Editorial Material									New York Med Coll, Westchester Med Ctr, Div Cardiol, Valhalla, NY 10595 USA; New York Med Coll, Westchester Med Ctr, Div Geriatr, Valhalla, NY 10595 USA	New York Medical College; Westchester Medical Center; New York Medical College; Westchester Medical Center	Aronow, WS (corresponding author), New York Med Coll, Westchester Med Ctr, Div Cardiol, Valhalla, NY 10595 USA.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 24	2002	360	9333					591	591		10.1016/S0140-6736(02)09780-5	http://dx.doi.org/10.1016/S0140-6736(02)09780-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	586TD	12241929				2022-12-28	WOS:000177600400007
J	Bodenheimer, T; Wagner, EH; Grumbach, K				Bodenheimer, T; Wagner, EH; Grumbach, K			Improving primary care for patients with chronic illness	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY	The chronic care model is a guide to higher-quality chronic illness management within primary care. The model predicts that improvement in its 6 interrelated components-self-management support, clinical information systems, delivery system redesign, decision support, health care organization, and community resources-can produce system reform in which informed, activated patients interact with prepared, proactive practice teams. Case studies are provided describing how components of the chronic care model have been implemented in the primary care practices of 4 health care organizations.	Univ Calif San Francisco, San Francisco, CA 94143 USA; Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, MacColl Inst Healthcare Innovat, Seattle, WA USA	University of California System; University of California San Francisco; Group Health Cooperative	Bodenheimer, T (corresponding author), San Francisco Gen Hosp, Ward 83,1001 Potrero Ave, San Francisco, CA 94110 USA.	tbodie@earthlink.net	Tao, Youyou/D-2367-2014; Grumbach, Kevin/L-9222-2016; Young, Alexander/A-1523-2009	Young, Alexander/0000-0002-9367-9213				[Anonymous], 1997, ARCH INTERN MED, V157, P2413; BYRNES J, 1998, DIS MANAG, V1, P39; Clark CM, 2000, JAMA-J AM MED ASSOC, V284, P363, DOI 10.1001/jama.284.3.363; Grumbach K, 2002, JAMA-J AM MED ASSOC, V288, P889, DOI 10.1001/jama.288.7.889; Hoffman C, 1996, JAMA-J AM MED ASSOC, V276, P1473, DOI 10.1001/jama.276.18.1473; Institute of Medicine, 2001, CROSSING QUALITY CHA; Legorreta AP, 2000, AM J MANAG CARE, V6, P445; Lorig K, 1993, GENERATIONS, V3, P11; McBride P, 1998, ARCH INTERN MED, V158, P1238, DOI 10.1001/archinte.158.11.1238; Ni HY, 1998, ARCH INTERN MED, V158, P1231, DOI 10.1001/archinte.158.11.1231; Perez-Stable EJ, 1998, WESTERN J MED, V169, P23; *RW JOHNS FDN, 2002, IMPR CHRON ILLN CAR; Samsa GP, 2000, ARCH INTERN MED, V160, P967, DOI 10.1001/archinte.160.7.967; Sperl-Hillen J, 2000, Jt Comm J Qual Improv, V26, P615; Stuart M E, 1991, HMO Pract, V5, P198; *US DEP HHS, 2000, HLTH US 2000; Wagner E H, 1999, Manag Care Q, V7, P56; Wagner E H, 2001, Jt Comm J Qual Improv, V27, P63; Wagner E H, 1998, Eff Clin Pract, V1, P2; Wagner EH, 2001, BMJ-BRIT MED J, V323, P945, DOI 10.1136/bmj.323.7319.945; Wagner EH, 2001, HEALTH AFFAIR, V20, P64, DOI 10.1377/hlthaff.20.6.64; Wagner EH, 1996, MILBANK Q, V74, P511, DOI 10.2307/3350391; Young AS, 2001, ARCH GEN PSYCHIAT, V58, P55, DOI 10.1001/archpsyc.58.1.55	24	1842	1863	7	143	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	2002	288	14					1775	1779		10.1001/jama.288.14.1775	http://dx.doi.org/10.1001/jama.288.14.1775			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	602BJ	12365965				2022-12-28	WOS:000178484700034
J	Carlton, JM; Angiuoli, SV; Suh, BB; Kooij, TW; Pertea, M; Silva, JC; Ermolaeva, MD; Allen, JE; Selengut, JD; Koo, HL; Peterson, JD; Pop, M; Kosack, DS; Shumway, MF; Bidwell, SL; Shallom, SJ; van Aken, SE; Riedmuller, SB; Feldblyum, TV; Cho, JK; Quackenbush, J; Sedegah, M; Shoaibi, A; Cummings, LM; Florens, L; Yates, JR; Raine, JD; Sinden, RE; Harris, MA; Cunningham, DA; Preiser, PR; Bergman, LW; Vaidya, AB; Van Lin, LH; Janse, CJ; Waters, AP; Smith, HO; White, OR; Salzberg, SL; Venter, JC; Fraser, CM; Hoffman, SL; Gardner, MJ; Carucci, DJ				Carlton, JM; Angiuoli, SV; Suh, BB; Kooij, TW; Pertea, M; Silva, JC; Ermolaeva, MD; Allen, JE; Selengut, JD; Koo, HL; Peterson, JD; Pop, M; Kosack, DS; Shumway, MF; Bidwell, SL; Shallom, SJ; van Aken, SE; Riedmuller, SB; Feldblyum, TV; Cho, JK; Quackenbush, J; Sedegah, M; Shoaibi, A; Cummings, LM; Florens, L; Yates, JR; Raine, JD; Sinden, RE; Harris, MA; Cunningham, DA; Preiser, PR; Bergman, LW; Vaidya, AB; Van Lin, LH; Janse, CJ; Waters, AP; Smith, HO; White, OR; Salzberg, SL; Venter, JC; Fraser, CM; Hoffman, SL; Gardner, MJ; Carucci, DJ			Genome sequence and comparative analysis of the model rodent malaria parasite Plasmodium yoelii yoelii	NATURE			English	Article							RESTRICTION MAP; PROTEIN FAMILY; MARKOV-MODELS; BLOOD STAGES; FALCIPARUM; BERGHEI; GENES; DNA; IDENTIFICATION; CHABAUDI	Species of malaria parasite that infect rodents have long been used as models for malaria disease research. Here we report the whole-genome shotgun sequence of one species, Plasmodium yoelii yoelii, and comparative studies with the genome of the human malaria parasite Plasmodium falciparum clone 3D7. A synteny map of 2,212 P. y. yoelii contiguous DNA sequences (contigs) aligned to 14 P. falciparum chromosomes reveals marked conservation of gene synteny within the body of each chromosome. Of about 5,300 P. falciparum genes, more than 3,300 P. y. yoelii orthologues of predominantly metabolic function were identified. Over 800 copies of a variant antigen gene located in subtelomeric regions were found. This is the first genome sequence of a model eukaryotic parasite, and it provides insight into the use of such systems in the modelling of Plasmodium biology and disease.	Inst Genom Res, Rockville, MD 20850 USA; Ctr Advancement Genom, Rockville, MD 20850 USA; Leiden Univ, Dept Parasitol, Med Ctr, NL-2300 RC Leiden, Netherlands; USN, Med Res Ctr, Malaria Program, Silver Spring, MD 20910 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Univ London Imperial Coll Sci Technol & Med, Infect & Immun Sect, Dept Biol Sci, London SW7 2AZ, England; Celara Genom, Rockville, MD 20850 USA; Natl Inst Med Res, Div Parasitol, London NW7 1AA, England; Drexel Univ, Div Mol Parasitol, Dept Microbiol & Immunol, Coll Med, Philadelphia, PA 19129 USA	J. Craig Venter Institute; J. Craig Venter Institute; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; United States Department of Defense; United States Navy; Scripps Research Institute; Imperial College London; MRC National Institute for Medical Research; Drexel University	Carlton, JM (corresponding author), Inst Genom Res, 9712 Med Ctr Dr, Rockville, MD 20850 USA.	carlton@tigr.org	Salzberg, Steven L/F-6162-2011; Pop, Mihai/A-7987-2013; Waters, Andy P/C-9377-2009; Salzberg, Steven/Q-6514-2019; Silva, Joana/GYQ-9526-2022; Angiuoli, Samuel V/H-7340-2014; Pertea, Mihaela/AAT-2705-2021; Silva, Joana/GVT-6441-2022; Kooij, Taco W.A./L-5623-2015; Preiser, Peter R/A-2201-2011	Salzberg, Steven L/0000-0002-8859-7432; Pop, Mihai/0000-0001-9617-5304; Waters, Andy P/0000-0001-8900-2982; Salzberg, Steven/0000-0002-8859-7432; Pertea, Mihaela/0000-0003-0762-8637; Kooij, Taco W.A./0000-0002-8547-7523; Harris, Michael/0000-0001-8789-0912; , Peter/0000-0003-4331-7000; Quackenbush, John/0000-0002-2702-5879; Florens, Laurence/0000-0002-9310-6650; Fraser, Claire/0000-0003-1462-2428; Allen, Jonathan/0000-0002-4359-8263; Angiuoli, Samuel/0000-0001-9525-4350; Janse, Chris J/0000-0002-6410-6205	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028398] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI028398] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ashburner M, 2001, GENOME RES, V11, P1425; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Beetsma AL, 1998, EXP PARASITOL, V88, P69, DOI 10.1006/expr.1998.4203; Benson G, 1999, NUCLEIC ACIDS RES, V27, P573, DOI 10.1093/nar/27.2.573; Black CG, 1999, INFECT IMMUN, V67, P2075, DOI 10.1128/IAI.67.5.2075-2081.1999; Carlton Jane M., 2002, Trends in Parasitology, V18, P100, DOI 10.1016/S1471-4922(01)02229-2; Carlton JMR, 1999, MOL BIOCHEM PARASIT, V101, P23, DOI 10.1016/S0166-6851(99)00045-6; Carlton JMR, 2001, CURR OPIN MICROBIOL, V4, P415, DOI 10.1016/S1369-5274(00)00228-9; Carlton JMR, 1998, MOL BIOCHEM PARASIT, V93, P285, DOI 10.1016/S0166-6851(98)00043-7; Carter R., 1977, P359; Cawley SE, 2001, MOL BIOCHEM PARASIT, V118, P167, DOI 10.1016/S0166-6851(01)00363-2; Cooke BM, 2001, ADV PARASIT, V50, P1, DOI 10.1016/S0065-308X(01)50029-9; Daly TM, 2001, MOL BIOCHEM PARASIT, V117, P27, DOI 10.1016/S0166-6851(01)00329-2; DAME JB, 1983, J BIOL CHEM, V258, P6984; del Portillo HA, 2001, NATURE, V410, P839, DOI 10.1038/35071118; Delcher AL, 2002, NUCLEIC ACIDS RES, V30, P2478, DOI 10.1093/nar/30.11.2478; Eddy SR, 1998, BIOINFORMATICS, V14, P755, DOI 10.1093/bioinformatics/14.9.755; ESCALANTE AA, 1994, P NATL ACAD SCI USA, V91, P11373, DOI 10.1073/pnas.91.24.11373; FAVALORO JM, 1993, MOL BIOCHEM PARASIT, V62, P263, DOI 10.1016/0166-6851(93)90115-E; Florens L, 2002, NATURE, V419, P520, DOI 10.1038/nature01107; Galinski MR, 2000, MOL BIOCHEM PARASIT, V108, P257, DOI 10.1016/S0166-6851(00)00219-X; Gardner MJ, 1998, SCIENCE, V282, P1126, DOI 10.1126/science.282.5391.1126; Gardner MJ, 2002, NATURE, V419, P531, DOI 10.1038/nature01094; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Garnham PCC., 1966, MALARIA PARASITES OT; Haft DH, 2001, NUCLEIC ACIDS RES, V29, P41, DOI 10.1093/nar/29.1.41; JANSE CJ, 1993, PARASITOL TODAY, V9, P19, DOI 10.1016/0169-4758(93)90158-C; JANSE CJ, 1994, MOL BIOCHEM PARASIT, V68, P285, DOI 10.1016/0166-6851(94)90173-2; JANSE CJ, 1992, EXP PARASITOL, V74, P1, DOI 10.1016/0014-4894(92)90133-U; Janssen CS, 2002, P ROY SOC B-BIOL SCI, V269, P431, DOI 10.1098/rspb.2001.1903; Jareborg N, 1999, GENOME RES, V9, P815, DOI 10.1101/gr.9.9.815; Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573; LANDAU I, 1965, CR HEBD ACAD SCI, V261, P230; LANDER E S, 1988, Genomics, V2, P231; LIU SL, 1995, P NATL ACAD SCI USA, V92, P1018, DOI 10.1073/pnas.92.4.1018; Makalowski W, 1998, P NATL ACAD SCI USA, V95, P9407, DOI 10.1073/pnas.95.16.9407; MCCUTCHAN TF, 1984, SCIENCE, V225, P808, DOI 10.1126/science.6382604; Mu JB, 2002, NATURE, V418, P323, DOI 10.1038/nature00836; Mural RJ, 2002, SCIENCE, V296, P1661, DOI 10.1126/science.1069193; Myers EW, 2000, SCIENCE, V287, P2196, DOI 10.1126/science.287.5461.2196; NEI M, 1986, MOL BIOL EVOL, V3, P418; OGURTSOV AY, IN PRESS BIOINFORMAT; Ohkanda J, 2001, BIOORG MED CHEM LETT, V11, P761, DOI 10.1016/S0960-894X(01)00055-5; Preiser PR, 1999, NATURE, V398, P618, DOI 10.1038/19309; Quackenbush J, 2001, NUCLEIC ACIDS RES, V29, P159, DOI 10.1093/nar/29.1.159; Rayner JC, 2000, P NATL ACAD SCI USA, V97, P9648, DOI 10.1073/pnas.160469097; Salzberg SL, 1999, GENOMICS, V59, P24, DOI 10.1006/geno.1999.5854; Scherf A, 2001, CURR OPIN MICROBIOL, V4, P409, DOI 10.1016/S1369-5274(00)00227-7; Shabalina SA, 2001, TRENDS GENET, V17, P373, DOI 10.1016/S0168-9525(01)02344-7; Spielmann T, 2000, MOL BIOCHEM PARASIT, V111, P453, DOI 10.1016/S0166-6851(00)00333-9; Surolia N, 2001, NAT MED, V7, P167, DOI 10.1038/84612; Sutton G. G., 1995, GENOME SCI TECHNOL, V1, P9, DOI [10.1089/gst.1995.1.9, DOI 10.1089/GST.1995.1.9]; Tchavtchitch M, 2001, MOL BIOCHEM PARASIT, V118, P211, DOI 10.1016/S0166-6851(01)00380-2; Thompson J, 2001, MOL BIOCHEM PARASIT, V118, P147, DOI 10.1016/S0166-6851(01)00377-2; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; van Lin LHM, 2001, NUCLEIC ACIDS RES, V29, P2059, DOI 10.1093/nar/29.10.2059; VANDIJK MR, 1995, SCIENCE, V268, P1358, DOI 10.1126/science.7761856; vanLin LHM, 1997, MOL BIOCHEM PARASIT, V86, P111, DOI 10.1016/S0166-6851(97)90012-8; WATERS AP, 1991, P NATL ACAD SCI USA, V88, P3140, DOI 10.1073/pnas.88.8.3140; WEINBAUM FI, 1976, J IMMUNOL, V116, P1280; Wiser MF, 1997, EXP PARASITOL, V85, P43, DOI 10.1006/expr.1996.4126	62	587	650	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 3	2002	419	6906					512	519		10.1038/nature01099	http://dx.doi.org/10.1038/nature01099			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	599RF	12368865	hybrid			2022-12-28	WOS:000178348400046
J	Gill, TM; Baker, DI; Gottschalk, M; Peduzzi, PN; Allore, H; Byers, A				Gill, TM; Baker, DI; Gottschalk, M; Peduzzi, PN; Allore, H; Byers, A			A program to prevent functional decline in physically frail, elderly persons who live at home	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OLDER PERSONS; CARE; DISABILITY; DEPENDENCE; STRATEGIES; EXERCISE; PEOPLE; ADULTS; RISK; AGE	Background: Functional decline in physically frail, elderly persons is associated with substantial morbidity. It is uncertain whether such functional decline can be prevented. Methods: We randomly assigned 188 persons 75 years of age or older who were physically frail and living at home to undergo a six-month, home-based intervention program that included physical therapy and that focused primarily on improving underlying impairments in physical abilities, including balance, muscle strength, ability to transfer from one position to another, and mobility, or to undergo an educational program (as a control). The primary outcome was the change between base line and 3, 7, and 12 months in the score on a disability scale based on eight activities of daily living: walking, bathing, upper- and lower-body dressing, transferring from a chair, using the toilet, eating, and grooming. Scores on the scale ranged from 0 to 16, with higher scores indicating more severe disability. Results: Participants in the intervention group had less functional decline over time, according to their disability scores, than participants in the control group. The disability scores in the intervention and control groups were 2.3 and 2.8, respectively, at base line; 2.0 and 3.6 at 7 months (P=0.008 for the comparison between the groups in the change from base line); and 2.7 and 4.2 at 12 months (P=0.02). The benefit of the intervention was observed among participants with moderate frailty but not those with severe frailty. The frequency of admission to a nursing home did not differ significantly between the intervention group and the control group (14 percent and 19 percent, respectively; P=0.37). Conclusions: A home-based program targeting underlying impairments in physical abilities can reduce the progression of functional decline among physically frail, elderly persons who live at home.	Yale Univ, Sch Med, Dorothy Adler Geriatr Assessment Ctr, Dept Internal Med, New Haven, CT 06504 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA; Yale New Haven Med Ctr, Dept Rehabil Serv, New Haven, CT 06504 USA; Connecticut Healthcare Syst, Dept Vet Affairs, West Haven, CT USA	Yale University; Yale University; Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System	Gill, TM (corresponding author), Yale Univ, Sch Med, Dorothy Adler Geriatr Assessment Ctr, Dept Internal Med, TMP 17B,20 York St, New Haven, CT 06504 USA.	gill@ynhh.org	Gill, Thomas M./H-7043-2019	Gill, Thomas M./0000-0002-6450-0368; Allore, Heather/0000-0001-7685-8175	NATIONAL INSTITUTE ON AGING [P60AG010469, K23AG000759] Funding Source: NIH RePORTER; NIA NIH HHS [P60AG10469, K23AG00759] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Campbell AJ, 1997, AGE AGEING, V26, P315, DOI 10.1093/ageing/26.4.315; COUGHLIN TA, 1992, HEALTH SERV RES, V27, P453; *DEP HLTH HUM SERV, 1990, DHHS PUBL; Diehr P, 1999, ANNU REV PUBL HEALTH, V20, P125, DOI 10.1146/annurev.publhealth.20.1.125; Ferrucci L, 1997, JAMA-J AM MED ASSOC, V277, P728; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fried LP, 1997, J AM GERIATR SOC, V45, P92, DOI 10.1111/j.1532-5415.1997.tb00986.x; GILL TM, 1995, J AM GERIATR SOC, V43, P603, DOI 10.1111/j.1532-5415.1995.tb07192.x; Gill TM, 1998, ANN INTERN MED, V128, P96, DOI 10.7326/0003-4819-128-2-199801150-00004; Gill TM, 1999, J GERONTOL A-BIOL, V54, pM377, DOI 10.1093/gerona/54.7.M377; Gill TM, 2001, J AM GERIATR SOC, V49, P1039, DOI 10.1046/j.1532-5415.2001.49206.x; GILL TM, IN PRESS ARCH PHYS M; GILL TM, IN PRESS ARCH INTERN; GILL TM, 1995, J GERONTOL MED SCI, V50, pM325; GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902; Guralnik JM, 2002, AM J PUBLIC HEALTH, V92, P1244, DOI 10.2105/AJPH.92.8.1244; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.1093/biomet/75.4.800; Jette AM, 1999, AM J PUBLIC HEALTH, V89, P66, DOI 10.2105/AJPH.89.1.66; KATZ S, 1983, NEW ENGL J MED, V309, P1218, DOI 10.1056/NEJM198311173092005; KEMPER P, 1992, HEALTH SERV RES, V27, P421; KING AC, 1988, AM J CARDIOL, V61, P628, DOI 10.1016/0002-9149(88)90778-3; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Levine C, 1999, NEW ENGL J MED, V340, P1587, DOI 10.1056/NEJM199905203402013; MANTON KG, 1988, J GERONTOL, V43, pS153, DOI 10.1093/geronj/43.5.S153; Manton KG, 2001, P NATL ACAD SCI USA, V98, P6354, DOI 10.1073/pnas.111152298; McCullagh P., 1989, GEN LINEAR MODELS, V2nd; MCKINLAY JB, 1995, J AGING HEALTH, V7, P497, DOI 10.1177/089826439500700403; SPECTOR WD, 1987, J CHRON DIS, V40, P481, DOI 10.1016/0021-9681(87)90004-X; Stuck AE, 2002, JAMA-J AM MED ASSOC, V287, P1022, DOI 10.1001/jama.287.8.1022; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; Wenger NS, 2001, ANN INTERN MED, V135, P642, DOI 10.7326/0003-4819-135-8_Part_2-200110161-00002	31	557	567	1	49	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 3	2002	347	14					1068	1074		10.1056/NEJMoa020423	http://dx.doi.org/10.1056/NEJMoa020423			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	599KD	12362007				2022-12-28	WOS:000178332900003
J	Pringle, M; Wilson, T; Grol, R				Pringle, M; Wilson, T; Grol, R			Measuring "goodness" in individuals and healthcare systems	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Univ Nottingham, Div Gen Practice, Nottingham NG7 2RD, England; Royal Coll Gen Practitioners, Qual Unit, London SW7 1PU, England; Univ Nijmegen, Directors Ctr Qual Care Res, NL-6500 HB Nijmegen, Netherlands	University of Nottingham; Radboud University Nijmegen	Pringle, M (corresponding author), Univ Nottingham, Div Gen Practice, Nottingham NG7 2RD, England.	mike.pringle@nottingham.ac.uk	Grol, Richard/C-8523-2013					Berwick DM, 1998, BRIT MED J, V317, P57, DOI 10.1136/bmj.317.7150.57; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; Davies HTO, 1999, LANCET, V353, P1639, DOI 10.1016/S0140-6736(99)90047-8; Grol R, 2001, MED CARE, V39, pII46; GROL R, 2002, JAMA-J AM MED ASSOC, V286, P2578; Institute of Medicine (US) Committee on Quality of Health Care in America, 2001, CROSS QUAL CHASM; Kassirer JP, 1999, NEW ENGL J MED, V340, P309, DOI 10.1056/NEJM199901283400410; Marshall MN, 2000, DYING KNOW PUBLIC RE; MARTIN N, 2000, Q HLTH CARE, V9, P53; Mohammed MA, 2001, LANCET, V357, P463, DOI 10.1016/S0140-6736(00)04019-8; ONEILL A, 2002 REITH LECT; Richards K F, 1994, Qual Health Care, V3 Suppl, P20, DOI 10.1136/qshc.3.Suppl.20; Scherkenbach W. W., 1986, DEMING ROUTE QUALITY; Walshe K, 1995, Qual Health Care, V4, P231, DOI 10.1136/qshc.4.4.231	14	42	44	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 28	2002	325	7366					704	707		10.1136/bmj.325.7366.704	http://dx.doi.org/10.1136/bmj.325.7366.704			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	600JV	12351367	Green Published			2022-12-28	WOS:000178387600032
J	Arbeitman, MN; Furlong, EEM; Imam, F; Johnson, E; Null, BH; Baker, BS; Krasnow, MA; Scott, MP; Davis, RW; White, KP				Arbeitman, MN; Furlong, EEM; Imam, F; Johnson, E; Null, BH; Baker, BS; Krasnow, MA; Scott, MP; Davis, RW; White, KP			Gene expression during the life cycle of Drosophila melanogaster	SCIENCE			English	Article							PATTERNS; MICROARRAY; PRESENILIN; SEQUENCE; COMPLEX; NOTCH; DNA	Molecular genetic studies of Drosophila melanogaster have led to profound advances in understanding the regulation of development. Here we report gene expression patterns for nearly one-third of all Drosophila genes during a complete time course of development. Mutations that eliminate eye or germline tissue were used to further analyze tissue-specific gene expression programs. These studies de ne major characteristics of the transcriptional programs that underlie the life cycle, compare development in males and females, and show that large-scale gene expression data collected from whole animals can be used to identify genes expressed in particular tissues and organs or genes involved in specific biological and biochemical processes.	Stanford Univ, Genome Technol Ctr, Palo Alto, CA 94306 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA; Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; Stanford Univ, Dept Dev Biol, Stanford, CA 94305 USA; Stanford Univ, Dept Genet, Stanford, CA 94305 USA; Stanford Univ, Dept Biochem, Stanford, CA 94305 USA; Stanford Univ, Howard Hughes Med Inst, Stanford, CA 94305 USA; European Mol Biol Lab, Dev Biol Program, D-69117 Heidelberg, Germany; Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA	Stanford University; Yale University; Stanford University; Stanford University; Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University; European Molecular Biology Laboratory (EMBL); University of Oregon	White, KP (corresponding author), Stanford Univ, Genome Technol Ctr, 855 Calif Ave, Palo Alto, CA 94306 USA.			Furlong, Eileen/0000-0002-9544-8339	Howard Hughes Medical Institute Funding Source: Medline; NIGMS NIH HHS [F32 GM019760] Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; AKAM M, 1987, DEVELOPMENT, V101, P1; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Baki L, 2001, P NATL ACAD SCI USA, V98, P2381, DOI 10.1073/pnas.041603398; BARNETT T, 1980, CELL, V21, P729, DOI 10.1016/0092-8674(80)90436-5; BATE M, 1993, DEV DROSOPHILA METAN, V2, P1013; BENDER W, 1983, J MOL BIOL, V168, P17, DOI 10.1016/S0022-2836(83)80320-9; Bertram MJ, 1996, INSECT BIOCHEM MOLEC, V26, P971, DOI 10.1016/S0965-1748(96)00064-1; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; BOSWELL RE, 1985, CELL, V43, P97, DOI 10.1016/0092-8674(85)90015-7; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Gateff E, 1982, Prog Clin Biol Res, V85 Pt B, P621; GRUNSTEIN M, 1975, P NATL ACAD SCI USA, V72, P3961, DOI 10.1073/pnas.72.10.3961; HAZELRIGG T, 1990, GENETICS, V126, P607; Lecuit T, 2002, DEV CELL, V2, P425, DOI 10.1016/S1534-5807(02)00141-7; LEVY LS, 1981, DEV BIOL, V85, P141, DOI 10.1016/0012-1606(81)90243-8; LINDSLEY DL, 1980, GENETICS BIOL DROSOP, P00225, DOI DOI 10.1111/J.1601-5223.1952.TB02915.X; Reiter LT, 2001, GENOME RES, V11, P1114, DOI 10.1101/gr.169101; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schmucker D, 2000, CELL, V101, P671, DOI 10.1016/S0092-8674(00)80878-8; Spradling Allan C., 1993, P1; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; White KP, 1999, SCIENCE, V286, P2179, DOI 10.1126/science.286.5447.2179; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Zuker CS, 1996, P NATL ACAD SCI USA, V93, P571, DOI 10.1073/pnas.93.2.571	28	686	710	2	94	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 27	2002	297	5590					2270	2275		10.1126/science.1072152	http://dx.doi.org/10.1126/science.1072152			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	597LA	12351791				2022-12-28	WOS:000178222000050
J	Maldonado, AM; Doerner, P; Dixon, RA; Lamb, CJ; Cameron, RK				Maldonado, AM; Doerner, P; Dixon, RA; Lamb, CJ; Cameron, RK			A putative lipid transfer protein involved in systemic resistance signalling in Arabidopsis	NATURE			English	Article							INDUCED DISEASE RESISTANCE; SYRINGAE PV. TOMATO; SALICYLIC-ACID; ACQUIRED-RESISTANCE; GENE; THALIANA; PLANTS; ACCUMULATION; TRANSDUCTION; PATHOGENS	Localized attack by a necrotizing pathogen induces systemic acquired resistance (SAR) to subsequent attack by a broad range of normally virulent pathogens. Salicylic acid accumulation is required for activation of local defenses, such as pathogenesis-related protein accumulation, at the initial site of attack, and for subsequent expression of SAR upon secondary, distant challenge(1,2). Although salicylic acid moves through the plant, it is apparently not an essential mobile signal(2). We screened Agrobacterium tumefaciens transfer DNA (tDNA) tagged lines of Arabidopsis thaliana for mutants specifically compromized in SAR. Here we show that Defective in induced resistance 1-1 (dir1-1) exhibits wild-type local resistance to avirulent and virulent Pseudomonas syringae, but that pathogenesis-related gene expression is abolished in uninoculated distant leaves and dir1-1 fails to develop SAR to virulent Pseudomonas or Peronospora parasitica. Petiole exudate experiments indicate that dir1-1 is defective in the production or transmission from the inoculated leaf of an essential mobile signal. DIR1 encodes a putative apoplastic lipid transfer protein and we propose that DIR1 interacts with a lipid-derived molecule to promote long distance signalling.	Salk Inst Biol Studies, La Jolla, CA 92037 USA; John Innes Ctr Plant Sci Res, Norwich NR4 7UH, Norfolk, England; Univ Toronto, Dept Bot, Toronto, ON M5S 3B2, Canada; Noble Fdn Inc, Ardmore, OK 73401 USA	Salk Institute; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; University of Toronto; Noble Research Institute	Cameron, RK (corresponding author), Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Mary, Ana/AAA-2822-2019	Mary, Ana/0000-0002-9357-012X; Doerner, Peter/0000-0001-7218-8469				Arondel V, 2000, PLANT SCI, V157, P1, DOI 10.1016/S0168-9452(00)00232-6; Blein JP, 2002, TRENDS PLANT SCI, V7, P293, DOI 10.1016/S1360-1385(02)02284-7; Cameron RK, 1999, PHYSIOL MOL PLANT P, V55, P121, DOI 10.1006/pmpp.1999.0214; CAO H, 1994, PLANT CELL, V6, P1583, DOI 10.1105/tpc.6.11.1583; Chapman KD, 2000, CHEM PHYS LIPIDS, V108, P221, DOI 10.1016/S0009-3084(00)00198-5; Chen SX, 2001, PLANT PHYSIOL, V127, P194, DOI 10.1104/pp.127.1.194; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Conrath U, 2002, TRENDS PLANT SCI, V7, P210, DOI 10.1016/S1360-1385(02)02244-6; DALESSIO JM, 1992, FOCUS, V14, P76; DELANEY TP, 1995, P NATL ACAD SCI USA, V92, P6602, DOI 10.1073/pnas.92.14.6602; Falk A, 1999, P NATL ACAD SCI USA, V96, P3292, DOI 10.1073/pnas.96.6.3292; Feldmann K. A., 1992, Methods in Arabidopsis research., P274; Feys BJ, 2000, TRENDS GENET, V16, P449, DOI 10.1016/S0168-9525(00)02107-7; Garcia-Olmedo Francisco, 1995, Trends in Microbiology, V3, P72, DOI 10.1016/S0966-842X(00)88879-4; Gomar J, 1998, PROTEINS, V31, P160, DOI 10.1002/(SICI)1097-0134(19980501)31:2<160::AID-PROT6>3.0.CO;2-Q; Hammerschmidt R, 1999, PHYSIOL MOL PLANT P, V55, P77, DOI 10.1006/pmpp.1999.0215; Jirage D, 1999, P NATL ACAD SCI USA, V96, P13583, DOI 10.1073/pnas.96.23.13583; Kader JC, 1997, TRENDS PLANT SCI, V2, P66, DOI 10.1016/S1360-1385(97)82565-4; KING RW, 1974, PLANT PHYSIOL, V53, P96, DOI 10.1104/pp.53.1.96; LIU YG, 1995, PLANT J, V8, P457, DOI 10.1046/j.1365-313X.1995.08030457.x; Mauch-Mani B, 1998, ANN BOT-LONDON, V82, P535, DOI 10.1006/anbo.1998.0726; Munnik T, 2001, TRENDS PLANT SCI, V6, P227, DOI 10.1016/S1360-1385(01)01918-5; Nawrath C, 1999, PLANT CELL, V11, P1393, DOI 10.1105/tpc.11.8.1393; Parker JE, 1996, PLANT CELL, V8, P2033, DOI 10.1105/tpc.8.11.2033; Shirasu K, 1997, PLANT CELL, V9, P261, DOI 10.1105/tpc.9.2.261; THOMA S, 1993, PLANT J, V3, P427, DOI 10.1046/j.1365-313X.1993.t01-21-00999.x; VERNOOIJ B, 1995, MOL PLANT MICROBE IN, V8, P228, DOI 10.1094/MPMI-8-0228; Wasternack C, 1997, TRENDS PLANT SCI, V2, P302, DOI 10.1016/S1360-1385(97)89952-9; Wirtz KWA, 1997, BIOCHEM J, V324, P353, DOI 10.1042/bj3240353; Wolfe J, 2000, PHYSIOL MOL PLANT P, V56, P253, DOI 10.1006/pmpp.2000.0270; Zhou N, 1998, PLANT CELL, V10, P1021, DOI 10.1105/tpc.10.6.1021	31	550	614	3	88	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 26	2002	419	6905					399	403		10.1038/nature00962	http://dx.doi.org/10.1038/nature00962			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	596ZB	12353036				2022-12-28	WOS:000178195400047
J	van Diest, PJ				van Diest, PJ			For and against - No consent should be needed for using leftover body material for scientific purposes - For	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BANK		Vrije Univ Amsterdam, Dept Pathol, NL-1007 MB Amsterdam, Netherlands	Vrije Universiteit Amsterdam	van Diest, PJ (corresponding author), Vrije Univ Amsterdam, Dept Pathol, POB 7057, NL-1007 MB Amsterdam, Netherlands.	pj.vandiest@vumc.nl						Burton JL, 2001, J CLIN PATHOL, V54, P820, DOI 10.1136/jcp.54.11.820; Evans HM, 2001, J CLIN PATHOL, V54, P824, DOI 10.1136/jcp.54.11.824; Gray N, 1999, J CLIN PATHOL, V52, P254, DOI 10.1136/jcp.52.4.254; Malone T, 2002, J NATL CANCER I, V94, P769; Prime W, 2002, BREAST CANCER RES, V2, P237; Schilsky RL, 2002, CLIN CANCER RES, V8, P943	6	206	207	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 21	2002	325	7365					648	649		10.1136/bmj.325.7365.648	http://dx.doi.org/10.1136/bmj.325.7365.648			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	597WM	12242180				2022-12-28	WOS:000178243800033
J	Mochizuki, K; Fine, NA; Fujisawa, T; Gorovsky, MA				Mochizuki, K; Fine, NA; Fujisawa, T; Gorovsky, MA			Analysis of a piwi-related gene implicates small RNAs in genome rearrangement in tetrahymena	CELL			English	Article							PROGRAMMED DNA ELIMINATION; CHROMODOMAIN PROTEIN; PARENTAL EXPRESSION; GERM-LINE; INTERFERENCE; THERMOPHILA; PDD1P; EXCISION; SEQUENCE; NUCLEI	During development of the somatic macronucleus from the germline micronucleus in ciliates, chromosome rearrangements occur in which specific regions of DNA are eliminated and flanking regions are healed, either by religation or construction of telomeres. We identified a gene, TWI1, in Tetrahymena thermophila that is homologous to piwi and is required for DNA elimination. We also found that small RNAs were specifically expressed prior to chromosome rearrangement during conjugation. These RNAs were not observed in TWI1 knockout cells and required PDD1, another gene required for rearrangement, for expression. We propose that these small RNAs function to specify sequences to be eliminated by a mechanism similar to RNA-mediated gene silencing.	Univ Rochester, Dept Biol, Rochester, NY 14627 USA; York Univ, Dept Biol, N York, ON M3J 1P3, Canada; Natl Inst Genet, Dept Dev Genet, Mishima, Shizuoka 4118540, Japan	University of Rochester; York University - Canada; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Gorovsky, MA (corresponding author), Univ Rochester, Dept Biol, Rochester, NY 14627 USA.	goro@mail.rochester.edu	Mochizuki, Kazufumi/AAW-4382-2020; Mochizuki, Kazufumi/A-5686-2016	Mochizuki, Kazufumi/0000-0001-7987-9852; Mochizuki, Kazufumi/0000-0001-7987-9852	NIGMS NIH HHS [GM21793] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021793] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akhtar A, 2000, NATURE, V407, P405, DOI 10.1038/35030169; Ambros V, 2001, SCIENCE, V293, P811, DOI 10.1126/science.1064400; AUSTERBERRY CF, 1984, P NATL ACAD SCI-BIOL, V81, P7383, DOI 10.1073/pnas.81.23.7383; Baldauf SL, 2000, SCIENCE, V290, P972, DOI 10.1126/science.290.5493.972; BUTLER JS, 1997, MRNA FORMATION FUNCT, P111; Callebaut I, 1997, BIOCHEM BIOPH RES CO, V235, P103, DOI 10.1006/bbrc.1997.6748; CassidyHanley D, 1997, GENETICS, V146, P135; Catalanotto C, 2002, GENE DEV, V16, P790, DOI 10.1101/gad.222402; Cerutti L, 2000, TRENDS BIOCHEM SCI, V25, P481, DOI 10.1016/S0968-0004(00)01641-8; Chalker DL, 1996, MOL CELL BIOL, V16, P3658; Chalker DL, 2001, GENE DEV, V15, P1287, DOI 10.1101/gad.884601; Cole ES, 1997, DEV BIOL, V189, P215, DOI 10.1006/dbio.1997.8648; Coyne RS, 1999, MOL CELL, V4, P865, DOI 10.1016/S1097-2765(00)80396-2; DUHARCOURT S, 1995, GENE DEV, V9, P2065, DOI 10.1101/gad.9.16.2065; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Forney JD, 1996, J EUKARYOT MICROBIOL, V43, P462, DOI 10.1111/j.1550-7408.1996.tb04505.x; Gorovsky M A, 1975, Methods Cell Biol, V9, P311, DOI 10.1016/S0091-679X(08)60080-1; Hai B, 2000, METHOD CELL BIOL, V62, P513; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Jacobsen SE, 1999, DEVELOPMENT, V126, P5231; KARLINSEY J, 1989, ANAL BIOCHEM, V180, P303, DOI 10.1016/0003-2697(89)90435-1; Karrer KM, 2000, METHOD CELL BIOL, V62, P127; Kennerdell JR, 2002, GENE DEV, V16, P1884, DOI 10.1101/gad.990802; Liao J, 1997, ANAL BIOCHEM, V253, P137, DOI 10.1006/abio.1997.2201; Mochizuki K, 2000, DEV GENES EVOL, V210, P591, DOI 10.1007/s004270000105; Morel JB, 2002, PLANT CELL, V14, P629, DOI 10.1105/tpc.010358; Nikiforov MA, 1999, GENE DEV, V13, P2852, DOI 10.1101/gad.13.21.2852; Nikiforov MA, 2000, MOL CELL BIOL, V20, P4128, DOI 10.1128/MCB.20.11.4128-4134.2000; OBARA S, 2000, P JAPAN ACAD, V76, pB57; Pal-Bhadra M, 2002, MOL CELL, V9, P315, DOI 10.1016/S1097-2765(02)00440-9; ROBERTSON HD, 1990, METHOD ENZYMOL, V181, P189; Sambrook J., 2001, MOL CLONING; Schmidt A, 1999, GENETICS, V151, P749; Shang YH, 2002, P NATL ACAD SCI USA, V99, P3734, DOI 10.1073/pnas.052016199; Smothers JF, 1997, DEVELOPMENT, V124, P4537; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; Vaucheret H, 2001, J CELL SCI, V114, P3083; Williams RW, 2002, P NATL ACAD SCI USA, V99, P6889, DOI 10.1073/pnas.072190799; WOODARD J, 1972, GENETICS, V70, P251; YAO MC, 1987, CELL, V48, P779, DOI 10.1016/0092-8674(87)90075-4; Yao MC, 2002, MOBILE DNA, P730; Zamore PD, 2001, NAT STRUCT BIOL, V8, P746, DOI 10.1038/nsb0901-746	42	467	500	0	22	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 20	2002	110	6					689	699		10.1016/S0092-8674(02)00909-1	http://dx.doi.org/10.1016/S0092-8674(02)00909-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	596TV	12297043	Bronze			2022-12-28	WOS:000178182800005
J	Taberlet, P; Cheddadi, R				Taberlet, P; Cheddadi, R			Quaternary refugia and persistence of biodiversity	SCIENCE			English	Editorial Material							ICE; TREES		Univ Grenoble 1, CNRS, UMR 5553, Lab Biol Populat Altitude, F-38041 Grenoble 9, France; Ctr Univ Arles, CNRS, UMR 6116, F-13200 Arles, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Universite de Savoie; Centre National de la Recherche Scientifique (CNRS)	Taberlet, P (corresponding author), Univ Grenoble 1, CNRS, UMR 5553, Lab Biol Populat Altitude, BP 53, F-38041 Grenoble 9, France.		Taberlet, Pierre/D-1178-2010	Taberlet, Pierre/0000-0002-3554-5954				BENNETT KD, 1991, J BIOGEOGR, V18, P103, DOI 10.2307/2845248; BENNETT KD, 1986, PHILOS T ROY SOC B, V314, P523, DOI 10.1098/rstb.1986.0071; BERGER AL, 1978, QUATERNARY RES, V9, P139, DOI 10.1016/0033-5894(78)90064-9; BOND G, 1993, NATURE, V365, P143, DOI 10.1038/365143a0; Cabeza M, 2001, TRENDS ECOL EVOL, V16, P242, DOI 10.1016/S0169-5347(01)02125-5; COOPE GR, 1994, PHILOS T ROY SOC B, V344, P19, DOI 10.1098/rstb.1994.0046; HEINRICH H, 1988, QUATERNARY RES, V29, P142, DOI 10.1016/0033-5894(88)90057-9; Hewitt GM, 1996, BIOL J LINN SOC, V58, P247, DOI 10.1111/j.1095-8312.1996.tb01434.x; PELTIER WR, 1994, SCIENCE, V265, P195, DOI 10.1126/science.265.5169.195; Pimm SL, 1998, SCIENCE, V279, P2068, DOI 10.1126/science.279.5359.2068; Taberlet P, 1998, MOL ECOL, V7, P453, DOI 10.1046/j.1365-294x.1998.00289.x; Tzedakis PC, 2002, SCIENCE, V297, P2044, DOI 10.1126/science.1073083	12	185	188	0	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 20	2002	297	5589					2009	2010		10.1126/science.297.5589.2009	http://dx.doi.org/10.1126/science.297.5589.2009			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	594XV	12242431				2022-12-28	WOS:000178078500034
J	Blackmore, S				Blackmore, S			Environment - Biodiversity update - Progress in taxonomy	SCIENCE			English	Editorial Material									Royal Bot Garden Edinburgh, Edinburgh EH3 5LR, Midlothian, Scotland		Blackmore, S (corresponding author), Royal Bot Garden Edinburgh, Inverleith Row, Edinburgh EH3 5LR, Midlothian, Scotland.							*AM SOC PLANT TAX, 1994, SYST AG 2000; Bisby FA, 2000, SCIENCE, V289, P2309, DOI 10.1126/science.289.5488.2309; Cronk QCB, 2001, NAT REV GENET, V2, P607, DOI 10.1038/35084556; Environment Australia, 1998, DARW DECL; Godfray HCJ, 2002, NATURE, V417, P17, DOI 10.1038/417017a; Pennisi E, 2001, SCIENCE, V293, P1979, DOI 10.1126/science.293.5537.1979; Smith AT, 2000, SCIENCE, V290, P2073; Stork Nigel E., 1997, P41; Wilson EO, 2000, SCIENCE, V289, P2279; 2002, WHAT EARTH THREAT SC	10	17	22	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 11	2002	298	5592					365	365		10.1126/science.1075026	http://dx.doi.org/10.1126/science.1075026			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	602NB	12376687				2022-12-28	WOS:000178510400029
J	Hausmann, D; Becker, J; Wang, SL; Gordon, RG				Hausmann, D; Becker, J; Wang, SL; Gordon, RG			Rapid vapor deposition of highly conformal silica nanolaminates	SCIENCE			English	Article							ATOMIC-LAYER DEPOSITION; MASS-SPECTROMETRY; TIN FILMS; AL2O3; SIO2; ALUMINUM; TRIMETHYLALUMINUM	Highly uniform and conformal coatings can be made by the alternating exposures of surface to vapors of two reactants, in process commonly called atomic layer deposition (ALD). The application of ALD has, however, been limited because of slow deposition rates, with theoretical maximum of one monolayer per cycle. We show that alternating exposure of surface to vapors of trimethylaluminum and tris(tert-butoxy) silanol deposits highly conformal layers of amorphous silicon dioxide and aluminum oxide nanolaminates at rates of 12 nanometers ( more than 32 monolayers) per cycle. This process allows for the uniform lining or filling of long, narrow holes. We propose that these ALD layers grow by previously unknown catalytic mechanism that also operates during the rapid ALD of many other metal silicates. This process should allow improved production of many devices, such as trench insulation between transistors in microelectronics, planar waveguides, microelectromechanical structures, multilayer optical filters, and protective layers against diffusion, oxidation, or corrosion.	Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA	Harvard University	Gordon, RG (corresponding author), Harvard Univ, Dept Chem & Biol Chem, 12 Oxford St, Cambridge, MA 02138 USA.	gordon@chemistry.harvard.edu						ABE Y, 1969, B CHEM SOC JPN, V42, P1118, DOI 10.1246/bcsj.42.1118; Braun A. E., 2001, Semiconductor International, V24, P52; DILLON AC, 1995, SURF SCI, V322, P230, DOI 10.1016/0039-6028(95)90033-0; Ferguson JD, 2000, APPL SURF SCI, V162, P280, DOI 10.1016/S0169-4332(00)00205-1; Frisch M. J., 1998, GAUSSIAN 98; GASSER W, 1994, THIN SOLID FILMS, V250, P213, DOI 10.1016/0040-6090(94)90188-0; GAUL JH, 1983, SPECTROSC LETT, V16, P651, DOI 10.1080/00387018308062378; GEORGE SM, 1994, APPL SURF SCI, V82-3, P460, DOI 10.1016/0169-4332(94)90259-3; Gordon RG, 2001, CHEM MATER, V13, P2463, DOI 10.1021/cm010145k; Juppo M, 2000, LANGMUIR, V16, P4034, DOI 10.1021/la991183+; Kingon AI, 2000, NATURE, V406, P1032, DOI 10.1038/35023243; Klaus JW, 2000, SURF SCI, V447, P81, DOI 10.1016/S0039-6028(99)01119-X; Klaus JW, 1999, SURF REV LETT, V6, P435, DOI 10.1142/S0218625X99000433; Kukli K, 1997, J ELECTROCHEM SOC, V144, P300, DOI 10.1149/1.1837399; Lim JW, 2000, J APPL PHYS, V87, P4632, DOI 10.1063/1.373116; Lugmair CG, 2002, CHEM MATER, V14, P888, DOI 10.1021/cm010846h; Min JS, 1998, JPN J APPL PHYS 1, V37, P4999, DOI 10.1143/JJAP.37.4999; MORISHITA S, 1995, J NON-CRYST SOLIDS, V187, P66, DOI 10.1016/0022-3093(95)00113-1; Rahtu A, 2001, LANGMUIR, V17, P6506, DOI 10.1021/la010103a; Ritala M., 2002, HDB THIN FILMS, P103, DOI 10.1016/B978-012512908-4/50005-9; SCHOTT G, 1979, Z ANORG ALLG CHEM, V459, P177, DOI 10.1002/zaac.19794590119; Smith DL., 1995, THIN FILM DEPOSITION; Suntola T, 1990, ATOMIC LAYER EPITAXY; TERRY KW, 1992, CHEM MATER, V4, P1290, DOI 10.1021/cm00024a032; VORONKOV MG, 1956, ZH OBSHCH KHIM+, V26, P3072; Yamaguchi K, 1998, APPL SURF SCI, V130, P202, DOI 10.1016/S0169-4332(98)00051-8; Ylilammi M, 1996, THIN SOLID FILMS, V279, P124, DOI 10.1016/0040-6090(95)08159-3; Zhang H, 2001, J ELECTROCHEM SOC, V148, pF63, DOI 10.1149/1.1355690	28	201	314	1	126	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 11	2002	298	5592					402	406		10.1126/science.1073552	http://dx.doi.org/10.1126/science.1073552			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	602NB	12376699				2022-12-28	WOS:000178510400045
J	Kodama, K; Takigawa, M; Horvatic, M; Berthier, C; Kageyama, H; Ueda, Y; Miyahara, S; Becca, F; Mila, F				Kodama, K; Takigawa, M; Horvatic, M; Berthier, C; Kageyama, H; Ueda, Y; Miyahara, S; Becca, F; Mila, F			Magnetic superstructure in the two-dimensional quantum antiferromagnet SrCu2(BO3)(2)	SCIENCE			English	Article							SHASTRY-SUTHERLAND MODEL; DIMER GROUND-STATE; STAGGERED MAGNETIZATION; PLATEAUS; GAP; CHAIN; EXCITATIONS; TRANSITIONS; IMPURITIES; PHASE	We report the observation of magnetic superstructure in a magnetization plateau state of SrCu2(BO3)(2), a frustrated quasi two-dimensional quantum spin system. The Cu and B nuclear magnetic resonance (NMR) spectra at 35 millikelvin indicate an apparently discontinuous phase transition from uniform magnetization to a modulated superstructure near 27 tesla, above which a magnetization plateau at 1/8 of the full saturation has been observed. Comparison of the Cu NMR spectrum and the theoretical analysis of a Heisenberg spin model demonstrates the crystallization of itinerant triplets in the plateau phase within a large rhomboid unit cell (16 spins per layer) showing oscillations of the spin polarization. Thus, we are now in possession of an interesting model system to study a localization transition of strongly interacting quantum particles.	Univ Tokyo, Inst Solid State Phys, Chiba 2778581, Japan; CNRS, Grenoble High Magnet Field Lab, F-38042 Grenoble, France; Max Planck Inst Festkorperforsch, F-38042 Grenoble, France; Univ Grenoble 1, Spectrometrie Phys Lab, F-38402 St Martin Dheres, France; Univ Lausanne, Inst Phys Theor, CH-1015 Lausanne, Switzerland	University of Tokyo; Centre National de la Recherche Scientifique (CNRS); Max Planck Society; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); University of Lausanne	Takigawa, M (corresponding author), Univ Tokyo, Inst Solid State Phys, Chiba 2778581, Japan.	masashi@issp.u-tokyo.ac.jp	Horvatic, Mladen/A-6665-2018; Kageyama, Hiroshi/A-4602-2010; Mila, Frederic/R-4871-2019; Becca, Federico/K-3915-2013; Berthier, Claude/D-9686-2011	Horvatic, Mladen/0000-0001-7161-0488; Mila, Frederic/0000-0003-4306-7996; Becca, Federico/0000-0002-6142-2050; Berthier, Claude/0000-0001-6796-0506				Abrahams E, 1996, SCIENCE, V274, P1853, DOI 10.1126/science.274.5294.1853; Albrecht M, 1996, EUROPHYS LETT, V34, P145, DOI 10.1209/epl/i1996-00430-0; Cepas O, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.167205; Dagotto E, 1996, SCIENCE, V271, P618, DOI 10.1126/science.271.5249.618; Dobry A., 1997, Physical Review B (Condensed Matter), V56, pR2912, DOI 10.1103/PhysRevB.56.R2912; Julien MH, 2000, PHYS REV LETT, V84, P3422, DOI 10.1103/PhysRevLett.84.3422; Kageyama H, 2000, PHYS REV LETT, V84, P5876, DOI 10.1103/PhysRevLett.84.5876; Kageyama H, 1999, J CRYST GROWTH, V206, P65, DOI 10.1016/S0022-0248(99)00313-9; Kageyama H, 1999, PHYS REV LETT, V82, P3168, DOI 10.1103/PhysRevLett.82.3168; Kodama K, 2002, J PHYS-CONDENS MAT, V14, pL319, DOI 10.1088/0953-8984/14/17/101; Koga A, 2000, PHYS REV LETT, V84, P4461, DOI 10.1103/PhysRevLett.84.4461; Miyahara S, 2000, J PHYS SOC JPN, V69, P72; Miyahara S, 1999, PHYS REV LETT, V82, P3701, DOI 10.1103/PhysRevLett.82.3701; Miyahara S, 2000, PHYS REV B, V61, P3417, DOI 10.1103/PhysRevB.61.3417; Momoi T, 2000, PHYS REV B, V61, P3231, DOI 10.1103/PhysRevB.61.3231; Momoi T, 2000, PHYS REV B, V62, P15067, DOI 10.1103/PhysRevB.62.15067; Narumi Y, 1998, PHYSICA B, V246, P509, DOI 10.1016/S0921-4526(97)00974-5; Nojiri H, 1999, J PHYS SOC JPN, V68, P2906, DOI 10.1143/JPSJ.68.2906; Onizuka K, 2000, J PHYS SOC JPN, V69, P1016, DOI 10.1143/JPSJ.69.1016; Osborne IS, 2000, SCIENCE, V288, P461, DOI 10.1126/science.288.5465.461; Oshikawa M, 1997, PHYS REV LETT, V78, P1984, DOI 10.1103/PhysRevLett.78.1984; SHASTRY BS, 1981, PHYSICA B & C, V108, P1069, DOI 10.1016/0378-4363(81)90838-X; Shiramura W, 1998, J PHYS SOC JPN, V67, P1548, DOI 10.1143/JPSJ.67.1548; SMITH RW, 1991, J SOLID STATE CHEM, V93, P430, DOI 10.1016/0022-4596(91)90316-A; Takigawa M, 1997, PHYS REV B, V55, P14129, DOI 10.1103/PhysRevB.55.14129; Tedoldi F, 1999, PHYS REV LETT, V83, P412, DOI 10.1103/PhysRevLett.83.412; Totsuka K, 1998, PHYS REV B, V57, P3454, DOI 10.1103/PhysRevB.57.3454; Wolf B, 2001, PHYS REV LETT, V86, P4847, DOI 10.1103/PhysRevLett.86.4847; [No title captured]	30	267	267	6	106	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 11	2002	298	5592					395	399		10.1126/science.1075045	http://dx.doi.org/10.1126/science.1075045			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	602NB	12376697	Green Submitted			2022-12-28	WOS:000178510400043
J	Bower, AS; Le Cann, B; Rossby, T; Zenk, W; Gould, J; Speer, K; Richardson, PL; Prater, MD; Zhang, HM				Bower, AS; Le Cann, B; Rossby, T; Zenk, W; Gould, J; Speer, K; Richardson, PL; Prater, MD; Zhang, HM			Directly measured mid-depth circulation in the northeastern North Atlantic Ocean	NATURE			English	Article							LABRADOR SEA-WATER; MIDDEPTH CIRCULATION; OUTFLOW	The circulation of water masses in the northeastern North Atlantic Ocean has a strong influence on global climate owing to the northward transport of warm subtropical water to high latitudes(1). But the ocean circulation at depths below the reach of satellite observations is difficult to measure, and only recently have comprehensive, direct observations of whole ocean basins been possible(2-4). Here we present quantitative maps of the absolute velocities at two levels in the northeastern North Atlantic as obtained from acoustically tracked floats. We find that most of the mean flow transported northward by the Gulf Stream system at the thermocline level (about 600 m depth) remains within the subpolar region, and only relatively little enters the Rockall trough or the Nordic seas. Contrary to previous work(5,6), our data indicate that warm, saline water from the Mediterranean Sea reaches the high latitudes through a combination of narrow slope currents and mixing processes. At both depths under investigation, currents cross the Mid-Atlantic Ridge preferentially over deep gaps in the ridge, demonstrating that sea-floor topography can constrain even upper-ocean circulation patterns.	Woods Hole Oceanog Inst, Woods Hole, MA 02543 USA; UFR Sci, CNRS, Lab Phys Oceans, F-29285 Brest, France; Univ Rhode Isl, Grad Sch Oceanog, Kingston, RI 02881 USA; Univ Kiel, Inst Meereskunde, D-24105 Kiel, Germany; Southampton Oceanog Ctr, Southampton SO14 3ZH, Hants, England; Florida State Univ, Dept Oceanog, Tallahassee, FL 32306 USA	Woods Hole Oceanographic Institution; Centre National de la Recherche Scientifique (CNRS); Ifremer; Institut de Recherche pour le Developpement (IRD); Universite de Bretagne Occidentale; University of Rhode Island; University of Kiel; NERC National Oceanography Centre; University of Southampton; State University System of Florida; Florida State University	Bower, AS (corresponding author), Woods Hole Oceanog Inst, Woods Hole, MA 02543 USA.	abower@whoi.edu	LE CANN, Bernard/L-2630-2015; Richardson, Philip L./AAV-5976-2021	LE CANN, Bernard/0000-0002-4353-2803; Bower, Amy/0000-0003-0902-4984				Belkin IM, 1996, J GEOPHYS RES-OCEANS, V101, P28317, DOI 10.1029/96JC02794; Bersch M, 1999, DEEP-SEA RES PT II, V46, P55, DOI 10.1016/S0967-0645(98)00114-3; BERSCH M, IN PRESS J GEOPHYS R; BOWER A, 2000, WOCE INT NEWSLETT, V38, P14; CURRY RG, 1996, WHOI9601; Davies IW, 2001, J AM CHEM SOC, V123, P10139, DOI 10.1021/ja016877v; Davis RE, 1998, J GEOPHYS RES-OCEANS, V103, P24619, DOI 10.1029/98JC01913; DICKSON RR, 1994, J GEOPHYS RES-OCEANS, V99, P12319, DOI 10.1029/94JC00530; FREELAND HJ, 1976, DEEP-SEA RES, V23, P915, DOI 10.1016/0011-7471(76)90822-6; HEYWOOD KJ, 1994, J GEOPHYS RES-OCEANS, V99, P22525, DOI 10.1029/94JC01740; Iorga MC, 1999, J GEOPHYS RES-OCEANS, V104, P26011, DOI 10.1029/1999JC900204; KRAUSS W, 1986, J GEOPHYS RES-OCEANS, V91, P5061, DOI 10.1029/JC091iC04p05061; Lavender KL, 2000, NATURE, V407, P66, DOI 10.1038/35024048; LECANN B, 1999, WOCE INT NEWSL, V34, P25; MCCARTNEY MS, 1984, J PHYS OCEANOGR, V14, P922, DOI 10.1175/1520-0485(1984)014<0922:WTCWCI>2.0.CO;2; McCartney MS, 2001, PROG OCEANOGR, V51, P125, DOI 10.1016/S0079-6611(01)00084-2; Paillet J, 1998, J GEOPHYS RES-OCEANS, V103, P10223, DOI 10.1029/98JC00262; PINGREE RD, 1990, J MAR BIOL ASSOC UK, V70, P857, DOI 10.1017/S0025315400059117; POLLARD R, 1999, WOCE INT NEWSL, V37, P21; REID JL, 1979, DEEP-SEA RES, V26, P1199, DOI 10.1016/0198-0149(79)90064-5; REID JL, 1978, J GEOPHYS RES-OCEANS, V83, P5063, DOI 10.1029/JC083iC10p05063; ROSSBY HT, 1985, PROG OCEANOGR, V14, P511, DOI 10.1016/0079-6611(85)90025-4; Rossby T, 1996, REV GEOPHYS, V34, P463, DOI 10.1029/96RG02214; SCHMITZ WJ, 1993, REV GEOPHYS, V31, P29, DOI 10.1029/92RG02583; Siedler G., 2001, OCEAN CIRCULATION CL, V77; Speer KG, 1999, DEEP-SEA RES PT II, V46, P165, DOI 10.1016/S0967-0645(98)00103-9; SY A, 1992, DEEP-SEA RES, V39, P825, DOI 10.1016/0198-0149(92)90124-C; TALLEY LD, 1982, J PHYS OCEANOGR, V12, P1189, DOI 10.1175/1520-0485(1982)012<1189:DACOLS>2.0.CO;2; WORTHINGTON LV, 1976, J HOPKINS OCEANOGR S, V6, P1; Zhang HM, 2001, J GEOPHYS RES-OCEANS, V106, P13817, DOI 10.1029/1999JC000101	30	172	174	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 10	2002	419	6907					603	607		10.1038/nature01078	http://dx.doi.org/10.1038/nature01078			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	602AT	12374975				2022-12-28	WOS:000178483100041
J	Ranson, H; Claudianos, C; Ortelli, F; Abgrall, C; Hemingway, J; Sharakhova, MV; Unger, MF; Collins, FH; Feyereisen, R				Ranson, H; Claudianos, C; Ortelli, F; Abgrall, C; Hemingway, J; Sharakhova, MV; Unger, MF; Collins, FH; Feyereisen, R			Evolution of supergene families associated with insecticide resistance	SCIENCE			English	Article							MALARIA VECTOR; CYTOCHROME-P450 MONOOXYGENASES; DROSOPHILA; GENE; TRANSFERASES; MOSQUITO; SITE; DDT	The emergence of insecticide resistance in the mosquito poses a serious threat to the efficacy of many malaria control programs. We have searched the Anopheles gambiae genome for members of the three major enzyme families-the carboxylesterases, glutathione transferases, and cytochrome P450s-that are primarily responsible for metabolic resistance to insecticides. A comparative genomic analysis with Drosophila melanogaster reveals that a considerable expansion of these supergene families has occurred in the mosquito. Low gene orthology and little chromosomal synteny paradoxically contrast the easily identified orthologous groups of genes presumably seeded by common ancestors. In A. gambiae, the independent expansion of paralogous genes is mainly a consequence of the formation of clusters among locally duplicated genes. These expansions may reflect the functional diversification of supergene families consistent with major differences in the life history and ecology of these organisms. These data provide a basis for identifying the resistance-associated enzymes within these families. This will enable the resistance status of mosquitoes, flies, and possibly other holometabolous insects to be monitored. The analyses also provide the means for identifying previously unknown molecules involved in fundamental biological processes such as development.	INRA, Ctr Rech Antibes, F-06560 Valbonne, France; Univ Notre Dame, Ctr Trop Dis Res & Training, Notre Dame, IN 46556 USA; Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England; Australian Natl Univ, Res Sch Biol Sci, Ctr Mol Genet Dev, Canberra, ACT 2601, Australia; CSIRO Entomol, Canberra, ACT 2601, Australia	INRAE; University of Notre Dame; Liverpool School of Tropical Medicine; University of Liverpool; Australian National University; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Feyereisen, R (corresponding author), INRA, Ctr Rech Antibes, 1382 Route Biot, F-06560 Valbonne, France.	rfeyer@salis.antibes.inra.fr	Feyereisen, René/Y-7514-2019; Feyereisen, René/I-3140-2012	Feyereisen, René/0000-0002-9560-571X; Feyereisen, René/0000-0002-9560-571X; Hemingway, Janet/0000-0002-3200-7173; Claudianos, Charles/0000-0002-9799-9572; Ranson, Hilary/0000-0003-2332-8247	NIAID NIH HHS [U01 AI48846, U01 AI50687] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI050687, U01AI048846] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Berge JB, 1998, PHILOS T R SOC B, V353, P1701, DOI 10.1098/rstb.1998.0321; Caccuri AM, 2001, J BIOL CHEM, V276, P5427, DOI 10.1074/jbc.M002819200; CHRISTOPHIDES GK, IN PRESS SCIENCE; CLAUDIANOS C, 2001, ACS SYM SER, V808, P90; Daborn PJ, 2002, SCIENCE, V297, P2253, DOI 10.1126/science.1074170; DANA A, UNPUB; Domanski TL, 2001, CURR DRUG METAB, V2, P117, DOI 10.2174/1389200013338612; Grisaru D, 1999, EUR J BIOCHEM, V264, P672, DOI 10.1046/j.1432-1327.1999.00693.x; Gu ZL, 2002, MOL BIOL EVOL, V19, P256, DOI 10.1093/oxfordjournals.molbev.a004079; Guzov VM, 1998, ARCH BIOCHEM BIOPHYS, V359, P231, DOI 10.1006/abbi.1998.0901; Hemingway J, 2002, SCIENCE, V298, P96, DOI 10.1126/science.1078052; Hung CF, 1996, P NATL ACAD SCI USA, V93, P12200, DOI 10.1073/pnas.93.22.12200; Oakeshott JG, 1999, BIOESSAYS, V21, P1031; Petrov DA, 2002, GENETICA, V115, P81, DOI 10.1023/A:1016076215168; Ranson H, 2000, INSECT MOL BIOL, V9, P499, DOI 10.1046/j.1365-2583.2000.00214.x; Ranson H, 1998, P NATL ACAD SCI USA, V95, P14284, DOI 10.1073/pnas.95.24.14284; Ranson H, 2002, INSECT MOL BIOL, V11, P409, DOI 10.1046/j.1365-2583.2002.00350.x; Ranson H, 2001, BIOCHEM J, V359, P295, DOI 10.1042/0264-6021:3590295; Reiss R.A., 1993, Insect Molecular Biology, V2, P25, DOI 10.1111/j.1365-2583.1993.tb00122.x; SCOTT JA, 1994, BIOCHEM BIOPH RES CO, V205, P1452, DOI 10.1006/bbrc.1994.2828; Sheehan D, 2001, BIOCHEM J, V360, P1, DOI 10.1042/0264-6021:3600001; Tijet N, 2001, GENE, V262, P189, DOI 10.1016/S0378-1119(00)00533-3; Warren JT, 2002, P NATL ACAD SCI USA, V99, P11043, DOI 10.1073/pnas.162375799; Werck-Reichhart D, 2000, GENOME BIOL, V1, P1, DOI DOI 10.1186/GB-2000-1-6-REVIEWS3003	25	451	517	3	172	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 4	2002	298	5591					179	181		10.1126/science.1076781	http://dx.doi.org/10.1126/science.1076781			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	600BJ	12364796				2022-12-28	WOS:000178370500053
J	Brundtland, GH				Brundtland, GH			Violence prevention: A public health approach	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									WHO, CH-1211 Geneva, Switzerland	World Health Organization	Brundtland, GH (corresponding author), WHO, CH-1211 Geneva, Switzerland.								0	10	11	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	2002	288	13					1580	1580		10.1001/jama.288.13.1580	http://dx.doi.org/10.1001/jama.288.13.1580			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	599BJ	12350180				2022-12-28	WOS:000178314000008
J	Crawford, LM				Crawford, LM			Advisory on clinical holds	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Commissioner Food & Drugs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Crawford, LM (corresponding author), US FDA, Off Commissioner Food & Drugs, HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	3	3	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	2002	288	13					1579	1579		10.1001/jama.288.13.1579-c	http://dx.doi.org/10.1001/jama.288.13.1579-c			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	599BJ	12350176				2022-12-28	WOS:000178314000007
J	Baird, P; Downie, J; Thompson, J				Baird, P; Downie, J; Thompson, J			Medicine - Clinical trials and industry	SCIENCE			English	Editorial Material									Univ British Columbia, Dept Med Genet, Vancouver, BC V6T 1Z3, Canada; Dalhousie Univ, Fac Law, Halifax, NS B3H 4H9, Canada; Dalhousie Univ, Fac Med, Halifax, NS B3H 4H9, Canada; Univ New Brunswick, Dept Math & Stat, Fredericton, NB E3B 5A3, Canada	University of British Columbia; Dalhousie University; Dalhousie University; University of New Brunswick	Baird, P (corresponding author), Univ British Columbia, Dept Med Genet, Vancouver, BC V6T 1Z3, Canada.	pbaird@interchange.ubc.ca						Birmingham K, 2000, NAT MED, V6, P609, DOI 10.1038/76146; BRODHEIMER T, 2000, NEW ENGL J MED, V342, P1539; *INT COMM MED J ED, 2001, NEW ENGL J MED, V345, P825; Lewis S, 2001, CAN MED ASSOC J, V165, P783; Nathan DG, 1999, LANCET, V353, P771, DOI 10.1016/S0140-6736(99)00072-0; Naylor CD, 2002, CAN MED ASSOC J, V166, P453; Rennie D, 1997, JAMA-J AM MED ASSOC, V277, P1238, DOI 10.1001/jama.277.15.1238; Roush W, 1997, SCIENCE, V276, P523; Shalala D, 2000, NEW ENGL J MED, V343, P808, DOI 10.1056/NEJM200009143431112; Thompson J., 2001, REPORT COMMITTEE INQ; THOMPSON J, 2002, REPORT COMMITTEE I S; 2002, ECONOMIST       0413, P65	12	16	16	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 27	2002	297	5590					2211	2211						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	597LA	12351773				2022-12-28	WOS:000178222000027
J	Visbeck, M				Visbeck, M			Climate - The ocean's role in Atlantic climate variability	SCIENCE			English	Editorial Material							OSCILLATION		Columbia Univ, Dept Earth & Environm Sci, Lamont Doherty Earth Observ, Palisades, NY 10960 USA	Columbia University	Visbeck, M (corresponding author), Columbia Univ, Dept Earth & Environm Sci, Lamont Doherty Earth Observ, Palisades, NY 10960 USA.	visbeck@ldeo.columbia.edu	Visbeck, Martin/G-2461-2011; Visbeck, Martin H/B-6541-2016; zhu, xiaoting/E-9873-2011	Visbeck, Martin/0000-0002-0844-834X; Visbeck, Martin H/0000-0002-0844-834X; 				[Anonymous], 2002, EOS T AGU, DOI DOI 10.1029/2002EO000207; Bond G, 1997, SCIENCE, V278, P1257, DOI 10.1126/science.278.5341.1257; Broecker WS, 1997, SCIENCE, V278, P1582, DOI 10.1126/science.278.5343.1582; Curry RG, 1998, NATURE, V391, P575, DOI 10.1038/35356; Dickson R, 1996, PROG OCEANOGR, V38, P241, DOI 10.1016/S0079-6611(97)00002-5; Eden C, 2001, J CLIMATE, V14, P2266, DOI 10.1175/1520-0442(2001)014<2266:MOITDV>2.0.CO;2; Hurrell JW, 2001, SCIENCE, V291, P603, DOI 10.1126/science.1058761; Joos F, 1999, SCIENCE, V284, P464, DOI 10.1126/science.284.5413.464; Kaplan A, 1998, J GEOPHYS RES-OCEANS, V103, P18567, DOI 10.1029/97JC01734; Kushnir Y, 2002, J CLIMATE, V15, P2233, DOI 10.1175/1520-0442(2002)015<2233:AGRTES>2.0.CO;2; Marshall J, 2001, INT J CLIMATOL, V21, P1863, DOI 10.1002/joc.693; Rahmstorf S, 1999, NATURE, V399, P523, DOI 10.1038/21066; Shindell DT, 1999, NATURE, V399, P452, DOI 10.1038/20905; Stenseth NC, 2002, SCIENCE, V297, P1292, DOI 10.1126/science.1071281; Sutton RT, 2000, J CLIMATE, V13, P3261, DOI 10.1175/1520-0442(2000)013<3261:TEOCVI>2.0.CO;2; Trenberth KE, 2001, J CLIMATE, V14, P3433, DOI 10.1175/1520-0442(2001)014<3433:EOMAAO>2.0.CO;2; Visbeck M, 1998, GEOPHYS RES LETT, V25, P4521, DOI 10.1029/1998GL900162; Visbeck MH, 2001, P NATL ACAD SCI USA, V98, P12876, DOI 10.1073/pnas.231391598	18	40	49	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 27	2002	297	5590					2223	2224		10.1126/science.1074029	http://dx.doi.org/10.1126/science.1074029			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	597LA	12351779				2022-12-28	WOS:000178222000035
J	Tsunoda, K; Sakai, Y; Watanabe, T; Suzuki, Y				Tsunoda, K; Sakai, Y; Watanabe, T; Suzuki, Y			Pseudo vocal paralysis caused by a fish bone	LANCET			English	Editorial Material									Nissan Tamagawa Hosp, Dept Otolaryngol, Tokyo 158, Japan		Tsunoda, K (corresponding author), Nissan Tamagawa Hosp, Dept Otolaryngol, Tokyo 158, Japan.		Tsunoda, Koichi/L-4188-2019						0	12	13	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 21	2002	360	9337					907	907		10.1016/S0140-6736(02)11026-9	http://dx.doi.org/10.1016/S0140-6736(02)11026-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	596AU	12354472				2022-12-28	WOS:000178142200009
J	Pappu, R; Recht, R; Taylor, J; Gershenfeld, N				Pappu, R; Recht, R; Taylor, J; Gershenfeld, N			Physical one-way functions	SCIENCE			English	Article							MULTIPLE-SCATTERING; SENSITIVITY	Modern cryptographic practice rests on the use of one-way functions, which are easy to evaluate but difficult to invert. Unfortunately, commonly used one-way functions are either based on unproven conjectures or have known vulnerabilities. We show that instead of relying on number theory, the mesoscopic physics of coherent transport through a disordered medium can be used to allocate and authenticate unique identifiers by physically reducing the medium's microstructure to a fixed-length string of binary digits. These physical one-way functions are inexpensive to fabricate, prohibitively difficult to duplicate, admit no compact mathematical representation, and are intrinsically tamper-resistant. We provide an authentication protocol based on the enormous address space that is a principal characteristic of physical one-way functions.	MIT, Media Labs, Ctr Bits & Atoms, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Pappu, R (corresponding author), ThingMagic, 1 Broadway,14th Floor, Cambridge, MA 02142 USA.	ravi@thingmagic.com						AMER N, 1998, Patent No. 5790025; Anderson R., 1998, SECURITY PROTOCOLS, P125; Atkins D, 1995, LECT NOTES COMPUT SC, V917, P263; BERKOVITS R, 1991, PHYS REV B, V43, P8638, DOI 10.1103/PhysRevB.43.8638; DAUGMAN JG, 1985, J OPT SOC AM A, V2, P1160, DOI 10.1364/JOSAA.2.001160; DIFFIE W, 1976, IEEE T INFORM THEORY, V22, P644, DOI 10.1109/TIT.1976.1055638; FENG SC, 1988, PHYS REV LETT, V61, P834, DOI 10.1103/PhysRevLett.61.834; FENG SC, 1991, SCIENCE, V251, P633, DOI 10.1126/science.251.4994.633; Gabor D., 1946, J I ELECT ENG LOND, V93, P429, DOI DOI 10.1049/JI-3-2.1946.0074; Goodman J. W., 1975, Laser speckle and related phenomena, P9; Hoadley D, 1999, PHYS REV B, V60, P5617, DOI 10.1103/PhysRevB.60.5617; Hoekstra AG, 1998, INT J MOD PHYS C, V9, P87, DOI 10.1142/S012918319800008X; JOHNSON KM, 1984, APPL OPTICS, V23, P218, DOI 10.1364/AO.23.000218; Marxer C, 1998, SENSOR MATER, V10, P351; Nestares O, 1998, J ELECTRON IMAGING, V7, P166, DOI 10.1117/1.482638; Pappu S., 2022, PERSONAL COMMUNICATI; Poor H.V., 2013, INTRO DETECTION ESTI; Ridley BA, 2000, MATER RES SOC SYMP P, V581, P115; Rivest R.L., 1321 RFC; RIVEST RL, 1978, COMMUN ACM, V21, P120, DOI [10.1145/359340.359342, 10.1145/357980.358017]; Shor PW, 1997, SIAM J COMPUT, V26, P1484, DOI [10.1137/S0097539795293172, 10.1137/S0036144598347011]; SLOCUM AH, 1992, PRECIS ENG, V14, P67, DOI 10.1016/0141-6359(92)90051-W; Smith J. R., 1999, P 2 WORKSH AUT ID AD, P79; Smith JH, 1998, P SOC PHOTO-OPT INS, V3514, P42, DOI 10.1117/12.323889; Spivak B, 2000, PHYS REV LETT, V84, P1970, DOI 10.1103/PhysRevLett.84.1970; van Renesse R. L., 1995, European Convention on Security and Detection (Conf. Publ. No.408), P45, DOI 10.1049/cp:19950467; van Rossum MCW, 1999, REV MOD PHYS, V71, P313, DOI 10.1103/RevModPhys.71.313; VANTIGGELEN B, 1992, THESIS U AMSTERDAM N; WILKES MV, 1972, TIME SHARING COMPUTE; WOOTTERS WK, 1982, NATURE, V299, P802, DOI 10.1038/299802a0	30	838	928	11	105	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 20	2002	297	5589					2026	2030		10.1126/science.1074376	http://dx.doi.org/10.1126/science.1074376			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	594XV	12242435	Green Submitted			2022-12-28	WOS:000178078500038
J	Goldhaber, SZ				Goldhaber, SZ			Perspective: Thrombolysis for pulmonary embolism	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Goldhaber, SZ (corresponding author), Harvard Univ, Sch Med, Boston, MA 02115 USA.								0	51	53	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 10	2002	347	15					1131	1132		10.1056/NEJMp020107	http://dx.doi.org/10.1056/NEJMp020107			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	601TW	12374871				2022-12-28	WOS:000178465100001
J	Wilmut, I; Beaujean, N; de Sousa, PA; Dinnyes, A; King, TJ; Paterson, LA; Wells, DN; Young, LE				Wilmut, I; Beaujean, N; de Sousa, PA; Dinnyes, A; King, TJ; Paterson, LA; Wells, DN; Young, LE			Somatic cell nuclear transfer	NATURE			English	Article							FIBROBLAST CELLS; DNA METHYLATION; MOUSE CLONING; CLONED MICE; EMBRYOS; CALVES; FETAL; EXPRESSION; CYTOPLASM; METAPHASE	Cloning by nuclear transfer from adult somatic cells is a remarkable demonstration of developmental plasticity. When a nucleus is placed in oocyte cytoplasm, the changes in chromatin structure that govern differentiation can be reversed, and the nucleus can be made to control development to term.	Roslin Inst, Roslin EH25 9PS, Midlothian, Scotland; AgResearch, Hamilton, New Zealand	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; AgResearch - New Zealand	Wilmut, I (corresponding author), Roslin Inst, Roslin EH25 9PS, Midlothian, Scotland.	ian.wilmut@bbsrc.ac.uk	De Sousa, Paul A/H-7416-2013; Beaujean, Nathalie/C-9883-2011; Dinnyes, Andras/D-5131-2013	De Sousa, Paul A/0000-0003-0745-2504; Beaujean, Nathalie/0000-0003-0188-9190; Young, Lorraine/0000-0001-5450-5723; Dinnyes, Andras/0000-0003-3791-2583; Wells, David/0000-0002-8729-4958				Bordignon V, 2001, DEV BIOL, V233, P192, DOI 10.1006/dbio.2001.0215; Campbell K H, 1996, Rev Reprod, V1, P40, DOI 10.1530/ror.0.0010040; Campbell KHS, 1996, NATURE, V380, P64, DOI 10.1038/380064a0; CHEONG HT, 1993, BIOL REPROD, V48, P958, DOI 10.1095/biolreprod48.5.958; Chesne P, 2002, NAT BIOTECHNOL, V20, P366, DOI 10.1038/nbt0402-366; Clarke HJ, 1998, DEV GENET, V22, P17, DOI 10.1002/(SICI)1520-6408(1998)22:1&lt;17::AID-DVG3&gt;3.0.CO;2-A; Daniels R, 2000, BIOL REPROD, V63, P1034, DOI 10.1095/biolreprod63.4.1034; Fairburn HR, 2002, CURR BIOL, V12, pR68, DOI 10.1016/S0960-9822(01)00677-7; HASLER JF, 1995, THERIOGENOLOGY, V43, P141, DOI 10.1016/0093-691X(94)00020-U; Heyman Y, 2002, BIOL REPROD, V66, P6, DOI 10.1095/biolreprod66.1.6; Hill JR, 1999, THERIOGENOLOGY, V51, P1451, DOI 10.1016/S0093-691X(99)00089-8; Hill JR, 2000, BIOL REPROD, V63, P1787, DOI 10.1095/biolreprod63.6.1787; Hochedlinger K, 2002, NATURE, V415, P1035, DOI 10.1038/nature718; Humpherys D, 2001, SCIENCE, V293, P95, DOI 10.1126/science.1061402; Inoue K, 2002, SCIENCE, V295, P297, DOI 10.1126/science.295.5553.297; Kasinathan P, 2001, NAT BIOTECHNOL, V19, P1176, DOI 10.1038/nbt1201-1176; Kikyo N, 2000, SCIENCE, V289, P2360, DOI 10.1126/science.289.5488.2360; Kubota C, 2000, P NATL ACAD SCI USA, V97, P990, DOI 10.1073/pnas.97.3.990; Lanza RP, 2001, SCIENCE, V294, P1893, DOI 10.1126/science.1063440; Misteli T, 2001, SCIENCE, V291, P843, DOI 10.1126/science.291.5505.843; Nakao M, 2001, GENE, V278, P25, DOI 10.1016/S0378-1119(01)00721-1; Ogonuki N, 2002, NAT GENET, V30, P253, DOI 10.1038/ng841; Ono Y, 2001, BIOL REPROD, V64, P44, DOI 10.1095/biolreprod64.1.44; Rideout WM, 2001, SCIENCE, V293, P1093, DOI 10.1126/science.1063206; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; Tamashiro KLK, 2002, NAT MED, V8, P262, DOI 10.1038/nm0302-262; Tanaka S, 2001, BIOL REPROD, V65, P1813, DOI 10.1095/biolreprod65.6.1813; Thompson EM, 1996, REPROD NUTR DEV, V36, P619; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; Wakayama T, 2001, REPRODUCTION, V122, P49, DOI 10.1530/rep.0.1220049; Wakayama T, 2001, MOL REPROD DEV, V58, P376, DOI 10.1002/1098-2795(20010401)58:4<376::AID-MRD4>3.0.CO;2-L; WELLS D, 2001, P 32 ANN C SOC REPRO; WELLS D, 2001, P CURR STATUS PERSPE, V73; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; WILMUT I, 2002, SOMATIC CELL NUCL TR; Yamazaki Y, 2001, P NATL ACAD SCI USA, V98, P14022, DOI 10.1073/pnas.231489398; Young LE, 2000, THERIOGENOLOGY, V53, P627, DOI 10.1016/S0093-691X(99)00263-0; Young LE, 2001, NAT GENET, V27, P153, DOI 10.1038/84769; Zhou Q, 2001, BIOL REPROD, V65, P412, DOI 10.1093/biolreprod/65.2.412	39	372	419	3	66	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 10	2002	419	6907					583	586		10.1038/nature01079	http://dx.doi.org/10.1038/nature01079			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	602AT	12374931	Green Submitted			2022-12-28	WOS:000178483100036
J	Conrad, CP; Lithgow-Bertelloni, C				Conrad, CP; Lithgow-Bertelloni, C			How mantle slabs drive plate tectonics	SCIENCE			English	Article							SUBDUCTION; DYNAMICS; MOTIONS; MODELS; CONSTRAINTS; STRENGTH; FORCES; FLOW	The gravitational pull of subducted slabs is thought to drive the motions of Earth's tectonic plates, but the coupling between slabs and plates is not well established. If a slab is mechanically attached to a subducting plate, it can exert a direct pull on the plate. Alternatively, a detached slab may drive a plate by exciting flow in the mantle that exerts a shear traction on the base of the plate. From the geologic history of subduction, we estimated the relative importance of "pull" versus "suction" for the present-day plates. Observed plate motions are best predicted if slabs in the upper mantle are attached to plates and generate slab pull forces that account for about half of the total driving force on plates. Slabs in the lower mantle are supported by viscous mantle forces and drive plates through slab suction.	Univ Michigan, Dept Geol Sci, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Conrad, CP (corresponding author), Univ Michigan, Dept Geol Sci, 1006 CC Little Bldg, Ann Arbor, MI 48109 USA.		Lithgow-Bertelloni, Carolina/C-4827-2011; Lithgow-Bertelloni, Carolina/P-3952-2019; Conrad, Clinton/ABG-4901-2020	Lithgow-Bertelloni, Carolina/0000-0003-0924-6587; Lithgow-Bertelloni, Carolina/0000-0003-0924-6587; Conrad, Clinton/0000-0003-4314-2351				Becker TW, 2001, GEOCHEM GEOPHY GEOSY, V2, DOI 10.1029/2001GC000171; Bijwaard H, 1998, J GEOPHYS RES-SOL EA, V103, P30055, DOI 10.1029/98JB02467; CHAPPLE WM, 1977, J GEOPHYS RES, V82, P1967, DOI 10.1029/JB082i014p01967; Christensen U, 2001, PHYS EARTH PLANET IN, V127, P25, DOI 10.1016/S0031-9201(01)00275-8; Conrad CP, 1999, J GEOPHYS RES-SOL EA, V104, P17551, DOI 10.1029/1999JB900149; Elsasser W.V., 1967, APPL MODERN PHYS EAR, P223; FORSYTH D, 1975, GEOPHYS J ROY ASTR S, V43, P163, DOI 10.1111/j.1365-246X.1975.tb00631.x; GORDON RG, 1986, J GEOPHYS RES-SOLID, V91, P2389, DOI 10.1029/JB091iB12p12389; Grand SP., 1997, GSA TODAY, V7, P1; GRIPP AE, 1990, GEOPHYS RES LETT, V17, P1109, DOI 10.1029/GL017i008p01109; HAGER BH, 1984, J GEOPHYS RES, V89, P6003, DOI 10.1029/JB089iB07p06003; HAGER BH, 1981, J GEOPHYS RES, V86, P4843, DOI 10.1029/JB086iB06p04843; HANKS TC, 1977, PURE APPL GEOPHYS, V115, P441, DOI 10.1007/BF01637120; ITO E, 1991, NATURE, V351, P140, DOI 10.1038/351140a0; JARRARD RD, 1986, REV GEOPHYS, V24, P217, DOI 10.1029/RG024i002p00217; KOHLSTEDT DL, 1995, J GEOPHYS RES-SOL EA, V100, P17587, DOI 10.1029/95JB01460; Lithgow-Bertelloni C, 1998, REV GEOPHYS, V36, P27, DOI 10.1029/97RG02282; MCKENZIE DP, 1969, GEOPHYS J ROY ASTR S, V18, P1, DOI 10.1111/j.1365-246X.1969.tb00259.x; Moresi L, 1996, EARTH PLANET SC LETT, V138, P15, DOI 10.1016/0012-821X(95)00221-W; RICARD Y, 1989, J GEOPHYS RES-SOLID, V94, P17543, DOI 10.1029/JB094iB12p17543; RICARD Y, 1993, J GEOPHYS RES-SOL EA, V98, P21895, DOI 10.1029/93JB02216; RICHTER F, 1978, J GEOPHYS-Z GEOPHYS, V44, P441; SOLOMON SC, 1974, J GEOPHYS RES, V79, P2557, DOI 10.1029/JB079i017p02557; TURCOTTE DL, 1967, J FLUID MECH, V28, P29, DOI 10.1017/S0022112067001880; Zhong SJ, 2001, J GEOPHYS RES-SOL EA, V106, P703, DOI 10.1029/2000JB900364	25	314	325	2	93	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 4	2002	298	5591					207	209		10.1126/science.1074161	http://dx.doi.org/10.1126/science.1074161			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	600BJ	12364804				2022-12-28	WOS:000178370500061
J	Corbel, S; Fender, RP; Tzioumis, AK; Tomsick, JA; Orosz, JA; Miller, JM; Wijnands, R; Kaaret, P				Corbel, S; Fender, RP; Tzioumis, AK; Tomsick, JA; Orosz, JA; Miller, JM; Wijnands, R; Kaaret, P			Large-scale, decelerating, relativistic X-ray jets from the microquasar XTE J1550-564	SCIENCE			English	Article							ASCA OBSERVATIONS; RADIO; SS-433; SYSTEM; STATES; GALAXY; ROSAT	We have detected, at x-ray and radio wavelengths, large-scale moving jets from the microquasar XTE J1550-564. Plasma ejected from near the black hole traveled at relativistic velocities for at least 4 years. We present direct evidence for gradual deceleration in a relativistic jet. The broadband spectrum of the jets is consistent with synchrotron emission from high-energy (up to 10 tera-electron volts) particles that were accelerated in the shock waves formed within the relativistic ejecta or by the interaction of the jets with the interstellar medium. XTE J1550-564 offers a rare opportunity to study the dynamical evolution of relativistic jets on time scales inaccessible for active galactic nuclei jets, with implications for our understanding of relativistic jets from Galactic x-ray binaries and active galactic nuclei.	Univ Paris 07, F-75221 Paris 05, France; Ctr Etud Saclay, CEA, Serv Astrophys, F-91191 Gif Sur Yvette, France; Univ Amsterdam, Astron Inst Anton Pannekoek, NL-1098 SJ Amsterdam, Netherlands; Ctr High Energy Astrophys, NL-1098 SJ Amsterdam, Netherlands; CSIRO, Australia Telescope Natl Facil, Epping, NSW 1710, Australia; Univ Calif San Diego, Ctr Astrophys & Space Sci, La Jolla, CA 92093 USA; Univ Utrecht, Astron Inst, NL-3508 TA Utrecht, Netherlands; MIT, Ctr Space Res, Cambridge, MA 02139 USA; Harvard Smithsonian Ctr Astrophys, Cambridge, MA 02138 USA	UDICE-French Research Universities; Universite Paris Cite; CEA; UDICE-French Research Universities; Universite Paris Saclay; University of Amsterdam; Commonwealth Scientific & Industrial Research Organisation (CSIRO); University of California System; University of California San Diego; Utrecht University; Massachusetts Institute of Technology (MIT); Harvard University; Smithsonian Astrophysical Observatory; Smithsonian Institution	Corbel, S (corresponding author), Univ Paris 07, F-75221 Paris 05, France.			Miller, Jon/0000-0003-2869-7682; Wijnands, Rudi/0000-0002-3516-2152; Tzioumis, Anastasios/0000-0002-0988-7969				BRIDLE AH, 1984, ANNU REV ASTRON ASTR, V22, P319, DOI 10.1146/annurev.aa.22.090184.001535; Brinkmann W, 1996, ASTRON ASTROPHYS, V312, P306; Corbel S, 2001, ASTROPHYS J, V554, P43, DOI 10.1086/321364; CORBEL S, 2002, 7795 INT ASTR UN; Dubner GM, 1998, ASTRON J, V116, P1842, DOI 10.1086/300537; Fender RP, 2001, MON NOT R ASTRON SOC, V322, P31, DOI 10.1046/j.1365-8711.2001.04080.x; Fender RP, 1999, MON NOT R ASTRON SOC, V304, P865, DOI 10.1046/j.1365-8711.1999.02364.x; Hannikainen D, 2001, ASTROPHYS SPACE SCI, V276, P45, DOI 10.1023/A:1011659517584; HANNIKAINEN D, COMMUNICATION; Hardee PE, 2000, ASTROPHYS J, V533, P176, DOI 10.1086/308656; Harris DE, 2002, ASTROPHYS J, V565, P244, DOI 10.1086/324544; HJELLMING RM, 1988, ASTROPHYS J, V328, P600, DOI 10.1086/166318; Kaiser CR, 2000, ASTRON ASTROPHYS, V356, P975; Kotani T, 2000, ASTROPHYS J, V543, pL133, DOI 10.1086/317276; Marshall HL, 2002, ASTROPHYS J, V564, P941, DOI 10.1086/324398; Migliari S, 2002, SCIENCE, V297, P1673, DOI 10.1126/science.1073660; Mirabel IF, 1999, ANNU REV ASTRON ASTR, V37, P409, DOI 10.1146/annurev.astro.37.1.409; MIRABEL IF, 1992, NATURE, V358, P215, DOI 10.1038/358215a0; Orosz JA, 2002, ASTROPHYS J, V568, P845, DOI 10.1086/338984; REES MJ, 1994, ASTROPHYS J, V430, pL93, DOI 10.1086/187446; RODRIGUEZ LF, 1992, ASTROPHYS J, V401, pL15, DOI 10.1086/186659; RUPEN M, COMMUNICATION; Safi-Harb S, 1999, ASTROPHYS J, V512, P784, DOI 10.1086/306803; SafiHarb S, 1997, ASTROPHYS J, V483, P868, DOI 10.1086/304274; Sambruna RM, 2001, ASTROPHYS J, V549, pL161, DOI 10.1086/319157; Sambruna RM, 2002, ASTROPHYS J, V571, P206, DOI 10.1086/339859; Sams BJ, 1996, NATURE, V382, P47, DOI 10.1038/382047a0; SEWARD F, 1980, NATURE, V287, P806, DOI 10.1038/287806a0; SMITH DA, 1998, 7008 INT ASTR UN; Sobczak GJ, 2000, ASTROPHYS J, V544, P993, DOI 10.1086/317229; SWANK J, 2002, 7792 INT ASTR UN; WATSON MG, 1983, ASTROPHYS J, V273, P688, DOI 10.1086/161403; Wilson AS, 2001, ASTROPHYS J, V547, P740, DOI 10.1086/318412	34	207	208	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 4	2002	298	5591					196	199		10.1126/science.1075857	http://dx.doi.org/10.1126/science.1075857			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	600BJ	12364800	Green Submitted			2022-12-28	WOS:000178370500057
J	Trievel, RC; Beach, BM; Dirk, LMA; Houtz, RL; Hurley, JH				Trievel, RC; Beach, BM; Dirk, LMA; Houtz, RL; Hurley, JH			Structure and catalytic mechanism of a SET domain protein methyltransferase	CELL			English	Article							RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE OXYGENASE; MULTIPLE ISOMORPHOUS REPLACEMENT; HISTONE H3 METHYLTRANSFERASE; FUNCTIONAL-CHARACTERIZATION; ARGININE METHYLTRANSFERASE; SACCHAROMYCES-CEREVISIAE; PARTIAL-PURIFICATION; CRYSTAL-STRUCTURE; DNA METHYLATION; LYSINE 9	Protein lysine methylation by SET domain enzymes regulates chromatin structure, gene silencing, transcriptional activation, plant metabolism, and other processes. The 2.6 Angstrom resolution structure of Rubisco large subunit methyltransferase in a pseudo-bisubstrate complex with S-adenosylhomocysteine and a HEPES ion reveals an all-beta architecture for the SET domain embedded within a larger alpha-helical enzyme fold. Conserved regions of the SET domain bind S-adenosylmethionine and substrate lysine at two sites connected by a pore. We propose that methyl transfer is catalyzed by a conserved Tyr at a narrow pore connecting the sites. The cofactor enters by a "back door" on the opposite side of the enzyme from substrate, promoting highly specific protein recognition and allowing addition of multiple methyl groups.	NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; Univ Kentucky, Dept Hort, Plant Physiol Biochem Mol Biol Program, Lexington, KY 40546 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Kentucky	Hurley, JH (corresponding author), NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.	jh8e@nih.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK036118] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Boggs BA, 2002, NAT GENET, V30, P73, DOI 10.1038/ng787; Briggs SD, 2001, GENE DEV, V15, P3286, DOI 10.1101/gad.940201; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bryk M, 2002, CURR BIOL, V12, P165, DOI 10.1016/S0960-9822(01)00652-2; CHIRPICH TP, 1970, J BIOL CHEM, V245, P1778; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DURBAN E, 1978, J BIOL CHEM, V253, P1427; Fang J, 2002, CURR BIOL, V12, P1086, DOI 10.1016/S0960-9822(02)00924-7; HOFFMAN JL, 1986, BIOCHEMISTRY-US, V25, P4444, DOI 10.1021/bi00363a041; HOUTZ RL, 1991, PLANT PHYSIOL, V97, P913, DOI 10.1104/pp.97.3.913; Jackson JP, 2002, NATURE, V416, P556, DOI 10.1038/nature731; Jacobs SA, 2002, SCIENCE, V295, P2080, DOI 10.1126/science.1069473; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLEIN RR, 1995, PLANT MOL BIOL, V27, P249, DOI 10.1007/BF00020181; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; Liu Y, 2002, PROTEIN SCI, V11, P1285, DOI 10.1110/ps.0201402; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MARKHAM GD, 1980, J BIOL CHEM, V255, P9082; MCCURRY SD, 1982, METHOD ENZYMOL, V90, P515; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Miller T, 2001, P NATL ACAD SCI USA, V98, P12902, DOI 10.1073/pnas.231473398; MURRAY K, 1964, BIOCHEMISTRY-US, V3, P10, DOI 10.1021/bi00889a003; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nielsen PR, 2002, NATURE, V416, P103, DOI 10.1038/nature722; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Nishioka K, 2002, MOL CELL, V9, P1201, DOI 10.1016/S1097-2765(02)00548-8; Nishioka K, 2002, GENE DEV, V16, P479, DOI 10.1101/gad.967202; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Roguev A, 2001, EMBO J, V20, P7137, DOI 10.1093/emboj/20.24.7137; Rojas JR, 1999, NATURE, V401, P93, DOI 10.1038/43487; ROWE PM, 1986, J BIOL CHEM, V261, P7060; SCHLUCKEBIER G, 1995, J MOL BIOL, V247, P16, DOI 10.1006/jmbi.1994.0117; SCHNEIDER G, 1992, ANNU REV BIOPH BIOM, V21, P119, DOI 10.1146/annurev.bb.21.060192.001003; Schneider R, 2002, TRENDS BIOCHEM SCI, V27, P396, DOI 10.1016/S0968-0004(02)02141-2; Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Sheffield P, 1999, PROTEIN EXPRES PURIF, V15, P34, DOI 10.1006/prep.1998.1003; Soltis SM, 1997, J APPL CRYSTALLOGR, V30, P190, DOI 10.1107/S0021889896012939; Strahl BD, 2002, MOL CELL BIOL, V22, P1298, DOI 10.1128/MCB.22.5.1298-1306.2002; Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; Terwilliger TC, 1996, ACTA CRYSTALLOGR D, V52, P749, DOI 10.1107/S0907444996000832; Wang HB, 2001, MOL CELL, V8, P1207, DOI 10.1016/S1097-2765(01)00405-1; WANG P, 1995, PROTEIN EXPRES PURIF, V6, P528, DOI 10.1006/prep.1995.1070; Weiss VH, 2000, NAT STRUCT BIOL, V7, P1165; Yang L, 2002, ONCOGENE, V21, P148, DOI 10.1038/sj.onc.1204998; Ying ZT, 1999, J BIOL CHEM, V274, P36750, DOI 10.1074/jbc.274.51.36750; Zhang X, 2000, EMBO J, V19, P3509, DOI 10.1093/emboj/19.14.3509; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301; Zheng Q, 1998, PROTEIN EXPRES PURIF, V14, P104, DOI 10.1006/prep.1998.0936	60	201	210	0	25	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 4	2002	111	1					91	103		10.1016/S0092-8674(02)01000-0	http://dx.doi.org/10.1016/S0092-8674(02)01000-0			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	601RQ	12372303	Bronze			2022-12-28	WOS:000178461900011
J	Kurtsiefer, C; Zarda, P; Halder, M; Weinfurter, H; Gorman, PM; Tapster, PR; Rarity, JG				Kurtsiefer, C; Zarda, P; Halder, M; Weinfurter, H; Gorman, PM; Tapster, PR; Rarity, JG			A step towards global key distribution	NATURE			English	Article							EXCHANGE		Univ Munich, D-80799 Munich, Germany; QinetiQ, Photon Dept, Malvern WR14 3PS, Worcs, England	University of Munich; Qinetiq Group Plc	Kurtsiefer, C (corresponding author), Univ Munich, D-80799 Munich, Germany.		Kurtsiefer, Christian/C-2849-2009; Weinfurter, Harald/F-8225-2015	Kurtsiefer, Christian/0000-0003-2190-0684; Weinfurter, Harald/0000-0001-6882-3909				Bennett C. H., 1992, Journal of Cryptology, V5, P3, DOI 10.1007/BF00191318; Buttler WT, 2000, PHYS REV LETT, V84, P5652, DOI 10.1103/PhysRevLett.84.5652; Gisin N, 2002, REV MOD PHYS, V74, P145, DOI 10.1103/RevModPhys.74.145; HUGHES RJ, 2002, NEW J PHYS, V4; Rarity JG, 2001, ELECTRON LETT, V37, P512, DOI 10.1049/el:20010334; Rarity JG, 2001, J MOD OPTIC, V48, P1887, DOI 10.1080/09500340110078318; Singh Simon, 1999, THE CODE BOOK	7	271	301	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 3	2002	419	6906					450	450		10.1038/419450a	http://dx.doi.org/10.1038/419450a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	599RF	12368846				2022-12-28	WOS:000178348400027
J	Menon, S; Hansen, J; Nazarenko, L; Luo, YF				Menon, S; Hansen, J; Nazarenko, L; Luo, YF			Climate effects of black carbon aerosols in China and India	SCIENCE			English	Article							CLOUD COVER; TEMPERATURE; OCEAN; MODEL	In recent decades, there has been a tendency toward increased summer floods in south China, increased drought in north China, and moderate cooling in China and India while most of the world has been warming. We used a global climate model to investigate possible aerosol contributions to these trends. We found precipitation and temperature changes in the model that were comparable to those observed if the aerosols included a large proportion of absorbing black carbon ("soot"), similar to observed amounts. Absorbing aerosols heat the air, alter regional atmospheric stability and vertical motions, and affect the large-scale circulation and hydrologic cycle with significant regional climate effects.	NASA, Goddard Inst Space Studies, New York, NY 10025 USA; Columbia Univ, Ctr Climate Syst Res, New York, NY 10025 USA; Natl Sci Fdn China, Haidian, Peoples R China	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Columbia University; National Natural Science Foundation of China (NSFC)	Menon, S (corresponding author), NASA, Goddard Inst Space Studies, New York, NY 10025 USA.							Ackerman AS, 2000, SCIENCE, V288, P1042, DOI 10.1126/science.288.5468.1042; Collins WD, 2001, J GEOPHYS RES-ATMOS, V106, P7313, DOI 10.1029/2000JD900507; French Howard W., 2002, NEW YORK TIMES  0810, P3; Hansen J, 2000, P NATL ACAD SCI USA, V97, P9875, DOI 10.1073/pnas.170278997; Hansen J, 1997, J GEOPHYS RES-ATMOS, V102, P6831, DOI 10.1029/96JD03436; Hansen J, 2001, J GEOPHYS RES-ATMOS, V106, P23947, DOI 10.1029/2001JD000354; HANSEN J, IN PRESS J GEOPHYS R; Husar RB, 2001, J GEOPHYS RES-ATMOS, V106, P18317, DOI 10.1029/2000JD900788; Jacobson MZ, 1998, J GEOPHYS RES-ATMOS, V103, P10593, DOI 10.1029/98JD00287; Jacobson MZ, 2001, NATURE, V409, P695, DOI 10.1038/35055518; Kaiser DP, 1998, GEOPHYS RES LETT, V25, P3599, DOI 10.1029/98GL52784; KAUFMAN YJ, 1997, SCIENCE, V277, P1573; Kunzli N, 2000, LANCET, V356, P795, DOI 10.1016/S0140-6736(00)02653-2; Lau KM, 1996, B AM METEOROL SOC, V77, P2209, DOI 10.1175/1520-0477(1996)077<2209:IOHPIA>2.0.CO;2; LAU KM, 1984, B AM METEOROL SOC, V65, P114, DOI 10.1175/1520-0477(1984)065<0114:TMOEAA>2.0.CO;2; Luo YF, 2001, J GEOPHYS RES-ATMOS, V106, P14501, DOI 10.1029/2001JD900030; Norris JR, 2001, GEOPHYS RES LETT, V28, P3271, DOI 10.1029/2001GL013547; Novakov T, 2000, GEOPHYS RES LETT, V27, P4061, DOI 10.1029/2000GL011759; Penner JE, 2001, CLIMATE CHANGE 2001: THE SCIENTIFIC BASIS, P289; Ramanathan V, 2001, J GEOPHYS RES-ATMOS, V106, P28371, DOI 10.1029/2001JD900133; RANDALL DA, 1989, J ATMOS SCI, V46, P1943, DOI 10.1175/1520-0469(1989)046<1943:IARCAL>2.0.CO;2; ROBINSON WA, IN PRESS J GEOPHYS R; Rosenfeld D, 2001, P NATL ACAD SCI USA, V98, P5975, DOI 10.1073/pnas.101122798; Rotstayn LD, 2002, J CLIMATE, V15, P2103, DOI 10.1175/1520-0442(2002)015&lt;2103:TRTATI&gt;2.0.CO;2; Streets DG, 2001, ATMOS ENVIRON, V35, P4281, DOI 10.1016/S1352-2310(01)00179-0; Sun B, 2000, J CLIMATE, V13, P4341, DOI 10.1175/1520-0442(2000)013<4341:TCITOR>2.0.CO;2; Xu Q, 2001, ATMOS ENVIRON, V35, P5029, DOI 10.1016/S1352-2310(01)00315-6	27	1593	1866	26	708	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 27	2002	297	5590					2250	2253		10.1126/science.1075159	http://dx.doi.org/10.1126/science.1075159			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	597LA	12351786				2022-12-28	WOS:000178222000044
J	Tomishige, M; Klopfenstein, DR; Vale, RD				Tomishige, M; Klopfenstein, DR; Vale, RD			Conversion of Unc104/KIF1A kinesin into a processive motor after dimerization	SCIENCE			English	Article							SUPERFAMILY PROTEIN KIF1A; AXONAL-TRANSPORT; K-LOOP; SINGLE; MECHANISM; ELEGANS; UNC-104; FAMILY	Unc104/KIF1A belongs to a class of monomeric kinesin motors that have been thought to possess an unusual motility mechanism. Unlike the unidirectional motion driven by the coordinated actions of the two heads in conventional kinesins, single-headed KIF1A was reported to undergo biased diffusional motion along microtubules. Here, we show that Unc104/KIF1A can dimerize and move unidirectionally and processively with rapid velocities characteristic of transport in living cells. These results suggest that Unc104/KIF1A operates in vivo by a mechanism similar to conventional kinesin and that regulation of motor dimerization may be used to control transport by this class of kinesins.	Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Vale, RD (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA.				NIAMS NIH HHS [AR42895] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR042895] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bloom GS, 2001, CURR OPIN CELL BIOL, V13, P36, DOI 10.1016/S0955-0674(00)00171-X; Dorner C, 1999, J BIOL CHEM, V274, P33654, DOI 10.1074/jbc.274.47.33654; Kikkawa M, 2000, CELL, V100, P241, DOI 10.1016/S0092-8674(00)81562-7; Kikkawa M, 2001, NATURE, V411, P439, DOI 10.1038/35078000; Klopfenstein DR, 2002, CELL, V109, P347, DOI 10.1016/S0092-8674(02)00708-0; Okada Y, 2000, P NATL ACAD SCI USA, V97, P640, DOI 10.1073/pnas.97.2.640; OKADA Y, 1995, CELL, V81, P769, DOI 10.1016/0092-8674(95)90538-3; Okada Y, 1999, SCIENCE, V283, P1152, DOI 10.1126/science.283.5405.1152; OTSUKA AJ, 1991, NEURON, V6, P113, DOI 10.1016/0896-6273(91)90126-K; Pierce DW, 1999, BIOCHEMISTRY-US, V38, P5412, DOI 10.1021/bi9830009; Rogers KR, 2001, EMBO J, V20, P5101, DOI 10.1093/emboj/20.18.5101; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; Thorn KS, 2000, J CELL BIOL, V151, P1093, DOI 10.1083/jcb.151.5.1093; Tomishige M, 2000, J CELL BIOL, V151, P1081, DOI 10.1083/jcb.151.5.1081; Vale RD, 2000, SCIENCE, V288, P88, DOI 10.1126/science.288.5463.88; Vale RD, 1997, ANNU REV CELL DEV BI, V13, P745, DOI 10.1146/annurev.cellbio.13.1.745; Zhou HM, 2001, J NEUROSCI, V21, P3749, DOI 10.1523/JNEUROSCI.21-11-03749.2001	17	200	204	1	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 27	2002	297	5590					2263	2267		10.1126/science.1073386	http://dx.doi.org/10.1126/science.1073386			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	597LA	12351789				2022-12-28	WOS:000178222000048
J	Deeks, JJ; Smith, LA; Bradley, MD				Deeks, JJ; Smith, LA; Bradley, MD			Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials	BRITISH MEDICAL JOURNAL			English	Article							QUALITY-OF-LIFE; NSAID USE; TOXICITY; DRUGS	Objective To determine the efficacy, gastrointestinal safety, and tolerability of celecoxib (a cyclo-oxygenase 2 (COX 2) inhibitor) used in the treatment of osteoarthritis and rheumatoid arthritis. Design Systematic review of randomised trials that compared at least 12 weeks' celecoxib treatment with another non-steroidal anti-inflammatory drug (NSAID) or placebo and reported efficacy, tolerability, or safety. Trials identified from manufacturer and by searching electronic databases and evaluated according to predefined inclusion and quality criteria. Data combined through meta-analysis. Participants 15 187 patients with osteoarthritis or, rheumatoid arthritis. Main outcome measures Efficacy: Western Ontario and McMaster universities osteoarthritis index; American College of Rheumatology responder index and joint scores for rheumatoid arthritis. Tolerability: withdrawal rates for adverse effects. Gastrointestinal safety: incidence of ulcers, bleeds, perforations, and obstructions. Results Nine randomised controlled trials were included. Celecoxib and NSAIDS were equally effective for all efficacy outcomes. Compared with those taking other NSAIDs, in patients taking celecoxib the rate of withdrawals due to adverse gastrointestinal events was 46% lower (95% confidence interval 29% to 58%; NNT 35 at three months), the incidence of ulcers detectable by endoscopy was 71% lower (59% to 79%; NNT 6 at three months), and the incidence of symptoms of ulcers, perforations, bleeds, and obstructions was 39% lower (4% to 61%; NNT 208 at six months). Subgroup analysis of patients taking aspirin showed that the incidence of ulcers detected by endoscopy was reduced by 51% (14% to 72%) in those given celecoxib compared with other NSAIDs. The reduction was greater (73%, 52% to 84%) in those not taking aspirin. Conclusion Celecoxib is as effective as other NSAIDs for relief of symptoms of osteoarthritis and rheumatoid arthritis and has significantly improved gastrointestinal safety and tolerability.	Inst Hlth Sci, Ctr Stat Med, Oxford OX3 7LF, England; Pfizer Global Res & Dev, Sandwich CT13 9NJ, Kent, England	University of Oxford; Pfizer	Deeks, JJ (corresponding author), Inst Hlth Sci, Ctr Stat Med, Oxford OX3 7LF, England.		Deeks, Jon/AAV-5745-2020	Deeks, Jon/0000-0002-8850-1971				Bensen WG, 1999, MAYO CLIN PROC, V74, P1095, DOI 10.4065/74.11.1095; Blower AL, 1997, ALIMENT PHARM THERAP, V11, P283, DOI 10.1046/j.1365-2036.1997.d01-604.x; BLOWER AL, 1997, UU, V11, P283; Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; *BRIT MED ASS, 2000, BRIT NATL FORMULARY, P447; Deeks JJ, 2001, SYSTEMATIC REV HLTH, P285, DOI DOI 10.1002/9780470693926.CH15; Emery P, 1999, LANCET, V354, P2106, DOI 10.1016/S0140-6736(99)02332-6; Gottlieb S, 2001, BRIT MED J, V323, P301, DOI 10.1136/bmj.323.7308.301; HAWKEY CJ, 1990, BMJ-BRIT MED J, V300, P278, DOI 10.1136/bmj.300.6720.278; Juni P, 2002, BRIT MED J, V324, P1287, DOI 10.1136/bmj.324.7349.1287; Silverstein FE, 2000, JAMA-J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247; Simon LS, 1999, JAMA-J AM MED ASSOC, V282, P1921, DOI 10.1001/jama.282.20.1921; Singh G, 2001, J RHEUMATOL, V28, P6; Tramer MR, 2000, PAIN, V85, P169, DOI 10.1016/S0304-3959(99)00267-5; Zhao SZ, 1999, PHARMACOTHERAPY, V19, P1269, DOI 10.1592/phco.19.16.1269.30879; Zhao SZ, 2000, ARTHRIT CARE RES, V13, P112, DOI 10.1002/1529-0131(200004)13:2<112::AID-ANR5>3.0.CO;2-L; 1997, PHARMACIA; 1998, PHARMACIA; 1977, PHARMACIA	19	255	261	0	15	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 21	2002	325	7365					619	623		10.1136/bmj.325.7365.619	http://dx.doi.org/10.1136/bmj.325.7365.619			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	597WM	12242171	Bronze, Green Published			2022-12-28	WOS:000178243800024
J	Hartshorn, K; Hovius, N; Dade, WB; Slingerland, RL				Hartshorn, K; Hovius, N; Dade, WB; Slingerland, RL			Climate-driven bedrock incision in an active mountain belt	SCIENCE			English	Article							RIVER INCISION; TAIWAN; SEDIMENT; EVOLUTION; COLLISION; RANGE	Measurements of fluvial bedrock incision were made with submillimeter precision in the East Central Range of Taiwan, where long-term exhumation rates and precipitation-driven river discharge are independently known. They indicate that valley lowering is driven by relatively frequent flows of moderate intensity, abrasion by suspended sediment is an important fluvial wear process, and channel bed geometry and the presence of widely spaced planes of weakness in the rock mass influence erosion rate and style.	Univ Cambridge, Dept Earth Sci, Cambridge CB2 3EQ, England; Univ Cambridge, Inst Theoret Geophys, Cambridge CB2 3EQ, England; Penn State Univ, Dept Geosci, College Pk, PA 16802 USA	University of Cambridge; University of Cambridge; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University	Hartshorn, K (corresponding author), Univ Cambridge, Dept Earth Sci, Downing St, Cambridge CB2 3EQ, England.		Hovius, Niels/F-1094-2013	Hovius, Niels/0000-0002-9158-9871				Bonilla M. G., 1977, MEM GEOL SOC CHAINA, V2, P43; DADE WB, 1994, EUROMECH, V310, P201; Finlayson DP, 2002, GEOLOGY, V30, P219, DOI 10.1130/0091-7613(2002)030<0219:SCORIE>2.0.CO;2; Hancock GS, 1998, GEOPH MONOG SERIES, V107, P35; Hovius N, 2000, J GEOL, V108, P73, DOI 10.1086/314387; HOWARD AD, 1994, J GEOPHYS RES-SOL EA, V99, P13971, DOI 10.1029/94JB00744; Lave J, 2001, J GEOPHYS RES-SOL EA, V106, P26561, DOI 10.1029/2001JB000359; LIEW PM, 1990, TECTONOPHYSICS, V183, P121, DOI 10.1016/0040-1951(90)90192-B; Liu TK, 2001, EARTH PLANET SC LETT, V186, P45, DOI 10.1016/S0012-821X(01)00232-1; Middleton G.V., 1984, SEPM SHORT COURSE 3, P401; MILLIMAN JD, 1992, J GEOL, V100, P525, DOI 10.1086/629606; Selby M.J., 1980, Z GEOMORPHOL, V24, P31, DOI [10.1127/zfg/24/1984/31, DOI 10.1127/ZFG/24/1984/31]; SKLAR L, COMMUNICATION; Sklar LS, 2001, GEOLOGY, V29, P1087, DOI 10.1130/0091-7613(2001)029<1087:SARSCO>2.0.CO;2; TENG LS, 1990, TECTONOPHYSICS, V183, P57, DOI 10.1016/0040-1951(90)90188-E; Tinkler K, 1998, GEOPH MONOG SERIES, V107, P1; *WAT RES BUR, 1960, HYDR YB TAIW ROC; Whipple KX, 2000, GEOLOGY, V28, P835, DOI 10.1130/0091-7613(2000)028<0835:RAPOBI>2.3.CO;2; Whipple KX, 2000, GEOL SOC AM BULL, V112, P490, DOI 10.1130/0016-7606(2000)112<0490:RIIBMA>2.3.CO;2; WOLMAN MG, 1960, J GEOL, V68, P54, DOI 10.1086/626637	20	200	209	2	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 20	2002	297	5589					2036	2038		10.1126/science.1075078	http://dx.doi.org/10.1126/science.1075078			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	594XV	12242438				2022-12-28	WOS:000178078500041
J	Moore, SL; Wilson, K				Moore, SL; Wilson, K			Parasites as a viability cost of sexual selection in natural populations of mammals	SCIENCE			English	Article							ECOLOGICAL CAUSES; DIMORPHISM; SIZE; IMMUNOCOMPETENCE; INFECTIONS; MALES; AGE	Sexual selection in mammals has resulted in the evolution of sexual size dimorphism (SSD), with males usually being the larger sex. Comparative analyses indicate that the evolution of SSD is associated with the evolution of male-biased mortality, suggesting a possible causal link between the two. Here, we use a comparative approach to investigate the possible role of parasites in generating this relation. We show that there is a robust association between male-biased parasitism and the degree of sexual selection, as measured by mating system ( monogamous or polygynous) and by the degree of SSD. There is also a positive correlation, across taxa, between male-biased mortality and male-biased parasitism. These results are consistent with the hypothesis that parasites contribute to the observed association between SSD and male-biased mortality.	Univ Stirling, Inst Biol Sci, Stirling FK9 4LA, Scotland	University of Stirling	Wilson, K (corresponding author), Univ Stirling, Inst Biol Sci, Stirling FK9 4LA, Scotland.	ken.wilson@stir.ac.uk	Wilson, Kenneth/B-7452-2008	Wilson, Kenneth/0000-0001-5264-6522				ALEXANDER RD, 1998, EVOLUTIONARY BIOL HU, P402; Andersson Malte, 1994; Bininda-Emonds ORP, 1999, BIOL REV, V74, P143, DOI 10.1017/S0006323199005307; CluttonBrock TH, 1997, AM NAT, V149, P195, DOI 10.1086/285987; CORBET GB, 1964, HDB BRIT MAMMALS; Coulson T, 2001, SCIENCE, V292, P1528, DOI 10.1126/science.292.5521.1528; Fairbairn DJ, 1997, ANNU REV ECOL SYST, V28, P659, DOI 10.1146/annurev.ecolsys.28.1.659; FOLSTAD I, 1992, AM NAT, V139, P603, DOI 10.1086/285346; GRAFEN A, 1989, PHILOS T R SOC B, V326, P119, DOI 10.1098/rstb.1989.0106; GULLAND FMD, 1992, PARASITOLOGY, V105, P493, DOI 10.1017/S0031182000074679; GULLAND FMD, 1993, P ROY SOC B-BIOL SCI, V254, P7, DOI 10.1098/rspb.1993.0119; HAMILTON WD, 1982, SCIENCE, V218, P384, DOI 10.1126/science.7123238; Hudson P., 2002, ECOLOGY WILDLIFE DIS; HUSSANIN A, 1999, PROC R SOC LOND B, V266, P893; Klein SL, 2000, BEHAV PROCESS, V51, P149, DOI 10.1016/S0376-6357(00)00125-X; Liu FGR, 2001, SCIENCE, V291, P1786, DOI 10.1126/science.1056346; MYERS P, 1978, AM NAT, V112, P701, DOI 10.1086/283312; Normand SLT, 1999, STAT MED, V18, P321, DOI 10.1002/(SICI)1097-0258(19990215)18:3<321::AID-SIM28>3.0.CO;2-P; Nunn CL, 2002, EVOLUTION, V56, P177; Nunn CL, 2000, SCIENCE, V290, P1168, DOI 10.1126/science.290.5494.1168; Owens IPF, 1999, TRENDS ECOL EVOL, V14, P170, DOI 10.1016/S0169-5347(98)01580-8; Poulin R, 1996, AM NAT, V147, P287, DOI 10.1086/285851; PROMISLOW DEL, 1992, P ROY SOC B-BIOL SCI, V247, P203, DOI 10.1098/rspb.1992.0030; PURVIS A, 1995, COMPUT APPL BIOSCI, V11, P247; RALLS K, 1976, Q REV BIOL, V51, P245, DOI 10.1086/409310; Rolff J, 2002, P ROY SOC B-BIOL SCI, V269, P867, DOI 10.1098/rspb.2002.1959; Rosenberg MS, 2000, METAWIN STAT SOFTWAR; ROSENTHAL R, 1979, PSYCHOL BULL, V86, P638, DOI 10.1037/0033-2909.86.3.638; Schalk G, 1997, OIKOS, V78, P67, DOI 10.2307/3545801; Sheldon BC, 1996, TRENDS ECOL EVOL, V11, P317, DOI 10.1016/0169-5347(96)10039-2; SHINE R, 1989, Q REV BIOL, V64, P419, DOI 10.1086/416458; Simmons NB, 1998, B AM MUS NAT HIST, P1; SLATKIN M, 1984, EVOLUTION, V38, P622, DOI 10.1111/j.1558-5646.1984.tb00327.x; Smith RJ, 1999, J HUM EVOL, V36, P423, DOI 10.1006/jhev.1998.0281; Wilson K., 2002, P6; ZUK M, 1990, PARASITOL TODAY, V6, P231, DOI 10.1016/0169-4758(90)90202-F; Zuk M, 1996, INT J PARASITOL, V26, P1009, DOI [10.1016/S0020-7519(96)00086-0, 10.1016/S0020-7519(96)80001-4]	37	429	436	3	142	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 20	2002	297	5589					2015	2018		10.1126/science.1074196	http://dx.doi.org/10.1126/science.1074196			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	594XV	12242433				2022-12-28	WOS:000178078500036
J	Yoshida, S; Shidoh, M; Shibuya, H; Nishida, R				Yoshida, S; Shidoh, M; Shibuya, H; Nishida, R			Ovarian obturator hernia	LANCET			English	Editorial Material									Muroran City Gen Hosp, Dept Radiol, Muroran, Hokkaido 0518512, Japan; Muroran City Gen Hosp, Dept Surg, Muroran, Hokkaido 0518512, Japan		Yoshida, S (corresponding author), Muroran City Gen Hosp, Dept Radiol, Yamatechou 3-8-1, Muroran, Hokkaido 0518512, Japan.								0	4	4	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 31	2002	360	9334					715	715		10.1016/S0140-6736(02)09833-1	http://dx.doi.org/10.1016/S0140-6736(02)09833-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	590AM	12241892				2022-12-28	WOS:000177795100027
J	Craig, JV; Lancaster, GA; Taylor, S; Williamson, PR; Smyth, RL				Craig, JV; Lancaster, GA; Taylor, S; Williamson, PR; Smyth, RL			Infrared ear thermometry compared with rectal thermometry in children: a systematic review	LANCET			English	Review							TYMPANIC THERMOMETRY; PEDIATRIC EMERGENCY; TEMPERATURE-MEASUREMENTS; YOUNG-CHILDREN; AXILLARY; INFANTS; FEVER; ESOPHAGEAL	Background Infrared ear thermometry is frequently used in children, because this. is a quick method of taking temperature and the ear is easily accessible. Our aim was to evaluate agreement between temperature measured at the rectum and ear in children. Methods We did a systematic review of studies comparing temperature measured at the rectum (the reference site) using mercury, electronic, or indwelling probe thermometers, with temperature measured at the ear (the test site) using infrared ear thermometers. Heterogeneity between studies was investigated by exploring subgroups according to the mode of the infrared, ear thermometer. I Findings 44 studies containing 58 comparisons (5935 children) were eligible for inclusion in this review. Outcome data were available in reports from 12 comparisons (2312 [39%] children), and data on individual patients were obtained for a further 19 comparisons (2129 [36%] children). 31 comparisons (4441 [75%] children) were therefore included in the meta-analysis. The pooled mean temperature difference (rectal minus ear) was 0.29degreesC (95% limits of agreement -0.74 to 1.32). We pooled data by ear device mode and the mean temperature differences were rectal mode 0.15degreesC (-0.95 to 1.25), actual 0.70degreesC (-0.20 to 1.60), core 0.25degreesC (-0.78 to 1.27), oral 0.34degreesC (-0.86 to 1.54), tympanic 0.62degreesC (-0.40 to 1.64) and mode not stated 0.32degreesC (-0.57 to 1.21). There was, significant residual heterogeneity in both mean differences and sample SDs within the groups of ear device mode. Interpretation Although the mean differences between rectal and ear temperature measurements were small, the wide limits of agreement mean that ear temperature is not a good approximation of rectal temperature, even when the ear thermometer is used in rectal mode. Our finding suggests that infrared ear thermometry does not show sufficient agreement with an established method of temperature measurement to be used in situations where body temperature needs to be measured with precision.	Univ Liverpool, Inst Child Hlth, Alder Hey Childrens Hosp, Liverpool L12 2AP, Merseyside, England; Univ Liverpool, Dept Math Sci, Liverpool L69 3BX, Merseyside, England	Alder Hey Children's NHS Foundation Trust; Alder Hey Children's Hospital; University of Liverpool; University of Liverpool	Smyth, RL (corresponding author), Univ Liverpool, Inst Child Hlth, Alder Hey Childrens Hosp, Liverpool L12 2AP, Merseyside, England.		Williamson, Paula R/B-6425-2016	Williamson, Paula R/0000-0001-9802-6636; Craig, Jean/0000-0003-2296-6773				BASH R, 1994, CANCER, V74, P198; Beckstrand R L, 1996, Pediatr Nurs, V22, P436; BENZINGER TH, 1969, J AMER MED ASSOC, V209, P1200, DOI 10.1001/jama.209.8.1200; Bernardo L M, 1996, J Emerg Nurs, V22, P403, DOI 10.1016/S0099-1767(96)80160-7; Bland JM, 1999, STAT METHODS MED RES, V8, P135, DOI 10.1177/096228029900800204; BLOCH EC, 1993, J CLIN MONITOR, V9, P73, DOI 10.1007/BF01616917; Brennan D F, 1994, Acad Emerg Med, V1, P354; BRENNAN DF, 1995, ANN EMERG MED, V25, P21, DOI 10.1016/S0196-0644(95)70350-0; Chamberlain J M, 1994, Contemp Pediatr, V11, P66; CHAMBERLAIN JM, 1991, CLIN PEDIATR, V30, P24, DOI 10.1177/0009922891030004S08; *CLIN EFF COMM MAN, 1998, EV BAS CLIN PROT GUI; Craig JV, 2000, BRIT MED J, V320, P1174, DOI 10.1136/bmj.320.7243.1174; Davis K, 1993, Pediatr Nurs, V19, P267; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Draaisma J M, 1997, Ned Tijdschr Geneeskd, V141, P938; ERICKSON RS, 1994, HEART LUNG, V23, P181; Fulbrook P, 1997, Intensive Crit Care Nurs, V13, P266, DOI 10.1016/S0964-3397(97)80425-9; GREEN M M, 1989, Journal of Emergency Medicine, V7, P437, DOI 10.1016/0736-4679(89)90136-4; Hoffman C, 1999, Can J Nurs Res, V31, P117; Hooker EA, 1996, ANN EMERG MED, V28, P313, DOI 10.1016/S0196-0644(96)70031-8; HOOKER EA, 1993, SOUTHERN MED J, V86, P855, DOI 10.1097/00007611-199308000-00001; Jirapaet K, 2000, NURSING HLTH SCI, V2, P1; JOHNSON KJ, 1991, PEDIATRICS, V87, P34; KENNEY RD, 1990, PEDIATRICS, V85, P854; Lanham D M, 1999, Pediatr Nurs, V25, P39; Loveys AA, 1999, CLIN PEDIATR, V38, P463, DOI 10.1177/000992289903800804; Mandell DL, 2001, ARCH OTOLARYNGOL, V127, P547, DOI 10.1001/archotol.127.5.547; MAZUR LJ, 1997, AMBULATORY CHILD HLT, V3, P21; MCKENZIE N, 1996, CLIN CONSIDERATIONS, P1; Montoya-Cabrera M A, 1998, Gac Med Mex, V134, P9; MORLEY CJ, 1991, ARCH DIS CHILD, V66, P100, DOI 10.1136/adc.66.1.100; MUMA BK, 1991, ANN EMERG MED, V20, P41, DOI 10.1016/S0196-0644(05)81116-3; NYPAVER M, 1991, AM J DIS CHILD, V145, P403; PETERSENSMITH A, 1994, J PEDIATR-US, V125, P83, DOI 10.1016/S0022-3476(94)70129-6; RHOADS FA, 1990, CLIN PEDIATR, V29, P112, DOI 10.1177/000992289002900209; Robinson JL, 1998, J PEDIATR-US, V133, P553, DOI 10.1016/S0022-3476(98)70067-8; ROMANO MJ, 1993, CRIT CARE MED, V21, P1181, DOI 10.1097/00003246-199308000-00018; Silverman BG, 1998, PUBLIC HEALTH REP, V113, P268; STEWART JV, 1992, ANN EMERG MED, V21, P158, DOI 10.1016/S0196-0644(05)80151-9; TERNDRUP TE, 1992, ANN EMERG MED, V21, P1483, DOI 10.1016/S0196-0644(05)80067-8; TERNDRUP TE, 1991, CLIN PEDIATR, V30, P18, DOI 10.1177/0009922891030004S07; Thomas V, 1994, J Emerg Nurs, V20, P505; TRELOAR D, 1988, ANN EMERG MED, V17, P435; Weiss M E, 1994, J Obstet Gynecol Neonatal Nurs, V23, P798, DOI 10.1111/j.1552-6909.1994.tb01955.x; WILLIAMSON PR, IN PRESS STAT MED; Wilshaw R, 1999, J Pediatr Nurs, V14, P88, DOI 10.1016/S0882-5963(99)80042-6; WILSON RD, 1971, SOUTHERN MED J, V64, P1452, DOI 10.1097/00007611-197112000-00005; YETMAN RJ, 1993, J PEDIATR-US, V122, P769, DOI 10.1016/S0022-3476(06)80024-7	48	162	170	0	20	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 24	2002	360	9333					603	609		10.1016/S0140-6736(02)09783-0	http://dx.doi.org/10.1016/S0140-6736(02)09783-0			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	586TD	12241932				2022-12-28	WOS:000177600400010
J	Jegoux, F; Legent, F; de Montreuil, CB				Jegoux, F; Legent, F; de Montreuil, CB			Chronic cough and ear wax	LANCET			English	Editorial Material									CHU Hotel Dieu, Serv Otorhinolaryngol & Chirurg Cervicofaciale, F-44000 Nantes, France	Nantes Universite; CHU de Nantes	Jegoux, F (corresponding author), CHU Hotel Dieu, Serv Otorhinolaryngol & Chirurg Cervicofaciale, Pl Alexis Ricordeau, F-44000 Nantes, France.		jegoux, franck/P-6231-2014					BLOUSTINE S, 1976, ANN OTO RHINOL LARYN, V85, P406, DOI 10.1177/000348947608500315; FELDMAN JI, 1993, ARCH OTOLARYNGOL, V119, P1042; GUPTA D, 1986, SURG RADIOL ANAT, V8, P217, DOI 10.1007/BF02425070; SHEEHY JL, 1988, AM J OTOL, V9, P392; TODISCO T, 1982, RESPIRATION, V43, P354, DOI 10.1159/000194505	5	21	26	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 24	2002	360	9333					618	618		10.1016/S0140-6736(02)09786-6	http://dx.doi.org/10.1016/S0140-6736(02)09786-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	586TD	12241935				2022-12-28	WOS:000177600400013
J	Moore, MJ				Moore, MJ			No end to nonsense	SCIENCE			English	Editorial Material							PREMATURE TERMINATION CODON; FRAME-DEPENDENT MANNER; MESSENGER-RNA; EXON		Brandeis Univ, Howard Hughes Med Inst, Dept Biochem, Waltham, MA 02454 USA	Brandeis University; Howard Hughes Medical Institute	Moore, MJ (corresponding author), Brandeis Univ, Howard Hughes Med Inst, Dept Biochem, Waltham, MA 02454 USA.							Cartegni L, 2002, NAT REV GENET, V3, P285, DOI 10.1038/nrg775; Gersappe A, 1999, MOL CELL BIOL, V19, P1640; Gersappe A, 1999, J BIOL CHEM, V274, P22452, DOI 10.1074/jbc.274.32.22452; Li BH, 2002, P NATL ACAD SCI USA, V99, P5277, DOI 10.1073/pnas.082095299; Maquat LE, 2002, GENE DEV, V16, P1743, DOI 10.1101/gad.1014502; Maquat LE, 2001, CELL, V104, P173, DOI 10.1016/S0092-8674(01)00202-1; Mendell JT, 2002, SCIENCE, V298, P419, DOI 10.1126/science.1074428; Muhlemann O, 2001, MOL CELL, V8, P33, DOI 10.1016/S1097-2765(01)00288-X; Valentine CR, 1998, MUTAT RES-REV MUTAT, V411, P87, DOI 10.1016/S1383-5742(98)00010-6; Wang J, 2002, SCIENCE, V297, P108, DOI 10.1126/science.1069757; WANG J, 2002, MOL CELL        0903; Wilusz CJ, 2001, GENE DEV, V15, P2781	12	14	14	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 11	2002	298	5592					370	371		10.1126/science.1078096	http://dx.doi.org/10.1126/science.1078096			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	602NB	12376689				2022-12-28	WOS:000178510400033
J	Enquist, BJ; Haskell, JP; Tiffney, BH				Enquist, BJ; Haskell, JP; Tiffney, BH			General patterns of taxonomic and biomass partitioning in extant and fossil plant communities	NATURE			English	Article							LIMITING SIMILARITY; DIVERSITY; RECRUITMENT	A central goal of evolutionary ecology is to identify the general features maintaining the diversity of species assemblages(1-3). Understanding the taxonomic and ecological characteristics of ecological communities provides a means to develop and test theories about the processes that regulate species coexistence and diversity. Here, using data from woody plant communities from different biogeographic regions, continents and geologic time periods, we show that the number of higher taxa is a general power-function of species richness that is significantly different from randomized assemblages. In general, we find that local communities are characterized by fewer higher taxa than would be expected by chance. The degree of taxonomic diversity is influenced by modes of dispersal and potential biotic interactions. Further, changes in local diversity are accompanied by regular changes in the partitioning of community biomass between taxa that are also described by a power function. Our results indicate that local and regional processes(2) have consistently regulated community diversity and biomass partitioning for millions of years.	Univ Arizona, Dept Ecol & Evolutionary Biol, Tucson, AZ 85721 USA; Conservat Int, Ctr Appl Biodivers Res, Washington, DC 20036 USA; Utah State Univ, Dept Fisheries & Wildlife, Logan, UT 84322 USA; Utah State Univ, Ctr Ecol, Logan, UT 84322 USA; Univ Calif Santa Barbara, Dept Geol, Santa Barbara, CA 93106 USA	University of Arizona; Conservation International; Utah System of Higher Education; Utah State University; Utah System of Higher Education; Utah State University; University of California System; University of California Santa Barbara	Enquist, BJ (corresponding author), Univ Arizona, Dept Ecol & Evolutionary Biol, Tucson, AZ 85721 USA.	benquist@u.arizona.edu	Enquist, Brian J/B-6436-2008	Enquist, Brian J/0000-0002-6124-7096				Darwin C., 1877, ORIGIN SPECIES; ELTON C, 1946, J ANIM ECOL, V15, P54, DOI 10.2307/1625; Enquist BJ, 2001, NATURE, V410, P655, DOI 10.1038/35070500; GENTRY AH, 1982, ANN MO BOT GARD, V69, P557, DOI 10.2307/2399084; GENTRY AH, 1993, BIOLOGICAL RELATIONSHIPS BETWEEN AFRICA AND SOUTH AMERICA, P500; Gotelli NJ, 2002, ECOLOGY, V83, P2091, DOI 10.2307/3072040; Hubbell SP, 1999, SCIENCE, V283, P554, DOI 10.1126/science.283.5401.554; Hubbell Stephen P., 2001, V32, pi; HUGHES L, 1994, J ECOL, V82, P933, DOI 10.2307/2261456; HUTCHINSON GE, 1959, AM NAT, V93, P145, DOI 10.1086/282070; Karr J.R., 1975, P258; Kinzig AP, 1999, AM NAT, V153, P371, DOI 10.1086/303182; MACARTHUR R, 1967, AM NAT, V101, P377, DOI 10.1086/282505; MacArthur R.H., 1967, THEORY ISLAND BIOGEO, DOI DOI 10.1080/00379271.2014.984955; Manly BFJ, 1997, RANDOMIZATION BOOTST; RIBBENS E, 1994, ECOLOGY, V75, P1794, DOI 10.2307/1939638; RICKLEFS RE, 1975, EVOLUTION, V29, P313, DOI 10.1111/j.1558-5646.1975.tb00211.x; Ricklefs Robert E., 1993, P350; Robeck HE, 2000, PALEOBIOLOGY, V26, P171, DOI 10.1666/0094-8373(2000)026<0171:TATDP>2.0.CO;2; Roy K, 1996, PHILOS T R SOC B, V351, P1605, DOI 10.1098/rstb.1996.0144; SEPKOSKI JJ, 1991, UNITY OF EVOLUTIONARY BIOLOGY, VOLS 1 AND 2, P210; SIMBERLOFF DS, 1970, EVOLUTION, V24, P23, DOI 10.1111/j.1558-5646.1970.tb01738.x; Tilman D, 1997, P NATL ACAD SCI USA, V94, P1857, DOI 10.1073/pnas.94.5.1857; VALENTINE J W, 1970, Journal of Paleontology, V44, P410; Vazquez JA, 1998, J ECOL, V86, P999, DOI 10.1046/j.1365-2745.1998.00325.x; Webb CO, 2000, AM NAT, V156, P145, DOI 10.1086/303378; Williams C. B., 1964, PATTERNS BALANCE NAT; WILLIAMS PH, 1994, P ROY SOC B-BIOL SCI, V256, P67, DOI 10.1098/rspb.1994.0050	28	79	84	2	25	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 10	2002	419	6907					610	613		10.1038/nature01069	http://dx.doi.org/10.1038/nature01069			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	602AT	12374977				2022-12-28	WOS:000178483100043
J	Reichhardt, T				Reichhardt, T			Discovery of giant asteroid gives Pluto a rocky outlook	NATURE			English	News Item																			0	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 10	2002	419	6907					546	546		10.1038/419546a	http://dx.doi.org/10.1038/419546a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	602AT	12374937	Bronze			2022-12-28	WOS:000178483100005
J	Shimizu, K; Ishikawa, H; Takao, D; Yagi, T; Amaya, K				Shimizu, K; Ishikawa, H; Takao, D; Yagi, T; Amaya, K			Superconductivity in compressed lithium at 20 K	NATURE			English	Article							HIGH-PRESSURE; TEMPERATURE	Superconductivity at high temperatures is expected in elements with low atomic numbers, based in part on conventional BCS (Bardeen-Cooper-Schrieffer) theory(1). For example, it has been predicted that when hydrogen is compressed to its dense metallic phase (at pressures exceeding 400 GPa), it will become superconducting with a transition temperature above room temperature(2). Such pressures are difficult to produce in a laboratory setting, so the predictions are not easily confirmed. Under normal conditions lithium is the lightest metal of all the elements, and may become superconducting at lower pressures(3,4); a tentative observation of a superconducting transition in Li has been previously reported(5). Here we show that Li becomes superconducting at pressures greater than 30 GPa, with a pressure-dependent transition temperature (T-c) of 20 K at 48 GPa. This is the highest observed Tc of any element; it confirms the expectation that elements with low atomic numbers will have high transition temperatures, and suggests that metallic hydrogen will have a very high T-c. Our results confirm that the earlier tentative claim(5) of superconductivity in Li was correct.	Osaka Univ, Grad Sch Engn Sci, Dept Phys Sci, Osaka 5608531, Japan; Osaka Univ, Res Ctr Mat Sci Extreme Condit, Osaka 5608531, Japan; Univ Tokyo, Inst Solid State Phys, Kashiwa, Chiba 2778581, Japan	Osaka University; Osaka University; University of Tokyo	Shimizu, K (corresponding author), Osaka Univ, Grad Sch Engn Sci, Dept Phys Sci, Osaka 5608531, Japan.			Shimizu, Katsuya/0000-0003-0560-8325				ALLEN PB, 1969, PHYS REV, V187, P525, DOI 10.1103/PhysRev.187.525; BARDEEN J, 1957, PHYS REV, V108, P1175, DOI 10.1103/PhysRev.108.1175; Christensen NE, 2001, PHYS REV LETT, V86, P1861, DOI 10.1103/PhysRevLett.86.1861; Hanfland M, 2000, NATURE, V408, P174, DOI 10.1038/35041515; Hanfland M, 1999, SOLID STATE COMMUN, V112, P123, DOI 10.1016/S0038-1098(99)00322-1; LIN TH, 1986, PHYS REV B, V33, P807, DOI 10.1103/PhysRevB.33.807; Neaton JB, 1999, NATURE, V400, P141, DOI 10.1038/22067; Richardson CF, 1997, PHYS REV LETT, V78, P118, DOI 10.1103/PhysRevLett.78.118; Richardson CF, 1997, PHYS REV B, V55, P15130, DOI 10.1103/PhysRevB.55.15130	9	268	273	2	68	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 10	2002	419	6907					597	599		10.1038/nature01098	http://dx.doi.org/10.1038/nature01098			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	602AT	12374973				2022-12-28	WOS:000178483100039
J	Donovan, J; Mills, N; Smith, M; Brindle, L; Jacoby, A; Peters, T; Frankel, S; Neal, D; Hamdy, F				Donovan, J; Mills, N; Smith, M; Brindle, L; Jacoby, A; Peters, T; Frankel, S; Neal, D; Hamdy, F		Protect Study Grp	Quality improvement report - Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; PARTICIPATION	Problem Recruitment to randomised trials is often difficult, and many important trials are not mounted because recruitment is thought to be "impossible." Design Controversial ProtecT (prostate testing for cancer and treatment), trial embedded within qualitative research. Background and setting Screening for prostate cancer is hotly debated, and evidence from trials about the effectiveness of treatments (surgery, radiotherapy, and monitoring) is lacking. Mounting a treatment trial is controversial because of past failures and concerns that differences in complications of treatment but not survival make randomisation unacceptable to patients and clinicians, particularly for a trial including monitoring. Strategy for change In-depth interviews explored interpretation of study information. Audiotape recordings of recruitment appointments enabled scrutiny of content and presentation of study information by recruiters. Initial qualitative findings showed that recruiters had difficulty discussing equipoise and presenting treatments equally; they unknowingly used terminology that was misinterpreted by participants. Findings were used to determine changes to content and presentation of information. Effects of change Changes to the order of presenting treatments encouraged emphasis on equivalence, misinterpreted terms were avoided, the non-radical arm was redefined, and randomisation and clinical equipoise were presented more convincingly. The randomisation rate increased from 40% to 70%, all treatments became acceptable, and the three arm trial became the preferred design. Lessons learnt Changes to information and presentation resulted in efficient recruitment acceptable to patients and clinicians. Embedding this controversial trial within qualitative research improved recruitment. Such methods probably have wider applicability and may enable even the most difficult evaluative questions to be tackled.	Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Newcastle Univ, Ctr Hlth Serv Res, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England; Univ Liverpool, Dept Primary Care, Liverpool L69 3BX, Merseyside, England; Univ Bristol, Div Primary Hlth Care, Bristol BS6 6JL, Avon, England; Newcastle Univ, Sch Surg Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Sheffield, Div Clin Sci, Sheffield S5 7AU, S Yorkshire, England	University of Bristol; Newcastle University - UK; University of Liverpool; University of Bristol; Newcastle University - UK; University of Sheffield	Donovan, J (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.	jenny.donovan@bris.ac.uk		Neal, David/0000-0002-6033-5086; Mills, Nicola/0000-0002-2960-2940; Peters, Tim/0000-0003-2881-4180; Hamdy, Freddie/0000-0003-2627-2154				Altman DG, 1996, BRIT MED J, V313, P570; Baum M, 1999, LANCET, V353, pSL6; Donovan JL, 2000, BRIT MED J, V320, P541, DOI 10.1136/bmj.320.7234.541; Featherstone K, 1998, BRIT MED J, V317, P1177, DOI 10.1136/bmj.317.7167.1177; Featherstone K, 2002, SOC SCI MED, V55, P709, DOI 10.1016/S0277-9536(01)00197-6; Glaser B.G., 1965, AWARENESS DYING; LIVESEY JE, 2000, CLIN ONCOL, V12, P63; Lovato LC, 1997, CONTROL CLIN TRIALS, V18, P328, DOI 10.1016/S0197-2456(96)00236-X; Mays N, 1996, QUALITATIVE RES HLTH; O'Reilly P, 1999, BRIT MED J, V318, P1556, DOI 10.1136/bmj.318.7197.1556a; PRINGLE M, 1995, BRIT MED J, V311, P1382, DOI 10.1136/bmj.311.7017.1382; Ritchie J, 2002, ANAL QUALITATIVE DAT, P187; ROBERSON NL, 1994, CANCER, V74, P2687, DOI 10.1002/1097-0142(19941101)74:9+<2687::AID-CNCR2820741817>3.0.CO;2-B; Ross S, 1999, J CLIN EPIDEMIOL, V52, P1143, DOI 10.1016/S0895-4356(99)00141-9; Selley S., 1997, HLTH TECHNOLOGY ASSE, V1, P1, DOI DOI 10.3310/HTA1020; Snowdon C, 1997, SOC SCI MED, V45, P1337, DOI 10.1016/S0277-9536(97)00063-4; TOGNONI G, 1991, BRIT MED J, V303, P969, DOI 10.1136/bmj.303.6808.969	17	395	398	0	38	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 5	2002	325	7367					766	769		10.1136/bmj.325.7367.766	http://dx.doi.org/10.1136/bmj.325.7367.766			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	603AU	12364308	Green Published			2022-12-28	WOS:000178537300023
J	Scott, TW; Takken, W; Knols, BGJ; Boete, C				Scott, TW; Takken, W; Knols, BGJ; Boete, C			The ecology of genetically modified mosquitoes	SCIENCE			English	Editorial Material							POPULATION-SIZE; AFRICA		Univ Calif Davis, Dept Entomol, Davis, CA 95616 USA; Univ Wageningen & Res Ctr, Entomol Lab, Wageningen, Netherlands; Univ Paris 06, Lab Parasitol Evolut, Paris 5, France	University of California System; University of California Davis; Wageningen University & Research; UDICE-French Research Universities; Sorbonne Universite	Scott, TW (corresponding author), Univ Calif Davis, Dept Entomol, Davis, CA 95616 USA.	twscott@ucdavis.edu	BOETE, Christophe/A-7926-2010; Knols, Bart/C-5765-2017	BOETE, Christophe/0000-0001-9043-8652; 				Alphey L, 2002, SCIENCE, V298, P119, DOI 10.1126/science.1078278; Alphey L, 2002, MOL BIOCHEM PARASIT, V121, P173, DOI 10.1016/S0166-6851(02)00040-3; Boete C, 2002, PARASITOLOGY, V125, P93, DOI 10.1017/S0031182002001944; BOETE C, IN PRESS TRENDS PARA; Boete Christopher, 2002, Malaria Journal, V1, pUnpaginated; Charlwood JD, 1998, AM J TROP MED HYG, V59, P243, DOI 10.4269/ajtmh.1998.59.243; della Torre A, 2002, SCIENCE, V298, P115, DOI 10.1126/science.1078170; Donnelly MJ, 2002, TRENDS PARASITOL, V18, P75, DOI 10.1016/S1471-4922(01)02198-5; Enserink M, 2002, SCIENCE, V297, P30; Focks DA, 2000, AM J TROP MED HYG, V62, P11, DOI 10.4269/ajtmh.2000.62.11; Ito J, 2002, NATURE, V417, P452, DOI 10.1038/417452a; James AA, 2000, INSECT TRANSGENESIS, P319, DOI 10.1201/9781420039399.ch18; Kiszewski AE, 2002, J MED ENTOMOL, V39, P847, DOI 10.1603/0022-2585-39.6.847; LORIMER N, 1976, J ECON ENTOMOL, V69, P405, DOI 10.1093/jee/69.3.405; MAXWELL CA, IN PRESS TROP MED IN; MORRISON AC, UNPUB; Novella IS, 1999, J MOL BIOL, V287, P459, DOI 10.1006/jmbi.1999.2635; Okanda F.M., 2002, Malaria Journal, pUnpaginated, DOI 10.1186/1475-2875-1-10; RIBEIRO JMC, 1994, J MED ENTOMOL, V31, P10, DOI 10.1093/jmedent/31.1.10; Rogers DJ, 2002, NATURE, V415, P710, DOI 10.1038/415710a; Scott TW, 2000, J MED ENTOMOL, V37, P89, DOI 10.1603/0022-2585-37.1.89; Smith TA, 2001, TRENDS PARASITOL, V17, P145, DOI 10.1016/S1471-4922(00)01814-6; TAKKEN W, IN PRESS TROP MED IN; TAYLOR CE, 1993, MED VET ENTOMOL, V7, P351, DOI 10.1111/j.1365-2915.1993.tb00704.x; Toure YT, 1998, MED VET ENTOMOL, V12, P74, DOI 10.1046/j.1365-2915.1998.00071.x; Trape JF, 2002, TRENDS PARASITOL, V18, P224, DOI 10.1016/S1471-4922(02)02249-3; Turelli M, 1999, INSECT MOL BIOL, V8, P243, DOI 10.1046/j.1365-2583.1999.820243.x; White NJ, 1999, LANCET, V353, P1965, DOI 10.1016/S0140-6736(98)07367-X	28	147	151	1	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 4	2002	298	5591					117	119		10.1126/science.298.5591.117	http://dx.doi.org/10.1126/science.298.5591.117			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	600BJ	12364785				2022-12-28	WOS:000178370500042
J	Mottram, DS; Wedzicha, BL; Dodson, AT				Mottram, DS; Wedzicha, BL; Dodson, AT			Acrylamide is formed in the Maillard reaction	NATURE			English	Article									Univ Reading, Sch Food Biosci, Reading RG6 6AP, Berks, England; Univ Leeds, Procter Dept Food Sci, Leeds LS2 9JT, W Yorkshire, England	University of Reading; University of Leeds	Mottram, DS (corresponding author), Univ Reading, Sch Food Biosci, Reading RG6 6AP, Berks, England.	d.s.mottram@reading.ac.uk						Belitz H -D, 1999, FOOD CHEM; CASTLE L, 1993, J AGR FOOD CHEM, V41, P1261, DOI 10.1021/jf00032a019; DEMBINSKI E, 1991, J PLANT PHYSIOL, V138, P494, DOI 10.1016/S0176-1617(11)80529-8; Martin FL, 2001, J AGR FOOD CHEM, V49, P3885, DOI 10.1021/jf010310g; Rosen J, 2002, ANALYST, V127, P880, DOI 10.1039/b204938d; Tareke E, 2002, J AGR FOOD CHEM, V50, P4998, DOI 10.1021/jf020302f; WHO INT AGCY RES CANC, 1994, IARC MONOG EVAL CARC, V60, P389	7	1564	1732	27	524	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 3	2002	419	6906					448	449		10.1038/419448a	http://dx.doi.org/10.1038/419448a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	599RF	12368844				2022-12-28	WOS:000178348400025
J	Clark, TJ; Voit, D; Gupta, JK; Hyde, C; Song, FJ; Khan, KS				Clark, TJ; Voit, D; Gupta, JK; Hyde, C; Song, FJ; Khan, KS			Accuracy of hysteroscopy in the diagnosis of endometrial cancer and hyperplasia - A systematic quantitative review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							SALINE INFUSION SONOGRAPHY; TRANSVAGINAL ULTRASONOGRAPHY; POSTMENOPAUSAL WOMEN; OFFICE HYSTEROSCOPY; MEDICAL LITERATURE; USERS GUIDES; OUTPATIENT HYSTEROSCOPY; CURETTAGE; ULTRASOUND; BIOPSY	Context Hysteroscopy (direct endoscopic visualization of the endometrial cavity) is used extensively in the evaluation of common gynecologic problems, such as menorrhagia and postmenopausal bleeding. However, there is a continuing debate about the value of this technology in the diagnosis of serious endometrial disease. Objective To determine the accuracy of hysteroscopy in diagnosing endometrial cancer and hyperplasia in women with abnormal uterine bleeding. Data Sources Relevant articles were identified through searches of the Cochrane Library, MEDLINE, and EMBASE (1984-2001), manual searches of bibliographies of known primary and review articles, and contact with manufacturers. Study Selection Studies were selected blindly, independently, and in duplicate if accuracy of hysteroscopy was estimated in women with abnormal uterine bleeding, using histopathologic findings as a reference standard. Our search identified 3486 articles; 208 of these were deemed to be potentially eligible and were retrieved for detailed data extraction. Sixty-five primary studies were analyzed, including 26346 women. Data Extraction Data were abstracted on characteristics and quality from each study. Results for diagnostic accuracy were extracted to form 2 X 2 contingency tables separately for endometrial cancer and endometrial disease (cancer, hyperplasia, or both). Pooled likelihood ratios (LRs) were used as summary accuracy measures. Data Synthesis The pretest probability of endometrial cancer was 3.9% (95% confidence interval [CI], 3.7%-4.2%). A positive hysteroscopy result (pooled LR, 60.9; 95% Cl, 51.2-72.5) increased the probability of cancer to 71.8% (95% Cl, 67.0%-76.6%), whereas a negative hysteroscopy result (pooled LR, 0.15; 95% Cl, 0.13-0.18) reduced the probability of cancer to 0.6% (95% Cl, 0.5%-0.8%). There was statistical heterogeneity in pooling of LRs, but an explanation for this could not be found in spectrum composition and study quality. The overall accuracy for the diagnosis of endometrial disease was modest compared with that of cancer, and the results were heterogeneous. The accuracy tended to be higher among postmenopausal women and in the outpatient setting. Conclusion The diagnostic accuracy of hysteroscopy is high for endometrial cancer, but only moderate for endometrial disease (cancer or hyperplasia).	Birmingham Maternity Hosp, Dept Obstet & Gynaecol, Birmingham B15 2TG, W Midlands, England; Univ Birmingham, Dept Epidemiol & Publ Hlth, Birmingham, W Midlands, England; Ninewells Hosp, Dept Obstet & Gynaecol, Dundee DD1 9SY, Scotland; Univ Zurich, Horten Zentrum, Zurich, Switzerland	University of Birmingham; University of Dundee; University of Zurich	Clark, TJ (corresponding author), Birmingham Maternity Hosp, Dept Obstet & Gynaecol, Birmingham B15 2TG, W Midlands, England.	T.J.Clark@bham.ac.uk	Khan, Khalid S/AAT-8824-2020; Song, Fujian/B-3516-2013	Khan, Khalid S/0000-0001-5084-7312; Christopher, Hyde/0000-0002-7349-0616				Alexopoulos ED, 1999, GYNAECOL ENDOSC, V8, P105, DOI 10.1046/j.1365-2508.1999.00237.x; ALTARAS MM, 1993, INT J GYNECOL OBSTET, V42, P255, DOI 10.1016/0020-7292(93)90221-H; AZZENA A, 1999, ITAL J OBSTET GYNAEC, V11, P112; Bakour SH, 1999, GYNAECOL ENDOSC, V8, P143, DOI 10.1046/j.1365-2508.1999.00255.x; Bakour SH, 2000, BRIT J OBSTET GYNAEC, V107, P1312, DOI 10.1111/j.1471-0528.2000.tb11627.x; Bakour SH, 2000, BRIT J OBSTET GYNAEC, V107, P295, DOI 10.1111/j.1471-0528.2000.tb11706.x; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Ben-Yehuda OM, 1998, GYNECOL ONCOL, V68, P4, DOI 10.1006/gyno.1997.4891; BENBARUCH G, 1994, GYNECOL OBSTET INVES, V37, P260, DOI 10.1159/000292573; BOCANERA AR, 1994, MATURITAS, V19, P67, DOI 10.1016/0378-5122(94)90043-4; Bronz L, 1997, ULTRASOUND OBST GYN, V9, P53, DOI 10.1046/j.1469-0705.1997.09010053.x; BUCHHOLZ F, 1988, ZBL GYNAKOL, V110, P884; CACCIATORE B, 1994, ACTA OBSTET GYN SCAN, V73, P413, DOI 10.3109/00016349409006254; Cameron ST, 2001, AUST NZ J OBSTET GYN, V41, P291, DOI 10.1111/j.1479-828X.2001.tb01230.x; Campo R, 1999, HUM REPROD UPDATE, V5, P73, DOI 10.1093/humupd/5.1.73; Caserta D, 1999, Minerva Ginecol, V51, P169; Cicinelli E, 1993, Eur J Gynaecol Oncol, V14, P425; Clark TJ, 2002, BJOG-INT J OBSTET GY, V109, P313, DOI 10.1016/S1470-0328(02)01088-1; Clark TJ, 2002, EUR J OBSTET GYN R B, V103, P65; Clark TJ, 2001, ACTA OBSTET GYN SCAN, V80, P784; CLARKE M, 2000, COCHRANES REV HDB; *COCHR METH WORK G, 2002, REC METH; COOK DJ, 1995, J CLIN EPIDEMIOL, V48, P167, DOI 10.1016/0895-4356(94)00172-M; Cooper JM, 1999, OBSTET GYN CLIN N AM, V26, P217, DOI 10.1016/S0889-8545(05)70068-1; COULTER A, 1995, EFFECTIVE HLTH CARE, V9, P1; Dargent D, 1984, Rev Fr Gynecol Obstet, V79, P293; DAVYDOV SN, 1989, AKUSH GINEKOL SOFIIA, V10, P35; De Silva B. Y., 1997, Journal of Obstetrics and Gynaecology (Abingdon), V17, P399; De Vivo D, 1986, Radiol Med, V72, P305; Decloedt JF, 1999, GYNAECOL ENDOSC, V8, P137, DOI 10.1046/j.1365-2508.1999.00258.x; Deeks JJ, 1996, BAILLIERE CLIN OB GY, V10, P613, DOI 10.1016/S0950-3552(96)80008-3; Deeks JJ., 2001, SYSTEMATIC REV HLTH, P248, DOI DOI 10.1002/9780470693926.CH14; DEJONG PR, 1993, GYNAECOL ENDOSC, V2, P242; DEMENDONCA R, 1995, AM J OBSTET GYNECOL, V173, P1352, DOI 10.1016/0002-9378(95)91389-0; DEMENDONCA R, 1994, INT J GYNECOL OBS S2, V46, P80; Descargues G, 2001, J Gynecol Obstet Biol Reprod (Paris), V30, P59; Deville W, 2002, EVIDENCE BASE CLIN D, P145; DUNN G, 1995, INTRO EVIDENCE BASED; Egger M., 2008, SYSTEMATIC REV HLTH, V2nd, DOI DOI 10.1002/9780470693926.CH12; Elewa AM, 2001, MIDDLE E FERTIL SOC, V6, P26; Epstein E, 2001, ULTRASOUND OBST GYN, V18, P157, DOI 10.1046/j.1469-0705.2001.00472.x; GABRYS M, 1994, ACTA ENDOSC, V4, P59; Garuti G, 2001, J AM ASSOC GYN LAP, V8, P207, DOI 10.1016/S1074-3804(05)60579-8; GIMPELSON RJ, 1988, AM J OBSTET GYNECOL, V158, P489, DOI 10.1016/0002-9378(88)90011-7; GIMPELSON RJ, 1995, AM J OBSTET GYNECOL, V173, P1637, DOI 10.1016/0002-9378(95)90670-3; Gorostiaga A, 2001, J Obstet Gynaecol, V21, P67; Greenhalgh T, 1997, BRIT MED J, V315, P540, DOI 10.1136/bmj.315.7107.540; GRIMES DA, 1982, AM J OBSTET GYNECOL, V142, P1; Grozdanov G, 1988, Akush Ginekol (Sofiia), V27, P76; Gucer F, 1996, GYNAKOL GEBURT RUNDS, V36, P9; Gupta JK, 1996, ACTA OBSTET GYN SCAN, V75, P475, DOI 10.3109/00016349609033357; GUYATT GH, 1992, J GEN INTERN MED, V7, P145, DOI 10.1007/BF02598003; GUYATT GH, 1986, CAN MED ASSOC J, V134, P587; Haller H, 1996, INT J GYNECOL OBSTET, V54, P155, DOI 10.1016/0020-7292(96)02677-X; HAYNES RB, 1981, CAN MED ASSOC J, V124, P703; IRWIG L, 1994, ANN INTERN MED, V120, P667, DOI 10.7326/0003-4819-120-8-199404150-00008; ITZKOWIC DJ, 1990, AUST NZ J OBSTET GYN, V30, P150, DOI 10.1111/j.1479-828X.1990.tb03250.x; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P389, DOI 10.1001/jama.271.5.389; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; Kent ASH, 1998, GYNAECOL ENDOSC, V7, P273, DOI 10.1046/j.1365-2508.1998.00199.x; KHAN K, 2001, UNDERTAKING SYSTEMAT; Khan KS, 1999, AM J OBSTET GYNECOL, V181, P112, DOI 10.1016/S0002-9378(99)70445-X; Khan KS, 2001, EUR J OBSTET GYN R B, V95, P6, DOI 10.1016/S0301-2115(00)00463-2; Kovar P, 2000, Ceska Gynekol, V65, P447; Krampl E, 2001, ACTA OBSTET GYN SCAN, V80, P616, DOI 10.1034/j.1600-0412.2001.800706.x; Kun K Y, 1999, J Obstet Gynaecol Res, V25, P119; LASALA GB, 1987, ACTA OBSTET GYN SCAN, P1; Lijmer JG, 1999, JAMA-J AM MED ASSOC, V282, P1061, DOI 10.1001/jama.282.11.1061; LITTA P, 1996, ITAL J OBSTET GYNAEC, V8, P22; LIU Y, 1905, CHUNG HUA FU CHAN KO, V30, P732; Lo KWK, 2000, J AM ASSOC GYN LAP, V7, P381, DOI 10.1016/S1074-3804(05)60482-3; Longacre Teri A., 1995, P421; LOSSA A, 1991, TUMORI, V77, P479; Loverro G, 1996, MATURITAS, V25, P187, DOI 10.1016/S0378-5122(96)01064-X; Loverro G, 1999, MATURITAS, V33, P139, DOI 10.1016/S0378-5122(99)00023-7; LUO QD, 1989, CHUNG HUA FU CHAN KO, V24, P150; Madan SM, 2001, SAUDI MED J, V22, P153; Maia H, 1996, INT J GYNECOL OBSTET, V52, P61, DOI 10.1016/0020-7292(95)02577-4; Maia H, 1998, GYNAECOL ENDOSC, V7, P319, DOI 10.1046/j.1365-2508.1998.00207.x; McAlister FA, 1999, LANCET, V354, P1721, DOI 10.1016/S0140-6736(99)01174-5; MENCAGLIA L, 1987, J REPROD MED, V32, P577; MENCAGLIA L, 1995, OBSTET GYN CLIN N AM, V22, P573; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; Mortakis AE, 1997, J AM ASSOC GYN LAP, V4, P449, DOI 10.1016/S1074-3804(05)80037-4; MOTASHAW ND, 1990, J REPROD MED, V35, P616; Nagele F, 1996, OBSTET GYNECOL, V88, P87, DOI 10.1016/0029-7844(96)00108-1; *NAT CANC GUID STE, 2002, GUID COMM CANC SERV; Neis K J, 1986, Acta Eur Fertil, V17, P445; Neumann T, 1994, Rev Chil Obstet Ginecol, V59, P349; Okeahialam M G, 2001, J Obstet Gynaecol, V21, P277; OXMAN AD, 1994, JAMA-J AM MED ASSOC, V272, P1367, DOI 10.1001/jama.272.17.1367; Paschopoulos M, 1997, J AM ASSOC GYN LAP, V4, P465, DOI 10.1016/S1074-3804(05)80040-4; PAUKER SG, 1980, NEW ENGL J MED, V302, P1109, DOI 10.1056/NEJM198005153022003; PAYA V, 1998, CLIN INVEST GINECOL, V25, P111; PEREZMEDINA T, 1994, PROG OBSTET GINECOL, V37, P479; POSSATI G, 1994, ANN NY ACAD SCI, V734, P479, DOI 10.1111/j.1749-6632.1994.tb21779.x; RAJU KS, 1986, BRIT J OBSTET GYNAEC, V93, P1259, DOI 10.1111/j.1471-0528.1986.tb07862.x; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; Rogerson L, 2001, GYNAECOL ENDOSC, V10, P343, DOI 10.1046/j.1365-2508.2001.00471.x; *ROYAL COLL OBST G, 1999, MAN MEN SEC CAR EV B; SACKETT DL, 1997, EVIDENCE BASED MED P, P118; Saidi MH, 1997, AM J OBSTET GYNECOL, V176, P492, DOI 10.1016/S0002-9378(97)70521-0; Salet-Lizee D., 1993, Journal de Gynecologie Obstetrique et Biologie de la Reproduction, V22, P593; SANFELIU F, 1990, PROG OBSTET GINECOL, V33, P44; Sankey SS, 1996, COMMUN STAT SIMULAT, V25, P1031, DOI 10.1080/03610919608813357; Schwarzler P, 1998, ULTRASOUND OBST GYN, V11, P337, DOI 10.1046/j.1469-0705.1998.11050337.x; Serden SP, 2000, OBSTET GYN CLIN N AM, V27, P277, DOI 10.1016/S0889-8545(00)80020-0; Sevcik L, 1998, Ceska Gynekol, V63, P95; Simon P., 1993, Journal de Gynecologie Obstetrique et Biologie de la Reproduction, V22, P141; Smith-Bindman R, 1998, JAMA-J AM MED ASSOC, V280, P1510, DOI 10.1001/jama.280.17.1510; Song FJ, 2001, EVAL HEALTH PROF, V24, P126, DOI 10.1177/01632780122034849; Sousa R, 2001, ACTA OBSTET GYN SCAN, V80, P856, DOI 10.1034/j.1600-0412.2001.080009856.x; Spencer CP, 1999, BRIT J OBSTET GYNAEC, V106, P623, DOI 10.1111/j.1471-0528.1999.tb08358.x; Sterne J. A. C., 2008, SYSTEMATIC REV HLTH, V323, P189, DOI [10.1002/9780470693926.ch11, DOI 10.1002/9780470693926.CH11]; Tahir MM, 1999, BRIT J OBSTET GYNAEC, V106, P1259, DOI 10.1111/j.1471-0528.1999.tb08179.x; Todorova M, 1998, Akush Ginekol (Sofiia), V37, P33; Towbin NA, 1996, AM J OBSTET GYNECOL, V174, P1678, DOI 10.1016/S0002-9378(96)70196-5; Uhiara JE, 1999, GYNAECOL ENDOSC, V8, P99, DOI 10.1046/j.1365-2508.1999.00248.x; Valle RF, 1999, CLIN OBSTET GYNECOL, V42, P276, DOI 10.1097/00003081-199906000-00011; VALLI E, 1995, J AM ASSOC GYN LAP, V2, P279, DOI 10.1016/S1074-3804(05)80109-4; vanBeek EJR, 1996, BRIT J HAEMATOL, V92, P725, DOI 10.1046/j.1365-2141.1996.375911.x; Vercellini P, 1997, HUM REPROD, V12, P1768, DOI 10.1093/humrep/12.8.1768; Vigada G, 1995, Minerva Ginecol, V47, P179; Widrich T, 1996, AM J OBSTET GYNECOL, V174, P1327, DOI 10.1016/S0002-9378(96)70680-4; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93	125	235	252	2	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	2002	288	13					1610	1621		10.1001/jama.288.13.1610	http://dx.doi.org/10.1001/jama.288.13.1610			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	599BJ	12350192				2022-12-28	WOS:000178314000022
J	Stone, JH				Stone, JH			Polyarteritis Nodosa	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFANTILE PERIARTERITIS-NODOSA; HEPATITIS-B VIRUS; PROGNOSTIC FACTORS; IMMUNE-COMPLEXES; DISEASE; NEUROPATHY; VASCULITIS; ARTERITIS; ANTIGEN; ADULT	Polyarteritis nodosa (PAN) is regarded rightly as the grandfather of the vasculitides. In this Grand Rounds, the case of a 30-year-old man with a 12-year illness is described. The patient presented with daily fevers, tachycardia, and cutaneous ulcers on his distal extremities. He eventually developed mononeuritis multiplex. Because of the striking pattern of his fevers, he was diagnosed for many years as having adult-onset Still disease. Following the addition of daily cyclophosphamide to his long-standing regimen of prednisone, the patient's disease entered remission for the first time in more than a decade. He was ultimately able to discontinue all of his immunosuppressive medications. The case is discussed in the context of the first patient ever described with PAN, the classic report of Kussmaul and Maier.	Johns Hopkins Univ, Sch Med, Johns Hopkins Vasculitis Ctr, Div Rheumatol, Baltimore, MD 21224 USA	Johns Hopkins University	Stone, JH (corresponding author), Johns Hopkins Univ, Sch Med, Johns Hopkins Vasculitis Ctr, Div Rheumatol, 5501 Hopkins Bayview Circle,JHAAC 1B-23, Baltimore, MD 21224 USA.							Arkin A, 1930, AM J PATHOL, V6, P401; Blidi M, 1996, ANN MED INTERNE, V147, P304; BYWATERS EG, 1971, ANN RHEUM DIS, V30, P121, DOI 10.1136/ard.30.2.121; CAMERON JS, 1991, BRIT J CLIN PRACT, V45, P50; CHURG J, 1951, AM J PATHOL, V27, P277; DAVSON J, 1948, Q J MED, V17, P175; Dickson WEC, 1908, J PATHOL BACTERIOL, V12, P31, DOI 10.1002/path.1700120107; Ferrari E, 1903, BEITR PATHOL ANAT AL, V34, P350; FYE KH, 1977, AM J MED, V62, P783, DOI 10.1016/0002-9343(77)90884-1; GOCKE DJ, 1970, LANCET, V2, P1149; Griffin JW, 2001, RHEUM DIS CLIN N AM, V27, P751, DOI 10.1016/S0889-857X(05)70233-7; Guillevin L, 1996, MEDICINE, V75, P17, DOI 10.1097/00005792-199601000-00003; Guillevin L, 1998, ARTHRITIS RHEUM, V41, P2100, DOI 10.1002/1529-0131(199812)41:12<2100::AID-ART3>3.3.CO;2-A; GUILLEVIN L, 1995, MEDICINE, V74, P238, DOI 10.1097/00005792-199509000-00002; Guillevin L, 2002, VASCULITIS, P300; Hoffman GS, 1998, ARTHRITIS RHEUM-US, V41, P1521, DOI 10.1002/1529-0131(199809)41:9<1521::AID-ART2>3.0.CO;2-A; HOLSINGER DR, 1962, CIRCULATION, V25, P610, DOI 10.1161/01.CIR.25.4.610; HUNDER GG, 1975, ANN INTERN MED, V82, P613, DOI 10.7326/0003-4819-82-5-613; JENNETTE JC, 1994, ARTHRITIS RHEUM-US, V37, P187, DOI 10.1002/art.1780370206; Klinger H, 1931, FRANKFURT Z PATHOL, V42, P455; KURLAND LT, 1984, EPIDEMIOLOGY RHEUMAT, P196; KUSSMAUL A, 1866, DTSCH ARCH KLIN MED, V1, P125; KUSSMAUL A, 1866, DTSCH ARCH KLIN MED, V1, P4841; LAM KC, 1981, NEW ENGL J MED, V304, P380, DOI 10.1056/NEJM198102123040702; LANDING BH, 1977, PEDIATRICS, V59, P651; Levine SM, 2002, AM J MED, V112, P386, DOI 10.1016/S0002-9343(01)01131-7; Mandell Brian F., 1998, Current Opinion in Rheumatology, V10, P51, DOI 10.1097/00002281-199801000-00008; Matteson EL, 1999, ARTHRIT CARE RES, V12, P294, DOI 10.1002/1529-0131(199908)12:4<294::AID-ART8>3.3.CO;2-Y; MATTESON EL, 1996, POLYARTERITIS NODOSA; MCMAHON BJ, 1989, HEPATOLOGY, V9, P97, DOI 10.1002/hep.1840090116; POUCHOT J, 1991, MEDICINE, V70, P118, DOI 10.1097/00005792-199103000-00004; SACK M, 1975, J RHEUMATOL, V2, P411; SAID G, 1988, ANN NEUROL, V23, P461, DOI 10.1002/ana.410230506; SCHRADER ML, 1985, AM HEART J, V109, P1353, DOI 10.1016/0002-8703(85)90365-5; SCOTT DGI, 1982, Q J MED, V203, P292; Still G F, 1897, Med Chir Trans, V80, P47; Stone JH, 2001, CURR OPIN RHEUMATOL, V13, P23, DOI 10.1097/00002281-200101000-00005; TANAKA N, 1976, ARCH PATHOL LAB MED, V100, P81; TSUKADA N, 1983, J NEUROL SCI, V61, P193, DOI 10.1016/0022-510X(83)90005-9; VONROKITANSKY K, 1852, DENKSCHRIFTEN KAI MN, V4, P1; WATTS RA, 1995, SEMIN ARTHRITIS RHEU, V25, P28, DOI 10.1016/S0049-0172(95)80015-8; Wohlwill F, 1923, ARCH PATHOL ANAT, V246, P377	42	52	57	1	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	2002	288	13					1632	1639		10.1001/jama.288.13.1632	http://dx.doi.org/10.1001/jama.288.13.1632			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	599BJ	12350194				2022-12-28	WOS:000178314000024
J	Shlipak, MG; Heidenreich, PA; Noguchi, H; Chertow, GM; Browner, WS; McClellan, MB				Shlipak, MG; Heidenreich, PA; Noguchi, H; Chertow, GM; Browner, WS; McClellan, MB			Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients	ANNALS OF INTERNAL MEDICINE			English	Article							QUALITY-OF-CARE; CARDIOVASCULAR-DISEASE; MEDICARE PATIENTS; TERM MORTALITY; BETA-BLOCKERS; RISK; EVENTS; PREDICTION; INHIBITORS; SURVIVAL	Background: Patients with end-stage renal disease are known to have decreased survival after myocardial infarction, but the association of less severe renal dysfunction with survival after myocardial infarction is unknown. Objectives: To determine how patients with renal insufficiency are treated during hospitalization for myocardial infarction and to determine the association of renal insufficiency with survival after myocardial infarction. Design: Cohort study. Setting: All nongovernment hospitals in the United States. Patients: 130 099 elderly patients with myocardial infarction hospitalized between April 1994 and July 1995. Measurements: Patients were categorized according to initial serum creatinine level: no renal insufficiency (creatinine level < 1.5 mg/dL [<132 mumol/L];. n = 82 455), mild renal insufficiency (creatinine level, 1.5 to 2.4 mg/dL [132 to 212 mumol/L]; n = 36 756), or moderate renal insufficiency (creatinine level, 2.5 to 3.9 mg/dL (221 to 345 mumol/L); n = 10 888). Vital status up to 1 year after discharge was obtained from Social Security records. Results: Compared with patients with no renal insufficiency, patients with moderate renal insufficiency were less likely to receive aspirin, beta-blockers, thrombolytic therapy, angiography, and angioplasty during hospitalization. One-year mortality was 24% in patients with no renal insufficiency, 46% in patients with mild renal insufficiency, and 66% in patients with moderate renal insufficiency (P < 0.001). After adjustment for patient and treatment characteristics, mild (hazard ratio, 1.68 [95% CI, 1.63 to 1.73]) and moderate (hazard ratio, 2.35 [CI 2.26 to 2.45]) renal insufficiency were associated with substantially elevated risk for death during the first month of follow-up. This increased mortality risk continued until 6 months after myocardial infarction. Conclusions: Renal insufficiency was an independent risk factor for death in elderly patients after myocardial infarction. Targeted interventions may be needed to improve treatment for this high-risk population.	Vet Affairs Med Ctr, Gen Internal Med Sect, San Francisco, CA 94121 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Palo Alto Vet Affairs Med Ctr, Palo Alto, CA USA; Stanford Univ, Palo Alto, CA 94304 USA; Toyo Eiwa Univ, Kanagawa, Japan	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; Stanford University	Shlipak, MG (corresponding author), Vet Affairs Med Ctr, Gen Internal Med Sect, 111A1,4150 Clement St, San Francisco, CA 94121 USA.	shlip@itsa.ucsf.edu	Noguchi, Haruko/ABF-3059-2020; Heidenreich, Paul/AAU-6864-2021	Noguchi, Haruko/0000-0002-4437-8238; Heidenreich, Paul/0000-0001-7730-8490; Chertow, Glenn/0000-0002-7599-0534	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R03HL068099] Funding Source: NIH RePORTER; NHLBI NIH HHS [R03 HL68099-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1998, Am J Kidney Dis, V32, pS1; BROWNER WS, 1992, JAMA-J AM MED ASSOC, V268, P228, DOI 10.1001/jama.268.2.228; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Cox D. R., 1984, ANAL SURVIVAL DATA; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; Fitzmaurice GM, 1997, BIOMETRICS, V53, P110, DOI 10.2307/2533101; Foley RN, 1998, AM J KIDNEY DIS, V32, pS112, DOI 10.1053/ajkd.1998.v32.pm9820470; Frances CD, 2000, ARCH INTERN MED, V160, P2645, DOI 10.1001/archinte.160.17.2645; Herlitz J, 1998, CARDIOLOGY, V90, P110, DOI 10.1159/000006828; Herzog CA, 1999, KIDNEY INT, V56, pS130, DOI 10.1046/j.1523-1755.1999.07132.x; Herzog CA, 1999, KIDNEY INT, V56, P324, DOI 10.1046/j.1523-1755.1999.00540.x; Herzog CA, 1998, NEW ENGL J MED, V339, P799, DOI 10.1056/NEJM199809173391203; Hjalmarson A, 1999, LANCET, V353, P2001; Jacobs DR, 1999, CIRCULATION, V100, P599, DOI 10.1161/01.CIR.100.6.599; Krumholz HM, 1998, JAMA-J AM MED ASSOC, V280, P623, DOI 10.1001/jama.280.7.623; Lechat P, 1999, LANCET, V353, P9; Lee TH, 1999, CIRCULATION, V100, P1043, DOI 10.1161/01.CIR.100.10.1043; Mann JFE, 2001, ANN INTERN MED, V134, P629, DOI 10.7326/0003-4819-134-8-200104170-00007; Marciniak TA, 1998, JAMA-J AM MED ASSOC, V279, P1351, DOI 10.1001/jama.279.17.1351; Meng X L, 1997, Stat Methods Med Res, V6, P3, DOI 10.1191/096228097675663031; Normand SLT, 1996, JAMA-J AM MED ASSOC, V275, P1322, DOI 10.1001/jama.275.17.1322; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; Ryan TJ, 1996, J AM COLL CARDIOL, V28, P1328; Samuels LE, 1996, J CARDIAC SURG, V11, P128, DOI 10.1111/j.1540-8191.1996.tb00026.x; Samuels LE, 1996, J CARDIOVASC SURG, V11, P134; Shlipak MG, 2001, J AM COLL CARDIOL, V38, P705, DOI 10.1016/S0735-1097(01)01450-4; Shlipak MG, 2001, AM J MED, V110, P425, DOI 10.1016/S0002-9343(01)00652-0; SIEGEL D, 1988, ANN INTERN MED, V109, P213, DOI 10.7326/0003-4819-109-3-213; Wheeler DC, 1996, LANCET, V348, P1673, DOI 10.1016/S0140-6736(05)65816-3; Yusuf S, 2000, NEW ENGL J MED, V342, P145	30	436	462	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	2002	137	7					555	562		10.7326/0003-4819-137-7-200210010-00006	http://dx.doi.org/10.7326/0003-4819-137-7-200210010-00006			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	599VD	12353942				2022-12-28	WOS:000178355100001
J	Sly, PD; Holt, PG				Sly, PD; Holt, PG			Breast is best for preventing asthma and allergies - or is it?	LANCET			English	Editorial Material									Telethon Inst Child Hlth Res, Perth, WA 6872, Australia; Ctr Child Hlth Res, Perth, WA 6872, Australia	Telethon Kids Institute; University of Western Australia; University of Western Australia	Sly, PD (corresponding author), Telethon Inst Child Hlth Res, Perth, WA 6872, Australia.	peters@ichr.uwa.edu.au	Holt, Patrick G/H-1548-2011; Sly, Peter D/F-1486-2010	Holt, Patrick G/0000-0003-1193-0935; Sly, Peter D/0000-0001-6305-2201				BUCKFIELD PM, 1978, NEW ZEAL MED J, V88, P244; HIDE DW, 1985, PEDIATRICS, V76, P973; Holt PG, 1999, NATURE, V402, pB12; Johnston SL, 1998, ALLERGY, V53, P922, DOI 10.1111/j.1398-9995.1998.tb03792.x; NEWNHAM JP, 1993, LANCET, V342, P887, DOI 10.1016/0140-6736(93)91944-H; Oddy WH, 1999, BMJ-BRIT MED J, V319, P815, DOI 10.1136/bmj.319.7213.815; Oddy WH, 2002, EUR RESPIR J, V19, P899, DOI 10.1183/09031936.02.00103602; Wright AL, 2001, THORAX, V56, P192, DOI 10.1136/thorax.56.3.192	8	19	19	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 21	2002	360	9337					887	888		10.1016/S0140-6736(02)11068-3	http://dx.doi.org/10.1016/S0140-6736(02)11068-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	596AU	12354466				2022-12-28	WOS:000178142200003
J	Chapin, DM; Cohen, KP; Davis, WK; Kintner, EE; Koch, LJ; Landis, JW; Levenson, M; Mandil, IH; Pate, ZT; Rockwell, T; Schriesheim, A; Simpson, JW; Squire, A; Starr, C; Stone, HE; Taylor, JJ; Todreas, NE; Wolfe, B; Zebroski, EL				Chapin, DM; Cohen, KP; Davis, WK; Kintner, EE; Koch, LJ; Landis, JW; Levenson, M; Mandil, IH; Pate, ZT; Rockwell, T; Schriesheim, A; Simpson, JW; Squire, A; Starr, C; Stone, HE; Taylor, JJ; Todreas, NE; Wolfe, B; Zebroski, EL			Nuclear safety - Nuclear power plants and their fuel as terrorist targets	SCIENCE			English	Editorial Material							BIOLOGIC RESPONSES; IONIZING-RADIATION; DOSE RESPONSES; DETRIMENT		MPR Associates Inc, Alexandria, VA 22314 USA; GE Co, Nucl Energy Grp, Schenectady, NY 12301 USA; Publ Safety Stand Grp, Weston, MA 02198 USA; WANO, Atlanta, GA 30339 USA; Argonne Natl Lab, Argonne, IL 60439 USA; Westinghouse Elect Corp, Pittsburgh, PA 15222 USA; Elect Power Res Inst, Palo Alto, CA 94393 USA; MIT, Cambridge, MA 02139 USA	General Electric; United States Department of Energy (DOE); Argonne National Laboratory; Paramount Global; Electric Power Research Institute (EPRI); Massachusetts Institute of Technology (MIT)	Rockwell, T (corresponding author), MPR Associates Inc, Alexandria, VA 22314 USA.	tedrock@cpcug.org						BRUES AM, 1958, SCIENCE, V128, P693, DOI 10.1126/science.128.3326.693; COLE N, 1985, TMI 2 LEARNING EXPER; DIAZ N, 2002, AM NUCL SOC C HOLL F; *DOE EIS, 2002, DOEEIS0250; Feinendegen LE, 2001, J NUCL MED, V42, p17N; Gerber LM, 1999, Q REV BIOL, V74, P273, DOI 10.1086/393162; HENDERSON B, 2001, SAN FRANCISCO C 1005, pA6; HENRY HF, 1961, JAMA-J AM MED ASSOC, V176, P671, DOI 10.1001/jama.1961.63040210001004; Jaworowski Z, 1999, PHYS TODAY, V52, P24, DOI 10.1063/1.882810; Jaworowski Z, 2001, SCIENCE, V293, P605; Kemeny J., 1979, NEED CHANGE LEGACY T; Luckey TD, 1991, RAD HORMESIS; Luckey TD, 1980, HORMESIS IONIZING RA; MUCKERHEIDE J, 1998, LOW LEV RAD HLTH EFF; *NCRP, 94 NCRP; NELSON D, 2001, ONEWORLD UK; *ORG EC COOP DEV, 1993, 3 MIL ISL REACT PRES; Pollycove M, 2001, J NUCL MED, V42, p26N; Service RF, 2001, SCIENCE, V291, P426, DOI 10.1126/science.291.5503.426; SMITH BC, 2002, TECH            0501; SPRUNG JL, 2000, NUREGCR6672 SAND NAT; *UN SCI COMM EFF A, CHERN ACC, V2; *UN SCI COMM EFF A, CHERN ACC, V1, P13; UNICEF, 2002, HUMAN CONSEQUENCES C; United Nations Scientific Committee on the Effects of Atomic Radiation. Sources and effects of ionizing radiation, 2000, SOURC EFF ION RAD UN; US Environmental Protection Agency, 2000, FED REG         1207, V65, P76708; WALINDER G, 1995, HAS RAD PROTECTION H; Williams D, 2002, NAT REV CANCER, V2, P543, DOI 10.1038/nrc845; YALOW RS, 1988, SCIENTIST, V2, P11; 2002, ASS PRESS       0805; 2000, FED REG         0421, V65, P21576	31	9	9	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 20	2002	297	5589					1997	+		10.1126/science.1077855	http://dx.doi.org/10.1126/science.1077855			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	594XV	12242425				2022-12-28	WOS:000178078500026
J	Tang, J; Xu, YJ; McKellar, ARW; Jager, W				Tang, J; Xu, YJ; McKellar, ARW; Jager, W			Quantum solvation of carbonyl sulfide with helium atoms	SCIENCE			English	Article							INFRARED-SPECTRUM; OCS; SPECTROSCOPY; MOLECULES; CLUSTER; COMPLEX; MODEL; HE-4	High-resolution infrared and microwave spectra of He-N-carbonyl sulfide (He-N-OCS) clusters with N ranging from 2 to 8 have been detected and unambiguously assigned. The spectra show the formation of a solvation layer beginning with an equatorial "donut" of five helium atoms around the OCS molecule. The cluster moment of inertia increases as a function of N and overshoots the liquid droplet limit for N > 5, implying that even atoms in the first solvation shell are decoupled from the OCS rotation in helium nanodroplets. To the extent that this is due to superfluidity, the results directly explore the microscopic evolution of a phenomenon that is formally macroscopic in nature.	Natl Res Council Canada, Steacie Inst Mol Sci, Ottawa, ON K1A 0R6, Canada; Univ Alberta, Dept Chem, Edmonton, AB T6G 2G2, Canada	National Research Council Canada; University of Alberta	McKellar, ARW (corresponding author), Natl Res Council Canada, Steacie Inst Mol Sci, 100 Sussex Dr, Ottawa, ON K1A 0R6, Canada.	wolfgang.jaeger@ualberta.ca	TANG, Jian/B-2574-2011	TANG, Jian/0000-0003-1488-2385				Babichenko VS, 1999, PHYS REV LETT, V83, P3458, DOI 10.1103/PhysRevLett.83.3458; Callegari C, 1999, PHYS REV LETT, V83, P5058, DOI 10.1103/PhysRevLett.83.5058; Callegari C, 2001, J CHEM PHYS, V115, P10090, DOI 10.1063/1.1418746; CEPERLEY DM, 1995, REV MOD PHYS, V67, P279, DOI 10.1103/RevModPhys.67.279; Even U, 2001, J CHEM PHYS, V115, P2069, DOI 10.1063/1.1385154; Gianturco FA, 2000, J CHEM PHYS, V113, P3011, DOI 10.1063/1.1287055; Grebenev S, 2000, J CHEM PHYS, V112, P4485, DOI 10.1063/1.481011; Grebenev S, 1998, SCIENCE, V279, P2083, DOI 10.1126/science.279.5359.2083; HARTMANN M, 1995, PHYS REV LETT, V75, P1566, DOI 10.1103/PhysRevLett.75.1566; Hernandez MI, 2000, J CHEM PHYS, V113, P7252, DOI 10.1063/1.1313786; Higgins K, 1999, J CHEM PHYS, V110, P1383, DOI 10.1063/1.478013; Howson JMM, 2001, J CHEM PHYS, V115, P5059, DOI 10.1063/1.1394940; Kwon Y, 2000, J CHEM PHYS, V113, P6469, DOI 10.1063/1.1310608; Lee E, 1999, PHYS REV LETT, V83, P3812, DOI 10.1103/PhysRevLett.83.3812; MAKI AG, 1991, NAT I STAND TECHN SP, V821; Markov VN, 1998, REV SCI INSTRUM, V69, P4061, DOI 10.1063/1.1149251; Nauta K, 2001, SCIENCE, V292, P481, DOI 10.1126/science.1058896; Paesani F, 2001, J CHEM PHYS, V115, P10225, DOI 10.1063/1.1412873; Stace A, 2001, SCIENCE, V294, P1292, DOI 10.1126/science.1066731; Tang J, 2001, J CHEM PHYS, V115, P3053, DOI 10.1063/1.1386920; Watson J. K. G., 1977, VIBRATIONAL SPECTRA, P1; Xia CB, 2000, J CHEM PHYS, V113, P525, DOI 10.1063/1.481912; Xu YJ, 1997, J CHEM PHYS, V106, P7968, DOI 10.1063/1.473808; Xu YJ, 2001, CHEM PHYS LETT, V350, P417, DOI 10.1016/S0009-2614(01)01314-8	24	187	189	0	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 20	2002	297	5589					2030	2033		10.1126/science.1073718	http://dx.doi.org/10.1126/science.1073718			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	594XV	12242436				2022-12-28	WOS:000178078500039
J	McLellan, F				McLellan, F			Academic freedom or speaking with the enemy?	LANCET			English	Article														McLellan, Faith/0000-0003-0744-1450				Cello J, 2002, SCIENCE, V297, P1016, DOI 10.1126/science.1072266	1	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 7	2002	360	9335					731	731		10.1016/S0140-6736(02)09937-3	http://dx.doi.org/10.1016/S0140-6736(02)09937-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	592HX	12296301	Bronze			2022-12-28	WOS:000177933000003
J	Vidal, J				Vidal, J			Ten years on - slow progress on sustainable development	LANCET			English	Article																			0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 7	2002	360	9335					737	737		10.1016/S0140-6736(02)09942-7	http://dx.doi.org/10.1016/S0140-6736(02)09942-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	592HX	12296306				2022-12-28	WOS:000177933000009
J	Vichinsky, E				Vichinsky, E			New therapies in sickle cell disease	LANCET			English	Review							ERYTHROCYTE DEHYDRATION; FETAL HEMOGLOBIN; GENE-THERAPY; ENDOTHELIUM; ADHESION; ANEMIA; TRANSFUSION; INHIBITION; INDUCTION; REDUCTION	New therapies have evolved from our improved understanding of the biology of sickle cell disease (SCD) and the availability of a useful transgenic animal model. Several therapeutic options are available that interrupt the sickling process at various key pathways. Nitric oxide (NO) is a critical factor in the pathophysiology of SCD and is a promising antisickling agent with vasodilation properties. NO regulates blood vessel tone, endothelial adhesion, and the severity of ischaemia reperfusion injury and anaemia in SCD. Although NO is difficult to administer, its precursor. L-arginine, is a oral supplement. Starting point J R Romero and colleagues recently demonstrated in sickle transgenic mice that oral arginine supplementation induced NO production and reduced red cell density by inhibiting the Gardos channel, which modulates cell hydration and polymerisation of haemoglobin S (Blood 2002; 99: 1103-08). Haemoglobinopathies can be cured by stem-cell transplantation. This therapy is now accepted treatment in symptomatic children. However, most patients lack a genotypically identical family donor. G La Nasa and colleagues demonstrated unrelated-donor stem-cell transplantation may give similar results to related-donor stem-cell transplantation when extended phenotypic matching is used (Blood 2002 99: 4350-56). This pilot study offers the possibility of cure to patients without a family donor. Where next Although potential opportunities to prevent morbidity in SCD through new therapies are exciting, most patients do not have access to standard multidisciplinary specialty care. Patients require both.	Childrens Hosp Oakland, Dept Hematol Oncol, Oakland, CA 94609 USA	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland	Vichinsky, E (corresponding author), Childrens Hosp Oakland, Dept Hematol Oncol, Oakland, CA 94609 USA.		Vichinsky, Elliott P/F-8541-2011	Vichinsky, Elliott P/0000-0002-0500-9579				Atweh GF, 2001, SEMIN HEMATOL, V38, P367, DOI 10.1053/shem.2001.27566; Brugnara C, 1996, J CLIN INVEST, V97, P1227, DOI 10.1172/JCI118537; Brugnara C, 2001, SEMIN HEMATOL, V38, P324, DOI 10.1053/shem.2001.27568; CHARACHE S, 1995, NEW ENGL J MED, V332, P1317, DOI 10.1056/NEJM199505183322001; DeFranceschi L, 1997, J CLIN INVEST, V100, P1847, DOI 10.1172/JCI119713; Hebbel RP, 2000, NEW ENGL J MED, V342, P1910, DOI 10.1056/NEJM200006223422512; HEBBEL RP, 1980, NEW ENGL J MED, V302, P992, DOI 10.1056/NEJM198005013021803; Hillery CA, 1996, BLOOD, V87, P4879, DOI 10.1182/blood.V87.11.4879.bloodjournal87114879; Koshy M, 2000, BLOOD, V96, P2379, DOI 10.1182/blood.V96.7.2379.h8002379_2379_2384; Kumar A, 1996, AM J HEMATOL, V53, P92, DOI 10.1002/(SICI)1096-8652(199610)53:2<92::AID-AJH6>3.0.CO;2-Z; La Nasa G, 2002, BLOOD, V99, P4350, DOI 10.1182/blood.V99.12.4350; LEFKOVITS J, 1995, CURR OPIN CARDIOL, V10, P420, DOI 10.1097/00001573-199507000-00012; MANKAD VN, 2001, PEDIAT PATHOLOGY MOL; Morris CR, 2000, BRIT J HAEMATOL, V111, P498, DOI 10.1046/j.1365-2141.2000.02403.x; Morrow N, 2000, J VOLCANOL GEOTH RES, V96, P1, DOI 10.1016/S0377-0273(99)00143-2; Nietert PJ, 2000, BLOOD, V95, P3057; Orringer EP, 2001, JAMA-J AM MED ASSOC, V286, P2099, DOI 10.1001/jama.286.17.2099; Pawliuk R, 2001, SCIENCE, V294, P2368, DOI 10.1126/science.1065806; Romero JR, 2002, BLOOD, V99, P1103, DOI 10.1182/blood.V99.4.1103; Solovey AA, 2001, BLOOD, V97, P1937, DOI 10.1182/blood.V97.7.1937; STYLES LA, 1994, J PEDIATR-US, V125, P909, DOI 10.1016/S0022-3476(05)82006-2; Tisdale J, 2001, SEMIN HEMATOL, V38, P382, DOI 10.1053/shem.2001.27571; Tomer A, 2001, J LAB CLIN MED, V137, P398, DOI 10.1067/mlc.2001.115450; Tomer A, 2001, THROMB HAEMOSTASIS, V85, P966, DOI 10.1055/s-0037-1615948; Udani M, 1998, J CLIN INVEST, V101, P2550, DOI 10.1172/JCI1204; Walters MC, 2001, BIOL BLOOD MARROW TR, V7, P665, DOI 10.1053/bbmt.2001.v7.pm11787529	26	50	51	0	9	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 24	2002	360	9333					629	631		10.1016/S0140-6736(02)09776-3	http://dx.doi.org/10.1016/S0140-6736(02)09776-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	586TD	12241949				2022-12-28	WOS:000177600400026
J	Mahoney, EM; Jurkovitz, CT; Chu, HT; Becker, ER; Culler, S; Kosinski, AS; Robertson, DH; Alexander, C; Nag, S; Cook, JR; Demopoulos, LA; DiBattiste, PM; Cannon, CP; Weintraub, WS				Mahoney, EM; Jurkovitz, CT; Chu, HT; Becker, ER; Culler, S; Kosinski, AS; Robertson, DH; Alexander, C; Nag, S; Cook, JR; Demopoulos, LA; DiBattiste, PM; Cannon, CP; Weintraub, WS		TACTICS-TIMI 18 Investigators	Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE CORONARY SYNDROMES; THROMBOLYTIC THERAPY; RANDOMIZED TRIAL; TIROFIBAN; MANAGEMENT	Context In the Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy (TACTICS)-Thrombolysis in Myocardial Infarction (TIMI) 18 trial, patients with either unstable angina or non-ST-segment elevation myocardial infarction (UA/NSTEMI) treated with the platelet glycoprotein (Gp IIb/IIIa) inhibitor tirofiban had a significantly reduced rate of major cardiac events at 6 months with an early invasive vs a conservative strategy. Objective To examine total 6-month costs and long-term cost-effectiveness of an invasive vs a conservative strategy. Design Randomized controlled trial including a priori economic end points. Setting Hospitalization for UA/NSTEMI with 6-month follow-up period. Patients A total of 2220 patients with UA/NSTEMI; economic data from 1722 patients at US-non-VA hospitals. Intervention Early invasive strategy with routine catheterization and revascularization as appropriate vs a conservative strategy with catheterization performed only for recurrent ischemia or a positive stress test. Main Outcome Measure Total 6-month costs and incremental cost-effectiveness ratio. Results The average initial hospitalization costs among those in the invasive strategy group were $15 714 vs $14 047 among those in the conservative stategy group, a difference of $1667 (95% confidence interval [CI], $387-3091). The in-hospital costs were offset significantly at the 6-month follow-up, with an average cost in the invasive group of $6098 vs $7180 in the conservative group, a difference of $1082 (95% Cl, -$2051 to $76). The average total costs at 6 months, including productivity costs, for the invasive group was $21813 vs $21227 for the conservative group, a $586 difference (95% Cl, -$1087 to $2486). The average 6-month costs excluding productivity costs in the invasive group Was $19780 vs $19111 in the conservative group, a difference of $670, 95% Cl; (-$1035 to $2321). Estimated cost per year of life gained for the invasive strategy, based on projected life expectancy, was $12 739 for the base case, and ranged from $8371 to $25769, based on model assumptions. Conclusions In patients with UA/NSTEMI treated with the Gp IIb/IIIa inhibitor tirofiban, the clinical benefit of an early invasive strategy was achieved with a small increase in cost, yielding favorable projected estimates of cost per year of life gained. These results support the broader use of an early invasive strategy in these patients.	Emory Univ, Sch Med, Dept Med, Div Cardiol,Emory Ctr Outcomes Res, Atlanta, GA 30306 USA; Emory Univ, Rollins Sch Publ Hlth, Dept Hlth Policy & Management, Atlanta, GA 30322 USA; Emory Univ, Rollins Sch Publ Hlth, Dept Biostat, Atlanta, GA 30322 USA; Merck & Co Inc, W Point, PA USA; Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA	Emory University; Emory University; Rollins School Public Health; Emory University; Rollins School Public Health; Merck & Company; Harvard University; Brigham & Women's Hospital	Mahoney, EM (corresponding author), Emory Univ, Sch Med, Dept Med, Div Cardiol,Emory Ctr Outcomes Res, 1256 Briarcliff Rd,Suite 1N, Atlanta, GA 30306 USA.		Cannon, Christopher P/AAY-7644-2020; Chu, Haitao/J-7576-2012	Cannon, Christopher P/0000-0003-4596-2791; Culler, Steven/0000-0002-6905-1186; Jurkovitz, Claudine/0000-0002-8957-0100; Chu, Haitao/0000-0003-0932-598X				Barnett PG, 2002, CIRCULATION, V105, P680, DOI 10.1161/hc0602.103584; Boden WE, 1998, NEW ENGL J MED, V338, P1785, DOI 10.1056/NEJM199806183382501; BRAUNWALD E, 1994, CIRCULATION, V89, P1545; Braunwald E, 2000, J AM COLL CARDIOL, V36, P970, DOI 10.1016/S0735-1097(00)00889-5; BRAUNWALD E, 2002, ACC AHA 2002 GUIDELI; Cannon CP, 1998, AM J CARDIOL, V82, P731, DOI 10.1016/S0002-9149(98)00540-2; Cannon CP, 2001, NEW ENGL J MED, V344, P1879, DOI 10.1056/NEJM200106213442501; Efron B., 1994, MONOGRAPHS STAT APPL; Feeny D. H., 1996, QUALITY LIFE PHARMAC, V2, P239; FIELLER EC, 1954, J ROY STAT SOC B, V16, P175; *HCIA, 1999, PROV SOFTW; Janzon M, 2002, EUR HEART J, V23, P31, DOI 10.1053/euhj.2001.2695; Mark DB, 2000, CIRCULATION, V101, P366, DOI 10.1161/01.CIR.101.4.366; MARK DB, 1995, NEW ENGL J MED, V332, P1418, DOI 10.1056/NEJM199505253322106; Mark DB, 2002, CIRCULATION, V105, P666, DOI 10.1161/circ.105.6.666; *MATHS, 2000, S PLUS 2000 WIND COM; McCullough PA, 1998, J AM COLL CARDIOL, V32, P596, DOI 10.1016/S0735-1097(98)00284-8; *MICR, 2000, RED BOOK WIND COMP P; MITCHELL JB, US DEPT COMMERCE NAT; Morrow DA, 2001, JAMA-J AM MED ASSOC, V286, P2405, DOI 10.1001/jama.286.19.2405; *NAT CTR HLTH STAT, 1998, DET DIAGN PROC NAT H, P13; Peeters A, 2002, EUR HEART J, V23, P458, DOI 10.1053/euhj.2001.2838; *SAS I INC, 2001, SAS PROC MI PROC MIA; *US BUR LAB STAT B, 2001, ANN DEM SURV S; Wallentin L, 1999, LANCET, V354, P708; Weintraub WS, 1999, AM J CARDIOL, V83, P317, DOI 10.1016/S0002-9149(98)00860-1	27	102	107	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 16	2002	288	15					1851	1858		10.1001/jama.288.15.1851	http://dx.doi.org/10.1001/jama.288.15.1851			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604EU	12377083	Bronze			2022-12-28	WOS:000178604200023
J	Meegaskumbura, M; Bossuyt, F; Pethiyagoda, R; Manamendra-Arachchi, K; Bahir, M; Milinkovitch, MC; Schneider, CJ				Meegaskumbura, M; Bossuyt, F; Pethiyagoda, R; Manamendra-Arachchi, K; Bahir, M; Milinkovitch, MC; Schneider, CJ			Sri Lanka: An amphibian hot spot	SCIENCE			English	Article									Boston Univ, Dept Biol, Boston, MA 02215 USA; Wildlife Heritage Trust, Colombo 8, Sri Lanka; Free Univ Brussels, Dept Biol, Unit Ecol & Systemat, B-1050 Brussels, Belgium; Inst Mol BIol & Med, Unit Evolut Genet, B-6041 Gosselies, Belgium	Boston University; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Schneider, CJ (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.	cschneid@bu.edu	Pethiyagoda, Rohan/C-2307-2009; Meegaskumbura, Madhava/F-8782-2013	Meegaskumbura, Madhava/0000-0002-4599-6724; Pethiyagoda, Rohan/0000-0001-7215-9617; Milinkovitch, Michel/0000-0002-2553-0724; Bossuyt, Franky/0000-0001-6804-9271				Bossuyt F, 2000, P NATL ACAD SCI USA, V97, P6585, DOI 10.1073/pnas.97.12.6585; Bossuyt F., 2001, ZEYLANICA, V6, P1; Dutta SK, 1996, AMPHIBIAN FAUNA SRI; Glaw Frank, 1998, Herpetological Review, V29, P11; Inger RF, 1999, PATTERNS OF DISTRIBUTION OF AMPHIBIANS: A GLOBAL PERSPECTIVE, P445; Kiesecker JM, 2001, NATURE, V410, P681, DOI 10.1038/35070552; Pethiyagoda R, 1998, OCC PAP WILDL HERITA, V2, P1	7	165	182	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 11	2002	298	5592					379	379		10.1126/science.298.5592.379	http://dx.doi.org/10.1126/science.298.5592.379			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	602NB	12376694	Green Submitted			2022-12-28	WOS:000178510400038
J	Kumanogoh, A; Marukawa, S; Suzuki, K; Takegahara, N; Watanabe, C; Ch'ng, ES; Ishida, I; Fujimura, H; Sakoda, S; Yoshida, K; Kikutani, H				Kumanogoh, A; Marukawa, S; Suzuki, K; Takegahara, N; Watanabe, C; Ch'ng, ES; Ishida, I; Fujimura, H; Sakoda, S; Yoshida, K; Kikutani, H			Class IV semaphorin Sema4A enhances T-cell activation and interacts with Tim-2	NATURE			English	Article							B-CELL; NONREDUNDANT ROLES; IMMUNE-RESPONSES; MICE REVEAL; GENE FAMILY; CD100; RECEPTOR; GUIDANCE; CD72; IDENTIFICATION	Semaphorins are a family of phylogenetically conserved soluble and transmembrane proteins(1,2). Although many soluble semaphorins deliver guidance cues to migrating axons during neuronal development(3-5), some members are involved in immune responses(6-9). For example, CD100 (also known as Sema4D), a class IV transmembrane semaphorin, signals through CD72 to effect nonredundant roles in immune responses(7,10-13) in a ligand-receptor system that is distinct from any seen previously in the nervous system(14,15). Here we report that the class IV semaphorin Sema4A, which is expressed in dendritic cells and B cells, enhances the in vitro activation and differentiation of T cells and the in vivo generation of antigen-specific T cells. Treating mice with monoclonal antibodies against Sema4A blocks the development of an experimental autoimmune encephalomyelitis that is induced by an antigenic peptide derived from myelin oligodendrocyte glycoprotein. In addition, expression cloning shows that the Sema4A receptor is Tim-2, a member of the family of T-cell immunoglobulin domain and mucin domain (Tim) proteins that is expressed on activated T cells.	Osaka Univ, Microbial Dis Res Inst, Dept Mol Immunol, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Neurol, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Internal Med & Mol Sci, Suita, Osaka 5650871, Japan	Osaka University; Osaka University; Osaka University	Kikutani, H (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Mol Immunol, 3-1 Yamada Oka, Suita, Osaka 5650871, Japan.		Ch'ng, Ewe Seng/F-2630-2010; Kikutani, Hitoshi/C-9525-2009; Suzuki, Kazuhiro/B-3886-2012; Kumanogoh, Atsushi/C-7354-2009; Takegahara, Noriko/AAP-1694-2021	Ch'ng, Ewe Seng/0000-0001-8831-8678; Suzuki, Kazuhiro/0000-0002-9081-538X				Adachi T, 1998, J IMMUNOL, V160, P4662; ALEXANDER BH, 2000, IMMUNITY, V13, P345; Chang TT, 1999, J EXP MED, V190, P733, DOI 10.1084/jem.190.5.733; Comeau MR, 1998, IMMUNITY, V8, P473, DOI 10.1016/S1074-7613(00)80552-X; Delaire S, 1998, CELL MOL LIFE SCI, V54, P1265, DOI 10.1007/s000180050252; Fang DY, 2002, NAT IMMUNOL, V3, P281, DOI 10.1038/ni763; Goodman CS, 1999, CELL, V97, P551, DOI 10.1016/S0092-8674(00)80766-7; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Kumanogoh A, 2002, J IMMUNOL, V169, P1175, DOI 10.4049/jimmunol.169.3.1175; Kumanogoh A, 2001, TRENDS IMMUNOL, V22, P670, DOI 10.1016/S1471-4906(01)02087-7; Kumanogoh A, 2000, IMMUNITY, V13, P621, DOI 10.1016/S1074-7613(00)00062-5; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; McIntire JJ, 2001, NAT IMMUNOL, V2, P1109, DOI 10.1038/ni739; Monney L, 2002, NATURE, V415, P536, DOI 10.1038/415536a; Pan C, 1999, IMMUNITY, V11, P495, DOI 10.1016/S1074-7613(00)80124-7; PUSCHEL AW, 1995, NEURON, V14, P941, DOI 10.1016/0896-6273(95)90332-1; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; Shi W, 2000, IMMUNITY, V13, P633, DOI 10.1016/S1074-7613(00)00063-7; SUDA T, 1994, J EXP MED, V179, P873, DOI 10.1084/jem.179.3.873; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; Tamagnone L, 2000, TRENDS CELL BIOL, V10, P377, DOI 10.1016/S0962-8924(00)01816-X; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Wang XS, 2001, BLOOD, V97, P3498, DOI 10.1182/blood.V97.11.3498; Watanabe C, 2001, J IMMUNOL, V167, P4321, DOI 10.4049/jimmunol.167.8.4321; Xu XM, 1998, J BIOL CHEM, V273, P22428, DOI 10.1074/jbc.273.35.22428; Yu HH, 1999, NEURON, V22, P11, DOI 10.1016/S0896-6273(00)80672-8	27	244	283	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 10	2002	419	6907					629	633		10.1038/nature01037	http://dx.doi.org/10.1038/nature01037			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	602AT	12374982				2022-12-28	WOS:000178483100048
J	Sharon, E; Roman, B; Marder, M; Shin, GS; Swinney, HL				Sharon, E; Roman, B; Marder, M; Shin, GS; Swinney, HL			Mechanics: Buckling cascades in free sheets - Wavy leaves may not depend only on their genes to make their edges crinkle.	NATURE			English	Article									Univ Texas, Ctr Nonlinear Dynam, Austin, TX 78712 USA; Univ Texas, Dept Phys, Austin, TX 78712 USA; Kyung Hee Univ, Dept Phys, Yongin, Kyunggi, South Korea	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; Kyung Hee University	Sharon, E (corresponding author), Univ Texas, Ctr Nonlinear Dynam, Austin, TX 78712 USA.		Roman, Benoit/C-6273-2014; Marder, Michael/GYI-9268-2022	Roman, Benoit/0000-0002-1473-2734; 				ARGON AS, 1989, J MATER SCI, V24, P1207, DOI 10.1007/BF02397049; BenAmar M, 1997, P ROY SOC A-MATH PHY, V453, P729, DOI 10.1098/rspa.1997.0041; DiDonna BA, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.016603; Gioia G, 1997, ADV APPL MECH, V33, P119, DOI 10.1016/S0065-2156(08)70386-7; Kramer EM, 1997, PHYS REV LETT, V78, P1303, DOI 10.1103/PhysRevLett.78.1303; Matan K, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.076101; RAYLEIGH, 1945, THEORY SOUND, V1, P396	7	167	169	3	65	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 10	2002	419	6907					579	579		10.1038/419579a	http://dx.doi.org/10.1038/419579a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	602AT	12374967	Bronze			2022-12-28	WOS:000178483100031
J	Gollust, SE; Hull, SC; Wilfond, BS				Gollust, SE; Hull, SC; Wilfond, BS			Limitations of direct-to-consumer advertising for clinical genetic testing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRESCRIPTION DRUGS; ALZHEIMER-DISEASE; OVARIAN-CANCER; BREAST-CANCER; RISK; PHYSICIANS; PRACTITIONERS; INFORMATION; KNOWLEDGE; MEDICINE	Although direct-to-consumer (DTC) advertisements for pharmaceuticals have been appearing in the mass media for 20 years, DTC advertisements for genetic testing have only recently appeared. Advertisements for genetic testing can provide both consumers and physicians with information about test availability in an expanding market. However, 3 factors limit the value and appropriateness of advertisements: complex information, a complicated social context surrounding genetics, and a lack of consensus about the clinical utility of some tests. Consideration of several advertisements suggests that they overstate the value of genetic testing for consumers' clinical care. Furthermore, advertisements may provide misinformation about genetics, exaggerate consumers' risks, endorse a deterministic relationship between genes and disease, and reinforce associations between diseases and ethnic groups. Advertising motivated by factors other than evidence of the clinical value of genetic tests can manipulate consumers' behavior by exploiting their fears and worries. At this time, DTC advertisements are inappropriate, given the public's limited sophistication regarding genetics and the lack of comprehensive premarket review of tests or oversight of advertisement content. Existing Federal Trade Commission and Food and Drug Administration regulations for other types of health-related advertising should be applied to advertisements for genetic tests.	NHGRI, Med Genet Branch, NIH, Bethesda, MD 20892 USA; NIH, Warren G Magnuson Clin Ctr, Dept Clin Bioeth, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA	Hull, SC (corresponding author), NHGRI, Med Genet Branch, NIH, Bldg 10,Room 1C118,9000 Rockville Pike,MSC 1156, Bethesda, MD 20892 USA.				NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000143] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Azuri J, 1998, GENET TEST, V2, P297, DOI 10.1089/gte.1998.2.297; Bell RA, 1999, J GEN INTERN MED, V14, P651, DOI 10.1046/j.1525-1497.1999.01049.x; Bell RA, 2000, J FAM PRACTICE, V49, P1092; Berger JT, 2001, MT SINAI J MED, V68, P197; *BUR CONS PROT BUR, 1996, MATT DIR CONS PROM; Carson P, 2001, Manag Care, V10, P43; Cho MK, 1999, AM J MED GENET, V83, P157, DOI 10.1002/(SICI)1096-8628(19990319)83:3<157::AID-AJMG4>3.0.CO;2-G; Cho MK, 1997, AM J MED GENET, V73, P314, DOI 10.1002/(SICI)1096-8628(19971219)73:3<314::AID-AJMG16>3.0.CO;2-M; Claus EB, 1996, CANCER, V77, P2318, DOI 10.1002/(SICI)1097-0142(19960601)77:11<2318::AID-CNCR21>3.0.CO;2-Z; COHEN MM, 1994, AM J HUM GENET, V55, pR1; COLLINS FS, 1994, JAMA-J AM MED ASSOC, V271, P785, DOI 10.1001/jama.1994.03510340075038; Condit CM, 1998, AM J HUM GENET, V62, P979, DOI 10.1086/301784; DIJCK JV, 1998, IMAGENATION POPULATI; Eddy DM, 1982, JUDGMENT UNCERTAINTY, P249; Edwards A, 1997, BRIT J GEN PRACT, V47, P739; *FOOD DRUG ADM, ATT BEH ASS DIR CONS; FORD D, 1995, AM J HUM GENET, V57, P1457; FROST, 2001, US GENETIC TESTING M; GELLER G, 1995, QUAL HEALTH RES, V5, P97, DOI 10.1177/104973239500500107; GOODMAN MJ, 1982, HASTINGS CENT REP, V12, P20, DOI 10.2307/3560660; GRAHAM J, 2002, CHICAGO TRIBUNE 0908, P12; Hoffrage U, 2000, SCIENCE, V290, P2261, DOI 10.1126/science.290.5500.2261; HOFMAN KJ, 1993, ACAD MED, V68, P625, DOI 10.1097/00001888-199308000-00013; Hollon MF, 1999, JAMA-J AM MED ASSOC, V281, P382, DOI 10.1001/jama.281.4.382; Holmer AF, 1999, JAMA-J AM MED ASSOC, V281, P380, DOI 10.1001/jama.281.4.380; Holtzman NA, 2000, NEW ENGL J MED, V343, P141, DOI 10.1056/NEJM200007133430213; Holtzman NA, 1999, SCIENCE, V286, P409, DOI 10.1126/science.286.5439.409; Holtzman NA., 1998, PROMOTING SAFE EFFEC; Huang AJ, 2000, JAMA-J AM MED ASSOC, V284, P2240, DOI 10.1001/jama.284.17.2240; Hull SC, 2001, HASTINGS CENT REP, V31, P33, DOI 10.2307/3527555; Hunter A, 1998, CLIN GENET, V53, P447; *IMS HLTH, INT SHAR VOIC COMP M; Juengst ET, 1997, GENET TEST, V1, P189, DOI 10.1089/gte.1997.1.189; Kravitz RL, 2000, JAMA-J AM MED ASSOC, V284, P2244, DOI 10.1001/jama.284.17.2244; Langston AA, 1996, NEW ENGL J MED, V334, P137, DOI 10.1056/NEJM199601183340301; Lee TH, 2002, NEW ENGL J MED, V346, P529, DOI 10.1056/NEJM200202143460715; Lloyd FJ, 2001, ARCH INTERN MED, V161, P2411, DOI 10.1001/archinte.161.20.2411; Marteau TM, 2001, BMJ-BRIT MED J, V322, P1056, DOI 10.1136/bmj.322.7293.1056; McConnell LM, 1999, GENET TEST, V3, P3, DOI 10.1089/gte.1999.3.3; Menasha JD, 2000, MT SINAI J MED, V67, P144; *MYR GEN INC, 2001, MYR GEN LAB EXCL PRE; Nelkin D., 1995, DNA MYSTIQUE GENE CU; Newborn Screening Task Force convened in Washington DC, 2000, PEDIATRICS, V106, P383; Offit K, 1996, J CLIN ONCOL, V14, P1730, DOI 10.1200/JCO.1996.14.5.1730; Peshkin BN, 2001, J CLIN ONCOL, V19, P2555, DOI 10.1200/JCO.2001.19.9.2555; Press N, 2000, NURS ETHICS, V7, P237, DOI 10.1177/096973300000700306; Rosenthal MB, 2002, NEW ENGL J MED, V346, P498, DOI 10.1056/NEJMsa012075; *SECR ADV COMM GEN, 2000, ENH OV GEN TESTS; Senior V, 1999, SOC SCI MED, V48, P1857, DOI 10.1016/S0277-9536(99)00099-4; SLAUGHTER E, 2002, 5 ANN SURVEY CONSUME; Stockdale A, 1999, GENET TEST, V3, P139, DOI 10.1089/gte.1999.3.139; Sugarman J, 1997, JAMA-J AM MED ASSOC, V278, P938, DOI 10.1001/jama.278.11.938; Talamo J, 2000, J REFRACT SURG, V16, P689; Tambor ES, 2002, GENET MED, V4, P31, DOI 10.1097/00125817-200201000-00006; Tanne JH, 1999, BRIT MED J, V319, P805, DOI 10.1136/bmj.319.7213.805; Turney J., 1995, EUROPEAN J GENETICS, V1, P5; Welch HG, 1998, JAMA-J AM MED ASSOC, V280, P1525, DOI 10.1001/jama.280.17.1525; WILFOND BS, 1993, JAMA-J AM MED ASSOC, V270, P2948, DOI 10.1001/jama.270.24.2948; Wolfe SM, 2002, NEW ENGL J MED, V346, P524, DOI 10.1056/NEJM200202143460713; 2001, FIT PREGNANCY    AUG, P39; 2001, NEW JERSEY JEWI 0725, pS5; 2002, GAZETTE         0123, pA8; 2001, SCOTTLEVINS PROMOTIO; FED REG, V64, P400; 2001, COPING           SEP, P31; 2001, HADASSAH MAGAZIN NOV, P25	66	134	136	2	25	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	2002	288	14					1762	1767		10.1001/jama.288.14.1762	http://dx.doi.org/10.1001/jama.288.14.1762			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	602BJ	12365961				2022-12-28	WOS:000178484700030
J	Amiel, S; Beveridge, S; Bradley, C; Gianfrancesco, C; Heller, S; James, P; McKeown, N; Newton, D; Newton, L; Oliver, L; Reid, H; Roberts, S; Robson, S; Rollingson, J; Scott, V; Speight, J; Taylor, C; Thompson, G; Turner, E; Wright, F				Amiel, S; Beveridge, S; Bradley, C; Gianfrancesco, C; Heller, S; James, P; McKeown, N; Newton, D; Newton, L; Oliver, L; Reid, H; Roberts, S; Robson, S; Rollingson, J; Scott, V; Speight, J; Taylor, C; Thompson, G; Turner, E; Wright, F		DAFNE Study Grp	Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							QUESTIONNAIRE; THERAPY; PROGRAM; IMPACT; RISK	Objectives To evaluate whether a course teaching flexible intensive insulin treatment combining dietary freedom and insulin adjustment can improve both glycaemic control and quality of life in type 1 diabetes. Design Randomised design with participants either attending training immediately (immediate DAFNE) or acting as waiting list controls and attending "delayed DAFNE" training 6 months later. Setting Secondary care diabetes clinics in three English health districts. Participants 169 adults with type 1 diabetes and moderate or poor glycaemic control. Main outcome measures Glycated haemoglobin (HbA(1c), severe hypoglycaemia, impact of diabetes on quality of life (ADDQoL). Results At 6 months, HbA(1c) was significantly better in immediate DAFNE patients (mean 8.4%) than in delayed DAFNE patients (9.4%) (t-6.1, P < 0.0001). The impact of diabetes on dietary freedom was significantly improved in immediate DAFNE patients compared with delayed DAFNE patients (t= - 5.4, P < 0.0001), as was the impact of diabetes on overall quality of life (t=2.9, P < 0.01). General wellbeing and treatment satisfaction were also significantly improved, but severe hypoglycaemia, weight, and lipids remained unchanged. Improvements in "present quality of life" did not reach significance at 6 months but were significant by 1 year. Conclusion Skills training promoting dietary freedom improved quality of life and glycaemic control in people with type 1 diabetes without worsening severe hypoglycaemia or cardiovascular risk. This approach has the potential to enable more people to adopt intensive insulin treatment and is worthy of further investigation.	No Gen Hosp, Ctr Clin Sci, Sheffield S5 7AU, S Yorkshire, England	Northern General Hospital	Heller, S (corresponding author), No Gen Hosp, Ctr Clin Sci, Herries Rd, Sheffield S5 7AU, S Yorkshire, England.		Gianfrancesco, Carla/AAU-3534-2020; Speight, Jane/AES-0292-2022	Speight, Jane/0000-0002-1204-6896; Heller, Simon/0000-0002-2425-9565; Gianfrancesco, Carla/0000-0001-5966-8871; Bradley, Clare/0000-0002-4079-0364				Bott S, 1997, DIABETOLOGIA, V40, P926, DOI 10.1007/s001250050769; Bradley C, 1999, QUAL LIFE RES, V8, P79, DOI 10.1023/A:1026485130100; Bradley C., 1998, HEALTH PSYCHOL, V8, P277; Bradley G, 2000, DIABETES CARE, V23, P875; IMURA H, 1993, NEW ENGL J MED, V329, P683, DOI 10.1056/NEJM199309023291002; Kinmonth AL, 1998, BMJ-BRIT MED J, V317, P1202, DOI 10.1136/bmj.317.7167.1202; MUHLHAUSER I, 1987, DIABETOLOGIA, V30, P681, DOI 10.1007/BF00296989; PIEBER TR, 1995, DIABETES CARE, V18, P625, DOI 10.2337/diacare.18.5.625; Wolpert HA, 2001, BMJ-BRIT MED J, V323, P994, DOI 10.1136/bmj.323.7319.994; [No title captured]	10	600	618	0	33	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 5	2002	325	7367					746	749		10.1136/bmj.325.7367.746	http://dx.doi.org/10.1136/bmj.325.7367.746			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	603AU	12364302	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000178537300016
J	Kaufman, TC; Severson, DW; Robinson, GE				Kaufman, TC; Severson, DW; Robinson, GE			The Anopheles genome and comparative insect genomics	SCIENCE			English	Editorial Material							HOX GENES; DROSOPHILA; MOSQUITO; PROBOSCIPEDIA; SEQUENCE; TRANSFORMATION; EVOLUTION; VECTORS; DIPTERA		Indiana Univ, Dept Biol, Bloomington, IN 47405 USA; Univ Notre Dame, Dept Biol Sci, Ctr Trop Dis Res & Training, Notre Dame, IN 46556 USA; Univ Illinois, Dept Entomol, Urbana, IL 61801 USA; Univ Illinois, Program Neurosci, Urbana, IL 61801 USA	Indiana University System; Indiana University Bloomington; University of Notre Dame; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Kaufman, TC (corresponding author), Indiana Univ, Dept Biol, Bloomington, IN 47405 USA.			Severson, David/0000-0002-5798-3365				Abouheif E, 2002, SCIENCE, V297, P249, DOI 10.1126/science.1071468; Abzhanov A, 2001, DEVELOPMENT, V128, P2803; Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Adelman ZN, 2002, MOL BIOCHEM PARASIT, V121, P1, DOI 10.1016/S0166-6851(02)00028-2; Allen ML, 2001, J MED ENTOMOL, V38, P701, DOI 10.1603/0022-2585-38.5.701; Anderson JR, 2001, MOL PHYLOGENET EVOL, V20, P316, DOI 10.1006/mpev.2001.0964; Aultman KS, 2001, TRENDS PARASITOL, V17, P507, DOI 10.1016/S1471-4922(01)02094-3; Beaty BJ, 2000, P NATL ACAD SCI USA, V97, P10295, DOI 10.1073/pnas.97.19.10295; Berman BP, 2002, P NATL ACAD SCI USA, V99, P757, DOI 10.1073/pnas.231608898; Brown S, 1999, DEV GENES EVOL, V209, P389, DOI 10.1007/s004270050269; BRUSCA RC, 1990, INVEREBRATES; Catteruccia F, 2000, NATURE, V405, P959, DOI 10.1038/35016096; DeCamillis MA, 2001, GENETICS, V159, P1643; Hoffman SL, 2002, NATURE, V415, P702, DOI 10.1038/415702a; Holt RA, 2002, SCIENCE, V298, P129, DOI 10.1126/science.1076181; Hughes CL, 2000, DEVELOPMENT, V127, P3683; Ishihara K, 2000, GENOME RES, V10, P664, DOI 10.1101/gr.10.5.664; Ito J, 2002, NATURE, V417, P452, DOI 10.1038/417452a; Loots GG, 2000, SCIENCE, V288, P136, DOI 10.1126/science.288.5463.136; Papatsenko DA, 2002, GENOME RES, V12, P470, DOI 10.1101/gr.212502. Article published online before print in February ; Pennisi E, 2002, SCIENCE, V296, P1589; Rai KS, 1999, ADV GENET, V41, P1, DOI 10.1016/S0065-2660(08)60149-2; Robinson GE, 2002, SCIENCE, V297, P204, DOI 10.1126/science.1074493; Robinson GE, 1999, TRENDS ECOL EVOL, V14, P202, DOI 10.1016/S0169-5347(98)01536-5; Rogers BT, 2002, EVOL DEV, V4, P96, DOI 10.1046/j.1525-142X.2002.01065.x; Rusch DB, 2000, GENETICS, V156, P183; Severson DW, 2001, ANNU REV ENTOMOL, V46, P183, DOI 10.1146/annurev.ento.46.1.183; SEVERSON DW, COMMUNICATION; Sharakhov IV, 2002, SCIENCE, V298, P182, DOI 10.1126/science.1076803; Wheeler WC, 2001, CLADISTICS, V17, P113, DOI [10.1111/j.1096-0031.2001.tb00115.x, 10.1006/clad.2000.0147]; World Health Organization, 2000, HLTH SYST IMPR PERF; ZBODNOV EM, 2002, SCIENCE, V298, P149	32	17	19	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 4	2002	298	5591					97	+		10.1126/science.1077901	http://dx.doi.org/10.1126/science.1077901			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	600BJ	12364783				2022-12-28	WOS:000178370500040
J	Sharakhov, IV; Serazin, AC; Grushko, OG; Dana, A; Lobo, N; Hillenmeyer, ME; Westerman, R; Romero-Severson, J; Costantini, C; Sagnon, N; Collins, FH; Besansky, NJ				Sharakhov, IV; Serazin, AC; Grushko, OG; Dana, A; Lobo, N; Hillenmeyer, ME; Westerman, R; Romero-Severson, J; Costantini, C; Sagnon, N; Collins, FH; Besansky, NJ			Inversions and gene order shuffling in Anopheles gambiae and A-funestus	SCIENCE			English	Article							POLYTENE CHROMOSOMES; COMPLEX	In tropical Africa, Anopheles funestus is one of the three most important malaria vectors. We physically mapped 157 A. funestus complementary DNAs (cDNAs) to the polytene chromosomes of this species. Sequences of the cDNAs were mapped in silico to the A. gambiae genome as part of a comparative genomic study of synteny, gene order, and sequence conservation between A. funestus and A. gambiae. These species are in the same subgenus and diverged about as recently as humans and chimpanzees. Despite nearly perfect preservation of synteny, we found substantial shuffling of gene order along corresponding chromosome arms. Since the divergence of these species, at least 70 chromosomal inversions have been fixed, the highest rate of rearrangement of any eukaryote studied to date. The high incidence of paracentric inversions and limited colinearity suggests that locating genes in one anopheline species based on gene order in another may be limited to closely related taxa.	Univ Notre Dame, Ctr Trop Dis Res & Training, Notre Dame, IN 46556 USA; Purdue Univ, Dept Hort, W Lafayette, IN 47907 USA; Purdue Univ, Dept Forestry & Nat Resources, W Lafayette, IN 47907 USA; Univ Roma La Sapienza, Dipartimento Sci Sanita Pubbl, I-00185 Rome, Italy; Ctr Natl Rech & Format Paludisme, Ouagadougou, Burkina Faso	University of Notre Dame; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Sapienza University Rome	Besansky, NJ (corresponding author), Univ Notre Dame, Ctr Trop Dis Res & Training, Notre Dame, IN 46556 USA.		Romero-Severson, Jeanne/B-5259-2011; Sharakhov, Igor/B-1972-2008; Costantini, Carlo/F-3470-2012	Romero-Severson, Jeanne/0000-0003-4112-7238; Sharakhov, Igor/0000-0003-0752-3747; Costantini, Carlo/0000-0003-1016-129X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI048846, R01AI048842, U01AI050687] Funding Source: NIH RePORTER; NIAID NIH HHS [U01 AI48846, AI48842, U01 AI50687] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		COLUZZI M, 1979, T ROY SOC TROP MED H, V73, P483, DOI 10.1016/0035-9203(79)90036-1; Costantini C., 1999, Parassitologia (Rome), V41, P595; Dia I., 2001, Parassitologia (Rome), V42, P227; Gonzalez J, 2002, GENETICS, V161, P1137; GREEN CA, 1980, GENETICA, V51, P187, DOI 10.1007/BF00121610; Holt RA, 2002, SCIENCE, V298, P129, DOI 10.1126/science.1076181; Li W. H, 1997, MOL EVOLUTION; NADEAU JH, 1984, P NATL ACAD SCI-BIOL, V81, P814, DOI 10.1073/pnas.81.3.814; PETRARCA V, 1992, AM J TROP MED HYG, V46, P229, DOI 10.4269/ajtmh.1992.46.229; Powell JR, 1997, P NATL ACAD SCI USA, V94, P7784, DOI 10.1073/pnas.94.15.7784; SERAZIN A, UNPUB; Sharakhov IV, 2001, GENETICS, V159, P211; Zheng LB, 1997, SCIENCE, V276, P425, DOI 10.1126/science.276.5311.425	13	89	97	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 4	2002	298	5591					182	185		10.1126/science.1076803	http://dx.doi.org/10.1126/science.1076803			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	600BJ	12364797				2022-12-28	WOS:000178370500054
J	Weaver, LK; Hopkins, RO; Chan, KJ; Churchill, S; Elliott, CG; Clemmer, TP; Orme, JF; Thomas, FO; Morris, AH				Weaver, LK; Hopkins, RO; Chan, KJ; Churchill, S; Elliott, CG; Clemmer, TP; Orme, JF; Thomas, FO; Morris, AH			Hyperbaric oxygen for acute carbon monoxide poisoning	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NORMOBARIC OXYGEN; PROGRESS	Background: Patients with acute carbon monoxide poisoning commonly have cognitive sequelae. We conducted a double-blind, randomized trial to evaluate the effect of hyperbaric-oxygen treatment on such cognitive sequelae. Methods: We randomly assigned patients with symptomatic acute carbon monoxide poisoning in equal proportions to three chamber sessions within a 24-hour period, consisting of either three hyperbaric-oxygen treatments or one normobaric-oxygen treatment plus two sessions of exposure to normobaric room air. Oxygen treatments were administered from a high-flow reservoir through a face mask that prevented rebreathing or by endotracheal tube. Neuropsychological tests were administered immediately after chamber sessions 1 and 3, and 2 weeks, 6 weeks, 6 months, and 12 months after enrollment. The primary outcome was cognitive sequelae six weeks after carbon monoxide poisoning. Results: The trial was stopped after the third of four scheduled interim analyses, at which point there were 76 patients in each group. Cognitive sequelae at six weeks were less frequent in the hyperbaric-oxygen group (19 of 76 [25.0 percent]) than in the normobaric-oxygen group (35 of 76 [46.1 percent], P=0.007), even after adjustment for cerebellar dysfunction and for stratification variables (adjusted odds ratio, 0.45 [95 percent confidence interval, 0.22 to 0.92]; P=0.03). The presence of cerebellar dysfunction before treatment was associated with the occurrence of cognitive sequelae (odds ratio, 5.71 [95 percent confidence interval, 1.69 to 19.31]; P=0.005) and was more frequent in the normobaric-oxygen group (15 percent vs. 4 percent, P=0.03). Cognitive sequelae were less frequent in the hyperbaric-oxygen group at 12 months, according to the intention-to-treat analysis (P=0.04). Conclusions: Three hyperbaric-oxygen treatments within a 24-hour period appeared to reduce the risk of cognitive sequelae 6 weeks and 12 months after acute carbon monoxide poisoning.	Latter Day St Hosp, Dept Internal Med, Div Pulm & Crit Care, Salt Lake City, UT 84143 USA; Latter Day St Hosp, Stat Data Ctr, Salt Lake City, UT 84143 USA; Univ Utah, Sch Med, Dept Internal Med, Salt Lake City, UT USA; Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA	Utah System of Higher Education; University of Utah; Brigham Young University	Weaver, LK (corresponding author), Latter Day St Hosp, Crit Care Div, 8th Ave & C St, Salt Lake City, UT 84143 USA.	lweaver@ihc.com	Isbister, Geoffrey K/G-8052-2015	Isbister, Geoffrey K/0000-0003-1519-7419				Brown S D, 1989, Adv Exp Med Biol, V248, P747; BROWN SD, 1989, LANCET, V2, P1032; CHOI IS, 1983, ARCH NEUROL-CHICAGO, V40, P433, DOI 10.1001/archneur.1983.04050070063016; CLARK JM, 1993, PHYSL MED DIVING, P121; Denman SB., 1984, DENMAN NEUROPSYCHOLO; DUCASSE JL, 1995, UNDERSEA HYPERBAR M, V22, P9; Ernst A, 1998, NEW ENGL J MED, V339, P1603, DOI 10.1056/NEJM199811263392206; GORMAN DF, 1992, ANAESTH INTENS CARE, V20, P311, DOI 10.1177/0310057X9202000306; Hampson NB, 1996, UNDERSEA HYPERBAR M, V23, P215; HAMPSON NB, 1999, HYPERBARIC OXYGEN TH; Hampson Neil B., 1995, Journal of Emergency Medicine, V13, P227, DOI 10.1016/0736-4679(94)00144-8; Heaton R., 1992, COMPREHENSIVE NORMS; Heaton RK, 1991, COMPREHENSIVE NORMS; HOPKINS RO, 1991, UNDERSEA BIOMED RES, V18, P34; JUURLINK DN, 2000, COCHRANE DB SYST REV, V2, P2041; KATZ S, 1970, GERONTOLOGIST, V10, P20, DOI 10.1093/geront/10.1_Part_1.20; Kindwall EP, 1988, HYPERBARIC MED PROCE, P32; Lezak M.D., 2012, NEUROPSYCHOLOGICAL A; MESSIER LD, 1991, J CLIN PSYCHOL, V47, P675, DOI 10.1002/1097-4679(199109)47:5<675::AID-JCLP2270470508>3.0.CO;2-H; Newman MF, 2001, NEW ENGL J MED, V344, P395, DOI 10.1056/NEJM200102083440601; NOTERMANS NC, 1994, J NEUROL NEUROSUR PS, V57, P22, DOI 10.1136/jnnp.57.1.22; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; PACE N, 1950, SCIENCE, V111, P652, DOI 10.1126/science.111.2894.652; Piantadosi C A, 1999, Respir Care Clin N Am, V5, P183; RAPHAEL JC, 1989, LANCET, V2, P414; Reitan RM., 1993, HALSTEAD REITAN NEUR, V2nd ed.; Scheinkestel CD, 1999, MED J AUSTRALIA, V170, P203, DOI 10.5694/j.1326-5377.1999.tb140318.x; Spilker B., 1991, GUIDE CLIN TRIALS; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; THOM SR, 1993, TOXICOL APPL PHARM, V123, P248, DOI 10.1006/taap.1993.1243; THOM SR, 1990, TOXICOL APPL PHARM, V105, P340, DOI 10.1016/0041-008X(90)90195-Z; THOM SR, 1997, UNDERSEA HYPER MED S, V24, P20; THOM SR, 1992, UNDERSEA BIOMED RES, V19, P47; THORN SR, 1995, ANN EMERG MED, V25, P474, DOI 10.1016/S0196-0644(95)70261-X; TIBBLES PM, 1994, ANN EMERG MED, V24, P269, DOI 10.1016/S0196-0644(94)70141-5; Tibbles PM, 1996, NEW ENGL J MED, V334, P1642, DOI 10.1056/NEJM199606203342506; TOMASZEWSKI C, 1992, ANN EMERG MED, V21, P1308, DOI 10.1016/S0196-0644(05)81892-X; Weaver LK, 2000, CHEST, V117, P801, DOI 10.1378/chest.117.3.801; Weaver LK, 1999, CRIT CARE CLIN, V15, P297, DOI 10.1016/S0749-0704(05)70056-7; Weaver LK, 1997, UNDERSEA HYPERB ME S, V24, P36; Wechsler D., 2008, WECHSLER ADULT INTEL, P257; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4	42	605	636	1	43	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 3	2002	347	14					1057	1067		10.1056/NEJMoa013121	http://dx.doi.org/10.1056/NEJMoa013121			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	599KD	12362006	Bronze			2022-12-28	WOS:000178332900002
J	Phillips, PS; Haas, RH; Bannykh, S; Hathaway, S; Gray, NL; Kimura, BJ; Vladutiu, GD; England, JDF				Phillips, PS; Haas, RH; Bannykh, S; Hathaway, S; Gray, NL; Kimura, BJ; Vladutiu, GD; England, JDF		Scripps Mercy Clin Res Ctr	Statin-associated myopathy with normal creatine kinase levels	ANNALS OF INTERNAL MEDICINE			English	Article							COA REDUCTASE INHIBITORS; SIMVASTATIN; PRAVASTATIN	Background: Muscle symptoms in patients who are treated with statins and have normal creatine kinase levels are not well understood. Objective: To report biopsy-confirmed myopathy and normal creatine kinase levels associated with statin use. Design: Case reports from preliminary analysis of an ongoing clinical trial. Setting: Clinical research center in a community hospital. Patients: Four patients with muscle symptoms that developed during statin therapy and reversed during placebo use. Measurements: 1) Patients' ability to identify blinded statin therapy and 2) standard measures of functional capacity and muscle strength. Results: All four patients repeatedly distinguished blinded statin therapy from placebo. Strength testing confirmed weakness during statin therapy that reversed during placebo use. Muscle biopsies showed evidence of mitochondrial dysfunction, including abnormally increased lipid stores, fibers that did not stain for cytochrome oxidase activity, and ragged red fibers. These findings reversed in the three patients who had repeated biopsy when they were not receiving statins. Creatine kinase levels were normal in all four patients despite the presence of significant myopathy. Conclusion: Some patients who develop muscle symptoms while receiving statin therapy have demonstrable weakness and histopathologic findings of myopathy despite normal serum creatine kinase levels.	Scripps Mercy Hosp, San Diego, CA 92103 USA; Univ Calif San Diego, Ctr Med, San Diego, CA 92103 USA; SUNY Buffalo, Buffalo, NY 14260 USA	University of California System; University of California San Diego; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Phillips, PS (corresponding author), Scripps Mercy Hosp, MER 74,4077 5th Ave, San Diego, CA 92103 USA.	inquire@impostertrial.com						Dubowitz V., 1985, MUSCLE BIOPSY PRACTI; ENGLAND JDF, 1995, AUST NZ J MED, V25, P374, DOI 10.1111/j.1445-5994.1995.tb01912.x; Farmer JA, 2001, LANCET, V358, P1383, DOI 10.1016/S0140-6736(01)06489-3; Gaist D, 2001, EPIDEMIOLOGY, V12, P565, DOI 10.1097/00001648-200109000-00017; Gruer PJK, 1999, AM J CARDIOL, V84, P811, DOI 10.1016/S0002-9149(99)00442-7; Lanctot KL, 1995, CLIN PHARMACOL THER, V58, P692, DOI 10.1016/0009-9236(95)90026-8; MARINO M, 1982, AM J SPORT MED, V10, P360, DOI 10.1177/036354658201000608; MASTERS BA, 1995, TOXICOL APPL PHARM, V131, P163, DOI 10.1006/taap.1995.1058; Nakahara K, 1998, TOXICOL APPL PHARM, V152, P99, DOI 10.1006/taap.1998.8491; OGASAHARA S, 1989, P NATL ACAD SCI USA, V86, P2379, DOI 10.1073/pnas.86.7.2379; PEDERSEN TR, 1994, LANCET, V344, P1383; Phillips PS, 2002, ATHEROSCLER THROMB V, V22, P878; Raskind JY, 2000, ANN PHARMACOTHER, V34, P630; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Scaglia F, 2001, J CHILD NEUROL, V16, P136, DOI 10.2310/7010.2001.7015; Sinzinger H, 1999, ATHEROSCLEROSIS, V143, P459; Stubbs R., 1990, DRUG INVEST S2, V2, P18, DOI 10.1007/BF03258190; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; Ucar M, 2000, DRUG SAFETY, V22, P441, DOI 10.2165/00002018-200022060-00003	19	411	428	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	2002	137	7					581	585		10.7326/0003-4819-137-7-200210010-00009	http://dx.doi.org/10.7326/0003-4819-137-7-200210010-00009			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	599VD	12353945				2022-12-28	WOS:000178355100004
J	Chun, HJ; Zheng, LX; Ahmad, M; Wang, J; Speirs, CK; Siegel, RM; Dale, MK; Puck, J; Davis, J; Hall, CG; Skoda-Smith, S; Atkinson, TP; Straus, SE; Lenardo, MJ				Chun, HJ; Zheng, LX; Ahmad, M; Wang, J; Speirs, CK; Siegel, RM; Dale, MK; Puck, J; Davis, J; Hall, CG; Skoda-Smith, S; Atkinson, TP; Straus, SE; Lenardo, MJ			Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency	NATURE			English	Article							AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; NATURAL-KILLER-CELLS; FAS GENE-MUTATIONS; T-CELLS; APOPTOSIS; INITIATION; CLEAVAGE; DISORDER; SIGNAL	Apoptosis is a form of programmed cell death that is controlled by aspartate-specific cysteine proteases called caspases. In the immune system, apoptosis counters the proliferation of lymphocytes to achieve a homeostatic balance, which allows potent responses to pathogens but avoids autoimmunity(1,2). The CD95 (Fas, Apo-1) receptor triggers lymphocyte apoptosis by recruiting Fas-associated death domain (FADD), caspase-8 and caspase-10 proteins into a death-inducing signalling complex(3,4). Heterozygous mutations in CD95, CD95 ligand or caspase-10 underlie most cases of autoimmune lymphoproliferative syndrome (ALPS), a human disorder that is characterized by defective lymphocyte apoptosis, lymphadenopathy, splenomegaly and autoimmunity(5-14). Mutations in caspase-8 have not been described in ALPS, and homozygous caspase-8 deficiency causes embryonic lethality in mice. Here we describe a human kindred with an inherited genetic deficiency of caspase-8. Homozygous individuals manifest defective lymphocyte apoptosis and homeostasis but, unlike individuals affected with ALPS, also have defects in their activation of T lymphocytes, B lymphocytes and natural killer cells, which leads to immunodeficiency. Thus, caspase-8 deficiency in humans is compatible with normal development and shows that caspase-8 has a postnatal role in immune activation of naive lymphocytes.	NIAID, Immunol Lab, NIH, Bethesda, MD 20892 USA; NIAID, Immunol Lab, NIH, Bethesda, MD 20892 USA; NHGRI, Genet & Mol Biol Branch, NIH, Bethesda, MD 20892 USA; Univ Alabama, Sch Med, Birmingham, AL 35294 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Alabama System; University of Alabama Birmingham	Lenardo, MJ (corresponding author), NIAID, Immunol Lab, NIH, Bldg 10, Bethesda, MD 20892 USA.		Siegel, Richard/C-7592-2009; chun, hyung/AAE-1463-2020; Chun, Hyung/K-1859-2013	Siegel, Richard/0000-0001-5953-9893; Chun, Hyung/0000-0003-3508-2678; Wang, Jin/0000-0002-3116-0838	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000034, Z01HG000116] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000718, ZIAAI000769, Z01AI000718, Z01AI000769, ZIAAI000732, Z01AI000732] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041133, ZIAAR041133] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abbas AK, 1996, CELL, V84, P655, DOI 10.1016/S0092-8674(00)81042-9; Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; Bettinardi A, 1997, BLOOD, V89, P902, DOI 10.1182/blood.V89.3.902; Chinnasamy D, 2000, BLOOD, V96, P1309, DOI 10.1182/blood.V96.4.1309.h8001309_1309_1316; Chun HJ, 2001, ADV EXP MED BIOL, V490, P49; Drappa J, 1996, NEW ENGL J MED, V335, P1643, DOI 10.1056/NEJM199611283352204; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; FINER MH, 1994, BLOOD, V83, P43; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; GARNIWAGNER BA, 1993, J IMMUNOL, V151, P60; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kasahara Y, 1998, INT IMMUNOL, V10, P195, DOI 10.1093/intimm/10.2.195; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Lenardo M, 1999, ANNU REV IMMUNOL, V17, P221, DOI 10.1146/annurev.immunol.17.1.221; Martin DA, 1999, P NATL ACAD SCI USA, V96, P4552, DOI 10.1073/pnas.96.8.4552; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; PETRAK D, 1994, J IMMUNOL, V153, P2046; Posmantur R, 1998, EXP CELL RES, V244, P302, DOI 10.1006/excr.1998.4214; RAGERZISMAN B, 1987, J IMMUNOL, V138, P884; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; Sneller MC, 1997, BLOOD, V89, P1341, DOI 10.1182/blood.V89.4.1341; STAHLS A, 1994, EUR J IMMUNOL, V24, P2491, DOI 10.1002/eji.1830241035; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Wang L, 2001, P NATL ACAD SCI USA, V98, P13884, DOI 10.1073/pnas.241358198; Wu JG, 1996, J CLIN INVEST, V98, P1107, DOI 10.1172/JCI118892	26	518	541	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 26	2002	419	6905					395	399		10.1038/nature01063	http://dx.doi.org/10.1038/nature01063			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	596ZB	12353035	Green Published			2022-12-28	WOS:000178195400046
J	Yao, TT; Cohen, RE				Yao, TT; Cohen, RE			A cryptic protease couples deubiquitination and degradation by the proteasome	NATURE			English	Article							REGULATORY PARTICLE; SACCHAROMYCES-CEREVISIAE; UBIQUITIN; ENZYMES; DOMAIN; GENE; THERMODYNAMICS; SIGNAL; ATP	The 26S proteasome is responsible for most intracellular proteolysis in eukaryotes(1,2). Efficient substrate recognition relies on conjugation of substrates with multiple ubiquitin molecules and recognition of the polyubiquitin moiety by the 19S regulatory complex-a multisubunit assembly that is bound to either end of the cylindrical 20S proteasome core. Only unfolded proteins can pass through narrow axial channels into the central proteolytic chamber of the 20S core, so the attached polyubiquitin chain must be released to allow full translocation of the substrate polypeptide. Whereas unfolding is rate-limiting for the degradation of some substrates and appears to involve chaperone-like activities associated with the proteasome(3-5), the importance and mechanism of degradation-associated deubiquitination has remained unclear. Here we report that the POH1 (also known as Rpn11 in yeast) subunit of the 19S complex is responsible for substrate deubiquitination during proteasomal degradation. The inability to remove ubiquitin can be rate-limiting for degradation in vitro and is lethal to yeast. Unlike all other known deubiquitinating enzymes (DUBs) that are cysteine proteases(6,7), POH1 appears to be a Zn2+-dependent protease.	Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA	University of Iowa	Cohen, RE (corresponding author), Univ Iowa, Dept Biochem, 51 Newton Rd, Iowa City, IA 52242 USA.							Alberts IL, 1998, PROTEIN SCI, V7, P1700, DOI 10.1002/pro.5560070805; Amerik AY, 2000, BIOL CHEM, V381, P981, DOI 10.1515/BC.2000.121; BEERS EP, 1993, J BIOL CHEM, V268, P21645; Borodovsky A, 2001, EMBO J, V20, P5187, DOI 10.1093/emboj/20.18.5187; Braun BC, 1999, NAT CELL BIOL, V1, P221, DOI 10.1038/12043; D'Andrea A, 1998, CRIT REV BIOCHEM MOL, V33, P337, DOI 10.1080/10409239891204251; DeKoster GT, 1997, BIOCHEMISTRY-US, V36, P2323, DOI 10.1021/bi962580b; EYTAN E, 1993, J BIOL CHEM, V268, P4668; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; HERSHKO A, 1987, P NATL ACAD SCI USA, V84, P1829, DOI 10.1073/pnas.84.7.1829; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P204, DOI 10.1016/S0968-0004(98)01217-1; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; LEGGETT DL, IN PRESS MOL CELL; Liu CW, 2002, J BIOL CHEM, V277, P26815, DOI 10.1074/jbc.M201782200; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Papa FR, 1999, MOL BIOL CELL, V10, P741, DOI 10.1091/mbc.10.3.741; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; Piotrowski J, 1997, J BIOL CHEM, V272, P23712, DOI 10.1074/jbc.272.38.23712; Ponting CP, 1999, J MOL BIOL, V289, P729, DOI 10.1006/jmbi.1999.2827; Rubin DM, 1998, EMBO J, V17, P4909, DOI 10.1093/emboj/17.17.4909; THICK J, 1994, LEUKEMIA, V8, P564; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Wilkinson KD, 1997, FASEB J, V11, P1245, DOI 10.1096/fasebj.11.14.9409543; WINTRODE PL, 1994, PROTEINS, V18, P246, DOI 10.1002/prot.340180305; Zwickl P, 2000, CURR OPIN STRUC BIOL, V10, P242, DOI 10.1016/S0959-440X(00)00075-0	30	556	573	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 26	2002	419	6905					403	407		10.1038/nature01071	http://dx.doi.org/10.1038/nature01071			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	596ZB	12353037				2022-12-28	WOS:000178195400048
J	Bielawski, CW; Benitez, D; Grubbs, RH				Bielawski, CW; Benitez, D; Grubbs, RH			An "endless" route to cyclic polymers	SCIENCE			English	Article							METATHESIS CATALYSTS; LIGANDS	A new synthetic route to cyclic polymers has been developed in which the ends of growing polymer chains remain attached to a metal complex throughout the entire polymerization process. The approach eliminates the need for linear polymeric precursors and high dilution, drawbacks of traditional macrocyclization strategies, and it effectively removes the barrier to producing large quantities of pure cyclic material. Ultimately, the strategy offers facile access to a unique macromolecular scaffold that may be used to meet the increasing demand of new applications for commercial polymers. As a demonstration of its potential utility, cyclic polyethylenes were prepared and found to exhibit a variety of physical properties that were distinguishable from their linear analogs.	CALTECH, Arnold & Mabel Beckman Labs Chem Synthesis, Div Chem & Chem Engn, Pasadena, CA 91125 USA	California Institute of Technology	Grubbs, RH (corresponding author), CALTECH, Arnold & Mabel Beckman Labs Chem Synthesis, Div Chem & Chem Engn, Pasadena, CA 91125 USA.		Benitez, Diego/E-4403-2011; grubbs, robert h/D-4293-2009	Benitez, Diego/0000-0003-1212-6957; grubbs, robert h/0000-0002-0057-7817				Bielawski CW, 2000, ANGEW CHEM INT EDIT, V39, P2903, DOI 10.1002/1521-3773(20000818)39:16<2903::AID-ANIE2903>3.0.CO;2-Q; Burchard W., 1986, CYCLIC POLYM, P43; Furstner A, 2001, CHEM-EUR J, V7, P3236, DOI 10.1002/1521-3765(20010803)7:15<3236::AID-CHEM3236>3.0.CO;2-S; HAHN SF, 1992, J POLYM SCI POL CHEM, V30, P397, DOI 10.1002/pola.1992.080300307; HOCKER H, 1977, MAKROMOL CHEM, V178, P3101; Ivin K. J., 1997, OLEFIN METATHESIS ME; Kwok DY, 1999, ADV COLLOID INTERFAC, V81, P167, DOI 10.1016/S0001-8686(98)00087-6; LEE KS, 1985, MAKROMOL CHEM-RAPID, V6, P203; Lee W, 2002, MACROMOLECULES, V35, P529, DOI 10.1021/ma0109222; Peacock, 2000, HDB POLYETHYLENE STR; Semlyen J. A., 2000, CYCLIC POLYM; Shea KJ, 1998, J ORG CHEM, V63, P5746, DOI 10.1021/jo981174q; Trnka TM, 2001, ACCOUNTS CHEM RES, V34, P18, DOI 10.1021/ar000114f; Wiberg K. B., 1965, OXIDATION ORGANIC CH; Wignall GD, 2000, MACROMOLECULES, V33, P551, DOI 10.1021/ma9912655; ZIMM BH, 1949, J CHEM PHYS, V17, P1301, DOI 10.1063/1.1747157	16	523	539	15	225	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 20	2002	297	5589					2041	2044		10.1126/science.1075401	http://dx.doi.org/10.1126/science.1075401			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	594XV	12242440				2022-12-28	WOS:000178078500043
J	McFadden, P				McFadden, P			Broadband biodetection: Holmes on a chip	SCIENCE			English	Editorial Material							BIOSENSORS; CELLS		Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA; Rainwater Res Inc, Albany, OR 97330 USA	Oregon State University	McFadden, P (corresponding author), Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA.							Biran I, 2002, ANAL CHEM, V74, P3046, DOI 10.1021/ac020009e; Danosky TR, 1997, BIOSENS BIOELECTRON, V12, P925, DOI 10.1016/S0956-5663(97)00028-6; DOYLE AC, 1993, STUDY SCARLET, P32; Karlsson AM, 2002, BIOSENS BIOELECTRON, V17, P331, DOI 10.1016/S0956-5663(01)00284-6; Preston RR, 2001, BIOSENS BIOELECTRON, V16, P447, DOI 10.1016/S0956-5663(01)00159-2; Sohn H, 2001, ANGEW CHEM INT EDIT, V40, P2104, DOI 10.1002/1521-3773(20010601)40:11<2104::AID-ANIE2104>3.0.CO;2-#; Stenger DA, 2001, TRENDS BIOTECHNOL, V19, P304, DOI 10.1016/S0167-7799(01)01690-0; Turner A. P. F., 1996, BIOSENSORS PRESENT F; Turner APF, 2001, BIOSENS BIOELECTRON, V16, P609, DOI 10.1016/S0956-5663(01)00184-1	9	36	39	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 20	2002	297	5589					2075	2076		10.1126/science.297.5589.2075	http://dx.doi.org/10.1126/science.297.5589.2075			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	594XV	12242448				2022-12-28	WOS:000178078500053
J	Bertheau, P; Plassa, F; Espie, M; Turpin, E; de Roquancourt, A; Marty, M; Lerebours, F; Beuzard, Y; Janin, A; de The, H				Bertheau, P; Plassa, F; Espie, M; Turpin, E; de Roquancourt, A; Marty, M; Lerebours, F; Beuzard, Y; Janin, A; de The, H			Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy	LANCET			English	Article							P53	TP53 activation by genotoxic drugs can induce apoptosis or cell-cycle arrest. Thus, whether the gene is mutated or wild type could affect the response of a tumour to chemotherapy. Clinical data are unclear, possibly as a result of heterogeneity of tumours, drugs, methods of assessing response, or TP53 status. We studied 50 non-inflammatory, locally advanced breast cancers that had been treated with high doses of a combination of epirubicin and cyclophosphamide. We noted eight complete responses, which all occurred in the 14 patients with tumours containing mutated TP53 (p<0.0001). In high-grade, advanced breast cancers, inactivation of the TP53 pathway could greatly improve the response to this chemotherapy regimen.	Hop St Louis, Serv Biochim B, F-75475 Paris 10, France; Hop St Louis, CNRS, UPR 9051, F-75475 Paris, France; Hop St Louis, INSERM, ERM 0220, F-75475 Paris 10, France; Hop St Louis, Serv Pathol, F-75475 Paris 10, France; Hop St Louis, Serv Oncol, F-75475 Paris 10, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	de The, H (corresponding author), Hop St Louis, Serv Biochim B, 1 Ave C Vellefaux, F-75475 Paris 10, France.							Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Lavarino C, 2000, J CLIN ONCOL, V18, P3936, DOI 10.1200/JCO.2000.18.23.3936; MAKRIS A, 1995, LANCET, V345, P1181, DOI 10.1016/S0140-6736(95)91014-X; McGill G, 1999, J CLIN INVEST, V104, P223, DOI 10.1172/JCI7861	5	114	119	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 14	2002	360	9336					852	854		10.1016/S0140-6736(02)09969-5	http://dx.doi.org/10.1016/S0140-6736(02)09969-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	594MC	12243922				2022-12-28	WOS:000178053500013
J	Powell, K				Powell, K			Call for clinical-trial reform leaves critics unmoved	NATURE			English	News Item																			0	1	1	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 10	2002	419	6907					546	546		10.1038/419546b	http://dx.doi.org/10.1038/419546b			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	602AT	12374938	Bronze			2022-12-28	WOS:000178483100004
J	Yasui, D; Miyano, M; Cai, ST; Varga-WEisz, P; Kohwi-Shigematsu, T				Yasui, D; Miyano, M; Cai, ST; Varga-WEisz, P; Kohwi-Shigematsu, T			SATB1 targets chromatin remodelling to regulate genes over long distances	NATURE			English	Article							CELL-SPECIFIC DEMETHYLATION; DNA-BINDING PROTEIN; NUCLEAR-MATRIX; HISTONE DEACETYLASE; IN-VIVO; COMPLEX; ENHANCER; REGION; ACETYLATION; EXPRESSION	Eukaryotic chromosomes are organized inside the nucleus in such a way that only a subset of the genome is expressed in any given cell type, but the details of this organization are largely unknown(1-3). SATB1 ('special AT-rich sequence binding 1'), a protein found predominantly in thymocytes(4), regulates genes by folding chromatin into loop domains, tethering specialized DNA elements to an SATB1 network structure(5). Ablation of SATB1 by gene targeting results in temporal and spatial mis-expression of numerous genes and arrested T-cell development, suggesting that SATB1 is a cell-type specific global gene regulator(6). Here we show that SATB1 targets chromatin remodelling to the IL-2Ralpha ('interleukin-2 receptor alpha') gene, which is ectopically transcribed in SATB1 null thymocytes. SATB1 recruits the histone deacetylase contained in the NURD chromatin remodelling complex to a SATB1-bound site in the IL-2Ralpha locus, and mediates the specific deacetylation of histones in a large domain within the locus. SATB1 also targets ACF1 and ISWI, subunits of CHRAC and ACF nucleosome mobilizing complexes, to this specific site and regulates nucleosome positioning over seven kilobases. SATB1 defines a class of transcriptional regulators that function as a 'landing platform' for several chromatin remodelling enzymes and hence regulate large chromatin domains.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Marie Curie Res Inst, Surrey RH8 OTL, England	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Kohwi-Shigematsu, T (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA.	terumiks@lbl.gov	Yasui, Dag/ABL-3626-2022; MIYANO, MASARU/I-1353-2015	Varga-Weisz, Patrick/0000-0001-7409-8686	NIA NIH HHS [AG00266] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alvarez JD, 2000, GENE DEV, V14, P521; BODE J, 1992, SCIENCE, V255, P195, DOI 10.1126/science.1553545; Bulger M, 1999, GENE DEV, V13, P2465, DOI 10.1101/gad.13.19.2465; CAI S, UNPUB CELL; COLLINS N, IN PRESS NATURE GENE; de Belle I, 1998, J CELL BIOL, V141, P335, DOI 10.1083/jcb.141.2.335; DICKINSON LA, 1995, MOL CELL BIOL, V15, P456, DOI 10.1128/MCB.15.1.456; DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; Fernandez LA, 2001, MOL CELL BIOL, V21, P196, DOI 10.1128/MCB.21.1.196-208.2001; Forrester WC, 1999, GENE DEV, V13, P3003, DOI 10.1101/gad.13.22.3003; Fry CJ, 2001, CURR BIOL, V11, pR185, DOI 10.1016/S0960-9822(01)00090-2; Galande S, 1999, J BIOL CHEM, V274, P20521, DOI 10.1074/jbc.274.29.20521; Jenuwein T, 1997, NATURE, V385, P269, DOI 10.1038/385269a0; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Kirillov A, 1996, NAT GENET, V13, P435, DOI 10.1038/ng0895-435; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Kohwi-Shigematsu T, 1998, METHOD CELL BIOL, V53, P323; KOHWISHIGEMATSU T, 1990, BIOCHEMISTRY-US, V29, P9551, DOI 10.1021/bi00493a009; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; Langst G, 2001, J CELL SCI, V114, P2561; LICHTENSTEIN M, 1994, CELL, V76, P913, DOI 10.1016/0092-8674(94)90365-4; Poot RA, 2000, EMBO J, V19, P3377, DOI 10.1093/emboj/19.13.3377; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; SOLDAINI E, 1995, J BIOL CHEM, V270, P10733, DOI 10.1074/jbc.270.18.10733; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Travers A, 1999, CELL, V96, P311, DOI 10.1016/S0092-8674(00)80543-7; Varga-Weisz P, 2001, ONCOGENE, V20, P3076, DOI 10.1038/sj.onc.1204332; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	30	383	405	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 10	2002	419	6907					641	645		10.1038/nature01084	http://dx.doi.org/10.1038/nature01084			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	602AT	12374985	Green Submitted			2022-12-28	WOS:000178483100051
J	Braveman, P				Braveman, P			Measuring health equity within countries: The challenge of limited information	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POLICY		Univ Calif San Francisco, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Braveman, P (corresponding author), Univ Calif San Francisco, San Francisco, CA 94143 USA.							Almeida C, 2001, LANCET, V357, P1692, DOI 10.1016/S0140-6736(00)04825-X; Braveman P, 2002, SOC SCI MED, V54, P1621, DOI 10.1016/S0277-9536(01)00331-8; Braveman P, 2001, BRIT MED J, V323, P678, DOI 10.1136/bmj.323.7314.678; Braveman P., 1998, WHOCHSHSS981; Evans T., 2001, CHALLENGING INEQUITI; Gwatkin DR, 2002, SOCIOECONOMIC DIFFER, V1996; Kim J., 2000, DYING GROWTH; Pamuk E., 1998, SOCIOECONOMIC STATUS; World Health Organization, 2000, WORLD HLTH REP 2000	9	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	2002	288	13					1650	1650		10.1001/jama.288.13.1650	http://dx.doi.org/10.1001/jama.288.13.1650			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	599BJ	12350200	hybrid			2022-12-28	WOS:000178314000029
J	Mulherin, SA; Miller, WC				Mulherin, SA; Miller, WC			Spectrum bias or spectrum effect? Subgroup variation in diagnostic test evaluation	ANNALS OF INTERNAL MEDICINE			English	Article							MEDICAL LITERATURE; USERS GUIDES; SPECIFICITY; SENSITIVITY; INFECTION; ARTICLE; BAYES	Diagnostic tests must be evaluated in a clinically relevant population. However, test performance often varies across population subgroups. Spectrum bias, a term commonly used to describe this heterogeneity, is typically thought to occur when diagnostic test performance varies across patient subgroups and a study of that test's performance does not adequately represent all subgroups. Yet subgroup variation is not a bias if appropriate analyses are conducted. Failure to recognize and address heterogeneity will lead to estimates of test performance that are not generalizable to the relevant clinical populations. Heterogeneity can be addressed with relatively simple stratification procedures, limited primarily by the sample size and the precision of the estimates. This paper proposes the use of the term spectrum effect, rather than spectrum bias, and outlines strategies for using stratified sensitivity and specificity estimates, likelihood ratios, and receiver-operating characteristic curves. Investigators of diagnostic tests should consider the potential for spectrum effect seriously and should address heterogeneity in their analyses. Furthermore, clinicians should consider study samples carefully to determine whether results are generalizable to their specific patient population.	Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Miller, WC (corresponding author), Univ N Carolina, Dept Epidemiol, CB 7435,2105F McGavran Greenberg, Chapel Hill, NC 27599 USA.		Miller, William C/H-4800-2014	Miller, William C/0000-0002-1934-7827	NCRR NIH HHS [RR00046] Funding Source: Medline; PHS HHS [UO131496] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000046] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BEGG CB, 1987, STAT MED, V6, P411, DOI 10.1002/sim.4780060402; COUGHLIN SS, 1992, J CLIN EPIDEMIOL, V45, P1, DOI 10.1016/0895-4356(92)90180-U; Curtin F, 1997, J CLIN EPIDEMIOL, V50, P837, DOI 10.1016/S0895-4356(97)00063-2; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HARRIS JM, 1981, JAMA-J AM MED ASSOC, V246, P2602, DOI 10.1001/jama.246.22.2602; HLATKY MA, 1984, AM J MED, V77, P64, DOI 10.1016/0002-9343(84)90437-6; HLATKY MA, 1987, AM J CARDIOL, V59, P1195, DOI 10.1016/0002-9149(87)90875-7; IRWIG L, 1994, ANN INTERN MED, V120, P667, DOI 10.7326/0003-4819-120-8-199404150-00008; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P389, DOI 10.1001/jama.271.5.389; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; LACHS MS, 1992, ANN INTERN MED, V117, P135, DOI 10.7326/0003-4819-117-2-135; MCNEIL BJ, 1984, MED DECIS MAKING, V4, P137, DOI 10.1177/0272989X8400400203; Miller WC, 2000, AM J PREV MED, V18, P115, DOI 10.1016/S0749-3797(99)00146-4; Moons KGM, 1997, EPIDEMIOLOGY, V8, P12, DOI 10.1097/00001648-199701000-00002; Mower WR, 1999, ANN EMERG MED, V33, P85, DOI 10.1016/S0196-0644(99)70422-1; OConnor PW, 1996, NEUROLOGY, V47, P140, DOI 10.1212/WNL.47.1.140; OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78; PHILBRICK JT, 1982, JAMA-J AM MED ASSOC, V248, P2467, DOI 10.1001/jama.248.19.2467; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; REID MC, 1995, JAMA-J AM MED ASSOC, V274, P645, DOI 10.1001/jama.274.8.645; Reid MC, 1998, AM J MED, V104, P374, DOI 10.1016/S0002-9343(98)00054-0; Rothman K., 1998, MODERN EPIDEMIOLOGY; SHEPS SB, 1984, JAMA-J AM MED ASSOC, V252, P2418, DOI 10.1001/jama.252.17.2418; SIMEL DL, 1991, J CLIN EPIDEMIOL, V44, P763, DOI 10.1016/0895-4356(91)90128-V; SOX HC, 1986, ANN INTERN MED, V104, P60, DOI 10.7326/0003-4819-104-1-60; Sox HC, 1996, ANNU REV MED, V47, P463	26	211	215	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	2002	137	7					598	602		10.7326/0003-4819-137-7-200210010-00011	http://dx.doi.org/10.7326/0003-4819-137-7-200210010-00011			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	599VD	12353947				2022-12-28	WOS:000178355100006
J	Khalifah, P; Osborn, R; Huang, Q; Zandbergen, HW; Jin, R; Liu, Y; Mandrus, D; Cava, RJ				Khalifah, P; Osborn, R; Huang, Q; Zandbergen, HW; Jin, R; Liu, Y; Mandrus, D; Cava, RJ			Orbital ordering transition in La4Ru2O10	SCIENCE			English	Article							PHYSICS	We report experimental evidence for a full orbital ordering transition in the two-dimensional lanthanum ruthenate La4Ru2O10. The observable consequences of this orbital ordering include the loss of the Ru local moment, a structural distortion which partitions Ru-O bonds into axially oriented short and long sets, a sharp jump in electrical resistivity, and the opening of a spin gap that is visible in neutron scattering experiments. This is a rare example of a discrete orbital ordering transition in a 4d transition metal oxide and demonstrates that orbital effects can have an influence on the properties of layered ruthenates, a family of compounds that notably includes the p-wave superconductor Sr2RuO4 and the field-tuned quantum critical metamagnet Sr3Ru2O7.	Princeton Univ, Dept Chem, Princeton, NJ 08540 USA; Princeton Univ, Princeton Mat Inst, Princeton, NJ 08540 USA; Argonne Natl Lab, Div Sci Mat, Argonne, IL 60439 USA; NIST, Ctr Neutron Res, Gaithersburg, MD 20899 USA; Univ Maryland, Dept Mat & Nucl Engn, College Pk, MD 20742 USA; Delft Univ Technol, Natl Ctr High Resolut Electron Microscopy, NL-2628 AL Delft, Netherlands; Penn State Univ, Dept Phys, University Pk, PA 16802 USA; Oak Ridge Natl Lab, Div Solid State, Oak Ridge, TN 37831 USA	Princeton University; Princeton University; United States Department of Energy (DOE); Argonne National Laboratory; National Institute of Standards & Technology (NIST) - USA; University System of Maryland; University of Maryland College Park; Delft University of Technology; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; United States Department of Energy (DOE); Oak Ridge National Laboratory	Khalifah, P (corresponding author), Oak Ridge Natl Lab, Div Solid State, POB 2008, Oak Ridge, TN 37831 USA.	kpete@ornl.gov	Osborn, Raymond/E-8676-2011; Mandrus, David/H-3090-2014	Osborn, Raymond/0000-0001-9565-3140; Khalifah, Peter/0000-0002-2216-0377				Anisimov VI, 2002, EUR PHYS J B, V25, P191, DOI 10.1140/epjb/e20020021; Blake GR, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.245501; Braden M, 1998, PHYS REV B, V58, P847, DOI 10.1103/PhysRevB.58.847; Chuang YD, 2001, SCIENCE, V292, P1509, DOI 10.1126/science.1059255; Fang Z, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.020509; FRIEDT O, 1998, PHYS REV B, V58, P847; Goldman AM, 1996, SCIENCE, V274, P1630, DOI 10.1126/science.274.5293.1630; Hotta T, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.017201; Ichikawa H, 2000, PHYSICA B, V281, P482, DOI 10.1016/S0921-4526(99)00950-3; Imada M, 1998, REV MOD PHYS, V70, P1039, DOI 10.1103/RevModPhys.70.1039; KHALIFAH P, UNPUB; Mizokawa T, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.077202; Mizokawa T, 1999, PHYS REV B, V60, P7309, DOI 10.1103/PhysRevB.60.7309; Moreo A, 1999, SCIENCE, V283, P2034, DOI 10.1126/science.283.5410.2034; NIKIFOROV AE, 1983, PHYS STATUS SOLIDI B, V118, P419, DOI 10.1002/pssb.2221180149; Tokura Y, 2000, SCIENCE, V288, P462, DOI 10.1126/science.288.5465.462	16	91	94	4	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 27	2002	297	5590					2237	2240		10.1126/science.1075556	http://dx.doi.org/10.1126/science.1075556			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	597LA	12351782				2022-12-28	WOS:000178222000039
J	Siegel, JP				Siegel, JP			Assessing the use of activated protein c in the treatment of severe sepsis.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Ctr Biol Evaluat & Res, Rockville, MD 20852 USA	US Food & Drug Administration (FDA)	Siegel, JP (corresponding author), Ctr Biol Evaluat & Res, Rockville, MD 20852 USA.							*ANT ADV COMM, 2001, FDA BRIEF DOC DROTR; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; *FDA, 2001, ANT DRUGS ADV COMM M; *FDA, IN PRESS FDA CLIN RE; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Warren HS, 2002, NEW ENGL J MED, V347, P1027, DOI 10.1056/NEJMsb020574	6	99	107	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 26	2002	347	13					1030	1034		10.1056/NEJMsb021512	http://dx.doi.org/10.1056/NEJMsb021512			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	596RD	12324563				2022-12-28	WOS:000178178400013
J	Richardson, CE; Williams, DW; Kingham, JGC				Richardson, CE; Williams, DW; Kingham, JGC			Gabapentin induced cholestasis	BRITISH MEDICAL JOURNAL			English	Article							NEUROPATHY; PAIN		Singleton Hosp, Dept Pathol, Swansea SA2 8QA, W Glam, Wales; Singleton Hosp, Dept Gastroenterol, Swansea SA2 8QA, W Glam, Wales	Singleton Hospital; Singleton Hospital	Kingham, JGC (corresponding author), Singleton Hosp, Dept Pathol, Swansea SA2 8QA, W Glam, Wales.							Backonja M, 1998, JAMA-J AM MED ASSOC, V280, P1831, DOI 10.1001/jama.280.21.1831; MAX MB, 1987, NEUROLOGY, V37, P589, DOI 10.1212/WNL.37.4.589; Morello CM, 2000, ARCH INTERN MED, V160, P1040; Tremont-Lukats IW, 2000, DRUGS, V60, P1029, DOI 10.2165/00003495-200060050-00005	4	16	19	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 21	2002	325	7365					635	635		10.1136/bmj.325.7365.635	http://dx.doi.org/10.1136/bmj.325.7365.635			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	597WM	12242176	Green Published, Bronze			2022-12-28	WOS:000178243800029
J	Tzedakis, PC; Lawson, IT; Frogley, MR; Hewitt, GM; Preece, RC				Tzedakis, PC; Lawson, IT; Frogley, MR; Hewitt, GM; Preece, RC			Buffered tree population changes in a quaternary refugium: Evolutionary implications	SCIENCE			English	Article							NORTHWEST GREECE; ICE AGES; VARIABILITY; SPECIATION; CALIBRATION; SCALE	A high-resolution pollen record from western Greece shows that the amplitude of millennial-scale oscillations in tree abundance during the last glacial period was subdued, with temperate tree populations surviving throughout the interval. This provides evidence for the existence of an area of relative ecological stability, reflecting the influence of continued moisture availability and varied topography. Long-term buffering of populations from climatic extremes, together with genetic isolation at such refugial sites, may have allowed lineage divergence to proceed through the Quaternary. Such ecologically stable areas may be critical not only for the long-term survival of species, but also for the emergence of new ones.	Univ Leeds, Sch Geog, Leeds LS2 9JT, W Yorkshire, England; Univ Cambridge, Dept Geog, Godwin Inst Quaternary Res, Cambridge CB2 3EN, England; Univ Sussex, Environm Res Ctr, Sch Chem Phys & Environm Sci, Brighton BN1 9QJ, E Sussex, England; Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England; Univ Cambridge, Dept Zool, Godwin Inst Quaternary Res, Cambridge CB2 3EJ, England	University of Leeds; University of Cambridge; University of Sussex; University of East Anglia; University of Cambridge	Tzedakis, PC (corresponding author), Univ Leeds, Sch Geog, Leeds LS2 9JT, W Yorkshire, England.		Tzedakis, Polychronis/J-1894-2012; Frogley, Michael R/H-2956-2016	Frogley, Michael R/0000-0003-4273-0901; Tzedakis, Polychronis/0000-0001-6072-1166; Lawson, Ian Thomas/0000-0002-3547-2425				Allen JRM, 1999, NATURE, V400, P740, DOI 10.1038/23432; [Anonymous], 1999, BIOL WILDLIFE MEDITE; Avise JC, 1998, P ROY SOC B-BIOL SCI, V265, P1707, DOI 10.1098/rspb.1998.0492; BARD E, 1990, NATURE, V345, P405, DOI 10.1038/345405a0; BARRON EJ, IN PRESS QUAT RES; BENNETT KD, 1997, EVOLUTION ECOLOGY; DELTSHEV C, IN PRESS BALKAN BIOD; FJELDSA J, 1997, BIODIVERS CONSERV, V6, P323; Follieri M, 1998, QUATERN INT, V47-8, P3, DOI 10.1016/S1040-6182(97)00065-7; Frogley MR, 2001, J BIOGEOGR, V28, P745, DOI 10.1046/j.1365-2699.2001.00582.x; Frogley MR, 1999, SCIENCE, V285, P1886, DOI 10.1126/science.285.5435.1886; GRIFFITHS HI, IN PRESS BALKAN BIOD; Griffiths SJ, 2002, SEDIMENT GEOL, V148, P79, DOI 10.1016/S0037-0738(01)00211-1; Grootes PM, 1997, J GEOPHYS RES-OCEANS, V102, P26455, DOI 10.1029/97JC00880; HAFFER J, 1969, SCIENCE, V165, P131, DOI 10.1126/science.165.3889.131; Hewitt G, 2000, NATURE, V405, P907, DOI 10.1038/35016000; Hewitt GM, 1999, BIOL J LINN SOC, V68, P87, DOI 10.1111/j.1095-8312.1999.tb01160.x; Klicka J, 1997, SCIENCE, V277, P1666, DOI 10.1126/science.277.5332.1666; Knowles LL, 2001, MOL ECOL, V10, P691, DOI 10.1046/j.1365-294x.2001.01206.x; Magri D, 2000, QUATERN INT, V73-4, P69, DOI 10.1016/S1040-6182(00)00065-3; MARGARI V, 2000, THESISU CAMBRIDGE; Meese DA, 1997, J GEOPHYS RES-OCEANS, V102, P26411, DOI 10.1029/97JC00269; Petit RJ, 2002, FOREST ECOL MANAG, V156, P49, DOI 10.1016/S0378-1127(01)00634-X; Roucoux KH, 2001, QUATERNARY RES, V56, P128, DOI 10.1006/qres.2001.2218; Roy K, 1996, TRENDS ECOL EVOL, V11, P458, DOI 10.1016/0169-5347(96)10054-9; Roy MS, 1997, P ROY SOC B-BIOL SCI, V264, P1337, DOI 10.1098/rspb.1997.0185; Sanchezgoni MF, 2002, CLIM DYNAM, V19, P95, DOI 10.1007/s00382-001-0212-x; Shackleton NJ, 2002, QUATERNARY RES, V58, P14, DOI 10.1006/qres.2001.2312; Shackleton NJ, 2000, PALEOCEANOGRAPHY, V15, P565, DOI 10.1029/2000PA000513; STUIVER M, 1993, RADIOCARBON, V35, P215, DOI 10.1017/S0033822200013904; TZEDAKIS PC, 1993, NATURE, V364, P437, DOI 10.1038/364437a0; Tzedakis PC, 2002, QUATERNARY RES, V58, P53, DOI 10.1006/qres.2002.2328; Tzedakis PC, 1999, J GEOL SOC LONDON, V156, P425, DOI 10.1144/gsjgs.156.2.0425; WIJMSTRA TA, 1969, ACTA BOT NEERL, V18, P511, DOI 10.1111/j.1438-8677.1969.tb00591.x; Willis KJ, 2000, SCIENCE, V287, P1406, DOI 10.1126/science.287.5457.1406; Zohary M, 1973, GEOBOTANICAL FDN MID	36	420	439	3	83	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 20	2002	297	5589					2044	2047		10.1126/science.1073083	http://dx.doi.org/10.1126/science.1073083			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	594XV	12242441				2022-12-28	WOS:000178078500044
J	William, J; Euler, C; Christensen, S; Shlomchik, MJ				William, J; Euler, C; Christensen, S; Shlomchik, MJ			Evolution of autoantibody responses via somatic hypermutation outside of germinal centers	SCIENCE			English	Article							AFFINITY MATURATION; CLONAL SELECTION; B-CELLS; MOUSE; FAS; MUTATION; ANTIGEN; GENES; MICE	Somatically mutated high-affinity autoantibodies are hallmark of some autoimmune diseases, including systemic lupus erythematosus. It has long been presumed that germinal centers (GCs) are critical in autoantibody production, because they are the only sites currently believed to sustain high rate of somatic hypermutation. Contrary to this idea, we found that splenic autoreactive B cells in autoimmune MRL.Fas(lpr) mice proliferated and underwent active somatic hypermutation at the T zone red pulp border rather than in GCs. Our results implicate this region as an important site for hypermutation and the loss of B cell self-tolerance.	Yale Univ, Sch Med, Dept Lab Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06520 USA	Yale University; Yale University	Shlomchik, MJ (corresponding author), Yale Univ, Sch Med, Dept Lab Med, Box 208035, New Haven, CT 06520 USA.		Shlomchik, Mark J./AAN-6189-2020	Shlomchik, Mark J./0000-0002-2152-0959	PHS HHS [P01-A36529] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CHANG B, 1994, IMMUNOL TODAY, V15, P367, DOI 10.1016/0167-5699(94)90175-9; de Vinuesa CG, 1999, EUR J IMMUNOL, V29, P3712; HAN SH, 1995, J IMMUNOL, V155, P556; Hannum LG, 1996, J EXP MED, V184, P1269, DOI 10.1084/jem.184.4.1269; Kallberg E, 1996, SCIENCE, V271, P1285, DOI 10.1126/science.271.5253.1285; KLEINSTEIN S, UNPUB; Leadbetter EA, 2002, NATURE, V416, P603, DOI 10.1038/416603a; Matsumoto M, 1996, NATURE, V382, P462, DOI 10.1038/382462a0; PULENDRAN B, 1995, J IMMUNOL, V155, P1141; Schroder AE, 1996, P NATL ACAD SCI USA, V93, P221, DOI 10.1073/pnas.93.1.221; SHLOMCHIK M, 1990, J EXP MED, V171, P265, DOI 10.1084/jem.171.1.265; SHLOMCHIK MJ, 1993, INT IMMUNOL, V5, P1329, DOI 10.1093/intimm/5.10.1329; SHLOMCHIK MJ, 1987, NATURE, V328, P805, DOI 10.1038/328805a0; Shlomchik MJ, 2001, NAT REV IMMUNOL, V1, P147, DOI 10.1038/35100573; SHOKAT KM, 1995, NATURE, V375, P334, DOI 10.1038/375334a0; SMITH KGC, 1995, P NATL ACAD SCI USA, V92, P11628, DOI 10.1073/pnas.92.25.11628; Takahashi Y, 2001, IMMUNITY, V14, P181, DOI 10.1016/S1074-7613(01)00100-5; Thiebe R, 1999, EUR J IMMUNOL, V29, P2072, DOI 10.1002/(SICI)1521-4141(199907)29:07&lt;2072::AID-IMMU2072&gt;3.0.CO;2-E; Wang HW, 1999, J EXP MED, V190, P639, DOI 10.1084/jem.190.5.639; Watanabe D, 1995, INT IMMUNOL, V7, P1949, DOI 10.1093/intimm/7.12.1949; Weller S, 2001, P NATL ACAD SCI USA, V98, P1166, DOI 10.1073/pnas.98.3.1166; WILLIAM J, UNPUB	22	386	390	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 20	2002	297	5589					2066	2070		10.1126/science.1073924	http://dx.doi.org/10.1126/science.1073924			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	594XV	12242446				2022-12-28	WOS:000178078500051
J	Horton, R				Horton, R			WHO leadership: a swift start but with few clear objectives	LANCET			English	Editorial Material									Lancet, London NW1 7BY, England		Horton, R (corresponding author), Lancet, London NW1 7BY, England.							Ludwig DS, 2001, LANCET, V357, P505, DOI 10.1016/S0140-6736(00)04041-1; MOCUMBI P, 2001, NY TIMES         JUN, P23	2	1	1	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 14	2002	360	9336					812	813		10.1016/S0140-6736(02)11008-7	http://dx.doi.org/10.1016/S0140-6736(02)11008-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	594MC	12243911				2022-12-28	WOS:000178053500002
J	MacKie, RM; Bray, CA; Hole, DJ; Morris, A; Nicolson, M; Evans, A; Doherty, V; Vestey, J				MacKie, RM; Bray, CA; Hole, DJ; Morris, A; Nicolson, M; Evans, A; Doherty, V; Vestey, J		Scottish Melanoma Grp	Incidence of and survival from malignant melanoma in Scotland: an epidemiological study	LANCET			English	Article							AMERICAN JOINT COMMITTEE; CUTANEOUS MELANOMA; STAGING SYSTEM; TRENDS; MORTALITY	Background We aimed to assess the incidence and survival for all patients with invasive primary cutaneous malignant melanoma diagnosed in Scotland, UK, during 1979-98. Methods The Scottish Melanoma Group obtained data for 8830 patients (3301 male and 5529 female) first diagnosed with invasive cutaneous malignant melanoma. Findings Age-standardised incidence rose from 3.5 in 1979 to 10.6 per 10(5) population in 1998 for men, and from 7.0 to 13.1 for women, a rise of 303% and 187%, respectively. After 1995, the rate of increase levelled in women younger than 65 years at diagnosis. Melanoma incidence increased most in men on the trunk, head, and neck and in women on the leg. 5-year survival rose from 58% to 80% for men diagnosed in 1979 and 1993, respectively, and from 74% to 85% for women; improvements of 38% (p<0.001) and 15% (p<0.001), respectively. Most improvement was attributable to a higher proportion of thinner tumours. Male mortality from melanoma was 1-9/10(5) population per year at the start and end of the study, whereas mortality for men younger than 65 years at diagnosis rose from 1.2 to 1.35 (p=0.24). For all women, mortality fell slightly from 1.9 to 1.85/10(5) population per year (p=0.61), whereas for women younger than 65 years at diagnosis, mortality fell from 1.3 to 1.15 (p=0.62). Interpretation Interventions aimed at both primary and secondary prevention of melanoma are justified. Specialist tumour registers for entire countries can be used to plan and monitor public health interventions.	Univ Glasgow, Dept Dermatol, Glasgow G12 8QQ, Lanark, Scotland; Univ Glasgow, Dept Publ Hlth, Glasgow G12 8QQ, Lanark, Scotland; Ninewells Hosp, Dept Plast Surg, Dundee DD1 9SY, Scotland; Ninewells Hosp, Dept Pathol, Dundee DD1 9SY, Scotland; Foresterhill Hosp, Dept Oncol, Aberdeen, Scotland; Royal Infirm, Dept Dermatol, Edinburgh, Midlothian, Scotland; Raigmore Hosp, Dept Dermatol, Inverness, Scotland	University of Glasgow; University of Glasgow; University of Dundee; University of Dundee; Royal Infirmary of Edinburgh	MacKie, RM (corresponding author), Univ Glasgow, Dept Dermatol, Glasgow G12 8QQ, Lanark, Scotland.		Kelly, Caroline/AAZ-4146-2021	Kelly, Caroline/0000-0002-5330-7888				Balch CM, 2001, J CLIN ONCOL, V19, P3622, DOI 10.1200/JCO.2001.19.16.3622; Balch CM, 2001, J CLIN ONCOL, V19, P3635, DOI 10.1200/JCO.2001.19.16.3635; Cohn-Cedermark G, 2000, CANCER-AM CANCER SOC, V89, P348, DOI 10.1002/1097-0142(20000715)89:2<348::AID-CNCR20>3.0.CO;2-X; Helliwell T, 2001, BRIT MED J, V322, P730; Jemal A, 2001, JNCI-J NATL CANCER I, V93, P678, DOI 10.1093/jnci/93.9.678; MACKIE R, 1992, LANCET, V339, P971, DOI 10.1016/0140-6736(92)91539-K; MACKIE RM, 1985, LANCET, V2, P859; MacKie RM, 1997, BRIT MED J, V315, P1117, DOI 10.1136/bmj.315.7116.1117; Marrett LD, 2001, INT J CANCER, V92, P457, DOI 10.1002/ijc.1203	9	166	171	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 24	2002	360	9333					587	591		10.1016/S0140-6736(02)09779-9	http://dx.doi.org/10.1016/S0140-6736(02)09779-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	586TD	12241928				2022-12-28	WOS:000177600400006
J	Zhang, LQ; Yu, WJ; He, T; Yu, J; Caffrey, RE; Dalmasso, EA; Fu, SY; Pham, T; Mei, JF; Ho, JJ; Zhang, WY; Lopez, P; Ho, DD				Zhang, LQ; Yu, WJ; He, T; Yu, J; Caffrey, RE; Dalmasso, EA; Fu, SY; Pham, T; Mei, JF; Ho, JJ; Zhang, WY; Lopez, P; Ho, DD			Contribution of human alpha-defensin 1, 2, and 3 to the anti-HIV-1 activity of CD8 antiviral factor	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS-REPLICATION; HUMAN NEUTROPHIL DEFENSINS; CELLULAR IMMUNE-RESPONSES; CYTOTOXIC T-LYMPHOCYTES; BETA-CHEMOKINES; INFECTED INDIVIDUALS; HIV REPLICATION; GENE-EXPRESSION; CELLS; SUPPRESSION	It has been known since 1986 that CD8 T lymphocytes from certain HIV-1- infected individuals who are immunologically stable secrete soluble factor, termed CAF, that suppresses HIV-1 replication. However, the identity of CAF remained elusive despite an extensive search. By means of protein-chip technology, we identified cluster of proteins that were secreted when CD8 T cells from long-term nonprogressors with HIV-1 infection were stimulated. These proteins were identified as alpha-defensin 1, 2, and 3 on the basis of specific antibody recognition and amino acid sequencing. CAF activity was eliminated or neutralized by an antibody specific for human alpha-defensins. Synthetic and purified preparations of alpha-defensins also inhibited the replication of HIV-1 isolates in vitro. Taken together, our results indicate that alpha-defensin 1, 2, and 3 collectively account for much of the anti HIV-1 activity of CAF that is not attributable to beta-chemokines.	Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA; Ciphergen Biosyst Inc, Fremont, CA 94555 USA	Rockefeller University	Zhang, LQ (corresponding author), Rockefeller Univ, Aaron Diamond AIDS Res Ctr, 455 1st Ave, New York, NY 10016 USA.		Abrams, William R/A-5782-2008	Lopez, Peter/0000-0002-8587-7148	NCRR NIH HHS [M01-RR00102] Funding Source: Medline; NIAID NIH HHS [AI-42848] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI042848] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agerberth B, 2000, BLOOD, V96, P3086, DOI 10.1182/blood.V96.9.3086.h8003086_3086_3093; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; BAIER M, 1995, NATURE, V378, P563, DOI 10.1038/378563a0; Barker E, 1998, P NATL ACAD SCI USA, V95, P1725, DOI 10.1073/pnas.95.4.1725; Barker E, 1998, BLOOD, V92, P3105, DOI 10.1182/blood.V92.9.3105.421k46_3105_3114; Barouch DH, 2002, NATURE, V415, P335, DOI 10.1038/415335a; Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; CASTRO BA, 1991, CELL IMMUNOL, V132, P246, DOI 10.1016/0008-8749(91)90023-5; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Cole AM, 2002, P NATL ACAD SCI USA, V99, P1813, DOI 10.1073/pnas.052706399; DAHER KA, 1986, J VIROL, V60, P1068, DOI 10.1128/JVI.60.3.1068-1074.1986; DAHER KA, 1988, P NATL ACAD SCI USA, V85, P7327, DOI 10.1073/pnas.85.19.7327; DENG D, 1996, NATURE, V381, P661; Diamond DL, 2001, J IMMUNOL METHODS, V256, P65, DOI 10.1016/S0022-1759(01)00442-2; ENNEN J, 1994, P NATL ACAD SCI USA, V91, P7207, DOI 10.1073/pnas.91.15.7207; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Fung ET, 2001, CURR OPIN BIOTECH, V12, P65, DOI 10.1016/S0958-1669(00)00167-1; GANZ T, 1985, J CLIN INVEST, V76, P1427, DOI 10.1172/JCI112120; Geiben-Lynn R, 2001, J VIROL, V75, P8306, DOI 10.1128/JVI.75.17.8306-8316.2001; Greco G, 1999, J GEN VIROL, V80, P2369, DOI 10.1099/0022-1317-80-9-2369; HSUEH FW, 1994, CELL IMMUNOL, V159, P271, DOI 10.1006/cimm.1994.1313; HUTCHENS TW, 1993, RAPID COMMUN MASS SP, V7, P576, DOI 10.1002/rcm.1290070703; Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991; KANNAGI M, 1988, J IMMUNOL, V140, P2237; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; Kuroda MJ, 1999, J IMMUNOL, V162, P5127; Lacey SF, 1997, P NATL ACAD SCI USA, V94, P9842, DOI 10.1073/pnas.94.18.9842; Lacey SF, 1998, AIDS RES HUM RETROV, V14, P521, DOI 10.1089/aid.1998.14.521; Lehrer RI, 2002, CURR OPIN IMMUNOL, V14, P96, DOI 10.1016/S0952-7915(01)00303-X; Levy JA, 1996, IMMUNOL TODAY, V17, P217, DOI 10.1016/0167-5699(96)10011-6; MACKEWICZ CE, 1995, P NATL ACAD SCI USA, V92, P2308, DOI 10.1073/pnas.92.6.2308; MACKEWICZ CE, 1991, J CLIN INVEST, V87, P1462, DOI 10.1172/JCI115153; Mars WM, 1995, J BIOL CHEM, V270, P30371, DOI 10.1074/jbc.270.51.30371; McMichael AJ, 2001, NATURE, V410, P980, DOI 10.1038/35073658; Moriuchi H, 1996, P NATL ACAD SCI USA, V93, P15341, DOI 10.1073/pnas.93.26.15341; Mosoian A, 2000, VIRAL IMMUNOL, V13, P481, DOI 10.1089/vim.2000.13.481; NAKASHIMA H, 1993, AIDS, V7, P1129, DOI 10.1097/00002030-199308000-00019; Pal R, 1997, SCIENCE, V278, P695, DOI 10.1126/science.278.5338.695; Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857; SELSTED ME, 1985, J CLIN INVEST, V76, P1436, DOI 10.1172/JCI112121; Tomaras GD, 2000, P NATL ACAD SCI USA, V97, P3503, DOI 10.1073/pnas.070521097; Wachinger M, 1998, J GEN VIROL, V79, P731, DOI 10.1099/0022-1317-79-4-731; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; Zhang L., UNPUB	46	386	438	3	86	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 1	2002	298	5595					995	1000		10.1126/science.1076185	http://dx.doi.org/10.1126/science.1076185			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609XQ	12351674				2022-12-28	WOS:000178932000047
J	Lawlor, DA; Ebrahim, S; Smith, GD				Lawlor, DA; Ebrahim, S; Smith, GD			Socioeconomic position in childhood and adulthood and insulin resistance: cross sectional survey using data from British women's heart and health study	BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR-DISEASE; RISK-FACTORS; MORTALITY; CIRCUMSTANCES; LIFE	Objective To assess the associations between childhood and adulthood social class and insulin resistance. Design Cross sectional survey. Setting 23 towns across England, Scotland, and Wales. Participants 4286 women aged 60-79 years. Main outcome measures Insulin resistance and other cardiovascular disease risk factors. Results Belonging to manual social classes in childhood and in adulthood was independently associated with increased insulin resistance, dyslipidaemia, and general obesity. The association between childhood social class and insulin resistance was stronger than that for adult social class. The effect, on insulin resistance and other risk factors, of belonging to a manual social class at either stage in the life course was cumulative, with no evidence of an interaction between childhood and adult social class. Women who were in manual social classes in childhood remained at increased risk of insulin resistance, dyslipidaemia, and obesity-even if they moved into non-manual social classes in adulthood-compared with women who were in non-manual social classes at both stages. Conclusions Adverse social circumstances in childhood, as well as adulthood, arc strongly and independently associated with increased risk of insulin resistance and other metabolic risk factors.	Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England	University of Bristol	Lawlor, DA (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.		Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314; Lawlor, Debbie A/0000-0002-6793-2262				BAO WH, 1994, ARCH INTERN MED, V154, P1842; Blane D, 1996, BMJ-BRIT MED J, V313, P1434, DOI 10.1136/bmj.313.7070.1434; Brunner E, 1999, J EPIDEMIOL COMMUN H, V53, P757, DOI 10.1136/jech.53.12.757; ERENS B, 1999, HLTH SURVEY ENGLAND; Ernster V, 2000, B WORLD HEALTH ORGAN, V78, P891; GRAHAM H, 1998, HLTH B, V56, P757; Heslop P, 2001, SOC SCI MED, V53, P477, DOI 10.1016/S0277-9536(00)00350-6; KAPLAN GA, 1990, BRIT MED J, V301, P1121, DOI 10.1136/bmj.301.6761.1121; Lawlor DA, 2002, DIABETOLOGIA, V45, P1097, DOI 10.1007/s00125-002-0887-5; Lawlor DA, 2002, BMJ-BRIT MED J, V325, P359, DOI 10.1136/bmj.325.7360.359; LAWLOR DA, IN PRESS J EPIDEMIOL; Marmot M, 2001, J EPIDEMIOL COMMUN H, V55, P301, DOI 10.1136/jech.55.5.301; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Office of Population Censuses and Surveys, 1980, CLASS OCC COD IND; Parsons TJ, 1999, INT J OBESITY, V23, pS1; Rose D, 1995, SOCIAL RES UPDAT JUL, P1; Smith GD, 2001, J EPIDEMIOL COMMUN H, V55, P867, DOI 10.1136/jech.55.12.867; Smith GD, 2002, STRESS AND THE HEART: PSYCHOSOCIAL PATHWAYS TO CORONARY HEART DISEASE, P20; Smith GD, 1997, LANCET, V349, P284, DOI 10.1016/S0140-6736(05)64894-5; Smith GD, 1998, BMJ-BRIT MED J, V316, P1631, DOI 10.1136/bmj.316.7145.1631; Smith GD, 2001, J EPIDEMIOL COMMUN H, V55, P340, DOI 10.1136/jech.55.5.340; Wadsworth MEJ, 2002, INT J EPIDEMIOL, V31, P383, DOI 10.1093/ije/31.2.383; Wamala SP, 2001, INT J EPIDEMIOL, V30, P275, DOI 10.1093/ije/30.2.275; Wannamethee SG, 1996, LANCET, V348, P1259, DOI 10.1016/S0140-6736(96)02465-8	24	141	141	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 12	2002	325	7368					805	807		10.1136/bmj.325.7368.805	http://dx.doi.org/10.1136/bmj.325.7368.805			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604YM	12376440	Green Published, Green Accepted, Bronze			2022-12-28	WOS:000178648700017
J	Schoonhoven, L; Haalboom, JRE; Bousema, MT; Algra, A; Grobbee, DE; Gyrpdonck, MH; Buskens, E				Schoonhoven, L; Haalboom, JRE; Bousema, MT; Algra, A; Grobbee, DE; Gyrpdonck, MH; Buskens, E		prePURSE Study Grp	Prospective cohort study of routine use of risk assessment scales for prediction of pressure ulcers	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BRADEN SCALE; SORE RISK; CALCULATORS; MULTISITE; VALIDITY; ISSUES	Objective To evaluate whether risk assessment scales can be used to identify patients who are likely to get pressure ulcers. Design Prospective cohort study. Setting Two large hospitals in the Netherlands. Participants 1229 patients admitted to the surgical, internal, neurological, or geriatric wards between January 1999 and June 2000. Main outcome measure Occurrence of a pressure ulcer of grade 2 or worse while in hospital. Results 135 patients developed pressure ulcers during four weeks after admission. The weekly incidence of patients with pressure ulcers was 6.2% (95% confidence interval 5.2% to 7.2%). The area under the receiver operating characteristic curve was 0.56 (0.51 to 0.61) for the Norton scale, 0.55 (0.49 to 0.60) for the Braden scale, and 0.61 (0.56 to 0.66) for the Waterlow scale; the areas for the subpopulation, excluding patients who received preventive measures without developing pressure ulcers and excluding surgical patients, were 0.71 (0.65 to 0.77), 0.71 (0.64 to 0.78), and 0.68 (0.61 to 0.74), respectively. In this points, subpopulation, using the recommended cut-off the positive predictive value was 7.0% for die Norton, 7.8% for the Braden, and 5.3% for the Waterlow scale. Conclusion Although risk assessment scales predict the occurrence of pressure ulcers to some extent, routine use of these scales leads to inefficient use of preventive measures. An accurate risk assessment scale based on prospectively gathered data should be developed.	Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, NL-3508 GA Utrecht, Netherlands; Univ Med Ctr Utrecht, Dept Internal Med, NL-3508 GA Utrecht, Netherlands; Eemland Hosp, Dept Dermatol, NL-3800 BM Amersfoort, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	Schoonhoven, L (corresponding author), Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, POB 85500, NL-3508 GA Utrecht, Netherlands.	L.Schoonhoven@jc.azu.nl	Schoonhoven, Lisette/O-3330-2013; Grobbee, Diederick/C-7651-2014	Grobbee, Diederick/0000-0003-4472-4468				*AG HLTH CAR POL R, 1992, AHCPR PUBL; ALLMAN RM, 1995, JAMA-J AM MED ASSOC, V273, P865, DOI 10.1001/jama.273.11.865; [Anonymous], 1975, INVESTIGATION GERIAT; Beckrich K, 1999, NURS ECON, V17, P263; Bergstrom N, 1996, J AM GERIATR SOC, V44, P22, DOI 10.1111/j.1532-5415.1996.tb05633.x; Bergstrom N, 1998, NURS RES, V47, P261, DOI 10.1097/00006199-199809000-00005; BERGSTROM N, 1987, NURS RES, V36, P205, DOI 10.1097/00006199-198707000-00002; BOURS GJJ, 1999, LANDELIJK PREVALENTI; *CENTR BEG ORG, 1992, HERZ CONS DEC; CLARK M, 1994, J ADV NURS, V20, P33, DOI 10.1046/j.1365-2648.1994.20010033.x; CLARK M, 1991, P 1 EUR C ADV WOUND, P158; Edwards M, 1996, J CLIN NURS, V5, P307, DOI 10.1111/jocn.1996.5.5.307; EDWARDS M, 1994, J ADV NURS, V20, P288, DOI 10.1046/j.1365-2648.1994.20020288.x; *EUR PRESS ULC ADV, 1999, GUID TREATM PRESS UL; *EUR PRESS ULC ADV, 1999, PRESS ULC PREV GUID; Goodridge D M, 1998, Can J Nurs Res, V30, P23; Haalboom J R, 1999, Ostomy Wound Manage, V45, P20; HAMILTON F, 1992, J CLIN NURS, V1, P185; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Health Council of the Netherlands, 1999, HLTH COUNC NETH PUBL, V1999/18; Nixon J, 2001, PREVENTION TREATMENT, P55; Norton D, 1989, Decubitus, V2, P24; Stotts N A, 1999, Adv Wound Care, V12, P127; Waterlow J, 1985, Nurs Times, V81, P49	25	101	106	1	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 12	2002	325	7368					797	800		10.1136/bmj.325.7368.797	http://dx.doi.org/10.1136/bmj.325.7368.797			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	604YM	12376437	Green Accepted, Bronze, Green Submitted, Green Published			2022-12-28	WOS:000178648700014
J	Lieberman, J				Lieberman, J			Defying death - HIV mutation to evade cytotoxic T lymphocytes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VARIANTS		Ctr Blood Res, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM)	Lieberman, J (corresponding author), Ctr Blood Res, 800 Huntington Ave, Boston, MA 02115 USA.		Lieberman, Judy/A-2717-2015					Allen TM, 2000, NATURE, V407, P386, DOI 10.1038/35030124; KLENERMAN P, 1994, NATURE, V369, P403, DOI 10.1038/369403a0; Lieberman J, 2001, BLOOD, V98, P1667, DOI 10.1182/blood.V98.6.1667; Moore CB, 2002, SCIENCE, V296, P1439, DOI 10.1126/science.1069660; Shankar P, 1996, IMMUNOL LETT, V52, P23, DOI 10.1016/0165-2478(96)02574-6	5	10	10	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 10	2002	347	15					1203	1204		10.1056/NEJMcibr022067	http://dx.doi.org/10.1056/NEJMcibr022067			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	601TW	12374884				2022-12-28	WOS:000178465100014
J	Levin, M; Thorlin, T; Robinson, KR; Nogi, T; Mercola, M				Levin, M; Thorlin, T; Robinson, KR; Nogi, T; Mercola, M			Asymmetries in H+/K+-ATPase and cell membrane potentials comprise a very early step in left-right patterning	CELL			English	Article							MESSENGER-RNA LOCALIZATION; RIGHT AXIS FORMATION; CHICK-EMBRYO; DROSOPHILA OOCYTES; INTRACELLULAR PH; PRIMITIVE STREAK; XENOPUS EMBRYOS; BUDDING YEAST; GAP-JUNCTIONS; ALPHA-SUBUNIT	A pharmacological screen identified the H+ and K+ ATPase transporter as obligatory for normal orientation of the left-right body axis in Xenopus. Maternal H+/K+-ATPase mRNA is symmetrically expressed in the 1-cell Xenopus embryo but becomes localized during the first two cell divisions, demonstrating that asymmetry is generated within two hours postfertilization. Although H+/K+-ATPase subunit mRNAs are symmetrically localized in chick embryos, an endogenous H+/K+-ATPase-dependent difference in membrane voltage potential exists between the left and right sides of the primitive streak. In both species, pharmacologic or genetic perturbation of endogenous H+/K+-ATPase randomized the sided pattern of asymmetrically expressed genes and induced organ heterotaxia. Thus, LR asymmetry determination depends on a very early differential ion flux created by H+/K+-ATPase activity.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Forsyth Inst, Cytokine Biol Dept, Boston, MA 02115 USA; Sahlgrens Univ Hosp, Inst Clin Neurosci, SE-41345 Gothenburg, Sweden; Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA	Harvard University; Harvard Medical School; Harvard University; Forsyth Institute; Sahlgrenska University Hospital; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Mercola, M (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Nogi, Taisaku/F-4675-2017; Nogi, Taisaku/C-7657-2009; Levin, Michael/A-5918-2011	Levin, Michael/0000-0001-7292-8084	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063271] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL63271] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altizer AM, 2001, DEV DYNAM, V221, P391, DOI 10.1002/dvdy.1158; Bashirullah A, 1999, EMBO J, V18, P2610, DOI 10.1093/emboj/18.9.2610; Beach DL, 2000, CURR BIOL, V10, P1497, DOI 10.1016/S0960-9822(00)00837-X; Boettger T, 1999, CURR BIOL, V9, P277, DOI 10.1016/S0960-9822(99)80119-5; BORGENS RB, 1995, DEV DYNAM, V203, P456, DOI 10.1002/aja.1002030408; BRAUNER T, 1984, BIOCHIM BIOPHYS ACTA, V771, P208, DOI 10.1016/0005-2736(84)90535-2; Brink P, 2000, J GEN PHYSIOL, V116, P11, DOI 10.1085/jgp.116.1.11; BROWN NA, 1990, DEVELOPMENT, V109, P1; Burdine RD, 2000, GENE DEV, V14, P763; Capdevila J, 2000, CELL, V101, P9, DOI 10.1016/S0092-8674(00)80619-4; Casey B, 2000, CURR OPIN GENET DEV, V10, P257, DOI 10.1016/S0959-437X(00)00085-X; Casey B, 1998, HUM MOL GENET, V7, P1565, DOI 10.1093/hmg/7.10.1565; COOPER MS, 1989, DEV BIOL, V132, P179, DOI 10.1016/0012-1606(89)90216-9; Croyle ML, 1997, EUR J BIOCHEM, V248, P488, DOI 10.1111/j.1432-1033.1997.00488.x; DANOS MC, 1995, DEVELOPMENT, V121, P1467; DIEHLJONES W, 1993, DEV BIOL, V158, P301, DOI 10.1006/dbio.1993.1190; ELINSON RP, 1975, DEV BIOL, V47, P257, DOI 10.1016/0012-1606(75)90281-X; EPPS DE, 1994, CHEM PHYS LIPIDS, V69, P137, DOI 10.1016/0009-3084(94)90035-3; Fujita A, 2002, J PHYSIOL-LONDON, V540, P85, DOI 10.1113/jphysiol.2001.013439; GERHART J, 1981, NATURE, V292, P511, DOI 10.1038/292511a0; GOTTARDI CJ, 1993, J CELL BIOL, V121, P283, DOI 10.1083/jcb.121.2.283; GOTTARDI CJ, 1993, J BIOL CHEM, V268, P14342; HAMBURGER V, 1992, DEV DYNAM, V195, P231, DOI 10.1002/dvdy.1001950404; HARLAND RM, 1991, XENOPUS LAEVIS PRACT, P685; Harris C, 1999, INT J MOL MED, V3, P315; HOTARY KB, 1992, DEVELOPMENT, V114, P985; HOTARY KB, 1994, DEV BIOL, V166, P789, DOI 10.1006/dbio.1994.1357; Hyatt BA, 1998, CELL, V93, P37, DOI 10.1016/S0092-8674(00)81144-7; Ikuma M, 1998, J MEMBRANE BIOL, V166, P205; JAFFE LF, 1981, PHILOS T ROY SOC B, V295, P553, DOI 10.1098/rstb.1981.0160; Jiang YX, 2000, J GEN PHYSIOL, V115, P269, DOI 10.1085/jgp.115.3.269; LANGE CS, 1978, DIFFERENTIATION, V11, P1, DOI 10.1111/j.1432-0436.1978.tb00965.x; Levin M, 1998, SEMIN CELL DEV BIOL, V9, P67, DOI 10.1006/scdb.1997.0192; Levin M, 1999, DEVELOPMENT, V126, P4703; Levin M, 1998, DEV BIOL, V203, P90, DOI 10.1006/dbio.1998.9024; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; Linask KK, 2001, DEV DYNAM, V221, P249, DOI 10.1002/dvdy.1131; Logan M, 1998, CELL, V94, P307, DOI 10.1016/S0092-8674(00)81474-9; Lohr JL, 1997, DEVELOPMENT, V124, P1465; MARINOS E, 1986, CELL DIFFER DEV, V18, P163, DOI 10.1016/0045-6039(86)90082-5; MATHEWS PM, 1995, AM J PHYSIOL-CELL PH, V268, pC1207, DOI 10.1152/ajpcell.1995.268.5.C1207; Mathur S, 1997, ANESTHESIOLOGY, V87, P1460, DOI 10.1097/00000542-199712000-00025; Meneton P, 1998, J CLIN INVEST, V101, P536, DOI 10.1172/JCI1720; Meneton P, 1999, SEMIN NEPHROL, V19, P438; Mercola M, 2001, ANNU REV CELL DEV BI, V17, P779, DOI 10.1146/annurev.cellbio.17.1.779; Micklem DR, 2000, EMBO J, V19, P1366, DOI 10.1093/emboj/19.6.1366; MIZUNASHI K, 1993, CALCIFIED TISSUE INT, V53, P21, DOI 10.1007/BF01352010; Morley GE, 1997, J CARDIOVASC ELECTR, V8, P939, DOI 10.1111/j.1540-8167.1997.tb00856.x; Munchow S, 1999, J CELL SCI, V112, P1511; Munson KB, 2000, BIOCHEMISTRY-US, V39, P2997, DOI 10.1021/bi991837d; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; Nonaka S, 1998, CELL, V95, P829, DOI 10.1016/S0092-8674(00)81705-5; Nonaka S, 2002, NATURE, V418, P96, DOI 10.1038/nature00849; Ohuchi H, 2000, MECH DEVELOP, V95, P55, DOI 10.1016/S0925-4773(00)00331-2; Pagan-Westphal SM, 1998, CELL, V93, P25, DOI 10.1016/S0092-8674(00)81143-5; Pennekamp P, 2002, CURR BIOL, V12, P938, DOI 10.1016/S0960-9822(02)00869-2; Pizzonia JH, 1996, J NEUROSCI RES, V44, P191, DOI 10.1002/(SICI)1097-4547(19960415)44:2<191::AID-JNR12>3.0.CO;2-9; Psychoyos D, 1996, DEVELOPMENT, V122, P3263; ROBINSON K, 1996, NERVE GROWTH GUIDANC; Rodriguez-Esteban C, 2001, DEVELOPMENT, V128, P3189; ROSE SM, 1970, AM ZOOL, V10, P91; SACHS G, 1995, ANNU REV PHARMACOL, V35, P277, DOI 10.1146/annurev.pa.35.040195.001425; SANDERS SW, 1992, ALIMENT PHARM THERAP, V6, P359; SCHARF SR, 1980, DEV BIOL, V79, P181, DOI 10.1016/0012-1606(80)90082-2; Schnorrer F, 2000, NAT CELL BIOL, V2, P185, DOI 10.1038/35008601; SHI R, 1994, DEV BIOL, V165, P105, DOI 10.1006/dbio.1994.1238; SHI RY, 1995, DEV DYNAM, V202, P101, DOI 10.1002/aja.1002020202; Spemann H., 1938, EMBRYONIC DEV INDUCT; Spicer Z, 2000, J BIOL CHEM, V275, P21555, DOI 10.1074/jbc.M001558200; Supp DM, 1999, DEVELOPMENT, V126, P5495; Supp DM, 1997, NATURE, V389, P963, DOI 10.1038/40140; Takeda S, 2000, J CELL BIOL, V148, P1255, DOI 10.1083/jcb.148.6.1255; Takeda S, 1999, J CELL BIOL, V145, P825, DOI 10.1083/jcb.145.4.825; Takizawa PA, 2000, P NATL ACAD SCI USA, V97, P5273, DOI 10.1073/pnas.080585897; TURIN L, 1980, J PHYSIOL-LONDON, V300, P489, DOI 10.1113/jphysiol.1980.sp013174; Waddington CH, 1937, J EXP BIOL, V14, P229; Weber J, 1998, J BIOL CHEM, V273, P33210, DOI 10.1074/jbc.273.50.33210; WHITE TW, 1994, NATURE, V371, P208, DOI 10.1038/371208a0; Wilhelm JE, 2000, J CELL BIOL, V148, P427, DOI 10.1083/jcb.148.3.427; WOODRUFF RI, 1980, NATURE, V286, P84, DOI 10.1038/286084a0; WOODRUFF RI, 1988, ROUX ARCH DEV BIOL, V197, P231, DOI 10.1007/BF02439430; Yost HJ, 2001, INT REV CYTOL, V203, P357; YU HY, 1994, BBA-BIOMEMBRANES, V1190, P189, DOI 10.1016/0005-2736(94)90052-3; Yuan SP, 1998, DEVELOPMENT, V125, P201; Zhu L, 1999, CURR BIOL, V9, P931, DOI 10.1016/S0960-9822(99)80419-9	85	320	327	1	37	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 4	2002	111	1					77	89		10.1016/S0092-8674(02)00939-X	http://dx.doi.org/10.1016/S0092-8674(02)00939-X			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	601RQ	12372302	Bronze			2022-12-28	WOS:000178461900010
J	Ma, Y; Erkner, A; Gong, RY; Yao, SQ; Taipale, J; Basler, K; Beachy, PA				Ma, Y; Erkner, A; Gong, RY; Yao, SQ; Taipale, J; Basler, K; Beachy, PA			Hedgehog-mediated patterning of the mammalian embryo requires transporter-like function of dispatched	CELL			English	Article							TERMINAL CLEAVAGE PRODUCT; STEROL-SENSING DOMAIN; HUMAN SONIC HEDGEHOG; CHOLESTEROL MODIFICATION; SCLEROTOME INDUCTION; DROSOPHILA SEGMENT; ANIMAL DEVELOPMENT; SIGNALING PATHWAY; MEMBRANE-PROTEIN; NODAL EXPRESSION	The dispatched (disp) gene is required for long-range Hedgehog (Hh) signaling in Drosophila. Here, we demonstrate that one of two murine homologs, rnDispA, can rescue disp function in Drosophila and is essential for all Hh patterning activities examined in the early mouse embryo. Embryonic fibroblasts lacking mDispA respond normally to exogenously provided Sonic hedgehog (Shh) signal, but are impaired in stimulation of other responding cells when expressing Shh. We have developed a biochemical assay that directly measures the activity of Disp proteins in release of soluble Hh proteins. This activity is disrupted by alteration of residues functionally conserved in Patched and in a related family of bacterial transmembrane transporters, thus suggesting similar mechanisms of action for all of these proteins.	Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Univ Zurich, Inst Mol Biol, CH-8057 Zurich, Switzerland	Howard Hughes Medical Institute; Johns Hopkins University; University of Zurich	Beachy, PA (corresponding author), Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Biol & Genet, Baltimore, MD 21205 USA.			Basler, Konrad/0000-0003-3534-1529				Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; Bitgood MJ, 1996, CURR BIOL, V6, P298, DOI 10.1016/S0960-9822(02)00480-3; Borycki AG, 1999, DEVELOPMENT, V126, P4053; BRAND AH, 1993, DEVELOPMENT, V118, P401; Briscoe J, 2001, MOL CELL, V7, P1279, DOI 10.1016/S1097-2765(01)00271-4; Burke R, 1999, CELL, V99, P803, DOI 10.1016/S0092-8674(00)81677-3; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; Chamoun Z, 2001, SCIENCE, V293, P2080, DOI 10.1126/science.1064437; Chen WB, 2001, DEVELOPMENT, V128, P2385; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; Cooper MK, 1998, SCIENCE, V280, P1603, DOI 10.1126/science.280.5369.1603; Davies JP, 2000, J BIOL CHEM, V275, P24367, DOI 10.1074/jbc.M002184200; Dudley AT, 2000, CURR OPIN GENET DEV, V10, P387, DOI 10.1016/S0959-437X(00)00101-5; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092-8674(94)90009-4; FAN CM, 1995, CELL, V81, P457, DOI 10.1016/0092-8674(95)90398-4; Fuse N, 1999, P NATL ACAD SCI USA, V96, P10992, DOI 10.1073/pnas.96.20.10992; Goldberg M, 1999, J BIOL CHEM, V274, P26065, DOI 10.1074/jbc.274.37.26065; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Greco V, 2001, CELL, V106, P633, DOI 10.1016/S0092-8674(01)00484-6; Gurdon JB, 2001, NATURE, V413, P797, DOI 10.1038/35101500; Gustafsson MK, 2002, GENE DEV, V16, P114, DOI 10.1101/gad.940702; HALL TMT, 1995, NATURE, V378, P212, DOI 10.1038/378212a0; HIDALGO A, 1990, DEVELOPMENT, V110, P291; Hogan B, 1994, MANIPULATING MOUSE E; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; Incardona JP, 1998, DEVELOPMENT, V125, P3553; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Jessell TM, 2000, NAT REV GENET, V1, P20, DOI 10.1038/35049541; JOHNSON RL, 1994, CELL, V79, P1165, DOI 10.1016/0092-8674(94)90008-6; KNECHT AK, 1995, DEVELOPMENT, V121, P1927; Lee JD, 2001, CURR BIOL, V11, P1147, DOI 10.1016/S0960-9822(01)00323-2; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; Lewis PM, 2001, CELL, V105, P599, DOI 10.1016/S0092-8674(01)00369-5; Linton KJ, 1998, MOL MICROBIOL, V28, P5, DOI 10.1046/j.1365-2958.1998.00764.x; Liu JX, 1999, GENE, V237, P153, DOI 10.1016/S0378-1119(99)00314-5; Lowe LA, 1996, NATURE, V381, P158, DOI 10.1038/381158a0; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Marigo V, 1996, DEVELOPMENT, V122, P1225; MUENKE M, 2001, METABOLIC MOL BASES, P6203; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NIES DH, 1995, J BACTERIOL, V177, P2707, DOI 10.1128/jb.177.10.2707-2712.1995; Pepinsky RB, 1998, J BIOL CHEM, V273, P14037, DOI 10.1074/jbc.273.22.14037; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Porter JA, 1996, CELL, V86, P21, DOI 10.1016/S0092-8674(00)80074-4; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; Roessler E, 1996, NAT GENET, V14, P357, DOI 10.1038/ng1196-357; Sasaki H, 1997, DEVELOPMENT, V124, P1313; St-Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Taipale J, 2002, NATURE, V418, P892, DOI 10.1038/nature00989; Teleman AA, 2001, CELL, V105, P559, DOI 10.1016/S0092-8674(01)00377-4; Tseng Tsai-Tien, 1999, Journal of Molecular Microbiology and Biotechnology, V1, P107; vandenHeuvel M, 1996, NATURE, V382, P547, DOI 10.1038/382547a0; Wang BL, 2000, CELL, V100, P423, DOI 10.1016/S0092-8674(00)80678-9; Yakushi T, 2000, NAT CELL BIOL, V2, P212, DOI 10.1038/35008635; Zeng X, 2001, NATURE, V411, P716, DOI 10.1038/35079648; Zhang XM, 2001, CELL, V105, P781, DOI 10.1016/S0092-8674(01)00385-3	62	230	246	0	6	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 4	2002	111	1					63	75		10.1016/S0092-8674(02)00977-7	http://dx.doi.org/10.1016/S0092-8674(02)00977-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	601RQ	12372301	Bronze, Green Accepted			2022-12-28	WOS:000178461900009
J	Malhotra, V; Emr, SD				Malhotra, V; Emr, SD			Rothman and Schekman SNAREd by Lasker for trafficking	CELL			English	Article								This year, the recipients of the Lasker Award for Basic Medical Research are James Rothman and Randy Schekman. This highly anticipated honor highlights their unique contributions to our understanding of the mechanisms of membrane traffic.	Univ Calif San Diego, Dept Cell & Dev Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Howard Hughes Med Inst, Dept Cellular & Mol Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego	Malhotra, V (corresponding author), Univ Calif San Diego, Dept Cell & Dev Biol, La Jolla, CA 92093 USA.		Malhotra, Vivek/O-9811-2014	Malhotra, Vivek/0000-0001-6198-7943					0	5	5	0	5	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 4	2002	111	1					1	3		10.1016/S0092-8674(02)01008-5	http://dx.doi.org/10.1016/S0092-8674(02)01008-5			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	601RQ	12372293	Bronze			2022-12-28	WOS:000178461900001
J	Ludwig, A; Debus, L; Lieckfeldt, D; Wirgin, I; Benecke, N; Jenneckens, I; Williot, P; Waldman, JR; Pitra, C				Ludwig, A; Debus, L; Lieckfeldt, D; Wirgin, I; Benecke, N; Jenneckens, I; Williot, P; Waldman, JR; Pitra, C			When the American sea sturgeon swam east - A colder Baltic Sea greeted this fish from across the Atantic Ocean in the Middle Ages	NATURE			English	Article							CONTROL REGION; ACIPENSER		Inst Zoo & Wildlife Res, Dept Evolutionary Genet, D-10252 Berlin, Germany; Univ Rostock, Inst Zool, D-18051 Rostock, Germany; NYU, Sch Med, Dept Environm Med, Tuxedo Pk, NY 10987 USA; German Archaeol Inst, D-14195 Berlin, Germany; Univ Gottingen, Inst Genet & Anim Breeding, D-37075 Gottingen, Germany; Cemagref, Inland Living Aquat Resources Res Unit, F-33612 Cestas, France; Hudson River Fdn Sci & Environm Res, New York, NY 10011 USA	Leibniz Institut fur Zoo und Wildtierforschung; University of Rostock; New York University; University of Gottingen; INRAE	Ludwig, A (corresponding author), Inst Zoo & Wildlife Res, Dept Evolutionary Genet, D-10252 Berlin, Germany.			Lieckfeldt, Dietmar/0000-0002-8040-8588				Artyukhin E, 1999, J APPL ICHTHYOL, V15, P35, DOI 10.1111/j.1439-0426.1999.tb00202.x; BROWN JR, 1993, MOL BIOL EVOL, V10, P326; ISORODIN N, 1925, T AM FISH SOC, V55, P184; King TL, 2001, CONSERV GENET, V2, P103, DOI 10.1023/A:1011895429669; Ludwig A, 2000, GENETICS, V156, P1933; MAGNIN ETIENNE, 1964, NATUR CAN, V91, P5; Quantz H., 1903, MITTEILUNGEN DTSCH S, V19, P176	7	92	100	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 3	2002	419	6906					447	448		10.1038/419447a	http://dx.doi.org/10.1038/419447a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	599RF	12368843				2022-12-28	WOS:000178348400024
J	Fried, MW; Shiffman, ML; Reddy, KR; Smith, C; Marinos, G; Goncales, FL; Haussinger, D; Diago, M; Carosi, G; Dhumeaux, D; Craxi, A; Lin, A; Hoffman, J; Yu, J				Fried, MW; Shiffman, ML; Reddy, KR; Smith, C; Marinos, G; Goncales, FL; Haussinger, D; Diago, M; Carosi, G; Dhumeaux, D; Craxi, A; Lin, A; Hoffman, J; Yu, J			Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTERFERON ALPHA-2A; INITIAL TREATMENT; PEG-IFN; EFFICACY; PHARMACOKINETICS; TRIAL	Background: Treatment with peginterferon alfa-2a alone produces significantly higher sustained virologic responses than treatment with interferon alfa-2a alone in patients with chronic hepatitis C virus (HCV) infection. We compared the efficacy and safety of peginterferon alfa-2a plus ribavirin, interferon alfa-2b plus ribavirin, and peginterferon alfa-2a alone in the initial treatment of chronic hepatitis C. Methods: A total of 1121 patients were randomly assigned to treatment and received at least one dose of study medication, consisting of 180 microg of peginterferon alfa-2a once weekly plus daily ribavirin (1000 or 1200 mg, depending on body weight), weekly peginterferon alfa-2a plus daily placebo, or 3 million units of interferon alfa-2b thrice weekly plus daily ribavirin for 48 weeks. Results: A significantly higher proportion of patients who received peginterferon alfa-2a plus ribavirin had a sustained virologic response (defined as the absence of detectable HCV RNA 24 weeks after cessation of therapy) than of patients who received interferon alfa-2b plus ribavirin (56 percent vs. 44 percent, P<0.001) or peginterferon alfa-2a alone (56 percent vs. 29 percent, P<0.001). The proportions of patients with HCV genotype 1 who had sustained virologic responses were 46 percent, 36 percent, and 21 percent, respectively, for the three regimens. Among patients with HCV genotype 1 and high base-line levels of HCV RNA, the proportions of those with sustained virologic responses were 41 percent, 33 percent, and 13 percent, respectively. The overall safety profiles of the three treatment regimens were similar; the incidence of influenza-like symptoms and depression was lower in the groups receiving peginterferon alfa-2a than in the group receiving interferon alfa-2b plus ribavirin. Conclusions: In patients with chronic hepatitis C, once-weekly peginterferon alfa-2a plus ribavirin was tolerated as well as interferon alfa-2b plus ribavirin and produced significant improvements in the rate of sustained virologic response, as compared with interferon alfa-2b plus ribavirin or peginterferon alfa-2a alone.	Univ N Carolina, Chapel Hill, NC 27599 USA; Virginia Commonwealth Univ, Med Coll Virginia, Richmond, VA 23298 USA; Univ Miami, Miami, FL 33152 USA; Minnesota Clin Res Ctr, St Paul, MN USA; Prince Wales Hosp, Randwick, NSW 2031, Australia; Cidade Univ Zeferino Vaz, Campinas, SP, Brazil; Univ Dusseldorf, D-4000 Dusseldorf, Germany; Gen Univ, Valencia, Spain; Univ Brescia, Brescia, Italy; Hop Henri Mondor, F-94010 Creteil, France; Univ Palermo, Palermo, Italy; Hoffmann La Roche Inc, Nutley, NJ 07110 USA	University of North Carolina; University of North Carolina Chapel Hill; Virginia Commonwealth University; University of Miami; Heinrich Heine University Dusseldorf; University of Brescia; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; University of Palermo; Roche Holding	Fried, MW (corresponding author), Univ N Carolina, CB 7080,Rm 708,Burnett Womack Bldg, Chapel Hill, NC 27599 USA.		DIAGO, MOISES/AAH-5364-2019; Craxi, Antonio/K-9529-2016	Craxi, Antonio/0000-0002-4480-9544	NCRR NIH HHS [RR00046] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000046] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Algranati NE, 1999, HEPATOLOGY, V30, p190A; [Anonymous], 1999, J Hepatol, V30, P956; BAUER P, 1991, STAT MED, V10, P871, DOI 10.1002/sim.4780100609; Booth JC, 2001, GUT               S1, V49, P11; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; Canadian Association for the Study of the Liver, 2000, CAN J GASTROENTEROL, V14, p5B; Ferenci P, 2001, HEPATOLOGY, V34, p351A; Germer JJ, 1999, J CLIN MICROBIOL, V37, P2625, DOI 10.1128/JCM.37.8.2625-2630.1999; Heathcote EJ, 2000, NEW ENGL J MED, V343, P1673, DOI 10.1056/NEJM200012073432302; Lai MY, 1996, GASTROENTEROLOGY, V111, P1307, DOI 10.1053/gast.1996.v111.pm8898645; Lindsay KL, 2001, HEPATOLOGY, V34, P395, DOI 10.1053/jhep.2001.26371; Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5; MARCUS R, 1976, BIOMETRIKA, V63, P655, DOI 10.1093/biomet/63.3.655; McHutchison JG, 1998, NEW ENGL J MED, V339, P1485, DOI 10.1056/NEJM199811193392101; Nieforth KA, 1996, CLIN PHARMACOL THER, V59, P636, DOI 10.1016/S0009-9236(96)90003-X; POCKROS PJ, 2002, 41 INT C ANT AG CHEM, P285; Poynard T, 1998, LANCET, V352, P1426, DOI 10.1016/S0140-6736(98)07124-4; Reddy KR, 2001, HEPATOLOGY, V33, P433, DOI 10.1053/jhep.2001.21747; Thomas HC, 1999, J HEPATOL, V31, P152, DOI 10.1016/S0168-8278(99)80393-6; WILLS RJ, 1990, CLIN PHARMACOKINET, V19, P390, DOI 10.2165/00003088-199019050-00003; Xu ZX, 1998, HEPATOLOGY, V28, p702A; Zeuzem S, 2000, NEW ENGL J MED, V343, P1666, DOI 10.1056/NEJM200012073432301	22	5078	5393	29	361	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 26	2002	347	13					975	982		10.1056/NEJMoa020047	http://dx.doi.org/10.1056/NEJMoa020047			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	596RD	12324553	Green Published, Bronze			2022-12-28	WOS:000178178400003
J	Bourgeois, C; Rocha, B; Tanchot, C				Bourgeois, C; Rocha, B; Tanchot, C			A role for CD40 expression on CD8(+) T cells in the generation of CD8(+) T cell memory	SCIENCE			English	Article							IN-VIVO; MICE; RESPONSES; LIGAND; IMMUNITY; HELP; INDUCTION; TOLERANCE; DIFFERENTIATION; COSTIMULATION	The delivery of CD4 help to CD8(+) T cell responses requires interactions between CD40 and CD40 ligand and is thought to occur through antigen-presenting cell (APC) activation. Here we show that generation of memory CD8(+) T cells displaying an enhanced capacity for cell division and cytokine secretion required CD4 help but not CD40 expression by the APCs. Activated CD4(+) and CD8(+) T cells expressed CD40; and in the absence of this protein, CD8(+) T cells were unable to differentiate into memory cells or receive CD4 help. These results suggest that, like B cells, CD8(+) T cells receive CD4 help directly through CD40 and that this interaction is fundamental for CD8(+) T cell memory generation.	Inst Necker, INSERM, U345, F-75730 Paris 15, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Tanchot, C (corresponding author), Inst Necker, INSERM, U345, 156 Rue Vaugirard, F-75730 Paris 15, France.		Bourgeois, Christine/ABA-1432-2021; Bourgeois, Christine/L-5944-2018	Bourgeois, Christine/0000-0003-1146-6087; Bourgeois, Christine/0000-0003-1146-6087; Tanchot, Corinne/0000-0002-2913-1755				Agarwal S, 1998, IMMUNITY, V9, P765, DOI 10.1016/S1074-7613(00)80642-1; Amrani A, 2002, IMMUNITY, V16, P719, DOI 10.1016/S1074-7613(02)00315-1; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; Bennett SRM, 1997, J EXP MED, V186, P65, DOI 10.1084/jem.186.1.65; BODMER H, 1993, EUR J IMMUNOL, V23, P1649, DOI 10.1002/eji.1830230738; Borrow P, 1996, J EXP MED, V183, P2129, DOI 10.1084/jem.183.5.2129; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; Gray D, 1994, Semin Immunol, V6, P303, DOI 10.1006/smim.1994.1039; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; Grewal IS, 1996, SCIENCE, V273, P1864, DOI 10.1126/science.273.5283.1864; Heath WR, 2001, ANNU REV IMMUNOL, V19, P47, DOI 10.1146/annurev.immunol.19.1.47; HERMANN P, 1995, EUR J IMMUNOL, V25, P2972, DOI 10.1002/eji.1830251039; Kassiotis G, 2002, NAT IMMUNOL, V3, P244, DOI 10.1038/ni766; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; Livingstone AM, 1999, EUR J IMMUNOL, V29, P2826, DOI 10.1002/(SICI)1521-4141(199909)29:09<2826::AID-IMMU2826>3.0.CO;2-M; Lu ZB, 2000, J EXP MED, V191, P541, DOI 10.1084/jem.191.3.541; MALISSEN M, 1995, EMBO J, V14, P4641, DOI 10.1002/j.1460-2075.1995.tb00146.x; Markiewicz MA, 1998, P NATL ACAD SCI USA, V95, P3065, DOI 10.1073/pnas.95.6.3065; Mintern JD, 2002, J IMMUNOL, V168, P977, DOI 10.4049/jimmunol.168.3.977; Noelle RJ, 1996, IMMUNITY, V4, P415, DOI 10.1016/S1074-7613(00)80408-2; Ozaki ME, 1999, J IMMUNOL, V163, P5250; Perarnau B, 1999, EUR J IMMUNOL, V29, P1243, DOI 10.1002/(SICI)1521-4141(199904)29:04<1243::AID-IMMU1243>3.0.CO;2-A; RAHEMTULLA A, 1991, NATURE, V353, P180, DOI 10.1038/353180a0; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; Ruedl C, 1999, J EXP MED, V189, P1875, DOI 10.1084/jem.189.12.1875; Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002; Shepherd DM, 1999, J IMMUNOL, V163, P2470; Tanchot C, 1998, IMMUNITY, V8, P581, DOI 10.1016/S1074-7613(00)80563-4; Tanchot C, 1997, SCIENCE, V276, P2057, DOI 10.1126/science.276.5321.2057; TANCHOT C, UNPUB; Veiga-Fernandes H, 2000, NAT IMMUNOL, V1, P47, DOI 10.1038/76907; Whitmire JK, 1999, J IMMUNOL, V163, P3194	35	515	542	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 20	2002	297	5589					2060	2063		10.1126/science.1072615	http://dx.doi.org/10.1126/science.1072615			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	594XV	12242444				2022-12-28	WOS:000178078500049
J	Garrett, TPJ; McKern, NM; Lou, MZ; Elleman, TC; Adams, TE; Lovrecz, GO; Zhu, HJ; Walker, F; Frenkel, MJ; Hoyne, PA; Jorissen, RN; Nice, EC; Burgess, AW; Ward, CW				Garrett, TPJ; McKern, NM; Lou, MZ; Elleman, TC; Adams, TE; Lovrecz, GO; Zhu, HJ; Walker, F; Frenkel, MJ; Hoyne, PA; Jorissen, RN; Nice, EC; Burgess, AW; Ward, CW			Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha	CELL			English	Article							LEUCINE-RICH REPEAT; FACTOR EGF RECEPTOR; ATOMIC-STRUCTURE; BINDING DOMAIN; LIGAND; COMPLEX; RECOGNITION; INSULIN; NMR; IDENTIFICATION	We report the crystal structure, at 2.5 Angstrom resolution, of a truncated human EGFR ectodomain bound to TGFalpha. TGFalpha interacts with both L1 and L2 domains of EGFR, making many main chain contacts with L1 and interacting with L2 via key conserved residues. The results indicate how EGFR family members can bind a family of highly variable ligands. In the 2:2 TGFalpha:sEGFR501 complex, each ligand interacts with only one receptor molecule. There are two types of dimers; in the asymmetric unit: a head-to-head dimer involving contacts between the L1 and L2 domains and a back-to-back dimer dominated by interactions between the CRI domains of each receptor. Based on sequence conservation, buried surface area, and mutagenesis experiments, the back-to-back dimer is favored to be biologically relevant.	Cooperat Res Ctr Cellular Growth Factors, Parkville, Vic 3050, Australia; Ludwig Inst Canc Res, Parkville, Vic 3050, Australia; Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; CSIRO, Hlth Sci & Nutr, Parkville, Vic 3052, Australia	Ludwig Institute for Cancer Research; Walter & Eliza Hall Institute; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Garrett, TPJ (corresponding author), Walter & Eliza Hall Inst Med Res, PO Royal Melbourne Hosp, Parkville, Vic 3050, Australia.	tgarrett@wehi.edu.au; tony.burgess@ludwig.edu.au; colin.ward@hsn.csiro.au	Lovrecz, George/H-8602-2013; Nice, Edouard C/B-1026-2011; Adams, Timothy E/I-6231-2012	Adams, Timothy E/0000-0003-3436-0066; Jorissen, Robert/0000-0001-9634-2803; Zhu, Hong-Jian/0000-0002-1478-995X				Aritomi M, 1999, NATURE, V401, P713, DOI 10.1038/44394; BAJAJ M, 1987, BIOCHIM BIOPHYS ACTA, V916, P220, DOI 10.1016/0167-4838(87)90112-9; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Barnham KJ, 1998, PROTEIN SCI, V7, P1738, DOI 10.1002/pro.5560070808; BRIZZARD BL, 1994, BIOTECHNIQUES, V16, P730; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cho HS, 2002, SCIENCE, V297, P1330, DOI 10.1126/science.1074611; COOKE RM, 1987, NATURE, V327, P339, DOI 10.1038/327339a0; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Degenhardt M, 1998, ACTA CRYSTALLOGR D, V54, P999, DOI 10.1107/S0907444998001851; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Elleman TC, 2001, BIOCHEMISTRY-US, V40, P8930, DOI 10.1021/bi010037b; Garrett TPJ, 1998, NATURE, V394, P395, DOI 10.1038/28668; GROENEN LC, 1994, GROWTH FACTORS, V11, P235, DOI 10.3109/08977199409010997; GUNTHER N, 1990, J BIOL CHEM, V265, P22082; HARVEY TS, 1991, EUR J BIOCHEM, V198, P555, DOI 10.1111/j.1432-1033.1991.tb16050.x; Jacobsen NE, 1996, BIOCHEMISTRY-US, V35, P3402, DOI 10.1021/bi952626l; Jorissen RN, 2000, PROTEIN SCI, V9, P310; Kirsch T, 2000, NAT STRUCT BIOL, V7, P492; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; KOHDA D, 1993, J BIOL CHEM, V268, P1976; KOHDA D, 1992, BIOCHEMISTRY-US, V31, P11928, DOI 10.1021/bi00162a036; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; LAX I, 1988, MOL CELL BIOL, V8, P1970, DOI 10.1128/MCB.8.5.1970; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; Lemmon MA, 1997, EMBO J, V16, P281, DOI 10.1093/emboj/16.2.281; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; Lo Conte L, 1999, J MOL BIOL, V285, P2177; Louie GV, 1997, MOL CELL, V1, P67, DOI 10.1016/S1097-2765(00)80008-8; Lu HS, 2001, J BIOL CHEM, V276, P34913, DOI 10.1074/jbc.M102874200; MONTELIONE GT, 1987, P NATL ACAD SCI USA, V84, P5226, DOI 10.1073/pnas.84.15.5226; Moriki T, 2001, J MOL BIOL, V311, P1011, DOI 10.1006/jmbi.2001.4923; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; MOY FJ, 1993, BIOCHEMISTRY-US, V32, P7334, DOI 10.1021/bi00080a003; NAGATA K, 1994, EMBO J, V13, P3517, DOI 10.1002/j.1460-2075.1994.tb06658.x; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; Plotnikov AN, 2000, CELL, V101, P413, DOI 10.1016/S0092-8674(00)80851-X; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Singer E, 2001, J BIOL CHEM, V276, P44266, DOI 10.1074/jbc.M105428200; SOROKIN A, 1994, J BIOL CHEM, V269, P9752; Summerfield AE, 1996, J BIOL CHEM, V271, P19656, DOI 10.1074/jbc.271.33.19656; Sundaresan S, 1998, ENDOCRINOLOGY, V139, P4756, DOI 10.1210/en.139.12.4756; TAPPIN MJ, 1989, EUR J BIOCHEM, V179, P629, DOI 10.1111/j.1432-1033.1989.tb14594.x; Thiel DJ, 2000, STRUCTURE, V8, P927, DOI 10.1016/S0969-2126(00)00184-2; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; Walker F, 1998, GROWTH FACTORS, V16, P53, DOI 10.3109/08977199809017491; Ward CW, 2001, BMC BIOINFORMATICS, V2, DOI 10.1186/1471-2105-2-4; WARD CW, 1995, PROTEINS, V22, P141, DOI 10.1002/prot.340220207; WEBER W, 1994, J CHROMATOGR A, V679, P181, DOI 10.1016/0021-9673(94)80325-0; Wiesmann C, 1999, NATURE, V401, P184, DOI 10.1038/43705; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; WOLTJER RL, 1992, P NATL ACAD SCI USA, V89, P7801, DOI 10.1073/pnas.89.16.7801; WU DG, 1989, J BIOL CHEM, V264, P17469; Yarden Y, 2001, EUR J CANCER, V37, pS3; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	58	584	638	6	57	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 20	2002	110	6					763	773		10.1016/S0092-8674(02)00940-6	http://dx.doi.org/10.1016/S0092-8674(02)00940-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	596TV	12297049	Bronze			2022-12-28	WOS:000178182800011
J	Smith, SR				Smith, SR			Multinational economic evaluations of pharmaceuticals	LANCET			English	Editorial Material							INDUSTRY; GLOBALIZATION		Univ N Carolina, Sch Pharm, Chapel Hill, NC 27599 USA; Univ N Carolina, Ctr AIDS Res, Div Pharmaceut Policy & Evaluat Sci, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Smith, SR (corresponding author), Univ N Carolina, Sch Pharm, Chapel Hill, NC 27599 USA.							Anis AH, 1998, J HEALTH ECON, V17, P21, DOI 10.1016/S0167-6296(97)00016-7; Bloor K, 1996, BRIT MED J, V313, P33, DOI 10.1136/bmj.313.7048.33; Ioannides-Demos LL, 2002, PHARMACOECONOMICS, V20, P577, DOI 10.2165/00019053-200220090-00002; Pang F, 2002, PHARMACOECONOMICS, V20, P75, DOI 10.2165/00019053-200220020-00001; SCHWEITZER SO, 1997, PHARM EC POLICY, P137; TAGERT J, 1993, WORLD PHARM IND, P33; Tarabusi CC, 1998, INT J HEALTH SERV, V28, P67, DOI 10.2190/7JDR-2TFN-2B3X-TYF5; Tarabusi CC, 1998, INT J HEALTH SERV, V28, P281, DOI 10.2190/B6VR-NND7-46BL-PY5G	8	2	2	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 14	2002	360	9336					816	816		10.1016/S0140-6736(02)11011-7	http://dx.doi.org/10.1016/S0140-6736(02)11011-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	594MC	12243914				2022-12-28	WOS:000178053500005
J	Klein, CA; Blankenstein, TJF; Schmidt-Kittler, O; Petronio, M; Polzer, B; Stoecklein, NH; Riethmuller, G				Klein, CA; Blankenstein, TJF; Schmidt-Kittler, O; Petronio, M; Polzer, B; Stoecklein, NH; Riethmuller, G			Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer	LANCET			English	Article							COMPARATIVE GENOMIC HYBRIDIZATION; HUMAN PROSTATE-CANCER; BONE-MARROW; BREAST-CANCER; PROGNOSTIC-SIGNIFICANCE; CYTOGENETIC ANALYSIS; ESOPHAGEAL CANCER; P53 MUTATIONS; LYMPH-NODES; LUNG-CANCER	Background Because cancer patients with small tumours often relapse despite local and systemic treatment, we investigated the genetic variation of the precursors of distant metastasis at the stage of minimal residual disease. Disseminated tumour cells can be detected by epithelial markers in mesenchymal tissues and represent targets for adjuvant therapies. Methods We screened 525 bone-marrow, blood, and lymphnode samples from 474 patients with breast, prostate, and gastrointestinal cancers for single disseminated cancer cells by immunocytochemistry with epithelial-specific markers. 71 (14%) of the samples contained two or more tumour cells whose genomic organisation we studied by single cell genomic hybridisation. In addition, we tested whether TP53 was mutated. Hierarchical clustering algorithms were used to determine the degree of clonal relatedness of sister cells that were isolated from individual patients. Findings Irrespective of cancer type, we saw an unexpectedly high genetic divergence in minimal residual cancer, particularly at the level of chromosomal imbalances. Although few disseminated cells harboured TP53 mutations at this stage of disease, we also saw microheterogeneity of the TP53 genotype. The genetic heterogeneity was strikingly reduced with the emergence of clinically evident metastasis. Interpretation Although the heterogeneity of primary tumours has long been known, we show here that early disseminated cancer cells are genomically very unstable as well. Selection of clonally expanding cells leading to metastasis, seems to occur after dissemination has taken place. Therefore, adjuvant therapies are confronted with an extremely large reservoir of variant cells from which resistant tumour cells can be selected.	Univ Munich, Inst Immunol, D-80336 Munich, Germany; Univ Hamburg, Klinikum Eppendorf, Chirurg Klin, Hamburg, Germany	University of Munich; University of Hamburg	Klein, CA (corresponding author), Univ Munich, Inst Immunol, D-80336 Munich, Germany.	christoph.klein@ifi.med.uni-muenchen.de	Califano, Andrea/F-7239-2012	Klein, Christoph A./0000-0001-7128-1725				Braun S, 2000, NEW ENGL J MED, V342, P525, DOI 10.1056/NEJM200002243420801; Braun S, 2000, J CLIN ONCOL, V18, P80, DOI 10.1200/JCO.2000.18.1.80; Chay C, 2001, SEMIN ONCOL, V28, P3, DOI 10.1053/sonc.2001.20744; Edwards BK, 2002, CANCER-AM CANCER SOC, V94, P2766, DOI 10.1002/cncr.10593; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fujii H, 1996, CANCER RES, V56, P1493; Gianni L, 2001, SEMIN ONCOL, V28, P13, DOI 10.1053/sonc.2001.20747; Gorunova L, 1998, GENE CHROMOSOME CANC, V23, P81, DOI 10.1002/(SICI)1098-2264(199810)23:2<81::AID-GCC1>3.0.CO;2-0; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; Harris DT, 2001, SEMIN ONCOL, V28, P1; Heim S, 1997, CANCER GENET CYTOGEN, V95, P16, DOI 10.1016/S0165-4608(96)00322-6; Izbicki JR, 1997, NEW ENGL J MED, V337, P1188, DOI 10.1056/NEJM199710233371702; Jauch KW, 1996, J CLIN ONCOL, V14, P1810, DOI 10.1200/JCO.1996.14.6.1810; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; Klein CA, 2000, TRENDS CELL BIOL, V10, P489, DOI 10.1016/S0962-8924(00)01846-8; Klein CA, 1999, P NATL ACAD SCI USA, V96, P4494, DOI 10.1073/pnas.96.8.4494; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LINDEMANN F, 1992, LANCET, V340, P685, DOI 10.1016/0140-6736(92)92230-D; Loeb LA, 2001, CANCER RES, V61, P3230; Macdonald JS, 2001, SEMIN ONCOL, V28, P30, DOI 10.1053/sonc.2001.20750; Macintosh CA, 1998, CANCER RES, V58, P23; MIRCHANDANI D, 1995, AM J PATHOL, V147, P92; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Pandis N, 1998, GENE CHROMOSOME CANC, V22, P122, DOI 10.1002/(SICI)1098-2264(199806)22:2<122::AID-GCC6>3.0.CO;2-Z; Pantel K, 1999, JNCI-J NATL CANCER I, V91, P1113, DOI 10.1093/jnci/91.13.1113; Pantel K, 1996, LANCET, V347, P649, DOI 10.1016/S0140-6736(96)91203-9; PASSLICK B, 1994, J CLIN ONCOL, V12, P1827, DOI 10.1200/JCO.1994.12.9.1827; SCHLIMOK G, 1987, P NATL ACAD SCI USA, V84, P8672, DOI 10.1073/pnas.84.23.8672; Stapleton AMF, 1997, CLIN CANCER RES, V3, P1389; Thorban S, 2000, BRIT J CANCER, V83, P35; Weckermann D, 2001, J UROLOGY, V166, P699, DOI 10.1016/S0022-5347(05)66046-6	33	391	401	0	27	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 31	2002	360	9334					683	689		10.1016/S0140-6736(02)09838-0	http://dx.doi.org/10.1016/S0140-6736(02)09838-0			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	590AM	12241875				2022-12-28	WOS:000177795100010
J	Thomas, SL; Wheeler, JG; Hall, AJ				Thomas, SL; Wheeler, JG; Hall, AJ			Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study	LANCET			English	Article							VIRUS-DNA; GANGLIA; CHICKENPOX	Background Whether exogenous exposure to varicella-zoster-virus protects individuals with latent varicella-zoster virus infection against herpes zoster by boosting immunity is not known. To test the hypothesis that contacts with children increase exposure to varicella-zoster virus and protect latently infected adults against zoster, we did a case-control study in south London, UK. Methods From 22 general practices, we identified patients with recently diagnosed zoster, and control individuals with no history of zoster, matched to patients by age, sex, and practice. Participants were asked about contacts with people with varicella or zoster in the past 10 years, and social and occupational contacts with children as proxies for varicella contacts. Odds ratios were estimated with conditional logistic regression. Findings Data from 244 patients and 485 controls were analysed. On multivariable analysis, protection associated with contacts with a few children in the household or via childcare seemed to be largely mediated by increased access to children outside the household. Social contacts with many children outside the household and occupational contacts with ill children were associated with graded protection against zoster, with less than a fifth the risk in the most heavily exposed groups compared with the least exposed. The strength of protection diminished after controlling for known varicella contacts; the latter remained significantly protective (odds ratio 0.29 [95% CI 0.10-0.84] for those with five contacts or more). Interpretation Re-exposure to varicella-zoster virus via contact with children seems to protect latently infected individuals against zoster. Reduction of childhood varicella by vaccination might lead to increased incidence of adult zoster. Vaccination of the elderly (if effective) should be considered in countries with childhood varicella vaccination programmes.	Univ London London Sch Hyg & Trop Med, Infect Dis Epidemiol Unit, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Thomas, SL (corresponding author), Univ London London Sch Hyg & Trop Med, Infect Dis Epidemiol Unit, Keppel St, London WC1E 7HT, England.							ARVIN AM, 1992, J INFECT DIS, V166, pS35, DOI 10.1093/infdis/166.Supplement_1.S35; ARVIN AM, 1983, J INFECT DIS, V148, P200, DOI 10.1093/infdis/148.2.200; BERGER R, 1981, INFECT IMMUN, V32, P24, DOI 10.1128/IAI.32.1.24-27.1981; BUCHBINDER SP, 1992, J INFECT DIS, V166, P1153, DOI 10.1093/infdis/166.5.1153; BURKE BL, 1982, ARCH INTERN MED, V142, P291, DOI 10.1001/archinte.142.2.291; Fairley CK, 1996, J INFECT DIS, V174, pS314, DOI 10.1093/infdis/174.Supplement_3.S314; FURUTA Y, 1992, J INFECT DIS, V166, P1157, DOI 10.1093/infdis/166.5.1157; GARNETT GP, 1992, EPIDEMIOL INFECT, V108, P513, DOI 10.1017/S0950268800050019; Gershon AA, 1996, J INFECT DIS, V173, P450, DOI 10.1093/infdis/173.2.450; GILDEN DH, 1983, NATURE, V306, P478, DOI 10.1038/306478a0; Gilden DH, 2000, NEW ENGL J MED, V342, P635, DOI 10.1056/NEJM200003023420906; HOPESIMPSON RE, 1964, P ROY SOC MED, V58, P9; Kennedy PGE, 1998, P NATL ACAD SCI USA, V95, P4658, DOI 10.1073/pnas.95.8.4658; KRAUSE PR, 1995, J PEDIATR-US, V127, P518, DOI 10.1016/S0022-3476(95)70106-0; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; NAHASS GT, 1992, JAMA-J AM MED ASSOC, V268, P2541, DOI 10.1001/jama.268.18.2541; OXMAN MN, 1995, NEUROLOGY S8, V45, P41; Schlesselman JJ, 1982, CASE CONTROL STUDIES; Schmader K, 1998, J AM GERIATR SOC, V46, P973, DOI 10.1111/j.1532-5415.1998.tb02751.x; Solomon BA, 1998, J AM ACAD DERMATOL, V38, P763, DOI 10.1016/S0190-9622(98)70207-5; *UNL AN SURV STEER, 2000, PREV HIV HEP INF UK; Victora CG, 1997, INT J EPIDEMIOL, V26, P224, DOI 10.1093/ije/26.1.224; Weller TH, 1997, VIRAL INFECT HUMANS, P866	23	201	211	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 31	2002	360	9334					678	682		10.1016/S0140-6736(02)09837-9	http://dx.doi.org/10.1016/S0140-6736(02)09837-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	590AM	12241874				2022-12-28	WOS:000177795100009
J	Horton, R				Horton, R			The case for a Global Development Organisation	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Horton, R (corresponding author), The Lancet, London NW1 7BY, England.							Calomiris Charles, 2002, GLOBALIST MANIFESTO; Horton R, 2001, LANCET, V358, P2141, DOI 10.1016/S0140-6736(01)07221-X; Horton R, 2002, LANCET, V359, P1605, DOI 10.1016/S0140-6736(02)08523-9; Horton R, 2000, LANCET, V355, P2231, DOI 10.1016/S0140-6736(00)02414-4; Human Development Report, 2002, HUMAN DEV REPORT 200; Lal D, 2002, POVERTY DEV EC; Stiglitz J, 2002, GLOBALISATION ITS DI; Subramanian SV, 2002, ANNU REV PUBL HEALTH, V23, P287, DOI 10.1146/annurev.publhealth.23.100901.140540; 2002, LANCET, V360, P181	9	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 24	2002	360	9333					582	583		10.1016/S0140-6736(02)09809-4	http://dx.doi.org/10.1016/S0140-6736(02)09809-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	586TD	12241924				2022-12-28	WOS:000177600400002
J	Pombo, DJ; Lawrence, G; Hirunpetcharat, C; Rzepczyk, C; Bryden, M; Cloonan, N; Anderson, K; Mahakunkijcharoen, Y; Martin, LB; Wilson, D; Elliott, S; Elliott, S; Eisen, DP; Weinberg, JB; Saul, A; Good, MF				Pombo, DJ; Lawrence, G; Hirunpetcharat, C; Rzepczyk, C; Bryden, M; Cloonan, N; Anderson, K; Mahakunkijcharoen, Y; Martin, LB; Wilson, D; Elliott, S; Elliott, S; Eisen, DP; Weinberg, JB; Saul, A; Good, MF			Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum	LANCET			English	Article							GROWTH IN-VITRO; CD4(+) T-CELLS; ANTIMICROBIAL ACTIVITY; MEDIATED-IMMUNITY; MICE; ANTIGENS; IMMUNOSUPPRESSION; ERYTHROCYTES; PARASITEMIA; MECHANISMS	Background The ability of T cells, acting independently of antibodies, to control malaria parasite growth in people has not been defined. If such cell-mediated immunity was shown to be effective, an additional vaccine strategy could be pursued. Our aim was to ascertain whether or not development of cell-mediated immunity to Plasmodium falciparum blood-stage infection could be induced in human beings by exposure to malaria parasites in very low density. Methods We enrolled five volunteers from the staff at our research institute who had never had malaria. We used a cryopreserved inoculum of red cells infected with P falciparum strain 3D7 to give them repeated subclinical infections of malaria that we then cured early with drugs, to induce cell-mediated immune responses. We tested for development of immunity by measurement of parasite concentrations in the blood of volunteers by PCR of the multicopy gene STEVOR and by following up the volunteers clinically, and by measuring antibody and cellular immune responses to the parasite. Findings After challenge and a extended period without drug cure, volunteers were protected against malaria as indicated by absence of parasites or parasite DNA in the blood, and absence of clinical symptoms. Immunity was characterised by absence of detectable antibodies that bind the parasite or infected red cells, but by the presence of a proliferative T-cell response, involving CD4+ and CD8+ T cells, a cytokine response, consisting of interferon gamma but not interleukin 4 or interleukin 10, induction of high concentrations of nitric oxide synthase activity in peripheral blood mononuclear cells, and a drop in the number of peripheral natural killer T cells. Interpretation People can be protected against the erythrocytic stage of malaria by a strong cell-mediated immune response, in the absence of detectable parasite-specific antibodies, suggesting an additional strategy for development of a malaria vaccine.	Queensland Inst Med Res, Australian Ctr Int & Trop Hlth & Nutr, Brisbane, Qld 4029, Australia; Cooperat Res Inst Vaccine Technol, Brisbane, Qld, Australia; LDS Hosp, Div Infect Dis, Salt Lake City, UT USA; Chiang Mai Univ, Res Inst Hlth Sci, Chiang Mai 50000, Thailand; Mahidol Univ, Dept Microbiol & Immunol, Fac Trop Med, Bangkok 10700, Thailand; Vet Affairs Med Ctr, Div Hematol Oncol, Durham, NC USA; Duke Univ, Med Ctr, Durham, NC USA; Univ Utah, Salt Lake City, UT USA	QIMR Berghofer Medical Research Institute; Chiang Mai University; Mahidol University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Duke University; Utah System of Higher Education; University of Utah	Good, MF (corresponding author), Queensland Inst Med Res, Australian Ctr Int & Trop Hlth & Nutr, PO Royal Brisbane Hosp, Brisbane, Qld 4029, Australia.	michaelG@qimr.edu.au	Wilson, Danny W/E-6186-2019; eisen, damon/AAC-7433-2019; Saul, Allan/ABH-2091-2020; Saul, Allan J/I-6968-2013; Cloonan, Nicole/B-5272-2008; Martin, Laura/N-1789-2013	Wilson, Danny W/0000-0002-5073-1405; Saul, Allan/0000-0003-0665-4091; Saul, Allan J/0000-0003-0665-4091; Cloonan, Nicole/0000-0001-7802-6647; Martin, Laura/0000-0002-4431-4381; Eisen, Damon/0000-0002-8987-4358				Amante FH, 1997, PARASITE IMMUNOL, V19, P111, DOI 10.1046/j.1365-3024.1997.d01-187.x; Anstey NM, 1996, J EXP MED, V184, P557, DOI 10.1084/jem.184.2.557; BRETSCHER PA, 1992, SCIENCE, V257, P539, DOI 10.1126/science.1636090; Bull PC, 1999, INFECT IMMUN, V67, P733, DOI 10.1128/IAI.67.2.733-739.1999; Bull PC, 1998, NAT MED, V4, P358, DOI 10.1038/nm0398-358; BUTCHER GA, 1992, PARASITOL TODAY, V8, P307, DOI 10.1016/0169-4758(92)90104-A; Cheng Q, 1997, AM J TROP MED HYG, V57, P495, DOI 10.4269/ajtmh.1997.57.495; COOMBS RRA, 1945, BRIT J EXP PATHOL, V26, P255; CURRIER J, 1992, INT IMMUNOL, V4, P985, DOI 10.1093/intimm/4.9.985; Fang FC, 1997, J CLIN INVEST, V99, P2818, DOI 10.1172/JCI119473; FELL AH, 1994, PARASITE IMMUNOL, V16, P579, DOI 10.1111/j.1365-3024.1994.tb00313.x; Godfrey DI, 2000, IMMUNOL TODAY, V21, P573, DOI 10.1016/S0167-5699(00)01735-7; Good MF, 2001, NAT REV IMMUNOL, V1, P117, DOI 10.1038/35100540; GYAN B, 1994, PARASITE IMMUNOL, V16, P371, DOI 10.1111/j.1365-3024.1994.tb00362.x; Hirunpetcharat C, 1998, P NATL ACAD SCI USA, V95, P1715, DOI 10.1073/pnas.95.4.1715; Hirunpetcharat C, 1997, J IMMUNOL, V159, P3400; HO M, 1986, J INFECT DIS, V153, P763, DOI 10.1093/infdis/153.4.763; Luty AJF, 1999, J INFECT DIS, V179, P980, DOI 10.1086/314689; MARSH K, 1989, T ROY SOC TROP MED H, V83, P293, DOI 10.1016/0035-9203(89)90478-1; MARSH K, 1986, SCIENCE, V231, P150, DOI 10.1126/science.2417315; Mohan K, 1997, J IMMUNOL, V159, P4990; Newbold CI, 1999, CURR OPIN MICROBIOL, V2, P420, DOI 10.1016/S1369-5274(99)80074-5; PARISH CR, 1972, TRANSPLANT REV-DENMA, V13, P35; Piper KP, 1999, INFECT IMMUN, V67, P6369; ROCKETT KA, 1991, INFECT IMMUN, V59, P3280, DOI 10.1128/IAI.59.9.3280-3283.1991; Seixas EMG, 1999, J IMMUNOL, V162, P2837; Staalsoe T, 1999, CYTOMETRY, V35, P329, DOI 10.1002/(SICI)1097-0320(19990401)35:4&lt;329::AID-CYTO5&gt;3.0.CO;2-Y; TAYLORROBINSON AW, 1993, SCIENCE, V260, P1931, DOI 10.1126/science.8100366; Thoma-Uszynski S, 2001, SCIENCE, V291, P1544, DOI 10.1126/science.291.5508.1544; WEINBERG JB, 1995, BLOOD, V86, P1184; Whitworth J, 2000, LANCET, V356, P1051, DOI 10.1016/S0140-6736(00)02727-6; Xu HJ, 2002, J EXP MED, V195, P881, DOI 10.1084/jem.20011174	32	329	352	0	22	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 24	2002	360	9333					610	617		10.1016/S0140-6736(02)09784-2	http://dx.doi.org/10.1016/S0140-6736(02)09784-2			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	586TD	12241933				2022-12-28	WOS:000177600400011
J	Anderson, MS; Venanzi, ES; Klein, L; Chen, ZB; Berzins, SP; Turley, SJ; von Boehmer, H; Bronson, R; Dierich, A; Benoist, C; Mathis, D				Anderson, MS; Venanzi, ES; Klein, L; Chen, ZB; Berzins, SP; Turley, SJ; von Boehmer, H; Bronson, R; Dierich, A; Benoist, C; Mathis, D			Projection of an immunological self shadow within the thymus by the aire protein	SCIENCE			English	Article							CANDIDIASIS-ECTODERMAL DYSTROPHY; T-CELL TOLERANCE; AUTOIMMUNE REGULATOR AIRE; EPITHELIAL-CELLS; SUBCELLULAR LOCATION; IMMUNE TOLERANCE; GENE-EXPRESSION; BINDING PROTEIN; STROMAL CELLS; ANTIGEN	Humans expressing a defective form of the transcription factor AIRE (autoimmune regulator) develop multiorgan autoimmune disease. We used aire-deficient mice to test the hypothesis that this transcription factor regulates autoimmunity by promoting the ectopic expression of peripheral tissue restricted antigens in medullary epithelial cells of the thymus. This hypothesis proved correct. The mutant animals exhibited a defined pro. le of autoimmune diseases that depended on the absence of aire in stromal cells of the thymus. Aire-deficient thymic medullary epithelial cells showed a specific reduction in ectopic transcription of genes encoding peripheral antigens. These findings highlight the importance of thymically imposed "central" tolerance in controlling autoimmunity.	Joslin Diabet Ctr, Sect Immunol & Immunogenet, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellualire, F-67404 Strasbourg, France	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Benoist, C (corresponding author), Joslin Diabet Ctr, Sect Immunol & Immunogenet, Boston, MA 02115 USA.		Klein, Ludger/G-8785-2011	Klein, Ludger/0000-0003-2054-071X; Venanzi, Emily/0000-0002-4185-0381	NATIONAL CANCER INSTITUTE [T32CA070083] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK059958, P30DK036836, T32DK007260, R01DK060027] Funding Source: NIH RePORTER; NCI NIH HHS [T32CA70083-05] Funding Source: Medline; NIDDK NIH HHS [2T32 DK07260-26, R01 DK60027-01, 2 P30 DK36836-16, KO8-DK59958-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson AC, 2000, J EXP MED, V191, P761, DOI 10.1084/jem.191.5.761; ANTONIA SJ, 1995, INT IMMUNOL, V7, P715, DOI 10.1093/intimm/7.5.715; Bjorses P, 2000, AM J HUM GENET, V66, P378, DOI 10.1086/302765; Bjorses P, 1998, HUM MOL GENET, V7, P1547, DOI 10.1093/hmg/7.10.1547; Derbinski J, 2001, NAT IMMUNOL, V2, P1032, DOI 10.1038/ni723; Egwuagu CE, 1997, J IMMUNOL, V159, P3109; Garza K M, 2000, Rev Immunogenet, V2, P2; Gylling M, 2000, J CLIN ENDOCR METAB, V85, P4434, DOI 10.1210/jc.85.12.4434; Halonen M, 2002, J CLIN ENDOCR METAB, V87, P2568, DOI 10.1210/jc.87.6.2568; Halonen M, 2001, J HISTOCHEM CYTOCHEM, V49, P197, DOI 10.1177/002215540104900207; Hanahan D, 1998, CURR OPIN IMMUNOL, V10, P656, DOI 10.1016/S0952-7915(98)80085-X; Heino M, 1999, BIOCHEM BIOPH RES CO, V257, P821, DOI 10.1006/bbrc.1999.0308; Heino M, 2000, EUR J IMMUNOL, V30, P1884, DOI 10.1002/1521-4141(200007)30:7<1884::AID-IMMU1884>3.0.CO;2-P; HOFFMANN MW, 1995, P NATL ACAD SCI USA, V92, P9851, DOI 10.1073/pnas.92.21.9851; HOFFMANN MW, 1992, P NATL ACAD SCI USA, V89, P2526, DOI 10.1073/pnas.89.7.2526; JOLICOEUR C, 1994, P NATL ACAD SCI USA, V91, P6707, DOI 10.1073/pnas.91.14.6707; Kishimoto H, 2000, CLIN IMMUNOL, V95, pS3, DOI 10.1006/clim.1999.4818; Klein L, 1998, J EXP MED, V188, P5, DOI 10.1084/jem.188.1.5; Klein L, 2000, CURR OPIN IMMUNOL, V12, P179, DOI 10.1016/S0952-7915(99)00069-2; Klein L, 2000, NAT MED, V6, P56, DOI 10.1038/71540; Klein L, 2001, EUR J IMMUNOL, V31, P2476, DOI 10.1002/1521-4141(200108)31:8<2476::AID-IMMU2476>3.0.CO;2-T; KOJIMA A, 1981, IMMUNOGENETICS, V14, P15, DOI 10.1007/BF00344296; Kumar PG, 2001, J BIOL CHEM, V276, P41357, DOI 10.1074/jbc.M104898200; NAGAMINE K, 1997, NAT GENET, V17, P399; Naquet P, 1999, SEMIN IMMUNOL, V11, P47, DOI 10.1006/smim.1998.0149; Oukka M, 1996, J IMMUNOL, V156, P968; Oukka M, 1996, IMMUNITY, V4, P545, DOI 10.1016/S1074-7613(00)80481-1; Peterson P, 1998, IMMUNOL TODAY, V19, P384, DOI 10.1016/S0167-5699(98)01293-6; Pitkanen J, 2000, J BIOL CHEM, V275, P16802, DOI 10.1074/jbc.M908944199; Pugliese A, 1997, NAT GENET, V15, P293, DOI 10.1038/ng0397-293; Ramsey C, 2002, HUM MOL GENET, V11, P397, DOI 10.1093/hmg/11.4.397; Rosatelli MC, 1998, HUM GENET, V103, P428, DOI 10.1007/s004390050846; Smith KM, 1997, INT IMMUNOL, V9, P1355, DOI 10.1093/intimm/9.9.1355; SPONAAS AM, 1994, INT IMMUNOL, V6, P277, DOI 10.1093/intimm/6.2.277; Vafiadis P, 1997, NAT GENET, V15, P289, DOI 10.1038/ng0397-289; VONHERRATH MG, 1994, IMMUNITY, V1, P231, DOI 10.1016/1074-7613(94)90101-5; Zuklys S, 2000, J IMMUNOL, V165, P1976, DOI 10.4049/jimmunol.165.4.1976	37	1693	1744	1	96	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 15	2002	298	5597					1395	1401		10.1126/science.1075958	http://dx.doi.org/10.1126/science.1075958			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	615AF	12376594				2022-12-28	WOS:000179223100044
J	Yin, YW; Steitz, TA				Yin, YW; Steitz, TA			Structural basis for the transition from initiation to elongation transcription in T7 RNA polymerase	SCIENCE			English	Article							DNA BUBBLE DUPLEXES; ANGSTROM RESOLUTION; COMPLEX; BACTERIOPHAGE-T7; PROMOTER; MECHANISM; LYSOZYME; DISPLACEMENT; STABILITY; CRYSTAL	To make messenger RNA transcripts, bacteriophage T7 RNA polymerase (T7 RNAP) undergoes a transition from an initiation phase, which only makes short RNA fragments, to a stable elongation phase. We have determined at 2.1 angstrom resolution the crystal structure of a T7 RNAP elongation complex with 30 base pairs of duplex DNA containing a "transcription bubble" interacting with a 17-nucleotide RNA transcript. The transition from an initiation to an elongation complex is accompanied by a major refolding of the amino-terminal 300 residues. This results in loss of the promoter binding site, facilitating promoter clearance, and creates a tunnel that surrounds the RNA transcript after it peels off a seven-base pair heteroduplex. Formation of the exit tunnel explains the enhanced processivity of the elongation complex. Downstream duplex DNA binds to the fingers domain, and its orientation relative to upstream DNA in the initiation complex implies an unwinding that could facilitate formation of the open promoter complex.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA; Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA	Yale University; Yale University; Howard Hughes Medical Institute; Yale University	Steitz, TA (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, 266 Whitney Ave, New Haven, CT 06520 USA.	eatherton@csb.yale.edu			NIGMS NIH HHS [GM57510] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057510] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bloomfield V.A., 2000, NUCL ACIDS STRUCTURE, V1st ed.; Brautigam CA, 1998, CURR OPIN STRUC BIOL, V8, P54, DOI 10.1016/S0959-440X(98)80010-9; Brieba LG, 2001, BIOCHEMISTRY-US, V40, P3882, DOI 10.1021/bi002716c; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Cheetham GMT, 1999, SCIENCE, V286, P2305, DOI 10.1126/science.286.5448.2305; Cheetham GMT, 2000, CURR OPIN STRUC BIOL, V10, P117, DOI 10.1016/S0959-440X(99)00058-5; Cheetham GMT, 1999, NATURE, V399, P80, DOI 10.1038/19999; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; DAUBE SS, 1994, BIOCHEMISTRY-US, V33, P340, DOI 10.1021/bi00167a044; DAUBE SS, 1992, SCIENCE, V258, P1320, DOI 10.1126/science.1280856; Daube SS, 1999, P NATL ACAD SCI USA, V96, P8390, DOI 10.1073/pnas.96.15.8390; DAVANLOO P, 1984, P NATL ACAD SCI-BIOL, V81, P2035, DOI 10.1073/pnas.81.7.2035; Diaz GA, 1996, BIOCHEMISTRY-US, V35, P10837, DOI 10.1021/bi960488+; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Doublie S, 1998, CURR OPIN STRUC BIOL, V8, P704, DOI 10.1016/S0959-440X(98)80089-4; Franklin MC, 2001, CELL, V105, P657, DOI 10.1016/S0092-8674(01)00367-1; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Gopal V, 1999, J MOL BIOL, V290, P411, DOI 10.1006/jmbi.1999.2836; GUNDERSON SI, 1987, BIOCHEMISTRY-US, V26, P1539, DOI 10.1021/bi00380a007; He B, 1997, J MOL BIOL, V265, P275, DOI 10.1006/jmbi.1996.0741; Huang JB, 1999, J MOL BIOL, V293, P457, DOI 10.1006/jmbi.1999.3135; Huang JB, 2000, J MOL BIOL, V303, P347, DOI 10.1006/jmbi.2000.4150; IKEDA RA, 1987, J BIOL CHEM, V262, P3790; IKEDA RA, 1986, P NATL ACAD SCI USA, V83, P3614, DOI 10.1073/pnas.83.11.3614; Jeruzalmi D, 1998, EMBO J, V17, P4101, DOI 10.1093/emboj/17.14.4101; Jia YP, 1997, BIOCHEMISTRY-US, V36, P4223, DOI 10.1021/bi9630467; Jia YP, 1996, J BIOL CHEM, V271, P30451, DOI 10.1074/jbc.271.48.30451; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; Kornberg A., 1991, DNA REPLICATION; Korzheva N, 1998, COLD SPRING HARB SYM, V63, P337, DOI 10.1101/sqb.1998.63.337; Kumar A, 1997, BIOCHEMISTRY-US, V36, P13954, DOI 10.1021/bi971432y; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; LING ML, 1989, NUCLEIC ACIDS RES, V17, P1605, DOI 10.1093/nar/17.4.1605; MARTIN CT, 1988, BIOCHEMISTRY-US, V27, P3966, DOI 10.1021/bi00411a012; MOFFATT BA, 1987, CELL, V49, P221, DOI 10.1016/0092-8674(87)90563-0; MULLER DK, 1988, BIOCHEMISTRY-US, V27, P5763, DOI 10.1021/bi00415a055; Murakami KS, 2002, SCIENCE, V296, P1285, DOI 10.1126/science.1069595; Navarro M, 1999, EMBO J, V18, P2265, DOI 10.1093/emboj/18.8.2265; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; Stano NM, 2002, J MOL BIOL, V315, P1009, DOI 10.1006/jmbi.2001.5313; Temiakov D, 2000, P NATL ACAD SCI USA, V97, P14109, DOI 10.1073/pnas.250473197; Ujvari A, 1997, J MOL BIOL, V273, P775, DOI 10.1006/jmbi.1997.1350; Urs UK, 1999, ACTA CRYSTALLOGR D, V55, P1971; Vassylyev DG, 2002, NATURE, V417, P712, DOI 10.1038/nature752; von Hippel PH, 1998, SCIENCE, V281, P660, DOI 10.1126/science.281.5377.660; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; Yin Y.G., UNPUB; Zhang X, 1997, J MOL BIOL, V269, P10, DOI 10.1006/jmbi.1997.1016; [No title captured]	57	265	275	3	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 15	2002	298	5597					1387	1395		10.1126/science.1077464	http://dx.doi.org/10.1126/science.1077464			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	615AF	12242451				2022-12-28	WOS:000179223100043
J	Mollerup, CL; Vestergaard, P; Frokjaer, VG; Mosekilde, L; Christiansen, P; Blichert-Toft, M				Mollerup, CL; Vestergaard, P; Frokjaer, VG; Mosekilde, L; Christiansen, P; Blichert-Toft, M			Risk of renal stone events in primary hyperparathyroidism before and after parathyroid surgery: controlled retrospective follow up study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ADENOMA WEIGHT	Aim To study the risk of renal stone episodes and risk factors for renal stones in primary hyperparathyroidism before and after surgery. Design Register based, controlled retrospective follow up study. Setting Tertiary hospitals in Denmark. Participants 674 consecutive, patients with surgically verified primary hyperparathyroidism. Each patient was compared with three age- and sex-matched controls randomly drawn from the background population. Hospital admissions for renal stone disease were compared between patients and controls. Risk factors for renal stones among patients were assessed. Main outcome measures Number of renal stone episodes; comparison of hospital admissions for renal stones in patients and controls; assessment of risk factors for renal stones. Results Relative risk of a stone episode was 40 (95% confidence interval 31 to 53) before surgery and 16 (12 to 23) after surgery. Risk was increased 10 years before surgery, and became normal more than 10 years after surgery. Stone-free survival 20 years after surgery was 90.4% in patients and 98.7% in controls (risk difference 8.3%, 4.8% to 11.7%). Patients with preoperative stones had 27 times the risk of postoperative stone incidents than controls. Before surgery, males had more stone episodes than females and younger patients had more stone episodes than older patients. Neither parathyroid pathology, weight of removed tissue, plasma calcium levels, nor skeletal pathology (fractures) influenced the risk of renal stones. After surgery, younger age, preoperative stones and ureteral strictures were significant risk factors for stones., Conclusions The risk of renal stones is increased in primary hyperparathyroidism and decreases after surgery. The risk profile is normal 10 years after surgery. Preoperative stone events increase the risk of postoperative stones. Stone formers and non-stone formers had the same risk of skeletal complications.	Univ Copenhagen Hosp, Rigshosp, Dept Endocrine & Breast Surg, DK-2100 Copenhagen, Denmark; Aarhus Univ Hosp, Dept Endocrinol & Metab C, Aarhus Kommune Hosp, DK-8000 Aarhus, Denmark; Aarhus Univ Hosp, Dept Surg L, DK-8000 Aarhus, Denmark	Rigshospitalet; University of Copenhagen; Aarhus University; Aarhus University	Mollerup, CL (corresponding author), Univ Copenhagen Hosp, Rigshosp, Dept Endocrine & Breast Surg, DK-2100 Copenhagen, Denmark.	CLMollerupmolle@rh.dk	Christiansen, Peer/B-7402-2015; Frøkjær, Vibe Gedsø/N-8955-2019	Christiansen, Peer/0000-0003-2748-9240; Frøkjær, Vibe Gedsø/0000-0002-9321-2365				Andersen TF, 1999, DAN MED BULL, V46, P263; Frokjaer VG, 2002, WORLD J SURG, V26, P532, DOI 10.1007/s00268-001-0262-6; HALABE A, 1992, DISORDERS BONE MINER, P671; HEDBACK G, 1995, SURGERY, V117, P134, DOI 10.1016/S0039-6060(05)80076-5; Klugman Vanessa A., 1994, P505; Mollerup CL, 1999, WORLD J SURG, V23, P173, DOI 10.1007/PL00013175; POSEN S, 1985, Q J MED, V54, P241; SILVERBERG SJ, 1990, AM J MED, V89, P327, DOI 10.1016/0002-9343(90)90346-F; Soreide JA, 1996, SURGERY, V120, P1033, DOI 10.1016/S0039-6060(96)80051-1; Vestergaard P, 2000, BRIT MED J, V321, P598, DOI 10.1136/bmj.321.7261.598; WILLIAMS JG, 1992, AM J SURG, V163, P301, DOI 10.1016/0002-9610(92)90007-E	11	117	124	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 12	2002	325	7368					807	810		10.1136/bmj.325.7368.807	http://dx.doi.org/10.1136/bmj.325.7368.807			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604YM	12376441	Bronze, Green Published			2022-12-28	WOS:000178648700018
J	Wells, AW; Mounter, PJ; Chapman, CE; Stainsby, D; Wallis, JP				Wells, AW; Mounter, PJ; Chapman, CE; Stainsby, D; Wallis, JP			Where does blood go? Prospective observational study of red cell transfusion in north England	BRITISH MEDICAL JOURNAL			English	Article							HOSPITALS	Objective To collect population based information on transfusion of red blood cells. Design Prospective observational study over 28 days. Setting Hospital blood banks in the north of England (population 2.9 million). Main outcome measures Indications for transfusion, number of units given, and the age and sex of transfusion recipients. Participants All patients who received a red cell transfusion during the study period. Data completed by hospital blood bank staff. Results The destination of 9848 units was recorded (97% of expected blood use). In total 9774 units were transfused: 5047 (51.6%) units were given to medical patients, 3982 (40.7%) to surgical patients, and 612 (6.3%) to obstetric and gynaecology patients. Nearly half (49.3%) of all blood is given to female recipients, and the mean age of recipients of individual units was 62.7 years. The most common surgical indications for transfusion were total hip replacement (4.6% of all blood transfused) and coronary artery bypass grafting (4.1%). Haematological disorders accounted for 15.5% of use. Overall use was 4274 units per 100 000 population per year. Conclusion In the north east of England more than half of red cell units are transfused for medical indications. Demand for red cell transfusion increases with age. With anticipated changes in the age structure of the population the demand for blood will increase by 4.9% by 2008.	Freeman Rd Hosp, Newcastle Tyne Hosp NHS Trust, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England; Newcastle Ctr, Natl Blood Serv, Newcastle Upon Tyne NE2 4NQ, Tyne & Wear, England	Newcastle Freeman Hospital; Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation Trust	Wallis, JP (corresponding author), Freeman Rd Hosp, Newcastle Tyne Hosp NHS Trust, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England.							Barrett-Lee PJ, 2000, BRIT J CANCER, V82, P93, DOI 10.1054/bjoc.1999.0883; Chapman J., 2001, British Journal of Haematology, V113, P58; Charlton BG, 1997, QJM-MON J ASSOC PHYS, V90, P147, DOI 10.1093/qjmed/90.2.147; Chiavetta JA, 1996, TRANSFUSION, V36, P699, DOI 10.1046/j.1537-2995.1996.36896374373.x; COOK SS, 1991, TRANSFUSION, V31, P355, DOI 10.1046/j.1537-2995.1991.31491213303.x; Mathoulin-Pelissier S, 2000, TRANSFUSION, V40, P1140, DOI 10.1046/j.1537-2995.2000.40091140.x; *NHS EX, 1998, 1998224 NHS EX HSC; SIRCHIA G, 1994, TRANSFUSION MED, V4, P251; Stover EP, 1998, ANESTHESIOLOGY, V88, P327, DOI 10.1097/00000542-199802000-00009; VAMVAKAS EC, 1994, TRANSFUSION, V34, P471, DOI 10.1046/j.1537-2995.1994.34694295060.x; VAMVAKAS EC, 1994, TRANSFUSION, V34, P464, DOI 10.1046/j.1537-2995.1994.34694295059.x; Wallace EL, 1998, TRANSFUSION, V38, P625, DOI 10.1046/j.1537-2995.1998.38798346630.x; WALLIS JP, 2000, TRANSFUSION MED, V10, P15	13	164	168	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 12	2002	325	7368					803	U7		10.1136/bmj.325.7368.803	http://dx.doi.org/10.1136/bmj.325.7368.803			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604YM	12376439	Bronze, Green Published			2022-12-28	WOS:000178648700016
J	Fam, NP; Verma, A				Fam, NP; Verma, A			Thrombolysis of a massive pulmonary embolism	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Toronto Gen Hosp, Toronto, ON M5G 2C4, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Fam, NP (corresponding author), Toronto Gen Hosp, Toronto, ON M5G 2C4, Canada.								0	1	1	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 10	2002	347	15					1161	1161		10.1056/NEJMicm020386	http://dx.doi.org/10.1056/NEJMicm020386			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	601TW	12374876				2022-12-28	WOS:000178465100006
J	Kulasingam, SL; Hughes, JP; Kiviat, NB; Mao, C; Weiss, NS; Kuypers, JM; Koutsky, LA				Kulasingam, SL; Hughes, JP; Kiviat, NB; Mao, C; Weiss, NS; Kuypers, JM; Koutsky, LA			Evaluation of human papillomavirus testing in primary screening for cervical abnormalities - Comparison of sensitivity, specificity, and frequency of referral	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIGH-RISK HPV; INTRAEPITHELIAL NEOPLASIA; PAPANICOLAOU SMEARS; CANCER; WOMEN; REPRODUCIBILITY; COLPOSCOPY; STRATEGIES; DIAGNOSIS; INFECTION	Context Human papillomavirus (HPV) DNA testing of women having Papanicolaou (Pap) smears showing atypical squamous cells of undetermined significance (ASCUS) has clinical usefulness. Whether HPV DNA testing alone is useful in primary screening remains to be determined. Objective To determine the accuracy of HPV DNA testing for detecting cervical intraepithelial neoplasia (CIN) grade 3 or cancer (the criterion standard). Design, Setting, and Participants Between December 1997 and October 2000, 4075 women who attended Planned Parenthood clinics in Washington State were screened simultaneously using thin-layer Pap and HPV DNA testing by a polymerase chain reaction (PCR)-based method and by a liquid-based RNA-DNA hybridization capture with signal amplification assay (signal amplification). Women who were positive for high-risk HPV types, or had Pap results of ASCUS or higher, were considered to have positive screening test results and were referred for colposcopy and biopsy. Additionally, a random sample of women with negative screening test results was referred for colposcopy. Based on individual and combined thin-layer Pap, HPV PCR, and HPV signal amplification test results from the screening and the colposcopy visits, 7 colposcopy triage strategies were defined and evaluated. Main Outcome Measure Sensitivity and specificity for detecting cervical lesions graded CIN 3 or higher for each of the 7 triage strategies. Results The estimated prevalence of CIN 3 or higher was 3.2%. The sensitivity (95% confidence interval) of thin-layer Pap (with a result of ASCUS) for identifying women with CIN 3 or higher was only 61.3% (48.5%-70.9%) compared with 88.2% (78.9%-93.8%) for HPV testing by PCR and 90.8% (83.1%-95.8%) by signal amplification. Differences in specificities were also observed: 82.4% (81.8%-83.1%) for thin-layer Pap (with a result of greater than or equal to ASCUS), 78.8% (77.9%-79.7%) for PCR, and 72.6% (69.4%75.0%) for signal amplification. Compared with referral for colposcopy of all women with ASCUS or higher, signal amplification testing of women with ASCUS and referral of those with a positive result was about as sensitive (61.3% vs 60.3%, respectively) and significantly more specific (82.4% vs 88.9%, respectively). The strategy requiring repeat positive PCR tests on 2 visits had a sensitivity of 84.2% (75.3%-91.0%) and a specificity of 86.2% (85.1%-87.3%). All tests were more specific and less sensitive in older (greater than or equal to30 years) vs younger women. Conclusions Testing for HPV has higher sensitivity but lower specificity than thin-layer Pap screening. In some settings, particularly where screening intervals are long or haphazard, screening for HPV DNA may be a reasonable alternative to cytology-based screening of reproductive-age women.	Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Dept Obstet & Gynecol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Koutsky, LA (corresponding author), HPV Res Grp, 1914 N 34th St,Suite 300, Seattle, WA 98103 USA.			Kulasingam, Shalini/0000-0002-0932-9166	NCI NIH HHS [CA 34493] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA034493] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bernstein SJ, 2001, AM J OBSTET GYNECOL, V185, P308, DOI 10.1067/mob.2001.116736; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; CONFORTINI M, 1993, ACTA CYTOL, V37, P49; *CTR DEV RAD HLTH, 2002, CLIN LAB IMPR METH; Cuzick J, 1999, BRIT J CANCER, V81, P554, DOI 10.1038/sj.bjc.6690730; CUZICK J, 1995, LANCET, V345, P1533, DOI 10.1016/S0140-6736(95)91086-7; Efron B., 1993, INTRO BOOTSTRAP, P436, DOI [10.1007/978-1-4899-4541-9, DOI 10.1007/978-1-4899-4541-9]; Eger RR, 1996, J REPROD MED, V41, P671; GAY JD, 1985, ACTA CYTOL, V29, P1043; Gravitt PE, 1998, J CLIN MICROBIOL, V36, P3020, DOI 10.1128/JCM.36.10.3020-3027.1998; HO GYF, 1995, JNCI-J NATL CANCER I, V87, P1365, DOI 10.1093/jnci/87.18.1365; *INT AG RES CANC, 1995, IARC MON EV CARC RIS, V64; Khanna N, 2001, J Am Board Fam Pract, V14, P123; KLINKHAMER PJJM, 1988, ACTA CYTOL, V32, P794; KOSS LG, 1989, JAMA-J AM MED ASSOC, V261, P737, DOI 10.1001/jama.261.5.737; Koutsky LA, 2000, J NATL CANCER I, V92, P397, DOI 10.1093/jnci/92.5.397; KOUTSKY LA, 1992, NEW ENGL J MED, V327, P1272, DOI 10.1056/NEJM199210293271804; LUFF RD, 1992, HUM PATHOL, V23, P719, DOI 10.1016/0046-8177(92)90338-4; Manos MM, 1999, JAMA-J AM MED ASSOC, V281, P1605, DOI 10.1001/jama.281.17.1605; PASKETT ED, 1995, OBSTET GYNECOL, V86, P353, DOI 10.1016/0029-7844(95)00176-R; Peyton CL, 1998, J CLIN MICROBIOL, V36, P3248, DOI 10.1128/JCM.36.11.3248-3254.1998; Ratnam S, 2000, CANCER EPIDEM BIOMAR, V9, P945; Sasieni PD, 1996, BRIT J CANCER, V73, P1001, DOI 10.1038/bjc.1996.196; Schneider A, 2000, INT J CANCER, V89, P529, DOI 10.1002/1097-0215(20001120)89:6&lt;529::AID-IJC11&gt;3.0.CO;2-G; SOLOMON D, 1989, JAMA-J AM MED ASSOC, V262, P931; Solomon D, 2001, J NATL CANCER I, V93, P293, DOI 10.1093/jnci/93.4.293; Stoler MH, 2001, JAMA-J AM MED ASSOC, V285, P1500, DOI 10.1001/jama.285.11.1500; Terry G, 2001, J MED VIROL, V65, P155, DOI 10.1002/jmv.2015; Wallin KL, 1999, NEW ENGL J MED, V341, P1633, DOI 10.1056/NEJM199911253412201	29	332	358	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	2002	288	14					1749	1757		10.1001/jama.288.14.1749	http://dx.doi.org/10.1001/jama.288.14.1749			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	602BJ	12365959	Bronze			2022-12-28	WOS:000178484700028
J	Hakala, P; Rimpela, A; Salminen, JJ; Virtanen, SM; Rimpela, M				Hakala, P; Rimpela, A; Salminen, JJ; Virtanen, SM; Rimpela, M			Back, neck, and shoulder pain in Finnish adolescents: national cross sectional surveys	BRITISH MEDICAL JOURNAL			English	Article							SCHOOL-CHILDREN; SCHOOLCHILDREN; PREVALENCE	Objectives To study changes in pain of the back and neck in adolescents between 1985 and 2001 and pain of the neck, shoulder, and lower back between 1991 and 2001. Design Biennial nationwide postal surveys, 1985-2001, and annual classroom surveys, 1996-2001. Setting Finland. Participants 62 677 12, 14, 16, and 18 year olds and 127 217 14-16 year olds. Main outcome measures Pain in the back and neck, neck and shoulder, or lower back, at least weekly. Results Prevalence of pain in the back and neck was greater in the 1990s than in the 1980s and increased steadily from 1993 to 1997. Pain of the neck and shoulder and pain of the lower back was much more common in 1999 than in 1991 and in 2001 than in 1999. Pain was more common among girls and older groups: pain of the neck and shoulder affected 24% of girls and 12% of boys in 14 year olds, 38% of girls and 16% of boys in 16 year olds, and 45% of girls mid 19% of boys in 18 year olds; pain in the lower back affected 8% of girls and 7% of boys in 14 year olds, 14% of girls and 11% of boys in 16 year olds, and 17% of boys and 13% of girls in 18 year olds. Conclusion Pain in the neck, shoulder, and lower back is becoming more common in Finnish adolescents. This pain suggests a new disease burden of degenerative musculoskeletal disorders in future adults.	Univ Tampere, Tampere Sch Publ Hlth, FIN-33014 Tampere, Finland; Turku Univ Hosp, Dept Phys Med & Rehabil, FIN-20520 Turku, Finland; Natl Res & Dev Ctr Welf & Hlth, FIN-00531 Helsinki, Finland	Tampere University; University of Turku	Hakala, P (corresponding author), Univ Tampere, Tampere Sch Publ Hlth, FIN-33014 Tampere, Finland.		Rimpela, Arja/J-3910-2014	Virtanen, Suvi/0000-0001-8928-0878; Rimpela, Arja/0000-0003-3273-6226				BALAGUE F, 1988, SCAND J REHABIL MED, V20, P175; BALAGUE F, 1994, J SPINAL DISORD, V7, P374; Balague F, 1999, EUR SPINE J, V8, P429, DOI 10.1007/s005860050201; BERNTSSON I, 2000, HLTH WELL BEING CHIL, P8; BERNTSSON L, 2000, HLTH WELL BEING CHIL, P8; BRATTBERG G, 1994, QUAL LIFE RES, V3, pS27, DOI 10.1007/BF00433372; CURRIE C, 2002, 1997836 HBSC; CURRIE G, 2002, 1997836 HBSC; FAIRBANK JCT, 1984, SPINE, V9, P461, DOI 10.1097/00007632-198407000-00007; Jensen C, 1998, SCAND J WORK ENV HEA, V24, P418, DOI 10.5271/sjweh.364; Kautiainen S, 2002, INT J OBESITY, V26, P544, DOI 10.1038/sj.ijo.0801928; KING A, 1996, WHO REG PUBL EUR SER, V69, P68; KING A, 1996, HLTH YOUTH CROSS NAT, P68; LEINO PI, 1994, SCAND J RHEUMATOL, V23, P269, DOI 10.3109/03009749409103728; MAKELA M, 1993, J CLIN EPIDEMIOL, V46, P549, DOI 10.1016/0895-4356(93)90128-N; Maniadakis N, 2000, PAIN, V84, P95, DOI 10.1016/S0304-3959(99)00187-6; Mikkelsson M, 1997, PAIN, V73, P29, DOI 10.1016/S0304-3959(97)00073-0; OLSEN TL, 1992, AM J PUBLIC HEALTH, V82, P606, DOI 10.2105/AJPH.82.4.606; Palmer KT, 2000, BRIT MED J, V320, P1577, DOI 10.1136/bmj.320.7249.1577; RIMPELA M, 1997, SUOM LAAKARILEHTI, V52, P2705; SALMINEN JJ, 1992, ACTA PAEDIATR, V81, P1035, DOI 10.1111/j.1651-2227.1992.tb12170.x; Salminen JJ, 1999, SPINE, V24, P1316, DOI 10.1097/00007632-199907010-00008; Salminen JJ, 1984, ACTA PAEDIAT SCAND, V315, P8; *STAT FINL, 2001, ROAD FINN INF SOC, V3; TROUSSIER B, 1994, SCAND J REHABIL MED, V26, P143; Vikat A, 2000, SCAND J PUBLIC HEALT, V28, P164, DOI 10.1177/14034948000280030401	26	213	226	1	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 5	2002	325	7367					743	745		10.1136/bmj.325.7367.743	http://dx.doi.org/10.1136/bmj.325.7367.743			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	603AU	12364301	Bronze, Green Published			2022-12-28	WOS:000178537300015
J	Abraham, RT				Abraham, RT			Identification of TOR signaling complexes: more TORC for the cell growth engine	CELL			English	Review							MAMMALIAN TARGET; S6 KINASE; IN-VITRO; RAPAMYCIN; TRANSLATION; PATHWAY	The Target of Rapamycin (TOR) proteins function in signaling pathways that promote protein synthesis and cell growth. In yeast, TOR signaling is regulated by nutrient availability, whereas in metazoan cells TOR activities may be controlled by both nutrients and growth factors. The recent identification of novel TOR-interacting proteins has provided crucial insights into TOR regulation and function.	Burnham Inst, Ctr Canc Res, Program Signal Transduct Res, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Abraham, RT (corresponding author), Burnham Inst, Ctr Canc Res, Program Signal Transduct Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.							Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Isotani S, 1999, J BIOL CHEM, V274, P34493, DOI 10.1074/jbc.274.48.34493; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Mills GB, 2001, P NATL ACAD SCI USA, V98, P10031, DOI 10.1073/pnas.191379498; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Radimerski T, 2002, NAT CELL BIOL, V4, P251, DOI 10.1038/ncb763; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Sekulic A, 2000, CANCER RES, V60, P3504; Tibbetts RS, 2000, CANC DRUG DISC DEV, V5, P267	19	126	131	0	6	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 4	2002	111	1					9	12		10.1016/S0092-8674(02)01009-7	http://dx.doi.org/10.1016/S0092-8674(02)01009-7			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	601RQ	12372295	Bronze			2022-12-28	WOS:000178461900003
J	Niare, O; Markianos, K; Volz, J; Oduol, F; Toure, A; Bagayoko, M; Sangare, D; Traore, SF; Wang, R; Blass, C; Dolo, G; Bouare, M; Kafatos, FC; Kruglyak, L; Toure, YT; Vernick, KD				Niare, O; Markianos, K; Volz, J; Oduol, F; Toure, A; Bagayoko, M; Sangare, D; Traore, SF; Wang, R; Blass, C; Dolo, G; Bouare, M; Kafatos, FC; Kruglyak, L; Toure, YT; Vernick, KD			Genetic loci affecting resistance to human malaria parasites in a West African mosquito vector population	SCIENCE			English	Article							QUANTITATIVE TRAIT LOCI; ANOPHELES-GAMBIAE; PLASMODIUM-FALCIPARUM; IMMUNE-RESPONSE; EXPRESSION; INFECTIONS; VIRULENCE; MECHANISM	Successful propagation of the malaria parasite Plasmodium falciparum within a susceptible mosquito vector is prerequisite for the transmission of malaria. A field-based genetic analysis of the major human malaria vector, Anopheles gambiae, has revealed natural factors that reduce the transmission of P. falciparum. Differences in P. falciparum oocyst numbers between mosquito isofemale families fed on the same infected blood indicated large genetic component affecting resistance to the parasite, and genome-wide scanning in pedigrees of wild mosquitoes detected segregating resistance alleles. The apparently high natural frequency of resistance alleles suggests that malaria parasites (or similar pathogen) exert significant selective pressure on vector populations.	NYU, Sch Med, Dept Med & Mol Parasitol, New York, NY 10010 USA; Fac Med Pharm & Odontostomatol, Dept Epidemiol Affectat Parasitaires, Bamako, Mali; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Howard Hughes Med Inst, Chevy Chase, MD 20815 USA; European Mol Biol Lab, D-69117 Heidelberg, Germany	New York University; Fred Hutchinson Cancer Center; Howard Hughes Medical Institute; European Molecular Biology Laboratory (EMBL)	Vernick, KD (corresponding author), NYU, Sch Med, Dept Med & Mol Parasitol, 341 E 25th St, New York, NY 10010 USA.		Wang-Sattler, Rui/B-5354-2014	Wang-Sattler, Rui/0000-0002-8794-8229; Markianos, Kyriacos/0000-0003-0214-6014				Anderson RA, 2000, PARASITOLOGY, V120, P329, DOI 10.1017/S0031182099005570; Bergelson J, 2001, SCIENCE, V292, P2281, DOI 10.1126/science.1061337; BILLINGSLEY PF, 1994, AM J TROP MED HYG, V51, P260, DOI 10.4269/ajtmh.1994.51.260; Bonnet S, 2001, CELL MICROBIOL, V3, P449, DOI 10.1046/j.1462-5822.2001.00128.x; CHURCHILL GA, 1994, GENETICS, V138, P963; COLLINS FH, 1986, SCIENCE, V234, P607, DOI 10.1126/science.3532325; DAY KP, 1993, P NATL ACAD SCI USA, V90, P8292, DOI 10.1073/pnas.90.17.8292; Deitsch KW, 1997, MICROBIOL MOL BIOL R, V61, P281, DOI 10.1128/.61.3.281-293.1997; Ferguson HM, 2002, P ROY SOC B-BIOL SCI, V269, P1217, DOI 10.1098/rspb.2002.2023; Flint J, 2001, NAT REV GENET, V2, P437, DOI 10.1038/35076585; Holub EB, 2001, NAT REV GENET, V2, P516, DOI 10.1038/35080508; Hopwood JA, 2001, J EXP BIOL, V204, P2773; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; MEDLEY GF, 1993, PARASITOLOGY, V106, P441, DOI 10.1017/S0031182000076721; Norris DE, 2001, J MED ENTOMOL, V38, P336, DOI 10.1603/0022-2585-38.2.336; Oduol F, 2000, P NATL ACAD SCI USA, V97, P11397, DOI 10.1073/pnas.180060997; Peichel CL, 2001, NATURE, V414, P901, DOI 10.1038/414901a; Pichon G, 1996, PARASITE, V3, P161, DOI 10.1051/parasite/1996032161; POLOGE LG, 1994, MOL BIOCHEM PARASIT, V68, P35, DOI 10.1016/0166-6851(94)00142-1; PRINGLE G, 1966, T ROY SOC TROP MED H, V60, P626, DOI 10.1016/0035-9203(66)90009-5; Richman AM, 1997, EMBO J, V16, P6114, DOI 10.1093/emboj/16.20.6114; SCHIEFER BA, 1977, EXP PARASITOL, V41, P397, DOI 10.1016/0014-4894(77)90111-4; Talbot CJ, 1999, NAT GENET, V21, P305, DOI 10.1038/6825; Tripet F, 2001, MOL ECOL, V10, P1725, DOI 10.1046/j.0962-1083.2001.01301.x; VERNICK KD, 1995, EXP PARASITOL, V80, P583, DOI 10.1006/expr.1995.1074; Zheng LB, 1996, GENETICS, V143, P941; Zheng LB, 1997, SCIENCE, V276, P425, DOI 10.1126/science.276.5311.425	27	107	108	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 4	2002	298	5591					213	216		10.1126/science.1073420	http://dx.doi.org/10.1126/science.1073420			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	600BJ	12364806				2022-12-28	WOS:000178370500063
J	Hall, N; Pain, A; Berriman, M; Churcher, C; Harris, B; Harris, D; Mungall, K; Bowman, S; Atkin, R; Baker, S; Barron, A; Brooks, K; Buckee, CO; Burrows, C; Cherevach, I; Chillingworth, C; Chillingworth, T; Christodoulou, Z; Clark, L; Clark, R; Corton, C; Cronin, A; Davies, R; Davis, P; Dear, P; Dearden, F; Doggett, J; Feltwell, T; Goble, A; Goodhead, I; Gwilliam, R; Hamlin, N; Hance, Z; Harper, D; Hauser, H; Hornsby, T; Holroyd, S; Horrocks, P; Humphray, S; Jagels, K; James, KD; Johnson, D; Kerhornou, A; Knights, A; Konfortov, B; Kyes, S; Larke, N; Lawson, D; Lennard, N; Line, A; Maddison, M; McLean, J; Mooney, P; Moule, S; Murphy, L; Oliver, K; Ormond, D; Price, C; Quail, MA; Rabbinowitsch, E; Rajandream, MA; Rutter, S; Rutherford, KM; Sanders, M; Simmonds, M; Seeger, K; Sharp, S; Smith, R; Squares, R; Squares, S; Stevens, K; Taylor, K; Tivey, A; Unwin, L; Whitehead, S; Woodward, J; Sulston, JE; Craig, A; Newbold, C; Barrell, BG				Hall, N; Pain, A; Berriman, M; Churcher, C; Harris, B; Harris, D; Mungall, K; Bowman, S; Atkin, R; Baker, S; Barron, A; Brooks, K; Buckee, CO; Burrows, C; Cherevach, I; Chillingworth, C; Chillingworth, T; Christodoulou, Z; Clark, L; Clark, R; Corton, C; Cronin, A; Davies, R; Davis, P; Dear, P; Dearden, F; Doggett, J; Feltwell, T; Goble, A; Goodhead, I; Gwilliam, R; Hamlin, N; Hance, Z; Harper, D; Hauser, H; Hornsby, T; Holroyd, S; Horrocks, P; Humphray, S; Jagels, K; James, KD; Johnson, D; Kerhornou, A; Knights, A; Konfortov, B; Kyes, S; Larke, N; Lawson, D; Lennard, N; Line, A; Maddison, M; McLean, J; Mooney, P; Moule, S; Murphy, L; Oliver, K; Ormond, D; Price, C; Quail, MA; Rabbinowitsch, E; Rajandream, MA; Rutter, S; Rutherford, KM; Sanders, M; Simmonds, M; Seeger, K; Sharp, S; Smith, R; Squares, R; Squares, S; Stevens, K; Taylor, K; Tivey, A; Unwin, L; Whitehead, S; Woodward, J; Sulston, JE; Craig, A; Newbold, C; Barrell, BG			Sequence of Plasmodium falciparum chromosomes 1, 3-9 and 13	NATURE			English	Article							PROTEIN FAMILIES; HAPPY MAP; MALARIA; EXPRESSION; ELEMENTS; SURFACE; CLONING; RICH	Since the sequencing of the first two chromosomes of the malaria parasite, Plasmodium falciparum(1,2), there has been a concerted effort to sequence and assemble the entire genome of this organism. Here we report the sequence of chromosomes 1, 3-9 and 13 of P. falciparum clone 3D7-these chromosomes account for approximately 55% of the total genome. We describe the methods used to map, sequence and annotate these chromosomes. By comparing our assemblies with the optical map, we indicate the completeness of the resulting sequence. During annotation, we assign Gene Ontology terms to the predicted gene products, and observe clustering of some malaria-specific terms to specific chromosomes. We identify a highly conserved sequence element found in the intergenic region of internal var genes that is not associated with their telomeric counterparts.	Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England; Univ Oxford, Weatherall Inst Mol Med, John Radcliffe Hosp, Oxford OX3 9DS, England; MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England	Wellcome Trust Sanger Institute; University of Oxford; MRC Laboratory Molecular Biology; Liverpool School of Tropical Medicine; University of Liverpool	Hamlin, N (corresponding author), Wellcome Trust Sanger Inst, Wellcome Trust Genome Campus, Cambridge CB10 1SA, England.	nh1@sanger.ac.uk	Quail, michael/ABE-6131-2020; Pain, Arnab/L-5766-2015; Berriman, Matthew/A-7618-2011; Rutherford, Kim/Y-7995-2018; Dear, Paul H/A-1162-2012; Hall, Neil/A-8717-2013; Goodhead, Ian/ABC-9200-2020; Horrocks, Paul/C-2615-2009	Pain, Arnab/0000-0002-1755-2819; Berriman, Matthew/0000-0002-9581-0377; Rutherford, Kim/0000-0001-6277-726X; Hall, Neil/0000-0002-7995-3810; Horrocks, Paul/0000-0003-3981-0732; Newbold, Chris/0000-0002-9274-3789; Davies, Robert/0000-0002-9983-1378; Lawson, Daniel/0000-0001-7765-983X; Murphy, Lee/0000-0001-6467-7449; Baker, Stephen/0000-0003-1308-5755; Davis, Paul/0000-0001-5545-0824; Hall, Neil/0000-0003-2808-0009; Craig, Alister/0000-0003-0914-6164; Goodhead, Ian/0000-0002-3110-9442; Kerhornou, Arnaud/0000-0002-2890-295X				ADHYA S, 1989, ANNU REV GENET, V23, P227, DOI 10.1146/annurev.genet.23.1.227; Apweiler R, 2001, NUCLEIC ACIDS RES, V29, P37, DOI 10.1093/nar/29.1.37; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Berriman M, 2001, TRENDS PARASITOL, V17, P463, DOI 10.1016/S1471-4922(01)02083-9; Bowman S, 1999, NATURE, V400, P532, DOI 10.1038/22964; Cawley SE, 2001, MOL BIOCHEM PARASIT, V118, P167, DOI 10.1016/S0166-6851(01)00363-2; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; DEBRUIN D, 1992, GENOMICS, V14, P332, DOI 10.1016/S0888-7543(05)80223-X; Deitsch KW, 2001, NATURE, V412, P875, DOI 10.1038/35091146; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Figueiredo LM, 2002, EMBO J, V21, P815, DOI 10.1093/emboj/21.4.815; Florens L, 2002, NATURE, V419, P520, DOI 10.1038/nature01107; Gardner MJ, 1998, SCIENCE, V282, P1126, DOI 10.1126/science.282.5391.1126; Glockner G, 2002, NATURE, V418, P79, DOI 10.1038/nature00847; Hapgood JP, 2001, CELL BIOL INT, V25, P17, DOI 10.1006/cbir.2000.0674; Hyman RW, 2002, NATURE, V419, P534, DOI 10.1038/nature01102; Katinka MD, 2001, NATURE, V414, P450, DOI 10.1038/35106579; Konfortov BA, 2000, GENOME RES, V10, P1737, DOI 10.1101/gr.141700; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Lai ZW, 1999, NAT GENET, V23, P309, DOI 10.1038/15484; Lasonder E, 2002, NATURE, V419, P537, DOI 10.1038/nature01111; Nielsen H, 1999, PROTEIN ENG, V12, P3, DOI 10.1093/protein/12.1.3; O'Donnell RA, 2002, EMBO J, V21, P1231, DOI 10.1093/emboj/21.5.1231; Pachebat JA, 2001, MOL BIOCHEM PARASIT, V117, P83, DOI 10.1016/S0166-6851(01)00336-X; Piper MB, 1998, GENOME RES, V8, P1299, DOI 10.1101/gr.8.12.1299; Quail MA, 2001, DNA SEQUENCE, V12, P355, DOI 10.3109/10425170109084459; Rutherford K, 2000, BIOINFORMATICS, V16, P944, DOI 10.1093/bioinformatics/16.10.944; Salzberg SL, 1999, GENOMICS, V59, P24, DOI 10.1006/geno.1999.5854; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Su XZ, 1999, SCIENCE, V286, P1351, DOI 10.1126/science.286.5443.1351; Vazquez-Macias A, 2002, MOL MICROBIOL, V45, P155, DOI 10.1046/j.1365-2958.2002.02999.x; Zdobnov EM, 2001, BIOINFORMATICS, V17, P847, DOI 10.1093/bioinformatics/17.9.847	33	136	268	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 3	2002	419	6906					527	531		10.1038/nature01095	http://dx.doi.org/10.1038/nature01095			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	599RF	12368867	Green Accepted			2022-12-28	WOS:000178348400048
J	Sin, WC; Haas, K; Ruthazer, ES; Cline, HT				Sin, WC; Haas, K; Ruthazer, ES; Cline, HT			Dendrite growth increased by visual activity requires NMDA receptor and Rho GTPases	NATURE			English	Article							CALCIUM CURRENT; IN-VIVO; INHIBITION; PLASTICITY; INTERACTS; PROTEINS; SYNGAP; FAMILY; DOMAIN; RAC	Previous studies suggest that neuronal activity may guide the development of synaptic connections in the central nervous system through mechanisms involving glutamate receptors and GTPase-dependent modulation of the actin cytoskeleton(1-7). Here we demonstrate by in vivo time-lapse imaging of optic tectal cells in Xenopus laevis tadpoles that enhanced visual activity driven by a light stimulus promotes dendritic arbor growth. The stimulus-induced dendritic arbor growth requires glutamate-receptor-mediated synaptic transmission, decreased RhoA activity and increased Rac and Cdc42 activity. The results delineate a role for Rho GTPases in the structural plasticity driven by visual stimulation in vivo.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Cline, HT (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.	cline@cshl.org	Jansen, Heiko T./A-5770-2008; Haas, Kurt/B-3812-2009; Ruthazer, Edward/H-4782-2019; Ruthazer, Edward S/P-5935-2014	Jansen, Heiko T./0000-0003-0178-396X; Haas, Kurt/0000-0003-4754-1560; Ruthazer, Edward/0000-0003-0452-3151; Ruthazer, Edward S/0000-0003-0452-3151	NATIONAL EYE INSTITUTE [F32EY006963, R01EY012102] Funding Source: NIH RePORTER; NEI NIH HHS [F32 EY006963-03, R01 EY012102] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Acebes A, 2000, TRENDS NEUROSCI, V23, P557, DOI 10.1016/S0166-2236(00)01646-5; Albertinazzi C, 1998, J CELL BIOL, V142, P815, DOI 10.1083/jcb.142.3.815; Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; Billuart P, 1998, NATURE, V392, P923, DOI 10.1038/31940; Chen HJ, 1998, NEURON, V20, P895, DOI 10.1016/S0896-6273(00)80471-7; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; Djouder N, 2000, J BIOL CHEM, V275, P18732, DOI 10.1074/jbc.M001425200; Engert F, 1999, NATURE, V399, P66, DOI 10.1038/19978; Fischer M, 2000, NAT NEUROSCI, V3, P887, DOI 10.1038/78791; Furuyashiki T, 1999, J NEUROSCI, V19, P109, DOI 10.1523/JNEUROSCI.19-01-00109.1999; Haas K, 2001, NEURON, V29, P583, DOI 10.1016/S0896-6273(01)00235-5; Kim JH, 1998, NEURON, V20, P683, DOI 10.1016/S0896-6273(00)81008-9; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Lawler S, 1999, CURR BIOL, V9, pR800, DOI 10.1016/S0960-9822(99)80493-X; Lendvai B, 2000, NATURE, V404, P876, DOI 10.1038/35009107; Leung T, 1996, MOL CELL BIOL, V16, P5313; Li Z, 2002, NEURON, V33, P741, DOI 10.1016/S0896-6273(02)00621-9; Li Z, 2000, NAT NEUROSCI, V3, P217, DOI 10.1038/72920; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; Maletic-Savatic M, 1999, SCIENCE, V283, P1923, DOI 10.1126/science.283.5409.1923; Penzes P, 2001, NEURON, V29, P229, DOI 10.1016/S0896-6273(01)00193-3; Rajan I, 1998, J NEUROSCI, V18, P7836; Ruthazer ES, 2002, REAL-TIME IMAGING, V8, P175, DOI 10.1006/rtim.2002.0284; VAN AL, 1997, GENE DEV, V11, P2295; WilkBlaszczak MA, 1997, J NEUROSCI, V17, P4094; Wong WT, 2000, J NEUROSCI, V20, P5024; Wu GY, 1999, J NEUROSCI, V19, P4472; Wu GY, 1998, SCIENCE, V279, P222, DOI 10.1126/science.279.5348.222; Zhang DF, 1999, SPECTROSC SPECT ANAL, V19, P108; Zhang LI, 2000, NAT NEUROSCI, V3, P708, DOI 10.1038/76665	30	346	350	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 3	2002	419	6906					475	480		10.1038/nature00987	http://dx.doi.org/10.1038/nature00987			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	599RF	12368855				2022-12-28	WOS:000178348400036
J	Stewart, KJ				Stewart, KJ			Exercise training and the cardiovascular consequences of type 2 diabetes and hypertension - Plausible mechanisms for improving cardiovascular health	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							LEFT-VENTRICULAR FUNCTION; BODY-FAT DISTRIBUTION; C-REACTIVE PROTEIN; NITRIC-OXIDE SYNTHESIS; BLOOD-PRESSURE; DIASTOLIC DYSFUNCTION; AEROBIC EXERCISE; ARTERIAL STIFFNESS; INSULIN-RESISTANCE; PHYSICAL-ACTIVITY	The coexistence of type 2 diabetes and hypertension is especially damaging to cardiovascular health. Most trials of exercise training for these conditions have focused on glycemic control and blood pressure reduction. Less is known about the effects of exercise on the cardiovascular consequences of diabetes and hypertension. This article reviews the available evidence and plausible mechanisms by which exercise training may improve the cardiovascular health of persons with type 2 diabetes and hypertension and provides practical guidelines for exercise prescription. A MEDLINE search was performed for January 1985 to June 2002. Bibliographies from relevant articles, professional society clinical practice guidelines, and books were also reviewed. Because few large, randomized trials exist on these topics, meta-analyses, smaller trials, nonrandomized trials, and animal studies were also considered. Data quality was determined by publication in peer-reviewed journals or professional society literature. Type 2 diabetes and hypertension result in abnormalities in central and peripheral parameters of cardiovascular structure and function. Evidence for an exercise training benefit is strongest for improvements in endothelial vasodilator function and left ventricular diastolic function. The data for exercise training's improvement of arterial stiffness and system inflammation and reduction of left ventricular mass are less robust. However, this assertion is based more on a lack of randomized controlled trials rather than data to the contrary. Exercise training also reduces total and abdominal fat. These changes in body composition mediate improvements in insulin sensitivity and blood pressure and may improve endothelial vasodilator function. The current evidence, albeit not fully confirmed in randomized trials, suggests that the benefits of exercise training go beyond the recognized benefits of glycemic control and blood pressure reduction.	Johns Hopkins Univ, Sch Med, Dept Med, Div Cardiol, Baltimore, MD 21205 USA	Johns Hopkins University	Stewart, KJ (corresponding author), Johns Hopkins Bayview Med Ctr, Johns Hopkins Heart Hlth, 4940 Eastern Ave, Baltimore, MD 21224 USA.	kstewart@mail.jhmi.edu						Abete P, 2000, J AM COLL CARDIOL, V36, P643, DOI 10.1016/S0735-1097(00)00722-1; Abramson JL, 2002, HYPERTENSION, V39, P197, DOI 10.1161/hy0202.104270; ACSM, 2000, GUID EX TEST PRESCR; Adamopoulos S, 2001, EUR HEART J, V22, P791, DOI 10.1053/euhj.2000.2285; Aiello LP, 2002, HDB EXERCISE DIABETE, P401; Albright A, 2000, MED SCI SPORT EXER, V32, P1345; *AM DIAB ASS, 2002, DIABETES CARE S1, V52, pS64; American College of Sports Medicine, 1993, MED SCI SPORTS EXERC, V25, pi, DOI DOI 10.1249/00005768-199310000-00024; American Diabetes Association, 2002, DIABETES CARE, V25, ps64; Arad Y, 2001, ARTERIOSCL THROM VAS, V21, P2051, DOI 10.1161/hq1201.100257; Arcaro G, 1999, INT J OBESITY, V23, P936, DOI 10.1038/sj.ijo.0801022; BADENHOP DT, 2001, CLIN EXERCISE PHYSL, V3, P71; Baron AD, 1999, AM J CARDIOL, V84, p25J; BELJIC T, 1994, ACTA DIABETOL, V31, P147, DOI 10.1007/BF00570369; Berger M, 2002, HDB EXERCISE DIABETE, P365; BLAIR SN, 1992, ANNU REV PUBL HEALTH, V13, P99, DOI 10.1146/annurev.pu.13.050192.000531; Boule NG, 2001, JAMA-J AM MED ASSOC, V286, P1218, DOI 10.1001/jama.286.10.1218; Brenner DA, 2001, CIRCULATION, V104, P221, DOI 10.1161/01.CIR.104.2.221; Brubaker P. H, 2002, CORONARY ARTERY DIS; BRUSH JE, 1992, J AM COLL CARDIOL, V19, P809, DOI 10.1016/0735-1097(92)90522-O; Caballero AE, 1999, DIABETES, V48, P1856, DOI 10.2337/diabetes.48.9.1856; Chae CU, 2001, HYPERTENSION, V38, P399, DOI 10.1161/01.HYP.38.3.399; Chipkin Stuart R., 2001, Cardiology Clinics, V19, P489, DOI 10.1016/S0733-8651(05)70231-9; Clarkson P, 1996, J AM COLL CARDIOL, V28, P573, DOI 10.1016/0735-1097(96)82380-1; Cockcroft JR, 2000, J HUM HYPERTENS, V14, P377, DOI 10.1038/sj.jhh.1001023; DEFRONZO RA, 1920, J CARDIOVASC PHA S11, V20, pS1; DESPRES JP, 1991, AM J PHYSIOL, V261, pE159, DOI 10.1152/ajpendo.1991.261.2.E159; DESPRES JP, 1993, NUTRITION, V9, P452; Devereux RB, 2000, CIRCULATION, V101, P2271, DOI 10.1161/01.CIR.101.19.2271; Duncan B B, 2001, Sao Paulo Med J, V119, P122; Estacio RO, 1998, DIABETES CARE, V21, P291, DOI 10.2337/diacare.21.2.291; Fang TC, 2001, J HYPERTENS, V19, P1255, DOI 10.1097/00004872-200107000-00010; Feigenbaum MS, 1999, MED SCI SPORT EXER, V31, P38, DOI 10.1097/00005768-199901000-00008; Ferrier KE, 2001, HYPERTENSION, V38, P222, DOI 10.1161/01.HYP.38.2.222; Fletcher GF, 1996, CIRCULATION, V94, P857, DOI 10.1161/01.CIR.94.4.857; FORMAN DE, 1992, J GERONTOL, V47, pM56, DOI 10.1093/geronj/47.2.M56; Garvey W T, 1998, Clin Cornerstone, V1, P13, DOI 10.1016/S1098-3597(98)90015-1; Geffken DF, 2001, AM J EPIDEMIOL, V153, P242, DOI 10.1093/aje/153.3.242; GOUGH SCL, 1995, ACTA DIABETOL, V32, P110, DOI 10.1007/BF00569568; Grossman E, 2000, ARCH INTERN MED, V160, P2447, DOI 10.1001/archinte.160.16.2447; Haffner SM, 2000, BRIT J NUTR, V83, pS67; Higashi Y, 1999, HYPERTENSION, V33, P591, DOI 10.1161/01.HYP.33.1.591; Higashi Y, 1999, CIRCULATION, V100, P1194, DOI 10.1161/01.CIR.100.11.1194; HIRAI J, 1992, INTERNAL MED, V31, P725, DOI 10.2169/internalmedicine.31.725; HODES RJ, 1995, J AM GERIATR SOC, V43, P581, DOI 10.1111/j.1532-5415.1995.tb06111.x; HORNSBY WG, 2002, HDB EXERCISE DIABETE, P311; Huang ES, 2001, AM J MED, V111, P633, DOI 10.1016/S0002-9343(01)00978-0; Irace L, 1998, CLIN CARDIOL, V21, P567, DOI 10.1002/clc.4960210807; Jensen-Urstad K, 1999, SCAND J MED SCI SPOR, V9, P88; JOHNSTONE MT, 1993, CIRCULATION, V88, P2510, DOI 10.1161/01.CIR.88.6.2510; KELEMEN MH, 1990, JAMA-J AM MED ASSOC, V263, P2766, DOI 10.1001/jama.263.20.2766; Kelley DE, 2001, MED SCI SPORT EXER, V33, pS495, DOI 10.1097/00005768-200106001-00020; Kelley G A, 2001, Prev Cardiol, V4, P73, DOI 10.1111/j.1520-037X.2001.00529.x; Kelley GA, 2001, PREV MED, V33, P120, DOI 10.1006/pmed.2001.0860; Kingwell BA, 1998, J HYPERTENS, V16, P181, DOI 10.1097/00004872-199816020-00008; Kuzuya M, 2001, DIABETOLOGIA, V44, P433, DOI 10.1007/s001250051640; LagadicGossmann D, 1996, AM J PHYSIOL-HEART C, V270, pH1529, DOI 10.1152/ajpheart.1996.270.5.H1529; LANGER A, 1991, AM J CARDIOL, V67, P1073, DOI 10.1016/0002-9149(91)90868-L; Lavrencic A, 2000, ARTERIOSCL THROM VAS, V20, P551, DOI 10.1161/01.ATV.20.2.551; LEVY WC, 1993, CIRCULATION, V88, P116, DOI 10.1161/01.CIR.88.1.116; London GM, 1999, J HYPERTENS, V17, pS3; Maiorana A, 2001, J AM COLL CARDIOL, V38, P860, DOI 10.1016/S0735-1097(01)01439-5; Maiorana A, 2001, MED SCI SPORT EXER, V33, P2022, DOI 10.1097/00005768-200112000-00008; Marks JB, 2000, J DIABETES COMPLICAT, V14, P108, DOI 10.1016/S1056-8727(00)00065-9; Mattusch F, 2000, INT J SPORTS MED, V21, P21; MCALLISTER RM, 1995, MED SCI SPORT EXER, V27, P1145; MCVEIGH GE, 1992, DIABETOLOGIA, V35, P771; Missault L H, 1993, Blood Press, V2, P284, DOI 10.3109/08037059309077169; Mokdad AH, 2001, JAMA-J AM MED ASSOC, V286, P1195, DOI 10.1001/jama.286.10.1195; Morgan CL, 2000, DIABETIC MED, V17, P146, DOI 10.1046/j.1464-5491.2000.00222.x; Mourier A, 1997, DIABETES CARE, V20, P385, DOI 10.2337/diacare.20.3.385; *NAT HIGH BLOOD PR, 1997, PUBL NIH; Osei K, 1999, AM J CARDIOL, V84, p33J; Otis CL, 1997, MED SCI SPORT EXER, V29, pR1, DOI 10.1097/00005768-199705000-00037; Paterick T E, 2001, Cardiol Rev, V9, P282, DOI 10.1097/00045415-200109000-00008; Pi-Sunyer FX, 1999, MED SCI SPORT EXER, V31, pS602, DOI 10.1097/00005768-199911001-00019; Poirier P, 2001, DIABETES CARE, V24, P5, DOI 10.2337/diacare.24.1.5; Poirier P, 2000, AM J CARDIOL, V85, P473, DOI 10.1016/S0002-9149(99)00774-2; Pollock ML, 2000, CIRCULATION, V101, P828, DOI 10.1161/01.CIR.101.7.828; Pradhan AD, 2001, JAMA-J AM MED ASSOC, V286, P327, DOI 10.1001/jama.286.3.327; RAEV DC, 1994, DIABETES CARE, V17, P633, DOI 10.2337/diacare.17.7.633; Rakowski H, 1996, J Am Soc Echocardiogr, V9, P736, DOI 10.1016/S0894-7317(96)90076-0; Ray NF, 1998, DIABETES CARE, V21, P296; ROBILLON JF, 1994, DIABETES METAB, V20, P473; Rodriguez-Moran M, 2000, ARCH MED RES, V31, P399, DOI 10.1016/S0188-4409(00)00089-8; Ross R, 2000, ANN INTERN MED, V133, P92, DOI 10.7326/0003-4819-133-2-200007180-00008; Ruderman N, 2002, HDB EXERCISE DIABETE, P269; RUDERMAN N, 2002, HDB EXERCISE DIABETE; SACHS R N, 1985, Revue de Medecine Interne, V6, P68, DOI 10.1016/S0248-8663(85)80082-5; Sakamoto S, 1998, DIABETES, V47, P82, DOI 10.2337/diabetes.47.1.82; SALOMAA V, 1995, CIRCULATION, V91, P1432, DOI 10.1161/01.CIR.91.5.1432; Scherrer U, 2000, EUR J ENDOCRINOL, V142, P315, DOI 10.1530/eje.0.1420315; SCHWARTZ RS, 1991, METABOLISM, V40, P545, DOI 10.1016/0026-0495(91)90239-S; SCHWARTZ RS, 1992, METABOLISM, V41, P649, DOI 10.1016/0026-0495(92)90058-I; STERN MP, 1986, ARTERIOSCLEROSIS, V6, P123, DOI 10.1161/01.ATV.6.2.123; STEWART K, 2001, ACSMS RESOURCE MANUA; STEWART KJ, 1990, MED SCI SPORT EXER, V22, P171; Stratton IM, 2000, BMJ-BRIT MED J, V321, P405, DOI 10.1136/bmj.321.7258.405; TAKEMOTO KA, 1992, AM HEART J, V124, P143, DOI 10.1016/0002-8703(92)90932-L; TAKENAKA K, 1988, AM J CARDIOL, V61, P1140, DOI 10.1016/0002-9149(88)90149-X; TARUMI N, 1993, CARDIOLOGY, V83, P316, DOI 10.1159/000175987; Tisi PV, 1997, EUR J VASC ENDOVASC, V14, P344, DOI 10.1016/S1078-5884(97)80283-3; Tomoike H, 1996, DIABETES RES CLIN PR, V30, pS55, DOI 10.1016/S0168-8227(96)80038-6; Turner MJ, 2000, J GERONTOL A-BIOL, V55, pM245, DOI 10.1093/gerona/55.4.M245; UUSITUPA M, 1983, ACTA MED SCAND, V213, P363; UUSITUPA MIJ, 1990, ANN MED, V22, P377, DOI 10.3109/07853899009147274; VAITKEVICIUS PV, 1993, CIRCULATION, V88, P1456, DOI 10.1161/01.CIR.88.4.1456; Whelton SP, 2002, ANN INTERN MED, V136, P493, DOI 10.7326/0003-4819-136-7-200204020-00006; Williams SB, 1996, J AM COLL CARDIOL, V27, P567, DOI 10.1016/0735-1097(95)00522-6; YAMADA J, 1991, J NUTR SCI VITAMINOL, V37, pS17; Yasuda I, 1992, J Cardiol, V22, P427; Zabalgoitia M, 2001, AM J CARDIOL, V87, P320, DOI 10.1016/S0002-9149(00)01366-7	112	183	188	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	2002	288	13					1622	1631		10.1001/jama.288.13.1622	http://dx.doi.org/10.1001/jama.288.13.1622			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	599BJ	12350193				2022-12-28	WOS:000178314000023
J	Davidson, JM; Lambert, TW; Goldacre, MJ; Parkhouse, J				Davidson, JM; Lambert, TW; Goldacre, MJ; Parkhouse, J			UK senior doctors' career destinations, job satisfaction, and future intentions: questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article									Univ Oxford, Dept Publ Hlth, Unit Hlth Care Epidemiol, UK Med Careers Res Grp, Oxford OX3 7LF, England	University of Oxford	Goldacre, MJ (corresponding author), Univ Oxford, Dept Publ Hlth, Unit Hlth Care Epidemiol, UK Med Careers Res Grp, Oxford OX3 7LF, England.			Lambert, Trevor/0000-0001-9688-3036				Davidson JM, 2001, J PUBLIC HEALTH MED, V23, P323, DOI 10.1093/pubmed/23.4.323; *DEP HLTH, 1999, IMPR WORK LIV NHS; Lambert TW, 2002, BRIT J GEN PRACT, V52, P364; Lambert TW, 1998, MED EDUC, V32, P533, DOI 10.1046/j.1365-2923.1998.00244.x	4	24	26	1	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 28	2002	325	7366					685	686		10.1136/bmj.325.7366.685	http://dx.doi.org/10.1136/bmj.325.7366.685			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	600JV	12351361	Bronze, Green Published			2022-12-28	WOS:000178387600022
J	Luck, J; Peabody, JW				Luck, J; Peabody, JW			Using standardised patients to measure physicians' practice: validation study using audio recordings	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SIMULATED PATIENTS; CHART ABSTRACTION; PERFORMANCE; QUALITY; SKILLS; CARE	Objective To assess the validity of standardised patients to measure the quality of physicians' practice. Design Validation study of standardised patients' assessments. Physicians saw unannounced standardised patients presenting with common outpatient conditions. The standardised patients covertly tape recorded their visit and completed a checklist of quality criteria immediately afterwards. Their assessments were compared against independent assessments of the recordings by a trained medical records abstractor. Setting Four general internal medicine primary care clinics in California. Participants 144 randomly selected consenting physicians. Main outcome measures Rates of agreement between the patients' assessments and independent assessment. Results 40 visits, one per standardised patient, were recorded. The overall rate of agreement between the standardised patients' checklists and the independent assessment of the audio transcripts was 91% (K=0.81). Disaggregating the data by medical condition, site, level of physicians' training, and domain (stage of the consultation) gave similar rates of agreement. Sensitivity of the standardised patients' assessments was 95%, and specificity was 85%. The area under the receiver operator characteristic curve was 90%. Conclusions Standardised patients' assessments seem to be a valid measure of the quality of physicians' care for a variety of common medical conditions in actual outpatient settings. Properly trained standardised. patients compare well with independent assessment of recordings of the consultations and may justify their use as a "gold standard" in comparing the quality of care across sites or evaluating data obtained from other sources, such as medical records and clinical vignettes.	Inst Global Hlth, San Francisco, CA 94105 USA; Vet Adm Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Peabody, JW (corresponding author), Inst Global Hlth, 74 New Montgomery St, San Francisco, CA 94105 USA.	peabody@psg.ucsf.edu						Badger L W, 1995, Fam Med, V27, P126; Beullens J, 1997, FAM PRACT, V14, P58, DOI 10.1093/fampra/14.1.58; CARNEY PA, 1993, ANN INTERN MED, V119, P129, DOI 10.7326/0003-4819-119-2-199307150-00007; Cohen DS, 1996, ACAD MED, V71, pS87, DOI 10.1097/00001888-199601000-00052; Colliver J A, 1997, JAMA, V278, P790, DOI 10.1001/jama.278.9.790; Colliver JA, 1998, ACAD MED, V73, pS81, DOI 10.1097/00001888-199810000-00053; COLLIVER JA, 1994, ACAD MED, V69, pS37, DOI 10.1097/00001888-199410000-00035; DAUPHINEE WD, 1995, JAMA-J AM MED ASSOC, V274, P741, DOI 10.1001/jama.274.9.741; Dresselhaus TR, 2002, J MED ETHICS, V28, P293, DOI 10.1136/jme.28.5.291; Fihn SD, 2000, JAMA-J AM MED ASSOC, V283, P1740, DOI 10.1001/jama.283.13.1740; Finlay IG, 1995, MED EDUC, V29, P424, DOI 10.1111/j.1365-2923.1995.tb02866.x; Glassman P A, 2000, Jt Comm J Qual Improv, V26, P644; Gomez JM, 1997, MED EDUC, V31, P94, DOI 10.1111/j.1365-2923.1997.tb02465.x; GORDON JJ, 1992, J GEN INTERN MED, V7, P57, DOI 10.1007/BF02599104; Grant C, 2002, BRIT MED J, V324, P1556, DOI 10.1136/bmj.324.7353.1556; KOPELOW ML, 1992, ACAD MED, V67, pS19, DOI 10.1097/00001888-199210000-00026; Luck J, 2000, AM J MED, V108, P642, DOI 10.1016/S0002-9343(00)00363-6; Margolis MJ, 1998, ACAD MED, V73, pS114, DOI 10.1097/00001888-199810000-00064; NORCINI JJ, 1995, ANN INTERN MED, V123, P795, DOI 10.7326/0003-4819-123-10-199511150-00008; NORMAN GR, 1993, JAMA-J AM MED ASSOC, V270, P1046; OHAGAN JJ, 1989, NEW ZEAL MED J, V102, P252; Peabody JW, 2000, JAMA-J AM MED ASSOC, V283, P1715, DOI 10.1001/jama.283.13.1715; RETHANS JJ, 1994, BRIT J GEN PRACT, V44, P153; Ross LP, 1996, ACAD MED, V71, pS4, DOI 10.1097/00001888-199610000-00027; RUSSELL NK, 1991, ACAD MED, V66, pS37, DOI 10.1097/00001888-199109000-00034; RUSSELL NK, 1992, AM J PREV MED, V8, P235, DOI 10.1016/S0749-3797(18)30811-0; Thompson JC, 1996, OPHTHALMOLOGY, V103, P117, DOI 10.1016/S0161-6420(96)30751-3; VANDERVLEUTEN CPM, 1991, MED EDUC, V25, P110; VU NV, 1987, J MED EDUC, V62, P1000; WOODWARD CA, 1985, MED CARE, V23, P1019, DOI 10.1097/00005650-198508000-00009	30	112	120	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 28	2002	325	7366					679	+		10.1136/bmj.325.7366.679	http://dx.doi.org/10.1136/bmj.325.7366.679			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	600JV	12351358	Green Published, Bronze			2022-12-28	WOS:000178387600018
J	Ricaurte, GA; Yuan, J; Hatzidimitriou, G; Cord, BJ; McCann, UD				Ricaurte, GA; Yuan, J; Hatzidimitriou, G; Cord, BJ; McCann, UD			Severe Dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA ("ecstasy")	SCIENCE			English	Article							CENTRAL SEROTONERGIC NEURONS; METHYLENEDIOXYMETHAMPHETAMINE MDMA; RHESUS-MONKEYS; COGNITIVE PERFORMANCE; 3,4-METHYLENEDIOXYMETHAMPHETAMINE; BRAIN; RAT; METABOLITES; SYSTEMS; HUMANS	The prevailing view is that the popular recreational drug (+/-)3,4-methylenedioxymethamphetamine (MDMA, or "ecstasy") is a selective serotonin neurotoxin in animals and possibly in humans. Nonhuman primates exposed to several sequential doses of MDMA, a regimen modeled after one used by humans, developed severe brain dopaminergic neurotoxicity, in addition to less pronounced serotonergic neurotoxicity. MDMA neurotoxicity was associated with increased vulnerability to motor dysfunction secondary to dopamine depletion. These results have implications for mechanisms of MDMA neurotoxicity and suggest that recreational MDMA users may unwittingly be putting themselves at risk, either as young adults or later in life, for developing neuropsychiatric disorders related to brain dopamine and/or serotonin deficiency.	Johns Hopkins Univ, Sch Med, Dept Neurol, Johns Hopkins Bayview Med Ctr, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Johns Hopkins Bayview Med Ctr, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat, Johns Hopkins Bayview Med Ctr, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Ricaurte, GA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurol, Johns Hopkins Bayview Med Ctr, Baltimore, MD 21224 USA.			Cord, Branden/0000-0002-9120-5989	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA009487, R01DA013790, R01DA005707, R29DA005707, R01DA010217] Funding Source: NIH RePORTER; NIDA NIH HHS [DA 00206, DA 10217, DA 09487, DA 13790, DA 5707] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		CALNE DB, 1987, CAN J NEUROL SCI, V14, P424, DOI 10.1017/S0317167100037847; de la Torre R, 2000, BRIT J CLIN PHARMACO, V49, P104, DOI 10.1046/j.1365-2125.2000.00121.x; ELAYAN I, 1992, EUR J PHARMACOL, V221, P281, DOI 10.1016/0014-2999(92)90714-F; European Commission, 2001, ANN REP STAT DRUG PR, P1; FARRE M, 2001, DRUG ALCOHOL DEPEN S, V63, pS46; FINK ROBERT P., 1967, BRAIN RES, V4, P369, DOI 10.1016/0006-8993(67)90166-7; FINNEGAN KT, 1988, BRAIN RES, V447, P141, DOI 10.1016/0006-8993(88)90974-2; FREDERICK DL, 1995, NEUROTOXICOL TERATOL, V17, P531, DOI 10.1016/0892-0362(95)00013-H; GIBB JW, 1994, AMPHETAMINE ITS ANAL, P269; Gouzoulis-Mayfrank E, 2000, J NEUROL NEUROSUR PS, V68, P719, DOI 10.1136/jnnp.68.6.719; GREEN AR, 1995, PSYCHOPHARMACOLOGY, V119, P247, DOI 10.1007/BF02246288; INSEL TR, 1989, J PHARMACOL EXP THER, V249, P713; JOHNSON M, 1992, J PHARMACOL EXP THER, V261, P447; JOHNSTON LD, 2001, NIH PUBLICATION; KLEVEN MS, 1989, BRAIN RES, V488, P121, DOI 10.1016/0006-8993(89)90700-2; Malberg JE, 1998, J NEUROSCI, V18, P5086; McCann UD, 1999, PSYCHOPHARMACOLOGY, V143, P417, DOI 10.1007/s002130050967; McCann UD, 1998, LANCET, V352, P1433, DOI 10.1016/S0140-6736(98)04329-3; Mintzer S, 1999, NEW ENGL J MED, V340, P1443, DOI 10.1056/NEJM199905063401817; Mordenti J., 1989, TOXICOKINETICS NEW D, P42; Morgan MJ, 1999, PSYCHOPHARMACOLOGY, V141, P30, DOI 10.1007/s002130050803; O'Shea E, 2001, NEUROPHARMACOLOGY, V40, P65, DOI 10.1016/S0028-3908(00)00106-4; Parrott AC, 2002, PHARMACOL BIOCHEM BE, V71, P837, DOI 10.1016/S0091-3057(01)00711-0; Parrott AC, 2001, HUM PSYCHOPHARM CLIN, V16, P557, DOI 10.1002/hup.351; PEROUTKA SJ, 1987, NEW ENGL J MED, V317, P1542; Ricaurte GA, 2000, NEUROPSYCHOBIOLOGY, V42, P5, DOI 10.1159/000026664; RICAURTE GA, 1988, JAMA-J AM MED ASSOC, V260, P51, DOI 10.1001/jama.260.1.51; RICAURTE GA, 1988, BRAIN RES, V446, P165, DOI 10.1016/0006-8993(88)91309-1; SLIKKER W, 1988, TOXICOL APPL PHARM, V94, P448, DOI 10.1016/0041-008X(88)90285-2; STONE DM, 1987, NEUROPHARMACOLOGY, V26, P1657, DOI 10.1016/0028-3908(87)90017-7; Weir E, 2000, CAN MED ASSOC J, V162, P1843; ZHAO ZY, 1992, CHEM RES TOXICOL, V5, P89, DOI 10.1021/tx00025a015	32	122	123	2	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 27	2002	297	5590					2260	2263		10.1126/science.1074501	http://dx.doi.org/10.1126/science.1074501			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	597LA	12351788				2022-12-28	WOS:000178222000047
J	Suerbaum, S; Michetti, P				Suerbaum, S; Michetti, P			Medical progress: Helicobacter pylori infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							RANITIDINE BISMUTH CITRATE; GASTRIC EPITHELIAL-CELLS; PROTON PUMP INHIBITOR; CYTOKINE MESSENGER-RNA; TRIPLE THERAPY; VACUOLATING CYTOTOXIN; ANTIMICROBIAL RESISTANCE; ANTIBIOTIC-RESISTANCE; PATHOGENICITY ISLAND; MUCOSAL INFLAMMATION		Univ Wurzburg, Inst Hyg & Microbiol, Wurzburg, Germany; Univ Lausanne, Med Ctr, Div Gastroenterol & Hepatol, Lausanne, Switzerland	University of Wurzburg; University of Lausanne	Michetti, P (corresponding author), CHU Vaudois, Div Gastroenterol & Hepatol, BH10N-531, CH-1010 Lausanne, Switzerland.	pierre.michetti@chuv.hospvd.ch						Alm RA, 1999, NATURE, V397, P719, DOI 10.1038/17837; Atherton JC, 1997, GASTROENTEROLOGY, V112, P92, DOI 10.1016/S0016-5085(97)70223-3; BANATVALA N, 1993, J INFECT DIS, V168, P219, DOI 10.1093/infdis/168.1.219; BAYERDORFFER E, 1995, LANCET, V345, P1591, DOI 10.1016/S0140-6736(95)90113-2; Bazzoli F, 2001, EUR J GASTROEN HEPAT, V13, pS3; Blanchard TG, 2000, GASTROENTEROL CLIN N, V29, P671, DOI 10.1016/S0889-8553(05)70137-0; Blum AL, 1998, NEW ENGL J MED, V339, P1875, DOI 10.1056/NEJM199812243392602; Calvet X, 2000, ALIMENT PHARM THER, V14, P603; Catalano F, 1999, HELICOBACTER, V4, P178, DOI 10.1046/j.1523-5378.1999.99274.x; Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648; Coelho LGV, 2000, AM J GASTROENTEROL, V95, P2688, DOI 10.1111/j.1572-0241.2000.03174.x; CRABTREE JE, 1994, J CLIN PATHOL, V47, P61, DOI 10.1136/jcp.47.1.61; CRABTREE JE, 1991, GUT, V32, P1473, DOI 10.1136/gut.32.12.1473; DELANEY BC, 2001, COCHRANE DB SYST REV, V3; DOOLEY CP, 1989, NEW ENGL J MED, V321, P1562, DOI 10.1056/NEJM198912073212302; Dore MP, 2000, DIGEST DIS SCI, V45, P68, DOI 10.1023/A:1005457226341; Dore MP, 2001, AM J GASTROENTEROL, V96, P1396; Drumm Brendan, 2000, JPGN, V30, P207, DOI 10.1097/00005176-200002000-00020; El-Omar EM, 2001, NATURE, V412, P99, DOI 10.1038/35083631; El-Omar EM, 2000, NATURE, V404, P398, DOI 10.1038/35006081; EVANS DJ, 1995, INFECT IMMUN, V63, P2213, DOI 10.1128/IAI.63.6.2213-2220.1995; Falush D, 2001, P NATL ACAD SCI USA, V98, P15056, DOI 10.1073/pnas.251396098; Fan XJ, 2000, J IMMUNOL, V165, P1918, DOI 10.4049/jimmunol.165.4.1918; Feldman RA, 2001, HELICOBACTER PYLORI: MOLECULAR AND CELLULAR BIOLOGY, P29; Fischer W, 2001, MOL MICROBIOL, V42, P1337, DOI 10.1046/j.1365-2958.2001.02714.x; FORMAN D, 1991, BRIT MED J, V302, P1302, DOI 10.1136/bmj.302.6788.1302; Fox JG, 1998, ALIMENT PHARM THER, V12, P37, DOI 10.1111/j.1365-2036.1998.00008.x; Fox JG, 2001, NEW ENGL J MED, V345, P829, DOI 10.1056/NEJM200109133451111; Galmiche A, 2000, EMBO J, V19, P6361, DOI 10.1093/emboj/19.23.6361; Gerhard M, 2001, HELICOBACTER PYLORI: MOLECULAR AND CELLULAR BIOLOGY, P185; Gisbert JP, 2000, ALIMENT PHARM THER, V14, P1141; Goodman KJ, 1996, AM J EPIDEMIOL, V144, P290, DOI 10.1093/oxfordjournals.aje.a008924; GOODWIN CS, 1986, J CLIN PATHOL, V39, P353, DOI 10.1136/jcp.39.4.353; GRAHAM DY, 2001, HELICOBACTER PYLORI, P499; Guruge JL, 1998, P NATL ACAD SCI USA, V95, P3925, DOI 10.1073/pnas.95.7.3925; HANDT LK, 1995, INFECT IMMUN, V63, P1146; HANDT LK, 1994, INFECT IMMUN, V62, P2367, DOI 10.1128/IAI.62.6.2367-2374.1994; Harris PR, 2000, J INFECT DIS, V181, P783, DOI 10.1086/315257; Higashi H, 2002, SCIENCE, V295, P683, DOI 10.1126/science.1067147; Hojo M, 2001, SCAND J GASTROENTERO, V36, P690, DOI 10.1080/003655201300191941; Houben MHMG, 1999, ALIMENT PHARM THER, V13, P1047; Howden CW, 1998, AM J GASTROENTEROL, V93, P2330, DOI 10.1111/j.1572-0241.1998.00684.x; Howden CW, 2000, HELICOBACTER PYLORI: BASIC MECHANISMS TO CLINICAL CURE 2000, P315; Ilver D, 1998, SCIENCE, V279, P373, DOI 10.1126/science.279.5349.373; Josenhans C, 2001, HELICOBACTER PYLORI: MOLECULAR AND CELLULAR BIOLOGY, P171; Keates S, 1999, J IMMUNOL, V163, P5552; Laheij RJF, 1999, ALIMENT PHARM THERAP, V13, P857; Laine L, 2000, AM J GASTROENTEROL, V95, P3393, DOI 10.1111/j.1572-0241.2000.03349.x; Lam SJ, 1998, J GASTROEN HEPATOL, V13, P1, DOI 10.1111/j.1440-1746.1998.tb00537.x; Lee M, 1999, ARCH INTERN MED, V159, P2312, DOI 10.1001/archinte.159.19.2312; Lind T, 1999, GASTROENTEROLOGY, V116, P248, DOI 10.1016/S0016-5085(99)70119-8; Lind T, 1996, Helicobacter, V1, P138, DOI 10.1111/j.1523-5378.1996.tb00027.x; Liu HX, 2001, LANCET, V357, P39, DOI 10.1016/S0140-6736(00)03571-6; MAI UEH, 1992, J EXP MED, V175, P517, DOI 10.1084/jem.175.2.517; MALATY HM, 1994, GUT, V35, P742, DOI 10.1136/gut.35.6.742; Malfertheiner P, 1999, ALIMENT PHARM THERAP, V13, P703, DOI 10.1046/j.1365-2036.1999.00535.x; MARSHALL BJ, 1988, LANCET, V2, P1437; McColl K, 1998, NEW ENGL J MED, V339, P1869, DOI 10.1056/NEJM199812243392601; Megraud F, 2001, INFEC AGENT, P511; Meining A, 1998, ALIMENT PHARM THER, V12, P735; Meyer JM, 2002, ANN INTERN MED, V136, P13, DOI 10.7326/0003-4819-136-1-200201010-00008; Michetti P, 1999, GASTROENTEROLOGY, V116, P804, DOI 10.1016/S0016-5085(99)70063-6; Misiewicz JJ, 1997, GUT, V41, P735, DOI 10.1136/gut.41.6.735; Miwa H, 1999, ALIMENT PHARM THERAP, V13, P741, DOI 10.1046/j.1365-2036.1999.00526.x; Moayyedi P, 2001, GASTROENTEROLOGY, V121, P1120, DOI 10.1053/gast.2001.29332; Moayyedi P, 2001, COCHRANE DB SYST REV, V1; Mobley HL, 2001, HELICOBACTER PYLORI; Mobley HLT, 2001, HELICOBACTER PYLORI: MOLECULAR AND CELLULAR BIOLOGY, P155; Montecucco C, 2001, HELICOBACTER PYLORI: MOLECULAR AND CELLULAR BIOLOGY, P245; Morgner A, 2000, GASTROENTEROLOGY, V118, P821, DOI 10.1016/S0016-5085(00)70167-3; National Committee for Clinical Laboratory Standards, 1999, PERF STAND ANT SUSC; Naumann M, 1999, J BIOL CHEM, V274, P31655, DOI 10.1074/jbc.274.44.31655; Negrini R, 1997, HELICOBACTER, V2, pS13; Neubauer A, 1997, JNCI-J NATL CANCER I, V89, P1350, DOI 10.1093/jnci/89.18.1350; Odenbreit S, 2000, SCIENCE, V287, P1497, DOI 10.1126/science.287.5457.1497; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; Parsonnet J, 1999, JAMA-J AM MED ASSOC, V282, P2240, DOI 10.1001/jama.282.23.2240; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; PEREZPEREZ GI, 1988, ANN INTERN MED, V109, P11, DOI 10.7326/0003-4819-109-1-11; Perri F, 2001, AM J GASTROENTEROL, V96, P58; Perri F, 2001, ALIMENT PHARM THER, V15, P1017, DOI 10.1046/j.1365-2036.2001.01002.x; Peterson WL, 1996, ALIMENT PHARM THERAP, V10, P251, DOI 10.1111/j.0953-0673.1996.00251.x; Rowland M, 1999, GASTROENTEROLOGY, V117, P336, DOI 10.1053/gast.1999.0029900336; Rudi J, 1998, J CLIN INVEST, V102, P1506, DOI 10.1172/JCI2808; Rupnow MFT, 2000, EMERG INFECT DIS, V6, P228, DOI 10.3201/eid0603.000302; Salama NR, 2001, INFECT IMMUN, V69, P730, DOI 10.1128/IAI.69.2.730-736.2001; Schlemper RJ, 1996, EUR J GASTROEN HEPAT, V8, P33, DOI 10.1097/00042737-199601000-00007; Schwizer W, 2001, LANCET, V358, P1734; Schwizer W, 2001, LANCET, V357, P1738, DOI 10.1016/S0140-6736(00)04894-7; Segal ED, 1999, P NATL ACAD SCI USA, V96, P14559, DOI 10.1073/pnas.96.25.14559; Smythies LE, 2000, J IMMUNOL, V165, P1022, DOI 10.4049/jimmunol.165.2.1022; Solnick JV, 2001, CLIN MICROBIOL REV, V14, P59, DOI 10.1128/CMR.14.1.59-97.2001; Suerbaum S, 1998, P NATL ACAD SCI USA, V95, P12619, DOI 10.1073/pnas.95.21.12619; Sung JJY, 1999, ALIMENT PHARM THER, V13, P1079, DOI 10.1046/j.1365-2036.1999.00580.x; Szabo I, 1999, EMBO J, V18, P5517, DOI 10.1093/emboj/18.20.5517; Tindberg Y, 1999, ACTA PAEDIATR, V88, P631, DOI 10.1080/08035259950169288; Tomb JF, 1997, NATURE, V389, P412, DOI 10.1038/38792; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Tomita T, 2001, J INFECT DIS, V183, P620, DOI 10.1086/318541; TUFANO MA, 1994, INFECT IMMUN, V62, P1392, DOI 10.1128/IAI.62.4.1392-1399.1994; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; Uemura N, 1997, CANCER EPIDEM BIOMAR, V6, P639; Unge P, 1998, EUR J SURG, V164, P16, DOI 10.1080/11024159850191391; Van Zanten SJOV, 1999, ALIMENT PHARM THERAP, V13, P289, DOI 10.1046/j.1365-2036.1999.00471.x; Wang J, 2001, J IMMUNOL, V167, P926, DOI 10.4049/jimmunol.167.2.926; Weeks DL, 2000, SCIENCE, V287, P482, DOI 10.1126/science.287.5452.482; Wotherspoon AC, 1998, BRIT MED BULL, V54, P79; Yamaoka Y, 1996, GASTROENTEROLOGY, V110, P1744, DOI 10.1053/gast.1996.v110.pm8964399; Yamaoka Y, 1997, GUT, V41, P442, DOI 10.1136/gut.41.4.442; Zhang QB, 1996, GUT, V38, P841, DOI 10.1136/gut.38.6.841	110	1925	2049	16	247	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 10	2002	347	15					1175	1186		10.1056/NEJMra020542	http://dx.doi.org/10.1056/NEJMra020542			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	601TW	12374879	Green Submitted			2022-12-28	WOS:000178465100009
J	Blann, AD; Landray, MJ; Lip, GYH				Blann, AD; Landray, MJ; Lip, GYH			ABC of antithrombotic therapy - An overview of antithrombotic therapy	BMJ-BRITISH MEDICAL JOURNAL			English	Review									Univ Birmingham, City Hosp, Dept Med, Haemostasis Thrombosis & Vasc Biol Unit, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Blann, AD (corresponding author), Univ Birmingham, City Hosp, Dept Med, Haemostasis Thrombosis & Vasc Biol Unit, Birmingham B15 2TT, W Midlands, England.			Landray, Martin/0000-0001-6646-827X				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; Blann AD, 2001, THROMB RES, V101, P321, DOI 10.1016/S0049-3848(00)00419-9; CatellaLawson F, 1997, CORONARY ARTERY DIS, V8, P105, DOI 10.1097/00019501-199702000-00007; Eriksson H, 1999, THROMB HAEMOSTASIS, V81, P358; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; Lewis BE, 2001, CIRCULATION, V103, P1838; Nurden AT, 1996, HAEMOSTASIS, V26, P78; Sandercock P, 1997, LANCET, V349, P1569; STIRLING Y, 1995, BLOOD COAGUL FIBRIN, V6, P361, DOI 10.1097/00001721-199507000-00001	9	76	84	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 5	2002	325	7367					762	765		10.1136/bmj.325.7367.762	http://dx.doi.org/10.1136/bmj.325.7367.762			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	603AU	12364307	Green Published			2022-12-28	WOS:000178537300022
J	Rutter, J; Probst, BL; McKnight, SL				Rutter, J; Probst, BL; McKnight, SL			Coordinate regulation of sugar flux and translation by PAS kinase	CELL			English	Article							YEAST GLYCOGEN-SYNTHETASE; P70 S6 KINASE; GLUCOSE 6-PHOSPHATE-DEPENDENT FORM; IN-GEL DIGESTION; SACCHAROMYCES-CEREVISIAE; BINDING-PROTEIN; UDP-GLUCOSE; DEPENDENT TRANSLATION; INITIATION FACTOR-4E; DOMAIN	PAS kinase is a serine/threonine kinase regulated in cis by a PAS domain. A genetic study of the two PAS kinase genes in budding yeast gave evidence of the involvement of these enzymes in the control of sugar metabolism and translation. Using a biochemical screen for PAS kinase substrates, three translation factors were identified as direct phosphorylation targets. PAS kinase was also found to phosphorylate UDP-glucose pyrophosphorylase and glycogen synthase, the enzymes catalyzing the two final steps in the glycogen biosynthetic pathway. Genetic, biochemical, and physiological data provide evidence that both of these enzymes are inhibited by PAS kinase-dependent phosphorylation, thereby downregulating carbohydrate storage. These studies provide evidence of a cell-autonomous signaling system that both controls and connects the balance of fuel consumption/storage to protein synthesis.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	McKnight, SL (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	smckni@biochem.swmed.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008291] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52031] Funding Source: Medline; NIGMS NIH HHS [5-T32-GM08291-12] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMANN M, 1989, NUCLEIC ACIDS RES, V17, P7520, DOI 10.1093/nar/17.18.7520; ALTMANN M, 1989, NUCLEIC ACIDS RES, V17, P5923, DOI 10.1093/nar/17.15.5923; Altmann M, 1997, EMBO J, V16, P1114, DOI 10.1093/emboj/16.5.1114; ALTMANN M, 1993, EMBO J, V12, P3997, DOI 10.1002/j.1460-2075.1993.tb06077.x; ALTMANN M, 1995, EMBO J, V14, P3820, DOI 10.1002/j.1460-2075.1995.tb00051.x; AMEZCUA CA, 2002, IN PRESS STRUCTURE, V10; Ashe MP, 2000, MOL BIOL CELL, V11, P833, DOI 10.1091/mbc.11.3.833; Battiste JL, 2000, MOL CELL, V5, P109, DOI 10.1016/S1097-2765(00)80407-4; BOLES E, 1994, EUR J BIOCHEM, V220, P83, DOI 10.1111/j.1432-1033.1994.tb18601.x; Buzan JM, 1996, P NATL ACAD SCI USA, V93, P91, DOI 10.1073/pnas.93.1.91; Castanie HP, 1997, ANAL BIOCHEM, V254, P150, DOI 10.1006/abio.1997.2423; Chaudhuri J, 1997, J BIOL CHEM, V272, P7883, DOI 10.1074/jbc.272.12.7883; Chuang RY, 1997, SCIENCE, V275, P1468, DOI 10.1126/science.275.5305.1468; Clauser KR, 1999, ANAL CHEM, V71, P2871, DOI 10.1021/ac9810516; COPPOLECCHIA R, 1993, EMBO J, V12, P4005, DOI 10.1002/j.1460-2075.1993.tb06078.x; DARAN JM, 1995, EUR J BIOCHEM, V233, P520, DOI 10.1111/j.1432-1033.1995.520_2.x; Daran JM, 1997, FEMS MICROBIOL LETT, V153, P89, DOI 10.1016/S0378-1097(97)00240-1; DAVID M, 1988, CELL, V54, P671, DOI 10.1016/S0092-8674(88)80012-6; delaCruz J, 1997, P NATL ACAD SCI USA, V94, P5201, DOI 10.1073/pnas.94.10.5201; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; FloresDiaz M, 1997, J BIOL CHEM, V272, P23784, DOI 10.1074/jbc.272.38.23784; Francois J, 2001, FEMS MICROBIOL REV, V25, P125, DOI 10.1016/S0168-6445(00)00059-0; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Grishin NV, 1998, TRENDS BIOCHEM SCI, V23, P329, DOI 10.1016/S0968-0004(98)01258-4; Hampsey M, 1997, YEAST, V13, P1099, DOI 10.1002/(SICI)1097-0061(19970930)13:12<1099::AID-YEA177>3.3.CO;2-Z; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; HARDY TA, 1994, J BIOL CHEM, V269, P27907; HARDY TA, 1993, J BIOL CHEM, V268, P23799; Hawkins NC, 1997, DEVELOPMENT, V124, P4801; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; HORAZDOVSKY BF, 1994, EMBO J, V13, P1297, DOI 10.1002/j.1460-2075.1994.tb06382.x; Huang DQ, 1997, J BIOL CHEM, V272, P22495, DOI 10.1074/jbc.272.36.22495; HUANG KP, 1974, J BIOL CHEM, V249, P3851; HUANG KP, 1974, J BIOL CHEM, V249, P3858; Johnston M., 1992, MOL CELLULAR BIOL YE, P193; Kimball Sr, 2000, COLD SPRING HARBOR M, V39, P561; Lawrence JC, 1997, DIABETES, V46, P541, DOI 10.2337/diabetes.46.4.541; Lawrence JC, 1997, TRENDS BIOCHEM SCI, V22, P345, DOI 10.1016/S0968-0004(97)01101-8; LILLIE SH, 1980, J BACTERIOL, V143, P1384, DOI 10.1128/JB.143.3.1384-1394.1980; LIN K, 1995, J BIOL CHEM, V270, P26833, DOI 10.1074/jbc.270.45.26833; Lin K, 1996, SCIENCE, V273, P1539, DOI 10.1126/science.273.5281.1539; Masuda CA, 2001, J BIOL CHEM, V276, P37794; Mathews MB, 2000, COLD SPRING HARBOR M, V39, P1; MEISENBERG G, 1998, PRINCIPLES MED BOCHE; Parrou JL, 1997, ANAL BIOCHEM, V248, P186, DOI 10.1006/abio.1997.2138; Patel J, 2001, BIOCHEM J, V358, P497, DOI 10.1042/0264-6021:3580497; Raught B, 2000, COLD SPRING HARBOR M, V39, P245; ROACH PJ, 1976, TRENDS BIOCHEM SCI, V1, P110, DOI 10.1016/0968-0004(76)90321-2; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; ROTHMANDENES LB, 1971, BIOCHEMISTRY-US, V10, P1236; Rutter J, 2001, P NATL ACAD SCI USA, V98, P8991, DOI 10.1073/pnas.161284798; Schmidt MC, 2000, EMBO J, V19, P4936, DOI 10.1093/emboj/19.18.4936; Sheffield P, 1999, PROTEIN EXPRES PURIF, V15, P34, DOI 10.1006/prep.1998.1003; SHERMAN F, 1991, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; Sobel SG, 1999, MOL BIOL CELL, V10, P3849, DOI 10.1091/mbc.10.11.3849; Stephenson K, 2001, P NATL ACAD SCI USA, V98, P15251, DOI 10.1073/pnas.251408398; Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479, DOI 10.1128/MMBR.63.2.479-506.1999; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; Vassilev A, 2001, GENE DEV, V15, P1229, DOI 10.1101/gad.888601; Wang XM, 1998, BIOCHEM J, V334, P261, DOI 10.1042/bj3340261; Warner JR, 1999, TRENDS BIOCHEM SCI, V24, P437, DOI 10.1016/S0968-0004(99)01460-7; Xu G, 1998, J BIOL CHEM, V273, P28178, DOI 10.1074/jbc.273.43.28178; ZANCHIN NIT, 1995, J BIOL CHEM, V270, P26505, DOI 10.1074/jbc.270.44.26505	67	89	94	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 4	2002	111	1					17	28		10.1016/S0092-8674(02)00974-1	http://dx.doi.org/10.1016/S0092-8674(02)00974-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	601RQ	12372297	Bronze			2022-12-28	WOS:000178461900005
J	Campion, P; Foulkes, J; Neighbour, R; Tate, P				Campion, P; Foulkes, J; Neighbour, R; Tate, P			Patient centredness in the MRCGP video examination: analysis of large cohort	BRITISH MEDICAL JOURNAL			English	Article									Univ Hull, Postgrad Med Sch, Dept Publ Hlth & Primary Care, Willerby HU10 6NS, England; Royal Coll Gen Practitioners, London SW7 1PU, England	University of Hull	Campion, P (corresponding author), Univ Hull, Postgrad Med Sch, Dept Publ Hlth & Primary Care, Willerby HU10 6NS, England.							Mead N, 2000, SOC SCI MED, V51, P1087, DOI 10.1016/S0277-9536(00)00098-8; Stewart MA, 1995, PATIENT CTR MED TRAN, P185; Tate P, 1999, J HEALTH COMMUN, V4, P143, DOI 10.1080/108107399127011	3	58	58	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 28	2002	325	7366					691	692		10.1136/bmj.325.7366.691	http://dx.doi.org/10.1136/bmj.325.7366.691			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	600JV	12351363	Green Published, Bronze			2022-12-28	WOS:000178387600027
J	Langewitz, W; Denz, M; Keller, A; Kiss, A; Ruttimann, S; Wossmer, B				Langewitz, W; Denz, M; Keller, A; Kiss, A; Ruttimann, S; Wossmer, B			Spontaneous talking time at start of consultation in outpatient clinic: cohort study	BRITISH MEDICAL JOURNAL			English	Article									Univ Basel Hosp, Dept Internal Med, Div Psychosomat Med, CH-4031 Basel, Switzerland; Univ Hosp, Zurich, Switzerland; Forel Klin, Ellikon An Der Thur, Switzerland; Kantonsspital, Dept Internal Med, Schaffhausen, Switzerland	University of Basel; University of Zurich; University Zurich Hospital; Kantonsspital Aarau AG (KSA)	Langewitz, W (corresponding author), Univ Basel Hosp, Dept Internal Med, Div Psychosomat Med, CH-4031 Basel, Switzerland.							BLAU JN, 1989, BRIT MED J, V298, P39, DOI 10.1136/bmj.298.6665.39; Martina B, 1994, Schweiz Rundsch Med Prax, V83, P147; Martina B, 1997, J GEN INTERN MED, V12, P459, DOI 10.1046/j.1525-1497.1997.00083.x; Marvel MK, 1999, JAMA-J AM MED ASSOC, V281, P283, DOI 10.1001/jama.281.3.283	4	100	104	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 28	2002	325	7366					682	+		10.1136/bmj.325.7366.682	http://dx.doi.org/10.1136/bmj.325.7366.682			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	600JV	12351359	Bronze, Green Published			2022-12-28	WOS:000178387600019
J	Mao, WL; Mao, HK; Goncharov, AF; Struzhkin, VV; Guo, QZ; Hu, JZ; Shu, JF; Hemley, RJ; Somayazulu, M; Zhao, YS				Mao, WL; Mao, HK; Goncharov, AF; Struzhkin, VV; Guo, QZ; Hu, JZ; Shu, JF; Hemley, RJ; Somayazulu, M; Zhao, YS			Hydrogen clusters in clathrate hydrate	SCIENCE			English	Article							HIGH-PRESSURES; MOLECULAR-HYDROGEN; METHANE HYDRATE; ICE; DYNAMICS; H-2; TEMPERATURE; GPA	High-pressure Raman, infrared, x-ray, and neutron studies show that H-2 and H2O mixtures crystallize into the sII clathrate structure with an approximate H-2/H2O molar ratio of 1:2. The clathrate cages are multiply occupied, with a cluster of two H-2 molecules in the small cage and four in the large cage. Substantial softening and splitting of hydrogen vibrons indicate increased intermolecular interactions. The quenched clathrate is stable up to 145 kelvin at ambient pressure. Retention of hydrogen at such high temperatures could help its condensation in planetary nebulae and may play a key role in the evolution of icy bodies.	Univ Chicago, Dept Geophys Sci, Chicago, IL 60637 USA; Carnegie Inst Washington, Geophys Lab, Washington, DC 20015 USA; Argonne Natl Lab, High Pressure Collaborat Team, Adv Photon Source, Argonne, IL 60439 USA; Los Alamos Natl Lab, Los Alamos Neutron Sci Ctr, Los Alamos, NM 87545 USA	University of Chicago; Carnegie Institution for Science; United States Department of Energy (DOE); Argonne National Laboratory; United States Department of Energy (DOE); Los Alamos National Laboratory	Mao, WL (corresponding author), Univ Chicago, Dept Geophys Sci, 5734 S Ellis Ave, Chicago, IL 60637 USA.		Zhao, Yusheng/V-1361-2018; Zhao, Yusheng/B-9448-2018; Mao, Wendy/D-1885-2009; Goncharov, Alexander F./AAX-9943-2020; zhao, yang/GXF-4424-2022; Zhao, Yusheng/ABB-2273-2021; Struzhkin, Viktor V/J-9847-2013	Zhao, Yusheng/0000-0003-1640-5216; Zhao, Yusheng/0000-0003-1640-5216; Goncharov, Alexander F./0000-0002-6422-8819; Zhao, Yusheng/0000-0003-1640-5216; Struzhkin, Viktor V/0000-0002-3468-0548				Chou IM, 2000, P NATL ACAD SCI USA, V97, P13484, DOI 10.1073/pnas.250466497; Chou IM, 1998, SCIENCE, V281, P809, DOI 10.1126/science.281.5378.809; Dyadin YA, 1999, J STRUCT CHEM+, V40, P790, DOI 10.1007/BF02903454; Dyadin YA, 1999, MENDELEEV COMMUN, P209; DYADIN YA, 1994, POL J CHEM, V68, P343; GINZBURG VL, 1972, JETP LETT-USSR, V15, P242; Hirai H, 2001, J CHEM PHYS, V115, P7066, DOI 10.1063/1.1403690; HUBER TE, 1987, PHYS REV LETT, V59, P1120, DOI 10.1103/PhysRevLett.59.1120; Itoh H, 2001, J CHEM PHYS, V115, P9414, DOI 10.1063/1.1414378; Klotz S, 1999, NATURE, V398, P681, DOI 10.1038/19480; KNUTH EL, 1995, J CHEM PHYS, V102, P6258, DOI 10.1063/1.469072; KUHS WF, 1999, P 2 INT C NAT GAS HY, P9; LAUFER D, 1987, PHYS REV B, V36, P9219, DOI 10.1103/PhysRevB.36.9219; LEE TJ, 1972, NATURE-PHYS SCI, V237, P99, DOI 10.1038/physci237099a0; Loveday JS, 2001, NATURE, V410, P661, DOI 10.1038/35070513; MAK TCW, 1965, J CHEM PHYS, V42, P2732, DOI 10.1063/1.1703229; MAO HK, 1994, REV MOD PHYS, V66, P671, DOI 10.1103/RevModPhys.66.671; Mao W., UNPUB; PETRENKO VF, 1999, PHYSICS ICE; SANDFORD SA, 1993, SCIENCE, V262, P400, DOI 10.1126/science.11542874; Shimizu H, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.212102; SHIMIZU H, 2002, J PHYS CHEM B, V106; Sloan E. D., 1997, CLATHRATE HYDRATES N; Stevenson DJ, 1999, NATURE, V400, P32, DOI 10.1038/21811; STRAUSS HL, 1994, J CHEM PHYS, V101, P7177, DOI 10.1063/1.468303; van Klaveren EP, 2001, J CHEM PHYS, V114, P5745, DOI 10.1063/1.1352078; VOS WL, 1993, PHYS REV LETT, V71, P3150, DOI 10.1103/PhysRevLett.71.3150	27	693	710	10	292	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 27	2002	297	5590					2247	2249		10.1126/science.1075394	http://dx.doi.org/10.1126/science.1075394			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	597LA	12351785				2022-12-28	WOS:000178222000043
J	Ohtomo, A; Muller, DA; Grazul, JL; Hwang, HY				Ohtomo, A; Muller, DA; Grazul, JL; Hwang, HY			Artificial charge-modulation in atomic-scale perovskite titanate superlattices	NATURE			English	Article							GRAIN-BOUNDARIES; MOTT-INSULATOR; HUBBARD-MODEL; HARTREE-FOCK; STEM; RESOLUTION; MAGNETISM	The nature and length scales of charge screening in complex oxides are fundamental to a wide range of systems, spanning ceramic voltage-dependent resistors (varistors), oxide tunnel junctions and charge ordering in mixed-valence compounds(1-6). There are wide variations in the degree of charge disproportionation, length scale, and orientation in the mixed-valence compounds: these have been the subject of intense theoretical study(7-11), but little is known about the microscopic electronic structure. Here we have fabricated an idealized structure to examine these issues by growing atomically abrupt layers of LaTi3+O3 embedded in SrTi4+O3. Using an atomic-scale electron beam, we have observed the spatial distribution of the extra electron on the titanium sites. This distribution results in metallic conductivity, even though the superlattice structure is based on two insulators. Despite the chemical abruptness of the interfaces, we find that a minimum thickness of five LaTiO3 layers is required for the centre titanium site to recover bulk-like electronic properties. This represents a framework within which the short-length-scale electronic response can be probed and incorporated in thin-film oxide heterostructures.	Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA	Alcatel-Lucent; Lucent Technologies; AT&T	Hwang, HY (corresponding author), Bell Labs, Lucent Technol, 600 Mt Ave, Murray Hill, NJ 07974 USA.		Hwang, Harold Y/I-6943-2012; Ohtomo, Akira/C-4944-2008; Muller, David/A-7745-2010	Ohtomo, Akira/0000-0003-0300-4712; Muller, David/0000-0003-4129-0473				ABBATE M, 1991, PHYS REV B, V44, P5419, DOI 10.1103/PhysRevB.44.5419; BATSON PE, 1993, NATURE, V366, P727, DOI 10.1038/366727a0; BROWNING ND, 1993, NATURE, V366, P143, DOI 10.1038/366143a0; CHAUDHARI P, 1988, PHYS REV LETT, V60, P1653, DOI 10.1103/PhysRevLett.60.1653; CHEN CH, 1993, PHYS REV LETT, V71, P2461, DOI 10.1103/PhysRevLett.71.2461; GREUTER F, 1990, SEMICOND SCI TECH, V5, P111, DOI 10.1088/0268-1242/5/2/001; HOWIE A, 1979, J MICROSC-OXFORD, V117, P11, DOI 10.1111/j.1365-2818.1979.tb00228.x; KAHN AH, 1964, PHYS REV, V135, P1321; KAWASAKI M, 1994, SCIENCE, V266, P1540, DOI 10.1126/science.266.5190.1540; KIRKLAND EJ, 1987, ULTRAMICROSCOPY, V23, P77, DOI 10.1016/0304-3991(87)90229-4; Kivelson SA, 1998, NATURE, V393, P550, DOI 10.1038/31177; LOEW U, 1994, PHYS REV LETT, V72, P1918; Mori S, 1998, NATURE, V392, P473, DOI 10.1038/33105; MULLER DA, 1993, NATURE, V366, P725, DOI 10.1038/366725a0; Ohtomo A, 2002, APPL PHYS LETT, V80, P3922, DOI 10.1063/1.1481767; PENNYCOOK SJ, 1989, ULTRAMICROSCOPY, V30, P58, DOI 10.1016/0304-3991(89)90173-3; POILBLANC D, 1989, PHYS REV B, V39, P9749, DOI 10.1103/PhysRevB.39.9749; Sun JZ, 1996, APPL PHYS LETT, V69, P3266, DOI 10.1063/1.118031; SUNSTROM JE, 1992, CHEM MATER, V4, P346, DOI 10.1021/cm00020a022; Taguchi Y, 1999, PHYS REV B, V59, P7917, DOI 10.1103/PhysRevB.59.7917; TOKURA Y, 1993, PHYS REV LETT, V70, P2126, DOI 10.1103/PhysRevLett.70.2126; TRANQUADA JM, 1995, NATURE, V375, P561, DOI 10.1038/375561a0; ZAANEN J, 1989, PHYS REV B, V40, P7391, DOI 10.1103/PhysRevB.40.7391; ZAANEN J, 1985, PHYS REV LETT, V55, P418, DOI 10.1103/PhysRevLett.55.418	25	860	872	11	485	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 26	2002	419	6905					378	380		10.1038/nature00977	http://dx.doi.org/10.1038/nature00977			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	596ZB	12353030				2022-12-28	WOS:000178195400040
J	House, MA; Gurnis, M; Kamp, PJJ; Sutherland, R				House, MA; Gurnis, M; Kamp, PJJ; Sutherland, R			Uplift in the Fiordland region, New Zealand: Implications for incipient subduction	SCIENCE			English	Article							LATE CENOZOIC TECTONICS; FISSION-TRACK ANALYSIS; SOUTHERN NEW-ZEALAND; ALPINE FAULT; CRUSTAL STRUCTURE; HELIUM DIFFUSION; PUYSEGUR TRENCH; PLATE BOUNDARY; APATITE; EVOLUTION	Low-temperature thermochronometry reveals regional Late Cenozoic denudation in Fiordland, New Zealand, consistent with geodynamic models showing uplift of the overriding plate during incipient subduction. The data show a northward progression of exhumation in response to northward migration of the initiation of subduction. The locus of most recent uplift coincides with a large positive Bouguer gravity anomaly within Fiordland. Thermochronometrically deduced crustal thinning, anomalous gravity, and estimates of surface uplift are all consistent with similar to2 kilometers of dynamic support. This amount of dynamic support is in accord with geodynamic predictions, suggesting that we have dated the initiation of subduction adjacent to Fiordland.	CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA; Univ Waikato, Dept Earth Sci, Hamilton 2001, New Zealand; IGNS Ltd, Lower Hutt, New Zealand	California Institute of Technology; University of Waikato; GNS Science - New Zealand	House, MA (corresponding author), CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA.		Sutherland, Rupert/Y-9290-2019; Sutherland, Rupert/G-5092-2012	Sutherland, Rupert/0000-0001-7430-0055; Kamp, Peter/0000-0002-2563-884X				ANDERSON H, 1993, GEOPHYS J INT, V115, P1032, DOI 10.1111/j.1365-246X.1993.tb01508.x; Batt GE, 1999, GEOPHYS J INT, V136, P403, DOI 10.1046/j.1365-246X.1999.00730.x; BISHOP DG, 1985, NEW ZEAL J GEOL GEOP, V28, P243; Bishop DG, 1991, SPECIAL PUBLICATIONS, V12, P69; Blythe AE, 2000, BASIN RES, V12, P97; BRAUN J, IN PRESS COMP GEOSCI; BROADBENT M, 1978, 124 NZ DEP SCI IND R; CARTER RM, 1976, EARTH PLANET SC LETT, V31, P85, DOI 10.1016/0012-821X(76)90099-6; CHRISTOFFEL DA, 1972, ANTARCT RES SER, V19, P235; COLLOT JY, 1995, GEOLOGY, V23, P519, DOI 10.1130/0091-7613(1995)023<0519:MOAISZ>2.3.CO;2; COLLOT JY, 1995, EOS T AGU, V76, P1; DAVEY FJ, 1983, GEOPHYS J ROY ASTR S, V72, P23, DOI 10.1111/j.1365-246X.1983.tb02802.x; DEMETS C, 1990, GEOPHYS J INT, V101, P425, DOI 10.1111/j.1365-246X.1990.tb06579.x; DEMETS C, 1994, GEOPHYS RES LETT, V21, P2191, DOI 10.1029/94GL02118; Eberhart-Phillips D, 2001, GEOPHYS J INT, V146, P731, DOI 10.1046/j.0956-540x.2001.01485.x; Farley KA, 1996, GEOCHIM COSMOCHIM AC, V60, P4223, DOI 10.1016/S0016-7037(96)00193-7; Farley KA, 2000, J GEOPHYS RES-SOL EA, V105, P2903, DOI 10.1029/1999JB900348; Farley KA, 2001, GEOLOGY, V29, P99, DOI 10.1130/0091-7613(2001)029<0099:PMUAEO>2.0.CO;2; GLEADOW AJW, 1986, CONTRIB MINERAL PETR, V94, P405, DOI 10.1007/BF00376334; GREEN PF, 1989, CHEM GEOL, V79, P155, DOI 10.1016/0168-9622(89)90018-3; GREEN PF, 1985, CHEM GEOL, V58, P1, DOI 10.1016/0168-9622(85)90023-5; House MA, 1997, EARTH PLANET SC LETT, V151, P167, DOI 10.1016/S0012-821X(97)81846-8; House MA, 1999, EARTH PLANET SC LETT, V170, P463, DOI 10.1016/S0012-821X(99)00120-X; House MA, 2000, EARTH PLANET SC LETT, V183, P365, DOI 10.1016/S0012-821X(00)00286-7; KAMP P, UNPUB; KAMP PJJ, 1989, GEOPHYS J INT, V96, P33, DOI 10.1111/j.1365-246X.1989.tb05248.x; KAMP PJJ, 1986, TECTONOPHYSICS, V121, P225, DOI 10.1016/0040-1951(86)90045-4; KAMP PJJ, 1992, TECTONICS, V11, P98, DOI 10.1029/91TC02362; KAMP PJJ, 1989, TECTONICS, V8, P169, DOI 10.1029/TC008i002p00169; Lebrun JF, 2000, TECTONICS, V19, P688, DOI 10.1029/2000TC900008; Lebrun JF, 1998, J GEOPHYS RES-SOL EA, V103, P7293, DOI 10.1029/98JB00025; MATTINSON JM, 1986, CONTRIB MINERAL PETR, V92, P383, DOI 10.1007/BF00572167; Melhuish A, 1999, TECTONOPHYSICS, V313, P335, DOI 10.1016/S0040-1951(99)00212-7; MOLNAR P, 1975, GEOPHYS J ROY ASTR S, V40, P383, DOI 10.1111/j.1365-246X.1975.tb04139.x; Molnar P, 1999, SCIENCE, V286, P516, DOI 10.1126/science.286.5439.516; NORRIS RJ, 1990, J STRUCT GEOL, V12, P715, DOI 10.1016/0191-8141(90)90084-C; Norris RJ., 1978, J GEOL SOC LONDON, V135, P191, DOI DOI 10.1144/GSJGS.135.2.0191; NORRIS RJ, 1993, S PACIFIC SEDIMENTAR, P251; OLIVER GJH, 1979, TECTONOPHYSICS, V54, P253, DOI 10.1016/0040-1951(79)90371-8; OLIVER GJH, 1990, EXPOSED CROSS SECTIO, P43; Pearson C, 1998, GEOPHYS RES LETT, V25, P3185, DOI 10.1029/98GL02421; SHEMENDA AI, 1992, J GEOPHYS RES-SOL EA, V97, P11097, DOI 10.1029/92JB00177; SMALE D, 1991, J ROY SOC NEW ZEAL, V21, P151; SUTHERLAND R, 1994, GEOLOGY, V22, P327, DOI 10.1130/0091-7613(1994)022<0327:DSTPAT>2.3.CO;2; Sutherland R, 1996, NEW ZEAL J GEOL GEOP, V39, P251, DOI 10.1080/00288306.1996.9514709; TIPPETT JM, 1993, J GEOPHYS RES, V98, P16; Toth J, 1998, J GEOPHYS RES-SOL EA, V103, P18053, DOI 10.1029/98JB01076; TURNBULL IM, 1993, 1 I GEOL NUCL SCI; Walcott RI, 1998, REV GEOPHYS, V36, P1, DOI 10.1029/97RG03084; WALCOTT RI, 1978, GEOPHYS J ROY ASTR S, V52, P137, DOI 10.1111/j.1365-246X.1978.tb04225.x; WARD CM, 1988, J ROY SOC NEW ZEAL, V18, P1; WARD CM, 1984, AM MINERAL, V69, P531; Wolf RA, 1998, CHEM GEOL, V148, P105, DOI 10.1016/S0009-2541(98)00024-2; Wood R, 2000, NEW ZEAL J GEOL GEOP, V43, P289, DOI 10.1080/00288306.2000.9514887; WOODWARD DJ, 1972, NEW ZEAL J GEOL GEOP, V15, P22, DOI 10.1080/00288306.1972.10423944	55	57	58	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 20	2002	297	5589					2038	2041		10.1126/science.1075328	http://dx.doi.org/10.1126/science.1075328			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	594XV	12242439				2022-12-28	WOS:000178078500042
J	Toole, M				Toole, M			Improving psychosocial survival in complex emergencies	LANCET			English	Editorial Material							TRAUMA		Macfarlane Burnet Inst Med Res & Publ Hlth, Ctr Int Hlth, Melbourne, Vic 3001, Australia	Burnet Institute	Toole, M (corresponding author), Macfarlane Burnet Inst Med Res & Publ Hlth, Ctr Int Hlth, GPO Box 2284, Melbourne, Vic 3001, Australia.							AGGER I, 1996, PSYCHOL ASSISTANCE V; Silove D, 1999, J NERV MENT DIS, V187, P200, DOI 10.1097/00005053-199904000-00002; Summerfield D, 1999, SOC SCI MED, V48, P1449, DOI 10.1016/S0277-9536(98)00450-X; The Sphere Project, 1998, HUM CHART MIN STAND	4	6	6	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 14	2002	360	9336					869	869		10.1016/S0140-6736(02)09959-2	http://dx.doi.org/10.1016/S0140-6736(02)09959-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	594MC	12243934				2022-12-28	WOS:000178053500024
J	Kleinert, S				Kleinert, S			The German way to express Europe's growing unease	LANCET			English	Article																			0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 7	2002	360	9335					734	734		10.1016/S0140-6736(02)09939-7	http://dx.doi.org/10.1016/S0140-6736(02)09939-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	592HX	12296304				2022-12-28	WOS:000177933000006
J	Rahi, JS; Logan, S; Borja, MC; Timms, C; Russell-Eggitt, I; Taylor, D				Rahi, JS; Logan, S; Borja, MC; Timms, C; Russell-Eggitt, I; Taylor, D			Prediction of improved vision in the amblyopic eye after visual loss in the non-amblyopic eye	LANCET			English	Article								Amblyopia arises from abnormal visual experiences in early childhood. Improved function of the amblyopic eye after visual loss in the non-amblyopic eye could be a model for residual neural plasticity. We aimed to establish the likelihood of, and predictive factors for, this improvement in function. We identified 254 individuals aged 11 years or older with unilateral amblyopia who were visually impaired after loss of vision in their non-amblyopic eye but had no other disorder affecting their amblyopic eye. 25 (10%) of 254 people had improved visual acuity in their amblyopic eye. These findings suggest there is some plasticity in the visual system of a few visually mature individuals with amblyopia, which warrants further study. Children should remain the focus of detection and treatment.	Inst Child Hlth, Ctr Paediat Epidemiol & Biostat, London WC1N 1EH, England; Great Ormond St Hosp Sick Children, Dept Ophthalmol, London, England; Inst Ophthalmol, Dept Epidemiol, London, England	University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London	Rahi, JS (corresponding author), Inst Child Hlth, Ctr Paediat Epidemiol & Biostat, 30 Guilford St, London WC1N 1EH, England.		Borja, Mario Cortina/A-3847-2009	Borja, Mario Cortina/0000-0003-0627-2624; Logan, Stuart/0000-0002-9279-261X; Rahi, Jugnoo/0000-0002-5718-9209				DAW NW, 1994, INVEST OPHTH VIS SCI, V35, P4168; El Mallah MK, 2000, BRIT J OPHTHALMOL, V84, P952, DOI 10.1136/bjo.84.9.952; Levi DM, 1996, P NATL ACAD SCI USA, V93, P6830, DOI 10.1073/pnas.93.13.6830; Moseley MJ, 1997, BRIT J OPHTHALMOL, V81, P956, DOI 10.1136/bjo.81.11.956; VEREECKEN EP, 1984, ARCH OPHTHALMOL-CHIC, V102, P220	5	57	59	0	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 24	2002	360	9333					621	622		10.1016/S0140-6736(02)09775-1	http://dx.doi.org/10.1016/S0140-6736(02)09775-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	586TD	12241937				2022-12-28	WOS:000177600400015
J	Wykurz, G; Kelly, D				Wykurz, G; Kelly, D			Developing the role of patients as teachers: literature review	BRITISH MEDICAL JOURNAL			English	Article							MEDICAL-STUDENTS; EXAMINATION SKILLS; MUSCULOSKELETAL EXAMINATION; INSTRUCTORS; EDUCATORS; ARTHRITIS; PARTNERS; CARE; RELIABILITY; CONFIDENCE	Objectives To identify the roles and settings in which patients participate as teachers in medical education and the benefits to learners, their educational institutions, and participating patients. Design Review of publications from 1970 to October 2001 providing descriptions, evaluations, or research of programmes involving patients as teachers in medical education. Data sources 1848 references were identified from various electronic databases. Applying inclusion criteria to abstracts generated 100 articles, from which 23 were selected after independent scrutiny. Results 13 articles discussed the role of patients in teaching physical examination skills, mostly musculoskeletal examination. Patients also taught pelvic and male genitorectal examination skills. Teaching roles varied, and 19 articles referred to patients' involvement as assessors. 18 articles described patients' training, with some patients being assessed. Reports of learners' experiences were all positive, many valuing the insights and confidence gained from practising skills on patients in a teaching role. Some learners preferred being taught by trained patients rather than doctors. Patients who were consulted enjoyed their teaching role. Several articles commented on the high quality of patients' teaching. Remuneration varied from payment of expenses to an hourly rate. Motivation for recruiting patients included the desire to reduce costs and the value attributed to the consumers' perspective. Conclusion Involving patients as teachers has important educational benefits for learners. Patients offer unique qualities that can enhance the acquisition of skills and change attitudes towards patients.	Univ Westminster, Sch Integrated Hlth, Dept Community & Collaborat Practice, London NW1 3ET, England; Guys Kings & St Thomass Sch Med Dent & Biomed Sci, Dept Med & Dent Educ, London SE1 9RT, England	University of Westminster; University of London; King's College London	Wykurz, G (corresponding author), Univ Westminster, Sch Integrated Hlth, Dept Community & Collaborat Practice, London NW1 3ET, England.							Bell MJ, 1997, ACAD MED, V72, P919, DOI 10.1097/00001888-199710000-00019; Blasco PA, 1999, MED EDUC, V33, P695, DOI 10.1046/j.1365-2923.1999.00334.x; Branch VK, 1998, ARTHRIT CARE RES, V11, P32, DOI 10.1002/art.1790110106; Branch VK, 1999, ARTHRIT CARE RES, V12, P61, DOI 10.1002/1529-0131(199902)12:1<61::AID-ART10>3.0.CO;2-G; Butterworth M, 1999, PSYCHIAT B, V23, P549; Collins JP, 1998, MED TEACH, V20, P508; Curry RH, 1996, ACAD MED, V71, P41, DOI 10.1097/00001888-199601000-00016; Davidson R, 2001, ACAD MED, V76, P840, DOI 10.1097/00001888-200108000-00019; Department of Health, 2001, EXP PAT NEW APPR CHR; ELLIOT DL, 1987, JAMA-J AM MED ASSOC, V258, P3405, DOI 10.1001/jama.258.23.3405; FISHER B, 2001, NEW BEGINNINGS PATIE; GALL EP, 1984, ARTHRITIS RHEUM, V27, P557, DOI 10.1002/art.1780270512; Gomm R., 2000, EVALUATING RES HLTH; Gruppen L D, 1996, Arthritis Care Res, V9, P302, DOI 10.1002/1529-0131(199608)9:4<302::AID-ANR1790090415>3.0.CO;2-R; Hendry GD, 1999, MED EDUC, V33, P674, DOI 10.1046/j.1365-2923.1999.00524.x; Holman H, 2000, BRIT MED J, V320, P526, DOI 10.1136/bmj.320.7234.526; Kelly D., 1998, ED HLTH, V11, P369; Khan K. S., 2001, 4 NHS CRD U YORK; LIVINGSTONE RA, 1978, AM J OBSTET GYNECOL, V132, P64, DOI 10.1016/0002-9378(78)90800-1; Plymale M A, 1999, J Cancer Educ, V14, P67; RIGGS GE, 1982, J MED EDUC, V57, P550; Robins LS, 1997, TEACH LEARN MED, V9, P264, DOI 10.1207/s15328015tlm0904_4; Salter RH, 1996, POSTGRAD MED J, V72, P385, DOI 10.1136/pgmj.72.849.385; Schrieber L, 1999, ARTHRITIS RHEUM, V42, pS116; Smith MD, 2000, J RHEUMATOL, V27, P1533; Spencer J, 2000, MED EDUC, V34, P851, DOI 10.1046/j.1365-2923.2000.00779.x; Stacy R, 1999, MED EDUC, V33, P688, DOI 10.1046/j.1365-2923.1999.00454.x; STILLMAN PL, 1980, J MED EDUC, V55, P186; THOMSON AN, 1994, MED EDUC, V28, P146, DOI 10.1111/j.1365-2923.1994.tb02535.x; Vail R, 1996, PATIENT EDUC COUNS, V27, P95, DOI 10.1016/0738-3991(95)00793-8; WEISSER RJ, 1985, J MED EDUC, V60, P63	31	164	167	0	18	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 12	2002	325	7368					818	821		10.1136/bmj.325.7368.818	http://dx.doi.org/10.1136/bmj.325.7368.818			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604YM	12376445	Green Published, Bronze			2022-12-28	WOS:000178648700022
J	Flegal, KM; Carroll, MD; Ogden, CL; Johnson, CL				Flegal, KM; Carroll, MD; Ogden, CL; Johnson, CL			Prevalence and trends in obesity among US adults, 1999-2000	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; LIFE-STYLE; HEALTH EXAMINATION; NATIONAL-HEALTH; PUBLIC-HEALTH; PREVENTION; GLUCOSE	Context The prevalence of obesity and overweight increased in the United States between 1978 and 1991. More recent reports have suggested continued increases but are based on self-reported data. Objective To examine trends and prevalences of overweight (body mass index [BMI] greater than or equal to25) and obesity (BMI; greater than or equal to30), using measured height and weight data. Design, Setting, and Participants Survey of 4115 adult men and women conducted in 1999 and 2000 as part of the National Health and Nutrition Examination Survey (NHANES), a nationally representative sample of the US population. Main Outcome Measure Age-adjusted prevalence of overweight,, obesity, and extreme obesity compared with prior surveys, and sex-, age-, and race/ethnicity-specific estimates. Results The age-adjusted prevalence of obesity was 30.5% in 1999-2000 compared with 22.9% in NHANES III (1988-1994; P<.001). The prevalence of overweight also increased during this period from 55.9% to 64.5% (P<.001). Extreme obesity (BMI; greater than or equal to40) also increased significantly in the population, from 2.9% to 4.7% (P=.002). Although not all changes were statistically significant,, increases occurred for both men and women in all age groups and for non-Hispanic whites, non-Hispanic blacks, And Mexican Americans. Racial/ethnic groups did not differ significantly in the prevalence of obesity or overweight for men. Among women, obesity and overweight prevalences were highest among non-Hispanic black women. More than half of non-Hispanic black women aged 40 years or older were obese and more than 80% were overweight. Conclusions The increases in the prevalences of obesity and overweight previously observed continued in 1999-2000. The potential health benefits from reduction in overweight and obesity are of considerable public health importance.	Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA	Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	Flegal, KM (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, 6525 Belcrest Rd,Room 900, Hyattsville, MD 20782 USA.	kmf2@cdc.gov	Flegal, Katherine M/A-4608-2013; Kohn, Geoffrey P/A-9056-2009; Bannuru, Raveendhara/G-2601-2011	Bannuru, Raveendhara/0000-0002-8069-5783; Flegal, Katherine/0000-0002-0838-469X				[Anonymous], MORB MORT 2002 CHART; [Anonymous], 1997, ARCH INTERN MED, V157, P2413; [Anonymous], 1994, VITAL HLTH STAT, V1, P1; BURT VL, 1995, HYPERTENSION, V26, P60, DOI 10.1161/01.HYP.26.1.60; Costa DL, 1997, NAT BUR EC, P47; Douketis JD, 1999, CAN MED ASSOC J, V160, P513; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; Flegal KM, 2000, INT J OBESITY, V24, P807, DOI 10.1038/sj.ijo.0801232; Harris MI, 1998, DIABETES CARE, V21, P518, DOI 10.2337/diacare.21.4.518; Jeffery RW, 2001, AM J HEALTH BEHAV, V25, P252, DOI 10.5993/AJHB.25.3.12; JOHNSON CL, 1993, JAMA-J AM MED ASSOC, V269, P3002, DOI 10.1001/jama.269.23.3002; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; Martinez JA, 2000, P NUTR SOC, V59, P337, DOI 10.1017/S0029665100000380; McDowell A, 1981, Vital Health Stat 1, P1; McKinlay J, 2000, LANCET, V356, P757, DOI 10.1016/S0140-6736(00)02641-6; Mokdad AH, 1999, JAMA-J AM MED ASSOC, V282, P1519, DOI 10.1001/jama.282.16.1519; Mokdad AH, 2001, JAMA-J AM MED ASSOC, V286, P1195, DOI 10.1001/jama.286.10.1195; *NAT CTR HLTH STAT, 1973, VITAL HLTH STAT, V1, P1; *NAT CTR HLTH STAT, 1965, VITAL HLTH STAT, V4, P1; National Cholesterol Education Program, 2002, 3 NAT CHOL ED PROGR; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; Russell A, 2000, WMJ, V99, P53; SORENSON TIA, 2000, DIABETES CARE S2, V23, P81; Taubes G, 1998, SCIENCE, V280, P1367, DOI 10.1126/science.280.5368.1367; TAYLOR H, 2002, HARRIS POLL     0306; Tuomilehto Jaakko, 2001, New England Journal of Medicine, V344, P1343, DOI 10.1056/NEJM200105033441801; Velleman P. F., 1981, APPL BASICS COMPUTIN; WHO Consultation on Obesity, 2000, WHO TECHN REP SER, V894; Wing RR, 2001, DIABETES CARE, V24, P117, DOI 10.2337/diacare.24.1.117; Wolter K., 1990, INTRO VARIANCE ESTIM	31	4629	4758	1	233	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	2002	288	14					1723	1727		10.1001/jama.288.14.1723	http://dx.doi.org/10.1001/jama.288.14.1723			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	602BJ	12365955	Bronze			2022-12-28	WOS:000178484700024
J	Ogden, CL; Flegal, KM; Carroll, MD; Johnson, CL				Ogden, CL; Flegal, KM; Carroll, MD; Johnson, CL			Prevalence and trends in overweight among US children and adolescents, 1999-2000	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NATIONAL-HEALTH; OBESITY; EPIDEMIC; GLUCOSE	Context The prevalence of overweight among children in the United States increased between 1976-1980 and 1988-1994, but estimates for the current decade are unknown. Objective To determine the prevalence of overweight in US children using the most recent national data with measured weights and heights and to examine trends in overweight prevalence. Design, Setting, and Participants Survey of 4722 children from birth through 19 years of age with weight and height measurements obtained in 1995-2000 as part of the National Health and Nutrition Examination Survey (NHANES), a cross-sectional, stratified, multistage probability sample of the US population. Main Outcome Measure Prevalence of overweight among US children by sex, age group, and race/ethnicity. Overweight among those aged 2 through 19 years was defined as at or above the 95th percentile of the sex-specific body mass index (BMI) for age growth charts. Results The prevalence of overweight was 15.5% among 12- through 19-year-olds, 15.3% among 6- through 11-year-olds, and 10.4% among 2-through 5-year-olds, compared with 10.5%, 11.3%, and 7.2%, respectively, in 1988-1994 (NHANES 111). The prevalence of overweight among non-Hispanic black and Mexican-American adolescents increased more than 10 percentage points between 1988-1994 and 1999-2000. Conclusion The prevalence of overweight among children in the United States is continuing to increase, especially among Mexican-American and non-Hispanic black adolescents.	Ctr Dis Control & Prevent, Div Hlth Examinat Stat, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA	Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	Ogden, CL (corresponding author), Ctr Dis Control & Prevent, Div Hlth Examinat Stat, Natl Ctr Hlth Stat, 6525 Belcrest Rd,Room 900, Hyattsville, MD 20782 USA.	cao9@cdc.gov	Flegal, Katherine M/A-4608-2013	Flegal, Katherine/0000-0002-0838-469X				[Anonymous], PREV OV CHILDR AD US; [Anonymous], [No title captured]; *CDCP, 1992, MMWR-MORBID MORTAL W, V41, pSS1; Dietz WH, 1998, PEDIATRICS, V101, P518; Fagot-Campagna A, 2000, J PEDIATR-US, V136, P664, DOI 10.1067/mpd.2000.105141; Fagot-Campagna A, 2001, DIABETES CARE, V24, P834, DOI 10.2337/diacare.24.5.834; Fagot-Campagna A, 2000, J PEDIATR ENDOCR MET, V13, P1395; Goran MI, 2001, PEDIATR CLIN N AM, V48, P931, DOI 10.1016/S0031-3955(05)70349-7; Guo, 2002, VITAL HLTH STAT, V11, DOI DOI 10.1016/J.BBRC.2015.06.114; HIMES JH, 1994, AM J CLIN NUTR, V59, P307, DOI 10.1093/ajcn/59.2.307; *I MED, 1996, WIC NUTR RISK CRIT S; McDowell A, 1981, Vital Health Stat 1, P1; *NAT CTR HLTH STAT, 1904, VITAL HLTH STAT, V1, P1; *NAT CTR HLTH STAT, 1967, VIT HLTH STAT 1, V1, P1; *NAT CTR HLTH STAT, 1973, VITAL HLTH STAT, V1, P1; *NAT CTR HLTH STAT, 1969, VIT HLTH STAT 1, V1, P1; Ogden CL, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.4.e1; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; PISUNYER FX, 1991, AM J CLIN NUTR, V53, pS1595; Rani S, 2022, SPAT INF RES, V30, P417, DOI 10.1007/s41324-022-00442-9; Robinson TN, 1999, JAMA-J AM MED ASSOC, V282, P1561, DOI 10.1001/jama.282.16.1561; Rosenbloom AL, 1999, DIABETES CARE, V22, P345, DOI 10.2337/diacare.22.2.345; SERDULA MK, 1993, PREV MED, V22, P167, DOI 10.1006/pmed.1993.1014; Sinha R, 2002, NEW ENGL J MED, V346, P802, DOI 10.1056/NEJMoa012578; Spruijt-Metz D, 2002, AM J CLIN NUTR, V75, P581, DOI 10.1093/ajcn/75.3.581; Strauss RS, 2001, JAMA-J AM MED ASSOC, V286, P2845, DOI 10.1001/jama.286.22.2845; TROIANO RP, 1995, ARCH PEDIAT ADOL MED, V149, P1085, DOI 10.1001/archpedi.1995.02170230039005; U.S. Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; WHO Consultation on Obesity, 2000, WHO TECHN REP SER, V894; Wright CM, 2001, BMJ-BRIT MED J, V323, P1280, DOI 10.1136/bmj.323.7324.1280	30	2690	2753	0	173	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	2002	288	14					1728	1732		10.1001/jama.288.14.1728	http://dx.doi.org/10.1001/jama.288.14.1728			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	602BJ	12365956	Bronze			2022-12-28	WOS:000178484700025
J	Marko, IE; Sterin, S; Buisine, O; Mignani, G; Branlard, P; Tinant, B; Declercq, JP				Marko, IE; Sterin, S; Buisine, O; Mignani, G; Branlard, P; Tinant, B; Declercq, JP			Selective and efficient platinum(0)-carbene complexes as hydrosilylation catalysts	SCIENCE			English	Article							ROUTE	The hydrosilylation reaction enables the production of silicon polymers. Platinum-carbene complexes are reported that catalyze the hydrosilylation reaction of alkenes with remarkable efficiency and exquisite selectivity and avoid the formation of platinum colloids. By-products, typically encountered with previous catalytic systems, are suppressed with these platinum derivatives.	Catholic Univ Louvain, Dept Chim, Unite Chim Organ & Med, B-1348 Louvain, Belgium; Catholic Univ Louvain, Dept Chim, Unite Anal Struct, B-1348 Louvain, Belgium; Rhodia Silicones, F-69192 St Fons, France	Universite Catholique Louvain; Universite Catholique Louvain	Marko, IE (corresponding author), Catholic Univ Louvain, Dept Chim, Unite Chim Organ & Med, Pl Louis Pasteur 1, B-1348 Louvain, Belgium.	marko@chim.ucl.ac.be						ARDUENGO AJ, 1994, J AM CHEM SOC, V116, P4391, DOI 10.1021/ja00089a029; Armitage D. A., 1982, COMPREHENSIVE ORGANO, V2, P117; Arnold PL, 1999, ORGANOMETALLICS, V18, P3228, DOI 10.1021/om990224u; BEUTER G, 1991, Z NATURFORSCH B, V46, P1694, DOI 10.1515/znb-1991-1219; Bohm VPW, 2000, ANGEW CHEM INT EDIT, V39, P4036, DOI 10.1002/1521-3773(20001117)39:22<4036::AID-ANIE4036>3.0.CO;2-L; Bourissou D, 2000, CHEM REV, V100, P39, DOI 10.1021/cr940472u; CHANDRA G, 1987, ORGANOMETALLICS, V6, P191, DOI 10.1021/om00144a036; GRATE JW, 1999, POLYM NEWS, V24, P149; HITCHCOCK PB, 1991, ANGEW CHEM INT EDIT, V30, P438, DOI 10.1002/anie.199104381; Hutchins, 1997, PLATIN MET REV, V41, P66; Marciniec B., 1992, COMPREHENSIVE HDB HY, DOI DOI 10.1016/C2009-0-11185-6; McGuinness DS, 2001, CHEM COMMUN, P355, DOI 10.1039/b009674l; Ojima I., 1989, CHEM ORGANIC SILICON, V2, P1479; Pukhnarevitch V. B., 1992, PERSPECTIVES HYDROSI; Speier J.L., 1979, ADV ORGANOMET CHE, V17, P407, DOI [10.1016/S0065-3055(08)60328-7, DOI 10.1016/S0065-3055(08)60328-7]; Stein J, 1999, J AM CHEM SOC, V121, P3693, DOI 10.1021/ja9825377	16	297	302	6	115	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 4	2002	298	5591					204	206		10.1126/science.1073338	http://dx.doi.org/10.1126/science.1073338			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	600BJ	12364803				2022-12-28	WOS:000178370500060
J	Wilson, JR; Jing, C; Walker, PA; Martin, SR; Howell, SA; Blackburn, GM; Gamblin, SJ; Xiao, B				Wilson, JR; Jing, C; Walker, PA; Martin, SR; Howell, SA; Blackburn, GM; Gamblin, SJ; Xiao, B			Crystal structure and functional analysis of the histone methyltransferase SET7/9	CELL			English	Article							CHROMATIN-STRUCTURE; LYSINE 9; METHYLATION; H3; HETEROCHROMATIN; BINDING; PROTEIN; TRANSCRIPTION; ACETYLATION; REPRESSOR	Methylation of lysine residues in the N-terminal tails of histones is thought to represent an important component of the mechanism that regulates chromatin structure. The evolutionarily conserved SET domain occurs in most proteins known to possess histone lysine methyltransferase activity. We present here the crystal structure of a large fragment of human SET7/9 that contains a N-terminal beta-sheet domain as well as the conserved SET domain. Mutagenesis identifies two residues in the C terminus of the protein that appear essential for catalytic activity toward lysine-4 of histone H3. Furthermore, we show how the cofactor AdoMet binds to this domain and present biochemical data supporting the role of invariant residues in catalysis, binding of AdoMet, and interactions with the peptide substrate.	Natl Inst Med Res, Struct Biol Grp, London NW7 1AA, England; Univ Sheffield, Krebs Inst, Dept Chem, Sheffield S3 7HF, S Yorkshire, England	MRC National Institute for Medical Research; University of Sheffield	Gamblin, SJ (corresponding author), Natl Inst Med Res, Struct Biol Grp, Ridgeway,Mill Hill, London NW7 1AA, England.	sgambli@nimr.mrc.ac.uk	Wilson, Jon R/B-7362-2019	Wilson, Jon R/0000-0002-5157-5432				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Cheng XD, 2001, NUCLEIC ACIDS RES, V29, P3784, DOI 10.1093/nar/29.18.3784; Dillon N, 2002, TRENDS GENET, V18, P252, DOI 10.1016/S0168-9525(02)02648-3; Dinner AR, 2001, NATURE, V413, P752, DOI 10.1038/35099587; Eissenberg JC, 2000, CURR OPIN GENET DEV, V10, P204, DOI 10.1016/S0959-437X(00)00058-7; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; HOFFMAN JL, 1986, BIOCHEMISTRY-US, V25, P4444, DOI 10.1021/bi00363a041; JONES RS, 1993, MOL CELL BIOL, V13, P6357, DOI 10.1128/MCB.13.10.6357; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Masino L, 2000, PROTEIN SCI, V9, P1519, DOI 10.1110/ps.9.8.1519; MURRAY K, 1964, BIOCHEMISTRY-US, V3, P10, DOI 10.1021/bi00889a003; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nishioka K, 2002, MOL CELL, V9, P1201, DOI 10.1016/S1097-2765(02)00548-8; Nishioka K, 2002, GENE DEV, V16, P479, DOI 10.1101/gad.967202; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RAFFERTY JB, 1989, NATURE, V341, P705, DOI 10.1038/341705a0; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Roguev A, 2001, EMBO J, V20, P7137, DOI 10.1093/emboj/20.24.7137; Spellman Paul T, 2002, J Biol, V1, P5, DOI 10.1186/1475-4924-1-5; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; TAKUSAGAWA F, 1998, S ADENOSYL METHIONIN, V1; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Thompson MJ, 1999, J ORG CHEM, V64, P7467, DOI 10.1021/jo9907742; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Wang HB, 2001, MOL CELL, V8, P1207, DOI 10.1016/S1097-2765(01)00405-1; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Wolffe A., 1998, CHROMATIN STRUCTURE; Zegerman P, 2002, J BIOL CHEM, V277, P11621, DOI 10.1074/jbc.C200045200; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	35	178	194	1	22	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 4	2002	111	1					105	115		10.1016/S0092-8674(02)00964-9	http://dx.doi.org/10.1016/S0092-8674(02)00964-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	601RQ	12372304	Bronze			2022-12-28	WOS:000178461900012
J	Blau, HM				Blau, HM			A twist of fate	NATURE			English	Editorial Material							CELL		Stanford Univ, Baxter Lab Genet Pharmacol, Stanford, CA 94305 USA	Stanford University	Blau, HM (corresponding author), Stanford Univ, Baxter Lab Genet Pharmacol, Stanford, CA 94305 USA.							Blau HM, 2001, CELL, V105, P829, DOI 10.1016/S0092-8674(01)00409-3; BLAU HM, 1992, ANNU REV BIOCHEM, V61, P1213, DOI 10.1146/annurev.bi.61.070192.010025; FENYO EM, 1973, JNCI-J NATL CANCER I, V51, P1865, DOI 10.1093/jnci/51.6.1865; WIENER F, 1972, NATURE-NEW BIOL, V238, P155, DOI 10.1038/newbio238155a0	4	62	64	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 3	2002	419	6906					437	437		10.1038/419437a	http://dx.doi.org/10.1038/419437a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	599RF	12374136	Bronze			2022-12-28	WOS:000178348400019
J	Wiltschko, W; Traudt, J; Gunturkun, O; Prior, H; Wiltschko, R				Wiltschko, W; Traudt, J; Gunturkun, O; Prior, H; Wiltschko, R			Lateralization of magnetic compass orientation in a migratory bird	NATURE			English	Article							EUROPEAN ROBINS; VISUAL-SYSTEM; AVIAN BRAIN; PIGEONS; LIGHT; MAGNETORECEPTION; INFORMATION; ASYMMETRIES; MEMORY; MODEL	Lateralization of brain functions, once believed to be a human characteristic, has now been found to be widespread among vertebrates(1-3). In birds, asymmetries of visual functions are well studied, with each hemisphere being specialized for different tasks(4-8). Here we report lateralized functions of the birds' visual system associated with magnetoperception, resulting in an extreme asymmetry of sensing the direction of the magnetic field. We found that captive migrants tested in cages with the magnetic field as the only available orientation cue were well oriented in their appropriate migratory direction when using their right eye only, but failed to show a significant directional preference when using their left eye. This implies that magnetoreception for compass orientation, assumed to take place in the eyes alongside the visual processes(9-11), is strongly lateralized, with a marked dominance of the right eye/left brain hemisphere.	Univ Frankfurt, Inst Zool, Fachbereich Biol, D-60054 Frankfurt, Germany; Ruhr Univ Bochum, Fak Psychol, D-44780 Bochum, Germany	Goethe University Frankfurt; Ruhr University Bochum	Wiltschko, W (corresponding author), Univ Frankfurt, Inst Zool, Fachbereich Biol, Siesmayerstr 70, D-60054 Frankfurt, Germany.							Batschelet E., 1981, CIRCULAR STAT BIOL; BEASON RC, 1987, NEUROSCI LETT, V80, P229, DOI 10.1016/0304-3940(87)90659-8; CLAYTON N, 1993, J COMP PHYSIOL A, V171, P799, DOI 10.1007/BF00213076; Diekamp B, 2001, NEUROSCI LETT, V305, P103, DOI 10.1016/S0304-3940(01)01819-5; Gunturkun O, 1999, BEHAV BRAIN RES, V98, P193, DOI 10.1016/S0166-4328(98)00084-9; Hellmann B, 2001, J COMP NEUROL, V429, P94, DOI 10.1002/1096-9861(20000101)429:1<94::AID-CNE8>3.0.CO;2-5; Hunt GR, 2001, NATURE, V414, P707, DOI 10.1038/414707a; MAI JK, 1990, J HIRNFORSCH, V31, P331; Prior H, 2001, LEARN MEMORY, V8, P44, DOI 10.1101/lm.36201; PRIOR H, 2001, ORIENTATION NAVIGATI; Ritz T, 2000, BIOPHYS J, V78, P707, DOI 10.1016/S0006-3495(00)76629-X; Rogers L, 1996, NEUROSCI BIOBEHAV R, V20, P487, DOI 10.1016/0149-7634(95)00024-0; Rogers LJ, 2002, COMP VERTEBRATE LATE; SEMM P, 1986, J COMP PHYSIOL A, V159, P619, DOI 10.1007/BF00612035; SEMM P, 1984, J COMP PHYSIOL, V155, P283, DOI 10.1007/BF00610581; Tommasi L, 2001, BEHAV NEUROSCI, V115, P602, DOI 10.1037//0735-7044.115.3.602; Ulrich C, 1999, BEHAV BRAIN RES, V104, P169, DOI 10.1016/S0166-4328(99)00062-5; Vallortigara G, 2000, BRAIN LANG, V73, P189, DOI 10.1006/brln.2000.2303; Vallortigara G, 1996, BEHAV BRAIN RES, V74, P135, DOI 10.1016/0166-4328(95)00037-2; Wiltschko R., 1995, TIEROSYCHOL; WILTSCHKO W, 1993, NATURE, V364, P525, DOI 10.1038/364525a0; Wiltschko W, 2001, NATURWISSENSCHAFTEN, V88, P387, DOI 10.1007/s001140100248; Wiltschko W, 2001, J EXP BIOL, V204, P3295; WILTSCHKO W, 1972, SCIENCE, V176, P42; [No title captured]	25	147	155	1	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 3	2002	419	6906					467	470		10.1038/nature00958	http://dx.doi.org/10.1038/nature00958			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	599RF	12368853				2022-12-28	WOS:000178348400034
J	Singler, J; Farmer, P				Singler, J; Farmer, P			Treating HIV in resource-poor settings	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							AIDS		Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA; Harvard Univ, Sch Med, Boston, MA USA	University of California System; University of California San Francisco; Harvard University; Harvard Medical School	Singler, J (corresponding author), Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA.							*CDCP, 1999, HIV AIDS SURV REP, P11; Dore GJ, 2002, J ACQ IMMUN DEF SYND, V29, P388, DOI 10.1097/00126334-200204010-00010; Farmer P, 2001, LANCET, V358, P404, DOI 10.1016/S0140-6736(01)05550-7; Farmer P, 2001, B WORLD HEALTH ORGAN, V79, P1145; Farmer P., 1999, INFECT INEQUALITIES; *JOINT UN PROGR HI, 2002, NEW UNAIDS REP WARNS; *JOINT UN PROGR HI, 2002, REP GLOB HIV AIDS EP; *JOINT UN PROGR HI, 2002, 14 INT C AICS BARC S; Kim J. Y., 2000, DYING GROWTH GLOBAL; LASANTE Z, 2002, RAPPORTS TRIMESTERIE; McNaghten AD, 1999, AIDS, V13, P1687, DOI 10.1097/00002030-199909100-00012; *MED SANS FRONT, AIDS TRIPL THER LESS; Mocroft A, 2000, LANCET, V356, P291, DOI 10.1016/S0140-6736(00)02504-6; PAPE J, 1993, CLIN INFECT DIS, V17, pS341, DOI 10.1093/clinids/17.Supplement_2.S341; Raviola G, 2002, CULT MED PSYCHIAT, V26, P55, DOI 10.1023/A:1015289132151; United Nations Development Program, 2000, HUM DEV REP 2000; Wood E, 2000, LANCET, V355, P2095, DOI 10.1016/S0140-6736(00)02375-8; HIV AIDS BRAZIL CLAI; 2002, B EPIDEMIOLOGICO AID	19	7	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	2002	288	13					1652	1653		10.1001/jama.288.13.1652	http://dx.doi.org/10.1001/jama.288.13.1652			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	599BJ	12350202				2022-12-28	WOS:000178314000031
J	McEwen, AS				McEwen, AS			Planetary science - Active volcanism on Io	SCIENCE			English	Editorial Material							SILICATE VOLCANISM		Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA	University of Arizona	McEwen, AS (corresponding author), Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA.							CARR MH, 1986, J GEOPHYS RES-SOLID, V91, P3521, DOI 10.1029/JB091iB03p03521; Geissler PE, 1999, ICARUS, V140, P265, DOI 10.1006/icar.1999.6128; JOHNSON TV, 1988, SCIENCE, V242, P1280, DOI 10.1126/science.242.4883.1280; Keszthelyi L, 1997, ICARUS, V130, P437, DOI 10.1006/icar.1997.5837; Keszthelyi L, 1999, ICARUS, V141, P415, DOI 10.1006/icar.1999.6179; KIVELSON MG, 2002, AM GEOPH UN SPRING M; Lopes RMC, 2001, J GEOPHYS RES-PLANET, V106, P33053, DOI 10.1029/2000JE001463; Lopes-Gautier R, 1999, ICARUS, V140, P243, DOI 10.1006/icar.1999.6129; McEwen AS, 1998, SCIENCE, V281, P87, DOI 10.1126/science.281.5373.87; SAGAN C, 1979, NATURE, V280, P750, DOI 10.1038/280750a0; SMITH BA, 1979, SCIENCE, V204, P951, DOI 10.1126/science.204.4396.951; Spencer JR, 2000, SCIENCE, V288, P1198, DOI 10.1126/science.288.5469.1198; 2001, J GEOPHYS RES, V106, P32959	13	7	7	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 27	2002	297	5590					2220	2221		10.1126/science.1076908	http://dx.doi.org/10.1126/science.1076908			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	597LA	12351777				2022-12-28	WOS:000178222000033
J	Verhoef, H; West, CE; Nzyuko, SM; de Vogel, S; van der Valk, R; Wanga, MA; Kuijsten, A; Veenemans, J; Kok, FJ				Verhoef, H; West, CE; Nzyuko, SM; de Vogel, S; van der Valk, R; Wanga, MA; Kuijsten, A; Veenemans, J; Kok, FJ			Intermittent administration of iron and sulfadoxine-pyrimethamine to control anaemia in Kenyan children: a randomised controlled trial	LANCET			English	Article							MALARIA; SUPPLEMENTATION; DEFICIENCY; MORBIDITY; GROWTH	Background Iron supplementation is recommended for children at high risk of anaemia, but its benefits may not outweigh the associated risk of malaria in areas of seasonal transmission. We investigated the effect on haemoglobin concentrations of intermittent administration of iron supplements and sulfadoxine-pyrimethamine in symptom-free children under intense health surveillance. Methods In a trial of two by two factorial design, 328 anaemic Kenyan children were randomly assigned either iron or placebo and sulfadoxine-pyrimethamine or placebo (82 to each group). Primary outcomes were haemological indicators of iron status and inflammation at the end of the follow-up, and occurrence of malaria attacks. Morbidity surveillance consisted of medical examinations every 4 weeks, continuous passive case detection, and visits twice a week to community healthworkers. Analyses were by intention to treat. Findings After 12 weeks, the groups assigned iron plus sulfadoxine-pyrimethamine, iron alone, or sulfadoxine-pyrimethamine alone had higher haemoglobin concentrations than the group assigned placebo (treatment effect adjusted for prognostic factors at baseline: 11.1 g/L [95% Cl 7.5 to 14.7]; 10.7 g/L [7.1 to 14.3]; and 3.1 g/L [-0.5 to 6.7]). Administration of iron plus sulfadoxine-pyrimethamine also lowered the proportion with anaemia from 100% at baseline to 36% at 12 weeks, and of iron deficiency from 66% at baseline to 8% at 12 weeks. Survival analysis showed no evidence of substantially increased risk of malaria after iron supplementation. Interpretation Iron supplementation gives substantial health benefits, which may outweigh possible inherent risks caused by malaria. A larger study than ours is needed to assess benefits and risks of intermittent administration of sulfadoxine-pyrimethamine in reducing the incidence of malaria attacks in areas of seasonal malaria transmission.	Univ Wageningen & Res Ctr, Div Human Nutr & Epidemiol, NL-6700 EV Wageningen, Netherlands; African Med & Res Fdn, Nairobi, Kenya; Univ Nijmegen, Med Ctr, Dept Gastroenterol, Nijmegen, Netherlands; Minist Hlth, Kibwezi Rural Hlth Ctr, Kibwezi, Kenya	Wageningen University & Research; African Medical & Research Foundation (AMREF); Radboud University Nijmegen	West, CE (corresponding author), Univ Wageningen & Res Ctr, Div Human Nutr & Epidemiol, POB 8129, NL-6700 EV Wageningen, Netherlands.	clive.west@staff.nutepi.wau.nl	Kuijsten, Anneleen/R-8073-2017; Verhoef, Hans/AGD-5388-2022; Verhoef, Hans/L-3024-2015	Kuijsten, Anneleen/0000-0001-8120-7027; Verhoef, Hans/0000-0002-9346-9689				Adam Z., 1997, THESIS LONDON SCH TR; BEATON GH, 1999, EFFICACY INTERMITTEN; Bouvier P, 1997, AM J EPIDEMIOL, V145, P850, DOI 10.1093/oxfordjournals.aje.a009179; BRABIN BJ, 1992, NESTLE NUTR WORKS SE, V30, P65; CHIPPAUX JP, 1991, B SOC PATHOL EXOT, V84, P54; DeMaeyer E, 1985, World Health Stat Q, V38, P302; Durrheim DN, 1998, T ROY SOC TROP MED H, V92, P32, DOI 10.1016/S0035-9203(98)90944-0; Eisen DP, 2000, T ROY SOC TROP MED H, V94, P169, DOI 10.1016/S0035-9203(00)90262-1; Gorissen E, 2000, TROP MED INT HEALTH, V5, P459, DOI 10.1046/j.1365-3156.2000.00570.x; Grantham-McGregor S, 2001, J NUTR, V131, p649S, DOI 10.1093/jn/131.2.649S; Greenwood BM, 1995, T ROY SOC TROP MED H, V89, P629, DOI 10.1016/0035-9203(95)90419-0; GREENWOOD BM, 1991, MALARIA : WAITING FOR THE VACCINE, P83; Haas JD, 2001, J NUTR, V131, p676S, DOI 10.1093/jn/131.2.676S; *INACG, 1999, SAF IR SUPPL PROGR M; Jurado RL, 1997, CLIN INFECT DIS, V25, P888, DOI 10.1086/515549; Kilian AHD, 1997, T ROY SOC TROP MED H, V91, P666, DOI 10.1016/S0035-9203(97)90514-9; LATHAM MC, 1990, NUTRITION, V6, P159; LAWLESS JW, 1994, J NUTR, V124, P645, DOI 10.1093/jn/124.5.645; Menendez C, 1997, LANCET, V350, P844, DOI 10.1016/S0140-6736(97)04229-3; Oppenheimer SJ, 2001, J NUTR, V131, p616S, DOI 10.1093/jn/131.2.616S; Schellenberg D, 2001, LANCET, V357, P1471, DOI 10.1016/S0140-6736(00)04643-2; SEARS DA, 1992, MED CLIN N AM, V76, P567, DOI 10.1016/S0025-7125(16)30340-6; Shankar AH, 2000, J INFECT DIS, V182, pS37, DOI 10.1086/315906; Singh N, 1997, T ROY SOC TROP MED H, V91, P396, DOI 10.1016/S0035-9203(97)90254-6; SMITH AW, 1989, ANN TROP PAEDIATR, V9, P17, DOI 10.1080/02724936.1989.11748589; Snow RW, 1998, BRIT MED BULL, V54, P293, DOI 10.1093/oxfordjournals.bmb.a011689; Spivak JL, 2000, LANCET, V355, P1707, DOI 10.1016/S0140-6736(00)02249-2; Stoltzfus RJ, 1998, GUIDELINES USE IRON; Verhoef H, 2001, AM J CLIN NUTR, V74, P767; *WHO, 1993, TECHN REP SER WHO, V839; 2000, NEW PERSPECTIVES MAL	31	76	76	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 21	2002	360	9337					908	914		10.1016/S0140-6736(02)11027-0	http://dx.doi.org/10.1016/S0140-6736(02)11027-0			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	596AU	12354473				2022-12-28	WOS:000178142200010
J	Llave, C; Xie, ZX; Kasschau, KD; Carrington, JC				Llave, C; Xie, ZX; Kasschau, KD; Carrington, JC			Cleavage of Scarecrow-like mRNA targets directed by a class of Arabidopsis miRNA	SCIENCE			English	Article							C-ELEGANS; GENE; INTERFERENCE; EXPRESSION; ENCODES; DICER; STEP	Micro-RNAs ( miRNAs) are regulatory molecules that mediate effects by interacting with messenger RNA ( mRNA) targets. Here we show that Arabidopsis thaliana miRNA 39 ( also known as miR171), a 21-ribonucleotide species that accumulates predominantly in inflorescence tissues, is produced from an intergenic region in chromosome III and functionally interacts with mRNA targets encoding several members of the Scarecrow-like (SCL) family of putative transcription factors. miRNA 39 is complementary to an internal region of three SCL mRNAs. The interaction results in specific cleavage of target mRNA within the region of complementarity, indicating that this class of miRNA functions like small interfering RNA associated with RNA silencing to guide sequence-specific cleavage in a developmentally controlled manner.	Oregon State Univ, Ctr Gene Res & Biotechnol, Corvallis, OR 97331 USA; Oregon State Univ, Dept Bot & Plant Pathol, Corvallis, OR 97331 USA	Oregon State University; Oregon State University	Carrington, JC (corresponding author), Oregon State Univ, Ctr Gene Res & Biotechnol, Corvallis, OR 97331 USA.	carrington@orst.edu	Llave, Cesar/ABF-5827-2021; Carrington, James C/A-4656-2012	Carrington, James C/0000-0003-3572-129X; Xie, Zhixin/0000-0002-6191-5170	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI043288, R37AI043288, R29AI027832, R01AI043288, R01AI027832] Funding Source: NIH RePORTER; NIAID NIH HHS [AI43288, AI27832] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Bolle C, 2000, GENE DEV, V14, P1269; CARRINGTON JC, 1990, EMBO J, V9, P1347, DOI 10.1002/j.1460-2075.1990.tb08249.x; Dalmay T, 2000, CELL, V101, P543, DOI 10.1016/S0092-8674(00)80864-8; DiLaurenzio L, 1996, CELL, V86, P423, DOI 10.1016/S0092-8674(00)80115-4; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; FEINBERG AP, 1983, ANAL BIOCHEM, V257, P8569; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Helariutta Y, 2000, CELL, V101, P555, DOI 10.1016/S0092-8674(00)80865-X; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Johansen LK, 2001, PLANT PHYSIOL, V126, P930, DOI 10.1104/pp.126.3.930; Jones Jonathan D. G., 1992, Transgenic Research, V1, P285, DOI 10.1007/BF02525170; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lai EC, 2002, NAT GENET, V30, P363, DOI 10.1038/ng865; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Llave C, 2000, P NATL ACAD SCI USA, V97, P13401, DOI 10.1073/pnas.230334397; Llave C, 2002, PLANT CELL, V14, P1605, DOI 10.1105/tpc.003210; LLAVE C, UNPUB; McManus MT, 2002, RNA, V8, P842, DOI 10.1017/S1355838202024032; Moss EG, 1997, CELL, V88, P637, DOI 10.1016/S0092-8674(00)81906-6; Mourelatos Z, 2002, GENE DEV, V16, P720, DOI 10.1101/gad.974702; Mourrain P, 2000, CELL, V101, P533, DOI 10.1016/S0092-8674(00)80863-6; Reinhart BJ, 2002, GENE DEV, V16, P1616, DOI 10.1101/gad.1004402; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Ruvkun G, 2001, SCIENCE, V294, P797, DOI 10.1126/science.1066315; Silverstone AL, 1998, PLANT CELL, V10, P155, DOI 10.1105/tpc.10.2.155; Slack FJ, 2000, MOL CELL, V5, P659, DOI 10.1016/S1097-2765(00)80245-2; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4	34	1218	1414	16	243	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 20	2002	297	5589					2053	2056		10.1126/science.1076311	http://dx.doi.org/10.1126/science.1076311			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	594XV	12242443				2022-12-28	WOS:000178078500047
J	Celedon, JC; Litonjua, AA; Ryan, L; Platts-Mills, T; Weiss, ST; Gold, DR				Celedon, JC; Litonjua, AA; Ryan, L; Platts-Mills, T; Weiss, ST; Gold, DR			Exposure to cat allergen, maternal history of asthma, and wheezing in first 5 years of life	LANCET			English	Article							CHILDREN	We looked for an association between early exposure to pets and asthma and wheezing in children whose mothers or fathers did or did not have a history of asthma. We followed up 448 children, who had at least one parent with a history of atopy, from birth to 5 years. Among children whose mothers had no history of asthma, exposure to a cat or a Fel d 1 concentration of at least 8 mug/g at the age of 2-3 months was associated with a reduced risk of wheezing between the ages of 1 and 5 years. However, among children whose mothers did have a history of asthma, such exposures were associated with an increased risk of wheezing at or after the age of 3 years. There was no association between wheezing and exposure to dog or dog allergen, and the father's allergy status had no effect on the relation between childhood wheezing and cat exposure.	Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA; Univ Virginia, Dept Med, Ctr Asthma & Allergy, Charlottesville, VA USA; Harvard Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; University of Virginia; Harvard University; Harvard T.H. Chan School of Public Health	Celedon, JC (corresponding author), Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA.	juan.celedon@channing.harvard.edu	Ryan, Louise M/A-4562-2009	Ryan, Louise M/0000-0001-5957-2490; Platts-Mills, Thomas/0000-0002-1263-329X; Litonjua, Augusto/0000-0003-0422-5875	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K01HL004370] Funding Source: NIH RePORTER; NHLBI NIH HHS [KO1 HL04370-01A1] Funding Source: Medline; NIEHS NIH HHS [ES35786] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Celedon JC, 1999, PEDIATRICS, V104, P495, DOI 10.1542/peds.104.3.495; Kitch BT, 2000, ENVIRON HEALTH PERSP, V108, P301, DOI 10.2307/3454347; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; Therneau TM, 2000, MODELING SURVIVAL DA	5	157	161	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 7	2002	360	9335					781	782		10.1016/S0140-6736(02)09906-3	http://dx.doi.org/10.1016/S0140-6736(02)09906-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	592HX	12241839				2022-12-28	WOS:000177933000022
J	Claxton, K; Sculpher, M; Drummond, M				Claxton, K; Sculpher, M; Drummond, M			A rational framework for decision making by the National Institute for Clinical Excellence (NICE)	LANCET			English	Editorial Material								Regulatory and reimbursement authorities face uncertain choices when considering the adoption of health-care technologies. in this Viewpoint, we present an analytic framework that separates the issue of whether a technology should be adopted on the basis of existing evidence from whether more research should be demanded to support future decisions. We show the application of this framework to the assessment of heath-care technologies using a published analysis of a new drug treatment for Alzheimer's disease. The results of the analysis show that the amount and type of evidence required to support the adoption of a health technology will differ substantially between technologies with different characteristics. Additionally, the analysis can be used to aid the efficient design of research. We discuss the implications of adoption of this new framework for regulatory and reimbursement decisions.	Univ York, Dept Econ & Related Studies, York YO10 5DD, N Yorkshire, England; Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England	University of York - UK; University of York - UK	Claxton, K (corresponding author), Univ York, Dept Econ & Related Studies, York YO10 5DD, N Yorkshire, England.	kpc1@york.ac.uk		Sculpher, Mark/0000-0003-3746-9913				Briggs A, 1998, PHARMACOECONOMICS, V13, P397, DOI 10.2165/00019053-199813040-00003; Claxton K, 1996, HEALTH ECON, V5, P513, DOI 10.1002/(SICI)1099-1050(199611)5:6<513::AID-HEC237>3.0.CO;2-9; Claxton K, 2001, INT J TECHNOL ASSESS, V17, P38, DOI 10.1017/S0266462301104058; Claxton K, 1999, J HEALTH ECON, V18, P341, DOI 10.1016/S0167-6296(98)00039-3; CLAXTON K, 1999, MED DECIS MAKING, V19, P4; CLEGG A, 2000, HEALTH TECHNOL ASSES, V5, P1; Commonwealth Department of Health Housing and Community Services, 1992, GUID PHARM IND PREP; CRITCHFIELD GC, 1986, MED DECIS MAKING, V6, P85, DOI 10.1177/0272989X8600600205; Drummond M F, 1991, Int J Technol Assess Health Care, V7, P561; Felli JC, 1998, MED DECIS MAKING, V18, P95, DOI 10.1177/0272989X9801800117; Fenwick E, 2000, 179 U YORK CTR HLTH; Fitzpatrick R, 1998, Health Technol Assess, V2, P1; Langley PC, 1999, PHARMACOECONOMICS, V16, P211, DOI 10.2165/00019053-199916030-00001; McDonagh M S, 2000, Health Technol Assess, V4, P1; Ministry of Health (Ontario), 1994, ONT GUID EC AN PHARM; Neumann PJ, 1999, NEUROLOGY, V52, P1138, DOI 10.1212/WNL.52.6.1138; Neumann PJ, 2000, HEALTH AFFAIR, V19, P129, DOI 10.1377/hlthaff.19.5.129; Sculpher M, 1997, J Health Serv Res Policy, V2, P26; SHERLAWJOHNSON C, 1994, J CLIN PATHOL, V47, P430, DOI 10.1136/jcp.47.5.430; Song, 2000, HEALTH TECHNOL ASSES, V4, P1, DOI DOI 10.3310/HTA4100; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; Thompson KM, 1997, RISK ANAL, V17, P253, DOI 10.1111/j.1539-6924.1997.tb00864.x	22	329	338	0	37	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 31	2002	360	9334					711	715		10.1016/S0140-6736(02)09832-X	http://dx.doi.org/10.1016/S0140-6736(02)09832-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	590AM	12241891				2022-12-28	WOS:000177795100026
J	Smith, RJH				Smith, RJH			Deafness: from bedside to bench and back	LANCET			English	Editorial Material							HEARING-LOSS; MUTATIONS; ATTITUDES; GENE		Univ Iowa, Dept Otolaryngol, Mol Otolaryngol Res Labs, Iowa City, IA 52242 USA	University of Iowa	Smith, RJH (corresponding author), Univ Iowa, Dept Otolaryngol, Mol Otolaryngol Res Labs, Iowa City, IA 52242 USA.	richard-smith@uiowa.edu		Smith, Richard/0000-0003-1201-6731				Ahmed ZM, 2002, HUM GENET, V110, P527, DOI 10.1007/s00439-002-0732-4; ARNOS KS, 1991, ANN NY ACAD SCI, V630, P212, DOI 10.1111/j.1749-6632.1991.tb19590.x; Brunger JW, 2000, AM J HUM GENET, V67, P1621, DOI 10.1086/316901; Campbell C, 2001, HUM MUTAT, V17, P403, DOI 10.1002/humu.1116; Cryns K, 2002, HUM GENET, V110, P389, DOI 10.1007/s00439-002-0719-1; Green GE, 1999, JAMA-J AM MED ASSOC, V281, P2211, DOI 10.1001/jama.281.23.2211; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; Kurima K, 2002, NAT GENET, V30, P277, DOI 10.1038/ng842; Middleton A, 1998, AM J HUM GENET, V63, P1175, DOI 10.1086/302060; Walsh T, 2002, P NATL ACAD SCI USA, V99, P7518, DOI 10.1073/pnas.102091699; Zelante L, 1997, HUM MOL GENET, V6, P1605, DOI 10.1093/hmg/6.9.1605; Zwaenepoel I, 2002, P NATL ACAD SCI USA, V99, P6240, DOI 10.1073/pnas.082515999; 2002, HEREDITARY HEARING L	13	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 31	2002	360	9334					656	657		10.1016/S0140-6736(02)09881-1	http://dx.doi.org/10.1016/S0140-6736(02)09881-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	590AM	12241869				2022-12-28	WOS:000177795100004
J	Fitzmaurice, DA; Blann, AD; Lip, GYH				Fitzmaurice, DA; Blann, AD; Lip, GYH			ABC of antithrombotic therapy - Bleeding risks of antithrombotic therapy	BMJ-BRITISH MEDICAL JOURNAL			English	Review							ANTICOAGULANT; COMPLICATIONS		Univ Birmingham, Birmingham B15 2TT, W Midlands, England; City Hosp, Univ Dept Med, Haemostasis Thrombosis & Vasc Biol Unit, Birmingham, W Midlands, England	University of Birmingham; University of Birmingham	Fitzmaurice, DA (corresponding author), Univ Birmingham, Birmingham B15 2TT, W Midlands, England.							Blann A, 1999, BRIT J HAEMATOL, V107, P207, DOI 10.1046/j.1365-2141.1999.01672.x; Erhardtsen E, 1998, BLOOD COAGUL FIBRIN, V9, P741, DOI 10.1097/00001721-199811000-00003; Fitzmaurice DA, 2000, ARCH INTERN MED, V160, P2343, DOI 10.1001/archinte.160.15.2343; GURWITZ JH, 1988, ARCH INTERN MED, V148, P1733, DOI 10.1001/archinte.148.8.1733; Haemostasis and Thrombosis Task Force, 1998, BRIT J HAEMATOL, V101, P374; He J, 1998, JAMA-J AM MED ASSOC, V280, P1930, DOI 10.1001/jama.280.22.1930; LANDEFELD CS, 1993, AM J MED, V95, P315, DOI 10.1016/0002-9343(93)90285-W; LEVINE MN, 1992, CHEST, V102, pS352, DOI 10.1378/chest.102.4.352S; Palareti G, 1996, LANCET, V348, P423, DOI 10.1016/S0140-6736(96)01109-9; Panneerselvam S, 1998, BRIT J HAEMATOL, V103, P422, DOI 10.1046/j.1365-2141.1998.00988.x; VANDERMEER FJM, 1993, ARCH INTERN MED, V153, P1557, DOI 10.1001/archinte.153.13.1557	11	121	125	1	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 12	2002	325	7368					828	831		10.1136/bmj.325.7368.828	http://dx.doi.org/10.1136/bmj.325.7368.828			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604YM	12376447	Green Published			2022-12-28	WOS:000178648700025
J	Auboeuf, D; Honig, A; Berget, SM; O'Malley, BW				Auboeuf, D; Honig, A; Berget, SM; O'Malley, BW			Coordinate regulation of transcription and splicing by steroid receptor coregulators	SCIENCE			English	Article							COMBINATORIAL CONTROL; ESTROGEN-RECEPTORS; NUCLEAR RECEPTORS; COACTIVATOR; PROTEIN; EXON	Recent observations indicating that promoter identity influences alternative RNA-processing decisions have created interest in the regulatory interactions between RNA polymerase II transcription and precursor messenger RNA (pre-mRNA) processing. We examined the impact of steroid receptor mediated transcription on RNA processing with reporter genes subject to alternative splicing driven by steroid- sensitive promoters. Steroid hormones affected the processing of pre-mRNA synthesized from steroid-sensitive promoters, but not from steroid-unresponsive promoters, in a steroid receptor dependent and receptor-selective manner. Several nuclear receptor coregulators showed differential splicing effects, suggesting that steroid hormone receptors may simultaneously control gene transcription activity and exon content of the product mRNA by recruiting coregulators involved in both processes.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	O'Malley, BW (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	berto@bcm.tmc.edu	Auboeuf, Didier/M-4610-2014	Auboeuf, Didier/0000-0002-3757-0002	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038526] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-08818] Funding Source: Medline; NIGMS NIH HHS [GM 38526] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cramer P, 1999, MOL CELL, V4, P251, DOI 10.1016/S1097-2765(00)80372-X; Cramer P, 1997, P NATL ACAD SCI USA, V94, P11456, DOI 10.1073/pnas.94.21.11456; Hirose Y, 2000, GENE DEV, V14, P1415; Iwasaki T, 2001, J BIOL CHEM, V276, P33375, DOI 10.1074/jbc.M101517200; Jung DJ, 2002, J BIOL CHEM, V277, P1229, DOI 10.1074/jbc.M110417200; Kadener S, 2001, EMBO J, V20, P5759, DOI 10.1093/emboj/20.20.5759; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lou H, 1999, MOL CELL BIOL, V19, P78; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Nilsson S, 2002, CRIT REV BIOCHEM MOL, V37, P1, DOI 10.1080/10409230290771438; Powers CA, 1998, MOL ENDOCRINOL, V12, P4, DOI 10.1210/mend.12.1.0043; Roberts GC, 1998, NUCLEIC ACIDS RES, V26, P5568, DOI 10.1093/nar/26.24.5568; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Stickeler E, 2001, EMBO J, V20, P3821, DOI 10.1093/emboj/20.14.3821; Watanabe M, 2001, EMBO J, V20, P1341, DOI 10.1093/emboj/20.6.1341	16	286	295	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 11	2002	298	5592					416	419		10.1126/science.1073734	http://dx.doi.org/10.1126/science.1073734			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	602NB	12376702				2022-12-28	WOS:000178510400049
J	Luo, J; Kaplitt, MG; Fitzsimons, HL; Zuzga, DS; Liu, YH; Oshinsky, ML; During, MJ				Luo, J; Kaplitt, MG; Fitzsimons, HL; Zuzga, DS; Liu, YH; Oshinsky, ML; During, MJ			Subthalamic GAD gene therapy in a Parkinson's disease rat model	SCIENCE			English	Article							TEMPORAL-LOBE EPILEPSY; NIGRA PARS RETICULATA; STRIATAL LESIONS; NUCLEUS LESIONS; GRANULE CELLS; NEURONS; GABA; EXPRESSION; GLUTAMATE; ACID	The motor abnormalities of Parkinson's disease (PD) are caused by alterations in basal ganglia network activity, including disinhibition of the subthalamic nucleus (STN), and excessive activity of the major output nuclei. Using adeno-associated viral vector mediated somatic cell gene transfer, we expressed glutamic acid decarboxylase (GAD), the enzyme that catalyzes synthesis of the neurotransmitter GABA, in excitatory glutamatergic neurons of the STN in rats. The transduced neurons, when driven by electrical stimulation, produced mixed inhibitory responses associated with GABA release. This phenotypic shift resulted in strong neuroprotection of nigral dopamine neurons and rescue of the parkinsonian behavioral phenotype. This strategy suggests that there is plasticity between excitatory and inhibitory neurotransmission in the mammalian brain that could be exploited for therapeutic benefit.	Univ Auckland, Dept Mol Med & Pathol, Funct Genom & Translat Neurosci Lab, Auckland 1, New Zealand; Thomas Jefferson Univ, Jefferson Med Coll, CNS Gene Therapy Ctr, Philadelphia, PA 19107 USA; Cornell Univ, Weill Med Coll, Dept Neurol Surg, Ctr Stereotact & Funct Neurosurg, New York, NY 10021 USA	University of Auckland; Jefferson University; Cornell University	During, MJ (corresponding author), Univ Auckland, Dept Mol Med & Pathol, Funct Genom & Translat Neurosci Lab, Auckland 1, New Zealand.		Andalman, Aaron S/C-7694-2011; During, Matthew/AAC-1388-2020	Fitzsimons, Helen/0000-0001-7825-3911; Oshinsky, Michael/0000-0002-0976-1047				Alvarez L, 2001, MOVEMENT DISORD, V16, P72, DOI 10.1002/1531-8257(200101)16:1<72::AID-MDS1019>3.0.CO;2-6; Benazzouz A, 2000, NEUROSCIENCE, V99, P289, DOI 10.1016/S0306-4522(00)00199-8; Cao YX, 1996, P NATL ACAD SCI USA, V93, P9844, DOI 10.1073/pnas.93.18.9844; Carvalho GA, 2001, EXP NEUROL, V171, P405, DOI 10.1006/exnr.2001.7742; Donello JE, 1998, J VIROL, V72, P5085, DOI 10.1128/JVI.72.6.5085-5092.1998; DURING MJ, 1995, NATURE, V376, P174, DOI 10.1038/376174a0; Esclapez M, 1999, J COMP NEUROL, V412, P488; Gill SS, 1997, LANCET, V350, P1224, DOI 10.1016/S0140-6736(05)63455-1; HEFTI F, 1980, PHARMACOL BIOCHEM BE, V12, P185, DOI 10.1016/0091-3057(80)90353-6; Henderson JM, 1999, EUR J NEUROSCI, V11, P2749, DOI 10.1046/j.1460-9568.1999.00692.x; Hutchison WD, 1998, ANN NEUROL, V44, P622, DOI 10.1002/ana.410440407; KAPLITT MG, 1994, NAT GENET, V8, P148, DOI 10.1038/ng1094-148; Klein RL, 2002, EXP NEUROL, V176, P66, DOI 10.1006/exnr.2002.7942; Levy R, 2001, BRAIN, V124, P2105, DOI 10.1093/brain/124.10.2105; LIMOUSIN P, 1995, LANCET, V345, P91, DOI 10.1016/S0140-6736(95)90062-4; Mastakov MY, 2002, J VIROL, V76, P8446, DOI 10.1128/JVI.76.16.8446-8454.2002; Nakao N, 1999, ANN NEUROL, V45, P640, DOI 10.1002/1531-8249(199905)45:5<640::AID-ANA13>3.3.CO;2-L; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Obeso JA, 2001, NEW ENGL J MED, V345, P956, DOI 10.1056/nejmoa000827; Obeso JA, 2000, NEUROLOGY, V55, pS7; Piallat B, 1996, EUR J NEUROSCI, V8, P1408, DOI 10.1111/j.1460-9568.1996.tb01603.x; RINVIK E, 1993, J CHEM NEUROANAT, V6, P19, DOI 10.1016/0891-0618(93)90004-N; SCHWARZER C, 1995, NEUROSCIENCE, V69, P705, DOI 10.1016/0306-4522(95)00348-M; Sloviter RS, 1996, J COMP NEUROL, V373, P593; SMITH Y, 1988, BRAIN RES, V453, P353, DOI 10.1016/0006-8993(88)90177-1; Su PC, 2001, ANN NEUROL, V50, P514, DOI 10.1002/ana.1232; Wichmann T, 2001, EXP NEUROL, V167, P410, DOI 10.1006/exnr.2000.7572; Young D, 1999, NAT MED, V5, P448, DOI 10.1038/7449	28	226	245	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 11	2002	298	5592					425	429		10.1126/science.1074549	http://dx.doi.org/10.1126/science.1074549			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	602NB	12376704				2022-12-28	WOS:000178510400052
J	Hendley, JO				Hendley, JO			Otitis media	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PNEUMOCOCCAL CONJUGATE VACCINE; TYMPANOSTOMY-TUBE PLACEMENT; MIDDLE-EAR EFFUSION; ANTIMICROBIAL AGENTS; CHILDREN; EFFICACY; ADENOIDECTOMY; ANTIBIOTICS; MANAGEMENT; TRIALS		Univ Virginia Hlth Syst, Div Pediat Infect Dis, Charlottesville, VA 22908 USA	University of Virginia	Hendley, JO (corresponding author), Univ Virginia Hlth Syst, Div Pediat Infect Dis, Charlottesville, VA 22908 USA.							Ah-Tye C, 2001, PEDIATRICS, V107, P1251, DOI 10.1542/peds.107.6.1251; Alho OP, 1996, J FAM PRACTICE, V43, P258; Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003; CASSELBRANT ML, 1992, PEDIATR INFECT DIS J, V11, P278, DOI 10.1097/00006454-199204000-00004; Chan LS, 2001, PEDIATRICS, V108, P248, DOI 10.1542/peds.108.2.248; CLEMENTS DA, 1995, ARCH PEDIAT ADOL MED, V149, P1113, DOI 10.1001/archpedi.1995.02170230067009; Damoiseaux RAMJ, 2000, BRIT MED J, V320, P350, DOI 10.1136/bmj.320.7231.350; DelMar C, 1997, BRIT MED J, V314, P1526, DOI 10.1136/bmj.314.7093.1526; Dowell SF, 1999, PEDIATR INFECT DIS J, V18, P341, DOI 10.1097/00006454-199904000-00006; Dowell SF, 1999, PEDIATR INFECT DIS J, V18, P1, DOI 10.1097/00006454-199901000-00002; Dowell SF, 1998, PEDIATRICS, V101, P165; Eskola J, 2001, NEW ENGL J MED, V344, P403, DOI 10.1056/NEJM200102083440602; Froom J, 1997, BRIT MED J, V315, P98, DOI 10.1136/bmj.315.7100.98; GEBHART DE, 1981, LARYNGOSCOPE, V91, P849; Gehanno P, 1998, PEDIATR INFECT DIS J, V17, P885, DOI 10.1097/00006454-199810000-00007; GLASZIOU PP, 2001, COCHRANE DATABASE SY, V4, DOI UNSP CD000219; HALSTED C, 1968, AM J DIS CHILD, V115, P542, DOI 10.1001/archpedi.1968.02100010544003; Heikkinen T, 1999, NEW ENGL J MED, V340, P260, DOI 10.1056/NEJM199901283400402; HEIKKINEN T, 1991, AM J DIS CHILD, V145, P445, DOI 10.1001/archpedi.1991.02160040103017; Little P, 2001, BMJ-BRIT MED J, V322, P336, DOI 10.1136/bmj.322.7282.336; McCormick DP, 2000, PEDIATR INFECT DIS J, V19, P256, DOI 10.1097/00006454-200003000-00019; McCracken GH, 1999, PEDIATR INFECT DIS J, V18, P1141, DOI 10.1097/00006454-199912000-00029; Paradise JL, 1999, JAMA-J AM MED ASSOC, V282, P945, DOI 10.1001/jama.282.10.945; PARADISE JL, 1990, JAMA-J AM MED ASSOC, V263, P2066, DOI 10.1001/jama.263.15.2066; Pitkaranta A, 1998, PEDIATRICS, V102, P291, DOI 10.1542/peds.102.2.291; ROSENFELD RM, 1994, J PEDIATR-US, V124, P355, DOI 10.1016/S0022-3476(94)70356-6; RYNNELDAGOO B, 1978, ANN OTO RHINOL LARYN, V87, P272, DOI 10.1177/000348947808700223; SANYAL MA, 1980, J PEDIATR-US, V97, P11, DOI 10.1016/S0022-3476(80)80121-1; SCHWARTZ RH, 1981, CLIN PEDIATR, V20, P549, DOI 10.1177/000992288102000901; SCHWARTZ RH, 1981, LARYNGOSCOPE, V91, P616, DOI 10.1288/00005537-198104000-00016; SCHWARTZ RH, 1981, CLIN PEDIATR, V20, P445, DOI 10.1177/000992288102000703; Takata GS, 2001, PEDIATRICS, V108, P239, DOI 10.1542/peds.108.2.239; Van Zuijlen DA, 2001, PEDIATR INFECT DIS J, V20, P140, DOI 10.1097/00006454-200102000-00004; WILLIAMS RL, 1994, JAMA-J AM MED ASSOC, V271, P430; Winther B, 2002, PEDIATRICS, V109, P826, DOI 10.1542/peds.109.5.826; WINTHER B, 2000, 40 INT C ANT AG CHEM, P480	36	71	75	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 10	2002	347	15					1169	1174		10.1056/NEJMcp010944	http://dx.doi.org/10.1056/NEJMcp010944			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	601TW	12374878				2022-12-28	WOS:000178465100008
J	Humler, E; Besse, J				Humler, E; Besse, J			A correlation between mid-ocean-ridge basalt chemistry and distance to continents	NATURE			English	Article							MANTLE CONVECTION; GLOBAL CORRELATIONS; HOTSPOTS; ATLANTIC; BENEATH; DEPTH; DEEP	To fully understand the structure and dynamics of the Earth's convecting mantle, the origins of temperature variations within the mantle need to be resolved. Different hypotheses have been proposed to account for these temperature variations: for example, heat coming from the decay of radioactive elements or heat flowing out of the Earth's core. In addition, theoretical studies(1-5) suggest that the thermal properties of continental masses can affect mantle convection, but quantitative data that could allow us to test these models are scarce. To address this latter problem, we have examined the chemistry of mid-ocean-ridge basalt-which reflects the temperature of the source mantle(6,7)-as a function of the distance of the ridge from the closest continental margin. No correlation is observed for oceanic ridges close to subduction zones or hotspots; subduction zones probably inhibit thermal transfer between the mantle beneath continents and ocean, whereas hotspots influence the major-element chemistry of ridge basalts, which makes their interpretation with respect to mantle temperature more difficult. However, we do observe a significant correlation for mid-oceanic basalts from the Atlantic and Indian oceans. From this, we conclude that the location of continental masses relative to active ridges influences the large-scale thermal structure of the mantle and we estimate that the mantle cools by 0.05 to 0.1degreesC per kilometre from the continental margins.	Univ Denis Diderot, IPGP, Lab Geosci Marines, F-75252 Paris 05, France; Univ Denis Diderot, IPGP, Lab Geomagnetisme & Palaeomagnetisme, F-75252 Paris, France	UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Humler, E (corresponding author), Univ Denis Diderot, IPGP, Lab Geosci Marines, 4 Pl Jussieu, F-75252 Paris 05, France.		Besse, jean/O-3223-2017	Besse, jean/0000-0001-7319-9450				ALBAREDE F, 1992, J GEOPHYS RES-SOL EA, V97, P10997, DOI 10.1029/91JB02927; ANDERSON DL, 1982, NATURE, V297, P391, DOI 10.1038/297391a0; ELDER J, 1976, BOWELS EARTH, V222; Guillou L, 1995, J GEOPHYS RES-SOL EA, V100, P24217, DOI 10.1029/95JB02518; GURNIS M, 1988, NATURE, V332, P695, DOI 10.1038/332695a0; HUMLER E, 1993, NATURE, V364, P225, DOI 10.1038/364225a0; Humler E, 1999, EARTH PLANET SC LETT, V173, P7, DOI 10.1016/S0012-821X(99)00218-6; HUMLER E, 1998, EOS, V79, P878; KEEN MJ, 1990, NATURE, V345, P423, DOI 10.1038/345423a0; KLEIN EM, 1987, J GEOPHYS RES-SOLID, V92, P8089, DOI 10.1029/JB092iB08p08089; Langmuir C.H., 1992, AM GEOPHYS UNION GEO, V71, P183, DOI DOI 10.1029/GM071P0183; LANGMUIR CH, 1993, NATURE, V364, P191, DOI 10.1038/364191a0; LOWMAN JP, 1993, GEOPHYS RES LETT, V20, P25485; MCKENZIE D, 1988, J PETROL, V25, P625; MULLER RD, 1993, GEOLOGY, V21, P275, DOI 10.1130/0091-7613(1993)021<0275:RPMRTT>2.3.CO;2; NIU YL, 1991, J GEOPHYS RES-SOL EA, V96, P21753, DOI 10.1029/91JB01933; OLSON P, 1980, GEOPHYS J ROY ASTR S, V62, P195, DOI 10.1111/j.1365-246X.1980.tb04851.x; SCHILLING JG, 1995, J GEOPHYS RES-SOL EA, V100, P10057, DOI 10.1029/95JB00668; ZHONG SJ, 1993, J GEOPHYS RES-SOL EA, V98, P12219, DOI 10.1029/93JB00193	19	15	16	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 10	2002	419	6907					607	609		10.1038/nature01052	http://dx.doi.org/10.1038/nature01052			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	602AT	12374976				2022-12-28	WOS:000178483100042
J	Bregman, JN				Bregman, JN			The cosmic web of baryons	SCIENCE			English	Editorial Material							ABSORPTION		Univ Michigan, Dept Astron, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Bregman, JN (corresponding author), Univ Michigan, Dept Astron, Ann Arbor, MI 48109 USA.	jbregman@umich.edu		Bregman, Joel/0000-0001-6276-9526				Bregman JN, 2002, ASTROPHYS J, V565, pL13, DOI 10.1086/339244; Cen RY, 1999, ASTROPHYS J, V514, P1, DOI 10.1086/306949; Fang TT, 2002, ASTROPHYS J, V572, pL127, DOI 10.1086/341665; Fukugita M, 1998, ASTROPHYS J, V503, P518, DOI 10.1086/306025; MATHUR S, UNPUB ASTROPHYS J; Nicastro F, 2002, ASTROPHYS J, V573, P157, DOI 10.1086/340489; NICASTRO F, IN PRESS NATURE; Perna R, 1998, ASTROPHYS J, V503, pL135, DOI 10.1086/311544; Savage BD, 2002, ASTROPHYS J, V564, P631, DOI 10.1086/324288; SEMBACH KR, UNPUB ASTROPHYS J S	10	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 4	2002	298	5591					72	73		10.1126/science.1077124	http://dx.doi.org/10.1126/science.1077124			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	600BJ	12364770				2022-12-28	WOS:000178370500029
J	Dobrilovic, N; Wright, CB				Dobrilovic, N; Wright, CB			Massive right atrial thrombus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Jewish Hosp, Cincinnati, OH 45236 USA		Dobrilovic, N (corresponding author), Jewish Hosp, Cincinnati, OH 45236 USA.								0	0	0	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 3	2002	347	14					E4	E4		10.1056/ENEJMicm020016	http://dx.doi.org/10.1056/ENEJMicm020016			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	599KD	12362024				2022-12-28	WOS:000178332900006
J	Leung, WC				Leung, WC			Competency based medical training: review	BRITISH MEDICAL JOURNAL			English	Article									Univ E Anglia, Norwich NR4 7TJ, Norfolk, England	University of East Anglia	Leung, WC (corresponding author), Univ E Anglia, Norwich NR4 7TJ, Norfolk, England.							Angoff W. H., 1971, ED MEASUREMENT; Bahrami J, 2001, BRIT MED J, V323, P581, DOI 10.1136/bmj.323.7312.581; BATES I, 1999, ED FUTURE WORK, V2, P98; *DEP ED, 1986, WORK TOG ED TRAIN; FLEMING D, 1993, COMPETENCE ASSESSMEN, V22, P6; GONCZI A, 1997, AUSTR NZ J VOCATIONA, V5, P77; GRANT G, 1975, COMPETENCE CRITICAL; Hyland T., 1994, COMPETENCE ED NVQS D; Kisely SR, 1997, J PUBLIC HEALTH MED, V19, P11, DOI 10.1093/oxfordjournals.pubmed.a024570; Leung, 2000, BMJ, V321, pS2; Mansfield B., 1989, COMPETENCY BASED ED; Marshall K., 1991, J FURTHER HIGHER ED, V15, P56; Norman G, 2002, BRIT MED J, V324, P748, DOI 10.1136/bmj.324.7340.748; Patterson F, 2000, BRIT J GEN PRACT, V50, P188; Patterson F, 2001, BMJ CAREER FOCUS, V323, pS2; ROTHMAN I, 1996, ACAD MED S, V71, pS1; Searle J, 2000, MED EDUC, V34, P363, DOI 10.1046/j.1365-2923.2000.00690.x; Southgate L, 2001, MED EDUC, V35, P20, DOI 10.1046/j.1365-2923.2001.0350s1020.x; Toohey S., 1995, AUSTR NZ J VOCATIONA, V3, P86; Wolf A., 1991, DEV ASSEMBLE STANDAR, P25; Wolf A., 1995, COMPETENCE BASED ASS; Wood LEP, 2000, BRIT MED J, V320, pS2	22	220	229	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 28	2002	325	7366					693	695		10.1136/bmj.325.7366.693	http://dx.doi.org/10.1136/bmj.325.7366.693			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	600JV	12351364	Green Published, Bronze			2022-12-28	WOS:000178387600028
J	Martin-Lluesma, S; Stucke, VM; Nigg, EA				Martin-Lluesma, S; Stucke, VM; Nigg, EA			Role of Hec1 in spindle checkpoint signaling and kinetochore recruitment of Mad1/Mad2	SCIENCE			English	Article							BUDDING YEAST; MITOTIC CHECKPOINT; MICROTUBULE ATTACHMENT; PROMOTING COMPLEX; MAMMALIAN-CELLS; PROTEIN MAD2; CENP-E; CHROMOSOME; ANAPHASE; CDC20	The spindle checkpoint delays sister chromatid separation until all chromosomes have undergone bipolar spindle attachment. Checkpoint failure may result in chromosome mis-segregation and may contribute to tumorigenesis. We showed that the human protein Hec1 was required for the recruitment of Mps1 kinase and Mad1/Mad2 complexes to kinetochores. Depletion of Hec1 impaired chromosome congression and caused persistent activation of the spindle checkpoint, indicating that high steady-state levels of Mad1/Mad2 complexes at kinetochores were not essential for checkpoint signaling. Simultaneous depletion of Hec1 and Mad2 caused catastrophic mitotic exit, making Hec1 an attractive target for the selective elimination of spindle checkpoint deficient cells.	Max Planck Inst Biochem, Dept Cell Biol, D-82152 Martinsried, Germany	Max Planck Society	Nigg, EA (corresponding author), Max Planck Inst Biochem, Dept Cell Biol, Klopferspitz 18A, D-82152 Martinsried, Germany.		Lluesma, Silvia Martin/P-8307-2019; Martin Lluesma, Silvia Martin/AFK-1632-2022	Lluesma, Silvia Martin/0000-0001-7491-1876; Martin Lluesma, Silvia Martin/0000-0001-7491-1876; nigg, erich/0000-0003-4835-5719				Abrieu A, 2001, CELL, V106, P83, DOI 10.1016/S0092-8674(01)00410-X; Campbell MS, 2001, J CELL SCI, V114, P953; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Chen YM, 1997, MOL CELL BIOL, V17, P6049, DOI 10.1128/MCB.17.10.6049; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; He XW, 2001, CELL, V106, P195, DOI 10.1016/S0092-8674(01)00438-X; Howell BJ, 2000, J CELL BIOL, V150, P1233, DOI 10.1083/jcb.150.6.1233; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Hwang LH, 1998, SCIENCE, V279, P1041, DOI 10.1126/science.279.5353.1041; Janke C, 2001, EMBO J, V20, P777, DOI 10.1093/emboj/20.4.777; Kallio M, 1998, J CELL BIOL, V141, P1393, DOI 10.1083/jcb.141.6.1393; Kapoor TM, 2000, J CELL BIOL, V150, P975, DOI 10.1083/jcb.150.5.975; Kitagawa K, 2001, NAT REV MOL CELL BIO, V2, P678, DOI 10.1038/35089568; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Luo XL, 2002, MOL CELL, V9, P59, DOI 10.1016/S1097-2765(01)00435-X; MARTINLLUESMA S, UNPUB; McEwen BF, 2001, MOL BIOL CELL, V12, P2776, DOI 10.1091/mbc.12.9.2776; MUSACCHIO A, IN PRESS NATURE REV; Nasmyth K, 2000, SCIENCE, V288, P1379, DOI 10.1126/science.288.5470.1379; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; Rieder CL, 1998, TRENDS CELL BIOL, V8, P310, DOI 10.1016/S0962-8924(98)01299-9; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Sironi L, 2001, EMBO J, V20, P6371, DOI 10.1093/emboj/20.22.6371; Skoufias DA, 2001, P NATL ACAD SCI USA, V98, P4492, DOI 10.1073/pnas.081076898; Stucke VM, 2002, EMBO J, V21, P1723, DOI 10.1093/emboj/21.7.1723; STUCKE VM, UNPUB; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Tang ZY, 2001, DEV CELL, V1, P227, DOI 10.1016/S1534-5807(01)00019-3; Taylor SS, 1998, J CELL BIOL, V142, P1, DOI 10.1083/jcb.142.1.1; Waters JC, 1998, J CELL BIOL, V141, P1181, DOI 10.1083/jcb.141.5.1181; Wigge PA, 2001, J CELL BIOL, V152, P349, DOI 10.1083/jcb.152.2.349; Wigge PA, 1998, J CELL BIOL, V141, P967, DOI 10.1083/jcb.141.4.967; Yao XB, 2000, NAT CELL BIOL, V2, P484, DOI 10.1038/35019518	36	358	379	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 27	2002	297	5590					2267	2270		10.1126/science.1075596	http://dx.doi.org/10.1126/science.1075596			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	597LA	12351790				2022-12-28	WOS:000178222000049
J	Shan, L; Molberg, O; Parrot, I; Hausch, F; Filiz, F; Gray, GM; Sollid, LM; Khosla, C				Shan, L; Molberg, O; Parrot, I; Hausch, F; Filiz, F; Gray, GM; Sollid, LM; Khosla, C			Structural basis for gluten intolerance in Celiac sprue	SCIENCE			English	Article							T-CELL EPITOPE; TISSUE TRANSGLUTAMINASE; PEPTIDE BINDING; DISEASE; GLIADIN; IDENTIFICATION	Celiac Sprue, a widely prevalent autoimmune disease of the small intestine, is induced in genetically susceptible individuals by exposure to dietary gluten. A 33-mer peptide was identified that has several characteristics suggesting it is the primary initiator of the inflammatory response to gluten in Celiac Sprue patients. In vitro and in vivo studies in rats and humans demonstrated that it is stable toward breakdown by all gastric, pancreatic, and intestinal brush-border membrane proteases. The peptide reacted with tissue transglutaminase, the major autoantigen in Celiac Sprue, with substantially greater selectivity than known natural substrates of this extracellular enzyme. It was a potent inducer of gut-derived human T cell lines from 14 of 14 Celiac Sprue patients. Homologs of this peptide were found in all food grains that are toxic to Celiac Sprue patients but are absent from all nontoxic food grains. The peptide could be detoxified in in vitro and in vivo assays by exposure to a bacterial prolyl endopeptidase, suggesting a strategy for oral peptidase supplement therapy for Celiac Sprue.	Stanford Univ, Dept Chem Engn, Stanford, CA 94305 USA; Stanford Univ, Dept Med, Stanford, CA 94305 USA; Stanford Univ, Dept Chem, Stanford, CA 94305 USA; Stanford Univ, Dept Biochem, Stanford, CA 94305 USA; Univ Oslo, Rikshosp, Inst Immunol, N-0027 Oslo, Norway	Stanford University; Stanford University; Stanford University; Stanford University; University of Oslo; National Hospital Norway	Khosla, C (corresponding author), Stanford Univ, Dept Chem Engn, Stanford, CA 94305 USA.		Sollid, Ludvig/N-9691-2015; parrot, isabelle/AAS-5546-2020	Sollid, Ludvig/0000-0001-8860-704X; Khosla, Chaitan/0000-0001-6529-495X; Shan, Lu/0000-0003-2334-9216	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK100619] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHNEN DJ, 1983, J BIOL CHEM, V258, P5960; Anderson RP, 2000, NAT MED, V6, P337, DOI 10.1038/73200; Arentz-Hansen EH, 2000, GUT, V46, P46, DOI 10.1136/gut.46.1.46; Arentz-Hansen H, 2000, J EXP MED, V191, P603, DOI 10.1084/jem.191.4.603; Arentz-Hansen H, 2002, GASTROENTEROLOGY, V123, P803, DOI 10.1053/gast.2002.35381; Boniface JJ, 1998, IMMUNITY, V9, P459, DOI 10.1016/S1074-7613(00)80629-9; Bordusa F, 1998, BIOORGAN MED CHEM, V6, P1775, DOI 10.1016/S0968-0896(98)00145-X; CHARLES IG, 1991, EUR J IMMUNOL, V21, P1147, DOI 10.1002/eji.1830210509; Cochran JR, 2000, IMMUNITY, V12, P241, DOI 10.1016/S1074-7613(00)80177-6; Corrao G, 2001, LANCET, V358, P356, DOI 10.1016/S0140-6736(01)05554-4; DARGENIO G, 1988, ENZYME, V39, P227, DOI 10.1159/000469123; DAVIES PJA, 1980, NATURE, V283, P162, DOI 10.1038/283162a0; DICKE W K, 1953, Acta Paediatr, V42, P34, DOI 10.1111/j.1651-2227.1953.tb05563.x; Dieterich W, 1997, NAT MED, V3, P797, DOI 10.1038/nm0797-797; Falk K, 2000, J EXP MED, V191, P717, DOI 10.1084/jem.191.4.717; GRAY GM, 1991, HDB PHYSL, P411; Guipponi M, 2001, HUM GENET, V109, P569, DOI 10.1007/s004390100607; HAUSCH F, IN PRESS AM J PHYSL; Kasson PM, 2000, BIOCHEMISTRY-US, V39, P1048, DOI 10.1021/bi9921337; Maki M, 1997, LANCET, V349, P1755, DOI 10.1016/S0140-6736(96)70237-4; McAdam SN, 2000, GUT, V47, P743, DOI 10.1136/gut.47.6.743; Molberg O, 2001, EUR J IMMUNOL, V31, P1317, DOI 10.1002/1521-4141(200105)31:5<1317::AID-IMMU1317>3.0.CO;2-I; Piper JL, 2002, BIOCHEMISTRY-US, V41, P386, DOI 10.1021/bi011715x; Rudolph MG, 2002, CURR OPIN IMMUNOL, V14, P52, DOI 10.1016/S0952-7915(01)00298-9; Schuppan D, 2000, GASTROENTEROLOGY, V119, P234, DOI 10.1053/gast.2000.8521; SHAN LY, UNPUB; SMITHSON KW, 1977, J CLIN INVEST, V60, P665, DOI 10.1172/JCI108818; Sollid LM, 2000, ANNU REV IMMUNOL, V18, P53, DOI 10.1146/annurev.immunol.18.1.53; SOLLID LM, 1989, J EXP MED, V169, P345, DOI 10.1084/jem.169.1.345; Stienekemeier M, 2001, P NATL ACAD SCI USA, V98, P13872, DOI 10.1073/pnas.241504598; Vader W, 2002, GASTROENTEROLOGY, V122, P1729, DOI 10.1053/gast.2002.33606; WIESER H, 1995, BAILLIERE CLIN GASTR, V9, P191, DOI 10.1016/0950-3528(95)90027-6	32	1119	1207	6	194	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 27	2002	297	5590					2275	2279		10.1126/science.1074129	http://dx.doi.org/10.1126/science.1074129			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	597LA	12351792				2022-12-28	WOS:000178222000051
J	Wenzel, RP				Wenzel, RP			Perspective: Treating sepsis.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Virginia Commonwealth Univ, Richmond, VA 23298 USA	Virginia Commonwealth University	Wenzel, RP (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia Campus, Richmond, VA 23298 USA.								0	90	107	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 26	2002	347	13					966	967		10.1056/NEJMp020096	http://dx.doi.org/10.1056/NEJMp020096			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	596RD	12324551				2022-12-28	WOS:000178178400001
J	Chen, F; Kook, H; Milewski, R; Gitler, AD; Lu, MM; Li, J; Nazarian, R; Schnepp, R; Jen, K; Biben, C; Runke, G; Mackay, JP; Novotny, J; Schwartz, RJ; Harvey, RP; Mullins, MC; Epstein, JA				Chen, F; Kook, H; Milewski, R; Gitler, AD; Lu, MM; Li, J; Nazarian, R; Schnepp, R; Jen, K; Biben, C; Runke, G; Mackay, JP; Novotny, J; Schwartz, RJ; Harvey, RP; Mullins, MC; Epstein, JA			Hop is an unusual homeobox gene that modulates cardiac development	CELL			English	Article							SERUM RESPONSE FACTOR; HOMEODOMAIN-DNA INTERACTIONS; TRANSCRIPTION FACTOR; CRYSTAL-STRUCTURE; TINMAN HOMOLOG; AMINO-ACID; HEART; NKX2-5; EXPRESSION; COMPLEX	Hop is a small, divergent homeodomain protein that lacks certain conserved residues required for DNA binding. Hop gene expression initiates early in cardiogenesis and continues in cardiomyocytes throughout embryonic and postnatal development. Genetic and biochemical data indicate that Hop functions directly downstream of Nkx2-5. Inactivation of Hop in mice by homologous recombination results in a partially penetrant embryonic lethal phenotype with severe developmental cardiac defects involving the myocardium. Inhibition of Hop activity in zebrafish embryos likewise disrupts cardiac development and results in severely impaired cardiac function. Hop physically interacts with serum response factor (SRF) and inhibits activation of SRF-dependent transcription by inhibiting SRF binding to DNA. Hop encodes an unusual homeodomain protein that modulates SRF-dependent cardiac-specific gene expression and cardiac development.	Univ Penn, Hlth Syst, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Hlth Syst, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; Victor Chang Cardiac Res Inst, Darlinghurst, NSW 2010, Australia; Univ New S Wales, Fac Med & Life Sci, Kensington, NSW 2051, Australia; Univ Sydney, Sch Mol & Microbiol Biosci, Sydney, NSW 2006, Australia; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	University of Pennsylvania; University of Pennsylvania; Victor Chang Cardiac Research Institute; University of New South Wales Sydney; University of Sydney; Baylor College of Medicine	Epstein, JA (corresponding author), Univ Penn, Hlth Syst, Dept Med, Philadelphia, PA 19104 USA.	epsteinj@mail.med.upenn.edu	Jen, Kuang-Yu/AAM-5722-2020; Jen, Kuang-Yu/AAM-5429-2020; Mackay, Joel P/D-6834-2011; Kook, Hyun/AAR-5405-2021	Mackay, Joel P/0000-0001-7508-8033; Kook, Hyun/0000-0002-0740-1806; Harvey, Richard/0000-0002-9950-9792; Jen, Kuang-Yu/0000-0003-2815-5912; Gitler, Aaron/0000-0001-8603-1526	NHLBI NIH HHS [K08 HL04491, HL61475, HL62974] Funding Source: Medline; NIDDK NIH HHS [DK57050, DK59176] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL004491, R01HL062974, R01HL061475] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057050, R01DK059176] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUERBACH R, 1954, J EXP ZOOL, V127, P305, DOI 10.1002/jez.1401270206; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Benson DW, 1999, J CLIN INVEST, V104, P1567, DOI 10.1172/JCI8154; BILLETER M, 1993, J MOL BIOL, V234, P1084, DOI 10.1006/jmbi.1993.1661; Chen CY, 1996, DEV GENET, V19, P119, DOI 10.1002/(SICI)1520-6408(1996)19:2<119::AID-DVG3>3.0.CO;2-C; Chen CY, 1996, MOL CELL BIOL, V16, P6372; CHEN WS, 1995, ONCOL REP, V2, P5; DUBOULE D, 1994, GUIDEBOOK HOMEOBOX G; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; Fu YC, 1998, DEVELOPMENT, V125, P4439; Harvey RP, 1996, DEV BIOL, V178, P203, DOI 10.1006/dbio.1996.0212; JONES DT, 1992, NATURE, V358, P86, DOI 10.1038/358086a0; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; Nadeau JH, 2001, NAT REV GENET, V2, P165, DOI 10.1038/35056009; Nasevicius A, 2000, NAT GENET, V26, P216, DOI 10.1038/79951; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; Ranganayakulu G, 1998, DEVELOPMENT, V125, P3037; Schott JJ, 1998, SCIENCE, V281, P108, DOI 10.1126/science.281.5373.108; SCHULTEMERKER S, 1992, DEVELOPMENT, V116, P1021; Schwartz RJ, 1999, DEVELOPMENT, V126, P4187; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; Shin CH, 2002, CELL, V110, P725, DOI 10.1016/S0092-8674(02)00933-9; SIPPL MJ, 1992, PROTEINS, V13, P258, DOI 10.1002/prot.340130308; Srivastava D, 1997, NAT GENET, V16, P154, DOI 10.1038/ng0697-154; TREISMAN J, 1989, CELL, V59, P553; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4; Wawersik S, 2000, METH MOL B, V137, P87; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; WITTMAN KS, 1968, J EXP ZOOL, V168, P137, DOI 10.1002/jez.1401680202; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5	35	215	227	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 20	2002	110	6					713	723		10.1016/S0092-8674(02)00932-7	http://dx.doi.org/10.1016/S0092-8674(02)00932-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	596TV	12297045	Bronze			2022-12-28	WOS:000178182800007
J	Goss, KH; Risinger, MA; Kordich, JJ; Sanz, MM; Straughen, JE; Slovek, LE; Capobianco, AJ; German, J; Boivin, GP; Groden, J				Goss, KH; Risinger, MA; Kordich, JJ; Sanz, MM; Straughen, JE; Slovek, LE; Capobianco, AJ; German, J; Boivin, GP; Groden, J			Enhanced tumor formation in mice heterozygous for Blm mutation	SCIENCE			English	Article							MULTIPLE INTESTINAL NEOPLASIA; SYNDROME GENE-PRODUCT; BLOOMS-SYNDROME; HELICASE; RECOMBINATION; FREQUENCY; ADENOMAS; MIN	Persons with the autosomal recessive disorder Bloom syndrome are predisposed to cancers of many types due to loss-of-function mutations in the BLM gene, which encodes a recQ-like helicase. Here we show that mice heterozygous for a targeted null mutation of Blm, the murine homolog of BLM, develop lymphoma earlier than wild-type littermates in response to challenge with murine leukemia virus and develop twice the number of intestinal tumors when crossed with mice carrying a mutation in the Apc tumor suppressor. These observations indicate that Blm is a modi er of tumor formation in the mouse and that Blm haploinsufficiency is associated with tumor predisposition, a finding with important implications for cancer risk in humans.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Howard Hughes Med Inst, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA; Cornell Univ, Weill Med Coll, Dept Pediat, New York, NY 10021 USA	University System of Ohio; University of Cincinnati; Howard Hughes Medical Institute; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Cornell University	Groden, J (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	Joanna.Groden@uc.edu		Capobianco, Anthony/0000-0002-3706-6797; Goss, Kathleen/0000-0002-7379-5639	NCI NIH HHS [CA63507, CA88460, CA84291] Funding Source: Medline; NIEHS NIH HHS [ES06096] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA088460, R29CA063507, U01CA084291, R01CA063507] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bahr A, 1998, ONCOGENE, V17, P2565, DOI 10.1038/sj.onc.1202389; Chester N, 1998, GENE DEV, V12, P3382, DOI 10.1101/gad.12.21.3382; Ellis NA, 1999, AM J HUM GENET, V65, P1368, DOI 10.1086/302616; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; German J, 1996, CLIN GENET, V49, P223; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; GERMAN J, 1977, AM J HUM GENET, V29, P248; GRODEN J, 1992, HUM GENET, V90, P360; GRODEN J, 1990, P NATL ACAD SCI USA, V87, P4315, DOI 10.1073/pnas.87.11.4315; GRODEN J, UNPUB; Gruber SB, 2002, SCIENCE, V297, P2013, DOI 10.1126/science.1074399; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Langland G, 2002, CANCER RES, V62, P2766; LEVY DB, 1994, CANCER RES, V54, P5953; Li L, 1998, MOL GENET METAB, V64, P286, DOI 10.1006/mgme.1998.2733; Lowy AM, 2001, GASTROENTEROLOGY, V121, P435, DOI 10.1053/gast.2001.26259; Luo GB, 2000, NAT GENET, V26, P424, DOI 10.1038/82548; LUONGO C, 1993, GENOMICS, V15, P3, DOI 10.1006/geno.1993.1002; LUONGO C, 1994, CANCER RES, V54, P5947; MARTIN RH, 1994, AM J HUM GENET, V55, P1242; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; ROSIN MP, 1985, HUM GENET, V71, P187, DOI 10.1007/BF00284570; SANZ MM, UNPUB; Shahrabani-Gargir L, 1998, GENET TEST, V2, P293, DOI 10.1089/gte.1998.2.293; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Sun H, 1998, J BIOL CHEM, V273, P27587, DOI 10.1074/jbc.273.42.27587; Wilson CL, 1997, P NATL ACAD SCI USA, V94, P1402, DOI 10.1073/pnas.94.4.1402; Wu L, 2000, J BIOL CHEM, V275, P9636, DOI 10.1074/jbc.275.13.9636	28	164	169	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 20	2002	297	5589					2051	2053		10.1126/science.1074340	http://dx.doi.org/10.1126/science.1074340			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	594XV	12242442				2022-12-28	WOS:000178078500046
J	Hunt, JF; Weinkauf, S; Henry, L; Fak, JJ; McNicholas, P; Oliver, DB; Deisenhofer, J				Hunt, JF; Weinkauf, S; Henry, L; Fak, JJ; McNicholas, P; Oliver, DB; Deisenhofer, J			Nucleotide control of interdomain interactions in the conformational reaction cycle of SecA	SCIENCE			English	Article							ESCHERICHIA-COLI SECA; TRANSLOCASE SUBUNIT SECA; ELECTRON-DENSITY MAPS; DISTINCT ATP-BINDING; INITIATION-FACTOR 4A; BOX RNA HELICASE; CRYSTAL-STRUCTURE; PROTEIN TRANSLOCATION; PREPROTEIN TRANSLOCASE; BACILLUS-SUBTILIS	The SecA adenosine triphosphatase (ATPase) mediates extrusion of the amino termini of secreted proteins from the eubacterial cytosol based on cycles of reversible binding to the SecYEG translocon. We have determined the crystal structure of SecA with and without magnesium adenosine diphosphate bound to the high-affinity ATPase site at 3.0 and 2.7 angstrom resolution, respectively. Candidate sites for preprotein binding are located on a surface containing the SecA epitopes exposed to the periplasm upon binding to SecYEG and are thus positioned to deliver preprotein to SecYEG. Comparisons with structurally related ATPases, including superfamily I and II ATP-dependent helicases, suggest that the interaction geometry of the tandem motor domains in SecA is modulated by nucleotide binding, which is shown by fluorescence anisotropy experiments to reverse an endothermic domain-dissociation reaction hypothesized to gate binding to SecYEG.	Columbia Univ, Dept Biol Sci, Fairchild Ctr 702A, New York, NY 10027 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Tech Univ Munich, Dept Chem, D-85748 Garching, Germany; Wesleyan Univ, Dept Biochem & Mol Biol, Middletown, CT 06459 USA	Columbia University; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Technical University of Munich; Wesleyan University	Hunt, JF (corresponding author), Columbia Univ, Dept Biol Sci, Fairchild Ctr 702A, MC2434, New York, NY 10027 USA.		Weinkauf, Sevil/C-1415-2010					ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; BAUD C, 2002, J BIOL CHEM; BREUKINK E, 1995, J BIOL CHEM, V270, P7902, DOI 10.1074/jbc.270.14.7902; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; CARTUTHERS JM, 2002, CURR OPIN STRUC BIOL, V12, P123; Caruthers JM, 2000, P NATL ACAD SCI USA, V97, P13080, DOI 10.1073/pnas.97.24.13080; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980; Dapic V, 2000, J BIOL CHEM, V275, P25000, DOI 10.1074/jbc.M001100200; de la Cruz J, 1999, TRENDS BIOCHEM SCI, V24, P192, DOI 10.1016/S0968-0004(99)01376-6; den Blaauwen T, 1999, FEBS LETT, V458, P145, DOI 10.1016/S0014-5793(99)01139-4; denBlaauwen T, 1996, BIOCHEMISTRY-US, V35, P11994, DOI 10.1021/bi9605088; Ding HY, 2001, BIOCHEMISTRY-US, V40, P1835, DOI 10.1021/bi002058w; Drenth J, 1994, PRINCIPLES PROTEIN X; Driessen AJM, 2001, NAT STRUCT BIOL, V8, P492, DOI 10.1038/88549; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; Eichler J, 1997, P NATL ACAD SCI USA, V94, P5574, DOI 10.1073/pnas.94.11.5574; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; FAK JJ, UNPUB; Fekkes P, 1999, BIOCHEMISTRY-US, V38, P5111, DOI 10.1021/bi982818r; Fekkes P, 1997, EMBO J, V16, P6105, DOI 10.1093/emboj/16.20.6105; FIKES JD, 1989, J BACTERIOL, V171, P402, DOI 10.1128/jb.171.1.402-409.1989; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; HUIE JL, 1995, J BACTERIOL, V177, P3518, DOI 10.1128/jb.177.12.3518-3526.1995; HUNT JD, UNPUB; Johnson ER, 1999, RNA, V5, P1526, DOI 10.1017/S1355838299991410; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Karamanou S, 1999, MOL MICROBIOL, V34, P1133, DOI 10.1046/j.1365-2958.1999.01686.x; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; KIMURA E, 1991, J BIOL CHEM, V266, P6600; Kleywegt GJ, 1999, ACTA CRYSTALLOGR D, V55, P941, DOI 10.1107/S0907444999001031; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; KOONIN EV, 1992, FEBS LETT, V298, P6, DOI 10.1016/0014-5793(92)80009-6; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; Machius M, 1999, P NATL ACAD SCI USA, V96, P11717, DOI 10.1073/pnas.96.21.11717; Matsumoto G, 2000, GENES CELLS, V5, P991, DOI 10.1046/j.1365-2443.2000.00388.x; Menz RI, 2001, CELL, V106, P331, DOI 10.1016/S0092-8674(01)00452-4; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MITCHELL C, 1993, MOL MICROBIOL, V10, P483, DOI 10.1111/j.1365-2958.1993.tb00921.x; Nakatogawa H, 2001, MOL CELL, V7, P185, DOI 10.1016/S1097-2765(01)00166-6; Nishiyama KI, 1996, CELL, V85, P71, DOI 10.1016/S0092-8674(00)81083-1; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RAJAPANDI T, 1994, BIOCHEM BIOPH RES CO, V200, P1477, DOI 10.1006/bbrc.1994.1617; Rajapandi T, 1996, MOL MICROBIOL, V20, P43, DOI 10.1111/j.1365-2958.1996.tb02487.x; Ramamurthy V, 1998, J BACTERIOL, V180, P6419; Ramamurthy V, 1997, J BIOL CHEM, V272, P23239, DOI 10.1074/jbc.272.37.23239; Salavati R, 1997, J MOL BIOL, V265, P142, DOI 10.1006/jmbi.1996.0724; Sawaya MR, 1999, CELL, V99, P167, DOI 10.1016/S0092-8674(00)81648-7; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; Schmidt M, 2000, J BIOL CHEM, V275, P15440, DOI 10.1074/jbc.M000605200; Shilton B, 1998, FEBS LETT, V436, P277, DOI 10.1016/S0014-5793(98)01141-7; Shirakihara Y, 1997, STRUCTURE, V5, P825, DOI 10.1016/S0969-2126(97)00236-0; Sianidis G, 2001, EMBO J, V20, P961, DOI 10.1093/emboj/20.5.961; Singleton MR, 2002, J BACTERIOL, V184, P1819, DOI 10.1128/JB.184.7.1819-1826.2002; Snyders S, 1997, J BIOL CHEM, V272, P11302; Song M, 1997, J BIOCHEM-TOKYO, V122, P1010; Story RM, 2001, P NATL ACAD SCI USA, V98, P1465, DOI 10.1073/pnas.98.4.1465; Triplett TL, 2001, J BIOL CHEM, V276, P19648, DOI 10.1074/jbc.M100098200; ULBRANDT ND, 1992, J BIOL CHEM, V267, P15184; van der Does C, 1998, BIOCHEMISTRY-US, V37, P201, DOI 10.1021/bi972105t; van der Wolk JPW, 1997, EMBO J, V16, P7297, DOI 10.1093/emboj/16.24.7297; van Voorst F, 2000, FEBS LETT, V486, P57, DOI 10.1016/S0014-5793(00)02209-2; vanderDoes C, 1996, MOL MICROBIOL, V22, P619, DOI 10.1046/j.1365-2958.1996.d01-1712.x; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Weinkauf S, 2001, ACTA CRYSTALLOGR D, V57, P559, DOI 10.1107/S0907444901001202; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; Woodbury RL, 2002, PROTEIN SCI, V11, P875, DOI 10.1110/ps.4090102	78	234	237	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 20	2002	297	5589					2018	2026		10.1126/science.1074424	http://dx.doi.org/10.1126/science.1074424			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	594XV	12242434				2022-12-28	WOS:000178078500037
J	McLeish, T				McLeish, T			Polymers without beginning or end	SCIENCE			English	Editorial Material							RING POLYMERS		Univ Leeds, Dept Phys & Astron, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	McLeish, T (corresponding author), Univ Leeds, Dept Phys & Astron, Leeds LS2 9JT, W Yorkshire, England.			McLeish, Tom/0000-0002-2025-0299				Bielawski CW, 2002, SCIENCE, V297, P2041, DOI 10.1126/science.1075401; Brown S, 2001, PHYS REV E, V63, DOI 10.1103/PhysRevE.63.052801; CATES ME, 1986, J PHYS-PARIS, V47, P2121, DOI 10.1051/jphys:0198600470120212100; Doi M., 1988, THEORY POLYM DYNAMIC; Eliot T.S, 1969, COMPLETE POEMS PLAYS; Obhukov S. P., 1994, PHYS REV LETT, V73, P1263; ROOVERS J, 1988, MACROMOLECULES, V21, P1517, DOI 10.1021/ma00183a049	7	136	138	0	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 20	2002	297	5589					2005	2006		10.1126/science.1076810	http://dx.doi.org/10.1126/science.1076810			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	594XV	12242428				2022-12-28	WOS:000178078500031
J	Mann, JI				Mann, JI			Diet and risk of coronary heart disease and type 2 diabetes	LANCET			English	Review							IMPAIRED GLUCOSE-TOLERANCE; LIFE-STYLE CHANGES; INSULIN SENSITIVITY; FOLIC-ACID; VITAMIN-E; PREVENTION; FAT; MELLITUS; FIBER; INTERVENTION	A high intake of saturated fat is an important risk factor for coronary heart disease (CHD) and type 2 diabetes. However the declining rates of CHD in many affluent societies and the steady increase in type 2 diabetes worldwide suggest that these important causes of serious morbidity and premature mortality have differing risk or protective factors worldwide. Changed macronutrient composition, reduced cigarette smoking, and improved treatment of risk factors and acute cardiac events might explain the reduction in risk of CHD, whereas the increasing rates of obesity are probably the most important explanation for the increase in diabetes. Coronary risk factors associated with diabetes could outweigh improvements in conventional cardiovascular risk factors such that the decline in CHD could be stopped or reversed unless rates of obesity can be reduced. Reduced intake of saturated fatty acids and other lifestyle interventions aimed at lowering rates of obesity are the changes most likely to reduce the epidemic numbers of people with type 2 diabetes and CHD.	Univ Otago, Dept Human Nutr, Dunedin, New Zealand; Univ Otago, Dept Med, Dunedin, New Zealand	University of Otago; University of Otago	Mann, JI (corresponding author), Univ Otago, Dept Human Nutr, POB 56, Dunedin, New Zealand.	jim.mann@stonebow.otago.ac.nz						American Diabetes Association, 1999, DIABETES CARE, V22, pS1; BOBAK M, 1995, HLTH CHALLENGES COUN, P8; Brattstrom L, 1998, BMJ-BRIT MED J, V316, P894, DOI 10.1136/bmj.316.7135.894; BURR ML, 1989, LANCET, V2, P757; Clarke P, 2001, DIABETOLOGIA, V44, P298, DOI 10.1007/s001250051617; Connor WE, 1997, NEW ENGL J MED, V337, P562; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; Devaraj S, 2000, CIRCULATION, V102, P191, DOI 10.1161/01.CIR.102.2.191; GRAY RP, 1997, TXB DIABETES; HJERMANN I, 1981, LANCET, V2, P1303; Hooper L, 2001, BMJ-BRIT MED J, V322, P757, DOI 10.1136/bmj.322.7289.757; Hu FB, 2000, NEW ENGL J MED, V343, P530, DOI 10.1056/NEJM200008243430802; Jacques PF, 1999, NEW ENGL J MED, V340, P1449, DOI 10.1056/NEJM199905133401901; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; King H, 1998, DIABETES CARE, V21, P1414, DOI 10.2337/diacare.21.9.1414; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Kushi LH, 1996, NEW ENGL J MED, V334, P1156, DOI 10.1056/NEJM199605023341803; LEWIS B, 1986, LANCET, V1, P956; Macaulay AC, 1997, PREV MED, V26, P779, DOI 10.1006/pmed.1997.0241; Malinow MR, 1998, NEW ENGL J MED, V338, P1009, DOI 10.1056/NEJM199804093381501; Mann J, 2000, LANCET, V356, P1454, DOI 10.1016/S0140-6736(00)02862-2; Mann J, 2001, EUR J CLIN NUTR, V55, P919, DOI 10.1038/sj.ejcn.1601258; MANN J, 2002, ESSENTIALS HUMAN NUT, P299; Mann JI, 2000, EUR J CLIN NUTR, V54, P353, DOI 10.1038/sj.ejcn.1600962; MANN JI, 1979, BMJ-BRIT MED J, V1, P732, DOI 10.1136/bmj.1.6165.732; MANN JI, 1980, DIABETOLOGIA, V18, P89, DOI 10.1007/BF00290483; MANSON JE, 1991, LANCET, V338, P774, DOI 10.1016/0140-6736(91)90664-B; McAuley KA, 2001, DIABETES CARE, V24, P460, DOI 10.2337/diacare.24.3.460; McAuley KA, 2002, DIABETES CARE, V25, P445, DOI 10.2337/diacare.25.3.445; MCMICHAEL J, 1979, BMJ-BRIT MED J, V1, P173, DOI 10.1136/bmj.1.6157.173; Narayan KMV, 2001, BMJ-BRIT MED J, V323, P63, DOI 10.1136/bmj.323.7304.63; Pan XR, 1997, DIABETES CARE, V20, P537, DOI 10.2337/diacare.20.4.537; PEDERSEN TR, 1994, LANCET, V344, P1383; Riddell LJ, 2000, AM J CLIN NUTR, V71, P1448; Ridker PM, 2001, LANCET, V358, P946, DOI 10.1016/S0140-6736(01)06112-8; Rowley KG, 2000, DIABETES CARE, V23, P898, DOI 10.2337/diacare.23.7.898; Rustin P, 1999, LANCET, V354, P477, DOI 10.1016/S0140-6736(99)01341-0; Salmeron J, 1997, JAMA-J AM MED ASSOC, V277, P472, DOI 10.1001/jama.277.6.472; Schnyder G, 2001, NEW ENGL J MED, V345, P1593, DOI 10.1056/NEJMoa011364; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; Storlien LH, 1996, DIABETOLOGIA, V39, P621, DOI 10.1007/BF00418533; Truswell AS, 2001, LANCET, V357, P1061, DOI 10.1016/S0140-6736(00)04308-7; Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801; *UK DEP HLTH, 1994, 46 UK DEP HLTH CARD; *UK DEP HLTH SOC S, 1984, 28 UK DEP HLTH SOC S; VENN BJ, 2002, IN PRESS AM J CLIN N; Vessby B, 2001, DIABETOLOGIA, V44, P312, DOI 10.1007/s001250051620; Wallace AJ, 2000, ATHEROSCLEROSIS, V152, P327, DOI 10.1016/S0021-9150(99)00490-6; World Health Organization,, 1998, WHO TECHN REP SER; YUDKIN J, 1969, BRIT MED J, V4, P110, DOI 10.1136/bmj.4.5675.110-b; Yusuf S, 2000, NEW ENGL J MED, V342, P154, DOI 10.1056/NEJM200001203420302	52	174	185	0	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 7	2002	360	9335					783	789		10.1016/S0140-6736(02)09901-4	http://dx.doi.org/10.1016/S0140-6736(02)09901-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	592HX	12241840				2022-12-28	WOS:000177933000023
J	Ansari, A				Ansari, A			Primary alidosteronism	LANCET			English	Editorial Material									Abbott NW Hosp, Dept Cardiovasc Med, Minneapolis, MN 55407 USA		Ansari, A (corresponding author), Abbott NW Hosp, Dept Cardiovasc Med, Minneapolis, MN 55407 USA.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 24	2002	360	9333					617	617		10.1016/S0140-6736(02)09785-4	http://dx.doi.org/10.1016/S0140-6736(02)09785-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	586TD	12241934				2022-12-28	WOS:000177600400012
J	Karanja, DMS; Hightower, AW; Colley, DG; Mwinzi, PNM; Galil, K; Andove, J; Secor, WE				Karanja, DMS; Hightower, AW; Colley, DG; Mwinzi, PNM; Galil, K; Andove, J; Secor, WE			Resistance to reinfection with Schistosoma mansoni in occupationally exposed adults and effect of HIV-1 co-infection on susceptibility to schistosomiasis: a longitudinal study	LANCET			English	Article							IMMUNE-RESPONSES; WESTERN KENYA; INDIVIDUALS; HAEMATOBIUM; CHEMOTHERAPY; VACCINES; IGG4; VIEW; AGE; IGE	Background Previous studies have reported age-dependent development of resistance to reinfection by schistosomes and identified immunological correlates of this resistance. However, whether resistance exists that is independent of age effects has been questioned. We did a longitudinal investigation of reinfection by Schistosoma mansoni in an adult population with high occupational exposure. Methods We monitored a cohort of 96 male car washers working along the shores of Lake Victoria, Kenya during 349.7 person-years for frequency of water contact and infection with S mansoni. Patients were treated with praziquantel upon study entry and after reinfection with S mansoni. Bivariate analyses and a multivariate proportional hazards model were used to assess the effects of water contact, previous infections, and HIV-1 on S mansoni reinfection rates. Findings 13 car washers did not get reinfected or only became reinfected after an extended time (91 weeks). 47 initially had a short time to reinfection (15 weeks) but on subsequent treatments showed increased time to reinfection (29-38 weeks). 36 consistently displayed short times to reinfection (<15 weeks) despite multiple reinfection and treatment cycles. Decreased CD4 T-cell counts in HIV-1-positive individuals corresponded to increased susceptibility to S mansoni reinfection. Interpretation Adults similarly exposed to schistosomiasis are either resistant to reinfection; susceptible, but develop resistance to reinfection after multiple treatments; or remain susceptible to reinfection. Thus, immunological resistance to reinfection with S mansoni exists or can develop independent of age effects. The consequence of HIV-1 co-infection suggests that CD4 T cells contribute to this resistance.	CDCP, Immunol Branch, Div Parasit Dis,Natl Ctr Infect Dis, US PHS,US Dept HHS, Atlanta, GA 30341 USA; Kenya Govt Med Res Ctr, Ctr Vector Biol & Control Res, Kisumu, Kenya	Centers for Disease Control & Prevention - USA; United States Public Health Service; Kenya Medical Research Institute	Secor, WE (corresponding author), CDCP, Immunol Branch, Div Parasit Dis,Natl Ctr Infect Dis, US PHS,US Dept HHS, 4770 Buford Hihway NE,MS-F13, Atlanta, GA 30341 USA.				FIC NIH HHS [D43 TW007123] Funding Source: Medline; NIAID NIH HHS [R01 AI053695] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [D43TW007123] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI053695] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABEL L, 1991, AM J HUM GENET, V51, P206; BENSTEDSMITH R, 1987, T ROY SOC TROP MED H, V81, P651, DOI 10.1016/0035-9203(87)90442-1; BUTTERWORTH AE, 1985, T ROY SOC TROP MED H, V79, P393, DOI 10.1016/0035-9203(85)90391-8; Fulford AJC, 1998, PARASITOL TODAY, V14, P23, DOI 10.1016/S0169-4758(97)01168-X; Grogan JL, 1997, J INFECT DIS, V176, P1344, DOI 10.1086/514131; Gryseels B, 2000, PARASITOL TODAY, V16, P46, DOI 10.1016/S0169-4758(99)01597-5; Hagan P, 2000, PARASITOL TODAY, V16, P322, DOI 10.1016/S0169-4758(00)01711-7; HAGAN P, 1991, NATURE, V349, P243, DOI 10.1038/349243a0; Karanja DHS, 1998, AM J TROP MED HYG, V59, P307, DOI 10.4269/ajtmh.1998.59.307; Karanja DMS, 1997, AM J TROP MED HYG, V56, P515, DOI 10.4269/ajtmh.1997.56.515; Lawn SD, 2000, AIDS, V14, P2437, DOI 10.1097/00002030-200011100-00004; Medhat A, 1998, J INFECT DIS, V178, P512, DOI 10.1086/515630; Mutapi F, 1998, J INFECT DIS, V178, P289, DOI 10.1086/517456; Mwinzi PNM, 2001, J INFECT DIS, V184, P488, DOI 10.1086/322783; ROBERTS M, 1993, INFECT IMMUN, V61, P4984, DOI 10.1128/IAI.61.12.4984-4993.1993; WARREN KS, 1973, J INFECT DIS, V127, P595, DOI 10.1093/infdis/127.5.595; Woolhouse MEJ, 1999, NAT MED, V5, P1225, DOI 10.1038/15169	18	110	111	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 24	2002	360	9333					592	596		10.1016/S0140-6736(02)09781-7	http://dx.doi.org/10.1016/S0140-6736(02)09781-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	586TD	12241930				2022-12-28	WOS:000177600400008
J	von Schirnding, Y				von Schirnding, Y			Health and sustainable development: can we rise to the challenge?	LANCET			English	Article							GLOBALIZATION	The forthcoming World Summit on Sustainable Development is an unprecedented opportunity to place health higher on the environmental and development agenda. The world's leaders will be grappling with some of the major challenges of our times-how to eradicate poverty and meet the world's development needs In a way that does not destroy the environment. Topping the agenda are water, energy, health, agriculture, and biodiversity. Improvement of access of the world's poor people to clean water, sanitation, and safe sources of household energy would have a huge effect on the main killers of young children-pneumonia and diarrhoea. Similarly, improved environmental management could substantially affect many infectious disease outcomes. At the same time, the growing epidemic of non-communicable diseases could be reversed if people's consumption patterns and lifestyles could be put on a more sustainable and healthy footing. A shared health, environmental, and development agenda could address the large share of the burden of disease that is environmentally related, and vice versa. The health sector Increasingly needs to work in partnership with others rather than work alone. New tools are needed to ensure that intersectoral action becomes embedded in the way that the health sector does business. Improving coordination might be one of the most important ways in which we can help put the planet back on a healthy and sustainable path.	WHO, CH-1211 Geneva, Switzerland	World Health Organization	von Schirnding, Y (corresponding author), WHO, CH-1211 Geneva, Switzerland.	vonschirndingy@who.int						ANNAN K, 2002, SUSTAINABLE FUTURE; BRUNDTLAND GH, 2001, WHO REG COMM AM 53 S; BRUNDTLAND GH, 2001, HRH PRINC WAL BUS EN; BRUNDTLAND GH, 2000, SUMM ROLL BACK MAL A; BRUNDTLAND GH, 2002, 55 WORLD HLTH ASS GE; DIALLO D, 2002, CHOICES MAGAZINE, V12, P2; DOBSON A, 1997, BIODIVERSITY HUMAN H, P87; Gallup JL, 2001, AM J TROP MED HYG, V64, P85, DOI 10.4269/ajtmh.2001.64.85; GARRET L, 1998, MED J AUSTRALIA, V168, P568; Gordon L J, 1992, J Public Health Policy, V13, P407, DOI 10.2307/3342530; MCGRANAHAN G, 1999, ENV CHANGE HUMAN HLT; McMichael AJ, 2001, J ROY SOC MED, V94, P111, DOI 10.1177/014107680109400303; McMichael AJ, 2000, B WORLD HEALTH ORGAN, V78, P1117; Smith KR, 2000, THORAX, V55, P518, DOI 10.1136/thorax.55.6.518; Tong S, 2000, B WORLD HEALTH ORGAN, V78, P1068; *UN, 2002, JOH SUMM 2002 PREP P; *UN, 2002, C ENV DEV RIO DE JAN; UN, 1972, C HUM ENV; *UN, 2000, MILL ASS 55 SESS NEW; *UN, 2002, UN INT C FIN DEV MON; *UNAIDS, 2001, REP GLOB HIV AIDS EP; United Nations, 2002, WORLD SUMMIT SUSTAIN; United Nations department of economic and social affairs, 2001, WORLD POP PROSP 2000; VONSCHINDING YE, 2001, SUSTAINABLE DEV INT, V3, P171; VONSCHINDING YE, 2002, ADDRESSING IMPACT HO; VONSCHIRNDING Y, 1991, ENVIRON HEALTH PERSP, V94, P125, DOI 10.2307/3431305; VONSCHIRNDING Y, 1997, ECOSYST HEALTH, V3, P220; VONSCHIRNDING YE, 2000, CITY DEV STRATEGIES, P2; *VONSCHIRNDING YE, 1997, INTERSECTORAL ACTION; Watson R.T., 2001, CLIMATE CHANGE 2001, P388; *WHO, 2002, WHO M MAK HLTH CENTR; *WHO, 2002, WHO M OSL NOV 29 DEC; *WHO, 2002, WHO M LOND MAY 21 22; WHO, 2001, MACR HLTH INV HLTH D; *WHO, 2002, HLTH SUST DEV M SEN; *WHO, 1999, CORP STRAT WHO SECR; *WHO, 2000, GLOB POL ER PROGR; *WHO UNICEF JOINT, 2000, GLOB WAT SUPPL SAN A; [WHO] World Health Organization, 1997, HLTH ENV SUST DEV 5; WHO - World Health Organization, 2002, HLTH SUST DEV KEY HL; *WORLD BANK IMF, 2002, REV POV RED STRAT PA; World Commission on Environment and Development, 1987, OUR COMMON FUTURE; *WORLD EN COUNC, 2001, ANN REP 2001; World Health Organization, 2002, JOH DECL HLTH SUST D; World Health Organization, 1994, 2 EUR C ENV HLTH HEL; *WORLD RES I UNEP, 1998, 1998 99 WORLD RES GU; *WORLD TRAD ORG, 2001, WORLD TRAD ORG 4 MIN; Yach D, 2000, TOB CONTROL, V9, P206, DOI 10.1136/tc.9.2.206; [No title captured]	49	42	42	1	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 24	2002	360	9333					632	637		10.1016/S0140-6736(02)09777-5	http://dx.doi.org/10.1016/S0140-6736(02)09777-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	586TD	12241950				2022-12-28	WOS:000177600400027
J	Wake, M; Hesketh, K				Wake, M; Hesketh, K			Teething symptoms: cross sectional survey of five groups of child health professionals	BRITISH MEDICAL JOURNAL			English	Article							INFANT		Royal Childrens Hosp, Ctr Community Child Hlth, Parkville, Vic 3052, Australia	Royal Children's Hospital Melbourne	Wake, M (corresponding author), Royal Childrens Hosp, Ctr Community Child Hlth, Flemington Rd, Parkville, Vic 3052, Australia.		Wake, Melissa/J-1396-2012; Hesketh, Kylie/B-7031-2013	Wake, Melissa/0000-0001-7501-9257; Hesketh, Kylie/0000-0002-2702-7110				COREIL J, 1995, CLIN PEDIATR, V34, P591, DOI 10.1177/000992289503401104; Macknin ML, 2000, PEDIATRICS, V105, P747, DOI 10.1542/peds.105.4.747; Wake M, 2000, PEDIATRICS, V106, P1374, DOI 10.1542/peds.106.6.1374; Wake M, 1999, J PAEDIATR CHILD H, V35, P446, DOI 10.1046/j.1440-1754.1999.355395.x; 1975, BMJ, V4, P604	5	23	24	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 12	2002	325	7368					814	814		10.1136/bmj.325.7368.814	http://dx.doi.org/10.1136/bmj.325.7368.814			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604YM	12376443	Bronze, Green Published			2022-12-28	WOS:000178648700020
J	Orrit, M				Orrit, M			Molecular entanglements	SCIENCE			English	Editorial Material							QUANTUM CRYPTOGRAPHY; MAGNETIC-RESONANCE; SINGLE PHOTONS		Leiden Univ, Huygens Lab, NL-2300 CA Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC	Orrit, M (corresponding author), Leiden Univ, Huygens Lab, Niels Bohrweg 2,POB 9504, NL-2300 CA Leiden, Netherlands.							Benjamin S, 2000, SCIENCE, V290, P2273, DOI 10.1126/science.290.5500.2273; BENNETT CH, 1993, PHYS REV LETT, V70, P1895, DOI 10.1103/PhysRevLett.70.1895; BENNETT CH, 1992, SCI AM, V267, P50, DOI 10.1038/scientificamerican1092-50; Brunel C, 1999, PHYS REV LETT, V83, P2722, DOI 10.1103/PhysRevLett.83.2722; Hettich C, 2002, SCIENCE, V298, P385, DOI 10.1126/science.1075606; Moerner WE, 1999, SCIENCE, V283, P1670, DOI 10.1126/science.283.5408.1670; Steane A, 1998, REP PROG PHYS, V61, P117, DOI 10.1088/0034-4885/61/2/002; Vandersypen LMK, 2001, NATURE, V414, P883, DOI 10.1038/414883a; VARADA GV, 1992, PHYS REV A, V45, P6721, DOI 10.1103/PhysRevA.45.6721; Wrachtrup J, 1997, CHEM PHYS LETT, V267, P179, DOI 10.1016/S0009-2614(97)00073-0	10	8	9	2	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 11	2002	298	5592					369	370		10.1126/science.1077574	http://dx.doi.org/10.1126/science.1077574			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	602NB	12376688				2022-12-28	WOS:000178510400032
J	Cerda, E; Ravi-Chandar, K; Mahadevan, L				Cerda, E; Ravi-Chandar, K; Mahadevan, L			Thin films - Wrinkling of an elastic sheet under tension	NATURE			English	Article									Univ Cambridge, Dept Appl Math & Theoret Phys, Cambridge CB3 9EW, England; Univ Santiago Chile, Dept Fis, Santiago, Chile; Univ Texas, Dept Aerosp Engn & Engn Mech, Austin, TX 78705 USA	University of Cambridge; Universidad de Santiago de Chile; University of Texas System; University of Texas Austin	Cerda, E (corresponding author), Univ Cambridge, Dept Appl Math & Theoret Phys, Silver St, Cambridge CB3 9EW, England.	l.mahadevan@damtp.cam.ac.uk	Ravi-Chandar, Krishnaswamy/D-9246-2011					BENTHEM JP, 1963, Q J MECH APPL MATH, V16, P413, DOI 10.1093/qjmam/16.4.413; HARRIS AK, 1980, SCIENCE, V208, P177, DOI 10.1126/science.6987736; Mansfield E. H., 1968, P 12 INT C THEOR APP; WAGNER HZ, 1929, FLUGTECH MOTORLUFTSC, V20	4	278	293	4	188	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 10	2002	419	6907					579	580		10.1038/419579b	http://dx.doi.org/10.1038/419579b			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	602AT	12374968				2022-12-28	WOS:000178483100032
J	Cowman, AF; Crabb, BS				Cowman, AF; Crabb, BS			The Plasmodium falciparum genome - a blueprint for erythrocyte invasion	SCIENCE			English	Editorial Material							SURFACE PROTEIN-1 COMPLEX; MEROZOITES; GENES; VIVAX; IDENTIFICATION; COMPONENT; HOMOLOG; IMMUNE		PO Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia	Royal Melbourne Hospital; Walter & Eliza Hall Institute	Cowman, AF (corresponding author), PO Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia.		Crabb, Brendan/F-5287-2013; Cowman, Alan F/C-7642-2013	Cowman, Alan F/0000-0001-5145-9004				Adams JH, 2001, TRENDS PARASITOL, V17, P297, DOI 10.1016/S1471-4922(01)01948-1; Barnwell John W., 1998, P93; Black CG, 1999, INFECT IMMUN, V67, P2075, DOI 10.1128/IAI.67.5.2075-2081.1999; Black CG, 2001, MOL BIOCHEM PARASIT, V114, P217, DOI 10.1016/S0166-6851(01)00265-1; BORRE MB, 1991, MOL BIOCHEM PARASIT, V49, P119, DOI 10.1016/0166-6851(91)90135-S; Bowman S, 1999, NATURE, V400, P532, DOI 10.1038/22964; COWMAN AF, 1985, CELL, V40, P775, DOI 10.1016/0092-8674(85)90337-X; DREW DR, UNPUB; Freitas-Junior LH, 2000, NATURE, V407, P1018, DOI 10.1038/35039531; GALINSKI MR, 1992, CELL, V69, P1213, DOI 10.1016/0092-8674(92)90642-P; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Holder AA, 1996, PARASITOL TODAY, V12, P173, DOI 10.1016/0169-4758(96)20009-2; HOLDER AA, 1985, MOL BIOCHEM PARASIT, V14, P293, DOI 10.1016/0166-6851(85)90057-X; Marshall VM, 1998, MOL BIOCHEM PARASIT, V94, P13, DOI 10.1016/S0166-6851(98)00045-0; Mayer DCG, 2001, P NATL ACAD SCI USA, V98, P5222, DOI 10.1073/pnas.081075398; MCCOLL DJ, 1994, MOL BIOCHEM PARASIT, V68, P53, DOI 10.1016/0166-6851(94)00149-9; Miller LH, 2002, NATURE, V415, P673, DOI 10.1038/415673a; MILLER SK, IN PRESS J BIOL CHEM; Mills KE, 2002, MOL MICROBIOL, V43, P1401, DOI 10.1046/j.1365-2958.2002.02834.x; O'Donnell RA, 2001, J EXP MED, V193, P1403, DOI 10.1084/jem.193.12.1403; Pachebat JA, 2001, MOL BIOCHEM PARASIT, V117, P83, DOI 10.1016/S0166-6851(01)00336-X; Rayner JC, 2001, J EXP MED, V194, P1571, DOI 10.1084/jem.194.11.1571; Stafford WHL, 1996, MOL BIOCHEM PARASIT, V80, P159, DOI 10.1016/0166-6851(96)02696-5; Thompson JK, 2001, MOL MICROBIOL, V41, P47, DOI 10.1046/j.1365-2958.2001.02484.x; Triglia T, 2001, INFECT IMMUN, V69, P1084, DOI 10.1128/IAI.69.2.1084-1092.2001; Trucco C, 2001, MOL BIOCHEM PARASIT, V112, P91, DOI 10.1016/S0166-6851(00)00350-9	26	23	24	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 4	2002	298	5591					126	128		10.1126/science.1078169	http://dx.doi.org/10.1126/science.1078169			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	600BJ	12364790				2022-12-28	WOS:000178370500047
J	Riehle, MA; Garczynski, SF; Crim, JW; Hill, CA; Brown, MR				Riehle, MA; Garczynski, SF; Crim, JW; Hill, CA; Brown, MR			Neuropeptides and peptide hormones in Anopheles gambiae	SCIENCE			English	Article							AEDES-AEGYPTI; MOSQUITO; IDENTIFICATION; INSULIN; CDNA; ACTIVATION; MECHANISMS; EXPRESSION; RECEPTOR; DIPTERA	The African malaria mosquito, Anopheles gambiae, is specialized for rapid completion of development and reproduction. A vertebrate blood meal is required for egg production, and multiple feedings subsequently allow transmission of malaria parasites, Plasmodium spp. Regulatory peptides from 35 genes annotated from the A. gambiae genome likely coordinate these and other physiological processes. Plasmodium parasites may affect actions of newly identified insulin-like peptides, which coordinate growth and reproduction of its vector, A. gambiae, as in Drosophila melanogaster, Caenorhabditis elegans, and mammals. This genomic information provides a basis to expand understanding of hematophagy and pathogen transmission in this mosquito.	Univ Georgia, Dept Entomol, Athens, GA 30602 USA; Univ Georgia, Dept Cellular Biol, Athens, GA 30602 USA; Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; University of Notre Dame	Brown, MR (corresponding author), Univ Georgia, Dept Entomol, Athens, GA 30602 USA.	mbrown@bugs.ent.uga.edu	Crim, Joe/GWC-6878-2022; Riehle, Michael A/O-2852-2017	Riehle, Michael/0000-0001-9747-3872	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033108, U01AI050687, U01AI048846] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI033108, AI33108, U01 AI48846, U01 AI50687] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEIER MS, 1994, J MED ENTOMOL, V31, P561, DOI 10.1093/jmedent/31.4.561; Bertenshaw GP, 2001, J BIOL CHEM, V276, P13248, DOI 10.1074/jbc.M011414200; BROWN MA, UNPUB; Brown MR, 1998, J BIOL CHEM, V273, P3967, DOI 10.1074/jbc.273.7.3967; BROWN MR, 2001, J INSECT SCI; Claeys I, 2002, PEPTIDES, V23, P807, DOI 10.1016/S0196-9781(01)00666-0; Clark TM, 1998, AM J PHYSIOL-RENAL, V274, pF834, DOI 10.1152/ajprenal.1998.274.5.F834; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Garczynski SF, 2002, PEPTIDES, V23, P773, DOI 10.1016/S0196-9781(01)00647-7; Hill CA, 2002, SCIENCE, V298, P176, DOI 10.1126/science.1076196; Hopwood JA, 2001, J EXP BIOL, V204, P2773; Horodyski FM, 1996, J INSECT PHYSIOL, V42, P917, DOI 10.1016/0022-1910(96)00035-2; JENKINS SP, 1992, INSECT BIOCHEM MOLEC, V22, P553, DOI 10.1016/0965-1748(92)90032-A; Klowden MJ, 1997, ARCH INSECT BIOCHEM, V35, P491, DOI 10.1002/(SICI)1520-6327(1997)35:4<491::AID-ARCH10>3.3.CO;2-5; Macdonald G., 1957, EPIDEMIOLOGY CONTROL; Ozes ON, 1999, NATURE, V401, P82; Partridge L, 2002, NAT REV GENET, V3, P165, DOI 10.1038/nrg753; Riehle MA, 2002, CELL TISSUE RES, V308, P409, DOI 10.1007/s00441-002-0561-8; SHAPIRO JP, 1983, INSECT BIOCHEM, V13, P273, DOI 10.1016/0020-1790(83)90049-5; Stanek DM, 2002, PEPTIDES, V23, P1367, DOI 10.1016/S0196-9781(02)00074-8; Stracker TH, 2002, J MED ENTOMOL, V39, P331, DOI 10.1603/0022-2585-39.2.331; TAGHERT PH, IN PRESS ADV GENET; Takken W, 2001, J INSECT PHYSIOL, V47, P303, DOI 10.1016/S0022-1910(00)00107-4; Veenstra JA, 1999, PEPTIDES, V20, P1145, DOI 10.1016/S0196-9781(99)00117-5; Veenstra JA, 1997, PEPTIDES, V18, P937, DOI 10.1016/S0196-9781(97)00032-6; Veenstra JA, 1997, J BIOL CHEM, V272, P10402, DOI 10.1074/jbc.272.16.10402; VEENSTRA JA, 1995, HISTOCHEM CELL BIOL, V104, P337, DOI 10.1007/BF01458127; Yu MJ, 2001, J INSECT PHYSIOL, V47, P263, DOI 10.1016/S0022-1910(00)00084-6	29	216	225	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 4	2002	298	5591					172	175		10.1126/science.1076827	http://dx.doi.org/10.1126/science.1076827			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	600BJ	12364794				2022-12-28	WOS:000178370500051
J	Gardner, MJ; Hall, N; Fung, E; White, O; Berriman, M; Hyman, RW; Carlton, JM; Pain, A; Nelson, KE; Bowman, S; Paulsen, IT; James, K; Eisen, JA; Rutherford, K; Salzberg, SL; Craig, A; Kyes, S; Chan, MS; Nene, V; Shallom, SJ; Suh, B; Peterson, J; Angiuoli, S; Pertea, M; Allen, J; Selengut, J; Haft, D; Mather, MW; Vaidya, AB; Martin, DMA; Fairlamb, AH; Fraunholz, MJ; Roos, DS; Ralph, SA; McFadden, GI; Cummings, LM; Subramanian, GM; Mungall, C; Venter, JC; Carucci, DJ; Hoffman, SL; Newbold, C; Davis, RW; Fraser, CM; Barrell, B				Gardner, MJ; Hall, N; Fung, E; White, O; Berriman, M; Hyman, RW; Carlton, JM; Pain, A; Nelson, KE; Bowman, S; Paulsen, IT; James, K; Eisen, JA; Rutherford, K; Salzberg, SL; Craig, A; Kyes, S; Chan, MS; Nene, V; Shallom, SJ; Suh, B; Peterson, J; Angiuoli, S; Pertea, M; Allen, J; Selengut, J; Haft, D; Mather, MW; Vaidya, AB; Martin, DMA; Fairlamb, AH; Fraunholz, MJ; Roos, DS; Ralph, SA; McFadden, GI; Cummings, LM; Subramanian, GM; Mungall, C; Venter, JC; Carucci, DJ; Hoffman, SL; Newbold, C; Davis, RW; Fraser, CM; Barrell, B			Genome sequence of the human malaria parasite Plasmodium falciparum	NATURE			English	Review							2C-METHYL-D-ERYTHRITOL 2,4-CYCLODIPHOSPHATE SYNTHASE; RED-CELL SURFACE; INFECTED ERYTHROCYTES; SHIKIMATE PATHWAY; TOXOPLASMA-GONDII; SUBCELLULAR-LOCALIZATION; RIBONUCLEOTIDE REDUCTASE; SACCHAROMYCES-CEREVISIAE; ISOPRENOID BIOSYNTHESIS; SUBTELOMERIC REGIONS	The parasite Plasmodium falciparum is responsible for hundreds of millions of cases of malaria, and kills more than one million African children annually. Here we report an analysis of the genome sequence of P. falciparum clone 3D7. The 23-megabase nuclear genome consists of 14 chromosomes, encodes about 5,300 genes, and is the most (A + T)-rich genome sequenced to date. Genes involved in antigenic variation are concentrated in the subtelomeric regions of the chromosomes. Compared to the genomes of free-living eukaryotic microbes, the genome of this intracellular parasite encodes fewer enzymes and transporters, but a large proportion of genes are devoted to immune evasion and host-parasite interactions. Many nuclear-encoded proteins are targeted to the apicoplast, an organelle involved in fatty-acid and isoprenoid metabolism. The genome sequence provides the foundation for future studies of this organism, and is being exploited in the search for new drugs and vaccines to fight malaria.	Inst Genom Res, Rockville, MD 20850 USA; Wellcome Trust Genome, Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England; Stanford Genome Technol Ctr, Palo Alto, CA 94304 USA; Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England; Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Oxford OX3 9DU, England; Drexel Univ, Coll Med, Dept Microbiol & Immunol, Philadelphia, PA 19129 USA; Univ Dundee, Wellcome Trust Bioctr, Sch Life Sci, Dundee DD1 5EH, Scotland; Univ Penn, Dept Biol, Philadelphia, PA 19104 USA; Univ Penn, Genom Inst, Philadelphia, PA 19104 USA; Univ Melbourne, Sch Bot, Plant Res Ctr, Melbourne, Vic 3010, Australia; Celera Genom, Rockville, MD 20850 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley Drosophila Genome Project, Berkeley, CA 94720 USA; Ctr Advancement Genom, Rockville, MD 20850 USA; USN, Med Res Ctr, Malaria Program, Silver Spring, MD 20910 USA	J. Craig Venter Institute; Wellcome Trust Sanger Institute; Stanford University; Liverpool School of Tropical Medicine; University of Liverpool; University of Oxford; Drexel University; University of Dundee; University of Pennsylvania; University of Pennsylvania; University of Melbourne; University of California System; University of California Berkeley; J. Craig Venter Institute; United States Department of Defense; United States Navy	Gardner, MJ (corresponding author), Inst Genom Res, 9712 Med Ctr Dr, Rockville, MD 20850 USA.	gardner@tigr.org	Angiuoli, Samuel V/H-7340-2014; Eisen, Jonathan A./H-2706-2019; Salzberg, Steven/Q-6514-2019; Martin, David/C-2984-2009; Fairlamb, Alan/A-5272-2009; Paulsen, Ian T/K-3832-2012; Pertea, Mihaela/AAT-2705-2021; Rutherford, Kim/Y-7995-2018; Berriman, Matthew/A-7618-2011; McFadden, Geoffrey McFadden I/F-7667-2014; Mungall, Chris/I-6006-2019; Salzberg, Steven L/F-6162-2011; Hall, Neil/A-8717-2013; Pain, Arnab/L-5766-2015; Ralph, Stuart/C-8590-2014	Eisen, Jonathan A./0000-0002-0159-2197; Salzberg, Steven/0000-0002-8859-7432; Fairlamb, Alan/0000-0001-5134-0329; Paulsen, Ian T/0000-0001-9015-9418; Pertea, Mihaela/0000-0003-0762-8637; Rutherford, Kim/0000-0001-6277-726X; Berriman, Matthew/0000-0002-9581-0377; McFadden, Geoffrey McFadden I/0000-0002-5351-1627; Mungall, Chris/0000-0002-6601-2165; Salzberg, Steven L/0000-0002-8859-7432; Hall, Neil/0000-0002-7995-3810; Pain, Arnab/0000-0002-1755-2819; Hall, Neil/0000-0003-2808-0009; Roos, David Siker/0000-0001-6725-4089; Allen, Jonathan/0000-0002-4359-8263; Fraser, Claire/0000-0003-1462-2428; Nene, Vishvanath/0000-0001-7066-4169; Fraunholz, Martin/0000-0002-4581-6244; Newbold, Chris/0000-0002-9274-3789; Craig, Alister/0000-0003-0914-6164; Martin, David/0000-0002-8732-204X; Ralph, Stuart/0000-0003-0114-7808; Mather, Michael/0000-0002-1062-0137; Angiuoli, Samuel/0000-0001-9525-4350	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028398, U01AI042243] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI028398] Funding Source: Medline; Wellcome Trust [061524] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome TrustEuropean Commission)		Adams KL, 2002, PLANT CELL, V14, P931, DOI 10.1105/tpc.010483; Adisa A, 2001, J CELL SCI, V114, P3377; Albano FR, 1999, EUR J CELL BIOL, V78, P453, DOI 10.1016/S0171-9335(99)80072-7; Apweiler R, 2001, NUCLEIC ACIDS RES, V29, P37, DOI 10.1093/nar/29.1.37; Arabidopsis Genome Initiative, 2000, Nature (London), V408, P796, DOI 10.1038/35048692; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; BABIKER HA, 1991, T ROY SOC TROP MED H, V85, P578, DOI 10.1016/0035-9203(91)90349-4; Baldauf SL, 2000, SCIENCE, V290, P972, DOI 10.1126/science.290.5493.972; Bannister LH, 2000, PARASITOL TODAY, V16, P427, DOI 10.1016/S0169-4758(00)01755-5; Baruch DI, 1997, BLOOD, V90, P3766, DOI 10.1182/blood.V90.9.3766; BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Benson G, 1999, NUCLEIC ACIDS RES, V27, P573, DOI 10.1093/nar/27.2.573; BLUM JJ, 1984, J PROTOZOOL, V31, P167, DOI 10.1111/j.1550-7408.1984.tb04310.x; Bojang KA, 2001, LANCET, V358, P1927, DOI 10.1016/S0140-6736(01)06957-4; Bonday ZQ, 1997, J BIOL CHEM, V272, P21839, DOI 10.1074/jbc.272.35.21839; Bonday ZQ, 2000, NAT MED, V6, P898, DOI 10.1038/78659; Bowman S, 1999, NATURE, V400, P532, DOI 10.1038/22964; Breman JG, 2001, AM J TROP MED HYG, V64, P1; BUCKWITZ D, 1988, MOL BIOCHEM PARASIT, V27, P225, DOI 10.1016/0166-6851(88)90041-2; BUCKWITZ D, 1990, BIOCHEM J, V267, P353, DOI 10.1042/bj2670353; Bull PC, 1998, NAT MED, V4, P358, DOI 10.1038/nm0398-358; Carlton JM, 2002, NATURE, V419, P512, DOI 10.1038/nature01099; CHAKRABARTI D, 1993, P NATL ACAD SCI USA, V90, P12020, DOI 10.1073/pnas.90.24.12020; Cheng Q, 1998, MOL BIOCHEM PARASIT, V97, P161, DOI 10.1016/S0166-6851(98)00144-3; Clarke JL, 2001, EUR J BIOCHEM, V268, P2013, DOI 10.1046/j.1432-1327.2001.02078.x; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; Critchlow SE, 1998, TRENDS BIOCHEM SCI, V23, P394, DOI 10.1016/S0968-0004(98)01284-5; DAY KP, 1993, P NATL ACAD SCI USA, V90, P8292, DOI 10.1073/pnas.90.17.8292; de Macedo CS, 2002, FEMS MICROBIOL LETT, V207, P13, DOI 10.1111/j.1574-6968.2002.tb11021.x; DEBRUIN D, 1994, P NATL ACAD SCI USA, V91, P619, DOI 10.1073/pnas.91.2.619; Deitsch KW, 2001, NATURE, V412, P875, DOI 10.1038/35091146; Delcher AL, 2002, NUCLEIC ACIDS RES, V30, P2478, DOI 10.1093/nar/30.11.2478; DeRocher A, 2000, J CELL SCI, V113, P3969; Desai SA, 2000, NATURE, V406, P1001, DOI 10.1038/35023000; DIECKMANN A, 1986, MOL BIOCHEM PARASIT, V19, P143, DOI 10.1016/0166-6851(86)90119-2; DUNCAN K, 1987, BIOCHEM J, V246, P375, DOI 10.1042/bj2460375; Duret L, 2000, TRENDS GENET, V16, P287, DOI 10.1016/S0168-9525(00)02041-2; DYER M, 1994, BBA-BIOENERGETICS, V1186, P133, DOI 10.1016/0005-2728(94)90145-7; Eisen JA, 1999, MUTAT RES-DNA REPAIR, V435, P171, DOI 10.1016/S0921-8777(99)00050-6; Eisen JA, 1998, GENOME RES, V8, P163, DOI 10.1101/gr.8.3.163; Elliott JL, 2001, BIOCHEM J, V355, P733, DOI 10.1042/bj3550733; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Fast NM, 2001, MOL BIOL EVOL, V18, P418, DOI 10.1093/oxfordjournals.molbev.a003818; Fichera ME, 1997, NATURE, V390, P407, DOI 10.1038/37132; Fidock DA, 2000, MOL CELL, V6, P861, DOI 10.1016/S1097-2765(05)00077-8; Figueiredo LM, 2002, EMBO J, V21, P815, DOI 10.1093/emboj/21.4.815; Fitzpatrick T, 2001, MOL MICROBIOL, V40, P65, DOI 10.1046/j.1365-2958.2001.02366.x; Florens L, 2002, NATURE, V419, P520, DOI 10.1038/nature01107; FOSTER J, 1995, PARASITOL TODAY, V11, P1, DOI 10.1016/0169-4758(95)80092-1; Freitas-Junior LH, 2000, NATURE, V407, P1018, DOI 10.1038/35039531; Fried M, 1996, SCIENCE, V272, P1502, DOI 10.1126/science.272.5267.1502; FRY M, 1991, PARASITOLOGY, V102, P17, DOI 10.1017/S0031182000060297; Gallup JL, 2001, AM J TROP MED HYG, V64, P85, DOI 10.4269/ajtmh.2001.64.85; Gamain B, 1996, FREE RADICAL BIO MED, V21, P559, DOI 10.1016/0891-5849(96)00120-7; Gardner MJ, 1998, SCIENCE, V282, P1126, DOI 10.1126/science.282.5391.1126; Gardner MJ, 2002, NATURE, V419, P531, DOI 10.1038/nature01094; Glockner G, 2002, NATURE, V418, P79, DOI 10.1038/nature00847; Greenwood B, 2002, NATURE, V415, P670, DOI 10.1038/415670a; Hall N, 2002, NATURE, V419, P527, DOI 10.1038/nature01095; Haltiwanger BM, 2000, BIOCHEMISTRY-US, V39, P763, DOI 10.1021/bi9923151; Hansen M, 2002, J BIOL CHEM, V277, P4874, DOI 10.1074/jbc.M110683200; Hayashi M, 2001, J BIOL CHEM, V276, P15249, DOI 10.1074/jbc.M011709200; He CY, 2001, J BIOL CHEM, V276, P28436, DOI 10.1074/jbc.M102000200; HernandezRivas R, 1996, MOL BIOCHEM PARASIT, V78, P137, DOI 10.1016/S0166-6851(96)02618-7; HINTERBERG K, 1994, EMBO J, V13, P4174, DOI 10.1002/j.1460-2075.1994.tb06735.x; Hoffman SL, 1997, NATURE, V387, P647, DOI 10.1038/42571; Hyman RW, 2002, NATURE, V419, P534, DOI 10.1038/nature01102; Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573; Kanehisa M, 2002, NUCLEIC ACIDS RES, V30, P42, DOI 10.1093/nar/30.1.42; Kapp C, 2002, LANCET, V359, P414, DOI 10.1016/S0140-6736(02)07634-1; Katinka MD, 2001, NATURE, V414, P450, DOI 10.1038/35106579; Keeling PJ, 1999, NATURE, V397, P219, DOI 10.1038/16618; Kemp LE, 2002, P NATL ACAD SCI USA, V99, P6591, DOI 10.1073/pnas.102679799; KNAPP B, 1989, MOL BIOCHEM PARASIT, V37, P47, DOI 10.1016/0166-6851(89)90101-1; Kohler S, 1997, SCIENCE, V275, P1485, DOI 10.1126/science.275.5305.1485; Krnajski Z, 2001, MOL BIOCHEM PARASIT, V112, P219, DOI 10.1016/S0166-6851(00)00372-8; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Kyes S, 2001, ANNU REV MICROBIOL, V55, P673, DOI 10.1146/annurev.micro.55.1.673; Kyes SA, 1999, P NATL ACAD SCI USA, V96, P9333, DOI 10.1073/pnas.96.16.9333; Lai ZW, 1999, NAT GENET, V23, P309, DOI 10.1038/15484; LANGUNNASCH N, 1992, MOL BIOCHEM PARASIT, V50, P17, DOI 10.1016/0166-6851(92)90240-K; Lasonder E, 2002, NATURE, V419, P537, DOI 10.1038/nature01111; LEECH JH, 1984, J EXP MED, V159, P1567, DOI 10.1084/jem.159.6.1567; LI J, 1994, MOL BIOCHEM PARASIT, V65, P283, DOI 10.1016/0166-6851(94)90079-5; LOUIS EJ, 1994, GENETICS, V136, P789; Loyevsky M, 2001, BLOOD, V98, P2555, DOI 10.1182/blood.V98.8.2555; Lue HQ, 2002, MICROBES INFECT, V4, P449, DOI 10.1016/S1286-4579(02)01560-5; McConkey GA, 1999, ANTIMICROB AGENTS CH, V43, P175, DOI 10.1128/AAC.43.1.175; McFadden GI, 1996, NATURE, V381, P482, DOI 10.1038/381482a0; McIntosh MT, 2001, MOL BIOCHEM PARASIT, V114, P183, DOI 10.1016/S0166-6851(01)00251-1; Miclet E, 2001, J BIOL CHEM, V276, P34840, DOI 10.1074/jbc.M105174200; Moriyama EN, 1997, J MOL EVOL, V45, P514, DOI 10.1007/PL00006256; Murphy AD, 1999, ANTIMICROB AGENTS CH, V43, P651, DOI 10.1128/AAC.43.3.651; Nabarro DN, 1998, SCIENCE, V280, P2067, DOI 10.1126/science.280.5372.2067; Nchinda TC, 1998, EMERG INFECT DIS, V4, P398, DOI 10.3201/eid0403.980313; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OQUENDO P, 1986, MOL BIOCHEM PARASIT, V18, P89, DOI 10.1016/0166-6851(86)90053-8; Pain A, 2001, P NATL ACAD SCI USA, V98, P1805, DOI 10.1073/pnas.98.4.1805; Palmer JD, 1996, P NATL ACAD SCI USA, V93, P7432, DOI 10.1073/pnas.93.15.7432; Papa S, 2000, J BIOENERG BIOMEMBR, V32, P401, DOI 10.1023/A:1005584221456; Pastrana DV, 1998, INFECT IMMUN, V66, P5955, DOI 10.1128/IAI.66.12.5955-5963.1998; Paulsen IT, 2000, J MOL BIOL, V301, P75, DOI 10.1006/jmbi.2000.3961; Pearson W R, 2000, Methods Mol Biol, V132, P185; Perez-Martinez X, 2001, J BIOL CHEM, V276, P11302, DOI 10.1074/jbc.M010244200; PETERSON DS, 1995, P NATL ACAD SCI USA, V92, P7100, DOI 10.1073/pnas.92.15.7100; POLOGE LG, 1986, NATURE, V322, P474, DOI 10.1038/322474a0; Rager N, 2001, J BIOL CHEM, V276, P41095, DOI 10.1074/jbc.M107037200; Ralph SA, 2001, DRUG RESIST UPDATE, V4, P145, DOI 10.1054/drup.2001.0205; Richie TL, 2002, NATURE, V415, P694, DOI 10.1038/415694a; Ridley RG, 2002, NATURE, V415, P686, DOI 10.1038/415686a; Roberts CW, 2002, J INFECT DIS, V185, pS25, DOI 10.1086/338004; Roberts F, 1998, NATURE, V393, P801, DOI 10.1038/31723; Rohdich F, 2001, EUR J BIOCHEM, V268, P3190, DOI 10.1046/j.1432-1327.2001.02204.x; Roos DS, 1999, CURR OPIN MICROBIOL, V2, P426, DOI 10.1016/S1369-5274(99)80075-7; Rowe JA, 2002, J INFECT DIS, V185, P1207, DOI 10.1086/339684; RUBIN H, 1993, P NATL ACAD SCI USA, V90, P9280, DOI 10.1073/pnas.90.20.9280; Rudenko G, 1996, MOL BIOCHEM PARASIT, V80, P65, DOI 10.1016/0166-6851(96)02669-2; Sacher M, 1998, EMBO J, V17, P2494, DOI 10.1093/emboj/17.9.2494; Sato S, 2000, INT J PARASITOL, V30, P427, DOI 10.1016/S0020-7519(99)00185-X; Sato S, 2002, CURR GENET, V40, P391, DOI 10.1007/s00294-002-0273-3; Scharfe C, 2000, NUCLEIC ACIDS RES, V28, P155, DOI 10.1093/nar/28.1.155; Scherf A, 2001, CURR OPIN MICROBIOL, V4, P409, DOI 10.1016/S1369-5274(00)00227-7; SCHERF A, 1992, EMBO J, V11, P2293, DOI 10.1002/j.1460-2075.1992.tb05288.x; Sherman Irwin W., 1998, P177; Sherman Irwin W., 1998, P135; Smith JD, 2001, TRENDS PARASITOL, V17, P538, DOI 10.1016/S1471-4922(01)02079-7; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; Smith JD, 2000, P NATL ACAD SCI USA, V97, P1766, DOI 10.1073/pnas.040545897; Stoebe B, 1999, TRENDS GENET, V15, P344, DOI 10.1016/S0168-9525(99)01815-6; Su XZ, 1999, SCIENCE, V286, P1351, DOI 10.1126/science.286.5443.1351; Su XZ, 1996, GENOMICS, V33, P430, DOI 10.1006/geno.1996.0218; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1; Surolia N, 2001, NAT MED, V7, P167, DOI 10.1038/84612; Tan THP, 2002, MOL CELL BIOL, V22, P3707, DOI 10.1128/MCB.22.11.3707-3716.2002; Tarassov IA, 1996, BIOCHIMIE, V78, P502, DOI 10.1016/0300-9084(96)84756-0; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; UDOMSANGPETCH R, 1989, J EXP MED, V169, P1835, DOI 10.1084/jem.169.5.1835; Urban BC, 1999, NATURE, V400, P73, DOI 10.1038/21900; VAIDYA AB, 1989, MOL BIOCHEM PARASIT, V35, P97, DOI 10.1016/0166-6851(89)90112-6; VAIDYA AB, 1993, MOL BIOCHEM PARASIT, V58, P33, DOI 10.1016/0166-6851(93)90088-F; VAIDYA AB, MEMBRANE STRUCTURE D; Vaidya Akhil B., 1998, P355; van Dooren GG, 2000, PARASITOL TODAY, V16, P421, DOI 10.1016/S0169-4758(00)01792-0; van Dooren GG, 2002, J BIOL CHEM, V277, P23612, DOI 10.1074/jbc.M201748200; van Dooren GG, 2001, BBA-MOL CELL RES, V1541, P34, DOI 10.1016/S0167-4889(01)00154-9; vanDeutekom JCT, 1996, HUM MOL GENET, V5, P1997, DOI 10.1093/hmg/5.12.1997; VERNICK KD, 1988, MOL BIOCHEM PARASIT, V28, P85, DOI 10.1016/0166-6851(88)90055-2; Vollmer M, 2001, J BIOL CHEM, V276, P5483, DOI 10.1074/jbc.M009452200; Voss TS, 2000, MOL BIOCHEM PARASIT, V107, P103, DOI 10.1016/S0166-6851(00)00176-6; Waller RF, 2000, EMBO J, V19, P1794, DOI 10.1093/emboj/19.8.1794; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352; Watanabe J, 2001, NUCLEIC ACIDS RES, V29, P70, DOI 10.1093/nar/29.1.70; WATERS AP, 1994, ADV PARASIT, V34, P33, DOI 10.1016/S0065-308X(08)60136-0; WEBER JL, 1988, MOL BIOCHEM PARASIT, V29, P117, DOI 10.1016/0166-6851(88)90066-7; Wilson CM, 1996, MOL BIOCHEM PARASIT, V75, P271, DOI 10.1016/0166-6851(95)02531-6; Wilson RJM, 2002, J MOL BIOL, V319, P257, DOI 10.1016/S0022-2836(02)00303-0; Wilson RJM, 1996, J MOL BIOL, V261, P155, DOI 10.1006/jmbi.1996.0449; Wiser MF, 1997, P NATL ACAD SCI USA, V94, P9108, DOI 10.1073/pnas.94.17.9108; Wood RD, 2001, SCIENCE, V291, P1284, DOI 10.1126/science.1056154; Wood V, 2002, NATURE, V415, P871, DOI 10.1038/nature724; Wood V, 2001, COMP FUNCT GENOM, V2, P143, DOI 10.1002/cfg.86; Woodrow CJ, 2000, P NATL ACAD SCI USA, V97, P9931, DOI 10.1073/pnas.170153097; Yung S, 2001, MOL BIOCHEM PARASIT, V118, P11, DOI 10.1016/S0166-6851(01)00359-0; Zuegge J, 2001, GENE, V280, P19, DOI 10.1016/S0378-1119(01)00776-4	165	3238	3591	10	499	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 3	2002	419	6906					498	511		10.1038/nature01097	http://dx.doi.org/10.1038/nature01097			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	599RF	12368864	Green Accepted, Bronze			2022-12-28	WOS:000178348400045
J	Schneiderman, LJ				Schneiderman, LJ			Empathy and the literary imagination	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ Calif San Diego, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Schneiderman, LJ (corresponding author), Dept Family & Prevent Med, 9500 Gilman Dr MC 0622, La Jolla, CA 92093 USA.	ljs@ucsd.edu						SALINGER JD, 1951, CATCHER RYE, P12; SPIRO H, 1992, ANN INTERN MED, V116, P843, DOI 10.7326/0003-4819-116-10-843	2	14	14	3	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	2002	137	7					627	629		10.7326/0003-4819-137-7-200210010-00033	http://dx.doi.org/10.7326/0003-4819-137-7-200210010-00033			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	599VD	12353969				2022-12-28	WOS:000178355100028
J	Van Tonder, GJ; Lyons, MJ; Ejima, Y				Van Tonder, GJ; Lyons, MJ; Ejima, Y			Visual structure of a Japanese Zen garden - The mysterious appeal of a simple and ancient composition of rocks is unveiled.	NATURE			English	Article									Kyoto Univ, Grad Sch Human & Environm Studies, Kyoto 6068501, Japan; ATR Media Informat Sci Labs, Kyoto 6190288, Japan	Kyoto University	Van Tonder, GJ (corresponding author), Kyoto Univ, Grad Sch Human & Environm Studies, Kyoto 6068501, Japan.		Lyons, Michael J./P-5974-2018	Lyons, Michael J./0000-0002-7426-0628	Grants-in-Aid for Scientific Research [15K05211] Funding Source: KAKEN	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))		BLUM H, 1973, J THEOR BIOL, V38, P205, DOI 10.1016/0022-5193(73)90175-6; KOVACS I, 1994, NATURE, V370, P644, DOI 10.1038/370644a0; LEYTON M, 1987, COMPUT VISION GRAPH, V38, P327, DOI 10.1016/0734-189X(87)90117-4; Nitschke Gunther, 1993, JAPANESE GARDENS; Oyama H., 1995, RYOANJI SEKITEI NANA; TAYLOR R, 2002, NATURE, V415, P961, DOI DOI 10.1038/415961A; Taylor RP, 1999, NATURE, V399, P422, DOI 10.1038/20833; VANTONDER GJ, IN PRESS IEEE T SYST	8	38	38	3	60	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 26	2002	419	6905					359	360		10.1038/419359a	http://dx.doi.org/10.1038/419359a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	596ZB	12353024				2022-12-28	WOS:000178195400034
J	Vincent, JL; Baron, JF; Reinhart, K; Gattinoni, L; Thijs, L; Webb, A; Meier-Hellmann, A; Nollet, G; Peres-Bota, D				Vincent, JL; Baron, JF; Reinhart, K; Gattinoni, L; Thijs, L; Webb, A; Meier-Hellmann, A; Nollet, G; Peres-Bota, D		ABC Investigators	Anemia and blood transfusion in critically ill patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RECOMBINANT-HUMAN-ERYTHROPOIETIN; INTENSIVE-CARE-UNIT; ELECTIVE COLORECTAL SURGERY; LEUKOCYTE DEPLETION; CARDIAC-SURGERY; CLINICAL-TRIAL; WHOLE-BLOOD; MORTALITY; SEPSIS; SCORE	Context Anemia is a common problem in critically ill patients admitted to intensive care units (ICUs), but the consequences of anemia on morbidity and mortality in the. critically ill is poorly defined. Objectives To prospectively define the incidence of anemia and use of red blood cell (RBC) transfusions in critically ill patients and to explore the potential benefits and risks associated with transfusion in the ICU. Design Prospective observational study conducted November 1999, with 2. components: a blood sampling study and an, anemia and blood transfusion study. Setting and Patients The blood sampling study included 1136 patients from 145 western European ICUs, and the anemia and blood transfusion study included 3534 patients from 146 western European ICUs. Patients were followed up for 28 days or until hospital discharge, interinstitutional transfer, or death. Main Outcome Measures Frequency of blood drawing and associated volume of blood drawn, collected over a 24-hour period; hemoglobin levels, transfusion rate, organ dysfunction (assessed using the Sequential Organ Failure Assessment score), and mortality, collected throughout a 2-week period. Results The mean (SD) volume per blood draw was 10.3 (6.6) mL, with an average total volume of 41.1 (39.7) mL during the 24-hour period. There was a positive correlation between organ dysfunction and the number of blood draws (r=0.34; P<.001) and total volume drawn (r=0.28; P<.001). The mean hemoglobin concentration at ICU admission was 11.3 (2.3) g/dL, with 29% (963/3295) having a concentration of less than 10 g/dL. The transfusion rate during the ICU period was 37.0% (1307/3534). Older patients and those with a longer ICU length of stay were more commonly transfused. Both ICU and overall mortality rates were significantly higher in patients who had vs had not received a transfusion (ICU rates: 18.5% vs 10.1%, respectively; chi(2)=50.1; P<.001; overall rates: 29.0% vs 14.9%, respectively; chi(2) =88.1; P<.001). For similar degrees of organ dysfunction, patients who had a transfusion had a higher mortality rate. For matched patients in the propensity analysis, the 28-day mortality was 22.7% among patients with transfusions and 17.1% among those without (P=.02); the Kaplan-Meier log-rank test confirmed this difference. Conclusions This multicenter observational study reveals the common occurrence of anemia and the large use of blood transfusion in critically ill patients. Additionally, this epidemiologic study provides evidence of an association between transfusions and diminished organ function as well as between transfusions and mortality.	Erasme Univ Hosp, Dept Intens Care, B-1070 Brussels, Belgium; Hop Broussais, Dept Anesthesiol, F-75674 Paris, France; Klinikum FSU Jena, Dept Anesthesiol, Jena, Germany; Osped Maggiore, Ist Anestesia & Rianimaz, Milan, Italy; VU Ziekenhuis, Med Intens Care Unit, Amsterdam, Netherlands; UCL Hosp, Dept Intens Care, London, England; Onze Lieve Vrouw Hosp, Dept Anesthesiol & Intens Care, Aalst, Belgium	Universite Libre de Bruxelles; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Friedrich Schiller University of Jena; University College London Hospitals NHS Foundation Trust; University of London; University College London	Vincent, JL (corresponding author), Erasme Univ Hosp, Dept Intens Care, Route Lennik 808, B-1070 Brussels, Belgium.	jlvincen@ulb.ac.be		Gattinoni, Luciano/0000-0001-5380-2494; Vincent, Jean-Louis/0000-0001-6011-6951				Ania BJ, 1997, J AM GERIATR SOC, V45, P825, DOI 10.1111/j.1532-5415.1997.tb01509.x; Balducci, 1998, Cancer Control, V5, P17; Blumberg N, 1996, AM J MED, V101, P299, DOI 10.1016/S0002-9343(96)00124-6; BLUMBERG N, 1986, BRIT MED J, V293, P530, DOI 10.1136/bmj.293.6546.530; BRUNSON ME, 1990, TRANSFUSION, V30, P651, DOI 10.1046/j.1537-2995.1990.30790385527.x; BURNUM JF, 1986, NEW ENGL J MED, V314, P1250, DOI 10.1056/NEJM198605083141910; CORWIN HL, 1995, CHEST, V108, P767, DOI 10.1378/chest.108.3.767; Corwin HL, 1999, CRIT CARE MED, V27, P2346, DOI 10.1097/00003246-199911000-00004; DALE JC, 1993, MAYO CLIN PROC, V68, P249, DOI 10.1016/S0025-6196(12)60044-5; Gabriel A, 1998, J TRAUMA, V44, P361, DOI 10.1097/00005373-199802000-00023; GOODNOUGH LT, 1995, ANN THORAC SURG, V60, P473, DOI 10.1016/0003-4975(95)98960-3; Gott JP, 1998, ANN THORAC SURG, V66, P747, DOI 10.1016/S0003-4975(98)00695-X; GROEGER JS, 1993, CRIT CARE MED, V21, P279, DOI 10.1097/00003246-199302000-00022; Gum PA, 2001, JAMA-J AM MED ASSOC, V286, P1187, DOI 10.1001/jama.286.10.1187; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hebert PC, 1997, AM J RESP CRIT CARE, V155, P1618, DOI 10.1164/ajrccm.155.5.9154866; Jensen LS, 1996, BRIT J SURG, V83, P973, DOI 10.1002/bjs.1800830727; JENSEN LS, 1992, BRIT J SURG, V79, P513, DOI 10.1002/bjs.1800790613; MARIK PE, 1993, JAMA-J AM MED ASSOC, V269, P3024, DOI 10.1001/jama.269.23.3024; NELSON AH, 1993, CRIT CARE MED, V21, P860, DOI 10.1097/00003246-199306000-00013; Rogiers P, 1997, INTENS CARE MED, V23, P159, DOI 10.1007/s001340050310; ROSENBAUM PR, 1984, J AM STAT ASSOC, V79, P516, DOI 10.2307/2288398; Rubin DB, 1997, ANN INTERN MED, V127, P757, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00064; Schallom L, 1999, Crit Care Nurs Clin North Am, V11, P99; SILVER MJ, 1993, CHEST, V104, P1711, DOI 10.1378/chest.104.6.1711; STEVENS CE, 1984, ANN INTERN MED, V101, P733, DOI 10.7326/0003-4819-101-6-733; Tartter PI, 1998, AM J SURG, V176, P462, DOI 10.1016/S0002-9610(98)00245-1; van de Watering LMG, 1998, CIRCULATION, V97, P562; van Iperen CE, 2000, CRIT CARE MED, V28, P2773, DOI 10.1097/00003246-200008000-00015; VILJOEN M, 1994, HAEMATOLOGICA, V79, P19; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/s001340050156; von Ahsen N, 1999, CRIT CARE MED, V27, P2630, DOI 10.1097/00003246-199912000-00005	32	1102	1173	1	56	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	2002	288	12					1499	1507		10.1001/jama.288.12.1499	http://dx.doi.org/10.1001/jama.288.12.1499			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	596AT	12243637				2022-12-28	WOS:000178142000021
J	Ghofrani, HA; Wiedemann, R; Rose, F; Schermuly, RT; Olschewski, H; Weissmann, N; Gunther, A; Walmrath, D; Seeger, W; Grimminger, F				Ghofrani, HA; Wiedemann, R; Rose, F; Schermuly, RT; Olschewski, H; Weissmann, N; Gunther, A; Walmrath, D; Seeger, W; Grimminger, F			Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial	LANCET			English	Article							INHALED NITRIC-OXIDE; AEROSOLIZED PROSTACYCLIN; HYPOXIC VASOCONSTRICTION; ORAL SILDENAFIL; ILOPROST; THERAPY; SYSTEM	Background Lung fibrosis can be complicated by pulmonary hypertension, limiting exercise tolerance and life expectancy. Furthermore, vasodilators might cause deterioration in gas exchange. Our aim was to compare acute effects of sildenafil, nitric oxide, and epoprostenol in individuals with pulmonary hypertension secondary to lung fibrosis. Methods We did a randomised controlled, open-label trial, in 16 individuals admitted to our hospital with pulmonary hypertension secondary to lung fibrosis. After inhalation of nitric oxide (10-20 ppm), we assigned patients to either maximum tolerated dose of intravenous epoprostenol (mean 8.0 ng/kg per min; n=8) or oral sildenafil (50 mg; n=8). Our primary objective was to assess pulmonary vasodilative potency (decrease in pulmonary vascular resistance index) of sildenafil by comparison with inhaled nitric oxide and infused epoprostenol. Analyses were by intention to treat. Findings Pulmonary vascular resistance index was reduced by nitric oxide (-21.9%, 95% CI -14.1 to -36.2), epoprostenol (-36.9%, -24.4 to -59.6), and sildenafil (-32.5%, -10.2 to -54.1). However, ratio of pulmonary to systemic vascular resistance decreased only in individuals who received nitric oxide and sildenafil. Baseline measurement of multiple-inert-gas elimination showed right-to-left shunt flow (4.8%, 0.0-28.2) and little perfusion of low ventilation(V)/perfusion(Q) areas (0.1%, 0.0-13.0). Prostacyclin increased V/Q mismatch (shunt 16.8%, 10.8-35.9; low V/Q 3.8%, 0.0-13.0) and decreased arterial oxygenation. By contrast, nitric oxide (4.5%, 0.0-18.0; 0.0%, 0.0-17.3) and sildenafil (3.3%, 0.0-11.3; 0.0%, 0.0-12.4) maintained V/Q matching, with raised arterial partial pressure of oxygen (14.3 mm Hg, -1.7 to 31.3) noted for sildenafil. We recorded no adverse events. Interpretation Sildenafil causes preferential pulmonary vasodilation and improves gas exchange in patients with severe lung fibrosis and secondary pulmonary hypertension.	Univ Giessen, Univ Hosp, Dept Internal Med, D-35392 Giessen, Germany	Justus Liebig University Giessen	Grimminger, F (corresponding author), Univ Giessen, Univ Hosp, Dept Internal Med, D-35392 Giessen, Germany.	friedrich.grimminger@innere.med.uni-giessen.de	Olschewski, Horst/L-3547-2019; Ghofrani, Ardeschir/AAD-5293-2020; Ghofrani, Hossein Ardeschir/AAD-2856-2022	Olschewski, Horst/0000-0002-2834-7466; Ghofrani, Ardeschir/0000-0002-2029-4419; Schermuly, Ralph/0000-0002-5167-6970; Weissmann, Norbert/0000-0003-2675-3871; Seeger, Werner/0000-0003-1946-0894; Grimminger, Friedrich/0000-0001-8725-6276				AGUSTI AGN, 1993, EUR RESPIR J, V6, P1371; AHN HS, 1991, ADV EXP MED BIOL, V308, P191; *AM THOR SOC, 2000, AM J RESP CRIT CARE, V161, P646, DOI DOI 10.1164/AJRCCM.161.2.ATS3-00; Barst RJ, 1996, NEW ENGL J MED, V334, P296, DOI 10.1056/NEJM199602013340504; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; Channick RN, 1996, CHEST, V109, P1545, DOI 10.1378/chest.109.6.1545; Egan JJ, 1999, LANCET, V354, P1839, DOI 10.1016/S0140-6736(99)00347-5; Ghofrani HA, 2002, ANN INTERN MED, V136, P515, DOI 10.7326/0003-4819-136-7-200204020-00008; GRIMMINGER F, 1995, J APPL PHYSIOL, V78, P1509, DOI 10.1152/jappl.1995.78.4.1509; Hoeper MM, 2000, J AM COLL CARDIOL, V35, P176, DOI 10.1016/S0735-1097(99)00494-5; Hoeper MM, 2000, NEW ENGL J MED, V342, P1866, DOI 10.1056/NEJM200006223422503; Ide H, 1999, J APPL PHYSIOL, V87, P1629, DOI 10.1152/jappl.1999.87.5.1629; King TE, 2001, AM J RESP CRIT CARE, V164, P1171, DOI 10.1164/ajrccm.164.7.2003140; Olschewski H, 2000, ANN INTERN MED, V132, P435, DOI 10.7326/0003-4819-132-6-200003210-00003; Olschewski H, 1999, AM J RESP CRIT CARE, V160, P600, DOI 10.1164/ajrccm.160.2.9810008; Olschewski H, 1996, ANN INTERN MED, V124, P820, DOI 10.7326/0003-4819-124-9-199605010-00006; RABE KF, 1994, AM J PHYSIOL, V266, pL536, DOI 10.1152/ajplung.1994.266.5.L536; ROSSAINT R, 1993, NEW ENGL J MED, V328, P399, DOI 10.1056/NEJM199302113280605; Schermuly RT, 2001, AM J PHYSIOL-LUNG C, V280, pL792, DOI 10.1152/ajplung.2001.280.4.L792; WAGNER PD, 1982, FED PROC, V41, P136; WALMRATH D, 1995, AM J RESP CRIT CARE, V151, P724; WALMRATH D, 1993, LANCET, V342, P961, DOI 10.1016/0140-6736(93)92004-D; Weimann J, 2000, ANESTHESIOLOGY, V92, P1702, DOI 10.1097/00000542-200006000-00030; Weissmann N, 2001, AM J PHYSIOL-LUNG C, V280, pL638, DOI 10.1152/ajplung.2001.280.4.L638; Wiedemann R, 2001, J AM COLL CARDIOL, V38, P1130, DOI 10.1016/S0735-1097(01)01490-5; Wilkens H, 2001, CIRCULATION, V104, P1218, DOI 10.1161/hc3601.096826	26	517	550	1	29	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 21	2002	360	9337					895	900		10.1016/S0140-6736(02)11024-5	http://dx.doi.org/10.1016/S0140-6736(02)11024-5			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	596AU	12354470				2022-12-28	WOS:000178142200007
J	Lunardi, C; Bason, C; Leandri, M; Navone, R; Lestani, M; Millo, E; Benatti, U; Cilli, M; Beri, R; Corrocher, R; Puccetti, A				Lunardi, C; Bason, C; Leandri, M; Navone, R; Lestani, M; Millo, E; Benatti, U; Cilli, M; Beri, R; Corrocher, R; Puccetti, A			Autoantibodies to inner ear and endothelial antigens in Cogan's syndrome	LANCET			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; SUPPORTING-CELL ANTIGEN; CONNEXIN-26; EXPRESSION; DEAFNESS; ANTIBODIES; VASCULITIS; MUTATIONS; INFECTION; APOPTOSIS	Background Cogan's syndrome is a chronic inflammatory disease of unknown origin, characterised by sensorineural hearing loss, episclentis, and vasculitis. An autoimmune origin has been suggested but not proven. Our aim was to establish whether or not an autoimmune process is the cause of the disease. Methods We used pooled IgG immunoglobulins derived from eight patients with Cogan's syndrome to screen a random peptide library to identify disease relevant autoantigen peptides. Among the identified peptides, one was recognised by all the patients' sera. Antibodies against peptides were affinity purified from patients' sera and used to characterise the autoantigen, to stain human cochlea, and to transfer the features of Cogan's disease into animals. Findings We identified an immunodominant peptide that shows similarity with autoantigens such as SSA/Ro and with the reovirus III major core protein lambda 1. The peptide sequence shows similarity also with the cell-density enhanced protein tyrosine phosphatase-1 (DEP-1/CD148), which is expressed on the sensory epithelia of the inner ear and on endothelial cells. IgG antibodies against the peptide, purified from the patients' sera, recognised autoantigens and DEP-1/CD148 protein, bound human cochlea, and inhibited proliferation of cells expressing DEP-1/CD148. The same antibodies bound connexin 26, gene mutations of which lead to congenital inner ear deafness. Furthermore, these antibodies were able to induce the features of Cogan's disease in mice. Interpretation Our results indicate that Cogan's syndrome is an autoimmune disease, characterised by the presence of autoantibodies able to induce tissue damage on binding of cell-surface molecules present on the sensory epithelia of the inner ear and on endothelial cells.	Univ Verona, Dept Clin & Expt Med, I-37100 Verona, Italy; Univ Verona, Dept Pathol, I-37100 Verona, Italy; Univ Genoa, Dept Expt Med, Genoa, Italy; Inst Giannina Gaslini, Genoa, Italy; Univ Genoa, Interuniv Ctr Pain Neurophysiol, Genoa, Italy; Natl Canc Inst IST, Genoa, Italy	University of Verona; University of Verona; University of Genoa; University of Genoa; IRCCS Istituto Giannina Gaslini; University of Genoa	Lunardi, C (corresponding author), Univ Verona, Dept Expt Med, Sect Internal Med, Policlin GB Rossi, Piazzale LA Scuro, I-37134 Verona, Italy.		Cilli, Michele/AAB-8529-2019; Millo, Enrico/K-3218-2018	Millo, Enrico/0000-0002-4019-0051; Leandri, Massimo/0000-0002-5197-7431; Cilli, Michele/0000-0003-4083-8986				Albayram MS, 2001, AM J NEURORADIOL, V22, P751; Autschbach F, 1999, TISSUE ANTIGENS, V54, P485, DOI 10.1034/j.1399-0039.1999.540506.x; BARTLETT JA, 1988, VIROLOGY, V167, P31, DOI 10.1016/0042-6822(88)90051-7; BICKNELL JM, 1978, NEUROLOGY, V28, P278, DOI 10.1212/WNL.28.3.278; CALLEJO FJG, 2001, AN ESP PEDIATR, V55, P87; de la Fuente-Garcia MA, 1998, BLOOD, V91, P2800, DOI 10.1182/blood.V91.8.2800.2800_2800_2809; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; Disher MJ, 1997, ANN NY ACAD SCI, V830, P253, DOI 10.1111/j.1749-6632.1997.tb51896.x; DONG Y, 1994, EUR J CELL BIOL, V64, P95; Estivill X, 1998, LANCET, V351, P394, DOI 10.1016/S0140-6736(97)11124-2; HEMCHEN C, 1999, ACTA OTORYNGOL, V119, P528; Hoch W, 2001, NAT MED, V7, P365, DOI 10.1038/85520; HUGHES GB, 1983, OTOLARYNG HEAD NECK, V91, P24, DOI 10.1177/019459988309100106; Ikeda M, 2002, ANN RHEUM DIS, V61, P761, DOI 10.1136/ard.61.8.761; Keane MM, 1996, CANCER RES, V56, P4236; Kelley PM, 2000, BRAIN RES REV, V32, P184, DOI 10.1016/S0165-0173(99)00080-6; Kikuchi T, 2000, BRAIN RES REV, V32, P163, DOI 10.1016/S0165-0173(99)00076-4; Kruger RP, 1999, J NEUROSCI, V19, P4815; Lefebvre PP, 2000, BRAIN RES REV, V32, P159; Lunardi C, 1998, EUR J IMMUNOL, V28, P936, DOI 10.1002/(SICI)1521-4141(199803)28:03<936::AID-IMMU936>3.3.CO;2-O; Lunardi C, 2000, NAT MED, V6, P1183, DOI 10.1038/80533; Oliveri M, 2001, EUR J IMMUNOL, V31, P743, DOI 10.1002/1521-4141(200103)31:3<743::AID-IMMU743>3.0.CO;2-9; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; REICHLIN M, 1991, British Journal of Rheumatology, V30, P58; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SPANAKIS SG, 1998, INVEST OPHTH VIS SCI, V39, P1198; St Clair E W, 1999, Curr Opin Rheumatol, V11, P47, DOI 10.1097/00002281-199901000-00008; Takahashi T, 1999, J AM SOC NEPHROL, V10, P2135; Van Doornum S, 2001, ANN RHEUM DIS, V60, P69, DOI 10.1136/ard.60.1.69; VOLLERTSEN RS, 1986, MAYO CLIN PROC, V61, P344, DOI 10.1016/S0025-6196(12)61951-X; VOLLERTSEN RS, 1990, RHEUM DIS CLIN N AM, V16, P433; Wellings DA, 1997, METHOD ENZYMOL, V289, P44; Zhao ZS, 1998, SCIENCE, V279, P1344, DOI 10.1126/science.279.5355.1344; Zheng QY, 1999, HEARING RES, V130, P94, DOI 10.1016/S0378-5955(99)00003-9	34	151	160	1	13	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 21	2002	360	9337					915	921		10.1016/S0140-6736(02)11028-2	http://dx.doi.org/10.1016/S0140-6736(02)11028-2			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	596AU	12354474				2022-12-28	WOS:000178142200011
J	Remuzzi, G; Chiurchiu, C; Abbate, M; Brusegan, V; Bontempelli, M; Ruggenenti, P				Remuzzi, G; Chiurchiu, C; Abbate, M; Brusegan, V; Bontempelli, M; Ruggenenti, P			Rituximab for idiopathic membranous nephropathy	LANCET			English	Article							GLOMERULONEPHRITIS	Treatments for idiopathic membranous nephropathy, a common cause of nephrotic syndrome, can be very toxic. In view of the pathogenic potential of B cells in this disease, we studied the effects of four weekly infusions of rituximab (375 mg/m(2))- the monoclonal antibody to B-cell antigen CD20-in eight patients who had idiopathic membranous nephropathy with persistent nephrotic syndrome. At weeks 4 and 20, urinary protein decreased from mean (SE) 8.6 g/24 h (1.4) to 3.8 (0.8) and 3.7 (0.9), respectively (p<0.0001). At week 20, albuminuria and albumin fractional clearance decreased by 70% and 65%, and serum albumin increased by 31%. CD20 B lymphocytes fell below normal ranges up to study end. The short-term risk-benefit profile of rituximab seems more favourable to that of any other immunosuppressive drug used to treat idiopathic membranous nephropathy.	Mario Negri Inst Pharmacol Res, Aldo & Cele Dacco Clin Res Ctr Rare Dis, I-24100 Bergamo, Italy; Mario Negri Inst Pharmacol Res, Unit Immunohaematol, I-24100 Bergamo, Italy; Osped Riuniti Bergamo, Unit Nephrol & Dialysis, I-24100 Bergamo, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Ospedali Riuniti di Bergamo	Chiurchiu, C (corresponding author), Mario Negri Inst Pharmacol Res, Aldo & Cele Dacco Clin Res Ctr Rare Dis, Via Gavazzeni 1124125, I-24100 Bergamo, Italy.		Mauro, Abbate/ABH-3533-2020; Remuzzi, Giuseppe/V-9766-2017	Mauro, Abbate/0000-0002-2092-7474; Remuzzi, Giuseppe/0000-0002-6194-3446				BIANCONE L, 1995, KIDNEY INT, V48, P458, DOI 10.1038/ki.1995.314; Cattran DC, 2001, KIDNEY INT, V59, P1983, DOI 10.1046/j.1523-1755.2001.0590051983.x; JOHNSON PWM, 2001, BRIT J CANCER, V85, P1609; KERJASCHKI D, 1983, J EXP MED, V157, P667, DOI 10.1084/jem.157.2.667; Schieppati A, 1997, Expert Opin Investig Drugs, V6, P521, DOI 10.1517/13543784.6.5.521	5	251	273	0	15	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 21	2002	360	9337					923	924		10.1016/S0140-6736(02)11042-7	http://dx.doi.org/10.1016/S0140-6736(02)11042-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	596AU	12354476	Green Published			2022-12-28	WOS:000178142200013
J	Schlessinger, J				Schlessinger, J			Ligand-induced, receptor-mediated dimerization and activation of EGF receptor	CELL			English	Review							EPIDERMAL-GROWTH-FACTOR; CRYSTAL-STRUCTURE; EXTRACELLULAR DOMAIN; SH2		Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA	Yale University	Schlessinger, J (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA.	joseph.schlessinger@yale.edu						Abe Y, 1998, J BIOL CHEM, V273, P11150, DOI 10.1074/jbc.273.18.11150; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; CARPENTER G, 1978, NATURE, V276, P409, DOI 10.1038/276409a0; Cho HS, 2002, SCIENCE, V297, P1330, DOI 10.1126/science.1074611; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; Garrett TPJ, 1998, NATURE, V394, P395, DOI 10.1038/28668; GOTOH N, 1992, BIOCHEM BIOPH RES CO, V186, P768, DOI 10.1016/0006-291X(92)90812-Y; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GULLICK WJ, 1994, EUR J CANCER, V30A, P2186, DOI 10.1016/0959-8049(94)00365-C; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Jiang GQ, 1999, CURR BIOL, V9, pR568, DOI 10.1016/S0960-9822(99)80357-1; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; Lemmon MA, 1997, EMBO J, V16, P281, DOI 10.1093/emboj/16.2.281; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; Pawson T, 2001, TRENDS CELL BIOL, V11, P504, DOI 10.1016/S0962-8924(01)02154-7; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Tzahar E, 1997, EMBO J, V16, P4938, DOI 10.1093/emboj/16.16.4938; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K	20	755	796	3	67	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 20	2002	110	6					669	672		10.1016/S0092-8674(02)00966-2	http://dx.doi.org/10.1016/S0092-8674(02)00966-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	596TV	12297041	Bronze			2022-12-28	WOS:000178182800003
J	Cutts, J; Lee, G; Berarducci, M; Thomas, C; Dempsey, PK; Kadish, SP				Cutts, J; Lee, G; Berarducci, M; Thomas, C; Dempsey, PK; Kadish, SP			Goosebumps	LANCET			English	Article									Lahey Clin Med Ctr, Burlington, MA 01805 USA	Lahey Hospital & Medical Center	Kadish, SP (corresponding author), Lahey Clin Med Ctr, Burlington, MA 01805 USA.							Boulant J., 1980, HDB HYPOTHALAMUS A, V3A, P1; FERE C, 1896, C R SOC BIOL, V48, P1034; Roze E, 2000, J NEUROL NEUROSUR PS, V68, P647, DOI 10.1136/jnnp.68.5.647	3	9	9	1	18	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 31	2002	360	9334					690	690		10.1016/S0140-6736(02)09840-9	http://dx.doi.org/10.1016/S0140-6736(02)09840-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	590AM	12241877				2022-12-28	WOS:000177795100012
J	Rupert, PB; Massey, AP; Sigurdsson, ST; Ferre-D'Amare, AR				Rupert, PB; Massey, AP; Sigurdsson, ST; Ferre-D'Amare, AR			Transition state stabilization by a catalytic RNA	SCIENCE			English	Article							HAIRPIN RIBOZYME CLEAVAGE; URIDINE VANADATE COMPLEX; RIBONUCLEASE-A; BINDING-ENERGY; MECHANISM; ANALOG; ENZYME; LOOP; ION	The hairpin ribozyme catalyzes sequence-specific cleavage of RNA through transesterification of the scissile phosphate. Vanadate has previously been used as a transition state mimic of protein enzymes that catalyze the same reaction. Comparison of the 2.2 angstrom resolution structure of a vanadate-hairpin ribozyme complex with structures of precursor and product complexes reveals a rigid active site that makes more hydrogen bonds to the transition state than to the precursor or product. Because of the paucity of RNA functional groups capable of general acid-base or electrostatic catalysis, transition state stabilization is likely to be an important catalytic strategy for ribozymes.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Ferre-D'Amare, AR (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, 1100 Fairview Ave N, Seattle, WA 98109 USA.		Sigurdsson, Snorri Th/B-9359-2008	Sigurdsson, Snorri Th/0000-0003-2492-1456	NCRR NIH HHS [RR15943] Funding Source: Medline; NIGMS NIH HHS [GM56947, GM63576] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR015943] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063576, R01GM056947] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Butcher SE, 1999, NAT STRUCT BIOL, V6, P212; Cai ZP, 1996, BIOCHEMISTRY-US, V35, P6026, DOI 10.1021/bi952985g; Deng H, 1998, J AM CHEM SOC, V120, P4717, DOI 10.1021/ja972824v; Fedor MJ, 2000, J MOL BIOL, V297, P269, DOI 10.1006/jmbi.2000.3560; Hampel A, 1997, CHEM BIOL, V4, P513, DOI 10.1016/S1074-5521(97)90323-9; Hertel KJ, 1997, P NATL ACAD SCI USA, V94, P8497, DOI 10.1073/pnas.94.16.8497; KRAUSS M, 1992, J AM CHEM SOC, V114, P3630, DOI 10.1021/ja00036a008; Lebruska LL, 2002, CHEM BIOL, V9, P465, DOI 10.1016/S1074-5521(02)00130-8; LINDQUIST RN, 1973, J AM CHEM SOC, V95, P8762, DOI 10.1021/ja00807a043; Massey A., UNPUB; Messmore JM, 2000, J AM CHEM SOC, V122, P9911, DOI 10.1021/ja0021058; Nakano S, 2000, SCIENCE, V287, P1493, DOI 10.1126/science.287.5457.1493; NARLIKAR GJ, 1995, P NATL ACAD SCI USA, V92, P3668, DOI 10.1073/pnas.92.9.3668; Nesbitt S, 1997, CHEM BIOL, V4, P619, DOI 10.1016/S1074-5521(97)90247-7; PAGE MI, 1971, P NATL ACAD SCI USA, V68, P1678, DOI 10.1073/pnas.68.8.1678; Pauling L., 1946, CHEM ENG NEWS, V24, P1375, DOI [10.1021/cen-v024n010.p1375, DOI 10.1021/CEN-V024N010.P1375]; Perrotta AT, 1999, SCIENCE, V286, P123, DOI 10.1126/science.286.5437.123; Pinard R, 2001, EMBO J, V20, P6434, DOI 10.1093/emboj/20.22.6434; Raines RT, 1998, CHEM REV, V98, P1045, DOI 10.1021/cr960427h; Rupert PB, 2001, NATURE, V410, P780, DOI 10.1038/35071009; Ryder SP, 2002, NUCLEIC ACIDS RES, V30, P1287, DOI 10.1093/nar/30.6.1287; Ryder SP, 2001, RNA, V7, P1454; Saenger W., 1984, PRINCIPLES NUCL ACID, P107; Shan SO, 1999, METHOD ENZYMOL, V308, P246; VEENSTRA TD, 1994, BIOPHYS J, V67, P331, DOI 10.1016/S0006-3495(94)80485-0; Wladkowski BD, 1998, J AM CHEM SOC, V120, P5488, DOI 10.1021/ja972296n; WLODAWER A, 1983, P NATL ACAD SCI-BIOL, V80, P3628, DOI 10.1073/pnas.80.12.3628; Young KJ, 1997, NUCLEIC ACIDS RES, V25, P3760, DOI 10.1093/nar/25.19.3760	28	232	238	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 15	2002	298	5597					1421	1424		10.1126/science.1076093	http://dx.doi.org/10.1126/science.1076093			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	615AF	12376595				2022-12-28	WOS:000179223100052
J	Blomqvist, D; Andersson, M; Kupper, C; Cuthill, IC; Kis, J; Lanctot, RB; Sandercock, BK; Szekely, T; Wallander, J; Kempenaers, B				Blomqvist, D; Andersson, M; Kupper, C; Cuthill, IC; Kis, J; Lanctot, RB; Sandercock, BK; Szekely, T; Wallander, J; Kempenaers, B			Genetic similarity between mates and extra-pair parentage in three species of shorebirds	NATURE			English	Article							GREAT REED WARBLER; HATCHING FAILURE; BIRDS; PATERNITY; MICROSATELLITES; FERTILIZATIONS; PROMISCUITY; SURVIVAL; REVEAL; LEKS	Matings between close relatives often reduce the fitness of offspring, probably because homozygosity leads to the expression of recessive deleterious alleles(1-5). Studies of several animals have shown that reproductive success is lower when genetic similarity between parents is high(4-7), and that survival and other measures of fitness increase with individual levels of genetic diversity(8-11). These studies indicate that natural selection may favour the avoidance of matings with genetically similar individuals. But constraints on social mate choice, such as a lack of alternatives, can lead to pairing with genetically similar mates. In such cases, it has been suggested that females may seek extra-pair copulations with less related males(4), but the evidence is weak or lacking(4,5). Here we report a strong positive relationship between the genetic similarity of social pair members and the occurrence of extra-pair paternity and maternity ('quasi-parasitism') in three species of shorebirds. We propose that extra-pair parentage may represent adaptive behavioural strategies to avoid the negative effects of pairing with a genetically similar mate.	Max Planck Res Ctr Ornithol, D-82305 Seewiesen, Germany; Austrian Acad Sci, Konrad Lorenz Inst Comparat Ethol, A-1160 Vienna, Austria; Univ Gothenburg, Dept Zool, SE-40530 Gothenburg, Sweden; Univ Bristol, Sch Biol Sci, Ctr Behav Biol, Bristol BS8 1UG, Avon, England; Szent Istvan Univ, Fac Vet Sci, Inst Zool, Behav Biol Res Grp, H-1400 Budapest, Hungary; US Fish & Wildlife Serv, Anchorage, AK 99503 USA; Kansas State Univ, Div Biol, Manhattan, KS 66505 USA; Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England	Max Planck Society; Austrian Academy of Sciences; University of Gothenburg; University of Bristol; Hungarian University of Agriculture & Life Sciences; United States Department of the Interior; US Fish & Wildlife Service; Kansas State University; University of Bath	Kempenaers, B (corresponding author), Max Planck Res Ctr Ornithol, POB 1564, D-82305 Seewiesen, Germany.		Kis, Janos/D-2558-2013; Kis, Janos/AAG-3738-2019; Sandercock, Brett K/L-1644-2016; Küpper, Clemens/D-8116-2011; Szekely, Tamas/I-7089-2016	Kis, Janos/0000-0001-9354-1292; Sandercock, Brett K/0000-0002-9240-0268; Küpper, Clemens/0000-0002-1507-8033; Szekely, Tamas/0000-0003-2093-0056; Kempenaers, Bart/0000-0002-7505-5458				Alves MAS, 1998, ANIM BEHAV, V56, P1323, DOI 10.1006/anbe.1998.0910; Amos W, 2001, P ROY SOC B-BIOL SCI, V268, P2021, DOI 10.1098/rspb.2001.1751; BENSCH S, 1994, EVOLUTION, V48, P317, DOI 10.1111/j.1558-5646.1994.tb01314.x; BROOKER MG, 1990, BEHAV ECOL SOCIOBIOL, V26, P191; Brown JL, 1997, BEHAV ECOL, V8, P60, DOI 10.1093/beheco/8.1.60; Carter Royston E., 2000, P113; Coltman DW, 1998, P ROY SOC B-BIOL SCI, V265, P803, DOI 10.1098/rspb.1998.0363; Coulson TN, 1998, P ROY SOC B-BIOL SCI, V265, P489, DOI 10.1098/rspb.1998.0321; DEL HOYO J., 1996, HDB BIRDS WORLD, V3; Ellegren H, 1997, NAT GENET, V17, P182, DOI 10.1038/ng1097-182; Griffiths R, 1998, MOL ECOL, V7, P1071, DOI 10.1046/j.1365-294x.1998.00389.x; Hansson B, 2001, P ROY SOC B-BIOL SCI, V268, P1287, DOI 10.1098/rspb.2001.1640; Hasselquist D, 1996, NATURE, V381, P229, DOI 10.1038/381229a0; Hoglund J, 1999, P ROY SOC B-BIOL SCI, V266, P813; Jennions MD, 2000, BIOL REV, V75, P21, DOI 10.1017/S0006323199005423; JIMENEZ JA, 1994, SCIENCE, V266, P271, DOI 10.1126/science.7939661; Kempenaers B, 1996, P ROY SOC B-BIOL SCI, V263, P179, DOI 10.1098/rspb.1996.0029; KEMPENAERS B, 1992, NATURE, V357, P494, DOI 10.1038/357494a0; Olsson M, 2001, J HERED, V92, P190, DOI 10.1093/jhered/92.2.190; Petrie M, 1999, NATURE, V401, P155, DOI 10.1038/43651; Petrie M, 1998, TRENDS ECOL EVOL, V13, P52, DOI 10.1016/S0169-5347(97)01232-9; SHIN HS, 1985, NATURE, V317, P445, DOI 10.1038/317445a0; Shorey L, 2000, NATURE, V408, P352, DOI 10.1038/35042562; STOCKLEY P, 1993, P ROY SOC B-BIOL SCI, V254, P173, DOI 10.1098/rspb.1993.0143; Thornhill N.W., 1993, NATURAL HIST INBREED; Tregenza T, 2002, NATURE, V415, P71, DOI 10.1038/415071a; VANNOORDWIJK AJ, 1981, EVOLUTION, V35, P674, DOI 10.1111/j.1558-5646.1981.tb04929.x; Wallander J, 2001, ETHOLOGY, V107, P561, DOI 10.1046/j.1439-0310.2001.00695.x; WESTNEAT DF, 1993, BEHAV ECOL, V4, P49, DOI 10.1093/beheco/4.1.49; Westneat DF, 1997, BEHAV ECOL SOCIOBIOL, V41, P205, DOI 10.1007/s002650050381	30	177	182	0	90	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 10	2002	419	6907					613	615		10.1038/nature01104	http://dx.doi.org/10.1038/nature01104			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	602AT	12374978				2022-12-28	WOS:000178483100044
J	Sachs, JD				Sachs, JD			A new global effort to control malaria	SCIENCE			English	Editorial Material									Columbia Univ, Earth Inst, New York, NY 10027 USA; WHO, Commiss Macroecon & Hlth, Geneva, Switzerland	Columbia University; World Health Organization	Sachs, JD (corresponding author), Columbia Univ, Earth Inst, New York, NY 10027 USA.							Dietz K., 1988, MALARIA PRINCIPLES P, V2, P1091; Gallup JL, 2001, AM J TROP MED HYG, V64, P85, DOI 10.4269/ajtmh.2001.64.85; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Holt RA, 2002, SCIENCE, V298, P129, DOI 10.1126/science.1076181; Long CA, 2002, SCIENCE, V297, P345, DOI 10.1126/science.1074484; Sachs J, 2002, NATURE, V415, P680, DOI 10.1038/415680a; Spielman A, 2002, IND ANTIMALARIA POLI; Utzinger J, 2002, TROP MED INT HEALTH, V7, P657, DOI 10.1046/j.1365-3156.2002.00916.x; Utzinger J, 2001, TROP MED INT HEALTH, V6, P677, DOI 10.1046/j.1365-3156.2001.00769.x; *WORLD EC FOR, 2002, GLOB HLTH IN RES PAP; World Health Organization, 2001, COMM MACR HLTH INV H	11	52	57	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 4	2002	298	5591					122	124		10.1126/science.1077900	http://dx.doi.org/10.1126/science.1077900			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	600BJ	12364788	Green Submitted			2022-12-28	WOS:000178370500045
J	Sidow, A				Sidow, A			Sequence first. Ask questions later.	CELL			English	Review								Comparative sequence analyses of eukaryotic genes and genomic regions are beginning to provide a wealth of information that is directly relevant to human biology. Functional changes that set us apart from apes are identifiable, as are functional constraints in proteins and genomic elements that arose in our relatively distant phylogenetic past.	Stanford Univ, Dept Pathol, Stanford, CA 94305 USA; Stanford Univ, Dept Genet, Stanford, CA 94305 USA	Stanford University; Stanford University	Sidow, A (corresponding author), Stanford Univ, Dept Pathol, SUMC R248B,300 Pasteur Dr, Stanford, CA 94305 USA.	arend@stanford.edu						Eddy SR, 2002, CELL, V109, P137, DOI 10.1016/S0092-8674(02)00727-4; Enard W, 2002, NATURE, V418, P869, DOI 10.1038/nature01025; Enard W, 2002, SCIENCE, V296, P340, DOI 10.1126/science.1068996; Fay JC, 2000, GENETICS, V155, P1405; Gottgens B, 2002, GENOME RES, V12, P749, DOI 10.1101/gr.45502; Gottgens B, 2001, GENOME RES, V11, P87, DOI 10.1101/gr.153001; Lai CSL, 2001, NATURE, V413, P519, DOI 10.1038/35097076; Li W. H, 1997, MOL EVOLUTION; Madsen O, 2001, NATURE, V409, P610, DOI 10.1038/35054544; Murphy WJ, 2001, NATURE, V409, P614, DOI 10.1038/35054550; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; Pennacchio LA, 2001, SCIENCE, V294, P169, DOI 10.1126/science.1064852; Pupko T, 2002, BIOINFORMATICS, V18, P1116, DOI 10.1093/bioinformatics/18.8.1116; Simon AL, 2002, P NATL ACAD SCI USA, V99, P2912, DOI 10.1073/pnas.042692299; Sumiyama K, 2001, GENOMICS, V71, P260, DOI 10.1006/geno.2000.6422; Tahirov TH, 2002, CELL, V108, P57, DOI 10.1016/S0092-8674(01)00636-5	16	34	36	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 4	2002	111	1					13	16		10.1016/S0092-8674(02)01003-6	http://dx.doi.org/10.1016/S0092-8674(02)01003-6			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	601RQ	12372296	Bronze			2022-12-28	WOS:000178461900004
J	Zdobnov, EM; von Mering, C; Letunic, I; Torrents, D; Suyama, M; Copley, RR; Christophides, GK; Thomasova, D; Holt, RA; Subramanian, GM; Mueller, HM; Dimopoulos, G; Law, JH; Wells, MA; Birney, E; Charlab, R; Halpern, AL; Kokoza, E; Kraft, CL; Lai, ZW; Lewis, S; Louis, C; Barillas-Mury, C; Nusskern, D; Rubin, GM; Salzberg, SL; Sutton, GG; Topalis, P; Wides, R; Wincker, P; Yandell, M; Collins, FH; Ribeiro, J; Gelbart, WM; Kafatos, FC; Bork, P				Zdobnov, EM; von Mering, C; Letunic, I; Torrents, D; Suyama, M; Copley, RR; Christophides, GK; Thomasova, D; Holt, RA; Subramanian, GM; Mueller, HM; Dimopoulos, G; Law, JH; Wells, MA; Birney, E; Charlab, R; Halpern, AL; Kokoza, E; Kraft, CL; Lai, ZW; Lewis, S; Louis, C; Barillas-Mury, C; Nusskern, D; Rubin, GM; Salzberg, SL; Sutton, GG; Topalis, P; Wides, R; Wincker, P; Yandell, M; Collins, FH; Ribeiro, J; Gelbart, WM; Kafatos, FC; Bork, P			Comparative genome and proteome analysis of anopheles gambiae and Drosophila melanogaster	SCIENCE			English	Article							DOSAGE-COMPENSATION; INNATE IMMUNITY; REGULATORY ELEMENTS; MALARIA MOSQUITO; GENE FAMILIES; FUGU-RUBRIPES; EVOLUTION; SEQUENCE; INSECTS; IDENTIFICATION	Comparison of the genomes and proteomes of the two diptera Anopheles gambiae and Drosophila melanogaster, which diverged about 250 million years ago, reveals considerable similarities. However, numerous differences are also observed; some of these must reflect the selection and subsequent adaptation associated with different ecologies and life strategies. Almost half of the genes in both genomes are interpreted as orthologs and show an average sequence identity of about 56%, which is slightly lower than that observed between the orthologs of the pufferfish and human (diverged about 450 million years ago). This indicates that these two insects diverged considerably faster than vertebrates. Aligned sequences reveal that orthologous genes have retained only half of their intron/exon structure, indicating that intron gains or losses have occurred at a rate of about one per gene per 125 million years. Chromosomal arms exhibit significant remnants of homology between the two species, although only 34% of the genes colocalize in small "microsyntenic" clusters, and major interarm transfers as well as intra-arm shuffling of gene order are detected.	European Mol Biol Lab, D-69117 Heidelberg, Germany; Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Celera Genom, Rockville, MD 20850 USA; Univ London Imperial Coll Sci Technol & Med, Ctr Mol Microbiol & Infect, Dept Biol Sci, London SW7 2AZ, England; Univ Arizona, Tucson, AZ 85721 USA; European Bioinformat Inst, Cambridge CB10 1SD, England; Univ Calif Berkeley, Berkeley, CA 94720 USA; Russian Acad Sci, Inst Cytol & Genet, Sibirian Div, Novosibirsk 630090, Russia; Fdn Res & Technol Hellas, Inst Mol Biol & Biotechnol, GR-71110 Iraklion, Crete, Greece; Univ Crete, GR-71110 Iraklion, Crete, Greece; Colorado State Univ, Ft Collins, CO 80523 USA; Inst Genome Res, Rockville, MD 20850 USA; Bar Ilan Univ, Fac Life Sci, Ramat Gan, Israel; Genoscope Ctr Natl Sequencage, F-91057 Evry 06, France; CNRS, UMR 8030, F-91057 Evry 06, France; Univ Notre Dame, Ctr Trop Dis Res & Training, Notre Dame, IN 46556 USA; NIAID, Lab Malaria & Vector Res, Bethesda, MD 20892 USA; Harvard Univ, Cambridge, MA 02138 USA	European Molecular Biology Laboratory (EMBL); University of Oxford; Wellcome Centre for Human Genetics; Imperial College London; University of Arizona; European Molecular Biology Laboratory (EMBL); University of California System; University of California Berkeley; Russian Academy of Sciences; Institute of Cytology & Genetics ICG SB RAS; Foundation for Research & Technology - Hellas (FORTH); University of Crete; Colorado State University; J. Craig Venter Institute; Bar Ilan University; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; CEA; University of Notre Dame; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Harvard University	Zdobnov, EM (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.		von Mering, Christian/B-3300-2008; Salzberg, Steven/Q-6514-2019; Salzberg, Steven L/F-6162-2011; Zdobnov, Evgeny M/K-1133-2012; Letunic, Ivica/K-1102-2019; Bork, Peer/F-1813-2013; Letunic, Ivica/A-6032-2009; Kokoza, E l e n a/N-8507-2015; Holt, Robert A/C-3303-2009; Zdobnov, Evgeny/AAB-2745-2022; Louis, Christos/F-2527-2012; Torrents, David/G-5785-2015	von Mering, Christian/0000-0001-7734-9102; Salzberg, Steven/0000-0002-8859-7432; Salzberg, Steven L/0000-0002-8859-7432; Letunic, Ivica/0000-0003-3560-4288; Bork, Peer/0000-0002-2627-833X; Holt, Robert A/0000-0002-7259-1247; Zdobnov, Evgeny/0000-0002-5178-1498; Muller, Hans-Michael/0000-0002-2384-7285; Suyama, Mikita/0000-0001-9526-3193; Lewis, Suzanna/0000-0002-8343-612X; Torrents, David/0000-0002-6086-9037; Rubin, Gerald/0000-0001-8762-8703; Birney, Ewan/0000-0001-8314-8497; Christophides, George/0000-0002-3323-1687; Ribeiro, Jose/0000-0002-9107-0818; Dimopoulos, George/0000-0001-6755-8111	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000810, Z01AI000810] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adema CM, 1997, P NATL ACAD SCI USA, V94, P8691, DOI 10.1073/pnas.94.16.8691; Affolter M, 2001, EMBO J, V20, P3298, DOI 10.1093/emboj/20.13.3298; Aguinaldo AMA, 1997, NATURE, V387, P489, DOI 10.1038/387489a0; Aparicio S, 2002, SCIENCE, V297, P1301, DOI 10.1126/science.1072104; APARICIO S, 1995, P NATL ACAD SCI USA, V92, P1684, DOI 10.1073/pnas.92.5.1684; Apweiler R, 2000, BIOINFORMATICS, V16, P1145, DOI 10.1093/bioinformatics/16.12.1145; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; ASHBURNER M, 1989, DROSOPHILA LAB HDB, P74; Bancroft I, 2001, TRENDS GENET, V17, P89, DOI 10.1016/S0168-9525(00)02179-X; BARILLASMURY C, UNPUB; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; BESANSKY NJ, 1992, J MED ENTOMOL, V29, P125, DOI 10.1093/jmedent/29.1.125; Blair JE, 2002, BMC EVOL BIOL, V2, DOI 10.1186/1471-2148-2-7; Bolshakov VN, 2002, GENOME RES, V12, P57, DOI 10.1101/gr.196101; Bork P, 2000, GENOME RES, V10, P398, DOI 10.1101/gr.10.4.398; Christophides GK, 2002, SCIENCE, V298, P159, DOI 10.1126/science.1077136; CLARK AJ, 1959, J BIOL CHEM, V234, P2578; Clements A. N., 1992, BIOL MOSQUITOES, V1; DIETMAIER W, 1994, CURR GENET, V26, P497, DOI 10.1007/BF00309940; Dimopoulos G, 2002, P NATL ACAD SCI USA, V99, P8814, DOI 10.1073/pnas.092274999; Dimopoulos G, 2000, P NATL ACAD SCI USA, V97, P6619, DOI 10.1073/pnas.97.12.6619; FITCH WM, 1970, SYST ZOOL, V19, P99, DOI 10.2307/2412448; Gaunt MW, 2002, MOL BIOL EVOL, V19, P748, DOI 10.1093/oxfordjournals.molbev.a004133; GEORGE EL, 1989, MOL CELL BIOL, V9, P2957, DOI 10.1128/MCB.9.7.2957; Gilbert W, 1997, P NATL ACAD SCI USA, V94, P7698, DOI 10.1073/pnas.94.15.7698; Gokudan S, 1999, P NATL ACAD SCI USA, V96, P10086, DOI 10.1073/pnas.96.18.10086; GREEN P, 1993, SCIENCE, V259, P1711, DOI 10.1126/science.8456298; Hardison RC, 2000, TRENDS GENET, V16, P369, DOI 10.1016/S0168-9525(00)02081-3; HATZOPOULOS P, 1987, EMBO J, V6, P3091, DOI 10.1002/j.1460-2075.1987.tb02617.x; Holt RA, 2002, SCIENCE, V298, P129, DOI 10.1126/science.1076181; Huxley J, 1940, NEW SYSTEMATICS, P185; Kairies N, 2001, P NATL ACAD SCI USA, V98, P13519, DOI 10.1073/pnas.201523798; Kanzok SM, 2001, SCIENCE, V291, P643, DOI 10.1126/science.291.5504.643; Kelley RL, 1999, CELL, V98, P513, DOI 10.1016/S0092-8674(00)81979-0; Korbel JO, 2002, TRENDS GENET, V18, P158, DOI 10.1016/S0168-9525(01)02597-5; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Letunic I, 2002, NUCLEIC ACIDS RES, V30, P242, DOI 10.1093/nar/30.1.242; Letunic I, 2002, HUM MOL GENET, V11, P1561, DOI 10.1093/hmg/11.13.1561; LI WH, 1981, NATURE, V292, P237, DOI 10.1038/292237a0; Lyko F, 2001, TRENDS GENET, V17, P169, DOI 10.1016/S0168-9525(01)02234-X; Meller VH, 2000, TRENDS CELL BIOL, V10, P54, DOI 10.1016/S0962-8924(99)01693-1; Monnerat AT, 2002, MEM I OSWALDO CRUZ, V97, P589, DOI 10.1590/S0074-02762002000400026; Pannuti A, 2000, CURR OPIN GENET DEV, V10, P644, DOI 10.1016/S0959-437X(00)00136-2; PARO R, 1983, EMBO J, V2, P853, DOI 10.1002/j.1460-2075.1983.tb01513.x; Petrov DA, 1996, NATURE, V384, P346, DOI 10.1038/384346a0; Petrov DA, 2001, TRENDS GENET, V17, P23, DOI 10.1016/S0168-9525(00)02157-0; Ranson H, 2002, SCIENCE, V298, P179, DOI 10.1126/science.1076781; Ribeiro JMC, 1999, J EXP BIOL, V202, P809; Rogozin IB, 2000, TRENDS GENET, V16, P430, DOI 10.1016/S0168-9525(00)02096-5; Schmid KJ, 1997, P NATL ACAD SCI USA, V94, P9746, DOI 10.1073/pnas.94.18.9746; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; Schmucker D, 2000, CELL, V101, P671, DOI 10.1016/S0092-8674(00)80878-8; Schutt C, 2000, DEVELOPMENT, V127, P667; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; Sokal R.R., 2012, BIOMETRY; Stoltzfus A, 1997, P NATL ACAD SCI USA, V94, P10739, DOI 10.1073/pnas.94.20.10739; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; Thomasova D, 2002, P NATL ACAD SCI USA, V99, P8179, DOI 10.1073/pnas.082235599; Wegener G, 1996, EXPERIENTIA, V52, P404, DOI 10.1007/BF01919307; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711; Wong S, 2002, P NATL ACAD SCI USA, V99, P9272, DOI 10.1073/pnas.142101099; Yeates DK, 1999, ANNU REV ENTOMOL, V44, P397, DOI 10.1146/annurev.ento.44.1.397; Youn HD, 1999, SCIENCE, V286, P790, DOI 10.1126/science.286.5440.790; Youn HD, 2000, IMMUNITY, V13, P85, DOI 10.1016/S1074-7613(00)00010-8; Zdobnov EM, 2001, BIOINFORMATICS, V17, P847, DOI 10.1093/bioinformatics/17.9.847	66	407	436	0	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 4	2002	298	5591					149	159		10.1126/science.1077061	http://dx.doi.org/10.1126/science.1077061			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	600BJ	12364792				2022-12-28	WOS:000178370500049
J	Florens, L; Washburn, MP; Raine, JD; Anthony, RM; Grainger, M; Haynes, JD; Moch, JK; Muster, N; Sacci, JB; Tabb, DL; Witney, AA; Wolters, D; Wu, YM; Gardner, MJ; Holder, AA; Sinden, RE; Yates, JR; Carucci, DJ				Florens, L; Washburn, MP; Raine, JD; Anthony, RM; Grainger, M; Haynes, JD; Moch, JK; Muster, N; Sacci, JB; Tabb, DL; Witney, AA; Wolters, D; Wu, YM; Gardner, MJ; Holder, AA; Sinden, RE; Yates, JR; Carucci, DJ			A proteomic view of the Plasmodium falciparum life cycle	NATURE			English	Article							MALARIA PARASITE; GENE-EXPRESSION; CHROMOSOMAL DOMAINS; IDENTIFICATION; SEQUENCE; PROTEINS; STAGE; MOSQUITO; TRANSCRIPTOME; ERYTHROCYTES	The completion of the Plasmodium falciparum clone 3D7 genome provides a basis on which to conduct comparative proteomics studies of this human pathogen. Here, we applied a high-throughput proteomics approach to identify new potential drug and vaccine targets and to better understand the biology of this complex protozoan parasite. We characterized four stages of the parasite life cycle (sporozoites, merozoites, trophozoites and gametocytes) by multidimensional protein identification technology. Functional profiling of over 2,400 proteins agreed with the physiology of each stage. Unexpectedly, the antigenically variant proteins of var and rif genes, defined as molecules on the surface of infected erythrocytes, were also largely expressed in sporozoites. The detection of chromosomal clusters encoding co-expressed proteins suggested a potential mechanism for controlling gene expression.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Syngenta Res & Technol, Dept Proteom & Metabolom, Torrey Mesa Res Inst, San Diego, CA 92121 USA; Univ London Imperial Coll Sci Technol & Med, Infect & Immun Sect, Dept Biol Sci, London SW7 2AZ, England; USN, Med Res Ctr, Malaria Program, Silver Spring, MD 20910 USA; Walter Reed Army Inst Res, Dept Immunol, Silver Spring, MD 20910 USA; Natl Inst Med Res, Div Parasitol, London NW7 1AA, England; Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA; Amer Type Culture Collect, Malaria Res & Reference Resource Ctr, Manassas, VA 20110 USA; Inst Genom Res, Rockville, MD 20850 USA	Scripps Research Institute; Syngenta; Imperial College London; United States Department of Defense; United States Navy; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); MRC National Institute for Medical Research; University of Washington; University of Washington Seattle; J. Craig Venter Institute	Yates, JR (corresponding author), Scripps Res Inst, Dept Cell Biol, SR-11,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jyates@scripps.edu	Pain, Arnab/L-5766-2015; Holder, Anthony A/A-7554-2013	Pain, Arnab/0000-0002-1755-2819; Holder, Anthony A/0000-0002-8490-6058; Florens, Laurence/0000-0002-9310-6650; Gardner, Malcolm/0000-0003-2180-5089; Tabb, David/0000-0001-7223-578X; Washburn, Michael/0000-0001-7568-2585; Witney, Adam/0000-0003-4561-7170	MRC [MC_U117532067] Funding Source: UKRI; Medical Research Council [MC_U117532067] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Banerjee R, 2002, P NATL ACAD SCI USA, V99, P990, DOI 10.1073/pnas.022630099; Billker O, 1998, NATURE, V392, P289, DOI 10.1038/32667; BLACKMAN MJ, 1994, METHOD CELL BIOL, V45, P213; Carlton JM, 2002, NATURE, V419, P512, DOI 10.1038/nature01099; Caron H, 2001, SCIENCE, V291, P1289, DOI 10.1126/science.1056794; Carter R, 1993, Methods Mol Biol, V21, P67; Cohen BA, 2000, NAT GENET, V26, P183, DOI 10.1038/79896; COPPEL RL, 1983, NATURE, V306, P751, DOI 10.1038/306751a0; Dechering KJ, 1999, MOL CELL BIOL, V19, P967; Deitsch KW, 1996, MOL BIOCHEM PARASIT, V76, P1, DOI 10.1016/0166-6851(95)02575-8; del Portillo HA, 2001, NATURE, V410, P839, DOI 10.1038/35071118; Dessens JT, 1999, EMBO J, V18, P6221, DOI 10.1093/emboj/18.22.6221; Eggleson KK, 1999, J BIOL CHEM, V274, P32411, DOI 10.1074/jbc.274.45.32411; Eisenhaber B, 1998, PROTEIN ENG, V11, P1155, DOI 10.1093/protein/11.12.1155; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Gardner MJ, 1998, SCIENCE, V282, P1126, DOI 10.1126/science.282.5391.1126; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Haynes J David, 2002, Methods Mol Med, V72, P535, DOI 10.1385/1-59259-271-6:535; Haynes J David, 2002, Methods Mol Med, V72, P489, DOI 10.1385/1-59259-271-6:489; Hayward RE, 2000, MOL MICROBIOL, V35, P6, DOI 10.1046/j.1365-2958.2000.01730.x; HernandezRivas R, 1997, MOL CELL BIOL, V17, P604, DOI 10.1128/MCB.17.2.604; Holder Anthony A., 1996, P77; KANAANI J, 1989, J BIOL CHEM, V264, P3194; Kaneko O, 2001, MOL BIOCHEM PARASIT, V118, P223, DOI 10.1016/S0166-6851(01)00391-7; Kappe SHI, 2001, P NATL ACAD SCI USA, V98, P9895, DOI 10.1073/pnas.171185198; Klemba M, 2002, ANNU REV BIOCHEM, V71, P275, DOI 10.1146/annurev.biochem.71.090501.145453; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Krungkrai J, 2000, PARASITE, V7, P19, DOI 10.1051/parasite/2000071019; Kyes SA, 1999, P NATL ACAD SCI USA, V96, P9333, DOI 10.1073/pnas.96.16.9333; Lercher MJ, 2002, NAT GENET, V31, P180, DOI 10.1038/ng887; Lockhart DJ, 2000, NATURE, V405, P827, DOI 10.1038/35015701; Mamoun CB, 2001, MOL MICROBIOL, V39, P26, DOI 10.1046/j.1365-2958.2001.02222.x; MELLOUK S, 1990, B WORLD HEALTH ORGAN, V68, P52; Mewes HW, 2002, NUCLEIC ACIDS RES, V30, P31, DOI 10.1093/nar/30.1.31; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; PACHECO ND, 1979, J PARASITOL, V65, P414, DOI 10.2307/3280286; Pinder JC, 1998, J CELL SCI, V111, P1831; Rabilloud T, 1999, ELECTROPHORESIS, V20, P3603, DOI 10.1002/(SICI)1522-2683(19991201)20:18&lt;3603::AID-ELPS3603&gt;3.0.CO;2-V; Rosenthal PJ, 2002, CURR PHARM DESIGN, V8, P1659, DOI 10.2174/1381612023394197; Sinden RE, 1996, ADV PARASIT, V38, P53, DOI 10.1016/S0065-308X(08)60033-0; Tabb DL, 2002, J PROTEOME RES, V1, P21, DOI 10.1021/pr015504q; Taylor HM, 2001, INFECT IMMUN, V69, P3635, DOI 10.1128/IAI.69.6.3635-3645.2001; Trenholme KR, 2000, P NATL ACAD SCI USA, V97, P4029, DOI 10.1073/pnas.040561197; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686	45	1008	1054	2	219	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 3	2002	419	6906					520	526		10.1038/nature01107	http://dx.doi.org/10.1038/nature01107			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	599RF	12368866				2022-12-28	WOS:000178348400047
J	Gardner, MJ; Shallom, SJ; Carlton, JM; Salzberg, SL; Nene, V; Shoaibi, A; Ciecko, A; Lynn, J; Rizzo, M; Weaver, B; Jarrahi, B; Brenner, M; Parvizi, B; Tallon, L; Moazzez, A; Granger, D; Fujii, C; Hansen, C; Pederson, J; Feldblyum, T; Peterson, J; Suh, B; Angiuoli, S; Pertea, M; Allen, J; Selengut, J; White, O; Cummings, LM; Smith, HO; Adams, MD; Venter, JC; Carucci, DJ; Hoffman, SL; Fraser, CM				Gardner, MJ; Shallom, SJ; Carlton, JM; Salzberg, SL; Nene, V; Shoaibi, A; Ciecko, A; Lynn, J; Rizzo, M; Weaver, B; Jarrahi, B; Brenner, M; Parvizi, B; Tallon, L; Moazzez, A; Granger, D; Fujii, C; Hansen, C; Pederson, J; Feldblyum, T; Peterson, J; Suh, B; Angiuoli, S; Pertea, M; Allen, J; Selengut, J; White, O; Cummings, LM; Smith, HO; Adams, MD; Venter, JC; Carucci, DJ; Hoffman, SL; Fraser, CM			Sequence of Plasmodium falciparum chromosomes 2, 10, 11 and 14	NATURE			English	Article							PROTEINS; RESOURCE; GENOME; SITES; MAP	The mosquito-borne malaria parasite Plasmodium falciparum kills an estimated 0.7-2.7 million people every year, primarily children in sub-Saharan Africa. Without effective interventions, a variety of factors-including the spread of parasites resistant to antimalarial drugs and the increasing insecticide resistance of mosquitoes-may cause the number of malaria cases to double over the next two decades(1). To stimulate basic research and facilitate the development of new drugs and vaccines, the genome of Plasmodium falciparum clone 3D7 has been sequenced using a chromosome- by-chromosome shotgun strategy(2-4). We report here the nucleotide sequences of chromosomes 10, 11 and 14, and a re-analysis of the chromosome 2 sequence(5). These chromosomes represent about 35% of the 23-megabase P. falciparum genome.	Inst Genom Res, Rockville, MD 20850 USA; USN, Malaria Program, Med Res Ctr, Silver Spring, MD 20910 USA	J. Craig Venter Institute; United States Department of Defense; United States Navy	Gardner, MJ (corresponding author), Inst Genom Res, 9712 Med Ctr Dr, Rockville, MD 20850 USA.		Salzberg, Steven L/F-6162-2011; Pertea, Mihaela/AAT-2705-2021; Angiuoli, Samuel V/H-7340-2014; Salzberg, Steven/Q-6514-2019	Salzberg, Steven L/0000-0002-8859-7432; Pertea, Mihaela/0000-0003-0762-8637; Salzberg, Steven/0000-0002-8859-7432; Angiuoli, Samuel/0000-0001-9525-4350; Nene, Vishvanath/0000-0001-7066-4169; Harper, David/0000-0002-8313-3516; Fraser, Claire/0000-0003-1462-2428; Allen, Jonathan/0000-0002-4359-8263				Apweiler R, 2001, NUCLEIC ACIDS RES, V29, P37, DOI 10.1093/nar/29.1.37; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Bowman S, 1999, NATURE, V400, P532, DOI 10.1038/22964; Breman JG, 2001, AM J TROP MED HYG, V64, P1; Cawley SE, 2001, MOL BIOCHEM PARASIT, V118, P167, DOI 10.1016/S0166-6851(01)00363-2; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Fairbrother WG, 2002, SCIENCE, V297, P1007, DOI 10.1126/science.1073774; Falquet L, 2002, NUCLEIC ACIDS RES, V30, P235, DOI 10.1093/nar/30.1.235; Florens L, 2002, NATURE, V419, P520, DOI 10.1038/nature01107; FOSTER J, 1995, PARASITOL TODAY, V11, P1, DOI 10.1016/0169-4758(95)80092-1; Gardner MJ, 1998, SCIENCE, V282, P1126, DOI 10.1126/science.282.5391.1126; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Glockner G, 2002, NATURE, V418, P79, DOI 10.1038/nature00847; Hall N, 2002, NATURE, V419, P527, DOI 10.1038/nature01095; Huestis R, 2001, MOL BIOCHEM PARASIT, V118, P187, DOI 10.1016/S0166-6851(01)00376-0; Hyman RW, 2002, NATURE, V419, P534, DOI 10.1038/nature01102; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Lai ZW, 1999, NAT GENET, V23, P309, DOI 10.1038/15484; Lasonder E, 2002, NATURE, V419, P537, DOI 10.1038/nature01111; LAWRENCE CE, 1993, SCIENCE, V262, P208, DOI 10.1126/science.8211139; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; Maniatis T, 2002, NATURE, V418, P236, DOI 10.1038/418236a; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; RAMCHATESINGH J, 1995, MOL CELL BIOL, V15, P4898; Salzberg SL, 1999, GENOMICS, V59, P24, DOI 10.1006/geno.1999.5854; Su XZ, 1999, SCIENCE, V286, P1351, DOI 10.1126/science.286.5443.1351; WALLIKER D, 1987, SCIENCE, V236, P1661, DOI 10.1126/science.3299700; Zuegge J, 2001, GENE, V280, P19, DOI 10.1016/S0378-1119(01)00776-4	30	146	155	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 3	2002	419	6906					531	534		10.1038/nature01094	http://dx.doi.org/10.1038/nature01094			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	599RF	12368868				2022-12-28	WOS:000178348400049
J	Gross, CP; Soffer, B; Bach, PB; Rajkumar, R; Forman, HP				Gross, CP; Soffer, B; Bach, PB; Rajkumar, R; Forman, HP			State expenditures for tobacco-control programs and the tobacco settlement	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SMOKING	Background: Despite controversy surrounding the use of funds arising from settlement agreements with the tobacco industry, little is known about the role of these funds in expenditures for state tobacco-control programs. Methods: We evaluated state expenditures for tobacco-control programs in fiscal year 2001 in the context of the amount of tobacco-settlement funds received and allocated to tobacco-control programs and in the context of other state-level economic and health data. Results: In 2001 the average state received $28.35 per capita from the tobacco settlement but allocated approximately 6 percent of these funds to tobacco-control programs. The average state dedicated $3.49 per capita (range, $0.10 to $15.47) to tobacco-control programs. The proportion of settlement funds allocated to tobacco-control programs varied from 0 to 100 percent and was strongly related to levels of tobacco-control funding (P<0.001). States with higher smoking rates tended to invest less per capita in tobacco-control programs (P=0.007), as did tobacco-producing states (the mean per capita expenditure was $1.20, as compared with $3.81 in non-tobacco-producing states; P<0.008). In a multivariate analysis, the proportion of the settlement revenue allocated to tobacco-control programs was the primary determinant of the level of total funding; the state tobacco-related health burden was unrelated to program funding. Conclusions: State health needs appear to have little effect on the funding of state tobacco-control programs. Because only a very small proportion of the tobacco settlement is being used for tobacco-control programs, the settlement represents an unrealized opportunity to reduce morbidity and mortality from smoking.	Yale Univ, Sch Med, Primary Care Ctr, Dept Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Radiol, New Haven, CT 06510 USA; Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA	Yale University; Yale University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Gross, CP (corresponding author), Yale Univ, Sch Med, Primary Care Ctr, Dept Med, 333 Cedar St,POB 208025, New Haven, CT 06520 USA.	cary.gross@yale.edu	Forman, Howard/ABH-8695-2020		NCI NIH HHS [1 K07 CA90402-01, K07 CA090402] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K07CA090402] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Biener L, 2000, BRIT MED J, V321, P351, DOI 10.1136/bmj.321.7257.351; *BUR EC AN, 2002, REG ACC DAT ANN STAT; *CDCP, 2002, CIG EXC TAX; *CDCP, 2002, STAT TOB ACT TRACK E; *CDCP, 2001, INV TOB CONTR STAT H, P19; *CDCP, 1999, CURR CIG SMOK AD 18; *CENS BUR, 2002, RANK TABL STAT POP 2; Chung PJ, 2002, HEALTH AFFAIR, V21, P254, DOI 10.1377/hlthaff.21.2.254; *CTR MED MED SERV, 2002, CMS64 MED FIN STAT T; *CTR TOB FREE KIDS, 2002, SHOW MON MID YEAR UP; *DEP HLTH HUM SERV, 2000, HLTH PEOPL 2010, V2; FARRAGHER T, 2001, SMOKE LITTLE DOLLAR2; Fichtenberg CM, 2000, NEW ENGL J MED, V343, P1772, DOI 10.1056/NEJM200012143432406; FINNEGAN M, 2002, LOS ANGELES TIM 0115, pB6; *HLTH POL TRACK SE, 2001, STAT ALL SETTL FUNDS; KAUFMAN M, 2001, WASHINGTON POST 1006, pA4; KEELER TE, 1993, J HEALTH ECON, V12, P1, DOI 10.1016/0167-6296(93)90037-F; Kessler DA, 2001, NEW ENGL J MED, V345, P535, DOI 10.1056/NEJM200108163450710; King C, 2001, NEW ENGL J MED, V345, P504, DOI 10.1056/NEJMsa003149; Lewitt E M, 1982, J Health Econ, V1, P121; MANSNERUS L, 2002, NY TIMES        1030, pA1; McCaffree DR, 1998, CHEST, V113, P1682, DOI 10.1378/chest.113.6.1682; Miller LS, 1998, PUBLIC HEALTH REP, V113, P140; MILLS R, 2000, HLTH INS COV, P10; *NAT AGR STAT SERV, 2000, CROP PROD 1999 SUMM; *NAT ASS ATT GEN, 2002, MAST SETTL AGR; *NAT CTR CHRON DIS, 1999, BEST PRACT COMPR TOB; PALCA J, 1990, SCIENCE, V250, P378, DOI 10.1126/science.2218543; Siegel M, 2000, AM J PUBLIC HEALTH, V90, P372, DOI 10.2105/AJPH.90.3.372; Wakefield M, 2000, TOB CONTROL, V9, P177, DOI 10.1136/tc.9.2.177	30	49	49	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 3	2002	347	14					1080	1086		10.1056/NEJMsa012743	http://dx.doi.org/10.1056/NEJMsa012743			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	599KD	12362010	Green Accepted, Bronze			2022-12-28	WOS:000178332900007
J	Hayashi, K; Matsuishi, S; Kamiya, T; Hirano, M; Hosono, H				Hayashi, K; Matsuishi, S; Kamiya, T; Hirano, M; Hosono, H			Light-induced conversion of an insulating refractory oxide into a persistent electronic conductor	NATURE			English	Article							ANION	Materials that are good electrical conductors are not in general optically transparent, yet a combination of high conductivity and transparency is desirable for many emerging opto-electronic applications(1-6). To this end, various transparent oxides composed of transition or post-transition metals (such as indium tin oxide) are rendered electrically conducting by ion doping(1-6). But such an approach does not work for the abundant transparent oxides of the main-group metals. Here we demonstrate process by which the transparent insulating oxide 12CaO.7Al(2)O(3) (refs 7-13) can be converted into an electrical conductor. H- ions are incorporated into the subnanometre-sized cages of the oxide by a thermal treatment in a hydrogen atmosphere; subsequent irradiation of the material with ultraviolet light results in a conductive state that persists after irradiation ceases. The photo-activated material exhibits moderate electrical conductivity (similar to0.3 S cm(-1)) at room temperature, with visible light absorption losses of only one per cent for 200-nm-thick films. We suggest that this concept can be applied to other main-group metal oxides, for the direct optical writing of conducting wires in insulating transparent media and the formation of a high-density optical memory.	Japan Sci & Technol Corp, Exploratory Res Adv Technol, Transparent Electroact Mat Project, Tatatsu Ku, Kawasaki, Kanagawa 2130012, Japan; Tokyo Inst Technol, Mat & Struct Lab, Midori Ku, Yokohama, Kanagawa 2268503, Japan	Japan Science & Technology Agency (JST); Tokyo Institute of Technology	Hayashi, K (corresponding author), Japan Sci & Technol Corp, Exploratory Res Adv Technol, Transparent Electroact Mat Project, Tatatsu Ku, KSP C-1232,3-2-1 Sakado, Kawasaki, Kanagawa 2130012, Japan.	k-hayashi@net.ksp.or.jp	Hosono, Hideo/T-1845-2019; Kamiya, Toshio/E-8615-2014; Hayashi, Katsuro/C-6157-2017; Hosono, HIdeo/J-3489-2013	Kamiya, Toshio/0000-0002-8358-240X; Hayashi, Katsuro/0000-0002-4413-6511; Hosono, HIdeo/0000-0001-9260-6728				AGULLOLOPEZ E, 1988, POINT DEFECTS MAT, pCH5; Bartl H., 1970, NEUES JB MINER MONAT, V35, P547, DOI DOI 10.1680/JADCR.16.00045; Giamello E, 1997, J PHYS CHEM B, V101, P971, DOI 10.1021/jp962619m; Ginley DS, 2000, MRS BULL, V25, P15, DOI 10.1557/mrs2000.256; HAMBERG I, 1986, J APPL PHYS, V60, pR123, DOI 10.1063/1.337534; Hayashi K, 2002, J AM CHEM SOC, V124, P738, DOI 10.1021/ja016112n; Hayward MA, 2002, SCIENCE, V295, P1882, DOI 10.1126/science.1068321; HENDERSON B, 1968, ADV PHYS, V17, P749, DOI 10.1080/00018736800101386; HOSONO H, 1990, J APPL PHYS, V67, P2840, DOI 10.1063/1.345453; HOSONO H, 1987, INORG CHEM, V26, P1192, DOI 10.1021/ic00255a003; Imlach J. A., 1971, CEMENT CONCRETE RES, V1, P57, DOI DOI 10.1016/0008-8846(71)90083-4; JEEVARATNAM J, 1964, J AM CERAM SOC, V47, P105, DOI 10.1111/j.1151-2916.1964.tb15669.x; Kawazoe H, 1997, NATURE, V389, P939, DOI 10.1038/40087; Kawazoe H, 2000, MRS BULL, V25, P28, DOI 10.1557/mrs2000.148; Li QX, 2002, APPL PHYS LETT, V80, P4259, DOI 10.1063/1.1476958; Mott N.F., 1979, ELECT PROCESSES NONC, Vsecond; OLIVER D, 1999, PHYS CHEM CHEM PHYS, V1, P713; ROBERTSON J, 1979, J PHYS C SOLID STATE, V12, P4767, DOI 10.1088/0022-3719/12/22/018; Thomas G, 1997, NATURE, V389, P907, DOI 10.1038/39999; Watauchi S, 2002, J CRYST GROWTH, V237, P801, DOI 10.1016/S0022-0248(01)02038-3; Weil J. A., 2006, ELECT PARAMAGNETIC R; WILLIAMS RT, 1986, CRC HDB LASER SCI 1, V3	22	383	395	4	176	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 3	2002	419	6906					462	465		10.1038/nature01053	http://dx.doi.org/10.1038/nature01053			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	599RF	12368851				2022-12-28	WOS:000178348400032
J	Nair, SR; Pearson, SB				Nair, SR; Pearson, SB			Mucous plug in the bronchus causing lung collapse	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Gen Infirm, Leeds LS1 3EX, W Yorkshire, England	Leeds General Infirmary	Nair, SR (corresponding author), Gen Infirm, Leeds LS1 3EX, W Yorkshire, England.								0	6	6	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 3	2002	347	14					1079	1079		10.1056/NEJMicm020362	http://dx.doi.org/10.1056/NEJMicm020362			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	599KD	12362009				2022-12-28	WOS:000178332900005
J	Saal, AE; Hauri, EH; Langmuir, CH; Perfit, MR				Saal, AE; Hauri, EH; Langmuir, CH; Perfit, MR			Vapour undersaturation in primitive mid-ocean-ridge basalt and the volatile content of Earth's upper mantle	NATURE			English	Article							CARBON-DIOXIDE SOLUBILITIES; MIDOCEAN RIDGES; TRACE-ELEMENTS; ATLANTIC RIDGE; POPPING ROCKS; WATER; SULFUR; H2O; STORAGE; MAGMAS	The analysis of volatiles in magmatic systems can be used to constrain the volatile content of the Earth's mantle and the influence that magmatic degassing has on the chemistry of the oceans and the atmosphere. But most volatile elements have very low solubilities in magmas at atmospheric pressure, and therefore virtually all erupted lavas are degassed and do not retain their primary volatile signatures. Here we report the undersaturated pre-eruptive volatile content for a suite of mid-ocean-ridge basalts from the Siqueiros intra-transform spreading centre. The undersaturation leads to correlations between volatiles and refractory trace elements that provide new constraints on volatile abundances and their behaviour in the upper mantle. Our data generate improved limits on the abundances of carbon dioxide, water, fluorine, sulphur and chlorine in the source of normal mid-ocean-ridge basalt. The incompatible behaviour of carbon dioxide, together with the CO2/Nb and CO2/Cl ratios, permit estimates of primitive carbon dioxide and chlorine to be made for degassed and chlorine-contaminated mid-ocean-ridge basalt magmas, and hence constrain degassing and contamination histories of mid-ocean ridges.	Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA; Carnegie Inst Washington, Dept Terr Magnetism, Washington, DC 20015 USA; Univ Florida, Dept Geol Sci, Gainesville, FL 32611 USA	Columbia University; Carnegie Institution for Science; State University System of Florida; University of Florida	Saal, AE (corresponding author), Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA.			Perfit, Michael/0000-0002-1399-8928				BOTTINGA Y, 1990, CHEM GEOL, V81, P255, DOI 10.1016/0009-2541(90)90050-H; BOUGAULT H, 1988, EARTH PLANET SC LETT, V88, P27, DOI 10.1016/0012-821X(88)90043-X; CARROLL MR, 1994, REV MINERAL, V30, P231; CHAUSSIDON M, 1989, EARTH PLANET SC LETT, V92, P144, DOI 10.1016/0012-821X(89)90042-3; CRISP JA, 1984, J VOLCANOL GEOTH RES, V20, P177, DOI 10.1016/0377-0273(84)90039-8; Danyushevsky LV, 2000, J PETROL, V41, P1329, DOI 10.1093/petrology/41.8.1329; Dixon JE, 1997, AM MINERAL, V82, P368; Dixon JE, 1995, J PETROL, V36, P1607; Dixon JE, 1995, J PETROL, V36, P1633; Donnelly K., 2002, GENESIS E MORB EXTEN; Gaetani GA, 1998, CONTRIB MINERAL PETR, V131, P323, DOI 10.1007/s004100050396; GERLACH TM, 1991, EARTH PLANET SC LETT, V105, P566, DOI 10.1016/0012-821X(91)90193-L; GRAHAM D, 1991, EARTH PLANET SC LETT, V105, P568, DOI 10.1016/0012-821X(91)90194-M; HAURI EH, IN PRESS CHEM GEOL; Hirth G, 1996, EARTH PLANET SC LETT, V144, P93, DOI 10.1016/0012-821X(96)00154-9; HOFMANN AW, 1988, EARTH PLANET SC LETT, V90, P297, DOI 10.1016/0012-821X(88)90132-X; JAVOY M, 1982, NATURE, V300, P171, DOI 10.1038/300171a0; JAVOY M, 1991, EARTH PLANET SC LETT, V107, P598, DOI 10.1016/0012-821X(91)90104-P; Jung H, 2001, SCIENCE, V293, P1460, DOI 10.1126/science.1062235; KINGSLEY RH, 1995, EARTH PLANET SC LETT, V129, P31, DOI 10.1016/0012-821X(94)00241-P; KLEIN EM, 1987, J GEOPHYS RES-SOLID, V92, P8089, DOI 10.1029/JB092iB08p08089; LORAND JP, 1990, GEOCHIM COSMOCHIM AC, V54, P1487, DOI 10.1016/0016-7037(90)90173-I; MARTY B, 1987, EARTH PLANET SC LETT, V83, P16, DOI 10.1016/0012-821X(87)90047-1; Marty B, 1998, CHEM GEOL, V145, P233, DOI 10.1016/S0009-2541(97)00145-9; MICHAEL P, 1995, EARTH PLANET SC LETT, V131, P301, DOI 10.1016/0012-821X(95)00023-6; MICHAEL PJ, 1988, GEOCHIM COSMOCHIM AC, V52, P555, DOI 10.1016/0016-7037(88)90110-X; Michael PJ, 1998, J GEOPHYS RES-SOL EA, V103, P18325, DOI 10.1029/98JB00791; MOORE JG, 1979, NATURE, V282, P250, DOI 10.1038/282250a0; MOORE JG, 1970, CONTRIB MINERAL PETR, V28, P272, DOI 10.1007/BF00388949; MORGAN JW, 1986, J GEOPHYS RES-SOLID, V91, P2375, DOI 10.1029/JB091iB12p12375; Perfit MR, 1996, EARTH PLANET SC LETT, V141, P91, DOI 10.1016/0012-821X(96)00052-0; Roedder E., 1984, REV MINERALOGY, V12; SCHILLING JG, 1980, PHILOS T R SOC A, V297, P147, DOI 10.1098/rsta.1980.0208; SIMONS K, IN PRESS GEOCHEM GEO; SIMS KW, IN PRESS GEOCHIM COS; Sobolev AV, 1996, EARTH PLANET SC LETT, V137, P45, DOI 10.1016/0012-821X(95)00203-O; WALLACE P, 1992, GEOCHIM COSMOCHIM AC, V56, P1863, DOI 10.1016/0016-7037(92)90316-B; Wallace P. J., 2000, ENCY VOLCANOES, P149; ZHANG YX, 1993, EARTH PLANET SC LETT, V117, P331, DOI 10.1016/0012-821X(93)90088-Q	39	586	611	8	183	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 3	2002	419	6906					451	455		10.1038/nature01073	http://dx.doi.org/10.1038/nature01073			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	599RF	12368848				2022-12-28	WOS:000178348400029
J	Greenberg, JO; Mazar, RM				Greenberg, JO; Mazar, RM			Toward a more global medical education	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH		Univ Penn, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Greenberg, JO (corresponding author), Univ Penn, Sch Med, Philadelphia, PA 19104 USA.							*ASS AM MED COLL, 2001, MED STUD GRAD QUEST; *ASS AM MED COLL, 1985, MED STUD GRAD QUEST; *ASS AM MED COLL, 1991, MED STUD GRAD QUEST; Bradford WD, 1996, ACAD MED, V71, P484, DOI 10.1097/00001888-199605000-00019; Gupta AR, 1999, AM J TROP MED HYG, V61, P1019, DOI 10.4269/ajtmh.1999.61.1019; Haq C, 2000, FAM MED, V32, P566; Heck J E, 1995, Fam Med, V27, P636; MILLER WC, 1995, AM J MED, V99, P291, DOI 10.1016/S0002-9343(99)80162-4; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; STOLBERG SG, 2002, NY TIMES        0512; *WHO COMM MACR HLT, 2002, REP; *WHO INF OFF, 2002, FACT SHEET; World Health Organization, 2002, GLOB FUND FIGHT AIDS; 2002, ECONOMIST       0629	14	3	3	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	2002	288	13					1651	1651		10.1001/jama.288.13.1651	http://dx.doi.org/10.1001/jama.288.13.1651			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	599BJ	12350201	hybrid			2022-12-28	WOS:000178314000030
J	Maguire, P; Pitceathly, C				Maguire, P; Pitceathly, C			Key communication skills and how to acquire them	BRITISH MEDICAL JOURNAL			English	Review							INTERVIEWING SKILLS; MEDICAL-STUDENTS; CANCER-PATIENTS; DISTRESS; FEEDBACK		Christie Hosp NHS Trust, Canc Res UK Psychol Med Grp, Manchester M20 4BX, Lancs, England	Christie NHS Foundation Trust; Christie Hospital	Maguire, P (corresponding author), Christie Hosp NHS Trust, Canc Res UK Psychol Med Grp, Manchester M20 4BX, Lancs, England.							Aspegren K, 1999, MED TEACH, V21, P563, DOI 10.1080/01421599978979; BECKMAN HB, 1984, ANN INTERN MED, V101, P692, DOI 10.7326/0003-4819-101-5-692; Booth K, 1996, J ADV NURS, V24, P522, DOI 10.1046/j.1365-2648.1996.22012.x; Butler C, 1996, CAN MED ASSOC J, V154, P1357; COX A, 1981, BRIT J PSYCHIAT, V138, P283, DOI 10.1192/bjp.138.4.283; Fallowfield L, 2002, LANCET, V359, P650, DOI 10.1016/S0140-6736(02)07810-8; GOLDBERG DP, 1993, PSYCHOL MED, V23, P185, DOI 10.1017/S0033291700038976; HARDMAN A, 1989, J PSYCHOSOM RES, V33, P235, DOI 10.1016/0022-3999(89)90051-2; HEAVEN C, 2001, THESIS U MANCHESTER; Kurtz S., 1998, TEACHING LEARNING CO; Ley P, 1988, COMMUNICATION PATIEN; Maguire P, 1996, EUR J CANCER, V32A, P1486, DOI 10.1016/0959-8049(96)00059-7; MAGUIRE P, 1978, PSYCHOL MED, V8, P695, DOI 10.1017/S0033291700018894; MAGUIRE P, 1986, BRIT MED J, V292, P1573, DOI 10.1136/bmj.292.6535.1573; Maguire P, 1996, EUR J CANCER, V32A, P78, DOI 10.1016/0959-8049(95)00527-7; NAJI SA, 1986, MED EDUC, V20, P140, DOI 10.1111/j.1365-2923.1986.tb01062.x; Parle M, 1996, PSYCHOL MED, V26, P735, DOI 10.1017/S0033291700037752; Parle M, 1997, SOC SCI MED, V44, P231, DOI 10.1016/S0277-9536(96)00148-7; RAMIREZ AJ, 1995, LANCET, V16, P724; ROTER DL, 1995, ARCH INTERN MED, V155, P1877, DOI 10.1001/archinte.155.17.1877; SILVERMAN J, 1998, SKILLS COMMUNICATING; STEWART MA, 1995, CAN MED ASSOC J, V152, P1423; Stewart ME, 1989, COMMUNICATING MED PA; TUCKETT D, 1985, M EXPERTS APPR SHAR	24	472	493	4	102	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 28	2002	325	7366					697	+		10.1136/bmj.325.7366.697	http://dx.doi.org/10.1136/bmj.325.7366.697			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	600JV	12351365	Green Published			2022-12-28	WOS:000178387600030
J	Spickard, A; Gabbe, SG; Christensen, JF				Spickard, A; Gabbe, SG; Christensen, JF			Mid-career burnout in generalist and specialist physicians	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							JOB-SATISFACTION; STRESS; HEALTH; CARE; MEDICINE; DOCTORS; IMPACT; WOMEN; LIFE		Vanderbilt Univ, Med Ctr, Nashville, TN USA; Legacy Hlth Syst, Portland, OR USA	Vanderbilt University; Legacy Health	Spickard, A (corresponding author), Ctr Profess Hlth, 1107 Oxford House, Nashville, TN 37232 USA.	Anderson.Spickard-Jr@vanderbilt.edu						[Anonymous], 1998, CAN MED ASSOC J, V158, P1191; Arnetz BB, 2001, SOC SCI MED, V52, P203, DOI 10.1016/S0277-9536(00)00220-3; Baruch-Feldman Caren, 2002, J Occup Health Psychol, V7, P84, DOI 10.1037/1076-8998.7.1.84; Buchbinder SB, 1999, AM J MANAG CARE, V5, P1431; Campbell DA, 2001, SURGERY, V130, P696, DOI 10.1067/msy.2001.116676; Christensen JB, 2001, WESTERN J MED, V174, P75, DOI 10.1136/ewjm.174.1.75; CHRISTENSEN JF, 1992, J GEN INTERN MED, V7, P424, DOI 10.1007/BF02599161; CHRISTENSEN JF, 2002, MED ENCOUNTER, V16, P20; Crane M, 1998, Med Econ, V75, P210; Crouse B J, 1995, Minn Med, V78, P29; DECKARD GJ, 1992, J INFECT DIS, V165, P224, DOI 10.1093/infdis/165.2.224; DOANWIGGINS L, 1995, ACAD EMERG MED, V2, P556, DOI 10.1111/j.1553-2712.1995.tb03261.x; Epstein R, 2001, WESTERN J MED, V174, P63, DOI 10.1136/ewjm.174.1.63; Epstein RM, 1999, JAMA-J AM MED ASSOC, V282, P833, DOI 10.1001/jama.282.9.833; FirthCozens J, 1997, SOC SCI MED, V44, P1017, DOI 10.1016/S0277-9536(96)00227-4; Freeborn DK, 2001, WESTERN J MED, V174, P13, DOI 10.1136/ewjm.174.1.13; GABBARD GO, 1989, JAMA-J AM MED ASSOC, V261, P2378, DOI 10.1001/jama.261.16.2378; GABBARD GO, 1985, JAMA-J AM MED ASSOC, V254, P2926, DOI 10.1001/jama.254.20.2926; Gabbe SG, 2002, AM J OBSTET GYNECOL, V186, P601, DOI 10.1067/mob.2002.122391; GARDNER JW, 1992, WESTERN J MED, V157, P457; Gautam M, 2001, WESTERN J MED, V174, P37, DOI 10.1136/ewjm.174.1.37; Gundersen L, 2001, ANN INTERN MED, V135, P145, DOI 10.7326/0003-4819-135-2-200107170-00023; Haas JS, 2000, J GEN INTERN MED, V15, P122, DOI 10.1046/j.1525-1497.2000.02219.x; Hirsch G, 1999, Physician Exec, V25, P30; Jackson SH, 1999, ACTA ANAESTH SCAND, V43, P583, DOI 10.1034/j.1399-6576.1999.430601.x; JOHNSON JV, 1995, J OCCUP ENVIRON MED, V37, P1151, DOI 10.1097/00043764-199509000-00018; Kmietowicz Z, 2001, BRIT MED J, V323, P887, DOI 10.1136/bmj.323.7318.887; LINN LS, 1985, JAMA-J AM MED ASSOC, V254, P2775, DOI 10.1001/jama.254.19.2775; Linzer M, 2000, J GEN INTERN MED, V15, P441, DOI 10.1046/j.1525-1497.2000.05239.x; MASLACH C, 1997, TRUTH BURNOUT, P13; MCCUE JD, 1982, NEW ENGL J MED, V306, P458, DOI 10.1056/NEJM198202253060805; McMurray JE, 2000, J GEN INTERN MED, V15, P372, DOI 10.1111/j.1525-1497.2000.im9908009.x; MCPHEE SJ, 2001, W J MED, V174, P75; Murray A, 2001, J GEN INTERN MED, V16, P451, DOI 10.1007/s11606-001-0040-z; Myers DG, 2000, AM PSYCHOL, V55, P56, DOI 10.1037/0003-066X.55.1.56; MYERS M, 1994, MED MARRIAGES LOOK P; NEUWIRTH ZE, 1999, NEWSWEEK        0913, P79; Novack DH, 1997, JAMA-J AM MED ASSOC, V278, P502, DOI 10.1001/jama.278.6.502; OConnor PG, 1997, MED CLIN N AM, V81, P1037, DOI 10.1016/S0025-7125(05)70562-9; Osler W., 1899, ALBANY MED ANN, V20, P307; Puddester D, 2001, WESTERN J MED, V174, P5, DOI 10.1136/ewjm.174.1.5; *RES SERV COMM, 1998, ANN INTERN MED, V109, P154; Ryan RM, 2000, AM PSYCHOL, V55, P68, DOI 10.1037/0003-066X.55.1.68; Ryff CD, 1996, PSYCHOTHER PSYCHOSOM, V65, P14, DOI 10.1159/000289026; SATTERFIELD JM, 2001, W J MED, V173, P26; Schmoldt R A, 1994, HMO Pract, V8, P58; Shanafelt TD, 2002, ANN INTERN MED, V136, P358, DOI 10.7326/0003-4819-136-5-200203050-00008; Spickard Jr A, 1998, FED B, V85, P8; Suchman AL, 2001, WESTERN J MED, V174, P43, DOI 10.1136/ewjm.174.1.43; Sullivan P, 1998, CAN MED ASSOC J, V159, P525; VAILLANT GE, 1972, NEW ENGL J MED, V287, P372, DOI 10.1056/NEJM197208242870802; Warde CM, 1999, J GEN INTERN MED, V14, P157, DOI 10.1046/j.1525-1497.1999.00307.x; Weiner EL, 2001, WESTERN J MED, V174, P19, DOI 10.1136/ewjm.174.1.19; WHITLEY TW, 1994, ANN EMERG MED, V23, P1068, DOI 10.1016/S0196-0644(94)70105-9; Williams ES, 2001, HEALTH CARE MANAGE R, V26, P7, DOI 10.1097/00004010-200101000-00002; Yamey G, 2001, BRIT MED J, V322, P252, DOI 10.1136/bmj.322.7281.252; Yao DC, 2000, JAMA-J AM MED ASSOC, V284, P1099, DOI 10.1001/jama.284.9.1099	57	341	350	0	38	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	2002	288	12					1447	1450		10.1001/jama.288.12.1447	http://dx.doi.org/10.1001/jama.288.12.1447			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	596AT	12243624				2022-12-28	WOS:000178142000002
J	Stein, MB				Stein, MB			A 46-year-old man with anxiety and nightmares after a motor vehicle collision	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							POSTTRAUMATIC-STRESS-DISORDER; CONFIRMATORY FACTOR-ANALYSIS; PSYCHIATRIC-DISORDERS; DOUBLE-BLIND; SLEEP DISTURBANCES; TERRORIST ATTACKS; CHILDHOOD ABUSE; COMBAT VETERANS; HEALTH-STATUS; RISK-FACTORS		Univ Calif San Diego, Dept Psychiat, Anxiety Disorders Program, La Jolla, CA 92037 USA; San Diego Vet Affairs Med Ctr, Anxiety & Traumat Stress Disorders Clin, San Diego, CA USA	University of California System; University of California San Diego	Stein, MB (corresponding author), Univ Calif San Diego, Dept Psychiat, Anxiety Disorders Program, 8950 Villa La Jolla Dr,Suite 2243, La Jolla, CA 92037 USA.	mstein@ucsd.edu			NATIONAL INSTITUTE OF MENTAL HEALTH [K24MH064122, R21MH062037] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Adshead G, 2000, BRIT J PSYCHIAT, V177, P144, DOI 10.1192/bjp.177.2.144; American Psychiatric Association, 2000, DIAGN STAT MAN MENT, V4th; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Asmundson GJG, 2000, BEHAV RES THER, V38, P203, DOI 10.1016/S0005-7967(99)00061-3; ASMUNDSON GJG, IN PRESS J NERV MENT; Baker DG, 1999, AM J PSYCHIAT, V156, P585; Blanchard EB, 1998, J TRAUMA STRESS, V11, P337, DOI 10.1023/A:1024407321677; Blanchard EB, 2002, J TRAUMA STRESS, V15, P199, DOI 10.1023/A:1015299126858; Brady K, 2000, JAMA-J AM MED ASSOC, V283, P1837, DOI 10.1001/jama.283.14.1837; Bremner JD, 1999, AM J PSYCHIAT, V156, P1787; BREMNER JD, 1995, AM J PSYCHIAT, V152, P973; Breslau N, 1998, ARCH GEN PSYCHIAT, V55, P626, DOI 10.1001/archpsyc.55.7.626; Breslau N, 1999, AM J PSYCHIAT, V156, P902, DOI 10.1176/ajp.156.6.902; Breslau N, 1997, ARCH GEN PSYCHIAT, V54, P81; Breslau Naomi, 2002, J Gend Specif Med, V5, P34; Bryant RA, 2000, J ABNORM PSYCHOL, V109, P341, DOI 10.1037/0021-843X.109.2.341; Bryant RA, 1999, AM J PSYCHIAT, V156, P1780; Campbell JC, 2002, LANCET, V359, P1331, DOI 10.1016/S0140-6736(02)08336-8; Chilcoat HD, 1998, ADDICT BEHAV, V23, P827, DOI 10.1016/S0306-4603(98)00069-0; Cohen J., 2013, STAT POWER ANAL BEHA, DOI DOI 10.4324/9780203771587; Connor KM, 1999, BRIT J PSYCHIAT, V175, P17, DOI 10.1192/bjp.175.1.17; Davidson J, 2001, AM J PSYCHIAT, V158, P1974, DOI 10.1176/appi.ajp.158.12.1974; Davidson JRT, 2001, JAMA-J AM MED ASSOC, V286, P584, DOI 10.1001/jama.286.5.584; Davidson JRT, 2001, ARCH GEN PSYCHIAT, V58, P485, DOI 10.1001/archpsyc.58.5.485; Davidson PR, 2001, J CONSULT CLIN PSYCH, V69, P305, DOI 10.1037/0022-006X.69.2.305; DAVIS M, 1999, NEUROBIOLOGY MENTAL, P463; Dyer C, 2002, BRIT MED J, V324, P563, DOI 10.1136/bmj.324.7337.563; Eisenstat SA, 1999, NEW ENGL J MED, V341, P886, DOI 10.1056/NEJM199909163411206; Foa EB, 1999, J CONSULT CLIN PSYCH, V67, P194, DOI 10.1037/0022-006X.67.2.194; Gabriel R, 2002, BRIT MED J, V324, P340, DOI 10.1136/bmj.324.7333.340; Galea S, 2002, NEW ENGL J MED, V346, P982, DOI 10.1056/NEJMsa013404; Gillespie K, 2002, BEHAV RES THER, V40, P345, DOI 10.1016/S0005-7967(02)00004-9; Gillin JC, 2001, J CLIN PSYCHIAT, V62, P789, DOI 10.4088/JCP.v62n1007; Gorman JM, 1999, J CLIN PSYCHIAT, V60, P33; Harvey AG, 1999, J CONSULT CLIN PSYCH, V67, P985, DOI 10.1037/0022-006X.67.6.985; Heim C, 2000, JAMA-J AM MED ASSOC, V284, P592, DOI 10.1001/jama.284.5.592; Holbrook TL, 2001, J TRAUMA, V51, P287, DOI 10.1097/00005373-200108000-00010; Keane TM, 1998, J CONSULT CLIN PSYCH, V66, P914, DOI 10.1037/0022-006X.66.6.914; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; King DW, 1998, PSYCHOL ASSESSMENT, V10, P90, DOI 10.1037/1040-3590.10.2.90; Koren D, 2002, AM J PSYCHIAT, V159, P855, DOI 10.1176/appi.ajp.159.5.855; Krakow B, 2001, JAMA-J AM MED ASSOC, V286, P537, DOI 10.1001/jama.286.5.537; Lavie P, 2001, NEW ENGL J MED, V345, P1825, DOI 10.1056/NEJMra012893; Marks I, 1998, ARCH GEN PSYCHIAT, V55, P317, DOI 10.1001/archpsyc.55.4.317; Marshall RD, 2001, AM J PSYCHIAT, V158, P1982, DOI 10.1176/appi.ajp.158.12.1982; Marshall RD, 2001, AM J PSYCHIAT, V158, P1467, DOI 10.1176/appi.ajp.158.9.1467; Martenyi F, 2002, J CLIN PSYCHIAT, V63, P199, DOI 10.4088/JCP.v63n0305; Mayou R, 2001, AM J PSYCHIAT, V158, P1231, DOI 10.1176/appi.ajp.158.8.1231; McCauley J, 1997, JAMA-J AM MED ASSOC, V277, P1362, DOI 10.1001/jama.277.17.1362; McGaugh JL, 1997, BEHAV BRAIN RES, V83, P31, DOI 10.1016/S0166-4328(97)86042-1; McQuaid JR, 2001, PSYCHOL MED, V31, P1249, DOI 10.1017/S0033291701004202; MELLMAN TA, 1992, AM J PSYCHIAT, V149, P1568; Mendlowicz MV, 2000, AM J PSYCHIAT, V157, P669, DOI 10.1176/appi.ajp.157.5.669; Michaels AJ, 1999, J TRAUMA, V47, P460, DOI 10.1097/00005373-199909000-00005; Mollica RF, 1999, JAMA-J AM MED ASSOC, V282, P433, DOI 10.1001/jama.282.5.433; Morrison PD, 2002, BRIT J PSYCHIAT, V180, P195, DOI 10.1192/bjp.180.3.195; Murray J, 2002, BRIT J PSYCHIAT, V180, P363, DOI 10.1192/bjp.180.4.363; *NAT CTR PTSD, FACTS PTSD; *NAT HIGHW TRAFF S, TRAFF SAF FACTS 2000; *NAT I MENT HLTH, REL TRAUM POST TRAUM; *NAT SAF COUNC, EST COSTS UN INJ 200; Neylan TC, 1998, AM J PSYCHIAT, V155, P929, DOI 10.1176/ajp.155.7.929; North CS, 1999, JAMA-J AM MED ASSOC, V282, P755, DOI 10.1001/jama.282.8.755; Ortega AN, 2000, AM J PSYCHIAT, V157, P615, DOI 10.1176/appi.ajp.157.4.615; Perkonigg A, 2000, ACTA PSYCHIAT SCAND, V101, P46, DOI 10.1034/j.1600-0447.2000.101001046.x; Pitman RK, 2002, BIOL PSYCHIAT, V51, P189, DOI 10.1016/S0006-3223(01)01279-3; Raskind MA, 2002, J CLIN PSYCHIAT, V63, P565, DOI 10.4088/JCP.v63n0705; Rauch SL, 2000, BIOL PSYCHIAT, V47, P769, DOI 10.1016/S0006-3223(00)00828-3; Richardson J., 2002, BRIT MED J, V324, P1, DOI DOI 10.1136/BMJ.324.7332.274; ROSE S, 2001, PSYCHOL DEBRIEFING P; Samson AY, 1999, J FAM PRACTICE, V48, P222; Saxe G, 2001, J AM ACAD CHILD PSY, V40, P915, DOI 10.1097/00004583-200108000-00013; Schlenger WE, 2002, JAMA-J AM MED ASSOC, V288, P581, DOI 10.1001/jama.288.5.581; Schnurr PP, 1999, J NERV MENT DIS, V187, P353, DOI 10.1097/00005053-199906000-00004; Schuster MA, 2001, NEW ENGL J MED, V345, P1507, DOI 10.1056/NEJM200111153452024; Shalev AY, 2002, BIOL PSYCHIAT, V51, P532, DOI 10.1016/S0006-3223(02)01335-5; Shalev AY, 1998, ARCH GEN PSYCHIAT, V55, P553, DOI 10.1001/archpsyc.55.6.553; Shalev AY, 1998, AM J PSYCHIAT, V155, P630, DOI 10.1176/ajp.155.5.630; Sharp TJ, 2001, CLIN PSYCHOL REV, V21, P857, DOI 10.1016/S0272-7358(00)00071-4; Silver RC, 2002, JAMA-J AM MED ASSOC, V288, P1235, DOI 10.1001/jama.288.10.1235; Stein MB, 2000, GEN HOSP PSYCHIAT, V22, P261, DOI 10.1016/S0163-8343(00)00080-3; Stein MB, 2000, BEHAV RES THER, V38, P619, DOI 10.1016/S0005-7967(99)00098-4; Stein MB, 1997, AM J PSYCHIAT, V154, P1114; Stein MB, 2001, J AFFECT DISORDERS, V66, P133, DOI 10.1016/S0165-0327(00)00301-3; STEIN MB, IN PRESS AM J PSYCHI; Stout SC, 2002, J PHARMACOL EXP THER, V300, P1085, DOI 10.1124/jpet.300.3.1085; Summerfield D, 2001, BRIT MED J, V322, P95, DOI 10.1136/bmj.322.7278.95; Taubman-Ben-Ari O, 2001, PSYCHOL MED, V31, P555, DOI 10.1017/S0033291701003658; Tucker P, 2001, J CLIN PSYCHIAT, V62, P860, DOI 10.4088/JCP.v62n1105; Ursano RJ, 1999, AM J PSYCHIAT, V156, P589; Van Ommeren M, 2001, ARCH GEN PSYCHIAT, V58, P475, DOI 10.1001/archpsyc.58.5.475; Walker EA, 1999, AM J MED, V107, P332, DOI 10.1016/S0002-9343(99)00235-1; Zatzick DF, 2002, ARCH SURG-CHICAGO, V137, P200, DOI 10.1001/archsurg.137.2.200; Zatzick DF, 2002, AM J PSYCHIAT, V159, P941, DOI 10.1176/appi.ajp.159.6.941; Zatzick DF, 2001, MED CARE, V39, P327, DOI 10.1097/00005650-200104000-00004	95	9	10	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	2002	288	12					1513	1522		10.1001/jama.288.12.1513	http://dx.doi.org/10.1001/jama.288.12.1513			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	596AT	12243639				2022-12-28	WOS:000178142000023
J	Baulcombe, D				Baulcombe, D			An RNA microcosm	SCIENCE			English	Editorial Material									John Innes Ctr Plant Sci Res, Sainsbury Lab, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Baulcombe, D (corresponding author), John Innes Ctr Plant Sci Res, Sainsbury Lab, Norwich NR4 7UH, Norfolk, England.			Baulcombe, David/0000-0003-0780-6878				Hamilton A, 2002, EMBO J, V21, P4671, DOI 10.1093/emboj/cdf464; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Llave C, 2002, SCIENCE, V297, P2053, DOI 10.1126/science.1076311; McConnell JR, 2001, NATURE, V411, P709, DOI 10.1038/35079635; MOCHIZUKI K, 2002, CELL            0814; Rhoades MW, 2002, CELL, V110, P513, DOI 10.1016/S0092-8674(02)00863-2; Ruvkun G, 2001, SCIENCE, V294, P797, DOI 10.1126/science.1066315; Tijsterman M, 2002, SCIENCE, V295, P694, DOI 10.1126/science.1067534; Zamore PD, 2002, SCIENCE, V296, P1265, DOI 10.1126/science.1072457	9	29	43	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 20	2002	297	5589					2002	2003		10.1126/science.1077906	http://dx.doi.org/10.1126/science.1077906			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	594XV	12242426				2022-12-28	WOS:000178078500029
J	Dudley, ME; Wunderlich, JR; Robbins, PF; Yang, JC; Hwu, P; Schwartzentruber, DJ; Topalian, SL; Sherry, R; Restifo, NP; Hubicki, AM; Robinson, MR; Raffeld, M; Duray, P; Seipp, CA; Rogers-Freezer, L; Morton, KE; Mavroukakis, SA; White, DE; Rosenberg, SA				Dudley, ME; Wunderlich, JR; Robbins, PF; Yang, JC; Hwu, P; Schwartzentruber, DJ; Topalian, SL; Sherry, R; Restifo, NP; Hubicki, AM; Robinson, MR; Raffeld, M; Duray, P; Seipp, CA; Rogers-Freezer, L; Morton, KE; Mavroukakis, SA; White, DE; Rosenberg, SA			Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes	SCIENCE			English	Article							TUMOR-INFILTRATING LYMPHOCYTES; T-CELL CLONES; ADOPTIVE IMMUNOTHERAPY; METASTATIC MELANOMA; IN-VIVO; INTERLEUKIN-2; RESPONSES; THERAPY; RECIPIENTS; INFECTION	We report here the adoptive transfer, to patients with metastatic melanoma, of highly selected tumor-reactive T cells directed against overexpressed self-derived differentiation antigens after a nonmyeloablative conditioning regimen. This approach resulted in the persistent clonal repopulation of T cells in those cancer patients, with the transferred cells proliferating in vivo, displaying functional activity, and trafficking to tumor sites. This led to regression of the patients metastatic melanoma as well as to the onset of autoimmune melanocyte destruction. This approach presents new possibilities for the treatment of patients with cancer as well as patients with human immunodeficiency virus related acquired immunodeficiency syndrome and other infectious diseases.	NCI, Surg Branch, NIH, Bethesda, MD 20902 USA; NEI, NIH, Bethesda, MD 20902 USA; NCI, Pathol Lab, NIH, Bethesda, MD 20902 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Rosenberg, SA (corresponding author), NCI, Surg Branch, NIH, Bethesda, MD 20902 USA.		Restifo, Nicholas Phillip/Z-1614-2019; Restifo, Nicholas Phillip/M-6549-2019; Restifo, Nicholas P/A-5713-2008	Restifo, Nicholas P./0000-0003-4229-4580	Intramural NIH HHS [Z01 BC010763-01, Z99 CA999999] Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		BERENSON JR, 1975, J IMMUNOL, V115, P234; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Callan MFC, 2000, J CLIN INVEST, V106, P1251, DOI 10.1172/JCI10590; CHESON BD, 1995, J CLIN ONCOL, V13, P2431, DOI 10.1200/JCO.1995.13.9.2431; Childs R, 2000, NEW ENGL J MED, V343, P750, DOI 10.1056/NEJM200009143431101; Dudley M., UNPUB; Dudley ME, 2001, J IMMUNOTHER, V24, P363, DOI 10.1097/00002371-200107000-00012; Dudley ME, 2002, J IMMUNOTHER, V25, P243, DOI 10.1097/00002371-200205000-00007; EBERLEIN TJ, 1982, J EXP MED, V156, P385; Hislop AD, 2002, J EXP MED, V195, P893, DOI 10.1084/jem.20011692; Jameson SC, 2002, NAT REV IMMUNOL, V2, P547, DOI 10.1038/nri853; KAWAKAMI Y, 1994, P NATL ACAD SCI USA, V91, P3515, DOI 10.1073/pnas.91.9.3515; MATLOUBIAN M, 1994, J VIROL, V68, P8056, DOI 10.1128/JVI.68.12.8056-8063.1994; Mitsuyasu RT, 2000, BLOOD, V96, P785, DOI 10.1182/blood.V96.3.785.015k10_785_793; NORTH RJ, 1982, J EXP MED, V155, P1063, DOI 10.1084/jem.155.4.1063; O'Reilly R J, 1996, Important Adv Oncol, P149; RIDDELL SR, 1990, J IMMUNOL METHODS, V128, P189, DOI 10.1016/0022-1759(90)90210-M; RIDDELL SR, 1992, SCIENCE, V257, P238; Rooney CM, 1998, BLOOD, V92, P1549, DOI 10.1182/blood.V92.5.1549.417k32_1549_1555; Rosenberg SA, 1998, ANN SURG, V228, P307, DOI 10.1097/00000658-199809000-00004; Rosenberg SA, 1998, NAT MED, V4, P321, DOI 10.1038/nm0398-321; ROSENBERG SA, 1990, NEW ENGL J MED, V323, P570, DOI 10.1056/NEJM199008303230904; ROSENBERG SA, 1994, J NATL CANCER I, V86, P1159, DOI 10.1093/jnci/86.15.1159; ROSENBERG SA, 1986, SCIENCE, V233, P1318, DOI 10.1126/science.3489291; Walker RE, 2000, BLOOD, V96, P467; WALTER EA, 1995, NEW ENGL J MED, V333, P1038, DOI 10.1056/NEJM199510193331603; Yee C, 2000, J EXP MED, V192, P1637, DOI 10.1084/jem.192.11.1637	27	2143	2374	2	166	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 25	2002	298	5594					850	854		10.1126/science.1076514	http://dx.doi.org/10.1126/science.1076514			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607KR	12242449	Green Accepted			2022-12-28	WOS:000178791200066
J	Vaughan-Sarrazin, MS; Hannan, EL; Gormley, CJ; Rosenthal, GE				Vaughan-Sarrazin, MS; Hannan, EL; Gormley, CJ; Rosenthal, GE			Mortality in medicare beneficiaries following coronary artery bypass graft surgery in states with and without certificate of need regulation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEW-YORK-STATE; CARDIAC-SURGERY; CABG SURGERY; VOLUME; QUALITY; OPERATIONS; RATES	Context Certificate of need regulation was designed to control health care costs by preventing health care facilities from expanding unnecessarily. While there have been several studies investigating whether these regulations have affected health care investment, few have evaluated the relationship between certificate of need regulation and quality of care. Objective To compare risk-adjusted mortality and hospital volumes for coronary artery bypass graft (CABG) surgery in states with and without certificate of need regulation. Design, Setting, and Participants Retrospective cohort study of 911407 Medicare beneficiaries aged 65 years or older, who underwent CABG surgery between 1994 and 1999 in 1063 US hospitals. Main Outcome Measures States (and the District of Columbia) with continuous (n=27), none (n=18), or intermittent (n=6) certificate of need regulation; mortality (in-hospital or within 30 days of CABG surgery) rates; and mean annual hospital volumes for CABG surgery. Results Unadjusted mortality was 5.1% in states without certificate of need regulation compared with 4.4% in states with continuous regulation, and 4.3% in states with intermittent certificate of need regulation (P<.001 for each comparison). Adjusting for demographic and clinical factors, mortality remained higher in states without certificate of need regulation compared with states with continuous certificate of need regulation (odds ratio [OR], 1.22; 95% confidence interval [CI], 1.15-1.28; P<.001). Using the same groups for comparison, the mean annual hospital volume for CABG surgery was 84% lower in states without certificate of need regulation (104 vs 191; P<.001) and more patients underwent CABG surgery in low-volume hospitals (<100 procedures annually) (30% vs 10% for states with continuous certificate of need programs; P<.001). Following the repeal of certificate of need regulation in states categorized as intermittent, the percentage of patients undergoing CABG surgery in low-volume hospitals tripled. Conclusions Mortality rates for Medicare patients undergoing CABG surgery were higher in states without certificate of need regulation. Repeal of certificate of need regulations during the study period was associated with declines in hospital volume for CABG surgery.	Univ Iowa Hosp & Clin, Div Gen Internal Med, Iowa City, IA 52242 USA; Vet Adm Med Ctr, Dept Med, Div Gen Internal Med, Iowa City, IA 52240 USA; SUNY Albany, Sch Publ Hlth, Albany, NY USA; Florida Hosp Assoc, Tallahassee, FL USA	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); State University of New York (SUNY) System; State University of New York (SUNY) Albany	Rosenthal, GE (corresponding author), Univ Iowa Hosp & Clin, Div Gen Internal Med, SE618 GH,200 Hawkins Dr, Iowa City, IA 52242 USA.			Vaughan Sarrazin, Mary/0000-0001-8717-1061				ALTMAN SH, 1991, HLTH SERVICES RES KE, P46; *AM HLTH PLANN ASS, 2000, NAT DIR HLTH PLANN P; ASH AS, 1997, RISK ADJUSTMENT MEAS, P427; Conover CJ, 1998, J HEALTH POLIT POLIC, V23, P455; Escarce J, 1999, MED CARE RES REV, V56, P340, DOI 10.1177/107755879905600304; FEINSTEIN AR, 1985, CLIN EPIDEMIOLOGY AR, P441; GROVER FL, 1993, ANN THORAC SURG, V56, P1296, DOI 10.1016/0003-4975(93)90670-D; GROVER FL, 1990, ANN THORAC SURG, V50, P12, DOI 10.1016/0003-4975(90)90073-F; HANNAN EL, 1990, JAMA-J AM MED ASSOC, V264, P2768, DOI 10.1001/jama.264.21.2768; Hannan EL, 1997, HEALTH SERV RES, V31, P659; HANNAN EL, 1992, MED CARE, V30, P892, DOI 10.1097/00005650-199210000-00002; HANNAN EL, 1989, JAMA-J AM MED ASSOC, V262, P503, DOI 10.1001/jama.262.4.503; HANNAN EL, 1994, JAMA-J AM MED ASSOC, V271, P761, DOI 10.1001/jama.271.10.761; Harrington C, 1997, MED CARE, V35, P574, DOI 10.1097/00005650-199706000-00004; HOWELL JR, 1997, HEALTH SERV RES, V19, P587; Huber PJ, 1967, P 5 BERK S MATH STAT, P221; LEMESHOW S, 1982, AM J EPIDEMIOL, V115, P92, DOI 10.1093/oxfordjournals.aje.a113284; LUFT HS, 1979, NEW ENGL J MED, V301, P1364, DOI 10.1056/NEJM197912203012503; LUFT HS, 1987, HEALTH SERV RES, V22, P157; Milstein A, 2000, Eff Clin Pract, V3, P313; MITCHELL JB, 1994, MED CARE S, V32, P38; Robinson JL, 2001, AM J MED QUAL, V16, P155, DOI 10.1177/106286060101600502; SHORTELL SM, 1988, NEW ENGL J MED, V318, P1100, DOI 10.1056/NEJM198804283181705; SHOWSTACK JA, 1987, JAMA-J AM MED ASSOC, V257, P785, DOI 10.1001/jama.257.6.785; SLOAN FA, 1980, J LAW ECON, V23, P81, DOI 10.1086/466953; WHITE H, 1980, ECONOMETRICA, V48, P817, DOI 10.2307/1912934	26	83	84	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 16	2002	288	15					1859	1866		10.1001/jama.288.15.1859	http://dx.doi.org/10.1001/jama.288.15.1859			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	604EU	12377084	Bronze			2022-12-28	WOS:000178604200024
J	Long, SB; Casey, PJ; Beese, LS				Long, SB; Casey, PJ; Beese, LS			Reaction path of protein farnesyltransferase at atomic resolution	NATURE			English	Article							CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; PYROPHOSPHATE BINDING; CONSERVED RESIDUES; SUBSTRATE-BINDING; PRODUCT RELEASE; BETA-SUBUNIT; TRANSFERASE; GERANYLGERANYLTRANSFERASE; INHIBITORS	Protein farnesyltransferase (FTase) catalyses the attachment of a farnesyl lipid group to numerous essential signal transduction proteins, including members of the Ras superfamily(1). The farnesylation of Ras oncoproteins, which are associated with 30% of human cancers, is essential for their transforming activity(2). FTase inhibitors are currently in clinical trials for the treatment of cancer(2-4). Here we present a complete series of structures representing the major steps along the reaction coordinate of this enzyme. From these observations can be deduced the determinants of substrate specificity and an unusual mechanism in which product release requires binding of substrate, analogous to classically processive enzymes. A structural model for the transition state consistent with previous mechanistic studies was also constructed. The processive nature of the reaction suggests the structural basis for the successive addition of two prenyl groups to Rab proteins by the homologous enzyme geranylgeranyltransferase type-II. Finally, known FTase inhibitors seem to differ in their mechanism of inhibiting the enzyme.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Long, SB (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.		beese, lorena/G-4993-2010	Casey, Patrick/0000-0002-7366-9309				Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; Ashby MN, 1998, CURR OPIN LIPIDOL, V9, P99, DOI 10.1097/00041433-199804000-00004; Bell IM, 2002, J MED CHEM, V45, P2388, DOI 10.1021/jm010531d; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; Cate JH, 1999, SCIENCE, V285, P2095, DOI 10.1126/science.285.5436.2095; Desnoyers L, 1998, P NATL ACAD SCI USA, V95, P12266, DOI 10.1073/pnas.95.21.12266; Dolence JM, 1997, BIOCHEMISTRY-US, V36, P9246, DOI 10.1021/bi970039p; FARNSWORTH CC, 1994, P NATL ACAD SCI USA, V91, P11963, DOI 10.1073/pnas.91.25.11963; FURFINE ES, 1995, BIOCHEMISTRY-US, V34, P6857, DOI 10.1021/bi00020a032; Huang CC, 2000, BIOCHEMISTRY-US, V39, P2593, DOI 10.1021/bi992356x; Johnston SRD, 2001, LANCET ONCOL, V2, P18, DOI 10.1016/S1470-2045(00)00191-1; Karp JE, 2001, CURR OPIN ONCOL, V13, P470, DOI 10.1097/00001622-200111000-00009; KOBLAN KS, 1995, PROTEIN SCI, V4, P681; Kral AM, 1997, J BIOL CHEM, V272, P27319, DOI 10.1074/jbc.272.43.27319; Long SB, 2000, STRUCTURE, V8, P209, DOI 10.1016/S0969-2126(00)00096-4; Long SB, 1998, BIOCHEMISTRY-US, V37, P9612, DOI 10.1021/bi980708e; Long SB, 2001, P NATL ACAD SCI USA, V98, P12948, DOI 10.1073/pnas.241407898; Mathis JR, 1997, BIOCHEMISTRY-US, V36, P6367, DOI 10.1021/bi9629182; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; Park HW, 1997, SCIENCE, V275, P1800, DOI 10.1126/science.275.5307.1800; REISS Y, 1992, J BIOL CHEM, V267, P6403; STRADLEY SJ, 1993, BIOCHEMISTRY-US, V32, P12586, DOI 10.1021/bi00210a006; Strickland CL, 1999, J MED CHEM, V42, P2125, DOI 10.1021/jm990030g; Strickland CL, 1998, BIOCHEMISTRY-US, V37, P16601, DOI 10.1021/bi981197z; Thoma NH, 2001, J BIOL CHEM, V276, P48631, DOI 10.1074/jbc.M106470200; Thoma NH, 2001, BIOCHEMISTRY-US, V40, P268, DOI 10.1021/bi002034p; Tschantz WR, 1997, J BIOL CHEM, V272, P9989; Wu Z, 1999, BIOCHEMISTRY-US, V38, P11239, DOI 10.1021/bi990583t; Yokoyama K, 1997, J BIOL CHEM, V272, P3944, DOI 10.1074/jbc.272.7.3944; Zhang H, 2000, STRUCTURE, V8, P241, DOI 10.1016/S0969-2126(00)00102-7	30	169	176	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 10	2002	419	6907					645	650		10.1038/nature00986	http://dx.doi.org/10.1038/nature00986			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	602AT	12374986				2022-12-28	WOS:000178483100052
J	Mishima, O; Suzuki, Y				Mishima, O; Suzuki, Y			Propagation of the polyamorphic transition of ice and the liquid-liquid critical point	NATURE			English	Article							DENSITY AMORPHOUS ICE; SINGULARITY-FREE INTERPRETATION; RAMAN-SPECTRUM; WATER; PRESSURE; THERMODYNAMICS; AMORPHIZATION; BEHAVIOR; H2O	Water has a rich metastable phase behaviour that includes transitions between high- and low-density amorphous ices, and between high- and low-density supercooled liquids. Because the transitions occur under conditions where crystalline ice is the stable phase, they are challenging to probe directly. In the case of the liquids, it remains unclear(1) whether their mutual transformation at low temperatures is continuous(2,3), or discontinuous(4,5) and terminating at a postulated second critical point of water that is metastable with respect to crystallization. The amorphous ices are more amenable to experiments(6-8), which have shown that their mutual transformation is sharp and reversible. But the non-equilibrium conditions of these studies make a firm thermodynamic interpretation of the results difficult. Here we use Raman spectroscopy and visual inspection to show that the transformation of high- density to low-density amorphous ices involves the propagation of a phase boundary-a region containing a mixture of both ices. We find that the boundary region becomes narrower as the transformation progresses, and at higher transformation temperatures. These findings strongly suggest that the polyamorphic ice transition is discontinuous; a continuous transformation should occur uniformly over the entire sample(9). Because the amorphous ices are structurally similar to their supercooled liquid counterparts, our results also imply that the liquids transform discontinuously at low temperatures and thus support the liquid-liquid critical-point theory(4,5).	NIMS, AML, Tsukuba, Ibaraki 3050044, Japan	National Institute for Materials Science	Mishima, O (corresponding author), NIMS, AML, 1-1 Namiki, Tsukuba, Ibaraki 3050044, Japan.	mishima.osamu@nims.go.jp	SUZUKI, Yoshiharu/H-2929-2011; MISHIMA, Osamu/H-2878-2011	MISHIMA, Osamu/0000-0002-7573-6827				AASLAND S, 1994, NATURE, V369, P633, DOI 10.1038/369633a0; BALAGUROV AM, 1991, JETP LETT+, V53, P30; BELLISSENTFUNEL MC, 1995, J CHEM PHYS, V102, P3727, DOI 10.1063/1.468555; Deb SK, 2001, NATURE, V414, P528, DOI 10.1038/35107036; Debenedetti P. G., 1996, METASTABLE LIQUIDS; Debenedetti PG, 1998, NATURE, V392, P127, DOI 10.1038/32286; Finney JL, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.225503; FLORIANO MA, 1989, J CHEM PHYS, V91, P7187, DOI 10.1063/1.457285; FLORIANO MA, 1986, PHYS REV LETT, V57, P3062, DOI 10.1103/PhysRevLett.57.3062; Franzese G, 2002, J PHYS-CONDENS MAT, V14, P2201, DOI 10.1088/0953-8984/14/9/309; Gromitskaya EL, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.094205; HANDA YP, 1986, J CHEM PHYS, V84, P2766, DOI 10.1063/1.450301; Katayama Y, 2000, NATURE, V403, P170, DOI 10.1038/35003143; KLUG DD, 1987, J CHEM PHYS, V86, P5323, DOI 10.1063/1.452557; KLUG DD, 1986, PHYSICA B & C, V139, P475, DOI 10.1016/0378-4363(86)90626-1; Loerting T, 2001, PHYS CHEM CHEM PHYS, V3, P5355, DOI 10.1039/b108676f; Mishima O, 1996, NATURE, V384, P546, DOI 10.1038/384546a0; MISHIMA O, 1994, J CHEM PHYS, V100, P5910, DOI 10.1063/1.467103; Mishima O, 2001, J CHEM PHYS, V115, P4199, DOI 10.1063/1.1392365; MISHIMA O, 1991, SCIENCE, V254, P406, DOI 10.1126/science.254.5030.406; MOYNIHAN CT, 1986, ANN NY ACAD SCI, V484, P287; NOYNIHAN CT, 1986, ANN NY ACAD SCI, V484, P94; POOLE PH, 1994, PHYS REV LETT, V73, P1632, DOI 10.1103/PhysRevLett.73.1632; POOLE PH, 1992, NATURE, V360, P324, DOI 10.1038/360324a0; Rebelo LPN, 1998, J CHEM PHYS, V109, P626, DOI 10.1063/1.476600; Sastry S, 1996, PHYS REV E, V53, P6144, DOI 10.1103/PhysRevE.53.6144; SIVAKUMAR TC, 1977, CHEM PHYS LETT, V48, P212, DOI 10.1016/0009-2614(77)80302-3; Soper AK, 2000, PHYS REV LETT, V84, P2881, DOI 10.1103/PhysRevLett.84.2881; Suzuki Y, 2000, CHEM PHYS LETT, V319, P81, DOI 10.1016/S0009-2614(00)00126-3; Truskett TM, 1999, J CHEM PHYS, V111, P2647, DOI 10.1063/1.479540; Tulk CA, 2002, SCIENCE, V297, P1320, DOI 10.1126/science.1074178; Wilding MC, 2001, J NON-CRYST SOLIDS, V293, P357, DOI 10.1016/S0022-3093(01)00686-X	32	172	174	0	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 10	2002	419	6907					599	603		10.1038/nature01106	http://dx.doi.org/10.1038/nature01106			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	602AT	12374974				2022-12-28	WOS:000178483100040
J	della Torre, A; Costantini, C; Besansky, NJ; Caccone, A; Petrarca, V; Powell, JR; Coluzzi, M				della Torre, A; Costantini, C; Besansky, NJ; Caccone, A; Petrarca, V; Powell, JR; Coluzzi, M			Speciation within Anopheles gambiae - the glass is half full	SCIENCE			English	Editorial Material							GENETIC DIFFERENTIATION; CHROMOSOMAL FORMS; MALARIA VECTOR; MOPTI; TAXA; AREA; FLOW; S.S.; MALI		Univ Roma La Sapienza, Dept Publ Hlth, Parasitol Unit, I-00185 Rome, Italy; Univ Roma La Sapienza, Dept Genet & Mol Biol, I-00185 Rome, Italy; Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA; Yale Univ, Dept Ecol & Evolutionary Biol, New Haven, CT 06520 USA	Sapienza University Rome; Sapienza University Rome; University of Notre Dame; Yale University	della Torre, A (corresponding author), Univ Roma La Sapienza, Dept Publ Hlth, Parasitol Unit, Piazzale Aldo Moro 5, I-00185 Rome, Italy.	ale.dellatorre@uniroma1.it; carlo.constantini@uniroma1.it	Costantini, Carlo/F-3470-2012; Caccone, Adalgisa/AAE-4238-2021	Costantini, Carlo/0000-0003-1016-129X; Caccone, Adalgisa/0000-0002-8949-9260				Alphey L, 2002, SCIENCE, V298, P119, DOI 10.1126/science.1078278; CARRARA GC, 2002, PARASSITOLOGIA, V44, P43; Chandre F, 1999, PARASSITOLOGIA, VOL 41, NOS 1-3, SEPTEMBER 1999, P319; Coluzzi M., 1982, Progress in Clinical and Biological Research, V96, P143; COLUZZI M, 1984, B WORLD HEALTH ORGAN, V62, P107; COLUZZI M, 2002, IN PRESS SCIENC 1003, DOI DOI 10.1126/SCIENCE.1077769; Costantini C., 1999, Parassitologia (Rome), V41, P595; COSTANTINI C, UNPUB; della Torre A, 2001, INSECT MOL BIOL, V10, P9, DOI 10.1046/j.1365-2583.2001.00235.x; Fanello C, 2000, T R SOC TROP MED HYG, V94, P132; FANELLO C, UNPUB; Favia G, 2001, INSECT MOL BIOL, V10, P19, DOI 10.1046/j.1365-2583.2001.00236.x; Favia G, 1997, INSECT MOL BIOL, V6, P377, DOI 10.1046/j.1365-2583.1997.00189.x; Gentile G, 2002, GENETICS, V161, P1561; Gentile G, 2001, INSECT MOL BIOL, V10, P25, DOI 10.1046/j.1365-2583.2001.00237.x; LEHMANN T, UNPUB; Mukabayire O, 2001, INSECT MOL BIOL, V10, P33, DOI 10.1046/j.1365-2583.2001.00238.x; Power E, 1999, CRIT-Q LIT ART, V41, P101; SAGNON NF, 2000, PARASSITOLOGIA, V42, P157; SANTOLAMAZZA F, 2002, PARASSITOLOGIA, V44, P165; Scott TW, 2002, SCIENCE, V298, P117, DOI 10.1126/science.298.5591.117; Taylor C, 2001, GENETICS, V157, P743; Toure Y. T., 1998, Parassitologia (Rome), V40, P477; TOURE YT, 1994, GENETICA, V94, P213, DOI 10.1007/BF01443435; Toure YT, 1996, MED VET ENTOMOL, V10, P197, DOI 10.1111/j.1365-2915.1996.tb00731.x; Tripet F, 2001, MOL ECOL, V10, P1725, DOI 10.1046/j.0962-1083.2001.01301.x; Wang R, 2001, P NATL ACAD SCI USA, V98, P10769, DOI 10.1073/pnas.191003598; Weill M, 2000, INSECT MOL BIOL, V9, P451, DOI 10.1046/j.1365-2583.2000.00206.x; Wondji C, 2002, INSECT MOL BIOL, V11, P11, DOI 10.1046/j.0962-1075.2001.00306.x; ZAHAR AR, 1985, VBC853MAP853 WHO	30	169	176	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 4	2002	298	5591					115	117		10.1126/science.1078170	http://dx.doi.org/10.1126/science.1078170			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	600BJ	12364784				2022-12-28	WOS:000178370500041
J	Morel, CM; Toure, YT; Dobrokhotov, B; Oduola, AMJ				Morel, CM; Toure, YT; Dobrokhotov, B; Oduola, AMJ			The mosquito genome - a breakthrough for public health	SCIENCE			English	Editorial Material							MALARIA MOSQUITO		WHO, Special Programme Res & Training Trop Dis, CH-1211 Geneva 27, Switzerland	World Health Organization	Morel, CM (corresponding author), WHO, Special Programme Res & Training Trop Dis, 20 Ave Appia, CH-1211 Geneva 27, Switzerland.		Morel, Carlos M/B-4079-2009; Morel, Carlos/Q-9657-2019; Morel, Carlos/AHD-9349-2022	Morel, Carlos M/0000-0003-2752-0009; Morel, Carlos/0000-0003-2752-0009; 				*ADV COMM HLTH RES, 2002, GEN WORLD HLTH, P1; Alphey L, 2002, SCIENCE, V298, P119, DOI 10.1126/science.1078278; Beaty BJ, 2000, P NATL ACAD SCI USA, V97, P10295, DOI 10.1073/pnas.97.19.10295; Catteruccia F, 2000, NATURE, V405, P959, DOI 10.1038/35016096; Collins FH, 2000, B WORLD HEALTH ORGAN, V78, P1412; Collins T, 1996, CLIN DIAGN LAB IMMUN, V3, P5, DOI 10.1128/CDLI.3.1.5-9.1996; Dimopoulos G, 2002, P NATL ACAD SCI USA, V99, P8814, DOI 10.1073/pnas.092274999; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Holt RA, 2002, SCIENCE, V298, P129, DOI 10.1126/science.1076181; Ito J, 2002, NATURE, V417, P452, DOI 10.1038/417452a; Kokoza V, 2000, P NATL ACAD SCI USA, V97, P9144, DOI 10.1073/pnas.160258197; Lycett GJ, 2002, NATURE, V417, P387, DOI 10.1038/417387a; Scott TW, 2002, SCIENCE, V298, P117, DOI 10.1126/science.298.5591.117; Singer PA, 2001, SCIENCE, V294, P87, DOI 10.1126/science.1062633; *SPEC PROGR RES TR, 1991, TDRBCVMALENT913 SPEC; Thomasova D, 2002, P NATL ACAD SCI USA, V99, P8179, DOI 10.1073/pnas.082235599; Tu ZJ, 2001, P NATL ACAD SCI USA, V98, P1699, DOI 10.1073/pnas.041593198	17	25	27	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 4	2002	298	5591					79	79		10.1126/science.1078047	http://dx.doi.org/10.1126/science.1078047			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	600BJ	12364774				2022-12-28	WOS:000178370500033
J	Ship, AN; Hartman, EE				Ship, AN; Hartman, EE			A woman with an extremely premature infant, 18 months later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Richardson DK, 2001, JAMA-J AM MED ASSOC, V286, P1498, DOI 10.1001/jama.286.12.1498	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 25	2002	288	12					1522	1522		10.1001/jama.288.12.1522	http://dx.doi.org/10.1001/jama.288.12.1522			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	596AT	12243640				2022-12-28	WOS:000178142000024
J	Bergfeldt, K; Rydh, B; Granath, F; Gronberg, H; Thalib, L; Adami, HO; Hall, P				Bergfeldt, K; Rydh, B; Granath, F; Gronberg, H; Thalib, L; Adami, HO; Hall, P			Risk of ovarian cancer in breast-cancer patients with a family history of breast or ovarian cancer: a population-based cohort study	LANCET			English	Article							BRCA2 MUTATIONS; SERIES	Background Patients with breast cancer who have mutations in the high penetrance genes BRCA1 and BRCA2, have an increased risk of ovarian cancer. Because these mutations are rare, easily obtained information such as age and family history of breast or ovarian cancer might be preferable for assessment of ovarian cancer risk in clinical practice. Methods We linked data from the Swedish Cancer Register to the Swedish Generation Register and generated a cohort of 30 552 breast-cancer patients born after 1931, with information on breast and ovarian cancer diagnosis from 146 117 first-degree relatives. Standardised incidence ratios (SIRs) with 95% Cis were calculated with nationwide rates of ovarian cancer, adjusted for age and calendar year. Findings During a mean follow-up of 6 years, 122 incident ovarian cancers were identified in the cohort, yielding an overall SIR of 2.0 (95% Cl 1.6-2.4). The risk was higher in breast-cancer patients diagnosed before the age of 40 years, with a family history of breast cancer (5.6; 1.8-13.1) or ovarian cancer (17.0; 3.5-50.0). A consistently increased risk was noted in patients with a relative who was diagnosed before the age of 50 years, with either breast or ovarian cancer. Women with a family history of ovarian cancer have an almost 10% risk of developing ovarian cancer before the age of 70. Interpretation In young women with breast cancer, the risk of ovarian cancer is greatly raised when a family history of breast or ovarian cancer is present. Close medical surveillance, and perhaps even prophylactic oophorectomy, might be justified in high-risk groups.	Karolinska Inst, Dept Med Epidemiol, S-17177 Stockholm, Sweden; Karolinska Inst, Dept Pathol & Oncol, Stockholm, Sweden; Univ Umea Hosp, Dept Oncol, S-90185 Umea, Sweden; Kuwait Univ, Fac Med, Kuwait, Kuwait	Karolinska Institutet; Karolinska Institutet; Umea University; Kuwait University	Bergfeldt, K (corresponding author), Karolinska Inst, Dept Med Epidemiol, S-17177 Stockholm, Sweden.		Bergfeldt, Kjell/C-3581-2012	Thalib, Lukman/0000-0002-1211-6495				BRENNER H, 1993, EUR J CANCER, V29A, P1410, DOI 10.1016/0959-8049(93)90013-6; Breslow N E, 1987, IARC Sci Publ, P1; Dees EC, 2001, SEMIN ONCOL, V28, P322, DOI 10.1053/sonc.2001.26143; Dorum A, 1996, EUR J CANCER, V32A, P1645, DOI 10.1016/0959-8049(96)00137-2; Ewertz M, 1985, Natl Cancer Inst Monogr, V68, P325; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; Frank TS, 1998, J CLIN ONCOL, V16, P2417, DOI 10.1200/JCO.1998.16.7.2417; Harvey E B, 1985, Natl Cancer Inst Monogr, V68, P99; Hensley ML, 2000, ONCOLOGY-NY, V14, P1601; Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201; Loman N, 2001, JNCI-J NATL CANCER I, V93, P1215, DOI 10.1093/jnci/93.16.1215; Menon U, 2000, CURR OPIN OBSTET GYN, V12, P39, DOI 10.1097/00001703-200002000-00007; Newman B, 1998, JAMA-J AM MED ASSOC, V279, P915, DOI 10.1001/jama.279.12.915; Papelard H, 2000, BRIT J CANCER, V83, P719, DOI 10.1054/bjoc.2000.1331; Ponder BAJ, 2000, BRIT J CANCER, V83, P1301; SurisSwirtz PJ, 1996, BREAST CANCER RES TR, V41, P21, DOI 10.1007/BF01807033; Syrjakoski K, 2000, J NATL CANCER I, V92, P1529, DOI 10.1093/jnci/92.18.1529; Volk N, 1997, CANCER CAUSE CONTROL, V8, P764, DOI 10.1023/A:1018487506546; 2000, CANC INCIDENCE SWEDE; 2000, CAUSES DEATH 1997; 2000, COCHRANE DATABASE SY, V3	21	50	53	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 21	2002	360	9337					891	894		10.1016/S0140-6736(02)11023-3	http://dx.doi.org/10.1016/S0140-6736(02)11023-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	596AU	12354469				2022-12-28	WOS:000178142200006
J	Brown, TM; Boyle, MF				Brown, TM; Boyle, MF			ABC of psychological medicine - Delirium	BMJ-BRITISH MEDICAL JOURNAL			English	Review							MANAGEMENT		St Johns Hosp Howden, Livingston, W Lothian, Scotland; Linlithgow Hlth Ctr, Linlithgow, W Lothian, Scotland		Brown, TM (corresponding author), St Johns Hosp Howden, Livingston, W Lothian, Scotland.							American Psychiatric Association, 1999, PRACT GUID TREATM PA; Cole MG, 1998, J GERIATR PSYCH NEUR, V11, P126, DOI 10.1177/089198879801100303; FRANCIS J, 1990, JAMA-J AM MED ASSOC, V263, P1097, DOI 10.1001/jama.263.8.1097; Meagher DJ, 1996, BRIT J PSYCHIAT, V168, P512, DOI 10.1192/bjp.168.4.512; Meagher DJ, 2001, BMJ-BRIT MED J, V322, P144, DOI 10.1136/bmj.322.7279.144; OKeeffe S, 1997, J AM GERIATR SOC, V45, P174, DOI 10.1111/j.1532-5415.1997.tb04503.x; TAYLOR D, 1993, J NEUROL NEUROSUR PS, V56, P742, DOI 10.1136/jnnp.56.7.742	7	81	86	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 21	2002	325	7365					644	647		10.1136/bmj.325.7365.644	http://dx.doi.org/10.1136/bmj.325.7365.644			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	597WM	12242179	Green Published			2022-12-28	WOS:000178243800032
J	Fergusson, D; Aaron, SD; Guyatt, G; Hebert, P				Fergusson, D; Aaron, SD; Guyatt, G; Hebert, P			Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED TRIAL; CLINICAL-TRIALS; DOUBLE-BLIND; EFFICACY; SEPSIS		Ottawa Hlth Res Inst, Ottawa, ON K1H 8L6, Canada; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada	University of Ottawa; Ottawa Hospital Research Institute; McMaster University; McMaster University	Fergusson, D (corresponding author), Ottawa Hlth Res Inst, 501 Smyth Rd,Box 201, Ottawa, ON K1H 8L6, Canada.	dafergusson@ohri.ca						BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Cohen J, 2001, CRIT CARE MED, V29, P880, DOI 10.1097/00003246-200104000-00039; FISHER CJ, 1994, JAMA-J AM MED ASSOC, V271, P1836, DOI 10.1001/jama.271.23.1836; GENT M, 1979, THROMB HAEMOSTASIS, V41, P123; Hollis S, 1999, BRIT MED J, V319, P670, DOI 10.1136/bmj.319.7211.670; HOUBIERS JGA, 1994, LANCET, V344, P573, DOI 10.1016/S0140-6736(94)91965-8; LEE YJ, 1991, STAT MED, V10, P1595, DOI 10.1002/sim.4780101011; Loughnan BA, 2000, BRIT J ANAESTH, V84, P715, DOI 10.1093/oxfordjournals.bja.a013580; NEWELL DJ, 1992, INT J EPIDEMIOL, V21, P837, DOI 10.1093/ije/21.5.837; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; Pocock SJ, 1998, STAT MED, V17, P303, DOI 10.1002/(SICI)1097-0258(19980215)17:3<303::AID-SIM764>3.3.CO;2-S; Rubin DB, 1998, STAT MED, V17, P371, DOI 10.1002/(SICI)1097-0258(19980215)17:3<371::AID-SIM768>3.0.CO;2-O; SCHWARTZ D, 1967, J CHRON DIS, V20, P637, DOI 10.1016/0021-9681(67)90041-0; SOMMER A, 1991, STAT MED, V10, P45, DOI 10.1002/sim.4780100110; Stiell IG, 2001, LANCET, V358, P105, DOI 10.1016/S0140-6736(01)05328-4; Treanor JJ, 2000, JAMA-J AM MED ASSOC, V283, P1016, DOI 10.1001/jama.283.8.1016	16	483	491	1	26	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 21	2002	325	7365					652	654		10.1136/bmj.325.7365.652	http://dx.doi.org/10.1136/bmj.325.7365.652			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	597WM	12242181	Green Published			2022-12-28	WOS:000178243800036
J	McPherson, K				McPherson, K			Epidemiology on trial - confessions of an expert witness	LANCET			English	Editorial Material							3RD-GENERATION ORAL-CONTRACEPTIVES; VENOUS THROMBOEMBOLISM; RISK		Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England	University of Bristol	McPherson, K (corresponding author), Univ Bristol, Dept Social Med, Canynge Hall, Bristol BS8 2PR, Avon, England.							Brock P, 2001, BRIT MED J, V322, P1605, DOI 10.1136/bmj.322.7302.1605; Cox D. R., 1984, ANAL SURVIVAL DATA; Farmer RDT, 2000, BMJ-BRIT MED J, V321, P477, DOI 10.1136/bmj.321.7259.477; Jick H, 2000, BMJ-BRIT MED J, V321, P1190, DOI 10.1136/bmj.321.7270.1190; Kemmeren JM, 2001, BRIT MED J, V323, P131, DOI 10.1136/bmj.323.7305.131; Lewis MA, 1999, HUM REPROD, V14, P1493, DOI 10.1093/humrep/14.6.1493; Lidegaard O, 2002, CONTRACEPTION, V65, P187, DOI 10.1016/S0010-7824(01)00307-9; Poulter NR, 1996, LANCET, V347, P547; Skegg DCG, 2000, BMJ-BRIT MED J, V321, P1171, DOI 10.1136/bmj.321.7270.1171; Spitzer WO, 1996, BRIT MED J, V312, P83; *WHO, 1998, WHO TECHN REP SER, V877; 2002, LANCET, V360, P421	12	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 21	2002	360	9337					889	890		10.1016/S0140-6736(02)11070-1	http://dx.doi.org/10.1016/S0140-6736(02)11070-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	596AU	12354468				2022-12-28	WOS:000178142200005
J	Walters, RW; Freimuth, P; Moninger, TO; Ganske, I; Zabner, J; Welsh, MJ				Walters, RW; Freimuth, P; Moninger, TO; Ganske, I; Zabner, J; Welsh, MJ			Adenovirus fiber disrupts CAR-mediated intercellular adhesion allowing virus escape	CELL			English	Article							CILIATED AIRWAY EPITHELIA; CELL-ADHESION; GENE-TRANSFER; MOLECULAR-BASIS; RECEPTOR; COXSACKIEVIRUS; BINDING; SURFACE; DOMAIN; ENTRY	Adenovirus binds its receptor (CAR), enters cells, and replicates. It must then escape to the environment to infect a new host. We found that following infection, human airway epithelia first released adenovirus to the basolateral surface. Virus then traveled between epithelial cells to emerge on the apical surface. Adenovirus fiber protein, which is produced during viral replication, facilitated apical escape. Fiber binds CAR, which sits on the basolateral membrane where it maintains tight junction integrity. When fiber bound CAR, it disrupted junctional integrity, allowing virus to filter between the cells and emerge apically. Thus, adenovirus exploits its receptor for two important but distinct steps in its life cycle: entry into host cells and escape across epithelial barriers to the environment.	Univ Iowa, Coll Med, Howard Hughes Med Inst, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	Howard Hughes Medical Institute; University of Iowa; University of Iowa; University of Iowa; United States Department of Energy (DOE); Brookhaven National Laboratory	Welsh, MJ (corresponding author), Univ Iowa, Coll Med, Howard Hughes Med Inst, Iowa City, IA 52242 USA.	michael-weish@uiowa.edu		Zabner, Joseph/0000-0002-9606-1339; Welsh, Michael/0000-0002-1646-6206	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036251, F31AI136251] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER; NIAID NIH HHS [AI36251] Funding Source: Medline; NIDDK NIH HHS [DK25295] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baranowski E, 2001, SCIENCE, V292, P1102, DOI 10.1126/science.1058613; Barton ES, 2001, CELL, V104, P441, DOI 10.1016/S0092-8674(01)00231-8; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Bewley MC, 1999, SCIENCE, V286, P1579, DOI 10.1126/science.286.5444.1579; BOULANGE.PA, 1973, EUR J BIOCHEM, V39, P37, DOI 10.1111/j.1432-1033.1973.tb03100.x; Carson SD, 1999, J VIROL, V73, P7077, DOI 10.1128/JVI.73.8.7077-7079.1999; Cohen CJ, 2001, P NATL ACAD SCI USA, V98, P15191, DOI 10.1073/pnas.261452898; Compans RW, 1995, CURR TOP MICROBIOL, V202, P209; Duan DS, 1998, HUM GENE THER, V9, P2761, DOI 10.1089/hum.1998.9.18-2761; Freire E, 1999, APPL MATH LETT, V12, P73, DOI 10.1016/S0893-9659(98)00152-9; Geraghty RJ, 1998, SCIENCE, V280, P1618, DOI 10.1126/science.280.5369.1618; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HENRY LJ, 1994, J VIROL, V68, P5239, DOI 10.1128/JVI.68.8.5239-5246.1994; HIRST GK, 1950, J EXP MED, V91, P161, DOI 10.1084/jem.91.2.161; Honda T, 2000, MOL BRAIN RES, V77, P19, DOI 10.1016/S0169-328X(00)00036-X; HORWITZ MS, 1999, VIROLOGY, P1723; Huber AH, 2001, CELL, V105, P391, DOI 10.1016/S0092-8674(01)00330-0; HUEBNER RJ, 1954, NEW ENGL J MED, V251, P1077, DOI 10.1056/NEJM195412302512701; Itoh M, 2001, J CELL BIOL, V154, P491, DOI 10.1083/jcb.200103047; Karp Philip H, 2002, Methods Mol Biol, V188, P115; Liang TW, 2000, AM J PHYSIOL-CELL PH, V279, pC1733, DOI 10.1152/ajpcell.2000.279.6.C1733; LOUIS N, 1994, J VIROL, V68, P4104, DOI 10.1128/JVI.68.6.4104-4106.1994; Pickles RJ, 1998, J VIROL, V72, P6014, DOI 10.1128/JVI.72.7.6014-6023.1998; Rajasekaran AK, 1996, J CELL BIOL, V132, P451, DOI 10.1083/jcb.132.3.451; RODRIGUEZBOULAN E, 1978, P NATL ACAD SCI USA, V75, P5071, DOI 10.1073/pnas.75.10.5071; Santis G, 1999, J GEN VIROL, V80, P1519, DOI 10.1099/0022-1317-80-6-1519; Schneider-Schaulies J, 2000, J GEN VIROL, V81, P1413, DOI 10.1099/0022-1317-81-6-1413; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; van Raaij MJ, 2000, STRUCTURE, V8, P1147, DOI 10.1016/S0969-2126(00)00528-1; Van't Hof W, 2001, HUM GENE THER, V12, P25, DOI 10.1089/104303401450933; Walters RW, 1999, J BIOL CHEM, V274, P10219, DOI 10.1074/jbc.274.15.10219; Wang GS, 1998, J VIROL, V72, P9818, DOI 10.1128/JVI.72.12.9818-9826.1998; Welsh MJ, 1999, J CLIN INVEST, V104, P1165, DOI 10.1172/JCI8634; WHITE JM, 1989, CELL, V56, P725, DOI 10.1016/0092-8674(89)90674-0; Zabner J, 1997, J CLIN INVEST, V100, P1144, DOI 10.1172/JCI119625; Zabner J, 1996, J VIROL, V70, P6994, DOI 10.1128/JVI.70.10.6994-7003.1996	39	301	315	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 20	2002	110	6					789	799		10.1016/S0092-8674(02)00912-1	http://dx.doi.org/10.1016/S0092-8674(02)00912-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	596TV	12297051	Bronze			2022-12-28	WOS:000178182800013
J	Key, TJ; Allen, NE; Spencer, EA; Travis, RC				Key, TJ; Allen, NE; Spencer, EA; Travis, RC			The effect of diet on risk of cancer	LANCET			English	Review							NUTRITION INTERVENTION TRIALS; DISEASE-SPECIFIC MORTALITY; SEX-HORMONE LEVELS; GROWTH-FACTOR-I; COLORECTAL-CANCER; BETA-CAROTENE; PROSTATE-CANCER; BREAST-CANCER; LUNG-CANCER; PHYSICAL-ACTIVITY	Diet-related factors are thought to account for about 30% of cancers in developed countries. Obesity increases the risk of cancers in the oesophagus, colorectum, breast, endometrium, and kidney. Alcohol causes cancers of the oral cavity, pharynx, larynx, oesophagus, and liver, and causes a small increase in the risk of breast cancer. Adequate intakes of fruit and vegetables probably lower the risk for several types of cancer, especially cancers of the gastrointestinal tract. The importance of other factors, including meat, fibre, and vitamins, is not yet clear. Prudent advice is to eat a varied diet including plenty of fruit, vegetables, and cereals; to maintain a healthy bodyweight with the help of regular physical activity; and to restrict consumption of alcohol.	Univ Oxford, Radcliffe Infirm, Canc Res UK Epidemiol Unit, Oxford OX2 6HE, England	Cancer Research UK; Radcliffe Infirmary; University of Oxford	Key, TJ (corresponding author), Univ Oxford, Radcliffe Infirm, Canc Res UK Epidemiol Unit, Gibson Bldg, Oxford OX2 6HE, England.	Tim.Key@cancer.org.uk		Spencer, Elizabeth/0000-0002-9079-8006				Adlercreutz H, 1997, ANN MED, V29, P95, DOI 10.3109/07853899709113696; Alberts DS, 2000, NEW ENGL J MED, V342, P1156, DOI 10.1056/NEJM200004203421602; Allen NE, 2000, BRIT J CANCER, V83, P95, DOI 10.1054/bjoc.2000.1509; Allen NE, 2000, NUTR RES REV, V13, P159, DOI 10.1079/095442200108729052; Allen NE, 2001, J NATL CANCER I, V93, P649, DOI 10.1093/jnci/93.8.649; Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501; [Anonymous], 1966, CANC INCIDENCE 5 CON, DOI DOI 10.1001/jamaoncol.2019.2996; ARMSTRONG B, 1975, INT J CANCER, V15, P617, DOI 10.1002/ijc.2910150411; Awad AB, 2000, J NUTR, V130, P2127, DOI 10.1093/jn/130.9.2127; Baron JA, 1999, ANN NY ACAD SCI, V889, P138, DOI 10.1111/j.1749-6632.1999.tb08731.x; Beral V, 2002, LANCET, V360, P187, DOI 10.1016/S0140-6736(02)09454-0; Bergstrom A, 2001, BRIT J CANCER, V85, P984, DOI 10.1038/sj.bjc.6692040; Bingham SA, 1996, CARCINOGENESIS, V17, P515, DOI 10.1093/carcin/17.3.515; BJELKE E, 1975, INT J CANCER, V15, P561, DOI 10.1002/ijc.2910150405; BLOT WJ, 1993, JNCI-J NATL CANCER I, V85, P1483, DOI 10.1093/jnci/85.18.1483; Bonithon-Kopp C, 2000, LANCET, V356, P1300, DOI 10.1016/S0140-6736(00)02813-0; BROWN LM, 1995, J NATL CANCER I, V87, P104, DOI 10.1093/jnci/87.2.104; BURKITT DP, 1971, CANCER, V28, P3, DOI 10.1002/1097-0142(197107)28:1<3::AID-CNCR2820280104>3.0.CO;2-N; Chen J, 1999, J NUTR, V129, p560S, DOI 10.1093/jn/129.2.560S; Clark LC, 1998, BRIT J UROL, V81, P730; *COLL GROUP HORM F, 2002, IN PRESS BR J CANC; *COMA, 1998, NUTR ASP DEV CANC; Correa P, 2000, JNCI-J NATL CANCER I, V92, P1881, DOI 10.1093/jnci/92.23.1881; Cummings JH, 1998, BMJ-BRIT MED J, V317, P1636, DOI 10.1136/bmj.317.7173.1636; DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192; Doll R, 1996, OXFORD TXB MED, P197; Doll R, 1970, CANC INCIDENCE 5 CON, VII; Dorgan JF, 2001, JNCI-J NATL CANCER I, V93, P710, DOI 10.1093/jnci/93.9.710; Dorgan JF, 2002, JNCI-J NATL CANCER I, V94, P606; Eaton NE, 1999, BRIT J CANCER, V80, P930, DOI 10.1038/sj.bjc.6690445; *EPIC INV, IN PRESS P EUR C NUT; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111; Fuchs CS, 1999, NEW ENGL J MED, V340, P169, DOI 10.1056/NEJM199901213400301; Gann PH, 1996, J NATL CANCER I, V88, P1118, DOI 10.1093/jnci/88.16.1118; GIOVANNUCCI E, 1995, JNCI-J NATL CANCER I, V87, P265, DOI 10.1093/jnci/87.4.265; Giovannucci E, 1999, JNCI-J NATL CANCER I, V91, P317, DOI 10.1093/jnci/91.4.317; GIOVANNUCCI E, 1993, AM J EPIDEMIOL, V137, P502, DOI 10.1093/oxfordjournals.aje.a116703; Glynn SA, 1996, CANCER CAUSE CONTROL, V7, P214, DOI 10.1007/BF00051297; Gooderham NJ, 1997, MUTAT RES-FUND MOL M, V376, P53, DOI 10.1016/S0027-5107(97)00025-0; HAGUE A, 1995, INT J CANCER, V60, P400, DOI 10.1002/ijc.2910600322; Hardman AE, 2001, P NUTR SOC, V60, P107, DOI 10.1079/PNS200076; Heaney RP, 1999, J AM DIET ASSOC, V99, P1228, DOI 10.1016/S0002-8223(99)00302-8; Heinonen OP, 1998, J NATL CANCER I, V90, P440, DOI 10.1093/jnci/90.6.440; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; Holmes MD, 2000, J CLIN ONCOL, V18, P3668, DOI 10.1200/JCO.2000.18.21.3668; *IARC, 1994, IARC MON EV CARC RIS, V59; IARC, 1993, IARC MON EV CARC RIS, V56; *IARC, 1995, IARC MON EV CARC RIS, V64; *INT AG RES CANC, 1994, IARC MON EV CARC RIS, V59; *INT AG RES CANC, 1990, IARC SCI PUBL, V100; *INT AG RES CANC, 2001, BLOB; International Agency for Research on Cancer, 2002, IARC HDB CANC PREV, V6; Jacobs DR, 1998, NUTR CANCER, V30, P85, DOI 10.1080/01635589809514647; JUDD HL, 1982, OBSTET GYNECOL, V59, P680; Kaaks R, 2001, P NUTR SOC, V60, P91, DOI 10.1079/PNS200070; Kaaks R, 2000, JNCI-J NATL CANCER I, V92, P1592, DOI 10.1093/jnci/92.19.1592; Kari F W, 1999, J Nutr Health Aging, V3, P92; Kazerouni N, 2001, FOOD CHEM TOXICOL, V39, P423, DOI 10.1016/S0278-6915(00)00158-7; Key TJ, 2001, LANCET ONCOL, V2, P133, DOI 10.1016/S1470-2045(00)00254-0; Key TJ, 1998, PUBLIC HEALTH NUTR, V1, P33, DOI 10.1079/PHN19980006; Key TJ, 2001, BREAST, V10, P9, DOI 10.1016/S0960-9776(16)30002-9; KEY TJA, 1988, BRIT J CANCER, V57, P205, DOI 10.1038/bjc.1988.44; Lee IM, 1999, J NATL CANCER I, V91, P2102, DOI 10.1093/jnci/91.24.2102; LI JY, 1993, J NATL CANCER I, V85, P1492, DOI 10.1093/jnci/85.18.1492; Lund EK, 1999, AM J CLIN NUTR, V69, P250; MCKEOWNEYSSEN G, 1994, CANCER EPIDEM BIOMAR, V3, P687; Michaud DS, 2001, JAMA-J AM MED ASSOC, V286, P921, DOI 10.1001/jama.286.8.921; Michels KB, 2000, JNCI-J NATL CANCER I, V92, P1740, DOI 10.1093/jnci/92.21.1740; Miller A. B., 2001, DIET CANC PREVENTION; Milner JA, 2001, ADV EXP MED BIOL, V492, P69; Missmer SA, 2002, INT J EPIDEMIOL, V31, P78, DOI 10.1093/ije/31.1.78; MURI C, 1987, CANC INCIDENCE 5 CON, V5; NAGENGAST FM, 1995, EUR J CANCER, V31A, P1067, DOI 10.1016/0959-8049(95)00216-6; Norat T, 2002, INT J CANCER, V98, P241, DOI 10.1002/ijc.10126; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; Palli Domenico, 2000, Journal of Gastroenterology, V35, P84; Parkin DM, 1997, CANC INCIDENCE 5 CON, VVII; Parkin DM, 1992, CANC INCIDENCE 5 CON, VVI; Potter JD, 1996, IARC SCI PUBL, P61; Potter JD, 1999, JNCI-J NATL CANCER I, V91, P916, DOI 10.1093/jnci/91.11.916; Rohan TE, 2002, CANCER CAUSE CONTROL, V13, P231, DOI 10.1023/A:1015048619413; Schatzkin A, 2000, NEW ENGL J MED, V342, P1149, DOI 10.1056/NEJM200004203421601; Shaheen N, 2002, JAMA-J AM MED ASSOC, V287, P1972, DOI 10.1001/jama.287.15.1972; Smith-Warner SA, 2001, INT J CANCER, V92, P767, DOI 10.1002/1097-0215(20010601)92:5&lt;767::AID-IJC1247&gt;3.0.CO;2-0; Stram DO, 2002, AM J EPIDEMIOL, V155, P622, DOI 10.1093/aje/155.7.622; Terry P, 2001, JNCI-J NATL CANCER I, V93, P525, DOI 10.1093/jnci/93.7.525; TRETLI S, 1989, INT J CANCER, V44, P23, DOI 10.1002/ijc.2910440105; *UK DEP ENV FOOD R, 2002, NAT FOOD SURV; Vineis P, 1996, CANCER CAUSE CONTROL, V7, P479, DOI 10.1007/BF00052675; Waterhouse JAH, 1982, CANC INCIDENCE 5 CON, VIV; Waterhouse JAH, 1976, CANC INCIDENCE 5 CON, VIII; Webb PM, 2001, GUT, V49, P347, DOI 10.1136/gut.49.3.347; Weinstein SJ, 2001, CANCER CAUSE CONTROL, V12, P317, DOI 10.1023/A:1011290103779; *WHO, 2001, WORLD HLTH STAT ANN; [World Cancer Research Fund American Institute for Cancer Research], 1997, FOOD NUTR PREV CANC; Wu K, 2002, JNCI-J NATL CANCER I, V94, P437, DOI 10.1093/jnci/94.6.437; Yoshiike N, 1996, J Epidemiol, V6, pS189; Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472; Yu M C, 1991, IARC Sci Publ, P39	99	346	354	1	64	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 14	2002	360	9336					861	868		10.1016/S0140-6736(02)09958-0	http://dx.doi.org/10.1016/S0140-6736(02)09958-0			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	594MC	12243933				2022-12-28	WOS:000178053500023
J	Wang, B; Matsuoka, S; Carpenter, PB; Elledge, SJ				Wang, B; Matsuoka, S; Carpenter, PB; Elledge, SJ			53BP1, a mediator of the DNA damage checkpoint	SCIENCE			English	Article							DOUBLE-STRAND BREAKS; PROTEIN; PHOSPHORYLATION; BRCA1; MODULE; ATM; P53	53BP1 binds to the tumor suppressor protein p53 and has a potential role in DNA damage responses. We used small interfering RNA (siRNA) directed against 53BP1 in mammalian cells to demonstrate that 53BP1 is a key transducer of the DNA damage checkpoint signal. 53BP1 was required for p53 accumulation, G(2)-M checkpoint arrest, and the intra-S-phase checkpoint in response to ionizing radiation. 53BP1 played a partially redundant role in phosphorylation of the downstream checkpoint effector proteins Brca1 and Chk2 but was required for the formation of Brca1 foci in a hierarchical branched pathway for the recruitment of repair and signaling proteins to sites of DNA damage.	Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; University of Texas System; University of Texas Health Science Center Houston	Elledge, SJ (corresponding author), Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA.							Anderson L, 2001, MOL CELL BIOL, V21, P1719, DOI 10.1128/MCB.21.5.1719-1729.2001; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; DITULLIO R, COMMUNICATION; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Iwabuchi K, 1998, J BIOL CHEM, V273, P26061, DOI 10.1074/jbc.273.40.26061; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Saka Y, 1997, GENE DEV, V11, P3387, DOI 10.1101/gad.11.24.3387; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Shiloh Y, 2001, ADV CANCER RES, V83, P209, DOI 10.1016/S0065-230X(01)83007-4; Wang B., UNPUB; Ward IM, 2001, J BIOL CHEM, V276, P47755, DOI 10.1074/jbc.C100587200; Williams RS, 2001, NAT STRUCT BIOL, V8, P838, DOI 10.1038/nsb1001-838; Xia ZF, 2001, J BIOL CHEM, V276, P2708, DOI 10.1074/jbc.M007665200; Zhang XD, 1998, EMBO J, V17, P6404, DOI 10.1093/emboj/17.21.6404; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	20	455	471	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 15	2002	298	5597					1435	1438		10.1126/science.1076182	http://dx.doi.org/10.1126/science.1076182			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	615AF	12364621				2022-12-28	WOS:000179223100056
J	Zhang, LW; Israel, C; Biswas, A; Greene, RL; de Lozanne, A				Zhang, LW; Israel, C; Biswas, A; Greene, RL; de Lozanne, A			Direct observation of percolation in a manganite thin film	SCIENCE			English	Article							MAGNETIC FORCE MICROSCOPY; PHASE-SEPARATION; MAGNETORESISTANCE; TRANSITION; LA1-XSRXMNO3; BEHAVIOR; OXIDES; FIELD	Upon cooling, the isolated ferromagnetic domains in thin films of La0.33Pr0.34Ca0.33MnO3 start to grow and merge at the metal-insulator transition temperature T-P1, leading to a steep drop in resistivity, and continue to grow far below T-P1. In contrast, upon warming, the ferromagnetic domain size remains unchanged until near the transition temperature. The jump in the resistivity results from the decrease in the average magnetization. The ferromagnetic domains almost disappear at a temperature T-P2 higher than T-P1, showing a local magnetic hysteresis in agreement with the resistivity hysteresis. Even well above T-P2, some ferromagnetic domains with higher transition temperatures are observed, indicating magnetic inhomogeneity. These results may shed more light on the origin of the magnetoresistance in these materials.	Univ Texas, Dept Phys, Austin, TX 78712 USA; Univ Maryland, Ctr Superconduct Res, Dept Phys, College Pk, MD 20742 USA; Tsinghua Univ, Dept Phys, Beijing 100084, Peoples R China	University of Texas System; University of Texas Austin; University System of Maryland; University of Maryland College Park; Tsinghua University	de Lozanne, A (corresponding author), Univ Texas, Dept Phys, Austin, TX 78712 USA.	lozanne@physics.utexas.edu	de Lozanne, Alex L/C-9693-2013	de Lozanne, Alex L/0000-0003-2950-4707; Biswas, Amlan/0000-0002-2873-022X				ASAMITSU A, 1995, NATURE, V373, P407, DOI 10.1038/373407a0; Biswas A, 2000, PHYS REV B, V61, P9665, DOI 10.1103/PhysRevB.61.9665; Desfeux R, 2001, APPL PHYS LETT, V78, P3681, DOI 10.1063/1.1376662; Fath M, 1999, SCIENCE, V285, P1540, DOI 10.1126/science.285.5433.1540; JIN S, 1994, SCIENCE, V264, P413, DOI 10.1126/science.264.5157.413; Kong LS, 1997, APPL PHYS LETT, V70, P2043, DOI 10.1063/1.118808; Levy P, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.140401; Lu QY, 1997, SCIENCE, V276, P2006, DOI 10.1126/science.276.5321.2006; Maezono R, 1998, PHYS REV B, V58, P11583, DOI 10.1103/PhysRevB.58.11583; Martin C, 2000, EUR PHYS J B, V16, P469, DOI 10.1007/s100510070205; Mathur ND, 2001, SOLID STATE COMMUN, V119, P271, DOI 10.1016/S0038-1098(01)00112-0; Millis AJ, 1998, NATURE, V392, P147, DOI 10.1038/32348; Parisi F, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.144419; Podzorov V, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.140406; Salamon MB, 2001, REV MOD PHYS, V73, P583, DOI 10.1103/RevModPhys.73.583; Soh YA, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.020402; Soh YA, 2000, J APPL PHYS, V87, P6743, DOI 10.1063/1.372827; Uehara M, 1999, NATURE, V399, P560, DOI 10.1038/21142; URUSHIBARA A, 1995, PHYS REV B, V51, P14103, DOI 10.1103/PhysRevB.51.14103; VONHELMOLT R, 1993, PHYS REV LETT, V71, P2331, DOI 10.1103/PhysRevLett.71.2331; YUAN CW, 1994, APPL PHYS LETT, V65, P1308, DOI 10.1063/1.112103; ZENER C, 1951, PHYS REV, V82, P403, DOI 10.1103/PhysRev.82.403	22	328	337	1	135	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 25	2002	298	5594					805	807		10.1126/science.1077346	http://dx.doi.org/10.1126/science.1077346			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	607KR	12242450				2022-12-28	WOS:000178791200052
J	Hernanz, M; Sala, G				Hernanz, M; Sala, G			A classical nova, V2487 Oph 1998, seen in X-rays before and after its explosion	SCIENCE			English	Article							SPECTRAL EVOLUTION; WHITE-DWARF; V1974 CYGNI; ROSAT DATA; EX-HYDRAE; EMISSION; ULTRAVIOLET; REANALYSIS; TURNOFF; TIMES	Classical nova explosions are very energetic and frequent phenomena caused by explosive hydrogen burning on top of an accreting white dwarf. Observations of the recent nova V2487 Oph 1998 by the X-ray Multi-Mirror satellite ( XMM-Newton) provide evidence that accretion ( probably on a magnetic white dwarf) was reestablished as early as 2.7 years after the explosion. In addition, positional correlation with a source previously discovered by the Rontgen Satellite (ROSAT) in 1990 suggests that the site of a nova explosion had been seen in x-rays before the outburst.	Consejo Super Invest Cient, Inst Estudis Espacials Catalunya, E-08034 Barcelona, Spain; Consejo Super Invest Cient, Inst Ciencias Espacio, E-08034 Barcelona, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Institut d'Estudis Espacials de Catalunya (IEEC); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Ciencias del Espacio (ICE)	Hernanz, M (corresponding author), Consejo Super Invest Cient, Inst Estudis Espacials Catalunya, Gran Capita 2-4, E-08034 Barcelona, Spain.		Hernanz, Margarita/K-1770-2014	Hernanz, Margarita/0000-0002-8651-7910				AMAUD K, 2001, XSPEC USERS GUIDE VE; Balman S, 1998, ASTROPHYS J, V499, P395, DOI 10.1086/305600; Balman S, 2001, MON NOT R ASTRON SOC, V326, P1441, DOI 10.1111/j.1365-2966.2001.04716.x; FILIPPENKO AV, 1998, 6943 INT ASTR UN; Fujimoto R, 1997, ASTROPHYS J, V474, P774, DOI 10.1086/303483; Gehrz RD, 1998, PUBL ASTRON SOC PAC, V110, P3, DOI 10.1086/316107; Gonzalez-Riestra R, 1998, ASTRON ASTROPHYS SUP, V129, P23, DOI 10.1051/aas:1998171; Harris MJ, 1999, ASTROPHYS J, V522, P424, DOI 10.1086/307625; Hellier C, 1996, MON NOT R ASTRON SOC, V280, P877; ISHIDA M, 1994, PUBL ASTRON SOC JPN, V46, pL81; Krautter J, 1996, ASTROPHYS J, V456, P788, DOI 10.1086/176697; LILLER W, 2000, INFORM B VAR STARS, V4870, P1; LIVIO M, 1988, ASTROPHYS J, V330, P264, DOI 10.1086/166470; Lynch DK, 2000, ASTROPHYS J, V541, P791, DOI 10.1086/309453; MACDONALD J, 1991, ASTROPHYS J, V373, pL51, DOI 10.1086/186049; MEWE R, 1995, LEGACY, V6, P16; NAKANO S, 1998, 6941 INT ASTR UN; OGELMAN H, 1993, NATURE, V361, P331, DOI 10.1038/361331a0; Orio M, 2002, AIP CONF PROC, V637, P355, DOI 10.1063/1.1518229; Orio M, 2001, ASTRON ASTROPHYS, V373, P542, DOI 10.1051/0004-6361:20010537; Orio M, 1999, ASTRON ASTROPHYS, V344, pL13; PATTERSON J, 1985, ASTROPHYS J, V292, P535, DOI 10.1086/163187; SHANLEY L, 1995, ASTROPHYS J, V438, pL95, DOI 10.1086/187724; Shore SN, 1996, ASTROPHYS J, V463, pL21, DOI 10.1086/310045; SNOWDEN S, 2001, INTRO XMM NEWTON DAT; Vanlandingham KM, 2001, ASTRON J, V121, P1126, DOI 10.1086/318778; Voges W, 1999, ASTRON ASTROPHYS, V349, P389	27	56	56	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 11	2002	298	5592					393	395		10.1126/science.298.5592.393	http://dx.doi.org/10.1126/science.298.5592.393			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	602NB	12376696				2022-12-28	WOS:000178510400042
J	Marsden, VS; O'Connor, L; O'Reilly, LA; Silke, J; Metcalf, D; Ekert, PG; Huang, DCS; Cecconi, F; Kuida, K; Tomaselli, KJ; Roy, S; Nicholson, DW; Vaux, DL; Bouillet, P; Adams, JM; Strasser, A				Marsden, VS; O'Connor, L; O'Reilly, LA; Silke, J; Metcalf, D; Ekert, PG; Huang, DCS; Cecconi, F; Kuida, K; Tomaselli, KJ; Roy, S; Nicholson, DW; Vaux, DL; Bouillet, P; Adams, JM; Strasser, A			Apoptosis initiated by Bcl-2-regulated caspase activation independently of the cytochrome c/Apaf-1/caspase-9 apoptosome	NATURE			English	Article							PROGRAMMED CELL-DEATH; BCL-2; MITOCHONDRIA; PATHWAYS; PROTEASE; MICE; DISTINCT; APAF1; DNA	Apoptosis is an evolutionarily conserved cell suicide process executed by cysteine proteases (caspases) and regulated by the opposing factions of the Bcl-2 protein family(1,2). Mammalian caspase-9 and its activator Apaf-1 were thought to be essential, because mice lacking either of them display neuronal hyperplasia and their lymphocytes and fibroblasts seem resistant to certain apoptotic stimuli(3-6). Because Apaf-1 requires cytochrome c to activate caspase-9, and Bcl-2 prevents mitochondrial cytochrome c release, Bcl-2 is widely believed to inhibit apoptosis by safeguarding mitochondrial membrane integrity(7-9). Our results suggest a different, broader role, because Bcl-2 overexpression increased lymphocyte numbers in mice and inhibited many apoptotic stimuli, but the absence of Apaf-1 or caspase-9 did not. Caspase activity was still discernible in cells lacking Apaf-1 or caspase-9, and a potent caspase antagonist both inhibited apoptosis and retarded cytochrome c release. We conclude that Bcl-2 regulates a caspase activation programme independently of the cytochrome c/Apaf-1/caspase-9 'apoptosome', which seems to amplify rather than initiate the caspase cascade.	Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia; Murdoch Childrens Res Inst, Melbourne, Vic 3050, Australia; Univ Roma Tor Vergata, Dept Biol, Rome, Italy; Vertex Pharmaceut, Genom Pharmacol, Cambridge, MA 02139 USA; Idun Pharmaceut, San Diego, CA 92121 USA; Merck Frosst Canada Inc, Pointe Claire, PQ H9H 3L1, Canada	Walter & Eliza Hall Institute; Murdoch Children's Research Institute; University of Rome Tor Vergata; Vertex Pharmaceuticals; Merck & Company	Strasser, A (corresponding author), Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia.		Huang, David C. S./C-7586-2013; Ekert, Paul G/C-7247-2013; Cecconi, Francesco/K-3969-2016; Vaux, David L/C-7249-2013; Adams, Jerry M/E-1199-2013; Bouillet, Philippe/E-1241-2013; Ekert, Paul/Q-1842-2015; Silke, John/B-7622-2008; Strasser, Andreas/C-7581-2013	Huang, David C. S./0000-0002-3101-4873; Ekert, Paul G/0000-0002-2976-8617; Cecconi, Francesco/0000-0002-5614-4359; Vaux, David L/0000-0003-2703-1651; Bouillet, Philippe/0000-0002-9012-6058; Ekert, Paul/0000-0002-2976-8617; Silke, John/0000-0002-7611-5774; Strasser, Andreas/0000-0002-5020-4891; Adams, Jerry/0000-0002-4360-8628	Telethon [TCP99038] Funding Source: Medline	Telethon(Fondazione Telethon)		ADAMS JM, IN PRESS CURR OPIN C; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bouillet P, 2002, NATURE, V415, P922, DOI 10.1038/415922a; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Dorstyn L, 2002, J CELL BIOL, V156, P1089, DOI 10.1083/jcb.200111107; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hara H, 2002, J IMMUNOL, V168, P2288, DOI 10.4049/jimmunol.168.5.2288; Haraguchi M, 2000, J EXP MED, V191, P1709, DOI 10.1084/jem.191.10.1709; Hausmann G, 2000, J CELL BIOL, V149, P623, DOI 10.1083/jcb.149.3.623; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hoglen NC, 2001, J PHARMACOL EXP THER, V297, P811; Honarpour N, 2000, DEV BIOL, V218, P248, DOI 10.1006/dbio.1999.9585; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; O'Reilly LA, 2002, CELL DEATH DIFFER, V9, P832, DOI 10.1038/sj.cdd.4401033; Ogilvy S, 1999, P NATL ACAD SCI USA, V96, P14943, DOI 10.1073/pnas.96.26.14943; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; Wang XD, 2001, GENE DEV, V15, P2922; Wu JC, 1999, METHODS, V17, P320, DOI 10.1006/meth.1999.0746; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zimmermann KC, 2002, J CELL BIOL, V156, P1077, DOI 10.1083/jcb.20112068	30	460	477	2	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 10	2002	419	6907					634	637		10.1038/nature01101	http://dx.doi.org/10.1038/nature01101			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	602AT	12374983				2022-12-28	WOS:000178483100049
J	Murakami, S; Nakashima, R; Yamashita, E; Yamaguchi, A				Murakami, S; Nakashima, R; Yamashita, E; Yamaguchi, A			Crystal structure of bacterial multidrug efflux transporter AcrB	NATURE			English	Article							ESCHERICHIA-COLI; MOLECULAR ARCHITECTURE; RESISTANCE; PUMP; PROTEINS; CRYSTALLIZATION; ANTIBIOTICS; PERIPLASM; SYSTEM; FAMILY	AcrB is a major multidrug exporter in Escherichia coli. It cooperates with a membrane fusion protein, AcrA, and an outer membrane channel, TolC. We have determined the crystal structure of AcrB at 3.5 Angstrom resolution. Three AcrB protomers are organized as a homotrimer in the shape of a jellyfish. Each protomer is composed of a transmembrane region 50 Angstrom thick and a 70 Angstrom protruding headpiece. The top of the headpiece opens like a funnel, where TolC might directly dock into AcrB. A pore formed by three alpha-helices connects the funnel with a central cavity located at the bottom of the headpiece. The cavity has three vestibules at the side of the headpiece which lead into the periplasm. In the transmembrane region, each protomer has twelve transmembrane alpha-helices. The structure implies that substrates translocated from the cell interior through the transmembrane region and from the periplasm through the vestibules are collected in the central cavity and then actively transported through the pore into the TolC tunnel.	Osaka Univ, Inst Sci & Ind Res, Dept Cell Membrane Biol, Osaka 5670047, Japan; Osaka Univ, Fac Pharmaceut Sci, Suita, Osaka 5650871, Japan; Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, CREST, Osaka 5670047, Japan	Osaka University; Osaka University; Osaka University; Japan Science & Technology Agency (JST)	Yamaguchi, A (corresponding author), Osaka Univ, Inst Sci & Ind Res, Dept Cell Membrane Biol, Osaka 5670047, Japan.	akihito@sanken.osaka-u.ac.jp	Yamashita, Eiki/V-6758-2019; Murakami, Satoshi/E-8155-2015	Yamashita, Eiki/0000-0002-4278-0039; Murakami, Satoshi/0000-0001-5553-7663				Avila-Sakar AJ, 2001, J STRUCT BIOL, V136, P81, DOI 10.1006/jsbi.2001.4418; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Davies JP, 2000, SCIENCE, V290, P2295, DOI 10.1126/science.290.5500.2295; DINH T, 1994, J BACTERIOL, V176, P3825, DOI 10.1128/JB.176.13.3825-3831.1994; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Fujihira E, 2002, J BIOCHEM, V131, P145, DOI 10.1093/oxfordjournals.jbchem.a003069; Guan L, 2001, J BACTERIOL, V183, P1734, DOI 10.1128/JB.183.5.1734-1739.2001; Heymann JAW, 2001, EMBO J, V20, P4408, DOI 10.1093/emboj/20.16.4408; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Koronakis V, 2000, NATURE, V405, P914, DOI 10.1038/35016007; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Ma Dzwokai, 1994, Trends in Microbiology, V2, P489, DOI 10.1016/0966-842X(94)90654-8; Mazzariol A, 2000, ANTIMICROB AGENTS CH, V44, P1387, DOI 10.1128/AAC.44.5.1387-1390.2000; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nikaido H, 2000, TRENDS MICROBIOL, V8, P481, DOI 10.1016/S0966-842X(00)01864-3; Nikaido H, 1998, J BACTERIOL, V180, P4686, DOI 10.1128/JB.180.17.4686-4692.1998; Nikaido H, 2001, J MOL MICROB BIOTECH, V3, P215; Okusu H, 1996, J BACTERIOL, V178, P306, DOI 10.1128/JB.178.1.306-308.1996; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OTWINOWSKI Z, 1991, CCP4 P, V80; Paulsen IT, 2000, J MOL BIOL, V301, P75, DOI 10.1006/jmbi.2000.3961; Paulsen IT, 1997, FEMS MICROBIOL LETT, V156, P1, DOI 10.1111/j.1574-6968.1997.tb12697.x; Poole K, 2001, J MOL MICROB BIOTECH, V3, P255; RAMAKRISHNAN C, 1965, BIOPHYS J, V5, P909, DOI 10.1016/S0006-3495(65)86759-5; Rowsell S, 1997, STRUCTURE, V5, P337, DOI 10.1016/S0969-2126(97)00191-3; Srikumar R, 1997, J BACTERIOL, V179, P7875, DOI 10.1128/jb.179.24.7875-7881.1997; Sulavik MC, 2001, ANTIMICROB AGENTS CH, V45, P1126, DOI 10.1128/AAC.45.4.1126-1136.2001; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P1863, DOI 10.1107/S0907444999010033; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Thanassi DG, 1997, J BACTERIOL, V179, P2512, DOI 10.1128/jb.179.8.2512-2518.1997; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Tseng Tsai-Tien, 1999, Journal of Molecular Microbiology and Biotechnology, V1, P107; WANG BC, 1985, METHOD ENZYMOL, V115, P90; Williams KA, 2000, NATURE, V403, P112, DOI 10.1038/47534; Yin CC, 2000, MOL MICROBIOL, V38, P482, DOI 10.1046/j.1365-2958.2000.02149.x; Zgurskaya HI, 1999, J MOL BIOL, V285, P409, DOI 10.1006/jmbi.1998.2313; Zgurskaya HI, 1999, P NATL ACAD SCI USA, V96, P7190, DOI 10.1073/pnas.96.13.7190; Zhuang JP, 1999, J STRUCT BIOL, V125, P63, DOI 10.1006/jsbi.1998.4059	45	736	770	1	73	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 10	2002	419	6907					587	593		10.1038/nature01050	http://dx.doi.org/10.1038/nature01050			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	602AT	12374972				2022-12-28	WOS:000178483100037
J	Lancaster, L; Kiel, MC; Kaji, A; Noller, HF				Lancaster, L; Kiel, MC; Kaji, A; Noller, HF			Orientation of ribosome recycling factor in the ribosome from directed hydroxyl radical probing	CELL			English	Article							ELONGATION-FACTOR-G; RELEASE FACTOR RF3; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; FACTOR RRF; PROTEIN-BIOSYNTHESIS; TRANSFER-RNA; TRANSLATION TERMINATION; ANGSTROM RESOLUTION; TETHERED FE(II)	Ribosome recycling factor (RRF) disassembles post-termination complexes in conjunction with elongation factor EF-G, liberating ribosomes for further rounds of translation. The striking resemblance of its L-shaped structure to that of tRNA has suggested that the mode of action of RRF may be based on mimicry of tRNA. Directed hydroxyl radical probing of 16S and 23S rRNA from Fe(II) tethered to ten positions on the surface of E. coli RRF constrains it to a well-defined location in the subunit interface cavity. Surprisingly, the orientation of RRF in the ribosome differs markedly from any of those previously observed for tRNA, suggesting that structural mimicry does not necessarily reflect functional mimicry.	Univ Calif Santa Cruz, Sinsheimer Labs, Ctr Mol Biol RNA, Santa Cruz, CA 95064 USA; Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA	University of California System; University of California Santa Cruz; University of Pennsylvania	Noller, HF (corresponding author), Univ Calif Santa Cruz, Sinsheimer Labs, Ctr Mol Biol RNA, Santa Cruz, CA 95064 USA.	harry@nuvolari.ucsc.edu			NIGMS NIH HHS [GM59140, GM17129] Funding Source: Medline; CGH CDC HHS [GH60429] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM017129, R01GM059140, R37GM017129] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); CGH CDC HHS; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal RK, 1996, SCIENCE, V271, P1000, DOI 10.1126/science.271.5251.1000; Agrawal RK, 1998, P NATL ACAD SCI USA, V95, P6134, DOI 10.1073/pnas.95.11.6134; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Culver GM, 1999, J MOL BIOL, V286, P355, DOI 10.1006/jmbi.1998.2483; Dallas A, 2001, MOL CELL, V8, P855, DOI 10.1016/S1097-2765(01)00356-2; Frank J, 2000, NATURE, V406, P318, DOI 10.1038/35018597; Freistroffer DV, 1997, EMBO J, V16, P4126, DOI 10.1093/emboj/16.13.4126; Harms J, 2001, CELL, V107, P679, DOI 10.1016/S0092-8674(01)00546-3; HAUSNER TP, 1987, BIOCHIMIE, V69, P911, DOI 10.1016/0300-9084(87)90225-2; Heilek GM, 1996, SCIENCE, V272, P1659, DOI 10.1126/science.272.5268.1659; HEILEK GM, 1995, P NATL ACAD SCI USA, V92, P1113, DOI 10.1073/pnas.92.4.1113; Heilek GM, 1996, RNA, V2, P597; HIRASHIM.A, 1970, BIOCHEM BIOPH RES CO, V41, P877, DOI 10.1016/0006-291X(70)90165-8; HIRASHIM.A, 1973, J BIOL CHEM, V248, P7580; HIRASHIMA A, 1972, J MOL BIOL, V65, P43, DOI 10.1016/0022-2836(72)90490-1; Hirokawa G, 2002, EMBO J, V21, P2272, DOI 10.1093/emboj/21.9.2272; HIROKAWA G, 2002, IN PRESS J BIOL CHEM; Inokuchi Y, 2000, EMBO J, V19, P3788, DOI 10.1093/emboj/19.14.3788; Ishino T, 2000, GENES CELLS, V5, P953, DOI 10.1046/j.1365-2443.2000.00382.x; Ito K, 2002, MOL CELL, V9, P1263, DOI 10.1016/S1097-2765(02)00547-6; Janosi L, 2000, J MOL BIOL, V295, P815, DOI 10.1006/jmbi.1999.3401; Janosi L, 1996, BIOCHIMIE, V78, P959, DOI 10.1016/S0300-9084(97)86718-1; Janosi L, 1998, EMBO J, V17, P1141, DOI 10.1093/emboj/17.4.1141; Janosi L, 1996, ADV BIOPHYS, V32, P121, DOI 10.1016/0065-227X(96)84743-5; JANOSI L, 1994, P NATL ACAD SCI USA, V91, P4249, DOI 10.1073/pnas.91.10.4249; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Joseph S, 1997, SCIENCE, V278, P1093, DOI 10.1126/science.278.5340.1093; Kaji A, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P527; Kaji A, 2001, COLD SPRING HARB SYM, V66, P515, DOI 10.1101/sqb.2001.66.515; Karimi R, 1999, MOL CELL, V3, P601, DOI 10.1016/S1097-2765(00)80353-6; Kim KK, 2000, EMBO J, V19, P2362, DOI 10.1093/emboj/19.10.2362; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lancaster L, 2000, RNA, V6, P717, DOI 10.1017/S1355838200000303; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; MOAZED D, 1995, J MOL BIOL, V248, P207, DOI 10.1016/S0022-2836(95)80042-5; Nakamura Y, 2000, CELL, V101, P349, DOI 10.1016/S0092-8674(00)80845-4; Nissen P, 2000, EMBO J, V19, P489, DOI 10.1093/emboj/19.4.489; Noller HF, 2001, COLD SPRING HARB SYM, V66, P57, DOI 10.1101/sqb.2001.66.57; Noller HF, 2002, FEBS LETT, V514, P11, DOI 10.1016/S0014-5793(02)02327-X; OGAWA K, 1975, EUR J BIOCHEM, V58, P411, DOI 10.1111/j.1432-1033.1975.tb02388.x; Pavlov MY, 1997, J MOL BIOL, V273, P389, DOI 10.1006/jmbi.1997.1324; Poole E, 2000, BBA-GENE STRUCT EXPR, V1493, P1, DOI 10.1016/S0167-4781(00)00162-7; POWERS T, 1991, EMBO J, V10, P2203, DOI 10.1002/j.1460-2075.1991.tb07756.x; Ramakrishnan V, 2002, CELL, V108, P557, DOI 10.1016/S0092-8674(02)00619-0; Rao AR, 2001, EMBO J, V20, P2977, DOI 10.1093/emboj/20.11.2977; ROBERTSON JM, 1981, J MOL BIOL, V151, P57, DOI 10.1016/0022-2836(81)90221-7; Rolland N, 1999, P NATL ACAD SCI USA, V96, P5464, DOI 10.1073/pnas.96.10.5464; RYOJI M, 1981, P NATL ACAD SCI-BIOL, V78, P5973, DOI 10.1073/pnas.78.10.5973; Selmer M, 1999, SCIENCE, V286, P2349, DOI 10.1126/science.286.5448.2349; SHIMIZU I, 1991, J BACTERIOL, V173, P5181, DOI 10.1128/jb.173.16.5181-5187.1991; STERN S, 1988, METHOD ENZYMOL, V164, P481; Toyoda T, 2000, RNA, V6, P1432, DOI 10.1017/S1355838200001060; Yoshida T, 2001, BIOCHEMISTRY-US, V40, P2387, DOI 10.1021/bi002474g; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089; Yusupova GZ, 2001, CELL, V106, P233, DOI 10.1016/S0092-8674(01)00435-4	57	100	104	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 4	2002	111	1					129	140		10.1016/S0092-8674(02)00938-8	http://dx.doi.org/10.1016/S0092-8674(02)00938-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	601RQ	12372306	Bronze			2022-12-28	WOS:000178461900014
J	Zhang, X; Tamaru, H; Khan, SI; Horton, JR; Keefe, LJ; Selker, EU; Cheng, XD				Zhang, X; Tamaru, H; Khan, SI; Horton, JR; Keefe, LJ; Selker, EU; Cheng, XD			Structure of the neurospora SET domain protein DIM-5, a histone H3 lysine methyltransferase	CELL			English	Article							HP1 CHROMO DOMAIN; CRYSTAL-STRUCTURE; METHYLATION; DNA; INSIGHTS; SITE	AdoMet-dependent methylation of histones is part of the "histone code" that can profoundly influence gene expression. We describe the crystal structure of Neurospora DIM-5, a histone H3 lysine 9 methyltranferase (HKMT), determined at 1.98 Angstrom resolution, as well as results of biochemical characterization and site-directed mutagenesis of key residues. This SET domain protein bears no structural similarity to previously characterized AdoMet-dependent methyltransferases but includes notable features such as a triangular Zn(3)Cys(9) zinc cluster in the pre-SET domain and a AdoMet binding site in the SET domain essential for methyl transfer. The structure suggests a mechanism for the methylation reaction and provides the structural basis for functional characterization of the HKMT family and the SET domain.	Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA; Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA; Argonne Natl Lab, Adv Photon Source IMCA CAT, Argonne, IL 60439 USA	Emory University; University of Oregon; United States Department of Energy (DOE); Argonne National Laboratory	Cheng, XD (corresponding author), Emory Univ, Sch Med, Dept Biochem, 1510 Clifton Rd, Atlanta, GA 30322 USA.		Horton, John/F-2375-2010; Hu, Ruogu/B-2203-2008; ID, IMCACAT/D-5867-2014; Horton, John R/ABB-4770-2020	Horton, John/0000-0001-9749-8068	NIGMS NIH HHS [R01 GM035690, R01 GM049245, R37 GM035690, R01 GM061355, R01 GM061355-03, GM49245, GM61355, GM35690] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061355, R01GM049245, R37GM035690, R01GM035690] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Baumbusch LO, 2001, NUCLEIC ACIDS RES, V29, P4319, DOI 10.1093/nar/29.21.4319; Blumenthal RM, 2001, NAT STRUCT BIOL, V8, P101, DOI 10.1038/84072; Boggs BA, 2002, NAT GENET, V30, P73, DOI 10.1038/ng787; Briggs SD, 2001, GENE DEV, V15, P3286, DOI 10.1101/gad.940201; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Cheng XD, 2001, NUCLEIC ACIDS RES, V29, P3784, DOI 10.1093/nar/29.18.3784; DUERRE JA, 1975, J BIOL CHEM, V250, P8457; Fang J, 2002, CURR BIOL, V12, P1086, DOI 10.1016/S0960-9822(02)00924-7; FAUMAN EB, 1999, S ADENOSYLMETHIONINE, P1, DOI DOI 10.1142/9789812813077_0001; Feng Q, 2002, CURR BIOL, V12, P1052, DOI 10.1016/S0960-9822(02)00901-6; Fu ZJ, 1996, BIOCHEMISTRY-US, V35, P11985, DOI 10.1021/bi961068n; Goedecke K, 2001, NAT STRUCT BIOL, V8, P121, DOI 10.1038/84104; Gong WM, 1997, NUCLEIC ACIDS RES, V25, P2702, DOI 10.1093/nar/25.14.2702; Heurgue-Hamard V, 2002, EMBO J, V21, P769, DOI 10.1093/emboj/21.4.769; Jackson JP, 2002, NATURE, V416, P556, DOI 10.1038/nature731; Jacobs SA, 2002, SCIENCE, V295, P2080, DOI 10.1126/science.1069473; Jacobs SA, 2001, EMBO J, V20, P5232, DOI 10.1093/emboj/20.18.5232; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jenuwein T, 1998, CELL MOL LIFE SCI, V54, P80, DOI 10.1007/s000180050127; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; Krogan NJ, 2002, J BIOL CHEM, V277, P10753, DOI 10.1074/jbc.C200023200; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lacoste N, 2002, J BIOL CHEM, V277, P30421, DOI 10.1074/jbc.C200366200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; Ma H, 2001, CURR BIOL, V11, P1981, DOI 10.1016/S0960-9822(01)00600-5; Nakahigashi K, 2002, P NATL ACAD SCI USA, V99, P1473, DOI 10.1073/pnas.032488499; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Ng HH, 2002, GENE DEV, V16, P1518, DOI 10.1101/gad.1001502; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nielsen PR, 2002, NATURE, V416, P103, DOI 10.1038/nature722; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Nishioka K, 2002, MOL CELL, V9, P1201, DOI 10.1016/S1097-2765(02)00548-8; Nishioka K, 2002, GENE DEV, V16, P479, DOI 10.1101/gad.967202; O'Carroll D, 2000, MOL CELL BIOL, V20, P9423, DOI 10.1128/MCB.20.24.9423-9433.2000; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; ROBBINS AH, 1991, J MOL BIOL, V221, P1269, DOI 10.1016/0022-2836(91)90933-W; Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strahl BD, 2001, CURR BIOL, V11, P996, DOI 10.1016/S0960-9822(01)00294-9; Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; van Leeuwen F, 2002, CELL, V109, P745, DOI 10.1016/S0092-8674(02)00759-6; Vasak M, 2000, CURR OPIN CHEM BIOL, V4, P177, DOI 10.1016/S1367-5931(00)00082-X; Wang HB, 2001, MOL CELL, V8, P1207, DOI 10.1016/S1097-2765(01)00405-1; Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781; Zhang X, 2000, EMBO J, V19, P3509, DOI 10.1093/emboj/19.14.3509	54	193	203	0	25	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 4	2002	111	1					117	127		10.1016/S0092-8674(02)00999-6	http://dx.doi.org/10.1016/S0092-8674(02)00999-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	601RQ	12372305	Green Accepted, Bronze			2022-12-28	WOS:000178461900013
J	Schiermeier, Q				Schiermeier, Q			Saddam gives viewers double vision	NATURE			English	News Item																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 3	2002	419	6906					421	421		10.1038/419421a	http://dx.doi.org/10.1038/419421a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	599RF	12368822	Bronze			2022-12-28	WOS:000178348400006
J	Lane, WG; Rubin, DM; Monteith, R; Christian, CW				Lane, WG; Rubin, DM; Monteith, R; Christian, CW			Racial differences in the evaluation of pediatric fractures for physical abuse	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHILD-ABUSE; REVASCULARIZATION PROCEDURES; YOUNG-CHILDREN; RACE; HOSPITALS; SEX	Context Child maltreatment is a significant problem within US society, and minority children have higher rates of substantiated maltreatment than do white children. However, it is unclear whether minority children are abused more frequently than whites or whether their cases are more likely to be reported. Objectives To determine whether there are racial differences in the evaluation and Child Protective Services (CPS) reporting of young children hospitalized for fractures. Design, Setting, and Patients Retrospective chart review conducted at an urban US academic children's hospital among 388 children younger than 3 years hospitalized for treatment of an acute primary skull or long-bone fracture between 1994 and 2000, Children with perpetrator-admitted child abuse, metabolic bone disease, birth trauma, or injury caused by vehicular crash were excluded. Main Outcome Measures Ordering of skeletal surveys and filing reports of suspected abuse. Results Reports of suspected abuse were filed for 22.5% of white and 52.9% of minority children (P<.001). Abusive injuries, as determined by expert review, were more common among minority children than among white children (27.6% vs 12.5%; P<.001). Minority children aged at least 12 months to 3 years (toddlers) were significantly more likely to have a skeletal survey performed compared with their white counterparts, even after controlling for insurance status, independent expert determination of likelihood of abuse, and appropriateness of performing a skeletal survey (adjusted odds ratio [OR], 8.75; 95% confidence interval [CI], 3.48-22.03; P<.001). This group of children was also more likely to be reported to CPS compared with white toddlers, even after controlling for insurance status and likelihood of abuse (adjusted OR, 4.32; 95% Cl, 1.63-11.43; P=.003). By likelihood of abuse, differential ordering of skeletal Surveys and reporting of suspected abuse were most pronounced for children at least 12 months old with accidental injuries; however, differences were also noted among toddlers with indeterminate injuries but not among infants or toddlers with abusive injuries. Minority children at least 12 months old with accidental injuries were more than 3 times more likely than their white counterparts to be reported for suspected abuse (for children with Medicaid or no insurance, relative risk [RR], 3.08; 95% Cl, 1.37-4.80; for children with private insurance, RR, 3.74; 95% Cl, 1.46-6.01). Conclusion While minority children had higher rates of abusive fractures in our sample, they were also more likely to be evaluated and reported for suspected abuse, even after controlling for the likelihood of abusive injury. This suggests that racial differences do exist in the evaluation and reporting of pediatric fractures for child abuse, particularly in toddlers with accidental injuries.	Childrens Hosp Philadelphia, Div Gen Pediat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	Lane, WG (corresponding author), Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, 660 W Redwood St, Baltimore, MD 21201 USA.	wlane@epi.umaryland.edu						[Anonymous], 1991, PEDIATRICS, V87, P262; Ards S, 1998, CHILD ABUSE NEGLECT, V22, P103, DOI 10.1016/S0145-2134(97)00131-2; ARDS S, 1993, CHILD ABUSE NEGLECT, V17, P337, DOI 10.1016/0145-2134(93)90056-B; AYANIAN JZ, 1993, JAMA-J AM MED ASSOC, V269, P2642, DOI 10.1001/jama.269.20.2642; Bach PB, 1999, NEW ENGL J MED, V341, P1198, DOI 10.1056/NEJM199910143411606; FLANDERS WD, 1987, J CHRON DIS, V40, P697, DOI 10.1016/0021-9681(87)90106-8; FLASKERUD JH, 1992, AM J PSYCHIAT, V149, P379; GILES WH, 1995, ARCH INTERN MED, V155, P318, DOI 10.1001/archinte.155.3.318; HAMPTON RL, 1985, AM J PUBLIC HEALTH, V75, P56, DOI 10.2105/AJPH.75.1.56; JASON J, 1982, AM J PUBLIC HEALTH, V72, P1353, DOI 10.2105/AJPH.72.12.1353; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; JOHNSON PA, 1993, ANN INTERN MED, V118, P593, DOI 10.7326/0003-4819-118-8-199304150-00004; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LEVENTHAL JM, 1993, AM J DIS CHILD, V147, P87, DOI 10.1001/archpedi.1993.02160250089028; ORENTLICHER D, 1990, JAMA-J AM MED ASSOC, V263, P2344; Peterson ED, 1997, NEW ENGL J MED, V336, P480, DOI 10.1056/NEJM199702133360706; PETERSON ED, 1994, JAMA-J AM MED ASSOC, V271, P1175, DOI 10.1001/jama.271.15.1175; Pope JH, 2000, NEW ENGL J MED, V342, P1163, DOI 10.1056/NEJM200004203421603; Schulman KA, 1999, NEW ENGL J MED, V340, P618, DOI 10.1056/NEJM199902253400806; SEDLACK AJ, 1996, 3 NATL INC STUDY CHI; Sedlak AJ, 2001, CHILD ABUSE NEGLECT, V25, P1, DOI 10.1016/S0145-2134(00)00222-2; Segal SP, 1996, PSYCHIAT SERV, V47, P282; STRAIT RT, 1995, PEDIATRICS, V96, P667; STRAKOWSKI SM, 1995, J CLIN PSYCHIAT, V56, P101; THOMAS SA, 1991, PEDIATRICS, V88, P471; TODD KH, 1993, JAMA-J AM MED ASSOC, V269, P1537, DOI 10.1001/jama.269.12.1537; *US DEPT HHS, 2001, CHILD MALTR 1999; WHITTLE J, 1993, NEW ENGL J MED, V329, P621, DOI 10.1056/NEJM199308263290907	28	229	231	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	2002	288	13					1603	1609		10.1001/jama.288.13.1603	http://dx.doi.org/10.1001/jama.288.13.1603			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	599BJ	12350191				2022-12-28	WOS:000178314000021
J	Bird, AW; Yu, DY; Pray-Grant, MG; Qiu, QF; Harmon, KE; Megee, PC; Grant, PA; Smith, MM; Christman, MF				Bird, AW; Yu, DY; Pray-Grant, MG; Qiu, QF; Harmon, KE; Megee, PC; Grant, PA; Smith, MM; Christman, MF			Acetylation of histone H4 by Esa1 is required for DNA double-strand break repair	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; ACETYLTRANSFERASE HBO1; NUCLEOSOMAL DNA; YEAST; PROTEIN; COMPLEX; TRANSCRIPTION; RECOMBINATION; REPLICATION; INVOLVEMENT	Although the acetylation of histones has a well-documented regulatory role in transcription(1-4), its role in other chromosomal functions remains largely unexplored. Here we show that distinct patterns of histone H4 acetylation are essential in two separate pathways of double-strand break repair. A budding yeast strain with mutations in wild-type H4 acetylation sites shows defects in nonhomologous end joining repair and in a newly described pathway of replication-coupled repair. Both pathways require the ESA1 histone acetyl transferase (HAT), which is responsible for acetylating all H4 tail lysines, including ectopic lysines that restore repair capacity to a mutant H4 tail. Arp4, a protein that binds histone H4 tails and is part of the Esa1-containing NuA4 HAT complex, is recruited specifically to DNA double-strand breaks that are generated in vivo. The purified Esa1-Arp4 HAT complex acetylates linear nucleosomal arrays with far greater efficiency than circular arrays in vitro, indicating that it preferentially acetylates nucleosomes near a break site. Together, our data show that histone tail acetylation is required directly for DNA repair and suggest that a related human HAT complex may function similarly.	Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Boston Univ, Med Ctr, Dept Genet & Genom, Boston, MA 02118 USA	University of Virginia; University of Virginia; Boston University	Christman, MF (corresponding author), Univ Virginia, Dept Microbiol, 1300 Jefferson Pk Ave, Charlottesville, VA 22908 USA.			Bird, Alexander/0000-0002-1061-0799; Megee, Paul/0000-0002-9397-2161				ALLFREY VG, 1968, SCIENCE, V159, P314, DOI 10.1126/science.159.3812.314; Barlev NA, 1998, MOL CELL BIOL, V18, P1349, DOI 10.1128/MCB.18.3.1349; Boulton SJ, 1996, EMBO J, V15, P5093, DOI 10.1002/j.1460-2075.1996.tb00890.x; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Burke TW, 2001, J BIOL CHEM, V276, P15397, DOI 10.1074/jbc.M011556200; Clarke AS, 1999, MOL CELL BIOL, V19, P2515; DARPA P, 1990, CANCER RES, V50, P6919; Downs JA, 2000, NATURE, V408, P1001, DOI 10.1038/35050000; Galarneau L, 2000, MOL CELL, V5, P927, DOI 10.1016/S1097-2765(00)80258-0; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Harata M, 1999, MOL BIOL CELL, V10, P2595, DOI 10.1091/mbc.10.8.2595; Iizuka M, 1999, J BIOL CHEM, V274, P23027, DOI 10.1074/jbc.274.33.23027; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Kowalczykowski SC, 2000, TRENDS BIOCHEM SCI, V25, P156, DOI 10.1016/S0968-0004(00)01569-3; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; Martin SG, 1999, CELL, V97, P621, DOI 10.1016/S0092-8674(00)80773-4; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; MEGEE PC, 1995, GENE DEV, V9, P1716, DOI 10.1101/gad.9.14.1716; Owen-Hughes T, 1999, METH MOL B, V119, P319; Reid JL, 2000, MOL CELL, V6, P1297, DOI 10.1016/S1097-2765(00)00128-3; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Tsukamoto Y, 1997, NATURE, V388, P900, DOI 10.1038/42288; VetteseDadey M, 1996, EMBO J, V15, P2508, DOI 10.1002/j.1460-2075.1996.tb00608.x; Vignali M, 2000, EMBO J, V19, P2629, DOI 10.1093/emboj/19.11.2629; Wilson TE, 1999, J BIOL CHEM, V274, P23599, DOI 10.1074/jbc.274.33.23599	27	426	438	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 26	2002	419	6905					411	415		10.1038/nature01035	http://dx.doi.org/10.1038/nature01035			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	596ZB	12353039				2022-12-28	WOS:000178195400050
J	Laskar, J; Levrard, B; Mustard, JF				Laskar, J; Levrard, B; Mustard, JF			Orbital forcing of the martian polar layered deposits	NATURE			English	Article							CHAOTIC OBLIQUITY; LASER ALTIMETER; MARS; DUST; HISTORY; CAMERA; AGES; CAPS; SIZE	Since the first images of polar regions on Mars revealed alternating bright and dark layers, there has been speculation that their formation might be tied to the planet's orbital climate forcing(1-4). But uncertainties in the deposition timescale exceed two orders of magnitude: estimates based on assumptions of dust deposition, ice formation and sublimation, and their variations with orbital forcing suggest a deposition rate of 10(-3) to 10(-2) cm yr(-1) (refs 5, 6), whereas estimates based on cratering rate result in values as high as 0.1 to 0.2 cm yr(-1) (ref. 7). Here we use a combination of high-resolution images of the polar layered terrains(8), high-resolution topography(9) and revised calculations of the orbital and rotational parameters of Mars to show that a correlation exists between ice-layer radiance as a function of depth (obtained from photometric data of the images of the layered terrains) and the insolation variations in summer at the martian north pole, similar to what has been shown for palaeoclimate studies of the Earth(10-12). For the best fit between the radiance profile and the simulated insolation parameters, we obtain an average deposition rate of 0.05 cm yr(-1) for the top 250 m of deposits on the ice cap of the north pole of Mars.	IMC, CNRS, UMR 8028, F-75014 Paris, France; Brown Univ, Dept Geol Sci, Providence, RI 02912 USA	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; Sorbonne Universite; Brown University	Laskar, J (corresponding author), IMC, CNRS, UMR 8028, 77 Av Denfert Rochereau, F-75014 Paris, France.		Laskar, Jacques/E-1098-2011	Laskar, Jacques/0000-0003-2634-789X				BLASIUS RK, 1982, ICARUS, V50, P140; Cantor BA, 2001, J GEOPHYS RES-PLANET, V106, P23653, DOI 10.1029/2000JE001310; CUTTS JA, 1982, ICARUS, V50, P216, DOI 10.1016/0019-1035(82)90124-5; Folkner WM, 1997, SCIENCE, V278, P1749, DOI 10.1126/science.278.5344.1749; HABERLE RM, 1990, J GEOPHYS RES-SOLID, V95, P1423, DOI 10.1029/JB095iB02p01423; HAYS JD, 1976, SCIENCE, V194, P1121, DOI 10.1126/science.194.4270.1121; Herkenhoff KE, 2000, ICARUS, V144, P243, DOI 10.1006/icar.1999.6287; HOWARD AD, 1982, ICARUS, V50, P161, DOI 10.1016/0019-1035(82)90123-3; Imbrie J, 1992, PALEOCEANOGRAPHY, V7, P701, DOI 10.1029/92PA02253; JAKOSKY BM, 1993, ICARUS, V102, P286, DOI 10.1006/icar.1993.1049; JAKOSKY BM, 1995, J GEOPHYS RES-PLANET, V100, P1579, DOI 10.1029/94JE02801; KIEFFER HH, 1990, J GEOPHYS RES-SOLID, V95, P1481, DOI 10.1029/JB095iB02p01481; LASKAR J, 1993, NATURE, V361, P608, DOI 10.1038/361608a0; Laskar J, 1999, PHILOS T R SOC A, V357, P1735, DOI 10.1098/rsta.1999.0399; Malin MC, 2001, J GEOPHYS RES-PLANET, V106, P23429, DOI 10.1029/2000JE001455; MARTIN LJ, 1993, J GEOPHYS RES-PLANET, V98, P3221, DOI 10.1029/92JE02937; MURRAY BC, 1972, ICARUS, V17, P328, DOI 10.1016/0019-1035(72)90004-8; PAIGE DA, 1985, SCIENCE, V228, P1160, DOI 10.1126/science.228.4704.1160; Petit JR, 1999, NATURE, V399, P429, DOI 10.1038/20859; POLLACK JB, 1979, J GEOPHYS RES, V84, P2929, DOI 10.1029/JB084iB06p02929; Richardson MI, 2002, NATURE, V416, P298, DOI 10.1038/416298a; Smith DE, 2001, J GEOPHYS RES-PLANET, V106, P23689, DOI 10.1029/2000JE001364; Smith DE, 2001, SCIENCE, V294, P2141, DOI 10.1126/science.1066556; Standish E. M., 1998, 312F98048 JET PROP L; Thomas P., 1992, MARS, P767; TOON OB, 1980, ICARUS, V44, P552, DOI 10.1016/0019-1035(80)90130-X; TOUMA J, 1993, SCIENCE, V259, P1294, DOI 10.1126/science.259.5099.1294; Zuber MT, 1998, SCIENCE, V282, P2053, DOI 10.1126/science.282.5396.2053	29	251	255	1	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 26	2002	419	6905					375	377		10.1038/nature01066	http://dx.doi.org/10.1038/nature01066			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	596ZB	12353029				2022-12-28	WOS:000178195400039
J	Chan, FKL; Leung, WK				Chan, FKL; Leung, WK			Peptic-ulcer disease	LANCET			English	News Item							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; HELICOBACTER-PYLORI INFECTION; SERIOUS GASTROINTESTINAL COMPLICATIONS; RANITIDINE BISMUTH CITRATE; GASTRIC-MUCOSAL DAMAGE; DUODENAL-ULCER; DOUBLE-BLIND; BICARBONATE SECRETION; RHEUMATOID-ARTHRITIS; CAMPYLOBACTER-PYLORI	The discovery of Helicobacter pylori has greatly changed our approach to peptic ulcer disease. Bacterial, host, and environmental factors all have a role in peptic-ulcer disease. Although the prevalence of uncomplicated peptic ulcers is failing, hospital admissions for ulcer complications associated with non-steroidal anti-inflammatory drugs (NSAIDs) are rising. Evidence suggests that coprescription of NSAIDs with potent antiulcer agents and the use of highly selective cyclo-oxygenase-2 inhibitors reduce gastroduodenal ulceration. Whether these therapeutic advances will translate into clinical benefits remains to be seen. The interaction between H pylori and NSAIDs is one of the most controversial issues in peptic ulcer disease. With the fall in rates of H pylori infection, the proportion of ulcers not related to this organism and NSAIDs has risen, which will affect the management of peptic ulcer.	Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital	Chan, FKL (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, 30-32 Ngan Shing St, Shatin, Hong Kong, Peoples R China.	fklchan@cuhk.edu.hk	Leung, Wai Keung/B-8140-2011; Chan, Francis K. L./F-4851-2010	Leung, Wai Keung/0000-0002-5993-1059; Chan, Francis K. L./0000-0001-7388-2436				ANDREWS FJ, 1994, AM J PHYSIOL, V266, pG657, DOI 10.1152/ajpgi.1994.266.4.G657; Appleyard CB, 1996, AM J PHYSIOL-GASTR L, V270, pG42, DOI 10.1152/ajpgi.1996.270.1.G42; Atherton JC, 1997, GASTROENTEROLOGY, V112, P92, DOI 10.1016/S0016-5085(97)70223-3; Beales I, 1997, GASTROENTEROLOGY, V113, P465, DOI 10.1053/gast.1997.v113.pm9247465; Beales I, 1997, GASTROENTEROLOGY, V112, P136, DOI 10.1016/S0016-5085(97)70228-2; Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; BORODY TJ, 1989, MED J AUSTRALIA, V151, P431, DOI 10.5694/j.1326-5377.1989.tb101251.x; Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648; Chan FKL, 2002, LANCET, V359, P9, DOI 10.1016/S0140-6736(02)07272-0; Chan FKL, 2001, ALIMENT PHARM THER, V15, P19, DOI 10.1046/j.1365-2036.2001.00890.x; Chan FKL, 2001, GASTROENTEROL CLIN N, V30, P937, DOI 10.1016/S0889-8553(05)70221-1; Chan FKL, 2001, NEW ENGL J MED, V344, P967, DOI 10.1056/NEJM200103293441304; Chan FKL, 1997, LANCET, V350, P975, DOI 10.1016/S0140-6736(97)04523-6; Chan HLY, 2001, GASTROINTEST ENDOSC, V53, P438, DOI 10.1067/mge.2001.112840; COVACCI A, 1993, P NATL ACAD SCI USA, V90, P5791, DOI 10.1073/pnas.90.12.5791; DAVENPOR.HW, 1969, GASTROENTEROLOGY, V56, P439; El-Omar EM, 2000, NATURE, V404, P398, DOI 10.1038/35006081; ELLIOTT SN, 1995, GASTROENTEROLOGY, V109, P524, DOI 10.1016/0016-5085(95)90341-0; ELOMAR EM, 1995, GASTROENTEROLOGY, V109, P681, DOI 10.1016/0016-5085(95)90374-7; Faber K, 1927, LANCET, V2, P902; Fandriks L, 1997, GASTROENTEROLOGY, V113, P1570, DOI 10.1053/gast.1997.v113.pm9352859; Frevel M, 2000, ALIMENT PHARM THER, V14, P1151; FROMM D, 1987, CLIN INVEST MED, V10, P251; FU JY, 1990, J BIOL CHEM, V265, P16737; GABRIEL SE, 1991, ANN INTERN MED, V115, P787, DOI 10.7326/0003-4819-115-10-787; Gerhard M, 1999, P NATL ACAD SCI USA, V96, P12778, DOI 10.1073/pnas.96.22.12778; Graham DY, 1997, GASTROENTEROLOGY, V113, P1983, DOI 10.1016/S0016-5085(97)70019-2; Graham DY, 2002, ARCH INTERN MED, V162, P169, DOI 10.1001/archinte.162.2.169; Graham DY, 2000, HELICOBACTER, V5, pS3; GRAHAM DY, 1997, HELICOBACTER S1, V2, P44; GRAHAM DY, 2000, GASTROENTEROLOGY, V118, P1; GRAHAM DY, 1998, GASTROENTEROLOGY, V114, P17; GREEN FW, 1978, GASTROENTEROLOGY, V74, P38; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; Hawkey CJ, 1998, NEW ENGL J MED, V338, P727, DOI 10.1056/NEJM199803123381105; Hawkey CJ, 1998, LANCET, V352, P1016, DOI 10.1016/S0140-6736(98)04206-8; Higashi H, 2002, SCIENCE, V295, P683, DOI 10.1126/science.1067147; Higham J, 2002, GUT, V50, P460, DOI 10.1136/gut.50.4.460; Hogan DL, 1996, GASTROENTEROLOGY, V110, P705, DOI 10.1053/gast.1996.v110.pm8608879; Huang JQ, 2002, LANCET, V359, P14, DOI 10.1016/S0140-6736(02)07273-2; Hudson N, 1997, GASTROENTEROLOGY, V112, P1817, DOI 10.1053/gast.1997.v112.pm9178671; ISENBERG JI, 1987, NEW ENGL J MED, V316, P374, DOI 10.1056/NEJM198702123160704; Jyotheeswaran S, 1998, AM J GASTROENTEROL, V93, P574, DOI 10.1111/j.1572-0241.1998.167_b.x; Kelly JP, 1996, LANCET, V348, P1413, DOI 10.1016/S0140-6736(96)01254-8; Konturek JW, 1998, GASTROENTEROLOGY, V114, P245, DOI 10.1016/S0016-5085(98)70474-3; KURATA JH, 1984, CLIN GASTROENTEROL, V13, P289; Labenz J, 1996, GASTROENTEROLOGY, V110, P725, DOI 10.1053/gast.1996.v110.pm8608881; LAINE L, 1995, ALIMENT PHARM THERAP, V9, P127; Laine L, 1998, AM J GASTROENTEROL, V93, P1409, DOI 10.1111/j.1572-0241.1998.452_a.x; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; LARKAI EN, 1987, AM J GASTROENTEROL, V82, P1153; Leung Wai K., 2002, Curr Treat Options Gastroenterol, V5, P133, DOI 10.1007/s11938-002-0060-8; LEVI S, 1989, LANCET, V1, P1167; LICHTENBERGER LM, 1995, NAT MED, V1, P154, DOI 10.1038/nm0295-154; Lind T, 1999, GASTROENTEROLOGY, V116, P248, DOI 10.1016/S0016-5085(99)70119-8; Lind T, 1996, Helicobacter, V1, P138, DOI 10.1111/j.1523-5378.1996.tb00027.x; LOGAN RPH, 1995, GUT, V36, P12, DOI 10.1136/gut.36.1.12; Malekzadeh R, 2000, ALIMENT PHARM THER, V14, P299; Malfertheiner P, 2002, ALIMENT PHARM THER, V16, P167, DOI 10.1046/j.1365-2036.2002.01169.x; Malfertheiner P, 1997, GUT, V41, P8; MARSHALL BJ, 1984, LANCET, V1, P1311; Megraud F, 2000, HELICOBACTER, V5, P222, DOI 10.1046/j.1523-5378.2000.00034.x; Meining A, 1998, ALIMENT PHARM THER, V12, P735; Misiewicz JJ, 1997, GUT, V41, P735, DOI 10.1136/gut.41.6.735; Mizuno H, 1997, GASTROENTEROLOGY, V112, P387, DOI 10.1053/gast.1997.v112.pm9024292; Mizushima T, 2001, J CLIN MICROBIOL, V39, P2463, DOI 10.1128/JCM.39.7.2463-2465.2001; MOSS SF, 1992, LANCET, V340, P930, DOI 10.1016/0140-6736(92)92816-X; Munnangi S, 1997, ARCH INTERN MED, V157, P1489, DOI 10.1001/archinte.157.13.1489; Nishikawa K, 2000, EUR J GASTROEN HEPAT, V12, P635, DOI 10.1097/00042737-200012060-00010; Odenbreit S, 2000, SCIENCE, V287, P1497, DOI 10.1126/science.287.5457.1497; Olbe L, 1996, GASTROENTEROLOGY, V110, P1386, DOI 10.1053/gast.1996.v110.pm8613042; Osato MS, 2001, ARCH INTERN MED, V161, P1217, DOI 10.1001/archinte.161.9.1217; Perri F, 2001, AM J GASTROENTEROL, V96, P58; RAINSFORD KD, 1982, DIGEST DIS SCI, V27, P624, DOI 10.1007/BF01297219; RAINSFORD KD, 1983, AGENTS ACTIONS, V13, P457, DOI 10.1007/BF02176417; ROSTOM A, 2000, COCHRANE DB SYST REV, V4, P2296; Savarino V, 1997, GASTROENTEROLOGY, V113, P741, DOI 10.1016/S0016-5085(97)70166-5; SCHMASSMANN A, 1995, AM J PHYSIOL, V268, P276; SCHRAGER J, 1967, GUT, V8, P497, DOI 10.1136/gut.8.5.497; Segal ED, 1999, P NATL ACAD SCI USA, V96, P14559, DOI 10.1073/pnas.96.25.14559; SILVERSTEIN FE, 1995, ANN INTERN MED, V123, P241, DOI 10.7326/0003-4819-123-4-199508150-00001; Silverstein FE, 2000, JAMA-J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247; Singh G, 1999, J RHEUMATOL, V26, P18; Sung JJY, 1999, ALIMENT PHARM THER, V13, P1079, DOI 10.1046/j.1365-2036.1999.00580.x; Taha AS, 1996, NEW ENGL J MED, V334, P1435, DOI 10.1056/NEJM199605303342204; TAHA AS, 1999, GASTROENTEROLOGY, V116, P1; To KF, 2001, ALIMENT PHARM THERAP, V15, P25, DOI 10.1046/j.1365-2036.2001.00889.x; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; *US FDA, 2002, STAT REV BRIEF DOC A; VAANANEN PM, 1992, INFLAMMATION, V16, P227, DOI 10.1007/BF00918812; Vaira D, 2002, ANN INTERN MED, V136, P280, DOI 10.7326/0003-4819-136-4-200202190-00007; Van Zanten SJOV, 1999, GASTROENTEROLOGY, V116, P1217, DOI 10.1016/S0016-5085(99)70025-9; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; Versalovic J, 1996, ANTIMICROB AGENTS CH, V40, P477, DOI 10.1128/AAC.40.2.477; Wallace JL, 1997, GASTROENTEROLOGY, V112, P1000, DOI 10.1053/gast.1997.v112.pm9041264; WALLACE JL, 1990, AM J PHYSIOL, V259, pG462, DOI 10.1152/ajpgi.1990.259.3.G462; WALLACE JL, 1994, GASTROENTEROLOGY, V107, P173, DOI 10.1016/0016-5085(94)90074-4; WALLACE JL, 1990, GASTROENTEROLOGY, V99, P295, DOI 10.1016/0016-5085(90)91009-U; Wallace JL, 2000, GASTROENTEROLOGY, V119, P706, DOI 10.1053/gast.2000.16510; WHITTLE BJR, 1981, GASTROENTEROLOGY, V80, P94; Wolfe MM, 1999, NEW ENGL J MED, V340, P1888, DOI 10.1056/NEJM199906173402407; WYATT JI, 1987, J CLIN PATHOL, V40, P841, DOI 10.1136/jcp.40.8.841; YAMADA T, 1994, JAMA-J AM MED ASSOC, V272, P65, DOI 10.1001/jama.272.1.65; Yamaoka Y, 1996, GASTROENTEROLOGY, V110, P1744, DOI 10.1053/gast.1996.v110.pm8964399; Yeomans ND, 1998, NEW ENGL J MED, V338, P719, DOI 10.1056/NEJM199803123381104	105	166	176	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 21	2002	360	9337					933	941		10.1016/S0140-6736(02)11030-0	http://dx.doi.org/10.1016/S0140-6736(02)11030-0			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	596AU	12354485				2022-12-28	WOS:000178142200022
J	Grosse, V; Bange, FC; Tischendorf, J; Schmidt, RE; Manns, MP				Grosse, V; Bange, FC; Tischendorf, J; Schmidt, RE; Manns, MP			A mass in the eye	LANCET			English	Article									Hannover Med Sch, Div Clin Immunol, D-30625 Hannover, Germany; Hannover Med Sch, Div Gastroenterol & Hepatol, D-30625 Hannover, Germany; Hannover Med Sch, Dept Microbiol, D-30625 Hannover, Germany	Hannover Medical School; Hannover Medical School; Hannover Medical School	Grosse, V (corresponding author), Hannover Med Sch, Div Clin Immunol, D-30625 Hannover, Germany.							Bodaghi B, 2000, Curr Opin Ophthalmol, V11, P443, DOI 10.1097/00055735-200012000-00010; FRIEDBERG DN, 1996, TUBERCULOSIS, P557; Sheu SJ, 2001, OPHTHALMOLOGY, V108, P1580, DOI 10.1016/S0161-6420(01)00693-5	3	13	13	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 21	2002	360	9337					922	922		10.1016/S0140-6736(02)11029-4	http://dx.doi.org/10.1016/S0140-6736(02)11029-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	596AU	12354475				2022-12-28	WOS:000178142200012
J	Ghose, GM; Maunsell, JHR				Ghose, GM; Maunsell, JHR			Attentional modulation in visual cortex depends on task timing	NATURE			English	Article							PARIETAL CORTEX; ORIENTING ATTENTION; SELECTIVE ATTENTION; NEURONAL RESPONSES; NEURAL MECHANISMS; TIME PERCEPTION; SINGLE NEURONS; CORTICAL AREAS; SHIFTS; V4	Paying attention to a stimulus selectively increases the ability to process it. For example, when subjects attend to a specific region of a visual scene, their sensitivity to changes at that location increases. A large number of studies describe the behavioural consequences and neurophysiological correlates of attending to spatial locations(1-8). There has, in contrast, been little study of the allocation of attention over time(9,10). Because subjects can anticipate predictable events with great temporal precision(11-15), it seems probable that they might dynamically shift their attention when performing a familiar perceptual task whose constraints changed over time. We trained monkeys to respond to a stimulus change where the probability of occurrence changed over time. Recording from area V4 of the visual cortex in these animals, we found that the modulation of neuronal responses changed according to the probability of the change occurring at that instant. Thus, we show that the attentional modulation of sensory neurons reflects a subject's anticipation of the timing of behaviourally relevant events.	Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute	Ghose, GM (corresponding author), Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA.		Maunsell, John/G-5702-2010	Maunsell, John/0000-0003-0018-4439; Ghose, Geoffrey/0000-0002-2227-3179				Colby CL, 1999, ANNU REV NEUROSCI, V22, P319, DOI 10.1146/annurev.neuro.22.1.319; Colby CL, 1996, J NEUROPHYSIOL, V76, P2841, DOI 10.1152/jn.1996.76.5.2841; Conner CE, 1997, J NEUROSCI, V17, P3201; Constantinidis C, 2001, CEREB CORTEX, V11, P592, DOI 10.1093/cercor/11.7.592; Coull JT, 2000, NEUROPSYCHOLOGIA, V38, P808, DOI 10.1016/S0028-3932(99)00132-3; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.ne.18.030195.001205; Harrington DL, 1998, J NEUROSCI, V18, P1085; KROSE BJA, 1989, VISION RES, V29, P1607, DOI 10.1016/0042-6989(89)90142-9; Luck SJ, 1997, J NEUROPHYSIOL, V77, P24, DOI 10.1152/jn.1997.77.1.24; McAdams CJ, 1999, J NEUROSCI, V19, P431, DOI 10.1523/JNEUROSCI.19-01-00431.1999; Migliore M, 2001, J NEUROPHYSIOL, V86, P2754, DOI 10.1152/jn.2001.86.6.2754; MORAN J, 1985, SCIENCE, V229, P782, DOI 10.1126/science.4023713; MOTTER BC, 1993, J NEUROPHYSIOL, V70, P909, DOI 10.1152/jn.1993.70.3.909; Nobre AC, 2001, NEUROPSYCHOLOGIA, V39, P1317; ROBINSON DL, 1995, J NEUROPHYSIOL, V74, P698, DOI 10.1152/jn.1995.74.2.698; SAARINEN J, 1991, P NATL ACAD SCI USA, V88, P1812, DOI 10.1073/pnas.88.5.1812; Seidemann E, 1999, J NEUROPHYSIOL, V81, P1783, DOI 10.1152/jn.1999.81.4.1783; SPITZER H, 1988, SCIENCE, V240, P338, DOI 10.1126/science.3353728; STEINMETZ MA, 1994, J NEUROPHYSIOL, V72, P1020, DOI 10.1152/jn.1994.72.2.1020; TREISMAN M, 1990, PERCEPTION, V19, P705, DOI 10.1068/p190705; Treue S, 1999, J NEUROSCI, V19, P7591, DOI 10.1523/JNEUROSCI.19-17-07591.1999; Verstraten FAJ, 2000, VISION RES, V40, P3651, DOI 10.1016/S0042-6989(00)00213-3; Westheimer G, 2000, VISUAL NEUROSCI, V17, P551, DOI 10.1017/S095252380017405X; Zakay D., 1996, ADV PSYCHOL, V115, P143, DOI [10.1016/S0166-4115(96)80057-4, DOI 10.1016/S0166-4115(96)80057-4]	24	211	212	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 10	2002	419	6907					616	620		10.1038/nature01057	http://dx.doi.org/10.1038/nature01057			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	602AT	12374979				2022-12-28	WOS:000178483100045
J	Cheung, YB; Khoo, KS; Karlberg, J; Machin, D				Cheung, YB; Khoo, KS; Karlberg, J; Machin, D			Association between psychological symptoms in adults and growth in early life: longitudinal follow up study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MALAISE INVENTORY; GESTATIONAL-AGE; BIRTH-WEIGHT; FETAL GROWTH; HYPOTHESIS; ORIGINS; STRESS; COHORT	Objectives 16 test the hypothesis that birth weight for gestational age and weight gain in early childhood have a long term association with psychological distress in adults. Design Longitudinal study of 1958 birth cohort followed to age 42 years. Setting Population based birth cohort study. Participants 9731 cohort members with valid perinatal, postnatal, and adult data. Main outcome measures Malaise inventory scores measured at ages 23, 33, and 42 years. Generalised estimating equations approach used to analyse repeated measures. Results Psychological distress score was inversely related to birthweight z score and weight gain from birth to the age of 7 years. A unit increase in birthweight z score or childhood weight gain was associated with a mean reduction in psychological distress score of 0.10 (95% confidence interval 0.05 to 0.14) and 0.06 (0.02 to 0.10), respectively. Birth weight and weight gain were also inversely related to the odds of having a high level of psychological distress, with odds ratios being 0.90 (0.85 to 0.95) and 0;93 (0.89 to 0.98), respectively. Conclusions Psychological health in adults is related to fetal growth and growth in early childhood.	Natl Canc Ctr, Div Clin Trials & Epidemiol Sci, Singapore 169610, Singapore; Natl Canc Ctr, Dept Med Oncol, Singapore, Singapore; Univ Hong Kong, Clin Trials Ctr, Hong Kong, Hong Kong, Peoples R China; Univ Sheffield, Clin Trial Res Unit, Sheffield S5 7AU, S Yorkshire, England	National Cancer Centre Singapore (NCCS); National Cancer Centre Singapore (NCCS); University of Hong Kong; University of Sheffield	Cheung, YB (corresponding author), Natl Canc Ctr, Div Clin Trials & Epidemiol Sci, Singapore 169610, Singapore.	ctecyb@nccs.com.sg	Karlberg, Johan Petter Einar/C-4290-2009; Karlberg, Johan/AAZ-7864-2020					BOX GEP, 1964, J ROY STAT SOC B, V26, P211, DOI 10.1111/j.2517-6161.1964.tb00553.x; Cheung YB, 2002, SOC SCI MED, V55, P937, DOI 10.1016/S0277-9536(01)00225-8; Cheung YB, 2001, J CLIN EPIDEMIOL, V54, P1238, DOI 10.1016/S0895-4356(01)00403-6; Cheung YB, 2000, HYPERTENSION, V36, P795, DOI 10.1161/01.HYP.36.5.795; Cianfarani S, 1999, ARCH DIS CHILD-FETAL, V81, pF71, DOI 10.1136/fn.81.1.F71; Fayers P., 2007, QUALITY LIFE ASSESSM; FAYERS PM, 2000, BIOMETRIKA; FERRI E, 1993, LIFE 33 5 FOLLOW NAT; GRANT G, 1990, SOC PSYCH PSYCH EPID, V25, P170; HIRST MA, 1983, J PSYCHOSOM RES, V27, P193, DOI 10.1016/0022-3999(83)90022-3; LAGERSTROM M, 1994, INT J PSYCHOPHYSIOL, V17, P175, DOI 10.1016/0167-8760(94)90033-7; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Lucas A, 1999, BRIT MED J, V319, P245, DOI 10.1136/bmj.319.7204.245; NIKLASSON A, 1991, ACTA PAEDIATR SCAND, V80, P756, DOI 10.1111/j.1651-2227.1991.tb11945.x; Nilsson PM, 2001, INT J EPIDEMIOL, V30, P75, DOI 10.1093/ije/30.1.75; Power C., 1991, HLTH CLASS EARLY YEA; Rodgers B, 1999, SOC PSYCH PSYCH EPID, V34, P333, DOI 10.1007/s001270050153; RUTTER M, 1970, EDUC HLTH BEHAV; Strauss RS, 2000, JAMA-J AM MED ASSOC, V283, P625, DOI 10.1001/jama.283.5.625	19	63	63	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 5	2002	325	7367					749	751		10.1136/bmj.325.7367.749	http://dx.doi.org/10.1136/bmj.325.7367.749			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	603AU	12364303	Green Published, Green Submitted, Bronze, Green Accepted			2022-12-28	WOS:000178537300017
J	Noel, PH; Pugh, JA				Noel, PH; Pugh, JA			Management of overweight and obese adults	BMJ-BRITISH MEDICAL JOURNAL			English	Review							CARE	New treatment strategies have failed to control the global increase in obesity. Here two scientists discuss common barriers that need to be overcome by both healthcare professionals and patients if weight reduction is to be achieved and maintained.	S Texas Vet Hlth Care Syst, VERDICT Hlth Serv Res Ctr Excellence, San Antonio, TX 78229 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Noel, PH (corresponding author), S Texas Vet Hlth Care Syst, VERDICT Hlth Serv Res Ctr Excellence, San Antonio, TX 78229 USA.	pollyh@verdict.uthscsa.edu	Pugh, Jacqueline/I-6199-2013	Pugh, Jacqueline/0000-0003-4933-141X; Noel, Polly/0000-0002-1519-7489				Arterburn D, 2001, BRIT MED J, V322, P1406, DOI 10.1136/bmj.322.7299.1406; Astrup A, 2000, BRIT J NUTR, V83, pS25; Atkins RC, 2002, DR ATKINS NEW DIET R; Billington CJ, 2000, ARCH INTERN MED, V160, P898, DOI 10.1001/archinte.160.7.898; Billington CJ, 2002, AM FAM PHYSICIAN, V65, P81; DICKSON R, 1997, EFFECTIVE HLTH CARE, V3, P1; Donato KA, 1998, ARCH INTERN MED, V158, P1855, DOI 10.1001/archinte.158.17.1855; Douketis JD, 1999, CAN MED ASSOC J, V160, P513; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; Glasgow RE, 2001, MILBANK Q, V79, P579, DOI 10.1111/1468-0009.00222; Harvey EL, 1999, INT J OBESITY, V23, P1213, DOI 10.1038/sj.ijo.0800932; Katz DL, 2001, PREV MED, V32, P66, DOI 10.1006/pmed.2000.0773; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Lee IM, 2001, J GERONTOL A-BIOL, V56, P7, DOI 10.1093/gerona/56.suppl_1.7; Lyznicki JM, 2001, AM FAM PHYSICIAN, V63, P2185; *NAT AUD OFF COMPT, 2001, HC220 NAT AUD OFF CO; *NAT I CLIN EXC, 2002, SURG AID WEIGHT RED; *NAT I DIAB DIG KI, 2001, GASTR SURG SEV OB; Nawaz H, 2001, AM J PREV MED, V21, P73, DOI 10.1016/S0749-3797(01)00317-8; NHLBI Obesity Education Initiative Expert Panel on the Identification Evaluation and Treatment of Obesity in Adults (US), 1998, CLIN GUID ID EV TREA; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; Rippe JM, 1998, J AM DIET ASSOC, V98, pS9, DOI 10.1016/S0002-8223(98)00704-4; Sears B., 1995, ZONE DIETARY ROAD MA; STEWARD HL, 1998, SUGAR BUSTERS CUT SU; Stockley L, 2001, Public Health Nutr, V4, P307; Taylor DH, 2001, J AM GERIATR SOC, V49, P1319, DOI 10.1046/j.1532-5415.2001.49259.x; *US PREV SERV TASK, 1996, SCREEN OB GUID CLIN, P219; WHO, 1997, WHO TECHN REP SER, V894; Wing RR, 2001, ANNU REV NUTR, V21, P323, DOI 10.1146/annurev.nutr.21.1.323; Yanovski SZ, 2000, ARCH INTERN MED, V160, P2581, DOI 10.1001/archinte.160.17.2581	30	50	53	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 5	2002	325	7367					757	761		10.1136/bmj.325.7367.757	http://dx.doi.org/10.1136/bmj.325.7367.757			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	603AU	12364306	Green Published			2022-12-28	WOS:000178537300021
J	Thomas, KS; Muir, KR; Doherty, M; Jones, AC; O'Reilly, SC; Bassey, EJ				Thomas, KS; Muir, KR; Doherty, M; Jones, AC; O'Reilly, SC; Bassey, EJ		Community Osteoarthritis Res Grp	Home based exercise programme for knee pain and knee osteoarthritis: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							OSTEO-ARTHRITIS; THERAPY; ADULTS; TREAT; HIP	Objectives To determine whether a home based exercise programme can improve outcomes in patients with knee pain. Design Pragmatic, factorial randomised controlled trial of two years' duration. Setting Two general practices in Nottingham. Participants 786 men and women aged greater than or equal to45 years with self reported knee pain. Interventions Participants were randomised to four groups to receive exercise therapy, monthly telephone contact, exercise therapy plus telephone contact, or no intervention. Patients in the no intervention and combined exercise and telephone groups were randomised to receive or not receive a placebo health food tablet. Main outcome measures Primary outcome was self reported score for knee pain on the Western Ontario and McMaster universities (WOMAC) osteoarthritis index at two years. Secondary outcomes included knee specific physical function and stiffness (scored on WOMAC index), general physical function (scored on SF-36 questionnaire), psychological outlook (scored on hospital anxiety and depression scale), and isometric muscle strength. Results 600 (76.3%) participants completed the study. At 24 months, highly significant reductions in knee pain were apparent for the pooled exercise groups compared with the non-exercise groups (mean difference -0.82, 95% confidence interval -1.3 to -0.3). Similar improvements were observed at 6, 12, and 18 months. Regular telephone contact alone did not reduce pain. The reduction in pain was greater the closer patients adhered to the exercise plan. Conclusions A simple home based exercise programme can significantly reduce knee pain. The lack of improvement in patients who received only telephone contact suggests that improvements are not just due to psychosocial effects because of contact with the therapist.	City Hosp, Nottingham NG5 1PB, England; Queens Med Ctr, Dept Epidemiol & Publ Hlth Med, Nottingham NG7 2UH, England; Queens Med Ctr, Sch Biomed Sci, Nottingham, England	University of Nottingham; University of Nottingham; University of Nottingham	Doherty, M (corresponding author), City Hosp, Nottingham NG5 1PB, England.	michael.doherty@nottingham.ac.uk		Thomas, Kim/0000-0001-7785-7465; Doherty, Michael/0000-0002-5763-8326				Altman DG, 1998, BRIT MED J, V317, P1309, DOI 10.1136/bmj.317.7168.1309; ALTMAN RD, 1995, OSTEOARTHR CARTILAGE, V3, P3; BADLEY EM, 1993, BRIT J RHEUMATOL, V32, P601; Bellamy N, 1988, J ORTHOP RHEUMATOL, V1, P95; BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; COOK RJ, 1995, BRIT MED J, V310, P452, DOI 10.1136/bmj.310.6977.452; DAVIS MA, 1992, J RHEUMATOL, V19, P1943; Deyle GD, 2000, ANN INTERN MED, V132, P173, DOI 10.7326/0003-4819-132-3-200002010-00002; Ettinger WH, 1997, JAMA-J AM MED ASSOC, V277, P25, DOI 10.1001/jama.277.1.25; FELSON DT, 1987, ARTHRITIS RHEUM, V30, P914, DOI 10.1002/art.1780300811; FISHER NM, 1991, ARCH PHYS MED REHAB, V72, P365; LAWRENCE JS, 1966, ANN RHEUM DIS, V25, P1; Maurer BT, 1999, ARCH PHYS MED REHAB, V80, P1293, DOI 10.1016/S0003-9993(99)90032-1; O'Reilly SC, 1999, ANN RHEUM DIS, V58, P15, DOI 10.1136/ard.58.1.15; OReilly SC, 1996, ANN RHEUM DIS, V55, P931, DOI 10.1136/ard.55.12.931; TORNVALL G, 1963, ACTA PHYSIOL SCAND, V58, P5; TORNVALL G, 1963, ACTA PHYSIOL SCAND S, V58, P201; van Baar ME, 2001, ANN RHEUM DIS, V60, P1123, DOI 10.1136/ard.60.12.1123; Van Baar ME, 1998, J RHEUMATOL, V25, P2432; WEINBERGER M, 1989, ARTHRITIS RHEUM, V32, P1577, DOI 10.1002/anr.1780321212; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	21	258	264	1	27	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 5	2002	325	7367					752	755		10.1136/bmj.325.7367.752	http://dx.doi.org/10.1136/bmj.325.7367.752			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	603AU	12364304	Bronze, Green Published, Green Accepted, Green Submitted			2022-12-28	WOS:000178537300018
J	Hamer, D				Hamer, D			Rethinking behavior genetics	SCIENCE			English	Editorial Material							MONOAMINE-OXIDASE; POLYMORPHISM; RISK		NCI, Biochem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Hamer, D (corresponding author), NCI, Biochem Lab, NIH, Bethesda, MD 20892 USA.							Bookheimer SY, 2000, NEW ENGL J MED, V343, P450, DOI 10.1056/NEJM200008173430701; Copeland P., 1998, LIVING OUR GENES; Egan MF, 2001, P NATL ACAD SCI USA, V98, P6917, DOI 10.1073/pnas.111134598; HAMER DH, 1993, SCIENCE, V261, P321, DOI 10.1126/science.8332896; Hariri AR, 2002, SCIENCE, V297, P400, DOI 10.1126/science.1071829; Lai CSL, 2001, NATURE, V413, P519, DOI 10.1038/35097076; Lesch KP, 1996, SCIENCE, V274, P1527, DOI 10.1126/science.274.5292.1527; Murphy DL, 2001, BRAIN RES BULL, V56, P487, DOI 10.1016/S0361-9230(01)00622-0; Sabol SZ, 1998, HUM GENET, V103, P273, DOI 10.1007/s004390050816; Shih JC, 1999, AM J HUM GENET, V65, P593, DOI 10.1086/302562; Yan H, 2002, SCIENCE, V297, P1143, DOI 10.1126/science.1072545	12	107	113	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 4	2002	298	5591					71	72		10.1126/science.1077582	http://dx.doi.org/10.1126/science.1077582			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	600BJ	12364769	Green Submitted			2022-12-28	WOS:000178370500028
J	Holt, RA; Subramanian, GM; Halpern, A; Sutton, GG; Charlab, R; Nusskern, DR; Wincker, P; Clark, AG; Ribeiro, JMC; Wides, R; Salzberg, SL; Loftus, B; Yandell, M; Majoros, WH; Rusch, DB; Lai, ZW; Kraft, CL; Abril, JF; Anthouard, V; Arensburger, P; Atkinson, PW; Baden, H; de Berardinis, V; Baldwin, D; Benes, V; Biedler, J; Blass, C; Bolanos, R; Boscus, D; Barnstead, M; Cai, S; Center, A; Chatuverdi, K; Christophides, GK; Chrystal, MA; Clamp, M; Cravchik, A; Curwen, V; Dana, A; Delcher, A; Dew, I; Evans, CA; Flanigan, M; Grundschober-Freimoser, A; Friedli, L; Gu, ZP; Guan, P; Guigo, R; Hillenmeyer, ME; Hladun, SL; Hogan, JR; Hong, YS; Hoover, J; Jaillon, O; Ke, ZX; Kodira, C; Kokoza, E; Koutsos, A; Letunic, I; Levitsky, A; Liang, Y; Lin, JJ; Lobo, NF; Lopez, JR; Malek, JA; McIntosh, TC; Meister, S; Miller, J; Mobarry, C; Mongin, E; Murphy, SD; O'Brochta, DA; Pfannkoch, C; Qi, R; Regier, MA; Remington, K; Shao, HG; Sharakhova, MV; Sitter, CD; Shetty, J; Smith, TJ; Strong, R; Sun, JT; Thomasova, D; Ton, LQ; Topalis, P; Tu, ZJ; Unger, MF; Walenz, B; Wang, AH; Wang, J; Wang, M; Wang, XL; Woodford, KJ; Wortman, JR; Wu, M; Yao, A; Zdobnov, EM; Zhang, HY; Zhao, Q; Zhao, SY; Zhu, SPC; Zhimulev, I; Coluzzi, M; della Torre, A; Roth, CW; Louis, C; Kalush, F; Mural, RJ; Myers, EW; Adams, MD; Smith, HO; Broder, S; Gardner, MJ; Fraser, CM; Birney, E; Bork, P; Brey, PT; Venter, JC; Weissenbach, J; Kafatos, FC; Collins, FH; Hoffman, SL				Holt, RA; Subramanian, GM; Halpern, A; Sutton, GG; Charlab, R; Nusskern, DR; Wincker, P; Clark, AG; Ribeiro, JMC; Wides, R; Salzberg, SL; Loftus, B; Yandell, M; Majoros, WH; Rusch, DB; Lai, ZW; Kraft, CL; Abril, JF; Anthouard, V; Arensburger, P; Atkinson, PW; Baden, H; de Berardinis, V; Baldwin, D; Benes, V; Biedler, J; Blass, C; Bolanos, R; Boscus, D; Barnstead, M; Cai, S; Center, A; Chatuverdi, K; Christophides, GK; Chrystal, MA; Clamp, M; Cravchik, A; Curwen, V; Dana, A; Delcher, A; Dew, I; Evans, CA; Flanigan, M; Grundschober-Freimoser, A; Friedli, L; Gu, ZP; Guan, P; Guigo, R; Hillenmeyer, ME; Hladun, SL; Hogan, JR; Hong, YS; Hoover, J; Jaillon, O; Ke, ZX; Kodira, C; Kokoza, E; Koutsos, A; Letunic, I; Levitsky, A; Liang, Y; Lin, JJ; Lobo, NF; Lopez, JR; Malek, JA; McIntosh, TC; Meister, S; Miller, J; Mobarry, C; Mongin, E; Murphy, SD; O'Brochta, DA; Pfannkoch, C; Qi, R; Regier, MA; Remington, K; Shao, HG; Sharakhova, MV; Sitter, CD; Shetty, J; Smith, TJ; Strong, R; Sun, JT; Thomasova, D; Ton, LQ; Topalis, P; Tu, ZJ; Unger, MF; Walenz, B; Wang, AH; Wang, J; Wang, M; Wang, XL; Woodford, KJ; Wortman, JR; Wu, M; Yao, A; Zdobnov, EM; Zhang, HY; Zhao, Q; Zhao, SY; Zhu, SPC; Zhimulev, I; Coluzzi, M; della Torre, A; Roth, CW; Louis, C; Kalush, F; Mural, RJ; Myers, EW; Adams, MD; Smith, HO; Broder, S; Gardner, MJ; Fraser, CM; Birney, E; Bork, P; Brey, PT; Venter, JC; Weissenbach, J; Kafatos, FC; Collins, FH; Hoffman, SL			The genome sequence of the malaria mosquito Anopheles gambiae	SCIENCE			English	Article							DROSOPHILA-MELANOGASTER; TRANSPOSABLE ELEMENTS; INCIPIENT SPECIATION; FAMILIES; LOCI; DIFFERENTIATION; REFRACTORINESS; IDENTIFICATION; RESISTANCE; EVOLUTION	Anopheles gambiae is the principal vector of malaria, a disease that afflicts more than 500 million people and causes more than 1 million deaths each year. Tenfold shotgun sequence coverage was obtained from the PEST strain of A. gambiae and assembled into scaffolds that span 278 million base pairs. A total of 91% of the genome was organized in 303 scaffolds; the largest scaffold was 23.1 million base pairs. There was substantial genetic variation within this strain, and the apparent existence of two haplotypes of approximately equal frequency ("dual haplotypes") in a substantial fraction of the genome likely reflects the outbred nature of the PEST strain. The sequence produced a conservative inference of more than 400,000 single-nucleotide polymorphisms that showed a markedly bimodal density distribution. Analysis of the genome sequence revealed strong evidence for about 14,000 protein-encoding transcripts. Prominent expansions in specific families of proteins likely involved in cell adhesion and immunity were noted. An expressed sequence tag analysis of genes regulated by blood feeding provided insights into the physiological adaptations of a hematophagous insect.	Celera Genom, Rockville, MD 20850 USA; Genoscope Ctr Natl Sequencage, F-91057 Evry 06, France; CNRS, UMR 8030, F-91057 Evry 06, France; Cornell Univ, Ithaca, NY 14853 USA; NIAID, Lab Malaria & Vector Res, Bethesda, MD 20892 USA; Bar Ilan Univ, Fac Life Sci, Ramat Gan, Israel; Inst Genom Res TIGR, Rockville, MD 20850 USA; CRG, UPF, IMIM, Grp Recerca Informat Biomed, Barcelona, Catalonia, Spain; Univ Calif Riverside, Dept Entomol, Riverside, CA 92521 USA; European Mol Biol Lab, D-69117 Heidelberg, Germany; Virginia Polytech Inst & State Univ, Blacksburg, VA 24061 USA; Univ Notre Dame, Ctr Trop Dis Res & Training, Notre Dame, IN 46556 USA; Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England; Univ Maryland, Inst Biotechnol, Agr Biotechnol Ctr, College Pk, MD 20742 USA; Russian Acad Sci, Inst Cytol & Genet, Novosibirsk 630090, Russia; Fdn Res & Technol Hellas, Inst Mol Biol & Biotechnol, GR-71110 Iraklion, Crete, Greece; Univ Crete, Dept Biol, GR-71110 Iraklion, Crete, Greece; European Bioinformat Inst, Cambridge CB10 1SD, England; Univ Roma La Sapienza, Dipartimento Sci Sanita Pubbl, Sez Parassitol, I-00185 Rome, Italy; Inst Pasteur, Unite Biochim & Biol Mol Insectes, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; CEA; Cornell University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Bar Ilan University; J. Craig Venter Institute; Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); Institut Hospital del Mar d'Investigacions Mediques (IMIM); University of California System; University of California Riverside; European Molecular Biology Laboratory (EMBL); Virginia Polytechnic Institute & State University; University of Notre Dame; Wellcome Trust Sanger Institute; University System of Maryland; University of Maryland Baltimore; University of Maryland College Park; Russian Academy of Sciences; Institute of Cytology & Genetics ICG SB RAS; Foundation for Research & Technology - Hellas (FORTH); University of Crete; European Molecular Biology Laboratory (EMBL); Sapienza University Rome; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Holt, RA (corresponding author), British Columbia Canc Agcy, Canadas Michael Smith Genome Sci Ctr, Room 3427,600 W 10th Ave, Vancouver, BC V5Z 4E6, Canada.	rholt@bcgsc.ca; frank.h.collins.75@nd.edu	Bork, Peer/F-1813-2013; Jaillon, Olivier/GRY-6287-2022; Meister, Stephan/M-6608-2014; Salzberg, Steven L/F-6162-2011; Zdobnov, Evgeny M/K-1133-2012; Ferrando, Josep F Abril/B-3877-2014; Salzberg, Steven/Q-6514-2019; Holt, Robert A/C-3303-2009; Zhimulev, Igor F/N-7978-2015; Louis, Christos/F-2527-2012; Letunic, Ivica/K-1102-2019; Kokoza, E l e n a/N-8507-2015; Guigo, Roderic/D-1303-2010; Zdobnov, Evgeny/AAB-2745-2022; Letunic, Ivica/A-6032-2009; Gasull, Martina/J-4076-2019	Bork, Peer/0000-0002-2627-833X; Meister, Stephan/0000-0003-2436-7037; Salzberg, Steven L/0000-0002-8859-7432; Ferrando, Josep F Abril/0000-0001-7793-589X; Salzberg, Steven/0000-0002-8859-7432; Holt, Robert A/0000-0002-7259-1247; Letunic, Ivica/0000-0003-3560-4288; Guigo, Roderic/0000-0002-5738-4477; Zdobnov, Evgeny/0000-0002-5178-1498; Birney, Ewan/0000-0001-8314-8497; de Berardinis, Veronique/0000-0002-3273-4135; Fraser, Claire/0000-0003-1462-2428; Miller, Jason/0000-0002-6912-2925; Christophides, George/0000-0002-3323-1687; Wortman, Jennifer/0000-0002-8713-1227; loftus, brendan/0000-0001-8871-8356; Ribeiro, Jose/0000-0002-9107-0818; Jaillon, Olivier/0000-0002-7237-9596; Wu, Martin/0000-0003-3093-4077; Clark, Andrew/0000-0001-7159-8511; Zhimulev, Igor/0000-0002-6220-3028; Benes, Vladimir/0000-0002-0352-2547	NIAID NIH HHS [R01AI44273, U01AI48846, U01AI50687] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044273, Z01AI000810, ZIAAI000810, U01AI050687, U01AI048846] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abril JF, 2000, BIOINFORMATICS, V16, P743, DOI 10.1093/bioinformatics/16.8.743; Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Andolfatto P, 2001, MOL BIOL EVOL, V18, P279, DOI 10.1093/oxfordjournals.molbev.a003804; Ansieau S, 2002, J BIOL CHEM, V277, P4906, DOI 10.1074/jbc.M110078200; Aparicio S, 2002, SCIENCE, V297, P1301, DOI 10.1126/science.1072104; Apweiler R, 2001, NUCLEIC ACIDS RES, V29, P37, DOI 10.1093/nar/29.1.37; AQUADRO CF, 1991, P NATL ACAD SCI USA, V88, P305, DOI 10.1073/pnas.88.1.305; ASHBURNER M, 1989, DROSOPHILA LAB HDB, P74; Begun DJ, 2000, P NATL ACAD SCI USA, V97, P5960, DOI 10.1073/pnas.97.11.5960; BESANSKY NJ, 1992, J MED ENTOMOL, V29, P125, DOI 10.1093/jmedent/29.1.125; Breman JG, 2001, AM J TROP MED HYG, V64, P1; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Christophides GK, 2002, SCIENCE, V298, P159, DOI 10.1126/science.1077136; Clements A. N., 1992, BIOL MOSQUITOES, V1; COLLINS FH, 1986, SCIENCE, V234, P607, DOI 10.1126/science.3532325; COLLINS FS, UNPUB; COLUZZI M, 1985, B ZOOL, V52, P45, DOI 10.1080/11250008509440343; COLUZZI M, 1979, T ROY SOC TROP MED H, V73, P483, DOI 10.1016/0035-9203(79)90036-1; Comeron JM, 2001, CURR OPIN GENET DEV, V11, P652, DOI 10.1016/S0959-437X(00)00249-5; Cornel AJ, 2000, J HERED, V91, P364, DOI 10.1093/jhered/91.5.364; della Torre A, 2001, INSECT MOL BIOL, V10, P9, DOI 10.1046/j.1365-2583.2001.00235.x; Dimopoulos G, 2002, P NATL ACAD SCI USA, V99, P8814, DOI 10.1073/pnas.092274999; Dimopoulos G, 2000, P NATL ACAD SCI USA, V97, P6619, DOI 10.1073/pnas.97.12.6619; Dimopoulos G, 2001, CURR OPIN IMMUNOL, V13, P79, DOI 10.1016/S0952-7915(00)00186-2; GITHEKO AK, 1992, T ROY SOC TROP MED H, V86, P355, DOI 10.1016/0035-9203(92)90216-Y; Gorman MJ, 2001, INSECT BIOCHEM MOLEC, V31, P257, DOI 10.1016/S0965-1748(00)00145-4; Hartl DL, 2000, NAT REV GENET, V1, P145, DOI 10.1038/35038580; Hill CA, 2002, SCIENCE, V298, P176, DOI 10.1126/science.1076196; Ito J, 2002, NATURE, V417, P452, DOI 10.1038/417452a; Le Borgne R, 2002, CURR BIOL, V12, P95, DOI 10.1016/S0960-9822(01)00648-0; Lee CH, 2001, NEURON, V30, P437, DOI 10.1016/S0896-6273(01)00291-4; MASON GF, 1967, GENET RES, V10, P205, DOI 10.1017/S001667230001096X; Matsushita M, 2001, IMMUNOL REV, V180, P78, DOI 10.1034/j.1600-065X.2001.1800107.x; Mukabayire O, 1996, CHROMOSOMA, V104, P585, DOI 10.1007/BF00352298; Mural RJ, 2002, SCIENCE, V296, P1661, DOI 10.1126/science.1069193; Myers EW, 2000, SCIENCE, V287, P2196, DOI 10.1126/science.287.5461.2196; Ranson H, 2000, INSECT MOL BIOL, V9, P499, DOI 10.1046/j.1365-2583.2000.00214.x; Ranson H, 2002, SCIENCE, V298, P179, DOI 10.1126/science.1076781; Ranson H, 2001, BIOCHEM J, V359, P295, DOI 10.1042/0264-6021:3590295; Rizzon C, 2002, GENOME RES, V12, P400, DOI 10.1101/gr.210802; Roest Crollius H, 2000, GENOME RES, V10, P939, DOI 10.1101/gr.10.7.939; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; SALZBERG SL, UNPUB; Thomasova D, 2002, P NATL ACAD SCI USA, V99, P8179, DOI 10.1073/pnas.082235599; Toure Y. T., 1998, Parassitologia (Rome), V40, P477; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wang R, 2001, P NATL ACAD SCI USA, V98, P10769, DOI 10.1073/pnas.191003598; Yeates DK, 1999, ANNU REV ENTOMOL, V44, P397, DOI 10.1146/annurev.ento.44.1.397; Zdobnov EM, 2002, SCIENCE, V298, P149, DOI 10.1126/science.1077061; Zdobnov EM, 2001, BIOINFORMATICS, V17, P847, DOI 10.1093/bioinformatics/17.9.847; Zhao SY, 2001, GENOME RES, V11, P1736, DOI 10.1101/gr.179201; Zheng LB, 1997, SCIENCE, V276, P425, DOI 10.1126/science.276.5311.425	52	1548	1896	5	280	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 4	2002	298	5591					129	+		10.1126/science.1076181	http://dx.doi.org/10.1126/science.1076181			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	600BJ	12364791				2022-12-28	WOS:000178370500048
J	Engert, F; Tao, HZW; Zhang, LI; Poo, MM				Engert, F; Tao, HZW; Zhang, LI; Poo, MM			Moving visual stimuli rapidly induce direction sensitivity of developing tectal neurons	NATURE			English	Article							LONG-TERM POTENTIATION; DEVELOPING RETINOTECTAL SYNAPSES; STROBOSCOPIC ILLUMINATION; RECEPTIVE-FIELDS; CORTEX; CIRCUITS; MAP; COMPETITION; PLASTICITY; XENOPUS	During development of the visual system, the pattern of visual inputs may have an instructive role in refining developing neural circuits(1-4). How visual inputs of specific spatiotemporal patterns shape the circuit development remains largely unknown. We report here that, in the developing Xenopus retinotectal system, the receptive field of tectal neurons can be 'trained' to become direction-sensitive within minutes after repetitive exposure of the retina to moving bars in a particular direction. The induction of direction-sensitivity depends on the speed of the moving bar, can not be induced by random visual stimuli, and is accompanied by an asymmetric modification of the tectal neuron's receptive field. Furthermore, such training-induced changes require spiking of the tectal neuron and activation of a NMDA (N-methyl-D-aspartate) subtype of glutamate receptors during training, and are attributable to an activity-induced enhancement of glutamate-mediated inputs. Thus, developing neural circuits can be modified rapidly and specifically by visual inputs of defined spatiotemporal patterns, in a manner consistent with predictions based on spike-time-dependent synaptic modification.	Univ Calif Berkeley, Dept Mol & Cell Biol, Div Neurobiol, Berkeley, CA 94720 USA; Univ Calif San Francisco, Keck Ctr Integrat Neurosci, San Francisco, CA 94143 USA	University of California System; University of California Berkeley; University of California System; University of California San Francisco	Poo, MM (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Div Neurobiol, Berkeley, CA 94720 USA.	mpoo@uclink.berkeley.edu	Tao, Huizhong W/HDM-9767-2022					Abbott LF, 1996, CEREB CORTEX, V6, P406, DOI 10.1093/cercor/6.3.406; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Boettiger CA, 2001, NEURON, V31, P809, DOI 10.1016/S0896-6273(01)00403-2; CYNADER M, 1973, P NATL ACAD SCI USA, V70, P1353, DOI 10.1073/pnas.70.5.1353; Feldman DE, 2000, NEURON, V27, P45, DOI 10.1016/S0896-6273(00)00008-8; FREGNAC Y, 1988, NATURE, V333, P367, DOI 10.1038/333367a0; GAZE RM, 1974, PROC R SOC SER B-BIO, V185, P301, DOI 10.1098/rspb.1974.0021; HOLT CE, 1983, NATURE, V301, P150, DOI 10.1038/301150a0; HUBEL DH, 1965, J NEUROPHYSIOL, V28, P1041, DOI 10.1152/jn.1965.28.6.1041; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; Markram H, 1997, SCIENCE, V275, P213, DOI 10.1126/science.275.5297.213; Mehta MR, 2000, NEURON, V25, P707, DOI 10.1016/S0896-6273(00)81072-7; Mehta MR, 1997, P NATL ACAD SCI USA, V94, P8918, DOI 10.1073/pnas.94.16.8918; MEISTER M, 1991, SCIENCE, V252, P939, DOI 10.1126/science.2035024; Penn AA, 1999, PEDIATR RES, V45, P447, DOI 10.1203/00006450-199904010-00001; Penn AA, 1998, SCIENCE, V279, P2108, DOI 10.1126/science.279.5359.2108; RAE J, 1991, J NEUROSCI METH, V37, P15, DOI 10.1016/0165-0270(91)90017-T; Rao RPN, 2001, NOVART FDN SYMP, V239, P208; Roberts PD, 1999, J COMPUT NEUROSCI, V7, P235, DOI 10.1023/A:1008910918445; SCHMIDT JT, 1985, NEUROSCIENCE, V14, P535, DOI 10.1016/0306-4522(85)90308-2; Schuett S, 2001, NEURON, V32, P325, DOI 10.1016/S0896-6273(01)00472-X; Sharma J, 2000, NATURE, V404, P841, DOI 10.1038/35009043; von Melchner L, 2000, NATURE, V404, P871, DOI 10.1038/35009102; Weliky M, 1997, NATURE, V386, P680, DOI 10.1038/386680a0; WIESEL TN, 1982, NATURE, V299, P583, DOI 10.1038/299583a0; ZANKER JM, 2000, MOTION VISION COMPUT; Zhang LI, 1998, NATURE, V395, P37, DOI 10.1038/25665; Zhang LI, 2000, NAT NEUROSCI, V3, P708, DOI 10.1038/76665; Zhang LI, 2001, NAT NEUROSCI, V4, P1207, DOI 10.1038/nn753	30	109	109	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 3	2002	419	6906					470	475		10.1038/nature00988	http://dx.doi.org/10.1038/nature00988			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	599RF	12368854				2022-12-28	WOS:000178348400035
J	Schuppan, D; Hahn, EG				Schuppan, D; Hahn, EG			Biomedicine - Gluten and the gut - Lessons for immune regulation	SCIENCE			English	Editorial Material							CELIAC-DISEASE; TISSUE TRANSGLUTAMINASE; T-CELLS; GLIADIN		Univ Erlangen Nurnberg, Dept Med 1, D-91054 Erlangen, Germany	University of Erlangen Nuremberg	Schuppan, D (corresponding author), Univ Erlangen Nurnberg, Dept Med 1, Ulmenweg 18, D-91054 Erlangen, Germany.	detlef.schuppan@med1.imed.uni-erlangen.de						Falk K, 2000, J EXP MED, V191, P717, DOI 10.1084/jem.191.4.717; Groux H, 2001, MICROBES INFECT, V3, P883, DOI 10.1016/S1286-4579(01)01448-4; LUNDIN KEA, 1993, J EXP MED, V178, P187, DOI 10.1084/jem.178.1.187; Molberg O, 1998, NAT MED, V4, P713, DOI 10.1038/nm0698-713; Piacentini M, 1999, IMMUNOL TODAY, V20, P130, DOI 10.1016/S0167-5699(98)01416-9; Roncarolo MG, 2001, IMMUNOL REV, V182, P68, DOI 10.1034/j.1600-065X.2001.1820105.x; Schuppan D, 2000, GASTROENTEROLOGY, V119, P234, DOI 10.1053/gast.2000.8521; Shan L, 2002, SCIENCE, V297, P2275, DOI 10.1126/science.1074129; Sollid LM, 2000, ANNU REV IMMUNOL, V18, P53, DOI 10.1146/annurev.immunol.18.1.53; TESHIGAWARA K, 1985, MICROBIOL IMMUNOL, V29, P737, DOI 10.1111/j.1348-0421.1985.tb00877.x; Trier JS, 1998, GASTROENTEROLOGY, V115, P211, DOI 10.1016/S0016-5085(98)70383-X; Vader LW, 2002, J EXP MED, V195, P643, DOI 10.1084/jem.20012028; Vader W, 2002, GASTROENTEROLOGY, V122, P1729, DOI 10.1053/gast.2002.33606	13	49	56	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 27	2002	297	5590					2218	2220		10.1126/science.1077572	http://dx.doi.org/10.1126/science.1077572			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	597LA	12351776				2022-12-28	WOS:000178222000032
J	Beral, V; Banks, E; Reeves, G				Beral, V; Banks, E; Reeves, G			Evidence from randomised trials on the long-term effects of hormone replacement therapy	LANCET			English	Review							ESTROGEN; RISK; PROGESTIN; DISEASE; STROKE; HEART		Radcliffe Infirm, Canc Res UK Epidemiol Unit, Oxford OX2 6HE, England	Cancer Research UK; Radcliffe Infirmary	Beral, V (corresponding author), Radcliffe Infirm, Epidemiol Unit, Gibson Bldg, Oxford OX2 6HE, England.			Banks, Emily/0000-0002-4617-1302				Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; Beral V, 1999, J Epidemiol Biostat, V4, P191; Collins N, 2002, CLIMACTERIC S1, V5, P133; Grady D, 2002, JAMA-J AM MED ASSOC, V288, P49, DOI 10.1001/jama.288.1.49; Hlatky MA, 2002, JAMA-J AM MED ASSOC, V287, P591, DOI 10.1001/jama.287.5.591; Hoibraaten E, 2000, THROMB HAEMOSTASIS, V84, P961; Hulley S, 2002, JAMA-J AM MED ASSOC, V288, P58, DOI 10.1001/jama.288.1.58; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; KAHN MA, 2000, Q J MED, V93, P699; Lacey JV, 2002, JAMA-J AM MED ASSOC, V288, P334, DOI 10.1001/jama.288.3.334; Meade T W, 1999, J Epidemiol Biostat, V4, P165; Mulnard RI, 2000, JAMA-J AM MED ASSOC, V283, P1007, DOI 10.1001/jama.283.8.1007; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Simon JA, 2001, CIRCULATION, V103, P638, DOI 10.1161/01.cir.103.5.638; Viscoli CM, 2001, NEW ENGL J MED, V345, P1243, DOI 10.1056/NEJMoa010534; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102	17	354	369	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 21	2002	360	9337					942	944		10.1016/S0140-6736(02)11032-4	http://dx.doi.org/10.1016/S0140-6736(02)11032-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	596AU	12354487				2022-12-28	WOS:000178142200024
J	Mamdani, M; Rochon, PA; Juurlink, DN; Kopp, A; Anderson, GM; Naglie, G; Austin, PC; Laupacis, A				Mamdani, M; Rochon, PA; Juurlink, DN; Kopp, A; Anderson, GM; Naglie, G; Austin, PC; Laupacis, A			Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs	BRITISH MEDICAL JOURNAL			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RHEUMATOID-ARTHRITIS; TOXICITY; RISK; CYCLOOXYGENASE-2; COMPLICATIONS; METAANALYSIS	Objective To compare rates of upper gastrointestinal haemorrhage among elderly patients given selective cyclo-oxygenase-2 (COX 2) inhibitors and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). Design Observational cohort study. Setting Administrative data from Ontario, Canada, used from 17 April 2000 to 31 March 2001 to identify population based, NSAID-naive cohorts of patients. Patients Subjects aged greater than or equal to 66 years who started taking non-selective NSAIDs (n=5391), diclofenac plus misoprostol (n=5087), rofecoxib (n=14 583), or celecoxib (n=18 908) and a randomly selected control cohort not exposed to NSAIDs (n=100 000). Main outcome measures Rate ratios of hospital admission for upper gastrointestinal haemorrhage in each drug cohort with adjustment for potential confounders. Results Relative to controls, the multivariate model revealed an increased short term risk of upper gastrointestinal haemorrhage for users of non-selective NSAIDs (adjusted rate ratio 4.0 (95% confidence intervals 2.3 to 6.9)), diclofenac plus misoprostol (3.0 (1.7 to 5.6)), and rofecoxib (1.9 (1.3 to 2.8)) but not celecoxib (1.0 (0.7 to 1.6)). Relative to celecoxib, significantly higher risks of upper gastrointestinal haemorrhage were observed for non-selective NSAIDs (4.4 (2.3 to 8.5)), diclofenac plus misoprostol (3.2 (1.6 to 6.5)), and rofecoxib (1.9 (1.2 to 2.8)). Relative to rofecoxib, non-selective NSAID users were at significantly higher risk of upper gastrointestinal haemorrhage (1.9 (1.0 to 3.5)). Conclusions This population based observational study found a lower short term risk of upper gastrointestinal haemorrhage for selective COX-2 inhibitors compared with non-selective NSAIDs.	Inst Clin Evaluat Sci, Toronto, ON, Canada; Baycrest Ctr Geriat Care, Kunin Lunenfeld Appl Res Unit, Toronto, ON, Canada; Sunnybrook & Womens Coll, Hlth Sci Ctr, Toronto, ON, Canada; Univ Toronto, Fac Med, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Baycrest; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Mamdani, M (corresponding author), Inst Clin Evaluat Sci, 2075 Bayview Ave,G215, Toronto, ON, Canada.		Rochon, Paula A/J-2918-2016	Rochon, Paula A/0000-0002-5973-4151; Austin, Peter/0000-0003-3337-233X; Naglie, Gary/0000-0002-6274-0894				Aalykke C, 2001, BEST PRACT RES CL GA, V15, P705, DOI 10.1053/bega.2001.0230; [Anonymous], 1990, DRUG THER B, V28, P25; Barat I, 2000, EUR J CLIN PHARMACOL, V56, P501, DOI 10.1007/s002280000157; Blain H, 2002, BRIT J CLIN PHARMACO, V53, P255, DOI 10.1046/j.0306-5251.2001.01533.x; Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Feldman M, 2000, ANN INTERN MED, V132, P134, DOI 10.7326/0003-4819-132-2-200001180-00008; FitzGerald GA, 2001, NEW ENGL J MED, V345, P433, DOI 10.1056/NEJM200108093450607; GABRIEL SE, 1991, ANN INTERN MED, V115, P787, DOI 10.7326/0003-4819-115-10-787; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; Hawk ET, 2002, JNCI-J NATL CANCER I, V94, P545; Hawkey CJ, 1999, LANCET, V353, P307, DOI 10.1016/S0140-6736(98)12154-2; Henry D, 1996, BRIT MED J, V312, P1563, DOI 10.1136/bmj.312.7046.1563; Hernandez-Diaz S, 2000, ARCH INTERN MED, V160, P2093, DOI 10.1001/archinte.160.14.2093; Hernandez-Diaz S, 2002, J CLIN EPIDEMIOL, V55, P157, DOI 10.1016/S0895-4356(01)00461-9; *IMS HLTH CAN, 1999, NEW ARTH MED ACH FAS; Juni P, 2002, BRIT MED J, V324, P1287, DOI 10.1136/bmj.324.7349.1287; Lassila HC, 1996, ANN PHARMACOTHER, V30, P589, DOI 10.1177/106002809603000604; LU HL, 2002, STAT REV BRIEFING DO; Patrignani P, 1997, J PHYSIOL PHARMACOL, V48, P623; Patti R, 2002, CANCER LETT, V180, P13, DOI 10.1016/S0304-3835(02)00003-4; RAIFORD DS, 1996, EPIDEMIOLOGY, V7; SAYER GP, 2002, MEASURES HLTH HLTH C; Schneeweiss S, 2001, AM J EPIDEMIOL, V154, P854, DOI 10.1093/aje/154.9.854; Silverstein FE, 2000, JAMA-J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247; Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563; Waskewich C, 2002, CANCER RES, V62, P2029	27	188	202	0	17	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 21	2002	325	7365					624	627		10.1136/bmj.325.7365.624	http://dx.doi.org/10.1136/bmj.325.7365.624			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	597WM	12242172	Bronze, Green Published			2022-12-28	WOS:000178243800025
J	Shin, CH; Liu, ZP; Passier, R; Zhang, CL; Wang, DZ; Harris, TM; Yamagishi, H; Richardson, JA; Childs, G; Olson, EN				Shin, CH; Liu, ZP; Passier, R; Zhang, CL; Wang, DZ; Harris, TM; Yamagishi, H; Richardson, JA; Childs, G; Olson, EN			Modulation of cardiac growth and development by HOP, an unusual homeodomain protein	CELL			English	Article							SERUM RESPONSE FACTOR; ACTIN GENE-TRANSCRIPTION; HEART DEVELOPMENT; TRANSGENIC MICE; DOMAIN PROTEIN; EXPRESSION; MUSCLE; DIFFERENTIATION; OVEREXPRESSION; NKX2-5	We have discovered an unusual homeodomain protein, called HOP, which is comprised simply of a homeodomain. HOP is highly expressed in the developing heart where its expression is dependent on the cardiac-restricted homeodomain protein Nkx2.5. HOP does not bind DNA and acts as an antagonist of serum response factor (SRF), which regulates the opposing processes of proliferation and myogenesis. Mice homozygous for a HOP null allele segregate into two phenotypic classes characterized by an excess or deficiency of cardiac myocytes. We propose that HOP modulates SRF activity during heart development; its absence results in an imbalance between cardiomyocyte proliferation and differentiation with consequent abnormalities in cardiac morphogenesis.	Univ Texas, SW Med Ctr, Dept Biol Mol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA; Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA; Hubrecht Lab, NL-3584 CT Utrecht, Netherlands	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Yeshiva University; Albert Einstein College of Medicine; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	Olson, EN (corresponding author), Univ Texas, SW Med Ctr, Dept Biol Mol, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.		Yamagishi, Hiroyuki/A-6345-2017	Shin, Chong/0000-0002-6385-5992				BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Chang PS, 2001, J BIOL CHEM, V276, P17206, DOI 10.1074/jbc.M010983200; Chen CY, 1996, MOL CELL BIOL, V16, P6372; Chen F, 2002, CELL, V110, P713, DOI 10.1016/S0092-8674(02)00932-7; Chen JN, 1996, DEVELOPMENT, V122, P3809; Cleaver OB, 1996, DEVELOPMENT, V122, P3549; Croissant JD, 1996, DEV BIOL, V177, P250, DOI 10.1006/dbio.1996.0160; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Harvey RP, 1996, DEV BIOL, V178, P203, DOI 10.1006/dbio.1996.0212; Herring BP, 2001, J BIOL CHEM, V276, P14482, DOI 10.1074/jbc.M011585200; Hiroi Y, 2001, NAT GENET, V28, P276, DOI 10.1038/90123; Kasahara H, 2001, J CLIN INVEST, V108, P189, DOI 10.1172/JCI200112694; KORNBERG TB, 1993, J BIOL CHEM, V268, P26813; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; Li L, 1997, DEV BIOL, V187, P311, DOI 10.1006/dbio.1997.8621; Liao HS, 2001, CIRC RES, V88, P443; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; LINTS TJ, 1993, DEVELOPMENT, V119, P969; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; Passier R, 2000, MECH DEVELOP, V92, P277, DOI 10.1016/S0925-4773(99)00330-5; Pasumarthi KBS, 2002, CIRC RES, V90, P1044, DOI 10.1161/01.RES.0000020201.44772.67; Poser S, 2000, EMBO J, V19, P4955, DOI 10.1093/emboj/19.18.4955; REECY J, 1998, HEART DEV, P273; Reiss K, 1996, P NATL ACAD SCI USA, V93, P8630, DOI 10.1073/pnas.93.16.8630; Schott JJ, 1998, SCIENCE, V281, P108, DOI 10.1126/science.281.5373.108; Sepulveda JL, 2002, J BIOL CHEM, V277, P25775, DOI 10.1074/jbc.M203122200; SMITH DL, 1992, CELL, V68, P133, DOI 10.1016/0092-8674(92)90212-U; Soulez M, 1996, MOL CELL BIOL, V16, P6065; Srivastava D, 2000, NATURE, V407, P221, DOI 10.1038/35025190; Srivastava D, 1997, NAT GENET, V16, P154, DOI 10.1038/ng0697-154; Sun T, 2001, CURR BIOL, V11, P1413, DOI 10.1016/S0960-9822(01)00441-9; Tamura T, 1998, J MOL CELL CARDIOL, V30, P2175, DOI 10.1006/jmcc.1998.0775; Tanaka M, 1999, DEVELOPMENT, V126, P1269; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; VANDROMME M, 1992, J CELL BIOL, V118, P1489, DOI 10.1083/jcb.118.6.1489; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4; Wei Y, 2002, DIFFERENTIATION, V70, P204, DOI 10.1046/j.1432-0436.2002.700409.x; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; Wu H, 1999, DEVELOPMENT, V126, P3597; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Zhang XL, 2001, MOL CELL ENDOCRINOL, V181, P81, DOI 10.1016/S0303-7207(01)00536-6; Zhang XM, 2001, AM J PHYSIOL-HEART C, V280, pH1782, DOI 10.1152/ajpheart.2001.280.4.H1782	46	189	197	0	9	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 20	2002	110	6					725	735		10.1016/S0092-8674(02)00933-9	http://dx.doi.org/10.1016/S0092-8674(02)00933-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	596TV	12297046	Bronze			2022-12-28	WOS:000178182800008
J	Larkin, M				Larkin, M			Mixed response to 9/11 anniversary among NYCs first responders	LANCET			English	Article																			0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 7	2002	360	9335					730	730		10.1016/S0140-6736(02)09936-1	http://dx.doi.org/10.1016/S0140-6736(02)09936-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	592HX	12296300	Bronze			2022-12-28	WOS:000177933000002
J	Ware, LB; Wang, YB; Fang, XH; Warnock, M; Sakuma, T; Hall, TS; Matthay, MA				Ware, LB; Wang, YB; Fang, XH; Warnock, M; Sakuma, T; Hall, TS; Matthay, MA			Assessment of lungs rejected for transplantation and implications for donor selection	LANCET			English	Article								Present criteria for donor-lung selection exclude more than 85% of lungs. We aimed to establish if potentially suitable lungs are rejected for transplantation. We obtained 29 pairs of rejected lungs and assessed them by physiological, microbiological, and histological methods. Most donor lungs had no or mild pulmonary oedema (24/29 [83%]), intact alveolar fluid clearance (17/23 [74%]), and normal or mildly abnormal histological findings (18/29 [62%]). When all factors were considered, Including microbiological and non-lung donor factors, 12 (41%) of 29 pairs of rejected lungs would have been potentially suitable for transplantation. Our findings emphasise the urgent need for prospective scientific assessment of selection of donors for lung transplantation.	Vanderbilt Univ, Div Allergy Pulm & Crit Care, Dept Med, Sch Med, Nashville, TN 37232 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Surg & Cardiothorac Transplantat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anaesthesia, San Francisco, CA 94143 USA; Kanazawa Med Univ, Dept Thorac Surg, Kanazawa, Ishikawa, Japan	Vanderbilt University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Kanazawa Medical University	Ware, LB (corresponding author), Vanderbilt Univ, Div Allergy Pulm & Crit Care, Dept Med, Sch Med, T1217 MCN, Nashville, TN 37232 USA.		Ware, Lorraine/AAJ-9307-2021	Ware, Lorraine/0000-0002-9429-4702	NHLBI NIH HHS [HL 51856, HL 70521, HL 51854] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL051856, K08HL070521, R01HL051854, R01HL051856] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arcasoy SM, 1999, NEW ENGL J MED, V340, P1081, DOI 10.1056/NEJM199904083401406; Frost AE, 1997, CLIN CHEST MED, V18, P231, DOI 10.1016/S0272-5231(05)70374-9; Matthay MA, 2002, PHYSIOL REV, V82, P569, DOI 10.1152/physrev.00003.2002; *US DEP HHS, 2000 ANN REP US SCI; Ware LB, 1999, AM J RESP CRIT CARE, V159, P980, DOI 10.1164/ajrccm.159.3.9802105	5	124	129	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 24	2002	360	9333					619	620		10.1016/S0140-6736(02)09774-X	http://dx.doi.org/10.1016/S0140-6736(02)09774-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	586TD	12241936				2022-12-28	WOS:000177600400014
J	Thorsen, T; Maerkl, SJ; Quake, SR				Thorsen, T; Maerkl, SJ; Quake, SR			Microfluidic large-scale integration	SCIENCE			English	Article							CHIP; DEVICE; POLY(DIMETHYLSILOXANE); IMMUNOASSAYS; CHANNELS; ASSAYS; SYSTEM	We developed high-density micro fluidic chips that contain plumbing networks with thousands of micromechanical valves and hundreds of individually addressable chambers. These fluidic devices are analogous to electronic integrated circuits fabricated using large-scale integration. A key component of these networks is the fluidic multiplexor, which is a combinatorial array of binary valve patterns that exponentially increases the processing power of a network by allowing complex fluid manipulations with a minimal number of inputs. We used these integrated micro fluidic networks to construct the micro fluidic analog of a comparator array and a micro fluidic memory storage device whose behavior resembles random-access memory.	CALTECH, Dept Appl Sci, Pasadena, CA 91125 USA	California Institute of Technology	Quake, SR (corresponding author), CALTECH, Dept Appl Sci, Pasadena, CA 91125 USA.		Maerkl, Sebastian J. J/C-5438-2008	Maerkl, Sebastian J. J/0000-0003-1917-5268				Chou HP, 1999, P NATL ACAD SCI USA, V96, P11, DOI 10.1073/pnas.96.1.11; Duffy DC, 1998, ANAL CHEM, V70, P4974, DOI 10.1021/ac980656z; Eteshola E, 2001, SENSOR ACTUAT B-CHEM, V72, P129, DOI 10.1016/S0925-4005(00)00640-7; Grzybowski BA, 1998, ANAL CHEM, V70, P4645, DOI 10.1021/ac9807621; Hadd AG, 1999, ANAL CHEM, V71, P5206, DOI 10.1021/ac990591f; Hadd AG, 1997, ANAL CHEM, V69, P3407, DOI 10.1021/ac970192p; HARRISON DJ, 1993, SCIENCE, V261, P895, DOI 10.1126/science.261.5123.895; Khandurina J, 2000, ANAL CHEM, V72, P2995, DOI 10.1021/ac991471a; Lagally ET, 2001, ANAL CHEM, V73, P565, DOI 10.1021/ac001026b; Li PCH, 1997, ANAL CHEM, V69, P1564, DOI 10.1021/ac9606564; Linder V, 2001, ANAL CHEM, V73, P4181, DOI 10.1021/ac010421e; REID TR, 1984, CHIP 2 AM INVENTED M; Unger MA, 2000, SCIENCE, V288, P113, DOI 10.1126/science.288.5463.113; Wang J, 2001, ANAL CHEM, V73, P5323, DOI 10.1021/ac010808h; Yang TL, 2001, ANAL CHEM, V73, P165, DOI 10.1021/ac000997o	15	1921	2180	37	946	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 18	2002	298	5593					580	584		10.1126/science.1076996	http://dx.doi.org/10.1126/science.1076996			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	604RL	12351675	Green Submitted			2022-12-28	WOS:000178634800035
J	Vanduffel, W; Fize, D; Peuskens, H; Denys, K; Sunaert, S; Todd, JT; Orban, GA				Vanduffel, W; Fize, D; Peuskens, H; Denys, K; Sunaert, S; Todd, JT; Orban, GA			Extracting 3D from motion: Differences in human and monkey intraparietal cortex	SCIENCE			English	Article							HUMAN VISUAL-CORTEX; 3-DIMENSIONAL STRUCTURE; MACAQUE; FMRI; NEURONS; DEPTH	We compared three-dimensional structure-from-motion (3D-SFM) processing in awake monkeys and humans using functional magnetic resonance imaging. Occipital and midlevel extrastriate visual areas showed similar activation by 3D-SFM stimuli in both species. In contrast, intraparietal areas showed significant 3D-SFM activation in humans but not in monkeys. This suggests that human intraparietal cortex contains visuospatial processing areas that are not present in monkeys.	Katholieke Univ Leuven, Neuro & Psychofysiol Lab, B-3000 Louvain, Belgium; MGH MIT HMS Athinoula A Martinos Ctr Biomed Imagi, Charlestown, MA 02129 USA; UZ Gasthuisberg, Afdeling Radiol, B-3000 Louvain, Belgium; Ohio State Univ, Dept Psychol, Columbus, OH 43210 USA	KU Leuven; KU Leuven; University Hospital Leuven; University System of Ohio; Ohio State University	Vanduffel, W (corresponding author), Katholieke Univ Leuven, Neuro & Psychofysiol Lab, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.		Fize, Denis/F-4525-2011; Sunaert, Stefan/E-8031-2011	Sunaert, Stefan/0000-0002-1177-4680; Orban, Guy/0000-0002-8179-9584				Bradley DC, 1998, NATURE, V392, P714, DOI 10.1038/33688; Cook EP, 2002, J NEUROSCI, V22, P1994, DOI 10.1523/JNEUROSCI.22-05-01994.2002; Dubowitz DJ, 1998, NEUROREPORT, V9, P2213, DOI 10.1097/00001756-199807130-00012; EIDELBERG D, 1984, ARCH NEUROL-CHICAGO, V41, P843, DOI 10.1001/archneur.1984.04050190049013; Grill-Spector K, 2001, VISION RES, V41, P1409, DOI 10.1016/S0042-6989(01)00073-6; Huk AC, 2001, NEURON, V32, P161, DOI 10.1016/S0896-6273(01)00452-4; Karnath HO, 2001, NAT REV NEUROSCI, V2, P568, DOI 10.1038/35086057; Logothetis NK, 2001, NATURE, V412, P150, DOI 10.1038/35084005; MALACH R, 1995, P NATL ACAD SCI USA, V92, P8135, DOI 10.1073/pnas.92.18.8135; MILNER AD, 1997, PARIETAL LOBE CONTRI, P843; Nakahara K, 2002, SCIENCE, V295, P1532, DOI 10.1126/science.1067653; NELISSEN K, 2000, 30 ANN M SOC NEUR NE; Orban GA, 1999, NEURON, V24, P929, DOI 10.1016/S0896-6273(00)81040-5; Sereno ME, 2002, NEURON, V33, P635, DOI 10.1016/S0896-6273(02)00598-6; SIEGEL RM, 1988, NATURE, V331, P259, DOI 10.1038/331259a0; Simon O, 2002, NEURON, V33, P475, DOI 10.1016/S0896-6273(02)00575-5; Stefanacci L, 1998, NEURON, V20, P1051, DOI 10.1016/S0896-6273(00)80485-7; TODD JT, 1998, HIGH LEVEL MOTION PR, P359; Tolias AS, 2001, J NEUROSCI, V21, P8594, DOI 10.1523/JNEUROSCI.21-21-08594.2001; Tootell RBH, 1996, TRENDS NEUROSCI, V19, P481, DOI 10.1016/S0166-2236(96)10053-9; Tootell RBH, 2001, CEREB CORTEX, V11, P298, DOI 10.1093/cercor/11.4.298; ULMANN S, 1979, INTERPRETATION VISUA; Vanduffel W, 2001, NEURON, V32, P565, DOI 10.1016/S0896-6273(01)00502-5; Xiao DK, 1997, EUR J NEUROSCI, V9, P956, DOI 10.1111/j.1460-9568.1997.tb01446.x	24	238	241	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 11	2002	298	5592					413	415		10.1126/science.1073574	http://dx.doi.org/10.1126/science.1073574			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	602NB	12376701	Green Accepted			2022-12-28	WOS:000178510400048
J	Wolpoff, MH; Senut, B; Pickford, M; Hawks, J				Wolpoff, MH; Senut, B; Pickford, M; Hawks, J			Palaeoanthropology - Sahelanthropus or 'Sahelpithecus'?	NATURE			English	Article									Univ Michigan, Dept Anthropol, Paleoanthropol Lab, Ann Arbor, MI 48109 USA; Coll France, Chaire Paleoanthropol & Prehist, CNRS, UMR 8569, F-75005 Paris, France; Museum Natl Hist Nat, Lab Paleontol, F-75005 Paris, France; Univ Wisconsin, Dept Anthropol, Madison, WI 53706 USA	University of Michigan System; University of Michigan; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; College de France; Museum National d'Histoire Naturelle (MNHN); University of Wisconsin System; University of Wisconsin Madison	Wolpoff, MH (corresponding author), Univ Michigan, Dept Anthropol, Paleoanthropol Lab, Ann Arbor, MI 48109 USA.		Hawks, John/H-5737-2015	Hawks, John/0000-0003-3187-3755				Brunet M, 2002, NATURE, V418, P145, DOI 10.1038/nature00879; Endo B., 1966, J FS U TOKYO, V3, P1; PILBEAM D, 1966, AM J PHYS ANTHROPOL, V25, P1, DOI 10.1002/ajpa.1330250102; RUSSELL MD, 1985, CURR ANTHROPOL, V26, P337, DOI 10.1086/203279; SESENUT B, 2001, CR HEBD ACAD SCI, V332, P137; Wood B, 2002, NATURE, V418, P133, DOI 10.1038/418133a	6	51	58	2	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 10	2002	419	6907					581	582		10.1038/419581a	http://dx.doi.org/10.1038/419581a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	602AT	12374970	Green Published			2022-12-28	WOS:000178483100034
J	Fiore, MC; Hatsukami, DK; Baker, TB				Fiore, MC; Hatsukami, DK; Baker, TB			Effective tobacco dependence treatment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							SMOKING-CESSATION; IMPACT; CALIFORNIA		Univ Wisconsin, Ctr Tobacco Res & Intervent, Sch Med, Madison, WI 53711 USA; Univ Wisconsin, Dept Med, Sch Med, Madison, WI 53711 USA; Univ Wisconsin, Dept Psychol, Madison, WI 53706 USA; Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Minnesota System; University of Minnesota Twin Cities	Fiore, MC (corresponding author), Univ Wisconsin, Ctr Tobacco Res & Intervent, Sch Med, 1930 Monroe St, Madison, WI 53711 USA.	mcf@ctri.medicine.wisc.edu			NCI NIH HHS [1 P50 CA84724] Funding Source: Medline; NIDA NIH HHS [1 P50 DA1333] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA084724] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bondurant, 2001, CLEARING SMOKE ASSES; [Centers for Disease Control and Prevention Centers for Disease Control and Prevention (CDC)], 2001, INV TOB CONTR STAT H; Centers for Disease Control and Prevention, 1994, PREV TOB US YOUNG PE; Centers for Disease Control and Prevention, 2000, RED TOB US REP SURG; Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P140; Curry SJ, 1998, NEW ENGL J MED, V339, P673, DOI 10.1056/NEJM199809033391006; Daynard RA, 2001, AM J PUBLIC HEALTH, V91, P1967, DOI 10.2105/AJPH.91.12.1967; DiFranza JR, 2000, TOB CONTROL, V9, P313, DOI 10.1136/tc.9.3.313; Fichtenberg CM, 2000, NEW ENGL J MED, V343, P1772, DOI 10.1056/NEJM200012143432406; Fiore MC, 2000, JAMA-J AM MED ASSOC, V283, P3244; FIORE MC, 2000, TREATING TOBACCO US; France EK, 2001, PREV MED, V32, P376, DOI 10.1006/pmed.2000.0824; Halpern MT, 2001, TOB CONTROL, V10, P233, DOI 10.1136/tc.10.3.233; Hays JT, 2001, ANN INTERN MED, V135, P423, DOI 10.7326/0003-4819-135-6-200109180-00011; Hopkins DP, 2001, AM J PREV MED, V20, P16, DOI 10.1016/S0749-3797(00)00297-X; Houston T, 2000, JAMA-J AM MED ASSOC, V284, P752, DOI 10.1001/jama.284.6.752; Irvin J E, 2000, Nicotine Tob Res, V2, P79; JACKSON FN, 1985, PRIMARY CARE, V12, P197; Lipkus IM, 2000, AM J PREV MED, V18, P1, DOI 10.1016/S0749-3797(99)00106-3; Moskowitz JM, 2000, AM J PUBLIC HEALTH, V90, P757, DOI 10.2105/AJPH.90.5.757; *NCI, 2000, NIH PUBL; *NCI, 2001, NIH PUBL; Owen L, 2000, TOB CONTROL, V9, P148, DOI 10.1136/tc.9.2.148; Piasecki TM, 1998, J ABNORM PSYCHOL, V107, P238, DOI 10.1037/0021-843X.107.2.238; Pronk NP, 1999, JAMA-J AM MED ASSOC, V282, P2235, DOI 10.1001/jama.282.23.2235; Rigotti NA, 2000, JAMA-J AM MED ASSOC, V284, P699, DOI 10.1001/jama.284.6.699; RIMER BK, 1990, CHEST, V97, P547, DOI 10.1378/chest.97.3.547; Robbins AS, 2000, TOB CONTROL, V9, P389, DOI 10.1136/tc.9.4.389; *US DEP HHS, 2000, TRACK HLTH PEOPL 201; 1996, MMWR MORB MORTAL WKL, V45, P996; 2001, MMWR MORB MORTAL WKL, V50, P869	31	69	70	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	2002	288	14					1768	1771		10.1001/jama.288.14.1768	http://dx.doi.org/10.1001/jama.288.14.1768			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	602BJ	12365962				2022-12-28	WOS:000178484700031
J	Deverman, BE; Cook, BL; Manson, SR; Niederhoff, RA; Langer, EM; Rosova, I; Kulans, LA; Fu, XY; Weinberg, JS; Heinecke, JW; Roth, KA; Weintraub, SJ				Deverman, BE; Cook, BL; Manson, SR; Niederhoff, RA; Langer, EM; Rosova, I; Kulans, LA; Fu, XY; Weinberg, JS; Heinecke, JW; Roth, KA; Weintraub, SJ			Bcl-X-L deamidation is a critical switch in the regulation of the response to DNA damage	CELL			English	Article							CYCLIN-DEPENDENT KINASES; P53-DEPENDENT G(1) ARREST; CELL-CYCLE; RETINOBLASTOMA PROTEIN; HUMAN FIBROBLASTS; APOPTOSIS; BCL-X(L); CANCER; FAMILY; INHIBITION	The therapeutic value of DNA-damaging antineoplastic agents is dependent upon their ability to induce tumor cell apoptosis while sparing most normal tissues. Here, we show that a component of the apoptotic response to these agents in several different types of tumor cells is the deamidation of two asparagines in the unstructured loop of Bcl-X-L, and we demonstrate that deamidation of these asparagines imports susceptibility to apoptosis by disrupting the ability of BcI-X-L to block the proapoptotic activity of BH3 domain-only proteins. Conversely, Bcl-X-L deamidation is actively suppressed in fibroblasts, and suppression of deamidation is an essential component of their resistance to DNA damage-induced apoptosis. Our results suggest that the regulation of Bcl-X-L deamidation has a critical role in the tumor-specific activity of DNA-damaging antineoplastic agents.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, Div Urol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Immunol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Weintraub, SJ (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, Div Urol, 660 S Euclid Ave,Campus Box 8052, St Louis, MO 63110 USA.		Weinbaum, Justin S/C-3192-2009	Weinbaum, Justin S/0000-0002-0626-6083; Roth, Kevin/0000-0002-0643-995X				ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Amundson SA, 2000, CANCER RES, V60, P6101; Aritomi M, 1997, J BIOL CHEM, V272, P27886, DOI 10.1074/jbc.272.44.27886; Aswad DW, 2000, J PHARMACEUT BIOMED, V21, P1129, DOI 10.1016/S0731-7085(99)00230-7; Chang BS, 1997, EMBO J, V16, P968, DOI 10.1093/emboj/16.5.968; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; FAN SJ, 1995, CANCER RES, V55, P1649; FLATMARK T, 1966, ACTA CHEM SCAND, V20, P1487, DOI 10.3891/acta.chem.scand.20-1487; Fu XY, 2002, BIOCHEMISTRY-US, V41, P1293, DOI 10.1021/bi015777z; Fu XY, 2001, J BIOL CHEM, V276, P41279, DOI 10.1074/jbc.M106958200; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; Hawkins DS, 1996, CANCER RES, V56, P892; JOHNSON BA, 1989, ARCH BIOCHEM BIOPHYS, V268, P276, DOI 10.1016/0003-9861(89)90589-4; Knudsen KE, 1999, J BIOL CHEM, V274, P27632, DOI 10.1074/jbc.274.39.27632; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; POIRIER MC, 1987, PROG EXP TUMOR RES, V31, P104; POIRIER MC, 1992, PROG CLIN BIOL RES, V374, P197; Poruchynsky MS, 1998, CANCER RES, V58, P3331; Robinson A B, 1974, Curr Top Cell Regul, V8, P247; Robinson NE, 2002, P NATL ACAD SCI USA, V99, P5283, DOI 10.1073/pnas.082102799; Robinson NE, 2001, P NATL ACAD SCI USA, V98, P944, DOI 10.1073/pnas.98.3.944; Schmitt CA, 1999, J PATHOL, V187, P127; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; Taylor JK, 1999, ONCOGENE, V18, P4495, DOI 10.1038/sj.onc.1202836; TERHEGGEN PMAB, 1987, CANCER RES, V47, P6719; TILBY MJ, 1991, CANCER RES, V51, P123; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1	47	190	193	1	6	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 4	2002	111	1					51	62		10.1016/S0092-8674(02)00972-8	http://dx.doi.org/10.1016/S0092-8674(02)00972-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	601RQ	12372300	Bronze			2022-12-28	WOS:000178461900008
J	Chameides, WL; Bergin, M				Chameides, WL; Bergin, M			Climate change - Soot takes center stage	SCIENCE			English	Editorial Material							AEROSOLS		Georgia Inst Technol, Sch Earth & Atmospher Sci, Atlanta, GA 30332 USA	University System of Georgia; Georgia Institute of Technology	Chameides, WL (corresponding author), Georgia Inst Technol, Sch Earth & Atmospher Sci, Atlanta, GA 30332 USA.							Ackerman AS, 2000, SCIENCE, V288, P1042, DOI 10.1126/science.288.5468.1042; Arrhenius S, 1908, WORLDS MAKING; Bond TC, 1998, GEOPHYS RES LETT, V25, P337, DOI 10.1029/98GL00039; CHARLSON RJ, 1992, SCIENCE, V255, P423, DOI 10.1126/science.255.5043.423; Chow JC, 2001, AEROSOL SCI TECH, V34, P23, DOI 10.1080/02786820119073; Hansen J, 2000, P NATL ACAD SCI USA, V97, P9875, DOI 10.1073/pnas.170278997; HORVATH H, 1993, ATMOS ENVIRON A-GEN, V27, P293, DOI 10.1016/0960-1686(93)90104-7; Houghton J. T., 2001, CLIMATE CHANGE 2001; Jacobson MZ, 2001, NATURE, V409, P695, DOI 10.1038/35055518; Kerr RA, 2001, SCIENCE, V294, P765; Lighty JS, 2000, J AIR WASTE MANAGE, V50, P1565, DOI 10.1080/10473289.2000.10464197; Menon S, 2002, SCIENCE, V297, P2250, DOI 10.1126/science.1075159; RAMANATHAN V, 1985, J GEOPHYS RES-ATMOS, V90, P5547, DOI 10.1029/JD090iD03p05547; SOLOMON PA, IN PRESS J GEOPHYS R; Xu Q, 2001, ATMOS ENVIRON, V35, P5029, DOI 10.1016/S1352-2310(01)00315-6	15	106	119	2	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 27	2002	297	5590					2214	2215		10.1126/science.1076866	http://dx.doi.org/10.1126/science.1076866			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	597LA	12351774				2022-12-28	WOS:000178222000030
J	Daborn, PJ; Yen, JL; Bogwitz, MR; Le Goff, G; Feil, E; Jeffers, S; Tijet, N; Perry, T; Heckel, D; Batterham, P; Feyereisen, R; Wilson, TG; ffrench-Constant, RH				Daborn, PJ; Yen, JL; Bogwitz, MR; Le Goff, G; Feil, E; Jeffers, S; Tijet, N; Perry, T; Heckel, D; Batterham, P; Feyereisen, R; Wilson, TG; ffrench-Constant, RH			A single P450 allele associated with insecticide resistance in Drosophila	SCIENCE			English	Article							LONG TERMINAL REPEAT; CYTOCHROME-P-450 SYSTEM; MELANOGASTER DIPTERA; GENETIC-REGULATION; EXPRESSION; LUFENURON; DDT	Insecticide resistance is one of the most widespread genetic changes caused by human activity, but we still understand little about the origins and spread of resistant alleles in global populations of insects. Here, via microarray analysis of all P450s in Drosophila melanogaster, we show that DDT-R, a gene conferring resistance to DDT, is associated with overtranscription of a single cytochrome P450 gene, Cyp6g1. Transgenic analysis of Cyp6g1 shows that overtranscription of this gene alone is both necessary and sufficient for resistance. Resistance and up-regulation in Drosophila populations are associated with a single Cyp6g1 allele that has spread globally. This allele is characterized by the insertion of an Accord transposable element into the 5' end of the Cyp6g1 gene.	Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England; Univ Melbourne, Ctr Environm Stress & Adaptat Res, Dept Genet, Parkville, Vic 3052, Australia; Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA; Univ Arizona, Dept Entomol, Tucson, AZ 85721 USA; INRA, Ctr Rech Antibes, F-06560 Valbonne, France	University of Bath; University of Melbourne; Colorado State University; University of Arizona; INRAE	ffrench-Constant, RH (corresponding author), Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England.		Heckel, David G/K-2138-2013; Legoff, Gaelle/B-7501-2015; Feyereisen, René/Y-7514-2019; Batterham, Philip/G-5914-2012; Feyereisen, René/I-3140-2012; Perry, Trent/A-7206-2012	Heckel, David G/0000-0001-8991-2150; Legoff, Gaelle/0000-0003-1973-7136; Feyereisen, René/0000-0002-9560-571X; Batterham, Philip/0000-0001-9840-9119; Feyereisen, René/0000-0002-9560-571X; Perry, Trent/0000-0002-8045-0487; ffrench-Constant, Richard/0000-0001-5385-9888				Berge JB, 1998, PHILOS T R SOC B, V353, P1701, DOI 10.1098/rstb.1998.0321; BRAND AH, 1993, DEVELOPMENT, V118, P401; Daborn P, 2001, MOL GENET GENOMICS, V266, P556, DOI 10.1007/s004380100531; DELPUECH JM, 1993, P NATL ACAD SCI USA, V90, P5643, DOI 10.1073/pnas.90.12.5643; Dunkov BC, 1997, DNA CELL BIOL, V16, P1345, DOI 10.1089/dna.1997.16.1345; Feyereisen R, 1999, ANNU REV ENTOMOL, V44, P507, DOI 10.1146/annurev.ento.44.1.507; FFRENCHCONSTANT RH, 1998, MOL BIOL TOXIC RESPO, P533; FFRENCHCONSTANT RH, 1992, MOL APPROACHES PURE, P1; GEORGHIOU GP, 1969, PESTICIDE RESISTANCE, P14; HALLSTROM I, 1985, CHEM-BIOL INTERACT, V56, P157, DOI 10.1016/0009-2797(85)90003-1; HALLSTROM I, 1985, CHEM-BIOL INTERACT, V56, P173, DOI 10.1016/0009-2797(85)90004-3; Kikkawa, 1961, ANN REP SCI WORKS FS, V9, P1; KIKKAWA H., 1964, Botyu-Kagaku = Scientific Insect Control, V29, P37; Lewis DFV, 2002, DRUG METAB REV, V34, P69, DOI 10.1081/DMR-120001391; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; OGITA Z., 1961, Botyu-Kagaku = Scientific Insect Control, V26, P88; Ogita Z., 1960, BOTYU KAGAKU, V26, P7; Ranson H, 2001, BIOCHEM J, V359, P295, DOI 10.1042/0264-6021:3590295; Raymond M, 1998, PHILOS T R SOC B, V353, P1707, DOI 10.1098/rstb.1998.0322; RAYMOND M, 1991, NATURE, V350, P151, DOI 10.1038/350151a0; RAYMOND M, 1992, RESISTANCE 91 : ACHIEVEMENTS AND DEVELOPMENTS IN COMBATING PESTICIDE RESISTANCE, P19; Roberts DR, 1997, EMERG INFECT DIS, V3, P295, DOI 10.3201/eid0303.970305; Sabourault C, 2001, INSECT MOL BIOL, V10, P609, DOI 10.1046/j.0962-1075.2001.00303.x; Scott JG, 1999, INSECT BIOCHEM MOLEC, V29, P757, DOI 10.1016/S0965-1748(99)00038-7; Tijet N, 2001, GENE, V262, P189, DOI 10.1016/S0378-1119(00)00533-3; WATERS LC, 1992, P NATL ACAD SCI USA, V89, P4855, DOI 10.1073/pnas.89.11.4855; WILSON TG, 1993, J ECON ENTOMOL, V86, P645, DOI 10.1093/jee/86.3.645; Wilson TG, 1997, J ECON ENTOMOL, V90, P1131, DOI 10.1093/jee/90.5.1131; WILSON TG, 1988, J ECON ENTOMOL, V81, P22, DOI 10.1093/jee/81.1.22; WILSON TG, 1996, ACS SYM SER, V645, P141	30	624	675	8	184	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 27	2002	297	5590					2253	2256		10.1126/science.1074170	http://dx.doi.org/10.1126/science.1074170			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	597LA	12351787				2022-12-28	WOS:000178222000045
J	Denholm, I; Devine, GJ; Williamson, MS				Denholm, I; Devine, GJ; Williamson, MS			Evolutionary genetics - Insecticide resistance on the move	SCIENCE			English	Editorial Material							MUTATIONS; GENES		Rothamsted Res, Harpenden AL5 2JQ, Herts, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research	Denholm, I (corresponding author), Rothamsted Res, Harpenden AL5 2JQ, Herts, England.		Devine, Gregor J/H-1141-2014; Denholm, Ian/F-7585-2011	Devine, Gregor J/0000-0001-6312-0390; 				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Daborn P, 2001, MOL GENET GENOMICS, V266, P556, DOI 10.1007/s004380100531; Daborn PJ, 2002, SCIENCE, V297, P2253, DOI 10.1126/science.1074170; FFRENCHCONSTANT RH, 1993, NATURE, V363, P449, DOI 10.1038/363449a0; Field LM, 1998, BIOCHEM J, V330, P169; MUTERO A, 1994, P NATL ACAD SCI USA, V91, P5922, DOI 10.1073/pnas.91.13.5922; RAYMOND M, 1991, NATURE, V350, P151, DOI 10.1038/350151a0; Sina B J, 2001, Trends Parasitol, V17, P305, DOI 10.1016/S1471-4922(01)02007-4; Williamson MS, 1996, MOL GEN GENET, V252, P51, DOI 10.1007/BF02173204	9	98	129	2	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 27	2002	297	5590					2222	2223		10.1126/science.1077266	http://dx.doi.org/10.1126/science.1077266			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	597LA	12351778				2022-12-28	WOS:000178222000034
J	Hippisley-Cox, J; Coupland, C; Pringle, M; Crown, N; Hammersley, V				Hippisley-Cox, J; Coupland, C; Pringle, M; Crown, N; Hammersley, V			Married couples' risk of same disease: cross sectional study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; BLOOD-PRESSURE; AGGREGATION; CONCORDANCE; POPULATION; FAMILIES; RECORDS	Objective To determine whether people whose marital partners have depression, diabetes, hypertension, ischaemic heart disease, stroke, hyperlipidaemia, peptic ulcer disease, or asthma or chronic obstructive pulmonary disease are at increased risk of die same disease. Design Cross sectional study. Setting 10 practices from the Trent Focus Collaborative Research Practice Network. Participants 8386 married couples (16 772 individuals) from a population of 29 014 participants aged 30-74 years. Outcomes Risk of disease in participants whose marital partner had that disease compared with those whose partner did not. Results After both partners' age, smoking, and obesity and which general practice they attend were adjusted for, participants whose marital partner had asthma, depression, hypertension, hyperlipidaemia, and peptic ulcer disease were at increased risk of having the same disease. The adjusted odds ratios were 1.69 (95% confidence interval 1.43 to 2.98) for asthma, 2.08 (1.71 to 2.54) for depression, 1.32 (1.04 to 1.67) for hypertension, 1.44 (1.19 to 1.75) for hyperlipidaemia, and 2.01 (1.48 to 2.73) for peptic ulcer disease. Conclusion Partners of people with specific diseases are at increased risk of the disease themselves-at least 70% increased risk for asthma, depression, and peptic ulcer disease. This implicates shared environmental causes in some diseases in addition to any genetic or distant exposure or shared behaviours with respect to seeking health care.	Univ Nottingham, Sch Hlth Sci, Div Gen Practice, Nottingham NG7 2RD, England; Collingham Med Ctr, Collingham NG23 7LB, England	University of Nottingham	Hippisley-Cox, J (corresponding author), Univ Nottingham, Sch Hlth Sci, Div Gen Practice, Nottingham NG7 2RD, England.	julia.hippisley-cox@nottingham.ac.uk	Hippisley-Cox, Julia/AAY-2788-2020	Hippisley-Cox, Julia/0000-0002-2479-7283; Coupland, Carol/0000-0002-2327-3306				An P, 1999, AM J HYPERTENS, V12, P264, DOI 10.1016/S0895-7061(98)00261-1; Brenn T, 1997, EUR J EPIDEMIOL, V13, P623, DOI 10.1023/A:1007333919898; Breslow NE, 1987, STAT METHODS CANC RE; Davis MA, 2000, J NUTR, V130, P2256, DOI 10.1093/jn/130.9.2256; Dovey SM, 1996, BRIT J GEN PRACT, V46, P749; DUFORT GG, 1994, PSYCHOL MED, V24, P431, DOI 10.1017/S0033291700027409; Friedman GD, 1999, CANCER, V86, P2413, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2413::AID-CNCR32>3.0.CO;2-J; GARRISON RJ, 1979, AM J EPIDEMIOL, V110, P313, DOI 10.1093/oxfordjournals.aje.a112816; HAMMERSLEY V, 1998, J INF PRIMARY CARE, V1, P3; Hassey A, 2001, BRIT MED J, V322, P1401, DOI 10.1136/bmj.322.7299.1401; Hippisley-Cox J, 1998, BRIT J GEN PRACT, V48, P1580; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; KOLONEL LN, 1981, AM J CLIN NUTR, V34, P99, DOI 10.1093/ajcn/34.1.99; *OFF NAT STAT, 2001, HLTH STAT Q POP AG S; PRINGLE M, 1995, BRIT MED J, V311, P1382, DOI 10.1136/bmj.311.7017.1382; RISSANEN AM, 1979, BRIT HEART J, V42, P373, DOI 10.1136/hrt.42.4.373; ROSE RJ, 1979, AM J EPIDEMIOL, V109, P503, DOI 10.1093/oxfordjournals.aje.a112707; SACKETT DL, 1975, CIRCULATION, V52, P589, DOI 10.1161/01.CIR.52.4.589; SEXTON M, 1987, J BEHAV MED, P10; Spector TD, 1996, BRIT MED J, V312, P940; TILYARD MW, 1995, NEW ZEAL MED J, V108, P118; vanHaeften TW, 1997, BMJ-BRIT MED J, V314, P1386; Whitelaw FG, 1996, BRIT J GEN PRACT, V46, P181	23	102	104	0	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 21	2002	325	7365					636	638A		10.1136/bmj.325.7365.636	http://dx.doi.org/10.1136/bmj.325.7365.636			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	597WM	12242177	Bronze, Green Published			2022-12-28	WOS:000178243800030
J	Indar, AA; Beckingham, IJ				Indar, AA; Beckingham, IJ			Acute cholecystitis	BRITISH MEDICAL JOURNAL			English	Review							ACUTE ACALCULOUS CHOLECYSTITIS; DELAYED LAPAROSCOPIC CHOLECYSTECTOMY; GALLBLADDER; GALLSTONES; PREGNANCY; STONES; TRIAL; RISK		Univ Nottingham Hosp, Sect Gastrointestinal Surg, Nottingham NG7 2UH, England	University of Nottingham	Beckingham, IJ (corresponding author), Univ Nottingham Hosp, Sect Gastrointestinal Surg, Nottingham NG7 2UH, England.							Akriviadis EA, 1997, GASTROENTEROLOGY, V113, P225, DOI 10.1016/S0016-5085(97)70099-4; Barone JE, 1999, AM J SURG, V177, P232, DOI 10.1016/S0002-9610(99)00007-0; BATES T, 1992, GUT, V33, P103, DOI 10.1136/gut.33.1.103; BERGER H, 1989, HEPATO-GASTROENTEROL, V36, P346; Brodsky A, 2000, SURG ENDOSC, V14, P755, DOI 10.1007/s004640000182; Cosenza CA, 1999, AM J SURG, V178, P545, DOI 10.1016/S0002-9610(99)00217-2; Draghi F, 2000, EUR RADIOL, V10, P1587, DOI 10.1007/s003300000371; du Plessis D J, 1973, Surg Clin North Am, V53, P1071; Eldar S, 1999, AM J SURG, V178, P303, DOI 10.1016/S0002-9610(99)00172-5; FRIEDMAN GD, 1993, AM J SURG, V165, P399, DOI 10.1016/S0002-9610(05)80930-4; GOMEZ NA, 1995, SURG ENDOSC-ULTRAS, V9, P730; JANOWITZ P, 1994, HEPATOLOGY, V20, P291, DOI 10.1016/0270-9139(94)90176-7; JENSEN KH, 1991, GASTROENTEROLOGY, V100, P790, DOI 10.1016/0016-5085(91)80027-7; KAMINSKI DL, 1985, DIGEST DIS SCI, V30, P933, DOI 10.1007/BF01308292; Khuroo MS, 1996, GASTROENTEROL CLIN N, V25, P553, DOI 10.1016/S0889-8553(05)70263-6; Lai PBS, 1998, BRIT J SURG, V85, P764; LANDAU Z, 1995, ISRAEL J MED SCI, V31, P696; Lo CM, 1998, ANN SURG, V227, P461, DOI 10.1097/00000658-199804000-00001; Merriam LT, 1999, SURGERY, V126, P680, DOI 10.1067/msy.2099.99881; NORRBY S, 1983, BRIT J SURG, V70, P163, DOI 10.1002/bjs.1800700309; Oates E, 1996, J NUCL MED, V37, P267; ODONNELL LJD, 1992, LANCET, V339, P269, DOI 10.1016/0140-6736(92)91333-4; Pessaux P, 2000, SURG ENDOSC, V14, P358, DOI 10.1007/s004640020088; SAVOCA PE, 1990, J CLIN GASTROENTEROL, V12, P33, DOI 10.1097/00004836-199002000-00009; Tomida S, 1999, HEPATOLOGY, V30, P6, DOI 10.1002/hep.510300108	25	123	128	1	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 21	2002	325	7365					639	643		10.1136/bmj.325.7365.639	http://dx.doi.org/10.1136/bmj.325.7365.639			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	597WM	12242178	Green Published			2022-12-28	WOS:000178243800031
J	Sears, MR; Greene, JM; Willan, AR; Taylor, DR; Flannery, EM; Cowan, JO; Herbison, GP; Poulton, R				Sears, MR; Greene, JM; Willan, AR; Taylor, DR; Flannery, EM; Cowan, JO; Herbison, GP; Poulton, R			Long-term relation between breastfeeding and development of atopy and asthma in children and young adults: a longitudinal study	LANCET			English	Article							CHILDHOOD ASTHMA; INFANTS; EPIDEMIOLOGY; MICROFLORA; ALLERGY; DISEASE; BIRTH	Background Breastfeeding is widely advocated to reduce risk of atopy and asthma, but the evidence for such an effect is conflicting. We aimed to assess long-term outcomes of asthma and atopy related to breastfeeding in a New Zealand birth cohort. Methods Our cohort consisted of 1037 of 1139 children born in Dunedin, New Zealand, between April, 1972, and March, 1973, and residing in Otago province at age 3 years. Children were assessed every 2-5 years from ages 9 to 26 years with respiratory questionnaires, pulmonary function, bronchial challenge, and allergy skin tests. History of breastfeeding had been independently recorded in early childhood. Findings 504 (49%) of 1037 eligible children were breastfed (4 weeks or longer) and 533 (51%) were not. More children who were breastfed were atopic at all ages from 13 to 21 years to cats (p=0.0001), house dust mites (p=0.0010), and grass pollen (p<0.0001) than those who were not. More children who were breastfed reported current asthma at each assessment between age 9 (p=0.0008) and 26 years (p=0.0008) than those who were not. Breastfeeding effects were not affected by parental history of hayfever or asthma. Multifactor analysis controlling for socioeconomic status, parental smoking, birth order, and use of sheepskin bedding in infancy, showed odds ratios of 1.94 (95% Cl 1.42-2-65, p<0.0001) for any allergen positive at age 13 years, 2.40 (1-36-4.26, p=0.0003) for current asthma at 9 years, and 1.83 (1.35-2.47, p<0.0001) for current asthma at 9-26 years by repeated-measures analysis. Interpretation Breastfeeding does not protect children against atopy and asthma and may even increase the risk.	McMaster Univ, Dept Med, Hamilton, ON, Canada; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; Univ Otago, Dunedin Sch Med, Dept Med, Dunedin, New Zealand; Univ Otago, Dunedin Sch Med, Dept Prevent & Social Med, Dunedin, New Zealand	McMaster University; McMaster University; University of Otago; University of Otago	Sears, MR (corresponding author), St Josephs Healthcare & McMaster Univ, Firestone Inst Resp Hlth, 50 Charlton Ave, Hamilton, ON L8N 4A6, Canada.	searsm@mcmaster.ca		Herbison, Graham Peter/0000-0002-5684-024X				Aarts C, 2000, INT J EPIDEMIOL, V29, P1041, DOI 10.1093/ije/29.6.1041; ABERG N, 1989, ACTA PAEDIATR SCAND, V78, P246, DOI 10.1111/j.1651-2227.1989.tb11064.x; BALDWIN A, 1999, UNPUB PLUNKET SOC PE; BEREZIN S, 1989, AM J DIS CHILD, V143, P361, DOI 10.1001/archpedi.1989.02150150119029; Bottcher MF, 2002, CLIN EXP ALLERGY, V32, P159, DOI 10.1046/j.1365-2222.2002.01343.x; BUCKFIELD PM, 1978, NEW ZEAL MED J, V88, P244; BURNEY P, 1987, CHEST, V91, pS79, DOI 10.1378/chest.91.6.79S; Chandra RK, 1997, J PEDIATR GASTR NUTR, V24, P380, DOI 10.1097/00005176-199704000-00005; Diggle PJ, 1994, ANAL LONGITUDINAL DA; ELLEY WB, 1976, NEW ZEAL J EDUC STUD, V11, P25; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; Heinig MJ, 2001, PEDIATR CLIN N AM, V48, P105, DOI 10.1016/S0031-3955(05)70288-1; HOOD LJ, 1978, NEW ZEAL MED J, V88, P273; JONES DT, 1987, BRIT J DIS CHEST, V81, P332, DOI 10.1016/0007-0971(87)90181-1; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; KAPLAN BA, 1985, J EPIDEMIOL COMMUN H, V39, P152, DOI 10.1136/jech.39.2.152; KAUFMAN HS, 1976, ANN ALLERGY, V37, P410; KRAMER MS, 1988, J PEDIATR-US, V112, P181, DOI 10.1016/S0022-3476(88)80054-4; LAKE AM, 1982, J PEDIATR-US, V101, P906, DOI 10.1016/S0022-3476(82)80008-5; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Martinez FD, 1999, LANCET, V354, pS12, DOI 10.1016/S0140-6736(99)90437-3; Oddy WH, 1999, BMJ-BRIT MED J, V319, P815, DOI 10.1136/bmj.319.7213.815; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194, DOI 10.1046/j.1365-2222.2000.00799.x; Romieu I, 2000, J ASTHMA, V37, P575, DOI 10.3109/02770900009090812; Rook GAW, 1998, IMMUNOL TODAY, V19, P113, DOI 10.1016/S0167-5699(97)01204-8; Rubaltelli FF, 1998, J PERINAT MED, V26, P186, DOI 10.1515/jpme.1998.26.3.186; Rusconi F, 1999, AM J RESP CRIT CARE, V160, P1617, DOI 10.1164/ajrccm.160.5.9811002; SEARS MR, 1986, THORAX, V41, P283, DOI 10.1136/thx.41.4.283; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; SEARS MR, 1982, NEW ZEAL MED J, V95, P533; Sepp E, 1997, ACTA PAEDIATR, V86, P956, DOI 10.1111/j.1651-2227.1997.tb15178.x; TAYLOR B, 1983, J EPIDEMIOL COMMUN H, V37, P95, DOI 10.1136/jech.37.2.95; TOELLE BG, 1992, AM REV RESPIR DIS, V146, P633, DOI 10.1164/ajrccm/146.3.633; Wafula EM, 1999, E AFR MED J, V76, P606; Wright AL, 1999, J ALLERGY CLIN IMMUN, V104, P589, DOI 10.1016/S0091-6749(99)70328-3; WRIGHT AL, 1989, BRIT MED J, V299, P946, DOI 10.1136/bmj.299.6705.946; Wright AL, 2001, THORAX, V56, P192, DOI 10.1136/thorax.56.3.192	37	406	423	1	42	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 21	2002	360	9337					901	907		10.1016/S0140-6736(02)11025-7	http://dx.doi.org/10.1016/S0140-6736(02)11025-7			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	596AU	12354471				2022-12-28	WOS:000178142200008
J	Sanderson, RJ; Ironside, JAD				Sanderson, RJ; Ironside, JAD			Squamous cell carcinomas of the head and neck	BMJ-BRITISH MEDICAL JOURNAL			English	Review							QUALITY-OF-LIFE; ORGAN PRESERVATION; LASER MICROSURGERY; RADIATION-THERAPY; CANCER PATIENTS; CISPLATIN; CHEMOTHERAPY; DISEASE		Western Gen Hosp, Edinburgh Canc Ctr, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Sanderson, RJ (corresponding author), Western Gen Hosp, Edinburgh Canc Ctr, Edinburgh EH4 2XU, Midlothian, Scotland.	sandtol@ukgateway.net						Bjordal K, 2001, LARYNGOSCOPE, V111, P1440, DOI 10.1097/00005537-200108000-00022; *BRIT ASS OT HEAD, 2000, EFF HEAD NECK CANC M; Browman GP, 2001, HEAD NECK-J SCI SPEC, V23, P579, DOI 10.1002/hed.1081; Capizzi RL, 2000, INT J HEMATOL, V72, P425; Caponigro F, 2001, ANN ONCOL, V12, P199, DOI 10.1023/A:1008322415335; *DEP HLTH, 2002, REF GUID SUSP CANC; Hammerlid E, 2001, LARYNGOSCOPE, V111, P669, DOI 10.1097/00005537-200104000-00021; Henk JM, 2001, CLIN ONCOL-UK, V13, P333, DOI 10.1053/clon.2001.9284; Jeremic B, 1997, RADIOTHER ONCOL, V43, P29, DOI 10.1016/S0167-8140(97)00048-0; Khuri FR, 2000, NAT MED, V6, P879, DOI 10.1038/78638; Lefebvre JL, 1996, J NATL CANCER I, V88, P890, DOI 10.1093/jnci/88.13.890; LODI G, 2002, COCHRANE DATABASE SY; MCGUIRT WF, 1978, LARYNGOSCOPE, V88, P594; MERINO OR, 1977, CANCER, V40, P145, DOI 10.1002/1097-0142(197707)40:1<145::AID-CNCR2820400124>3.0.CO;2-9; Newkirk KA, 2001, HEAD NECK-J SCI SPEC, V23, P73, DOI 10.1002/1097-0347(200102)23:2<73::AID-HED1001>3.0.CO;2-6; NORTHROP M, 1972, CANCER-AM CANCER SOC, V29, P23, DOI 10.1002/1097-0142(197201)29:1<23::AID-CNCR2820290104>3.0.CO;2-Y; Nutting C, 2000, BRIT J RADIOL, V73, P459, DOI 10.1259/bjr.73.869.10884741; Overgaard J, 1998, RADIOTHER ONCOL, V48, P345; PANOSETTI E, 1989, LARYNGOSCOPE, V99, P1267; Pignon JP, 2000, LANCET, V355, P949, DOI 10.1016/S0140-6736(00)90011-4; Quinn MJ, 2001, STUDIES MED POPULATI; Scottish Cancer Intelligence Unit, 2000, TRENDS CANC SURV SCO; SOBIN LH, 1997, CLASSIFICATION MALIG; STEINER W, 1993, AM J OTOLARYNG, V14, P116, DOI 10.1016/0196-0709(93)90050-H; Steiner W, 2001, OTOLARYNG HEAD NECK, V124, P58, DOI 10.1067/mhn.2001.111597; THAMES HD, 1982, INT J RADIAT ONCOL, V8, P219, DOI 10.1016/0360-3016(82)90517-X; TOBIAS JS, 2001, RADIOTHER ONCOL S1, V58, pS16; VANDERRIET P, 1994, CANCER RES, V54, P1156; WOLF GT, 1991, NEW ENGL J MED, V324, P1685, DOI 10.1056/nejm199106133242402	29	193	207	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 12	2002	325	7368					822	827		10.1136/bmj.325.7368.822	http://dx.doi.org/10.1136/bmj.325.7368.822			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604YM	12376446	Green Published			2022-12-28	WOS:000178648700023
J	Cebria, F; Kobayashi, C; Umesono, Y; Nakazawa, M; Mineta, K; Ikeo, K; Gojobori, T; Itoh, M; Taira, M; Alvarado, AS; Agata, K				Cebria, F; Kobayashi, C; Umesono, Y; Nakazawa, M; Mineta, K; Ikeo, K; Gojobori, T; Itoh, M; Taira, M; Alvarado, AS; Agata, K			FGFR-related gene nou-darake restricts brain tissues to the head region of planarians	NATURE			English	Article							DOUBLE-STRANDED-RNA; STEM-CELLS; NEURAL INDUCTION; EXPRESSION; REGENERATION; INTERFERENCE; REVEALS; SEF	The study of planarian regeneration may help us to understand how we can rebuild organs and tissues after injury, disease or ageing(1). The robust regenerative abilities of planarians are based upon a population of totipotent stem cells (neoblasts)(2-4), and among the organs regenerated by these animals is a well-organized central nervous system(5,6). In recent years, methodologies such as whole-mount in situ hybridizations and double-stranded RNA have been extended to planarians with the aim of unravelling the molecular basis of their regenerative capacities(7-11). Here we report the identification and characterization of nou-darake (ndk), a gene encoding a fibroblast growth factor receptor (FGFR)-like molecule specifically expressed in the head region of the planarian Dugesia japonica. Loss of function of ndk by RNA interference results in the induction of ectopic brain tissues throughout the body. This ectopic brain formation was suppressed by inhibition of two planarian FGFR homologues (FGFR1 and FGFR2). Additionally, ndk inhibits FGF signalling in Xenopus embryos. The data suggest that ndk may modulate FGF signalling in stem cells to restrict brain tissues to the head region of planarians.	RIKEN Kobe, Ctr Dev Biol, Grp Evolutionary Regenerat Biol, Kobe, Hyogo 6500047, Japan; Grad Univ Adv Studies, Dept Genet, Mishima, Shizuoka 4118540, Japan; Grad Univ Adv Studies, DNA Data Bank Japan, Natl Inst Genet, Mishima, Shizuoka 4118540, Japan; Grad Univ Adv Studies, Ctr Informat Biol, Natl Inst Genet, Mishima, Shizuoka 4118540, Japan; Univ Tokyo, Grad Sch Sci, Dept Sci Biol, Bunkyo Ku, Tokyo 1130033, Japan; Japan Sci & Technol Corp, CREST, Bunkyo Ku, Tokyo 1130033, Japan; Univ Utah, Sch Med, Dept Neurobiol & Anat, Salt Lake City, UT 84132 USA; Okayama Univ, Fac Sci, Dept Biol, Okayama 7008530, Japan	RIKEN; Graduate University for Advanced Studies - Japan; Graduate University for Advanced Studies - Japan; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Graduate University for Advanced Studies - Japan; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; University of Tokyo; Japan Science & Technology Agency (JST); Utah System of Higher Education; University of Utah; Okayama University	Agata, K (corresponding author), RIKEN Kobe, Ctr Dev Biol, Grp Evolutionary Regenerat Biol, 2-2-3 Minatojima Minamimachi, Kobe, Hyogo 6500047, Japan.	agata@cdb.riken.go.jp	TAIRA, MASANORI/G-4923-2014; Mineta, Katsuhiko/A-5455-2012; Cebria, Francesc/C-5574-2017	Mineta, Katsuhiko/0000-0002-4727-045X; Cebria, Francesc/0000-0002-4028-3135; Agata, Kiyokazu/0000-0002-5195-2576; Sanchez Alvarado, Alejandro/0000-0002-1966-6959				Agata K, 1999, SEMIN CELL DEV BIOL, V10, P377, DOI 10.1006/scdb.1999.0324; Agata K, 1998, ZOOL SCI, V15, P433, DOI 10.2108/zsj.15.433; Alvarado AS, 1999, P NATL ACAD SCI USA, V96, P5049, DOI 10.1073/pnas.96.9.5049; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BAGUNA J, 1989, DEVELOPMENT, V107, P77; Cebria F, 2002, MECH DEVELOP, V116, P199, DOI 10.1016/S0925-4773(02)00134-X; Cebria F, 2002, DEV GROWTH DIFFER, V44, P135; Conlon FL, 1999, DEV BIOL, V213, P85, DOI 10.1006/dbio.1999.9330; Dowd CJ, 1999, J BIOL CHEM, V274, P5236, DOI 10.1074/jbc.274.8.5236; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Furthauer M, 2002, NAT CELL BIOL, V4, P170, DOI 10.1038/ncb750; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; ISAACS HV, 1994, EMBO J, V13, P4469, DOI 10.1002/j.1460-2075.1994.tb06769.x; Kato K, 1999, DEVELOPMENT, V126, P1031; Kobayashi C, 1999, MECH DEVELOP, V89, P25, DOI 10.1016/S0925-4773(99)00192-6; Launay C, 1996, DEVELOPMENT, V122, P869; Newmark PA, 2002, NAT REV GENET, V3, P210, DOI 10.1038/nrg759; Ogawa K, 2002, DEV GROWTH DIFFER, V44, P191; Onichtchouk D, 1999, NATURE, V401, P480, DOI 10.1038/46794; Orii H, 1999, DEV BIOL, V210, P456, DOI 10.1006/dbio.1999.9275; Pearson H, 2001, NATURE, V414, P388, DOI 10.1038/35106653; Sakai F, 2000, ZOOL SCI, V17, P375, DOI 10.2108/jsz.17.375; Shibata N, 1999, DEV BIOL, V206, P73, DOI 10.1006/dbio.1998.9130; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; Streit A, 2000, NATURE, V406, P74, DOI 10.1038/35017617; TAIRA M, 1994, NATURE, V372, P677, DOI 10.1038/372677a0; Tazaki A, 1999, BIOCHEM BIOPH RES CO, V260, P426, DOI 10.1006/bbrc.1999.0933; Tsang M, 2002, NAT CELL BIOL, V4, P165, DOI 10.1038/ncb749; Umesono Y, 1999, DEV GENES EVOL, V209, P31, DOI 10.1007/s004270050224; Wiedemann M, 2000, GENOMICS, V69, P275, DOI 10.1006/geno.2000.6332	30	217	225	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 10	2002	419	6907					620	624		10.1038/nature01042	http://dx.doi.org/10.1038/nature01042			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	602AT	12374980				2022-12-28	WOS:000178483100046
J	Chapple, A; Ziebland, S; Shepperd, S; Miller, R; Herxheimer, A; McPherson, A				Chapple, A; Ziebland, S; Shepperd, S; Miller, R; Herxheimer, A; McPherson, A			Why men with prostate cancer want wider access to prostate specific antigen testing: qualitative study	BRITISH MEDICAL JOURNAL			English	Article								Objectives To explore the attitudes of men with confirmed or suspected prostate cancer to testing for prostate specific antigen. Design Qualitative interview study with a purposive sample. Setting Great Britain. Participants 52 men with suspected or confirmed prostate cancer, recruited through general practitioners, urologists, patient support groups, and charities. Results Almost all men remembered their prostate specific antigen test but recalled being given little information beforehand. Arguments in favour of increased access to testing included the belief that early diagnosis would reduce mortality, improve quality of life, and save the NHS money. Men also thought that a national screening programme should be available because symptoms can be ambiguous, screening for cancer is responsible health behaviour, and screening would encourage men to be tested. Four men who opposed a screening programme had gathered information alerting them to uncertainty about the benefits of treatment, and two regretted that they had been tested., Others thought that access to testing is restricted in the United Kingdom because of a lack of government backing, concerns about the accuracy of the test, and a lack of resources. Conclusions The few men in this study who subscribed to the argument that evidence of the benefits of treatment is a prerequisite for a screening programme did not want to see screening introduced. Men who proposed an alternative set of principles for testing gave reasons that did not all relate to overoptimism about the benefits of early diagnosis. People who plan services and people who respond to requests for testing need to understand men's perspectives and concerns.	Univ Oxford, Inst Hlth Sci, Dept Primary Hlth Care, DIPEx, Oxford OX3 7LF, England; Univ Oxford, Dept Primary Hlth Care, Canc Res UK Gen Practice Res Grp, Oxford OX1 2JD, England	University of Oxford; University of Oxford	Chapple, A (corresponding author), Univ Oxford, Inst Hlth Sci, Dept Primary Hlth Care, DIPEx, Oxford OX3 7LF, England.			Shepperd, Sasha/0000-0001-6384-8322; Ziebland, Sue/0000-0002-6496-4859				Barry MJ, 2001, NEW ENGL J MED, V344, P1373, DOI 10.1056/NEJM200105033441806; Brawley OW, 1997, CANCER-AM CANCER SOC, V80, P1857, DOI 10.1002/(SICI)1097-0142(19971101)80:9<1857::AID-CNCR26>3.0.CO;2-3; Coyne IT, 1997, J ADV NURS, V26, P623, DOI 10.1046/j.1365-2648.1997.t01-25-00999.x; Donovan JL, 2001, BMJ-BRIT MED J, V323, P763, DOI 10.1136/bmj.323.7316.763; Grimes DA, 2002, LANCET, V359, P881, DOI 10.1016/S0140-6736(02)07948-5; Herxheimer A, 2000, LANCET, V355, P1540, DOI 10.1016/S0140-6736(00)02174-7; Howson A, 1999, SOCIOL HEALTH ILL, V21, P401, DOI 10.1111/1467-9566.00164; LEEPOTTER L, 2000, DAILY MAIL      0708, P4; Malterud K, 2001, LANCET, V358, P397, DOI 10.1016/S0140-6736(01)05548-9; Malterud K, 2001, LANCET, V358, P483, DOI 10.1016/S0140-6736(01)05627-6; Morse JM, 1997, QUAL HEALTH RES, V7, P445, DOI 10.1177/104973239700700401; Neal D E, 2000, Lancet Oncol, V1, P17, DOI 10.1016/S1470-2045(00)00005-X; Pope C, 2000, BMJ-BRIT MED J, V320, P114, DOI 10.1136/bmj.320.7227.114; SILVERMAN D, 1994, INTERPRETING QUALITA; SLEVIN T, 1997, MED J AUSTRALIA, V171, P185; STUTTAFORD T, 2000, TIMES           0608, P21; STUTTAFORD T, 2000, TIMES           0914, P10; TANNOCK IF, 2000, LANCET ONCOL     MAY, P17; Taylor KL, 1999, CANCER, V85, P1305, DOI 10.1002/(SICI)1097-0142(19990315)85:6<1305::AID-CNCR13>3.0.CO;2-I; UK National Screening Committee, 2000, 2 REP UK NAT SCREEN; Volk RJ, 2000, J FAM PRACTICE, V49, P425; Ward JE, 1997, MED J AUSTRALIA, V167, P250, DOI 10.5694/j.1326-5377.1997.tb125048.x; 2000, PSA NEWSLETTER, V4, P2	23	34	35	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 5	2002	325	7367					737	739		10.1136/bmj.325.7367.737	http://dx.doi.org/10.1136/bmj.325.7367.737			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	603AU	12364299	Green Published, Bronze			2022-12-28	WOS:000178537300013
J	Luck, AJ; Morgan, JF; Reid, F; O'Brien, A; Brunton, J; Price, C; Perry, L; Lacey, JH				Luck, AJ; Morgan, JF; Reid, F; O'Brien, A; Brunton, J; Price, C; Perry, L; Lacey, JH			The SCOFF questionnaire and clinical interview for eating disorders in general practice: comparative study	BRITISH MEDICAL JOURNAL			English	Article									Univ London St Georges Hosp, Sch Med, Dept Psychiat, London SW17 0RE, England; Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London, England; Univ London St Georges Hosp, Sch Med, Fac Hlth & Social Care Sci, London, England	St Georges University London; St Georges University London; St Georges University London	Morgan, JF (corresponding author), Univ London St Georges Hosp, Sch Med, Dept Psychiat, London SW17 0RE, England.							BEGLIN SJ, 1992, PSYCHIAT RES, V44, P191, DOI 10.1016/0165-1781(92)90023-V; Department of Health, 1999, NAT SERV FRAM MENT H; GARNER DM, 1983, INT J EAT DISORDER, V2, P15, DOI 10.1002/1098-108X(198321)2:2<15::AID-EAT2260020203>3.0.CO;2-6; Morgan JF, 1999, BRIT MED J, V319, P1467, DOI 10.1136/bmj.319.7223.1467; PERRY L, IN PRESS INT J EATIN	5	134	136	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 5	2002	325	7367					755	756		10.1136/bmj.325.7367.755	http://dx.doi.org/10.1136/bmj.325.7367.755			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	603AU	12364305	Bronze, Green Published			2022-12-28	WOS:000178537300019
J	Alphey, L; Beard, CB; Billingsley, P; Coetzee, M; Crisanti, A; Curtis, C; Eggleston, P; Godfray, C; Hemingway, J; Jacobs-Lorena, M; James, AA; Kafatos, FC; Mukwaya, LG; Paton, M; Powell, JR; Schneider, W; Scott, TW; Sina, B; Sinden, R; Sinkins, S; Spielman, A; Toure, Y; Collins, FH				Alphey, L; Beard, CB; Billingsley, P; Coetzee, M; Crisanti, A; Curtis, C; Eggleston, P; Godfray, C; Hemingway, J; Jacobs-Lorena, M; James, AA; Kafatos, FC; Mukwaya, LG; Paton, M; Powell, JR; Schneider, W; Scott, TW; Sina, B; Sinden, R; Sinkins, S; Spielman, A; Toure, Y; Collins, FH			Malaria control with genetically manipulated insect vectors	SCIENCE			English	Editorial Material							ANOPHELES-GAMBIAE; TRANSFORMATION; MOSQUITOS		Univ Oxford, Oxford OX1 2JD, England; Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Atlanta, GA USA; Univ Aberdeen, Aberdeen AB9 1FX, Scotland; S African Inst Med Res, ZA-2000 Johannesburg, South Africa; Univ London Imperial Coll Sci Technol & Med, London, England; Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England; Case Western Reserve Univ, Cleveland, OH 44106 USA; Univ Calif Irvine, Irvine, CA 92717 USA; European Mol Biol Lab, Heidelberg, Germany; Uganda Virus Res Inst, Entebbe, Uganda; Hlth & Safety Execut, HSC, Sheffield S3 7HQ, S Yorkshire, England; Yale Univ, New Haven, CT 06520 USA; US EPA, Washington, DC 20460 USA; Univ Calif Davis, Davis, CA 95616 USA; NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA; Harvard Univ, Sch Publ Hlth, Cambridge, MA 02138 USA; WHO, Special Programme Res & Training Trop Dis, Geneva, Switzerland; Univ Notre Dame, Notre Dame, IN 46556 USA	University of Oxford; Centers for Disease Control & Prevention - USA; University of Aberdeen; Imperial College London; University of London; London School of Hygiene & Tropical Medicine; Case Western Reserve University; University of California System; University of California Irvine; European Molecular Biology Laboratory (EMBL); Uganda Virus Research Institute; Yale University; United States Environmental Protection Agency; University of California System; University of California Davis; National Institutes of Health (NIH) - USA; NIH Fogarty International Center (FIC); Harvard University; Harvard T.H. Chan School of Public Health; World Health Organization; University of Notre Dame	Alphey, L (corresponding author), Univ Oxford, Oxford OX1 2JD, England.		Coetzee, Maureen/AAW-4739-2020; Coetzee, Maureen/AAI-1413-2020	Coetzee, Maureen/0000-0003-2019-866X; James, Anthony/0000-0001-5577-3308; Alphey, Luke/0000-0002-2916-3802; Hemingway, Janet/0000-0002-3200-7173; Crisanti, Andrea/0000-0002-2406-4426				[Anonymous], 1991, TDRBCVMALENT913 WHO; Black WC, 2001, INSECT MOL BIOL, V10, P3, DOI 10.1046/j.1365-2583.2001.00234.x; Capurro MD, 2000, AM J TROP MED HYG, V62, P427, DOI 10.4269/ajtmh.2000.62.427; Catteruccia F, 2000, NATURE, V405, P959, DOI 10.1038/35016096; Coates CJ, 1998, P NATL ACAD SCI USA, V95, P3748, DOI 10.1073/pnas.95.7.3748; CURTIS CF, 1968, NATURE, V218, P368, DOI 10.1038/218368a0; Donnelly MJ, 2001, MOL BIOL EVOL, V18, P1353, DOI 10.1093/oxfordjournals.molbev.a003919; Grossman GL, 2001, INSECT MOL BIOL, V10, P597, DOI 10.1046/j.0962-1075.2001.00299.x; Ito J, 2002, NATURE, V417, P452, DOI 10.1038/417452a; Morel CM, 2002, SCIENCE, V298, P79, DOI 10.1126/science.1078047; Onyabe DY, 2001, HEREDITY, V87, P647, DOI 10.1046/j.1365-2540.2001.00957.x; Scott TW, 2002, SCIENCE, V298, P117, DOI 10.1126/science.298.5591.117; Thomas DD, 2000, SCIENCE, V287, P2474, DOI 10.1126/science.287.5462.2474; Walton C, 2001, MOL ECOL, V10, P569, DOI 10.1046/j.1365-294x.2001.01201.x; Wang R, 1999, PARASITOL TODAY, V15, P33, DOI 10.1016/S0169-4758(98)01360-X	15	185	195	1	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 4	2002	298	5591					119	121		10.1126/science.1078278	http://dx.doi.org/10.1126/science.1078278			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	600BJ	12364786				2022-12-28	WOS:000178370500043
J	Chen, JY; Huang, DY				Chen, JY; Huang, DY			A possible Lower Cambrian chaetognath (arrow worm)	SCIENCE			English	Article									Nanjing Inst Geol & Paleontol, Nanjing 210008, Peoples R China	Chinese Academy of Sciences; Nanjing Institute of Geology & Paleontology, CAS	Chen, JY (corresponding author), Nanjing Inst Geol & Paleontol, Nanjing 210008, Peoples R China.							Bone Q, 1991, BIOL CHAETOGNATHS; Brusca R.C., 1990, INVERTEBRATES; SCHRAM FR, 1973, J PALEONTOL, V47, P985; SZANIAWSKI H, 1982, J PALEONTOL, V56, P806; Walcott C.D., 1911, SMITHSONIAN MISCELLA, V57, P109, DOI DOI 10.1126/SCIENCE.1091376	5	55	65	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 4	2002	298	5591					187	187		10.1126/science.1075059	http://dx.doi.org/10.1126/science.1075059			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	600BJ	12364798				2022-12-28	WOS:000178370500055
J	Miller, LH; Greenwood, B				Miller, LH; Greenwood, B			Malaria - a shadow over Africa	SCIENCE			English	Editorial Material							GENOME SEQUENCE; RESISTANCE		NIAID, Lab Malaria & Vector Res, Bethesda, MD 20892 USA; London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1B 3DP, England	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of London; London School of Hygiene & Tropical Medicine	Miller, LH (corresponding author), NIAID, Lab Malaria & Vector Res, 9000 Rockville Pike, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000241, Z01AI000241] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Chandre F, 1999, B WORLD HEALTH ORGAN, V77, P230; Desai SA, 2000, NATURE, V406, P1001, DOI 10.1038/35023000; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Greenwood B, 2002, NATURE, V415, P670, DOI 10.1038/415670a; Holt RA, 2002, SCIENCE, V298, P129, DOI 10.1126/science.1076181; LINDSAY SW, 1989, MED VET ENTOMOL, V3, P263, DOI 10.1111/j.1365-2915.1989.tb00226.x; Macdonald G., 1957, EPIDEMIOLOGY CONTROL; Molineaux L, 1980, THE GARKI PROJECT; Packard R. M., 1994, Parassitologia (Rome), V36, P197; Richie TL, 2002, NATURE, V415, P694, DOI 10.1038/415694a; Ridley RG, 2002, NATURE, V415, P686, DOI 10.1038/415686a; Rosenthal P.J., 2001, ANTIMALARIAL CHEMOTH; Sachs JD, 2002, SCIENCE, V298, P122, DOI 10.1126/science.1077900; White NJ, 1998, DRUG RESIST UPDATE, V1, P3, DOI 10.1016/S1368-7646(98)80208-2	14	22	22	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 4	2002	298	5591					121	122		10.1126/science.1078048	http://dx.doi.org/10.1126/science.1078048			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	600BJ	12364787				2022-12-28	WOS:000178370500044
J	Jafari, M; Forsberg, J; Gilcher, RO; Smith, JW; Crutcher, JM; McDermott, M; Brown, BR; George, JN				Jafari, M; Forsberg, J; Gilcher, RO; Smith, JW; Crutcher, JM; McDermott, M; Brown, BR; George, JN			Salmonella sepsis caused by a platelet transfusion from a donor with a pet snake	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UNITED-STATES; SEPTICEMIA		Univ Oklahoma, Hlth Sci Ctr, Hematol Oncol Sect, Dept Med, Oklahoma City, OK 73190 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK USA; Oklahoma Blood Inst, Oklahoma City, OK USA; Oklahoma Dept Hlth, Oklahoma City, OK USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	George, JN (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Hematol Oncol Sect, Dept Med, POB 26901, Oklahoma City, OK 73190 USA.							BRENNER FW, 1998, MODIFIED KAUFFMANNWH; CHIODINI RJ, 1981, AM J EPIDEMIOL, V113, P494, DOI 10.1093/oxfordjournals.aje.a113124; HEAL JM, 1987, TRANSFUSION, V27, P2, DOI 10.1046/j.1537-2995.1987.27187121466.x; Jacobs MR, 2001, TRANSFUSION, V41, P1331, DOI 10.1046/j.1537-2995.2001.41111331.x; Kuehnert MJ, 2001, TRANSFUSION, V41, P1493, DOI 10.1046/j.1537-2995.2001.41121493.x; Mermin J, 1997, PEDIATRICS, V99, P399, DOI 10.1542/peds.99.3.399; MERMIN J, 1998, 36 ANN M INF DIS SOC; Ness P, 2001, TRANSFUSION, V41, P857, DOI 10.1046/j.1537-2995.2001.41070857.x; RHAME FS, 1973, ANN INTERN MED, V78, P633, DOI 10.7326/0003-4819-78-5-633; SHANE SM, 1990, EPIDEMIOL INFECT, V105, P307, DOI 10.1017/S0950268800047907; Swaminathan B, 2001, EMERG INFECT DIS, V7, P382; VOETSCH D, 2002, 126 ANN M EXP AM PUB; Wollowitz S, 2001, SEMIN HEMATOL, V38, P4, DOI 10.1053/shem.2001.29495; 1999, MMWR MORB MORTAL WKL, V48, P1009; 1995, MMWR MORB MORTAL WKL, V44, P347; 1999, MMWR MORB MORTAL WKL, V48, P1051	16	40	41	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 3	2002	347	14					1075	1078		10.1056/NEJMoa021050	http://dx.doi.org/10.1056/NEJMoa021050			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	599KD	12362008				2022-12-28	WOS:000178332900004
J	Stadler, RH; Blank, I; Varga, N; Robert, F; Hau, J; Guy, PA; Robert, MC; Riediker, S				Stadler, RH; Blank, I; Varga, N; Robert, F; Hau, J; Guy, PA; Robert, MC; Riediker, S			Acrylamide from Maillard reaction products	NATURE			English	Article									Nestle Res Ctr, CH-1000 Lausanne 26, Switzerland	Nestle SA	Stadler, RH (corresponding author), Nestle Res Ctr, Vers Chez Blanc, CH-1000 Lausanne 26, Switzerland.		Hau, Jann/C-8692-2012	Hau, Jann/0000-0001-8586-5705; Guy, philippe/0000-0002-2968-8625				[Anonymous], CARBOHYDRATES CHEM B; CHEN JT, 1989, Z NATURFORSCH B, V44, P459; European Commission Scientific Committee on Food, 2002, OP SCI COMM FOOD NEW; LEDL F, 1990, ANGEW CHEM INT EDIT, V29, P565, DOI 10.1002/anie.199005653; Rosen J, 2002, ANALYST, V127, P880, DOI 10.1039/b204938d; VONEULER H, 1926, CHEM BER, V59, P1581; *WHO, 2002, FAOWHO CONS HLTH IMP	7	1207	1294	13	288	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 3	2002	419	6906					449	450		10.1038/419449a	http://dx.doi.org/10.1038/419449a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	599RF	12368845				2022-12-28	WOS:000178348400026
J	Jarvik, JG; Deyo, RA				Jarvik, JG; Deyo, RA			Diagnostic evaluation of low back pain with emphasis on imaging	ANNALS OF INTERNAL MEDICINE			English	Article							HIGH-INTENSITY ZONE; EMISSION COMPUTED-TOMOGRAPHY; LUMBAR SPINAL STENOSIS; NERVE-ROOT COMPRESSION; ANKYLOSING-SPONDYLITIS; VERTEBRAL METASTASES; BONE-SCINTIGRAPHY; DISK HERNIATION; PRIMARY-CARE; PROVOCATIVE DISCOGRAPHY	Purpose: To review evidence on the diagnostic accuracy of clinical information and imaging for patients with low back pain in primary care settings. Data Source: MEDLINE search (January 1966 to September 2001) for articles and reviews relevant to the accuracy of the clinical and radiographic examination of patients with low back pain. Study Selection: The authors reviewed abstracts and selected articles for review on the basis of a combined judgment. Data on the clinical examination were based primarily on recent systematic reviews; data on imaging tests were based primarily on original articles. Data Extraction: Diagnostic results were extracted by one or the other author. Quality of methods was evaluated informally. Major potential biases were identified, but neither quantitative data extraction nor scoring was done. Data Synthesis: Formal meta-analysis was not used because the diagnostic hardware and software, gold standards, and patient selection methods were heterogeneous and the number of studies was small. Sensitivity for cancer was highest for magnetic resonance imaging (0.83 to 0.93) and radionuclide scanning (0.74 to 0.98); specificity was highest for magnetic resonance imaging (0.9 to 0.97.) and radiography (0.95 to 0.99). Magnetic resonance imaging was the most sensitive (0.96) and specific (0.92) test for infection. The sensitivity and specificity of magnetic resonance imaging for herniated discs were slightly higher than those for computed tomography but very similar for the diagnosis of spinal stenosis'. Conclusions: The data suggest a diagnostic strategy similar to the 1994 Agency for Health Care Policy and Research guidelines. For adults younger than 50 years of age with no signs or symptoms of systemic disease, symptomatic therapy without imaging is appropriate. For patients 50 years of age and older or those whose findings suggest systemic disease, plain radiography and simple laboratory tests can almost completely rule out underlying systemic diseases. Advanced imaging should be reserved I for patients who are considering surgery or those in whom systemic disease is strongly suspected.	Univ Washington, Dept Radiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Jarvik, JG (corresponding author), Univ Washington, Dept Radiol, Box 357115,1959 NE Pacific St, Seattle, WA 98195 USA.	jarvikj@u.washington.edu	Jarvik, Jeffrey/AAL-4292-2021		AHRQ HHS [HS-08194, HS-094990] Funding Source: Medline; NIAMS NIH HHS [1 P60 AR48093] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS008194] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR048093] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBECK MJ, 1995, ACTA NEUROCHIR, V133, P3, DOI 10.1007/BF01404939; ALBECK MJ, 1995, SPINE, V20, P443, DOI 10.1097/00007632-199502001-00006; ALGRA PR, 1991, RADIOGRAPHICS, V11, P219, DOI 10.1148/radiographics.11.2.2028061; ANTOKU S, 1971, RADIOLOGY, V101, P669, DOI 10.1148/101.3.669; APRILL C, 1992, BRIT J RADIOL, V65, P361, DOI 10.1259/0007-1285-65-773-361; AVRAHAMI E, 1989, J COMPUT ASSIST TOMO, V13, P598, DOI 10.1097/00004728-198907000-00008; BARONDESS JA, 1993, ANN INTERN MED, V119, P153, DOI 10.7326/0003-4819-119-2-199307150-00010; BAUER RL, 1987, ARCH INTERN MED, V147, P1437, DOI 10.1001/archinte.147.8.1437; Beattie PF, 2000, SPINE, V25, P819, DOI 10.1097/00007632-200004010-00010; BELLAH RD, 1991, RADIOLOGY, V180, P509, DOI 10.1148/radiology.180.2.1829845; BIGOS SJ, 1994, CLIN PRACTICE GUIDEL, V14; BODEN SD, 1990, J BONE JOINT SURG AM, V72A, P403, DOI 10.2106/00004623-199072030-00013; Boos N, 1995, SPINE, V20, P2613, DOI 10.1097/00007632-199512150-00002; BRANTZAWADZKI MN, 1995, SPINE, V20, P1257, DOI 10.1097/00007632-199506000-00010; Burns JW, 1996, AVIAT SPACE ENVIR MD, V67, P849; CALIN A, 1980, SPINE, V5, P201, DOI 10.1097/00007632-198003000-00016; CARMODY RF, 1989, RADIOLOGY, V173, P225, DOI 10.1148/radiology.173.1.2675185; Carragee EJ, 2000, SPINE, V25, P2987, DOI 10.1097/00007632-200012010-00005; Carragee EJ, 2000, SPINE, V25, P1373, DOI 10.1097/00007632-200006010-00009; Carroll KW, 1997, JMRI-J MAGN RESON IM, V7, P394, DOI 10.1002/jmri.1880070224; COLLIER BD, 1985, RADIOLOGY, V154, P207, DOI 10.1148/radiology.154.1.3155479; COOPER C, 1991, OSTEOPOROSIS INT, V2, P48, DOI 10.1007/BF01627079; CORCORAN RJ, 1976, RADIOLOGY, V121, P663, DOI 10.1148/121.3.663; CRISI G, 1993, AM J NEURORADIOL, V14, P1379; CURREY HLF, 1979, RHEUMATOL REHABIL, V18, P94, DOI 10.1093/rheumatology/18.2.94; DEYO RA, 1987, SPINE, V12, P264, DOI 10.1097/00007632-198704000-00013; DEYO RA, 1986, J GEN INTERN MED, V1, P328, DOI 10.1007/BF02596214; Deyo RA, 2001, NEW ENGL J MED, V344, P363, DOI 10.1056/NEJM200102013440508; DEYO RA, 1988, J GEN INTERN MED, V3, P230, DOI 10.1007/BF02596337; EVENSAPIR E, 1993, RADIOLOGY, V187, P193, DOI 10.1148/radiology.187.1.8451412; FRYMOYER JW, 1988, NEW ENGL J MED, V318, P291, DOI 10.1056/NEJM198802043180506; Gillams AR, 1996, AM J ROENTGENOL, V166, P903, DOI 10.2214/ajr.166.4.8610571; GRAN JT, 1985, CLIN RHEUMATOL, V4, P161, DOI 10.1007/BF02032287; HALL FM, 1976, RADIOLOGY, V120, P443, DOI 10.1148/120.2.443; Han LJ, 1998, EUR J NUCL MED, V25, P635, DOI 10.1007/s002590050266; HANLY JG, 1993, J RHEUMATOL, V20, P2062; HART LG, 1995, SPINE, V20, P11, DOI 10.1097/00007632-199501000-00003; HELLSTROM M, 1990, ACTA RADIOL, V31, P127; HITSELBE.WE, 1968, J NEUROSURG, V28, P204, DOI 10.3171/jns.1968.28.3.0204; JACKSON RP, 1989, SPINE, V14, P1362, DOI 10.1097/00007632-198912000-00013; Jacobson AF, 1997, ARCH INTERN MED, V157, P105, DOI 10.1001/archinte.157.1.105; JACOBSSON H, 1984, BRIT J RADIOL, V57, P133, DOI 10.1259/0007-1285-57-674-133; JANSSEN ME, 1994, ORTHOPEDICS, V17, P121; Jarvik JJ, 2001, SPINE, V26, P1158, DOI 10.1097/00007632-200105150-00014; JENSEN MC, 1994, NEW ENGL J MED, V331, P69, DOI 10.1056/NEJM199407143310201; Joines JD, 2001, J GEN INTERN MED, V16, P14, DOI 10.1111/j.1525-1497.2001.00249.x; KATZ JN, 1995, ARTHRITIS RHEUM, V38, P1236, DOI 10.1002/art.1780380910; KENT DL, 1992, AM J ROENTGENOL, V158, P1135, DOI 10.2214/ajr.158.5.1533084; Kikkawa I, 2001, J Orthop Sci, V6, P101, DOI 10.1007/s007760100055; Kosuda S, 1996, J NUCL MED, V37, P975; Lam KS, 2000, EUR SPINE J, V9, P36, DOI 10.1007/s005860050006; LANE JI, 1994, AM J NEURORADIOL, V15, P1317; LIANG M, 1982, ARCH INTERN MED, V142, P1108, DOI 10.1001/archinte.142.6.1108; Marc V, 1997, REV RHUM, V64, P465; MCNEIL BJ, 1978, SEMIN NUCL MED, V8, P336, DOI 10.1016/S0001-2998(78)80019-1; MODIC MT, 1985, RADIOLOGY, V157, P157, DOI 10.1148/radiology.157.1.3875878; Nevitt MC, 1998, ANN INTERN MED, V128, P793, DOI 10.7326/0003-4819-128-10-199805150-00001; Peh WCG, 1997, CLIN IMAG, V21, P54, DOI 10.1016/0899-7071(95)00065-8; PETRENMALLMIN M, 1994, ACTA RADIOL, V35, P2; PISTENMA DA, 1975, JAMA-J AM MED ASSOC, V231, P46, DOI 10.1001/jama.1975.03240130028020; PORTER RW, 1994, SPINE, V19, P173, DOI 10.1097/00007632-199401001-00010; Pui M H, 2000, Australas Radiol, V44, P281, DOI 10.1046/j.1440-1673.2000.00813.x; Rankine JJ, 1999, SPINE, V24, P1913, DOI 10.1097/00007632-199909150-00009; Rankine JJ, 1998, SPINE, V23, P1668, DOI 10.1097/00007632-199808010-00011; RHYNE AL, 1995, SPINE, V20, P1997, DOI 10.1097/00007632-199509150-00007; Robbins SE, 1996, CLIN RADIOL, V51, P637, DOI 10.1016/S0009-9260(96)80058-4; SALKEVER D, 1985, 863343 PHS; Sandhu HS, 2000, J SPINAL DISORD, V13, P438, DOI 10.1097/00002517-200010000-00012; SARTORIS DJ, 1986, RADIOLOGY, V160, P707, DOI 10.1148/radiology.160.3.3755536; SARTORIS DJ, 1986, RADIOLOGY, V160, P479, DOI 10.1148/radiology.160.2.3726130; Savelli G, 2000, ANTICANCER RES, V20, P1115; SCAVONE JG, 1981, AM J ROENTGENOL, V136, P715, DOI 10.2214/ajr.136.4.715; SCHWARZER AC, 1995, SPINE, V20, P907, DOI 10.1097/00007632-199504150-00005; SMITH AS, 1989, AM J ROENTGENOL, V153, P399, DOI 10.2214/ajr.153.2.399; Smith SE, 1995, SPINE, V20, P2000; SPANGFORT EV, 1972, ACTA ORTHOP SCAND, P1; SPECTOR TD, 1993, J BONE MINER RES, V8, P817; Stadnik TW, 1998, RADIOLOGY, V206, P49, DOI 10.1148/radiology.206.1.9423651; SUBRAMANIAN G, 1971, RADIOLOGY, V99, P192, DOI 10.1148/99.1.192; SWANSON D, 1987, CLIN NUCL MED, V12, P210, DOI 10.1097/00003072-198703000-00011; THORNBURY JR, 1993, RADIOLOGY, V186, P731, DOI 10.1148/radiology.186.3.8267688; TURNER JA, 1992, SPINE, V17, P1, DOI 10.1097/00007632-199201000-00001; VANDENHOOGEN HMM, 1995, SPINE, V20, P318, DOI 10.1097/00007632-199502000-00010; vanTulder MW, 1997, SPINE, V22, P427, DOI 10.1097/00007632-199702150-00015; Vroomen PCAJ, 2000, J NEUROSURG, V92, P135, DOI 10.3171/spi.2000.92.2.0135; WALDVOGEL FA, 1980, NEW ENGL J MED, V303, P360, DOI 10.1056/NEJM198008143030703; WEBSTER EW, 1957, NEW ENGL J MED, V257, P811, DOI 10.1056/NEJM195710242571705; WEINREB JC, 1989, RADIOLOGY, V170, P125, DOI 10.1148/radiology.170.1.2521192; Weishaupt D, 1998, RADIOLOGY, V209, P661, DOI 10.1148/radiology.209.3.9844656; WHITE AA, 1982, SPINE, V7, P141, DOI 10.1097/00007632-198203000-00009; WIESEL SW, 1984, SPINE, V9, P549, DOI 10.1097/00007632-198409000-00003; WILMINK JT, 1989, AM J NEURORADIOL, V10, P233; Yamato M, 1998, Radiat Med, V16, P329	93	393	408	0	33	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	2002	137	7					586	597		10.7326/0003-4819-137-7-200210010-00010	http://dx.doi.org/10.7326/0003-4819-137-7-200210010-00010			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	599VD	12353946				2022-12-28	WOS:000178355100005
J	Hooper, L; Bartlett, C; Smith, GD; Ebrahim, S				Hooper, L; Bartlett, C; Smith, GD; Ebrahim, S			Systematic review of long term effects of advice to reduce dietary salt in adults	BMJ-BRITISH MEDICAL JOURNAL			English	Review							LOW-SODIUM DIET; BLOOD-PRESSURE; NONPHARMACOLOGIC INTERVENTIONS; MYOCARDIAL-INFARCTION; URINARY SODIUM; WEIGHT-LOSS; HYPERTENSION; RESTRICTION; TRIALS; RISK	Objective To assess the long term effects of advice to restrict dietary sodium in adults with and without hypertension. Design Systematic review and meta-analysis of randomised controlled trials. Data sources Cochrane library, Medline, Embase, and bibliographies. Study selection Unconfounded randomised trials that aimed to reduce sodium intake in healthy adults over at least 6 months. Inclusion decisions, validity and data extraction were duplicated. Random effects meta-analysis, subgrouping, sensitivity analysis, and meta-regression were performed. Outcomes Mortality, cardiovascular events, blood pressure, urinary sodium excretion, quality of life, and use of antihypertensive drugs. Results Three trials in normotensive people (n=2326), five trials in those with untreated hypertension (n=387), and three trials in people being treated for hypertension (n=801) were included, with follow up from six months to seven years. The large high quality (and therefore most informative) studies used intensive behavioural interventions. Deaths and cardiovascular events were inconsistently defined and reported. There were 17 deaths, equally distributed between intervention and control groups. Systolic and diastolic blood pressures were reduced (systolic by 1.1 mm Hg, 95% confidence interval 1.8 to 0.4 mm Hg; diastolic by 0.6 mm Hg, 1.5 to -0.3 mm Hg) at 13 to 60 months, as was urinary 24 hour sodium excretion (by 35.5 mmol/24 hours, 47.2 to 23.9). Degree of reduction in sodium intake and change in blood pressure were not related. Conclusions Intensive interventions, unsuited to primary care or population prevention programmes, provide only small reductions in blood pressure and sodium excretion, and effects on deaths and cardiovascular events are unclear. Advice to reduce sodium intake may help people on antihypertensive drugs to stop their medication while maintaining good blood pressure control.	Univ Dent Hosp Manchester, MANDEC, Manchester M15 6FH, Lancs, England; Univ Bristol, Dept Social Med, MRC, Hlth Serv Res Collaborat, Bristol BS8 2PR, Avon, England	University of Manchester; University of Bristol	Hooper, L (corresponding author), Univ Dent Hosp Manchester, MANDEC, Manchester M15 6FH, Lancs, England.	lee.hooper@man.ac.uk	Hooper, Lee/D-2795-2009; Davey Smith, George/A-7407-2013	Hooper, Lee/0000-0002-7904-3331; Davey Smith, George/0000-0002-1407-8314				Alam S, 1999, J HUM HYPERTENS, V13, P367, DOI 10.1038/sj.jhh.1000817; ALDERMAN MH, 1995, HYPERTENSION, V25, P1144, DOI 10.1161/01.HYP.25.6.1144; Alderman MH, 1998, LANCET, V351, P781, DOI 10.1016/S0140-6736(97)09092-2; Alderman MH, 2000, AM J HYPERTENS, V13, P313, DOI 10.1016/S0895-7061(00)00251-X; Alderman MH, 1997, AM J HYPERTENS, V10, P1, DOI 10.1016/S0895-7061(96)00301-9; ALLI C, 1992, J HUM HYPERTENS, V6, P281; [Anonymous], 1990, Arch Intern Med, V150, P153, DOI 10.1001/archinte.150.1.153; ARROLL B, 1995, NEW ZEAL MED J, V108, P266; BERKEY CS, 1995, STAT MED, V14, P395, DOI 10.1002/sim.4780140406; Clarke M, 2000, COCHRANE REV HDB 4 1; COSTA FV, 1981, CLIN SCI, V61, pS21, DOI 10.1042/cs061021s; Cutler JA, 1997, AM J CLIN NUTR, V65, P643, DOI 10.1093/ajcn/65.2.643S; CUTLER JA, 1997, JAM J CLIN NUTR S2, V65, pS643; *DEP HLTH, 2001, ANN REP CHIEF MED OF; DONNER A, 1982, INT J EPIDEMIOL, V11, P283, DOI 10.1093/ije/11.3.283; Ebrahim S, 1998, J PUBLIC HEALTH MED, V20, P441, DOI 10.1093/oxfordjournals.pubmed.a024800; EBRAHIM S, 1996, HLTH PROMOTION OLDER; FOLLMANN D, 1992, J CLIN EPIDEMIOL, V45, P769, DOI 10.1016/0895-4356(92)90054-Q; FORSTER JL, 1990, AM J CLIN NUTR, V51, P253, DOI 10.1093/ajcn/51.2.253; Graudal NA, 1998, JAMA-J AM MED ASSOC, V279, P1383, DOI 10.1001/jama.279.17.1383; HAUCK WW, 1991, NURS RES, V40, P356; He JA, 2000, HYPERTENSION, V35, P544, DOI 10.1161/01.HYP.35.2.544; He JA, 1999, JAMA-J AM MED ASSOC, V282, P2027, DOI 10.1001/jama.282.21.2027; Hooper L, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD011834, 10.1002/14651858.CD002137.pub2]; JEFFERY RW, 1990, HEALTH PSYCHOL, V9, P315, DOI 10.1037/0278-6133.9.3.315; Kostis JB, 1998, AM J CARDIOL, V82, P1501, DOI 10.1016/S0002-9149(98)00694-8; LAW MR, 1991, BMJ-BRIT MED J, V302, P819, DOI 10.1136/bmj.302.6780.819; MacGregor GA, 1996, BRIT MED J, V312, P1287, DOI 10.1136/bmj.312.7041.1287; *MAFF, 1999, NAT FOOD SURV 1998 A; Midgley JP, 1996, JAMA-J AM MED ASSOC, V275, P1590, DOI 10.1001/jama.275.20.1590; MORGAN T, 1987, CAN J PHYSIOL PHARM, V65, P1752, DOI 10.1139/y87-274; MORGAN T, 1978, LANCET, V1, P227; MORGAN TO, 1980, MED J AUSTRALIA, V2, P27, DOI 10.5694/j.1326-5377.1980.tb131808.x; Ramsay LE, 1999, J HUM HYPERTENS, V13, P569, DOI 10.1038/sj.jhh.1000917; Sacks FM, 2001, NEW ENGL J MED, V344, P3, DOI 10.1056/NEJM200101043440101; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Selmer RM, 2000, J EPIDEMIOL COMMUN H, V54, P697, DOI 10.1136/jech.54.9.697; Sharp S, 1998, STATA TECH B, V7, DOI DOI 10.1002/SIM.1187/FULL); SILMAN AJ, 1983, LANCET, V1, P1179; STAMLER R, 1991, HYPERTENSION, V17, pI16, DOI 10.1161/01.HYP.17.1_Suppl.I16; Taubes C, 1998, SCIENCE, V281, P898, DOI 10.1126/science.281.5379.898; THALER BI, 1982, NEW ZEAL MED J, V95, P839; TunstallPedoe H, 1997, BRIT MED J, V315, P722, DOI 10.1136/bmj.315.7110.722; Tuomilehto J, 2001, LANCET, V357, P848, DOI 10.1016/S0140-6736(00)04199-4; WHELTON PK, 1992, JAMA-J AM MED ASSOC, V267, P1213, DOI 10.1001/jama.1992.03480090061028; Whelton PK, 1998, JAMA-J AM MED ASSOC, V279, P839, DOI 10.1001/jama.279.11.839; Whelton PK, 1997, ARCH INTERN MED, V157, P657, DOI 10.1001/archinte.157.6.657; Whelton PK, 1997, AM J CLIN NUTR, V65, P652	48	191	198	1	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 21	2002	325	7365					628	632A		10.1136/bmj.325.7365.628	http://dx.doi.org/10.1136/bmj.325.7365.628			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	597WM	12242173	Green Accepted, Green Published, Bronze			2022-12-28	WOS:000178243800026
J	Murphy, DJ				Murphy, DJ			An obstetric perspective	LANCET			English	News Item									Univ Bristol, St Michaels Hosp, Div Obstet & Gynecol, Bristol BS2 8EG, Avon, England	University of Bristol	Murphy, DJ (corresponding author), Univ Bristol, St Michaels Hosp, Div Obstet & Gynecol, Bristol BS2 8EG, Avon, England.			Murphy, Deirdre/0000-0001-6074-6718					0	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 21	2002	360	9337					941	941		10.1016/S0140-6736(02)11031-2	http://dx.doi.org/10.1016/S0140-6736(02)11031-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	596AU	12354486				2022-12-28	WOS:000178142200023
J	Taverna, SD; Coyne, RS; Allis, CD				Taverna, SD; Coyne, RS; Allis, CD			Methylation of histone H3 at lysine 9 targets programmed DNA elimination in Tetrahymena	CELL			English	Article							MACRONUCLEAR DEVELOPMENT; CHROMODOMAIN PROTEIN; DEVELOPMENTAL-CHANGES; PARENTAL EXPRESSION; EUCHROMATIC GENES; CONJUGATING CELLS; HP1; HETEROCHROMATIN; CHROMATIN; THERMOPHILA	Histone H3 lysine 9 methylation [Me(Lys9)H3] is an epigenetic mark for heterochromatin-dependent gene silencing, mediated by direct binding to chromodomain-containing proteins such as Heterochromatin Protein 1. In the ciliate Tetrahymena, two chromodomain proteins, Pdd1p and Pdd3p, are involved in the massive programmed DNA elimination that accompanies macronuclear development. We report that both proteins bind H3(Lys9)Me in vitro. In vivo, H3(Lys9)Me is confined to the time period and location where DNA elimination occurs, and associates with eliminated sequences. Loss of parental Pdd1p expression drastically reduces H3(Lys9)Me. Finally, tethering Pdd1p is sufficient to promote DNA excision. These results extend the range of H3(Lys9)Me involvement in chromatin activities outside transcriptional regulation and also strengthen the link between heterochromatin formation and programmed DNA elimination.	Univ Virginia, Hlth Syst, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia	Allis, CD (corresponding author), Univ Virginia, Hlth Syst, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA.	allis@virginia.edu		Taverna, Sean/0000-0003-0278-0592	NIGMS NIH HHS [GM-53512] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM053512, R01GM053512] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akhtar A, 2000, NATURE, V407, P405, DOI 10.1038/35030169; ALLIS CD, 1984, DEV BIOL, V101, P282, DOI 10.1016/0012-1606(84)90142-8; ALLIS CD, 1982, DEV BIOL, V93, P519, DOI 10.1016/0012-1606(82)90139-7; Aravind L, 1999, J MOL EVOL, V48, P291, DOI 10.1007/PL00006472; AUSTERBERRY CF, 1984, P NATL ACAD SCI-BIOL, V81, P7383, DOI 10.1073/pnas.81.23.7383; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Boggs BA, 2002, NAT GENET, V30, P73, DOI 10.1038/ng787; Briggs SD, 2001, GENE DEV, V15, P3286, DOI 10.1101/gad.940201; Bruns PJ, 2000, METHOD CELL BIOL, V62, P501; Callebaut I, 1997, BIOCHEM BIOPH RES CO, V235, P103, DOI 10.1006/bbrc.1997.6748; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Chalker DL, 1999, MOL CELL BIOL, V19, P5631; Chalker DL, 2001, GENE DEV, V15, P1287, DOI 10.1101/gad.884601; Chau MF, 1996, BIOL CELL, V86, P111, DOI 10.1016/0248-4900(96)84773-3; Coyne RS, 1999, MOL CELL, V4, P865, DOI 10.1016/S1097-2765(00)80396-2; Coyne RS, 1996, ANNU REV GENET, V30, P557, DOI 10.1146/annurev.genet.30.1.557; Czermin B, 2001, EMBO REP, V2, P915, DOI 10.1093/embo-reports/kve210; DEDON PC, 1991, MOL CELL BIOL, V11, P1729, DOI 10.1128/MCB.11.3.1729; Duharcourt S, 2002, EUKARYOT CELL, V1, P293, DOI 10.1128/EC.1.2.293-303.2002; Gaertig J, 2000, METHOD CELL BIOL, V62, P485; GODISKA R, 1990, CELL, V61, P1237, DOI 10.1016/0092-8674(90)90688-B; GODISKA R, 1993, GENE DEV, V7, P2357, DOI 10.1101/gad.7.12a.2357; Gorovsky M A, 1975, Methods Cell Biol, V9, P311, DOI 10.1016/S0091-679X(08)60080-1; GUTTMAN SD, 1980, CELL, V22, P299, DOI 10.1016/0092-8674(80)90177-4; HEINONEN TYK, 1994, J BIOL CHEM, V269, P17428; Hwang KK, 2001, P NATL ACAD SCI USA, V98, P11423, DOI 10.1073/pnas.211303598; Jacobs SA, 2002, SCIENCE, V295, P2080, DOI 10.1126/science.1069473; Jacobs SA, 2001, EMBO J, V20, P5232, DOI 10.1093/emboj/20.18.5232; JAMES TC, 1989, EUR J CELL BIOL, V50, P170; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; KATOH M, 1993, NUCLEIC ACIDS RES, V21, P2409, DOI 10.1093/nar/21.10.2409; Klotz I. M., 1997, LIGAND RECEPTOR ENER; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN RL, 1991, GENE DEV, V5, P1601, DOI 10.1101/gad.5.9.1601; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; MADIREDDI MT, 1994, DEV BIOL, V165, P418, DOI 10.1006/dbio.1994.1264; Madireddi MT, 1996, CELL, V87, P75, DOI 10.1016/S0092-8674(00)81324-0; Matzke M, 2001, SCIENCE, V293, P1080, DOI 10.1126/science.1063051; Meyer E, 2002, ADV GENET, V46, P305; Mochizuki K, 2002, CELL, V110, P689, DOI 10.1016/S0092-8674(02)00909-1; MULLER J, 1995, EMBO J, V14, P1209, DOI 10.1002/j.1460-2075.1995.tb07104.x; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nakayama J, 2000, CELL, V101, P307, DOI 10.1016/S0092-8674(00)80840-5; Nielsen PR, 2002, NATURE, V416, P103, DOI 10.1038/nature722; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Nikiforov MA, 1999, GENE DEV, V13, P2852, DOI 10.1101/gad.13.21.2852; Nikiforov MA, 2000, MOL CELL BIOL, V20, P4128, DOI 10.1128/MCB.20.11.4128-4134.2000; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; PLATERO JS, 1995, EMBO J, V14, P3977, DOI 10.1002/j.1460-2075.1995.tb00069.x; Poux S, 2001, DEVELOPMENT, V128, P75; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; SAVELIEV SV, 1995, GENE DEV, V9, P248, DOI 10.1101/gad.9.2.248; Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302; Smothers JF, 1997, DEVELOPMENT, V124, P4537; Smothers JF, 1997, J EUKARYOT MICROBIOL, V44, P79, DOI 10.1111/j.1550-7408.1997.tb05942.x; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strahl BD, 1999, P NATL ACAD SCI USA, V96, P14967, DOI 10.1073/pnas.96.26.14967; VANHOLDE KE, 1988, CHROMATIN, P111; Weiler KS, 1995, ANNU REV GENET, V29, P577, DOI 10.1146/annurev.ge.29.120195.003045; Wolffe A., 1998, CHROMATIN STRUCTURE; Wolffe AP, 1999, NUCLEIC ACIDS RES, V27, P711, DOI 10.1093/nar/27.3.711; YAO MC, 1991, P NATL ACAD SCI USA, V88, P9493, DOI 10.1073/pnas.88.21.9493; Yao MC, 2002, MOBILE DNA, P730; YOKOYAMA RW, 1982, CHROMOSOMA, V85, P11, DOI 10.1007/BF00344591; Zamore PD, 2002, SCIENCE, V296, P1265, DOI 10.1126/science.1072457	68	228	241	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 20	2002	110	6					701	711		10.1016/S0092-8674(02)00941-8	http://dx.doi.org/10.1016/S0092-8674(02)00941-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	596TV	12297044	Bronze			2022-12-28	WOS:000178182800006
J	Bonnefoy, E; Lapostolle, F; Leizorovicz, A; Steg, G; McFadden, EP; Dubien, PY; Cattan, S; Boullenger, E; Machecourt, J; Lacroute, JM; Cassagnes, J; Dissait, F; Touboul, P				Bonnefoy, E; Lapostolle, F; Leizorovicz, A; Steg, G; McFadden, EP; Dubien, PY; Cattan, S; Boullenger, E; Machecourt, J; Lacroute, JM; Cassagnes, J; Dissait, F; Touboul, P		Comparison Angioplasty Prehospital	Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study	LANCET			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; PRIMARY CORONARY ANGIOPLASTY; THROMBOLYTIC THERAPY; IMMEDIATE ANGIOPLASTY; RESCUE ANGIOPLASTY; MORTALITY; MANAGEMENT; ALTEPLASE; TRIAL	Background Although both prehospital fibrinolysis and primary angioplasty provide a clinical benefit over in-hospital fibrinolysis in acute myocardial infarction, they have not been directly compared. Our aim was to find out whether primary angioplasty was better than prehospital fibrinolysis. Methods We did a randomised multicentre trial of 840 patients (of 1200 planned) who presented within 6 h of acute myocardial infarction with ST-segment elevation, initially managed by mobile emergency-care units. We assigned patients to prehospital fibrinolysis (n=419) with accelerated alteplase or primary angioplasty (n=421), and transferred all to a centre with access to emergency angioplasty. Our primary endpoint was a composite of death, non-fatal reinfarction, and non-fatal disabling stroke at 30 days. Analyses were by intention to treat. Findings The median delay between onset of symptoms and treatment was 130 min in the prehospital-fibrinolysis group and 190 min (time to first balloon inflation) in the primary-angioplasty group. Rescue angioplasty was done in 26% of the patients in the fibrinolysis group. The rate of the primary endpoint was 8.2% (34 patients) in the prehospital-fibrinolysis group and 6.2% (26 patients) in the primary-angioplasty group (risk difference 1.96, 95% Cl -1.53 to 5.46). 16 (3.8%) patients assigned prehospital fibrinolysis and 20 (4.8%) assigned primary angioplasty died (p=0.61). Interpretation A strategy of primary angioplasty was not better than a strategy of prehospital fibrinolysis (with transfer to an interventional facility for possible rescue angioplasty) in patients presenting with early myocardial infarction.	Hop Louis Pradel, Hospices Civils Lyon, Coronary Care Unit, Lyon, France; Hop Louis Pradel, Hospices Civils Lyon, Dept Cardiovasc Radiol, Lyon, France; Laennec Univ, Clin Pharmacol Unit, Lyon, France; SAMU 93, Bobigny, France; SAMU 31, Lyon, France; Hop Bichat Claude Bernard, F-75877 Paris, France; CHI Le Raincy, Montfermeil, France; SAMU 31, Toulouse, France; CHU Grenoble, F-38043 Grenoble, France; SAMU 38, Grenoble, France; CHU Clermont Ferrand, Clermont Ferrand, France; SAMU 63, Clermont Ferrand, France	CHU Lyon; CHU Lyon; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); CHU Clermont Ferrand	Touboul, P (corresponding author), Hop Cardiovasc & Pneumol Louis Pradel, BP Lyon Montchat, F-69394 Lyon, France.	paul.touboul@chu-lyon.fr		STEG, Philippe Gabriel/0000-0001-6896-2941				APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Bar F, 2000, J AM COLL CARDIOL, V36, P51, DOI 10.1016/S0735-1097(00)00718-X; Betriu A, 1997, NEW ENGL J MED, V336, P1621; Bode C, 1996, CIRCULATION, V94, P891, DOI 10.1161/01.CIR.94.5.891; Boersma E, 1996, LANCET, V348, P771, DOI 10.1016/S0140-6736(96)02514-7; Brass LM, 2000, STROKE, V31, P1802, DOI 10.1161/01.STR.31.8.1802; Cannon CP, 1998, CIRCULATION, V98, P2805, DOI 10.1161/01.CIR.98.25.2805; Cannon CP, 2000, JAMA-J AM MED ASSOC, V283, P2941, DOI 10.1001/jama.283.22.2941; Carli P, 1997, Acta Anaesthesiol Scand Suppl, V110, P69; den Heijer P, 1998, CIRCULATION, V98, P2117, DOI 10.1161/01.CIR.98.20.2117; ELLIS SG, 1994, CIRCULATION, V90, P2280, DOI 10.1161/01.CIR.90.5.2280; Every NR, 1996, NEW ENGL J MED, V335, P1253, DOI 10.1056/NEJM199610243351701; GIBBONS RJ, 1993, NEW ENGL J MED, V328, P685, DOI 10.1056/NEJM199303113281003; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; Juliard JM, 1999, AM J CARDIOL, V83, P305, DOI 10.1016/S0002-9149(98)00858-3; LEIZOROVICZ A, 1993, NEW ENGL J MED, V329, P383; Magid DJ, 2000, JAMA-J AM MED ASSOC, V284, P3131, DOI 10.1001/jama.284.24.3131; Montalescot G, 2001, NEW ENGL J MED, V344, P1895, DOI 10.1056/NEJM200106213442503; RAWLES J, 1994, J AM COLL CARDIOL, V23, P1, DOI 10.1016/0735-1097(94)90494-4; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; Ryan TJ, 1999, J AM COLL CARDIOL, V34, P890, DOI 10.1016/S0735-1097(99)00351-4; Van de Werf F, 1999, LANCET, V354, P716, DOI 10.1016/S0140-6736(99)07403-6; Van de Werf F, 2001, LANCET, V358, P605; Weaver WD, 1997, JAMA-J AM MED ASSOC, V278, P2093, DOI 10.1001/jama.278.23.2093; WEAVER WD, 1993, JAMA-J AM MED ASSOC, V270, P1211, DOI 10.1001/jama.270.10.1211; Zahn R, 2001, J AM COLL CARDIOL, V37, P1827, DOI 10.1016/S0735-1097(01)01264-5; ZIJLSTRA F, 1993, NEW ENGL J MED, V328, P680, DOI 10.1056/NEJM199303113281002; 2002, DANAMI 2 STUDY	28	417	456	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 14	2002	360	9336					825	829		10.1016/S0140-6736(02)09963-4	http://dx.doi.org/10.1016/S0140-6736(02)09963-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	594MC	12243916				2022-12-28	WOS:000178053500007
J	Cuzick, J; Forbes, J; Edwards, R; Baum, M; Cawthorn, S; Coates, A; Hamed, H; Howell, A; Powles, T; Clunie, G; Collins, R; Day, N; Northover, J				Cuzick, J; Forbes, J; Edwards, R; Baum, M; Cawthorn, S; Coates, A; Hamed, H; Howell, A; Powles, T; Clunie, G; Collins, R; Day, N; Northover, J		IBIS Investigators	First results from the International Breast Cancer Intervention Study (IBIS-1): a randomised prevention trial	LANCET			English	Article							POSTMENOPAUSAL WOMEN; TAMOXIFEN; RISK; REPLACEMENT; THERAPY; DISEASE; HEART	Background Three clinical trials on the use of tamoxifen to prevent breast cancer have reported mixed results. The overall evidence supports a reduction in the risk of breast cancer, but whether this benefit outweighs the risks and side-effects associated with tamoxifen is unclear. Methods We undertook a double-blind placebo-controlled randomised trial of tamoxifen, 20 mg/day for 5 years, in 7152 women aged 35-70 years, who were at increased risk of breast cancer. The primary outcome measure was the frequency of breast cancer (including ductal carcinoma in situ). Analyses were by intention to treat after exclusion of 13 women found to have breast cancer at baseline mammography. Findings After median follow-up of 50 months (IQR 32-67), 69 breast cancers had been diagnosed in 3578 women in the tamoxifen group and 101 in 3566 in the placebo group (risk reduction 32% [95% Cl 8-50]; p=0.013). Age, degree of risk, and use of hormone-replacement therapy did not affect the reduction. Endometrial cancer was non-significantly increased (11 vs 5; p=0.2) and thromboembolic events were significantly increased with tamoxifen (43 vs 17; odds ratio 2.5 [1.5-4.4], p=0.001), particularly after surgery. There was a significant excess of deaths from all causes in the tamoxifen group (25 vs 11, p=0.028). Interpretation Prophylactic tamoxifen reduces the risk of breast cancer by about a third. Temporary cessation of tamoxifen should be considered and the use of appropriate antithrombotic measures is recommended during and after major surgery or periods of immobilisation. Prophylactic use of tamoxifen is contraindicated in women at high risk of thromboembolic disease. The combined evidence indicates that mortality from non-breast-cancer causes is not increased by tamoxifen. The overall risk to benefit ratio for the use of tamoxifen in prevention is still unclear, and continued follow-up of the current trials is essential.	CTSU, Oxford, England; Strangeways Labs, Cambridge, England; St Marks Hosp, London EC1V 2PS, England	University of Oxford; Imperial College London	Cuzick, J (corresponding author), Canc Res UK, IBIS Trials Ctr, London WC2A 3PX, England.		Simes, Robert John/P-1497-2014; Ward, Robyn L/I-2313-2013	Ward, Robyn L/0000-0002-6877-8906; Evans, Gareth/0000-0002-8482-5784; Eccles, Diana M/0000-0002-9935-3169; Gilbert, Fiona/0000-0002-0124-9962				Baum M, 2002, LANCET, V359, P2131; Beatson G., 1896, LANCET, V2, P104, DOI DOI 10.1016/S0140-6736(01)72307-0; Cauley JA, 2001, BREAST CANCER RES TR, V65, P125, DOI 10.1023/A:1006478317173; Clarke M, 1998, LANCET, V351, P1451; CUZICK J, 1985, LANCET, V2, P282; Cuzick J, 2000, EUR J CANCER, V36, P1298, DOI 10.1016/S0959-8049(00)00106-4; CUZICK J, 1986, LANCET, V1, P83; CUZICK J, 1996, IARC SCI PUBL, V136, P95; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Grady D, 2000, ANN INTERN MED, V132, P689, DOI 10.7326/0003-4819-132-9-200005020-00002; LACASSAGNE A., 1936, AMER JOUR CANCER, V27, P217; Mosca L, 2001, CIRCULATION, V104, P499, DOI 10.1161/hc2901.092200; *NAT HLTH SERV, 2001, CLIN TERMS; PIKE MC, 1983, NATURE, V303, P767, DOI 10.1038/303767a0; Powles T, 1998, LANCET, V352, P98; POWLES TJ, 1990, EUR J CANCER, V26, P680, DOI 10.1016/0277-5379(90)90116-B; Thomas HV, 1997, BRIT J CANCER, V76, P401, DOI 10.1038/bjc.1997.398; Veronesi U, 1998, LANCET, V352, P93	18	548	582	0	25	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 14	2002	360	9336					817	824						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	594MC	12243915				2022-12-28	WOS:000178053500006
J	Eswaran, H; Wilson, JD; Preissl, H; Robinson, SE; Vrba, J; Murphy, P; Rose, DF; Lowery, CL				Eswaran, H; Wilson, JD; Preissl, H; Robinson, SE; Vrba, J; Murphy, P; Rose, DF; Lowery, CL			Magnetoencephalographic recordings of visual evoked brain activity in the human fetus	LANCET			English	Article							LIGHT STIMULATION	We investigated the feasibility of recording visual evoked brain activity in the human fetus by use of non-invasive magnetoencephalography (MEG). Each recording lasted 6 min and consisted of a sequence of 180 flashes with 33 ms duration delivered 2 s apart over the maternal abdomen. Four of ten fetuses included showed a response; the ranges of amplitude and latency of peak response were 15-30x10(-15) Tesla and 180-390 ms, respectively. Six fetuses showed no discernible response. With improvement, this method could aid in the testing of fetal neurological status throughout pregnancy.	Univ Arkansas Med Sci, Dept Obstet & Gynecol, Little Rock, AR 72205 USA; Univ Arkansas, Grad Inst Technol, Little Rock, AR 72204 USA; Univ Tubingen, Inst Med Psychol & Behav Neurobiol, MEG Ctr, Tubingen, Germany; CTF Syst, Port Coquitlam, BC, Canada; Childrens Hosp Med Ctr Cincinnati, Dept Pediat & Neurol, Cincinnati, OH USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Fayetteville; University of Arkansas Little Rock; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Lowery, CL (corresponding author), Univ Arkansas Med Sci, Dept Obstet & Gynecol, 4301 W Markham,Slot 518, Little Rock, AR 72205 USA.		Preißl, Hubert/E-9070-2012	Preißl, Hubert/0000-0002-8859-4661	NINDS NIH HHS [1R01NS36277] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036277] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLUM T, 1985, BRIT J OBSTET GYNAEC, V92, P1224, DOI 10.1111/j.1471-0528.1985.tb04866.x; Hykin J, 1999, LANCET, V354, P645, DOI 10.1016/S0140-6736(99)02901-3; Kiuchi M, 2000, EARLY HUM DEV, V58, P153, DOI 10.1016/S0378-3782(00)00074-8; PELEG D, 1980, J PERINAT MED, V8, P38; Shepherd AJ, 1999, DEV MED CHILD NEUROL, V41, P9, DOI 10.1017/S0012162299000031	5	62	62	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 7	2002	360	9335					779	780		10.1016/S0140-6736(02)09905-1	http://dx.doi.org/10.1016/S0140-6736(02)09905-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	592HX	12241838				2022-12-28	WOS:000177933000021
J	Krause, TG; Koch, A; Friborg, J; Poulsen, LK; Kristensen, B; Melbye, M				Krause, TG; Koch, A; Friborg, J; Poulsen, LK; Kristensen, B; Melbye, M			Frequency of atopy in the Arctic in 1987 and 1998	LANCET			English	Article							ALLERGY; IGE	Few studies have measured the frequency of atopy with objective measures, and most of these studies have been done in industrialised countries. We analysed serum samples from 859 15-80-year-old Greenlanders who had participated in population-based screening campaigns in 1987 and in 1998. We defined atopy as a positive result In an assay that tests for specific IgE against the eight most common inhalant allergens in one pool (grass, birch, mugwort, dog, cat, horse, Cladosporum herbarum, house dust mite). The frequency of atopy doubled between 1987 (39 [10%] of 392) and 1998 (87 [19%] of 467; risk ratio 1-88 [95% Cl 1.31-2.68]). This increase was largest in 15-19-year olds, but also occurred in older people, suggesting that the risk factors responsible for the increase in atopy do not operate only in childhood.	Statens Serum Inst, Dept Epidemiol Res, Danish Epidemiol Sci Ctr, DK-2300 Copenhagen S, Denmark; Natl Univ Hosp, Allergy Unit, Copenhagen, Denmark; Pharmacia, Copenhagen, Denmark	Aarhus University; Statens Serum Institut; Pfizer	Krause, TG (corresponding author), Statens Serum Inst, Dept Epidemiol Res, Danish Epidemiol Sci Ctr, Artillerivej 5, DK-2300 Copenhagen S, Denmark.		Poulsen, Lars K/J-3065-2019	Poulsen, Lars K/0000-0002-1730-847X; Koch, Anders/0000-0001-9205-1048; Friborg, Jeppe/0000-0001-5423-0627; melbye, mads/0000-0001-8264-6785				Linneberg A, 2000, J ALLERGY CLIN IMMUN, V106, P247, DOI 10.1067/mai.2000.108312; Misfeldt J, 1988, Arctic Med Res, V47, P173; Olsen O R, 2000, Ugeskr Laeger, V162, P4652; Paganelli R, 1998, ALLERGY, V53, P763; Wieringa MH, 2001, CLIN EXP ALLERGY, V31, P1553, DOI 10.1046/j.1365-2222.2001.01188.x	5	68	69	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 31	2002	360	9334					691	692		10.1016/S0140-6736(02)09841-0	http://dx.doi.org/10.1016/S0140-6736(02)09841-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	590AM	12241878				2022-12-28	WOS:000177795100013
J	Sicherer, SH				Sicherer, SH			Food allergy	LANCET			English	Review							COWS MILK PROTEIN; SKIN-PRICK TESTS; EOSINOPHIL CATIONIC PROTEIN; TREE NUT ALLERGY; 1ST 3 YEARS; NATURAL-HISTORY; PEANUT ALLERGY; IGE CONCENTRATIONS; ATOPIC-DERMATITIS; ORAL TOLERANCE	Food allergy encompasses a range of disorders that result from adverse immune responses to dietary antigens. This group of conditions Includes acute, potentially fatal reactions, and a host of chronic diseases that mainly affect the skin and gastrointestinal tract. Tools for diagnosis and management have not changed much in the past two decades, and include the clinical history, physical examination, tests for specific IgE antibody to suspected foods, elimination diets, oral food challenges, and provision of medications such as epinephrine for emergency treatment. However, much research in the past few years has enhanced our understanding of the clinical, epidemiological, and immunological aspects of these disorders. In this review I will discuss these advances and incorporate them into an improved diagnostic and management scheme. Additionally, emergent diagnostic, treatment, and prevention strategies are reviewed.	Mt Sinai Sch Med, Dept Pediat, Div Allergy & Immunol, Elliot Roslyn Jaffe Food Allergy Inst, New York, NY USA	Icahn School of Medicine at Mount Sinai	Sicherer, SH (corresponding author), Mt Sinai Hosp, Div Allergy & Immunol, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.	scott.sicherer@mssm.edu			NIAID NIH HHS [K23 AI 01709-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI001709] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABERNATHYCARVER KJ, 1995, J CLIN INVEST, V95, P913, DOI 10.1172/JCI117743; Adel-Patient K, 2001, INT ARCH ALLERGY IMM, V126, P59, DOI 10.1159/000049495; Asero R, 1999, ANN ALLERG ASTHMA IM, V83, P377, DOI 10.1016/S1081-1206(10)62834-7; Baker SS, 2000, PEDIATRICS, V106, P346; Bannon GA, 2001, INT ARCH ALLERGY IMM, V124, P70, DOI 10.1159/000053672; Barnes KC, 2000, ALLERGY, V55, P803, DOI 10.1034/j.1398-9995.2000.00123.x; Benlounes N, 1999, J ALLERGY CLIN IMMUN, V104, P863, DOI 10.1016/S0091-6749(99)70300-3; BERNHISELBROADBENT J, 1992, J ALLERGY CLIN IMMUN, V90, P622, DOI 10.1016/0091-6749(92)90135-O; Beyer KB, 2001, J ALLERGY CLIN IMMUN, V107, P1077, DOI 10.1067/mai.2001.115480; Bischoff SC, 1997, INT ARCH ALLERGY IMM, V113, P348, DOI 10.1159/000237598; *BOARD DIR AM AC A, 1998, J ALLERGY CLIN IMMUN, V102, P173; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; BOCK SA, 1978, CLIN ALLERGY, V8, P559, DOI 10.1111/j.1365-2222.1978.tb01509.x; BOCK SA, 1987, PEDIATRICS, V79, P683; Bottcher MF, 2000, CLIN EXP ALLERGY, V30, P1590, DOI 10.1046/j.1365-2222.2000.00982.x; Breiteneder H, 2000, J ALLERGY CLIN IMMUN, V106, P27, DOI 10.1067/mai.2000.106929; BRUIJNZEELKOOMEN C, 1995, ALLERGY, V50, P623, DOI 10.1111/j.1398-9995.1995.tb02579.x; Burks AW, 1999, INT ARCH ALLERGY IMM, V118, P313, DOI 10.1159/000024114; Caffarelli C, 2001, LANCET, V358, P1871, DOI 10.1016/S0140-6736(01)06897-0; Caffarelli C, 2001, ANN ALLERG ASTHMA IM, V86, P665, DOI 10.1016/S1081-1206(10)62296-X; Casale TB, 2001, JAMA-J AM MED ASSOC, V286, P2956, DOI 10.1001/jama.286.23.2956; CHAMPION RH, 1969, BRIT J DERMATOL, V81, P588, DOI 10.1111/j.1365-2133.1969.tb16041.x; Chatchatee P, 2001, J ALLERGY CLIN IMMUN, V107, P379, DOI 10.1067/mai.2001.112372; Chung HL, 2002, J ALLERGY CLIN IMMUN, V109, P150, DOI 10.1067/mai.2002.120562; Cooke SK, 1997, J IMMUNOL, V159, P2026; Cookson WOC, 2000, HUM MOL GENET, V9, P2359, DOI 10.1093/hmg/9.16.2359; DAVID TJ, 1984, ARCH DIS CHILD, V59, P983, DOI 10.1136/adc.59.10.983; Egan CA, 2001, AM J GASTROENTEROL, V96, P1927, DOI 10.1016/S0002-9270(01)02460-1; Eggesbo M, 2001, ALLERGY, V56, P403, DOI 10.1034/j.1398-9995.2001.056005403.x; Eggesbo M, 2001, ALLERGY, V56, P393, DOI 10.1034/j.1398-9995.2001.056005393.x; Eigenmann PA, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.3.e8; Eigenmann PA, 1998, PEDIAT ALLERG IMM-UK, V9, P186, DOI 10.1111/j.1399-3038.1998.tb00371.x; Emmett SE, 1999, ALLERGY, V54, P380, DOI 10.1034/j.1398-9995.1999.00768.x; Ewan PW, 2001, LANCET, V357, P111, DOI 10.1016/S0140-6736(00)03543-1; Farrell RJ, 2002, NEW ENGL J MED, V346, P180, DOI 10.1056/NEJMra010852; FERGUSSON DM, 1990, PEDIATRICS, V86, P541; Fernandez-Rivas M, 1999, CLIN EXP ALLERGY, V29, P1239, DOI 10.1046/j.1365-2222.1999.00628.x; Garcia-Ara C, 2001, J ALLERGY CLIN IMMUN, V107, P185, DOI 10.1067/mai.2001.111592; Gdalevich M, 2001, J PEDIATR-US, V139, P261, DOI 10.1067/mpd.2001.117006; Gdalevich M, 2001, J AM ACAD DERMATOL, V45, P520, DOI 10.1067/mjd.2001.114741; Harada S, 2001, BRIT J DERMATOL, V145, P336, DOI 10.1046/j.1365-2133.2001.04329.x; Hattevig G, 1999, ACTA PAEDIATR, V88, P7, DOI 10.1080/080352599750029268; Hide DW, 1996, ALLERGY, V51, P89, DOI 10.1111/j.1398-9995.1996.tb04563.x; Hidvegi E, 2001, J PEDIATR GASTR NUTR, V32, P475, DOI 10.1097/00005176-200104000-00016; Hill DJ, 1999, J PEDIATR-US, V135, P118, DOI 10.1016/S0022-3476(99)70341-0; Host A, 1999, ARCH DIS CHILD, V81, P80, DOI 10.1136/adc.81.1.80; HOST A, 1990, ALLERGY, V45, P587, DOI 10.1111/j.1398-9995.1990.tb00944.x; Hourihane JO, 1998, BRIT MED J, V316, P1271, DOI 10.1136/bmj.316.7140.1271; Howell WM, 1998, CLIN EXP ALLERGY, V28, P156, DOI 10.1046/j.1365-2222.1998.00224.x; HUSBY S, 1994, J IMMUNOL, V152, P4663; Husby S, 2000, J PEDIATR GASTR NUTR, V30, pS13, DOI 10.1097/00005176-200001001-00003; Iacono G, 1998, NEW ENGL J MED, V339, P1100, DOI 10.1056/NEJM199810153391602; Iacono G, 1996, J ALLERGY CLIN IMMUN, V97, P822, DOI 10.1016/S0091-6749(96)80160-6; Inobe J, 1998, EUR J IMMUNOL, V28, P2780, DOI 10.1002/(SICI)1521-4141(199809)28:09<2780::AID-IMMU2780>3.0.CO;2-J; Isolauri E, 1999, J PEDIATR-US, V134, P27, DOI 10.1016/S0022-3476(99)70368-9; Isolauri E, 1996, J ALLERGY CLIN IMMUN, V97, P9, DOI 10.1016/S0091-6749(96)70277-4; JAKOBSSON I, 1979, ACTA PAEDIATR SCAND, V68, P853; JAMES JM, 1994, AM J RESP CRIT CARE, V149, P59, DOI 10.1164/ajrccm.149.1.8111598; Jarvinen KM, 2000, PEDIATR RES, V48, P457, DOI 10.1203/00006450-200010000-00007; *JOINT TASK FORC P, 1998, J ALLERGY CLIN IMMUN, V101, pS465; Jones CA, 2001, J ALLERGY CLIN IMMUN, V108, P235, DOI 10.1067/mai.2001.117178; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kanny G, 2001, J ALLERGY CLIN IMMUN, V108, P133, DOI 10.1067/mai.2001.116427; Kazemi-Shirazi L, 2000, J ALLERGY CLIN IMMUN, V105, P116, DOI 10.1016/S0091-6749(00)90186-6; KEMP SF, 1995, ARCH INTERN MED, V155, P1749, DOI 10.1001/archinte.155.16.1749; Kokkonen J, 2001, J PEDIATR-US, V139, P797, DOI 10.1067/mpd.2001.118882; LAKE AM, 1982, J PEDIATR-US, V101, P906, DOI 10.1016/S0022-3476(82)80008-5; Lever R, 1998, PEDIATR ALLERGY IMMU, V9, P13, DOI 10.1111/j.1399-3038.1998.tb00294.x; Li XM, 1999, J IMMUNOL, V162, P3045; Li XM, 2001, J ALLERGY CLIN IMMUN, V108, P639, DOI 10.1067/mai.2001.118787; LILJA G, 1989, CLIN EXP ALLERGY, V19, P473, DOI 10.1111/j.1365-2222.1989.tb02416.x; Lin XP, 2002, J ALLERGY CLIN IMMUN, V109, P879, DOI 10.1067/mai.2002.123238; Majamaa H, 2001, CLIN EXP ALLERGY, V31, P590, DOI 10.1046/j.1365-2222.2001.01035.x; Maleki SJ, 2000, J ALLERGY CLIN IMMUN, V106, P763, DOI 10.1067/mai.2000.109620; Martinez TB, 2001, CLIN EXP ALLERGY, V31, P1464; Mayer L, 2001, ALLERGY, V56, P12, DOI 10.1111/j.1398-9995.2001.00904.x; Mishra A, 2001, J CLIN INVEST, V107, P83, DOI 10.1172/JCI10224; Nagata S, 2000, J IMMUNOL, V165, P5315, DOI 10.4049/jimmunol.165.9.5315; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; NOVEMBRE E, 1988, J ALLERGY CLIN IMMUN, V81, P1059, DOI 10.1016/0091-6749(88)90181-9; Orenstein SR, 2000, AM J GASTROENTEROL, V95, P1422; ORTOLANI C, 1989, J ALLERGY CLIN IMMUN, V83, P683, DOI 10.1016/0091-6749(89)90083-3; ORTOLANI C, 1988, ANN ALLERGY, V61, P47; Palosuo K, 2001, J ALLERGY CLIN IMMUN, V108, P634, DOI 10.1067/mai.2001.118602; Planchon S, 1999, J CELL PHYSIOL, V181, P55, DOI 10.1002/(SICI)1097-4652(199910)181:1<55::AID-JCP6>3.3.CO;2-D; POWELL GK, 1978, J PEDIATR-US, V93, P553, DOI 10.1016/S0022-3476(78)80887-7; Pumphrey RSH, 1996, CLIN EXP ALLERGY, V26, P1364, DOI 10.1111/j.1365-2222.1996.tb00537.x; Pumphrey RSH, 2000, CLIN EXP ALLERGY, V30, P1144, DOI 10.1046/j.1365-2222.2000.00864.x; Reekers R, 1999, J ALLERGY CLIN IMMUN, V104, P466, DOI 10.1016/S0091-6749(99)70395-7; Roehr CC, 2001, J ALLERGY CLIN IMMUN, V107, P548, DOI 10.1067/mai.2001.112849; Romano A, 2001, INT ARCH ALLERGY IMM, V125, P264, DOI 10.1159/000053825; Roy K, 1999, NAT MED, V5, P387, DOI 10.1038/7385; Rudloff S, 1999, ALLERGY, V54, P206, DOI 10.1034/j.1398-9995.1999.00765.x; Saarinen KM, 2001, CLIN EXP ALLERGY, V31, P423, DOI 10.1046/j.1365-2222.2001.01015.x; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P981, DOI 10.1016/S0091-6749(99)70167-3; SAMPSON HA, 1989, J PEDIATR-US, V115, P23, DOI 10.1016/S0022-3476(89)80323-3; SAMPSON HA, 1984, J ALLERGY CLIN IMMUN, V74, P26, DOI 10.1016/0091-6749(84)90083-6; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444, DOI 10.1016/S0091-6749(97)70133-7; Sampson HA, 2001, GASTROENTEROLOGY, V120, P1026, DOI 10.1053/gast.2001.23031; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sampson HA, 2000, J PEDIATR GASTR NUTR, V30, pS87, DOI 10.1097/00005176-200001001-00013; SAMPSON HA, 1999, LUNG BIOL HEALTH DIS, V123, P95; SCHRANDER JJP, 1993, EUR J PEDIATR, V152, P640, DOI 10.1007/BF01955238; Schwab D, 2001, AM J GASTROENTEROL, V96, P508, DOI 10.1111/j.1572-0241.2001.03467.x; SEHGAL VN, 1973, ANN ALLERGY, V31, P279; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V104, pS114, DOI 10.1016/S0091-6749(99)70053-9; Sicherer SH, 2000, PEDIATRICS, V105, P359, DOI 10.1542/peds.105.2.359; Sicherer SH, 2000, J ALLERGY CLIN IMMUN, V106, P53, DOI [10.1067/mai.2000.108105, 10.1067/mai.2000.110158]; Sicherer SH, 1999, CLIN EXP ALLERGY, V29, P507, DOI 10.1046/j.1365-2222.1999.00520.x; Sicherer SH, 1998, J PEDIATR-US, V133, P214, DOI 10.1016/S0022-3476(98)70222-7; Sicherer SH, 1999, PEDIAT ALLERG IMM-UK, V10, P226, DOI 10.1034/j.1399-3038.1999.00040.x; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P881, DOI 10.1067/mai.2001.118515; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P128, DOI 10.1067/mai.2001.115755; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; SIGURS N, 1992, PEDIATRICS, V89, P735; Simonato B, 2001, CLIN EXP ALLERGY, V31, P1771, DOI 10.1046/j.1365-2222.2001.01200.x; Simons FER, 1998, J ALLERGY CLIN IMMUN, V101, P33, DOI 10.1016/S0091-6749(98)70190-3; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; Spergel JM, 2002, J ALLERGY CLIN IMMUN, V109, P363, DOI 10.1067/mai.2002.121458; Sporik R, 2000, CLIN EXP ALLERGY, V30, P1540, DOI 10.1046/j.1365-2222.2000.00928.x; Strobel S, 1998, IMMUNOL TODAY, V19, P173, DOI 10.1016/S0167-5699(97)01239-5; Strober W, 1998, J CLIN IMMUNOL, V18, P1, DOI 10.1023/A:1023222003039; Taylor SL, 2001, J ALLERGY CLIN IMMUN, V107, P765, DOI 10.1067/mai.2001.114241; TERR AI, 1996, ALLERGY ASTHMA IMMUN, P749; Urisu A, 1997, J ALLERGY CLIN IMMUN, V100, P171, DOI 10.1016/S0091-6749(97)70220-3; Vadas P, 2001, JAMA-J AM MED ASSOC, V285, P1746, DOI 10.1001/jama.285.13.1746; Vila L, 2001, CLIN EXP ALLERGY, V31, P1599, DOI 10.1046/j.1365-2222.2001.01218.x; Vila L, 2001, ALLERGY, V56, P568, DOI 10.1034/j.1398-9995.2001.056006568.x; Wahn U, 2001, J ALLERGY CLIN IMMUN, V107, P567, DOI 10.1067/mai.2001.112943; WALKERSMITH JA, 1992, J PEDIATR-US, V121, pS111, DOI 10.1016/S0022-3476(05)81418-0; Woods RK, 2001, EUR J CLIN NUTR, V55, P298, DOI 10.1038/sj.ejcn.1601159; Wright AL, 1999, J ALLERGY CLIN IMMUN, V104, P589, DOI 10.1016/S0091-6749(99)70328-3; Yocum MW, 1999, J ALLERGY CLIN IMMUN, V104, P452, DOI 10.1016/S0091-6749(99)70392-1; YOUNG E, 1987, J ROY COLL PHYS LOND, V21, P241; YOUNG E, 1994, LANCET, V343, P1127, DOI 10.1016/S0140-6736(94)90234-8; Yu LCH, 2001, GASTROENTEROLOGY, V121, P370, DOI 10.1053/gast.2001.26470; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450; Zeiger R, 1992, PEDIAT ALLERG IMM-UK, V3, P110, DOI [DOI 10.1111/J.1399-3038.1992.TB00035.X, 10.1111/j.1399-3038.1992.tb00035.x]; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9	141	198	209	0	34	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 31	2002	360	9334					701	710		10.1016/S0140-6736(02)09831-8	http://dx.doi.org/10.1016/S0140-6736(02)09831-8			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	590AM	12241890				2022-12-28	WOS:000177795100025
J	Weiner, S; Addadi, L				Weiner, S; Addadi, L			At the cutting edge	SCIENCE			English	Editorial Material									Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Weiner, S (corresponding author), Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel.							BRYAN GW, 1979, J MAR BIOL ASSOC UK, V59, P969, DOI 10.1017/S0025315400036961; CHISHOLM JE, 1987, MINERAL MAG, V51, P715, DOI 10.1180/minmag.1987.051.363.12; HILLERTON JE, 1982, J EXP BIOL, V101, P333; Lichtenegger HC, 2002, SCIENCE, V298, P389, DOI 10.1126/science.1075433; LOWENSTAM HA, 1962, GEOL SOC AM BULL, V73, P435, DOI 10.1130/0016-7606(1962)73[435:MIDCIR]2.0.CO;2; Lowenstam HA, 1989, BIOMINERALIZATION; Voss-Foucart M.-F., 1973, Biochemical Syst, V1, P119, DOI 10.1016/0305-1978(73)90025-2; Weiner S, 1998, ANNU REV MATER SCI, V28, P271, DOI 10.1146/annurev.matsci.28.1.271	8	36	38	2	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 11	2002	298	5592					375	376		10.1126/science.1078093	http://dx.doi.org/10.1126/science.1078093			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	602NB	12376692				2022-12-28	WOS:000178510400036
J	Liu, YG; Daum, PH				Liu, YG; Daum, PH			Anthropogenica erosols - Indirect warming effect from dispersion forcing	NATURE			English	Article							CLOUD SUSCEPTIBILITY; EFFECTIVE RADIUS; MARINE STRATUS; PARAMETERIZATION; AEROSOLS; CONTRASTS; CLIMATE; ALBEDO; TRACKS		Brookhaven Natl Lab, Upton, NY 11973 USA	United States Department of Energy (DOE); Brookhaven National Laboratory	Liu, YG (corresponding author), Brookhaven Natl Lab, Upton, NY 11973 USA.		Liu, Yangang/H-6154-2011					Ackerman AS, 2000, J ATMOS SCI, V57, P2684, DOI 10.1175/1520-0469(2000)057<2684:EOAOCA>2.0.CO;2; CHARLSON RJ, 1992, SCIENCE, V255, P423, DOI 10.1126/science.255.5043.423; GARRETT TJ, 1995, J ATMOS SCI, V52, P2977, DOI 10.1175/1520-0469(1995)052<2977:LRTOCA>2.0.CO;2; HUDSON JG, 1995, J ATMOS SCI, V52, P3031, DOI 10.1175/1520-0469(1995)052<3031:MCIAS>2.0.CO;2; Hudson JG, 1997, J ATMOS SCI, V54, P2642, DOI 10.1175/1520-0469(1997)054<2642:DSBIMS>2.0.CO;2; Hudson JG, 2001, J ATMOS SCI, V58, P915, DOI 10.1175/1520-0469(2001)058<0915:MCDCIS>2.0.CO;2; LIU Y, 2000, P 13 INT C CLOUDS PR, P586; Liu YG, 2000, GEOPHYS RES LETT, V27, P1903, DOI 10.1029/1999GL011011; MARTIN GM, 1994, J ATMOS SCI, V51, P1823, DOI 10.1175/1520-0469(1994)051<1823:TMAPOE>2.0.CO;2; McFarquhar GM, 2001, J GEOPHYS RES-ATMOS, V106, P28675, DOI 10.1029/2000JD900777; Noone KJ, 2000, J ATMOS SCI, V57, P2748, DOI 10.1175/1520-0469(2000)057<2748:ACSOST>2.0.CO;2; Noone KJ, 2000, J ATMOS SCI, V57, P2729, DOI 10.1175/1520-0469(2000)057<2729:ACSOSF>2.0.CO;2; NOONKESTER VR, 1984, J ATMOS SCI, V41, P829, DOI 10.1175/1520-0469(1984)041<0829:DSOIMS>2.0.CO;2; TWOMEY S, 1974, ATMOS ENVIRON, V8, P1251, DOI 10.1016/0004-6981(74)90004-3; Yum SS, 2001, ATMOS RES, V57, P81, DOI 10.1016/S0169-8095(00)00099-5	15	163	173	3	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 10	2002	419	6907					580	581		10.1038/419580a	http://dx.doi.org/10.1038/419580a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	602AT	12374969				2022-12-28	WOS:000178483100033
J	Castellanos, FX; Lee, PP; Sharp, W; Jeffries, NO; Greenstein, DK; Clasen, LS; Blumenthal, JD; James, RS; Ebens, CL; Walter, JM; Zijdenbos, A; Evans, AC; Giedd, JN; Rapoport, JL				Castellanos, FX; Lee, PP; Sharp, W; Jeffries, NO; Greenstein, DK; Clasen, LS; Blumenthal, JD; James, RS; Ebens, CL; Walter, JM; Zijdenbos, A; Evans, AC; Giedd, JN; Rapoport, JL			Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/hyperactivity disorder	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEFICIT-HYPERACTIVITY DISORDER; CHILDHOOD-ONSET SCHIZOPHRENIA; CORPUS-CALLOSUM MORPHOLOGY; MORPHOMETRIC ANALYSIS; QUANTITATIVE MORPHOLOGY; CAUDATE-NUCLEUS; BASAL GANGLIA; MRI; ASYMMETRY; VOXEL	Context Various anatomic brain abnormalities have been reported for attention-deficit/hyperactivity disorder (ADHD), with varying methods, small samples, cross-sectional designs, and without accounting for stimulant drug exposure. Objective To compare regional brain volumes at initial scan and their change over time in medicated and previously unmedicated male and female patients with ADHD and healthy controls. Design, Setting, and Participants Case-control study conducted from 19912001 at the National Institute of Mental Health, Bethesda, Md, of 152 children and adolescents with ADHD (age range, 5-18 years) and 139 age- and sex-matched controls (age range, 4.5-19 years) recruited from the local community, who contributed 544 anatomic magnetic resonance images. Main Outcome Measures Using completely automated methods, initial volumes and prospective age-related changes of total cerebrum, cerebellum, gray and white matter for the 4 major lobes, and caudate nucleus of the brain were compared in patients and controls. Results On initial scan, patients with ADHD had significantly smaller brain volumes in all regions, even after adjustment for significant covariates. This global difference was reflected in smaller total cerebral volumes (-3.2%, adjusted F-1,F-280=8.30, P=.004) and in significantly smaller cerebellar volumes (-3.5%, adjusted F-1,F-280=12.29, P=.001). Compared with controls, previously unmedicated children with ADHD demonstrated significantly smaller total cerebral volumes (overall F-2,F-288=6.65; all pairwise comparisons Bonferroni corrected, -5.8%; P=.002) and cerebellar volumes (-6.2%, F-2,F-288=8.97, P<.001). Unmedicated children with ADHD also exhibited strikingly smaller total white matter volumes (F-2,F-288= 11.65) compared with controls (-10.7%, P<.001) and with medicated children with ADHD (-8.9%, P<.001). Volumetric abnormalities persisted with age in total and regional cerebral measures (P=.002) and in the cerebellum (P=.003). Caudate nucleus volumes were initially abnormal for patients with ADHD (P=.05), but diagnostic differences disappeared as caudate volumes decreased for patients and controls during adolescence. Results were comparable for male and female patients on all measures. Frontal and temporal gray matter, caudate, and cerebellar volumes correlated significantly with parent- and clinician-rated severity measures within the ADHD sample (Pearson coefficients between -0.16 and -0.26; all P values were <.05). Conclusions Developmental trajectories for all structures, except caudate, remain roughly parallel for patients and controls during childhood and adolescence, suggesting that genetic and/or early environmental influences on brain development in ADHD are fixed, nonprogressive, and unrelated to stimulant treatment.	NIMH, Child Psychiat Branch, NIH, Bethesda, MD 20892 USA; NINDS, Biostat Branch, NIH, Bethesda, MD 20892 USA; McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); McGill University	Castellanos, FX (corresponding author), NYU, Ctr Child Study, 577 1st Ave, New York, NY 10016 USA.		Giedd, Jay N/B-7302-2012; Evans, Alan C/B-2373-2013; Castellanos, Francisco Xavier/K-1892-2014; Giedd, Jay N./A-3080-2008; Giedd, Jay/J-9644-2015	Giedd, Jay N/0000-0003-0827-3460; Evans, Alan C/0000-0003-3841-6098; Castellanos, Francisco Xavier/0000-0001-9192-9437; Giedd, Jay/0000-0003-2002-8978; Ebens, Christen/0000-0003-2430-911X	NATIONAL INSTITUTE OF MENTAL HEALTH [Z01MH000178] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Achenbach T M, 2000, Pediatr Rev, V21, P265, DOI 10.1542/pir.21-8-265; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Aylward EH, 1996, J CHILD NEUROL, V11, P112, DOI 10.1177/088307389601100210; Baumeister AA, 2001, CLIN NEUROPHARMACOL, V24, P2, DOI 10.1097/00002826-200101000-00002; Baumgardner TL, 1996, NEUROLOGY, V47, P477, DOI 10.1212/WNL.47.2.477; Berquin PC, 1998, NEUROLOGY, V50, P1087, DOI 10.1212/WNL.50.4.1087; Breggin PR, 1998, TALKING BACK RITALIN; Bullmore ET, 1999, IEEE T MED IMAGING, V18, P32, DOI 10.1109/42.750253; Bush G, 1999, BIOL PSYCHIAT, V45, P1542, DOI 10.1016/S0006-3223(99)00083-9; Casey BJ, 1997, J AM ACAD CHILD PSY, V36, P374, DOI 10.1097/00004583-199703000-00016; Castellanos FX, 2001, ARCH GEN PSYCHIAT, V58, P289, DOI 10.1001/archpsyc.58.3.289; CASTELLANOS FX, 1994, AM J PSYCHIAT, V151, P1791; Castellanos FX, 2002, NAT REV NEUROSCI, V3, P617, DOI 10.1038/nrn896; Castellanos FX, 1996, ARCH GEN PSYCHIAT, V53, P607; *CLIN GLOB IMPR, 1985, PSYCHO B, V21, P839; COLLINS DL, 1994, J COMPUT ASSIST TOMO, V18, P192, DOI 10.1097/00004728-199403000-00005; Collins DL, 1995, HUM BRAIN MAPP, V3, P190, DOI 10.1002/hbm.460030304; Conners C.K., 1997, CONNERS RATING SCALE; DENCKLA MB, 1985, PSYCHOPHARMACOL BULL, V21, P773; Diggle PJ, 1994, ANAL LONGITUDINAL DA; Eaton WO, 2001, DEV REV, V21, P205, DOI 10.1006/drev.2000.0519; Filipek PA, 1997, NEUROLOGY, V48, P589, DOI 10.1212/WNL.48.3.589; GIEDD JN, 1994, AM J PSYCHIAT, V151, P665; Giedd JN, 1999, BIOL PSYCHIAT, V46, P892, DOI 10.1016/S0006-3223(99)00072-4; Giedd JN, 1999, PROG NEURO-PSYCHOPH, V23, P571; Good CD, 2001, NEUROIMAGE, V14, P685, DOI 10.1006/nimg.2001.0857; HAND D, 1996, PRACTICAL LONGITUDIN; HART EL, 1995, J ABNORM CHILD PSYCH, V23, P729, DOI 10.1007/BF01447474; HYND GW, 1991, J LEARN DISABIL, V24, P141, DOI 10.1177/002221949102400302; HYND GW, 1990, ARCH NEUROL-CHICAGO, V47, P919, DOI 10.1001/archneur.1990.00530080107018; HYND GW, 1993, J CHILD NEUROL, V8, P339, DOI 10.1177/088307389300800409; KRUESI MJP, 1990, J AM ACAD CHILD PSY, V29, P449, DOI 10.1097/00004583-199005000-00017; Lange N, 1997, PSYCHIAT RES-NEUROIM, V74, P1, DOI 10.1016/S0925-4927(96)03054-5; Lyoo IK, 1996, BIOL PSYCHIAT, V40, P1060; Mostofsky SH, 1998, J CHILD NEUROL, V13, P434, DOI 10.1177/088307389801300904; Nopoulos P, 2000, PSYCHIAT RES-NEUROIM, V98, P1, DOI 10.1016/S0925-4927(99)00044-X; Overmeyer S, 2001, PSYCHOL MED, V31, P1425, DOI 10.1017/S0033291701004706; Paus T, 1999, SCIENCE, V283, P1908, DOI 10.1126/science.283.5409.1908; Paus T, 2001, BRAIN RES BULL, V54, P255, DOI 10.1016/S0361-9230(00)00434-2; Rapoport JL, 1999, ARCH GEN PSYCHIAT, V56, P649, DOI 10.1001/archpsyc.56.7.649; Reich W, 2000, J AM ACAD CHILD PSY, V39, P59, DOI 10.1097/00004583-200001000-00017; REYNOLDS CR, 1984, J SPEC EDUC, V18, P451, DOI 10.1177/002246698401800403; Rubia K, 1999, AM J PSYCHIAT, V156, P891, DOI 10.1176/ajp.156.6.891; SEMRUDCLIKEMAN M, 1994, J AM ACAD CHILD PSY, V33, P875, DOI 10.1097/00004583-199407000-00014; Sharp WS, 1999, J AM ACAD CHILD PSY, V38, P40, DOI 10.1097/00004583-199901000-00018; Tannock R, 1998, J CHILD PSYCHOL PSYC, V39, P65, DOI 10.1017/S0021963097001777; Teicher MH, 2000, NAT MED, V6, P470, DOI 10.1038/74737; Wechsler D., 1974, MANUAL WECHSLER INTE; Wechsler D., 1967, WPPSI MANUAL WECHSLE; Wechsler D., 2007, WASI 2 WECHSLER ABBR; Wechsler D., 1981, WAIS R MANUAL WECHSL; Wechsler D., 1991, WISC 3 WECHSLER INTE; WERRY JS, 1975, J ABNORM CHILD PSYCH, V3, P217	53	1040	1064	1	177	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	2002	288	14					1740	1748		10.1001/jama.288.14.1740	http://dx.doi.org/10.1001/jama.288.14.1740			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	602BJ	12365958	Bronze			2022-12-28	WOS:000178484700027
J	Freedman, DS; Khan, LK; Serdula, MK; Galuska, DA; Dietz, WH				Freedman, DS; Khan, LK; Serdula, MK; Galuska, DA; Dietz, WH			Trends and correlates of class 3 obesity in the United States from 1990 through 2000	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BODY-MASS INDEX; SELF-REPORTED HEIGHT; SOCIOECONOMIC-STATUS; RELATIVE WEIGHT; US ADULTS; OVERWEIGHT; MORTALITY; HEALTH; ADIPOSITY; POPULATION	Context Although the prevalence of obesity has markedly increased among US adults, health risks vary according to the severity of obesity. Persons with class 3 obesity (body mass index [BMI] greater than or equal to 40) are at greatest risk, but there is little information about this subgroup. Objective To examine correlates of class 3 obesity and secular trends. Design, Setting, and Participants Adults (aged greater than or equal to 18 years) in the United States who participated in the Behavioral Risk Factor Surveillance System telephone survey between 1990 (75600 persons) and 2000 (164250 persons). Main Outcome Measure Body mass index calculated from self-reported weight and height. Results The prevalence of class 3 obesity increased from 0.78% (1990) to 2.2% (2000). In 2000, class 3 obesity was highest among black women (6.0%), persons who had not completed high school (3.4%), and persons who are short. During the 11-year period, the median BMI level increased by 1.2 units and the 95th percentile increased by 3.2 units. Conclusion The prevalence of class 3 obesity is increasing rapidly among adults. Because these extreme BMI levels are associated with the most severe. health complications, the incidence of various diseases will increase substantially in the future.	Ctr Dis Control & Prevent, Div Nutr & Phys Act, Atlanta, GA USA	Centers for Disease Control & Prevention - USA	Freedman, DS (corresponding author), CDC, Mailstop K-26,4770 Buford Hwy, Atlanta, GA 30341 USA.			Freedman, David/0000-0001-8014-0289				[Anonymous], 2001, NIH PUBL; BILLEWICZ WZ, 1962, BRIT J PREV SOC MED, V16, P183; Bowlin SJ, 1996, J CLIN EPIDEMIOL, V49, P511, DOI 10.1016/0895-4356(96)00010-8; BRAY GA, 1997, HDB OBESITY, P31; Calle EE, 1999, NEW ENGL J MED, V341, P1097, DOI 10.1056/NEJM199910073411501; Cleveland W.S., 1985, ELEMENTS GRAPHING DA, P135; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; Flegal KM, 1999, MED SCI SPORT EXER, V31, pS509, DOI 10.1097/00005768-199911001-00004; Flegal KM, 2000, INT J OBESITY, V24, P807, DOI 10.1038/sj.ijo.0801232; Folsom AR, 1996, INT J OBESITY, V20, P704; Freedman DS, 1997, PEDIATRICS, V99, P420, DOI 10.1542/peds.99.3.420; FREEMAN JV, 1995, INT J EPIDEMIOL, V24, P970, DOI 10.1093/ije/24.5.970; Galuska DA, 1996, AM J PUBLIC HEALTH, V86, P1729, DOI 10.2105/AJPH.86.12.1729; Gentry E M, 1985, Am J Prev Med, V1, P9; GutierrezFisac JL, 1996, J CLIN EPIDEMIOL, V49, P351, DOI 10.1016/0895-4356(95)00535-8; Kuczmarski MF, 2001, J AM DIET ASSOC, V101, P28, DOI 10.1016/S0002-8223(01)00008-6; Kuczmarski RJ, 2000, AM J CLIN NUTR, V72, P1074; Lahmann PH, 2000, INT J OBESITY, V24, P685, DOI 10.1038/sj.ijo.0801219; Lauderdale DS, 2000, INT J OBESITY, V24, P1188, DOI 10.1038/sj.ijo.0801365; LEDERMAN SA, 2000, OBSTET GYNECOL, V24, P685; LEE IM, 1993, JAMA-J AM MED ASSOC, V270, P2823, DOI 10.1001/jama.270.23.2823; Lewis CE, 2000, AM J EPIDEMIOL, V151, P1172, DOI 10.1093/oxfordjournals.aje.a010167; Maillard G, 1999, INT J OBESITY, V23, P389, DOI 10.1038/sj.ijo.0800831; Martorell R, 2000, EUR J CLIN NUTR, V54, P247, DOI 10.1038/sj.ejcn.1600931; Mokdad AH, 2001, JAMA-J AM MED ASSOC, V286, P1195, DOI 10.1001/jama.286.10.1195; Must A, 1999, JAMA-J AM MED ASSOC, V282, P1523, DOI 10.1001/jama.282.16.1523; Nieto-Garcia F J, 1990, Epidemiology, V1, P146, DOI 10.1097/00001648-199003000-00011; NIH Consensus Development Conference Panel, 1992, AM J CLIN NUTR, V55, p615S; Rahkonen O, 1998, J PUBLIC HEALTH POL, V19, P88, DOI 10.2307/3343091; REMINGTON PL, 1988, PUBLIC HEALTH REP, V103, P366; ROWLAND ML, 1990, AM J CLIN NUTR, V52, P1125, DOI 10.1093/ajcn/52.6.1125; Shah BV, 1997, SUDAAN USERS MANUAL; SJOSTROM L V, 1992, American Journal of Clinical Nutrition, V55, p508S, DOI 10.1093/ajcn/55.2.508s; SOBAL J, 1989, PSYCHOL BULL, V105, P260, DOI 10.1037/0033-2909.105.2.260; STEWART AW, 1987, AM J EPIDEMIOL, V125, P122, DOI 10.1093/oxfordjournals.aje.a114494; Strawbridge WJ, 2000, AM J PUBLIC HEALTH, V90, P340, DOI 10.2105/AJPH.90.3.340; Welborn TA, 2000, INT J OBESITY, V24, P108, DOI 10.1038/sj.ijo.0801093; World Health Organization Expert Committee on Physical Status, 1995, WHO TECHN REP SER, V854; 1999, PREVALENCE OVERWEIGH	39	323	326	1	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 9	2002	288	14					1758	1761		10.1001/jama.288.14.1758	http://dx.doi.org/10.1001/jama.288.14.1758			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	602BJ	12365960				2022-12-28	WOS:000178484700029
J	Savulescu, J				Savulescu, J			Deaf lesbians, "designer disability" and the future of medicine	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DISEASE	With the completion of the human genome project, the genetic basis of disease is becoming better understood. Genetic tests for disabilities are increasingly becoming available to allow couples with a family history of genetic disease to select healthy offspring. But some couples wish to select for disability. Might there be good reasons for acceding to such requests?.	Oxford Ctr Appl Eth, Oxford OX1 1PT, England	University of Oxford	Savulescu, J (corresponding author), Oxford Ctr Appl Eth, Oxford OX1 1PT, England.	julian.savulescu@philosophy.oxford.ac.uk						BARRY E, 2002, HERALD SUN      0410, P15; Boyd KM, 2001, J MED ETHICS, V27, P361, DOI 10.1136/jme.27.6.361; Davis D., 2001, GENETIC DILEMMAS REP; Diesfeld K, 2001, J MED ETHICS, V27, P388, DOI 10.1136/jme.27.6.388; Edwards SD, 2001, J MED ETHICS, V27, P380, DOI 10.1136/jme.27.6.380; Gillam L, 1999, J MED ETHICS, V25, P163, DOI 10.1136/jme.25.2.163; GLOVER J, 1998, FUTURE HUMAN REPROD, P55; Harris J, 2002, J MED ETHICS, V28, P204, DOI 10.1136/jme.28.3.204; Harris J, 2001, J MED ETHICS, V27, P383, DOI 10.1136/jme.27.6.383; Harris J, 2000, J MED ETHICS, V26, P95, DOI 10.1136/jme.26.2.95; Jones RB, 2001, J MED ETHICS, V27, P377, DOI 10.1136/jme.27.6.377; Koch T, 2001, J MED ETHICS, V27, P370, DOI 10.1136/jme.27.6.370; Lane H, 1997, KENNEDY INST ETHIC J, V7, P231; Middleton A, 1998, AM J HUM GENET, V63, P1175, DOI 10.1086/302060; Mill J. S., 1910, LIBERTY; MUNDY L, 2002, WASHINGTON POST 0331, pW22; Newell C, 1999, J MED ETHICS, V25, P172, DOI 10.1136/jme.25.2.172; PYEAU M, 2002, DEAF LESBIANS CRITIC; Reindal SM, 2000, J MED ETHICS, V26, P89, DOI 10.1136/jme.26.2.89; RILEY R, 2002, HERALD SUN      0630, P3; Savulescu J, 2001, BIOETHICS, V15, P413, DOI 10.1111/1467-8519.00251; Spriggs M, 2002, J MED ETHICS, V28, P283, DOI 10.1136/jme.28.5.283; Tucker BP, 1997, ANN AM ACAD POLIT SS, V549, P24, DOI 10.1177/0002716297549001003; Tucker BP, 1998, HASTINGS CENT REP, V28, P6, DOI 10.2307/3528607	24	105	105	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 5	2002	325	7367					771	773		10.1136/bmj.325.7367.771	http://dx.doi.org/10.1136/bmj.325.7367.771			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	603AU	12364309	Green Published			2022-12-28	WOS:000178537300025
J	Clark, PU				Clark, PU			Early deglaciation in the tropical Andes	SCIENCE			English	Editorial Material							LAST GLACIAL PERIOD; OXYGEN-ISOTOPE; CLIMATE-CHANGE; SIERRA-NEVADA; GREENLAND; GISP2; VARIABILITY; RECORDS; AGES; GRIP		Oregon State Univ, Dept Geosci, Corvallis, OR 97331 USA	Oregon State University	Clark, PU (corresponding author), Oregon State Univ, Dept Geosci, Corvallis, OR 97331 USA.							Alley RB, 2002, QUATERNARY SCI REV, V21, P431, DOI 10.1016/S0277-3791(01)00072-5; Benson LV, 1996, SCIENCE, V274, P746, DOI 10.1126/science.274.5288.746; BERGER A, 1992, WORLD DATA CTR A PAL; Blunier T, 1998, NATURE, V394, P739, DOI 10.1038/29447; Blunier T, 2001, SCIENCE, V291, P109, DOI 10.1126/science.291.5501.109; Dyke AS, 2002, QUATERNARY SCI REV, V21, P9, DOI 10.1016/S0277-3791(01)00095-6; Goodman AY, 2001, QUATERNARY RES, V56, P31, DOI 10.1006/qres.2001.2221; GOSSE JC, 1995, SCIENCE, V268, P1329, DOI 10.1126/science.268.5215.1329; GROOTES PM, 1993, NATURE, V366, P552, DOI 10.1038/366552a0; HICOCK SR, 1995, CAN J EARTH SCI, V32, P758, DOI 10.1139/e95-065; Hostetler SW, 2000, SCIENCE, V290, P1747, DOI 10.1126/science.290.5497.1747; Johnsen SJ, 2001, J QUATERNARY SCI, V16, P299, DOI 10.1002/jqs.622; McCabe AM, 1998, NATURE, V392, P373, DOI 10.1038/32866; Phillips FM, 1996, SCIENCE, V274, P749, DOI 10.1126/science.274.5288.749; PHILLIPS FM, COMMUNICATION; Seltzer GO, 2002, SCIENCE, V296, P1685, DOI 10.1126/science.1070136; Stuiver M, 2000, QUATERNARY RES, V53, P277, DOI 10.1006/qres.2000.2127; STURCHIO NC, 1994, QUATERNARY RES, V41, P265, DOI 10.1006/qres.1994.1030; Thackray GD, 2001, QUATERNARY RES, V55, P257, DOI 10.1006/qres.2001.2220; VORREN TO, 1988, BOREAS, V17, P41; Wang YJ, 2001, SCIENCE, V294, P2345, DOI 10.1126/science.1064618	21	11	11	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 4	2002	298	5591								10.1126/science.298.5591.7	http://dx.doi.org/10.1126/science.298.5591.7			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	600BJ	12364751	Green Submitted			2022-12-28	WOS:000178370500001
J	Robertson, WH; Johnson, MA				Robertson, WH; Johnson, MA			Caught in the act of dissolution	SCIENCE			English	Editorial Material							WATER CLUSTERS; IONIC DISSOCIATION; SPECTRA; PHOTODISSOCIATION; SPECTROSCOPY; HCL		Yale Univ, Sterling Chem Lab, New Haven, CT 06520 USA	Yale University	Robertson, WH (corresponding author), Yale Univ, Sterling Chem Lab, New Haven, CT 06520 USA.							Arrhenius S., 1887, Z PHYS CHEM, V1U, P631, DOI [10.1515/zpch-1887-0164, DOI 10.1515/ZPCH-1887-0164]; Ayotte P, 1999, J CHEM PHYS, V110, P7129, DOI 10.1063/1.478616; Born M, 1920, Z PHYS, V1, P45, DOI 10.1007/BF01881023; Buck U, 1998, PHYS REV LETT, V80, P2578, DOI 10.1103/PhysRevLett.80.2578; Conley C, 1999, CHEM PHYS LETT, V301, P29, DOI 10.1016/S0009-2614(99)00018-4; Gertner BJ, 1999, ISR J CHEM, V39, P273; Greenblatt BJ, 1997, SCIENCE, V276, P1675, DOI 10.1126/science.276.5319.1675; Hurley SM, 2002, SCIENCE, V298, P202, DOI 10.1126/science.1075307; Lee CT, 1996, J CHEM PHYS, V104, P7081, DOI 10.1063/1.471426; Milet A, 2001, J CHEM PHYS, V115, P349, DOI 10.1063/1.1377875; Nauta K, 2000, SCIENCE, V287, P293, DOI 10.1126/science.287.5451.293; OKUMURA M, 1986, J CHEM PHYS, V85, P2328, DOI 10.1063/1.451079; Sanov A, 1998, J CHEM PHYS, V108, P5155, DOI 10.1063/1.475928; Scoles G, 2000, SCIENCE, V287, P2429, DOI 10.1126/science.287.5462.2429; Serxner D, 1996, J CHEM PHYS, V105, P7231, DOI 10.1063/1.472529; Wang XB, 2001, SCIENCE, V294, P1322, DOI 10.1126/science.1064916	16	39	39	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 4	2002	298	5591					69	69		10.1126/science.1076959	http://dx.doi.org/10.1126/science.1076959			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	600BJ	12364768				2022-12-28	WOS:000178370500027
J	Rupen, MP				Rupen, MP			Microquasar fireworks	SCIENCE			English	Editorial Material							RADIO		Natl Radio Astron Observ, Socorro, NM 87081 USA	National Radio Astronomy Observatory (NRAO)	Rupen, MP (corresponding author), Natl Radio Astron Observ, Socorro, NM 87081 USA.							BEGELMAN MC, 1984, REV MOD PHYS, V56, P255, DOI 10.1103/RevModPhys.56.255; BRIDLE AH, 1984, ANNU REV ASTRON ASTR, V22, P319, DOI 10.1146/annurev.aa.22.090184.001535; Corbel S, 2002, SCIENCE, V298, P196, DOI 10.1126/science.1075857; Dubner GM, 1998, ASTRON J, V116, P1842, DOI 10.1086/300537; Hannikainen D, 2001, ASTROPHYS SPACE SCI, V276, P45, DOI 10.1023/A:1011659517584; Harris DE, 2002, ASTROPHYS J, V565, P244, DOI 10.1086/324544; PERLEY RA, 1984, ASTROPHYS J, V285, pL35, DOI 10.1086/184360; RODRIGUEZ LF, 1909, ANNU REV ASTRON ASTR, V37, P409	8	0	0	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 4	2002	298	5591					73	74		10.1126/science.1076961	http://dx.doi.org/10.1126/science.1076961			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	600BJ	12364771				2022-12-28	WOS:000178370500030
J	Wellems, TE				Wellems, TE			Plasmodium chloroquine resistance and the search for a replacement antimalarial drug	SCIENCE			English	Editorial Material							HEMATIN POLYMERIZATION; FALCIPARUM; MALARIA; INHIBITION; MUTATIONS; BINDING		NIAID, Lab Malaria & Vector Res, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Wellems, TE (corresponding author), NIAID, Lab Malaria & Vector Res, 9000 Rockville Pike, Bethesda, MD 20892 USA.	tew@helix.nih.gov			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000483, ZIAAI000483] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		De DY, 1996, AM J TROP MED HYG, V55, P579, DOI 10.4269/ajtmh.1996.55.579; Djimde A, 2001, NEW ENGL J MED, V344, P257, DOI 10.1056/NEJM200101253440403; Dorn A, 1998, BIOCHEM PHARMACOL, V55, P727, DOI 10.1016/S0006-2952(97)00510-8; Fidock DA, 2000, MOL CELL, V6, P861, DOI 10.1016/S1097-2765(05)00077-8; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; HASTINGS MD, IN PRESS P NATL ACAD; Hawley SR, 1996, ANTIMICROB AGENTS CH, V40, P2345, DOI 10.1128/AAC.40.10.2345; Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573; Kwiatkowski D, 1999, PARASSITOLOGIA, VOL 41, NOS 1-3, SEPTEMBER 1999, P233; Levin BR, 2000, GENETICS, V154, P985; Maguire JD, 2002, LANCET, V360, P58, DOI 10.1016/S0140-6736(02)09336-4; Mu JB, 2002, NATURE, V418, P323, DOI 10.1038/nature00836; Nomura T, 2001, J INFECT DIS, V183, P1653, DOI 10.1086/320707; Reed MB, 2000, NATURE, V403, P906, DOI 10.1038/35002615; Ridley RG, 1996, ANTIMICROB AGENTS CH, V40, P1846, DOI 10.1128/AAC.40.8.1846; Sidhu ABS, 2002, SCIENCE, V298, P210, DOI 10.1126/science.1074045; Surolia N, 2001, NAT MED, V7, P167, DOI 10.1038/84612; Trape JF, 2001, AM J TROP MED HYG, V64, P12, DOI 10.4269/ajtmh.2001.64.12; Vippagunta SR, 1999, J MED CHEM, V42, P4630, DOI 10.1021/jm9902180; Volkman SK, 2002, SCIENCE, V298, P216, DOI 10.1126/science.1075642; Wellems TE, 2001, J INFECT DIS, V184, P770, DOI 10.1086/322858; Wiesner J, 2002, ANTIMICROB AGENTS CH, V46, P2889, DOI 10.1128/AAC.46.9.2889-2894.2002; Wootton JC, 2002, NATURE, V418, P320, DOI 10.1038/nature00813	23	85	92	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 4	2002	298	5591					124	126		10.1126/science.1078167	http://dx.doi.org/10.1126/science.1078167			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	600BJ	12364789				2022-12-28	WOS:000178370500046
J	Gordeliy, VI; Labahn, J; Moukhametzianov, R; Efremov, R; Granzin, J; Schlesinger, R; Buldt, G; Savopol, T; Scheidig, AJ; Klare, JP; Engelhard, M				Gordeliy, VI; Labahn, J; Moukhametzianov, R; Efremov, R; Granzin, J; Schlesinger, R; Buldt, G; Savopol, T; Scheidig, AJ; Klare, JP; Engelhard, M			Molecular basis of transmembrane signalling by sensory rhodopsin II-transducer complex	NATURE			English	Article							STRUCTURAL-CHANGES; SERINE CHEMOTAXIS; PHOTOCYCLE; RECEPTOR; PROTEIN; DIFFRACTION; RESOLUTION; MEMBRANE; INSIGHTS; DOMAIN	Microbial rhodopsins, which constitute a family of seven-helix membrane proteins with retinal as a prosthetic group, are distributed throughout the Bacteria, Archaea and Eukaryota(1-3). This family of photoactive proteins uses a common structural design for two distinct functions: light-driven ion transport and phototaxis. The sensors activate a signal transduction chain similar to that of the two-component system of eubacterial chemotaxis(4). The link between the photoreceptor and the following cytoplasmic signal cascade is formed by a transducer molecule that binds tightly and specifically 5 to its cognate receptor by means of two transmembrane helices (TM1 and TM2). It is thought that light excitation of sensory rhodopsin II from Natronobacterium pharaonis (SRII) in complex with its transducer (HtrII) induces an outward movement of its helix F (ref. 6), which in turn triggers a rotation of TM2 (ref. 7). It is unclear how this TM2 transition is converted into a cellular signal. Here we present the X-ray structure of the complex between N. pharaonis SRII and the receptor-binding domain of HtrII at 1.94 Angstrom resolution, which provides an atomic picture of the first signal transduction step. Our results provide evidence for a common mechanism for this process in phototaxis and chemotaxis.	Res Ctr Julich, Inst Struct Biol IBI2, D-52425 Julich, Germany; Moscow Phys Tech Inst, Ctr Biophys & Phys Chem Supramol Struct, Dolgoprudnyi 141700, Moscow District, Russia; Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany	Helmholtz Association; Research Center Julich; Moscow Institute of Physics & Technology; Max Planck Society	Buldt, G (corresponding author), Res Ctr Julich, Inst Struct Biol IBI2, D-52425 Julich, Germany.	g.bueldt@fz-juelich.de; martin.engelhard@mpi-dortmund.mpg.de	Klare, Johann P./C-1428-2009; Granzin, Joachim/G-8937-2013; Buldt, Georg/K-5345-2013; Büldt, Georg/H-9509-2014; Gordeliy, Valentin I/J-3636-2013; Efremov, Rouslan/P-9085-2015; Savopol, Tudor/B-5670-2011; Labahn, Jörg/G-9593-2013; Scheidig, Axel/C-9141-2011; Schlesinger, Ramona/W-2620-2018	Klare, Johann P./0000-0002-5761-5968; Granzin, Joachim/0000-0001-6604-950X; Gordeliy, Valentin I/0000-0001-5782-5896; Efremov, Rouslan/0000-0001-7516-8658; Savopol, Tudor/0000-0001-7231-3581; Labahn, Jörg/0000-0002-0648-8145; Schlesinger, Ramona/0000-0002-7716-4439				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beja O, 2000, SCIENCE, V289, P1902, DOI 10.1126/science.289.5486.1902; Bieszke JA, 1999, BIOCHEMISTRY-US, V38, P14138, DOI 10.1021/bi9916170; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Falke JJ, 2001, TRENDS BIOCHEM SCI, V26, P257, DOI 10.1016/S0968-0004(00)01770-9; GERWERT K, 1990, FEBS LETT, V261, P449, DOI 10.1016/0014-5793(90)80613-N; Hohenfeld IP, 1999, FEBS LETT, V442, P198, DOI 10.1016/S0014-5793(98)01659-7; Hou SB, 1998, J BACTERIOL, V180, P1600, DOI 10.1128/JB.180.6.1600-1602.1998; Ihara K, 1999, J MOL BIOL, V285, P163, DOI 10.1006/jmbi.1998.2286; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim KK, 1999, NATURE, V400, P787, DOI 10.1038/23512; Klostermeier D, 1998, J MOL BIOL, V279, P841, DOI 10.1006/jmbi.1998.1816; KOCH MHJ, 1991, EMBO J, V10, P521, DOI 10.1002/j.1460-2075.1991.tb07978.x; Koshland DE, 1996, CURR OPIN STRUC BIOL, V6, P757, DOI 10.1016/S0959-440X(96)80004-2; Landau EM, 1996, P NATL ACAD SCI USA, V93, P14532, DOI 10.1073/pnas.93.25.14532; LESLIE AGW, 2002, CCP4 ESF EACMB NEWSL, V26; Luecke H, 2001, SCIENCE, V293, P1499, DOI 10.1126/science.1062977; LYNCH BA, 1992, FEBS LETT, V307, P3, DOI 10.1016/0014-5793(92)80891-J; OESTERHELT D, 1971, NATURE-NEW BIOL, V233, P149, DOI 10.1038/newbio233149a0; Royant A, 2001, P NATL ACAD SCI USA, V98, P10131, DOI 10.1073/pnas.181203898; Rudolph J, 1996, J MOL BIOL, V258, P548, DOI 10.1006/jmbi.1996.0267; Sasaki J, 1999, BIOPHYS J, V77, P2145, DOI 10.1016/S0006-3495(99)77055-4; Schmies G, 2001, P NATL ACAD SCI USA, V98, P1555, DOI 10.1073/pnas.031562298; Shimono K, 1997, FEBS LETT, V420, P54, DOI 10.1016/S0014-5793(97)01487-7; SUBRAMANIAM S, 1993, EMBO J, V12, P1; Wegener AA, 2000, J MOL BIOL, V301, P881, DOI 10.1006/jmbi.2000.4008; Wegener AA, 2001, EMBO J, V20, P5312, DOI 10.1093/emboj/20.19.5312; Yeh JI, 1996, J MOL BIOL, V262, P186, DOI 10.1006/jmbi.1996.0507; Zhang WS, 1996, P NATL ACAD SCI USA, V93, P8230, DOI 10.1073/pnas.93.16.8230; Zhang XN, 1999, P NATL ACAD SCI USA, V96, P857, DOI 10.1073/pnas.96.3.857	31	324	335	1	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 3	2002	419	6906					484	487		10.1038/nature01109	http://dx.doi.org/10.1038/nature01109			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	599RF	12368857				2022-12-28	WOS:000178348400038
J	Prince, AS				Prince, AS			Clinical implications of basic research: Biofilms, antimicrobial resistance, and airway infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Columbia Univ Coll Phys & Surg, New York, NY 10032 USA	Columbia University	Prince, AS (corresponding author), Columbia Univ Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA.							Drenkard E, 2002, NATURE, V416, P740, DOI 10.1038/416740a; Singh PK, 2002, NATURE, V417, P552, DOI 10.1038/417552a	2	139	143	1	11	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 3	2002	347	14					1110	1111		10.1056/NEJMcibr021776	http://dx.doi.org/10.1056/NEJMcibr021776			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	599KD	12362015				2022-12-28	WOS:000178332900012
J	Yeh, A; Soh, YA; Brooke, J; Aeppli, G; Rosenbaum, TF; Hayden, SM				Yeh, A; Soh, YA; Brooke, J; Aeppli, G; Rosenbaum, TF; Hayden, SM			Quantum phase transition in a common metal	NATURE			English	Article							DENSITY-WAVE ANTIFERROMAGNETISM; SPIN FLUCTUATIONS; NORMAL-STATE; TEMPERATURE; HEAVY; CHROMIUM; ALLOYS; CONDUCTIVITY; DEPENDENCE	The classical theory of solids, based on the quantum mechanics of single electrons moving in periodic potentials, provides an excellent description of substances ranging from semiconducting silicon to superconducting aluminium. Over the last fifteen years, it has become increasingly clear that there are substances for which the conventional approach fails. Among these are certain rare earth compounds(1,2) and transition metal oxides(3,4), including high-temperature superconductors(5,6). A common feature of these materials is complexity, in the sense that they have relatively large unit cells containing heterogeneous mixtures of atoms. Although many explanations have been put forward for their anomalous properties(7), it is still possible that the classical theory might suffice. Here we show that a very common chromium alloy has some of the same peculiarities as the more exotic materials, including a quantum critical point(8), a strongly temperature-dependent Hall resistance(4,5) and evidence for a 'pseudogap'(9). This implies that complexity is not a prerequisite for unconventional behaviour. Moreover, it should simplify the general task of explaining anomalous properties because chromium is a relatively simple system in which to work out in quantitative detail the consequences of the conventional theory of solids.	NEC Res Inst, Princeton, NJ 08540 USA; Univ Chicago, James Franck Inst, Chicago, IL 60637 USA; Univ Chicago, Dept Phys, Chicago, IL 60637 USA; Univ Bristol, HH Wills Phys Lab, Bristol BS8 1TL, Avon, England	NEC Corporation; University of Chicago; University of Chicago; University of Bristol	Aeppli, G (corresponding author), NEC Res Inst, 4 Independence Way, Princeton, NJ 08540 USA.	gabe@research.nj.nec.com	Hayden, Stephen M/F-4162-2011	Hayden, Stephen M/0000-0002-3209-027X				Aeppli G, 1997, SCIENCE, V278, P1432, DOI 10.1126/science.278.5342.1432; AEPPLI G, 1994, HANDB PHYSI, V19, P123; Allen PB, 2001, NATURE, V412, P494, DOI 10.1038/35087696; Basov DN, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.054516; CHIEN TR, 1991, PHYS REV B, V43, P6242, DOI 10.1103/PhysRevB.43.6242; Coleman P, 2001, J PHYS-CONDENS MAT, V13, pR723, DOI 10.1088/0953-8984/13/35/202; DEVRIES G, 1959, J PHYS-PARIS, V20, P438, DOI 10.1051/jphysrad:01959002002-3043800; FAWCETT E, 1988, REV MOD PHYS, V60, P209, DOI 10.1103/RevModPhys.60.209; FAWCETT E, 1994, REV MOD PHYS, V66, P25, DOI 10.1103/RevModPhys.66.25; FURUYA Y, 1976, J PHYS SOC JPN, V40, P490, DOI 10.1143/JPSJ.40.490; Grigera SA, 2001, SCIENCE, V294, P329, DOI 10.1126/science.1063539; Hayden SM, 2000, PHYS REV LETT, V84, P999, DOI 10.1103/PhysRevLett.84.999; HIRAI K, 1993, J PHYS SOC JPN, V62, P690, DOI 10.1143/JPSJ.62.690; HLUBINA R, 1995, PHYS REV B, V51, P9253, DOI 10.1103/PhysRevB.51.9253; KOEHLER WC, 1966, PHYS REV, V151, P405, DOI 10.1103/PhysRev.151.405; LAURENT DG, 1981, PHYS REV B, V23, P4977, DOI 10.1103/PhysRevB.23.4977; LOHNEYSON HV, 1994, PHYS REV LETT, V72, P3262; MILLIS AJ, 1993, PHYS REV B, V48, P7183, DOI 10.1103/PhysRevB.48.7183; Rosch A, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.174407; Rosenbaum TF, 1998, PHYS REV B, V57, pR13997, DOI 10.1103/PhysRevB.57.R13997; Sachdev S., 1999, QUANTUM PHASE TRANSI; Schroder A, 2000, NATURE, V407, P351, DOI 10.1038/35030039; Si QM, 2001, NATURE, V413, P804, DOI 10.1038/35101507; Staunton JB, 1999, PHYS REV LETT, V82, P3340, DOI 10.1103/PhysRevLett.82.3340; TAKAGI H, 1992, PHYS REV LETT, V69, P2975, DOI 10.1103/PhysRevLett.69.2975; TAKEUCHI J, 1980, J PHYS SOC JPN, V49, P508, DOI 10.1143/JPSJ.49.508; Timusk T, 1999, REP PROG PHYS, V62, P61, DOI 10.1088/0034-4885/62/1/002; VARMA CM, 1989, PHYS REV LETT, V63, P1996, DOI 10.1103/PhysRevLett.63.1996	28	118	118	1	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 3	2002	419	6906					459	462		10.1038/nature01044	http://dx.doi.org/10.1038/nature01044			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	599RF	12368850				2022-12-28	WOS:000178348400031
J	Snow, M; Cox, SL; Jenkin, G; Trounson, A; Shaw, J				Snow, M; Cox, SL; Jenkin, G; Trounson, A; Shaw, J			Generation of live young from xenografted mouse ovaries	SCIENCE			English	Article							FOLLICULAR DEVELOPMENT; FOLLICLES; TISSUE; MICE		Monash Univ, Dept Physiol, Clayton, Vic 3800, Australia; Monash Univ, Monash Inst Reprod & Dev, Clayton, Vic 3800, Australia	Monash University; Monash University	Cox, SL (corresponding author), Monash Univ, Dept Physiol, Clayton, Vic 3800, Australia.			Trounson, Alan/0000-0001-5469-0500				GOSDEN RG, 1994, J REPROD FERTIL, V101, P619, DOI 10.1530/jrf.0.1010619; Gunasena KT, 1998, ANIM REPROD SCI, V53, P265, DOI 10.1016/S0378-4320(98)00132-8; Mattiske D, 2002, REPRODUCTION, V123, P143, DOI 10.1530/reprod/123.1.143; Obata Y, 2002, NATURE, V418, P497, DOI 10.1038/418497a; Oktay K, 1998, HUM REPROD, V13, P1133, DOI 10.1093/humrep/13.5.1133; Weissman A, 1999, BIOL REPROD, V60, P1462, DOI 10.1095/biolreprod60.6.1462; Wolvekamp MCJ, 2001, ANIM REPROD SCI, V65, P135, DOI 10.1016/S0378-4320(00)00228-1	7	60	77	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 27	2002	297	5590					2227	2227		10.1126/science.1073693	http://dx.doi.org/10.1126/science.1073693			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	597LA	12351780				2022-12-28	WOS:000178222000036
J	Ford, MGJ; Mills, IG; Peter, BJ; Vallis, Y; Praefcke, GJK; Evans, PR; McMahon, HT				Ford, MGJ; Mills, IG; Peter, BJ; Vallis, Y; Praefcke, GJK; Evans, PR; McMahon, HT			Curvature of clathrin-coated pits driven by epsin	NATURE			English	Article							ENTH DOMAIN; VESICLE FORMATION; BINDING; EPS15; AMPHIPHYSIN; UNDERGOES; DYNAMIN; NUMBER	Clathrin-mediated endocytosis involves cargo selection and membrane budding into vesicles with the aid of a protein coat. Formation of invaginated pits on the plasma membrane and subsequent budding of vesicles is an energetically demanding process that involves the cooperation of clathrin with many different proteins. Here we investigate the role of the brain-enriched protein epsin 1 in this process. Epsin is targeted to areas of endocytosis by binding the membrane lipid phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5) P-2). We show here that epsin 1 directly modifies membrane curvature on binding to PtdIns(4,5) P-2 in conjunction with clathrin polymerization. We have discovered that formation of an amphipathic alpha-helix in epsin is coupled to PtdIns(4,5)P-2 binding. Mutation of residues on the hydrophobic region of this helix abolishes the ability to curve membranes. We propose that this helix is inserted into one leaflet of the lipid bilayer, inducing curvature. On lipid monolayers epsin alone is sufficient to facilitate the formation of clathrin-coated invaginations.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	McMahon, HT (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	pre@mrc-lmb.cam.ac.uk; hmm@mrc-lmb.cam.ac.uk	Mills, Ian/AAK-9292-2020; Peter, Brian/AAZ-7323-2020	Mills, Ian/0000-0001-5347-5083; Praefcke, Gerrit/0000-0001-8818-1499				Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; Cadavid ALM, 2000, DEVELOPMENT, V127, P1727; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; Drake MT, 2000, J BIOL CHEM, V275, P6479, DOI 10.1074/jbc.275.9.6479; Farsad K, 2001, J CELL BIOL, V155, P193, DOI 10.1083/jcb.200107075; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; Hyman J, 2000, J CELL BIOL, V149, P537, DOI 10.1083/jcb.149.3.537; Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047; Kalthoff C, 2002, J BIOL CHEM, V277, P8209, DOI 10.1074/jbc.M111587200; Marsh M, 1999, SCIENCE, V285, P215, DOI 10.1126/science.285.5425.215; McPherson PS, 1998, BIOCHEM BIOPH RES CO, V244, P701, DOI 10.1006/bbrc.1998.8331; Morgan JR, 2001, NEURON, V32, P289, DOI 10.1016/S0896-6273(01)00467-6; Nossal R, 2001, TRAFFIC, V2, P138, DOI 10.1034/j.1600-0854.2001.020208.x; Owen DJ, 2000, EMBO J, V19, P4216, DOI 10.1093/emboj/19.16.4216; Owen DJ, 1999, CELL, V97, P805, DOI 10.1016/S0092-8674(00)80791-6; Razzaq A, 2001, GENE DEV, V15, P2967, DOI 10.1101/gad.207801; Salcini AE, 1999, INT J BIOCHEM CELL B, V31, P805, DOI 10.1016/S1357-2725(99)00042-4; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; Takei K, 1999, NAT CELL BIOL, V1, P33, DOI 10.1038/9004; Tebar F, 1996, J BIOL CHEM, V271, P28727, DOI 10.1074/jbc.271.46.28727; Wendland B, 1999, EMBO J, V18, P4383, DOI 10.1093/emboj/18.16.4383; Zhang B, 1998, NEURON, V21, P1465, DOI 10.1016/S0896-6273(00)80664-9	27	756	768	2	86	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 26	2002	419	6905					361	366		10.1038/nature01020	http://dx.doi.org/10.1038/nature01020			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	596ZB	12353027				2022-12-28	WOS:000178195400037
J	Klein, JA; Longo-Guess, CM; Rossmann, MP; Seburn, KL; Hurd, RE; Frankel, WN; Bronson, RT; Ackerman, SL				Klein, JA; Longo-Guess, CM; Rossmann, MP; Seburn, KL; Hurd, RE; Frankel, WN; Bronson, RT; Ackerman, SL			The harlequin mouse mutation down-regulates apoptosis-inducing factor	NATURE			English	Article							NEURONAL CELL-DEATH; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; TRANSGENIC MICE; CYCLE; PROTEIN; GENE; NEURODEGENERATION; EXPRESSION; MECHANISM	Harlequin (Hq) mutant mice have progressive degeneration of terminally differentiated cerebellar and retinal neurons. We have identified the Hq mutation as a proviral insertion in the apoptosis-inducing factor (Aif) gene, causing about an 80% reduction in AIF expression. Mutant cerebellar granule cells are susceptible to exogenous and endogenous peroxide-mediated apoptosis, but can be rescued by AIF expression. Overexpression of AIF in wild-type granule cells further decreases peroxide-mediated cell death, suggesting that AIF serves as a free radical scavenger. In agreement, dying neurons in aged Hq mutant mice show oxidative stress. In addition, neurons damaged by oxidative stress in both the cerebellum and retina of Hq mutant mice re-enter the cell cycle before undergoing apoptosis. Our results provide a genetic model of oxidative stress-mediated neurodegeneration and demonstrate a direct connection between cell cycle re-entry and oxidative stress in the ageing central nervous system.	Jackson Lab, Bar Harbor, ME 04609 USA; Tufts Univ, Sch Vet Med, North Grafton, MA 01536 USA	Jackson Laboratory; Tufts University	Ackerman, SL (corresponding author), Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA.	sla@jax.org	Rossmann, Marlies/AAJ-1943-2021	Rossmann, Marlies/0000-0003-2056-6792				Ackerman SL, 1997, NATURE, V386, P838, DOI 10.1038/386838a0; BAILLIE TA, 1991, ACCOUNTS CHEM RES, V24, P264, DOI 10.1021/ar00009a003; Barber BR, 1971, MOUSE NEWS LETT, V45, P34; BRONSON RT, 1990, MOUSE GENOME, V87, P110; Busser J, 1998, J NEUROSCI, V18, P2801; CAMBRAYDEAKIN MA, 1995, NEURAL CELL CULTURE, P3; Cassarino DS, 1999, BRAIN RES REV, V29, P1, DOI 10.1016/S0165-0173(98)00046-0; COFFIN JM, 1989, ANN NY ACAD SCI, V567, P39, DOI 10.1111/j.1749-6632.1989.tb16457.x; COFFIN JM, 1984, RNA TUMOR VIRUSES 1, P261; Costa GL, 2000, J IMMUNOL, V164, P3581, DOI 10.4049/jimmunol.164.7.3581; Daugas E, 2000, FEBS LETT, V476, P118, DOI 10.1016/S0014-5793(00)01731-2; DEISSEROTH A, 1970, PHYSIOL REV, V50, P319, DOI 10.1152/physrev.1970.50.3.319; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; ElShamy WM, 1998, NEURON, V21, P1003, DOI 10.1016/S0896-6273(00)80619-4; FEDDERSEN RM, 1992, NEURON, V9, P955, DOI 10.1016/0896-6273(92)90247-B; Frade JM, 2000, J CELL SCI, V113, P1139; Gill JS, 1998, J CLIN INVEST, V101, P2842, DOI 10.1172/JCI1130; Griendling KK, 2000, ARTERIOSCL THROM VAS, V20, P2175, DOI 10.1161/01.ATV.20.10.2175; Grignani F, 1998, CANCER RES, V58, P14; HAMMANG JP, 1993, NEURON, V10, P1197, DOI 10.1016/0896-6273(93)90067-2; Hawes NL, 2000, INVEST OPHTH VIS SCI, V41, P3149; Heintz N, 2000, ANNU REV PHYSIOL, V62, P779, DOI 10.1146/annurev.physiol.62.1.779; HERRUP K, 1995, DEVELOPMENT, V121, P2385; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Katchanov J, 2001, J NEUROSCI, V21, P5045, DOI 10.1523/JNEUROSCI.21-14-05045.2001; Kimura H, 1996, GENES CELLS, V1, P977, DOI 10.1046/j.1365-2443.1996.840284.x; KURKI P, 1986, EXP CELL RES, V166, P209, DOI 10.1016/0014-4827(86)90520-3; Lavoie J N, 1996, Prog Cell Cycle Res, V2, P49; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; Lynn RB, 1997, J AUTONOM NERV SYST, V62, P174, DOI 10.1016/S0165-1838(96)00125-7; Mate MJ, 2002, NAT STRUCT BIOL, V9, P442, DOI 10.1038/nsb793; McShea A, 1999, MED HYPOTHESES, V52, P525, DOI 10.1054/mehy.1997.0680; Migheli A, 1999, AM J PATHOL, V155, P365, DOI 10.1016/S0002-9440(10)65133-4; Miramar MD, 2001, J BIOL CHEM, V276, P16391, DOI 10.1074/jbc.M010498200; Mundy WR, 2000, NEUROTOXICOLOGY, V21, P1135; Mustacich D, 2000, BIOCHEM J, V346, P1, DOI 10.1042/0264-6021:3460001; Nagy Z, 1997, ACTA NEUROPATHOL, V93, P294, DOI 10.1007/s004010050617; Osuga H, 2000, P NATL ACAD SCI USA, V97, P10254, DOI 10.1073/pnas.170144197; Raina A K, 2000, Prog Cell Cycle Res, V4, P235; Sayre LM, 2001, CURR MED CHEM, V8, P721, DOI 10.2174/0929867013372922; Shackelford RE, 2000, FREE RADICAL BIO MED, V28, P1387, DOI 10.1016/S0891-5849(00)00224-0; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; TAYLOR BA, 1989, GENOMICS, V5, P221, DOI 10.1016/0888-7543(89)90050-5; White AR, 1998, J NEUROSCI, V18, P6207; WILLIAMS J, 1995, CHEM BIOCH FLAVOENZY, P121; Yang Y, 2001, J NEUROSCI, V21, P2661, DOI 10.1523/JNEUROSCI.21-08-02661.2001	47	480	499	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 26	2002	419	6905					367	374		10.1038/nature01034	http://dx.doi.org/10.1038/nature01034			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	596ZB	12353028				2022-12-28	WOS:000178195400038
J	Martin, JD; Goettler, SJ; Fosse, N; Iton, L				Martin, JD; Goettler, SJ; Fosse, N; Iton, L			Designing intermediate-range order in amorphous materials	NATURE			English	Article							SHARP DIFFRACTION PEAK; NEUTRON-DIFFRACTION; ZINC-CHLORIDE; ISOTOPIC-SUBSTITUTION; GLASSES; LIQUID	Amorphous materials are commonly understood to consist of random organizations of molecular-type structural units. However, it has long been known that structural organizations intermediate between discrete chemical bonds and periodic crystalline lattices are present even in liquids(1,2). Numerous models-including random networks and crystalline-type structures with networks composed of clusters(3,4) and voids(5,6)-have been proposed to account for this intermediate-range order(7). Nevertheless, understanding and controlling structural features that determine intermediate-range order in amorphous materials remain fundamental, yet presently unresolved, issues(7-9). The most characteristic signature of such order is the first peak in the total structure factor, referred to as the first sharp diffraction peak or 'low Q' structure. These features correspond to large real-space distances in the materials, and understanding their origin is key to unravelling details of intermediate-range order. Here we employ principles of crystal engineering to design specific patterns of intermediate-range order within amorphous zinc-chloride networks. Using crystalline models, we demonstrate the impact of various structural features on diffraction at low values of Q. Such amorphous network engineering is anticipated to provide the structure/property relationships necessary to tailor specific optical, electronic and mechanical properties.	N Carolina State Univ, Dept Chem, Raleigh, NC 27695 USA; Argonne Natl Lab, Div Mat Sci, Argonne, IL 60439 USA	University of North Carolina; North Carolina State University; United States Department of Energy (DOE); Argonne National Laboratory	Martin, JD (corresponding author), N Carolina State Univ, Dept Chem, Box 8204, Raleigh, NC 27695 USA.			Martin, James/0000-0001-7414-2683				Badyal YS, 1996, J PHYS-CONDENS MAT, V8, P3733, DOI 10.1088/0953-8984/8/21/003; BIGGIN S, 1981, J PHYS C SOLID STATE, V14, P3129, DOI 10.1088/0022-3719/14/22/008; CERVINKA L, 1988, J NON-CRYST SOLIDS, V106, P291, DOI 10.1016/0022-3093(88)90277-3; Debye P., 1916, MATHEMATISCH PHYSIKA, V1916, P16; DESA JAE, 1982, J NON-CRYST SOLIDS, V51, P57, DOI 10.1016/0022-3093(82)90189-2; Egami T, 1997, MAT SCI ENG A-STRUCT, V226, P261, DOI 10.1016/S0921-5093(97)80041-X; ELLIOTT SR, 1992, J PHYS-CONDENS MAT, V4, P7661, DOI 10.1088/0953-8984/4/38/003; ELLIOTT SR, 1991, NATURE, V354, P445, DOI 10.1038/354445a0; Gaskell PH, 2000, MINERAL MAG, V64, P425, DOI 10.1180/002646100549481; GASKELL PH, 1991, NATURE, V350, P675, DOI 10.1038/350675a0; GLADDEN LF, 1989, J NON-CRYST SOLIDS, V109, P223, DOI 10.1016/0022-3093(89)90034-3; Hirotsu Y, 1997, MAT SCI ENG A-STRUCT, V226, P274, DOI 10.1016/S0921-5093(96)10629-8; Lee JH, 1996, PHYS REV B, V54, P12109, DOI 10.1103/PhysRevB.54.12109; Martin JD, 1997, ANGEW CHEM INT EDIT, V36, P2072, DOI 10.1002/anie.199720721; Martin JD, 1999, MATER RES SOC SYMP P, V559, P243, DOI 10.1557/PROC-559-243; Martin JD, 1998, CHEM MATER, V10, P2699, DOI 10.1021/cm9802550; ROUSSELOT C, 1991, SOLID STATE IONICS, V44, P151, DOI 10.1016/0167-2738(91)90002-S; SALMON PS, 1994, P R SOC-MATH PHYS SC, V445, P351, DOI 10.1098/rspa.1994.0065; Scherrer P., 1916, LEHRB, V1912, P387; Swenson J, 1997, PHYS REV LETT, V79, P1421, DOI 10.1103/PhysRevLett.79.1421; TACHEZ M, 1987, SOLID STATE IONICS, V25, P263, DOI 10.1016/0167-2738(87)90190-1; TEO BK, 1976, INORG CHEM, V15, P2474, DOI 10.1021/ic50164a032; van der Lugt W., 1996, CHEM MET CLUST, P183; Wasse JC, 1998, J PHYS-CONDENS MAT, V10, P8139, DOI 10.1088/0953-8984/10/37/003; Wilson M, 1998, PHYS REV LETT, V80, P532, DOI 10.1103/PhysRevLett.80.532; Wright AC, 1998, GLASS PHYS CHEM+, V24, P148	26	57	59	2	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 26	2002	419	6905					381	384		10.1038/nature01022	http://dx.doi.org/10.1038/nature01022			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	596ZB	12353031				2022-12-28	WOS:000178195400041
J	Crackower, MA; Oudit, GY; Kozieradzki, I; Sarao, R; Sun, H; Sasaki, T; Hirsch, E; Suzuki, A; Shioi, T; Irie-Sasaki, J; Sah, R; Cheng, HYM; Rybin, VO; Lembo, G; Fratta, L; Oliveira-dos-Santos, AJ; Benovic, JL; Kahn, CR; Izumo, S; Steinberg, SF; Wymann, MP; Backx, PH; Penninger, JM				Crackower, MA; Oudit, GY; Kozieradzki, I; Sarao, R; Sun, H; Sasaki, T; Hirsch, E; Suzuki, A; Shioi, T; Irie-Sasaki, J; Sah, R; Cheng, HYM; Rybin, VO; Lembo, G; Fratta, L; Oliveira-dos-Santos, AJ; Benovic, JL; Kahn, CR; Izumo, S; Steinberg, SF; Wymann, MP; Backx, PH; Penninger, JM			Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways	CELL			English	Article							PROTEIN-COUPLED RECEPTORS; TUMOR-SUPPRESSOR GENE; PHOSPHOINOSITIDE 3-KINASE; CARDIAC-HYPERTROPHY; PTEN; ACTIVATION; KINASE; PHOSPHOLAMBAN; PI3K-GAMMA; HEART	The PTEN/PI3K signaling pathway regulates a vast array of fundamental cellular responses. We show that cardiomyocyte-specific inactivation of tumor suppressor PTEN results in hypertrophy, and unexpectedly, a dramatic decrease in cardiac contractility. Analysis of double-mutant mice revealed that the cardiac hypertrophy and the contractility defects could be genetically uncoupled. PI3Kalpha mediates the alteration in cell size while PI3Kgamma acts as a negative regulator of cardiac contractility. Mechanistically, PI3Kgamma inhibits cAMP production and hypercontractility can be reverted by blocking cAMP function. These data show that PTEN has an important in vivo role in cardiomyocyte hypertrophy and GPCR signaling and identify a function for the PTEN-PI3Kgamma pathway in the modulation of heart muscle contractility.	Austrian Acad Sci, Inst Mol Biotechnol, IMBA, A-1030 Vienna, Austria; Univ Toronto, Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5G 2C1, Canada; Univ Toronto, Ontario Canc Inst, Dept Immunol, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Physiol, Toronto, ON, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Toronto, Univ Hlth Network Richard Lewar Heart & Stroke Ct, Toronto, ON, Canada; Tokyo Metropolitan Inst Med Sci, Dept Pharmacol, Tokyo 113, Japan; JST, PRESTO, Tokyo, Japan; Univ Turin, Dipartimento Genet Biol & Biochim, I-10126 Turin, Italy; Akita Univ, Dept Biochem, Sch Med, Akita 0108543, Japan; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Cardiovasc, Boston, MA 02215 USA; Columbia Univ, Dept Pharmacol, New York, NY 10032 USA; Columbia Univ, Dept Med, New York, NY 10032 USA; Neuromed Inst, Dept Neurocardiol, Pozzilli, Italy; Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Immunol, Philadelphia, PA 19107 USA; Harvard Univ, Sch Med, Div Res, Joslin Diabet Ctr, Boston, MA 02215 USA; Univ Fribourg, Dept Med, Div Biochem, CH-1700 Fribourg, Switzerland	Austrian Academy of Sciences; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA); University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Tokyo Metropolitan Institute of Medical Science; Japan Science & Technology Agency (JST); University of Turin; Akita University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Columbia University; Columbia University; IRCCS Neuromed; Jefferson University; Jefferson University; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; University of Fribourg	Penninger, JM (corresponding author), Austrian Acad Sci, Inst Mol Biotechnol, IMBA, Dr Bohr Gasse 7, A-1030 Vienna, Austria.		Penninger, Josef M/I-6860-2013; Suzuki, Akira/GYD-6697-2022; Lembo, Giuseppe/AAE-8096-2020; Kahn, Ronald/AAY-2435-2021; Wymann, Matthias P/C-3227-2008; Hirsch, Emilio/F-4848-2013	Penninger, Josef M/0000-0002-8194-3777; Suzuki, Akira/0000-0002-5950-8808; Lembo, Giuseppe/0000-0002-3510-223X; Kahn, Ronald/0000-0002-7583-9228; Wymann, Matthias P/0000-0003-3349-4281; Hirsch, Emilio/0000-0002-9073-6024; Sasaki, Takehiko/0000-0003-1837-3748	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065742, P01HL028958] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL28958, HL65742] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Backman SA, 2001, NAT GENET, V29, P396, DOI 10.1038/ng782; Baliga RR, 1999, AM J PHYSIOL-HEART C, V277, pH2026, DOI 10.1152/ajpheart.1999.277.5.H2026; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; Brittsan AG, 2000, J MOL CELL CARDIOL, V32, P2131, DOI 10.1006/jmcc.2000.1270; Bruning JC, 1998, MOL CELL, V2, P559, DOI 10.1016/S1097-2765(00)80155-0; Colan Steven D., 1997, Cardiology Clinics, V15, P355, DOI 10.1016/S0733-8651(05)70345-3; Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Frank K, 2000, ANN MED, V32, P572, DOI 10.3109/07853890008998837; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Hunter JJ, 1999, NEW ENGL J MED, V341, P1276, DOI 10.1056/NEJM199910213411706; Kodama H, 2000, AM J PHYSIOL-HEART C, V279, pH1635, DOI 10.1152/ajpheart.2000.279.4.H1635; Komalavilas P, 2001, J APPL PHYSIOL, V91, P1819, DOI 10.1152/jappl.2001.91.4.1819; KUZNETSOV V, 1995, CIRC RES, V76, P40, DOI 10.1161/01.RES.76.1.40; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Matsui T, 2002, J BIOL CHEM, V277, P22896, DOI 10.1074/jbc.M200347200; Milligan G, 2001, TRENDS PHARMACOL SCI, V22, P513, DOI 10.1016/S0165-6147(00)01801-0; Minamisawa S, 1999, CELL, V99, P313, DOI 10.1016/S0092-8674(00)81662-1; Naga Prasad SV, 2001, TRENDS GENET, V17, pS44; Prasad SVN, 2000, J BIOL CHEM, V275, P4693, DOI 10.1074/jbc.275.7.4693; Prasad SVN, 2001, J BIOL CHEM, V276, P18953, DOI 10.1074/jbc.M102376200; Rabkin SW, 1997, J HYPERTENS, V15, P891, DOI 10.1097/00004872-199715080-00014; Rockman HA, 2002, NATURE, V415, P206, DOI 10.1038/415206a; Sah R, 2002, CIRCULATION, V105, P1850, DOI 10.1161/01.CIR.0000014211.47830.4D; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Scanga SE, 2000, ONCOGENE, V19, P3971, DOI 10.1038/sj.onc.1203739; Schluter KD, 1999, AM J PHYSIOL-HEART C, V276, pH1655, DOI 10.1152/ajpheart.1999.276.5.H1655; Schwartzbauer G, 2001, J BIOL CHEM, V276, P35786, DOI 10.1074/jbc.M102479200; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Shioi T, 2000, EMBO J, V19, P2537, DOI 10.1093/emboj/19.11.2537; Shioi T, 2002, MOL CELL BIOL, V22, P2799, DOI 10.1128/MCB.22.8.2799-2809.2002; STEINBERG SF, 1991, CIRC RES, V68, P1216, DOI 10.1161/01.RES.68.5.1216; STEINBERG SF, 1995, CIRCULATION, V91, P2824, DOI 10.1161/01.CIR.91.11.2824; STEPHENS L, 1993, EMBO J, V12, P2265, DOI 10.1002/j.1460-2075.1993.tb05880.x; Suzuki A, 2001, IMMUNITY, V14, P523, DOI 10.1016/S1074-7613(01)00134-0; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Xiao RP, 1999, CIRC RES, V84, P43; Yusuf S, 2001, CIRCULATION, V104, P2746, DOI 10.1161/hc4601.099487; Zvaritch E, 2000, J BIOL CHEM, V275, P14985, DOI 10.1074/jbc.275.20.14985	47	484	525	0	20	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 20	2002	110	6					737	749		10.1016/S0092-8674(02)00969-8	http://dx.doi.org/10.1016/S0092-8674(02)00969-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	596TV	12297047	Bronze			2022-12-28	WOS:000178182800009
J	Hynes, RO				Hynes, RO			Integrins: Bidirectional, allosteric signaling machines	CELL			English	Review							MEMBRANE-PROXIMAL REGION; LIGAND-BINDING REGION; INSIDE-OUT ACTIVATION; VON-WILLEBRAND-FACTOR; CRYSTAL-STRUCTURE; I-DOMAIN; CELL-ADHESION; CYTOPLASMIC DOMAINS; A-DOMAIN; EXTRACELLULAR SEGMENT		MIT, Howard Hughes Med Inst, Ctr Canc Res, Dept Biol, Cambridge, MA 02139 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Hynes, RO (corresponding author), MIT, Howard Hughes Med Inst, Ctr Canc Res, Dept Biol, Cambridge, MA 02139 USA.	rohynes@mit.edu	Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763				Alonso JL, 2002, CURR BIOL, V12, pR340, DOI 10.1016/S0960-9822(02)00852-7; Armulik A, 1999, J BIOL CHEM, V274, P37030, DOI 10.1074/jbc.274.52.37030; Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; BAJT ML, 1994, J BIOL CHEM, V269, P20913; Bazzoni G, 1998, TRENDS BIOCHEM SCI, V23, P30, DOI 10.1016/S0968-0004(97)01141-9; BEER JH, 1992, BLOOD, V79, P117; Beglova N, 2002, NAT STRUCT BIOL, V9, P282, DOI 10.1038/nsb779; Bertoni A, 2002, J BIOL CHEM, V277, P25715, DOI 10.1074/jbc.M202791200; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Bouvard D, 2001, CIRC RES, V89, P211, DOI 10.1161/hh1501.094874; Brown EJ, 2001, TRENDS CELL BIOL, V11, P130, DOI 10.1016/S0962-8924(00)01906-1; Burke RD, 1999, INT REV CYTOL, V191, P257, DOI 10.1016/S0074-7696(08)60161-8; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; Calderwood DA, 2000, J BIOL CHEM, V275, P22607, DOI 10.1074/jbc.R900037199; Calderwood DA, 2002, J BIOL CHEM, V277, P21749, DOI 10.1074/jbc.M111996200; Clark EA, 1997, BBA-REV CANCER, V1333, pR9, DOI 10.1016/S0304-419X(97)00028-0; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COLLER BS, 1986, J CELL BIOL, V103, P451, DOI 10.1083/jcb.103.2.451; Coller BS, 1997, J CLIN INVEST, V99, P1467, DOI 10.1172/JCI119307; Critchley DR, 1999, BIOCHEM SOC SYMP, V65, P79; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; De Arcangelis A, 2000, TRENDS GENET, V16, P389, DOI 10.1016/S0168-9525(00)02074-6; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DU XP, 1993, J BIOL CHEM, V268, P23087; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Etzioni A, 1999, BLOOD, V94, P3281, DOI 10.1182/blood.V94.10.3281.422k37_3281_3288; Fenczik CA, 1997, NATURE, V390, P81, DOI 10.1038/36349; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Garcia AJ, 2002, BIOCHEMISTRY-US, V41, P9063, DOI 10.1021/bi025752f; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; Gottlieb A, 2000, J AM ACAD DERMATOL, V42, P428, DOI 10.1016/S0190-9622(00)90214-7; Hantgan RR, 1999, BIOCHEMISTRY-US, V38, P14461, DOI 10.1021/bi9907680; Hato T, 1998, J CELL BIOL, V141, P1685, DOI 10.1083/jcb.141.7.1685; Hemler M. E., 1999, GUIDEBOOK EXTRACELLU, P196; Hemler ME, 2001, J CELL BIOL, V155, P1103, DOI 10.1083/jcb.200108061; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; Hogg N, 2000, MATRIX BIOL, V19, P211, DOI 10.1016/S0945-053X(00)00066-4; Huang CC, 2000, J BIOL CHEM, V275, P21514, DOI 10.1074/jbc.M002286200; Hughes AL, 2001, J MOL EVOL, V52, P63, DOI 10.1007/s002390010134; Hughes PE, 1998, TRENDS CELL BIOL, V8, P359, DOI 10.1016/S0962-8924(98)01339-7; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Humphries MJ, 2002, ARTHRITIS RES THER, V4, pS69, DOI 10.1186/ar563; Humphries MJ, 2000, BIOCHEM SOC T, V28, P311, DOI 10.1042/0300-5127:0280311; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; Hynes RO, 2000, J CELL BIOL, V150, pF89, DOI 10.1083/jcb.150.2.F89; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 2002, NAT MED, V8, P918, DOI 10.1038/nm0902-918; Hynes RO, 1996, DEV BIOL, V180, P402, DOI 10.1006/dbio.1996.0314; Jackson DY, 2002, CURR PHARM DESIGN, V8, P1229, DOI 10.2174/1381612023394737; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Kato A, 1997, CRIT REV ONCOL HEMAT, V26, P1, DOI 10.1016/S1040-8428(97)00011-5; Kolesnikova TV, 2001, BMC BIOCHEM, V2, DOI 10.1186/1472-2091-2-10; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; Li RH, 2001, P NATL ACAD SCI USA, V98, P12462, DOI 10.1073/pnas.221463098; Liddington RC, 2002, J CELL BIOL, V158, P833, DOI 10.1083/jcb.200206011; Liddington RC, 2002, STRUCTURE, V10, P605, DOI 10.1016/S0969-2126(02)00766-9; LOFTUS JC, 1994, J BIOL CHEM, V269, P25235; Loftus JC, 1997, J CLIN INVEST, V99, P2302, DOI 10.1172/JCI119408; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2387, DOI 10.1073/pnas.041606398; Lu CF, 2001, J BIOL CHEM, V276, P14642, DOI 10.1074/jbc.M100600200; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2393, DOI 10.1073/pnas.041618598; Martel V, 2001, J BIOL CHEM, V276, P21217, DOI 10.1074/jbc.M102373200; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; Mould AP, 2002, J BIOL CHEM, V277, P19800, DOI 10.1074/jbc.M201571200; Mould AP, 1997, J BIOL CHEM, V272, P17283, DOI 10.1074/jbc.272.28.17283; O'Neill S, 2000, J BIOL CHEM, V275, P36984, DOI 10.1074/jbc.M003279200; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Patil S, 1999, J BIOL CHEM, V274, P28575, DOI 10.1074/jbc.274.40.28575; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; Pulkkinen L, 1999, MATRIX BIOL, V18, P29, DOI 10.1016/S0945-053X(98)00005-5; Qu AD, 1996, STRUCTURE, V4, P931, DOI 10.1016/S0969-2126(96)00100-1; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; Rosenkranz AR, 1999, EXP NEPHROL, V7, P125; Scarborough RM, 2000, J MED CHEM, V43, P3453, DOI 10.1021/jm000022w; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Schwartz MA, 2001, J CELL SCI, V114, P2553; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; Sheppard D, 2000, MATRIX BIOL, V19, P203, DOI 10.1016/S0945-053X(00)00065-2; Shimaoka M, 2001, P NATL ACAD SCI USA, V98, P6009, DOI 10.1073/pnas.101130498; Shimaoka M, 2002, ANNU REV BIOPH BIOM, V31, P485, DOI 10.1146/annurev.biophys.31.101101.140922; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takagi J, 2001, NAT STRUCT BIOL, V8, P412, DOI 10.1038/87569; Tozer EC, 1996, J BIOL CHEM, V271, P21978, DOI 10.1074/jbc.271.36.21978; Tuckwell D, 1999, BIOCHEM SOC T, V27, P835, DOI 10.1042/bst0270835; Tuckwell DS, 1997, FEBS LETT, V400, P297, DOI 10.1016/S0014-5793(96)01368-3; Ulmer TS, 2001, BIOCHEMISTRY-US, V40, P7498, DOI 10.1021/bi010338l; Vallar L, 1999, J BIOL CHEM, V274, P17257, DOI 10.1074/jbc.274.24.17257; van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WEISEL JW, 1992, J BIOL CHEM, V267, P16637; Weljie AM, 2002, P NATL ACAD SCI USA, V99, P5878, DOI 10.1073/pnas.092515799; Whittaker CA, 2002, MOL BIOL CELL, V13, P3369, DOI 10.1091/mbc.E02-05-0259; Williams Michael J., 1994, Trends in Cell Biology, V4, P109, DOI 10.1016/0962-8924(94)90059-0; Woodside DG, 2001, THROMB HAEMOSTASIS, V86, P316, DOI 10.1055/s-0037-1616229; Wu CY, 2001, J CELL BIOL, V155, P505, DOI 10.1083/jcb.200108077; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2000, J BIOL CHEM, V275, P38762, DOI 10.1074/jbc.C000563200; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Yan B, 2001, J BIOL CHEM, V276, P28164, DOI 10.1074/jbc.M104161200; Yan BX, 2001, BIOCHEMISTRY-US, V40, P8861, DOI 10.1021/bi002902i; Zamir E, 2001, J CELL SCI, V114, P3583; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	118	6470	6713	16	510	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 20	2002	110	6					673	687		10.1016/S0092-8674(02)00971-6	http://dx.doi.org/10.1016/S0092-8674(02)00971-6			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	596TV	12297042	Bronze			2022-12-28	WOS:000178182800004
J	Owens, IPF				Owens, IPF			Sex differences in mortality rate	SCIENCE			English	Editorial Material							PATTERNS; SIGNALS; STRESS		Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, Ascot SL5 7PY, Berks, England; Univ London Imperial Coll Sci Technol & Med, NERC, Ctr Populat Biol, Ascot SL5 7PY, Berks, England	Imperial College London; Imperial College London; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC)	Owens, IPF (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, Silwood Pk, Ascot SL5 7PY, Berks, England.		Owens, Ian PF/F-1392-2010	Owens, Ian/0000-0001-6080-3321				Bronikowski AM, 2002, P NATL ACAD SCI USA, V99, P9591, DOI 10.1073/pnas.142675599; BUNDY DAP, 1988, PARASITOL TODAY, V4, P186, DOI 10.1016/0169-4758(88)90076-2; HAMILTON JB, 1969, J GERONTOL, V24, P395, DOI 10.1093/geronj/24.4.395; Moore SL, 2002, SCIENCE, V297, P2015, DOI 10.1126/science.1074196; Olson VA, 1998, TRENDS ECOL EVOL, V13, P510, DOI 10.1016/S0169-5347(98)01484-0; PROMISLOW DEL, 1992, P ROY SOC B-BIOL SCI, V247, P203, DOI 10.1098/rspb.1992.0030; Raberg L, 1998, P ROY SOC B-BIOL SCI, V265, P1637, DOI 10.1098/rspb.1998.0482; von Schantz T, 1999, P ROY SOC B-BIOL SCI, V266, P1, DOI 10.1098/rspb.1999.0597; *WHO, 2001, WORLD HLTH STAT ANN; Zuk M, 1996, INT J PARASITOL, V26, P1009, DOI [10.1016/S0020-7519(96)00086-0, 10.1016/S0020-7519(96)80001-4]	10	158	159	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 20	2002	297	5589					2008	2009		10.1126/science.1076813	http://dx.doi.org/10.1126/science.1076813			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	594XV	12242430				2022-12-28	WOS:000178078500033
J	Rahi, JS; Logan, S; Timms, C; Russell-Eggitt, I; Taylor, D				Rahi, JS; Logan, S; Timms, C; Russell-Eggitt, I; Taylor, D			Risk, causes, and outcomes of visual impairment after loss of vision in the non-amblyopic eye: a population-based study	LANCET			English	Article							PREVALENCE; CHILDREN; BLINDNESS; GLAUCOMA	Background Screening for amblyopia in early childhood is done in many countries to ensure that affected children are detected and treated within the critical period, and achieve a level of vision in their amblyopic eye that would be useful should they lose vision in their non-amblyopic eye later in life. We aimed to investigate the risk, causes, and outcomes of visual impairment attributable to loss of vision in the non-amblyopic eye. Methods For 24 months from July, 1997, national surveillance was done to identify all individuals in the UK with unilateral amblyopia (acuity worse than 6/12) who had newly acquired vision loss in the non-amblyopic eye, resulting in acuity of worse than 6/12 or visual-field restriction precluding driving. Information about participants was obtained at presentation and 1 year later. Participants were categorised as having socially significant visual impairment, or visual impairment, severe visual impairment, or blindness, in accordance with WHO taxonomy. Findings Of 370 eligible individuals, at presentation 104 (28%) had socially significant visual impairment, 180 (49%) visual impairment, and 86 (23%) severe visual impairment or blindness. The minimum risk of permanent visual impairment by age 95 years was 32.9 (95% Cl 29.1-36.9) per 100 000 total population. The projected lifetime risk of vision loss for an individual with amblyopia was at least 1.2% (95% Cl 1.1-1.4). Only 36 (35%) of 102 people previously in paid employment were able to continue. Interpretation In the UK, where screening for amblyopia is under review, risk of serious vision loss affecting the nonamblyopic eye and its results are greater than that previously assumed. Thus, in addition to the-benefits of improved vision in the amblyopic eye, treatment of amblyopia during childhood is a potentially valuable strategy to prevent incapacitating vision loss later in life.	Inst Child Hlth, Ctr Paediat Epidemiol & Biostat, London WC1N 1EH, England; Great Ormond St Hosp Sick Children, Dept Ophthalmol, London, England; Inst Ophthalmol, Dept Epidemiol, London, England	University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London	Rahi, JS (corresponding author), Inst Child Hlth, Ctr Paediat Epidemiol & Biostat, 30 Guilford St, London WC1N 1EH, England.	j.rahi@ich.ucl.ac.uk		Rahi, Jugnoo/0000-0002-5718-9209; Logan, Stuart/0000-0002-9279-261X				Adams GGW, 1999, BRIT J OPHTHALMOL, V83, P380; Arnold JJ, 2000, BRIT MED J, V321, P741, DOI 10.1136/bmj.321.7263.741; Attebo K, 1998, OPHTHALMOLOGY, V105, P154, DOI 10.1016/S0161-6420(98)91862-0; Bray LC, 1996, EYE, V10, P714, DOI 10.1038/eye.1996.166; Breslow NE., 1987, STAT METHODS CANC RE, P81; *BRIT OPHTH SURV U, 2000, BOSU NEWS BRIT OPHTH; CAMPOS E, 1995, SURV OPHTHALMOL, V40, P23, DOI 10.1016/S0039-6257(95)80044-1; Dandona L, 1999, OPHTHALMOLOGY, V106, P497, DOI 10.1016/S0161-6420(99)90107-0; Daw NW, 1998, ARCH OPHTHALMOL-CHIC, V116, P502, DOI 10.1001/archopht.116.4.502; Evans J., 1995, STUDIES MED POPULATI, V57; Hattenhauer MG, 1998, OPHTHALMOLOGY, V105, P2099, DOI 10.1016/S0161-6420(98)91133-2; JAKOBSSON P, 1997, T 24 M EUR STRAB ASS, P317; KEECH RV, 1995, J PEDIATR OPHTHALMOL, V32, P89; Klein R, 1997, LANCET, V350, P197, DOI 10.1016/S0140-6736(97)04195-0; KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182; Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2; Kvarnstrom G, 1998, ACTA PAEDIATR, V87, P1173; Leske MC, 2001, ARCH OPHTHALMOL-CHIC, V119, P89; MacEwen CJ, 1999, BRIT J OPHTHALMOL, V83, P933, DOI 10.1136/bjo.83.8.933; McCarty CA, 2001, BRIT J OPHTHALMOL, V85, P322, DOI 10.1136/bjo.85.3.322; MUNTON G, 1995, MED ASPECTS FITNESS, P118; Newman D K, 2000, Ophthalmic Epidemiol, V7, P67, DOI 10.1076/0928-6586(200003)7:1;1-2;FT067; *OFF NAT STAT, 2000, POP TRENDS, V102; Reidy A, 1998, BRIT MED J, V316, P1643, DOI 10.1136/bmj.316.7145.1643; Risser WL, 1996, PEDIATRICS, V98, P311; SNOWDON S, 1997, 9 CRD NHS; Stanford MR, 1997, BRIT J OPHTHALMOL, V81, P932, DOI 10.1136/bjo.81.11.932; TAYLOR D, 1985, T OPHTHAL SOC UK, V104, P637; Taylor HR, 2001, BRIT J OPHTHALMOL, V85, P261, DOI 10.1136/bjo.85.3.261; THOMPSON JR, 1991, PUBLIC HEALTH, V105, P455, DOI 10.1016/S0033-3506(05)80616-X; TOMMILA V, 1981, BRIT J OPHTHALMOL, V65, P575, DOI 10.1136/bjo.65.8.575; VEREECKEN EP, 1984, ARCH OPHTHALMOL-CHIC, V102, P220; VINDING T, 1991, ACTA OPHTHALMOL, V69, P796; Von Noorden GK, 1995, BINOCULAR VISION OCU, V5; World Health Organization, 1992, INT STAT CLASS DIS H; WORMALD RPL, 1992, BRIT MED J, V304, P1226, DOI 10.1136/bmj.304.6836.1226	36	162	168	0	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 24	2002	360	9333					597	602		10.1016/S0140-6736(02)09782-9	http://dx.doi.org/10.1016/S0140-6736(02)09782-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	586TD	12241931				2022-12-28	WOS:000177600400009
J	Cao, R; Wang, LJ; Wang, HB; Xia, L; Erdjument-Bromage, H; Tempst, P; Jones, RS; Zhang, Y				Cao, R; Wang, LJ; Wang, HB; Xia, L; Erdjument-Bromage, H; Tempst, P; Jones, RS; Zhang, Y			Role of histone H3 lysine 27 methylation in polycomb-group silencing	SCIENCE			English	Article							DROSOPHILA-MELANOGASTER; CHROMO DOMAIN; GROUP GENE; BITHORAX COMPLEX; GROUP PROTEINS; ENHANCER; ZESTE; HP1; REPRESSION; SITE	Polycomb group (PcG) proteins play important roles in maintaining the silent state of HOX genes. Recent studies have implicated histone methylation in long-term gene silencing. However, a connection between PcG-mediated gene silencing and histone methylation has not been established. Here we report the purification and characterization of an EED-EZH2 complex, the human counterpart of the Drosophila ESC-E(Z) complex. We demonstrate that the complex specifically methylates nucleosomal histone H3 at lysine 27 (H3-K27). Using chromatin immunoprecipitation assays, we show that H3-K27 methylation colocalizes with, and is dependent on, E(Z) binding at an Ultrabithorax (Ubx) Polycomb response element (PRE), and that this methylation correlates with Ubx repression. Methylation on H3-K27 facilitates binding of Polycomb (PC), a component of the PRC1 complex, to histone H3 amino-terminal tail. Thus, these studies establish a link between histone methylation and PcG-mediated gene silencing.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; So Methodist Univ, Dept Biol Sci, Dallas, TX 75275 USA; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Southern Methodist University; Memorial Sloan Kettering Cancer Center	Zhang, Y (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.			Tempst, Paul/0000-0002-6680-3987; Wang, Hengbin/0000-0003-2414-0609; Zhang, Yi/0000-0002-2789-0811; Erdjument-Bromage, Hediye/0000-0003-0224-3594				Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; BENDER W, 1983, SCIENCE, V221, P23, DOI 10.1126/science.221.4605.23; Birve A, 2001, DEVELOPMENT, V128, P3371; Breiling A, 2001, NATURE, V412, P651, DOI 10.1038/35088090; CABRERA CV, 1985, NATURE, V318, P569, DOI 10.1038/318569a0; Carrington EA, 1996, DEVELOPMENT, V122, P4073; Fang J, 2002, CURR BIOL, V12, P1086, DOI 10.1016/S0960-9822(02)00924-7; Feng Q, 2002, CURR BIOL, V12, P1052, DOI 10.1016/S0960-9822(02)00901-6; Francis NJ, 2001, NAT REV MOL CELL BIO, V2, P409, DOI 10.1038/35073039; Fritsch C, 1999, DEVELOPMENT, V126, P3905; He GP, 1999, J BIOL CHEM, V274, P14678, DOI 10.1074/jbc.274.21.14678; Jacobs SA, 2002, SCIENCE, V295, P2080, DOI 10.1126/science.1069473; JONES RS, 1990, GENETICS, V126, P185; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; LaJeunesse D, 1996, DEVELOPMENT, V122, P2189; MESSMER S, 1992, GENE DEV, V6, P1241, DOI 10.1101/gad.6.7.1241; Ng HH, 2002, GENE DEV, V16, P1518, DOI 10.1101/gad.1001502; Nielsen PR, 2002, NATURE, V416, P103, DOI 10.1038/nature722; O'Carroll D, 2001, MOL CELL BIOL, V21, P4330, DOI 10.1128/MCB.21.13.4330-4336.2001; Pirrotta V, 1998, CELL, V93, P333, DOI 10.1016/S0092-8674(00)81162-9; PLATERO JS, 1995, EMBO J, V14, P3977, DOI 10.1002/j.1460-2075.1995.tb00069.x; Platero JS, 1996, CHROMOSOMA, V104, P393, DOI 10.1007/BF00352263; Poux S, 2001, GENE DEV, V15, P2509, DOI 10.1101/gad.208901; RASTELLI L, 1993, EMBO J, V12, P1513, DOI 10.1002/j.1460-2075.1993.tb05795.x; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Schumacher A, 1996, NATURE, V384, P648, DOI 10.1038/384648a0; Shao ZH, 1999, CELL, V98, P37, DOI 10.1016/S0092-8674(00)80604-2; Simon JA, 2002, CURR OPIN GENET DEV, V12, P210, DOI 10.1016/S0959-437X(02)00288-5; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Tie F, 2001, DEVELOPMENT, V128, P275; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; van Leeuwen F, 2002, CELL, V109, P745, DOI 10.1016/S0092-8674(02)00759-6; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	33	2697	2802	3	249	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 1	2002	298	5595					1039	1043		10.1126/science.1076997	http://dx.doi.org/10.1126/science.1076997			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609XQ	12351676				2022-12-28	WOS:000178932000061
J	Ozawa, S; Murakami, M; Kaidzu, M; Tada, T; Sagiya, T; Hatanaka, Y; Yarai, H; Nishimura, T				Ozawa, S; Murakami, M; Kaidzu, M; Tada, T; Sagiya, T; Hatanaka, Y; Yarai, H; Nishimura, T			Detection and monitoring of ongoing aseismic slip in the Tokai region, Central Japan	SCIENCE			English	Article							GEODETIC DATA; DEFORMATION; INVERSION	Analysis of global positioning system data shows that the rate of crustal deformations in the Tokai region of Japan, a seismic gap area, changed over the past 18 months. Kalman filtering analysis shows aseismic slip on the plate boundary in the western Tokai region centered on Lake Hamana, adjacent to the anticipated Tokai earthquake source area. The cumulative moment magnitude reaches 6.7 in June 2002 with a relative slip increase northeast of Lake Haman from January 2002. An existence of aseismic slip in the western Tokai supports the hypothesis of a silent event as the cause of uplifting several days before the 1944 Tonankai earthquake.	Geog Survey Inst Japan, Crustal Dynam Res Ctr, Tsukuba, Ibaraki 3050013, Japan		Ozawa, S (corresponding author), Geog Survey Inst Japan, Crustal Dynam Res Ctr, Kitasato 1, Tsukuba, Ibaraki 3050013, Japan.		Nishimura, Takuya/G-2789-2013; Sagiya, Takeshi/N-8417-2018	Nishimura, Takuya/0000-0002-2469-8146; Sagiya, Takeshi/0000-0001-7949-8048				FUKAHATA Y, UNPUB; Harris RA, 1998, J GEOPHYS RES-SOL EA, V103, P24347, DOI 10.1029/98JB01576; Hirose H, 1999, GEOPHYS RES LETT, V26, P3237, DOI 10.1029/1999GL010999; HIROSE I, 2000, J SEISMOL SOC JPN, V53, P11; INOUCHI N, 1975, B GEOGR SURV I JPN, V21, P10; Ishibashi K, 1981, M EWING SERIES, V4, P297; ISHIDA M, 1992, J GEOPHYS RES-SOL EA, V97, P489, DOI 10.1029/91JB02567; KIMATA F, 2001, EOS, V82, pF266; LINDE AT, 1997, EOS T AGU S, V78, pF156; Matsumura S, 1997, TECTONOPHYSICS, V273, P271, DOI 10.1016/S0040-1951(96)00277-6; MCGUIRE JJ, 2001, EOS, V82, pF265; MOGI K, 1981, M EWING SERIES, V4, P43; Nishimura T, 2001, GEOPHYS RES LETT, V28, P3745, DOI 10.1029/2001GL013051; OKADA Y, 1985, B SEISMOL SOC AM, V75, P1135; Ozawa S, 2001, J GEOPHYS RES-SOL EA, V106, P787, DOI 10.1029/2000JB900317; Sagiya T, 1999, GEOPHYS RES LETT, V26, P2315, DOI 10.1029/1999GL900511; SAGIYA T, 2001, EOS, V82, pE1265; SAKAI S, 2001, GEOL MAG, V110, P145; Segall P, 1997, J GEOPHYS RES-SOL EA, V102, P22391, DOI 10.1029/97JB01795; YABUKI T, 1992, GEOPHYS J INT, V109, P363, DOI 10.1111/j.1365-246X.1992.tb00102.x	20	208	211	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 1	2002	298	5595					1009	1012		10.1126/science.1076780	http://dx.doi.org/10.1126/science.1076780			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	609XQ	12364622				2022-12-28	WOS:000178932000051
J	Konstantinides, S; Geibel, A; Heusel, G; Heinrich, F; Kasper, W				Konstantinides, S; Geibel, A; Heusel, G; Heinrich, F; Kasper, W		Management Strategies Prognosis Pu	Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							THROMBOLYTIC THERAPY; PLASMINOGEN-ACTIVATOR; UROKINASE; TRIAL; RESOLUTION	Background: The use of thrombolytic agents in the treatment of hemodynamically stable patients with acute submassive pulmonary embolism remains controversial. Methods: We conducted a study of patients with acute pulmonary embolism and pulmonary hypertension or right ventricular dysfunction but without arterial hypotension or shock. The patients were randomly assigned in double-blind fashion to receive heparin plus 100 mg of alteplase or heparin plus placebo over a period of two hours. The primary end point was in-hospital death or clinical deterioration requiring an escalation of treatment, which was defined as catecholamine infusion, secondary thrombolysis, endotracheal intubation, cardiopulmonary resuscitation, or emergency surgical embolectomy or thrombus fragmentation by catheter. Results: Of 256 patients enrolled, 118 were randomly assigned to receive heparin plus alteplase and 138 to receive heparin plus placebo. The incidence of the primary end point was significantly higher in the heparin-plus-placebo group than in the heparin-plus-alteplase group (P=0.006), and the probability of 30-day event-free survival (according to Kaplan-Meier analysis) was higher in the heparin-plus-alteplase group (P=0.005). This difference was due to the higher incidence of treatment escalation in the heparin-plus-placebo group (24.6 percent vs. 10.2 percent, P=0.004), since mortality was low in both groups (3.4 percent in the heparin-plus-alteplase group and 2.2 percent in the heparin-plus-placebo group, P=0.71). Treatment with heparin plus placebo was associated with almost three times the risk of death or treatment escalation that was associated with heparin plus alteplase (P=0.006). No fatal bleeding or cerebral bleeding occurred in patients receiving heparin plus alteplase. Conclusions: When given in conjunction with heparin, alteplase can improve the clinical course of stable patients who have acute submassive pulmonary embolism and can prevent clinical deterioration requiring the escalation of treatment during the hospital stay.	Univ Gottingen, Dept Cardiol & Pulm Med, D-37075 Gottingen, Germany; Univ Freiburg, Dept Cardiol & Angiol, Freiburg, Germany; Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany; Krankenhaus Bruchsal, Bruchsal, Germany; St Josefs Hosp, Dept Internal Med, Wiesbaden, Germany	University of Gottingen; University of Freiburg; Boehringer Ingelheim	Konstantinides, S (corresponding author), Univ Gottingen, Dept Cardiol & Pulm Med, Robert Koch Str 40, D-37075 Gottingen, Germany.	skonstan@med.uni-goettingen.de	Konstantinides, Stavros/AAL-3174-2021	Konstantinides, Stavros/0000-0001-6359-7279				ALPERT JS, 1976, JAMA-J AM MED ASSOC, V236, P1477, DOI 10.1001/jama.236.13.1477; CARSON JL, 1992, NEW ENGL J MED, V326, P1240, DOI 10.1056/NEJM199205073261902; Dalen JE, 1997, ARCH INTERN MED, V157, P2550, DOI 10.1001/archinte.157.22.2550; DALEN JE, 1969, NEW ENGL J MED, V280, P1194, DOI 10.1056/NEJM196905292802202; DALLAVOLTA S, 1992, J AM COLL CARDIOL, V20, P520, DOI 10.1016/0735-1097(92)90002-5; Goldhaber SZ, 2002, ANN INTERN MED, V136, P691, DOI 10.7326/0003-4819-136-9-200205070-00012; GOLDHABER SZ, 1992, J AM COLL CARDIOL, V20, P24, DOI 10.1016/0735-1097(92)90132-7; Goldhaber SZ, 1999, LANCET, V353, P1386, DOI 10.1016/S0140-6736(98)07534-5; GOLDHABER SZ, 1993, LANCET, V341, P507, DOI 10.1016/0140-6736(93)90274-K; GOLDHABER SZ, 1986, LANCET, V2, P886; GOLDHABER SZ, 1988, LANCET, V2, P293; Goldhaber SZ, 2001, THROMB HAEMOSTASIS, V86, P444; Goldhaber SZ, 2001, CIRCULATION, V104, P2876, DOI 10.1161/circ.104.24.2876; GULBA DC, 1994, LANCET, V343, P576, DOI 10.1016/S0140-6736(94)91523-7; Hamel E, 2001, CHEST, V120, P120, DOI 10.1378/chest.120.1.120; Jerjes-Sanchez, 1995, J Thromb Thrombolysis, V2, P227; Kanter DS, 1997, CHEST, V111, P1241, DOI 10.1378/chest.111.5.1241; KASPER W, 1993, BRIT HEART J, V70, P352; Kasper W, 1997, J AM COLL CARDIOL, V30, P1165, DOI 10.1016/S0735-1097(97)00319-7; Kasper W, 1997, HEART, V77, P346, DOI 10.1136/hrt.77.4.346; Konstantinides S, 1998, AM J CARDIOL, V82, P966, DOI 10.1016/S0002-9149(98)00513-X; Konstantinides S, 1997, CIRCULATION, V96, P882; Konstantinides Stavros, 1999, Thrombosis and Haemostasis, V82, P104; LEVINE MN, 1995, CLIN CHEST MED, V16, P321; MCINTYRE KM, 1971, AM J CARDIOL, V28, P288, DOI 10.1016/0002-9149(71)90116-0; MEYER G, 1992, J AM COLL CARDIOL, V19, P239, DOI 10.1016/0735-1097(92)90472-Y; MILLER GAH, 1971, BRIT HEART J, V33, P616; Sharma GVRK, 2000, VASC MED, V5, P91, DOI 10.1191/135886300666830773; SUDLOW MF, 1992, LANCET, V340, P873; The urokinase pulmonary embolism trial, 1973, CIRCULATION, V47, pII1	30	703	742	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 10	2002	347	15					1143	1150		10.1056/NEJMoa021274	http://dx.doi.org/10.1056/NEJMoa021274			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	601TW	12374874				2022-12-28	WOS:000178465100004
J	Sidhu, ABS; Verdier-Pinard, D; Fidock, DA				Sidhu, ABS; Verdier-Pinard, D; Fidock, DA			Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations	SCIENCE			English	Article							DIGESTIVE VACUOLE; P-GLYCOPROTEIN; PFMDR1 GENE; AMPLIFICATION; ANTIMALARIALS; AMODIAQUINE; SENSITIVITY; MEFLOQUINE; MECHANISM; VERAPAMIL	Plasmodium falciparum chloroquine resistance is major cause of worldwide increases in malaria mortality and morbidity. Recent laboratory and clinical studies have associated chloroquine resistance with point mutations in the gene pfcrt. However, direct proof of causal relationship has remained elusive and most models have posited multigenic basis of resistance. Here, we provide conclusive evidence that mutant haplotypes of the pfcrt gene product of Asian, African, or South American origin confer chloroquine resistance with characteristic verapamil reversibility and reduced chloroquine accumulation. pfcrt mutations increased susceptibility to artemisinin and quinine and minimally affected amodiaquine activity; hence, these antimalarials warrant further investigation as agents to control chloroquine-resistant falciparum malaria.	Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Fidock, DA (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	dfidock@aecom.yu.edu		Fidock, David/0000-0001-6753-8938	NIAID NIH HHS [R01 AI50234, R37 AI050234, R01 AI050234-03, R01 AI050234] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI050234, R01AI050234] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adjuik M, 2002, LANCET, V359, P1365, DOI 10.1016/S0140-6736(02)08348-4; Basco LK, 1995, MOL BIOCHEM PARASIT, V74, P157, DOI 10.1016/0166-6851(95)02492-1; BASCO LK, 1993, AM J TROP MED HYG, V48, P120, DOI 10.4269/ajtmh.1993.48.120; Ben Mamoun C, 1999, P NATL ACAD SCI USA, V96, P8716, DOI 10.1073/pnas.96.15.8716; BRASSEUR P, 1992, AM J TROP MED HYG, V46, P1; Bray PG, 1998, MOL PHARMACOL, V54, P170, DOI 10.1124/mol.54.1.170; Bray PG, 1996, MOL PHARMACOL, V50, P1559; Chaiyaroj SC, 1999, AM J TROP MED HYG, V61, P780, DOI 10.4269/ajtmh.1999.61.780; CHILDS GE, 1989, AM J TROP MED HYG, V40, P7, DOI 10.4269/ajtmh.1989.40.7; Cooper RA, 2002, MOL PHARMACOL, V61, P35, DOI 10.1124/mol.61.1.35; COWMAN AF, 1991, J CELL BIOL, V113, P1033, DOI 10.1083/jcb.113.5.1033; CREMER G, 1995, EXP PARASITOL, V81, P1, DOI 10.1006/expr.1995.1086; De DY, 1996, AM J TROP MED HYG, V55, P579, DOI 10.4269/ajtmh.1996.55.579; Djimde A, 2001, NEW ENGL J MED, V344, P257, DOI 10.1056/NEJM200101253440403; Duraisingh MT, 2000, MOL MICROBIOL, V36, P955, DOI 10.1046/j.1365-2958.2000.01914.x; Fidock DA, 1997, P NATL ACAD SCI USA, V94, P10931, DOI 10.1073/pnas.94.20.10931; Fidock DA, 2000, MOL CELL, V6, P861, DOI 10.1016/S1097-2765(05)00077-8; Foley M, 1998, PHARMACOL THERAPEUT, V79, P55, DOI 10.1016/S0163-7258(98)00012-6; FOOTE SJ, 1990, NATURE, V345, P255, DOI 10.1038/345255a0; FOOTE SJ, 1989, CELL, V57, P921, DOI 10.1016/0092-8674(89)90330-9; Ginsburg H, 1999, PARASITOL TODAY, V15, P357, DOI 10.1016/S0169-4758(99)01502-1; KROGSTAD DJ, 1992, BIOCHEM PHARMACOL, V43, P57, DOI 10.1016/0006-2952(92)90661-2; KROGSTAD DJ, 1987, SCIENCE, V238, P1283, DOI 10.1126/science.3317830; MARTIN SK, 1987, SCIENCE, V235, P899, DOI 10.1126/science.3544220; Mehlotra RK, 2001, P NATL ACAD SCI USA, V98, P12689, DOI 10.1073/pnas.221440898; O'Neill PM, 1998, PHARMACOL THERAPEUT, V77, P29, DOI 10.1016/S0163-7258(97)00084-3; Olliaro P, 1996, LANCET, V348, P1196, DOI 10.1016/S0140-6736(96)06217-4; Pagola S, 2000, NATURE, V404, P307, DOI 10.1038/35005132; Price RN, 1999, ANTIMICROB AGENTS CH, V43, P2943, DOI 10.1128/AAC.43.12.2943; Reed MB, 2000, NATURE, V403, P906, DOI 10.1038/35002615; Ridley RG, 2002, NATURE, V415, P686, DOI 10.1038/415686a; Ridley RG, 1996, ANTIMICROB AGENTS CH, V40, P1846, DOI 10.1128/AAC.40.8.1846; Su XZ, 1997, CELL, V91, P593, DOI 10.1016/S0092-8674(00)80447-X; Sullivan DJ, 1998, J BIOL CHEM, V273, P31103, DOI 10.1074/jbc.273.47.31103; Ursos LMB, 2000, MOL BIOCHEM PARASIT, V110, P125, DOI 10.1016/S0166-6851(00)00262-0; Wellems TE, 2001, J INFECT DIS, V184, P770, DOI 10.1086/322858; WELLEMS TE, 1990, NATURE, V345, P253, DOI 10.1038/345253a0; White NJ, 1999, PARASSITOLOGIA, VOL 41, NOS 1-3, SEPTEMBER 1999, P301; WILSON CM, 1989, SCIENCE, V244, P1184, DOI 10.1126/science.2658061; Wootton JC, 2002, NATURE, V418, P320, DOI 10.1038/nature00813	40	532	552	0	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 4	2002	298	5591					210	213		10.1126/science.1074045	http://dx.doi.org/10.1126/science.1074045			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	600BJ	12364805	Green Accepted			2022-12-28	WOS:000178370500062
J	Calvert, PM; Frucht, H				Calvert, PM; Frucht, H			The genetics of colorectal cancer	ANNALS OF INTERNAL MEDICINE			English	Review							FAMILIAL ADENOMATOUS POLYPOSIS; DNA MISMATCH REPAIR; FECAL BILE-ACIDS; COLON-CANCER; MICROSATELLITE INSTABILITY; CHOLINERGIC-RECEPTOR; TUMOR-DEVELOPMENT; PROGNOSTIC VALUE; CELLS; MUTATIONS	Colon cancer is a common disease that can be sporadic, familial, or inherited. Recent advances have contributed to the understanding of the molecular basis of these various patterns of colon cancer. Germline genetic mutations are the basis of inherited colon cancer syndromes; an accumulation of somatic mutations in a cell is the basis of sporadic colon cancer; and, in Ashkenazi Jewish persons, a mutation that was previously thought to be a polymorphism may cause familial colon cancer. Mutations of three different classes of genes have been described in colon cancer etiology: oncogenes, suppressor genes, and mismatch repair genes. Knowledge of many of the specific mutations responsible for colon carcinogenesis allows an understanding of the phenotypic manifestations observed and forms the basis of genetic testing for inherited disease. Although genetic testing is possible and available, it is only an adjunct to the clinical management of persons at risk for colon cancer and patients with colon cancer. As a result of advances in the understanding of the molecular causes of colon cancer and the availability of colon cancer screening methods such as colonoscopy, it should be possible to prevent the vast majority of colon cancer in our society. Practicing clinicians should recognize the patterns of clinical colon cancer, understand its causes, and be able to use genetic testing and endoscopic screening for prevention.	Columbia Univ Coll Phys & Surg, Div Digest & Liver Dis, New York, NY 10032 USA; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	Columbia University; Fox Chase Cancer Center	Frucht, H (corresponding author), Columbia Univ Coll Phys & Surg, Div Digest & Liver Dis, 630 W 168th St,Box 83, New York, NY 10032 USA.				NCI NIH HHS [CA 70335] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA070335] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*AM SOC CLIN ONC, 1998, CANC GEN CANC PRED T; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; Boland CR, 1998, CANCER RES, V58, P5248; Burt RW, 2000, GASTROENTEROLOGY, V119, P837, DOI 10.1053/gast.2000.16508; Cartwright C, 1998, GASTROENTEROLOGY, V114, P1335, DOI 10.1016/S0016-5085(98)70443-3; CHENG K, 2002, IN PRESS BIOCH BIOPH; CHUNG DC, 1995, GASTROENTEROLOGY, V109, P1685, DOI 10.1016/0016-5085(95)90660-6; Desch CE, 1999, J CLIN ONCOL, V17, P1312, DOI 10.1200/JCO.1999.17.4.1312; EKBOM A, 1993, GASTROENTEROLOGY, V105, P142, DOI 10.1016/0016-5085(93)90019-9; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FORGACS I, 1988, GUT, V29, P417, DOI 10.1136/gut.29.4.417; Frazier ML, 2000, J CLIN ONCOL, V18, p70S; Frucht H, 1999, CLIN CANCER RES, V5, P2532; FRUCHT H, 1992, CANCER RES, V52, P1114; Giardiello FM, 1997, NEW ENGL J MED, V336, P823, DOI 10.1056/NEJM199703203361202; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; GIOVANNUCCI E, 1993, GASTROENTEROLOGY, V105, P130, DOI 10.1016/0016-5085(93)90018-8; HAMILTON SR, 1993, GASTROENTEROLOGY, V105, P3, DOI 10.1016/0016-5085(93)90003-U; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; HILL MJ, 1975, LANCET, V1, P535; HILL MJ, 1991, EUROPEAN JOURNAL OF CANCER PREVENTION, VOL 1, SUPPLEMENT 2, OCTOBER 1991, P69, DOI 10.1097/00008469-199110002-00012; Hruban RH, 2000, CLIN CANCER RES, V6, P2969; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Kapitanovic S, 1997, GASTROENTEROLOGY, V112, P1103, DOI 10.1016/S0016-5085(97)70120-3; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kinzler KW, 1998, SCIENCE, V280, P1036, DOI 10.1126/science.280.5366.1036; Kirsch DG, 1998, J CLIN ONCOL, V16, P3158, DOI 10.1200/JCO.1998.16.9.3158; KNUDSON AG, 1985, CANCER RES, V45, P1437; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kressner U, 1999, J CLIN ONCOL, V17, P593, DOI 10.1200/JCO.1999.17.2.593; Laken SJ, 1997, NAT GENET, V17, P79, DOI 10.1038/ng0997-79; Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201; Lynch HT, 1999, DIS COLON RECTUM, V42, P31, DOI 10.1007/BF02235179; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Matloff ET, 2000, J CLIN ONCOL, V18, P2484, DOI 10.1200/JCO.2000.18.12.2484; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; Parc YR, 2000, CANCER RES, V60, P2225; Petersen G M, 1996, Oncology (Williston Park), V10, P89; Peterson WL, 1996, ALIMENT PHARM THERAP, V10, P97, DOI 10.1046/j.1365-2036.1996.22164010.x; Ponder B, 1997, SCIENCE, V278, P1050, DOI 10.1126/science.278.5340.1050; REDDY BS, 1977, CANCER-AM CANCER SOC, V39, P2533, DOI 10.1002/1097-0142(197706)39:6<2533::AID-CNCR2820390634>3.0.CO;2-X; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Sun XF, 1999, J CLIN ONCOL, V17, P1745, DOI 10.1200/JCO.1999.17.6.1745; Syngal S, 1999, JAMA-J AM MED ASSOC, V282, P247, DOI 10.1001/jama.282.3.247; Syngal S, 1998, ANN INTERN MED, V129, P787, DOI 10.7326/0003-4819-129-10-199811150-00007; Terdiman JP, 2001, GASTROENTEROLOGY, V120, P21, DOI 10.1053/gast.2001.20874; Tortola S, 1999, J CLIN ONCOL, V17, P1375, DOI 10.1200/JCO.1999.17.5.1375; Vasen HFA, 1999, GASTROENTEROLOGY, V116, P1453, DOI 10.1016/S0016-5085(99)70510-X; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; Villa E, 1996, GASTROENTEROLOGY, V110, P1346, DOI 10.1053/gast.1996.v110.pm8613038; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WEINBERG RA, 1994, CA-CANCER J CLIN, V44, P160, DOI 10.3322/canjclin.44.3.160; Winawer SJ, 1997, GASTROENTEROLOGY, V112, P594, DOI 10.1053/gast.1997.v112.agast970594; Yang WL, 2000, CARCINOGENESIS, V21, P1789, DOI 10.1093/carcin/21.10.1789; Yang WL, 2001, CARCINOGENESIS, V22, P1379, DOI 10.1093/carcin/22.9.1379; ZUCCATO E, 1993, DIGEST DIS SCI, V38, P514, DOI 10.1007/BF01316508	59	159	177	0	18	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	2002	137	7					603	612		10.7326/0003-4819-137-7-200210010-00012	http://dx.doi.org/10.7326/0003-4819-137-7-200210010-00012			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	599VD	12353948				2022-12-28	WOS:000178355100007
J	Guthrie, E; Thompson, D				Guthrie, E; Thompson, D			ABC of psychological medicine - Abdominal pain and functional gastrointestinal disorders	BMJ-BRITISH MEDICAL JOURNAL			English	Review							IRRITABLE-BOWEL-SYNDROME		Univ Manchester, Sch Psychiat & Behav Sci, Manchester M13 9PL, Lancs, England; Hope Hosp, Sect Gastrointestinal Sci, Salford, Lancs, England	University of Manchester	Guthrie, E (corresponding author), Univ Manchester, Sch Psychiat & Behav Sci, Manchester M13 9PL, Lancs, England.			Guthrie, Elspeth/0000-0002-5834-6616				Akehurst R, 2001, GUT, V48, P272, DOI 10.1136/gut.48.2.272; Bytzer P, 2002, GUT, V50, P58; Drossman DA, 1995, GASTROENTEROL INT, V8, P47; Jackson JL, 2000, AM J MED, V108, P65, DOI 10.1016/S0002-9343(99)00299-5; Jailwala J, 2000, ANN INTERN MED, V133, P136, DOI 10.7326/0003-4819-133-2-200007180-00013; Talley NJ, 1996, AM J GASTROENTEROL, V91, P277; Thompson WG, 2000, GUT, V46, P78, DOI 10.1136/gut.46.1.78	7	19	20	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 28	2002	325	7366					701	703		10.1136/bmj.325.7366.701	http://dx.doi.org/10.1136/bmj.325.7366.701			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	600JV	12351366				2022-12-28	WOS:000178387600031
J	O'Flynn, N; Rymer, J				O'Flynn, N; Rymer, J			Women's attitudes to the sex of medical students in a gynaecology clinic: cross sectional survey	BRITISH MEDICAL JOURNAL			English	Article									Guys Kings & St Thomass Sch Med, Dept Gen Practice & Primary Care, London SE11 6SP, England	University of London; King's College London	O'Flynn, N (corresponding author), Guys Kings & St Thomass Sch Med, Dept Gen Practice & Primary Care, London SE11 6SP, England.							Ching SL, 2000, AM J OBSTET GYNECOL, V182, P1429, DOI 10.1067/mob.2000.106133; General Medical Council, 1993, TOM DOCT; Kleinman DE, 1996, ACAD MED, V71, P1239, DOI 10.1097/00001888-199611000-00021	3	47	52	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 28	2002	325	7366					683	684		10.1136/bmj.325.7366.683	http://dx.doi.org/10.1136/bmj.325.7366.683			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	600JV	12351360	Green Published, Bronze			2022-12-28	WOS:000178387600020
J	Furrer, G; Phillips, BL; Ulrich, KU; Pothig, R; Casey, WH				Furrer, G; Phillips, BL; Ulrich, KU; Pothig, R; Casey, WH			The origin of aluminum flocs in polluted streams	SCIENCE			English	Article							AL-27 NMR; SPECIATION; POLYMER; SPECTROSCOPY; CHEMISTRY; COMPLEXES; SULFATE; AL13	About 240,000 square kilometers of Earths surface is disrupted by mining, which creates watersheds that are polluted by acidity, aluminum, and heavy metals. Mixing of acidic effluent from old mines and acidic soils into waters with a higher pH causes precipitation of amorphous aluminum oxyhydroxide flocs that move in streams as suspended solids and transport adsorbed contaminants. On the basis of samples from nine streams, we show that these flocs probably form from aggregation of the epsilon-Keggin polyoxocation AlO4Al12(OH)(24)(H2O)(12)(7+)(aq)(Al-13), because all of the flocs contain distinct Al(O)(4) centers similar to that of the Al-13 nanocluster.	Swiss Fed Inst Technol, Inst Terr Ecol, CH-8952 Schlieren, Switzerland; SUNY Stony Brook, Dept Geosci, Stony Brook, NY 11794 USA; Tech Univ Dresden, Ecol Stn Neunzehnhain, D-09514 Lengefeld, Germany; Leibniz Inst Freshwater Ecol & Inland Fisheries, D-12587 Berlin, Germany; Univ Calif Davis, Dept Land Air & Water Resources, Davis, CA 95616 USA; Univ Calif Davis, Dept Geol, Davis, CA 95616 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Technische Universitat Dresden; Leibniz Institut fur Gewasserokologie und Binnenfischerei (IGB); University of California System; University of California Davis; University of California System; University of California Davis	Furrer, G (corresponding author), Swiss Fed Inst Technol, Inst Terr Ecol, Grabenstr 3, CH-8952 Schlieren, Switzerland.							ALEMANY LB, 1986, J AM CHEM SOC, V108, P6158, DOI 10.1021/ja00280a008; Allouche L, 2000, ANGEW CHEM INT EDIT, V39, P511, DOI 10.1002/(SICI)1521-3773(20000204)39:3<511::AID-ANIE511>3.0.CO;2-N; Bertsch PM., 1996, ENV CHEM ALUM, V2, P117; Boisvert JP, 1999, COLLOID SURFACE A, V155, P161, DOI 10.1016/S0927-7757(98)00647-5; BOTTERO JY, 1987, J COLLOID INTERF SCI, V117, P47, DOI 10.1016/0021-9797(87)90166-4; BRADLEY SM, 1993, J COLLOID INTERF SCI, V159, P405, DOI 10.1006/jcis.1993.1340; BRADLEY SM, 1992, INORG CHEM, V31, P1181, DOI 10.1021/ic00033a012; CRUICKSHANK MC, 1986, J CHEM SOC CHEM COMM, P23; FURRER G, 1992, J COLLOID INTERF SCI, V149, P56, DOI 10.1016/0021-9797(92)90391-X; FURRER G, 1992, GEOCHIM COSMOCHIM AC, V56, P3831, DOI 10.1016/0016-7037(92)90174-H; Furrer G, 1999, GEOCHIM COSMOCHIM AC, V63, P3069, DOI 10.1016/S0016-7037(99)00234-3; HUNTER D, 1991, SCIENCE, V251, P1056, DOI 10.1126/science.251.4997.1056; Lothenbach B, 1997, ENVIRON SCI TECHNOL, V31, P1452, DOI 10.1021/es960697h; Masion A, 2000, ENVIRON SCI TECHNOL, V34, P3242, DOI 10.1021/es9911418; Massiot D., 1990, MAGN RESON CHEM, V28, P82; Nordstrom D.K., 1996, ENV CHEM ALUMINUM, P29; NORDSTROM DK, 1982, GEOCHIM COSMOCHIM AC, V46, P681, DOI 10.1016/0016-7037(82)90168-5; PARKER DR, 1989, SOIL SCI SOC AM J, V53, P789, DOI 10.2136/sssaj1989.03615995005300030027x; PHILLIPS BL, 1987, AM MINERAL, V72, P1190; Phillips BL, 2000, NATURE, V404, P379, DOI 10.1038/35006036; POLEO ABS, 1995, AQUAT TOXICOL, V31, P347, DOI 10.1016/0166-445X(94)00083-3; Rowsell J, 2000, J AM CHEM SOC, V122, P3777, DOI 10.1021/ja993711+; SMITH RW, 1972, 1827D US GEOL SURV W; Ulrich KU, 2000, ACTA HYDROCH HYDROB, V28, P313, DOI 10.1002/1521-401X(200012)28:6<313::AID-AHEH313>3.3.CO;2-X; WOESSNER DE, 1989, AM MINERAL, V74, P203	25	202	210	3	111	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 27	2002	297	5590					2245	2247		10.1126/science.1076505	http://dx.doi.org/10.1126/science.1076505			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	597LA	12351784				2022-12-28	WOS:000178222000042
J	Pirrotta, V				Pirrotta, V			Silence in the germ	CELL			English	Review							POLYCOMB-GROUP GENE; CAENORHABDITIS-ELEGANS; C-ELEGANS; EXPRESSION; PROTEIN; MES-2		Univ Geneva, Dept Zool, CH-1211 Geneva, Switzerland	University of Geneva	Pirrotta, V (corresponding author), Univ Geneva, Dept Zool, CH-1211 Geneva, Switzerland.							Fong YY, 2002, SCIENCE, V296, P2235, DOI 10.1126/science.1070790; Francis NJ, 2001, NAT REV MOL CELL BIO, V2, P409, DOI 10.1038/35073039; Garvin C, 1998, GENETICS, V148, P167; Holdeman R, 1998, DEVELOPMENT, V125, P2457; Kelly WG, 1998, DEVELOPMENT, V125, P2451; Kelly WG, 2002, DEVELOPMENT, V129, P479; Korf I, 1998, DEVELOPMENT, V125, P2469; Mello CC, 1996, NATURE, V382, P710, DOI 10.1038/382710a0; Nishioka K, 2002, GENE DEV, V16, P479, DOI 10.1101/gad.967202; O'Carroll D, 2001, MOL CELL BIOL, V21, P4330, DOI 10.1128/MCB.21.13.4330-4336.2001; Pirrotta V, 1998, CELL, V93, P333, DOI 10.1016/S0092-8674(00)81162-9; Poux S, 2001, GENE DEV, V15, P2509, DOI 10.1101/gad.208901; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Reinke V, 2000, MOL CELL, V6, P605, DOI 10.1016/S1097-2765(00)00059-9; Seydoux G, 1996, NATURE, V382, P713, DOI 10.1038/382713a0; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Wang JB, 2001, NAT GENET, V28, P371, DOI 10.1038/ng574; Xu L, 2001, GENETICS, V159, P1007	18	21	26	0	1	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 20	2002	110	6					661	664		10.1016/S0092-8674(02)00967-4	http://dx.doi.org/10.1016/S0092-8674(02)00967-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	596TV	12297039	Bronze			2022-12-28	WOS:000178182800001
J	McCarthy, M				McCarthy, M			USA moves quickly to push biodefence research	LANCET			English	Article																		Bradley KA, 2001, NATURE, V414, P225, DOI 10.1038/n35101999; Frey SE, 2002, NEW ENGL J MED, V346, P1265, DOI 10.1056/NEJMoa020534; NABEL G, 2000, NATURE, V408, P608; Pannifer AD, 2001, NATURE, V414, P229, DOI 10.1038/n35101998; Schuch R, 2002, NATURE, V418, P884, DOI 10.1038/nature01026	5	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 7	2002	360	9335					732	732		10.1016/S0140-6736(02)09938-5	http://dx.doi.org/10.1016/S0140-6736(02)09938-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	592HX	12296302				2022-12-28	WOS:000177933000004
J	Watanabe, S; Fukumoto, S; Chang, HG; Takeuchi, Y; Hasegawa, Y; Okazaki, R; Chikatsu, N; Fujita, T				Watanabe, S; Fukumoto, S; Chang, HG; Takeuchi, Y; Hasegawa, Y; Okazaki, R; Chikatsu, N; Fujita, T			Association between activating mutations of calcium-sensing receptor and Bartter's syndrome	LANCET			English	Article								Bartter's syndrome is a heterogeneous disorder characterised by deficient renal reabsorption of sodium and chloride, and hypokalaemic metabolic alkalosis with hyper-reninaemia and hyperaldosteronaemia. Mutations In several Ion transporters and channels have been associated with the pathogenesis of Bartter's syndrome. We describe two hypocalcaemic patients with deficient parathyroid hormone secretion who also showed characteristics of Bartter's syndrome. We found activating mutations of the gene for the calcium-sensing receptor (CASR) In both patients. Activation of this calcium-sensing receptor Inhibits the activity of a renal outer-medullary potassium channel that is mutated In type 2 Bartter's syndrome. We therefore suggest that some activating mutations of CASR could provide new mechanisms for the development of Bartter's syndrome.	Univ Tokyo, Sch Med, Dept Lab Med, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Sch Med, Dept Internal Med, Tokyo 1138655, Japan; Univ Tokyo, Hlth Serv Ctr, Tokyo 1138655, Japan; Tokyo Metropolitan Kiyose Childrens Hosp, Endocrinol Metab & Genet Unit, Tokyo, Japan; Teikyo Univ, Dept Internal Med 3, Chiba, Japan; Hitachi Gen Hosp, Dept Med, Ibaraki, Japan	University of Tokyo; University of Tokyo; University of Tokyo; Teikyo University	Fukumoto, S (corresponding author), Univ Tokyo, Sch Med, Dept Lab Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	fukumoto-tky@umin.ac.jp	Fukumoto, Seiji/B-7853-2015	Fukumoto, Seiji/0000-0003-3610-3469				Birkenhager R, 2001, NAT GENET, V29, P310, DOI 10.1038/ng752; Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239; Okzaki R, 1999, J CLIN ENDOCR METAB, V84, P363; Pearce SHS, 1996, NEW ENGL J MED, V335, P1115, DOI 10.1056/NEJM199610103351505; Zhao XM, 1999, FEBS LETT, V448, P180, DOI 10.1016/S0014-5793(99)00368-3	5	269	288	0	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 31	2002	360	9334					692	694		10.1016/S0140-6736(02)09842-2	http://dx.doi.org/10.1016/S0140-6736(02)09842-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	590AM	12241879				2022-12-28	WOS:000177795100014
J	Coluzzi, M; Sabatini, A; della Torre, A; Di Deco, MA; Petrarca, V				Coluzzi, M; Sabatini, A; della Torre, A; Di Deco, MA; Petrarca, V			A polytene chromosome analysis of the Anopheles gambiae species complex	SCIENCE			English	Article							INCIPIENT SPECIATION; RECENT ORIGIN; TRANSMISSION	Field-collected specimens of all known taxa in the Anopheles gambiae complex were analyzed on the basis of chromosome inversions with reference to a standard polytene chromosome map. The phylogenetic relationships among the seven described species in the complex could be inferred from the distribution of fixed inversions. Nonrandom patterns of inversion distribution were observed and, particularly on chromosome arm 2R, provided evidence for genetically distinct populations in A. gambiae, A. arabiensis, and A. melas. In A. gambiae from Mali, stable genetic differentiation was observed even in populations living in the same region, suggesting a process of incipient speciation which is being confirmed by studies with molecular markers. The possible role of chromosome differentiation in speciation of the A. gambiae complex and in the emergence of distinct chromosomal forms within the nominal species is discussed in relation to human malaria.	Univ Roma La Sapienza, Dipartimento Sci Sanita Pubbl, Rome, Italy; Univ Roma La Sapienza, Ist Pasteur Cenci Bolognetti, Rome, Italy; Univ Roma La Sapienza, Dipartimento Genet & Biol Mol, Rome, Italy	Sapienza University Rome; Fondazione Cenci Bolognetti; Sapienza University Rome; Sapienza University Rome	Coluzzi, M (corresponding author), Univ Roma La Sapienza, Dipartimento Sci Sanita Pubbl, Rome, Italy.	mario.coluzzi@uniroma1.it						Bryan J.H., 1987, Parassitologia (Rome), V29, P221; CARSON HL, 1969, AM NAT, V103, P323, DOI 10.1086/282605; CARSON HL, 1967, P NATL ACAD SCI USA, V57, P1280, DOI 10.1073/pnas.57.5.1280; Cavalli-Sforza LL, 1994, HIST GEOGRAPHY HUMAN, P1; COLUZZI M, 1985, B ZOOL, V52, P45, DOI 10.1080/11250008509440343; Coluzzi M., 1968, Parassitologia, V10, P155; Coluzzi M., 1969, Parassitologia, V11, P177; COLUZZI M, 1979, T ROY SOC TROP MED H, V73, P483, DOI 10.1016/0035-9203(79)90036-1; COLUZZI M, 1992, PARASITOL TODAY, V8, P113, DOI 10.1016/0169-4758(92)90277-9; Coluzzi M., 1982, Progress in Clinical and Biological Research, V96, P143; Coluzzi M, 1999, PARASSITOLOGIA, VOL 41, NOS 1-3, SEPTEMBER 1999, P277; COLUZZI M, 1966, ATTI ACCAD NAZ LIN, V40, P671; Coluzzi M., 1967, Parassitologia, V9, P73; COLUZZI M, 1997, ACC NAZ LINCEI SEMIN, V23, P263; COLUZZI M, UNPUB; COSTANTINI C, UNPUB; DAVIDSON G, 1962, B WORLD HEALTH ORGAN, V27, P303; DAVIDSON G, 1964, Riv Malariol, V43, P167; della Torre A, 2001, INSECT MOL BIOL, V10, P9, DOI 10.1046/j.1365-2583.2001.00235.x; della Torre A, 2002, SCIENCE, V298, P115, DOI 10.1126/science.1078170; dellaTorre A, 1997, GENETICS, V146, P239; FANELLO C, IN PRESS INSECT MOL; Favia G, 1997, INSECT MOL BIOL, V6, P377, DOI 10.1046/j.1365-2583.1997.00189.x; FLINT J, 1993, BAILLIERE CLIN HAEM, V6, P215, DOI 10.1016/S0950-3536(05)80071-X; GARRETTJONES C, 1964, NATURE, V204, P1173, DOI 10.1038/2041173a0; Holt RA, 2002, SCIENCE, V298, P129, DOI 10.1126/science.1076181; Hunt RH, 1998, T ROY SOC TROP MED H, V92, P231, DOI 10.1016/S0035-9203(98)90761-1; Lavachery P., 1996, ANTHROPOLOGIE PREHIS, V107, P197; LIVINGSTONE FB, 1958, AM ANTHROPOL, V60, P533, DOI 10.1525/aa.1958.60.3.02a00110; Maley J, 2002, IDS BULL-I DEV STUD, V33, P13, DOI 10.1111/j.1759-5436.2002.tb00003.x; Maley J, 1997, NATO ASI SER SER I, V49, P611; Modiano D, 2001, NATURE, V414, P305, DOI 10.1038/35104556; OSLISLY R, 1995, AZANIA, V24, P324; Petrarca V, 2000, MED VET ENTOMOL, V14, P149, DOI 10.1046/j.1365-2915.2000.00231.x; Petrarca V., 1984, Parassitologia (Rome), V26, P247; Power E, 1999, CRIT-Q LIT ART, V41, P101; Rich SM, 1998, P NATL ACAD SCI USA, V95, P4425, DOI 10.1073/pnas.95.8.4425; Tishkoff SA, 2001, SCIENCE, V293, P455, DOI 10.1126/science.1061573; Toure Y. T., 1998, Parassitologia (Rome), V40, P477; TOURE YT, 1994, GENETICA, V94, P213, DOI 10.1007/BF01443435; TOURE YT, 1983, PARASSITOLOGIA, V25, P367; Volkman SK, 2001, SCIENCE, V293, P482, DOI 10.1126/science.1059878; WASSERMAN M, 1963, AM NAT, V97, P333, DOI 10.1086/282284; WHITE GB, 1974, T ROY SOC TROP MED H, V68, P278, DOI 10.1016/0035-9203(74)90035-2	44	324	334	1	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 15	2002	298	5597					1415	1418		10.1126/science.1077769	http://dx.doi.org/10.1126/science.1077769			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	615AF	12364623				2022-12-28	WOS:000179223100050
J	Kroeger, A; Avila, EV; Morison, L				Kroeger, A; Avila, EV; Morison, L			Insecticide impregnated curtains to control domestic transmission of cutaneous leishmaniasis in Venezuela: cluster randomised trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PRIMARY HYPERPARATHYROIDISM; PHLEBOTOMINE SANDFLIES; ADENOMA WEIGHT; NEPHROLITHIASIS; PATHOGENESIS; EFFICACY; BEDNETS; STONES; RISK	Objective To measure the impact on transmission of leishmaniasis of curtains impregnated with insecticide. Design Cluster randomised controlled trial: household interview survey, observational study of people's behaviour, entomological study with light trap captures of sandflies inside houses. Setting 14 urban sectors in Trujillo, Venezuela. Participants 2913 inhabitants of 569 houses. Intervention Sectors were paired according to their 12 month cumulative incidence of cutaneous leishmaniasis, one sector in each pair was randomly allocated to receive polyester curtains impregnated with lambdacyhalothrin (intervention group) while the other sector received curtains without insecticide or no curtains (control groups). After 12 months a follow up household survey was conducted. Main outcome measures Reduction in abundance of sandflies indoors and 12 month incidence of clinical cases of cutaneous leishmaniasis. Results Transmission of cutaneous leishmaniasis occurred mainly in the domestic setting, with the incidence over 12 months of 4%. The mean number of sandflies per trap per night was 16. After follow up the 12 month incidence of cutaneous leishmaniasis was 0% in the intervention group and 8% in the six pairs in the control group that received unimpregnated curtains (mean difference 8, 95% confidence interval 4.22 to 11.78; P=0.001). There were significantly fewer sandflies in the intervention group (2 v 15, mean difference 13 sandflies per trap; 9 to 17; P < 0.001). Conclusion Curtains impregnated with insecticide provide a high degree of protection against indoor transmission of cutaneous leishmaniasis.	Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England; Univ Los Andes, Res Ctr Jose W Torrealba Nucl Univ Rafael Rangel, Trujillo, Venezuela; Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England	Liverpool School of Tropical Medicine; University of Liverpool; University of Los Andes Venezuela; University of London; London School of Hygiene & Tropical Medicine	Kroeger, A (corresponding author), Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England.	A.Kroeger@liverpool.ac.uk	Morison, Linda A/H-9738-2013	Kroeger, Axel/0000-0001-8438-2904				Akerstrom G, 1997, SEMIN SURG ONCOL, V13, P104, DOI 10.1002/(SICI)1098-2388(199703/04)13:2<104::AID-SSU6>3.0.CO;2-D; ALEXANDER B, 1995, MED VET ENTOMOL, V9, P279, DOI 10.1111/j.1365-2915.1995.tb00134.x; Andersen TF, 1999, DAN MED BULL, V46, P263; Brandao SP, 1999, T ROY SOC TROP MED H, V93, P488, DOI 10.1016/S0035-9203(99)90346-2; BROADUS AE, 1980, NEW ENGL J MED, V302, P421, DOI 10.1056/NEJM198002213020801; Campbell-Lendrum D, 2001, MEM I OSWALDO CRUZ, V96, P159, DOI 10.1590/S0074-02762001000200004; COE FL, 1992, NEW ENGL J MED, V327, P1141, DOI 10.1056/NEJM199210153271607; DANGELO A, 1992, MINER ELECTROL METAB, V18, P359; Davies C R, 2000, Cad Saude Publica, V16, P925, DOI 10.1590/S0102-311X2000000400013; Davies CR, 2000, T ROY SOC TROP MED H, V94, P631, DOI 10.1016/S0035-9203(00)90214-1; Elnaiem DA, 1999, MED VET ENTOMOL, V13, P310, DOI 10.1046/j.1365-2915.1999.00191.x; Elnaiem DA, 1999, MED VET ENTOMOL, V13, P191, DOI 10.1046/j.1365-2915.1999.00183.x; FELICIANGELI M D, 1987, Memorias do Instituto Oswaldo Cruz, V82, P125, DOI 10.1590/S0074-02761987000100020; Feliciangeli M.D., 1995, B DIRECCION MALARIOL, V35, P127; Feliciangeli MD, 1997, J MED ENTOMOL, V34, P110, DOI 10.1093/jmedent/34.2.110; Frokjaer VG, 2002, WORLD J SURG, V26, P532, DOI 10.1007/s00268-001-0262-6; GUEVARA P, 1993, MEM I O CRUZ, V88, P80; HALABE A, 1992, DISORDERS BONE MINER, P671; HEDBACK G, 1995, SURGERY, V117, P134, DOI 10.1016/S0039-6060(05)80076-5; JOHANSSON H, 1975, SURGERY, V77, P691; Klugman Vanessa A., 1994, P505; LLOYD HM, 1968, MEDICINE, V47, P53, DOI 10.1097/00005792-196801000-00003; MAJORI G, 1989, MED VET ENTOMOL, V3, P441, DOI 10.1111/j.1365-2915.1989.tb00253.x; Martinez E, 1998, ACTA TROP, V71, P97, DOI 10.1016/S0001-706X(98)00049-7; Mollerup CL, 1999, WORLD J SURG, V23, P173, DOI 10.1007/PL00013175; MOSEKILDE L, 1989, BONE MINER, V5, P279, DOI 10.1016/0169-6009(89)90006-8; PAK CYC, 1981, J CLIN ENDOCR METAB, V53, P536, DOI 10.1210/jcem-53-3-536; PARFITT MA, 1994, PARATHYROID, P373; PERRUOLO G, 1995, B DIRECCION MALARIOL, V35, P295; POSEN S, 1985, Q J MED, V54, P241; Scorza J. V., 1985, Boletin de la Direccion de Malariologia y Saneamiento Ambiental, V25, P45; Scorza J.V., 1989, Boletin de la Direccion de Malariologia y Saneamiento Ambiental, V29, P64; Scorza J. V., 1999, Boletin de la Direccion de Malariologia y Saneamiento Ambiental, V39, P83; Scorza J. V., 1990, B DIRECCION MALARIOL, V30, P14; SILVERBERG SJ, 1990, AM J MED, V89, P327, DOI 10.1016/0002-9343(90)90346-F; Soreide JA, 1996, SURGERY, V120, P1033, DOI 10.1016/S0039-6060(96)80051-1; TOLEZANO JE, 1994, MEM I OSWALDO CRUZ, V89, P427, DOI 10.1590/S0074-02761994000300026; Torrez M, 1998, ACTA TROP, V71, P311, DOI 10.1016/S0001-706X(98)00068-0; Ukoumunne OC, 1999, BRIT MED J, V319, P376, DOI 10.1136/bmj.319.7206.376; Vestergaard P, 2000, BRIT MED J, V321, P598, DOI 10.1136/bmj.321.7261.598; WILLIAMS JG, 1992, AM J SURG, V163, P301, DOI 10.1016/0002-9610(92)90007-E	41	68	72	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 12	2002	325	7368					810	813		10.1136/bmj.325.7368.810	http://dx.doi.org/10.1136/bmj.325.7368.810			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	604YM	12376442	Green Published, Bronze, Green Accepted			2022-12-28	WOS:000178648700019
J	Tsutsui, KI; Sakata, H; Naganuma, T; Taira, M				Tsutsui, KI; Sakata, H; Naganuma, T; Taira, M			Neural correlates for perception of 3D surface orientation from texture gradient	SCIENCE			English	Article							INFERIOR TEMPORAL CORTEX; DISPARITY SELECTIVITY; BINOCULAR DISPARITY; VISUAL-CORTEX; NEURONS; DISCRIMINATION; MACAQUE; FMRI	A goal in visual neuroscience is to reveal how the visual system reconstructs the three-dimensional (3D) representation of the world from two-dimensional retinal images. Although the importance of texture gradient cues in the process of 3D vision has been pointed out, most studies concentrate on the neural process based on binocular disparity. We report the neural correlates of depth perception from texture gradient in the cortex. In the caudal part of the lateral bank of intraparietal sulcus, many neurons were selective to 3D surface orientation defined by texture gradient, and their response was invariant over different types of texture pattern. Most of these neurons were also sensitive to a disparity gradient, suggesting that they integrate texture and disparity gradient signals to construct a generalized representation of 3D surface orientation.	Nihon Univ, Sch Med, Dept Physiol, Tokyo 1738610, Japan; Nihon Univ, Sch Med, Dept Neurol, Tokyo 1738610, Japan; Seitoku Jr Coll Nutr, Lab Anat & Physiol, Tokyo 1248530, Japan	Nihon University; Nihon University	Tsutsui, KI (corresponding author), Nihon Univ, Sch Med, Dept Physiol, Tokyo 1738610, Japan.		Tsutsui, Ken-Ichiro/B-4378-2008	Tsutsui, Ken-Ichiro/0000-0001-5781-2948				Adams DL, 2001, J NEUROPHYSIOL, V86, P2195, DOI 10.1152/jn.2001.86.5.2195; ADAMS DL, 1997, THESIS U COLL LONDON; BARLOW HB, 1967, J PHYSIOL-LONDON, V193, P327, DOI 10.1113/jphysiol.1967.sp008360; CUTTING JE, 1984, J EXP PSYCHOL GEN, V113, P198, DOI 10.1037/0096-3445.113.2.198; Gallant Jack L., 1995, P89; Gibson JJ, 1950, PERCEPTION VISUAL WO; GULYAS B, 1994, P NATL ACAD SCI USA, V91, P1239, DOI 10.1073/pnas.91.4.1239; Hinkle DA, 2002, NAT NEUROSCI, V5, P665, DOI 10.1038/nn875; Howard IP, 1995, BINOCULAR VISION STE; HUBEL DH, 1987, J NEUROSCI, V7, P3378; Janssen P, 2000, NEURON, V27, P385, DOI 10.1016/S0896-6273(00)00045-3; Julesz B., 1971, FDN CYCLOPEAN PERCEP; NIKARA T, 1968, EXP BRAIN RES, V6, P353; OGLE KN, 1964, BINOCULAR VISION; POGGIO GF, 1988, J NEUROSCI, V8, P4531; POGGIO GF, 1985, VISION RES, V25, P397, DOI 10.1016/0042-6989(85)90065-3; Sereno ME, 2002, NEURON, V33, P635, DOI 10.1016/S0896-6273(02)00598-6; Shikata E, 1996, NEUROREPORT, V7, P2389, DOI 10.1097/00001756-199610020-00022; Shikata E, 2001, J NEUROPHYSIOL, V85, P1309, DOI 10.1152/jn.2001.85.3.1309; STEVENS KA, 1981, BIOL CYBERN, V42, P95, DOI 10.1007/BF00336727; Taira M, 2000, J NEUROPHYSIOL, V83, P3140, DOI 10.1152/jn.2000.83.5.3140; Taira M, 2001, NEUROIMAGE, V14, P959, DOI 10.1006/nimg.2001.0895; Tsutsui KI, 2001, J NEUROPHYSIOL, V86, P2856, DOI 10.1152/jn.2001.86.6.2856; Uka T, 2000, J NEUROPHYSIOL, V84, P120, DOI 10.1152/jn.2000.84.1.120	24	157	159	1	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 11	2002	298	5592					409	412		10.1126/science.1074128	http://dx.doi.org/10.1126/science.1074128			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	602NB	12376700				2022-12-28	WOS:000178510400047
J	Christophides, GK; Zdobnov, E; Barillas-Mury, C; Birney, E; Blandin, S; Blass, C; Brey, PT; Collins, FH; Danielli, A; Dimopoulos, G; Hetru, C; Hoa, NT; Hoffmann, JA; Kanzok, SM; Letunic, I; Levashina, EA; Loukeris, TG; Lycett, G; Meister, S; Michel, K; Moita, LF; Muller, HM; Osta, MA; Paskewitz, SM; Reichhart, JM; Rzhetsky, A; Troxler, L; Vernick, KD; Vlachou, D; Volz, J; von Mering, C; Xu, JN; Zheng, LB; Bork, P; Kafatos, FC				Christophides, GK; Zdobnov, E; Barillas-Mury, C; Birney, E; Blandin, S; Blass, C; Brey, PT; Collins, FH; Danielli, A; Dimopoulos, G; Hetru, C; Hoa, NT; Hoffmann, JA; Kanzok, SM; Letunic, I; Levashina, EA; Loukeris, TG; Lycett, G; Meister, S; Michel, K; Moita, LF; Muller, HM; Osta, MA; Paskewitz, SM; Reichhart, JM; Rzhetsky, A; Troxler, L; Vernick, KD; Vlachou, D; Volz, J; von Mering, C; Xu, JN; Zheng, LB; Bork, P; Kafatos, FC			Immunity-related genes and gene families in Anopheles gambiae	SCIENCE			English	Article							COMPLEMENT-LIKE PROTEIN; GRAM-NEGATIVE BACTERIA; MALARIA VECTOR; GERMLINE TRANSFORMATION; MOLECULAR-CLONING; DROSOPHILA TOLL; MOSQUITO; ACTIVATION; RECEPTOR; PROPHENOLOXIDASE	We have identified 242 Anopheles gambiae genes from 18 gene families implicated in innate immunity and have detected marked diversification relative to Drosophila melanogaster. Immune-related gene families involved in recognition, signal modulation, and effector systems show a marked deficit of orthologs and excessive gene expansions, possibly reflecting selection pressures from different pathogens encountered in these insects very different life-styles. In contrast, the multifunctional Toll signal transduction pathway is substantially conserved, presumably because of counterselection for developmental stability. Representative expression profiles confirm that sequence diversification is accompanied by specific responses to different immune challenges. Alternative RNA splicing may also contribute to expansion of the immune repertoire.	European Mol Biol Lab, D-69117 Heidelberg, Germany; Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA; European Bioinformat Inst, European Mol Biol Lab, Cambridge CB10 1SD, England; Inst Pasteur, Unite Biochim & Biol Mol Insectes, F-75724 Paris 15, France; Univ Notre Dame, Ctr Trop Dis Res & Training, Notre Dame, IN 46556 USA; Univ London Imperial Coll Sci Technol & Med, Ctr Mol Microbiol & Infect, Dept Biol Sci, London SW7 2AZ, England; CNRS, Inst Biol Mol & Cellulaire, Unite Propre Rech 9022, F-67084 Strasbourg, France; Yale Univ, Sch Med Epidemiol & Publ Hlth, New Haven, CT 06520 USA; Fdn Res & Technol Hellas, Inst Mol Biol & Biotechnol, GR-71110 Iraklion, Crete, Greece; Univ Wisconsin, Dept Entomol, Russell Lab 237, Madison, WI 53706 USA; Columbia Univ, Dept Med Informat, New York, NY 10032 USA; Columbia Univ, Columbia Genome Ctr, New York, NY 10032 USA; NYU, Sch Med, Dept Med & Mol Parasitol, New York, NY 10010 USA	European Molecular Biology Laboratory (EMBL); Colorado State University; European Molecular Biology Laboratory (EMBL); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Notre Dame; Imperial College London; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Yale University; Foundation for Research & Technology - Hellas (FORTH); University of Wisconsin System; University of Wisconsin Madison; Columbia University; Columbia University; New York University	Kafatos, FC (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.	dg-office@embl-heidelberg.de	Bremner, James D/B-1632-2013; Moita, Luis/HCI-2793-2022; Zdobnov, Evgeny/AAB-2745-2022; Michel, Kristin/F-3400-2011; Blandin, Stephanie/ABH-2267-2021; Moita, Luis F./L-1296-2013; DANIELLI, ALBERTO/AFQ-1474-2022; Blandin, Stephanie/I-2786-2016; Bork, Peer/F-1813-2013; Letunic, Ivica/K-1102-2019; Letunic, Ivica/A-6032-2009; rzhetsky, andrey/B-6118-2012; von Mering, Christian/B-3300-2008; Meister, Stephan/M-6608-2014; Zdobnov, Evgeny M/K-1133-2012	Moita, Luis/0000-0003-0707-315X; Zdobnov, Evgeny/0000-0002-5178-1498; Blandin, Stephanie/0000-0003-4566-1200; Moita, Luis F./0000-0003-0707-315X; DANIELLI, ALBERTO/0000-0002-9414-9898; Blandin, Stephanie/0000-0003-4566-1200; Bork, Peer/0000-0002-2627-833X; Letunic, Ivica/0000-0003-3560-4288; rzhetsky, andrey/0000-0001-6959-7405; von Mering, Christian/0000-0001-7734-9102; Meister, Stephan/0000-0003-2436-7037; Ngo, Hoa/0000-0001-9320-4050; Christophides, George/0000-0002-3323-1687; Dimopoulos, George/0000-0001-6755-8111; Lycett, Gareth/0000-0002-2422-053X; Muller, Hans-Michael/0000-0002-2384-7285; Levashina, Elena/0000-0003-4605-906X; Vlachou, Dina/0000-0002-8305-3014; Birney, Ewan/0000-0001-8314-8497	NIAID NIH HHS [R01 AI046031] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barillas-Mury C, 1999, EMBO J, V18, P959, DOI 10.1093/emboj/18.4.959; BarillasMury C, 1996, EMBO J, V15, P4691, DOI 10.1002/j.1460-2075.1996.tb00846.x; Beerntsen BT, 2000, MICROBIOL MOL BIOL R, V64, P115, DOI 10.1128/MMBR.64.1.115-137.2000; Blandin S, 2002, EMBO REP, V3, P852, DOI 10.1093/embo-reports/kvf180; Catteruccia F, 2000, NATURE, V405, P959, DOI 10.1038/35016096; Catteruccia F, 2000, P NATL ACAD SCI USA, V97, P6236; Choe KM, 2002, SCIENCE, V296, P359, DOI 10.1126/science.1070216; COLLINS FH, 1986, SCIENCE, V234, P607, DOI 10.1126/science.3532325; DANIELLI A, UNPUB; De Gregorio E, 2002, EMBO J, V21, P2568, DOI 10.1093/emboj/21.11.2568; Dimopoulos G, 1998, EMBO J, V17, P6115, DOI 10.1093/emboj/17.21.6115; Dimopoulos G, 2001, CURR OPIN IMMUNOL, V13, P79, DOI 10.1016/S0952-7915(00)00186-2; Dimopoulos G, 1997, P NATL ACAD SCI USA, V94, P11508, DOI 10.1073/pnas.94.21.11508; Franc NC, 1996, IMMUNITY, V4, P431, DOI 10.1016/S1074-7613(00)80410-0; Gottar M, 2002, NATURE, V416, P640, DOI 10.1038/nature734; Grossman GL, 2001, INSECT MOL BIOL, V10, P597, DOI 10.1046/j.0962-1075.2001.00299.x; Han YS, 2000, EMBO J, V19, P6030, DOI 10.1093/emboj/19.22.6030; Hoffmann JA, 2002, NAT IMMUNOL, V3, P121, DOI 10.1038/ni0202-121; Jiang HB, 1997, INSECT BIOCHEM MOLEC, V27, P693, DOI 10.1016/S0965-1748(97)00045-3; Jiang HB, 2000, INSECT BIOCHEM MOLEC, V30, P95, DOI 10.1016/S0965-1748(99)00113-7; Kim YS, 2000, J BIOL CHEM, V275, P32721, DOI 10.1074/jbc.M003934200; Lagueux M, 2000, P NATL ACAD SCI USA, V97, P11427, DOI 10.1073/pnas.97.21.11427; Lai SC, 2002, J MED ENTOMOL, V39, P266, DOI 10.1603/0022-2585-39.2.266; Lee WJ, 1998, INSECT MOL BIOL, V7, P41, DOI 10.1046/j.1365-2583.1998.71047.x; Leulier F, 2000, EMBO REP, V1, P353, DOI 10.1093/embo-reports/kvd073; Levashina EA, 1999, SCIENCE, V285, P1917, DOI 10.1126/science.285.5435.1917; Levashina EA, 2001, CELL, V104, P709, DOI 10.1016/S0092-8674(01)00267-7; Ligoxygakis P, 2002, SCIENCE, V297, P114, DOI 10.1126/science.1072391; Luna C, 2002, INSECT BIOCHEM MOLEC, V32, P1171, DOI 10.1016/S0965-1748(02)00053-X; LYCETT G, UNPUB; Michel T, 2001, NATURE, V414, P756, DOI 10.1038/414756a; Muller HM, 1999, J BIOL CHEM, V274, P11727, DOI 10.1074/jbc.274.17.11727; MULLER HSP, UNPUB; Nagai T, 2000, J BIOL CHEM, V275, P29264, DOI 10.1074/jbc.M002556200; Oduol F, 2000, P NATL ACAD SCI USA, V97, P11397, DOI 10.1073/pnas.180060997; Ramet M, 2002, NATURE, V416, P644, DOI 10.1038/nature735; Shen BH, 1998, DEVELOPMENT, V125, P4719; Tauszig-Delamasure S, 2002, NAT IMMUNOL, V3, P91, DOI 10.1038/ni747; Vernooy SY, 2000, J CELL BIOL, V150, pF69, DOI 10.1083/jcb.150.2.F69; Vizioli J, 2001, P NATL ACAD SCI USA, V98, P12630, DOI 10.1073/pnas.221466798; Werner T, 2000, P NATL ACAD SCI USA, V97, P13772, DOI 10.1073/pnas.97.25.13772; Zdobnov EM, 2002, SCIENCE, V298, P149, DOI 10.1126/science.1077061	43	763	827	3	132	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 4	2002	298	5591					159	165		10.1126/science.1077136	http://dx.doi.org/10.1126/science.1077136			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	600BJ	12364793				2022-12-28	WOS:000178370500050
J	Deng, H; Weihs, G; Santori, C; Bloch, J; Yamamoto, Y				Deng, H; Weihs, G; Santori, C; Bloch, J; Yamamoto, Y			Condensation of semiconductor microcavity exciton polaritons	SCIENCE			English	Article							STIMULATED SCATTERING; QUANTUM-THEORY; COHERENCE; AMPLIFIER; DYNAMICS; LASERS	A phase transition from a classical thermal mixed state to a quantum-mechanical pure state of exciton polaritons is observed in a GaAs multiple quantum-well microcavity from the decrease of the second-order coherence function. Supporting evidence is obtained from the observation of a nonlinear threshold behavior in the pump-intensity dependence of the emission, a polariton-like dispersion relation above threshold, and a decrease of the relaxation time into the lower polariton state. The condensation of microcavity exciton polaritons is confirmed.	Stanford Univ, Edward L Ginzton Lab, JST,ICORP, Quantum Entanglement Project, Stanford, CA 94305 USA; Univ Vienna, Inst Expt Phys, A-1090 Vienna, Austria; CNRS, LPN, F-91460 Marcoussis, France; NTT Corp, Basic Res Labs, Kanagawa, Japan	Stanford University; University of Vienna; Centre National de la Recherche Scientifique (CNRS); Nippon Telegraph & Telephone Corporation	Deng, H (corresponding author), Stanford Univ, Edward L Ginzton Lab, JST,ICORP, Quantum Entanglement Project, Stanford, CA 94305 USA.	dhui@stanford.edu	Bloch, Jacqueline/S-2062-2017; Deng, Hui/AAD-6979-2020; Yamamoto, Yoshihisa/A-2811-2012; Deng, Hui/A-7115-2009; Santori, Charles/A-7314-2009; Weihs, Gregor/G-2564-2013; Deng, Hui/E-8950-2010	Bloch, Jacqueline/0000-0001-7823-8420; Deng, Hui/0000-0003-0629-3230; Yamamoto, Yoshihisa/0000-0002-4150-6804; Weihs, Gregor/0000-0003-2260-3008; Deng, Hui/0000-0003-0629-3230				Baumberg JJ, 2000, PHYS REV B, V62, P16247, DOI 10.1103/PhysRevB.62.R16247; Bloch J, 1998, APPL PHYS LETT, V73, P1694, DOI 10.1063/1.122248; Burt EA, 1997, PHYS REV LETT, V79, P337, DOI 10.1103/PhysRevLett.79.337; Cao H, 1997, PHYS REV A, V55, P4632, DOI 10.1103/PhysRevA.55.4632; Ciuti C, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.041303; Ciuti C, 2000, PHYS REV B, V62, pR4825, DOI 10.1103/PhysRevB.62.R4825; Dang LS, 1998, PHYS REV LETT, V81, P3920, DOI 10.1103/PhysRevLett.81.3920; Dasbach G, 2000, PHYS REV B, V62, P13076, DOI 10.1103/PhysRevB.62.13076; Gardiner C. W., 1991, QUANTUM NOISE; GLAUBER RJ, 1963, PHYS REV, V130, P2529, DOI 10.1103/PhysRev.130.2529; GRIFFIN A, 1995, BOSEEINSTEIN CONDENS; Huang R, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.165314; Huang R, 2000, PHYS REV B, V61, pR7854, DOI 10.1103/PhysRevB.61.R7854; Imamoglu A, 1996, PHYS LETT A, V214, P193, DOI 10.1016/0375-9601(96)00175-2; Ketterle W, 1997, PHYS REV A, V56, P3291, DOI 10.1103/PhysRevA.56.3291; Khurgin JB, 2001, SOLID STATE COMMUN, V117, P307, DOI 10.1016/S0038-1098(00)00469-5; Kira M, 1997, PHYS REV LETT, V79, P5170, DOI 10.1103/PhysRevLett.79.5170; Kuwata-Gonokami M, 1997, PHYS REV LETT, V79, P1341, DOI 10.1103/PhysRevLett.79.1341; Moskalenko S. A., 2000, BOSEEINSTEIN CONDENS; Naraschewski M, 1999, PHYS REV A, V59, P4595, DOI 10.1103/PhysRevA.59.4595; Saba M, 2001, NATURE, V414, P731, DOI 10.1038/414731a; Savvidis PG, 2000, PHYS REV LETT, V84, P1547, DOI 10.1103/PhysRevLett.84.1547; Senellart P, 1999, PHYS REV LETT, V82, P1233, DOI 10.1103/PhysRevLett.82.1233; SMITHEY DT, 1993, PHYS REV LETT, V70, P1244, DOI 10.1103/PhysRevLett.70.1244; Tassone F, 1999, PHYS REV B, V59, P10830, DOI 10.1103/PhysRevB.59.10830; Tassone F, 2000, PHYS REV A, V62, DOI 10.1103/PhysRevA.62.063809; WEISBUCH C, 1992, PHYS REV LETT, V69, P3314, DOI 10.1103/PhysRevLett.69.3314; Yamamoto Y, 2000, NATURE, V405, P629, DOI 10.1038/35015196	28	648	656	3	172	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 4	2002	298	5591					199	202		10.1126/science.1074464	http://dx.doi.org/10.1126/science.1074464			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	600BJ	12364801				2022-12-28	WOS:000178370500058
J	Hastings, IM; Bray, PG; Ward, SA				Hastings, IM; Bray, PG; Ward, SA			A requiem for chloroquine	SCIENCE			English	Editorial Material							RESISTANT MALARIA		Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England	Liverpool School of Tropical Medicine; University of Liverpool	Hastings, IM (corresponding author), Univ Liverpool, Liverpool Sch Trop Med, Pembroke Pl, Liverpool L3 5QA, Merseyside, England.		Ward, Steve/G-6003-2015	Ward, Steve/0000-0003-2331-3192; Hastings, Ian/0000-0002-1332-742X				CURTIS CF, 1986, T ROY SOC TROP MED H, V80, P889, DOI 10.1016/0035-9203(86)90248-8; Dye C, 1997, P ROY SOC B-BIOL SCI, V264, P61, DOI 10.1098/rspb.1997.0009; Greenwood B, 2002, NATURE, V415, P670, DOI 10.1038/415670a; Hastings IM, 2000, PARASITOL TODAY, V16, P340, DOI 10.1016/S0169-4758(00)01707-5; Hastings IM, 2002, PHILOS T ROY SOC B, V357, P505, DOI 10.1098/rstb.2001.1036; Sibley CH, 2001, TRENDS PARASITOL, V17, P582, DOI 10.1016/S1471-4922(01)02085-2; Sidhu ABS, 2002, SCIENCE, V298, P210, DOI 10.1126/science.1074045; Trape JF, 1998, CR ACAD SCI III-VIE, V321, P689, DOI 10.1016/S0764-4469(98)80009-7; Wellems TE, 2002, SCIENCE, V298, P124, DOI 10.1126/science.1078167; Wellems TE, 2001, J INFECT DIS, V184, P770, DOI 10.1086/322858	10	58	58	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 4	2002	298	5591					74	75		10.1126/science.1077573	http://dx.doi.org/10.1126/science.1077573			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	600BJ	12364772				2022-12-28	WOS:000178370500031
J	Chouard, T; Weiss, U; Dhand, R				Chouard, T; Weiss, U; Dhand, R			Good 'omics' for the poor?	NATURE			English	Editorial Material																		Weiss U, 2002, NATURE, V415, P669; 2002, NATURE, V419, P426; 2002, NATURE, V419, P493; 2001, NATURE MEDICINE, V7, P167	4	4	4	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 3	2002	419	6906					489	489		10.1038/419489a	http://dx.doi.org/10.1038/419489a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	599RF	12368859	Bronze			2022-12-28	WOS:000178348400040
J	Goyal, M; Mehta, RL; Schneiderman, LJ; Sehgal, AR				Goyal, M; Mehta, RL; Schneiderman, LJ; Sehgal, AR			Economic and health consequences of selling a kidney in India	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNCONVENTIONAL RENAL-TRANSPLANTATION; ORGAN DONATION; HIGH MORTALITY; SINGLE-CENTER; RECIPIENTS; DONORS; LIFE; INCENTIVES; DIALYSIS; QUALITY	Context Many countries have a shortage of kidneys available for transplantation. Paying people to donate kidneys is often proposed or justified as a way to benefit recipients by increasing the supply of organs and to benefit donors by improving their economic status. However, whether individuals who sell their kidneys actually benefit from the sale is controversial. Objective To determine the economic and health effects of selling a kidney. Design, Setting, and Participants Cross-sectional survey conducted in February 2001 among 305 individuals who had sold a kidney in Chennai, India, an average of 6 years before the survey. Main Outcome Measures Reasons for selling kidney, amount received from sale, how money was spent, change in economic status, change in health status, advice for others contemplating selling a kidney. Results Ninety-six percent of participants sold their kidneys to pay off debts. The average amount received was $1070. Most of the money received was spent on debts, food, and clothing. Average family income declined by one third after nephrectomy (P<.001), and the number of participants living below the poverty line increased. Three fourths of participants were still in debt at the time of the survey. About 86% of participants reported a deterioration in their health status after nephrectomy. Seventy-nine percent would not recommend that others sell a kidney. Conclusions Among paid donors in India, selling a kidney does not lead to a long-term economic benefit and may be associated with a decline in health. Physicians and policy makers should reexamine the value of using financial incentives to increase the supply of organs for transplantation.	Geisinger Hlth Syst, Dept Internal Med, State Coll, PA 16801 USA; Univ Calif San Diego, Dept Nephrol, San Diego, CA 92103 USA; Univ Calif San Diego, Sch Med, Dept Family & Prevent Med, San Diego, CA 92103 USA; Univ Calif San Diego, Sch Med, Dept Med, San Diego, CA 92103 USA; Metrohlth Med Ctr, Div Nephrol, Cleveland, OH USA; Metrohlth Med Ctr, Ctr Hlth Care Res & Policy, Cleveland, OH USA; Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Biomed Eth, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA	Geisinger Health System; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; MetroHealth System; MetroHealth System; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Goyal, M (corresponding author), Geisinger Hlth Syst, Dept Internal Med, 200 Scenery Dr, State Coll, PA 16801 USA.	madhavg1@yahoo.com	Mehta, Ravindra/ACD-4769-2022	Mehta, Ravindra/0000-0002-0908-2968				ABOUNA GM, 1990, TRANSPLANT P, V22, P918; ALKHADER AA, 1990, LANCET, V336, P1002, DOI 10.1016/0140-6736(90)92460-Y; Bloembergen WE, 1996, J AM SOC NEPHROL, V7, P1139; CAPLAN AL, 1993, TRANSPL P, V25, P2740; Chengappa, 1990, INDIA TODAY     0731, P60; Chugh KS, 1996, KIDNEY INT, V49, P1181, DOI 10.1038/ki.1996.171; Cohen L, 1999, DAEDALUS, V128, P135; COLABAWALLA BN, 1990, LANCET, V336, P1194, DOI 10.1016/0140-6736(90)92811-U; Council o f The Transplantation Society, 1985, LANCET, V2, P715; DAAR AS, 1992, TRANSPLANT P, V24, P2207; Delmonico FL, 2002, NEW ENGL J MED, V346, P2002, DOI 10.1056/NEJMsb013216; DREZE J, 1995, IND EC DEV SOCIAL OP, P109; Drukker A, 1998, LANCET, V352, P483, DOI 10.1016/S0140-6736(05)79215-1; EVANS RW, 1985, NEW ENGL J MED, V312, P553, DOI 10.1056/NEJM198502283120905; Finkel M, 2001, N Y Times Mag, P26; *FRONTL, 2002, KIDN STILL SAL; *FRONTL, 2002, KARN UN KIDN TRAD; *GOV IND PLANN COM, 2002, POV EST 1999 2000; *INT LAB OFF, 2002, YB LAB STAT 2000; Jha V, 2001, AM J KIDNEY DIS, V37, P119, DOI 10.1053/ajkd.2001.20596; Josefson D, 2002, BRIT MED J, V324, P1541, DOI 10.1136/bmj.324.7353.1541; Kennedy I, 1998, LANCET, V351, P1650, DOI 10.1016/S0140-6736(97)08212-3; Khan IH, 1998, LANCET, V352, P484, DOI 10.1016/S0140-6736(05)79218-7; Kher V, 2002, KIDNEY INT, V62, P350, DOI 10.1046/j.1523-1755.2002.00426.x; *LAB BUR, 2002, GOV IND; Lopes CS, 1996, INT J EPIDEMIOL, V25, P1267, DOI 10.1093/ije/25.6.1267; Lyon S, 1998, LANCET, V352, P484, DOI 10.1016/S0140-6736(05)79216-3; MANI MK, 1992, TRANSPLANT P, V24, P1828; Marshall P A, 1998, Ann Transplant, V3, P7; MEDAWAR P, 1984, LANCET, V2, P1344; MURRAY TH, 1992, TRANSPLANT IMMUNOL L, V8, P5; Oreopoulos DG, 1998, LANCET, V352, P484, DOI 10.1016/S0140-6736(05)79217-5; PATEL CT, 1988, TRANSPLANT P, V20, P1068; PELLEGRINO ED, 1991, JAMA-J AM MED ASSOC, V265, P1305, DOI 10.1001/jama.265.10.1305; PETERS TG, 1991, JAMA-J AM MED ASSOC, V265, P1302, DOI 10.1001/jama.265.10.1302; RADCLIFFERICHAR.J, 1991, ORGAN REPLACEMENT TH, P191; Reddy K. C., 1991, ORGAN REPLACEMENT TH, P173; REDDY KC, 1990, TRANSPLANT P, V22, P910; SALAHUDEEN AK, 1990, LANCET, V336, P725, DOI 10.1016/0140-6736(90)92214-3; Saran R, 1997, NEPHROL DIAL TRANSPL, V12, P1615, DOI 10.1093/ndt/12.8.1615; Scheper-Hughes N, 2000, CURR ANTHROPOL, V41, P191, DOI 10.1086/300123; Sehgal AR, 1997, AM J KIDNEY DIS, V29, P410, DOI 10.1016/S0272-6386(97)90203-1; Soper C, 1998, LANCET, V352, P484, DOI 10.1016/S0140-6736(05)79219-9; *STAT GOV TAM NAD, 2002, TAM NAD GLANC 2000; THIAGARAJAN CM, 1990, TRANSPLANT P, V22, P912; *UN NETW ORG SHAR, 2002, US FACTS TRANSPL; *UN POP FUND UN SY, 1997, IND POP DEV GOALS; Velasco N, 1998, LANCET, V352, P483, DOI 10.1016/S0140-6736(98)26032-6; Wolfe RA, 1999, NEW ENGL J MED, V341, P1725, DOI 10.1056/NEJM199912023412303; Zargooshi J, 2001, J UROLOGY, V166, P1790, DOI 10.1016/S0022-5347(05)65677-7; Zargooshi J, 2001, J UROLOGY, V165, P386, DOI 10.1097/00005392-200102000-00008; 2000, INDIA REDUCING POVER; 1994, STAT YB 1992, P341	53	252	254	1	21	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	2002	288	13					1589	1593		10.1001/jama.288.13.1589	http://dx.doi.org/10.1001/jama.288.13.1589			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	599BJ	12350189	Bronze			2022-12-28	WOS:000178314000019
J	Llopart, A; Elwyn, S; Coyne, JA				Llopart, A; Elwyn, S; Coyne, JA			Fruitflies - Pigmentation and mate choice in Drosophila	NATURE			English	Article									Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA	University of Chicago	Llopart, A (corresponding author), Univ Chicago, Dept Ecol & Evolut, 940 E 57th St, Chicago, IL 60637 USA.	j-coyne@uchicago.edu						DAVID JR, 1985, GENET SEL EVOL, V17, P211, DOI 10.1186/1297-9686-17-2-211; Kopp A, 2001, NATURE, V410, P611, DOI 10.1038/35069125	2	15	15	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 26	2002	419	6905					360	360		10.1038/419360a	http://dx.doi.org/10.1038/419360a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	596ZB	12353025	Bronze			2022-12-28	WOS:000178195400035
J	Prie, D; Huart, V; Bakouh, N; Planelles, G; Dellis, O; Gerard, B; Hulin, P; Benque-Blanchet, F; Silve, C; Grandchamp, B; Friedlander, G				Prie, D; Huart, V; Bakouh, N; Planelles, G; Dellis, O; Gerard, B; Hulin, P; Benque-Blanchet, F; Silve, C; Grandchamp, B; Friedlander, G			Nephrolithiasis and osteoporosis associated with hypophosphatemia caused by mutations in the type 2a sodium-phosphate cotransporter.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MINERAL DENSITY; IDIOPATHIC HYPERCALCIURIA; FAMILIAL RESEMBLANCE; RICKETS; HERITABILITY; ULTRASOUND; PREVALENCE; PHOSPHORUS; THRESHOLD; NPT2	Background: Epidemiologic studies suggest that genetic factors confer a predisposition to the formation of renal calcium stones or bone demineralization. Low serum phosphate concentrations due to a decrease in renal phosphate reabsorption have been reported in some patients with these conditions, suggesting that genetic factors leading to a decrease in renal phosphate reabsorption may contribute to them. We hypothesized that mutations in the gene coding for the main renal sodium-phosphate cotransporter (NPT2a) may be present in patients with these disorders. Methods: We studied 20 patients with urolithiasis or bone demineralization and persistent idiopathic hypophosphatemia associated with a decrease in maximal renal phosphate reabsorption. The coding region of the gene for NPT2a was sequenced in all patients. The functional consequences of the mutations identified were analyzed by expressing the mutated RNA in Xenopus laevis oocytes. Results: Two patients, one with recurrent urolithiasis and one with bone demineralization, were heterozygous for two distinct mutations. One mutation resulted in the substitution of phenylalanine for alanine at position 48, and the other in a substitution of methionine for valine at position 147. Phosphate-induced current and sodium-dependent phosphate uptake were impaired in oocytes expressing the mutant NPT2a. Coinjection of oocytes with wild-type and mutant RNA indicated that the mutant protein had altered function. Conclusions: Heterozygous mutations in the NPT2a gene may be responsible for hypophosphatemia and urinary phosphate loss in persons with urolithiasis or bone demineralization.	Univ Paris 07, INSERM, U426, F-75018 Paris, France; Hop Bichat, Assistance Publ Hop Paris, Serv Physiol Explorat Fonct, F-75877 Paris, France; Hop Bichat, Assistance Publ Hop Paris, Serv Biochim B, F-75877 Paris, France; Inst Federatif Rech, Paris, France; Univ Paris 07, INSERM, U409, F-75018 Paris, France; Fac Med Necker Enfants Malad, INSERM, U467, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Prie, D (corresponding author), Univ Paris 07, INSERM, U426, 16 Rue Henri Huchard, F-75018 Paris, France.		Planelles, Gabrielle/F-9603-2013; Dellis, Olivier/E-8501-2011	Planelles, Gabrielle/0000-0002-7314-8837; Dellis, Olivier/0000-0003-0377-9163; Friedlander, Gerard/0000-0002-6854-4261				Arden NK, 1996, J BONE MINER RES, V11, P530; Beck L, 1998, P NATL ACAD SCI USA, V95, P5372, DOI 10.1073/pnas.95.9.5372; BUSCH A, 1994, P NATL ACAD SCI USA, V91, P8205, DOI 10.1073/pnas.91.17.8205; Chau Hien, 2001, Journal of the American Society of Nephrology, V12, p751A; COE FL, 1979, NEW ENGL J MED, V300, P337, DOI 10.1056/NEJM197902153000703; Danielson ME, 1999, J BONE MINER RES, V14, P102, DOI 10.1359/jbmr.1999.14.1.102; DEVERNEJOUL MC, 1982, CALCIFIED TISSUE INT, V34, P219, DOI 10.1007/BF02411240; Ferrari S, 1998, J CLIN ENDOCR METAB, V83, P358, DOI 10.1210/jc.83.2.358; FRANCIS F, 1995, NAT GENET, V11, P130, DOI 10.1038/ng1095-130; GRAY RW, 1977, J CLIN ENDOCR METAB, V45, P299, DOI 10.1210/jcem-45-2-299; HANSEN MA, 1992, J BONE MINER RES, V7, P1037; Jones AO, 2001, J AM SOC NEPHROL, V12, P507, DOI 10.1681/ASN.V123507; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; Lambert G, 2000, J MEMBRANE BIOL, V176, P133, DOI 10.1007/s002320001082; LJUNGHALL S, 1985, BRIT J UROL, V57, P370, DOI 10.1111/j.1464-410X.1985.tb06290.x; LUTZ J, 1990, AM J CLIN NUTR, V52, P872, DOI 10.1093/ajcn/52.5.872; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Murer H, 2000, PHYSIOL REV, V80, P1373, DOI 10.1152/physrev.2000.80.4.1373; PABICO RC, 1983, P EUR DIAL TRANS, V20, P450; Polito C, 2000, PEDIATR NEPHROL, V14, P1102; PORTALE AA, 1989, J CLIN INVEST, V83, P1494, DOI 10.1172/JCI114043; PRIDGEN DB, 1968, LANCET, V1, P537; Prie D, 1998, J AM SOC NEPHROL, V9, P1264; Prie D, 2001, KIDNEY INT, V60, P272, DOI 10.1046/j.1523-1755.2001.00796.x; RESNICK M, 1968, NEW ENGL J MED, V278, P1313, DOI 10.1056/NEJM196806132782403; ROBERTSON WG, 1983, BRIT J UROL, V55, P595, DOI 10.1111/j.1464-410X.1983.tb03383.x; Shen F H, 1978, Adv Exp Med Biol, V103, P217; SUKI WN, 2000, BRENNER RECTORS KIDN, V1, P520; TIEDER M, 1987, NEW ENGL J MED, V316, P125, DOI 10.1056/NEJM198701153160302; van den Heuvel L, 2001, NEPHROL DIAL TRANSPL, V16, P48, DOI 10.1093/ndt/16.1.48; WALTON RJ, 1975, LANCET, V2, P309, DOI 10.1016/S0140-6736(75)92736-1; White KE, 2000, NAT GENET, V26, P345, DOI 10.1038/81664; Williams CP, 1996, J CLIN PATHOL, V49, P881, DOI 10.1136/jcp.49.11.881; Xiao YS, 1997, BIOCHEM J, V323, P401, DOI 10.1042/bj3230401	35	243	248	2	11	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 26	2002	347	13					983	991		10.1056/NEJMoa020028	http://dx.doi.org/10.1056/NEJMoa020028			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	596RD	12324554				2022-12-28	WOS:000178178400004
J	Stegmayr, B; Asplund, K				Stegmayr, B; Asplund, K			Informed consent for genetic research on blood stored for more than a decade: a population based study	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Umea Univ Hosp, Dept Publ Hlth & Clin Med, S-90185 Umea, Sweden	Umea University	Stegmayr, B (corresponding author), Umea Univ Hosp, Dept Publ Hlth & Clin Med, S-90185 Umea, Sweden.	birgitta.stegmayr@medicin.umu.se						World Medical Association, 2013, JAMA, V310, P2191, DOI 10.1001/jama.2013.281053; HUHTASAARI F, 1993, CARDIOVASC RISK FACT, V3, P215; TUNSTALL-PEDOE H, 1988, Journal of Clinical Epidemiology, V41, P105	3	82	82	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 21	2002	325	7365					634	635		10.1136/bmj.325.7365.634	http://dx.doi.org/10.1136/bmj.325.7365.634			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	597WM	12242175	Green Published, Bronze			2022-12-28	WOS:000178243800028
J	Ogiso, H; Ishitani, R; Nureki, O; Fukai, S; Yamanaka, M; Kim, JH; Saito, K; Sakamoto, A; Inoue, M; Shirouzu, M; Yokoyama, S				Ogiso, H; Ishitani, R; Nureki, O; Fukai, S; Yamanaka, M; Kim, JH; Saito, K; Sakamoto, A; Inoue, M; Shirouzu, M; Yokoyama, S			Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains	CELL			English	Article							SITE-DIRECTED MUTAGENESIS; BINDING-DOMAIN; FACTOR-ALPHA; SIGNAL-TRANSDUCTION; ERBB RECEPTORS; FACTOR EGF; LIGAND; DIMERIZATION; RESIDUES; IDENTIFICATION	Epidermal growth factor (EGF) regulates cell proliferation and differentiation by binding to the EGF receptor (EGFR) extracellular region, comprising domains I-IV, with the resultant dimerization of the receptor tyrosine kinase. In this study, the crystal structure of a 2:2 complex of human EGF and the EGFR extracellular region has been determined at 3.3 Angstrom resolution. EGFR domains I-III are arranged in a C shape, and EGF is docked between domains I and III. The 1:1 EGF.EGFR complex dimerizes through a direct receptor.receptor interaction, in which a protruding beta-hairpin arm of each domain II holds the body of the other. The unique "receptor-mediated dimerization" was verified by EGFR mutagenesis.	RIKEN, Genom Sci Ctr, Yokohama, Kanagawa 2300045, Japan; Japan Sci & Technol Corp, ERATO, Yokoyama CytoLog Project, Tokyo, Japan; Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1130033, Japan; SPring 8, Harima Inst, RIKEN, Cellular Signaling Lab, Sayo, Hyogo 6795148, Japan; SPring 8, Harima Inst, RIKEN, Structurome Grp, Sayo, Hyogo 6795148, Japan	RIKEN; Japan Science & Technology Agency (JST); University of Tokyo; Japan Synchrotron Radiation Research Institute; RIKEN; Japan Synchrotron Radiation Research Institute; RIKEN	Yokoyama, S (corresponding author), RIKEN, Genom Sci Ctr, 1-7-22 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan.	yokoyama@biochem.s.u-tokyo.ac.jp	Shirouzu, Mikako/A-6521-2016; Yokoyama, Shigeyuki/N-6911-2015; Fukai, Shuya/X-4838-2018; Saito, Kazuki/K-6016-2012	Yokoyama, Shigeyuki/0000-0003-3133-7338; Fukai, Shuya/0000-0002-1241-1443; Saito, Kazuki/0000-0003-4663-1134; Ogiso, Hideo/0000-0002-8241-3006				Abe Y, 1998, J BIOL CHEM, V273, P11150, DOI 10.1074/jbc.273.18.11150; Aritomi M, 1999, NATURE, V401, P713, DOI 10.1038/44394; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAJAJ M, 1987, BIOCHIM BIOPHYS ACTA, V916, P220, DOI 10.1016/0167-4838(87)90112-9; BARBACCI EG, 1995, J BIOL CHEM, V270, P9585, DOI 10.1074/jbc.270.16.9585; BROWN PM, 1994, EUR J BIOCHEM, V225, P223, DOI 10.1111/j.1432-1033.1994.00223.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAMPION SR, 1990, BIOCHEMISTRY-US, V29, P9988, DOI 10.1021/bi00494a032; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; Degenhardt M, 1998, ACTA CRYSTALLOGR D, V54, P999, DOI 10.1107/S0907444998001851; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Domagala T, 2000, GROWTH FACTORS, V18, P11, DOI 10.3109/08977190009003231; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; Elleman TC, 2001, BIOCHEMISTRY-US, V40, P8930, DOI 10.1021/bi010037b; ENGLER DA, 1992, J BIOL CHEM, V267, P2274; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; Garrett TPJ, 1998, NATURE, V394, P395, DOI 10.1038/28668; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GROENEN LC, 1994, GROWTH FACTORS, V11, P235, DOI 10.3109/08977199409010997; GUNTHER N, 1990, J BIOL CHEM, V265, P22082; HALEY JD, 1989, ONCOGENE, V4, P273; HARVEY TS, 1991, EUR J BIOCHEM, V198, P555, DOI 10.1111/j.1432-1033.1991.tb16050.x; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim JH, 2002, EUR J BIOCHEM, V269, P2323, DOI 10.1046/j.1432-1033.2002.02877.x; KOHDA D, 1993, J BIOL CHEM, V268, P1976; KOHDA D, 1992, BIOCHEMISTRY-US, V31, P11928, DOI 10.1021/bi00162a036; KOIDE H, 1992, FEBS LETT, V302, P39, DOI 10.1016/0014-5793(92)80279-P; KOIDE H, 1992, BIOCHIM BIOPHYS ACTA, V1120, P257, DOI 10.1016/0167-4838(92)90245-9; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; Lemmon MA, 1997, EMBO J, V16, P281, DOI 10.1093/emboj/16.2.281; Lu HS, 2001, J BIOL CHEM, V276, P34913, DOI 10.1074/jbc.M102874200; MARQUARDT H, 1984, SCIENCE, V223, P1079, DOI 10.1126/science.6320373; McInnes C, 2000, PROTEIN ENG, V13, P143, DOI 10.1093/protein/13.3.143; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Odaka M, 1997, J BIOCHEM-TOKYO, V122, P116; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; Plotnikov AN, 2000, CELL, V101, P413, DOI 10.1016/S0092-8674(00)80851-X; Sako Y, 2000, NAT CELL BIOL, V2, P168, DOI 10.1038/35004044; Sato C, 2000, J BIOCHEM-TOKYO, V127, P65, DOI 10.1093/oxfordjournals.jbchem.a022585; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Stauber DJ, 2000, P NATL ACAD SCI USA, V97, P49, DOI 10.1073/pnas.97.1.49; Summerfield AE, 1996, J BIOL CHEM, V271, P19656, DOI 10.1074/jbc.271.33.19656; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; TADAKI DK, 1993, J BIOL CHEM, V268, P10114; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WARD CW, 1995, PROTEINS, V22, P141, DOI 10.1002/prot.340220207; Weeks CM, 1999, J APPL CRYSTALLOGR, V32, P120, DOI 10.1107/S0021889898010504; Wiesmann C, 1999, NATURE, V401, P184, DOI 10.1038/43705; WOLTJER RL, 1992, P NATL ACAD SCI USA, V89, P7801, DOI 10.1073/pnas.89.16.7801; WU DG, 1989, J BIOL CHEM, V264, P17469; WU DG, 1990, P NATL ACAD SCI USA, V87, P3151, DOI 10.1073/pnas.87.8.3151; YAMAMOTO T, 1983, CELL, V35, P71, DOI 10.1016/0092-8674(83)90209-X	62	842	928	12	117	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 20	2002	110	6					775	787		10.1016/S0092-8674(02)00963-7	http://dx.doi.org/10.1016/S0092-8674(02)00963-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	596TV	12297050	Bronze			2022-12-28	WOS:000178182800012
J	Hales, S; de Wet, N; Maindonald, J; Woodward, A				Hales, S; de Wet, N; Maindonald, J; Woodward, A			Potential effect of population and climate changes on global distribution of dengue fever: an empirical model	LANCET			English	Article							MALARIA; FUTURE; DISEASE	Background Existing theoretical models of the potential effects of climate change on vector-borne diseases do not account for social factors such as population increase, or interactions between climate variables. Our aim was to investigate the potential effects of global climate change on human health, and in particular, on the transmission of vector-borne diseases. Methods We modelled the reported global distribution of dengue fever on the basis of vapour pressure, which is a measure of humidity. We assessed changes in the geographical limits of dengue fever transmission, and in the number of people at risk of dengue by incorporating future climate change and human population projections into our model. Findings We showed that the current geographical limits of dengue fever transmission can be modelled with 89% accuracy on the basis of long-term average vapour pressure. In 1990, almost 30% of the world population, 1.5 billion people, lived in regions where the estimated risk of dengue transmission was greater than 50%. With population and climate change projections for 2085, we estimate that about 5-6 billion people (50-60% of the projected global population) would be at risk of dengue transmission, compared with 3.5 billion people, or 35% of the population, if climate change did not happen. Interpretation We conclude that climate change is likely to increase the area of land with a climate suitable for dengue fever transmission, and that if no other contributing factors were to change, a large proportion of the human population would then be put at risk.	Wellington Sch Med & Hlth Sci, Dept Publ Hlth, Wellington, New Zealand; Int Global Change Inst, Hamilton, New Zealand; Australian Natl Univ, Inst Math Sci, Canberra, ACT, Australia; Australian Natl Univ, John Curtin Sch Med Res, Ctr Bioinformat Sci, Canberra, ACT 2601, Australia	University of Otago; Australian National University; Australian National University; John Curtin School of Medical Research	Hales, S (corresponding author), Wellington Sch Med & Hlth Sci, Dept Publ Hlth, POB 7343,Mein St, Wellington, New Zealand.		hales, simon/E-5768-2010	Woodward, Alistair/0000-0001-5425-6018; Hales, Simon/0000-0002-4529-7595				Bos E, 1994, WORLD POPULATION PRO; Carter T. R., 1999, GUIDELINES USE SCENA; *COMM CLIM EC INF, 2001, WEATH CLIM EC INF DI; *DAT DISTR CTR, 2002, INT PAN CLIM CHANG; Emori S, 1999, J METEOROL SOC JPN, V77, P1299, DOI 10.2151/jmsj1965.77.6_1299; Flato GM, 2001, GEOPHYS RES LETT, V28, P195, DOI 10.1029/2000GL012121; Flato GM, 2000, CLIM DYNAM, V16, P451, DOI 10.1007/s003820050339; FOCKS DA, 1993, J MED ENTOMOL, V30, P1003, DOI 10.1093/jmedent/30.6.1003; Hales S, 1999, ENVIRON HEALTH PERSP, V107, P99, DOI 10.2307/3434364; Intergovernmental Panel on Climate Change, 2001, CLIM CHANG 2001 IMP; Johns TC, 1997, CLIM DYNAM, V13, P103, DOI 10.1007/s003820050155; LI Y, 2002, GLOBAL POPULATION DI; Martens P, 1999, GLOBAL ENVIRON CHANG, V9, pS89, DOI 10.1016/S0959-3780(99)00020-5; Martens WJM, 1997, CLIMATIC CHANGE, V35, P145, DOI 10.1023/A:1005365413932; New M, 1999, J CLIMATE, V12, P829, DOI 10.1175/1520-0442(1999)012<0829:RTCSTC>2.0.CO;2; Patz JA, 1998, ENVIRON HEALTH PERSP, V106, P147, DOI 10.1289/ehp.98106147; Reiter P, 2001, ENVIRON HEALTH PERSP, V109, P141, DOI 10.2307/3434853; Roeckner E., 1996, ATMOSPHERIC GEN CIRC; Rogers DJ, 2000, SCIENCE, V289, P1763, DOI 10.1126/science.289.5485.1763; World Health Organization, 2000, WHO REP GLOB SURV EP	20	589	629	8	217	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 14	2002	360	9336					830	834		10.1016/S0140-6736(02)09964-6	http://dx.doi.org/10.1016/S0140-6736(02)09964-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	594MC	12243917				2022-12-28	WOS:000178053500008
J	Koentges, G; Matsuoka, T				Koentges, G; Matsuoka, T			Jaws of the fates	SCIENCE			English	Editorial Material							EVOLUTION; GENES		Univ Coll, Wolfson Inst Biomed Res, London WC1E 6AU, England	University of London; University College London	Koentges, G (corresponding author), Univ Coll, Wolfson Inst Biomed Res, London WC1E 6AU, England.							Couly G, 2002, DEVELOPMENT, V129, P1061; Depew MJ, 2002, SCIENCE, V298, P381, DOI 10.1126/science.1075703; Gaupp E, 1912, ARCH ANAT PHYSL S, P1; Janvier P., 1996, EARLY VERTEBRATES; Le Douarin NM, 1999, NEURAL CREST, V2; Neidert AH, 2001, P NATL ACAD SCI USA, V98, P1665, DOI 10.1073/pnas.98.4.1665; Panganiban G, 1997, P NATL ACAD SCI USA, V94, P5162, DOI 10.1073/pnas.94.10.5162; Qiu MS, 1997, DEV BIOL, V185, P165, DOI 10.1006/dbio.1997.8556; Shigetani Y, 2002, SCIENCE, V296, P1316, DOI 10.1126/science.1068310; [No title captured]	10	11	12	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 11	2002	298	5592					371	+		10.1126/science.1077706	http://dx.doi.org/10.1126/science.1077706			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	602NB	12376690				2022-12-28	WOS:000178510400034
J	Fu, LN; Pelicano, H; Liu, JS; Huang, P; Lee, CC				Fu, LN; Pelicano, H; Liu, JS; Huang, P; Lee, CC			The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo	CELL			English	Article							C-MYC; CELL-CYCLE; INDUCED APOPTOSIS; SENSITIVE METHOD; P53; EXPRESSION; CLOCK; MPER2; PROLIFERATION; MECHANISM	The Period2 gene plays a key role in controlling circadian rhythm in mice. We report here that mice deficient in the mPer2 gene are cancer prone. After 7 radiation, these mice, show a marked increase in tumor development and reduced apoptosis in thymocytes. The core circadian genes are induced by gamma radiation in wildtype mice but not in mPer2 mutant mice. Temporal expression of genes involved in cell cycle regulation and tumor suppression, such as Cyclin D1, Cyclin A, Mdm-2, and Gadd45alpha, is deregulated in mPer2 mutant mice. In particular, the transcription of c-myc is controlled directly by circadian regulators and is deregulated in the mPer2 mutant. Our studies suggest that the mPer2 gene functions in tumor suppression by regulating DNA damage-responsive pathways.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Div Pathol & Lab Med, Houston, TX 77030 USA	Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Lee, CC (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza, Houston, TX 77030 USA.	ching@bcm.tmc.edu						Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; Anderson LE, 2000, CANCER LETT, V148, P121, DOI 10.1016/S0304-3835(99)00320-1; Bae K, 2001, NEURON, V30, P525, DOI 10.1016/S0896-6273(01)00302-6; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; Barbason H, 1995, IN VIVO, V9, P539; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; Bjarnason G A, 2000, Prog Cell Cycle Res, V4, P193; Bjarnason GA, 1999, AM J PATHOL, V154, P613, DOI 10.1016/S0002-9440(10)65306-0; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Facchini LM, 1997, MOL CELL BIOL, V17, P100, DOI 10.1128/MCB.17.1.100; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Fu LN, 1997, EMBO J, V16, P4117, DOI 10.1093/emboj/16.13.4117; Gao CF, 2001, EXP CELL RES, V265, P145; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hansen J, 2001, EPIDEMIOLOGY, V12, P74, DOI 10.1097/00001648-200101000-00013; Hecht JL, 2000, J CLIN ONCOL, V18, P3707, DOI 10.1200/JCO.2000.18.21.3707; Hrushesky WJM, 2001, J CONTROL RELEASE, V74, P27, DOI 10.1016/S0168-3659(01)00307-8; KLEVECZ RR, 1987, CANCER RES, V47, P6267; Kornmann B, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.11.e51; Lee TC, 1999, J BIOL CHEM, V274, P595, DOI 10.1074/jbc.274.2.595; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; McNamara P, 2001, CELL, V105, P877, DOI 10.1016/S0092-8674(01)00401-9; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Panda S, 2002, CELL, V109, P307, DOI 10.1016/S0092-8674(02)00722-5; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Pucci B, 2000, NEOPLASIA, V2, P291, DOI 10.1038/sj.neo.7900101; Reick M, 2001, SCIENCE, V293, P506, DOI 10.1126/science.1060699; Reppert SM, 2001, ANNU REV PHYSIOL, V63, P647, DOI 10.1146/annurev.physiol.63.1.647; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; Ruifrok ACC, 1998, RADIAT RES, V149, P360, DOI 10.2307/3579698; Rutter J, 2001, SCIENCE, V293, P510, DOI 10.1126/science.1060698; Shearman LP, 2000, SCIENCE, V288, P1013, DOI 10.1126/science.288.5468.1013; Sheen JH, 2002, MOL CELL BIOL, V22, P1819, DOI 10.1128/MCB.22.6.1819-1833.2002; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SPENCER CA, 1991, ADV CANCER RES, V56, P1; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Toh KL, 2001, SCIENCE, V291, P1040, DOI 10.1126/science.1057499; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Winningham ML, 2001, CANCER-AM CANCER SOC, V92, P988, DOI 10.1002/1097-0142(20010815)92:4+<988::AID-CNCR1411>3.0.CO;2-O; Wood PA, 1998, EXP HEMATOL, V26, P523; Yamaguchi S, 2000, CURR BIOL, V10, P873, DOI 10.1016/S0960-9822(00)00602-3; You ZB, 2002, J CELL BIOL, V157, P429, DOI 10.1083/jcb.200201110; Young MW, 2001, NAT REV GENET, V2, P702, DOI 10.1038/35088576; Zheng BH, 2001, CELL, V105, P683, DOI 10.1016/S0092-8674(01)00380-4; Zheng BH, 1999, NATURE, V400, P169, DOI 10.1038/22118; Zylka MJ, 1998, NEURON, V20, P1103, DOI 10.1016/S0896-6273(00)80492-4	54	953	1015	3	71	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 4	2002	111	1					41	50		10.1016/S0092-8674(02)00961-3	http://dx.doi.org/10.1016/S0092-8674(02)00961-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	601RQ	12372299	Bronze			2022-12-28	WOS:000178461900007
J	Kissinger, JC; Brunk, BP; Crabtree, J; Fraunholz, MJ; Gajria, B; Milgram, AJ; Pearson, DS; Schug, J; Bahl, A; Diskin, SJ; Ginsburg, H; Grant, GR; Gupta, D; Labo, P; Li, L; Mailman, MD; Mcweeney, SK; Whetzel, P; Stoeckert, CJ; Roos, DS				Kissinger, JC; Brunk, BP; Crabtree, J; Fraunholz, MJ; Gajria, B; Milgram, AJ; Pearson, DS; Schug, J; Bahl, A; Diskin, SJ; Ginsburg, H; Grant, GR; Gupta, D; Labo, P; Li, L; Mailman, MD; Mcweeney, SK; Whetzel, P; Stoeckert, CJ; Roos, DS			The Plasmodium genome database - Designing and mining a eukaryotic genomics resource	NATURE			English	Editorial Material									Univ Penn, Dept Biol, Philadelphia, PA 19104 USA; Univ Penn, Dept Genet, Ctr Bioinformat, Philadelphia, PA 19104 USA; Univ Penn, Genom Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Roos, DS (corresponding author), Univ Penn, Dept Biol, Philadelphia, PA 19104 USA.		Gupta, Dinesh/C-1079-2009; Kissinger, Jessica/M-9920-2019; Gupta, Dinesh/AAW-4243-2020; Kissinger, Jessica C/E-9610-2010; Grant, Gregory Robert/I-3599-2019	Gupta, Dinesh/0000-0002-7548-8835; Kissinger, Jessica/0000-0002-6413-1101; Gupta, Dinesh/0000-0002-7548-8835; Kissinger, Jessica C/0000-0002-6413-1101; Grant, Gregory Robert/0000-0002-0139-7658; McWeeney, Shannon/0000-0001-8333-6607; Fraunholz, Martin/0000-0002-4581-6244; Roos, David Siker/0000-0001-6725-4089				Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097	1	132	138	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 3	2002	419	6906					490	492		10.1038/419490a	http://dx.doi.org/10.1038/419490a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	599RF	12368860	Bronze			2022-12-28	WOS:000178348400041
J	Crawford, LM				Crawford, LM			Pharmacy compounding guidance	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Commissioner Food & Drugs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Crawford, LM (corresponding author), US FDA, Off Commissioner Food & Drugs, HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	3	3	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	2002	288	13					1579	1579		10.1001/jama.288.13.1579-c	http://dx.doi.org/10.1001/jama.288.13.1579-c			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	599BJ	12350176				2022-12-28	WOS:000178314000005
J	Wright, RS; Reeder, GS; Herzog, CA; Albright, RC; Williams, BA; Dvorak, DL; Miller, WL; Murphy, JG; Kopecky, SL; Jaffe, AS				Wright, RS; Reeder, GS; Herzog, CA; Albright, RC; Williams, BA; Dvorak, DL; Miller, WL; Murphy, JG; Kopecky, SL; Jaffe, AS			Acute myocardial infarction and renal dysfunction: A high-risk combination	ANNALS OF INTERNAL MEDICINE			English	Article							END-SYSTOLIC VOLUME; LONG-TERM SURVIVAL; THERAPY; FAILURE; DISEASE	Background: Survival is poor in patients with acute myocardial infarction (MI) who also have severe renal disease. Less is known about the outcome of acute MI in patients with mild to moderate renal insufficiency. Objective: To compare outcomes after acute MI in patients with varying levels of renal disease and in patients without renal failure. Design: Retrospective cohort study. Setting: Academic medical center. Patients: 3106 total patients admitted with acute MI and endstage renal disease (n = 44), severe renal insufficiency (creatinine clearance < 0.59 mL/s [<35 mL/min]) (n = 391), moderate renal dysfunction (creatinine clearance greater than or equal to 0.59 mL/s [<35 mL/min] but less than or equal to0.84 mL/s [less than or equal to50 mL/min]) (n = 491), mild chronic renal insufficiency (creatinine clearance > 0.84 mL/s [>50 mL/min] but less than or equal to1.25 mL/s [less than or equal to75 mL/min]) (n = 860), or no renal disease (n 1320). Measurements: Clinical characteristics, treatment strategies, and short- and long-term survival were compared after patients were stratified by creatinine clearance. Results: in-hospital mortality rates were 2% in patients with normal renal function, 6% in those with mild renal failure, 14% in those with moderate renal failure, 21% in those with severe renal failure, and 30% in those with end-stage renal disease (P < 0.001). Compared with patients without renal disease, similar adjusted trends were present for post-discharge death in patients with end-stage renal disease (hazard ratio, 5.4 95% CI, 3.0 to 9.71; P < 0.001), severe renal insufficiency (hazard ratio, 1.9 [Cl, 1.2 to 3.0]; P = 0.006), moderate renal dysfunction (hazard ratio, 2.2 [CI, 1.5 to 3.3]; P < 0.001), and mild chronic renal insufficiency (hazard ratio, 2.4 [Cl, 1.7 to 3.3]; P < 0.001). Patients with renal failure received adjunctive and reperfusion therapies less frequently than those with normal renal function (P < 0.001). Postdischarge death was less likely in patients who received acute reperfusion therapy (odds ratio, 0.7 [Cl, 0.6 to 0.9]), aspirin (odds ratio, 0.7 [CI, 0.5 to 0.8]), and beta-blocker therapy (odds ratio, 0.7 [Cl, 0.6 to 0.9]). Conclusion: Patients with renal failure are at increased risk for death after acute MI and receive less aggressive treatment than patients with normal renal function.	Mayo Clin, Mayo Alliance Clin Trials, Div Cardiol, Rochester, MN 55902 USA; Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA; Univ Minnesota, Hennepin Cty Med Ctr, Minneapolis, MN 55455 USA	Mayo Clinic; University of Minnesota System; University of Minnesota Twin Cities; Hennepin County Medical Center; University of Minnesota System; University of Minnesota Twin Cities	Wright, RS (corresponding author), Mayo Clin, Mayo Alliance Clin Trials, Div Cardiol, Stabile 5,150 3rd St SW, Rochester, MN 55902 USA.	wright.scott@mayo.edu						[Anonymous], 1986, Lancet, V2, P57; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Beattie JN, 2001, AM J KIDNEY DIS, V37, P1191, DOI 10.1053/ajkd.2001.24522; Becker BN, 1997, J AM SOC NEPHROL, V8, P475; Chertow GM, 2000, AM J KIDNEY DIS, V35, P1044, DOI 10.1016/S0272-6386(00)70038-2; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; GILLUM RF, 1984, AM HEART J, V108, P150, DOI 10.1016/0002-8703(84)90558-1; *GUSTO ANG INV, 1992, NEW ENGL J MED, V329, P1615; Hennekens CH, 1996, NEW ENGL J MED, V335, P1660, DOI 10.1056/NEJM199611283352207; HERLITZ J, 1991, J INTERN MED, V230, P233; Herzog CA, 2000, AM J KIDNEY DIS, V36, P145, DOI 10.1053/ajkd.2000.8287; Herzog CA, 1998, NEW ENGL J MED, V339, P799, DOI 10.1056/NEJM199809173391203; Herzog CA, 1997, CIRCULATION, V96, P2075; HJALMARSON A, 1985, EUR HEART J, V6, P199; Jungers P, 1997, NEPHROL DIAL TRANSPL, V12, P2597, DOI 10.1093/ndt/12.12.2597; Kasiske BL, 1996, J AM SOC NEPHROL, V7, P158; KILLIP T, 1967, AM J CARDIOL, V20, P457, DOI 10.1016/0002-9149(67)90023-9; KIMMEL PJ, 1998, PRIMER KIDNEY DIS; KONG TQ, 1993, CIRCULATION, V88, P49; Luke RG, 1998, NEW ENGL J MED, V339, P841, DOI 10.1056/NEJM199809173391211; Migrino RQ, 1997, CIRCULATION, V96, P116; Mourad JJ, 1997, HYPERTENSION, V30, P1425, DOI 10.1161/01.HYP.30.6.1425; *NAT I DIAB DIG KI, 1998, US REN DAT SYST 1998, P79; *NAT I DIAB DIG KI, 1998, US REN DAT SYST 1998, P51; *NIH, 1997, NIH PUBL, P35; *NIH, 1992, NIH PUBL, P61; Orth SR, 1997, KIDNEY INT, V51, P1669, DOI 10.1038/ki.1997.232; PEDERSEN TR, 1981, NEW ENGL J MED, V304, P801; Ritz E, 1998, NEPHROL DIAL TRANSPL, V13, P16, DOI 10.1093/ndt/13.suppl_2.16; ROBERTS R, 1991, CIRCULATION, V83, P422, DOI 10.1161/01.CIR.83.2.422; Rubin Timothy A., 1996, Journal of the American College of Cardiology, V27, p67A; Venkatesan J, 1997, SEMIN NEPHROL, V17, P257; WHITE HD, 1987, CIRCULATION, V76, P44, DOI 10.1161/01.CIR.76.1.44; 1998, AM J KIDNEY DIS S1, V32, pS9	34	471	496	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	2002	137	7					563	570		10.7326/0003-4819-137-7-200210010-00007	http://dx.doi.org/10.7326/0003-4819-137-7-200210010-00007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	599VD	12353943				2022-12-28	WOS:000178355100002
J	Fu, YX; Storb, U				Fu, YX; Storb, U			Autoreactive B cells migrate into T cell territory	SCIENCE			English	Editorial Material							CLONAL SELECTION; SOMATIC MUTATION; IMMUNOGLOBULIN; MATURATION; FAS		Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Fu, YX (corresponding author), Univ Chicago, Dept Pathol, 5841 S Maryland Ave, Chicago, IL 60637 USA.			fu, yang-xin/0000-0001-8441-6617				Cyster JG, 2000, IMMUNOL REV, V176, P181; Fu YX, 1999, ANNU REV IMMUNOL, V17, P399, DOI 10.1146/annurev.immunol.17.1.399; GOODNOW CC, 1997, CURR BIOL, V7, P219; Kelsoe G, 1996, Semin Immunol, V8, P179, DOI 10.1006/smim.1996.0022; Masuda A, 1999, LAB INVEST, V79, P849; Reif K, 2002, NATURE, V416, P94, DOI 10.1038/416094a; SHLOMCHIK MJ, 1987, NATURE, V328, P805, DOI 10.1038/328805a0; Storb U, 1999, COLD SPRING HARB SYM, V64, P227, DOI 10.1101/sqb.1999.64.227; Suzuki I, 2000, P NATL ACAD SCI USA, V97, P1707, DOI 10.1073/pnas.97.4.1707; Takahashi Y, 2001, IMMUNITY, V14, P181, DOI 10.1016/S1074-7613(01)00100-5; Wang Y, 2000, EUR J IMMUNOL, V30, P2226, DOI 10.1002/1521-4141(2000)30:18<2226::AID-IMMU2226>3.0.CO;2-M; William J, 2002, SCIENCE, V297, P2066, DOI 10.1126/science.1073924	12	4	4	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 20	2002	297	5589					2006	2008		10.1126/science.1077011	http://dx.doi.org/10.1126/science.1077011			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	594XV	12242429				2022-12-28	WOS:000178078500032
J	Thurmer, K; Williams, E; Reutt-Robey, J				Thurmer, K; Williams, E; Reutt-Robey, J			Autocatalytic oxidation of lead crystallite surfaces	SCIENCE			English	Article							RUO2(110); OXYGEN; STEP	Growth of an ultrathin lead oxide layer causes massive changes in the shape of lead crystallites. The dynamics of this process was investigated with time-lapsed scanning tunneling microscopy. Pure lead crystallites proved extremely resistant to oxidation. Once nucleated by surface impurities, monolayer films of lead oxide grew readily on lead (111) microfacets in an autocatalytic process. The anisotropic growth of orthorhombic lead oxide films (massicot structure) was most rapid along the direction of weakest lead-oxygen bonding, which suggests that the growth edge autocatalyzes oxygen dissociation by providing proximal sites for oxygen dissociation and attachment.	Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA; Univ Maryland, Dept Phys, College Pk, MD 20742 USA	University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park	Reutt-Robey, J (corresponding author), Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA.		Thürmer, Konrad/ABF-6374-2021; Thürmer, Konrad/L-4699-2013; Reutt-Robey, Janice E/C-3517-2009	Thürmer, Konrad/0000-0002-3078-7372; Thürmer, Konrad/0000-0002-3078-7372; Reutt-Robey, Janice E/0000-0002-9309-7854				BAO X, 1995, CATAL LETT, V32, P171, DOI 10.1007/BF00806112; Bottcher A, 1999, J CHEM PHYS, V110, P3186, DOI 10.1063/1.477839; CABRERA N, 1948, REP PROG PHYS, V12, P163, DOI 10.1088/0034-4885/12/1/308; Emundts A, 2002, SURF SCI, V496, pL35, DOI 10.1016/S0039-6028(01)01614-4; Emundts A, 2001, SURF SCI, V481, P13, DOI 10.1016/S0039-6028(01)01055-X; Feibelman PJ, 2000, PHYS REV B, V62, P17020, DOI 10.1103/PhysRevB.62.17020; FEIBELMAN PJ, UNPUB; Hammer B, 2000, ADV CATAL, V45, P71; HILL RJ, 1985, ACTA CRYSTALLOGR C, V41, P1281, DOI 10.1107/S0108270185007454; Jeong HC, 1999, SURF SCI REP, V34, P171, DOI 10.1016/S0167-5729(98)00010-7; Joyner R. W., 1977, Proceedings of the Royal Society of London, Series A (Mathematical and Physical Sciences), V358, P223, DOI 10.1098/rspa.1978.0006; Kim YD, 2001, J PHYS CHEM B, V105, P3752, DOI 10.1021/jp003213j; LIGHT TB, 1975, J APPL PHYS, V46, P1489, DOI 10.1063/1.321799; METOIS JJ, 1982, PHILOS MAG A, V46, P1015, DOI 10.1080/01418618208236947; Over H, 2001, J AM CHEM SOC, V123, P11807, DOI 10.1021/ja016408t; Over H, 2000, SCIENCE, V287, P1474, DOI 10.1126/science.287.5457.1474; Thurmer K, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.186102; TRINQUIER G, 1984, J PHYS CHEM-US, V88, P6696, DOI 10.1021/j150670a038; WORTIS M, 1988, CHEM PHYSICS SOLID S, V7, P367	19	85	88	0	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 20	2002	297	5589					2033	2035		10.1126/science.297.5589.2033	http://dx.doi.org/10.1126/science.297.5589.2033			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	594XV	12242437				2022-12-28	WOS:000178078500040
J	Stone, GW				Stone, GW			Primary angioplasty versus "earlier" thrombolysis - time for a wake-up call	LANCET			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; RANDOMIZED TRIAL; THERAPY; STRATEGY; DEATH		Cardiovasc Res Fdn, Lenox Hill Heart & Vasc Inst, New York, NY 10022 USA	Cardiovascular Research Foundation (CRF); Lenox Hill Heart & Vascular Institute of New York	Stone, GW (corresponding author), Cardiovasc Res Fdn, Lenox Hill Heart & Vasc Inst, New York, NY 10022 USA.							ANDERSEN HR, 2002, DANISH MULTICENTER R; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Aversano T, 2002, JAMA-J AM MED ASSOC, V287, P1943, DOI 10.1001/jama.287.15.1943; Cannon CP, 2000, JAMA-J AM MED ASSOC, V283, P2941, DOI 10.1001/jama.283.22.2941; DAVIES MJ, 1985, BRIT HEART J, V53, P363; Montalescot G, 2001, NEW ENGL J MED, V344, P1895, DOI 10.1056/NEJM200106213442503; ONEILL WW, 1992, CIRCULATION, V86, P1710, DOI 10.1161/01.CIR.86.6.1710; REIMER KA, 1977, CIRCULATION, V56, P786, DOI 10.1161/01.CIR.56.5.786; Ross AM, 1999, J AM COLL CARDIOL, V34, P1954, DOI 10.1016/S0735-1097(99)00444-1; Schomig A, 2000, NEW ENGL J MED, V343, P385, DOI 10.1056/NEJM200008103430602; Stone GW, 2002, NEW ENGL J MED, V346, P957, DOI 10.1056/NEJMoa013404; Stone GW, 2001, CIRCULATION, V104, P636, DOI 10.1161/hc3101.093701; STONE GW, 2001, INTERVENTIONAL CARDI, P227; Vermeer F, 1999, HEART, V82, P426, DOI 10.1136/hrt.82.4.426; Weaver WD, 1997, JAMA-J AM MED ASSOC, V278, P2093, DOI 10.1001/jama.278.23.2093; Widimsky P, 2000, EUR HEART J, V21, P823, DOI 10.1053/euhj.1999.1993; Zahn R, 2001, J AM COLL CARDIOL, V37, P1827, DOI 10.1016/S0735-1097(01)01264-5	17	20	20	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 14	2002	360	9336					814	816		10.1016/S0140-6736(02)11010-5	http://dx.doi.org/10.1016/S0140-6736(02)11010-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	594MC	12243913				2022-12-28	WOS:000178053500004
J	Robbins, JB; Schneerson, R; Trollfors, B				Robbins, JB; Schneerson, R; Trollfors, B			Pertussis in developed countries	LANCET			English	Editorial Material							VACCINE		NICHHD, NIH, Bethesda, MD 20892 USA; Dept Paediat, Gothenburg, Sweden	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Robbins, JB (corresponding author), NICHHD, NIH, Bethesda, MD 20892 USA.	robbinsjo@mail.nih.gov						BERFORS B, 1999, INT J INFECT DIS, V3, P140; Boursaux-Eude C, 1999, VACCINE, V17, P2651, DOI 10.1016/S0264-410X(99)00038-9; *CDCP, 2002, MMWR-MORBID MORTAL W, V51, P73; Crowcroft NS, 2002, ARCH DIS CHILD, V86, P336, DOI 10.1136/adc.86.5.336; Gangarosa EJ, 1998, LANCET, V351, P356, DOI 10.1016/S0140-6736(97)04334-1; JENKINSON D, 1988, BRIT MED J, V296, P612, DOI 10.1136/bmj.296.6622.612; Kendrick P, 1935, AM J PUBLIC HEALTH N, V25, P147, DOI 10.2105/AJPH.25.2.147; MARCHANT CD, 1994, J INFECT DIS, V169, P1297, DOI 10.1093/infdis/169.6.1297; Mooi FR, 2001, EMERG INFECT DIS, V7, P526, DOI 10.3201/eid0707.017708; *ROYAL COLL GEN PR, 1981, BMJ-BRIT MED J, V282, P23; Schneerson R, 1996, LANCET, V348, P1289, DOI 10.1016/S0140-6736(96)05243-9; SHAHIN RD, 1990, J EXP MED, V171, P63, DOI 10.1084/jem.171.1.63; Skowronski DM, 2002, J INFECT DIS, V185, P1448, DOI 10.1086/340280; Taranger J, 2001, CLIN INFECT DIS, V33, P1004, DOI 10.1086/322639; Taranger J, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.6.e115; *WHO, 1991, CAS DEF PERT	16	8	9	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 31	2002	360	9334					657	658		10.1016/S0140-6736(02)09882-3	http://dx.doi.org/10.1016/S0140-6736(02)09882-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	590AM	12241870				2022-12-28	WOS:000177795100005
J	Sandercock, P; Roberts, I				Sandercock, P; Roberts, I			Systematic reviews of animal experiments	LANCET			English	Editorial Material									Western Gen Hosp, Dept Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland; London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1, England	University of Edinburgh; University of London; London School of Hygiene & Tropical Medicine	Sandercock, P (corresponding author), Western Gen Hosp, Dept Clin Neurosci, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.		sandercock, peter/GQI-3167-2022	sandercock, peter/0000-0001-8484-0135				CHALMERS I, 1994, BMJ-BRIT MED J, V309, P862, DOI 10.1136/bmj.309.6958.862; Horn J, 2001, STROKE, V32, P570, DOI 10.1161/01.STR.32.2.570; Horn J, 2001, STROKE, V32, P2433, DOI 10.1161/hs1001.096009; HORN J, 2002, COCHRANE LIB; McMahon AD, 2002, STAT MED, V21, P1365, DOI 10.1002/sim.1120; Roberts I, 2002, BRIT MED J, V324, P474, DOI 10.1136/bmj.324.7335.474	6	88	96	1	13	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 24	2002	360	9333					586	586		10.1016/S0140-6736(02)09812-4	http://dx.doi.org/10.1016/S0140-6736(02)09812-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	586TD	12241927				2022-12-28	WOS:000177600400005
J	Crawford, LM				Crawford, LM			FDA statement on Prempro	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Commissioner Food & Drugs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Crawford, LM (corresponding author), US FDA, Off Commissioner Food & Drugs, HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	3	3	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	2002	288	13					1579	1579		10.1001/jama.288.13.1579-c	http://dx.doi.org/10.1001/jama.288.13.1579-c			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	599BJ	12350176				2022-12-28	WOS:000178314000006
J	Crawford, LM				Crawford, LM			Device for young diabetics	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Commissioner Food & Drugs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Crawford, LM (corresponding author), US FDA, Off Commissioner Food & Drugs, HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.								0	3	3	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 2	2002	288	13					1579	1579		10.1001/jama.288.13.1579-c	http://dx.doi.org/10.1001/jama.288.13.1579-c			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	599BJ	12350176				2022-12-28	WOS:000178314000004
